{"data": [{"Element": "<div class=\"WordSection1\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nI</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">SUMMARY\nOF PRODUCT CHARACTERISTICS</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE\nMEDICINAL PRODUCT</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade 100\u00a0mg powder for concentrate\nfor solution for infusion.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\nAND QUANTITATIVE COMPOSITION</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains 100\u00a0mg of\ninfliximab. Infliximab is a chimeric human\u2011murine IgG1\u00a0monoclonal\nantibody produced in murine hybridoma cells by recombinant DNA technology.\nAfter reconstitution each ml contains 10\u00a0mg of infliximab.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the full list of excipients, see\nsection\u00a06.1.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Powder for concentrate for solution for\ninfusion (</span><span lang=\"EN-GB\">powder for concentrate).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The powder is a freeze\u2011dried white\npellet.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL\nPARTICULARS</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Rheumatoid\narthritis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade, in combination with methotrexate,\nis indicated for the reduction of signs and symptoms as well as the improvement\nin physical function in:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">adult patients with active disease when the\nresponse to disease\u2011modifying antirheumatic drugs (DMARDs), including\nmethotrexate, has been inadequate.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">adult patients with severe, active and\nprogressive disease not previously treated with methotrexate or other DMARDs.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In these patient populations, a reduction\nin the rate of the progression of joint damage, as measured by X\u2011ray, has\nbeen demonstrated (see section\u00a05.1).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Adult\nCrohn\u2019s disease</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is indicated for:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">treatment of moderately to severely active\nCrohn\u2019s disease, in adult patients who have not responded despite a full\nand adequate course of therapy with a corticosteroid and/or an\nimmunosuppressant; or who are intolerant to or have medical contraindications\nfor such therapies.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">treatment of fistulising, active Crohn\u2019s\ndisease, in adult patients who have not responded despite a full and adequate\ncourse of therapy with conventional treatment (including antibiotics, drainage\nand immunosuppressive therapy).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\nCrohn\u2019s disease</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is indicated for treatment of\nsevere, active Crohn\u2019s disease, in children and adolescents aged 6 to 17\u00a0years,\nwho have not responded to conventional therapy including a corticosteroid, an\nimmunomodulator and primary nutrition therapy; or who are intolerant to or have\ncontraindications for such therapies. Remicade has been studied only in\ncombination with conventional immunosuppressive therapy.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ulcerative\ncolitis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is indicated for treatment of\nmoderately to severely active ulcerative colitis in adult patients who have had\nan inadequate response to conventional therapy including corticosteroids and 6\u2011mercaptopurine\n(6\u2011MP) or azathioprine (AZA), or who are intolerant to or have medical\ncontraindications for such therapies.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\nulcerative colitis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is indicated for treatment of\nseverely active ulcerative colitis, in children and adolescents aged 6 to 17\u00a0years,\nwho have had an inadequate response to conventional therapy including\ncorticosteroids</span><span lang=\"EN-GB\"> and 6\u2011MP or AZA, or who are\nintolerant to or have medical contraindications for such therapies.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Ankylosing spondylitis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Remicade is\nindicated for treatment of severe, active ankylosing spondylitis, in adult\npatients who have responded inadequately to conventional therapy.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"OLE_LINK1\"><u><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Psoriatic arthritis</span></u></a></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Remicade is\nindicated for treatment of active and progressive psoriatic arthritis in adult\npatients when the response to previous DMARD therapy has been inadequate.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Remicade should\nbe administered</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">in combination with methotrexate</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">or alone in patients who show intolerance to\nmethotrexate or for whom methotrexate is contraindicated</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade has been shown to improve physical\nfunction in patients with psoriatic arthritis, and to reduce the rate of\nprogression of peripheral joint damage as measured by X\u2011ray in patients\nwith polyarticular symmetrical subtypes of the disease (see section\u00a05.1).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Psoriasis</span></u></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Remicade is\nindicated for treatment of moderate to severe plaque psoriasis in adult\npatients who failed to respond to, or who have a contraindication to, or are\nintolerant to other systemic therapy including ciclosporin, methotrexate or\nPUVA (see section\u00a05.1).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of\nadministration</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade treatment is to be initiated and\nsupervised by qualified physicians experienced in the diagnosis and treatment\nof rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis,\npsoriatic arthritis or psoriasis. </span><span lang=\"EN-GB\">Remicade should be\nadministered intravenously. </span><span lang=\"EN-GB\">Remicade infusions should\nbe\u00a0administered by qualified healthcare professionals trained </span><span lang=\"EN-GB\">to detect any infusion\u2011related issues.</span><span lang=\"EN-GB\">\nPatients treated with Remicade should be given the package leaflet and the patient\nreminder card.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">During Remicade treatment, other concomitant\ntherapies, e.g., corticosteroids and immunosuppressants should be optimised.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Posology</span></u></b></p>\n<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Adults (\u2265\u00a018\u00a0years)</span></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Rheumatoid\narthritis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">3\u00a0mg/kg given as an intravenous\ninfusion followed by additional 3\u00a0mg/kg infusion doses at 2 and\n6\u00a0weeks after the first infusion, then every 8\u00a0weeks thereafter.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade must be given concomitantly with\nmethotrexate.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Available data suggest that the clinical\nresponse is usually achieved within 12\u00a0weeks of treatment. </span><span lang=\"EN-GB\">If a patient has an inadequate response or loses response after this\nperiod, consideration may be given to increase the dose step\u2011wise by </span><span lang=\"EN-GB\">approximately 1.5\u00a0mg/kg, </span><span lang=\"EN-GB\">up to a\nmaximum of 7.5\u00a0mg/kg every 8\u00a0weeks. Alternatively, administration of\n3\u00a0mg/kg as often as every 4\u00a0weeks may be considered. If adequate\nresponse is achieved, patients should be continued on the selected dose or dose\nfrequency. </span><span lang=\"EN-GB\">Continued therapy should be carefully\nreconsidered in patients who show no evidence of therapeutic benefit within the\nfirst 12\u00a0weeks of treatment or after dose adjustment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Moderately to severely active\nCrohn\u2019s disease</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by an additional 5\u00a0mg/kg infusion 2\u00a0weeks after the\nfirst infusion. If a patient does not respond after 2\u00a0doses, no additional\ntreatment with infliximab should be given. Available data do not support\nfurther infliximab treatment, in patients not responding within 6\u00a0weeks of\nthe initial infusion.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In responding patients, the alternative\nstrategies for continued treatment are:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Maintenance: Additional infusion of 5\u00a0mg/kg\nat 6\u00a0weeks after the initial dose, followed by infusions every 8\u00a0weeks\nor</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Re\u2011administration: Infusion of 5\u00a0mg/kg\nif signs and symptoms of the disease recur (see \u2018Re\u2011administration\u2019\nbelow and section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Although comparative data are lacking, l</span><span lang=\"EN-GB\">imited data in patients who initially responded to 5\u00a0mg/kg but\nwho lost response indicate that some patients may regain response with dose\nescalation (see section\u00a05.1). Continued therapy should be carefully\nreconsidered in patients who show no evidence of therapeutic benefit after dose\nadjustment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Fistulising, active Crohn\u2019s\ndisease</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by additional 5\u00a0mg/kg infusions at 2 and 6\u00a0weeks\nafter the first infusion. If a patient does not respond after 3\u00a0doses, no\nadditional treatment with infliximab should be given.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In responding patients, the alternative\nstrategies for continued treatment are:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Maintenance: Additional infusions of 5\u00a0mg/kg\nevery 8\u00a0weeks or</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Re\u2011administration: Infusion of 5\u00a0mg/kg\nif signs and symptoms of the disease recur followed by infusions of 5\u00a0mg/kg\nevery 8\u00a0weeks (see \u2018Re\u2011administration\u2019 below and section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Although\ncomparative data are lacking, l</span><span lang=\"EN-GB\">imited data in patients\nwho initially responded to 5\u00a0mg/kg but who lost response indicate that\nsome patients may regain response with dose escalation (see section\u00a05.1).\nContinued therapy should be carefully reconsidered in patients who show no\nevidence of therapeutic benefit after dose adjustment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In Crohn\u2019s disease, experience with\nre</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration if signs\nand symptoms of disease recur is limited and comparative data on the\nbenefit/risk of the alternative strategies for continued treatment are lacking.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ulcerative\ncolitis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks\nafter the first infusion, then every 8\u00a0weeks thereafter.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Available data suggest that the clinical\nresponse is usually achieved within 14\u00a0weeks of treatment, i.e. three\ndoses. Continued therapy should be carefully reconsidered in patients who show\nno evidence of therapeutic benefit within this time period.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ankylosing\nspondylitis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks\nafter the first infusion, then every 6 to 8\u00a0weeks. If a patient does not\nrespond by 6\u00a0weeks (i.e. after 2\u00a0doses), no additional treatment with\ninfliximab should be given.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Psoriatic\narthritis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">5\u00a0mg/kg\ngiven as an intravenous infusion followed by additional 5\u00a0mg/kg infusion\ndoses at 2 and 6\u00a0weeks after the first infusion, then every 8\u00a0weeks\nthereafter.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Psoriasis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">5\u00a0mg/kg\ngiven as an intravenous infusion followed by additional 5\u00a0mg/kg infusion\ndoses at 2 and 6\u00a0weeks after the first infusion, then every 8\u00a0weeks\nthereafter.</span><span lang=\"EN-GB\"> If a patient shows no response after\n14\u00a0weeks (i.e. after 4\u00a0doses), no additional treatment with\ninfliximab should be given.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Re</span></u><u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for Crohn\u2019s disease and rheumatoid arthritis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If the signs and symptoms of disease recur,\nRemicade can be re\u2011administered within 16\u00a0weeks following the last infusion.\nIn clinical studies, delayed hypersensitivity reactions have been uncommon and\nhave occurred after Remicade\u2011free intervals of less than 1\u00a0year (see\nsections\u00a04.4 and 4.8). The safety and efficacy of re\u2011administration\nafter a Remicade\u2011free interval of more than 16\u00a0weeks has not been\nestablished. This applies to both Crohn\u2019s disease patients and rheumatoid\narthritis patients.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Re</span></u><u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for ulcerative colitis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of re\u2011administration,\nother than every 8\u00a0weeks, has not been established </span><span lang=\"EN-GB\">(see sections\u00a04.4 and 4.8)</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Re</span></u><u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for ankylosing\nspondylitis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of re\u2011administration,\nother than every 6 to 8\u00a0weeks, has not been established </span><span lang=\"EN-GB\">(see sections\u00a04.4 and 4.8)</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Re</span></u><u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for psoriatic arthritis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of re\u2011administration,\nother than every 8\u00a0weeks, has not been established </span><span lang=\"EN-GB\">(see sections\u00a04.4 and 4.8)</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Re</span></u><u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for psoriasis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Limited experience from re\u2011treatment\nwith one single Remicade dose in psoriasis after an interval of 20\u00a0weeks\nsuggests reduced efficacy and a higher incidence of mild to moderate infusion\nreactions when compared to the initial induction regimen (see section\u00a05.1).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Limited experience from re</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">treatment following disease flare by\na re\u2011induction regimen suggests a higher incidence of infusion reactions,\nincluding serious ones, when compared to 8\u2011weekly maintenance treatment\n(see section\u00a04.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Re</span></u><u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration across indications</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In case maintenance therapy is interrupted,\nand there is a need to restart treatment, use of a re\u2011induction regimen\nis not recommended (see section\u00a04.8). In this situation, Remicade should\nbe re\u2011initiated as a single dose followed by the maintenance dose\nrecommendations described above.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Special\npopulations</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Specific studies of Remicade in elderly\npatients have not been conducted. No major age\u2011related differences in\nclearance or volume of distribution were observed in clinical studies. No dose\nadjustment is required (see section\u00a05.2). For more information about the\nsafety of Remicade in elderly patients (see sections\u00a04.4 and 4.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal\nand/or hepatic impairment</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade has not been studied in these\npatient populations. No dose recommendations can be made (see section\u00a05.2).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric\npopulation</span></i></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Crohn\u2019s\ndisease (6 to 17\u00a0years)</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous infusion\nfollowed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks after\nthe first infusion, then every 8\u00a0weeks thereafter. Available data do not\nsupport further infliximab treatment in children and adolescents not responding\nwithin the first 10\u00a0weeks of treatment (see section\u00a05.1).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Some patients may require a shorter dosing\ninterval to maintain clinical benefit, while for others a longer dosing\ninterval may be sufficient. Patients who have had their dose interval shortened\nto less than 8\u00a0weeks may be at greater risk for adverse reactions.\nContinued therapy with a shortened interval should be carefully considered in\nthose patients who show no evidence of additional therapeutic benefit after a\nchange in dosing interval.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Remicade have\nnot been studied in children with Crohn\u2019s disease below the age of 6\u00a0years.\nCurrently available pharmacokinetic data are described in section\u00a05.2 but\nno recommendation on a posology can be made in children younger than 6\u00a0years.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ulcerative\ncolitis (6 to 17\u00a0years)</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks\nafter the first infusion, then every 8\u00a0weeks thereafter. Available data do\nnot support further infliximab treatment in paediatric patients not responding\nwithin the first 8\u00a0weeks of treatment (see section\u00a05.1).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Remicade have\nnot been studied in children with ulcerative colitis below the age of 6\u00a0years.\nCurrently available pharmacokinetic data are described in section\u00a05.2 but\nno recommendation on a posology can be made in children younger than 6\u00a0years.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Psoriasis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Remicade in\nchildren and adolescents younger than 18\u00a0years for the indication of psoriasis\nhave not been established. Currently available data are described in section\u00a05.2\nbut no recommendation on a posology can be made.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Juvenile\nidiopathic arthritis, psoriatic arthritis and ankylosing spondylitis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Remicade in children\nand adolescents younger than 18\u00a0years for the indications of juvenile\nidiopathic arthritis, psoriatic arthritis and ankylosing spondylitis have not\nbeen established. Currently available data are described in section\u00a05.2\nbut no recommendation on a posology can be made.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Juvenile\nrheumatoid arthritis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Remicade in\nchildren and adolescents younger than 18\u00a0years for the indication of juvenile\nrheumatoid arthritis have not been established. Currently available data</span><span lang=\"EN-GB\"> are</span><span lang=\"EN-GB\"> described in sections\u00a04.8\u00a0and\n5.2 but no recommendation on a posology can be made.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Method\nof administration</span></u></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade should be administered\nintravenously over a 2\u00a0hour period. All patients administered Remicade are\nto be observed for at least 1\u20112\u00a0hours post\u2011infusion for acute\ninfusion\u2011related reactions. Emergency equipment, such as adrenaline,\nantihistamines, corticosteroids and an artificial airway must be available.\nPatients may be pre\u2011treated with e.g., an antihistamine, hydrocortisone\nand/or paracetamol and infusion rate may be slowed in order to decrease the\nrisk of infusion\u2011related reactions especially if infusion\u2011related\nreactions have occurred previously (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Shortened\ninfusions across adult indications</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In carefully selected adult patients who have\ntolerated at least 3</span><span lang=\"EN-GB\">\u00a0initial 2\u2011hour\ninfusions of Remicade (induction phase) and are receiving maintenance therapy,\nconsideration may be given to administering subsequent infusions over a period\nof not less than 1\u00a0hour.</span><span lang=\"EN-GB\"> If an infusion reaction\noccurs in association with a shortened infusion, a slower infusion rate may be\nconsidered for future infusions if treatment is to be continued. Shortened\ninfusions at doses &gt;\u00a06\u00a0mg/kg have not been studied (see section\u00a04.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For preparation and administration instructions,\nsee section\u00a06.6.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypersensitivity to the active substance,\nto other murine proteins, or to any of the excipients listed in\nsection\u00a06.1.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with tuberculosis or other severe\ninfections such as sepsis, abscesses, and opportunistic infections (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with moderate or severe heart\nfailure (NYHA class III/IV) (see sections\u00a04.4 and 4.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and\nprecautions for use</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Traceability</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In order to improve the traceability of\nbiological medicinal products, the tradename and the batch number of the\nadministered product should be clearly recorded.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infusion\nreactions and hypersensitivity</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab has been associated with acute\ninfusion\u2011related reactions, including anaphylactic shock, and delayed\nhypersensitivity reactions (see section\u00a04.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Acute infusion reactions including\nanaphylactic reactions may develop during (within seconds) or within a few\nhours following infusion. If acute infusion reactions occur, the infusion must\nbe interrupted immediately. Emergency equipment, such as adrenaline,\nantihistamines, corticosteroids and an artificial airway must be available.\nPatients may be pre\u2011treated with e.g., an antihistamine, hydrocortisone\nand/or paracetamol to prevent mild and transient effects.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Antibodies to infliximab may develop and\nhave been associated with an increased frequency of infusion reactions. A low\nproportion of the infusion reactions was serious allergic reactions. An\nassociation between development of antibodies to infliximab and reduced\nduration of response has also been observed. Concomitant administration of\nimmunomodulators has been associated with lower incidence of antibodies to\ninfliximab and a reduction in the frequency of infusion reactions. The effect\nof concomitant immunomodulator therapy was more profound in episodically\u2011treated\npatients than in patients given maintenance therapy. Patients who discontinue\nimmunosuppressants prior to or during Remicade treatment are at greater risk of\ndeveloping these antibodies. Antibodies to infliximab cannot always be detected\nin serum samples. If serious reactions occur, symptomatic treatment must be\ngiven and further Remicade infusions must not be administered (see section\u00a04.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical studies, delayed\nhypersensitivity reactions have been reported. Available data suggest an\nincreased risk for delayed hypersensitivity with increasing Remicade\u2011free\ninterval. Patients should be advised to seek immediate medical advice if they\nexperience any delayed adverse reaction (see section\u00a04.8). If patients are\nre\u2011treated after a prolonged period, they must be closely monitored for\nsigns and symptoms of delayed hypersensitivity.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infections</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients must be monitored closely for\ninfections including tuberculosis before, during and after treatment with\nRemicade. Because the elimination of infliximab may take up to six months,\nmonitoring should be continued throughout this period. Further treatment with\nRemicade must not be given if a patient develops a serious infection or sepsis.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Caution should be\nexercised when considering the use of Remicade in patients with chronic\ninfection or a history of recurrent infections, including concomitant\nimmunosuppressive therapy. Patients should be advised of and avoid exposure to\npotential risk factors for infection as appropriate.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tumour necrosis\nfactor alpha (<a name=\"OLE_LINK5\">TNF</a></span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">) mediates\ninflammation and modulates cellular immune responses. Experimental data show\nthat TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> is essential for the clearing of intracellular infections. Clinical\nexperience shows that host defence against infection is compromised in some\npatients treated with infliximab.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">It should be\nnoted that suppression of TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:\nSymbol\">a</span></sub><span lang=\"EN-GB\"> may mask symptoms of infection such as\nfever.</span><span lang=\"EN-GB\"> Early recognition of atypical clinical\npresentations of serious infections </span><span lang=\"EN-GB\">and of typical clinical\npresentation of rare and unusual infections </span><span lang=\"EN-GB\">is critical\nin order to minimise delays in diagnosis and treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients taking TNF\u2011blockers are more\nsusceptible to serious infections.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tuberculosis, bacterial infections, </span><span lang=\"EN-GB\">including sepsis and pneumonia</span><span lang=\"EN-GB\">, invasive\nfungal, viral, and other opportunistic infections</span><span lang=\"EN-GB\"> have\nbeen observed in patients treated with infliximab. Some of these infections\nhave been fatal</span><span lang=\"EN-GB\">; </span><span lang=\"EN-GB\">the most\nfrequently reported opportunistic infections with a mortality rate of\n&gt;\u00a05% include pneumocystosis, candidiasis, listeriosis and aspergillosis</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients who develop a new infection while\nundergoing treatment with Remicade, should be monitored closely and undergo a\ncomplete diagnostic evaluation. Administration of Remicade should be discontinued\nif a patient develops a new serious infection or sepsis, and appropriate\nantimicrobial or antifungal therapy should be initiated until the infection is\ncontrolled.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Tuberculosis</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There have been reports of active\ntuberculosis in patients receiving Remicade. It should be noted that in the\nmajority of these reports tuberculosis was extrapulmonary, presenting as either\nlocal or disseminated disease.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Before starting treatment with Remicade,\nall patients must be evaluated for both active and inactive (\u2018latent\u2019)\ntuberculosis. This evaluation should include a detailed medical history with\npersonal history of tuberculosis or possible previous contact with tuberculosis\nand previous and/or current immunosuppressive therapy. Appropriate screening\ntests (e.g. tuberculin skin test, chest X\u2011ray, and/or Interferon Gamma\nRelease Assay), should be performed in all patients (local recommendations may\napply). It is recommended that t<span style=\"layout-grid-mode:line\">he conduct\nof these tests should be recorded in the </span>patient\u2019s reminder card.\nPrescribers are reminded of the risk of false negative tuberculin skin test\nresults, especially in patients who are severely ill or immunocompromised<span style=\"layout-grid-mode:line\">.</span></span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">If active\ntuberculosis is diagnosed, Remicade therapy must not be initiated (see section\u00a04.3).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If latent tuberculosis is suspected, a\nphysician with expertise in the treatment of tuberculosis should be consulted.\nIn all situations described below, the benefit/risk balance of Remicade therapy\nshould be very carefully considered.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If inactive (\u2018latent\u2019)\ntuberculosis is diagnosed, treatment for latent tuberculosis must be started\nwith antituberculosis therapy before the initiation of Remicade, and in\naccordance with local recommendations.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients who have several or significant\nrisk factors for tuberculosis and have a negative test for latent tuberculosis,\nantituberculosis therapy should be considered before the initiation of\nRemicade.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Use of antituberculosis therapy should also\nbe considered before the initiation of Remicade in patients with a past history\nof latent or active tuberculosis in whom an adequate course of treatment cannot\nbe confirmed.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Some cases of active tuberculosis have been\nreported in patients treated with Remicade during and after treatment for\nlatent tuberculosis.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">All patients should be informed to seek\nmedical advice if signs/symptoms suggestive of tuberculosis</span><span lang=\"EN-GB\"> (e.g. persistent cough, wasting/weight loss, low\u2011grade fever)\nappear during or after Remicade treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Invasive\nfungal infections</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients treated with Remicade, an\ninvasive fungal infection such as aspergillosis, candidiasis, pneumocystosis,\nhistoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they\ndevelop a serious systemic illness</span><span lang=\"EN-GB\">, and a physician\nwith expertise in the diagnosis and treatment of invasive fungal infections\nshould be consulted at an early stage when investigating these patients</span><span lang=\"EN-GB\">. Invasive fungal infections may present as disseminated rather than\nlocalised disease, and antigen and antibody testing may be negative in some\npatients with active infection. Appropriate empiric antifungal therapy should\nbe considered while a diagnostic workup is being performed taking into account\nboth the risk for severe fungal infection and the risks of antifungal therapy.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For patients who have resided in or\ntravelled to regions where invasive fungal infections such as histoplasmosis,\ncoccidioidomycosis, or blastomycosis are endemic, the benefits and risks of\nRemicade treatment should be carefully considered before initiation of Remicade\ntherapy.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Fistulising\nCrohn\u2019s disease</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with fistulising Crohn\u2019s\ndisease with acute suppurative fistulas must not initiate Remicade therapy\nuntil a source for possible infection, specifically abscess, has been excluded\n(see section\u00a04.3).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatitis\nB (HBV) reactivation</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reactivation of hepatitis B has occurred in\npatients receiving a TNF\u2011antagonist including infliximab, who are chronic\ncarriers of this virus. Some cases have had fatal outcome.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should be tested for HBV infection\nbefore initiating treatment with Remicade. For patients who test positive for\nHBV infection, consultation with a physician with expertise in the treatment of\nhepatitis B is recommended.</span><span lang=\"EN-GB\"> Carriers of HBV who require\ntreatment with Remicade should be closely monitored for signs and symptoms of\nactive HBV infection throughout therapy and for several months following\ntermination of therapy. Adequate data of treating patients who are carriers of\nHBV with antiviral therapy in conjunction with TNF\u2011antagonist therapy to\nprevent HBV reactivation are not available. In patients who develop HBV\nreactivation, Remicade should be stopped and effective antiviral therapy with\nappropriate supportive treatment should be initiated.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\nevents</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cases of jaundice and non\u2011infectious\nhepatitis, some with features of autoimmune hepatitis, have been observed in\nthe post\u2011marketing experience of Remicade. Isolated cases of liver\nfailure resulting in liver transplantation or death have occurred. Patients\nwith symptoms or signs of liver dysfunction should be evaluated for evidence of\nliver injury. If jaundice and/or ALT elevations \u2265\u00a05\u00a0times the\nupper limit of normal develop(s), Remicade should be discontinued, and a\nthorough investigation of the abnormality should be undertaken.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Concurrent\nadministration of TNF\u2011alpha inhibitor and anakinra</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Serious infections </span><span lang=\"EN-GB\">and\nneutropenia </span><span lang=\"EN-GB\">were seen in clinical studies with\nconcurrent use of anakinra and another TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">\u2011blocking\nagent, etanercept, with no added clinical benefit compared to etanercept alone.\nBecause of the nature of the adverse reactions seen with combination of\netanercept and anakinra therapy, similar toxicities may also result from the\ncombination of anakinra and other TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">\u2011blocking\nagents. Therefore, the combination of Remicade and anakinra is not recommended.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Concurrent\nadministration of TNF\u2011alpha inhibitor and abatacept</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical studies concurrent\nadministration of TNF\u2011antagonists and abatacept has been associated with\nan increased risk of infections including serious infections compared to TNF\u2011antagonists\nalone, without increased clinical benefit. The combination of Remicade and\nabatacept is not recommended.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Concurrent\nadministration with other biological therapeutics</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There is insufficient information regarding\nthe concomitant use of infliximab with other biological therapeutics used to\ntreat the same conditions as infliximab. The concomitant use of infliximab with\nthese biologics is not recommended </span><span lang=\"EN-GB\">because of the\npossibility of an increased risk of infection, and other potential\npharmacological interactions.</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Switching\nbetween biological DMARDS</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Care should be taken and patients should\ncontinue to be monitored when switching from one biologic to another, since\noverlapping biological activity may further increase the risk for adverse reactions,\nincluding infection.</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"_Hlk502758333\"><u><span lang=\"EN-GB\">Vaccinations</span></u></a><a name=\"_Hlk502758339\"></a></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is recommended that patients, if possible,\nbe brought up to date with all vaccinations in agreement with current\nvaccination guidelines prior to initiating Remicade therapy. Patients on\ninfliximab may receive concurrent vaccinations, except for live vaccines (see\nsections\u00a04.5 and\u00a04.6).</span></p>\n<p class=\"MsoNormal\"><a name=\"_Hlk503547227\"><span lang=\"EN-GB\">\u00a0</span></a></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In a subset of 90 adult patients with\nrheumatoid arthritis from the ASPIRE study a similar proportion of patients in\neach treatment group (methotrexate plus: placebo [n\u00a0=\u00a017],\n3\u00a0mg/kg [n\u00a0=\u00a027] or 6\u00a0mg/kg Remicade [n\u00a0=\u00a046])\nmounted an effective two-fold increase in titers to a polyvalent pneumococcal\nvaccine, indicating that Remicade did not interfere with T-cell independent\nhumoral immune responses. However, studies from the published literature in\nvarious indications (e.g. rheumatoid arthritis, psoriasis, Crohn\u2019s\ndisease) suggest that non-live vaccinations received during treatment with\nanti-TNF therapies, including Remicade, may elicit a lower immune response than\nin patients not receiving anti-TNF therapy.</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Live\nvaccines/therapeutic infectious agents</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients receiving anti\u2011TNF\ntherapy, limited data are available on the response to vaccination with live\nvaccines or on the secondary transmission of infection by live vaccines. Use of\nlive vaccines can result in clinical infections, including disseminated infections.\nThe concurrent administration of live vaccines with Remicade is not\nrecommended.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In </span><span lang=\"EN-GB\">infants exposed <i>in\nutero</i> to infliximab</span><span lang=\"EN-GB\">, fatal outcome due to\ndisseminated Bacillus Calmette\u2011Gu\u00e9rin (BCG) infection has been\nreported following administration of BCG vaccine after birth. At least a six\nmonth waiting period following birth is recommended before the administration\nof live vaccines to infants exposed <i>in utero </i>to infliximab (see\nsection\u00a04.6).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Other uses of therapeutic infectious agents\nsuch as live attenuated bacteria (e.g., BCG bladder instillation for the\ntreatment of cancer) could result in clinical infections, including\ndisseminated infections. It is recommended that therapeutic infectious agents\nnot be given concurrently with Remicade.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Autoimmune\nprocesses</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The relative deficiency of TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> caused by\nanti\u2011TNF therapy may result in the initiation of an autoimmune process.\nIf a patient develops symptoms suggestive of a lupus\u2011like syndrome\nfollowing treatment with Remicade and is positive for antibodies against double\u2011stranded\nDNA, further treatment with Remicade must not be given (see section\u00a04.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Neurological\nevents</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Use of TNF\u2011blocking agents, including\ninfliximab, has been associated with cases of new onset or exacerbation of\nclinical symptoms and/or radiographic evidence of central nervous system\ndemyelinating disorders, including multiple sclerosis, and peripheral\ndemyelinating disorders, including Guillain\u2011Barr\u00e9 syndrome. In\npatients with pre\u2011existing or recent onset of demyelinating disorders, the\nbenefits and risks of anti\u2011TNF treatment should be carefully considered\nbefore initiation of Remicade therapy. Discontinuation of Remicade should be\nconsidered if these disorders develop.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Malignancies\nand lymphoproliferative disorders</span></u></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In the\ncontrolled portions of clinical studies of TNF\u2011blocking agents, more\ncases of malignancies including lymphoma have been observed among patients\nreceiving a TNF blocker compared with control patients. During clinical studies\nof Remicade across all approved indications the incidence of lymphoma in\nRemicade\u2011treated patients was higher than expected in the general\npopulation, but the occurrence of lymphoma was rare. </span><span lang=\"EN-GB\">In\nthe post\u2011marketing setting, cases of leukaemia have been reported in\npatients treated with a TNF\u2011antagonist. </span><span lang=\"EN-GB\">There is\nan increased background risk for lymphoma and leukaemia in rheumatoid arthritis\npatients with long\u2011standing, highly active, inflammatory disease, which\ncomplicates risk estimation.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In an exploratory clinical study evaluating\nthe use of Remicade in patients with moderate to severe chronic obstructive\npulmonary disease (COPD), more malignancies were reported in Remicade\u2011treated\npatients compared with control patients. All patients had a history of heavy\nsmoking. Caution should be exercised in considering treatment of patients with\nincreased risk for malignancy due to heavy smoking.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">With the current knowledge, a risk for the\ndevelopment of lymphomas or other malignancies in patients treated with a TNF\u2011blocking\nagent cannot be excluded (see section\u00a04.8). </span><span lang=\"EN-GB\">Caution\nshould be exercised when considering TNF\u2011blocking therapy for patients\nwith a history of malignancy or when considering continuing treatment in\npatients who develop a malignancy.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Caution should also be exercised in\npatients with psoriasis and a medical history of extensive immunosuppressant\ntherapy or prolonged PUVA treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Malignancies, some fatal, have been\nreported among children, adolescents and young adults (up to 22\u00a0years of\nage) treated with TNF\u2011blocking agents (initiation of therapy\n\u2264\u00a018\u00a0years of age), including Remicade in the post\u2011marketing\nsetting. Approximately half the cases were lymphomas. The other cases\nrepresented a variety of different malignancies and included rare malignancies\nusually associated with immunosuppression. A risk for the development of\nmalignancies in patients treated with TNF\u2011blockers cannot be excluded.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Post</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">marketing cases of hepatosplenic T</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">cell lymphoma (HSTCL) have been reported in patients </span><span lang=\"EN-GB\">treated with<b> </b>TNF</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">blocking agents including infliximab.\u00a0This rare type of T</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">cell lymphoma has a very aggressive\ndisease course and is usually fatal. Almost all patients had received treatment\nwith AZA or 6</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">MP\nconcomitantly with or immediately prior to a TNF</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">blocker. The vast majority of Remicade cases have occurred in\npatients </span><span lang=\"EN-GB\">with Crohn\u2019s disease </span><span lang=\"EN-GB\">or ulcerative colitis and most were reported in adolescent or young\nadult males.</span><span lang=\"EN-GB\"> The potential risk with the combination of\nAZA or 6</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">MP and Remicade\nshould be carefully considered. A risk for the development for hepatosplenic T</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">cell lymphoma in patients treated\nwith Remicade cannot be excluded (see section 4.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Melanoma and Merkel cell carcinoma have\nbeen reported in patients treated with TNF blocker therapy, including Remicade\n(see section\u00a04.8). Periodic skin examination is recommended, particularly for\npatients with risk factors for skin cancer.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">A population</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">based retrospective cohort study using data from Swedish national\nhealth registries found an increased incidence of cervical cancer in women with\nrheumatoid arthritis treated with infliximab compared to biologics</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">na\u00efve patients or the general\npopulation, including those over 60\u00a0years of age. Periodic screening\nshould continue in women treated with Remicade, including those over\n60\u00a0years of age.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">All patients with ulcerative colitis who\nare at increased risk for dysplasia or colon carcinoma (for example, patients\nwith long</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">standing\nulcerative colitis or primary sclerosing cholangitis), or who had a prior\nhistory of dysplasia or colon carcinoma should be screened for dysplasia at\nregular intervals before therapy and throughout their disease course. This\nevaluation should include colonoscopy and biopsies per local recommendations. Current\ndata do not indicate that infliximab treatment influences the risk for\ndeveloping dysplasia or colon cancer.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Since the possibility of increased risk of\ncancer development in patients with newly diagnosed dysplasia treated with\nRemicade is not established, the risk and benefits of continued therapy to the\nindividual patients should be carefully considered by the clinician.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Heart\nfailure</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade should be used with caution in\npatients with mild heart failure (NYHA class I/II). Patients should be closely\nmonitored and Remicade must not be continued in patients who develop new or\nworsening symptoms of heart failure (see sections\u00a04.3 and 4.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Haematologic\nreactions</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There have been reports of pancytopenia,\nleucopenia, neutropenia, and thrombocytopenia in patients receiving TNF</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">blockers, including Remicade. </span><span lang=\"EN-GB\">All patients should be advised to seek immediate medical attention\nif they develop signs and symptoms suggestive of blood dyscrasias (e.g.\npersistent fever, bruising, bleeding, pallor). Discontinuation of Remicade\ntherapy should be considered in patients with confirmed significant haematologic\nabnormalities.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Others</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There is limited safety experience of\nRemicade treatment in patients who have undergone surgical procedures,\nincluding arthroplasty. The long half\u2011life of infliximab should be taken\ninto consideration if a surgical procedure is planned. A patient who requires\nsurgery while on Remicade should be closely monitored for infections, and\nappropriate actions should be taken.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Failure to respond to treatment for\nCrohn\u2019s disease may indicate the presence of a fixed fibrotic stricture\nthat may require surgical treatment. There is no evidence to suggest that\ninfliximab worsens or causes fibrotic strictures.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Special\npopulations</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">The incidence\nof serious infections in Remicade</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">treated patients 65\u00a0years and\nolder was greater than in those under 65\u00a0years of age. </span><span lang=\"EN-GB\">Some of those had a fatal outcome.</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> </span><span lang=\"EN-GB\">Particular attention\nregarding the risk for infection should be paid when treating the elderly (see\nsection\u00a04.8)</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><u><span lang=\"EN-GB\">Paediatric population</span></u></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Infections</span></u></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In clinical\nstudies, infections have been reported in a higher proportion of paediatric\npatients compared to adult patients (see section\u00a04.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vaccinations</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is recommended that paediatric patients,\nif possible, be brought up to date with all vaccinations in agreement with\ncurrent vaccination guidelines prior to initiating Remicade therapy. Paediatric\npatients on infliximab may receive concurrent vaccinations, except for live\nvaccines (see sections\u00a04.5 and\u00a04.6).</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Malignancies and lymphoproliferative disorders</span></u></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Malignancies,\nsome fatal, have been reported among children, adolescents and young adults (up\nto 22\u00a0years of age) treated with TNF\u2011blocking agents (initiation of\ntherapy \u2264\u00a018\u00a0years of age), including Remicade in the post\u2011marketing\nsetting. Approximately half the cases were lymphomas. The other cases\nrepresented a variety of different malignancies and included rare malignancies\nusually associated with immunosuppression. A risk for the development of\nmalignancies in children and adolescents treated with TNF\u2011blockers cannot\nbe excluded.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Post\u2011marketing cases of hepatosplenic\nT\u2011cell lymphoma have been reported in patients </span><span lang=\"EN-GB\">treated\nwith<b> </b></span><span lang=\"EN-GB\">TNF\u2011blocking agents </span><span lang=\"EN-GB\">including infliximab.\u00a0This rare type of T\u2011cell lymphoma\nhas a very aggressive disease course and is usually fatal. </span><span lang=\"EN-GB\">Almost all patients had received treatment with AZA or 6\u2011MP\nconcomitantly with or immediately prior to a TNF\u2011blocker. </span><span lang=\"EN-GB\">The vast majority of Remicade cases have occurred in patients </span><span lang=\"EN-GB\">with Crohn\u2019s disease </span><span lang=\"EN-GB\">or ulcerative\ncolitis and most were reported in adolescent or young adult males.</span><span lang=\"EN-GB\"> The potential risk with the combination of AZA or 6\u2011MP and\nRemicade should be carefully considered. A risk for the development for\nhepatosplenic T\u2011cell lymphoma in patients treated with Remicade cannot be\nexcluded (see section 4.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Sodium\ncontent</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade contains less than 1\u00a0mmol\nsodium (23\u00a0mg) per dose, i.e. essentially \u2018sodium\u2011free\u2019.\nRemicade is however, diluted in sodium chloride 9\u00a0mg/ml (0.9%) solution\nfor infusion. This should be taken into consideration for patients on a\ncontrolled sodium diet (see section\u00a06.6).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other\nmedicinal products and other forms of interaction</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">No interaction studies have been performed.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In </span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">rheumatoid arthritis, psoriatic arthritis and\nCrohn's disease</span><span lang=\"EN-GB\"> patients, there are indications that\nconcomitant use of methotrexate and other immunomodulators reduces the\nformation of antibodies against infliximab and increases the plasma\nconcentrations of infliximab. However, the results are uncertain due to\nlimitations in the methods used for serum analyses of infliximab and antibodies\nagainst infliximab.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Corticosteroids do not appear to affect the\npharmacokinetics of infliximab to a clinically relevant extent.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The combination of Remicade with other\nbiological therapeutics used to treat the same conditions as Remicade, including\nanakinra and abatacept, is not recommended (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is recommended that live vaccines not be\ngiven concurrently with Remicade. It is also recommended that live vaccines not\nbe given to infants after <i>in utero</i> exposure to infliximab for at least\n6\u00a0months following birth (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is recommended that therapeutic\ninfectious agents not be given concurrently with Remicade (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and\nlactation</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Women of\nchildbearing potential</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Women of childbearing potential should\nconsider the use of adequate contraception to prevent pregnancy and continue\nits use for at least 6\u00a0months after the last Remicade treatment.</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The moderate number of prospectively\ncollected pregnancies exposed to infliximab resulting in live birth with known\noutcomes, including approximately 1100\u00a0exposed during the first trimester,\n</span><span lang=\"EN-GB\">does not indicate an increase in the rate of\nmalformation in the newborn.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Based on an observational study from\nNorthern Europe, an increased risk (OR, 95% CI; p\u2011value) for C\u2011section\n(1.50, 1.14\u20111.96; p\u00a0=\u00a00.0032), preterm birth (1.48, 1.05\u20112.09;\np\u00a0=\u00a00.024), small for gestational age (2.79, 1.54\u20115.04; p\u00a0=\u00a00.0007),\nand low birth weight (2.03, 1.41\u20112.94; p\u00a0=\u00a00.0002) was observed\nin women exposed during pregnancy to infliximab (with or without\nimmunomodulators/corticosteroids, 270\u00a0pregnancies) as compared to women\nexposed to immunomodulators and/or corticosteroids only (6,460\u00a0pregnancies).\nThe potential contribution of exposure to infliximab and/or the severity of the\nunderlying disease in these outcomes remains unclear.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Due to its inhibition of TNF</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span><span lang=\"EN-GB\">, infliximab\nadministered during pregnancy could affect normal immune responses in the\nnewborn. In a developmental toxicity study conducted in mice using an analogous\nantibody that selectively inhibits the functional activity of mouse TNF</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span><span lang=\"EN-GB\">, there was no\nindication of maternal toxicity, embryotoxicity or teratogenicity (see section\u00a05.3).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The available clinical experience is\nlimited. Infliximab should only be used during pregnancy if clearly needed.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab crosses the placenta and has\nbeen detected in the serum of infants up to 6\u00a0months following birth.\nAfter <i>in utero</i> exposure to infliximab, infants may be at increased risk\nof infection, including serious disseminated infection that can become fatal.\nAdministration of live vaccines (e.g.\u00a0BCG vaccine) to infants exposed to\ninfliximab <i>in utero</i> is not recommended for at least 6\u00a0months after\nbirth (see sections\u00a04.4 and 4.5). Cases of agranulocytosis have also been reported\n(see section\u00a04.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast\u2011feeding</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is unknown whether infliximab is\nexcreted in human milk or absorbed systemically after ingestion. Because human\nimmunoglobulins are excreted in milk, women must not breast feed for at least 6\u00a0months\nafter Remicade treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There are insufficient preclinical data to\ndraw conclusions on the effects of infliximab on fertility and general\nreproductive function (see section\u00a05.3).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to\ndrive and use machines</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade may have a minor influence on the\nability to drive and use machines. Dizziness may occur following administration\nof Remicade (see section\u00a04.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Summary\nof the safety profile</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Upper respiratory tract infection was the\nmost common adverse drug reaction (ADR) reported in clinical trials, occurring\nin 25.3% of infliximab\u2011treated patients compared with 16.5% of control\npatients</span><span lang=\"EN-GB\">. The most serious ADRs associated with the use\nof TNF blockers that have been reported for Remicade include HBV reactivation,\nCHF (congestive heart failure), serious infections (including sepsis,\nopportunistic infections and TB), serum sickness (delayed hypersensitivity\nreactions), haematologic reactions, systemic lupus erythematosus/lupus\u2011like\nsyndrome, demyelinating disorders, hepatobiliary events, lymphoma, HSTCL, leukaemia,\nMerkel cell carcinoma, melanoma, paediatric malignancy, sarcoidosis/sarcoid\u2011like\nreaction, intestinal or perianal abscess (in Crohn\u2019s disease), and\nserious infusion reactions (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Tabulated\nlist of adverse reactions</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Table\u00a01 lists ADRs based on experience\nfrom clinical studies as well as adverse reactions, some with fatal outcome,\nreported from post\u2011marketing experience. Within the organ system classes,\nadverse reactions are listed under headings of frequency using the following\ncategories: very common (\u2265\u00a01/10); common (\u2265\u00a01/100 to &lt;\u00a01/10);\nuncommon\u00a0(\u2265\u00a01/1,000 to &lt;\u00a01/100); rare (\u2265\u00a01/10,000\nto &lt;\u00a01/1,000); very rare (&lt;\u00a01/10,000), not known (cannot be\nestimated from the available data). Within each frequency grouping, undesirable\neffects are presented in order of decreasing seriousness.</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a01</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Undesirable effects in clinical studies and from\n  post\u2011marketing experience</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections\n  and infestations</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Viral infection (e.g. influenza, herpes\n  virus infection).</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bacterial infections (e.g. sepsis,\n  cellulitis, abscess). </span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tuberculosis, fungal infections (e.g.\n  candidiasis, onychomycosis).</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Meningitis, opportunistic infections\n  (such as invasive fungal infections [pneumocystosis, histoplasmosis,\n  aspergillosis, coccidioidomycosis, cryptococcosis, blastomycosis], bacterial\n  infections [atypical mycobacterial, listeriosis, salmonellosis], and viral\n  infections [cytomegalovirus]), parasitic infections, hepatitis B\n  reactivation.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vaccine breakthrough infection (after <i>in\n  utero </i>exposure to infliximab)*.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Neoplasms\n  benign, malignant and unspecified (including cysts and polyps)</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lymphoma,</span><span lang=\"EN-GB\"> non\u2011Hodgkin\u2019s\n  lymphoma, Hodgkin\u2019s disease, leukaemia, melanoma, cervical cancer.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatosplenic T\u2011cell lymphoma\n  (primarily in adolescents and young adult males with Crohn\u2019s disease or\n  ulcerative colitis), Merkel cell carcinoma<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">, Kaposi\u2019s sarcoma</ins></span>.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Blood and\n  lymphatic system disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia, leucopenia, anaemia,\n  lymphadenopathy.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Thrombocytopenia, lymphopenia, lymphocytosis.\n  </span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Agranulocytosis (including infants\n  exposed <i>in utero </i>to infliximab), thrombotic thrombocytopenic purpura,\n  pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Immune\n  system disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Allergic respiratory symptom<span style=\"layout-grid-mode:line\">.</span></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reaction, lupus\u2011like\n  syndrome, serum sickness or<span style=\"layout-grid-mode:line\"> serum\n  sickness\u2011like reaction</span>.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid !msorm\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-left:solid windowtext 1.0pt !msorm;\n  padding:0in 5.4pt 0in 5.4pt !msorm\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-right:solid windowtext 1.0pt !msorm;\n  padding:0in 5.4pt 0in 5.4pt !msorm\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic shock, vasculitis, sarcoid\u2011like\n  reaction.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Psychiatric\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Depression, insomnia.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"FR\">Amnesia, agitation, confusion, somnolence,\n  nervousness.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Apathy.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nervous\n  system disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Headache.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertigo, dizziness, hypoaesthesia,\n  paraesthesia.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Seizure, neuropathy.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Transverse myelitis, central nervous\n  system demyelinating disorders (multiple sclerosis\u2011like disease and\n  optic neuritis), peripheral demyelinating disorders (such as Guillain\u2011Barr\u00e9\n  syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal\n  motor neuropathy).</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cerebrovascular accidents in close temporal\n  association with infusion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Eye\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Conjunctivitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keratitis, periorbital oedema, hordeolum.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Endophthalmitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Transient visual loss occurring during or\n  within 2\u00a0hours of infusion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Cardiac disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tachycardia, palpitation.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cardiac failure (new onset or worsening),\n  arrhythmia, syncope, bradycardia.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cyanosis, pericardial effusion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Myocardial ischaemia/myocardial\n  infarction</span><span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vascular\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypotension, hypertension, ecchymosis,\n  hot flush, flushing.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Peripheral ischaemia, thrombophlebitis,\n  haematoma.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Circulatory failure, petechia, vasospasm.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Respiratory,\n  thoracic and mediastinal disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Upper respiratory tract infection, sinusitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lower respiratory tract infection (e.g.\n  bronchitis, pneumonia), dyspnoea, epistaxis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pulmonary oedema, bronchospasm, pleurisy,\n  pleural effusion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Interstitial lung disease (including\n  rapidly progressive disease, lung fibrosis and pneumonitis).</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Gastrointestinal\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Abdominal pain, nausea.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gastrointestinal haemorrhage, diarrhoea,\n  dyspepsia, gastroesophageal reflux, constipation.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intestinal perforation, intestinal stenosis,\n  diverticulitis, pancreatitis, cheilitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatobiliary\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatic function abnormal, transaminases\n  increased.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatitis, hepatocellular damage,\n  cholecystitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoimmune hepatitis, jaundice.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Liver failure.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Skin and subcutaneous\n  tissue disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">New onset or worsening psoriasis\n  including pustular psoriasis (primarily palm &amp; soles), urticaria, rash,\n  pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bullous eruption, seborrhoea, rosacea,\n  skin papilloma, hyperkeratosis, abnormal skin pigmentation.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Toxic epidermal necrolysis, Stevens\u2011Johnson\n  Syndrome, erythema multiforme, furunculosis, linear IgA bullous dermatosis\n  (LABD), acute generalised exanthematous pustulosis (AGEP), lichenoid\n  reactions.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Worsening of symptoms of dermatomyositis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Musculoskeletal\n  and connective tissue disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arthralgia, myalgia, back pain.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Renal and\n  urinary disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Urinary tract infection.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pyelonephritis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reproductive\n  system and breast disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vaginitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">General\n  disorders and administration site conditions</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infusion\u2011related reaction, pain.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Chest pain, fatigue, fever, injection\n  site reaction, chills, oedema.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Impaired healing.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Granulomatous lesion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Investigations</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoantibody positive.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Complement factor abnormal.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\">*\u00a0\u00a0 </span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">including\n  bovine tuberculosis (disseminated BCG infection), see section\u00a04.4</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Description of selected adverse drug reactions</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Infusion\u2011related reactions</span></u></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">An infusion\u2011related\nreaction was defined in clinical studies as any adverse event occurring during an\ninfusion or within 1\u00a0hour after an infusion. In Phase III clinical\nstudies, 18% of infliximab\u2011treated patients compared with 5% of placebo\u2011treated\npatients experienced an infusion\u2011related reaction. Overall, a higher\nproportion of patients receiving infliximab monotherapy experienced an infusion\u2011related\nreaction compared to patients receiving infliximab with concomitant immunomodulators.\nApproximately 3% of patients discontinued treatment due to infusion\u2011related\nreactions and all patients recovered with or without medical therapy. Of\ninfliximab\u2011treated patients who had an infusion reaction during the\ninduction period, through week\u00a06, 27% experienced an infusion reaction\nduring the maintenance period, week\u00a07 through week\u00a054. Of patients\nwho did not have an infusion reaction during the induction period, 9%\nexperienced an infusion reaction during the maintenance period.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In a clinical\nstudy of patients with rheumatoid arthritis (ASPIRE), </span><span lang=\"EN-GB\">infusions\nwere to be administered over 2\u00a0hours for the first 3\u00a0infusions. The\nduration of subsequent infusions could be shortened to not less than\n40\u00a0minutes in patients who did not experience serious infusion reactions.\nIn this trial, </span><span lang=\"EN-GB\">sixty six percent of the patients (686\nout of 1,040) received at least one shortened infusion of 90\u00a0minutes or\nless and 44% of the patients (454 out of 1,040) received at least one shortened\ninfusion of 60\u00a0minutes or less. Of the infliximab</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">treated patients who received at least one shortened infusion,\ninfusion\u2011related reactions occurred in 15% of patients and serious\ninfusion reactions occurred in 0.4% of patients.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In a clinical study of patients with\nCrohn\u2019s disease (SONIC), infusion\u2011related reactions occurred in\n16.6% (27/163) of patients receiving infliximab monotherapy, 5% (9/179) of\npatients receiving infliximab in combination with AZA, and 5.6% (9/161) of\npatients receiving AZA monotherapy. </span><span lang=\"EN-GB\">One</span><span lang=\"EN-GB\"> serious infusion reaction (&lt;\u00a01%) occurred in a patient on\ninfliximab monotherapy.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">In post\u2011marketing\nexperience, cases of anaphylactic\u2011like reactions, including\nlaryngeal/pharyngeal oedema and severe bronchospasm, and seizure have been\nassociated with Remicade administration </span><span lang=\"EN-GB\">(see\nsection\u00a04.4)</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cases of transient visual loss occurring\nduring or within 2\u00a0hours of Remicade infusion have been reported. Events\n(some fatal) of m</span><span lang=\"EN-GB\">yocardial ischaemia/infarction and\narrhythmia have been reported, some in close temporal association with infusion\nof infliximab; </span><span lang=\"EN-GB\">cerebrovascular accidents have also been\nreported in close temporal association with infusion of infliximab</span><span lang=\"EN-GB\">.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infusion\nreactions following re\u2011administration of Remicade</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">A clinical study in patients with moderate to\nsevere psoriasis was designed to assess the efficacy and safety of long\u2011term\nmaintenance therapy versus re\u2011treatment with an induction regimen of\nRemicade (maximum of four infusions at 0, 2, 6 and 14\u00a0weeks) following\ndisease flare. Patients did not receive any concomitant immunosuppressant\ntherapy. In the re\u2011treatment arm, 4% (8/219) of patients experienced a\nserious infusion reaction versus &lt;\u00a01% (1/222) on maintenance therapy.\nThe majority of serious infusion reactions occurred during the second infusion\nat week\u00a02. The interval between the last maintenance dose and the first re\u2011induction\ndose ranged from 35\u2011231\u00a0days. Symptoms included, but were not\nlimited to, dyspnea, urticaria, facial oedema, and hypotension. In all cases,\nRemicade treatment was discontinued and/or other treatment instituted with\ncomplete resolution of signs and symptoms.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Delayed\nhypersensitivity</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical studies delayed\nhypersensitivity reactions have been uncommon and have occurred after Remicade\u2011free\nintervals of less than 1\u00a0year. In the psoriasis studies, delayed\nhypersensitivity reactions occurred early in the treatment course. Signs and\nsymptoms included myalgia and/or arthralgia with fever and/or rash, with some\npatients experiencing pruritus, facial, hand or lip oedema, dysphagia, urticaria,\nsore throat and headache.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There are insufficient data on the\nincidence of delayed hypersensitivity reactions after Remicade\u2011free\nintervals of more than 1\u00a0year but limited data from clinical studies\nsuggest an increased risk for delayed hypersensitivity with increasing Remicade\u2011free\ninterval </span><span lang=\"EN-GB\">(see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">In a 1\u2011year\nclinical study with repeated infusions in patients with Crohn's disease (ACCENT\nI study), the incidence of serum sickness\u2011like reactions was 2.4%.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immunogenicity</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients who developed antibodies to\ninfliximab were more likely (approximately 2\u20113\u00a0fold) to develop\ninfusion\u2011related reactions. Use of concomitant immunosuppressant agents\nappeared to reduce the frequency of infusion\u2011related reactions.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical studies using single and multiple\ninfliximab doses ranging from 1 to 20\u00a0mg/kg, antibodies to infliximab were\ndetected in 14% of\u00a0patients with any immunosuppressant therapy, and in 24%\nof\u00a0patients without immunosuppressant therapy. In rheumatoid arthritis\npatients who received the recommended repeated treatment dose regimens with\nmethotrexate, 8% of\u00a0patients developed antibodies to infliximab. In\npsoriatic arthritis patients who received 5\u00a0mg/kg with and without\nmethotrexate, antibodies occurred overall in 15% of patients (antibodies occurred\nin 4% of patients receiving methotrexate and in 26% of patients not receiving\nmethotrexate at baseline). In Crohn's disease patients who received maintenance\ntreatment, antibodies to infliximab occurred overall in 3.3% of patients receiving\nimmunosuppressants and in 13.3% of patients not receiving immunosuppressants.\nThe antibody incidence was 2\u20113\u00a0fold higher for patients treated\nepisodically. Due to methodological limitations, a negative assay did not\nexclude the presence of antibodies to infliximab. Some patients who developed\nhigh titres of antibodies to infliximab had evidence of reduced efficacy. In\npsoriasis patients treated with infliximab as a maintenance regimen in the\nabsence of concomitant immunomodulators, approximately 28% developed antibodies\nto infliximab (see section\u00a04.4: \u201cInfusion reactions and\nhypersensitivity\u201d).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infections</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tuberculosis, bacterial infections,\nincluding sepsis and pneumonia, invasive fungal, viral, and other opportunistic\ninfections have been observed in patients receiving Remicade. Some of these\ninfections have been fatal; the most frequently reported opportunistic\ninfections </span><span lang=\"EN-GB\">with a mortality rate of &gt;\u00a05% </span><span lang=\"EN-GB\">include pneumocystosis, candidiasis, listeriosis and aspergillosis\n(see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical studies 36% of infliximab\u2011treated\npatients were treated for infections compared with 25% of placebo\u2011treated\npatients.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In rheumatoid arthritis clinical studies,\nthe incidence of serious infections including pneumonia was higher in\ninfliximab plus methotrexate\u2011treated patients compared with methotrexate\nalone especially at doses of 6\u00a0mg/kg or greater (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In post\u2011marketing spontaneous\nreporting, infections are the most common serious adverse reaction. Some of the\ncases have resulted in a fatal outcome. Nearly 50% of reported deaths have been\nassociated with infection. Cases of tuberculosis, sometimes fatal, including\nmiliary tuberculosis and tuberculosis with extra\u2011pulmonary location have\nbeen reported (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Malignancies and lymphoproliferative disorders</span></u></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">In clinical studies with infliximab </span><span lang=\"EN-GB\">in which 5,780\u00a0patients were treated,</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> representing </span><span lang=\"EN-GB\">5,494</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0patient years, </span><span lang=\"EN-GB\">5\u00a0</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">cases\nof lymphomas and </span><span lang=\"EN-GB\">26\u00a0non\u2011lymphoma\nmalignancies</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> were\ndetected as compared with </span><span lang=\"EN-GB\">no lymphomas and 1\u00a0non\u2011lymphoma\nmalignancy</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> in 1,600\u00a0placebo\u2011treated\npatients representing</span><span lang=\"EN-GB\"> 941</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0patient years.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In long\u2011term\nsafety follow\u2011up of clinical studies with infliximab of up to 5\u00a0years,\nrepresenting 6,234\u00a0patients\u2011years (3,210\u00a0patients), 5\u00a0cases\nof lymphoma and 38\u00a0cases of non\u2011lymphoma malignancies were reported.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Cases of malignancies, including lymphoma, have\nalso been reported in the post\u2011marketing setting </span><span lang=\"EN-GB\">(see\nsection\u00a04.4).</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In an\nexploratory clinical study involving patients with moderate to severe COPD who\nwere either current smokers or ex\u2011smokers, 157\u00a0adult patients were\ntreated with Remicade at doses similar to those used in rheumatoid arthritis\nand Crohn\u2019s disease. Nine of these patients developed malignancies,\nincluding 1\u00a0lymphoma. The median duration of follow\u2011up was 0.8\u00a0years\n(incidence 5.7% [95% CI 2.65%\u201110.6%]. There was one reported malignancy\namongst 77\u00a0control patients (median duration of follow\u2011up 0.8\u00a0years;\nincidence 1.3% [95% CI 0.03%\u20117.0%]). The majority of the malignancies\ndeveloped in the lung or head and neck.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">A population\u2011based retrospective\ncohort study found an increased incidence of cervical cancer in women with\nrheumatoid arthritis treated with infliximab compared to biologics\u2011na\u00efve\npatients or the general population, including those over 60\u00a0years of age\n(see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In addition, post\u2011marketing cases of\nhepatosplenic T\u2011cell lymphoma have been reported in patients treated with\nRemicade with the vast majority of cases occurring in Crohn\u2019s disease </span><span lang=\"EN-GB\">and ulcerative colitis, and most of whom were adolescent or young\nadult males</span><span lang=\"EN-GB\"> (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Heart\nfailure</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In a Phase II study aimed at evaluating\nRemicade in CHF, higher incidence of mortality due to worsening of heart\nfailure were seen in patients treated with Remicade, especially those treated\nwith the higher dose of 10\u00a0mg/kg (i.e. twice the maximum approved dose).\nIn this study 150\u00a0patients with NYHA Class III\u2011IV CHF (left\nventricular ejection fraction \u2264\u00a035%) were treated with\n3\u00a0infusions of Remicade 5\u00a0mg/kg, 10\u00a0mg/kg, or placebo over 6\u00a0weeks.\nAt 38\u00a0weeks, 9 of 101\u00a0patients treated with Remicade (2 at 5\u00a0mg/kg\nand 7 at 10\u00a0mg/kg) died compared to one death among the 49\u00a0patients\non placebo.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There have been post\u2011marketing\nreports of worsening heart failure, with and without identifiable precipitating\nfactors, in patients taking Remicade. There have also been post\u2011marketing\nreports of new onset heart failure, including heart failure in patients without\nknown pre\u2011existing cardiovascular disease. Some of these patients have\nbeen under 50\u00a0years of age.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\nevents</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical studies, mild or moderate\nelevations of ALT and AST have been observed in patients receiving Remicade\nwithout progression to severe hepatic injury. Elevations of ALT \u2265\u00a05\u00a0x\u00a0Upper\nLimit of Normal (ULN) have been observed (see Table\u00a02). Elevations of\naminotransferases were observed (ALT more common than AST) in a greater\nproportion of patients receiving Remicade than in controls, both when Remicade\nwas given as monotherapy and when it was used in combination with other\nimmunosuppressive agents. Most aminotransferase abnormalities were transient;\nhowever, a small number of patients experienced more prolonged elevations. In\ngeneral, patients who developed ALT and AST elevations were asymptomatic, and\nthe abnormalities decreased or resolved with either continuation or\ndiscontinuation of Remicade, or modification of concomitant therapy.<i> </i>In\npost\u2011marketing surveillance, cases of jaundice and hepatitis, some with\nfeatures of autoimmune hepatitis, have been reported in patients receiving\nRemicade (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"9\" style=\"width:457.9pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"611\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a02</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Proportion of patients with increased ALT activity\n  in clinical studies</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td rowspan=\"2\" style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Indication</span></p>\n</td>\n<td colspan=\"2\" style=\"width:99.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"133\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Number of patients<sup>3</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:99.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"133\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median follow\u2011up (wks)<sup>4</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:98.55pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a03\u00a0x ULN</span></p>\n</td>\n<td colspan=\"2\" style=\"width:100.25pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a05\u00a0x ULN</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Rheumatoid\n  arthritis<sup>1</sup></span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">375</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,087</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.3</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.2%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.9%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.8%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.9%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Crohn\u2019s\n  disease<sup>2</sup></span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">324</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1034</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.7</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">54.0</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.9%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Crohn\u2019s disease</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">139</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.0</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.4%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ulcerative\n  colitis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">242</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">482</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.8</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.2%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.5%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Ulcerative colitis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">60</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">49.4</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.7%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.7%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ankylosing\n  spondylitis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">76</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">275</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">24.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">101.9</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">9.5%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.6%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Psoriatic\n  arthritis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">98</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">191</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">18.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">39.1</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.8%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Plaque psoriasis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">281</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,175</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">16.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">50.1</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.7%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.4%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"9\" style=\"width:457.9pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"611\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">1</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients received methotrexate while infliximab patients received both\n  infliximab and methotrexate.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">2</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients in the 2\u00a0Phase III studies in Crohn\u2019s disease, ACCENT I and\n  ACCENT II, received an initial dose of 5\u00a0mg/kg infliximab at study start\n  and were on placebo in the maintenance phase. Patients who were randomised to\n  the placebo maintenance group and then later crossed over to infliximab are\n  included in the infliximab group in the ALT analysis. In the Phase IIIb trial\n  in Crohn\u2019s disease, SONIC, placebo patients received AZA 2.5\u00a0mg/kg/day\n  as active control in addition to placebo infliximab infusions.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">3</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Number\n  of patients evaluated for ALT.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">4</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Median\n  follow\u2011up is based on patients treated.</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Antinuclear\nantibodies (ANA)/Anti\u2011double\u2011stranded DNA (dsDNA) antibodies</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Approximately half of infliximab\u2011treated\npatients in clinical studies who were ANA negative at baseline developed a\npositive ANA during the study compared with approximately one\u00a0fifth of\nplacebo\u2011treated patients. Anti\u2011dsDNA antibodies were newly detected\nin approximately 17% of infliximab\u2011treated patients compared with 0% of\nplacebo\u2011treated patients. At the last evaluation, 57% of infliximab\u2011treated\npatients remained anti\u2011dsDNA positive. Reports of lupus and lupus\u2011like\nsyndromes, however, remain uncommon (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Paediatric\npopulation</span></u></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Juvenile\nrheumatoid arthritis patients</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade was studied in a clinical study </span><span lang=\"EN-GB\">in</span><span lang=\"EN-GB\"> 120\u00a0patients </span><span lang=\"EN-GB\">(age range: 4\u201117\u00a0years old) </span><span lang=\"EN-GB\">with\nactive juvenile rheumatoid arthritis despite methotrexate. </span><span lang=\"EN-GB\">Patients received 3 or 6\u00a0mg/kg infliximab as a 3\u2011dose\ninduction regimen (weeks\u00a00, 2, 6 or weeks\u00a014, 16, 20\u00a0respectively)\nfollowed by maintenance therapy every 8\u00a0weeks, in combination with methotrexate.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion\nreactions</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infusion reactions occurred in 35% of\npatients with juvenile rheumatoid arthritis receiving 3\u00a0mg/kg compared\nwith 17.5% of patients receiving 6\u00a0mg/kg. In the 3\u00a0mg/kg Remicade\ngroup, 4 out of 60\u00a0patients had a serious infusion reaction and\n3\u00a0patients reported a possible anaphylactic reaction (2 of which were\namong the serious infusion reactions). In the 6\u00a0mg/kg group, 2 out of 57\u00a0patients\nhad a serious infusion reaction, one of whom had a possible anaphylactic\nreaction (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Immunogenicity</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Antibodies to infliximab developed in 38%\nof patients receiving 3\u00a0mg/kg compared with 12% of patients receiving 6\u00a0mg/kg.\nThe antibody titres were notably higher for the 3\u00a0mg/kg compared to the 6\u00a0mg/kg\ngroup.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infections occurred in 68% (41/60) of\nchildren receiving 3\u00a0mg/kg over 52\u00a0weeks, 65% (37/57) of children\nreceiving infliximab 6\u00a0mg/kg over 38\u00a0weeks and 47% (28/60) of\nchildren receiving placebo over 14\u00a0weeks (see section\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\nCrohn\u2019s disease patients</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The following adverse reactions were\nreported more commonly in paediatric Crohn\u2019s disease patients in the\nREACH study (see section\u00a05.1) than in adult Crohn\u2019s disease\npatients: anaemia (10.7%), blood in stool (9.7%), leucopenia (8.7%), flushing\n(8.7%), viral infection (7.8%), neutropenia (6.8%), bacterial infection (5.8%),\nand respiratory tract allergic reaction (5.8%). In addition, bone fracture\n(6.8%) was reported, however, a causal association has not been established. Other\nspecial considerations are discussed below.</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion\u2011related\nreactions</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In REACH, 17.5% of randomised patients\nexperienced 1 or more infusion reactions. There were no serious infusion\nreactions, and 2\u00a0subjects in REACH had non\u2011serious anaphylactic\nreactions.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Immunogenicity</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Antibodies to infliximab were detected in 3\n(2.9%) paediatric patients.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the REACH study, infections were\nreported in 56.3% of randomised subjects treated with infliximab. Infections\nwere reported more frequently for subjects who received q8\u00a0week as opposed\nto q12\u00a0week infusions (73.6% and 38.0%, respectively), while serious\ninfections were reported for 3\u00a0subjects in the q8\u00a0week and\n4\u00a0subjects in the q12\u00a0week maintenance treatment group. The most\ncommonly reported infections were upper respiratory tract infection and\npharyngitis, and the most commonly reported serious infection was abscess.\nThree cases of pneumonia (1\u00a0serious) and 2\u00a0cases of herpes zoster\n(both non\u2011serious) were reported.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\nulcerative colitis patients</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Overall, the adverse reactions reported in\nthe paediatric ulcerative colitis trial (C0168T72) and adult ulcerative colitis\n(ACT\u00a01 and ACT\u00a02) studies were generally consistent. In C0168T72, the\nmost common adverse reactions were upper respiratory tract infection,\npharyngitis, abdominal pain, fever, and headache. The most common adverse event\nwas worsening of ulcerative colitis, the incidence of which was higher in\npatients on the q12\u00a0week vs. the q8\u00a0week dosing regimen.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion\u2011related\nreactions</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Overall, 8 (13.3%) of 60\u00a0treated patients\nexperienced one or more infusion reactions, with 4 of 22 (18.2%) in the q8\u00a0week\nand 3 of 23 (13.0%) in the q12\u00a0week treatment maintenance group. No\nserious infusion reactions were reported. All infusion reactions were mild or\nmoderate in intensity.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Immunogenicity</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Antibodies to infliximab were detected in\n4\u00a0(7.7%) patients through week\u00a054.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infections were reported in 31 (51.7%) of\n60\u00a0treated patients in C0168T72 and 22 (36.7%) required oral or parenteral\nantimicrobial treatment. The proportion of patients with infections in C0168T72\nwas similar to that in the paediatric Crohn\u2019s disease study (REACH) but\nhigher than the proportion in the adults ulcerative colitis studies (ACT\u00a01\nand ACT\u00a02). The overall incidence of infections in C0168T72 was 13/22\n(59%) in the every 8\u00a0week maintenance treatment group and 14/23 (60.9%) in\nthe every 12\u00a0week maintenance treatment group. Upper respiratory tract\ninfection (7/60 [12%]) and pharyngitis (5/60 [8%]) were the most frequently\nreported respiratory system infections. Serious infections were reported in 12%\n(7/60) of all treated patients.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In this study, there were more patients in\nthe 12 to 17\u00a0year age group than in the 6 to 11\u00a0year age group (45/60\n[75.0%]) vs.15/60 [25.0%]). While the numbers of patients in each subgroup are\ntoo small to make any definitive conclusions about the effect of age on safety\nevents, there were higher proportions of patients with serious adverse events\nand discontinuation due to adverse events in the younger age group than in the older\nage group. While the proportion of patients with infections was also higher in\nthe younger age group, for serious infections, the proportions were similar in\nthe two age groups. Overall proportions of adverse events and infusion\nreactions were similar between the 6 to 11 and 12 to 17\u00a0year age groups.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Post\u2011marketing\nexperience</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Post\u2011marketing spontaneous serious\nadverse reactions with infliximab in the paediatric population have included\nmalignancies including hepatosplenic T\u2011cell lymphomas, transient hepatic\nenzyme abnormalities, lupus\u2011like syndromes, and positive auto\u2011antibodies\n(see sections\u00a04.4 and 4.8).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Additional\ninformation on special populations</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">In rheumatoid\narthritis clinical studies, the incidence of serious infections was greater in\ninfliximab plus methotrexate\u2011treated patients 65\u00a0years and older\n(11.3%) than in those under 65\u00a0years of age (</span><span lang=\"EN-GB\">4.6%).\nIn patients treated with methotrexate alone, the incidence of serious\ninfections<span style=\"layout-grid-mode:line\"> was 5.2% </span>in patients 65\u00a0years\nand older compared to 2.7% in patients under 65 </span><span lang=\"EN-GB\">(see\nsection\u00a04.4).</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after\nauthorisation of the medicinal product is important. It allows continued\nmonitoring of the benefit/risk balance of the medicinal product. Healthcare\nprofessionals are asked to report any suspected adverse reactions <span style=\"background:silver\">via the national reporting system listed in <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a></span>.</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">No case of overdose has been reported.\nSingle doses up to 20\u00a0mg/kg have been administered without toxic effects.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pharmacotherapeutic group: </span><a name=\"_Hlk509410677\"><span lang=\"EN-GB\">Immunosuppressants</span></a><span lang=\"EN-GB\">, tumour necrosis factor alpha (TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">) inhibitors, ATC\ncode: L04AB02.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Mechanism\nof action</span></u></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab is a chimeric human\u2011murine\nmonoclonal antibody that binds with high affinity to both soluble and\ntransmembrane forms of TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> but not to lymphotoxin </span><span lang=\"EN-GB\" style=\"font-family:\nSymbol\">a</span><span lang=\"EN-GB\"> (TNF<sub>\u00df</sub>).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Pharmacodynamic\neffects</span></u></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab inhibits the functional activity\nof TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> in a wide variety of <i>in vitro </i>bioassays. Infliximab\nprevented disease in transgenic mice that develop polyarthritis as a result of\nconstitutive expression of human TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> and when\nadministered after disease onset, it allowed eroded joints to heal. <i>In vivo</i>,\ninfliximab rapidly forms stable complexes with human TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">, a\nprocess that parallels the loss of TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> bioactivity.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Elevated concentrations of TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> have been\nfound in the joints of rheumatoid arthritis patients and correlate with\nelevated disease activity. In rheumatoid arthritis, treatment with infliximab\nreduced infiltration of inflammatory cells into inflamed areas of the joint as\nwell as expression of molecules mediating cellular adhesion, chemoattraction\nand tissue degradation. After infliximab treatment, patients exhibited\ndecreased levels of serum interleukin\u00a06 (IL\u20116) and C\u2011reactive\nprotein (CRP)<b>, </b>and increased haemoglobin levels in rheumatoid arthritis\npatients with reduced haemoglobin levels, compared with baseline. Peripheral\nblood lymphocytes further showed no significant decrease in number or in\nproliferative responses to <i>in vitro</i> mitogenic stimulation when compared\nwith untreated patients\u2019 cells. In psoriasis patients, treatment with\ninfliximab resulted in decreases in epidermal inflammation and normalisation of\nkeratinocyte differentiation in psoriatic plaques. In psoriatic arthritis,\nshort term treatment with Remicade reduced the number of T\u2011cells and\nblood vessels in the synovium and psoriatic skin.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Histological evaluation of colonic\nbiopsies, obtained before and 4\u00a0weeks after administration of infliximab,\nrevealed a substantial reduction in detectable TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">. Infliximab\ntreatment of Crohn\u2019s disease patients was also associated with a substantial\nreduction of the commonly elevated serum inflammatory marker, CRP. Total\nperipheral white blood cell counts were minimally affected in infliximab\u2011treated\npatients, although changes in lymphocytes, monocytes and neutrophils reflected\nshifts towards normal ranges. Peripheral blood mononuclear cells (PBMC) from\ninfliximab\u2011treated patients showed undiminished proliferative\nresponsiveness to stimuli compared with untreated patients, and no substantial\nchanges in cytokine production by stimulated PBMC were observed following\ntreatment with infliximab. Analysis of lamina propria mononuclear cells\nobtained by biopsy of the intestinal mucosa showed that infliximab treatment\ncaused a reduction in the number of cells capable of expressing TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> and\ninterferon</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">g</span><span lang=\"EN-GB\">. Additional histological studies provided evidence that treatment\nwith infliximab reduces the infiltration of inflammatory cells into affected\nareas of the intestine and the presence of inflammation markers at these sites.\nEndoscopic studies of intestinal mucosa have shown evidence of mucosal healing\nin infliximab\u2011treated patients.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Clinical\nefficacy and safety</span></u></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Adult\nrheumatoid arthritis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of infliximab was assessed in\ntwo multicentre, randomised, double\u2011blind,<b> </b>pivotal clinical\nstudies: ATTRACT and ASPIRE. In both studies concurrent use of stable doses of\nfolic acid, oral corticosteroids (\u2264\u00a010\u00a0mg/day) and/or non\u2011steroidal\nantiinflammatory drugs (NSAIDs) was permitted.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoints were the reduction of\nsigns and symptoms as assessed by the American College of Rheumatology criteria\n(ACR20 for ATTRACT, landmark ACR\u2011N for ASPIRE), the prevention of\nstructural joint damage, and the improvement in physical function. A reduction\nin signs and symptoms was defined to be at least a 20% improvement (ACR20) in\nboth tender and swollen joint counts, and in 3 of the following 5\u00a0criteria:\n(1) evaluator\u2019s global assessment, (2) patient\u2019s global assessment,\n(3) functional/disability measure, (4) visual analogue pain scale and (5)\nerythrocyte sedimentation rate or C\u2011reactive protein. ACR\u2011N uses\nthe same criteria as the ACR20, calculated by taking the lowest percent\nimprovement in swollen joint count, tender joint count, and the median of the\nremaining 5\u00a0components of the ACR response. Structural joint damage (erosions\nand joint space narrowing) in both hands and feet was measured by the change\nfrom baseline in the total van der Heijde\u2011modified Sharp score (0\u2011440).\nThe Health Assessment Questionnaire (HAQ; scale\u00a00\u20113) was used to\nmeasure patients\u2019 average change from baseline scores over time, in\nphysical function.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The ATTRACT study evaluated responses at\n30, 54 and 102\u00a0weeks in a placebo\u2011controlled study of 428\u00a0patients\nwith active rheumatoid arthritis despite treatment with methotrexate.\nApproximately 50% of patients were in functional Class III. Patients received\nplacebo, 3\u00a0mg/kg or 10\u00a0mg/kg infliximab at weeks\u00a00, 2 and 6, and\nthen every 4 or 8\u00a0weeks thereafter. All patients were on stable\nmethotrexate doses (median 15\u00a0mg/wk) for 6\u00a0months prior to enrolment\nand were to remain on stable doses throughout the study.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Results from week\u00a054 (ACR20, total van\nder Heijde\u2011modified Sharp score and HAQ) are shown in Table\u00a03.\nHigher degrees of clinical response (ACR50 and ACR70) were observed in all\ninfliximab groups at 30 and 54\u00a0weeks compared with methotrexate alone.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">A reduction in the rate of the progression\nof structural joint damage (erosions and joint space narrowing) was observed in\nall infliximab groups at 54\u00a0weeks (Table\u00a03).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The effects observed at 54\u00a0weeks were\nmaintained through 102\u00a0weeks. Due to a number of treatment withdrawals,\nthe magnitude of the effect difference between infliximab and the methotrexate\nalone group cannot be defined.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Table\u00a03</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Effects on ACR20,\n  Structural Joint Damage and Physical Function at week\u00a054, ATTRACT</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:204.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"273\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td colspan=\"5\" style=\"width:257.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" width=\"343\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span><sup><span lang=\"EN-GB\">b</span></sup></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"205\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Control</span><sup><span lang=\"EN-GB\">a</span></sup></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">All infliximab</span><sup><span lang=\"EN-GB\">b</span></sup></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with\n  ACR20 response/</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients\n  evaluated (%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">15/88</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(17%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">36/86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(42%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">41/86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">51/87</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">48/81</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">176/340</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(52%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Total score</span><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> (van der\n  Heijde\u2011modified Sharp score)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Change from\n  baseline (Mean \u00b1 SD</span><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\">)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.0\u00a0\u00b1\u00a010.3</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.3\u00a0\u00b1\u00a06.0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.6\u00a0\u00b1\u00a08.5</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.2\u00a0\u00b1\u00a03.6</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u20110.7\u00a0\u00b1\u00a03.8</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6\u00a0\u00b1\u00a05.9</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(Interquartile\n  range)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.5,9.7)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,3.0)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20112.5,3.0)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,2.0)</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">\u20110.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20113.0,1.5)</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.8,2.0)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with no\n  deterioration/patients evaluated (%)</span><sup><span lang=\"EN-GB\">c</span></sup></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">13/64</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">34/71</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">35/71</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(49%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">37/77</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">44/66</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(67%)</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">150/285</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(53%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:\n  line\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">HAQ change from\n  baseline over time<sup>e</sup> (patients evaluated)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">86</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">85</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">81</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">339</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Mean \u00b1 SD</span><sup><span lang=\"EN-GB\">c</span></sup></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.2\u00a0\u00b1\u00a00.3</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.3</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.4</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.5</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 control\u00a0=\u00a0</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">All patients had active RA despite\n  treatment with stable methotrexate doses for 6\u00a0months prior to enrolment\n  and were to remain on stable doses throughout the study. Concurrent use of\n  stable doses of oral corticosteroids (\u2264\u00a010\u00a0mg/day) and/or\n  NSAIDs was permitted, and folate supplementation was given.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 all\n  infliximab doses given in combination with methotrexate and</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> folate with some on corticosteroids\n  and/or NSAIDs</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">e</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The ASPIRE study evaluated responses at\n54\u00a0weeks in 1,004\u00a0methotrexate naive patients with early (<span style=\"layout-grid-mode:line\">\u2264\u00a03\u00a0years disease duration, median\n0.6\u00a0years) </span>active rheumatoid arthritis (median swollen and tender\njoint count of 19 and 31, respectively). All patients received methotrexate\n(optimised to 20\u00a0mg/wk by week\u00a08) and either placebo, 3\u00a0mg/kg or\n6\u00a0mg/kg infliximab at weeks\u00a00, 2, and 6 and every 8\u00a0weeks\nthereafter. Results from week\u00a054 are shown in Table\u00a04.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">After 54\u00a0weeks of treatment, both\ndoses of infliximab + methotrexate resulted in statistically significantly\ngreater improvement in signs and symptoms compared to methotrexate alone as\nmeasured by the proportion of patients achieving ACR20, 50 and\n70\u00a0responses.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In ASPIRE, more than 90% of patients had at\nleast two evaluable X\u2011rays. Reduction in the rate of progression of\nstructural damage was observed at weeks\u00a030 and 54 in the infliximab +\nmethotrexate groups compared to methotrexate alone.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"5\" style=\"width:452.25pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"603\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a04</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on ACRn, Structural Joint Damage and\n  Physical Function at week\u00a054, ASPIRE</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:254.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"339\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:197.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"264\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab +\u00a0MTX</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo +\u00a0MTX</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">6\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combined</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Subjects randomised</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">282</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">359</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">363</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">722</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Percentage ACR improvement</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24.8\u00a0\u00b1\u00a059.7</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">37.3\u00a0\u00b1\u00a052.8</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">42.0\u00a0\u00b1\u00a047.3</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">39.6\u00a0\u00b1\u00a050.1</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Change from baseline in total van der\n  Heijde\u2011modified Sharp score<sup>b</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3.70\u00a0\u00b1\u00a09.61</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.42\u00a0\u00b1\u00a05.82</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.51\u00a0\u00b1\u00a05.55</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.46\u00a0\u00b1\u00a05.68</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.43</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Improvement from baseline in HAQ averaged\n  over time from week\u00a030 to week\u00a054<sup>c</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>d</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.68\u00a0\u00b1\u00a00.63</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.80\u00a0\u00b1\u00a00.65</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.88\u00a0\u00b1\u00a00.65</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.84\u00a0\u00b1\u00a00.65</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"5\" style=\"width:452.25pt;border:none;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"603\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control.</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 p\u00a0=\u00a00.030\n  and &lt;\u00a00.001 for the 3\u00a0mg/kg and 6\u00a0mg/kg treatment groups\n  respectively vs. placebo + MTX.</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Data to support\ndose titration in rheumatoid arthritis come from ATTRACT, ASPIRE and the START\nstudy. START was a randomised, multicenter, double\u2011blind, 3\u2011arm,\nparallel\u2011group safety study. In one of the study arms (group 2, n\u00a0=\u00a0329),\npatients with an inadequate response were allowed to dose titrate with 1.5\u00a0mg/kg\nincrements from 3 up to 9\u00a0mg/kg. <a name=\"OLE_LINK2\">The majority (67%) of\nthese patients did not require any dose titration. </a>Of the patients who\nrequired a dose titration, 80% achieved clinical response and the majority\n(64%) of these required only one adjustment of 1.5\u00a0mg/kg.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Adult Crohn\u2019s disease</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Induction\ntreatment in moderately to severely active Crohn\u2019s disease</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of a single dose treatment\nwith infliximab was assessed in 108\u00a0patients with active Crohn\u2019s\ndisease (Crohn\u2019s Disease Activity Index (CDAI)\u00a0\u2265\u00a0220\u00a0\u2264\u00a0400)\nin a randomised, double\u2011blinded, placebo\u2011controlled, dose\u2011response\nstudy. Of these 108\u00a0patients, 27 were treated with the recommended dosage\nof infliximab 5\u00a0mg/kg. All patients had experienced an inadequate response\nto prior conventional therapies. Concurrent use of stable doses of conventional\ntherapies was permitted, and 92% of patients continued to receive these\ntherapies.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint was the proportion of\npatients who experienced a clinical response, defined as a decrease in CDAI by \u2265\u00a070\u00a0points\nfrom baseline at the 4\u2011week evaluation and without an increase in the use\nof medicinal products or surgery for Crohn\u2019s disease. Patients who\nresponded at week\u00a04 were followed to week\u00a012. Secondary endpoints\nincluded the proportion of patients in clinical remission at week\u00a04\n(CDAI\u00a0&lt;\u00a0150) and clinical response over time.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">At week\u00a04, following administration of\na single dose, 22/27\u00a0(81%) of infliximab\u2011treated patients receiving\na 5\u00a0mg/kg dose achieved a clinical response vs. 4/25\u00a0(16%) of the\nplacebo\u2011treated patients (p\u00a0&lt;\u00a00.001). Also at week\u00a04,\n13/27\u00a0(48%) of infliximab\u2011treated patients achieved a clinical\nremission (CDAI\u00a0&lt;\u00a0150) vs. 1/25\u00a0(4%) of placebo\u2011treated\npatients. A response was observed within 2\u00a0weeks, with a maximum response\nat 4\u00a0weeks. At the last observation at 12\u00a0weeks, 13/27\u00a0(48%) of\ninfliximab\u2011treated patients were still responding.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Maintenance\ntreatment in moderately to severely active Crohn\u2019s disease in adults</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of repeated infusions with\ninfliximab was studied in a 1\u2011year clinical study (ACCENT I).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">A total of 573\u00a0patients with\nmoderately to severely active Crohn\u2019s disease (CDAI\u00a0\u2265\u00a0220\u00a0\u2264\u00a0400)\nreceived a single infusion of 5\u00a0mg/kg at week\u00a00. 178 of the\n580\u00a0enrolled patients (30.7%) were defined as having severe disease (CDAI\nscore &gt;\u00a0300 and concomitant corticosteroid and/or immunosuppressants)\ncorresponding to the population defined in the indication (see section\u00a04.1).\nAt week\u00a02, all patients were assessed for clinical response and randomised\nto one of 3\u00a0treatment groups; a placebo maintenance group, 5\u00a0mg/kg\nmaintenance group and 10\u00a0mg/kg maintenance group. All 3\u00a0groups\nreceived repeated infusions at week\u00a02, 6 and every 8\u00a0weeks\nthereafter.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Of the 573\u00a0patients randomised, 335\n(58%) achieved clinical response by week\u00a02. These patients were classified\nas week\u20112 responders and were included in the primary analysis (see Table\u00a05).\nAmong patients classified as non\u2011responders at week\u00a02, 32% (26/81)\nin the placebo maintenance group and 42% (68/163) in the infliximab group\nachieved clinical response by week\u00a06. There was no difference between\ngroups in the number of late responders thereafter.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The co\u2011primary endpoints were the\nproportion of patients in clinical remission (CDAI\u00a0&lt;\u00a0150) at week\u00a030\nand time to loss of response through week\u00a054. Corticosteroid tapering was\npermitted after week\u00a06.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a05</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on response and remission rate, data from\n  ACCENT I (week\u20112 responders)</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:325.95pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"435\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">ACCENT I (week\u20112 responders)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">% of Patients</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0110)</span></p>\n</td>\n<td style=\"width:108.65pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0113)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(p value)</span></p>\n</td>\n<td style=\"width:108.65pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0112)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(p value)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median time to loss of response through week\u00a054</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19\u00a0weeks</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38\u00a0weeks</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.002)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&gt;\u00a054\u00a0weeks</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a030</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Response<sup>a</sup></span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.3</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">51.3</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">59.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Remission</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">20.9</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.9</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.003)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Steroid\u2011Free Remission</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">10.7\n  (6/56)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">31.0\n  (18/58)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.008)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.8\n  (21/57)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a054</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Response<sup>a</sup></span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15.5</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47.7</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Remission</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13.6</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">28.3</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.007)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.4</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained Steroid\u2011Free Remission<sup>b</sup></span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5.7\n  (3/53)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">17.9\n  (10/56)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.075)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">28.6\n  (16/56)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.002)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Reduction\n  in CDAI \u2265\u00a025% and \u2265\u00a070\u00a0points.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 CDAI\u00a0&lt;\u00a0150\n  at both week\u00a030 and 54 and not receiving corticosteroids in the\n  3\u00a0months prior to week\u00a054 among patients who were receiving\n  corticosteroids at baseline.</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Beginning at\nweek\u00a014, patients who had responded to treatment, but subsequently lost\ntheir clinical benefit, were allowed to cross over to a dose of infliximab 5\u00a0mg/kg\nhigher than the dose to which they were originally randomised. Eighty\u00a0nine\npercent (50/56) of patients who lost clinical response on infliximab 5\u00a0mg/kg\nmaintenance therapy after week\u00a014 responded to treatment with infliximab\n10\u00a0mg/kg.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Improvements in quality of life measures, a\nreduction in disease\u2011related hospitalisations and corticosteroid use were\nseen in the infliximab maintenance groups compared with the placebo maintenance\ngroup at weeks\u00a030 and 54.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab with or without AZA was assessed\nin a randomised, double\u2011blind, active comparator study (SONIC) of 508\u00a0adult\npatients with moderate to severe Crohn\u2019s disease (CDAI\u00a0\u2265\u00a0220\u00a0\u2264\u00a0450)\nwho were naive to biologics and immunosuppressants </span><span lang=\"EN-GB\">and\nhad a median disease duration of 2.3\u00a0years. </span><span lang=\"EN-GB\">At\nbaseline 27.4% of patients were receiving systemic corticosteroids, 14.2% of\npatients were receiving budesonide, and 54.3% of patients were receiving 5\u2011ASA\ncompounds. Patients were randomised to receive AZA monotherapy, infliximab\nmonotherapy, or infliximab plus AZA combination therapy. Infliximab was\nadministered at a dose of 5\u00a0mg/kg at weeks\u00a00, 2, 6, and then every 8\u00a0weeks.\nAZA was given at a dose of 2.5\u00a0mg/kg daily.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint of the study was\ncorticosteroid\u2011free clinical remission at week\u00a026, defined as\npatients in clinical remission (CDAI of &lt;\u00a0150) who, for at least\n3\u00a0weeks, had not taken oral systemic corticosteroids (prednisone or\nequivalent) or budesonide at a dose &gt;\u00a06\u00a0mg/day. For results see\nTable\u00a06. The proportions of patients with mucosal healing at week\u00a026\u00a0were\nsignificantly greater in the infliximab plus AZA combination (43.9%,\np\u00a0&lt;\u00a00.001) and infliximab monotherapy groups (30.1%, p\u00a0=\u00a00.023)\ncompared to the AZA monotherapy group (16.5%).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a06</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Percent of patients achieving corticosteroid\u2011free\n  clinical remission at week\u00a026, SONIC</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"185\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">AZA</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab + AZA</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combination Therapy</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a026</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"185\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">All randomised patients</span></p>\n</td>\n<td style=\"width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">30.0%\n  (51/170)</span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">44.4%\n  (75/169)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(p\u00a0=\u00a00.006)<sup>*</sup></span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56.8%\n  (96/169)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(p\u00a0&lt;\u00a00.001)<sup>*</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 P\u2011values\n  represent each infliximab treatment group vs. AZA monotherapy.</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Similar trends in the achievement of\ncorticosteroid\u2011free clinical remission were observed at week\u00a050. </span><span lang=\"EN-GB\">Furthermore, improved quality of life as measured by IBDQ was\nobserved with infliximab.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Induction\ntreatment in fistulising active Crohn\u2019s disease</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy was assessed in a randomised,\ndouble\u2011blinded, placebo\u2011controlled study in 94\u00a0patients with\nfistulising Crohn\u2019s disease who had fistulae that were of at least\n3\u00a0months\u2019 duration. Thirty\u00a0one of these patients were treated\nwith infliximab 5\u00a0mg/kg. Approximately 93% of the patients had previously\nreceived antibiotic or immunosuppressive therapy.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Concurrent use of stable doses of\nconventional therapies was permitted, and 83% of patients continued to receive\nat least one of these therapies. Patients received three doses of either\nplacebo or infliximab at weeks\u00a00, 2 and 6. Patients were followed up to 26\u00a0weeks.\nThe primary endpoint was the proportion of patients who experienced a clinical\nresponse, defined as\u00a0\u2265\u00a050% reduction from baseline in the\nnumber of fistulae draining upon gentle compression on at least two consecutive\nvisits (4\u00a0weeks apart), without an increase in the use of medicinal\nproducts or surgery for Crohn\u2019s disease.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sixty\u00a0eight percent (21/31) of\ninfliximab\u2011treated patients receiving a 5\u00a0mg/kg dose regimen\nachieved a clinical response vs. 26% (8/31) placebo\u2011treated patients (p\u00a0=\u00a00.002).\nThe median time to onset of response in the infliximab\u2011treated group was\n2\u00a0weeks. The median duration of response was 12\u00a0weeks. Additionally,\nclosure of all fistulae was achieved in 55% of infliximab\u2011treated\npatients compared with 13% of placebo\u2011treated patients (p\u00a0=\u00a00.001).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Maintenance\ntreatment in fistulising active Crohn\u2019s disease</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of repeated infusions with\ninfliximab in patients with fistulising Crohn\u2019s disease was studied in a\n1\u2011year clinical study (ACCENT II). A total of 306\u00a0patients received\n3\u00a0doses of infliximab 5\u00a0mg/kg at week\u00a00, 2 and 6. At baseline,\n87% of the patients had perianal fistulae, 14% had abdominal fistulae, 9% had\nrectovaginal fistulae. The median CDAI score was 180. At week\u00a014,\n282\u00a0patients were assessed for clinical response and randomised to receive\neither placebo or 5\u00a0mg/kg infliximab every 8\u00a0weeks through week\u00a046.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u201114\u00a0responders (195/282)\nwere analysed for the primary endpoint, which was time from randomisation to\nloss of response (see Table\u00a07). Corticosteroid tapering was permitted\nafter week\u00a06.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div align=\"center\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a07</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on response rate, data from ACCENT II\n  (week\u201114\u00a0responders)</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:265.25pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"354\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ACCENT II\n  (week\u201114\u00a0responders)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:88.4pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a099)</span></p>\n</td>\n<td style=\"width:88.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(5\u00a0mg/kg)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a096)</span></p>\n</td>\n<td style=\"width:88.45pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">p\u2011value</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median time to loss of response<sup> </sup>through\n  week\u00a054</span></p>\n</td>\n<td style=\"width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14\u00a0weeks</span></p>\n</td>\n<td style=\"width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&gt;\u00a040\u00a0weeks</span></p>\n</td>\n<td style=\"width:88.45pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&lt;\u00a00.001</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a054</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Fistula Response (%)<sup>a</sup></span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">23.5</span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46.2</span></p>\n</td>\n<td style=\"width:88.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.001</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Complete fistula response (%)<sup>b</sup></span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.4</span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.3</span></p>\n</td>\n<td style=\"width:88.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.009</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;border-top:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 A\n  \u2265\u00a050% reduction from baseline in the number of draining fistulas\n  over a period of \u2265\u00a04\u00a0weeks.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Absence\n  of any draining fistulas.</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Beginning at week\u00a022, patients who\ninitially responded to treatment and subsequently lost their response were\neligible to cross over to active re\u2011treatment every 8\u00a0weeks at a\ndose of infliximab 5\u00a0mg/kg higher than the dose to which they were\noriginally randomised. Among patients in the infliximab 5\u00a0mg/kg group who\ncrossed over because of loss of fistula response after week\u00a022, 57%\n(12/21) responded to re\u2011treatment with infliximab 10\u00a0mg/kg every 8\u00a0weeks.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">There was no significant difference between\nplacebo and infliximab for the proportion of patients with sustained closure of\nall fistulas through week\u00a054, for symptoms such as proctalgia, abscesses\nand urinary tract infection or for number of newly developed fistulas during\ntreatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Maintenance therapy with infliximab every 8\u00a0weeks\nsignificantly reduced disease\u2011related hospitalisations and surgeries\ncompared with placebo. Furthermore, a reduction in corticosteroid use and\nimprovements in quality of life were observed.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Adult ulcerative\ncolitis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Remicade were\nassessed in two (ACT\u00a01 and ACT\u00a02) randomised, double\u2011blind,\nplacebo\u2011controlled clinical studies in adult patients with moderately to\nseverely active ulcerative colitis (Mayo score 6 to 12; Endoscopy subscore \u2265\u00a02)\nwith an inadequate response to conventional therapies [</span><span lang=\"EN-GB\">oral\ncorticosteroids, aminosalicylates and/or immunomodulators (6\u2011MP, AZA)]. </span><span lang=\"EN-GB\">Concomitant stable doses of oral aminosalicylates, corticosteroids,\nand/or immunomodulatory agents were permitted. In both studies, patients were\nrandomised to receive either placebo, 5\u00a0mg/kg Remicade, or 10\u00a0mg/kg\nRemicade at weeks\u00a00, 2, 6, 14 and 22, and in ACT\u00a01 at weeks\u00a030,\n38 and 46. Corticosteroid taper was permitted after week\u00a08.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div align=\"center\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a08</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on clinical response, clinical remission\n  and mucosal healing at weeks\u00a08 and\u00a030.</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Combined data from ACT\u00a01 &amp; 2</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:223.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"298\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"4\" style=\"width:230.75pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"308\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo</span></p>\n</td>\n<td style=\"width:77.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:77.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:75.3pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combined</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Subjects randomised</span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">244</span></p>\n</td>\n<td style=\"width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242</span></p>\n</td>\n<td style=\"width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242</span></p>\n</td>\n<td style=\"width:75.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">484</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical response and in sustained clinical response</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical response at week\u00a08<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.2%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">66.9%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">65.3%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">66.1%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical response at week\u00a030<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.9%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">49.6%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">55.4%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52.5%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(clinical response at both</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.3%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45.0%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">49.6%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47.3%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical remission and sustained remission</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical remission at week\u00a08<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">10.2%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.4%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">29.8%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.1%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical remission at week\u00a030<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13.1%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">29.8%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.4%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.1%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained remission</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(in remission at both</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5.3%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.0%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24.4%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">21.7%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects with mucosal healing</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mucosal healing at week\u00a08<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">32.4%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61.2%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">60.3%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">60.7%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mucosal healing at week\u00a030<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.5%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48.3%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52.9%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">50.6%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"606\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. placebo.</span></span></p>\n</td>\n</tr>\n<tr height=\"0\">\n<td style=\"border:none\" width=\"195\"></td>\n<td style=\"border:none\" width=\"103\"></td>\n<td style=\"border:none\" width=\"0\"></td>\n<td style=\"border:none\" width=\"103\"></td>\n<td style=\"border:none\" width=\"103\"></td>\n<td style=\"border:none\" width=\"100\"></td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of Remicade through week\u00a054\nwas assessed in the ACT\u00a01 study.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">At\u00a054\u00a0weeks, 44.9% of patients in\nthe combined infliximab treatment group were in clinical response compared to\n19.8% in the placebo treatment group (p\u00a0&lt;\u00a00.001). Clinical\nremission and mucosal healing occurred in a greater proportion of patients in\nthe combined infliximab treatment group compared to the placebo treatment group\nat week\u00a054 (34.6% vs. 16.5%, p\u00a0&lt;\u00a00.001 and 46.1% vs. 18.2%,\np\u00a0&lt;\u00a00.001, respectively). The proportions of patients in sustained\nresponse and sustained remission at week\u00a054 were greater in the combined\ninfliximab treatment group than in the placebo treatment group (37.9% vs.\n14.0%, p\u00a0&lt;\u00a00.001; and 20.2% vs. 6.6%, p\u00a0&lt;\u00a00.001,\nrespectively).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">A greater proportion of patients in the\ncombined infliximab treatment group were able to discontinue corticosteroids\nwhile remaining in clinical remission compared to the placebo treatment group\nat both week\u00a030 (22.3% vs. 7.2%, p\u00a0&lt;\u00a00.001, pooled ACT\u00a01\n&amp; ACT\u00a02 data) and week\u00a054 (21.0% vs. 8.9%, p\u00a0=\u00a00.022,\nACT1 data).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The pooled data\nanalysis from the ACT\u00a01 and ACT\u00a02 studies and their extensions,\nanalysed from baseline through 54\u00a0weeks, demonstrated a reduction of\nulcerative colitis\u2011related hospitalisations and surgical procedures with\ninfliximab treatment. The number of ulcerative colitis\u2011related\nhospitalisations was significantly lower in the 5 and 10\u00a0mg/kg infliximab\ntreatment groups than in the placebo group (mean number of hospitalisations per\n100\u00a0subject\u2011years: 21 and 19 vs. 40 in the placebo group; p\u00a0=\u00a00.019\nand p\u00a0=\u00a00.007, respectively). The number of ulcerative colitis\u2011related\nsurgical procedures was also lower in the 5 and 10\u00a0mg/kg infliximab\ntreatment groups than in the placebo group (mean number of surgical procedures\nper 100\u00a0subject\u2011years: 22 and 19 vs. 34<i>; </i>p\u00a0=\u00a00.145\nand p\u00a0=\u00a00.022, respectively).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The proportion\nof subjects who underwent colectomy at any time within 54\u00a0weeks following\nthe first infusion of study agent were collected and pooled from the ACT\u00a01\nand ACT\u00a02 studies and their extensions. Fewer subjects underwent colectomy\nin the 5\u00a0mg/kg infliximab group (28/242 or 11.6% [N.S.]) and the\n10\u00a0mg/kg infliximab group (18/242 or 7.4% [p\u00a0=\u00a00.011]) than in\nthe placebo group (36/244; 14.8%).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The reduction in incidence of colectomy was\nalso examined in another randomised, double\u2011blind study (C0168Y06) in\nhospitalised patients </span><span lang=\"EN-GB\">(n\u00a0=\u00a045) </span><span lang=\"EN-GB\">with moderately to severely active ulcerative colitis who failed to\nrespond to intravenous corticosteroids and who were therefore at higher risk\nfor colectomy. Significantly fewer colectomies occurred within 3\u00a0months of\nstudy infusion in patients who received a single dose of 5\u00a0mg/kg\ninfliximab compared to patients who received placebo (29.2% vs. 66.7%\nrespectively, p\u00a0=\u00a00.017).</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In ACT\u00a01 and ACT\u00a02, infliximab\nimproved quality of life, confirmed by statistically significant improvement in\nboth a disease specific measure, IBDQ, and by improvement in the generic 36\u2011item\nshort form survey SF\u201136.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Adult\nankylosing spondylitis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Efficacy and safety of infliximab were\nassessed in two multicenter, double\u2011blind, placebo\u2011controlled\nstudies in patients with active ankylosing spondylitis (Bath Ankylosing\nSpondylitis Disease Activity Index [BASDAI] score \u2265\u00a04 and spinal\npain \u2265\u00a04 on a scale of 1\u201110).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the first study (P01522), which had a\n3\u00a0month double\u2011blind phase, 70\u00a0patients received either 5\u00a0mg/kg\ninfliximab or placebo at weeks\u00a00, 2, 6 (35\u00a0patients in each group).\nAt week\u00a012, placebo patients were switched to infliximab 5\u00a0mg/kg\nevery 6\u00a0weeks up to week\u00a054. After the first year of the study,\n53\u00a0patients continued into an open\u2011label extension to week\u00a0102.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the second clinical study (ASSERT), 279\u00a0patients\nwere randomised to receive either placebo (Group\u00a01, n\u00a0=\u00a078) or 5\u00a0mg/kg\ninfliximab (Group\u00a02, n\u00a0=\u00a0201) at 0, 2 and 6\u00a0weeks and every\n6\u00a0weeks to week\u00a024. Thereafter, all subjects continued on infliximab\nevery 6\u00a0weeks to week\u00a096. Group\u00a01 received 5\u00a0mg/kg\ninfliximab. In group\u00a02, starting with the week\u00a036 infusion, patients\nwho had a BASDAI \u2265\u00a03 at 2\u00a0consecutive visits, received 7.5\u00a0mg/kg\ninfliximab every 6\u00a0weeks thereafter through week\u00a096.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In ASSERT, improvement in signs and\nsymptoms was observed as early as week\u00a02. At week\u00a024, the number of\nASAS\u00a020 responders was 15/78 (19%) in the placebo group, and 123/201 (61%)\nin the 5\u00a0mg/kg infliximab group (p\u00a0&lt;\u00a00.001). There were 95\u00a0subjects\nfrom group\u00a02 who continued on 5\u00a0mg/kg every 6\u00a0weeks. At\n102\u00a0weeks there were 80\u00a0subjects still on infliximab treatment and among\nthose, 71 (89%) were ASAS\u00a020 responders.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In P01522, improvement in signs and\nsymptoms was also observed as early as week\u00a02. At week\u00a012, the number\nof BASDAI\u00a050 responders were 3/35 (9%) in the placebo group, and 20/35\n(57%) in the 5\u00a0mg/kg group (p\u00a0&lt;\u00a00.01). There were\n53\u00a0subjects who continued on 5\u00a0mg/kg every 6\u00a0weeks. At\n102\u00a0weeks there were 49\u00a0subjects still on infliximab treatment and\namong those, 30 (61%) were BASDAI\u00a050 responders.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In both studies, physical function and\nquality of life as measured by the BASFI and the physical component score of\nthe SF\u201136 were also improved significantly.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Adult\npsoriatic arthritis</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Efficacy and safety were assessed in two\nmulticenter, double\u2011blind, placebo\u2011controlled studies in patients\nwith active psoriatic arthritis.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the first clinical study (IMPACT),\nefficacy and safety of infliximab were studied in 104\u00a0patients with active\npolyarticular psoriatic arthritis. During the 16\u2011week double\u2011blind\nphase, patients received either 5\u00a0mg/kg infliximab or placebo at weeks\u00a00,\n2, 6, and 14 (52\u00a0patients in each group). Starting at week\u00a016,\nplacebo patients were switched to infliximab and all patients subsequently\nreceived 5\u00a0mg/kg infliximab every 8\u00a0weeks up to week\u00a046. After\nthe first year of the study, 78\u00a0patients continued into an open\u2011label\nextension to week\u00a098.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the second clinical study (IMPACT\u00a02),\nefficacy and safety of infliximab were studied in 200\u00a0patients with active\npsoriatic arthritis (\u2265\u00a05\u00a0swollen joints and \u2265\u00a05\u00a0tender\njoints). Forty\u00a0six percent of patients continued on stable doses of\nmethotrexate (\u2264\u00a025\u00a0mg/week). During the 24\u2011week double\u2011blind\nphase, patients received either 5\u00a0mg/kg infliximab or placebo at weeks\u00a00,\n2, 6, 14, and 22 (100\u00a0patients in each group). At week\u00a016,\n47\u00a0placebo patients with &lt;\u00a010% improvement from baseline in both\nswollen and tender joint counts were switched to infliximab induction (early\nescape). At week\u00a024, all placebo\u2011treated patients crossed over to\ninfliximab induction. Dosing continued for all patients through week\u00a046.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Key efficacy results for IMPACT and IMPACT\u00a02\nare shown in Table\u00a09 below:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"8\" style=\"width:100.0%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a09</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on ACR and PASI in IMPACT and IMPACT\u00a02</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"4\" style=\"width:38.86%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">IMPACT</span></p>\n</td>\n<td colspan=\"3\" style=\"width:38.68%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">IMPACT\u00a02*</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Placebo\n  (week\u00a016)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab\n  (week\u00a016)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a098)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Placebo</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a024)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab\n  (week\u00a024)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a054)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients randomised</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">N/A<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">ACR response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(% of patients)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">78</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a020\n  response*</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5(10%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34\n  (65%)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48\n  (62%)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">16\n  (16%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">54\n  (54%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">53\n  (53%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a050\n  response*</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0(0%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24\n  (46%)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">35\n  (45%)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">4\n  (4%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">41(41%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33\n  (33%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a070\n  response*</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0(0%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15\n  (29%)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27\n  (35%)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27\n  (27%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">20\n  (20%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PASI response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(% of patients)<sup>b</sup></span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">87</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">83</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">82</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">PASI\u00a075\n  response**</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">50\n  (60%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40\n  (48.8%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"8\" style=\"width:100.0%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 ITT\u2011analysis\n  where subjects with missing data were included as non\u2011responders.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Week\u00a098\n  data for IMPACT includes combined placebo crossover and infliximab patients\n  who entered the open\u2011label extension.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Based\n  on patients with PASI \u2265\u00a02.5 at baseline for IMPACT, and patients\n  with \u2265\u00a03% BSA psoriasis skin involvement at baseline in IMPACT\u00a02.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">**\u00a0 PASI\u00a075 response for IMPACT\n  not included due to low N; p\u00a0&lt;\u00a00.001 for infliximab vs. placebo\n  at week\u00a024 for IMPACT\u00a02.</span></p>\n</td>\n</tr>\n<tr height=\"0\">\n<td style=\"border:none\" width=\"136\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"0\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In IMPACT and IMPACT\u00a02, clinical\nresponses were observed as early as week\u00a02 and were maintained through\nweek\u00a098 and week\u00a054 respectively. Efficacy has been demonstrated with\nor without concomitant use of methotrexate. Decreases in parameters of\nperipheral activity characteristic of psoriatic arthritis (such as number of\nswollen joints, number of painful/tender joints, dactylitis and presence of\nenthesopathy) were seen in the infliximab\u2011treated patients.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Radiographic changes were assessed in\nIMPACT\u00a02. Radiographs of hands and feet were collected at baseline, weeks\u00a024\nand\u00a054. Infliximab treatment reduced the rate of progression of peripheral\njoint damage compared with placebo treatment at the week\u00a024 primary\nendpoint as measured by change from baseline in total modified vdH\u2011S\nscore (mean \u00b1 SD score was 0.82\u00a0\u00b1\u00a02.62 in the placebo\ngroup compared with \u20110.70\u00a0\u00b1\u00a02.53 in the infliximab\ngroup; p\u00a0&lt;\u00a00.001). In the infliximab group, the mean change in\ntotal modified vdH\u2011S score remained below 0 at the week\u00a054\ntimepoint.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab\u2011treated patients\ndemonstrated significant improvement in physical function as assessed by HAQ.\nSignificant improvements in health\u2011related quality of life were also\ndemonstrated as measured by the physical and mental component summary scores of\nthe SF\u201136 in IMPACT\u00a02.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Adult\npsoriasis</span></u></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The efficacy of\ninfliximab was assessed in two multicenter, randomised, double\u2011blind<b> </b>studies:\nSPIRIT and EXPRESS. Patients in both studies had plaque psoriasis (Body Surface\nArea [BSA] \u2265\u00a010% and Psoriasis Area and Severity Index [PASI] score \u2265\u00a012).\nThe primary endpoint in both studies was the percent of patients who achieved \u2265\u00a075%\nimprovement in PASI from baseline at week\u00a010.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">SPIRIT\nevaluated the efficacy of infliximab induction therapy in 249\u00a0patients\nwith plaque psoriasis that had previously received PUVA or systemic therapy.\nPatients received either 3 or 5\u00a0mg/kg infliximab or placebo infusions at\nweeks\u00a00, 2 and 6. Patients with a PGA score \u2265\u00a03 were eligible\nto receive an additional infusion of the same treatment at week\u00a026.</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In SPIRIT, </span><span lang=\"EN-GB\">the proportion of patients achieving PASI\u00a075 at week\u00a010\nwas 71.7% in the 3\u00a0mg/kg infliximab group, 87.9% in the 5\u00a0mg/kg\ninfliximab group, and 5.9% in the placebo group (p\u00a0&lt;\u00a00.001). By\nweek\u00a026, twenty weeks after the last induction dose, 30% of patients in\nthe 5\u00a0mg/kg group and 13.8% of patients in the 3\u00a0mg/kg group were\nPASI\u00a075 responders. Between weeks\u00a06 and 26, symptoms of psoriasis\ngradually returned with a median time to disease relapse of &gt;\u00a020\u00a0weeks.\nNo rebound was observed.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXPRESS evaluated the efficacy of\ninfliximab induction and maintenance therapy in 378\u00a0patients with plaque\npsoriasis. Patients received 5\u00a0mg/kg infliximab\u2011 or placebo\u2011infusions\nat weeks\u00a00, 2 and 6 followed by maintenance therapy every 8\u00a0weeks\nthrough week\u00a022 in the placebo group and through week\u00a046 in the\ninfliximab group. A</span><span lang=\"EN-GB\">t week\u00a024, the placebo group\ncrossed over to infliximab induction therapy (5\u00a0mg/kg) followed by\ninfliximab maintenance therapy (5\u00a0mg/kg).</span><span lang=\"EN-GB\"> Nail\npsoriasis was assessed using the Nail Psoriasis Severity Index (NAPSI). </span><span lang=\"EN-GB\">Prior therapy with PUVA, methotrexate, ciclosporin, or acitretin had\nbeen received by 71.4% of patients</span><span lang=\"EN-GB\">, although they were\nnot necessarily therapy resistant</span><span lang=\"EN-GB\">. </span><span lang=\"EN-GB\">Key results are presented in Table\u00a010. In infliximab treated\nsubjects, significant PASI\u00a050 responses were apparent at the first visit\n(week\u00a02) and PASI\u00a075 responses by the second visit (week\u00a06).\nEfficacy was similar in the subgroup of patients that were exposed to previous\nsystemic therapies compared to the overall study population.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div align=\"center\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:448.4pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"598\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a010</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Summary of PASI response, PGA response and percent\n  of patients with all nails cleared at weeks\u00a010, 24 and 50. EXPRESS</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:127.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo \u2192 Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(at week\u00a024)</span></p>\n</td>\n<td style=\"width:84.0pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a010</span></b></p>\n</td>\n<td style=\"width:127.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">301</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1.3%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">172\n  (57.1%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242\n  (80.4%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">6\n  (7.8%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">274\n  (91.0%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3\n  (3.9%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242\n  (82.9%)<sup>ab</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14\n  (18.2%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">275\n  (94.2%)<sup>ab</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a024</span></b></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">276</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1.3%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">161\n  (58.3%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3\n  (3.9%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">227\n  (82.2%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5\n  (6.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">248\n  (89.9%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">203\n  (73.6%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15\n  (19.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">246\n  (89.1%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a050</span></b></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">68</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">281</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34\n  (50.0%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">127\n  (45.2%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52\n  (76.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">170\n  (60.5%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61\n  (89.7%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">193\n  (68.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46\n  (67.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">149\n  (53.0%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">59\n  (86.8%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">189\n  (67.3%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">All\n  nails cleared<sup>c</sup></span></b></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a010</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1/65\n  (1.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">16/235\n  (6.8%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a024</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3/65\n  (4.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">58/223\n  (26.0%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a050</span></p>\n</td>\n<td style=\"width:127.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27/64\n  (42.2%)</span></p>\n</td>\n<td style=\"width:84.0pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">92/226\n  (40.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:448.4pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"598\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 p\u00a0&lt;\u00a00.001,\n  for each infliximab treatment group vs. control.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 n\u00a0=\u00a0292.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Analysis\n  was based on subjects with nail psoriasis at baseline (81.8% of subjects).\n  Mean baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group.</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Significant improvements from baseline were\ndemonstrated in DLQI (p\u00a0&lt;\u00a00.001) and the physical and mental\ncomponent scores of the SF 36 (p\u00a0&lt;\u00a00.001 for each component\ncomparison).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Paediatric\npopulation</span></u></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\nCrohn\u2019s disease (6 to\u00a017\u00a0years)</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the REACH study, 112\u00a0patients (6 to\n17\u00a0years, median age 13.0\u00a0years) with moderate to severe, active\nCrohn\u2019s disease (median paediatric CDAI of 40) and an inadequate response\nto conventional therapies were to receive 5\u00a0mg/kg infliximab at weeks\u00a00,\n2, and 6. All patients were required to be on a stable dose of 6\u2011MP, AZA\nor MTX (35% were also receiving corticosteroids at baseline). Patients assessed\nby the investigator to be in clinical response at week\u00a010 were randomised\nand received 5\u00a0mg/kg infliximab at either q8\u00a0weeks or q12\u00a0weeks\nas a maintenance treatment regimen. If response was lost during maintenance\ntreatment, crossing over to a higher dose (10\u00a0mg/kg) and/or shorter dosing\ninterval (q8\u00a0weeks) was allowed. Thirty\u00a0two (32) evaluable paediatric\npatients crossed over (9\u00a0subjects in the q8\u00a0weeks and\n23\u00a0subjects in the q12\u00a0weeks maintenance groups). Twenty\u00a0four of\nthese patients (75.0%) regained clinical response after crossing over.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The proportion of subjects in clinical\nresponse at week\u00a010 was 88.4% (99/112). The proportion of subjects\nachieving clinical remission at week\u00a010 was 58.9% (66/112).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">At week\u00a030, the proportion of subjects\nin clinical remission was higher in the q8\u00a0week (59.6%, 31/52) than the\nq12\u00a0week maintenance treatment group (35.3%, 18/51; p\u00a0=\u00a00.013).\nAt week\u00a054, the figures were 55.8% (29/52) and 23.5% (12/51) in the q8\u00a0weeks\nand q12\u00a0weeks maintenance groups, respectively (p\u00a0&lt;\u00a00.001).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Data about fistulas were derived from PCDAI\nscores. Of the 22\u00a0subjects that had fistulas at baseline, 63.6% (14/22),\n59.1% (13/22) and 68.2% (15/22) were in complete fistula response at week\u00a010,\n30 and 54, respectively, in the combined q8\u00a0weeks and q12\u00a0weeks\nmaintenance groups.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In addition, statistically and clinically\nsignificant improvements in quality of life and height, as well as a\nsignificant reduction in corticosteroid use, were observed versus baseline.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\nulcerative colitis (6 to 17\u00a0years)</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of infliximab were\nassessed in a multicenter, randomised, open\u2011label, parallel\u2011group\nclinical study (C0168T72) in 60\u00a0paediatric patients aged 6 through 17\u00a0years\n(median age 14.5\u00a0years) with moderately to severely active ulcerative\ncolitis (Mayo score of 6 to 12; endoscopic subscore \u2265\u00a02) with an\ninadequate response to conventional therapies. At baseline 53% of patients were\nreceiving immunomodulator therapy (6\u2011MP, AZA and/or MTX) and 62% of\npatients were receiving corticosteroids. Discontinuation of immunomodulators\nand corticosteroid taper were permitted after week\u00a00.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">All patients received an induction regimen\nof 5\u00a0mg/kg infliximab at weeks\u00a00, 2, and 6. Patients who did not\nrespond to infliximab at week\u00a08 (n\u00a0=\u00a015) received no further medicinal\nproduct and returned for safety follow\u2011up. At week\u00a08, 45\u00a0patients\nwere randomised and received 5\u00a0mg/kg infliximab at either q8\u00a0weeks or\nq12\u00a0weeks as a maintenance treatment regimen.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The proportion of patients in clinical\nresponse at week\u00a08\u00a0was 73.3% (44/60). Clinical response at week\u00a08\nwas similar between those with or without concomitant immunomodulator use at\nbaseline. Clinical remission at week\u00a08 was 33.3% (17/51) as measured by\nthe Paediatric Ulcerative Colitis Activity Index (PUCAI) score.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">At week\u00a054, the proportion of patients\nin clinical remission as measured by the PUCAI score was 38% (8/21) in the\nq8\u00a0week maintenance group and 18% (4/22) in the q12\u00a0week maintenance\ntreatment group. </span><span lang=\"EN-GB\">For patients receiving corticosteroids\nat baseline, the proportion of patients in remission and not receiving\ncorticosteroids at week\u00a054 was 38.5% (5/13) for the q8\u00a0week and 0%\n(0/13) for the q12\u00a0week maintenance treatment group.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In this study, there were more patients in\nthe 12 to 17\u00a0year age group than in the 6 to 11\u00a0year age group (45/60\nvs.15/60). While the numbers of patients in each subgroup are too small to draw\ndefinitive conclusions about the effect of age, there was a higher number of\npatients in the younger age group who stepped up in dose or discontinued\ntreatment due to inadequate efficacy.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Other paediatric indications</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The European Medicines Agency has waived\nthe obligation to submit the results of studies with Remicade in all subsets of\nthe paediatric population in rheumatoid arthritis, juvenile idiopathic\narthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis and Crohn's\ndisease (see section\u00a04.2 for information on paediatric use).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic\nproperties</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Single\nintravenous infusions of 1, 3, 5, 10\u00a0or 20\u00a0mg/kg of infliximab\nyielded dose proportional increases in the maximum serum concentration (C<sub>max</sub>)\nand area under the concentration\u2011time curve (AUC). The volume of\ndistribution at steady state (median\u00a0V<sub>d </sub>of 3.0 to\n4.1\u00a0litres) was not dependent on the administered dose and indicated that\ninfliximab is predominantly distributed within the vascular compartment. No\ntime\u2011dependency of the Pharmacokinetics was observed. The elimination\npathways for infliximab have not been characterised. Unchanged infliximab was\nnot detected in urine. No major age\u2011 or weight\u2011related differences\nin clearance or volume of distribution were observed in rheumatoid arthritis\npatients. </span><span lang=\"EN-GB\">The pharmacokinetics of infliximab in elderly\npatients has not been studied. Studies have not been performed in patients with\nliver or renal disease.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">At single\ndoses of 3, 5, or 10\u00a0mg/kg, the median C<sub>max</sub> values were 77, 118\nand 277\u00a0micrograms/ml, respectively. The median terminal half\u2011life\nat these doses ranged from 8 to 9.5\u00a0days. In most patients, infliximab\ncould be detected in the serum for at least 8\u00a0weeks after the recommended\nsingle dose of 5\u00a0mg/kg for Crohn\u2019s disease and the rheumatoid\narthritis maintenance dose of 3\u00a0mg/kg every 8\u00a0weeks.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Repeated administration of infliximab (5\u00a0mg/kg\nat 0, 2 and 6\u00a0weeks in fistulising Crohn\u2019s disease, 3 or\n10\u00a0mg/kg every 4 or 8\u00a0weeks in rheumatoid arthritis) resulted in a\nslight accumulation of infliximab in serum after the second dose. No further\nclinically relevant accumulation was observed. In most fistulising\nCrohn\u2019s disease patients, infliximab was detected in serum for\n12\u00a0weeks (range 4\u201128\u00a0weeks) after administration of the\nregimen.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric\npopulation</span></i></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Population\npharmacokinetic analysis based on data obtained from patients with ulcerative\ncolitis (N\u00a0=\u00a060), Crohn\u2019s disease (N\u00a0=\u00a0112), juvenile\nrheumatoid arthritis (N\u00a0=\u00a0117) and Kawasaki disease (N\u00a0=\u00a016)\nwith an overall age range from 2\u00a0months to 17\u00a0years indicated that\nexposure to infliximab was dependent on body weight in a non\u2011linear way.\nFollowing administration of 5\u00a0mg/kg Remicade every 8\u00a0weeks, the\npredicted median steady\u2011state infliximab exposure (area under\nconcentration\u2011time curve at steady state, AUC<sub>ss</sub>) in paediatric\npatients aged 6\u00a0years to 17\u00a0years was approximately 20% lower than\nthe predicted median steady\u2011state drug exposure in adults. The median AUC<sub>ss</sub>\nin paediatric patients aged 2\u00a0years to less than 6\u00a0years was\npredicted to be approximately 40% lower than that in adults, although the\nnumber of patients supporting this estimate is limited.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab does not cross react with TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> from\nspecies other than human and chimpanzees. Therefore, conventional preclinical\nsafety data with infliximab are limited. In a developmental toxicity study conducted\nin mice using an analogous antibody that selectively inhibits the functional\nactivity of mouse TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">, there was no indication of maternal toxicity, embryotoxicity or\nteratogenicity. In a fertility and general reproductive function study, the\nnumber of pregnant mice was reduced following administration of the same\nanalogous antibody. It is not known whether this finding was due to effects on\nthe males and/or the females. <span style=\"layout-grid-mode:line\">In a 6\u2011month\nrepeated dose toxicity study in mice, using the same analogous antibody against\nmouse TNF</span></span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">, crystalline deposits were observed\non the lens capsule of some of the treated male mice. No specific\nophthalmologic examinations have been performed in patients to investigate the\nrelevance of this finding for humans.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Long\u2011term studies have not been\nperformed to evaluate the carcinogenic potential of infliximab. Studies in mice\ndeficient in TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> demonstrated no increase in tumours when challenged with known\ntumour initiators and/or promoters.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sucrose</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Polysorbate\u00a080</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Monobasic sodium phosphate</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dibasic sodium phosphate</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the absence of compatibility studies,\nthis medicinal product must not be mixed with other medicinal products.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Before\nreconstitution:</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3\u00a0years\nat 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u2013<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade may be stored at temperatures up\nto a maximum of 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C for a single period of up\nto 6\u00a0months, but not exceeding the original expiry date. The new expiry\ndate must be written on the carton. Upon removal from refrigerated storage,\nRemicade must not be returned to refrigerated storage.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">After reconstitution and dilution:</span></u></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Chemical and physical in use stability of\nthe diluted solution has been demonstrated for up to 28\u00a0days at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C to 8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C and for an additional 24\u00a0hours\nat 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C after removal from\nrefrigeration. From a microbiological point of view, the infusion solution should\nbe administered immediately, in use storage times and conditions prior to use\nare the responsibility of the user and would normally not be longer than\n24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C to 8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C, unless\nreconstitution/dilution has been taken place in controlled and validated\naseptic conditions.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for\nstorage</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store in a refrigerator (2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For storage conditions up to 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C before reconstitution of\nthe medicinal product, see section\u00a06.3.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For storage conditions after reconstitution\nof the medicinal product, see section\u00a06.3.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of\ncontainer</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Type\u00a01 glass vial with rubber stopper\nand aluminium crimp protected by a plastic cap.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is available in packs of 1, 2, 3,\n4 or 5\u00a0vials.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for\ndisposal and other handling</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Calculate the dose and the\nnumber of Remicade vials needed. Each Remicade vial contains 100\u00a0mg\ninfliximab. Calculate the total volume of reconstituted Remicade solution\nrequired.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Under aseptic conditions,\nreconstitute each Remicade vial with 10\u00a0ml of water for injections, using\na syringe equipped with a 21\u2011gauge (0.8\u00a0mm) or smaller needle.\nRemove flip\u2011top from the vial and wipe the top with a 70% alcohol swab.\nInsert the syringe needle into the vial through the centre of the rubber\nstopper and direct the stream of water for injections to the glass wall of the\nvial. Gently swirl the solution by rotating the vial to dissolve the\nlyophilised powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE.\nFoaming of the solution on reconstitution is not unusual. Allow the\nreconstituted solution to stand for 5\u00a0minutes. Check that the solution is\ncolourless to light yellow and opalescent. The solution may develop a few fine\ntranslucent particles, as infliximab is a protein. Do not use if opaque\nparticles, discolouration, or other foreign particles are present.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dilute the total volume of\nthe reconstituted Remicade solution dose to 250\u00a0ml with sodium chloride\n9\u00a0mg/ml (0.9%) solution for infusion. Do not dilute the reconstituted\nRemicade solution with any other diluent. The dilution can be accomplished by\nwithdrawing a volume of the sodium chloride 9\u00a0mg/ml (0.9%) solution for\ninfusion from the 250\u2011ml glass bottle or infusion bag equal to the volume\nof reconstituted Remicade. Slowly add the total volume of reconstituted\nRemicade solution to the 250\u2011ml infusion bottle or bag. Gently mix. For\nvolumes greater than 250\u00a0ml, either use a larger infusion bag (e.g. 500\u00a0ml,\n1000\u00a0ml) or use multiple 250\u00a0ml infusion bags to ensure that the\nconcentration of the infusion solution does not exceed 4\u00a0mg/ml. If stored\nrefrigerated after reconstitution and dilution, the infusion solution must be\nallowed to equilibrate at room temperature to 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>\u00b0C for 3\u00a0hours prior to\nStep\u00a04 (infusion). Storage beyond 24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>\u00b0C applies to preparation of\nRemicade in the infusion bag only.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Administer the infusion\nsolution over a period of not less than the infusion time recommended (see\nsection\u00a04.2). Use only an infusion set with an in\u2011line, sterile, non\u2011pyrogenic,\nlow protein\u2011binding filter (pore size 1.2\u00a0micrometre or less). Since\nno preservative is present, it is recommended that the administration of the\nsolution for infusion is to be started as soon as possible and within\n3\u00a0hours of reconstitution and dilution. If not used immediately, in use\nstorage times and conditions prior to use are the responsibility of the user and\nwould normally not be longer than 24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:13\">\u00a0</del></span>\u00b0C to 8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:13\">\u00a0</del></span>\u00b0C, unless reconstitution/dilution\nhas been taken place in controlled and validated aseptic conditions, (see\nsection\u00a06.3 above). Do not store any unused portion of the infusion\nsolution for reuse.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 No physical biochemical\ncompatibility studies have been conducted to evaluate the co\u2011administration\nof Remicade with other agents. Do not infuse Remicade concomitantly in the same\nintravenous line with other agents.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Visually inspect Remicade for\nparticulate matter or discolouration prior to administration. Do not use if\nvisibly opaque particles, discolouration or foreign particles are observed.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Any unused medicinal product\nor waste material should be disposed of in accordance with local requirements.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Janssen Biologics B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Einsteinweg 101</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">2333 CB Leiden</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">The Netherlands</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"DE\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">EU/1/99/116/001</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">EU/1/99/116/002</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/99/116/003</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/99/116/004</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/99/116/005</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of first authorisation: 13 August\n1999.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Date of latest renewal: 2 July 2009.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE\nTEXT</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Detailed\ninformation on this product is available on the website of the European\nMedicines Agency <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a></span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nII</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:42.55pt;margin-bottom:\n0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) OF THE BIOLOGICAL\nACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:42.55pt;margin-bottom:\n0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS\nREGARDING SUPPLY AND USE</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:42.55pt;margin-bottom:\n0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS\nOF THE MARKETING AUTHORISATION</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:42.55pt;margin-bottom:\n0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH\nREGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) OF\nTHE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH\nRELEASE</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Names and\naddresses of the manufacturer(s) of the biological active substance(s)</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Janssen\nBiologics B.V., Einsteinweg 101, 2333 CB Leiden, The Netherlands</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Janssen Biotech\nInc., 200 Great Valley Parkway Malvern, Pennsylvania 19355\u20111307, United\nStates of America</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Name and\naddress of the manufacturer(s) responsible for batch release</span></u></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Janssen Biologics B.V., Einsteinweg 101,\n2333 CB Leiden, The Netherlands</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (see Annex I: Summary of Product Characteristics, section\u00a04.2).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS\nAND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Periodic <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">S</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">s</ins></span>afety <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">U</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">u</ins></span>pdate <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">R</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">r</ins></span>eports<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\"> (PSURs)</ins></span></span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The requirements for submission of <span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">PSURs</ins></span><span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">periodic safety update reports</del></span> for\nthis medicinal product are set out in the list of Union reference dates (EURD\nlist) provided for under Article 107c(7) of Directive 2001/83</span><span lang=\"EN-GB\">/EC and any subsequent updates published on the European medicines\nweb\u2011portal.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Risk <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">M</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">m</ins></span>anagement <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">P</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">p</ins></span>lan (RMP)</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The <span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:13\">marketing au</ins></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:29\">thorisation holder (</ins></span>MAH<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:29\">)</ins></span> shall perform the required pharmacovigilance\nactivities and interventions detailed in the agreed RMP presented in Module\n1.8.2 of the <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">M</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">m</ins></span>arketing <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">A</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">a</ins></span>uthorisation and any agreed subsequent\nupdates of the RMP.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">An updated RMP should be submitted:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">At the request of the European Medicines Agency;</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Whenever the risk management system is modified,\nespecially as the result of new information being received that may lead to a\nsignificant change to the benefit/risk profile or as the result of an important\n(pharmacovigilance or risk minimisation) milestone being reached.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Additional risk minimisation measures</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The educational programme consists of a patient\nreminder card to be held by the patient. The card is aimed at both serving as a\nreminder to record the dates and outcomes of specific tests and to facilitate\nthe patient sharing of special information with healthcare professionals(s) (HCPs)\ntreating the patient about on\u2011going treatment with the product.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">The patient reminder card </span></b><span lang=\"EN-GB\">shall contain the following key messages:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A reminder to patients to show the patient reminder\ncard to all treating HCPs, including in conditions of emergency, and a message for\nHCPs that the patient is using Remicade</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A statement that the brand name and batch number\nshould be recorded</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Provision to record the type, date, and result\nof TB screenings</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">That treatment with Remicade may increase the\nrisks of serious infections/sepsis, opportunistic infections, tuberculosis,\nhepatitis B reactivation, and BCG breakthrough in infants with <i>in utero</i>\nexposure to infliximab, and when to seek attention from a HCP</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Contact details of the prescriber</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nIII</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">LABELLING\nAND PACKAGE LEAFLET</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">A.\nLABELLING</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE\nOUTER PACKAGING</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Remicade 100\u00a0mg powder for concentrate for\nsolution for infusion</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">infliximab</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains 100\u00a0mg of\ninfliximab.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">After reconstitution one ml contains 10\u00a0mg\nof infliximab.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Excipients: sucrose, polysorbate\u00a080, monobasic\nsodium phosphate and dibasic sodium phosphate.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">Powder for concentrate for solution for infusion</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">1\u00a0vial 100\u00a0mg</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\" style=\"background:silver\">2\u00a0vials\n100\u00a0mg</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\" style=\"background:silver\">3\u00a0vials\n100\u00a0mg</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\" style=\"background:silver\">4\u00a0vials\n100\u00a0mg</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">5\u00a0vials\n100\u00a0mg</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Read the package leaflet before use.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Intravenous use.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reconstitute and dilute before use.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">EXP, if not\nrefrigerated ___________________</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store in a refrigerator.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Can be stored at room temperature (up to 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">\u00a0</del></span>\u00b0C) for a single period up\nto 6\u00a0months, but not exceeding the original expiry date.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME AND ADDRESS OF THE MARKETING\nAUTHORISATION HOLDER</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Janssen\nBiologics B.V.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Einsteinweg\n101</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2333 CB\nLeiden</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The\nNetherlands</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">EU/1/99/116/001\n<span style=\"background:silver\">1\u00a0vial 100\u00a0mg</span></span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">EU/1/99/116/002 2\u00a0vials 100\u00a0mg</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">EU/1/99/116/003 3\u00a0vials 100\u00a0mg</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">EU/1/99/116/004 4\u00a0vials 100\u00a0mg</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">EU/1/99/116/005 5\u00a0vials 100\u00a0mg</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">Justification for\nnot including Braille accepted.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode\ncarrying the unique identifier included.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 HUMAN READABLE\nDATA</span></b></p>\n</div>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PC<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del></span></span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">SN<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del></span></span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">NN<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del></span></span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR\nON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL LABEL</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Remicade\n100\u00a0mg powder for concentrate</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">infliximab</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">IV</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD OF ADMINISTRATION</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">For intravenous\nuse after reconstitution and dilution.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS BY WEIGHT, BY VOLUME\nOR BY UNIT</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">100\u00a0mg</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b></p>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"619\">\n<tr>\n<td style=\"width:232.2pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"font-size:16.0pt\">Remicade</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">infliximab</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"font-size:16.0pt\">Patient Reminder Card</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Name patient:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Name doctor:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Telephone number doctor:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">This patient reminder card contains\n  important safety information that you need to be aware of before and during\n  treatment with Remicade.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Show this card to any doctor involved in\n  your treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Please read the Remicade \u2018Package\n  Leaflet\u2019 carefully before you start using this medicine.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of Remicade therapy initiation:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Current administrations:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is important that you and your doctor\n  record the brand name and batch number of your medicine.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ask your doctor to record the type and\n  date of last screening(s) for tuberculosis (TB) below:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Test\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Test</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Date</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Result:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Result:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Please make sure you also have a list of\n  all other medicines that you are using with you at any visit to a healthcare\n  professional.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">List of allergies:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">List of other medicines:</span></p>\n</td>\n<td style=\"width:232.2pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:14.0pt\">Infections</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Before treatment with Remicade</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor if you have an infection even\n  if it is a very minor one</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">It is very important that you tell your doctor\n  if you have ever had TB, or if you have been in close contact with someone\n  who has had TB. Your doctor will test you to see if you have TB. Ask your\n  doctor to record the type and date of your last screening(s) for TB on the\n  card</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor if you have hepatitis B or if\n  you know or suspect you are a carrier of the hepatitis B virus.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">During treatment with Remicade</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor straight away if you have\n  signs of an infection. Signs include a fever, feeling tired, (persistent)\n  cough, shortness of breath, weight loss, night sweats, diarrhea, wounds,\n  dental problems, burning when urinating or \u2018flu\u2011like\u2019\n  signs.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:14.0pt\">Pregnancy and\n  Vaccinations</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">In case you have received Remicade while you\n  were pregnant, it is important that you inform your baby\u2019s doctor about\n  it before your baby receives any vaccine. Your baby should not receive a\n  \u2018live vaccine\u2019, such as BCG (used to prevent tuberculosis) within\n  6\u00a0months after birth.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep this card with you for 4\u00a0months\n  after your dose of Remicade, or in case of pregnancy for at least\n  6\u00a0months after the birth of your baby. Side effects may occur a long\n  time after your last dose.</span></p>\n</td>\n</tr>\n</table>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">B.\nPACKAGE LEAFLET</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:avoid\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:avoid\"><b><span lang=\"EN-GB\">Remicade </span></b><b><span lang=\"EN-GB\">100\u00a0mg powder for\nconcentrate for solution for infusion</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:avoid\"><span lang=\"EN-GB\">infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Read all\nof this leaflet carefully before you start using this medicine because it\ncontains important information for you.</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it\nagain.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Your doctor will also give you a patient reminder\ncard, which contains important safety information you need to be aware of\nbefore and during your treatment with Remicade.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you have any further questions, ask your\ndoctor.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">This medicine has been prescribed for you only.\nDo not pass it on to others. It may harm them, even if their signs of illness are\nthe same as yours.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you get any side effects, talk to your\ndoctor. This includes any possible side effects not listed in this leaflet. See\nsection 4.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What is\nin this leaflet:</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nRemicade is and what it is used for</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you use Remicade</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nRemicade will be given</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Remicade</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Remicade\nis and what it is used for</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade contains the active substance\ninfliximab. Infliximab is a monoclonal antibody \u2013 a type of protein that\nattaches to a specific target in the body called TNF (tumour necrosis factor)\nalpha.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade belongs to a group of medicines\ncalled \u2018TNF blockers\u2019. It is used in adults for the following\ninflammatory diseases:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Rheumatoid arthritis</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Psoriatic arthritis</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Ankylosing spondylitis (Bechterew\u2019s\ndisease)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Psoriasis.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is also used in adults and\nchildren 6\u00a0years of age or older for:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Crohn\u2019s disease</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Ulcerative colitis.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade works by selectively attaching to\nTNF alpha and blocking its action. TNF alpha is involved in inflammatory\nprocesses of the body so blocking it can reduce the inflammation in your body.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Rheumatoid\narthritis</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Rheumatoid arthritis is an inflammatory\ndisease of the joints. If you have active rheumatoid arthritis you will first\nbe given other medicines. If these medicines do not work well enough, you will\nbe given Remicade which you will take in combination with another medicine\ncalled methotrexate to:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Reduce the signs and symptoms of your disease</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Slow down the damage in your joints</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Improve your physical function.</span></p>\n<p class=\"MsoDate\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Psoriatic\narthritis</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Psoriatic arthritis is an inflammatory\ndisease of the joints, usually accompanied by psoriasis. If you have active\npsoriatic arthritis you will first be given other medicines. If these medicines\ndo not work well enough, you will be given Remicade to:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Reduce the signs and symptoms of your disease</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Slow down the damage in your joints</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Improve your physical function.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Ankylosing\nspondylitis (Bechterew\u2019s disease)</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ankylosing spondylitis is an inflammatory\ndisease of the spine. If you have ankylosing spondylitis you will first be given\nother medicines. If these medicines do not work well enough, you will be given\nRemicade to:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Reduce the signs and symptoms of your disease</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Improve your physical function.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Psoriasis</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Psoriasis is an inflammatory disease of the\nskin. If you have moderate to severe plaque psoriasis, you will first be given\nother medicines or treatments, such as phototherapy. If these medicines or\ntreatments do not work well enough, you will be given Remicade to reduce the signs\nand symptoms of your disease.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Ulcerative\ncolitis</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ulcerative colitis is an inflammatory\ndisease of the bowel. If you have ulcerative colitis you will first be given\nother medicines. If these medicines do not work well enough, you will be given\nRemicade to treat your disease.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Crohn\u2019s\ndisease</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Crohn\u2019s disease is an inflammatory\ndisease of the bowel. If you have Crohn\u2019s disease you will first be given\nother medicines. If these medicines do not work well enough, you will be given\nRemicade to:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Treat active Crohn\u2019s disease</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Reduce the number of abnormal openings\n(fistulae) between your bowel and your skin that have not been controlled by\nother medicines or surgery.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need\nto know before you use Remicade</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">You\nshould not be given Remicade if:</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You are allergic to infliximab or to any of the\nother ingredients in Remicade (listed in section\u00a06).</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You are allergic (hypersensitive) to proteins\nthat come from mice.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You have tuberculosis (TB) or another serious\ninfection such as pneumonia or sepsis.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You have heart failure that is moderate or\nsevere.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not use Remicade if any of the above\napplies to you. If you are not sure, talk to your doctor before you are given\nRemicade.</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings\nand precautions</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Talk to your doctor before or during\ntreatment with Remicade if you have:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Had treatment with Remicade before</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor if you have had treatment with\nRemicade in the past and are now starting Remicade treatment again.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">If you have had\na break in your Remicade treatment of more than 16\u00a0weeks, there is a higher\nrisk for allergic reactions when you start the treatment again.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Infections</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou have an infection even if it is a very minor one.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou have ever lived in or travelled to an area where infections called histoplasmosis,\ncoccidioidomycosis, or blastomycosis are common. These infections are caused by\nspecific types of fungi that can affect the lungs or other parts of your body.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You may get infections more easily when you are\nbeing treated with Remicade. If you are 65 or older, you have a greater risk.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">These infections may be serious and include\ntuberculosis, infections caused by viruses, fungi, bacteria, or other organisms\nin the environment and sepsis that may be life\u2011threatening.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Tell your\ndoctor straight away if you get signs of infection during treatment with\nRemicade. Signs include fever, cough, flu\u2011like signs, feeling unwell, red\nor hot skin, wounds or dental problems. Your doctor may recommend temporarily stopping\nRemicade.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Tuberculosis (TB)</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">It is very important that you tell your doctor\nif you have ever had TB or if you have been in close contact with someone who\nhas had or has TB.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Your doctor will test you to see if you have TB.\nCases of TB have been reported in patients treated with Remicade, even in patients\nwho have already been treated with medicines for TB. Your doctor will record\nthese tests on your patient reminder card.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If your doctor feels that you are at risk for\nTB, you may be treated with medicines for TB before you are given Remicade.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Tell your doctor\nstraight away if you get signs of TB during treatment with Remicade. Signs\ninclude persistent cough, weight loss, feeling tired, fever, night sweats.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatitis B virus</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou are a carrier of hepatitis B or have ever had it.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor if you think you might be at\nrisk of contracting hepatitis B.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Your doctor should test you for hepatitis B\nvirus.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Treatment with TNF blockers such as Remicade may\nresult in reactivation of hepatitis B virus in patients who carry this virus,\nwhich can be life\u2011threatening in some cases.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Heart problems</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor if you have any heart problems,\nsuch as mild heart failure.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Your doctor will want to closely monitor your\nheart.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Tell your\ndoctor straight away if you get new or worsening signs of heart failure during\ntreatment with Remicade. Signs include shortness of breath or swelling of your\nfeet.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Cancer and lymphoma</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou have or have ever had lymphoma (a type of blood cancer) or any other\ncancer.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Patients with severe rheumatoid arthritis, who\nhave had the disease for a long time, may be at higher risk of developing\nlymphoma.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Children and adults taking Remicade may have an\nincreased risk of developing lymphoma or another cancer.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Some patients who have received TNF\u2011blockers,\nincluding Remicade have developed a rare type of cancer called hepatosplenic T\u2011cell\nlymphoma. Of these patients, most were teenage boys or young men and most had\neither Crohn\u2019s disease or ulcerative colitis. This type of cancer has\nusually resulted in death. Almost all patients had also received medicines\ncontaining azathioprine or 6\u2011mercaptopurine in addition to TNF\u2011blockers.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Some patients treated with infliximab have\ndeveloped certain kinds of skin cancer. If there are any changes in your skin\nor growths on the skin during or after therapy, tell your doctor.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Some women being treated for rheumatoid\narthritis with Remicade have developed cervical cancer. For women taking\nRemicade including those over 60\u00a0years of age, your doctor may recommend\nregular screening for cervical cancer.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Lung disease or heavy smoking</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou have a lung disease called Chronic Obstructive Pulmonary Disease (COPD) or\nif you are a heavy smoker.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Patients with COPD and patients who are heavy\nsmokers may have a higher risk of developing cancer with Remicade treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous system disease</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor if you have or have ever had a\nproblem that affects your nervous system before you are given Remicade. This\nincludes multiple sclerosis, Guillain\u2011Barre syndrome, if you have fits or\nhave been diagnosed with \u2018optic neuritis\u2019.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Tell your\ndoctor straight away if you get symptoms of a nerve disease during treatment\nwith Remicade. Signs include changes in your vision, weakness in your arms or\nlegs, numbness or tingling in any part of your body.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Abnormal skin openings</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor if you have any abnormal skin\nopenings (fistulae) before you are given Remicade.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Vaccinations</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Talk to your doctor if you recently have had or\nare due to have a vaccine.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You should receive recommended vaccinations\nbefore starting Remicade treatment. You may receive some vaccines during\ntreatment with Remicade but you should not receive live vaccines (vaccines that\ncontain a living but weakened infectious agent) while using Remicade because\nthey may cause infections.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you received Remicade while you were\npregnant, your baby may also be at higher risk for getting an infection with\nlive vaccines for up to six months after birth. It is important that you tell\nyour baby's doctors and other healthcare professionals about your Remicade use\nso they can decide when your baby should receive any vaccine, including live vaccines\nsuch as BCG (used to prevent tuberculosis). For more information see section on\nPregnancy and breast\u2011feeding.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Therapeutic infectious agents</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Talk to you doctor if you have recently received\nor are scheduled to receive treatment with a therapeutic infectious agent (such\nas BCG instillation used for the treatment of cancer).</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Operations or dental procedures</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor if you are going to have any\noperations or dental procedures.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your surgeon or dentist that you are having\ntreatment with Remicade by showing them your patient reminder card.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Liver problems</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Some patients receiving Remicade have developed\nserious liver problems.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Tell your\ndoctor straight away if you get symptoms of liver problems during treatment\nwith Remicade. Signs include yellowing of the skin and eyes, dark-brown</span><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> </span><span lang=\"EN-GB\">coloured urine,\npain or swelling in the upper right side of the stomach area, joint pain, skin\nrashes, or fever.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Low blood counts</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">In some patients receiving Remicade, the body\nmay not make enough of the blood cells that help fight infections or help stop\nbleeding.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor straight away if you get\nsymptoms of low blood counts during treatment with Remicade. Signs include persistent\nfever, bleeding or bruising more easily, small red or purple spots caused by bleeding\nunder the skin, or looking pale.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune system disorder</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Some patients receiving Remicade have developed\nsymptoms of an immune system disorder called lupus.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Tell your\ndoctor straight away if you develop symptoms of lupus during treatment with\nRemicade. Signs include joint pain or a rash on cheeks or arms that is\nsensitive to the sun.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Children and adolescents</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">The information above also applies to children and adolescents. In\naddition:</span></u></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Some children and teenage patients who have\nreceived TNF\u2011blockers such as Remicade have developed cancers, including\nunusual types, which sometimes resulted in death.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">More children taking Remicade developed\ninfections as compared to adults.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Children should receive recommended vaccinations\nbefore starting Remicade treatment. Children may receive some vaccines during treatment\nwith Remicade but should not receive live vaccines while using Remicade.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you are not sure if any of the above\napply to you, talk to your doctor before you are given Remicade.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Other\nmedicines and Remicade</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients who have inflammatory diseases\nalready take medicines to treat their problem. These medicines may cause side\neffects. Your doctor will advise you what other medicines you must keep using\nwhile you are having Remicade.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you are using or have\nrecently used any other medicines, including any other medicines to treat\nCrohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, ankylosing\nspondylitis, psoriatic arthritis or psoriasis or medicines obtained without a\nprescription, such as vitamins and herbal medicines.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">In particular, tell your doctor if you are\nusing any of the following medicines:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Medicines that affect your immune system.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kineret (anakinra). Remicade and Kineret should\nnot be used together.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Orencia (abatacept). Remicade and Orencia should\nnot be used together.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">While using Remicade you should not receive\nlive vaccines. If you were using Remicade during pregnancy, tell your\nbaby\u2019s doctor and other healthcare professionals caring for your baby\nabout your Remicade use before the baby receives any vaccines.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">If you are\nnot sure if any of the above apply to you, talk to your doctor or pharmacist\nbefore using Remicade.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy,\nbreast\u2011feeding, and fertility</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you are pregnant or breast\u2011feeding,\nthink you may be pregnant or are planning to have a baby, ask your doctor for\nadvice before taking this medicine. Remicade</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">should only be used during pregnancy if your doctor feels it is\nnecessary for you.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You should avoid getting pregnant when you are\nbeing treated with Remicade and for 6\u00a0months after you stop being treated\nwith it. Discuss the use of contraception during this time with your doctor.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not breast\u2011feed when you are being\ntreated with Remicade or for 6\u00a0months after your last treatment with\nRemicade.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you received Remicade during your pregnancy,\nyour baby may have a higher risk for getting an infection.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">It is important that you tell your baby\u2019s\ndoctors and other healthcare professionals about your Remicade use before your\nbaby is given any vaccine. If you received Remicade while pregnant, giving BCG\nvaccine (used to prevent tuberculosis) to your baby within 6\u00a0months after\nbirth may result in infection with serious complications, including death. Live\nvaccines such as BCG should not be given to your baby within 6\u00a0months\nafter birth. For more information see section on vaccination.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Severely decreased numbers of white blood cells\nhave been reported in infants born to women treated with Remicade during\npregnancy. If your baby has continual fevers or infections, contact your\nbaby\u2019s doctor immediately.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Driving\nand using machines</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is not likely to affect your\nability to drive or use tools or machines. If you feel tired, dizzy, or unwell\nafter having Remicade, do not drive or use any tools or machines.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Remicade contains\nsodium</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade contains less than 1\u00a0mmol sodium\n(23\u00a0mg) per dose, that is to say essentially \u2018sodium\u2011free\u2019.\nHowever, before Remicade is given to you, it is mixed with a solution that\ncontains sodium. Talk to your doctor if you are on a low salt diet.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Remicade\nwill be given</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Rheumatoid\narthritis</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The usual dose is 3\u00a0mg for every kg of\nbody weight.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Psoriatic\narthritis, ankylosing spondylitis (Bechterew\u2019s disease), psoriasis,\nulcerative colitis and Crohn's disease</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The usual dose is 5\u00a0mg for every kg of\nbody weight.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">How\nRemicade is given</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Remicade will be given to you by your doctor or\nnurse.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Your doctor or nurse will prepare the medicine\nfor infusion.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The medicine will be given as an infusion (drip)\n(over 2\u00a0hours) into one of your veins, usually in your arm. After the\nthird treatment, your doctor may decide to give your dose of Remicade over\n1\u00a0hour.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You will be monitored while you are given\nRemicade and also for 1 to 2\u00a0hours afterwards.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">How much\nRemicade is given</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The doctor will decide your dose and how often\nyou will be given Remicade. This will depend on your disease, weight and how\nwell you respond to Remicade.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The table below shows how often you will usually\nhave this medicine after your first dose.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:174.0pt;border:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2<sup>nd</sup> dose</span></p>\n</td>\n<td style=\"width:222.0pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2\u00a0weeks after your 1<sup>st</sup> dose</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:174.0pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">3<sup>rd</sup> dose</span></p>\n</td>\n<td style=\"width:222.0pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">6\u00a0weeks after your 1<sup>st</sup> dose</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:174.0pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Further doses</span></p>\n</td>\n<td style=\"width:222.0pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Every 6 to 8\u00a0weeks depending on your\n  disease </span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Use in\nchildren and adolescents</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Remicade\nshould only be used in children if they are being treated for Crohn\u2019s\ndisease or ulcerative colitis. These children must be 6\u00a0years of age or\nolder.</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\nare given too much Remicade</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">As this medicine is being given by your\ndoctor or nurse, it is unlikely that you will be given too much. There are no\nknown side effects of having too much of Remicade.</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\nforget or miss your Remicade infusion</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you forget or miss an appointment to\nreceive Remicade, make another appointment as soon as possible.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have any further questions on the\nuse of this medicine, ask your doctor.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side\neffects</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Like all medicines, this medicine can cause\nside effects, although not everybody gets them. Most side effects are mild to\nmoderate. However some patients may experience serious side effects and may\nrequire treatment. Side effects may also occur after your treatment with Remicade\nhas stopped.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Tell your\ndoctor straight away if you notice any of the following:</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of an allergic reaction</span></b><span lang=\"EN-GB\"> such as swelling of your face, lips, mouth or throat which may\ncause difficulty in swallowing or breathing, skin rash, hives, swelling of the\nhands, feet or ankles. Some of these reactions may be serious or\nlife-threatening. An allergic reaction could happen within 2\u00a0hours of your\ninjection or later. More signs of allergic side effects that may happen up to\n12\u00a0days after your injection include pain in the muscles, fever, joint or\njaw pain, sore throat or headache.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of a heart problem</span></b><span lang=\"EN-GB\"> such as chest discomfort or pain, arm pain, stomach pain, shortness\nof breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea\n(feeling sick), vomiting, fluttering or pounding in your chest, a fast or a\nslow heartbeat, and swelling of your feet.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of infection (including TB)</span></b><span lang=\"EN-GB\"> such as fever, feeling tired, cough which may be persistent,\nshortness of breath, flu\u2011like symptoms, weight loss, night sweats,\ndiarrhoea, wounds, collection of pus in the gut or around the anus (abscess), dental\nproblems or burning sensation when urinating.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Possible signs of cancer</span></b><span lang=\"EN-GB\"> including but not limited to swelling of lymph nodes, weight loss,\nfever, unusual skin nodules, changes in moles or skin colouring, or unusual\nvaginal bleeding.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of a lung problem</span></b><span lang=\"EN-GB\"> such as coughing, breathing difficulties or tightness in the chest.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of a nervous system problem (including\neye problems)</span></b><span lang=\"EN-GB\"> such as signs of a stroke (sudden\nnumbness or weakness of your face, arm or leg, especially on one side of your\nbody; sudden confusion, trouble speaking or understanding; trouble seeing in\none or both eyes, trouble walking, dizziness, loss of balance or coordination\nor a severe headache), fits, tingling/numbness in any part of your body, or weakness\nin arms or legs, changes in eyesight such as double vision or other eye\nproblems.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of a liver problem</span></b><span lang=\"EN-GB\"> (including hepatitis B infection when you have had hepatitis B in\nthe past) such as yellowing of the skin or eyes, dark\u2011brown coloured urine,\npain or swelling in the upper right side of the stomach area, joint pain, skin\nrashes, or fever.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of an immune system disorder </span></b><span lang=\"EN-GB\">such as joint pain or a rash on cheeks or arms that is sensitive to\nthe sun (lupus) or cough, shortness of breath, fever or skin rash (sarcoidosis).</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of low blood counts</span></b><span lang=\"EN-GB\"> such as persistent fever, bleeding or bruising more easily, small\nred or purple spots caused by bleeding under the skin, or looking pale.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of serious skin problems </span></b><span lang=\"EN-GB\">such as reddish-target-like spots or circular patches often with\ncentral blisters on the trunk, large areas of peeling and shedding\n(exfoliating) skin, ulcers of mouth, throat, nose, genitals and eyes or small\npus-filled bumps that can spread over the body. These skin reactions can be accompanied\nby fever.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor straight away if you\nnotice any of the above.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The following side effects have been\nobserved with Remicade:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Very\ncommon: may affect more than 1\u00a0in 10\u00a0people</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Stomach pain, feeling sick</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Viral infections such as herpes or flu</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Upper respiratory infections such as sinusitis</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Headache</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Side effect due to an infusion</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Pain.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Common:\nmay affect up to 1\u00a0in 10\u00a0people</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Changes in how your liver works, increase in\nliver enzymes (shown in blood tests)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Lung or chest infections such as bronchitis or\npneumonia</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Difficult or painful breathing, chest pain</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Bleeding in the stomach or intestines,\ndiarrhoea, indigestion, heartburn, constipation</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Nettle\u2011type rash (hives), itchy rash or\ndry skin</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Balance problems or feeling dizzy</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fever, increased sweating</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Circulation problems such as low or high blood\npressure</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Bruising, hot flush or nosebleed, warm, red skin\n(flushing)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling tired or weak</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Bacterial infections such as blood poisoning,\nabscess or infection of the skin (cellulitis)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Infection of the skin due to a fungus</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Blood problems such as anaemia or low white\nblood cell count</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Swollen lymph nodes</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Depression, problems sleeping</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Eye problems, including red eyes and infections</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fast heart beat (tachycardia) or palpitations</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Pain in the joints, muscles or back</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Urinary tract infection</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Psoriasis, skin problems such as eczema and hair\nloss</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Reactions at the injection site such as pain,\nswelling, redness or itching</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Chills, a build up of fluid under the skin causing\nswelling</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling numb or having a tingling feeling.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Uncommon:\nmay affect up to 1\u00a0in 100\u00a0people</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Shortage of blood supply, swelling of a vein</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Collection of blood outside the blood vessels (haematoma)\nor bruising</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Skin problems such as blistering, warts,\nabnormal skin colouration or pigmentation, or swollen lips, or thickening of the\nskin, or red, scaly, and flaky skin</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Severe allergic reactions (e.g. anaphylaxis), an\nimmune system disorder called lupus, allergic reactions to foreign proteins</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Wounds taking longer to heal</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Swelling of the liver (hepatitis) or gall\nbladder, liver damage</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling forgetful, irritable, confused, nervous</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Eye problems including blurred or reduced\nvision, puffy eyes or sties</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">New or worsening heart failure, slow heart rate</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fainting</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Convulsions, nerve problems</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A hole in the bowel or blockage of the\nintestine, stomach pain or cramps</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Swelling of your pancreas (pancreatitis)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fungal infections such as yeast infection or\nfungal infection of the nails</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Lung problems (such as oedema)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fluid around the lungs (pleural effusion)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Narrowed airway in the lungs, causing difficulty\nbreathing</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflamed lining of the lung, causing sharp chest\npains that feel worse with breathing (pleurisy)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tuberculosis</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney infections</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Low platelet count, too many white blood cells</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Infections of the vagina</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Blood test result showing\n\u2018antibodies\u2019 against your own body.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Rare: may\naffect up to 1\u00a0in 1,000\u00a0people</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A type of blood cancer (lymphoma)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Your blood not supplying enough oxygen to your\nbody, circulation problems such as narrowing of a blood vessel</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of the lining of the brain\n(meningitis)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Infections due to a weakened immune system</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Hepatitis B infection when you have had\nhepatitis B in the past</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflamed liver caused by a problem with the\nimmune system (autoimmune hepatitis)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Liver problem that causes yellowing of the skin\nor eyes (jaundice)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Abnormal tissue swelling or growth</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><a name=\"OLE_LINK3\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Severe allergic reaction that may cause loss of\nconsciousness and could be life-threatening (anaphylactic shock)</span></a></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Swelling of small blood vessels (vasculitis)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune disorders that could affect the lungs,\nskin and lymph nodes (such as sarcoidosis).</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Collections of immune cells resulting from an\ninflammatory response (granulomatous lesions)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Lack of interest or emotion</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Serious skin problems such as toxic epidermal\nnecrolysis, Stevens\u2011Johnson Syndrome and acute generalised exanthematous\npustulosis</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Other skin problems such as erythema multiforme,\nlichenoid reactions (itchy reddish-purple skin rash and/or threadlike\nwhite-grey lines on mucous membranes), blisters and peeling skin, or boils\n(furunculosis)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Serious nervous system disorders such as\ntransverse myelitis, multiple sclerosis\u2011like disease, optic neuritis and\nGuillain\u2011Barr\u00e9 syndrome</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation in the eye that may cause changes\nin the vision, including blindness</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fluid in the lining of the heart (pericardial\neffusion)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Serious</span><span lang=\"EN-GB\"> lung problems\n(such as interstitial lung disease)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Melanoma (a type of skin cancer)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Cervical cancer</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Low blood counts, including a severely decreased\nnumber of white blood cells</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Small red or purple spots caused by bleeding under\nthe skin</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Abnormal values of a blood protein called\n\u2018complement factor\u2019 which is part of the immune system.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Not\nknown: frequency cannot be estimated from the available data</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Cancer in children and adults</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A rare blood cancer affecting mostly teenage boys\nor young men (hepatosplenic T\u2011cell lymphoma)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Liver failure</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Merkel cell carcinoma (a type of skin cancer)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">Ka</ins></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:10\">posi\u2019s sarcoma, a rare cancer related to\ninfection with human herpes virus 8. Kaposi\u2019s sarcoma most commonly\nappears as purple lesions on the skin.</ins></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Worsening of a condition called dermatomyositis\n(seen as a skin rash accompanying muscle weakness)</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Heart attack</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Stroke</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Temporary loss of sight during or within 2\u00a0hours\nof infusion</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Infection due to a live vaccine because of a\nweakened immune system.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Additional\nside effects in children and adolescents</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Children who\ntook Remicade for Crohn\u2019s disease showed some differences in side effects\ncompared with adults who took Remicade for Crohn's disease. The side effects\nthat happened more in children were: low red blood cells (anaemia), blood in\nstool, low overall levels of white blood cells (leucopenia), redness or\nblushing (flushing), viral infections, low levels of white blood cells that\nfight infection (neutropenia), bone fracture, bacterial infection and allergic\nreactions of the breathing tract.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting\nof side effects</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">If you get\nany side effects, talk to your doctor, pharmacist or nurse. This includes any\npossible side effects not listed in this leaflet. You can also report side\neffects directly via <span style=\"background:silver\">the national reporting\nsystem listed in <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a></span>. By reporting side effects you can help provide more information\non the safety of this medicine.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><a name=\"_Hlk503423848\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Remicade</span></b></a></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade will generally be stored by the\nhealth professionals. The storage details should you need them are as follows:</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Keep this medicine out of the sight and reach of\nchildren.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not use this medicine after the expiry date\nwhich is stated on the label and the carton after \u201cEXP\u201d. The expiry\ndate refers to the last day of that month.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Store in a refrigerator (2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:17\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>-<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C).</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">This medicine can also be stored in the original\ncarton outside of refrigerated storage up to a maximum of 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C for a single period of up\nto six months, but not beyond the original expiry date. In this situation, do\nnot return to refrigerated storage again. Write the new expiry date on the\ncarton including day/month/year. Discard this medicine if not used by the new\nexpiry date or the expiry date printed on the carton, whichever is earlier.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">It is recommended that when Remicade is prepared\nfor infusion, it is used as soon as possible (within 3\u00a0hours). However, if\nthe solution is prepared in germ\u2011free conditions, it can be stored in a\nrefrigerator at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C to 8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C up to 28\u00a0days and for\nan additional 24\u00a0hours at 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C after removal from the\nrefrigerator.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not use this medicine if it is discoloured or\nif there are particles present.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of\nthe pack and other information</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nRemicade contains</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The active substance is infliximab. Each vial\ncontains 100\u00a0mg of infliximab. After preparation each ml contains 10\u00a0mg\nof infliximab</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The other ingredients are sucrose, polysorbate\u00a080,\nmonobasic sodium phosphate and dibasic sodium phosphate.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nRemicade looks like and contents of the pack</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is supplied as a glass vial\ncontaining a powder for concentrate for solution for infusion. The powder is a\nfreeze\u2011dried white pellet.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is produced in packs of 1, 2, 3, 4\nor 5\u00a0vials. Not all pack sizes may be marketed.</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing\nAuthorisation Holder and Manufacturer</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Janssen Biologics B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Einsteinweg\u00a0101</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2333\u00a0CB\u00a0Leiden</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">The Netherlands</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">For any information about this medicine,\nplease contact the local representative of the Marketing Authorisation Holder:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<div align=\"center\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Belgium BVBA/SPRL</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_belux@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">UAB Merck\n  Sharp &amp; Dohme</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel. + 370 5\n  278 02 47</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_lietuva@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u041c\u0435\u0440\u043a\n  \u0428\u0430\u0440\u043f \u0438 \u0414\u043e\u0443\u043c\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0422\u0435\u043b.: +359 2 819 3737</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">info\u2011msdbg@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD Belgium BVBA/SPRL</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_belux@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +420 233 010 111</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Pharma Hungary Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +36\u00a01\u00a0888\u00a05300</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">hungary_msd@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD Danmark ApS</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tlf: + 45 4482 4000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dkmail@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: 8007\n  4433 (+356 99917558)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">malta_info@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD SHARP &amp; DOHME GMBH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: 0800 673 673 673 (+49 (0) 89 4561 2612)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">e\u2011mail@msd.de</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: 0800 9999000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(+31 23 5153153)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinfo.nl@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme O\u00dc</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel.:\n  +372\u00a06144 200</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">msdeesti@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD (Norge) AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +47 32 20 73 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdnorge@msd.no</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD </span><span lang=\"EN-GB\">\u0391.\u03a6.\u0392.\u0395.\u0395.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb</span><span lang=\"EN-GB\">: +30 210 98 97 300</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_greece@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Merck Sharp &amp; Dohme Ges.m.b.H.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +43 (0) 1 26 044</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">msd\u2011medizin@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Merck Sharp &amp; Dohme de Espa\u00f1a,\n  S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 91 321 06 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_info@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Polska Sp. z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 22 549 51 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdpolska@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">MSD France</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l: + 33 (0) 1 80 46 40 40</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"PT-BR\">Merck Sharp\n  &amp; Dohme, Lda</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"PT-BR\">Tel: +351 21\n  4465700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">inform_pt@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 385 1 6611 333</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">croatia_info@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Merck Sharp &amp; Dohme Romania S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 529 29 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdromania@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme Ireland (Human Health)\n  Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: +353\n  (0)1 2998700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medinfo_ireland@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme, inovativna\n  zdravila d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +386 1 5204 201</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd.slovenia@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Vistor hf.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi: + 354 535 7000</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovensk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme, s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +421 2 58282010</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Italia S.r.l.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +39 06 361911</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinformation.it@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">MSD Finland\n  Oy</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Puh/Tel: +358\n  (0)9 804 650</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">info@msd.fi</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb.:\n  800 00 673 (+357 22866700)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">cyprus_info@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Sverige</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"DE\">Merck Sharp\n  &amp; Dohme (Sweden) AB</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: +46 77\n  5700488</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicinskinfo@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">SIA Merck\n  Sharp &amp; Dohme Latvija</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 371 67364224</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_lv@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme Limited</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1992 467272</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinformationuk@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>\n</div>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">This leaflet was last revised in\n{MM/YYYY}.</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other sources of information</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Detailed\ninformation on this medicine is available on the European Medicines Agency web\nsite: <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a>.</span></p>\n<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"OLE_LINK4\"><span lang=\"EN-GB\">The following information is intended for healthcare professionals\nonly:</span></a></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Patients\ntreated with Remicade should be given the patient reminder card.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Instructions\nfor use and handling \u2013 storage conditions</span></i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade may be stored at temperatures up\nto a maximum of 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C for a single period of up\nto 6\u00a0months, but not exceeding the original expiry date. The new expiry\ndate must be written on the carton. Upon removal from refrigerated storage,\nRemicade must not be returned to refrigerated storage.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Instructions\nfor use and handling \u2013 reconstitution, dilution and administration</span></i></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In order to\nimprove the traceability of biological medicinal products, the tradename and\nbatch number of the administered medicinal product should be clearly recorded.</span></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Calculate the dose and the\nnumber of Remicade vials needed. Each Remicade vial contains 100\u00a0mg\ninfliximab. Calculate the total volume of reconstituted Remicade solution\nrequired.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Under aseptic conditions,\nreconstitute each Remicade vial with 10\u00a0ml of water for injections, using\na syringe equipped with a 21\u2011gauge (0.8\u00a0mm) or smaller needle.\nRemove flip\u2011top from the vial and wipe the top with a 70% alcohol swab.\nInsert the syringe needle into the vial through the centre of the rubber\nstopper and direct the stream of water for injections to the glass wall of the\nvial. Gently swirl the solution by rotating the vial to dissolve the\nlyophilised powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE.\nFoaming of the solution on reconstitution is not unusual. Allow the\nreconstituted solution to stand for 5\u00a0minutes. Check that the solution is\ncolourless to light yellow and opalescent. The solution may develop a few fine\ntranslucent particles, as infliximab is a protein. Do not use if opaque\nparticles, discolouration, or other foreign particles are present.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dilute the total volume of\nthe reconstituted Remicade solution dose to 250\u00a0ml with sodium chloride\n9\u00a0mg/ml (0.9%) solution for infusion. Do not dilute the reconstituted\nRemicade solution with any other diluent. The dilution can be accomplished by\nwithdrawing a volume of the sodium chloride 9\u00a0mg/ml (0.9%) solution for\ninfusion from the 250\u2011ml glass bottle or infusion bag equal to the volume\nof reconstituted Remicade. Slowly add the total volume of reconstituted\nRemicade solution to the 250\u2011ml infusion bottle or bag. Gently mix. For\nvolumes greater than 250\u00a0ml, either use a larger infusion bag (e.g. 500\u00a0ml,\n1000\u00a0ml) or use multiple 250\u00a0ml infusion bags to ensure that the\nconcentration of the infusion solution does not exceed 4\u00a0mg/ml. If stored\nrefrigerated after reconstitution and dilution, the infusion solution must be\nallowed to equilibrate at room temperature to 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C for 3\u00a0hours prior to\nStep\u00a04 (infusion). Storage beyond 24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C applies to preparation of\nRemicade in the infusion bag only.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Administer the infusion\nsolution over a period of not less than the infusion time recommended. Use only\nan infusion set with an in\u2011line, sterile, non\u2011pyrogenic, low\nprotein\u2011binding filter (pore size 1.2\u00a0micrometre or less). Since no\npreservative is present, it is recommended that the administration of the\nsolution for infusion is to be started as soon as possible and within\n3\u00a0hours of reconstitution and dilution. If not used immediately, in use\nstorage times and conditions prior to use are the responsibility of the user\nand would normally not be longer than 24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C, unless reconstitution/dilution\nhas been taken place in controlled and validated aseptic conditions. Do not\nstore any unused portion of the infusion solution for reuse.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 No physical biochemical\ncompatibility studies have been conducted to evaluate the co\u2011administration\nof Remicade with other agents. Do not infuse Remicade concomitantly in the same\nintravenous line with other agents.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Visually inspect Remicade for\nparticulate matter or discolouration prior to administration. Do not use if\nvisibly opaque particles, discolouration or foreign particles are observed.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Any unused product or waste\nmaterial should be disposed of in accordance with local requirements.</span></p>\n</div>", "ID": "8c47ffa8-0259-475d-acf9-2d9675807e72", "Styles": "None", "Classes": "['WordSection1']", "Text": "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ", "ParentId": "a84fa060-6a5f-4cc6-b761-0ebaab8f12aa"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b19627b5-3b5d-4a9d-a851-250d5c125dc0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "077e206b-2be8-49a5-be6b-50d246d081a9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b19627b5-3b5d-4a9d-a851-250d5c125dc0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ffdc2b69-1b7e-4c3d-b85a-a8eb9c21ceef", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d429cb55-3473-47e3-b862-6d178b7dc09a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ffdc2b69-1b7e-4c3d-b85a-a8eb9c21ceef"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0eb5ecbc-ec0a-4142-9c22-4c91a4813898", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c14e5f8d-4abe-4395-aa12-3cd0b0b8a330", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0eb5ecbc-ec0a-4142-9c22-4c91a4813898"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5fd6b591-44f0-4ad7-9c54-d27c7f59ff44", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c1f92549-08b2-444a-8766-fb2a12f338bd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5fd6b591-44f0-4ad7-9c54-d27c7f59ff44"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "85c47910-2417-43ca-a8f0-fa0427fd4b1d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "84e0f5c3-aeba-4bef-8eb1-c14d3fb56e0f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "85c47910-2417-43ca-a8f0-fa0427fd4b1d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0061b530-30b7-4153-9748-7a8a291ea047", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "71804101-f539-460b-8948-647478ea6666", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0061b530-30b7-4153-9748-7a8a291ea047"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "df38dedb-09ea-418a-ad2a-ed9b0fe679bb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3ea8fcef-3f64-4c91-b900-fd5d423a144e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "df38dedb-09ea-418a-ad2a-ed9b0fe679bb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fe7dcf8f-9771-4576-9e3f-3a479f97c487", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be2627ab-cd85-4116-b317-563f41826d7e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fe7dcf8f-9771-4576-9e3f-3a479f97c487"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7cacfd49-6e70-42b6-a69b-e39d3570d64e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e27cbddd-29b4-4144-9db2-8cb5c6c4cba3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7cacfd49-6e70-42b6-a69b-e39d3570d64e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "75f1257e-dbbc-4f10-b04e-256b1d924681", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "431923bc-e033-4204-a7ae-efa1e83859bd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "75f1257e-dbbc-4f10-b04e-256b1d924681"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "96b3cf77-4d6b-434f-81b2-9691587605cd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bf4801c1-6e36-4aea-9b48-ba560bf8c179", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "96b3cf77-4d6b-434f-81b2-9691587605cd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0e0cdda8-a7c5-453d-b06b-56a20892bfde", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa5ef162-cf59-46e6-98e2-24c5d3d590a1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0e0cdda8-a7c5-453d-b06b-56a20892bfde"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6a6debfa-e3f6-49f7-b89f-dd66e05b29bf", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b69b858-6c72-4c76-942f-0ffb7ea53e9d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6a6debfa-e3f6-49f7-b89f-dd66e05b29bf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b4d131e1-c574-4882-8659-16db545475ba", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6751fce1-d068-4ab5-a34e-46c6dca41306", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b4d131e1-c574-4882-8659-16db545475ba"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "190c6868-1030-4f6c-ab4e-8d5ced2d8aeb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "05d33117-bd86-495e-9e65-849f2594c9ba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "190c6868-1030-4f6c-ab4e-8d5ced2d8aeb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d046d942-b826-438e-9bde-e96ea960746a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4c1ad592-31b9-4259-bdfb-61701e414c49", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d046d942-b826-438e-9bde-e96ea960746a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e08825c8-1565-46ea-bf68-17bac6a87aa7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "47a46c60-eba1-43a3-b5c3-2fcbaa45a717", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e08825c8-1565-46ea-bf68-17bac6a87aa7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5925270c-96fa-492c-b70c-28bb92176165", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4109ef41-45fc-4091-aafe-3721138675f0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5925270c-96fa-492c-b70c-28bb92176165"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fcbaa390-781d-40a3-99bb-606a3df294a9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b7e54ab2-0c12-4670-a469-1dd15b85c3d5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fcbaa390-781d-40a3-99bb-606a3df294a9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "23476483-e9b2-45aa-b4e8-2f11027f7f71", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d81ed25f-4c70-491f-9ae6-db51342d1227", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "23476483-e9b2-45aa-b4e8-2f11027f7f71"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6e315a5c-92eb-4a8d-bb2e-9bd7a0cd90cf", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "43f120fe-30d6-4195-9d1d-d4b3d3b1011d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6e315a5c-92eb-4a8d-bb2e-9bd7a0cd90cf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a9ccf210-6b3f-4b4d-8c4d-532bbf1433d6", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cfac684b-717f-49bd-b554-63b2c15baf7d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a9ccf210-6b3f-4b4d-8c4d-532bbf1433d6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4d192541-842a-4149-bf45-2e5ea2e9b782", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bcb4af61-8a1f-4e81-b9e3-676495d4a28a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4d192541-842a-4149-bf45-2e5ea2e9b782"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nI</span></b></p>", "ID": "92bf9917-33da-4f32-9fe2-46bf164cc9ba", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX\nI</span></b>", "ID": "2d7a50d9-f73f-40e8-af14-fab5700caffe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "92bf9917-33da-4f32-9fe2-46bf164cc9ba"}, {"Element": "<span lang=\"EN-GB\">ANNEX\nI</span>", "ID": "427c75d0-15ea-4306-8829-9d2a575f280a", "Styles": "None", "Classes": "None", "Text": "ANNEX I", "ParentId": "2d7a50d9-f73f-40e8-af14-fab5700caffe"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "46f1cc61-d8d5-41bc-9bcf-a03bf5c681cf", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "5aaff2b1-48a9-4ca8-b71b-de4e38160429", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "46f1cc61-d8d5-41bc-9bcf-a03bf5c681cf"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e72024b0-9916-465f-b574-f3d417640c7e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5aaff2b1-48a9-4ca8-b71b-de4e38160429"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">SUMMARY\nOF PRODUCT CHARACTERISTICS</span></b></p>", "ID": "7d7b72af-3d7d-4f7e-88ff-34a102d87863", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">SUMMARY\nOF PRODUCT CHARACTERISTICS</span></b>", "ID": "d6e7656c-4c19-4c09-a705-d6bc6812a9d4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7d7b72af-3d7d-4f7e-88ff-34a102d87863"}, {"Element": "<span lang=\"EN-GB\">SUMMARY\nOF PRODUCT CHARACTERISTICS</span>", "ID": "753b4a93-363a-4641-a189-54e917c780d9", "Styles": "None", "Classes": "None", "Text": "SUMMARY OF PRODUCT CHARACTERISTICS", "ParentId": "d6e7656c-4c19-4c09-a705-d6bc6812a9d4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "c0a33fca-ffb6-462c-92ce-431c78571b6e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "d90a2c6b-975f-4433-8d68-e3d2799b3693", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c0a33fca-ffb6-462c-92ce-431c78571b6e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ce8c0ce1-e3dc-40e0-af80-bf2281a06d40", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d90a2c6b-975f-4433-8d68-e3d2799b3693"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "e803c3a7-0ca1-45d2-a0f6-90d435bca383", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "0af91cff-9163-4cc1-87c7-e093c50a65f7", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "e803c3a7-0ca1-45d2-a0f6-90d435bca383"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "e03c8fc0-3376-4b06-9e81-1063c6f5bdf1", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "0af91cff-9163-4cc1-87c7-e093c50a65f7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE\nMEDICINAL PRODUCT</span></b></p>", "ID": "26aa0760-322c-457a-ac41-418078cfd2fb", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE\nMEDICINAL PRODUCT</span></b>", "ID": "78a35a75-bddf-4dba-8768-75d17fb55903", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "26aa0760-322c-457a-ac41-418078cfd2fb"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE\nMEDICINAL PRODUCT</span>", "ID": "2e999a37-e6eb-4a16-952e-095b485ba7c9", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "78a35a75-bddf-4dba-8768-75d17fb55903"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "11221763-8809-4fcc-9bdb-cd84b187af8c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d7101e04-0891-4543-b4ef-14e1a43bf361", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "11221763-8809-4fcc-9bdb-cd84b187af8c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade 100\u00a0mg powder for concentrate\nfor solution for infusion.</span></p>", "ID": "bf27a31e-9e61-41a9-9a4f-ce622a1de33a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade 100\u00a0mg powder for concentrate\nfor solution for infusion.</span>", "ID": "3c459eb5-6def-4c5f-a4a7-0047bcb7f617", "Styles": "None", "Classes": "None", "Text": "Remicade 100\u00a0mg powder for concentrate for solution for infusion.", "ParentId": "bf27a31e-9e61-41a9-9a4f-ce622a1de33a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "56a72632-eb27-458e-bd73-9eb6fe07c645", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b48fe70a-c9cc-436b-9cbe-aa4f495913ba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "56a72632-eb27-458e-bd73-9eb6fe07c645"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c916afb-6eea-42cd-980b-1a32bc09d260", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "24e1d0e0-1f2f-460e-9802-b22333b3d6df", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c916afb-6eea-42cd-980b-1a32bc09d260"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\nAND QUANTITATIVE COMPOSITION</span></b></p>", "ID": "d8f3f6f5-05ee-4326-be5e-b7204309410b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\nAND QUANTITATIVE COMPOSITION</span></b>", "ID": "d94342d7-1e33-4985-9bed-e77e3c5dd15a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d8f3f6f5-05ee-4326-be5e-b7204309410b"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE\nAND QUANTITATIVE COMPOSITION</span>", "ID": "dc45044d-df0e-4808-b092-13a9f8e07ea8", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 QUALITATIVE AND QUANTITATIVE COMPOSITION", "ParentId": "d94342d7-1e33-4985-9bed-e77e3c5dd15a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "54eb1b7e-1a2c-44f7-98c9-911dbcffd772", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "59c80e7d-6708-4f52-877d-70647fea064b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "54eb1b7e-1a2c-44f7-98c9-911dbcffd772"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains 100\u00a0mg of\ninfliximab. Infliximab is a chimeric human\u2011murine IgG1\u00a0monoclonal\nantibody produced in murine hybridoma cells by recombinant DNA technology.\nAfter reconstitution each ml contains 10\u00a0mg of infliximab.</span></p>", "ID": "0a34a4b7-8a66-4f56-be98-3754b73c5056", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Each vial contains 100\u00a0mg of\ninfliximab. Infliximab is a chimeric human\u2011murine IgG1\u00a0monoclonal\nantibody produced in murine hybridoma cells by recombinant DNA technology.\nAfter reconstitution each ml contains 10\u00a0mg of infliximab.</span>", "ID": "8db55cb1-a56f-483b-bad8-0e6ef13206ba", "Styles": "None", "Classes": "None", "Text": "Each vial contains 100\u00a0mg of infliximab. Infliximab is a chimeric human\u2011murine IgG1\u00a0monoclonal antibody produced in murine hybridoma cells by recombinant DNA technology. After reconstitution each ml contains 10\u00a0mg of infliximab.", "ParentId": "0a34a4b7-8a66-4f56-be98-3754b73c5056"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1857135d-260b-446d-9c58-f6c3f9c3d402", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8529e0a5-3aba-4ee6-b502-6e7aff3b9ce1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1857135d-260b-446d-9c58-f6c3f9c3d402"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For the full list of excipients, see\nsection\u00a06.1.</span></p>", "ID": "4b718d54-5e3f-452b-81fd-e3eec7fd3aee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">For the full list of excipients, see\nsection\u00a06.1.</span>", "ID": "9aa2f093-e0b2-460d-98a1-5e45df3b6cc0", "Styles": "None", "Classes": "None", "Text": "For the full list of excipients, see section\u00a06.1.", "ParentId": "4b718d54-5e3f-452b-81fd-e3eec7fd3aee"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dee09b48-7d74-418d-adb7-f966794ba5d2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7d82f058-600c-49dc-897e-44899f913286", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dee09b48-7d74-418d-adb7-f966794ba5d2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4cd9b0b2-fd89-4cd9-bb7d-7a11aa55423b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c7a23eb9-dd79-43a7-9d87-8730969ba7eb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4cd9b0b2-fd89-4cd9-bb7d-7a11aa55423b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM</span></b></p>", "ID": "d5891d35-14a7-42e8-989f-36c000c13e63", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM</span></b>", "ID": "df8c382d-317a-4d54-bcc7-df3f1020398d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d5891d35-14a7-42e8-989f-36c000c13e63"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM</span>", "ID": "15c415bf-3c01-49b2-b6ad-5d9e984a7c04", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM", "ParentId": "df8c382d-317a-4d54-bcc7-df3f1020398d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "906399cf-eeb9-4686-9f49-310febfb594d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cc40d6f9-61b6-497e-9a42-bf5706ef5271", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "906399cf-eeb9-4686-9f49-310febfb594d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Powder for concentrate for solution for\ninfusion (</span><span lang=\"EN-GB\">powder for concentrate).</span></p>", "ID": "ad1f6d6f-ba63-494d-81d2-a81c18415d14", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Powder for concentrate for solution for\ninfusion (</span>", "ID": "d8638d32-19ad-486b-bf56-cb4c37fca4bb", "Styles": "None", "Classes": "None", "Text": "Powder for concentrate for solution for infusion (", "ParentId": "ad1f6d6f-ba63-494d-81d2-a81c18415d14"}, {"Element": "<span lang=\"EN-GB\">powder for concentrate).</span>", "ID": "863bae4f-0f5c-4c1c-96d5-5311965b258b", "Styles": "None", "Classes": "None", "Text": "powder for concentrate).", "ParentId": "ad1f6d6f-ba63-494d-81d2-a81c18415d14"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2fbe9bfe-81ed-4c12-bca7-04fe19a052a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c0bdb51b-cc38-4a06-8005-95dc47b62aa9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2fbe9bfe-81ed-4c12-bca7-04fe19a052a7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The powder is a freeze\u2011dried white\npellet.</span></p>", "ID": "38cac111-4777-4d04-a8eb-2be6e7360275", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The powder is a freeze\u2011dried white\npellet.</span>", "ID": "57ab078f-cb94-4277-949b-7784790f456d", "Styles": "None", "Classes": "None", "Text": "The powder is a freeze\u2011dried white pellet.", "ParentId": "38cac111-4777-4d04-a8eb-2be6e7360275"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7e49245b-512b-44c6-a654-5e843b497ae5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "03eaf89d-96c4-49cc-9436-3280f8a9ab2f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7e49245b-512b-44c6-a654-5e843b497ae5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0e54732a-00f3-4786-aa65-1738a7640042", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b8f6af80-c7f5-4928-82c5-528b72562edc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0e54732a-00f3-4786-aa65-1738a7640042"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL\nPARTICULARS</span></b></p>", "ID": "13cf2a41-4eaa-4432-be8b-8e6ef8ecd3e3", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL\nPARTICULARS</span></b>", "ID": "19519132-df51-4275-8081-4f5666348f85", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "13cf2a41-4eaa-4432-be8b-8e6ef8ecd3e3"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL\nPARTICULARS</span>", "ID": "a675921b-332f-4be7-ba14-1b8f840eac71", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CLINICAL PARTICULARS", "ParentId": "19519132-df51-4275-8081-4f5666348f85"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7eb00fee-d64f-49a4-98d1-cde01c2fc60a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8a49d993-0043-4996-8305-7127285c1f85", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7eb00fee-d64f-49a4-98d1-cde01c2fc60a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span></b></p>", "ID": "22d75c03-b795-4c54-8732-d1f06ee68fa0", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span></b>", "ID": "2938f7f9-27b6-470b-85c1-5ca061d7f1a7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "22d75c03-b795-4c54-8732-d1f06ee68fa0"}, {"Element": "<span lang=\"EN-GB\">4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications</span>", "ID": "53b86789-8693-4b21-bebe-77a148cc8d7d", "Styles": "None", "Classes": "None", "Text": "4.1\u00a0\u00a0\u00a0\u00a0 Therapeutic indications", "ParentId": "2938f7f9-27b6-470b-85c1-5ca061d7f1a7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f015d570-db9f-42c3-a86b-3b088e5b7c61", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a0aba450-43dd-4cff-ad65-812a57abeae7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f015d570-db9f-42c3-a86b-3b088e5b7c61"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Rheumatoid\narthritis</span></u></p>", "ID": "16f6c6df-760f-4855-9257-37a3421a0732", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Rheumatoid\narthritis</span></u>", "ID": "26c4091a-56dc-4c05-a665-d90f16a4e7ea", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "16f6c6df-760f-4855-9257-37a3421a0732"}, {"Element": "<span lang=\"EN-GB\">Rheumatoid\narthritis</span>", "ID": "5bace88f-1d9f-4b0d-b733-a37c9a20b3fc", "Styles": "None", "Classes": "None", "Text": "Rheumatoid arthritis", "ParentId": "26c4091a-56dc-4c05-a665-d90f16a4e7ea"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade, in combination with methotrexate,\nis indicated for the reduction of signs and symptoms as well as the improvement\nin physical function in:</span></p>", "ID": "87960a45-d06d-4b5f-9cfc-5ff1ec225fd4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade, in combination with methotrexate,\nis indicated for the reduction of signs and symptoms as well as the improvement\nin physical function in:</span>", "ID": "b59439a9-ac65-4918-a5eb-8c70159e8043", "Styles": "None", "Classes": "None", "Text": "Remicade, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:", "ParentId": "87960a45-d06d-4b5f-9cfc-5ff1ec225fd4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">adult patients with active disease when the\nresponse to disease\u2011modifying antirheumatic drugs (DMARDs), including\nmethotrexate, has been inadequate.</span></p>", "ID": "840bb497-cea4-414b-bd15-b19ef08e261d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7e00e2cc-deaf-477e-95c7-e006f4c7d576", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "840bb497-cea4-414b-bd15-b19ef08e261d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0587be29-0e37-4a11-a76a-912f4a85d311", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7e00e2cc-deaf-477e-95c7-e006f4c7d576"}, {"Element": "<span lang=\"EN-GB\">adult patients with active disease when the\nresponse to disease\u2011modifying antirheumatic drugs (DMARDs), including\nmethotrexate, has been inadequate.</span>", "ID": "08f008a5-30ae-4a65-994f-e4cbeceda4d8", "Styles": "None", "Classes": "None", "Text": "adult patients with active disease when the response to disease\u2011modifying antirheumatic drugs (DMARDs), including methotrexate, has been inadequate.", "ParentId": "840bb497-cea4-414b-bd15-b19ef08e261d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">adult patients with severe, active and\nprogressive disease not previously treated with methotrexate or other DMARDs.</span></p>", "ID": "f0ccf8f9-886b-464a-aa69-28a45a91c82b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7cafc21d-7f40-4c66-82d3-ae903bb9e956", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f0ccf8f9-886b-464a-aa69-28a45a91c82b"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0ce254d6-baed-4c88-8e6c-64cad89d1eda", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7cafc21d-7f40-4c66-82d3-ae903bb9e956"}, {"Element": "<span lang=\"EN-GB\">adult patients with severe, active and\nprogressive disease not previously treated with methotrexate or other DMARDs.</span>", "ID": "f8c6a410-d1b6-455f-b5e0-ee674807ac4c", "Styles": "None", "Classes": "None", "Text": "adult patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.", "ParentId": "f0ccf8f9-886b-464a-aa69-28a45a91c82b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In these patient populations, a reduction\nin the rate of the progression of joint damage, as measured by X\u2011ray, has\nbeen demonstrated (see section\u00a05.1).</span></p>", "ID": "c442f608-113d-4b66-a5a5-5b6c12aaae4b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In these patient populations, a reduction\nin the rate of the progression of joint damage, as measured by X\u2011ray, has\nbeen demonstrated (see section\u00a05.1).</span>", "ID": "9f5ee9e0-caa0-4149-8613-31825c6a0efd", "Styles": "None", "Classes": "None", "Text": "In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X\u2011ray, has been demonstrated (see section\u00a05.1).", "ParentId": "c442f608-113d-4b66-a5a5-5b6c12aaae4b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "03b7ac1c-3935-4d98-9499-59e703aeacef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "00d54aa6-f36c-4d16-abe9-726d19026ed6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03b7ac1c-3935-4d98-9499-59e703aeacef"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Adult\nCrohn\u2019s disease</span></u></p>", "ID": "2319dfb3-0cca-45a7-8b54-f477591d0345", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Adult\nCrohn\u2019s disease</span></u>", "ID": "fde2d39d-f7ff-44b4-be1b-5cdea6da0b5f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2319dfb3-0cca-45a7-8b54-f477591d0345"}, {"Element": "<span lang=\"EN-GB\">Adult\nCrohn\u2019s disease</span>", "ID": "ec0a3ab6-0c7c-44cc-95b6-53fd05847cd7", "Styles": "None", "Classes": "None", "Text": "Adult Crohn\u2019s disease", "ParentId": "fde2d39d-f7ff-44b4-be1b-5cdea6da0b5f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is indicated for:</span></p>", "ID": "e5f04f7d-c276-4756-a510-725e1bc2dc1a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade is indicated for:</span>", "ID": "e83ba116-fc66-449e-bba2-24f287afee85", "Styles": "None", "Classes": "None", "Text": "Remicade is indicated for:", "ParentId": "e5f04f7d-c276-4756-a510-725e1bc2dc1a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">treatment of moderately to severely active\nCrohn\u2019s disease, in adult patients who have not responded despite a full\nand adequate course of therapy with a corticosteroid and/or an\nimmunosuppressant; or who are intolerant to or have medical contraindications\nfor such therapies.</span></p>", "ID": "2e8d7b0d-e457-4509-bfeb-7bdc705ae7e9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "9b7eb315-d199-4d97-b211-7820db643d2d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2e8d7b0d-e457-4509-bfeb-7bdc705ae7e9"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "5d7479d5-1499-4c1d-bef4-948ced07a72f", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "9b7eb315-d199-4d97-b211-7820db643d2d"}, {"Element": "<span lang=\"EN-GB\">treatment of moderately to severely active\nCrohn\u2019s disease, in adult patients who have not responded despite a full\nand adequate course of therapy with a corticosteroid and/or an\nimmunosuppressant; or who are intolerant to or have medical contraindications\nfor such therapies.</span>", "ID": "1018595c-5f41-4416-b3c2-67bb16116858", "Styles": "None", "Classes": "None", "Text": "treatment of moderately to severely active Crohn\u2019s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.", "ParentId": "2e8d7b0d-e457-4509-bfeb-7bdc705ae7e9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">treatment of fistulising, active Crohn\u2019s\ndisease, in adult patients who have not responded despite a full and adequate\ncourse of therapy with conventional treatment (including antibiotics, drainage\nand immunosuppressive therapy).</span></p>", "ID": "8d3ed5b0-08ac-4f92-bd71-ec00fed869ec", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "74150c82-def4-42c3-9ab6-d553f7083e29", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8d3ed5b0-08ac-4f92-bd71-ec00fed869ec"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "41b06ba9-20e2-49bb-b5e8-d9e3a2f9a499", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "74150c82-def4-42c3-9ab6-d553f7083e29"}, {"Element": "<span lang=\"EN-GB\">treatment of fistulising, active Crohn\u2019s\ndisease, in adult patients who have not responded despite a full and adequate\ncourse of therapy with conventional treatment (including antibiotics, drainage\nand immunosuppressive therapy).</span>", "ID": "d058ec73-e4b8-4289-9735-20765707f950", "Styles": "None", "Classes": "None", "Text": "treatment of fistulising, active Crohn\u2019s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).", "ParentId": "8d3ed5b0-08ac-4f92-bd71-ec00fed869ec"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b13ebb09-0c6c-489e-9264-39c2c37b513b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "42a4facd-9af0-422d-863f-1b668dcfb365", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b13ebb09-0c6c-489e-9264-39c2c37b513b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\nCrohn\u2019s disease</span></u></p>", "ID": "4eb55045-eff6-468f-b6ce-fbdda28d87ab", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Paediatric\nCrohn\u2019s disease</span></u>", "ID": "912010fd-8245-4431-8181-b2e0a5ed9c01", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4eb55045-eff6-468f-b6ce-fbdda28d87ab"}, {"Element": "<span lang=\"EN-GB\">Paediatric\nCrohn\u2019s disease</span>", "ID": "c0579c3c-d296-4e73-b7c5-bbb36f31383b", "Styles": "None", "Classes": "None", "Text": "Paediatric Crohn\u2019s disease", "ParentId": "912010fd-8245-4431-8181-b2e0a5ed9c01"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is indicated for treatment of\nsevere, active Crohn\u2019s disease, in children and adolescents aged 6 to 17\u00a0years,\nwho have not responded to conventional therapy including a corticosteroid, an\nimmunomodulator and primary nutrition therapy; or who are intolerant to or have\ncontraindications for such therapies. Remicade has been studied only in\ncombination with conventional immunosuppressive therapy.</span></p>", "ID": "b44efa51-1516-424f-b9fa-9e6f612d4e6c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade is indicated for treatment of\nsevere, active Crohn\u2019s disease, in children and adolescents aged 6 to 17\u00a0years,\nwho have not responded to conventional therapy including a corticosteroid, an\nimmunomodulator and primary nutrition therapy; or who are intolerant to or have\ncontraindications for such therapies. Remicade has been studied only in\ncombination with conventional immunosuppressive therapy.</span>", "ID": "6d86724b-e1e1-4c6d-9b68-ec4b4fcf03d3", "Styles": "None", "Classes": "None", "Text": "Remicade is indicated for treatment of severe, active Crohn\u2019s disease, in children and adolescents aged 6 to 17\u00a0years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy.", "ParentId": "b44efa51-1516-424f-b9fa-9e6f612d4e6c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8f166f7e-9faa-41ea-af3d-9ffe83f08c0d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6bbc8995-d6bb-4dc7-8fd1-870869b56fc3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8f166f7e-9faa-41ea-af3d-9ffe83f08c0d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ulcerative\ncolitis</span></u></p>", "ID": "08da3c16-ffd9-4c18-9562-69597abc891a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Ulcerative\ncolitis</span></u>", "ID": "e98511bb-8d0b-4d0b-978c-3f03516c68af", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "08da3c16-ffd9-4c18-9562-69597abc891a"}, {"Element": "<span lang=\"EN-GB\">Ulcerative\ncolitis</span>", "ID": "c9fca149-a205-4f4b-9fd0-834a2cc8da34", "Styles": "None", "Classes": "None", "Text": "Ulcerative colitis", "ParentId": "e98511bb-8d0b-4d0b-978c-3f03516c68af"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is indicated for treatment of\nmoderately to severely active ulcerative colitis in adult patients who have had\nan inadequate response to conventional therapy including corticosteroids and 6\u2011mercaptopurine\n(6\u2011MP) or azathioprine (AZA), or who are intolerant to or have medical\ncontraindications for such therapies.</span></p>", "ID": "c3b2a7cf-2324-45f2-bc5d-0cec11ada6f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade is indicated for treatment of\nmoderately to severely active ulcerative colitis in adult patients who have had\nan inadequate response to conventional therapy including corticosteroids and 6\u2011mercaptopurine\n(6\u2011MP) or azathioprine (AZA), or who are intolerant to or have medical\ncontraindications for such therapies.</span>", "ID": "b9af5680-4241-4b1d-a431-995fb8549749", "Styles": "None", "Classes": "None", "Text": "Remicade is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6\u2011mercaptopurine (6\u2011MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.", "ParentId": "c3b2a7cf-2324-45f2-bc5d-0cec11ada6f2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "46b294be-05d8-45e3-8942-49fc3bd1bfc5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "da427ba2-67f0-4446-8913-e2b0a844a22c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "46b294be-05d8-45e3-8942-49fc3bd1bfc5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\nulcerative colitis</span></u></p>", "ID": "00df070f-84da-41c8-bf65-a6310a485487", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Paediatric\nulcerative colitis</span></u>", "ID": "c5c71866-0acc-4ad7-ab3b-58191e2b99d1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "00df070f-84da-41c8-bf65-a6310a485487"}, {"Element": "<span lang=\"EN-GB\">Paediatric\nulcerative colitis</span>", "ID": "410a52c2-738d-4aec-a8f3-b741af89eac4", "Styles": "None", "Classes": "None", "Text": "Paediatric ulcerative colitis", "ParentId": "c5c71866-0acc-4ad7-ab3b-58191e2b99d1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is indicated for treatment of\nseverely active ulcerative colitis, in children and adolescents aged 6 to 17\u00a0years,\nwho have had an inadequate response to conventional therapy including\ncorticosteroids</span><span lang=\"EN-GB\"> and 6\u2011MP or AZA, or who are\nintolerant to or have medical contraindications for such therapies.</span></p>", "ID": "708cd913-bbb6-4a7c-9563-9f46133774f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade is indicated for treatment of\nseverely active ulcerative colitis, in children and adolescents aged 6 to 17\u00a0years,\nwho have had an inadequate response to conventional therapy including\ncorticosteroids</span>", "ID": "af1f7bd2-fe70-4ff6-9394-49f909b6cddc", "Styles": "None", "Classes": "None", "Text": "Remicade is indicated for treatment of severely active ulcerative colitis, in children and adolescents aged 6 to 17\u00a0years, who have had an inadequate response to conventional therapy including corticosteroids", "ParentId": "708cd913-bbb6-4a7c-9563-9f46133774f2"}, {"Element": "<span lang=\"EN-GB\"> and 6\u2011MP or AZA, or who are\nintolerant to or have medical contraindications for such therapies.</span>", "ID": "13270cf5-ff14-468e-b14a-7efd55d7cae1", "Styles": "None", "Classes": "None", "Text": " and 6\u2011MP or AZA, or who are intolerant to or have medical contraindications for such therapies.", "ParentId": "708cd913-bbb6-4a7c-9563-9f46133774f2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "140c6870-444f-4173-b7d4-990c122b75e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e7c0ea8b-25b6-4d67-8641-46d28166be5d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "140c6870-444f-4173-b7d4-990c122b75e5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Ankylosing spondylitis</span></u></p>", "ID": "86641e8f-85d7-4f95-98e1-87139f84ec3f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Ankylosing spondylitis</span></u>", "ID": "3b5796f1-cf3b-4a9d-9ab1-409839638df9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "86641e8f-85d7-4f95-98e1-87139f84ec3f"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Ankylosing spondylitis</span>", "ID": "83d468c0-88e3-43b8-9645-52cede95a94c", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Ankylosing spondylitis", "ParentId": "3b5796f1-cf3b-4a9d-9ab1-409839638df9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Remicade is\nindicated for treatment of severe, active ankylosing spondylitis, in adult\npatients who have responded inadequately to conventional therapy.</span></p>", "ID": "545790fa-5f86-4159-b483-cdba896dcad1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Remicade is\nindicated for treatment of severe, active ankylosing spondylitis, in adult\npatients who have responded inadequately to conventional therapy.</span>", "ID": "cfa42d6e-148d-4116-aed7-5f48a75ccb5e", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Remicade is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.", "ParentId": "545790fa-5f86-4159-b483-cdba896dcad1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "4607e873-298e-4d0b-acc9-b6938b15be01", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "12889453-6893-49f7-b41f-4e380431223d", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "4607e873-298e-4d0b-acc9-b6938b15be01"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"OLE_LINK1\"><u><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Psoriatic arthritis</span></u></a></p>", "ID": "7d870cb7-7abd-46f4-86fc-13385cb658d6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<a name=\"OLE_LINK1\"><u><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Psoriatic arthritis</span></u></a>", "ID": "e7e214c1-48fe-4716-bf23-8235684c8294", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7d870cb7-7abd-46f4-86fc-13385cb658d6"}, {"Element": "<u><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Psoriatic arthritis</span></u>", "ID": "2a8f2e3f-e999-4b97-8d75-9705ceb1da62", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e7e214c1-48fe-4716-bf23-8235684c8294"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Psoriatic arthritis</span>", "ID": "9df10317-b75e-4f28-a8ca-8763b565ca41", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Psoriatic arthritis", "ParentId": "2a8f2e3f-e999-4b97-8d75-9705ceb1da62"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Remicade is\nindicated for treatment of active and progressive psoriatic arthritis in adult\npatients when the response to previous DMARD therapy has been inadequate.</span></p>", "ID": "188b5942-9df7-4cd8-846b-1e3969a5cf79", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Remicade is\nindicated for treatment of active and progressive psoriatic arthritis in adult\npatients when the response to previous DMARD therapy has been inadequate.</span>", "ID": "b6e83c22-36ae-4805-88c4-5f1c209d24c9", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Remicade is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.", "ParentId": "188b5942-9df7-4cd8-846b-1e3969a5cf79"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Remicade should\nbe administered</span></p>", "ID": "c8390217-ebbb-4f2a-9cb8-75dfa23b5b7a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Remicade should\nbe administered</span>", "ID": "78d6436a-0408-4166-b541-703175598f96", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Remicade should be administered", "ParentId": "c8390217-ebbb-4f2a-9cb8-75dfa23b5b7a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">in combination with methotrexate</span></p>", "ID": "013691bd-c5ef-4e4d-be18-1373dea5b601", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "fac85439-ee92-4b59-b352-d6729ac25eed", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "013691bd-c5ef-4e4d-be18-1373dea5b601"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "1cd2f7b9-7a93-4240-8595-a67a6df16dcb", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "fac85439-ee92-4b59-b352-d6729ac25eed"}, {"Element": "<span lang=\"EN-GB\">in combination with methotrexate</span>", "ID": "dc5235e0-e6d8-4f8e-8541-95cbb6625508", "Styles": "None", "Classes": "None", "Text": "in combination with methotrexate", "ParentId": "013691bd-c5ef-4e4d-be18-1373dea5b601"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">or alone in patients who show intolerance to\nmethotrexate or for whom methotrexate is contraindicated</span></p>", "ID": "f9e1be02-cc1b-4d87-84a2-d0f905453068", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "0c09ca08-4bcd-4df9-b9d0-815f1fb107ce", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f9e1be02-cc1b-4d87-84a2-d0f905453068"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "9140cd00-b15a-468a-bea0-15dcc21f7c9e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "0c09ca08-4bcd-4df9-b9d0-815f1fb107ce"}, {"Element": "<span lang=\"EN-GB\">or alone in patients who show intolerance to\nmethotrexate or for whom methotrexate is contraindicated</span>", "ID": "52ba42b5-8e86-406c-95aa-b0babad8e85d", "Styles": "None", "Classes": "None", "Text": "or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated", "ParentId": "f9e1be02-cc1b-4d87-84a2-d0f905453068"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade has been shown to improve physical\nfunction in patients with psoriatic arthritis, and to reduce the rate of\nprogression of peripheral joint damage as measured by X\u2011ray in patients\nwith polyarticular symmetrical subtypes of the disease (see section\u00a05.1).</span></p>", "ID": "633a3ef9-2014-4d65-a8d9-f5c0f669a64b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade has been shown to improve physical\nfunction in patients with psoriatic arthritis, and to reduce the rate of\nprogression of peripheral joint damage as measured by X\u2011ray in patients\nwith polyarticular symmetrical subtypes of the disease (see section\u00a05.1).</span>", "ID": "1b03060b-0a5b-4f76-b6c9-f5ff3572368b", "Styles": "None", "Classes": "None", "Text": "Remicade has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X\u2011ray in patients with polyarticular symmetrical subtypes of the disease (see section\u00a05.1).", "ParentId": "633a3ef9-2014-4d65-a8d9-f5c0f669a64b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cfebd6fb-eeb0-4a02-9666-35b114d35652", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a8cea170-79f4-4682-998a-f1a9ec44ed54", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cfebd6fb-eeb0-4a02-9666-35b114d35652"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Psoriasis</span></u></p>", "ID": "b5b15ef0-0371-4f21-a69c-1944306976f5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Psoriasis</span></u>", "ID": "ab5aa32f-4228-492d-86ac-40d91fe2a66e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b5b15ef0-0371-4f21-a69c-1944306976f5"}, {"Element": "<span lang=\"EN-GB\">Psoriasis</span>", "ID": "8e5e0893-a4d7-4b44-a6e9-94a824dbbcf3", "Styles": "None", "Classes": "None", "Text": "Psoriasis", "ParentId": "ab5aa32f-4228-492d-86ac-40d91fe2a66e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Remicade is\nindicated for treatment of moderate to severe plaque psoriasis in adult\npatients who failed to respond to, or who have a contraindication to, or are\nintolerant to other systemic therapy including ciclosporin, methotrexate or\nPUVA (see section\u00a05.1).</span></p>", "ID": "2612f6a4-4e7d-4b5c-b7cc-09529211b68b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade is\nindicated for treatment of moderate to severe plaque psoriasis in adult\npatients who failed to respond to, or who have a contraindication to, or are\nintolerant to other systemic therapy including ciclosporin, methotrexate or\nPUVA (see section\u00a05.1).</span>", "ID": "877e5eb4-bd97-4bb8-bd14-43427534f237", "Styles": "None", "Classes": "None", "Text": "Remicade is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or PUVA (see section\u00a05.1).", "ParentId": "2612f6a4-4e7d-4b5c-b7cc-09529211b68b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "040322e6-7cfb-4ed0-98b9-b5ee9b804cfb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7a376137-902a-4ed9-8f6c-45770e72de08", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "040322e6-7cfb-4ed0-98b9-b5ee9b804cfb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of\nadministration</span></b></p>", "ID": "5bffd459-bdf2-498d-b739-34c534d2bea4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of\nadministration</span></b>", "ID": "83ca9146-481d-4be2-b981-43c07a8f5962", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5bffd459-bdf2-498d-b739-34c534d2bea4"}, {"Element": "<span lang=\"EN-GB\">4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of\nadministration</span>", "ID": "4b24c485-ef78-4f8f-bd95-6db298354a85", "Styles": "None", "Classes": "None", "Text": "4.2\u00a0\u00a0\u00a0\u00a0 Posology and method of administration", "ParentId": "83ca9146-481d-4be2-b981-43c07a8f5962"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1203b258-3714-40c1-8f08-a8253693699b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6e87dfc4-b130-4152-87f3-c06037b8fe99", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1203b258-3714-40c1-8f08-a8253693699b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade treatment is to be initiated and\nsupervised by qualified physicians experienced in the diagnosis and treatment\nof rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis,\npsoriatic arthritis or psoriasis. </span><span lang=\"EN-GB\">Remicade should be\nadministered intravenously. </span><span lang=\"EN-GB\">Remicade infusions should\nbe\u00a0administered by qualified healthcare professionals trained </span><span lang=\"EN-GB\">to detect any infusion\u2011related issues.</span><span lang=\"EN-GB\">\nPatients treated with Remicade should be given the package leaflet and the patient\nreminder card.</span></p>", "ID": "b2ba368a-0fb1-40f7-909e-41bdd91545bd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade treatment is to be initiated and\nsupervised by qualified physicians experienced in the diagnosis and treatment\nof rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis,\npsoriatic arthritis or psoriasis. </span>", "ID": "434933a2-fc4e-40cb-82c5-9d81c44d4a04", "Styles": "None", "Classes": "None", "Text": "Remicade treatment is to be initiated and supervised by qualified physicians experienced in the diagnosis and treatment of rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis, psoriatic arthritis or psoriasis. ", "ParentId": "b2ba368a-0fb1-40f7-909e-41bdd91545bd"}, {"Element": "<span lang=\"EN-GB\">Remicade should be\nadministered intravenously. </span>", "ID": "d1b0cbb3-e54d-4338-8dca-df1c0b0a4f80", "Styles": "None", "Classes": "None", "Text": "Remicade should be administered intravenously. ", "ParentId": "b2ba368a-0fb1-40f7-909e-41bdd91545bd"}, {"Element": "<span lang=\"EN-GB\">Remicade infusions should\nbe\u00a0administered by qualified healthcare professionals trained </span>", "ID": "368a61b7-7ae9-4270-a93b-e0f56c237cce", "Styles": "None", "Classes": "None", "Text": "Remicade infusions should be\u00a0administered by qualified healthcare professionals trained ", "ParentId": "b2ba368a-0fb1-40f7-909e-41bdd91545bd"}, {"Element": "<span lang=\"EN-GB\">to detect any infusion\u2011related issues.</span>", "ID": "aa837b96-d9ee-4220-a9e8-9ba5bf03a9cf", "Styles": "None", "Classes": "None", "Text": "to detect any infusion\u2011related issues.", "ParentId": "b2ba368a-0fb1-40f7-909e-41bdd91545bd"}, {"Element": "<span lang=\"EN-GB\">\nPatients treated with Remicade should be given the package leaflet and the patient\nreminder card.</span>", "ID": "eb8baf5c-f895-4f04-b6c0-b993743eee8c", "Styles": "None", "Classes": "None", "Text": " Patients treated with Remicade should be given the package leaflet and the patient reminder card.", "ParentId": "b2ba368a-0fb1-40f7-909e-41bdd91545bd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4b24eeaa-1b09-4f49-9d89-d6a7eb320bfa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "37348211-0b5a-400a-834e-c5e2eaa1b76e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4b24eeaa-1b09-4f49-9d89-d6a7eb320bfa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">During Remicade treatment, other concomitant\ntherapies, e.g., corticosteroids and immunosuppressants should be optimised.</span></p>", "ID": "e46077a6-b5ae-4fd4-a9bf-20d7de1324f3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">During Remicade treatment, other concomitant\ntherapies, e.g., corticosteroids and immunosuppressants should be optimised.</span>", "ID": "f0d58ff4-15a3-41db-a452-1964a6b383db", "Styles": "None", "Classes": "None", "Text": "During Remicade treatment, other concomitant therapies, e.g., corticosteroids and immunosuppressants should be optimised.", "ParentId": "e46077a6-b5ae-4fd4-a9bf-20d7de1324f3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a7ee8ac0-eb72-4e0c-97dd-02f48083970f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a22f4194-ef59-4dc2-9443-323966f0355d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a7ee8ac0-eb72-4e0c-97dd-02f48083970f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Posology</span></u></b></p>", "ID": "335b2b4b-3616-4eb2-af98-ea072f6d0524", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><u><span lang=\"EN-GB\">Posology</span></u></b>", "ID": "b8262f09-470b-4bd1-bf5f-2a78ca2d9da9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "335b2b4b-3616-4eb2-af98-ea072f6d0524"}, {"Element": "<u><span lang=\"EN-GB\">Posology</span></u>", "ID": "a6b5b91e-7d4a-4f1f-8b3e-c8002aa4b2e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b8262f09-470b-4bd1-bf5f-2a78ca2d9da9"}, {"Element": "<span lang=\"EN-GB\">Posology</span>", "ID": "b2f23fd9-8209-4e22-a838-5b5f038c58ab", "Styles": "None", "Classes": "None", "Text": "Posology", "ParentId": "a6b5b91e-7d4a-4f1f-8b3e-c8002aa4b2e3"}, {"Element": "<p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Adults (\u2265\u00a018\u00a0years)</span></i></p>", "ID": "bcd656c5-c61e-4059-a690-9feef471c5cc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Adults (\u2265\u00a018\u00a0years)</span></i>", "ID": "42253f1d-372d-4900-9d0f-f84ed595e32c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bcd656c5-c61e-4059-a690-9feef471c5cc"}, {"Element": "<span lang=\"EN-GB\">Adults (\u2265\u00a018\u00a0years)</span>", "ID": "6cfab940-fa34-4732-91fd-c6c35b75d7b8", "Styles": "None", "Classes": "None", "Text": "Adults (\u2265\u00a018\u00a0years)", "ParentId": "42253f1d-372d-4900-9d0f-f84ed595e32c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Rheumatoid\narthritis</span></u></p>", "ID": "a7afeb24-14a1-477e-a1f3-b55f1fc466b6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Rheumatoid\narthritis</span></u>", "ID": "5bd09d64-1cdd-4544-b735-409262989441", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a7afeb24-14a1-477e-a1f3-b55f1fc466b6"}, {"Element": "<span lang=\"EN-GB\">Rheumatoid\narthritis</span>", "ID": "1d01371b-3f91-44f8-b3a7-240e6f4c442c", "Styles": "None", "Classes": "None", "Text": "Rheumatoid arthritis", "ParentId": "5bd09d64-1cdd-4544-b735-409262989441"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">3\u00a0mg/kg given as an intravenous\ninfusion followed by additional 3\u00a0mg/kg infusion doses at 2 and\n6\u00a0weeks after the first infusion, then every 8\u00a0weeks thereafter.</span></p>", "ID": "51905c0d-4532-4939-bfa1-2dbf1c08a3fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">3\u00a0mg/kg given as an intravenous\ninfusion followed by additional 3\u00a0mg/kg infusion doses at 2 and\n6\u00a0weeks after the first infusion, then every 8\u00a0weeks thereafter.</span>", "ID": "8cb2fc11-17a1-47fd-abeb-c2305f68d6a4", "Styles": "None", "Classes": "None", "Text": "3\u00a0mg/kg given as an intravenous infusion followed by additional 3\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks after the first infusion, then every 8\u00a0weeks thereafter.", "ParentId": "51905c0d-4532-4939-bfa1-2dbf1c08a3fd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "09defc7c-22ba-4caa-bee6-55111bc6c786", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d8f2a580-c793-4ac9-937f-0cbd05c96ea6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "09defc7c-22ba-4caa-bee6-55111bc6c786"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade must be given concomitantly with\nmethotrexate.</span></p>", "ID": "d4d7692c-c72e-4300-b6bc-9d8cbf9f9eea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade must be given concomitantly with\nmethotrexate.</span>", "ID": "a8a215f6-f6c3-4dfc-84b0-6d135066e028", "Styles": "None", "Classes": "None", "Text": "Remicade must be given concomitantly with methotrexate.", "ParentId": "d4d7692c-c72e-4300-b6bc-9d8cbf9f9eea"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3ade2d2f-13ec-479a-8b6f-66eac9fffd7f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a3382e48-c345-4564-8f12-89a762ee0ca5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3ade2d2f-13ec-479a-8b6f-66eac9fffd7f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Available data suggest that the clinical\nresponse is usually achieved within 12\u00a0weeks of treatment. </span><span lang=\"EN-GB\">If a patient has an inadequate response or loses response after this\nperiod, consideration may be given to increase the dose step\u2011wise by </span><span lang=\"EN-GB\">approximately 1.5\u00a0mg/kg, </span><span lang=\"EN-GB\">up to a\nmaximum of 7.5\u00a0mg/kg every 8\u00a0weeks. Alternatively, administration of\n3\u00a0mg/kg as often as every 4\u00a0weeks may be considered. If adequate\nresponse is achieved, patients should be continued on the selected dose or dose\nfrequency. </span><span lang=\"EN-GB\">Continued therapy should be carefully\nreconsidered in patients who show no evidence of therapeutic benefit within the\nfirst 12\u00a0weeks of treatment or after dose adjustment.</span></p>", "ID": "a26ba8d3-6e42-478b-afef-c74029c3cb12", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Available data suggest that the clinical\nresponse is usually achieved within 12\u00a0weeks of treatment. </span>", "ID": "cb85c058-a73f-45ed-ba74-c1104ac62737", "Styles": "None", "Classes": "None", "Text": "Available data suggest that the clinical response is usually achieved within 12\u00a0weeks of treatment. ", "ParentId": "a26ba8d3-6e42-478b-afef-c74029c3cb12"}, {"Element": "<span lang=\"EN-GB\">If a patient has an inadequate response or loses response after this\nperiod, consideration may be given to increase the dose step\u2011wise by </span>", "ID": "4675676c-c780-42f2-9d7d-d0085e4b1406", "Styles": "None", "Classes": "None", "Text": "If a patient has an inadequate response or loses response after this period, consideration may be given to increase the dose step\u2011wise by ", "ParentId": "a26ba8d3-6e42-478b-afef-c74029c3cb12"}, {"Element": "<span lang=\"EN-GB\">approximately 1.5\u00a0mg/kg, </span>", "ID": "fe8dc139-873b-426f-9a9d-7533c8dc8540", "Styles": "None", "Classes": "None", "Text": "approximately 1.5\u00a0mg/kg, ", "ParentId": "a26ba8d3-6e42-478b-afef-c74029c3cb12"}, {"Element": "<span lang=\"EN-GB\">up to a\nmaximum of 7.5\u00a0mg/kg every 8\u00a0weeks. Alternatively, administration of\n3\u00a0mg/kg as often as every 4\u00a0weeks may be considered. If adequate\nresponse is achieved, patients should be continued on the selected dose or dose\nfrequency. </span>", "ID": "6d76a10c-dec7-4e13-959f-66adcef0d115", "Styles": "None", "Classes": "None", "Text": "up to a maximum of 7.5\u00a0mg/kg every 8\u00a0weeks. Alternatively, administration of 3\u00a0mg/kg as often as every 4\u00a0weeks may be considered. If adequate response is achieved, patients should be continued on the selected dose or dose frequency. ", "ParentId": "a26ba8d3-6e42-478b-afef-c74029c3cb12"}, {"Element": "<span lang=\"EN-GB\">Continued therapy should be carefully\nreconsidered in patients who show no evidence of therapeutic benefit within the\nfirst 12\u00a0weeks of treatment or after dose adjustment.</span>", "ID": "d0f698fd-b8fc-4c4b-9667-2ab1620f96e8", "Styles": "None", "Classes": "None", "Text": "Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit within the first 12\u00a0weeks of treatment or after dose adjustment.", "ParentId": "a26ba8d3-6e42-478b-afef-c74029c3cb12"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a608d246-b5f4-4859-aa00-2ea61c831adb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1f086191-edcd-4409-b925-e6cd5f52e3cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a608d246-b5f4-4859-aa00-2ea61c831adb"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Moderately to severely active\nCrohn\u2019s disease</span></u></p>", "ID": "b63dc4ce-637a-41a5-a2e1-000c7c302112", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Moderately to severely active\nCrohn\u2019s disease</span></u>", "ID": "03914b52-b24a-433e-ae2d-7ed9da49d4ba", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b63dc4ce-637a-41a5-a2e1-000c7c302112"}, {"Element": "<span lang=\"EN-GB\">Moderately to severely active\nCrohn\u2019s disease</span>", "ID": "d78a7115-a99e-4e8a-8e2e-71bfbac206da", "Styles": "None", "Classes": "None", "Text": "Moderately to severely active Crohn\u2019s disease", "ParentId": "03914b52-b24a-433e-ae2d-7ed9da49d4ba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by an additional 5\u00a0mg/kg infusion 2\u00a0weeks after the\nfirst infusion. If a patient does not respond after 2\u00a0doses, no additional\ntreatment with infliximab should be given. Available data do not support\nfurther infliximab treatment, in patients not responding within 6\u00a0weeks of\nthe initial infusion.</span></p>", "ID": "c3d625e9-ba7e-4804-8176-f45d36442adb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by an additional 5\u00a0mg/kg infusion 2\u00a0weeks after the\nfirst infusion. If a patient does not respond after 2\u00a0doses, no additional\ntreatment with infliximab should be given. Available data do not support\nfurther infliximab treatment, in patients not responding within 6\u00a0weeks of\nthe initial infusion.</span>", "ID": "8d443d60-37e7-4232-9576-e5bc056e56c0", "Styles": "None", "Classes": "None", "Text": "5\u00a0mg/kg given as an intravenous infusion followed by an additional 5\u00a0mg/kg infusion 2\u00a0weeks after the first infusion. If a patient does not respond after 2\u00a0doses, no additional treatment with infliximab should be given. Available data do not support further infliximab treatment, in patients not responding within 6\u00a0weeks of the initial infusion.", "ParentId": "c3d625e9-ba7e-4804-8176-f45d36442adb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c5a0ce73-ba43-4391-ad6b-3fa4e26ad522", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5d8fbdcc-0085-4acb-abdc-151ab044a3da", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5a0ce73-ba43-4391-ad6b-3fa4e26ad522"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In responding patients, the alternative\nstrategies for continued treatment are:</span></p>", "ID": "1c07212b-1776-46f4-8d9a-15c28f5886fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In responding patients, the alternative\nstrategies for continued treatment are:</span>", "ID": "ec6ec392-e141-49b9-a466-1eb5ecd9a755", "Styles": "None", "Classes": "None", "Text": "In responding patients, the alternative strategies for continued treatment are:", "ParentId": "1c07212b-1776-46f4-8d9a-15c28f5886fe"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Maintenance: Additional infusion of 5\u00a0mg/kg\nat 6\u00a0weeks after the initial dose, followed by infusions every 8\u00a0weeks\nor</span></p>", "ID": "8a32f67a-26de-421d-af34-c47d2ee7e37f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4ae1e2a1-bbe2-46a8-b662-35ef45b3b47e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8a32f67a-26de-421d-af34-c47d2ee7e37f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c7157085-07a8-41d3-acde-f328a94bc31d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4ae1e2a1-bbe2-46a8-b662-35ef45b3b47e"}, {"Element": "<span lang=\"EN-GB\">Maintenance: Additional infusion of 5\u00a0mg/kg\nat 6\u00a0weeks after the initial dose, followed by infusions every 8\u00a0weeks\nor</span>", "ID": "51937ef4-fa4f-48cc-b0f6-292c16d9ea83", "Styles": "None", "Classes": "None", "Text": "Maintenance: Additional infusion of 5\u00a0mg/kg at 6\u00a0weeks after the initial dose, followed by infusions every 8\u00a0weeks or", "ParentId": "8a32f67a-26de-421d-af34-c47d2ee7e37f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Re\u2011administration: Infusion of 5\u00a0mg/kg\nif signs and symptoms of the disease recur (see \u2018Re\u2011administration\u2019\nbelow and section\u00a04.4).</span></p>", "ID": "985766a9-8d19-414c-be6c-de261d1caf3f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "19028a6b-8fb5-4187-acef-edc21711c8b1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "985766a9-8d19-414c-be6c-de261d1caf3f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "18161840-f7a1-4516-af63-cdfe729f336b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "19028a6b-8fb5-4187-acef-edc21711c8b1"}, {"Element": "<span lang=\"EN-GB\">Re\u2011administration: Infusion of 5\u00a0mg/kg\nif signs and symptoms of the disease recur (see \u2018Re\u2011administration\u2019\nbelow and section\u00a04.4).</span>", "ID": "5426dd6b-cb00-4104-8d42-c5353a81430c", "Styles": "None", "Classes": "None", "Text": "Re\u2011administration: Infusion of 5\u00a0mg/kg if signs and symptoms of the disease recur (see \u2018Re\u2011administration\u2019 below and section\u00a04.4).", "ParentId": "985766a9-8d19-414c-be6c-de261d1caf3f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7de5baa0-928b-4a4e-a7c6-1bbb61af55f7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0cdea4cd-aecb-4a92-be7f-bb5f0e81bbab", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7de5baa0-928b-4a4e-a7c6-1bbb61af55f7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Although comparative data are lacking, l</span><span lang=\"EN-GB\">imited data in patients who initially responded to 5\u00a0mg/kg but\nwho lost response indicate that some patients may regain response with dose\nescalation (see section\u00a05.1). Continued therapy should be carefully\nreconsidered in patients who show no evidence of therapeutic benefit after dose\nadjustment.</span></p>", "ID": "fed87081-3935-4fcf-97c0-ea054610c524", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Although comparative data are lacking, l</span>", "ID": "e2d3754c-94ba-4858-9a49-5bed83211c14", "Styles": "None", "Classes": "None", "Text": "Although comparative data are lacking, l", "ParentId": "fed87081-3935-4fcf-97c0-ea054610c524"}, {"Element": "<span lang=\"EN-GB\">imited data in patients who initially responded to 5\u00a0mg/kg but\nwho lost response indicate that some patients may regain response with dose\nescalation (see section\u00a05.1). Continued therapy should be carefully\nreconsidered in patients who show no evidence of therapeutic benefit after dose\nadjustment.</span>", "ID": "c8227f4c-b574-4c06-935e-2f8774796c8e", "Styles": "None", "Classes": "None", "Text": "imited data in patients who initially responded to 5\u00a0mg/kg but who lost response indicate that some patients may regain response with dose escalation (see section\u00a05.1). Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit after dose adjustment.", "ParentId": "fed87081-3935-4fcf-97c0-ea054610c524"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e24857eb-e388-4675-b664-770b4dbbce60", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a389684d-34bc-4f92-a982-3317737d80cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e24857eb-e388-4675-b664-770b4dbbce60"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Fistulising, active Crohn\u2019s\ndisease</span></u></p>", "ID": "1070f378-33e1-4275-aced-2909b38740f5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Fistulising, active Crohn\u2019s\ndisease</span></u>", "ID": "f09fd1d9-9d15-4d8e-b21b-bfc0038cfd6c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1070f378-33e1-4275-aced-2909b38740f5"}, {"Element": "<span lang=\"EN-GB\">Fistulising, active Crohn\u2019s\ndisease</span>", "ID": "0d8274a9-9c67-4810-93da-353f31604e73", "Styles": "None", "Classes": "None", "Text": "Fistulising, active Crohn\u2019s disease", "ParentId": "f09fd1d9-9d15-4d8e-b21b-bfc0038cfd6c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by additional 5\u00a0mg/kg infusions at 2 and 6\u00a0weeks\nafter the first infusion. If a patient does not respond after 3\u00a0doses, no\nadditional treatment with infliximab should be given.</span></p>", "ID": "1207321c-e823-444f-9429-01fe2abed564", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by additional 5\u00a0mg/kg infusions at 2 and 6\u00a0weeks\nafter the first infusion. If a patient does not respond after 3\u00a0doses, no\nadditional treatment with infliximab should be given.</span>", "ID": "79a821a0-3049-439c-9e52-a47e4c67f6b8", "Styles": "None", "Classes": "None", "Text": "5\u00a0mg/kg given as an intravenous infusion followed by additional 5\u00a0mg/kg infusions at 2 and 6\u00a0weeks after the first infusion. If a patient does not respond after 3\u00a0doses, no additional treatment with infliximab should be given.", "ParentId": "1207321c-e823-444f-9429-01fe2abed564"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f6179dd0-6985-44df-abfb-948b46f85fe2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1f3da587-f4d7-4a1f-995d-8f2346e4a19f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f6179dd0-6985-44df-abfb-948b46f85fe2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In responding patients, the alternative\nstrategies for continued treatment are:</span></p>", "ID": "526c6165-83c1-46d6-b879-2396904c59b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In responding patients, the alternative\nstrategies for continued treatment are:</span>", "ID": "5e06388d-9aae-49d4-b378-bc48fcde3ef6", "Styles": "None", "Classes": "None", "Text": "In responding patients, the alternative strategies for continued treatment are:", "ParentId": "526c6165-83c1-46d6-b879-2396904c59b4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Maintenance: Additional infusions of 5\u00a0mg/kg\nevery 8\u00a0weeks or</span></p>", "ID": "b0f94b14-1959-4ccc-82c5-20dbf9b90f48", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "9177d69b-3c53-4bc5-bb62-c446b6fbab55", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b0f94b14-1959-4ccc-82c5-20dbf9b90f48"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ce53a7ed-dfc1-4605-8b61-2d510b18b2f1", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "9177d69b-3c53-4bc5-bb62-c446b6fbab55"}, {"Element": "<span lang=\"EN-GB\">Maintenance: Additional infusions of 5\u00a0mg/kg\nevery 8\u00a0weeks or</span>", "ID": "51b10466-9a86-4a2f-80ac-ed89897fdf92", "Styles": "None", "Classes": "None", "Text": "Maintenance: Additional infusions of 5\u00a0mg/kg every 8\u00a0weeks or", "ParentId": "b0f94b14-1959-4ccc-82c5-20dbf9b90f48"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Re\u2011administration: Infusion of 5\u00a0mg/kg\nif signs and symptoms of the disease recur followed by infusions of 5\u00a0mg/kg\nevery 8\u00a0weeks (see \u2018Re\u2011administration\u2019 below and section\u00a04.4).</span></p>", "ID": "5ea5a48a-f67a-47f8-ba08-9b8600948597", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3a14a1ff-016c-4fa0-9f47-82197d90fd52", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5ea5a48a-f67a-47f8-ba08-9b8600948597"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6990cb7e-6450-4c0a-88f1-4798890488d2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3a14a1ff-016c-4fa0-9f47-82197d90fd52"}, {"Element": "<span lang=\"EN-GB\">Re\u2011administration: Infusion of 5\u00a0mg/kg\nif signs and symptoms of the disease recur followed by infusions of 5\u00a0mg/kg\nevery 8\u00a0weeks (see \u2018Re\u2011administration\u2019 below and section\u00a04.4).</span>", "ID": "1db94f1d-cde7-46fa-8b95-d0c822081031", "Styles": "None", "Classes": "None", "Text": "Re\u2011administration: Infusion of 5\u00a0mg/kg if signs and symptoms of the disease recur followed by infusions of 5\u00a0mg/kg every 8\u00a0weeks (see \u2018Re\u2011administration\u2019 below and section\u00a04.4).", "ParentId": "5ea5a48a-f67a-47f8-ba08-9b8600948597"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6a43b0b6-9cc8-47f6-bdb9-489186f92fec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "42bcb90b-b17e-4e69-b1cf-e138d728cb44", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6a43b0b6-9cc8-47f6-bdb9-489186f92fec"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Although\ncomparative data are lacking, l</span><span lang=\"EN-GB\">imited data in patients\nwho initially responded to 5\u00a0mg/kg but who lost response indicate that\nsome patients may regain response with dose escalation (see section\u00a05.1).\nContinued therapy should be carefully reconsidered in patients who show no\nevidence of therapeutic benefit after dose adjustment.</span></p>", "ID": "8a1a3dd2-7219-429e-84d3-62b753983af8", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Although\ncomparative data are lacking, l</span>", "ID": "1ac86073-6ee8-45ea-8335-dc9453524d7e", "Styles": "None", "Classes": "None", "Text": "Although comparative data are lacking, l", "ParentId": "8a1a3dd2-7219-429e-84d3-62b753983af8"}, {"Element": "<span lang=\"EN-GB\">imited data in patients\nwho initially responded to 5\u00a0mg/kg but who lost response indicate that\nsome patients may regain response with dose escalation (see section\u00a05.1).\nContinued therapy should be carefully reconsidered in patients who show no\nevidence of therapeutic benefit after dose adjustment.</span>", "ID": "788019d3-8883-4266-b09c-2f570b33c54e", "Styles": "None", "Classes": "None", "Text": "imited data in patients who initially responded to 5\u00a0mg/kg but who lost response indicate that some patients may regain response with dose escalation (see section\u00a05.1). Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit after dose adjustment.", "ParentId": "8a1a3dd2-7219-429e-84d3-62b753983af8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "24bb6a34-f2d7-4393-a641-5ca676d949e1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8511c9d3-52f3-4896-892e-21a6d6745caf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "24bb6a34-f2d7-4393-a641-5ca676d949e1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In Crohn\u2019s disease, experience with\nre</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration if signs\nand symptoms of disease recur is limited and comparative data on the\nbenefit/risk of the alternative strategies for continued treatment are lacking.</span></p>", "ID": "eac6fad9-b52e-4bd2-aff9-bfda06f0b745", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In Crohn\u2019s disease, experience with\nre</span>", "ID": "8607a676-541b-42a4-a82d-d5aab1b1362a", "Styles": "None", "Classes": "None", "Text": "In Crohn\u2019s disease, experience with re", "ParentId": "eac6fad9-b52e-4bd2-aff9-bfda06f0b745"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "e23495fd-edd5-4594-9381-8986ceb52239", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "eac6fad9-b52e-4bd2-aff9-bfda06f0b745"}, {"Element": "<span lang=\"EN-GB\">administration if signs\nand symptoms of disease recur is limited and comparative data on the\nbenefit/risk of the alternative strategies for continued treatment are lacking.</span>", "ID": "d44a8975-9afd-48ac-8d79-e4ce1c533094", "Styles": "None", "Classes": "None", "Text": "administration if signs and symptoms of disease recur is limited and comparative data on the benefit/risk of the alternative strategies for continued treatment are lacking.", "ParentId": "eac6fad9-b52e-4bd2-aff9-bfda06f0b745"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c48acc3-595a-4a80-a6a1-8129314e974b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "05ceb7a8-228a-4a4b-a15d-360619323ad2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c48acc3-595a-4a80-a6a1-8129314e974b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ulcerative\ncolitis</span></u></p>", "ID": "717eb52a-6d08-4a63-a312-11e1c0fedf87", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Ulcerative\ncolitis</span></u>", "ID": "3f338df1-eb60-4c7f-97c5-8f3614b130e5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "717eb52a-6d08-4a63-a312-11e1c0fedf87"}, {"Element": "<span lang=\"EN-GB\">Ulcerative\ncolitis</span>", "ID": "b724818c-b9f2-4d0c-ade9-f7474c18b4e1", "Styles": "None", "Classes": "None", "Text": "Ulcerative colitis", "ParentId": "3f338df1-eb60-4c7f-97c5-8f3614b130e5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks\nafter the first infusion, then every 8\u00a0weeks thereafter.</span></p>", "ID": "7b4e6514-9374-4e1e-9456-b0bbc01f07e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks\nafter the first infusion, then every 8\u00a0weeks thereafter.</span>", "ID": "83d09f89-ef74-4f8a-95fc-668f87940938", "Styles": "None", "Classes": "None", "Text": "5\u00a0mg/kg given as an intravenous infusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks after the first infusion, then every 8\u00a0weeks thereafter.", "ParentId": "7b4e6514-9374-4e1e-9456-b0bbc01f07e5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "db2b442c-8866-4e33-b933-8d9d8f14684d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8128605a-4fbc-4d2d-9b10-767c57fd5382", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "db2b442c-8866-4e33-b933-8d9d8f14684d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Available data suggest that the clinical\nresponse is usually achieved within 14\u00a0weeks of treatment, i.e. three\ndoses. Continued therapy should be carefully reconsidered in patients who show\nno evidence of therapeutic benefit within this time period.</span></p>", "ID": "9b2fe295-41f2-4f3d-ac95-37356d9e2d9e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Available data suggest that the clinical\nresponse is usually achieved within 14\u00a0weeks of treatment, i.e. three\ndoses. Continued therapy should be carefully reconsidered in patients who show\nno evidence of therapeutic benefit within this time period.</span>", "ID": "1a9a7a40-88cc-4ec9-a3f4-8eee4a0ec527", "Styles": "None", "Classes": "None", "Text": "Available data suggest that the clinical response is usually achieved within 14\u00a0weeks of treatment, i.e. three doses. Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit within this time period.", "ParentId": "9b2fe295-41f2-4f3d-ac95-37356d9e2d9e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3d13c22c-b982-48a1-9c26-f5cfa0ee76c0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e87b5798-b0a1-4b69-b777-0997493ab57e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3d13c22c-b982-48a1-9c26-f5cfa0ee76c0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ankylosing\nspondylitis</span></u></p>", "ID": "25fba55c-befc-4299-a277-0de48d7c459d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Ankylosing\nspondylitis</span></u>", "ID": "dc42ce3b-c1f5-4517-ae97-c8c4265d9620", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "25fba55c-befc-4299-a277-0de48d7c459d"}, {"Element": "<span lang=\"EN-GB\">Ankylosing\nspondylitis</span>", "ID": "308a6bed-f293-4a71-8bef-68c4723ee492", "Styles": "None", "Classes": "None", "Text": "Ankylosing spondylitis", "ParentId": "dc42ce3b-c1f5-4517-ae97-c8c4265d9620"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks\nafter the first infusion, then every 6 to 8\u00a0weeks. If a patient does not\nrespond by 6\u00a0weeks (i.e. after 2\u00a0doses), no additional treatment with\ninfliximab should be given.</span></p>", "ID": "c934058e-2b87-4fae-8a02-b78ccb8ff58c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks\nafter the first infusion, then every 6 to 8\u00a0weeks. If a patient does not\nrespond by 6\u00a0weeks (i.e. after 2\u00a0doses), no additional treatment with\ninfliximab should be given.</span>", "ID": "04dfc83e-c16e-4b07-b0a8-e3cf16a6d5fc", "Styles": "None", "Classes": "None", "Text": "5\u00a0mg/kg given as an intravenous infusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks after the first infusion, then every 6 to 8\u00a0weeks. If a patient does not respond by 6\u00a0weeks (i.e. after 2\u00a0doses), no additional treatment with infliximab should be given.", "ParentId": "c934058e-2b87-4fae-8a02-b78ccb8ff58c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "80afe933-6294-4959-9e49-e2743bf2480e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c1884b46-4985-49f8-9199-dc2d8752c8fc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "80afe933-6294-4959-9e49-e2743bf2480e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Psoriatic\narthritis</span></u></p>", "ID": "275d6cae-2f95-4789-9cc7-67d9e14a2801", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Psoriatic\narthritis</span></u>", "ID": "6496fb85-c0c0-40e4-a5ec-50b152b92b84", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "275d6cae-2f95-4789-9cc7-67d9e14a2801"}, {"Element": "<span lang=\"EN-GB\">Psoriatic\narthritis</span>", "ID": "e532887e-6389-4b8b-abb4-e430185c9cc5", "Styles": "None", "Classes": "None", "Text": "Psoriatic arthritis", "ParentId": "6496fb85-c0c0-40e4-a5ec-50b152b92b84"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">5\u00a0mg/kg\ngiven as an intravenous infusion followed by additional 5\u00a0mg/kg infusion\ndoses at 2 and 6\u00a0weeks after the first infusion, then every 8\u00a0weeks\nthereafter.</span></p>", "ID": "6cc3a37f-0867-4920-914a-f26180b0eed7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">5\u00a0mg/kg\ngiven as an intravenous infusion followed by additional 5\u00a0mg/kg infusion\ndoses at 2 and 6\u00a0weeks after the first infusion, then every 8\u00a0weeks\nthereafter.</span>", "ID": "9fd28cfd-ae66-4ead-abfe-dc50be00aabb", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "5\u00a0mg/kg given as an intravenous infusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks after the first infusion, then every 8\u00a0weeks thereafter.", "ParentId": "6cc3a37f-0867-4920-914a-f26180b0eed7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bc64d67b-f4a0-4e37-8dee-81229dae2d4e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ade6c1c1-a7a5-45bb-893b-26960fd850db", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bc64d67b-f4a0-4e37-8dee-81229dae2d4e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Psoriasis</span></u></p>", "ID": "3c3f0fa8-6079-4295-a050-4ecc9cdd8d57", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Psoriasis</span></u>", "ID": "6bbaae1e-2898-4778-a3e2-cf4662b16d9c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3c3f0fa8-6079-4295-a050-4ecc9cdd8d57"}, {"Element": "<span lang=\"EN-GB\">Psoriasis</span>", "ID": "18710c49-0658-4768-8d5c-c598ce69fa5d", "Styles": "None", "Classes": "None", "Text": "Psoriasis", "ParentId": "6bbaae1e-2898-4778-a3e2-cf4662b16d9c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">5\u00a0mg/kg\ngiven as an intravenous infusion followed by additional 5\u00a0mg/kg infusion\ndoses at 2 and 6\u00a0weeks after the first infusion, then every 8\u00a0weeks\nthereafter.</span><span lang=\"EN-GB\"> If a patient shows no response after\n14\u00a0weeks (i.e. after 4\u00a0doses), no additional treatment with\ninfliximab should be given.</span></p>", "ID": "d91ebc97-bec6-40a2-8bdb-f1d2e6b0c0a1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">5\u00a0mg/kg\ngiven as an intravenous infusion followed by additional 5\u00a0mg/kg infusion\ndoses at 2 and 6\u00a0weeks after the first infusion, then every 8\u00a0weeks\nthereafter.</span>", "ID": "c6d76db3-3bc8-4023-a261-d1e83c622358", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "5\u00a0mg/kg given as an intravenous infusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks after the first infusion, then every 8\u00a0weeks thereafter.", "ParentId": "d91ebc97-bec6-40a2-8bdb-f1d2e6b0c0a1"}, {"Element": "<span lang=\"EN-GB\"> If a patient shows no response after\n14\u00a0weeks (i.e. after 4\u00a0doses), no additional treatment with\ninfliximab should be given.</span>", "ID": "cdae9073-d402-468a-89ad-9062c6b9cd79", "Styles": "None", "Classes": "None", "Text": " If a patient shows no response after 14\u00a0weeks (i.e. after 4\u00a0doses), no additional treatment with infliximab should be given.", "ParentId": "d91ebc97-bec6-40a2-8bdb-f1d2e6b0c0a1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d14dee11-3b31-483b-8274-f53464d5ebe5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1f649459-449a-4404-bfb7-25a9004e3cb9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d14dee11-3b31-483b-8274-f53464d5ebe5"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Re</span></u><u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for Crohn\u2019s disease and rheumatoid arthritis</span></u></p>", "ID": "c817cc47-1ffe-49b2-880c-334b1dddc38f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Re</span></u>", "ID": "d3bc1bc8-8558-4155-aad2-0d06c2634e97", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c817cc47-1ffe-49b2-880c-334b1dddc38f"}, {"Element": "<span lang=\"EN-GB\">Re</span>", "ID": "1e507423-0755-4cb1-8f37-0f3af5139045", "Styles": "None", "Classes": "None", "Text": "Re", "ParentId": "d3bc1bc8-8558-4155-aad2-0d06c2634e97"}, {"Element": "<u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for Crohn\u2019s disease and rheumatoid arthritis</span></u>", "ID": "84fc27dd-d8fd-4ff9-bb48-a573494b0891", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c817cc47-1ffe-49b2-880c-334b1dddc38f"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "c6eaae7d-6dc2-4088-aaff-86a81d2a7d89", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "84fc27dd-d8fd-4ff9-bb48-a573494b0891"}, {"Element": "<span lang=\"EN-GB\">administration for Crohn\u2019s disease and rheumatoid arthritis</span>", "ID": "2e66728e-1e10-4a00-b68d-69200709b7c0", "Styles": "None", "Classes": "None", "Text": "administration for Crohn\u2019s disease and rheumatoid arthritis", "ParentId": "84fc27dd-d8fd-4ff9-bb48-a573494b0891"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If the signs and symptoms of disease recur,\nRemicade can be re\u2011administered within 16\u00a0weeks following the last infusion.\nIn clinical studies, delayed hypersensitivity reactions have been uncommon and\nhave occurred after Remicade\u2011free intervals of less than 1\u00a0year (see\nsections\u00a04.4 and 4.8). The safety and efficacy of re\u2011administration\nafter a Remicade\u2011free interval of more than 16\u00a0weeks has not been\nestablished. This applies to both Crohn\u2019s disease patients and rheumatoid\narthritis patients.</span></p>", "ID": "a9fa65ab-d356-4d55-b3e4-a0372e1fa3b1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">If the signs and symptoms of disease recur,\nRemicade can be re\u2011administered within 16\u00a0weeks following the last infusion.\nIn clinical studies, delayed hypersensitivity reactions have been uncommon and\nhave occurred after Remicade\u2011free intervals of less than 1\u00a0year (see\nsections\u00a04.4 and 4.8). The safety and efficacy of re\u2011administration\nafter a Remicade\u2011free interval of more than 16\u00a0weeks has not been\nestablished. This applies to both Crohn\u2019s disease patients and rheumatoid\narthritis patients.</span>", "ID": "ee6442c9-622d-42c7-a7e2-3aad767c4ddd", "Styles": "None", "Classes": "None", "Text": "If the signs and symptoms of disease recur, Remicade can be re\u2011administered within 16\u00a0weeks following the last infusion. In clinical studies, delayed hypersensitivity reactions have been uncommon and have occurred after Remicade\u2011free intervals of less than 1\u00a0year (see sections\u00a04.4 and 4.8). The safety and efficacy of re\u2011administration after a Remicade\u2011free interval of more than 16\u00a0weeks has not been established. This applies to both Crohn\u2019s disease patients and rheumatoid arthritis patients.", "ParentId": "a9fa65ab-d356-4d55-b3e4-a0372e1fa3b1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b256d50c-07c1-4fa7-ace4-fa6e34b4c07c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "741e190b-529a-47bc-93d0-1445f489f5c6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b256d50c-07c1-4fa7-ace4-fa6e34b4c07c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Re</span></u><u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for ulcerative colitis</span></u></p>", "ID": "d6007824-5ed2-49af-bcc1-583c82ab6b1b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Re</span></u>", "ID": "1c81ed91-6c16-4c3e-af08-df3e88d9f3af", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d6007824-5ed2-49af-bcc1-583c82ab6b1b"}, {"Element": "<span lang=\"EN-GB\">Re</span>", "ID": "a0837350-7877-4a7e-a98e-d409dc84b2ea", "Styles": "None", "Classes": "None", "Text": "Re", "ParentId": "1c81ed91-6c16-4c3e-af08-df3e88d9f3af"}, {"Element": "<u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for ulcerative colitis</span></u>", "ID": "784d2044-cdea-4404-9069-e44d26891478", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d6007824-5ed2-49af-bcc1-583c82ab6b1b"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "c83492ed-bbb0-45da-ad7b-3da380d90e12", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "784d2044-cdea-4404-9069-e44d26891478"}, {"Element": "<span lang=\"EN-GB\">administration for ulcerative colitis</span>", "ID": "36b7257f-8f56-457a-9752-271deec2a4fb", "Styles": "None", "Classes": "None", "Text": "administration for ulcerative colitis", "ParentId": "784d2044-cdea-4404-9069-e44d26891478"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of re\u2011administration,\nother than every 8\u00a0weeks, has not been established </span><span lang=\"EN-GB\">(see sections\u00a04.4 and 4.8)</span><span lang=\"EN-GB\">.</span></p>", "ID": "552a76ba-fd8c-4a6c-9f96-5481be4417df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of re\u2011administration,\nother than every 8\u00a0weeks, has not been established </span>", "ID": "9061169f-c0b2-47e4-b593-b326ec175254", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of re\u2011administration, other than every 8\u00a0weeks, has not been established ", "ParentId": "552a76ba-fd8c-4a6c-9f96-5481be4417df"}, {"Element": "<span lang=\"EN-GB\">(see sections\u00a04.4 and 4.8)</span>", "ID": "56104ea9-7e1f-4e8d-8a7b-ed92ee525c10", "Styles": "None", "Classes": "None", "Text": "(see sections\u00a04.4 and 4.8)", "ParentId": "552a76ba-fd8c-4a6c-9f96-5481be4417df"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "2cafab59-3bc2-4f13-b2b6-d9080579c9b6", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "552a76ba-fd8c-4a6c-9f96-5481be4417df"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7b0c4030-3b96-45d1-ba1b-d4389f3cdd6e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "99f4cdfb-0628-4a17-8a57-51792ec38287", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7b0c4030-3b96-45d1-ba1b-d4389f3cdd6e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Re</span></u><u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for ankylosing\nspondylitis</span></u></p>", "ID": "956daed2-4b94-4811-a7c2-6af8aac567f1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Re</span></u>", "ID": "c3fb30b2-01a0-4ae2-9eb0-c93ead29274b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "956daed2-4b94-4811-a7c2-6af8aac567f1"}, {"Element": "<span lang=\"EN-GB\">Re</span>", "ID": "e43bfff6-1465-43c9-9443-5f679d63700b", "Styles": "None", "Classes": "None", "Text": "Re", "ParentId": "c3fb30b2-01a0-4ae2-9eb0-c93ead29274b"}, {"Element": "<u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for ankylosing\nspondylitis</span></u>", "ID": "fa5abdc5-6f86-4cab-8b2d-08e7a2ee9931", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "956daed2-4b94-4811-a7c2-6af8aac567f1"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "854cfe1d-c955-40ec-863b-a4c49f120db8", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "fa5abdc5-6f86-4cab-8b2d-08e7a2ee9931"}, {"Element": "<span lang=\"EN-GB\">administration for ankylosing\nspondylitis</span>", "ID": "40734aee-65f2-4edd-a8e7-7c3efc15c4b0", "Styles": "None", "Classes": "None", "Text": "administration for ankylosing spondylitis", "ParentId": "fa5abdc5-6f86-4cab-8b2d-08e7a2ee9931"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of re\u2011administration,\nother than every 6 to 8\u00a0weeks, has not been established </span><span lang=\"EN-GB\">(see sections\u00a04.4 and 4.8)</span><span lang=\"EN-GB\">.</span></p>", "ID": "7e129a20-b003-4737-b3d5-305126cb006e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of re\u2011administration,\nother than every 6 to 8\u00a0weeks, has not been established </span>", "ID": "d6b81306-7c16-4a76-9f12-0885a6b794f0", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of re\u2011administration, other than every 6 to 8\u00a0weeks, has not been established ", "ParentId": "7e129a20-b003-4737-b3d5-305126cb006e"}, {"Element": "<span lang=\"EN-GB\">(see sections\u00a04.4 and 4.8)</span>", "ID": "3e17b6ea-8fd0-49d3-bbaa-b7362cd778e6", "Styles": "None", "Classes": "None", "Text": "(see sections\u00a04.4 and 4.8)", "ParentId": "7e129a20-b003-4737-b3d5-305126cb006e"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "4444e0e8-0b07-43fd-a55e-bec757ebcde6", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "7e129a20-b003-4737-b3d5-305126cb006e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3033ba56-0733-485d-8df0-ca4de2a3d721", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9569dfac-0c1a-4913-a348-2d30f1fd4164", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3033ba56-0733-485d-8df0-ca4de2a3d721"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Re</span></u><u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for psoriatic arthritis</span></u></p>", "ID": "74a113ca-d9c6-407e-961d-eb5ea5d8e1e4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Re</span></u>", "ID": "c915b562-f6d1-46ea-bb32-2f74a88832ad", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "74a113ca-d9c6-407e-961d-eb5ea5d8e1e4"}, {"Element": "<span lang=\"EN-GB\">Re</span>", "ID": "6f256fbc-b2ed-424f-9633-bd94898bde86", "Styles": "None", "Classes": "None", "Text": "Re", "ParentId": "c915b562-f6d1-46ea-bb32-2f74a88832ad"}, {"Element": "<u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for psoriatic arthritis</span></u>", "ID": "797366b1-8cf6-4e92-9bc4-04d15092da69", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "74a113ca-d9c6-407e-961d-eb5ea5d8e1e4"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "5729bf7a-37e6-4d7d-8d57-e6fdafead8b3", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "797366b1-8cf6-4e92-9bc4-04d15092da69"}, {"Element": "<span lang=\"EN-GB\">administration for psoriatic arthritis</span>", "ID": "5e5f9423-6277-4181-b083-55c21f8504ef", "Styles": "None", "Classes": "None", "Text": "administration for psoriatic arthritis", "ParentId": "797366b1-8cf6-4e92-9bc4-04d15092da69"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of re\u2011administration,\nother than every 8\u00a0weeks, has not been established </span><span lang=\"EN-GB\">(see sections\u00a04.4 and 4.8)</span><span lang=\"EN-GB\">.</span></p>", "ID": "0ca2793e-e437-44bd-b0f8-99aaa80705c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of re\u2011administration,\nother than every 8\u00a0weeks, has not been established </span>", "ID": "7e69188a-78de-49a2-909a-ee919fe6b756", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of re\u2011administration, other than every 8\u00a0weeks, has not been established ", "ParentId": "0ca2793e-e437-44bd-b0f8-99aaa80705c8"}, {"Element": "<span lang=\"EN-GB\">(see sections\u00a04.4 and 4.8)</span>", "ID": "7f50f665-dee6-430d-b83e-aa5897744817", "Styles": "None", "Classes": "None", "Text": "(see sections\u00a04.4 and 4.8)", "ParentId": "0ca2793e-e437-44bd-b0f8-99aaa80705c8"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "d1ad59e0-e2c2-4a30-92c6-400f87fbc06f", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "0ca2793e-e437-44bd-b0f8-99aaa80705c8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "155aaeef-a226-44fc-86de-fe2f8cd6949b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "026b304f-f769-4732-baac-8d4828d03f2d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "155aaeef-a226-44fc-86de-fe2f8cd6949b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Re</span></u><u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for psoriasis</span></u></p>", "ID": "4f28d780-0ec2-4e7a-b533-ebb2dfc59b99", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Re</span></u>", "ID": "a9c129f1-3589-4854-a014-bf1c8b44abfd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4f28d780-0ec2-4e7a-b533-ebb2dfc59b99"}, {"Element": "<span lang=\"EN-GB\">Re</span>", "ID": "89fad543-21fb-446d-8296-ac2503050b32", "Styles": "None", "Classes": "None", "Text": "Re", "ParentId": "a9c129f1-3589-4854-a014-bf1c8b44abfd"}, {"Element": "<u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration for psoriasis</span></u>", "ID": "b7dc2793-7ac5-456b-a471-83a36096ec30", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4f28d780-0ec2-4e7a-b533-ebb2dfc59b99"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "bcf5984d-5e5e-490d-b185-2b842d8858c6", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "b7dc2793-7ac5-456b-a471-83a36096ec30"}, {"Element": "<span lang=\"EN-GB\">administration for psoriasis</span>", "ID": "54a347ae-e7a5-48b7-9ef5-2c41f0970c7b", "Styles": "None", "Classes": "None", "Text": "administration for psoriasis", "ParentId": "b7dc2793-7ac5-456b-a471-83a36096ec30"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Limited experience from re\u2011treatment\nwith one single Remicade dose in psoriasis after an interval of 20\u00a0weeks\nsuggests reduced efficacy and a higher incidence of mild to moderate infusion\nreactions when compared to the initial induction regimen (see section\u00a05.1).</span></p>", "ID": "8dfeb20e-f372-46eb-9db9-53e6c0d68eea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Limited experience from re\u2011treatment\nwith one single Remicade dose in psoriasis after an interval of 20\u00a0weeks\nsuggests reduced efficacy and a higher incidence of mild to moderate infusion\nreactions when compared to the initial induction regimen (see section\u00a05.1).</span>", "ID": "64fdf528-a9d8-43a8-b260-0e2df160b81c", "Styles": "None", "Classes": "None", "Text": "Limited experience from re\u2011treatment with one single Remicade dose in psoriasis after an interval of 20\u00a0weeks suggests reduced efficacy and a higher incidence of mild to moderate infusion reactions when compared to the initial induction regimen (see section\u00a05.1).", "ParentId": "8dfeb20e-f372-46eb-9db9-53e6c0d68eea"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6099d965-f688-4b14-9c13-7edc9d1bc20f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "de198607-d64c-46e2-8c3e-29fae55bc1be", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6099d965-f688-4b14-9c13-7edc9d1bc20f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Limited experience from re</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">treatment following disease flare by\na re\u2011induction regimen suggests a higher incidence of infusion reactions,\nincluding serious ones, when compared to 8\u2011weekly maintenance treatment\n(see section\u00a04.8).</span></p>", "ID": "39b42583-22d5-4afd-b169-158bb5c3868e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Limited experience from re</span>", "ID": "328fcc1d-9fd4-4943-9b9b-ed91347db477", "Styles": "None", "Classes": "None", "Text": "Limited experience from re", "ParentId": "39b42583-22d5-4afd-b169-158bb5c3868e"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "2dfc703c-0d0e-400e-a2ba-36f0edbc9886", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "39b42583-22d5-4afd-b169-158bb5c3868e"}, {"Element": "<span lang=\"EN-GB\">treatment following disease flare by\na re\u2011induction regimen suggests a higher incidence of infusion reactions,\nincluding serious ones, when compared to 8\u2011weekly maintenance treatment\n(see section\u00a04.8).</span>", "ID": "68fd162e-cec8-4ca4-b741-030afb43f5d3", "Styles": "None", "Classes": "None", "Text": "treatment following disease flare by a re\u2011induction regimen suggests a higher incidence of infusion reactions, including serious ones, when compared to 8\u2011weekly maintenance treatment (see section\u00a04.8).", "ParentId": "39b42583-22d5-4afd-b169-158bb5c3868e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d2ad3cca-b353-499e-a26e-f6c3fe669a10", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a97f7833-d84e-4afa-9e4b-6a7814f59791", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d2ad3cca-b353-499e-a26e-f6c3fe669a10"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Re</span></u><u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration across indications</span></u></p>", "ID": "aa66e575-1ed6-4314-85f2-88cef6e9d469", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Re</span></u>", "ID": "5033b145-53af-4605-91df-38344101512c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aa66e575-1ed6-4314-85f2-88cef6e9d469"}, {"Element": "<span lang=\"EN-GB\">Re</span>", "ID": "8e0ef872-af8f-48b4-81e6-06ab753333cd", "Styles": "None", "Classes": "None", "Text": "Re", "ParentId": "5033b145-53af-4605-91df-38344101512c"}, {"Element": "<u><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">administration across indications</span></u>", "ID": "5919a1d6-b94b-4885-812e-009f38708f59", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aa66e575-1ed6-4314-85f2-88cef6e9d469"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "3b91fb22-b314-4a75-88ee-8f7c740a2c70", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "5919a1d6-b94b-4885-812e-009f38708f59"}, {"Element": "<span lang=\"EN-GB\">administration across indications</span>", "ID": "e200a979-342d-472b-83bf-46b7d5b548c2", "Styles": "None", "Classes": "None", "Text": "administration across indications", "ParentId": "5919a1d6-b94b-4885-812e-009f38708f59"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In case maintenance therapy is interrupted,\nand there is a need to restart treatment, use of a re\u2011induction regimen\nis not recommended (see section\u00a04.8). In this situation, Remicade should\nbe re\u2011initiated as a single dose followed by the maintenance dose\nrecommendations described above.</span></p>", "ID": "9622545f-aa51-4c9c-b5c5-3cb40df22308", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In case maintenance therapy is interrupted,\nand there is a need to restart treatment, use of a re\u2011induction regimen\nis not recommended (see section\u00a04.8). In this situation, Remicade should\nbe re\u2011initiated as a single dose followed by the maintenance dose\nrecommendations described above.</span>", "ID": "c6ba3d08-da7c-46b1-86d5-9ce08e498590", "Styles": "None", "Classes": "None", "Text": "In case maintenance therapy is interrupted, and there is a need to restart treatment, use of a re\u2011induction regimen is not recommended (see section\u00a04.8). In this situation, Remicade should be re\u2011initiated as a single dose followed by the maintenance dose recommendations described above.", "ParentId": "9622545f-aa51-4c9c-b5c5-3cb40df22308"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "98c6ce5b-23a4-41f1-b448-29f3167f60c2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "02baaaf1-04b6-4d96-8e54-decfd8d71842", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "98c6ce5b-23a4-41f1-b448-29f3167f60c2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Special\npopulations</span></u></p>", "ID": "848cda3a-52b5-4839-bec0-47966da39f3c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Special\npopulations</span></u>", "ID": "4723b865-4429-4c93-8430-cd3eb9a326eb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "848cda3a-52b5-4839-bec0-47966da39f3c"}, {"Element": "<span lang=\"EN-GB\">Special\npopulations</span>", "ID": "f4668168-f782-4359-bf31-e5e4b912e31a", "Styles": "None", "Classes": "None", "Text": "Special populations", "ParentId": "4723b865-4429-4c93-8430-cd3eb9a326eb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly</span></i></p>", "ID": "faf7d2e8-0b3f-4eeb-a2c9-f4d82bedd665", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Elderly</span></i>", "ID": "df06a5ee-5ce4-4c78-b057-46532971c1e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "faf7d2e8-0b3f-4eeb-a2c9-f4d82bedd665"}, {"Element": "<span lang=\"EN-GB\">Elderly</span>", "ID": "bedf06c0-4eff-4327-826d-5f2f0cb7c7bf", "Styles": "None", "Classes": "None", "Text": "Elderly", "ParentId": "df06a5ee-5ce4-4c78-b057-46532971c1e3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Specific studies of Remicade in elderly\npatients have not been conducted. No major age\u2011related differences in\nclearance or volume of distribution were observed in clinical studies. No dose\nadjustment is required (see section\u00a05.2). For more information about the\nsafety of Remicade in elderly patients (see sections\u00a04.4 and 4.8).</span></p>", "ID": "69c7697e-97d1-4df4-9c2f-5666d6c08de6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Specific studies of Remicade in elderly\npatients have not been conducted. No major age\u2011related differences in\nclearance or volume of distribution were observed in clinical studies. No dose\nadjustment is required (see section\u00a05.2). For more information about the\nsafety of Remicade in elderly patients (see sections\u00a04.4 and 4.8).</span>", "ID": "2ae0ece4-d3e2-4b06-887b-5305ce15c0d1", "Styles": "None", "Classes": "None", "Text": "Specific studies of Remicade in elderly patients have not been conducted. No major age\u2011related differences in clearance or volume of distribution were observed in clinical studies. No dose adjustment is required (see section\u00a05.2). For more information about the safety of Remicade in elderly patients (see sections\u00a04.4 and 4.8).", "ParentId": "69c7697e-97d1-4df4-9c2f-5666d6c08de6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "41483fb6-e555-41c4-be2b-5891d7f247b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6132ca2a-20ab-4442-8a2d-c6f23142fc5f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "41483fb6-e555-41c4-be2b-5891d7f247b4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal\nand/or hepatic impairment</span></i></p>", "ID": "693b13ed-c35b-45f8-bd62-41867b1311fe", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Renal\nand/or hepatic impairment</span></i>", "ID": "602bdf2f-3e01-40cf-9f38-8ed54d3fb06b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "693b13ed-c35b-45f8-bd62-41867b1311fe"}, {"Element": "<span lang=\"EN-GB\">Renal\nand/or hepatic impairment</span>", "ID": "3638e315-9bcd-4d8f-ae30-0e13d3457d1e", "Styles": "None", "Classes": "None", "Text": "Renal and/or hepatic impairment", "ParentId": "602bdf2f-3e01-40cf-9f38-8ed54d3fb06b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade has not been studied in these\npatient populations. No dose recommendations can be made (see section\u00a05.2).</span></p>", "ID": "65e82b5c-e33b-4f5f-8bb1-16c18decac72", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade has not been studied in these\npatient populations. No dose recommendations can be made (see section\u00a05.2).</span>", "ID": "9b924b73-c263-485a-8420-80175f9040d9", "Styles": "None", "Classes": "None", "Text": "Remicade has not been studied in these patient populations. No dose recommendations can be made (see section\u00a05.2).", "ParentId": "65e82b5c-e33b-4f5f-8bb1-16c18decac72"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "95707739-078c-4d16-8dc2-dfd27154d191", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ff3050ab-1d8b-4b9a-ad84-f7b3c36f3328", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "95707739-078c-4d16-8dc2-dfd27154d191"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric\npopulation</span></i></p>", "ID": "8160bc95-2b3d-420a-8160-ea0b26536caf", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Paediatric\npopulation</span></i>", "ID": "c5c92f3a-616c-476f-a2d0-edb02b9d2941", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8160bc95-2b3d-420a-8160-ea0b26536caf"}, {"Element": "<span lang=\"EN-GB\">Paediatric\npopulation</span>", "ID": "a75d7b9d-4896-4a0f-ab96-873a7be1f599", "Styles": "None", "Classes": "None", "Text": "Paediatric population", "ParentId": "c5c92f3a-616c-476f-a2d0-edb02b9d2941"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Crohn\u2019s\ndisease (6 to 17\u00a0years)</span></u></p>", "ID": "d1a95ded-1bbd-47a7-afd8-4bdd38392ddd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Crohn\u2019s\ndisease (6 to 17\u00a0years)</span></u>", "ID": "3e386140-9cae-4461-9b37-3f772c700f04", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d1a95ded-1bbd-47a7-afd8-4bdd38392ddd"}, {"Element": "<span lang=\"EN-GB\">Crohn\u2019s\ndisease (6 to 17\u00a0years)</span>", "ID": "f1ef1b41-5c93-44fb-9d56-9aba45c34930", "Styles": "None", "Classes": "None", "Text": "Crohn\u2019s disease (6 to 17\u00a0years)", "ParentId": "3e386140-9cae-4461-9b37-3f772c700f04"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous infusion\nfollowed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks after\nthe first infusion, then every 8\u00a0weeks thereafter. Available data do not\nsupport further infliximab treatment in children and adolescents not responding\nwithin the first 10\u00a0weeks of treatment (see section\u00a05.1).</span></p>", "ID": "b47f1083-e8cb-4247-ac15-caf9678f82e7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous infusion\nfollowed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks after\nthe first infusion, then every 8\u00a0weeks thereafter. Available data do not\nsupport further infliximab treatment in children and adolescents not responding\nwithin the first 10\u00a0weeks of treatment (see section\u00a05.1).</span>", "ID": "185493fd-69ac-4afa-8ba8-874177f02050", "Styles": "None", "Classes": "None", "Text": "5\u00a0mg/kg given as an intravenous infusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks after the first infusion, then every 8\u00a0weeks thereafter. Available data do not support further infliximab treatment in children and adolescents not responding within the first 10\u00a0weeks of treatment (see section\u00a05.1).", "ParentId": "b47f1083-e8cb-4247-ac15-caf9678f82e7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4f073116-0818-47db-acbc-868c12376de9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "96e7181e-f55b-4df0-95e0-b6935cbc0449", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4f073116-0818-47db-acbc-868c12376de9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Some patients may require a shorter dosing\ninterval to maintain clinical benefit, while for others a longer dosing\ninterval may be sufficient. Patients who have had their dose interval shortened\nto less than 8\u00a0weeks may be at greater risk for adverse reactions.\nContinued therapy with a shortened interval should be carefully considered in\nthose patients who show no evidence of additional therapeutic benefit after a\nchange in dosing interval.</span></p>", "ID": "c92a6eb0-ca97-46d3-bca3-1086704011f4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Some patients may require a shorter dosing\ninterval to maintain clinical benefit, while for others a longer dosing\ninterval may be sufficient. Patients who have had their dose interval shortened\nto less than 8\u00a0weeks may be at greater risk for adverse reactions.\nContinued therapy with a shortened interval should be carefully considered in\nthose patients who show no evidence of additional therapeutic benefit after a\nchange in dosing interval.</span>", "ID": "4e3e41bf-005f-4638-b8b6-6cd7565793f7", "Styles": "None", "Classes": "None", "Text": "Some patients may require a shorter dosing interval to maintain clinical benefit, while for others a longer dosing interval may be sufficient. Patients who have had their dose interval shortened to less than 8\u00a0weeks may be at greater risk for adverse reactions. Continued therapy with a shortened interval should be carefully considered in those patients who show no evidence of additional therapeutic benefit after a change in dosing interval.", "ParentId": "c92a6eb0-ca97-46d3-bca3-1086704011f4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "77864605-5975-4361-a5d3-1533f56f6b82", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a316c9f7-bcac-4f94-be16-1a02c1213997", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "77864605-5975-4361-a5d3-1533f56f6b82"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Remicade have\nnot been studied in children with Crohn\u2019s disease below the age of 6\u00a0years.\nCurrently available pharmacokinetic data are described in section\u00a05.2 but\nno recommendation on a posology can be made in children younger than 6\u00a0years.</span></p>", "ID": "a403fd1a-fdcf-4aac-8495-481f3f912851", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of Remicade have\nnot been studied in children with Crohn\u2019s disease below the age of 6\u00a0years.\nCurrently available pharmacokinetic data are described in section\u00a05.2 but\nno recommendation on a posology can be made in children younger than 6\u00a0years.</span>", "ID": "a24fce90-d7d3-4858-997c-986014986907", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of Remicade have not been studied in children with Crohn\u2019s disease below the age of 6\u00a0years. Currently available pharmacokinetic data are described in section\u00a05.2 but no recommendation on a posology can be made in children younger than 6\u00a0years.", "ParentId": "a403fd1a-fdcf-4aac-8495-481f3f912851"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1cd3e339-db39-4048-9a24-172c6e69f5af", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f4607d6f-127f-4965-8224-509f6ceb8e5d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1cd3e339-db39-4048-9a24-172c6e69f5af"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ulcerative\ncolitis (6 to 17\u00a0years)</span></u></p>", "ID": "c5382bc8-8ec7-4451-8f9c-673727f0c16e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Ulcerative\ncolitis (6 to 17\u00a0years)</span></u>", "ID": "2f167081-be07-4d7a-872f-2e7217af4bc0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c5382bc8-8ec7-4451-8f9c-673727f0c16e"}, {"Element": "<span lang=\"EN-GB\">Ulcerative\ncolitis (6 to 17\u00a0years)</span>", "ID": "156b8f06-2f1c-4782-87d2-9bd40aaa6ba4", "Styles": "None", "Classes": "None", "Text": "Ulcerative colitis (6 to 17\u00a0years)", "ParentId": "2f167081-be07-4d7a-872f-2e7217af4bc0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks\nafter the first infusion, then every 8\u00a0weeks thereafter. Available data do\nnot support further infliximab treatment in paediatric patients not responding\nwithin the first 8\u00a0weeks of treatment (see section\u00a05.1).</span></p>", "ID": "78ca376f-6694-4422-8344-2945ab0d5259", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">5\u00a0mg/kg given as an intravenous\ninfusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks\nafter the first infusion, then every 8\u00a0weeks thereafter. Available data do\nnot support further infliximab treatment in paediatric patients not responding\nwithin the first 8\u00a0weeks of treatment (see section\u00a05.1).</span>", "ID": "47f7b061-2123-413c-9598-c4f17b5bfcbc", "Styles": "None", "Classes": "None", "Text": "5\u00a0mg/kg given as an intravenous infusion followed by additional 5\u00a0mg/kg infusion doses at 2 and 6\u00a0weeks after the first infusion, then every 8\u00a0weeks thereafter. Available data do not support further infliximab treatment in paediatric patients not responding within the first 8\u00a0weeks of treatment (see section\u00a05.1).", "ParentId": "78ca376f-6694-4422-8344-2945ab0d5259"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3b47077a-352d-4974-a0be-8ffe5cdd0ecf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa80b10f-583c-4170-b6de-21929a549f65", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3b47077a-352d-4974-a0be-8ffe5cdd0ecf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Remicade have\nnot been studied in children with ulcerative colitis below the age of 6\u00a0years.\nCurrently available pharmacokinetic data are described in section\u00a05.2 but\nno recommendation on a posology can be made in children younger than 6\u00a0years.</span></p>", "ID": "f7233093-66d6-4fe6-b4c2-d15def3b030e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of Remicade have\nnot been studied in children with ulcerative colitis below the age of 6\u00a0years.\nCurrently available pharmacokinetic data are described in section\u00a05.2 but\nno recommendation on a posology can be made in children younger than 6\u00a0years.</span>", "ID": "2194c530-0fd8-4398-8d46-8c49e1604e80", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of Remicade have not been studied in children with ulcerative colitis below the age of 6\u00a0years. Currently available pharmacokinetic data are described in section\u00a05.2 but no recommendation on a posology can be made in children younger than 6\u00a0years.", "ParentId": "f7233093-66d6-4fe6-b4c2-d15def3b030e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ebaaad4f-ceba-46aa-87c1-e1334ce48ff6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "34958689-0225-4f2f-9944-ff67b781316c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ebaaad4f-ceba-46aa-87c1-e1334ce48ff6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Psoriasis</span></u></p>", "ID": "182bb0fd-8f75-483f-9c5f-f66b9f015f64", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Psoriasis</span></u>", "ID": "e1496d0f-2654-416e-80ab-87eafa390f46", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "182bb0fd-8f75-483f-9c5f-f66b9f015f64"}, {"Element": "<span lang=\"EN-GB\">Psoriasis</span>", "ID": "a30710bd-aacf-4a84-a492-92acd6ec7538", "Styles": "None", "Classes": "None", "Text": "Psoriasis", "ParentId": "e1496d0f-2654-416e-80ab-87eafa390f46"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Remicade in\nchildren and adolescents younger than 18\u00a0years for the indication of psoriasis\nhave not been established. Currently available data are described in section\u00a05.2\nbut no recommendation on a posology can be made.</span></p>", "ID": "1c191490-cce4-41af-aae3-63d05b489192", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of Remicade in\nchildren and adolescents younger than 18\u00a0years for the indication of psoriasis\nhave not been established. Currently available data are described in section\u00a05.2\nbut no recommendation on a posology can be made.</span>", "ID": "e89eb8d0-9433-446f-a640-d4678ef8025f", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of Remicade in children and adolescents younger than 18\u00a0years for the indication of psoriasis have not been established. Currently available data are described in section\u00a05.2 but no recommendation on a posology can be made.", "ParentId": "1c191490-cce4-41af-aae3-63d05b489192"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "106e0e93-b7a3-46a0-9f96-71bef2ddad82", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ea626a90-ff67-4de2-a7bb-27043cc8e000", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "106e0e93-b7a3-46a0-9f96-71bef2ddad82"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Juvenile\nidiopathic arthritis, psoriatic arthritis and ankylosing spondylitis</span></u></p>", "ID": "1195ecaf-a5fb-43bf-975a-c1b6dd078a8a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Juvenile\nidiopathic arthritis, psoriatic arthritis and ankylosing spondylitis</span></u>", "ID": "283122a4-b0bd-4519-b04f-3d3d0c874007", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1195ecaf-a5fb-43bf-975a-c1b6dd078a8a"}, {"Element": "<span lang=\"EN-GB\">Juvenile\nidiopathic arthritis, psoriatic arthritis and ankylosing spondylitis</span>", "ID": "af936fc7-dd1f-4506-80ce-b4a1af6de31e", "Styles": "None", "Classes": "None", "Text": "Juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis", "ParentId": "283122a4-b0bd-4519-b04f-3d3d0c874007"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Remicade in children\nand adolescents younger than 18\u00a0years for the indications of juvenile\nidiopathic arthritis, psoriatic arthritis and ankylosing spondylitis have not\nbeen established. Currently available data are described in section\u00a05.2\nbut no recommendation on a posology can be made.</span></p>", "ID": "fa574654-bbd6-4ef4-909d-8a9249ec32fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of Remicade in children\nand adolescents younger than 18\u00a0years for the indications of juvenile\nidiopathic arthritis, psoriatic arthritis and ankylosing spondylitis have not\nbeen established. Currently available data are described in section\u00a05.2\nbut no recommendation on a posology can be made.</span>", "ID": "694b3315-3b48-4556-8c1a-08a5722fc759", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of Remicade in children and adolescents younger than 18\u00a0years for the indications of juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis have not been established. Currently available data are described in section\u00a05.2 but no recommendation on a posology can be made.", "ParentId": "fa574654-bbd6-4ef4-909d-8a9249ec32fd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8f1e9066-7628-417e-8e99-9b70893e0721", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ddbaec85-590f-4b75-9e3e-eb6a7eed99dc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8f1e9066-7628-417e-8e99-9b70893e0721"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Juvenile\nrheumatoid arthritis</span></u></p>", "ID": "ccc48140-b7cc-4dbb-a094-3133ed820215", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Juvenile\nrheumatoid arthritis</span></u>", "ID": "67c92436-1f93-452e-a678-d9d8d6576c16", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ccc48140-b7cc-4dbb-a094-3133ed820215"}, {"Element": "<span lang=\"EN-GB\">Juvenile\nrheumatoid arthritis</span>", "ID": "47215c5a-08b0-4850-ae08-3662f517ff17", "Styles": "None", "Classes": "None", "Text": "Juvenile rheumatoid arthritis", "ParentId": "67c92436-1f93-452e-a678-d9d8d6576c16"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Remicade in\nchildren and adolescents younger than 18\u00a0years for the indication of juvenile\nrheumatoid arthritis have not been established. Currently available data</span><span lang=\"EN-GB\"> are</span><span lang=\"EN-GB\"> described in sections\u00a04.8\u00a0and\n5.2 but no recommendation on a posology can be made.</span></p>", "ID": "79af4705-0851-4d54-9aba-36767b87b6a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of Remicade in\nchildren and adolescents younger than 18\u00a0years for the indication of juvenile\nrheumatoid arthritis have not been established. Currently available data</span>", "ID": "fd8e2621-1caa-4651-b91d-a7987eaabafb", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of Remicade in children and adolescents younger than 18\u00a0years for the indication of juvenile rheumatoid arthritis have not been established. Currently available data", "ParentId": "79af4705-0851-4d54-9aba-36767b87b6a7"}, {"Element": "<span lang=\"EN-GB\"> are</span>", "ID": "7dfe93d9-3471-4894-853c-f84b03649d99", "Styles": "None", "Classes": "None", "Text": " are", "ParentId": "79af4705-0851-4d54-9aba-36767b87b6a7"}, {"Element": "<span lang=\"EN-GB\"> described in sections\u00a04.8\u00a0and\n5.2 but no recommendation on a posology can be made.</span>", "ID": "1e769407-3d80-4172-859b-fd4ef0a1c1ce", "Styles": "None", "Classes": "None", "Text": " described in sections\u00a04.8\u00a0and 5.2 but no recommendation on a posology can be made.", "ParentId": "79af4705-0851-4d54-9aba-36767b87b6a7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dea12a88-73b3-4110-aa6b-1fca2ad9b392", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c448e319-b89d-4d72-88ea-38729e8a6003", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dea12a88-73b3-4110-aa6b-1fca2ad9b392"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Method\nof administration</span></u></b></p>", "ID": "8f50aa0b-951e-4f72-b644-2f93e22e8634", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><u><span lang=\"EN-GB\">Method\nof administration</span></u></b>", "ID": "dbe612a5-3938-4c92-800d-7e9c1da1002c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8f50aa0b-951e-4f72-b644-2f93e22e8634"}, {"Element": "<u><span lang=\"EN-GB\">Method\nof administration</span></u>", "ID": "f203b55a-a00a-4bf2-b4ec-db86f6e769d9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dbe612a5-3938-4c92-800d-7e9c1da1002c"}, {"Element": "<span lang=\"EN-GB\">Method\nof administration</span>", "ID": "f840128c-4f44-4d32-9396-3dda18369089", "Styles": "None", "Classes": "None", "Text": "Method of administration", "ParentId": "f203b55a-a00a-4bf2-b4ec-db86f6e769d9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade should be administered\nintravenously over a 2\u00a0hour period. All patients administered Remicade are\nto be observed for at least 1\u20112\u00a0hours post\u2011infusion for acute\ninfusion\u2011related reactions. Emergency equipment, such as adrenaline,\nantihistamines, corticosteroids and an artificial airway must be available.\nPatients may be pre\u2011treated with e.g., an antihistamine, hydrocortisone\nand/or paracetamol and infusion rate may be slowed in order to decrease the\nrisk of infusion\u2011related reactions especially if infusion\u2011related\nreactions have occurred previously (see section\u00a04.4).</span></p>", "ID": "d75ed5f2-7ad7-49e0-9af2-889d42a1335c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade should be administered\nintravenously over a 2\u00a0hour period. All patients administered Remicade are\nto be observed for at least 1\u20112\u00a0hours post\u2011infusion for acute\ninfusion\u2011related reactions. Emergency equipment, such as adrenaline,\nantihistamines, corticosteroids and an artificial airway must be available.\nPatients may be pre\u2011treated with e.g., an antihistamine, hydrocortisone\nand/or paracetamol and infusion rate may be slowed in order to decrease the\nrisk of infusion\u2011related reactions especially if infusion\u2011related\nreactions have occurred previously (see section\u00a04.4).</span>", "ID": "5353d024-bbff-4e13-b36d-3ad8f55f9078", "Styles": "None", "Classes": "None", "Text": "Remicade should be administered intravenously over a 2\u00a0hour period. All patients administered Remicade are to be observed for at least 1\u20112\u00a0hours post\u2011infusion for acute infusion\u2011related reactions. Emergency equipment, such as adrenaline, antihistamines, corticosteroids and an artificial airway must be available. Patients may be pre\u2011treated with e.g., an antihistamine, hydrocortisone and/or paracetamol and infusion rate may be slowed in order to decrease the risk of infusion\u2011related reactions especially if infusion\u2011related reactions have occurred previously (see section\u00a04.4).", "ParentId": "d75ed5f2-7ad7-49e0-9af2-889d42a1335c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bb153d84-ee31-4658-9507-d22844967c7b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0779eef6-108e-4263-9ddb-7739b6435cbe", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bb153d84-ee31-4658-9507-d22844967c7b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Shortened\ninfusions across adult indications</span></u></p>", "ID": "25c97533-4925-4db6-bda4-365d2a256645", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Shortened\ninfusions across adult indications</span></u>", "ID": "80adc2b1-9b9c-44b6-98e4-18322f88f767", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "25c97533-4925-4db6-bda4-365d2a256645"}, {"Element": "<span lang=\"EN-GB\">Shortened\ninfusions across adult indications</span>", "ID": "5d8dd607-a590-4326-a280-0a2960412fe8", "Styles": "None", "Classes": "None", "Text": "Shortened infusions across adult indications", "ParentId": "80adc2b1-9b9c-44b6-98e4-18322f88f767"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In carefully selected adult patients who have\ntolerated at least 3</span><span lang=\"EN-GB\">\u00a0initial 2\u2011hour\ninfusions of Remicade (induction phase) and are receiving maintenance therapy,\nconsideration may be given to administering subsequent infusions over a period\nof not less than 1\u00a0hour.</span><span lang=\"EN-GB\"> If an infusion reaction\noccurs in association with a shortened infusion, a slower infusion rate may be\nconsidered for future infusions if treatment is to be continued. Shortened\ninfusions at doses &gt;\u00a06\u00a0mg/kg have not been studied (see section\u00a04.8).</span></p>", "ID": "b042d44f-9301-4099-b82c-d0e72954dcf7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In carefully selected adult patients who have\ntolerated at least 3</span>", "ID": "03e6f711-7a6b-4f82-a451-204a5f9d433d", "Styles": "None", "Classes": "None", "Text": "In carefully selected adult patients who have tolerated at least 3", "ParentId": "b042d44f-9301-4099-b82c-d0e72954dcf7"}, {"Element": "<span lang=\"EN-GB\">\u00a0initial 2\u2011hour\ninfusions of Remicade (induction phase) and are receiving maintenance therapy,\nconsideration may be given to administering subsequent infusions over a period\nof not less than 1\u00a0hour.</span>", "ID": "2f3ef628-1a67-4aa6-ba71-2474473e7cd7", "Styles": "None", "Classes": "None", "Text": "\u00a0initial 2\u2011hour infusions of Remicade (induction phase) and are receiving maintenance therapy, consideration may be given to administering subsequent infusions over a period of not less than 1\u00a0hour.", "ParentId": "b042d44f-9301-4099-b82c-d0e72954dcf7"}, {"Element": "<span lang=\"EN-GB\"> If an infusion reaction\noccurs in association with a shortened infusion, a slower infusion rate may be\nconsidered for future infusions if treatment is to be continued. Shortened\ninfusions at doses &gt;\u00a06\u00a0mg/kg have not been studied (see section\u00a04.8).</span>", "ID": "1a293da9-04fb-4dc6-a728-2a2c926356b2", "Styles": "None", "Classes": "None", "Text": " If an infusion reaction occurs in association with a shortened infusion, a slower infusion rate may be considered for future infusions if treatment is to be continued. Shortened infusions at doses >\u00a06\u00a0mg/kg have not been studied (see section\u00a04.8).", "ParentId": "b042d44f-9301-4099-b82c-d0e72954dcf7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b616e6f4-c5ce-4444-b449-c708dfb97afc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "058338f7-8c72-4be0-9ab6-c0acd6cf525c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b616e6f4-c5ce-4444-b449-c708dfb97afc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For preparation and administration instructions,\nsee section\u00a06.6.</span></p>", "ID": "9dde7134-cfc5-48da-8c46-ea2dbd47086d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">For preparation and administration instructions,\nsee section\u00a06.6.</span>", "ID": "e84e40bc-de97-419c-98af-7a08ec672a1c", "Styles": "None", "Classes": "None", "Text": "For preparation and administration instructions, see section\u00a06.6.", "ParentId": "9dde7134-cfc5-48da-8c46-ea2dbd47086d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b609d099-9340-43d7-ac08-1b8fa21d3159", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2a4aa48f-26d2-4726-9f0b-e574b09eed8a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b609d099-9340-43d7-ac08-1b8fa21d3159"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span></b></p>", "ID": "4db80947-97c4-457f-ba4e-a75c0cacbde6", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span></b>", "ID": "6b5ed2f9-6fac-4d8e-a375-3f5d8ab5eb7e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4db80947-97c4-457f-ba4e-a75c0cacbde6"}, {"Element": "<span lang=\"EN-GB\">4.3\u00a0\u00a0\u00a0\u00a0 Contraindications</span>", "ID": "553b51ca-e2a1-4998-aad7-d89bb4019cd9", "Styles": "None", "Classes": "None", "Text": "4.3\u00a0\u00a0\u00a0\u00a0 Contraindications", "ParentId": "6b5ed2f9-6fac-4d8e-a375-3f5d8ab5eb7e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "89dd02cb-7480-4499-94aa-b2cb6120f5df", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cebf83b4-39cc-4d3d-8332-f82871d5c09e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "89dd02cb-7480-4499-94aa-b2cb6120f5df"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypersensitivity to the active substance,\nto other murine proteins, or to any of the excipients listed in\nsection\u00a06.1.</span></p>", "ID": "c8e86e38-89f0-40de-bbb0-7135dd742efc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Hypersensitivity to the active substance,\nto other murine proteins, or to any of the excipients listed in\nsection\u00a06.1.</span>", "ID": "d7f65768-dc33-42a8-a2fd-9e939a89321c", "Styles": "None", "Classes": "None", "Text": "Hypersensitivity to the active substance, to other murine proteins, or to any of the excipients listed in section\u00a06.1.", "ParentId": "c8e86e38-89f0-40de-bbb0-7135dd742efc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "694c7a43-57d8-4210-b4a7-09c6647614b9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dbc6b689-849a-4147-a9a2-513dfc86730b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "694c7a43-57d8-4210-b4a7-09c6647614b9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with tuberculosis or other severe\ninfections such as sepsis, abscesses, and opportunistic infections (see section\u00a04.4).</span></p>", "ID": "68d2be1f-0f2d-4702-8bf5-b9e496f23fb9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Patients with tuberculosis or other severe\ninfections such as sepsis, abscesses, and opportunistic infections (see section\u00a04.4).</span>", "ID": "18d53a60-bd1d-4f13-b512-8f0b8e3ed686", "Styles": "None", "Classes": "None", "Text": "Patients with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections (see section\u00a04.4).", "ParentId": "68d2be1f-0f2d-4702-8bf5-b9e496f23fb9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "52aa0567-0460-48e5-baf5-852510401f26", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a23d06d1-e3a5-48cd-a924-3458a523f403", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "52aa0567-0460-48e5-baf5-852510401f26"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with moderate or severe heart\nfailure (NYHA class III/IV) (see sections\u00a04.4 and 4.8).</span></p>", "ID": "db54ce6e-9b77-494b-a5f2-cb0a3c241d5c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Patients with moderate or severe heart\nfailure (NYHA class III/IV) (see sections\u00a04.4 and 4.8).</span>", "ID": "7c91c6cb-4ec7-4eab-a01f-7083f696e4a2", "Styles": "None", "Classes": "None", "Text": "Patients with moderate or severe heart failure (NYHA class III/IV) (see sections\u00a04.4 and 4.8).", "ParentId": "db54ce6e-9b77-494b-a5f2-cb0a3c241d5c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cd49272a-afdc-450d-8a3d-955b1db32828", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ba8f6b14-abf0-43a0-ad7f-a6e27ae3d0d3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cd49272a-afdc-450d-8a3d-955b1db32828"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and\nprecautions for use</span></b></p>", "ID": "0c2bf687-c5b9-4d35-a2a9-ef2d37a478de", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and\nprecautions for use</span></b>", "ID": "079d782a-d81c-4989-b329-e006a5735d38", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0c2bf687-c5b9-4d35-a2a9-ef2d37a478de"}, {"Element": "<span lang=\"EN-GB\">4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and\nprecautions for use</span>", "ID": "670938c6-3535-48c9-b216-9a9d201b510e", "Styles": "None", "Classes": "None", "Text": "4.4\u00a0\u00a0\u00a0\u00a0 Special warnings and precautions for use", "ParentId": "079d782a-d81c-4989-b329-e006a5735d38"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "56eccd18-c23a-4f9a-ac03-1ce13419400d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b7311c0-331c-4494-8a9c-bc00467a313d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "56eccd18-c23a-4f9a-ac03-1ce13419400d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Traceability</span></u></p>", "ID": "fa2afbb7-aa7c-4564-b0e0-776e1072853d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Traceability</span></u>", "ID": "9e6ffdcf-890e-4e8c-bdce-b5ae26385ce4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fa2afbb7-aa7c-4564-b0e0-776e1072853d"}, {"Element": "<span lang=\"EN-GB\">Traceability</span>", "ID": "7d355a0f-3ba6-4644-8138-a5452957849f", "Styles": "None", "Classes": "None", "Text": "Traceability", "ParentId": "9e6ffdcf-890e-4e8c-bdce-b5ae26385ce4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ad9e0cd6-8925-46b4-9cf0-edc94f697d37", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c55e8664-dea8-4591-b28f-fe0b85d471a0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ad9e0cd6-8925-46b4-9cf0-edc94f697d37"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In order to improve the traceability of\nbiological medicinal products, the tradename and the batch number of the\nadministered product should be clearly recorded.</span></p>", "ID": "59439937-c82d-468b-9a2d-645f58059e12", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In order to improve the traceability of\nbiological medicinal products, the tradename and the batch number of the\nadministered product should be clearly recorded.</span>", "ID": "95e78a04-1547-464f-b8ac-4623a28d802b", "Styles": "None", "Classes": "None", "Text": "In order to improve the traceability of biological medicinal products, the tradename and the batch number of the administered product should be clearly recorded.", "ParentId": "59439937-c82d-468b-9a2d-645f58059e12"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fac4cfa7-742b-43a3-841d-abc9f97d8722", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "873427d3-7e06-41c8-8516-0e37b298c9d6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fac4cfa7-742b-43a3-841d-abc9f97d8722"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infusion\nreactions and hypersensitivity</span></u></p>", "ID": "1711a618-17db-45ac-8111-ce8199ed13d6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Infusion\nreactions and hypersensitivity</span></u>", "ID": "ee4832f8-e35f-46ab-92be-36477f4232ad", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1711a618-17db-45ac-8111-ce8199ed13d6"}, {"Element": "<span lang=\"EN-GB\">Infusion\nreactions and hypersensitivity</span>", "ID": "9274ea77-9bfb-4ce0-bbab-8ad1107385ee", "Styles": "None", "Classes": "None", "Text": "Infusion reactions and hypersensitivity", "ParentId": "ee4832f8-e35f-46ab-92be-36477f4232ad"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab has been associated with acute\ninfusion\u2011related reactions, including anaphylactic shock, and delayed\nhypersensitivity reactions (see section\u00a04.8).</span></p>", "ID": "ec9de80a-dced-43a1-8297-5b5dba46eb11", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infliximab has been associated with acute\ninfusion\u2011related reactions, including anaphylactic shock, and delayed\nhypersensitivity reactions (see section\u00a04.8).</span>", "ID": "066a3ccd-1237-4fcc-96d0-bcd7c55e44a0", "Styles": "None", "Classes": "None", "Text": "Infliximab has been associated with acute infusion\u2011related reactions, including anaphylactic shock, and delayed hypersensitivity reactions (see section\u00a04.8).", "ParentId": "ec9de80a-dced-43a1-8297-5b5dba46eb11"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fd3cdcfd-28e0-4ee4-acc9-7cf83c9b664f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "931664f9-23f4-420f-b307-02b7c3e778b4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fd3cdcfd-28e0-4ee4-acc9-7cf83c9b664f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Acute infusion reactions including\nanaphylactic reactions may develop during (within seconds) or within a few\nhours following infusion. If acute infusion reactions occur, the infusion must\nbe interrupted immediately. Emergency equipment, such as adrenaline,\nantihistamines, corticosteroids and an artificial airway must be available.\nPatients may be pre\u2011treated with e.g., an antihistamine, hydrocortisone\nand/or paracetamol to prevent mild and transient effects.</span></p>", "ID": "e098491c-d081-473e-8582-64ffcd794769", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Acute infusion reactions including\nanaphylactic reactions may develop during (within seconds) or within a few\nhours following infusion. If acute infusion reactions occur, the infusion must\nbe interrupted immediately. Emergency equipment, such as adrenaline,\nantihistamines, corticosteroids and an artificial airway must be available.\nPatients may be pre\u2011treated with e.g., an antihistamine, hydrocortisone\nand/or paracetamol to prevent mild and transient effects.</span>", "ID": "805c8391-4a7e-40f7-9b81-18884b61112b", "Styles": "None", "Classes": "None", "Text": "Acute infusion reactions including anaphylactic reactions may develop during (within seconds) or within a few hours following infusion. If acute infusion reactions occur, the infusion must be interrupted immediately. Emergency equipment, such as adrenaline, antihistamines, corticosteroids and an artificial airway must be available. Patients may be pre\u2011treated with e.g., an antihistamine, hydrocortisone and/or paracetamol to prevent mild and transient effects.", "ParentId": "e098491c-d081-473e-8582-64ffcd794769"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Antibodies to infliximab may develop and\nhave been associated with an increased frequency of infusion reactions. A low\nproportion of the infusion reactions was serious allergic reactions. An\nassociation between development of antibodies to infliximab and reduced\nduration of response has also been observed. Concomitant administration of\nimmunomodulators has been associated with lower incidence of antibodies to\ninfliximab and a reduction in the frequency of infusion reactions. The effect\nof concomitant immunomodulator therapy was more profound in episodically\u2011treated\npatients than in patients given maintenance therapy. Patients who discontinue\nimmunosuppressants prior to or during Remicade treatment are at greater risk of\ndeveloping these antibodies. Antibodies to infliximab cannot always be detected\nin serum samples. If serious reactions occur, symptomatic treatment must be\ngiven and further Remicade infusions must not be administered (see section\u00a04.8).</span></p>", "ID": "753a2c97-1155-4b29-bf8f-e9bc3d123018", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Antibodies to infliximab may develop and\nhave been associated with an increased frequency of infusion reactions. A low\nproportion of the infusion reactions was serious allergic reactions. An\nassociation between development of antibodies to infliximab and reduced\nduration of response has also been observed. Concomitant administration of\nimmunomodulators has been associated with lower incidence of antibodies to\ninfliximab and a reduction in the frequency of infusion reactions. The effect\nof concomitant immunomodulator therapy was more profound in episodically\u2011treated\npatients than in patients given maintenance therapy. Patients who discontinue\nimmunosuppressants prior to or during Remicade treatment are at greater risk of\ndeveloping these antibodies. Antibodies to infliximab cannot always be detected\nin serum samples. If serious reactions occur, symptomatic treatment must be\ngiven and further Remicade infusions must not be administered (see section\u00a04.8).</span>", "ID": "77c744c9-ebf5-4273-b7b9-e2185301d47d", "Styles": "None", "Classes": "None", "Text": "Antibodies to infliximab may develop and have been associated with an increased frequency of infusion reactions. A low proportion of the infusion reactions was serious allergic reactions. An association between development of antibodies to infliximab and reduced duration of response has also been observed. Concomitant administration of immunomodulators has been associated with lower incidence of antibodies to infliximab and a reduction in the frequency of infusion reactions. The effect of concomitant immunomodulator therapy was more profound in episodically\u2011treated patients than in patients given maintenance therapy. Patients who discontinue immunosuppressants prior to or during Remicade treatment are at greater risk of developing these antibodies. Antibodies to infliximab cannot always be detected in serum samples. If serious reactions occur, symptomatic treatment must be given and further Remicade infusions must not be administered (see section\u00a04.8).", "ParentId": "753a2c97-1155-4b29-bf8f-e9bc3d123018"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b84a7b3a-8fb0-48c6-bfa8-91eead054bf6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "252e3af6-a6e9-4ee9-a032-4b14ccb9d5f7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b84a7b3a-8fb0-48c6-bfa8-91eead054bf6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical studies, delayed\nhypersensitivity reactions have been reported. Available data suggest an\nincreased risk for delayed hypersensitivity with increasing Remicade\u2011free\ninterval. Patients should be advised to seek immediate medical advice if they\nexperience any delayed adverse reaction (see section\u00a04.8). If patients are\nre\u2011treated after a prolonged period, they must be closely monitored for\nsigns and symptoms of delayed hypersensitivity.</span></p>", "ID": "10cc034a-c289-4ed1-adfc-9b64f9a4bdd3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In clinical studies, delayed\nhypersensitivity reactions have been reported. Available data suggest an\nincreased risk for delayed hypersensitivity with increasing Remicade\u2011free\ninterval. Patients should be advised to seek immediate medical advice if they\nexperience any delayed adverse reaction (see section\u00a04.8). If patients are\nre\u2011treated after a prolonged period, they must be closely monitored for\nsigns and symptoms of delayed hypersensitivity.</span>", "ID": "ff36b1ea-dd5d-4ee0-b5bb-eee0cdd25a3d", "Styles": "None", "Classes": "None", "Text": "In clinical studies, delayed hypersensitivity reactions have been reported. Available data suggest an increased risk for delayed hypersensitivity with increasing Remicade\u2011free interval. Patients should be advised to seek immediate medical advice if they experience any delayed adverse reaction (see section\u00a04.8). If patients are re\u2011treated after a prolonged period, they must be closely monitored for signs and symptoms of delayed hypersensitivity.", "ParentId": "10cc034a-c289-4ed1-adfc-9b64f9a4bdd3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8abe6fb6-0874-430c-aff8-b93478e27550", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "349b90dc-64ac-4e08-8791-bfd63ad8e8b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8abe6fb6-0874-430c-aff8-b93478e27550"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infections</span></u></p>", "ID": "52494414-d418-45eb-ac58-2f5e51660cb6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Infections</span></u>", "ID": "fb0a171e-d3a4-415d-baeb-12015da4e108", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "52494414-d418-45eb-ac58-2f5e51660cb6"}, {"Element": "<span lang=\"EN-GB\">Infections</span>", "ID": "b45c08be-12cc-475d-b068-73a10f2174e5", "Styles": "None", "Classes": "None", "Text": "Infections", "ParentId": "fb0a171e-d3a4-415d-baeb-12015da4e108"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients must be monitored closely for\ninfections including tuberculosis before, during and after treatment with\nRemicade. Because the elimination of infliximab may take up to six months,\nmonitoring should be continued throughout this period. Further treatment with\nRemicade must not be given if a patient develops a serious infection or sepsis.</span></p>", "ID": "60a538e8-45cc-435c-8d88-31610d8a38a0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Patients must be monitored closely for\ninfections including tuberculosis before, during and after treatment with\nRemicade. Because the elimination of infliximab may take up to six months,\nmonitoring should be continued throughout this period. Further treatment with\nRemicade must not be given if a patient develops a serious infection or sepsis.</span>", "ID": "93a8118b-9181-4eea-b942-99867133b900", "Styles": "None", "Classes": "None", "Text": "Patients must be monitored closely for infections including tuberculosis before, during and after treatment with Remicade. Because the elimination of infliximab may take up to six months, monitoring should be continued throughout this period. Further treatment with Remicade must not be given if a patient develops a serious infection or sepsis.", "ParentId": "60a538e8-45cc-435c-8d88-31610d8a38a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "99e3fa63-6f96-48af-86db-651ed209cc8e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a2dcf248-b87d-4739-b469-7352efa16c84", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99e3fa63-6f96-48af-86db-651ed209cc8e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Caution should be\nexercised when considering the use of Remicade in patients with chronic\ninfection or a history of recurrent infections, including concomitant\nimmunosuppressive therapy. Patients should be advised of and avoid exposure to\npotential risk factors for infection as appropriate.</span></p>", "ID": "372e8193-bd63-496e-9668-4a91c3459f07", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Caution should be\nexercised when considering the use of Remicade in patients with chronic\ninfection or a history of recurrent infections, including concomitant\nimmunosuppressive therapy. Patients should be advised of and avoid exposure to\npotential risk factors for infection as appropriate.</span>", "ID": "31187669-3f15-4ce6-b639-d0c5ccb1d198", "Styles": "None", "Classes": "None", "Text": "Caution should be exercised when considering the use of Remicade in patients with chronic infection or a history of recurrent infections, including concomitant immunosuppressive therapy. Patients should be advised of and avoid exposure to potential risk factors for infection as appropriate.", "ParentId": "372e8193-bd63-496e-9668-4a91c3459f07"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a5e97a40-59cd-4406-afd7-392e2feae1b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7c0fb1ad-d732-4fe5-8277-602753506465", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a5e97a40-59cd-4406-afd7-392e2feae1b6"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tumour necrosis\nfactor alpha (<a name=\"OLE_LINK5\">TNF</a></span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">) mediates\ninflammation and modulates cellular immune responses. Experimental data show\nthat TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> is essential for the clearing of intracellular infections. Clinical\nexperience shows that host defence against infection is compromised in some\npatients treated with infliximab.</span></p>", "ID": "29efb380-aa18-4731-a093-ed018b63d17e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Tumour necrosis\nfactor alpha (<a name=\"OLE_LINK5\">TNF</a></span>", "ID": "2e969d5c-0f0f-455d-903f-ef72ed6513f4", "Styles": "None", "Classes": "None", "Text": "Tumour necrosis factor alpha (", "ParentId": "29efb380-aa18-4731-a093-ed018b63d17e"}, {"Element": "<a name=\"OLE_LINK5\">TNF</a>", "ID": "5a9c3464-3568-4548-9b87-9b909dafc876", "Styles": "None", "Classes": "None", "Text": "TNF", "ParentId": "2e969d5c-0f0f-455d-903f-ef72ed6513f4"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "46e219a1-9dcf-42d2-ab03-e3445517d8fa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "29efb380-aa18-4731-a093-ed018b63d17e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "84f4c895-23b7-48ab-b47b-f7ce3224e429", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "46e219a1-9dcf-42d2-ab03-e3445517d8fa"}, {"Element": "<span lang=\"EN-GB\">) mediates\ninflammation and modulates cellular immune responses. Experimental data show\nthat TNF</span>", "ID": "f6a4eea0-8003-44f5-a476-db76658492e3", "Styles": "None", "Classes": "None", "Text": ") mediates inflammation and modulates cellular immune responses. Experimental data show that TNF", "ParentId": "29efb380-aa18-4731-a093-ed018b63d17e"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "9b617095-f3ed-4289-a667-9ea9cea68aff", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "29efb380-aa18-4731-a093-ed018b63d17e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "0b94349e-2197-46d6-a4a1-17051346be33", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "9b617095-f3ed-4289-a667-9ea9cea68aff"}, {"Element": "<span lang=\"EN-GB\"> is essential for the clearing of intracellular infections. Clinical\nexperience shows that host defence against infection is compromised in some\npatients treated with infliximab.</span>", "ID": "8ec8ff8d-9f67-467a-a2a5-eaadb7365ecd", "Styles": "None", "Classes": "None", "Text": " is essential for the clearing of intracellular infections. Clinical experience shows that host defence against infection is compromised in some patients treated with infliximab.", "ParentId": "29efb380-aa18-4731-a093-ed018b63d17e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "030d55e9-dc3b-4942-bdc8-59d9f33e2a97", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1056b043-4ec1-4c2a-9e26-ec30f8f4df03", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "030d55e9-dc3b-4942-bdc8-59d9f33e2a97"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">It should be\nnoted that suppression of TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:\nSymbol\">a</span></sub><span lang=\"EN-GB\"> may mask symptoms of infection such as\nfever.</span><span lang=\"EN-GB\"> Early recognition of atypical clinical\npresentations of serious infections </span><span lang=\"EN-GB\">and of typical clinical\npresentation of rare and unusual infections </span><span lang=\"EN-GB\">is critical\nin order to minimise delays in diagnosis and treatment.</span></p>", "ID": "578a7f10-e2ee-48a8-9db3-099c38c6376a", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">It should be\nnoted that suppression of TNF</span>", "ID": "74288540-74ba-4587-9463-fc1058d4e415", "Styles": "None", "Classes": "None", "Text": "It should be noted that suppression of TNF", "ParentId": "578a7f10-e2ee-48a8-9db3-099c38c6376a"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:\nSymbol\">a</span></sub>", "ID": "ce6b05b0-ffb3-41b3-ad58-d08e4bdf7084", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "578a7f10-e2ee-48a8-9db3-099c38c6376a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:\nSymbol\">a</span>", "ID": "989c52a3-96b1-4540-86a5-b7a555030f1a", "Styles": "font-family:\nSymbol", "Classes": "None", "Text": "a", "ParentId": "ce6b05b0-ffb3-41b3-ad58-d08e4bdf7084"}, {"Element": "<span lang=\"EN-GB\"> may mask symptoms of infection such as\nfever.</span>", "ID": "0f32433a-c3e0-4aef-b48b-79ebd041e6ca", "Styles": "None", "Classes": "None", "Text": " may mask symptoms of infection such as fever.", "ParentId": "578a7f10-e2ee-48a8-9db3-099c38c6376a"}, {"Element": "<span lang=\"EN-GB\"> Early recognition of atypical clinical\npresentations of serious infections </span>", "ID": "ee67b85a-5a14-4303-8880-cbb14a32d1f1", "Styles": "None", "Classes": "None", "Text": " Early recognition of atypical clinical presentations of serious infections ", "ParentId": "578a7f10-e2ee-48a8-9db3-099c38c6376a"}, {"Element": "<span lang=\"EN-GB\">and of typical clinical\npresentation of rare and unusual infections </span>", "ID": "47cb4616-2823-410c-a0de-40f7ab956172", "Styles": "None", "Classes": "None", "Text": "and of typical clinical presentation of rare and unusual infections ", "ParentId": "578a7f10-e2ee-48a8-9db3-099c38c6376a"}, {"Element": "<span lang=\"EN-GB\">is critical\nin order to minimise delays in diagnosis and treatment.</span>", "ID": "7aa777cc-185d-4229-adee-5197fdf419d1", "Styles": "None", "Classes": "None", "Text": "is critical in order to minimise delays in diagnosis and treatment.", "ParentId": "578a7f10-e2ee-48a8-9db3-099c38c6376a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "18cd4c1c-f516-443e-9ff0-8435640e3561", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d61e53cc-4de7-46c1-8b54-f10f16b18b94", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "18cd4c1c-f516-443e-9ff0-8435640e3561"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients taking TNF\u2011blockers are more\nsusceptible to serious infections.</span></p>", "ID": "f66f56ef-3f02-47a4-84cb-24c7e4edf97d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Patients taking TNF\u2011blockers are more\nsusceptible to serious infections.</span>", "ID": "dbb3fc25-a57c-4d02-a73d-09e645a282fc", "Styles": "None", "Classes": "None", "Text": "Patients taking TNF\u2011blockers are more susceptible to serious infections.", "ParentId": "f66f56ef-3f02-47a4-84cb-24c7e4edf97d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tuberculosis, bacterial infections, </span><span lang=\"EN-GB\">including sepsis and pneumonia</span><span lang=\"EN-GB\">, invasive\nfungal, viral, and other opportunistic infections</span><span lang=\"EN-GB\"> have\nbeen observed in patients treated with infliximab. Some of these infections\nhave been fatal</span><span lang=\"EN-GB\">; </span><span lang=\"EN-GB\">the most\nfrequently reported opportunistic infections with a mortality rate of\n&gt;\u00a05% include pneumocystosis, candidiasis, listeriosis and aspergillosis</span><span lang=\"EN-GB\">.</span></p>", "ID": "87110b30-d6e3-4306-a2ab-e0493c007dca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Tuberculosis, bacterial infections, </span>", "ID": "9b7a1601-3272-4a13-8d98-5c6a636725a7", "Styles": "None", "Classes": "None", "Text": "Tuberculosis, bacterial infections, ", "ParentId": "87110b30-d6e3-4306-a2ab-e0493c007dca"}, {"Element": "<span lang=\"EN-GB\">including sepsis and pneumonia</span>", "ID": "7df3f14b-bc78-40b8-8959-8b1f85ce3071", "Styles": "None", "Classes": "None", "Text": "including sepsis and pneumonia", "ParentId": "87110b30-d6e3-4306-a2ab-e0493c007dca"}, {"Element": "<span lang=\"EN-GB\">, invasive\nfungal, viral, and other opportunistic infections</span>", "ID": "12060395-4485-44a0-b150-e709edb6c76f", "Styles": "None", "Classes": "None", "Text": ", invasive fungal, viral, and other opportunistic infections", "ParentId": "87110b30-d6e3-4306-a2ab-e0493c007dca"}, {"Element": "<span lang=\"EN-GB\"> have\nbeen observed in patients treated with infliximab. Some of these infections\nhave been fatal</span>", "ID": "b4579bf8-b4e9-4df1-a6e3-2761f519174b", "Styles": "None", "Classes": "None", "Text": " have been observed in patients treated with infliximab. Some of these infections have been fatal", "ParentId": "87110b30-d6e3-4306-a2ab-e0493c007dca"}, {"Element": "<span lang=\"EN-GB\">; </span>", "ID": "b35a27e0-654f-4376-a29e-91153e0fb4cc", "Styles": "None", "Classes": "None", "Text": "; ", "ParentId": "87110b30-d6e3-4306-a2ab-e0493c007dca"}, {"Element": "<span lang=\"EN-GB\">the most\nfrequently reported opportunistic infections with a mortality rate of\n&gt;\u00a05% include pneumocystosis, candidiasis, listeriosis and aspergillosis</span>", "ID": "6e76dde3-86aa-4b28-9fba-028c25b611df", "Styles": "None", "Classes": "None", "Text": "the most frequently reported opportunistic infections with a mortality rate of >\u00a05% include pneumocystosis, candidiasis, listeriosis and aspergillosis", "ParentId": "87110b30-d6e3-4306-a2ab-e0493c007dca"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "210926ac-6149-40b5-bb52-32e1c4fcd05a", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "87110b30-d6e3-4306-a2ab-e0493c007dca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients who develop a new infection while\nundergoing treatment with Remicade, should be monitored closely and undergo a\ncomplete diagnostic evaluation. Administration of Remicade should be discontinued\nif a patient develops a new serious infection or sepsis, and appropriate\nantimicrobial or antifungal therapy should be initiated until the infection is\ncontrolled.</span></p>", "ID": "73c84e2f-f8c5-4dcc-b593-9f6840047351", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Patients who develop a new infection while\nundergoing treatment with Remicade, should be monitored closely and undergo a\ncomplete diagnostic evaluation. Administration of Remicade should be discontinued\nif a patient develops a new serious infection or sepsis, and appropriate\nantimicrobial or antifungal therapy should be initiated until the infection is\ncontrolled.</span>", "ID": "f84a07c6-c0f3-4d8b-bc38-0981a62c6b6a", "Styles": "None", "Classes": "None", "Text": "Patients who develop a new infection while undergoing treatment with Remicade, should be monitored closely and undergo a complete diagnostic evaluation. Administration of Remicade should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled.", "ParentId": "73c84e2f-f8c5-4dcc-b593-9f6840047351"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a5096e95-2e88-48a0-883e-fec95e60fabb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a4d25489-1064-4b1e-a9f5-fe9ab9ee3b6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a5096e95-2e88-48a0-883e-fec95e60fabb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Tuberculosis</span></i></p>", "ID": "8c63e885-14d7-4c28-b526-33efb1857d73", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Tuberculosis</span></i>", "ID": "60498455-6dc2-463b-a608-d4b124027b7f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c63e885-14d7-4c28-b526-33efb1857d73"}, {"Element": "<span lang=\"EN-GB\">Tuberculosis</span>", "ID": "981c8123-96c4-483f-844a-4e65c88bac44", "Styles": "None", "Classes": "None", "Text": "Tuberculosis", "ParentId": "60498455-6dc2-463b-a608-d4b124027b7f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There have been reports of active\ntuberculosis in patients receiving Remicade. It should be noted that in the\nmajority of these reports tuberculosis was extrapulmonary, presenting as either\nlocal or disseminated disease.</span></p>", "ID": "0aad44eb-f0d2-4bb7-b494-1bacf7c74a3e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">There have been reports of active\ntuberculosis in patients receiving Remicade. It should be noted that in the\nmajority of these reports tuberculosis was extrapulmonary, presenting as either\nlocal or disseminated disease.</span>", "ID": "4b41eaff-cc88-4b20-9dbe-8c7b71792ecb", "Styles": "None", "Classes": "None", "Text": "There have been reports of active tuberculosis in patients receiving Remicade. It should be noted that in the majority of these reports tuberculosis was extrapulmonary, presenting as either local or disseminated disease.", "ParentId": "0aad44eb-f0d2-4bb7-b494-1bacf7c74a3e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cc8fa294-a797-405b-84af-db46b052cef8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "73cd8e54-de6d-468c-9f0e-e03a367b7bc2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cc8fa294-a797-405b-84af-db46b052cef8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Before starting treatment with Remicade,\nall patients must be evaluated for both active and inactive (\u2018latent\u2019)\ntuberculosis. This evaluation should include a detailed medical history with\npersonal history of tuberculosis or possible previous contact with tuberculosis\nand previous and/or current immunosuppressive therapy. Appropriate screening\ntests (e.g. tuberculin skin test, chest X\u2011ray, and/or Interferon Gamma\nRelease Assay), should be performed in all patients (local recommendations may\napply). It is recommended that t<span style=\"layout-grid-mode:line\">he conduct\nof these tests should be recorded in the </span>patient\u2019s reminder card.\nPrescribers are reminded of the risk of false negative tuberculin skin test\nresults, especially in patients who are severely ill or immunocompromised<span style=\"layout-grid-mode:line\">.</span></span></p>", "ID": "628d5c78-edeb-4328-9bf6-76fe7bc24587", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Before starting treatment with Remicade,\nall patients must be evaluated for both active and inactive (\u2018latent\u2019)\ntuberculosis. This evaluation should include a detailed medical history with\npersonal history of tuberculosis or possible previous contact with tuberculosis\nand previous and/or current immunosuppressive therapy. Appropriate screening\ntests (e.g. tuberculin skin test, chest X\u2011ray, and/or Interferon Gamma\nRelease Assay), should be performed in all patients (local recommendations may\napply). It is recommended that t<span style=\"layout-grid-mode:line\">he conduct\nof these tests should be recorded in the </span>patient\u2019s reminder card.\nPrescribers are reminded of the risk of false negative tuberculin skin test\nresults, especially in patients who are severely ill or immunocompromised<span style=\"layout-grid-mode:line\">.</span></span>", "ID": "8c65a3f1-5149-4d7b-8c9f-f44c3b739cb5", "Styles": "None", "Classes": "None", "Text": "Before starting treatment with Remicade, all patients must be evaluated for both active and inactive (\u2018latent\u2019) tuberculosis. This evaluation should include a detailed medical history with personal history of tuberculosis or possible previous contact with tuberculosis and previous and/or current immunosuppressive therapy. Appropriate screening tests (e.g. tuberculin skin test, chest X\u2011ray, and/or Interferon Gamma Release Assay), should be performed in all patients (local recommendations may apply). It is recommended that tpatient\u2019s reminder card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised", "ParentId": "628d5c78-edeb-4328-9bf6-76fe7bc24587"}, {"Element": "<span style=\"layout-grid-mode:line\">he conduct\nof these tests should be recorded in the </span>", "ID": "293310a6-eabc-430e-8e54-a7e4b09c3582", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "he conduct of these tests should be recorded in the ", "ParentId": "8c65a3f1-5149-4d7b-8c9f-f44c3b739cb5"}, {"Element": "<span style=\"layout-grid-mode:line\">.</span>", "ID": "af975fb4-df51-4e2a-850f-d92cb89a54c0", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": ".", "ParentId": "8c65a3f1-5149-4d7b-8c9f-f44c3b739cb5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "66edbec9-863e-4bf9-a405-fd59505f5501", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "511f94b9-967c-47c3-a73a-1e7da1cd30cc", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "66edbec9-863e-4bf9-a405-fd59505f5501"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">If active\ntuberculosis is diagnosed, Remicade therapy must not be initiated (see section\u00a04.3).</span></p>", "ID": "0c65398e-730c-4927-8c1e-866b0cc62e6b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">If active\ntuberculosis is diagnosed, Remicade therapy must not be initiated (see section\u00a04.3).</span>", "ID": "04fca9ce-a303-4eba-8e0f-9f93c51e3963", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "If active tuberculosis is diagnosed, Remicade therapy must not be initiated (see section\u00a04.3).", "ParentId": "0c65398e-730c-4927-8c1e-866b0cc62e6b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "394dff5d-84a1-4bec-876a-0773db48feb9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6fec7f1d-9e90-4e4c-bfa7-0cda1a3a45e5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "394dff5d-84a1-4bec-876a-0773db48feb9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If latent tuberculosis is suspected, a\nphysician with expertise in the treatment of tuberculosis should be consulted.\nIn all situations described below, the benefit/risk balance of Remicade therapy\nshould be very carefully considered.</span></p>", "ID": "d1a9a5a3-9f19-4c26-9299-3cb4ad617702", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">If latent tuberculosis is suspected, a\nphysician with expertise in the treatment of tuberculosis should be consulted.\nIn all situations described below, the benefit/risk balance of Remicade therapy\nshould be very carefully considered.</span>", "ID": "f44630e0-2ed8-4af9-b677-4ae2a0660351", "Styles": "None", "Classes": "None", "Text": "If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted. In all situations described below, the benefit/risk balance of Remicade therapy should be very carefully considered.", "ParentId": "d1a9a5a3-9f19-4c26-9299-3cb4ad617702"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "91b86cd1-7a01-409e-8ade-3d16be381260", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4f11d049-7ea9-4b38-a914-da69217f808a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "91b86cd1-7a01-409e-8ade-3d16be381260"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If inactive (\u2018latent\u2019)\ntuberculosis is diagnosed, treatment for latent tuberculosis must be started\nwith antituberculosis therapy before the initiation of Remicade, and in\naccordance with local recommendations.</span></p>", "ID": "71047d29-bad8-457e-bba3-560a992cef83", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">If inactive (\u2018latent\u2019)\ntuberculosis is diagnosed, treatment for latent tuberculosis must be started\nwith antituberculosis therapy before the initiation of Remicade, and in\naccordance with local recommendations.</span>", "ID": "6b1ecba3-2fc6-450e-a5ea-b8383530a4f8", "Styles": "None", "Classes": "None", "Text": "If inactive (\u2018latent\u2019) tuberculosis is diagnosed, treatment for latent tuberculosis must be started with antituberculosis therapy before the initiation of Remicade, and in accordance with local recommendations.", "ParentId": "71047d29-bad8-457e-bba3-560a992cef83"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ae6efbae-1abc-46f0-8377-aacf3da6cbb4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dbfc2d39-61ba-4132-929f-3850726abd24", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae6efbae-1abc-46f0-8377-aacf3da6cbb4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients who have several or significant\nrisk factors for tuberculosis and have a negative test for latent tuberculosis,\nantituberculosis therapy should be considered before the initiation of\nRemicade.</span></p>", "ID": "4d40a833-06b0-4573-9776-7c5466827cb2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In patients who have several or significant\nrisk factors for tuberculosis and have a negative test for latent tuberculosis,\nantituberculosis therapy should be considered before the initiation of\nRemicade.</span>", "ID": "f085e0f7-9161-4910-b4c5-728004d3461f", "Styles": "None", "Classes": "None", "Text": "In patients who have several or significant risk factors for tuberculosis and have a negative test for latent tuberculosis, antituberculosis therapy should be considered before the initiation of Remicade.", "ParentId": "4d40a833-06b0-4573-9776-7c5466827cb2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "72c2e64d-eb58-454c-828b-afae5bbedd58", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "db8c936f-0b3e-4bc5-8d1c-137953202656", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "72c2e64d-eb58-454c-828b-afae5bbedd58"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Use of antituberculosis therapy should also\nbe considered before the initiation of Remicade in patients with a past history\nof latent or active tuberculosis in whom an adequate course of treatment cannot\nbe confirmed.</span></p>", "ID": "d4669b00-d28a-4624-aa14-764637d7fb42", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Use of antituberculosis therapy should also\nbe considered before the initiation of Remicade in patients with a past history\nof latent or active tuberculosis in whom an adequate course of treatment cannot\nbe confirmed.</span>", "ID": "faf2b6fa-b48a-4fb1-8e27-86b551fd09c4", "Styles": "None", "Classes": "None", "Text": "Use of antituberculosis therapy should also be considered before the initiation of Remicade in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.", "ParentId": "d4669b00-d28a-4624-aa14-764637d7fb42"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Some cases of active tuberculosis have been\nreported in patients treated with Remicade during and after treatment for\nlatent tuberculosis.</span></p>", "ID": "39b88641-340c-4882-94d6-6d365f6bcb30", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Some cases of active tuberculosis have been\nreported in patients treated with Remicade during and after treatment for\nlatent tuberculosis.</span>", "ID": "dddf4772-3e39-411b-9fb9-bb35e8d92a72", "Styles": "None", "Classes": "None", "Text": "Some cases of active tuberculosis have been reported in patients treated with Remicade during and after treatment for latent tuberculosis.", "ParentId": "39b88641-340c-4882-94d6-6d365f6bcb30"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">All patients should be informed to seek\nmedical advice if signs/symptoms suggestive of tuberculosis</span><span lang=\"EN-GB\"> (e.g. persistent cough, wasting/weight loss, low\u2011grade fever)\nappear during or after Remicade treatment.</span></p>", "ID": "2e561ac8-06e4-4e14-bae4-06417a9482d7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">All patients should be informed to seek\nmedical advice if signs/symptoms suggestive of tuberculosis</span>", "ID": "b5a927d5-ccf3-4576-bc40-cb202b831cee", "Styles": "None", "Classes": "None", "Text": "All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis", "ParentId": "2e561ac8-06e4-4e14-bae4-06417a9482d7"}, {"Element": "<span lang=\"EN-GB\"> (e.g. persistent cough, wasting/weight loss, low\u2011grade fever)\nappear during or after Remicade treatment.</span>", "ID": "f22457fb-2674-4f01-9b72-a669b65281df", "Styles": "None", "Classes": "None", "Text": " (e.g. persistent cough, wasting/weight loss, low\u2011grade fever) appear during or after Remicade treatment.", "ParentId": "2e561ac8-06e4-4e14-bae4-06417a9482d7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c59e1941-3230-4139-a420-6dfd50dadd4b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b95d0b35-280c-4c96-b605-efba60b1262f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c59e1941-3230-4139-a420-6dfd50dadd4b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Invasive\nfungal infections</span></i></p>", "ID": "4ab1b416-ead5-43c4-9cb1-0343b70eb267", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Invasive\nfungal infections</span></i>", "ID": "d99d0f92-ec2e-429a-ab7f-90c5e08742d5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4ab1b416-ead5-43c4-9cb1-0343b70eb267"}, {"Element": "<span lang=\"EN-GB\">Invasive\nfungal infections</span>", "ID": "3a49970e-856b-4823-af6f-42d866852be0", "Styles": "None", "Classes": "None", "Text": "Invasive fungal infections", "ParentId": "d99d0f92-ec2e-429a-ab7f-90c5e08742d5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients treated with Remicade, an\ninvasive fungal infection such as aspergillosis, candidiasis, pneumocystosis,\nhistoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they\ndevelop a serious systemic illness</span><span lang=\"EN-GB\">, and a physician\nwith expertise in the diagnosis and treatment of invasive fungal infections\nshould be consulted at an early stage when investigating these patients</span><span lang=\"EN-GB\">. Invasive fungal infections may present as disseminated rather than\nlocalised disease, and antigen and antibody testing may be negative in some\npatients with active infection. Appropriate empiric antifungal therapy should\nbe considered while a diagnostic workup is being performed taking into account\nboth the risk for severe fungal infection and the risks of antifungal therapy.</span></p>", "ID": "bee0abfa-f11c-4662-8e3e-cca0a988faf6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In patients treated with Remicade, an\ninvasive fungal infection such as aspergillosis, candidiasis, pneumocystosis,\nhistoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they\ndevelop a serious systemic illness</span>", "ID": "aa4f1c2a-cf8e-404a-b3be-e1e38ecf97f5", "Styles": "None", "Classes": "None", "Text": "In patients treated with Remicade, an invasive fungal infection such as aspergillosis, candidiasis, pneumocystosis, histoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they develop a serious systemic illness", "ParentId": "bee0abfa-f11c-4662-8e3e-cca0a988faf6"}, {"Element": "<span lang=\"EN-GB\">, and a physician\nwith expertise in the diagnosis and treatment of invasive fungal infections\nshould be consulted at an early stage when investigating these patients</span>", "ID": "220b61d6-5521-4613-ad1b-1634bbe75783", "Styles": "None", "Classes": "None", "Text": ", and a physician with expertise in the diagnosis and treatment of invasive fungal infections should be consulted at an early stage when investigating these patients", "ParentId": "bee0abfa-f11c-4662-8e3e-cca0a988faf6"}, {"Element": "<span lang=\"EN-GB\">. Invasive fungal infections may present as disseminated rather than\nlocalised disease, and antigen and antibody testing may be negative in some\npatients with active infection. Appropriate empiric antifungal therapy should\nbe considered while a diagnostic workup is being performed taking into account\nboth the risk for severe fungal infection and the risks of antifungal therapy.</span>", "ID": "627a8aac-8d88-4f61-99a5-a70c311811a3", "Styles": "None", "Classes": "None", "Text": ". Invasive fungal infections may present as disseminated rather than localised disease, and antigen and antibody testing may be negative in some patients with active infection. Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed taking into account both the risk for severe fungal infection and the risks of antifungal therapy.", "ParentId": "bee0abfa-f11c-4662-8e3e-cca0a988faf6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0a57a54e-e225-4437-b8c8-1239e8c5c151", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fcb7658c-49e5-4985-be7d-49c9942b244b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a57a54e-e225-4437-b8c8-1239e8c5c151"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For patients who have resided in or\ntravelled to regions where invasive fungal infections such as histoplasmosis,\ncoccidioidomycosis, or blastomycosis are endemic, the benefits and risks of\nRemicade treatment should be carefully considered before initiation of Remicade\ntherapy.</span></p>", "ID": "8a653398-3d72-4a12-83c4-50ce695ec640", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">For patients who have resided in or\ntravelled to regions where invasive fungal infections such as histoplasmosis,\ncoccidioidomycosis, or blastomycosis are endemic, the benefits and risks of\nRemicade treatment should be carefully considered before initiation of Remicade\ntherapy.</span>", "ID": "038d40ce-fb4c-4d0a-b5e2-7417fa6b2469", "Styles": "None", "Classes": "None", "Text": "For patients who have resided in or travelled to regions where invasive fungal infections such as histoplasmosis, coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of Remicade treatment should be carefully considered before initiation of Remicade therapy.", "ParentId": "8a653398-3d72-4a12-83c4-50ce695ec640"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "40a7e5c6-94a3-4a09-b8e1-879017212988", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f03cf8f9-bc1e-4e5e-b1b3-4b3925d85567", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "40a7e5c6-94a3-4a09-b8e1-879017212988"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Fistulising\nCrohn\u2019s disease</span></i></p>", "ID": "7f5bba5c-1682-4c52-ae17-e67c831b99b0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Fistulising\nCrohn\u2019s disease</span></i>", "ID": "6f6c8085-6f8c-4875-b5d7-238ca443dfbe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7f5bba5c-1682-4c52-ae17-e67c831b99b0"}, {"Element": "<span lang=\"EN-GB\">Fistulising\nCrohn\u2019s disease</span>", "ID": "9209ee07-1bce-423b-82c8-afd179a48925", "Styles": "None", "Classes": "None", "Text": "Fistulising Crohn\u2019s disease", "ParentId": "6f6c8085-6f8c-4875-b5d7-238ca443dfbe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients with fistulising Crohn\u2019s\ndisease with acute suppurative fistulas must not initiate Remicade therapy\nuntil a source for possible infection, specifically abscess, has been excluded\n(see section\u00a04.3).</span></p>", "ID": "dd445e41-4d51-4b26-a917-28404a3a6629", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Patients with fistulising Crohn\u2019s\ndisease with acute suppurative fistulas must not initiate Remicade therapy\nuntil a source for possible infection, specifically abscess, has been excluded\n(see section\u00a04.3).</span>", "ID": "fc92e13e-b66d-46d9-ba70-a32a290aa2e1", "Styles": "None", "Classes": "None", "Text": "Patients with fistulising Crohn\u2019s disease with acute suppurative fistulas must not initiate Remicade therapy until a source for possible infection, specifically abscess, has been excluded (see section\u00a04.3).", "ParentId": "dd445e41-4d51-4b26-a917-28404a3a6629"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "69998fe0-b251-48f9-a3e5-210aa36d46cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c199688c-c2aa-4cd2-90b6-b799bac5f1ae", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "69998fe0-b251-48f9-a3e5-210aa36d46cb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatitis\nB (HBV) reactivation</span></u></p>", "ID": "9cb826b0-beb4-4209-90eb-ec3094f8d564", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Hepatitis\nB (HBV) reactivation</span></u>", "ID": "1ee445cf-36f1-48b9-8164-7200b4d61ac6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9cb826b0-beb4-4209-90eb-ec3094f8d564"}, {"Element": "<span lang=\"EN-GB\">Hepatitis\nB (HBV) reactivation</span>", "ID": "374da43e-269f-4e31-b1e1-277dd1c3237e", "Styles": "None", "Classes": "None", "Text": "Hepatitis B (HBV) reactivation", "ParentId": "1ee445cf-36f1-48b9-8164-7200b4d61ac6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reactivation of hepatitis B has occurred in\npatients receiving a TNF\u2011antagonist including infliximab, who are chronic\ncarriers of this virus. Some cases have had fatal outcome.</span></p>", "ID": "0bf82b9b-cd29-42cd-a0da-5938320feefc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Reactivation of hepatitis B has occurred in\npatients receiving a TNF\u2011antagonist including infliximab, who are chronic\ncarriers of this virus. Some cases have had fatal outcome.</span>", "ID": "da8abdec-d64b-4531-88fe-c7ecd23a6200", "Styles": "None", "Classes": "None", "Text": "Reactivation of hepatitis B has occurred in patients receiving a TNF\u2011antagonist including infliximab, who are chronic carriers of this virus. Some cases have had fatal outcome.", "ParentId": "0bf82b9b-cd29-42cd-a0da-5938320feefc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ae5ba5a0-cd57-4827-8e29-ca2c6cdf89e4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "494884d4-78ed-4781-aebf-d083b4b188fc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae5ba5a0-cd57-4827-8e29-ca2c6cdf89e4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients should be tested for HBV infection\nbefore initiating treatment with Remicade. For patients who test positive for\nHBV infection, consultation with a physician with expertise in the treatment of\nhepatitis B is recommended.</span><span lang=\"EN-GB\"> Carriers of HBV who require\ntreatment with Remicade should be closely monitored for signs and symptoms of\nactive HBV infection throughout therapy and for several months following\ntermination of therapy. Adequate data of treating patients who are carriers of\nHBV with antiviral therapy in conjunction with TNF\u2011antagonist therapy to\nprevent HBV reactivation are not available. In patients who develop HBV\nreactivation, Remicade should be stopped and effective antiviral therapy with\nappropriate supportive treatment should be initiated.</span></p>", "ID": "99af9520-5f4c-4ace-a4ba-65ec28179898", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Patients should be tested for HBV infection\nbefore initiating treatment with Remicade. For patients who test positive for\nHBV infection, consultation with a physician with expertise in the treatment of\nhepatitis B is recommended.</span>", "ID": "af161d4a-edc6-4abb-88e7-d5cf3600c0a6", "Styles": "None", "Classes": "None", "Text": "Patients should be tested for HBV infection before initiating treatment with Remicade. For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended.", "ParentId": "99af9520-5f4c-4ace-a4ba-65ec28179898"}, {"Element": "<span lang=\"EN-GB\"> Carriers of HBV who require\ntreatment with Remicade should be closely monitored for signs and symptoms of\nactive HBV infection throughout therapy and for several months following\ntermination of therapy. Adequate data of treating patients who are carriers of\nHBV with antiviral therapy in conjunction with TNF\u2011antagonist therapy to\nprevent HBV reactivation are not available. In patients who develop HBV\nreactivation, Remicade should be stopped and effective antiviral therapy with\nappropriate supportive treatment should be initiated.</span>", "ID": "7385787b-9f62-4dd1-89d3-50ccaa7a160f", "Styles": "None", "Classes": "None", "Text": " Carriers of HBV who require treatment with Remicade should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy. Adequate data of treating patients who are carriers of HBV with antiviral therapy in conjunction with TNF\u2011antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV reactivation, Remicade should be stopped and effective antiviral therapy with appropriate supportive treatment should be initiated.", "ParentId": "99af9520-5f4c-4ace-a4ba-65ec28179898"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7681b52b-6405-4fc7-b32d-ce733e6b7ec9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa42d703-133e-4a36-b682-a74964327fc2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7681b52b-6405-4fc7-b32d-ce733e6b7ec9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\nevents</span></u></p>", "ID": "046a2077-d6dc-4eda-acc9-18e42801970f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Hepatobiliary\nevents</span></u>", "ID": "336337a7-26b4-4e4b-a82d-30bf2da89e2e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "046a2077-d6dc-4eda-acc9-18e42801970f"}, {"Element": "<span lang=\"EN-GB\">Hepatobiliary\nevents</span>", "ID": "20a1231f-fc11-4e3e-9b81-c754b0c64acc", "Styles": "None", "Classes": "None", "Text": "Hepatobiliary events", "ParentId": "336337a7-26b4-4e4b-a82d-30bf2da89e2e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cases of jaundice and non\u2011infectious\nhepatitis, some with features of autoimmune hepatitis, have been observed in\nthe post\u2011marketing experience of Remicade. Isolated cases of liver\nfailure resulting in liver transplantation or death have occurred. Patients\nwith symptoms or signs of liver dysfunction should be evaluated for evidence of\nliver injury. If jaundice and/or ALT elevations \u2265\u00a05\u00a0times the\nupper limit of normal develop(s), Remicade should be discontinued, and a\nthorough investigation of the abnormality should be undertaken.</span></p>", "ID": "2986649f-4ccf-4c24-9a68-095a3ff85507", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Cases of jaundice and non\u2011infectious\nhepatitis, some with features of autoimmune hepatitis, have been observed in\nthe post\u2011marketing experience of Remicade. Isolated cases of liver\nfailure resulting in liver transplantation or death have occurred. Patients\nwith symptoms or signs of liver dysfunction should be evaluated for evidence of\nliver injury. If jaundice and/or ALT elevations \u2265\u00a05\u00a0times the\nupper limit of normal develop(s), Remicade should be discontinued, and a\nthorough investigation of the abnormality should be undertaken.</span>", "ID": "09b7136a-33cc-44ac-be75-9642f3e32c71", "Styles": "None", "Classes": "None", "Text": "Cases of jaundice and non\u2011infectious hepatitis, some with features of autoimmune hepatitis, have been observed in the post\u2011marketing experience of Remicade. Isolated cases of liver failure resulting in liver transplantation or death have occurred. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or ALT elevations \u2265\u00a05\u00a0times the upper limit of normal develop(s), Remicade should be discontinued, and a thorough investigation of the abnormality should be undertaken.", "ParentId": "2986649f-4ccf-4c24-9a68-095a3ff85507"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1e39d455-4fdb-4d04-b890-d8d3f6c19bc5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f1d0d130-6176-48a6-a48a-ef1968ad7493", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1e39d455-4fdb-4d04-b890-d8d3f6c19bc5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Concurrent\nadministration of TNF\u2011alpha inhibitor and anakinra</span></u></p>", "ID": "c06ebb90-3d9c-4025-b23c-b06e1403a9d3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Concurrent\nadministration of TNF\u2011alpha inhibitor and anakinra</span></u>", "ID": "3f0b6a28-b49e-40aa-bd8d-e889e54acd6d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c06ebb90-3d9c-4025-b23c-b06e1403a9d3"}, {"Element": "<span lang=\"EN-GB\">Concurrent\nadministration of TNF\u2011alpha inhibitor and anakinra</span>", "ID": "b63de23b-4918-46e0-964e-3d651137b3ee", "Styles": "None", "Classes": "None", "Text": "Concurrent administration of TNF\u2011alpha inhibitor and anakinra", "ParentId": "3f0b6a28-b49e-40aa-bd8d-e889e54acd6d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Serious infections </span><span lang=\"EN-GB\">and\nneutropenia </span><span lang=\"EN-GB\">were seen in clinical studies with\nconcurrent use of anakinra and another TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">\u2011blocking\nagent, etanercept, with no added clinical benefit compared to etanercept alone.\nBecause of the nature of the adverse reactions seen with combination of\netanercept and anakinra therapy, similar toxicities may also result from the\ncombination of anakinra and other TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">\u2011blocking\nagents. Therefore, the combination of Remicade and anakinra is not recommended.</span></p>", "ID": "08c87466-2dde-4ab8-b768-f01f1a178510", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Serious infections </span>", "ID": "0b21042c-7a2c-4b6b-86f8-de4f349e1e6b", "Styles": "None", "Classes": "None", "Text": "Serious infections ", "ParentId": "08c87466-2dde-4ab8-b768-f01f1a178510"}, {"Element": "<span lang=\"EN-GB\">and\nneutropenia </span>", "ID": "0507b743-9a13-4abc-9fd7-347d1c99e577", "Styles": "None", "Classes": "None", "Text": "and neutropenia ", "ParentId": "08c87466-2dde-4ab8-b768-f01f1a178510"}, {"Element": "<span lang=\"EN-GB\">were seen in clinical studies with\nconcurrent use of anakinra and another TNF</span>", "ID": "344bd18a-5d74-4224-b00d-7cf0f211b624", "Styles": "None", "Classes": "None", "Text": "were seen in clinical studies with concurrent use of anakinra and another TNF", "ParentId": "08c87466-2dde-4ab8-b768-f01f1a178510"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "9805d5f7-3e08-43d9-a932-ec6d6e312ab3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "08c87466-2dde-4ab8-b768-f01f1a178510"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "7baa889b-efd8-4534-9f9f-6439b4d6a3ca", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "9805d5f7-3e08-43d9-a932-ec6d6e312ab3"}, {"Element": "<span lang=\"EN-GB\">\u2011blocking\nagent, etanercept, with no added clinical benefit compared to etanercept alone.\nBecause of the nature of the adverse reactions seen with combination of\netanercept and anakinra therapy, similar toxicities may also result from the\ncombination of anakinra and other TNF</span>", "ID": "55c3f282-6b9b-436c-897f-383b28a6221b", "Styles": "None", "Classes": "None", "Text": "\u2011blocking agent, etanercept, with no added clinical benefit compared to etanercept alone. Because of the nature of the adverse reactions seen with combination of etanercept and anakinra therapy, similar toxicities may also result from the combination of anakinra and other TNF", "ParentId": "08c87466-2dde-4ab8-b768-f01f1a178510"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "1462dd00-b5ce-46d0-98a9-d9147ed231b8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "08c87466-2dde-4ab8-b768-f01f1a178510"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "b54a839f-f813-4be4-9c2b-15bb0e96c7a2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "1462dd00-b5ce-46d0-98a9-d9147ed231b8"}, {"Element": "<span lang=\"EN-GB\">\u2011blocking\nagents. Therefore, the combination of Remicade and anakinra is not recommended.</span>", "ID": "a2e959c0-c000-47de-be0e-4006790f8368", "Styles": "None", "Classes": "None", "Text": "\u2011blocking agents. Therefore, the combination of Remicade and anakinra is not recommended.", "ParentId": "08c87466-2dde-4ab8-b768-f01f1a178510"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8214c2a8-f66a-4139-bad7-d5a32d983a8d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "87c83fda-48d0-40c2-a4cd-00f8ddc8e50d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8214c2a8-f66a-4139-bad7-d5a32d983a8d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Concurrent\nadministration of TNF\u2011alpha inhibitor and abatacept</span></u></p>", "ID": "e98c64b5-8460-4670-a9f6-e29e8605c160", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Concurrent\nadministration of TNF\u2011alpha inhibitor and abatacept</span></u>", "ID": "133aeed1-64ca-4702-85e0-f457c7341827", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e98c64b5-8460-4670-a9f6-e29e8605c160"}, {"Element": "<span lang=\"EN-GB\">Concurrent\nadministration of TNF\u2011alpha inhibitor and abatacept</span>", "ID": "61e335ae-adbb-417d-a4c1-9dd9a3d20841", "Styles": "None", "Classes": "None", "Text": "Concurrent administration of TNF\u2011alpha inhibitor and abatacept", "ParentId": "133aeed1-64ca-4702-85e0-f457c7341827"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical studies concurrent\nadministration of TNF\u2011antagonists and abatacept has been associated with\nan increased risk of infections including serious infections compared to TNF\u2011antagonists\nalone, without increased clinical benefit. The combination of Remicade and\nabatacept is not recommended.</span></p>", "ID": "bbabcdbc-c93f-4b2f-9dad-08c2d20d9a1c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In clinical studies concurrent\nadministration of TNF\u2011antagonists and abatacept has been associated with\nan increased risk of infections including serious infections compared to TNF\u2011antagonists\nalone, without increased clinical benefit. The combination of Remicade and\nabatacept is not recommended.</span>", "ID": "2c045694-8253-43a3-9b35-bc688db99c2d", "Styles": "None", "Classes": "None", "Text": "In clinical studies concurrent administration of TNF\u2011antagonists and abatacept has been associated with an increased risk of infections including serious infections compared to TNF\u2011antagonists alone, without increased clinical benefit. The combination of Remicade and abatacept is not recommended.", "ParentId": "bbabcdbc-c93f-4b2f-9dad-08c2d20d9a1c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "73118a57-16f2-4237-8974-ac0a48955aed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8506b457-e894-4856-9266-ad2667374975", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "73118a57-16f2-4237-8974-ac0a48955aed"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Concurrent\nadministration with other biological therapeutics</span></u></p>", "ID": "8833c104-85cb-4923-b39f-25697f2ce790", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Concurrent\nadministration with other biological therapeutics</span></u>", "ID": "8d7df8cf-a5ed-44b6-9a51-614c5c6b97bd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8833c104-85cb-4923-b39f-25697f2ce790"}, {"Element": "<span lang=\"EN-GB\">Concurrent\nadministration with other biological therapeutics</span>", "ID": "8047aea7-a490-4c12-960b-6faf01499451", "Styles": "None", "Classes": "None", "Text": "Concurrent administration with other biological therapeutics", "ParentId": "8d7df8cf-a5ed-44b6-9a51-614c5c6b97bd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There is insufficient information regarding\nthe concomitant use of infliximab with other biological therapeutics used to\ntreat the same conditions as infliximab. The concomitant use of infliximab with\nthese biologics is not recommended </span><span lang=\"EN-GB\">because of the\npossibility of an increased risk of infection, and other potential\npharmacological interactions.</span></p>", "ID": "9ceb7fd9-e10c-4a68-8a9d-07bea1e63ce4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">There is insufficient information regarding\nthe concomitant use of infliximab with other biological therapeutics used to\ntreat the same conditions as infliximab. The concomitant use of infliximab with\nthese biologics is not recommended </span>", "ID": "d404d04c-3e30-4f9d-b378-63f620808e40", "Styles": "None", "Classes": "None", "Text": "There is insufficient information regarding the concomitant use of infliximab with other biological therapeutics used to treat the same conditions as infliximab. The concomitant use of infliximab with these biologics is not recommended ", "ParentId": "9ceb7fd9-e10c-4a68-8a9d-07bea1e63ce4"}, {"Element": "<span lang=\"EN-GB\">because of the\npossibility of an increased risk of infection, and other potential\npharmacological interactions.</span>", "ID": "d6f81a16-9395-460d-b3a8-fadba3bb3f5f", "Styles": "None", "Classes": "None", "Text": "because of the possibility of an increased risk of infection, and other potential pharmacological interactions.", "ParentId": "9ceb7fd9-e10c-4a68-8a9d-07bea1e63ce4"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "88d2bb08-5f90-42cb-b572-8c3da6343353", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "b6de813d-64fc-41f3-99e1-2c8b6a7c423b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "88d2bb08-5f90-42cb-b572-8c3da6343353"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "0a87fd41-7250-4b10-95e1-11199463b1ba", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b6de813d-64fc-41f3-99e1-2c8b6a7c423b"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "b65e228c-dbb3-4943-be13-6e9508547b55", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "0a87fd41-7250-4b10-95e1-11199463b1ba"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Switching\nbetween biological DMARDS</span></u></p>", "ID": "db468cc3-2e4a-413f-8aab-30625ecd4c16", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Switching\nbetween biological DMARDS</span></u>", "ID": "1a63f662-7129-4fa5-b042-4c48cd25feff", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "db468cc3-2e4a-413f-8aab-30625ecd4c16"}, {"Element": "<span lang=\"EN-GB\">Switching\nbetween biological DMARDS</span>", "ID": "f6ac1330-2a50-4bf0-946b-16a06c7e8edd", "Styles": "None", "Classes": "None", "Text": "Switching between biological DMARDS", "ParentId": "1a63f662-7129-4fa5-b042-4c48cd25feff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Care should be taken and patients should\ncontinue to be monitored when switching from one biologic to another, since\noverlapping biological activity may further increase the risk for adverse reactions,\nincluding infection.</span></p>", "ID": "5d5cf18b-1f60-44be-adac-c80ed1187331", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Care should be taken and patients should\ncontinue to be monitored when switching from one biologic to another, since\noverlapping biological activity may further increase the risk for adverse reactions,\nincluding infection.</span>", "ID": "b0e25f30-3039-4246-aa5a-cd03a4191919", "Styles": "None", "Classes": "None", "Text": "Care should be taken and patients should continue to be monitored when switching from one biologic to another, since overlapping biological activity may further increase the risk for adverse reactions, including infection.", "ParentId": "5d5cf18b-1f60-44be-adac-c80ed1187331"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "a18a5fd0-4f3d-4048-ab82-474c8bb7fc5a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "ce15f839-dfff-4b99-ac12-a09f5763acc2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a18a5fd0-4f3d-4048-ab82-474c8bb7fc5a"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "d27646f4-c17c-4ebf-865b-28f0ff5d47af", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ce15f839-dfff-4b99-ac12-a09f5763acc2"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "68b9eefe-f3b5-4f13-acc9-c9e62a860885", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "d27646f4-c17c-4ebf-865b-28f0ff5d47af"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"_Hlk502758333\"><u><span lang=\"EN-GB\">Vaccinations</span></u></a><a name=\"_Hlk502758339\"></a></p>", "ID": "8eb633f5-c45b-4ba9-aeed-03510639e168", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<a name=\"_Hlk502758333\"><u><span lang=\"EN-GB\">Vaccinations</span></u></a>", "ID": "84c54bec-237b-48c9-92da-9cadc1687e95", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8eb633f5-c45b-4ba9-aeed-03510639e168"}, {"Element": "<u><span lang=\"EN-GB\">Vaccinations</span></u>", "ID": "9cf4505e-f07e-470f-ae63-a5c6d28595ff", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "84c54bec-237b-48c9-92da-9cadc1687e95"}, {"Element": "<span lang=\"EN-GB\">Vaccinations</span>", "ID": "d58c6851-fb06-4d93-acee-419deee6c48b", "Styles": "None", "Classes": "None", "Text": "Vaccinations", "ParentId": "9cf4505e-f07e-470f-ae63-a5c6d28595ff"}, {"Element": "<a name=\"_Hlk502758339\"></a>", "ID": "4ee491a4-c5c6-4100-aa13-e24bd003fd04", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8eb633f5-c45b-4ba9-aeed-03510639e168"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is recommended that patients, if possible,\nbe brought up to date with all vaccinations in agreement with current\nvaccination guidelines prior to initiating Remicade therapy. Patients on\ninfliximab may receive concurrent vaccinations, except for live vaccines (see\nsections\u00a04.5 and\u00a04.6).</span></p>", "ID": "9f9688ff-2adf-47b5-aad0-4d5473479856", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">It is recommended that patients, if possible,\nbe brought up to date with all vaccinations in agreement with current\nvaccination guidelines prior to initiating Remicade therapy. Patients on\ninfliximab may receive concurrent vaccinations, except for live vaccines (see\nsections\u00a04.5 and\u00a04.6).</span>", "ID": "d7266212-c0be-4014-89b8-ab77f2333858", "Styles": "None", "Classes": "None", "Text": "It is recommended that patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Remicade therapy. Patients on infliximab may receive concurrent vaccinations, except for live vaccines (see sections\u00a04.5 and\u00a04.6).", "ParentId": "9f9688ff-2adf-47b5-aad0-4d5473479856"}, {"Element": "<p class=\"MsoNormal\"><a name=\"_Hlk503547227\"><span lang=\"EN-GB\">\u00a0</span></a></p>", "ID": "c54daafe-a3d9-4712-9002-f97ed3356924", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<a name=\"_Hlk503547227\"><span lang=\"EN-GB\">\u00a0</span></a>", "ID": "3c12eea0-9079-4736-996d-0e77404361c8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c54daafe-a3d9-4712-9002-f97ed3356924"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cdbfc6aa-9300-4a06-a28b-59523f0bc284", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3c12eea0-9079-4736-996d-0e77404361c8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In a subset of 90 adult patients with\nrheumatoid arthritis from the ASPIRE study a similar proportion of patients in\neach treatment group (methotrexate plus: placebo [n\u00a0=\u00a017],\n3\u00a0mg/kg [n\u00a0=\u00a027] or 6\u00a0mg/kg Remicade [n\u00a0=\u00a046])\nmounted an effective two-fold increase in titers to a polyvalent pneumococcal\nvaccine, indicating that Remicade did not interfere with T-cell independent\nhumoral immune responses. However, studies from the published literature in\nvarious indications (e.g. rheumatoid arthritis, psoriasis, Crohn\u2019s\ndisease) suggest that non-live vaccinations received during treatment with\nanti-TNF therapies, including Remicade, may elicit a lower immune response than\nin patients not receiving anti-TNF therapy.</span></p>", "ID": "2125f400-277a-495e-ae0b-edfdffa99acd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In a subset of 90 adult patients with\nrheumatoid arthritis from the ASPIRE study a similar proportion of patients in\neach treatment group (methotrexate plus: placebo [n\u00a0=\u00a017],\n3\u00a0mg/kg [n\u00a0=\u00a027] or 6\u00a0mg/kg Remicade [n\u00a0=\u00a046])\nmounted an effective two-fold increase in titers to a polyvalent pneumococcal\nvaccine, indicating that Remicade did not interfere with T-cell independent\nhumoral immune responses. However, studies from the published literature in\nvarious indications (e.g. rheumatoid arthritis, psoriasis, Crohn\u2019s\ndisease) suggest that non-live vaccinations received during treatment with\nanti-TNF therapies, including Remicade, may elicit a lower immune response than\nin patients not receiving anti-TNF therapy.</span>", "ID": "fe09ffb6-d7b0-4549-b684-fef7d984c904", "Styles": "None", "Classes": "None", "Text": "In a subset of 90 adult patients with rheumatoid arthritis from the ASPIRE study a similar proportion of patients in each treatment group (methotrexate plus: placebo [n\u00a0=\u00a017], 3\u00a0mg/kg [n\u00a0=\u00a027] or 6\u00a0mg/kg Remicade [n\u00a0=\u00a046]) mounted an effective two-fold increase in titers to a polyvalent pneumococcal vaccine, indicating that Remicade did not interfere with T-cell independent humoral immune responses. However, studies from the published literature in various indications (e.g. rheumatoid arthritis, psoriasis, Crohn\u2019s disease) suggest that non-live vaccinations received during treatment with anti-TNF therapies, including Remicade, may elicit a lower immune response than in patients not receiving anti-TNF therapy.", "ParentId": "2125f400-277a-495e-ae0b-edfdffa99acd"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "b1058a47-2c63-4ca1-8a71-e05c9cc27c8d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "faceff63-cced-4a5b-8570-8c5091ada953", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b1058a47-2c63-4ca1-8a71-e05c9cc27c8d"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "86ee0464-929c-43e0-b5b5-f283be88b67d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "faceff63-cced-4a5b-8570-8c5091ada953"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "7c2bc115-8a87-43af-bec1-209a2bfb0d7e", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "86ee0464-929c-43e0-b5b5-f283be88b67d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Live\nvaccines/therapeutic infectious agents</span></u></p>", "ID": "021c011e-69d3-44ad-b2b6-faa3739eb37e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Live\nvaccines/therapeutic infectious agents</span></u>", "ID": "1787b692-4bcb-45cf-a3e3-83e569b614ef", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "021c011e-69d3-44ad-b2b6-faa3739eb37e"}, {"Element": "<span lang=\"EN-GB\">Live\nvaccines/therapeutic infectious agents</span>", "ID": "650cdb3d-58e6-46ec-907a-d775461e23a5", "Styles": "None", "Classes": "None", "Text": "Live vaccines/therapeutic infectious agents", "ParentId": "1787b692-4bcb-45cf-a3e3-83e569b614ef"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In patients receiving anti\u2011TNF\ntherapy, limited data are available on the response to vaccination with live\nvaccines or on the secondary transmission of infection by live vaccines. Use of\nlive vaccines can result in clinical infections, including disseminated infections.\nThe concurrent administration of live vaccines with Remicade is not\nrecommended.</span></p>", "ID": "eeca332e-756f-42e8-a342-d0f923beb11e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In patients receiving anti\u2011TNF\ntherapy, limited data are available on the response to vaccination with live\nvaccines or on the secondary transmission of infection by live vaccines. Use of\nlive vaccines can result in clinical infections, including disseminated infections.\nThe concurrent administration of live vaccines with Remicade is not\nrecommended.</span>", "ID": "2366a61e-c314-4caa-8891-688ab155fb64", "Styles": "None", "Classes": "None", "Text": "In patients receiving anti\u2011TNF therapy, limited data are available on the response to vaccination with live vaccines or on the secondary transmission of infection by live vaccines. Use of live vaccines can result in clinical infections, including disseminated infections. The concurrent administration of live vaccines with Remicade is not recommended.", "ParentId": "eeca332e-756f-42e8-a342-d0f923beb11e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b24927a5-6a04-460d-96a3-3232c07f923a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ebc69696-d4f3-4a20-b0a0-53cbfd89c17b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b24927a5-6a04-460d-96a3-3232c07f923a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In </span><span lang=\"EN-GB\">infants exposed <i>in\nutero</i> to infliximab</span><span lang=\"EN-GB\">, fatal outcome due to\ndisseminated Bacillus Calmette\u2011Gu\u00e9rin (BCG) infection has been\nreported following administration of BCG vaccine after birth. At least a six\nmonth waiting period following birth is recommended before the administration\nof live vaccines to infants exposed <i>in utero </i>to infliximab (see\nsection\u00a04.6).</span></p>", "ID": "53a304a8-3d27-4d8b-a920-7676207426b9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In </span>", "ID": "37e5f35f-ebed-47a9-ab95-fefc5ce4ab0b", "Styles": "None", "Classes": "None", "Text": "In ", "ParentId": "53a304a8-3d27-4d8b-a920-7676207426b9"}, {"Element": "<span lang=\"EN-GB\">infants exposed <i>in\nutero</i> to infliximab</span>", "ID": "552a4e69-c616-494f-8283-e88d1f8c46c1", "Styles": "None", "Classes": "None", "Text": "infants exposed  to infliximab", "ParentId": "53a304a8-3d27-4d8b-a920-7676207426b9"}, {"Element": "<i>in\nutero</i>", "ID": "69d2bda5-1c00-431f-b019-b86ad014025f", "Styles": "None", "Classes": "None", "Text": "in utero", "ParentId": "552a4e69-c616-494f-8283-e88d1f8c46c1"}, {"Element": "<span lang=\"EN-GB\">, fatal outcome due to\ndisseminated Bacillus Calmette\u2011Gu\u00e9rin (BCG) infection has been\nreported following administration of BCG vaccine after birth. At least a six\nmonth waiting period following birth is recommended before the administration\nof live vaccines to infants exposed <i>in utero </i>to infliximab (see\nsection\u00a04.6).</span>", "ID": "9bbb0764-bf3d-43b8-a8af-1ddf3ba0569b", "Styles": "None", "Classes": "None", "Text": ", fatal outcome due to disseminated Bacillus Calmette\u2011Gu\u00e9rin (BCG) infection has been reported following administration of BCG vaccine after birth. At least a six month waiting period following birth is recommended before the administration of live vaccines to infants exposed to infliximab (see section\u00a04.6).", "ParentId": "53a304a8-3d27-4d8b-a920-7676207426b9"}, {"Element": "<i>in utero </i>", "ID": "85b03a5c-3c85-4913-98bd-e5d99238b620", "Styles": "None", "Classes": "None", "Text": "in utero ", "ParentId": "9bbb0764-bf3d-43b8-a8af-1ddf3ba0569b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "004db0db-df27-4d63-bb1d-49d2b72c4a44", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7e4b32ef-5fe7-48b3-88b6-d705f1ef2950", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "004db0db-df27-4d63-bb1d-49d2b72c4a44"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Other uses of therapeutic infectious agents\nsuch as live attenuated bacteria (e.g., BCG bladder instillation for the\ntreatment of cancer) could result in clinical infections, including\ndisseminated infections. It is recommended that therapeutic infectious agents\nnot be given concurrently with Remicade.</span></p>", "ID": "cbbe7cf7-4197-49da-9465-7fd998aee55a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Other uses of therapeutic infectious agents\nsuch as live attenuated bacteria (e.g., BCG bladder instillation for the\ntreatment of cancer) could result in clinical infections, including\ndisseminated infections. It is recommended that therapeutic infectious agents\nnot be given concurrently with Remicade.</span>", "ID": "8ae03524-82c7-42d0-99d6-9ddd92ef0d54", "Styles": "None", "Classes": "None", "Text": "Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder instillation for the treatment of cancer) could result in clinical infections, including disseminated infections. It is recommended that therapeutic infectious agents not be given concurrently with Remicade.", "ParentId": "cbbe7cf7-4197-49da-9465-7fd998aee55a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8b0c0d7f-372f-49a1-910e-0a9659898d42", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2416e511-5cba-4590-86d2-f182ec332f31", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8b0c0d7f-372f-49a1-910e-0a9659898d42"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Autoimmune\nprocesses</span></u></p>", "ID": "11a4d6f4-e38f-4e6a-9bdc-335fdb6bf49e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Autoimmune\nprocesses</span></u>", "ID": "0052ea21-5e29-4bc4-be36-8eeebab2b127", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "11a4d6f4-e38f-4e6a-9bdc-335fdb6bf49e"}, {"Element": "<span lang=\"EN-GB\">Autoimmune\nprocesses</span>", "ID": "82db7f1a-a6ab-4900-a0f6-e0a1674b1aa1", "Styles": "None", "Classes": "None", "Text": "Autoimmune processes", "ParentId": "0052ea21-5e29-4bc4-be36-8eeebab2b127"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The relative deficiency of TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> caused by\nanti\u2011TNF therapy may result in the initiation of an autoimmune process.\nIf a patient develops symptoms suggestive of a lupus\u2011like syndrome\nfollowing treatment with Remicade and is positive for antibodies against double\u2011stranded\nDNA, further treatment with Remicade must not be given (see section\u00a04.8).</span></p>", "ID": "4aa802ce-671d-4654-b5b4-6cca36d672da", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The relative deficiency of TNF</span>", "ID": "82fb94d3-f2de-4d26-b740-3790592ddc34", "Styles": "None", "Classes": "None", "Text": "The relative deficiency of TNF", "ParentId": "4aa802ce-671d-4654-b5b4-6cca36d672da"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "8a900743-661b-485d-9898-75c9ba16f060", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4aa802ce-671d-4654-b5b4-6cca36d672da"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "1c3dd7c2-cd3a-4006-98bf-2bddfe538b88", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "8a900743-661b-485d-9898-75c9ba16f060"}, {"Element": "<span lang=\"EN-GB\"> caused by\nanti\u2011TNF therapy may result in the initiation of an autoimmune process.\nIf a patient develops symptoms suggestive of a lupus\u2011like syndrome\nfollowing treatment with Remicade and is positive for antibodies against double\u2011stranded\nDNA, further treatment with Remicade must not be given (see section\u00a04.8).</span>", "ID": "8b8c1109-4fd1-4b2e-8d0b-d737e881d8cd", "Styles": "None", "Classes": "None", "Text": " caused by anti\u2011TNF therapy may result in the initiation of an autoimmune process. If a patient develops symptoms suggestive of a lupus\u2011like syndrome following treatment with Remicade and is positive for antibodies against double\u2011stranded DNA, further treatment with Remicade must not be given (see section\u00a04.8).", "ParentId": "4aa802ce-671d-4654-b5b4-6cca36d672da"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d6683628-39f5-4373-bf16-d6d3fdb90ab5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ceecced6-cddd-4f58-9d6d-9c1d24dc8f9e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d6683628-39f5-4373-bf16-d6d3fdb90ab5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Neurological\nevents</span></u></p>", "ID": "a65615f8-d1eb-4e3d-bed7-18a3f41f604c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Neurological\nevents</span></u>", "ID": "6a342739-7759-4324-a482-dcc1f94e7a59", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a65615f8-d1eb-4e3d-bed7-18a3f41f604c"}, {"Element": "<span lang=\"EN-GB\">Neurological\nevents</span>", "ID": "7bf9f9cb-80da-44bf-812c-b32da837caf6", "Styles": "None", "Classes": "None", "Text": "Neurological events", "ParentId": "6a342739-7759-4324-a482-dcc1f94e7a59"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Use of TNF\u2011blocking agents, including\ninfliximab, has been associated with cases of new onset or exacerbation of\nclinical symptoms and/or radiographic evidence of central nervous system\ndemyelinating disorders, including multiple sclerosis, and peripheral\ndemyelinating disorders, including Guillain\u2011Barr\u00e9 syndrome. In\npatients with pre\u2011existing or recent onset of demyelinating disorders, the\nbenefits and risks of anti\u2011TNF treatment should be carefully considered\nbefore initiation of Remicade therapy. Discontinuation of Remicade should be\nconsidered if these disorders develop.</span></p>", "ID": "4ca7e27c-2a76-48b6-b50c-b627747f7d2f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Use of TNF\u2011blocking agents, including\ninfliximab, has been associated with cases of new onset or exacerbation of\nclinical symptoms and/or radiographic evidence of central nervous system\ndemyelinating disorders, including multiple sclerosis, and peripheral\ndemyelinating disorders, including Guillain\u2011Barr\u00e9 syndrome. In\npatients with pre\u2011existing or recent onset of demyelinating disorders, the\nbenefits and risks of anti\u2011TNF treatment should be carefully considered\nbefore initiation of Remicade therapy. Discontinuation of Remicade should be\nconsidered if these disorders develop.</span>", "ID": "173b4577-f957-4ff1-b999-ef20bd3b647b", "Styles": "None", "Classes": "None", "Text": "Use of TNF\u2011blocking agents, including infliximab, has been associated with cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis, and peripheral demyelinating disorders, including Guillain\u2011Barr\u00e9 syndrome. In patients with pre\u2011existing or recent onset of demyelinating disorders, the benefits and risks of anti\u2011TNF treatment should be carefully considered before initiation of Remicade therapy. Discontinuation of Remicade should be considered if these disorders develop.", "ParentId": "4ca7e27c-2a76-48b6-b50c-b627747f7d2f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7f7f1576-37f7-435b-aade-32819f7713c5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4aea7d62-24ad-457f-ae77-dd7e49b30e9d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7f7f1576-37f7-435b-aade-32819f7713c5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Malignancies\nand lymphoproliferative disorders</span></u></p>", "ID": "aaee61bb-967a-40fe-ba4e-00315e84036b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Malignancies\nand lymphoproliferative disorders</span></u>", "ID": "8b92fc2e-74e6-446d-9aba-ac1bb150ef31", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aaee61bb-967a-40fe-ba4e-00315e84036b"}, {"Element": "<span lang=\"EN-GB\">Malignancies\nand lymphoproliferative disorders</span>", "ID": "f6f59f02-33b4-4314-a528-bdf246e9f495", "Styles": "None", "Classes": "None", "Text": "Malignancies and lymphoproliferative disorders", "ParentId": "8b92fc2e-74e6-446d-9aba-ac1bb150ef31"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In the\ncontrolled portions of clinical studies of TNF\u2011blocking agents, more\ncases of malignancies including lymphoma have been observed among patients\nreceiving a TNF blocker compared with control patients. During clinical studies\nof Remicade across all approved indications the incidence of lymphoma in\nRemicade\u2011treated patients was higher than expected in the general\npopulation, but the occurrence of lymphoma was rare. </span><span lang=\"EN-GB\">In\nthe post\u2011marketing setting, cases of leukaemia have been reported in\npatients treated with a TNF\u2011antagonist. </span><span lang=\"EN-GB\">There is\nan increased background risk for lymphoma and leukaemia in rheumatoid arthritis\npatients with long\u2011standing, highly active, inflammatory disease, which\ncomplicates risk estimation.</span></p>", "ID": "1fb2a710-18ae-4d1b-8444-dc25d91527b1", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In the\ncontrolled portions of clinical studies of TNF\u2011blocking agents, more\ncases of malignancies including lymphoma have been observed among patients\nreceiving a TNF blocker compared with control patients. During clinical studies\nof Remicade across all approved indications the incidence of lymphoma in\nRemicade\u2011treated patients was higher than expected in the general\npopulation, but the occurrence of lymphoma was rare. </span>", "ID": "a758f2d8-0452-4d30-a82c-afb9a0a81eea", "Styles": "None", "Classes": "None", "Text": "In the controlled portions of clinical studies of TNF\u2011blocking agents, more cases of malignancies including lymphoma have been observed among patients receiving a TNF blocker compared with control patients. During clinical studies of Remicade across all approved indications the incidence of lymphoma in Remicade\u2011treated patients was higher than expected in the general population, but the occurrence of lymphoma was rare. ", "ParentId": "1fb2a710-18ae-4d1b-8444-dc25d91527b1"}, {"Element": "<span lang=\"EN-GB\">In\nthe post\u2011marketing setting, cases of leukaemia have been reported in\npatients treated with a TNF\u2011antagonist. </span>", "ID": "8e433f7b-a799-4886-ab57-dacab05b2a1f", "Styles": "None", "Classes": "None", "Text": "In the post\u2011marketing setting, cases of leukaemia have been reported in patients treated with a TNF\u2011antagonist. ", "ParentId": "1fb2a710-18ae-4d1b-8444-dc25d91527b1"}, {"Element": "<span lang=\"EN-GB\">There is\nan increased background risk for lymphoma and leukaemia in rheumatoid arthritis\npatients with long\u2011standing, highly active, inflammatory disease, which\ncomplicates risk estimation.</span>", "ID": "06a6b246-051c-479e-9be8-1cd175dd0009", "Styles": "None", "Classes": "None", "Text": "There is an increased background risk for lymphoma and leukaemia in rheumatoid arthritis patients with long\u2011standing, highly active, inflammatory disease, which complicates risk estimation.", "ParentId": "1fb2a710-18ae-4d1b-8444-dc25d91527b1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "93e3b256-1d90-49c8-9d38-e82f1d572586", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1d46403b-d358-4d54-acbd-94f2963749a2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "93e3b256-1d90-49c8-9d38-e82f1d572586"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In an exploratory clinical study evaluating\nthe use of Remicade in patients with moderate to severe chronic obstructive\npulmonary disease (COPD), more malignancies were reported in Remicade\u2011treated\npatients compared with control patients. All patients had a history of heavy\nsmoking. Caution should be exercised in considering treatment of patients with\nincreased risk for malignancy due to heavy smoking.</span></p>", "ID": "c3868296-9dea-472d-bf7d-ff2f29fce409", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In an exploratory clinical study evaluating\nthe use of Remicade in patients with moderate to severe chronic obstructive\npulmonary disease (COPD), more malignancies were reported in Remicade\u2011treated\npatients compared with control patients. All patients had a history of heavy\nsmoking. Caution should be exercised in considering treatment of patients with\nincreased risk for malignancy due to heavy smoking.</span>", "ID": "21a2c5d3-ae9d-49d2-b2cc-b53f9ea8958d", "Styles": "None", "Classes": "None", "Text": "In an exploratory clinical study evaluating the use of Remicade in patients with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies were reported in Remicade\u2011treated patients compared with control patients. All patients had a history of heavy smoking. Caution should be exercised in considering treatment of patients with increased risk for malignancy due to heavy smoking.", "ParentId": "c3868296-9dea-472d-bf7d-ff2f29fce409"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "edbb24eb-56e6-4ac3-8121-8cd000ba6093", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7a59a536-1134-4024-b686-d94fc7c7846a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "edbb24eb-56e6-4ac3-8121-8cd000ba6093"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">With the current knowledge, a risk for the\ndevelopment of lymphomas or other malignancies in patients treated with a TNF\u2011blocking\nagent cannot be excluded (see section\u00a04.8). </span><span lang=\"EN-GB\">Caution\nshould be exercised when considering TNF\u2011blocking therapy for patients\nwith a history of malignancy or when considering continuing treatment in\npatients who develop a malignancy.</span></p>", "ID": "fc56484c-f84e-43c5-83ab-6bbaf9989f91", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">With the current knowledge, a risk for the\ndevelopment of lymphomas or other malignancies in patients treated with a TNF\u2011blocking\nagent cannot be excluded (see section\u00a04.8). </span>", "ID": "a03fc854-ca84-4805-90a5-d716096ca4ab", "Styles": "None", "Classes": "None", "Text": "With the current knowledge, a risk for the development of lymphomas or other malignancies in patients treated with a TNF\u2011blocking agent cannot be excluded (see section\u00a04.8). ", "ParentId": "fc56484c-f84e-43c5-83ab-6bbaf9989f91"}, {"Element": "<span lang=\"EN-GB\">Caution\nshould be exercised when considering TNF\u2011blocking therapy for patients\nwith a history of malignancy or when considering continuing treatment in\npatients who develop a malignancy.</span>", "ID": "e9c2f520-c95b-4ad1-9d08-7ea66562e1a1", "Styles": "None", "Classes": "None", "Text": "Caution should be exercised when considering TNF\u2011blocking therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop a malignancy.", "ParentId": "fc56484c-f84e-43c5-83ab-6bbaf9989f91"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bb8d7bdd-e895-42c6-b6f8-298edc1cfe18", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1af48b56-bc6c-4982-9205-b0509ca39c06", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bb8d7bdd-e895-42c6-b6f8-298edc1cfe18"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Caution should also be exercised in\npatients with psoriasis and a medical history of extensive immunosuppressant\ntherapy or prolonged PUVA treatment.</span></p>", "ID": "61fdcb87-2a27-4e3d-b313-1f872a9c5f10", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Caution should also be exercised in\npatients with psoriasis and a medical history of extensive immunosuppressant\ntherapy or prolonged PUVA treatment.</span>", "ID": "249a558f-ed8e-4846-bfe0-ccf50381e350", "Styles": "None", "Classes": "None", "Text": "Caution should also be exercised in patients with psoriasis and a medical history of extensive immunosuppressant therapy or prolonged PUVA treatment.", "ParentId": "61fdcb87-2a27-4e3d-b313-1f872a9c5f10"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6d3cc38f-27a1-4c80-88e0-35da4f63d76b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b2cd5890-755c-4a29-96c6-52b68f763b2e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6d3cc38f-27a1-4c80-88e0-35da4f63d76b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Malignancies, some fatal, have been\nreported among children, adolescents and young adults (up to 22\u00a0years of\nage) treated with TNF\u2011blocking agents (initiation of therapy\n\u2264\u00a018\u00a0years of age), including Remicade in the post\u2011marketing\nsetting. Approximately half the cases were lymphomas. The other cases\nrepresented a variety of different malignancies and included rare malignancies\nusually associated with immunosuppression. A risk for the development of\nmalignancies in patients treated with TNF\u2011blockers cannot be excluded.</span></p>", "ID": "7e6c24c6-64d3-489d-8c09-16b349d79efc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Malignancies, some fatal, have been\nreported among children, adolescents and young adults (up to 22\u00a0years of\nage) treated with TNF\u2011blocking agents (initiation of therapy\n\u2264\u00a018\u00a0years of age), including Remicade in the post\u2011marketing\nsetting. Approximately half the cases were lymphomas. The other cases\nrepresented a variety of different malignancies and included rare malignancies\nusually associated with immunosuppression. A risk for the development of\nmalignancies in patients treated with TNF\u2011blockers cannot be excluded.</span>", "ID": "468704c8-0c73-43cc-a5ab-e2014a8169a9", "Styles": "None", "Classes": "None", "Text": "Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22\u00a0years of age) treated with TNF\u2011blocking agents (initiation of therapy \u2264\u00a018\u00a0years of age), including Remicade in the post\u2011marketing setting. Approximately half the cases were lymphomas. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression. A risk for the development of malignancies in patients treated with TNF\u2011blockers cannot be excluded.", "ParentId": "7e6c24c6-64d3-489d-8c09-16b349d79efc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "134d4502-d500-41a5-8d20-18b28c915d6b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3b19c5b4-0919-4663-a3b2-ee170eb8969b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "134d4502-d500-41a5-8d20-18b28c915d6b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Post</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">marketing cases of hepatosplenic T</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">cell lymphoma (HSTCL) have been reported in patients </span><span lang=\"EN-GB\">treated with<b> </b>TNF</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">blocking agents including infliximab.\u00a0This rare type of T</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">cell lymphoma has a very aggressive\ndisease course and is usually fatal. Almost all patients had received treatment\nwith AZA or 6</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">MP\nconcomitantly with or immediately prior to a TNF</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">blocker. The vast majority of Remicade cases have occurred in\npatients </span><span lang=\"EN-GB\">with Crohn\u2019s disease </span><span lang=\"EN-GB\">or ulcerative colitis and most were reported in adolescent or young\nadult males.</span><span lang=\"EN-GB\"> The potential risk with the combination of\nAZA or 6</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">MP and Remicade\nshould be carefully considered. A risk for the development for hepatosplenic T</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">cell lymphoma in patients treated\nwith Remicade cannot be excluded (see section 4.8).</span></p>", "ID": "ce0d5d01-014b-4a41-88e6-6546083f7fe3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Post</span>", "ID": "cfca970c-9387-4b61-b2bb-9dd98bee4e52", "Styles": "None", "Classes": "None", "Text": "Post", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "c8d1dbd2-6343-4491-89ae-67940834b693", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">marketing cases of hepatosplenic T</span>", "ID": "af0880ae-3613-4a0f-b95c-e2756c487546", "Styles": "None", "Classes": "None", "Text": "marketing cases of hepatosplenic T", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "3ef5cd83-0ea5-4bf2-8172-bba6d993301e", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">cell lymphoma (HSTCL) have been reported in patients </span>", "ID": "66ffcf13-6bb4-478d-9b8e-5a72aac97aa8", "Styles": "None", "Classes": "None", "Text": "cell lymphoma (HSTCL) have been reported in patients ", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">treated with<b> </b>TNF</span>", "ID": "da33b8fe-9f21-44fd-953a-79ba654b0ffb", "Styles": "None", "Classes": "None", "Text": "treated withTNF", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<b> </b>", "ID": "51be925a-f015-4e20-aa0e-e6a922b317ff", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "da33b8fe-9f21-44fd-953a-79ba654b0ffb"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "eae35341-fb38-4bfa-bd65-cec5635e3edf", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">blocking agents including infliximab.\u00a0This rare type of T</span>", "ID": "695d5f79-7a9f-4d02-85be-1595c7143ac5", "Styles": "None", "Classes": "None", "Text": "blocking agents including infliximab.\u00a0This rare type of T", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "6fd770c5-c016-420a-8289-8f820ad21be9", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">cell lymphoma has a very aggressive\ndisease course and is usually fatal. Almost all patients had received treatment\nwith AZA or 6</span>", "ID": "41dd3ab4-93a9-4659-9ee9-fa7da8e55ad0", "Styles": "None", "Classes": "None", "Text": "cell lymphoma has a very aggressive disease course and is usually fatal. Almost all patients had received treatment with AZA or 6", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "a503fac1-749d-4aee-856b-9f1030e56e18", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">MP\nconcomitantly with or immediately prior to a TNF</span>", "ID": "b896aad3-671c-4549-a3d5-b536091a019d", "Styles": "None", "Classes": "None", "Text": "MP concomitantly with or immediately prior to a TNF", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "ce67af98-a524-4571-845f-795d6b246820", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">blocker. The vast majority of Remicade cases have occurred in\npatients </span>", "ID": "d90466a9-476b-477a-953d-2d8295701e17", "Styles": "None", "Classes": "None", "Text": "blocker. The vast majority of Remicade cases have occurred in patients ", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">with Crohn\u2019s disease </span>", "ID": "e4226218-465b-4a5a-a56b-0e406911640f", "Styles": "None", "Classes": "None", "Text": "with Crohn\u2019s disease ", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">or ulcerative colitis and most were reported in adolescent or young\nadult males.</span>", "ID": "230a7b5a-1285-433c-9a9b-95ea26182489", "Styles": "None", "Classes": "None", "Text": "or ulcerative colitis and most were reported in adolescent or young adult males.", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\"> The potential risk with the combination of\nAZA or 6</span>", "ID": "6722927b-f66d-4329-9dc0-c9e3bf94327e", "Styles": "None", "Classes": "None", "Text": " The potential risk with the combination of AZA or 6", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "c1dd9c5c-c7e3-4c87-82ef-0f197c1c82ec", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">MP and Remicade\nshould be carefully considered. A risk for the development for hepatosplenic T</span>", "ID": "b788308b-9432-4d27-83fc-4bc9a37c0f70", "Styles": "None", "Classes": "None", "Text": "MP and Remicade should be carefully considered. A risk for the development for hepatosplenic T", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "8dbdc44c-e5b6-40b9-aee2-f212503c6ec0", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<span lang=\"EN-GB\">cell lymphoma in patients treated\nwith Remicade cannot be excluded (see section 4.8).</span>", "ID": "a9bb1dc8-fd1c-4495-a3b8-b4005a2bc35a", "Styles": "None", "Classes": "None", "Text": "cell lymphoma in patients treated with Remicade cannot be excluded (see section 4.8).", "ParentId": "ce0d5d01-014b-4a41-88e6-6546083f7fe3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c3b227b4-a0e5-4af9-87db-15bb37e17af1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e672a872-9e01-4636-a981-f0f1db50378b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c3b227b4-a0e5-4af9-87db-15bb37e17af1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Melanoma and Merkel cell carcinoma have\nbeen reported in patients treated with TNF blocker therapy, including Remicade\n(see section\u00a04.8). Periodic skin examination is recommended, particularly for\npatients with risk factors for skin cancer.</span></p>", "ID": "c90c80f4-d1c3-4232-bee9-a31ef62921db", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Melanoma and Merkel cell carcinoma have\nbeen reported in patients treated with TNF blocker therapy, including Remicade\n(see section\u00a04.8). Periodic skin examination is recommended, particularly for\npatients with risk factors for skin cancer.</span>", "ID": "c394cacf-6ed0-4d20-a3e6-e05ab530ca9b", "Styles": "None", "Classes": "None", "Text": "Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy, including Remicade (see section\u00a04.8). Periodic skin examination is recommended, particularly for patients with risk factors for skin cancer.", "ParentId": "c90c80f4-d1c3-4232-bee9-a31ef62921db"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6edbbb60-c290-4ae2-a74a-b7e6f6a2aaa2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a74b9d9e-8f5c-47d2-bf01-e7532cf7debf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6edbbb60-c290-4ae2-a74a-b7e6f6a2aaa2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">A population</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">based retrospective cohort study using data from Swedish national\nhealth registries found an increased incidence of cervical cancer in women with\nrheumatoid arthritis treated with infliximab compared to biologics</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">na\u00efve patients or the general\npopulation, including those over 60\u00a0years of age. Periodic screening\nshould continue in women treated with Remicade, including those over\n60\u00a0years of age.</span></p>", "ID": "cd375d4b-77a3-417c-9178-5381afd81afe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">A population</span>", "ID": "90e226b3-3c1e-47a0-930d-124a30a3721e", "Styles": "None", "Classes": "None", "Text": "A population", "ParentId": "cd375d4b-77a3-417c-9178-5381afd81afe"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "5f158eb5-53de-460b-ae69-83069bd1da26", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "cd375d4b-77a3-417c-9178-5381afd81afe"}, {"Element": "<span lang=\"EN-GB\">based retrospective cohort study using data from Swedish national\nhealth registries found an increased incidence of cervical cancer in women with\nrheumatoid arthritis treated with infliximab compared to biologics</span>", "ID": "c3f61d50-010f-4551-adca-5d90fb3f4bce", "Styles": "None", "Classes": "None", "Text": "based retrospective cohort study using data from Swedish national health registries found an increased incidence of cervical cancer in women with rheumatoid arthritis treated with infliximab compared to biologics", "ParentId": "cd375d4b-77a3-417c-9178-5381afd81afe"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "9de545dc-475c-4103-a6df-7d6cfca1c55c", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "cd375d4b-77a3-417c-9178-5381afd81afe"}, {"Element": "<span lang=\"EN-GB\">na\u00efve patients or the general\npopulation, including those over 60\u00a0years of age. Periodic screening\nshould continue in women treated with Remicade, including those over\n60\u00a0years of age.</span>", "ID": "ac40bee7-a1d0-41c2-b167-6b552df6f078", "Styles": "None", "Classes": "None", "Text": "na\u00efve patients or the general population, including those over 60\u00a0years of age. Periodic screening should continue in women treated with Remicade, including those over 60\u00a0years of age.", "ParentId": "cd375d4b-77a3-417c-9178-5381afd81afe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1f4b4625-e75f-4f47-a1e2-fa0e8ba21039", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4f824729-2d98-4c68-a798-f9e7dc69e926", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1f4b4625-e75f-4f47-a1e2-fa0e8ba21039"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">All patients with ulcerative colitis who\nare at increased risk for dysplasia or colon carcinoma (for example, patients\nwith long</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">standing\nulcerative colitis or primary sclerosing cholangitis), or who had a prior\nhistory of dysplasia or colon carcinoma should be screened for dysplasia at\nregular intervals before therapy and throughout their disease course. This\nevaluation should include colonoscopy and biopsies per local recommendations. Current\ndata do not indicate that infliximab treatment influences the risk for\ndeveloping dysplasia or colon cancer.</span></p>", "ID": "b1d23b4d-86a7-44c2-9c03-24b8bd41187d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">All patients with ulcerative colitis who\nare at increased risk for dysplasia or colon carcinoma (for example, patients\nwith long</span>", "ID": "5b59af8d-e940-43ed-aed5-41c6f4a232f7", "Styles": "None", "Classes": "None", "Text": "All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for example, patients with long", "ParentId": "b1d23b4d-86a7-44c2-9c03-24b8bd41187d"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "ebb904a2-b084-4268-908c-6afef73a7b95", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "b1d23b4d-86a7-44c2-9c03-24b8bd41187d"}, {"Element": "<span lang=\"EN-GB\">standing\nulcerative colitis or primary sclerosing cholangitis), or who had a prior\nhistory of dysplasia or colon carcinoma should be screened for dysplasia at\nregular intervals before therapy and throughout their disease course. This\nevaluation should include colonoscopy and biopsies per local recommendations. Current\ndata do not indicate that infliximab treatment influences the risk for\ndeveloping dysplasia or colon cancer.</span>", "ID": "8ebbfbbc-1793-4a6b-973e-716308e67b17", "Styles": "None", "Classes": "None", "Text": "standing ulcerative colitis or primary sclerosing cholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before therapy and throughout their disease course. This evaluation should include colonoscopy and biopsies per local recommendations. Current data do not indicate that infliximab treatment influences the risk for developing dysplasia or colon cancer.", "ParentId": "b1d23b4d-86a7-44c2-9c03-24b8bd41187d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c40fad36-03e7-40f5-b330-023baee5c289", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e7769ed7-34a2-4245-88f0-76cbf497d9c3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c40fad36-03e7-40f5-b330-023baee5c289"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Since the possibility of increased risk of\ncancer development in patients with newly diagnosed dysplasia treated with\nRemicade is not established, the risk and benefits of continued therapy to the\nindividual patients should be carefully considered by the clinician.</span></p>", "ID": "9f37014f-be78-4590-a61e-ba3d3bf3c74a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Since the possibility of increased risk of\ncancer development in patients with newly diagnosed dysplasia treated with\nRemicade is not established, the risk and benefits of continued therapy to the\nindividual patients should be carefully considered by the clinician.</span>", "ID": "e931b14d-d759-4d95-9907-7cd6fe08df56", "Styles": "None", "Classes": "None", "Text": "Since the possibility of increased risk of cancer development in patients with newly diagnosed dysplasia treated with Remicade is not established, the risk and benefits of continued therapy to the individual patients should be carefully considered by the clinician.", "ParentId": "9f37014f-be78-4590-a61e-ba3d3bf3c74a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d161bc51-1589-418e-aa23-f135aa6218a5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0c62ac4e-715c-4d3b-a991-b4f020563cd5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d161bc51-1589-418e-aa23-f135aa6218a5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Heart\nfailure</span></u></p>", "ID": "6e7796e8-f3f2-4a9d-b301-151180f086a7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Heart\nfailure</span></u>", "ID": "e6cfc83b-5363-43a1-9ff0-e460528b48cd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6e7796e8-f3f2-4a9d-b301-151180f086a7"}, {"Element": "<span lang=\"EN-GB\">Heart\nfailure</span>", "ID": "af8075ad-96f2-45e4-99af-8be1349a2880", "Styles": "None", "Classes": "None", "Text": "Heart failure", "ParentId": "e6cfc83b-5363-43a1-9ff0-e460528b48cd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade should be used with caution in\npatients with mild heart failure (NYHA class I/II). Patients should be closely\nmonitored and Remicade must not be continued in patients who develop new or\nworsening symptoms of heart failure (see sections\u00a04.3 and 4.8).</span></p>", "ID": "d9ef9543-aae9-44c5-8f69-5343c44008a8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade should be used with caution in\npatients with mild heart failure (NYHA class I/II). Patients should be closely\nmonitored and Remicade must not be continued in patients who develop new or\nworsening symptoms of heart failure (see sections\u00a04.3 and 4.8).</span>", "ID": "3539359e-bbfd-4afe-9fb6-656606279425", "Styles": "None", "Classes": "None", "Text": "Remicade should be used with caution in patients with mild heart failure (NYHA class I/II). Patients should be closely monitored and Remicade must not be continued in patients who develop new or worsening symptoms of heart failure (see sections\u00a04.3 and 4.8).", "ParentId": "d9ef9543-aae9-44c5-8f69-5343c44008a8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "82619513-4131-41ab-bdc8-49c85adf1fae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eb95c7de-5573-41b5-a08f-40795e0b4452", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "82619513-4131-41ab-bdc8-49c85adf1fae"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Haematologic\nreactions</span></u></p>", "ID": "f05dbc03-5d7a-4c36-bd36-3984f3024e60", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Haematologic\nreactions</span></u>", "ID": "7b365112-8a4e-42da-9632-1d169c870d87", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f05dbc03-5d7a-4c36-bd36-3984f3024e60"}, {"Element": "<span lang=\"EN-GB\">Haematologic\nreactions</span>", "ID": "1365cfcb-2653-4eb2-aa4f-157c3fbc0e5d", "Styles": "None", "Classes": "None", "Text": "Haematologic reactions", "ParentId": "7b365112-8a4e-42da-9632-1d169c870d87"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There have been reports of pancytopenia,\nleucopenia, neutropenia, and thrombocytopenia in patients receiving TNF</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">blockers, including Remicade. </span><span lang=\"EN-GB\">All patients should be advised to seek immediate medical attention\nif they develop signs and symptoms suggestive of blood dyscrasias (e.g.\npersistent fever, bruising, bleeding, pallor). Discontinuation of Remicade\ntherapy should be considered in patients with confirmed significant haematologic\nabnormalities.</span></p>", "ID": "72e82ba0-dd3e-4644-8e24-d822990b33ed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">There have been reports of pancytopenia,\nleucopenia, neutropenia, and thrombocytopenia in patients receiving TNF</span>", "ID": "70f61e56-b920-40f8-a4ba-94f5807411f4", "Styles": "None", "Classes": "None", "Text": "There have been reports of pancytopenia, leucopenia, neutropenia, and thrombocytopenia in patients receiving TNF", "ParentId": "72e82ba0-dd3e-4644-8e24-d822990b33ed"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "df385b15-d550-4f5e-9662-184924eb9774", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "72e82ba0-dd3e-4644-8e24-d822990b33ed"}, {"Element": "<span lang=\"EN-GB\">blockers, including Remicade. </span>", "ID": "3056b2cf-de6f-4f3b-a3e9-5621e0db5cde", "Styles": "None", "Classes": "None", "Text": "blockers, including Remicade. ", "ParentId": "72e82ba0-dd3e-4644-8e24-d822990b33ed"}, {"Element": "<span lang=\"EN-GB\">All patients should be advised to seek immediate medical attention\nif they develop signs and symptoms suggestive of blood dyscrasias (e.g.\npersistent fever, bruising, bleeding, pallor). Discontinuation of Remicade\ntherapy should be considered in patients with confirmed significant haematologic\nabnormalities.</span>", "ID": "a7c842b9-f829-4bd5-8fe9-801144978085", "Styles": "None", "Classes": "None", "Text": "All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor). Discontinuation of Remicade therapy should be considered in patients with confirmed significant haematologic abnormalities.", "ParentId": "72e82ba0-dd3e-4644-8e24-d822990b33ed"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4ec014b4-f185-4c36-bdab-2915ae2cfa7a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "68c9f71f-3424-45ee-bf7f-bb36cdb88bbe", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4ec014b4-f185-4c36-bdab-2915ae2cfa7a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Others</span></u></p>", "ID": "d9e9991c-d3ce-4468-9b7a-23552bcecb01", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Others</span></u>", "ID": "dde6174e-e2e5-4ca3-9f45-07e00b3548d2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d9e9991c-d3ce-4468-9b7a-23552bcecb01"}, {"Element": "<span lang=\"EN-GB\">Others</span>", "ID": "95af82f9-337b-42d3-bfac-2f0c6a4dc726", "Styles": "None", "Classes": "None", "Text": "Others", "ParentId": "dde6174e-e2e5-4ca3-9f45-07e00b3548d2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There is limited safety experience of\nRemicade treatment in patients who have undergone surgical procedures,\nincluding arthroplasty. The long half\u2011life of infliximab should be taken\ninto consideration if a surgical procedure is planned. A patient who requires\nsurgery while on Remicade should be closely monitored for infections, and\nappropriate actions should be taken.</span></p>", "ID": "fe41056c-920c-405b-85e4-b2bad4a618ee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">There is limited safety experience of\nRemicade treatment in patients who have undergone surgical procedures,\nincluding arthroplasty. The long half\u2011life of infliximab should be taken\ninto consideration if a surgical procedure is planned. A patient who requires\nsurgery while on Remicade should be closely monitored for infections, and\nappropriate actions should be taken.</span>", "ID": "9cb04410-1745-471b-8f43-8acf556c0c4a", "Styles": "None", "Classes": "None", "Text": "There is limited safety experience of Remicade treatment in patients who have undergone surgical procedures, including arthroplasty. The long half\u2011life of infliximab should be taken into consideration if a surgical procedure is planned. A patient who requires surgery while on Remicade should be closely monitored for infections, and appropriate actions should be taken.", "ParentId": "fe41056c-920c-405b-85e4-b2bad4a618ee"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d9b37f6c-81ee-45ed-9bdf-511722c7c919", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "78ea8767-1a62-4602-b4f8-ea01a9da2708", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d9b37f6c-81ee-45ed-9bdf-511722c7c919"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Failure to respond to treatment for\nCrohn\u2019s disease may indicate the presence of a fixed fibrotic stricture\nthat may require surgical treatment. There is no evidence to suggest that\ninfliximab worsens or causes fibrotic strictures.</span></p>", "ID": "8df85e24-4be7-4c78-9aae-028460a0b843", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Failure to respond to treatment for\nCrohn\u2019s disease may indicate the presence of a fixed fibrotic stricture\nthat may require surgical treatment. There is no evidence to suggest that\ninfliximab worsens or causes fibrotic strictures.</span>", "ID": "57b10854-d554-49aa-8e2c-0cc5b817c1f1", "Styles": "None", "Classes": "None", "Text": "Failure to respond to treatment for Crohn\u2019s disease may indicate the presence of a fixed fibrotic stricture that may require surgical treatment. There is no evidence to suggest that infliximab worsens or causes fibrotic strictures.", "ParentId": "8df85e24-4be7-4c78-9aae-028460a0b843"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8cd45ff3-293e-41fd-906c-d02ce2a7e9ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c719cdaa-31be-4160-b740-9a02f8f5ba68", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8cd45ff3-293e-41fd-906c-d02ce2a7e9ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Special\npopulations</span></u></p>", "ID": "5ad745c4-4230-4908-b736-9b590ad0a11a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Special\npopulations</span></u>", "ID": "8eaf0c5d-92ff-40b4-abf9-5d3e599ec57e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5ad745c4-4230-4908-b736-9b590ad0a11a"}, {"Element": "<span lang=\"EN-GB\">Special\npopulations</span>", "ID": "f8d1e04a-78c1-4dd3-9589-ea6b6fe63349", "Styles": "None", "Classes": "None", "Text": "Special populations", "ParentId": "8eaf0c5d-92ff-40b4-abf9-5d3e599ec57e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly</span></i></p>", "ID": "6714365f-eb65-4df8-9b6a-c099dcdfb4b6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Elderly</span></i>", "ID": "a3639282-851e-4d3d-87af-88b990b85ff0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6714365f-eb65-4df8-9b6a-c099dcdfb4b6"}, {"Element": "<span lang=\"EN-GB\">Elderly</span>", "ID": "a0a8607e-10b1-4de4-b6dd-8586023e7f88", "Styles": "None", "Classes": "None", "Text": "Elderly", "ParentId": "a3639282-851e-4d3d-87af-88b990b85ff0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">The incidence\nof serious infections in Remicade</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">treated patients 65\u00a0years and\nolder was greater than in those under 65\u00a0years of age. </span><span lang=\"EN-GB\">Some of those had a fatal outcome.</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> </span><span lang=\"EN-GB\">Particular attention\nregarding the risk for infection should be paid when treating the elderly (see\nsection\u00a04.8)</span><span lang=\"EN-GB\">.</span></p>", "ID": "a48dfb81-cfb3-407c-a6b3-a61895871dea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">The incidence\nof serious infections in Remicade</span>", "ID": "7450c84f-cb3e-4a5a-a89d-e9894acfc42d", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "The incidence of serious infections in Remicade", "ParentId": "a48dfb81-cfb3-407c-a6b3-a61895871dea"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "a49ef973-3a3d-49c2-a2be-1dba6bb8346e", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "a48dfb81-cfb3-407c-a6b3-a61895871dea"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">treated patients 65\u00a0years and\nolder was greater than in those under 65\u00a0years of age. </span>", "ID": "ab505815-299b-4330-8763-6314263c1428", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "treated patients 65\u00a0years and older was greater than in those under 65\u00a0years of age. ", "ParentId": "a48dfb81-cfb3-407c-a6b3-a61895871dea"}, {"Element": "<span lang=\"EN-GB\">Some of those had a fatal outcome.</span>", "ID": "aede1835-b223-4709-96c0-8fe947af5b48", "Styles": "None", "Classes": "None", "Text": "Some of those had a fatal outcome.", "ParentId": "a48dfb81-cfb3-407c-a6b3-a61895871dea"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> </span>", "ID": "e2c81dae-23e2-41a6-b53a-7e69ba63c316", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": " ", "ParentId": "a48dfb81-cfb3-407c-a6b3-a61895871dea"}, {"Element": "<span lang=\"EN-GB\">Particular attention\nregarding the risk for infection should be paid when treating the elderly (see\nsection\u00a04.8)</span>", "ID": "b6d6f4eb-fe00-4523-b13f-c47419b00baa", "Styles": "None", "Classes": "None", "Text": "Particular attention regarding the risk for infection should be paid when treating the elderly (see section\u00a04.8)", "ParentId": "a48dfb81-cfb3-407c-a6b3-a61895871dea"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "b3964a90-64a1-4523-a4b7-3fcc634aa477", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "a48dfb81-cfb3-407c-a6b3-a61895871dea"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "c721b70f-218d-4c13-9ebd-0ebb2923a833", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "3515dccd-4f2a-46d2-a5ee-4218f953c247", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c721b70f-218d-4c13-9ebd-0ebb2923a833"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "e179554c-ab32-4e58-9b0e-0ca6c5a55c4c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3515dccd-4f2a-46d2-a5ee-4218f953c247"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "bdebc4ed-14be-45f7-8c72-31b9cbfafd58", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "e179554c-ab32-4e58-9b0e-0ca6c5a55c4c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><b><u><span lang=\"EN-GB\">Paediatric population</span></u></b></p>", "ID": "897dffb2-8d5e-49b8-b74f-d0fb7b3a680b", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><u><span lang=\"EN-GB\">Paediatric population</span></u></b>", "ID": "148373ad-3376-48d4-8c9d-9d8b51307c31", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "897dffb2-8d5e-49b8-b74f-d0fb7b3a680b"}, {"Element": "<u><span lang=\"EN-GB\">Paediatric population</span></u>", "ID": "02c3a87a-f6ee-4cb1-a24c-8884c5518648", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "148373ad-3376-48d4-8c9d-9d8b51307c31"}, {"Element": "<span lang=\"EN-GB\">Paediatric population</span>", "ID": "1752651f-b735-4ed5-9120-afb2b29b55d2", "Styles": "None", "Classes": "None", "Text": "Paediatric population", "ParentId": "02c3a87a-f6ee-4cb1-a24c-8884c5518648"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Infections</span></u></p>", "ID": "78b1145f-65dc-41c0-8a5c-c0f7827493b4", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Infections</span></u>", "ID": "d97bf810-b684-4f34-8347-f29f48a98a12", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "78b1145f-65dc-41c0-8a5c-c0f7827493b4"}, {"Element": "<span lang=\"EN-GB\">Infections</span>", "ID": "5f6f006b-25b3-4a71-a06b-31889df5deaa", "Styles": "None", "Classes": "None", "Text": "Infections", "ParentId": "d97bf810-b684-4f34-8347-f29f48a98a12"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In clinical\nstudies, infections have been reported in a higher proportion of paediatric\npatients compared to adult patients (see section\u00a04.8).</span></p>", "ID": "bf1e7ae4-1654-4dac-93b0-85c58d997f25", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In clinical\nstudies, infections have been reported in a higher proportion of paediatric\npatients compared to adult patients (see section\u00a04.8).</span>", "ID": "f445e4f3-e2ec-4286-8532-54e5f6ef52df", "Styles": "None", "Classes": "None", "Text": "In clinical studies, infections have been reported in a higher proportion of paediatric patients compared to adult patients (see section\u00a04.8).", "ParentId": "bf1e7ae4-1654-4dac-93b0-85c58d997f25"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "05db6fb6-8110-4db9-a010-25f19d1bfee3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6a287e77-9aa2-4240-b419-bc61dda014e8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "05db6fb6-8110-4db9-a010-25f19d1bfee3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vaccinations</span></u></p>", "ID": "4b104844-6c95-4aeb-bb10-496203a2cb81", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Vaccinations</span></u>", "ID": "67a69248-d8dd-44df-8905-468b62f8eb39", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4b104844-6c95-4aeb-bb10-496203a2cb81"}, {"Element": "<span lang=\"EN-GB\">Vaccinations</span>", "ID": "ecad8131-d217-47c7-a46e-b5ac132cf8e5", "Styles": "None", "Classes": "None", "Text": "Vaccinations", "ParentId": "67a69248-d8dd-44df-8905-468b62f8eb39"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is recommended that paediatric patients,\nif possible, be brought up to date with all vaccinations in agreement with\ncurrent vaccination guidelines prior to initiating Remicade therapy. Paediatric\npatients on infliximab may receive concurrent vaccinations, except for live\nvaccines (see sections\u00a04.5 and\u00a04.6).</span></p>", "ID": "4770c1e5-c043-4e19-b7a7-9d3a8ab146d8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">It is recommended that paediatric patients,\nif possible, be brought up to date with all vaccinations in agreement with\ncurrent vaccination guidelines prior to initiating Remicade therapy. Paediatric\npatients on infliximab may receive concurrent vaccinations, except for live\nvaccines (see sections\u00a04.5 and\u00a04.6).</span>", "ID": "e78fb6b9-acde-4373-896b-cc9f26d9bd4d", "Styles": "None", "Classes": "None", "Text": "It is recommended that paediatric patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Remicade therapy. Paediatric patients on infliximab may receive concurrent vaccinations, except for live vaccines (see sections\u00a04.5 and\u00a04.6).", "ParentId": "4770c1e5-c043-4e19-b7a7-9d3a8ab146d8"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "dd4e33f0-e897-4960-8f44-9a3b7506e48f", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "e87f8129-8c66-4997-8587-d5e7a63fee0d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dd4e33f0-e897-4960-8f44-9a3b7506e48f"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "ad1f0ba3-ffc5-40b4-9519-8dfc77d84a22", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e87f8129-8c66-4997-8587-d5e7a63fee0d"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "0278a524-c922-4cac-8ff3-a4e6e3c888e4", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "ad1f0ba3-ffc5-40b4-9519-8dfc77d84a22"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Malignancies and lymphoproliferative disorders</span></u></p>", "ID": "a861c629-9517-4044-81fd-47436496f182", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Malignancies and lymphoproliferative disorders</span></u>", "ID": "7ce971b2-8498-4bbb-9168-60759b5654f5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a861c629-9517-4044-81fd-47436496f182"}, {"Element": "<span lang=\"EN-GB\">Malignancies and lymphoproliferative disorders</span>", "ID": "a142c6c3-20be-42a5-a497-9ca09dc01e9d", "Styles": "None", "Classes": "None", "Text": "Malignancies and lymphoproliferative disorders", "ParentId": "7ce971b2-8498-4bbb-9168-60759b5654f5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Malignancies,\nsome fatal, have been reported among children, adolescents and young adults (up\nto 22\u00a0years of age) treated with TNF\u2011blocking agents (initiation of\ntherapy \u2264\u00a018\u00a0years of age), including Remicade in the post\u2011marketing\nsetting. Approximately half the cases were lymphomas. The other cases\nrepresented a variety of different malignancies and included rare malignancies\nusually associated with immunosuppression. A risk for the development of\nmalignancies in children and adolescents treated with TNF\u2011blockers cannot\nbe excluded.</span></p>", "ID": "8797c019-6994-4614-9329-9ce3da5bbe53", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Malignancies,\nsome fatal, have been reported among children, adolescents and young adults (up\nto 22\u00a0years of age) treated with TNF\u2011blocking agents (initiation of\ntherapy \u2264\u00a018\u00a0years of age), including Remicade in the post\u2011marketing\nsetting. Approximately half the cases were lymphomas. The other cases\nrepresented a variety of different malignancies and included rare malignancies\nusually associated with immunosuppression. A risk for the development of\nmalignancies in children and adolescents treated with TNF\u2011blockers cannot\nbe excluded.</span>", "ID": "cbfe8f4e-4d92-4fe8-8b1b-b69d67fd5e85", "Styles": "None", "Classes": "None", "Text": "Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22\u00a0years of age) treated with TNF\u2011blocking agents (initiation of therapy \u2264\u00a018\u00a0years of age), including Remicade in the post\u2011marketing setting. Approximately half the cases were lymphomas. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression. A risk for the development of malignancies in children and adolescents treated with TNF\u2011blockers cannot be excluded.", "ParentId": "8797c019-6994-4614-9329-9ce3da5bbe53"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "009738ff-db23-461a-980e-a4d2d220e653", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "11bcf12b-da34-4785-bb0d-c89f2a354a7f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "009738ff-db23-461a-980e-a4d2d220e653"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Post\u2011marketing cases of hepatosplenic\nT\u2011cell lymphoma have been reported in patients </span><span lang=\"EN-GB\">treated\nwith<b> </b></span><span lang=\"EN-GB\">TNF\u2011blocking agents </span><span lang=\"EN-GB\">including infliximab.\u00a0This rare type of T\u2011cell lymphoma\nhas a very aggressive disease course and is usually fatal. </span><span lang=\"EN-GB\">Almost all patients had received treatment with AZA or 6\u2011MP\nconcomitantly with or immediately prior to a TNF\u2011blocker. </span><span lang=\"EN-GB\">The vast majority of Remicade cases have occurred in patients </span><span lang=\"EN-GB\">with Crohn\u2019s disease </span><span lang=\"EN-GB\">or ulcerative\ncolitis and most were reported in adolescent or young adult males.</span><span lang=\"EN-GB\"> The potential risk with the combination of AZA or 6\u2011MP and\nRemicade should be carefully considered. A risk for the development for\nhepatosplenic T\u2011cell lymphoma in patients treated with Remicade cannot be\nexcluded (see section 4.8).</span></p>", "ID": "21ac9b06-8325-4997-9a22-bddf365c79ab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Post\u2011marketing cases of hepatosplenic\nT\u2011cell lymphoma have been reported in patients </span>", "ID": "f0c9f725-ed76-4eeb-99d7-488339f4bec5", "Styles": "None", "Classes": "None", "Text": "Post\u2011marketing cases of hepatosplenic T\u2011cell lymphoma have been reported in patients ", "ParentId": "21ac9b06-8325-4997-9a22-bddf365c79ab"}, {"Element": "<span lang=\"EN-GB\">treated\nwith<b> </b></span>", "ID": "436ed1f5-86fa-4f19-b3fe-b8b8e3e0458d", "Styles": "None", "Classes": "None", "Text": "treated with", "ParentId": "21ac9b06-8325-4997-9a22-bddf365c79ab"}, {"Element": "<b> </b>", "ID": "b9030461-b622-4d5b-a5a7-dd06a28f7c8b", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "436ed1f5-86fa-4f19-b3fe-b8b8e3e0458d"}, {"Element": "<span lang=\"EN-GB\">TNF\u2011blocking agents </span>", "ID": "15ead368-a9f9-4341-ba58-b4d6f01a45c7", "Styles": "None", "Classes": "None", "Text": "TNF\u2011blocking agents ", "ParentId": "21ac9b06-8325-4997-9a22-bddf365c79ab"}, {"Element": "<span lang=\"EN-GB\">including infliximab.\u00a0This rare type of T\u2011cell lymphoma\nhas a very aggressive disease course and is usually fatal. </span>", "ID": "f3799e8e-b215-4781-abdb-f4dad8750678", "Styles": "None", "Classes": "None", "Text": "including infliximab.\u00a0This rare type of T\u2011cell lymphoma has a very aggressive disease course and is usually fatal. ", "ParentId": "21ac9b06-8325-4997-9a22-bddf365c79ab"}, {"Element": "<span lang=\"EN-GB\">Almost all patients had received treatment with AZA or 6\u2011MP\nconcomitantly with or immediately prior to a TNF\u2011blocker. </span>", "ID": "557a4474-bb3d-4082-a64d-2069ae0286e2", "Styles": "None", "Classes": "None", "Text": "Almost all patients had received treatment with AZA or 6\u2011MP concomitantly with or immediately prior to a TNF\u2011blocker. ", "ParentId": "21ac9b06-8325-4997-9a22-bddf365c79ab"}, {"Element": "<span lang=\"EN-GB\">The vast majority of Remicade cases have occurred in patients </span>", "ID": "8034b86e-c645-4dbb-b8bf-fe25951cf37f", "Styles": "None", "Classes": "None", "Text": "The vast majority of Remicade cases have occurred in patients ", "ParentId": "21ac9b06-8325-4997-9a22-bddf365c79ab"}, {"Element": "<span lang=\"EN-GB\">with Crohn\u2019s disease </span>", "ID": "5e902d33-cbfa-4412-8ea9-0345afbfd4b4", "Styles": "None", "Classes": "None", "Text": "with Crohn\u2019s disease ", "ParentId": "21ac9b06-8325-4997-9a22-bddf365c79ab"}, {"Element": "<span lang=\"EN-GB\">or ulcerative\ncolitis and most were reported in adolescent or young adult males.</span>", "ID": "2a3e6798-4d60-4c86-8f45-e74f8f244a8f", "Styles": "None", "Classes": "None", "Text": "or ulcerative colitis and most were reported in adolescent or young adult males.", "ParentId": "21ac9b06-8325-4997-9a22-bddf365c79ab"}, {"Element": "<span lang=\"EN-GB\"> The potential risk with the combination of AZA or 6\u2011MP and\nRemicade should be carefully considered. A risk for the development for\nhepatosplenic T\u2011cell lymphoma in patients treated with Remicade cannot be\nexcluded (see section 4.8).</span>", "ID": "4fa8bb60-718b-4a7a-9d7d-85be2a9d9ccd", "Styles": "None", "Classes": "None", "Text": " The potential risk with the combination of AZA or 6\u2011MP and Remicade should be carefully considered. A risk for the development for hepatosplenic T\u2011cell lymphoma in patients treated with Remicade cannot be excluded (see section 4.8).", "ParentId": "21ac9b06-8325-4997-9a22-bddf365c79ab"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b8e3b43a-4931-4c51-a052-f4f5f2dd60bc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6d71b4d6-521b-4941-905a-b0ad75022a4a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b8e3b43a-4931-4c51-a052-f4f5f2dd60bc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Sodium\ncontent</span></u></p>", "ID": "b3d69d45-8063-43ee-ab0e-9aad59ad2141", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Sodium\ncontent</span></u>", "ID": "941c9d6e-93de-4cbf-b14b-990a3138ecdc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b3d69d45-8063-43ee-ab0e-9aad59ad2141"}, {"Element": "<span lang=\"EN-GB\">Sodium\ncontent</span>", "ID": "b4d2d873-2b9d-4d81-b399-0e2ae6b43766", "Styles": "None", "Classes": "None", "Text": "Sodium content", "ParentId": "941c9d6e-93de-4cbf-b14b-990a3138ecdc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade contains less than 1\u00a0mmol\nsodium (23\u00a0mg) per dose, i.e. essentially \u2018sodium\u2011free\u2019.\nRemicade is however, diluted in sodium chloride 9\u00a0mg/ml (0.9%) solution\nfor infusion. This should be taken into consideration for patients on a\ncontrolled sodium diet (see section\u00a06.6).</span></p>", "ID": "e160576c-bff4-419a-8439-8f21ca196902", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade contains less than 1\u00a0mmol\nsodium (23\u00a0mg) per dose, i.e. essentially \u2018sodium\u2011free\u2019.\nRemicade is however, diluted in sodium chloride 9\u00a0mg/ml (0.9%) solution\nfor infusion. This should be taken into consideration for patients on a\ncontrolled sodium diet (see section\u00a06.6).</span>", "ID": "e8982fca-e43e-4910-b95d-1e18a0c73ecb", "Styles": "None", "Classes": "None", "Text": "Remicade contains less than 1\u00a0mmol sodium (23\u00a0mg) per dose, i.e. essentially \u2018sodium\u2011free\u2019. Remicade is however, diluted in sodium chloride 9\u00a0mg/ml (0.9%) solution for infusion. This should be taken into consideration for patients on a controlled sodium diet (see section\u00a06.6).", "ParentId": "e160576c-bff4-419a-8439-8f21ca196902"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "109aba5e-1b0f-490e-b272-851ad2543e4f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6328e544-1cc7-49cf-88c1-15675b9f2975", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "109aba5e-1b0f-490e-b272-851ad2543e4f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other\nmedicinal products and other forms of interaction</span></b></p>", "ID": "88f52d4d-ae28-4794-9cf1-7c6683ff204b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other\nmedicinal products and other forms of interaction</span></b>", "ID": "f9f32463-d58f-49cc-9013-89d62b75c17a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "88f52d4d-ae28-4794-9cf1-7c6683ff204b"}, {"Element": "<span lang=\"EN-GB\">4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other\nmedicinal products and other forms of interaction</span>", "ID": "07786de2-34cc-4343-99c1-b1cb738c07e6", "Styles": "None", "Classes": "None", "Text": "4.5\u00a0\u00a0\u00a0\u00a0 Interaction with other medicinal products and other forms of interaction", "ParentId": "f9f32463-d58f-49cc-9013-89d62b75c17a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a8e93190-fc34-4444-b884-bf0c48e49d8c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "28772341-47ba-4156-b082-b86885e6e6d9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a8e93190-fc34-4444-b884-bf0c48e49d8c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">No interaction studies have been performed.</span></p>", "ID": "5e4ec845-3f04-4db6-b87e-e3f9307a9142", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">No interaction studies have been performed.</span>", "ID": "69f7f7d1-7ce9-46a0-a5e4-4ed204fe0fea", "Styles": "None", "Classes": "None", "Text": "No interaction studies have been performed.", "ParentId": "5e4ec845-3f04-4db6-b87e-e3f9307a9142"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "122eaf8b-3e75-43fa-855e-794d372528cf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bcca7480-3848-45e5-96f4-689586542285", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "122eaf8b-3e75-43fa-855e-794d372528cf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In </span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">rheumatoid arthritis, psoriatic arthritis and\nCrohn's disease</span><span lang=\"EN-GB\"> patients, there are indications that\nconcomitant use of methotrexate and other immunomodulators reduces the\nformation of antibodies against infliximab and increases the plasma\nconcentrations of infliximab. However, the results are uncertain due to\nlimitations in the methods used for serum analyses of infliximab and antibodies\nagainst infliximab.</span></p>", "ID": "e199730e-8f2e-4cda-9c31-1faea265b8d2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In </span>", "ID": "a4c39270-fc48-4269-b4c7-33bd37d02aa4", "Styles": "None", "Classes": "None", "Text": "In ", "ParentId": "e199730e-8f2e-4cda-9c31-1faea265b8d2"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">rheumatoid arthritis, psoriatic arthritis and\nCrohn's disease</span>", "ID": "52332fe6-3ddc-4175-be46-6027b6062762", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "rheumatoid arthritis, psoriatic arthritis and Crohn's disease", "ParentId": "e199730e-8f2e-4cda-9c31-1faea265b8d2"}, {"Element": "<span lang=\"EN-GB\"> patients, there are indications that\nconcomitant use of methotrexate and other immunomodulators reduces the\nformation of antibodies against infliximab and increases the plasma\nconcentrations of infliximab. However, the results are uncertain due to\nlimitations in the methods used for serum analyses of infliximab and antibodies\nagainst infliximab.</span>", "ID": "fa8fb646-4a9c-4267-bea4-55731475592a", "Styles": "None", "Classes": "None", "Text": " patients, there are indications that concomitant use of methotrexate and other immunomodulators reduces the formation of antibodies against infliximab and increases the plasma concentrations of infliximab. However, the results are uncertain due to limitations in the methods used for serum analyses of infliximab and antibodies against infliximab.", "ParentId": "e199730e-8f2e-4cda-9c31-1faea265b8d2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b4df75a2-e4e1-4103-bee1-6ce190a8421e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d9ad2309-b211-42a9-8b4d-515fa00d5d6e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b4df75a2-e4e1-4103-bee1-6ce190a8421e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Corticosteroids do not appear to affect the\npharmacokinetics of infliximab to a clinically relevant extent.</span></p>", "ID": "7145390a-df8c-46ee-a3bf-441440ddb81a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Corticosteroids do not appear to affect the\npharmacokinetics of infliximab to a clinically relevant extent.</span>", "ID": "9afab1c1-8f87-44fe-aef1-74f1397f9339", "Styles": "None", "Classes": "None", "Text": "Corticosteroids do not appear to affect the pharmacokinetics of infliximab to a clinically relevant extent.", "ParentId": "7145390a-df8c-46ee-a3bf-441440ddb81a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e008af5d-bf28-47d1-b05f-84b4444afffc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2e365fef-c5bc-4142-9ead-3fa1821f2342", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e008af5d-bf28-47d1-b05f-84b4444afffc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The combination of Remicade with other\nbiological therapeutics used to treat the same conditions as Remicade, including\nanakinra and abatacept, is not recommended (see section\u00a04.4).</span></p>", "ID": "7161a861-4140-4298-9401-2c34281bd06e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The combination of Remicade with other\nbiological therapeutics used to treat the same conditions as Remicade, including\nanakinra and abatacept, is not recommended (see section\u00a04.4).</span>", "ID": "e61fc166-9acf-40eb-a2a5-6c0255181d5e", "Styles": "None", "Classes": "None", "Text": "The combination of Remicade with other biological therapeutics used to treat the same conditions as Remicade, including anakinra and abatacept, is not recommended (see section\u00a04.4).", "ParentId": "7161a861-4140-4298-9401-2c34281bd06e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b09a4a6d-7ae0-4dde-9dce-5b67a56422f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bcff4f2b-9050-40ce-807a-e1ee1e2511d9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b09a4a6d-7ae0-4dde-9dce-5b67a56422f6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is recommended that live vaccines not be\ngiven concurrently with Remicade. It is also recommended that live vaccines not\nbe given to infants after <i>in utero</i> exposure to infliximab for at least\n6\u00a0months following birth (see section\u00a04.4).</span></p>", "ID": "6fd9f4eb-c349-4f6b-87df-536ae1215da5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">It is recommended that live vaccines not be\ngiven concurrently with Remicade. It is also recommended that live vaccines not\nbe given to infants after <i>in utero</i> exposure to infliximab for at least\n6\u00a0months following birth (see section\u00a04.4).</span>", "ID": "01f8eb86-7705-44f0-8ef5-e9ac55217a54", "Styles": "None", "Classes": "None", "Text": "It is recommended that live vaccines not be given concurrently with Remicade. It is also recommended that live vaccines not be given to infants after  exposure to infliximab for at least 6\u00a0months following birth (see section\u00a04.4).", "ParentId": "6fd9f4eb-c349-4f6b-87df-536ae1215da5"}, {"Element": "<i>in utero</i>", "ID": "7b644e28-e4d9-4912-b710-580aa3ff0edc", "Styles": "None", "Classes": "None", "Text": "in utero", "ParentId": "01f8eb86-7705-44f0-8ef5-e9ac55217a54"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "036c71f3-c598-445b-8af2-837b055bfb53", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2ab8ec15-a945-4e9f-801d-e34b076ed4ec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "036c71f3-c598-445b-8af2-837b055bfb53"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is recommended that therapeutic\ninfectious agents not be given concurrently with Remicade (see section\u00a04.4).</span></p>", "ID": "6c34e684-6f0c-41bd-9503-455ab4bbff4b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">It is recommended that therapeutic\ninfectious agents not be given concurrently with Remicade (see section\u00a04.4).</span>", "ID": "bf937a03-8040-4774-afe1-27cebe4b95c1", "Styles": "None", "Classes": "None", "Text": "It is recommended that therapeutic infectious agents not be given concurrently with Remicade (see section\u00a04.4).", "ParentId": "6c34e684-6f0c-41bd-9503-455ab4bbff4b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5ccf8960-9829-4e05-9ce2-6e76157d3761", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2afb7ad0-c4ed-47e9-9010-cb280eb719fd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5ccf8960-9829-4e05-9ce2-6e76157d3761"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and\nlactation</span></b></p>", "ID": "fb185f2b-b1d6-4d76-a5d6-cd2dc4ca74a5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and\nlactation</span></b>", "ID": "b7036b75-d5b9-4222-9071-e9cc1c900a92", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fb185f2b-b1d6-4d76-a5d6-cd2dc4ca74a5"}, {"Element": "<span lang=\"EN-GB\">4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and\nlactation</span>", "ID": "6499678b-d83b-4fe7-97be-c468fb5d0ce4", "Styles": "None", "Classes": "None", "Text": "4.6\u00a0\u00a0\u00a0\u00a0 Fertility, pregnancy and lactation", "ParentId": "b7036b75-d5b9-4222-9071-e9cc1c900a92"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "47f91551-2cce-4651-9c35-16d82526ce9a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "48242ec1-010e-45b0-bc28-b7a697337291", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "47f91551-2cce-4651-9c35-16d82526ce9a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Women of\nchildbearing potential</span></u></p>", "ID": "32b8d82d-54cd-4e1b-a74e-2aa17041f79b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Women of\nchildbearing potential</span></u>", "ID": "6ea466e8-fffd-4a2d-a0d0-4b2117d4df9e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "32b8d82d-54cd-4e1b-a74e-2aa17041f79b"}, {"Element": "<span lang=\"EN-GB\">Women of\nchildbearing potential</span>", "ID": "060eefbb-5bb3-4b84-b8db-ad70e2e4cd9f", "Styles": "None", "Classes": "None", "Text": "Women of childbearing potential", "ParentId": "6ea466e8-fffd-4a2d-a0d0-4b2117d4df9e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Women of childbearing potential should\nconsider the use of adequate contraception to prevent pregnancy and continue\nits use for at least 6\u00a0months after the last Remicade treatment.</span></p>", "ID": "f2b48127-fc72-4e9d-b992-8ed7f07324e4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Women of childbearing potential should\nconsider the use of adequate contraception to prevent pregnancy and continue\nits use for at least 6\u00a0months after the last Remicade treatment.</span>", "ID": "eb7b7b0d-3b1c-4cd0-b2f1-26cac6d44491", "Styles": "None", "Classes": "None", "Text": "Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy and continue its use for at least 6\u00a0months after the last Remicade treatment.", "ParentId": "f2b48127-fc72-4e9d-b992-8ed7f07324e4"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "d1a54f40-ff8c-4169-a6e3-9ec351e45ca0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "ad8d02d8-ede4-4e31-a3de-1457610ede41", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d1a54f40-ff8c-4169-a6e3-9ec351e45ca0"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "5a2d7151-dff1-4b68-8bd4-028b75b61dbe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ad8d02d8-ede4-4e31-a3de-1457610ede41"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "21d752d1-10b4-4c78-b9a9-386efc16dfad", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "5a2d7151-dff1-4b68-8bd4-028b75b61dbe"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy</span></u></p>", "ID": "1455a0f8-d484-4265-ba44-e0130a41262e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Pregnancy</span></u>", "ID": "fd45b966-0793-4e84-8e43-78dcf96e1522", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1455a0f8-d484-4265-ba44-e0130a41262e"}, {"Element": "<span lang=\"EN-GB\">Pregnancy</span>", "ID": "b4a37e2a-696c-4903-a095-2f32ba0a609e", "Styles": "None", "Classes": "None", "Text": "Pregnancy", "ParentId": "fd45b966-0793-4e84-8e43-78dcf96e1522"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The moderate number of prospectively\ncollected pregnancies exposed to infliximab resulting in live birth with known\noutcomes, including approximately 1100\u00a0exposed during the first trimester,\n</span><span lang=\"EN-GB\">does not indicate an increase in the rate of\nmalformation in the newborn.</span></p>", "ID": "fe25c69f-df6c-4015-a065-4e1adf938ada", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The moderate number of prospectively\ncollected pregnancies exposed to infliximab resulting in live birth with known\noutcomes, including approximately 1100\u00a0exposed during the first trimester,\n</span>", "ID": "fd922cfe-e8ca-4b01-9382-a829b89ebcc3", "Styles": "None", "Classes": "None", "Text": "The moderate number of prospectively collected pregnancies exposed to infliximab resulting in live birth with known outcomes, including approximately 1100\u00a0exposed during the first trimester, ", "ParentId": "fe25c69f-df6c-4015-a065-4e1adf938ada"}, {"Element": "<span lang=\"EN-GB\">does not indicate an increase in the rate of\nmalformation in the newborn.</span>", "ID": "3174f5f3-9b01-4770-9da4-12e78a58b027", "Styles": "None", "Classes": "None", "Text": "does not indicate an increase in the rate of malformation in the newborn.", "ParentId": "fe25c69f-df6c-4015-a065-4e1adf938ada"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d4eac4e8-c19d-4e83-a144-b32f03bf5127", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d93dbf5c-b6e1-45c1-8121-0280c4e4f62b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d4eac4e8-c19d-4e83-a144-b32f03bf5127"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Based on an observational study from\nNorthern Europe, an increased risk (OR, 95% CI; p\u2011value) for C\u2011section\n(1.50, 1.14\u20111.96; p\u00a0=\u00a00.0032), preterm birth (1.48, 1.05\u20112.09;\np\u00a0=\u00a00.024), small for gestational age (2.79, 1.54\u20115.04; p\u00a0=\u00a00.0007),\nand low birth weight (2.03, 1.41\u20112.94; p\u00a0=\u00a00.0002) was observed\nin women exposed during pregnancy to infliximab (with or without\nimmunomodulators/corticosteroids, 270\u00a0pregnancies) as compared to women\nexposed to immunomodulators and/or corticosteroids only (6,460\u00a0pregnancies).\nThe potential contribution of exposure to infliximab and/or the severity of the\nunderlying disease in these outcomes remains unclear.</span></p>", "ID": "c8ecd41f-e673-4e57-87ba-348f8a404d4d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Based on an observational study from\nNorthern Europe, an increased risk (OR, 95% CI; p\u2011value) for C\u2011section\n(1.50, 1.14\u20111.96; p\u00a0=\u00a00.0032), preterm birth (1.48, 1.05\u20112.09;\np\u00a0=\u00a00.024), small for gestational age (2.79, 1.54\u20115.04; p\u00a0=\u00a00.0007),\nand low birth weight (2.03, 1.41\u20112.94; p\u00a0=\u00a00.0002) was observed\nin women exposed during pregnancy to infliximab (with or without\nimmunomodulators/corticosteroids, 270\u00a0pregnancies) as compared to women\nexposed to immunomodulators and/or corticosteroids only (6,460\u00a0pregnancies).\nThe potential contribution of exposure to infliximab and/or the severity of the\nunderlying disease in these outcomes remains unclear.</span>", "ID": "79d9b5bc-6938-45a0-8fbe-b8241f0d7bba", "Styles": "None", "Classes": "None", "Text": "Based on an observational study from Northern Europe, an increased risk (OR, 95% CI; p\u2011value) for C\u2011section (1.50, 1.14\u20111.96; p\u00a0=\u00a00.0032), preterm birth (1.48, 1.05\u20112.09; p\u00a0=\u00a00.024), small for gestational age (2.79, 1.54\u20115.04; p\u00a0=\u00a00.0007), and low birth weight (2.03, 1.41\u20112.94; p\u00a0=\u00a00.0002) was observed in women exposed during pregnancy to infliximab (with or without immunomodulators/corticosteroids, 270\u00a0pregnancies) as compared to women exposed to immunomodulators and/or corticosteroids only (6,460\u00a0pregnancies). The potential contribution of exposure to infliximab and/or the severity of the underlying disease in these outcomes remains unclear.", "ParentId": "c8ecd41f-e673-4e57-87ba-348f8a404d4d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fa43d3ff-2073-4051-a553-1a752f069d2c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e226d0de-44d1-40d9-bf24-4414deef8461", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fa43d3ff-2073-4051-a553-1a752f069d2c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Due to its inhibition of TNF</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span><span lang=\"EN-GB\">, infliximab\nadministered during pregnancy could affect normal immune responses in the\nnewborn. In a developmental toxicity study conducted in mice using an analogous\nantibody that selectively inhibits the functional activity of mouse TNF</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span><span lang=\"EN-GB\">, there was no\nindication of maternal toxicity, embryotoxicity or teratogenicity (see section\u00a05.3).</span></p>", "ID": "74b5bd26-1c92-4f01-aaf5-5ae9710ad5a2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Due to its inhibition of TNF</span>", "ID": "af2c5475-49a7-43a5-bfa0-ed358e6096cb", "Styles": "None", "Classes": "None", "Text": "Due to its inhibition of TNF", "ParentId": "74b5bd26-1c92-4f01-aaf5-5ae9710ad5a2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "26a63ff9-e463-4736-9f7c-5c29f135f32f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "74b5bd26-1c92-4f01-aaf5-5ae9710ad5a2"}, {"Element": "<span lang=\"EN-GB\">, infliximab\nadministered during pregnancy could affect normal immune responses in the\nnewborn. In a developmental toxicity study conducted in mice using an analogous\nantibody that selectively inhibits the functional activity of mouse TNF</span>", "ID": "caa48712-6ee5-4591-88ea-1cd4cae0d7bc", "Styles": "None", "Classes": "None", "Text": ", infliximab administered during pregnancy could affect normal immune responses in the newborn. In a developmental toxicity study conducted in mice using an analogous antibody that selectively inhibits the functional activity of mouse TNF", "ParentId": "74b5bd26-1c92-4f01-aaf5-5ae9710ad5a2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "c3b07e89-3125-4574-9ede-77bd0c0f9956", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "74b5bd26-1c92-4f01-aaf5-5ae9710ad5a2"}, {"Element": "<span lang=\"EN-GB\">, there was no\nindication of maternal toxicity, embryotoxicity or teratogenicity (see section\u00a05.3).</span>", "ID": "e79e1c5b-0f78-4802-8e78-c25a421c171a", "Styles": "None", "Classes": "None", "Text": ", there was no indication of maternal toxicity, embryotoxicity or teratogenicity (see section\u00a05.3).", "ParentId": "74b5bd26-1c92-4f01-aaf5-5ae9710ad5a2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "57b2deef-0c3b-49c5-b2ee-8dcce48b0a95", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a110928c-9903-4eaa-8a97-f3dc94cf154a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "57b2deef-0c3b-49c5-b2ee-8dcce48b0a95"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The available clinical experience is\nlimited. Infliximab should only be used during pregnancy if clearly needed.</span></p>", "ID": "f954f1c8-3564-4372-9f89-5dce423ee8d6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The available clinical experience is\nlimited. Infliximab should only be used during pregnancy if clearly needed.</span>", "ID": "e9b5d159-03a5-496b-bc1b-900c5c3ccd56", "Styles": "None", "Classes": "None", "Text": "The available clinical experience is limited. Infliximab should only be used during pregnancy if clearly needed.", "ParentId": "f954f1c8-3564-4372-9f89-5dce423ee8d6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ab41b400-1ec1-40b6-9fa8-800296b696e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f6734606-42a1-4a01-8750-57ee78b37116", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ab41b400-1ec1-40b6-9fa8-800296b696e5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab crosses the placenta and has\nbeen detected in the serum of infants up to 6\u00a0months following birth.\nAfter <i>in utero</i> exposure to infliximab, infants may be at increased risk\nof infection, including serious disseminated infection that can become fatal.\nAdministration of live vaccines (e.g.\u00a0BCG vaccine) to infants exposed to\ninfliximab <i>in utero</i> is not recommended for at least 6\u00a0months after\nbirth (see sections\u00a04.4 and 4.5). Cases of agranulocytosis have also been reported\n(see section\u00a04.8).</span></p>", "ID": "ab95527f-3cfa-470a-a949-ce4376dd70d1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infliximab crosses the placenta and has\nbeen detected in the serum of infants up to 6\u00a0months following birth.\nAfter <i>in utero</i> exposure to infliximab, infants may be at increased risk\nof infection, including serious disseminated infection that can become fatal.\nAdministration of live vaccines (e.g.\u00a0BCG vaccine) to infants exposed to\ninfliximab <i>in utero</i> is not recommended for at least 6\u00a0months after\nbirth (see sections\u00a04.4 and 4.5). Cases of agranulocytosis have also been reported\n(see section\u00a04.8).</span>", "ID": "f855b76f-ae3f-4326-a9c2-7c55c8ffe949", "Styles": "None", "Classes": "None", "Text": "Infliximab crosses the placenta and has been detected in the serum of infants up to 6\u00a0months following birth. After  exposure to infliximab, infants may be at increased risk of infection, including serious disseminated infection that can become fatal. Administration of live vaccines (e.g.\u00a0BCG vaccine) to infants exposed to infliximab  is not recommended for at least 6\u00a0months after birth (see sections\u00a04.4 and 4.5). Cases of agranulocytosis have also been reported (see section\u00a04.8).", "ParentId": "ab95527f-3cfa-470a-a949-ce4376dd70d1"}, {"Element": "<i>in utero</i>", "ID": "e70280e6-1a1d-4754-ae89-c9b5220d091d", "Styles": "None", "Classes": "None", "Text": "in utero", "ParentId": "f855b76f-ae3f-4326-a9c2-7c55c8ffe949"}, {"Element": "<i>in utero</i>", "ID": "9d729d30-0365-438f-8135-e53f11806d0f", "Styles": "None", "Classes": "None", "Text": "in utero", "ParentId": "f855b76f-ae3f-4326-a9c2-7c55c8ffe949"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a2f9784c-9239-4bad-8499-24b0ea3e3519", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "02d66be5-bfdb-4520-8054-2ec0eafa916e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a2f9784c-9239-4bad-8499-24b0ea3e3519"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast\u2011feeding</span></u></p>", "ID": "2ae3bbb2-73a8-40a9-b3c4-4d335b0affa5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Breast\u2011feeding</span></u>", "ID": "675ea182-ee93-493b-9686-52c4e02be15e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2ae3bbb2-73a8-40a9-b3c4-4d335b0affa5"}, {"Element": "<span lang=\"EN-GB\">Breast\u2011feeding</span>", "ID": "b88ce822-bf7a-48e6-a397-5e6352dd9491", "Styles": "None", "Classes": "None", "Text": "Breast\u2011feeding", "ParentId": "675ea182-ee93-493b-9686-52c4e02be15e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is unknown whether infliximab is\nexcreted in human milk or absorbed systemically after ingestion. Because human\nimmunoglobulins are excreted in milk, women must not breast feed for at least 6\u00a0months\nafter Remicade treatment.</span></p>", "ID": "fb19cff0-bb38-46b7-bc7e-144460c405c5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">It is unknown whether infliximab is\nexcreted in human milk or absorbed systemically after ingestion. Because human\nimmunoglobulins are excreted in milk, women must not breast feed for at least 6\u00a0months\nafter Remicade treatment.</span>", "ID": "9c4132ea-6bf0-4d83-9eb3-2cce4f41d2fd", "Styles": "None", "Classes": "None", "Text": "It is unknown whether infliximab is excreted in human milk or absorbed systemically after ingestion. Because human immunoglobulins are excreted in milk, women must not breast feed for at least 6\u00a0months after Remicade treatment.", "ParentId": "fb19cff0-bb38-46b7-bc7e-144460c405c5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ba94cb3d-e1c0-4785-8ce6-576688cd97f9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dd626788-2d58-459c-9bca-d64331720b37", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ba94cb3d-e1c0-4785-8ce6-576688cd97f9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility</span></u></p>", "ID": "aae3e36a-bf2e-4dd9-beaa-685b48d4a646", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Fertility</span></u>", "ID": "87726486-06fc-4acb-b97c-232763da2583", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "aae3e36a-bf2e-4dd9-beaa-685b48d4a646"}, {"Element": "<span lang=\"EN-GB\">Fertility</span>", "ID": "51f76920-e015-41d5-a97f-d692db51d714", "Styles": "None", "Classes": "None", "Text": "Fertility", "ParentId": "87726486-06fc-4acb-b97c-232763da2583"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There are insufficient preclinical data to\ndraw conclusions on the effects of infliximab on fertility and general\nreproductive function (see section\u00a05.3).</span></p>", "ID": "ddd1b607-14d9-4ac1-8a3b-b601fed25462", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">There are insufficient preclinical data to\ndraw conclusions on the effects of infliximab on fertility and general\nreproductive function (see section\u00a05.3).</span>", "ID": "9b5a38bc-09f3-40ea-9257-3207a7bf6cc4", "Styles": "None", "Classes": "None", "Text": "There are insufficient preclinical data to draw conclusions on the effects of infliximab on fertility and general reproductive function (see section\u00a05.3).", "ParentId": "ddd1b607-14d9-4ac1-8a3b-b601fed25462"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e2d32f06-6263-4e5e-93c5-9d5f152d94b5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ac8c0664-053a-441e-866d-0d5728dcc643", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e2d32f06-6263-4e5e-93c5-9d5f152d94b5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to\ndrive and use machines</span></b></p>", "ID": "81cd91b6-53f3-48c3-93a3-d2644c1b6d25", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to\ndrive and use machines</span></b>", "ID": "7804fd4c-8d5e-44cb-8293-35741aa6de8c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "81cd91b6-53f3-48c3-93a3-d2644c1b6d25"}, {"Element": "<span lang=\"EN-GB\">4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to\ndrive and use machines</span>", "ID": "10b5b746-48ad-4c0a-b373-cdbb69b125bd", "Styles": "None", "Classes": "None", "Text": "4.7\u00a0\u00a0\u00a0\u00a0 Effects on ability to drive and use machines", "ParentId": "7804fd4c-8d5e-44cb-8293-35741aa6de8c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4d8704b4-2a74-406e-8a24-5a6c0b476bf8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e1d0e906-bcdc-4934-883d-ab052f78fff3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4d8704b4-2a74-406e-8a24-5a6c0b476bf8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade may have a minor influence on the\nability to drive and use machines. Dizziness may occur following administration\nof Remicade (see section\u00a04.8).</span></p>", "ID": "a5ec3131-d1d1-4d3a-a36a-1a5ebf5cdef2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade may have a minor influence on the\nability to drive and use machines. Dizziness may occur following administration\nof Remicade (see section\u00a04.8).</span>", "ID": "4b99db58-25f1-4e0a-a6f7-cfda0c81d9b0", "Styles": "None", "Classes": "None", "Text": "Remicade may have a minor influence on the ability to drive and use machines. Dizziness may occur following administration of Remicade (see section\u00a04.8).", "ParentId": "a5ec3131-d1d1-4d3a-a36a-1a5ebf5cdef2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "94b00159-2938-4a9a-b017-f38b18220f87", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "05e56064-a255-4596-9725-fd9820902827", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94b00159-2938-4a9a-b017-f38b18220f87"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b></p>", "ID": "2761770b-b676-499b-b2cf-f6abdd4b1059", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span></b>", "ID": "fbd7c12f-1e19-453c-86e7-7de0230e01fd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2761770b-b676-499b-b2cf-f6abdd4b1059"}, {"Element": "<span lang=\"EN-GB\">4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects</span>", "ID": "8b0cda44-0175-4ca2-97de-597b2340220c", "Styles": "None", "Classes": "None", "Text": "4.8\u00a0\u00a0\u00a0\u00a0 Undesirable effects", "ParentId": "fbd7c12f-1e19-453c-86e7-7de0230e01fd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "819c65ea-b23f-4571-be67-b601105d5955", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f949cbe4-835c-433c-9403-1ebcae0753f3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "819c65ea-b23f-4571-be67-b601105d5955"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Summary\nof the safety profile</span></b></p>", "ID": "5d4af8a4-5be3-48b1-90bd-f2c6c96ab509", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Summary\nof the safety profile</span></b>", "ID": "887ef569-8175-4ea0-8ae9-9a0a46e058e7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5d4af8a4-5be3-48b1-90bd-f2c6c96ab509"}, {"Element": "<span lang=\"EN-GB\">Summary\nof the safety profile</span>", "ID": "a0aa9591-d291-4c88-8aa8-10a4c3f45fb5", "Styles": "None", "Classes": "None", "Text": "Summary of the safety profile", "ParentId": "887ef569-8175-4ea0-8ae9-9a0a46e058e7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Upper respiratory tract infection was the\nmost common adverse drug reaction (ADR) reported in clinical trials, occurring\nin 25.3% of infliximab\u2011treated patients compared with 16.5% of control\npatients</span><span lang=\"EN-GB\">. The most serious ADRs associated with the use\nof TNF blockers that have been reported for Remicade include HBV reactivation,\nCHF (congestive heart failure), serious infections (including sepsis,\nopportunistic infections and TB), serum sickness (delayed hypersensitivity\nreactions), haematologic reactions, systemic lupus erythematosus/lupus\u2011like\nsyndrome, demyelinating disorders, hepatobiliary events, lymphoma, HSTCL, leukaemia,\nMerkel cell carcinoma, melanoma, paediatric malignancy, sarcoidosis/sarcoid\u2011like\nreaction, intestinal or perianal abscess (in Crohn\u2019s disease), and\nserious infusion reactions (see section\u00a04.4).</span></p>", "ID": "c01e6874-0467-47cf-86c6-0cdca6e72de7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Upper respiratory tract infection was the\nmost common adverse drug reaction (ADR) reported in clinical trials, occurring\nin 25.3% of infliximab\u2011treated patients compared with 16.5% of control\npatients</span>", "ID": "23e0a87c-fa14-4114-a9e0-9d16f3c2ae79", "Styles": "None", "Classes": "None", "Text": "Upper respiratory tract infection was the most common adverse drug reaction (ADR) reported in clinical trials, occurring in 25.3% of infliximab\u2011treated patients compared with 16.5% of control patients", "ParentId": "c01e6874-0467-47cf-86c6-0cdca6e72de7"}, {"Element": "<span lang=\"EN-GB\">. The most serious ADRs associated with the use\nof TNF blockers that have been reported for Remicade include HBV reactivation,\nCHF (congestive heart failure), serious infections (including sepsis,\nopportunistic infections and TB), serum sickness (delayed hypersensitivity\nreactions), haematologic reactions, systemic lupus erythematosus/lupus\u2011like\nsyndrome, demyelinating disorders, hepatobiliary events, lymphoma, HSTCL, leukaemia,\nMerkel cell carcinoma, melanoma, paediatric malignancy, sarcoidosis/sarcoid\u2011like\nreaction, intestinal or perianal abscess (in Crohn\u2019s disease), and\nserious infusion reactions (see section\u00a04.4).</span>", "ID": "81b55936-b9bf-4c9d-96d2-2c621d79ce85", "Styles": "None", "Classes": "None", "Text": ". The most serious ADRs associated with the use of TNF blockers that have been reported for Remicade include HBV reactivation, CHF (congestive heart failure), serious infections (including sepsis, opportunistic infections and TB), serum sickness (delayed hypersensitivity reactions), haematologic reactions, systemic lupus erythematosus/lupus\u2011like syndrome, demyelinating disorders, hepatobiliary events, lymphoma, HSTCL, leukaemia, Merkel cell carcinoma, melanoma, paediatric malignancy, sarcoidosis/sarcoid\u2011like reaction, intestinal or perianal abscess (in Crohn\u2019s disease), and serious infusion reactions (see section\u00a04.4).", "ParentId": "c01e6874-0467-47cf-86c6-0cdca6e72de7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2a1545a0-9edf-4c27-a50b-7a704f1194f7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5719906e-edf0-49e5-bf3c-4997d861a6bd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2a1545a0-9edf-4c27-a50b-7a704f1194f7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Tabulated\nlist of adverse reactions</span></b></p>", "ID": "555e8b23-623a-49d2-ab95-f7cfcbe6cf7a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Tabulated\nlist of adverse reactions</span></b>", "ID": "cede680b-98a6-4e0c-8eb3-c9b859dc7179", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "555e8b23-623a-49d2-ab95-f7cfcbe6cf7a"}, {"Element": "<span lang=\"EN-GB\">Tabulated\nlist of adverse reactions</span>", "ID": "a901c66b-111a-431f-a09e-a7458c5722e0", "Styles": "None", "Classes": "None", "Text": "Tabulated list of adverse reactions", "ParentId": "cede680b-98a6-4e0c-8eb3-c9b859dc7179"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Table\u00a01 lists ADRs based on experience\nfrom clinical studies as well as adverse reactions, some with fatal outcome,\nreported from post\u2011marketing experience. Within the organ system classes,\nadverse reactions are listed under headings of frequency using the following\ncategories: very common (\u2265\u00a01/10); common (\u2265\u00a01/100 to &lt;\u00a01/10);\nuncommon\u00a0(\u2265\u00a01/1,000 to &lt;\u00a01/100); rare (\u2265\u00a01/10,000\nto &lt;\u00a01/1,000); very rare (&lt;\u00a01/10,000), not known (cannot be\nestimated from the available data). Within each frequency grouping, undesirable\neffects are presented in order of decreasing seriousness.</span></p>", "ID": "e5375904-1c4f-4c17-a167-6e5da4a242cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Table\u00a01 lists ADRs based on experience\nfrom clinical studies as well as adverse reactions, some with fatal outcome,\nreported from post\u2011marketing experience. Within the organ system classes,\nadverse reactions are listed under headings of frequency using the following\ncategories: very common (\u2265\u00a01/10); common (\u2265\u00a01/100 to &lt;\u00a01/10);\nuncommon\u00a0(\u2265\u00a01/1,000 to &lt;\u00a01/100); rare (\u2265\u00a01/10,000\nto &lt;\u00a01/1,000); very rare (&lt;\u00a01/10,000), not known (cannot be\nestimated from the available data). Within each frequency grouping, undesirable\neffects are presented in order of decreasing seriousness.</span>", "ID": "e59e77f8-c17e-46f5-9846-c40ad878168a", "Styles": "None", "Classes": "None", "Text": "Table\u00a01 lists ADRs based on experience from clinical studies as well as adverse reactions, some with fatal outcome, reported from post\u2011marketing experience. Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (\u2265\u00a01/10); common (\u2265\u00a01/100 to <\u00a01/10); uncommon\u00a0(\u2265\u00a01/1,000 to <\u00a01/100); rare (\u2265\u00a01/10,000 to <\u00a01/1,000); very rare (<\u00a01/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.", "ParentId": "e5375904-1c4f-4c17-a167-6e5da4a242cb"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "b009d226-f910-4cdc-b5de-8898f6fe4668", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "fa6335b1-80f1-4620-acf3-ceed6c063c99", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b009d226-f910-4cdc-b5de-8898f6fe4668"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a53f568c-086e-452e-b98d-e7bcb0221c07", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fa6335b1-80f1-4620-acf3-ceed6c063c99"}, {"Element": "<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a01</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Undesirable effects in clinical studies and from\n  post\u2011marketing experience</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections\n  and infestations</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Viral infection (e.g. influenza, herpes\n  virus infection).</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bacterial infections (e.g. sepsis,\n  cellulitis, abscess). </span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tuberculosis, fungal infections (e.g.\n  candidiasis, onychomycosis).</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Meningitis, opportunistic infections\n  (such as invasive fungal infections [pneumocystosis, histoplasmosis,\n  aspergillosis, coccidioidomycosis, cryptococcosis, blastomycosis], bacterial\n  infections [atypical mycobacterial, listeriosis, salmonellosis], and viral\n  infections [cytomegalovirus]), parasitic infections, hepatitis B\n  reactivation.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vaccine breakthrough infection (after <i>in\n  utero </i>exposure to infliximab)*.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Neoplasms\n  benign, malignant and unspecified (including cysts and polyps)</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lymphoma,</span><span lang=\"EN-GB\"> non\u2011Hodgkin\u2019s\n  lymphoma, Hodgkin\u2019s disease, leukaemia, melanoma, cervical cancer.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatosplenic T\u2011cell lymphoma\n  (primarily in adolescents and young adult males with Crohn\u2019s disease or\n  ulcerative colitis), Merkel cell carcinoma<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">, Kaposi\u2019s sarcoma</ins></span>.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Blood and\n  lymphatic system disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia, leucopenia, anaemia,\n  lymphadenopathy.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Thrombocytopenia, lymphopenia, lymphocytosis.\n  </span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Agranulocytosis (including infants\n  exposed <i>in utero </i>to infliximab), thrombotic thrombocytopenic purpura,\n  pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Immune\n  system disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Allergic respiratory symptom<span style=\"layout-grid-mode:line\">.</span></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reaction, lupus\u2011like\n  syndrome, serum sickness or<span style=\"layout-grid-mode:line\"> serum\n  sickness\u2011like reaction</span>.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid !msorm\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-left:solid windowtext 1.0pt !msorm;\n  padding:0in 5.4pt 0in 5.4pt !msorm\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-right:solid windowtext 1.0pt !msorm;\n  padding:0in 5.4pt 0in 5.4pt !msorm\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic shock, vasculitis, sarcoid\u2011like\n  reaction.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Psychiatric\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Depression, insomnia.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"FR\">Amnesia, agitation, confusion, somnolence,\n  nervousness.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Apathy.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nervous\n  system disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Headache.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertigo, dizziness, hypoaesthesia,\n  paraesthesia.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Seizure, neuropathy.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Transverse myelitis, central nervous\n  system demyelinating disorders (multiple sclerosis\u2011like disease and\n  optic neuritis), peripheral demyelinating disorders (such as Guillain\u2011Barr\u00e9\n  syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal\n  motor neuropathy).</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cerebrovascular accidents in close temporal\n  association with infusion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Eye\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Conjunctivitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keratitis, periorbital oedema, hordeolum.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Endophthalmitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Transient visual loss occurring during or\n  within 2\u00a0hours of infusion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Cardiac disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tachycardia, palpitation.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cardiac failure (new onset or worsening),\n  arrhythmia, syncope, bradycardia.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cyanosis, pericardial effusion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Myocardial ischaemia/myocardial\n  infarction</span><span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vascular\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypotension, hypertension, ecchymosis,\n  hot flush, flushing.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Peripheral ischaemia, thrombophlebitis,\n  haematoma.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Circulatory failure, petechia, vasospasm.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Respiratory,\n  thoracic and mediastinal disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Upper respiratory tract infection, sinusitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lower respiratory tract infection (e.g.\n  bronchitis, pneumonia), dyspnoea, epistaxis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pulmonary oedema, bronchospasm, pleurisy,\n  pleural effusion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Interstitial lung disease (including\n  rapidly progressive disease, lung fibrosis and pneumonitis).</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Gastrointestinal\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Abdominal pain, nausea.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gastrointestinal haemorrhage, diarrhoea,\n  dyspepsia, gastroesophageal reflux, constipation.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intestinal perforation, intestinal stenosis,\n  diverticulitis, pancreatitis, cheilitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatobiliary\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatic function abnormal, transaminases\n  increased.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatitis, hepatocellular damage,\n  cholecystitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoimmune hepatitis, jaundice.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Liver failure.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Skin and subcutaneous\n  tissue disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">New onset or worsening psoriasis\n  including pustular psoriasis (primarily palm &amp; soles), urticaria, rash,\n  pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bullous eruption, seborrhoea, rosacea,\n  skin papilloma, hyperkeratosis, abnormal skin pigmentation.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Toxic epidermal necrolysis, Stevens\u2011Johnson\n  Syndrome, erythema multiforme, furunculosis, linear IgA bullous dermatosis\n  (LABD), acute generalised exanthematous pustulosis (AGEP), lichenoid\n  reactions.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Worsening of symptoms of dermatomyositis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Musculoskeletal\n  and connective tissue disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arthralgia, myalgia, back pain.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Renal and\n  urinary disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Urinary tract infection.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pyelonephritis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reproductive\n  system and breast disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vaginitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">General\n  disorders and administration site conditions</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infusion\u2011related reaction, pain.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Chest pain, fatigue, fever, injection\n  site reaction, chills, oedema.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Impaired healing.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Granulomatous lesion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Investigations</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoantibody positive.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Complement factor abnormal.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\">*\u00a0\u00a0 </span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">including\n  bovine tuberculosis (disseminated BCG infection), see section\u00a04.4</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "a71dc829-10a1-4421-af8f-da3b6a69ed3f", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a01</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Undesirable effects in clinical studies and from\n  post\u2011marketing experience</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections\n  and infestations</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Viral infection (e.g. influenza, herpes\n  virus infection).</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bacterial infections (e.g. sepsis,\n  cellulitis, abscess). </span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tuberculosis, fungal infections (e.g.\n  candidiasis, onychomycosis).</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Meningitis, opportunistic infections\n  (such as invasive fungal infections [pneumocystosis, histoplasmosis,\n  aspergillosis, coccidioidomycosis, cryptococcosis, blastomycosis], bacterial\n  infections [atypical mycobacterial, listeriosis, salmonellosis], and viral\n  infections [cytomegalovirus]), parasitic infections, hepatitis B\n  reactivation.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vaccine breakthrough infection (after <i>in\n  utero </i>exposure to infliximab)*.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Neoplasms\n  benign, malignant and unspecified (including cysts and polyps)</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lymphoma,</span><span lang=\"EN-GB\"> non\u2011Hodgkin\u2019s\n  lymphoma, Hodgkin\u2019s disease, leukaemia, melanoma, cervical cancer.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatosplenic T\u2011cell lymphoma\n  (primarily in adolescents and young adult males with Crohn\u2019s disease or\n  ulcerative colitis), Merkel cell carcinoma<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">, Kaposi\u2019s sarcoma</ins></span>.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Blood and\n  lymphatic system disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia, leucopenia, anaemia,\n  lymphadenopathy.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Thrombocytopenia, lymphopenia, lymphocytosis.\n  </span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Agranulocytosis (including infants\n  exposed <i>in utero </i>to infliximab), thrombotic thrombocytopenic purpura,\n  pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Immune\n  system disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Allergic respiratory symptom<span style=\"layout-grid-mode:line\">.</span></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reaction, lupus\u2011like\n  syndrome, serum sickness or<span style=\"layout-grid-mode:line\"> serum\n  sickness\u2011like reaction</span>.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid !msorm\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-left:solid windowtext 1.0pt !msorm;\n  padding:0in 5.4pt 0in 5.4pt !msorm\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-right:solid windowtext 1.0pt !msorm;\n  padding:0in 5.4pt 0in 5.4pt !msorm\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic shock, vasculitis, sarcoid\u2011like\n  reaction.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Psychiatric\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Depression, insomnia.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"FR\">Amnesia, agitation, confusion, somnolence,\n  nervousness.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Apathy.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nervous\n  system disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Headache.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertigo, dizziness, hypoaesthesia,\n  paraesthesia.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Seizure, neuropathy.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Transverse myelitis, central nervous\n  system demyelinating disorders (multiple sclerosis\u2011like disease and\n  optic neuritis), peripheral demyelinating disorders (such as Guillain\u2011Barr\u00e9\n  syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal\n  motor neuropathy).</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cerebrovascular accidents in close temporal\n  association with infusion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Eye\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Conjunctivitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keratitis, periorbital oedema, hordeolum.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Endophthalmitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Transient visual loss occurring during or\n  within 2\u00a0hours of infusion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Cardiac disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tachycardia, palpitation.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cardiac failure (new onset or worsening),\n  arrhythmia, syncope, bradycardia.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cyanosis, pericardial effusion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Myocardial ischaemia/myocardial\n  infarction</span><span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vascular\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypotension, hypertension, ecchymosis,\n  hot flush, flushing.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Peripheral ischaemia, thrombophlebitis,\n  haematoma.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Circulatory failure, petechia, vasospasm.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Respiratory,\n  thoracic and mediastinal disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Upper respiratory tract infection, sinusitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lower respiratory tract infection (e.g.\n  bronchitis, pneumonia), dyspnoea, epistaxis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pulmonary oedema, bronchospasm, pleurisy,\n  pleural effusion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Interstitial lung disease (including\n  rapidly progressive disease, lung fibrosis and pneumonitis).</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Gastrointestinal\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Abdominal pain, nausea.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gastrointestinal haemorrhage, diarrhoea,\n  dyspepsia, gastroesophageal reflux, constipation.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intestinal perforation, intestinal stenosis,\n  diverticulitis, pancreatitis, cheilitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatobiliary\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatic function abnormal, transaminases\n  increased.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatitis, hepatocellular damage,\n  cholecystitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoimmune hepatitis, jaundice.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Liver failure.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Skin and subcutaneous\n  tissue disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">New onset or worsening psoriasis\n  including pustular psoriasis (primarily palm &amp; soles), urticaria, rash,\n  pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bullous eruption, seborrhoea, rosacea,\n  skin papilloma, hyperkeratosis, abnormal skin pigmentation.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Toxic epidermal necrolysis, Stevens\u2011Johnson\n  Syndrome, erythema multiforme, furunculosis, linear IgA bullous dermatosis\n  (LABD), acute generalised exanthematous pustulosis (AGEP), lichenoid\n  reactions.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Worsening of symptoms of dermatomyositis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Musculoskeletal\n  and connective tissue disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arthralgia, myalgia, back pain.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Renal and\n  urinary disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Urinary tract infection.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pyelonephritis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reproductive\n  system and breast disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vaginitis.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">General\n  disorders and administration site conditions</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infusion\u2011related reaction, pain.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Chest pain, fatigue, fever, injection\n  site reaction, chills, oedema.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Impaired healing.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Granulomatous lesion.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Investigations</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoantibody positive.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Complement factor abnormal.</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\">*\u00a0\u00a0 </span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">including\n  bovine tuberculosis (disseminated BCG infection), see section\u00a04.4</span></p>\n</td>\n</tr>\n</table>", "ID": "3e2337c4-ad07-4bd9-b459-2257a80adc8f", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                                                                              ", "ParentId": "a71dc829-10a1-4421-af8f-da3b6a69ed3f"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a01</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Undesirable effects in clinical studies and from\n  post\u2011marketing experience</span></b></p>\n</td>\n</tr>", "ID": "ec44d009-890d-494c-87a6-b8e09b6f582f", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td colspan=\"2\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a01</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Undesirable effects in clinical studies and from\n  post\u2011marketing experience</span></b></p>\n</td>", "ID": "0d9b6ad0-fb41-4de0-a2d4-5b085b783d7f", "Styles": "width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "ec44d009-890d-494c-87a6-b8e09b6f582f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a01</span></b></p>", "ID": "11a40e33-7a12-417b-bb41-d9d7150fe341", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0d9b6ad0-fb41-4de0-a2d4-5b085b783d7f"}, {"Element": "<b><span lang=\"EN-GB\">Table\u00a01</span></b>", "ID": "5d8f0f3e-ad18-42dd-bfc0-9ada99e8e819", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "11a40e33-7a12-417b-bb41-d9d7150fe341"}, {"Element": "<span lang=\"EN-GB\">Table\u00a01</span>", "ID": "a2f1984c-4cbd-4aa8-bf39-538740c4c1ee", "Styles": "None", "Classes": "None", "Text": "Table\u00a01", "ParentId": "5d8f0f3e-ad18-42dd-bfc0-9ada99e8e819"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Undesirable effects in clinical studies and from\n  post\u2011marketing experience</span></b></p>", "ID": "d11723ac-955f-458b-81cd-920ffca0a75b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0d9b6ad0-fb41-4de0-a2d4-5b085b783d7f"}, {"Element": "<b><span lang=\"EN-GB\">Undesirable effects in clinical studies and from\n  post\u2011marketing experience</span></b>", "ID": "92c12ae2-2534-485d-9cc0-b84464160c73", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d11723ac-955f-458b-81cd-920ffca0a75b"}, {"Element": "<span lang=\"EN-GB\">Undesirable effects in clinical studies and from\n  post\u2011marketing experience</span>", "ID": "defdcf2c-3bd2-4584-9f62-5c39f80ffc45", "Styles": "None", "Classes": "None", "Text": "Undesirable effects in clinical studies and from   post\u2011marketing experience", "ParentId": "92c12ae2-2534-485d-9cc0-b84464160c73"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections\n  and infestations</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "7e93ba92-082b-4bbc-957b-effc9facb487", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections\n  and infestations</span></p>\n</td>", "ID": "f2d57642-02c7-49f0-ab6f-ba09dd276d57", "Styles": "width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7e93ba92-082b-4bbc-957b-effc9facb487"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections\n  and infestations</span></p>", "ID": "bfdd8faa-7f21-4a2c-9cbf-1a1d6d26e61e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f2d57642-02c7-49f0-ab6f-ba09dd276d57"}, {"Element": "<span lang=\"EN-GB\">Infections\n  and infestations</span>", "ID": "28e7df28-3392-4d3c-b0a1-8c8edb6aad65", "Styles": "None", "Classes": "None", "Text": "Infections   and infestations", "ParentId": "bfdd8faa-7f21-4a2c-9cbf-1a1d6d26e61e"}, {"Element": "<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "16227aea-2ce5-4729-8586-d221cacf8ae1", "Styles": "width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7e93ba92-082b-4bbc-957b-effc9facb487"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "79258993-91f7-46cb-bbdd-b996f592a3f7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "16227aea-2ce5-4729-8586-d221cacf8ae1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e1f5cf92-f99c-44ca-815e-a143068a6706", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "79258993-91f7-46cb-bbdd-b996f592a3f7"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Viral infection (e.g. influenza, herpes\n  virus infection).</span></p>\n</td>\n</tr>", "ID": "73d1936e-1157-4667-8987-bab4a2f0ce27", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  Common:</span></p>\n</td>", "ID": "60185ca6-8bb1-4e98-8cf5-f71dc7c288d7", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "73d1936e-1157-4667-8987-bab4a2f0ce27"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  Common:</span></p>", "ID": "fa9e9997-117d-4e3e-8a16-8357f1bfcd62", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "60185ca6-8bb1-4e98-8cf5-f71dc7c288d7"}, {"Element": "<span lang=\"EN-GB\">Very\n  Common:</span>", "ID": "ec942743-f8c6-4b6a-ae54-596eea036824", "Styles": "None", "Classes": "None", "Text": "Very   Common:", "ParentId": "fa9e9997-117d-4e3e-8a16-8357f1bfcd62"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Viral infection (e.g. influenza, herpes\n  virus infection).</span></p>\n</td>", "ID": "09971690-1249-4988-a0a4-74c8203cd83a", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "73d1936e-1157-4667-8987-bab4a2f0ce27"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Viral infection (e.g. influenza, herpes\n  virus infection).</span></p>", "ID": "6a0a0995-7863-44d9-a978-101d82141b14", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "09971690-1249-4988-a0a4-74c8203cd83a"}, {"Element": "<span lang=\"EN-GB\">Viral infection (e.g. influenza, herpes\n  virus infection).</span>", "ID": "aeae7871-1194-406a-927b-4556ff4d9aad", "Styles": "None", "Classes": "None", "Text": "Viral infection (e.g. influenza, herpes   virus infection).", "ParentId": "6a0a0995-7863-44d9-a978-101d82141b14"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bacterial infections (e.g. sepsis,\n  cellulitis, abscess). </span></p>\n</td>\n</tr>", "ID": "47533c6d-cd07-42f7-b054-267ad260f8d1", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "8aeea40b-7e49-4e51-911c-563057e2cf9b", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "47533c6d-cd07-42f7-b054-267ad260f8d1"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "f749d521-d8d5-4acf-97a6-6a4ce45f0a53", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8aeea40b-7e49-4e51-911c-563057e2cf9b"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "c2168df6-2871-4b5d-8297-e8c03bfed0df", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "f749d521-d8d5-4acf-97a6-6a4ce45f0a53"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bacterial infections (e.g. sepsis,\n  cellulitis, abscess). </span></p>\n</td>", "ID": "4051dc6c-37fd-40e6-9545-1914b650acd0", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "47533c6d-cd07-42f7-b054-267ad260f8d1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bacterial infections (e.g. sepsis,\n  cellulitis, abscess). </span></p>", "ID": "7c7cb713-d3ae-4125-8aef-5091fa07a977", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4051dc6c-37fd-40e6-9545-1914b650acd0"}, {"Element": "<span lang=\"EN-GB\">Bacterial infections (e.g. sepsis,\n  cellulitis, abscess). </span>", "ID": "48a9a151-d80d-43a0-ad1e-a9b1cef00ceb", "Styles": "None", "Classes": "None", "Text": "Bacterial infections (e.g. sepsis,   cellulitis, abscess). ", "ParentId": "7c7cb713-d3ae-4125-8aef-5091fa07a977"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tuberculosis, fungal infections (e.g.\n  candidiasis, onychomycosis).</span></p>\n</td>\n</tr>", "ID": "082e2d83-eb7e-4207-9b29-eba66bc5a78c", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "211547b5-889b-4df6-8ab6-776aba70e04e", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "082e2d83-eb7e-4207-9b29-eba66bc5a78c"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "74033205-e59a-4986-a9ab-b82acaefcaf0", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "211547b5-889b-4df6-8ab6-776aba70e04e"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "a0981c8f-ba09-465c-91ae-d335f3709ed2", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "74033205-e59a-4986-a9ab-b82acaefcaf0"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tuberculosis, fungal infections (e.g.\n  candidiasis, onychomycosis).</span></p>\n</td>", "ID": "c7cdf647-457b-49fc-b251-4f284e3afbfe", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "082e2d83-eb7e-4207-9b29-eba66bc5a78c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tuberculosis, fungal infections (e.g.\n  candidiasis, onychomycosis).</span></p>", "ID": "9d4e51a2-9e6f-495b-9a2f-ccf1ead00807", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c7cdf647-457b-49fc-b251-4f284e3afbfe"}, {"Element": "<span lang=\"EN-GB\">Tuberculosis, fungal infections (e.g.\n  candidiasis, onychomycosis).</span>", "ID": "3118812d-b696-4dae-997d-078d6ebd9c6e", "Styles": "None", "Classes": "None", "Text": "Tuberculosis, fungal infections (e.g.   candidiasis, onychomycosis).", "ParentId": "9d4e51a2-9e6f-495b-9a2f-ccf1ead00807"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Meningitis, opportunistic infections\n  (such as invasive fungal infections [pneumocystosis, histoplasmosis,\n  aspergillosis, coccidioidomycosis, cryptococcosis, blastomycosis], bacterial\n  infections [atypical mycobacterial, listeriosis, salmonellosis], and viral\n  infections [cytomegalovirus]), parasitic infections, hepatitis B\n  reactivation.</span></p>\n</td>\n</tr>", "ID": "62c85d16-fa3e-4af5-adf2-3854f7e3b113", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "ced0d5a5-e7fe-47ce-aa22-fe432bd2defc", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "62c85d16-fa3e-4af5-adf2-3854f7e3b113"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "dfbfaa65-87b7-4666-811f-235f254e96ef", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ced0d5a5-e7fe-47ce-aa22-fe432bd2defc"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "c82383d4-f797-4b54-9a0a-c06b879c2bdf", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "dfbfaa65-87b7-4666-811f-235f254e96ef"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Meningitis, opportunistic infections\n  (such as invasive fungal infections [pneumocystosis, histoplasmosis,\n  aspergillosis, coccidioidomycosis, cryptococcosis, blastomycosis], bacterial\n  infections [atypical mycobacterial, listeriosis, salmonellosis], and viral\n  infections [cytomegalovirus]), parasitic infections, hepatitis B\n  reactivation.</span></p>\n</td>", "ID": "6965a804-3c7d-4f94-8aac-cd4133dfbf18", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "62c85d16-fa3e-4af5-adf2-3854f7e3b113"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Meningitis, opportunistic infections\n  (such as invasive fungal infections [pneumocystosis, histoplasmosis,\n  aspergillosis, coccidioidomycosis, cryptococcosis, blastomycosis], bacterial\n  infections [atypical mycobacterial, listeriosis, salmonellosis], and viral\n  infections [cytomegalovirus]), parasitic infections, hepatitis B\n  reactivation.</span></p>", "ID": "3ec94afa-f665-4a50-9d22-42cd25e5a8c7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6965a804-3c7d-4f94-8aac-cd4133dfbf18"}, {"Element": "<span lang=\"EN-GB\">Meningitis, opportunistic infections\n  (such as invasive fungal infections [pneumocystosis, histoplasmosis,\n  aspergillosis, coccidioidomycosis, cryptococcosis, blastomycosis], bacterial\n  infections [atypical mycobacterial, listeriosis, salmonellosis], and viral\n  infections [cytomegalovirus]), parasitic infections, hepatitis B\n  reactivation.</span>", "ID": "c0a48319-e151-4669-8c9c-4bb372da659b", "Styles": "None", "Classes": "None", "Text": "Meningitis, opportunistic infections   (such as invasive fungal infections [pneumocystosis, histoplasmosis,   aspergillosis, coccidioidomycosis, cryptococcosis, blastomycosis], bacterial   infections [atypical mycobacterial, listeriosis, salmonellosis], and viral   infections [cytomegalovirus]), parasitic infections, hepatitis B   reactivation.", "ParentId": "3ec94afa-f665-4a50-9d22-42cd25e5a8c7"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vaccine breakthrough infection (after <i>in\n  utero </i>exposure to infliximab)*.</span></p>\n</td>\n</tr>", "ID": "1a586be1-bc89-4780-941b-f792eb0d7f48", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>", "ID": "c1a56da9-f9a3-4bae-bc40-718ec343cb29", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1a586be1-bc89-4780-941b-f792eb0d7f48"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>", "ID": "dbed3914-4a40-4da8-8270-ad173110faff", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c1a56da9-f9a3-4bae-bc40-718ec343cb29"}, {"Element": "<span lang=\"EN-GB\">Not\n  known:</span>", "ID": "703bbdb8-eab3-4aa8-8b0e-0fbb9f86135d", "Styles": "None", "Classes": "None", "Text": "Not   known:", "ParentId": "dbed3914-4a40-4da8-8270-ad173110faff"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vaccine breakthrough infection (after <i>in\n  utero </i>exposure to infliximab)*.</span></p>\n</td>", "ID": "f0d61320-8d12-4604-be92-9d4a3dd2a30d", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1a586be1-bc89-4780-941b-f792eb0d7f48"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vaccine breakthrough infection (after <i>in\n  utero </i>exposure to infliximab)*.</span></p>", "ID": "2dad2d52-d930-4171-9893-964d437745bf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f0d61320-8d12-4604-be92-9d4a3dd2a30d"}, {"Element": "<span lang=\"EN-GB\">Vaccine breakthrough infection (after <i>in\n  utero </i>exposure to infliximab)*.</span>", "ID": "b0442e21-4023-429c-a805-76c638c4055a", "Styles": "None", "Classes": "None", "Text": "Vaccine breakthrough infection (after exposure to infliximab)*.", "ParentId": "2dad2d52-d930-4171-9893-964d437745bf"}, {"Element": "<i>in\n  utero </i>", "ID": "88c7a41b-1acc-4fc2-bd38-1786b0d5dec4", "Styles": "None", "Classes": "None", "Text": "in   utero ", "ParentId": "b0442e21-4023-429c-a805-76c638c4055a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Neoplasms\n  benign, malignant and unspecified (including cysts and polyps)</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "fcf2e13e-3f4b-434d-bcaa-be1d64990f0c", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Neoplasms\n  benign, malignant and unspecified (including cysts and polyps)</span></p>\n</td>", "ID": "33096c38-e850-4a48-a537-e1a94d1ec12a", "Styles": "width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fcf2e13e-3f4b-434d-bcaa-be1d64990f0c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Neoplasms\n  benign, malignant and unspecified (including cysts and polyps)</span></p>", "ID": "11eb36c6-aaa1-4ad8-8451-d8c7404a732b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "33096c38-e850-4a48-a537-e1a94d1ec12a"}, {"Element": "<span lang=\"EN-GB\">Neoplasms\n  benign, malignant and unspecified (including cysts and polyps)</span>", "ID": "77b1b70a-99dd-48f8-a1ab-06e1635dcec6", "Styles": "None", "Classes": "None", "Text": "Neoplasms   benign, malignant and unspecified (including cysts and polyps)", "ParentId": "11eb36c6-aaa1-4ad8-8451-d8c7404a732b"}, {"Element": "<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "a60a5748-b346-4ed3-b904-eb45a6312081", "Styles": "width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "fcf2e13e-3f4b-434d-bcaa-be1d64990f0c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c21e5647-5395-459b-a758-fdcc42dcfa48", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a60a5748-b346-4ed3-b904-eb45a6312081"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "521806b0-cf7f-46bb-abd8-cbb6d4facd9f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c21e5647-5395-459b-a758-fdcc42dcfa48"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lymphoma,</span><span lang=\"EN-GB\"> non\u2011Hodgkin\u2019s\n  lymphoma, Hodgkin\u2019s disease, leukaemia, melanoma, cervical cancer.</span></p>\n</td>\n</tr>", "ID": "88136bb5-a4d5-4614-8e33-eedadab56b56", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "8a17b491-c133-4e06-a5d6-aa96a4afb02c", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "88136bb5-a4d5-4614-8e33-eedadab56b56"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "05aade62-cf5d-4ae8-b9ea-8ed8e99e5b06", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8a17b491-c133-4e06-a5d6-aa96a4afb02c"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "d1c3c31f-3511-4b7f-bc76-926d348893de", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "05aade62-cf5d-4ae8-b9ea-8ed8e99e5b06"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lymphoma,</span><span lang=\"EN-GB\"> non\u2011Hodgkin\u2019s\n  lymphoma, Hodgkin\u2019s disease, leukaemia, melanoma, cervical cancer.</span></p>\n</td>", "ID": "6e310017-6479-4526-b335-67daa8f31213", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "88136bb5-a4d5-4614-8e33-eedadab56b56"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lymphoma,</span><span lang=\"EN-GB\"> non\u2011Hodgkin\u2019s\n  lymphoma, Hodgkin\u2019s disease, leukaemia, melanoma, cervical cancer.</span></p>", "ID": "d7b16637-a7f0-404c-858b-299edc777495", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6e310017-6479-4526-b335-67daa8f31213"}, {"Element": "<span lang=\"EN-GB\">Lymphoma,</span>", "ID": "3f408999-875a-4125-b752-58af3052e62d", "Styles": "None", "Classes": "None", "Text": "Lymphoma,", "ParentId": "d7b16637-a7f0-404c-858b-299edc777495"}, {"Element": "<span lang=\"EN-GB\"> non\u2011Hodgkin\u2019s\n  lymphoma, Hodgkin\u2019s disease, leukaemia, melanoma, cervical cancer.</span>", "ID": "5e2d5b7f-3eaa-4fba-bcd7-d8ceca2f6fc0", "Styles": "None", "Classes": "None", "Text": " non\u2011Hodgkin\u2019s   lymphoma, Hodgkin\u2019s disease, leukaemia, melanoma, cervical cancer.", "ParentId": "d7b16637-a7f0-404c-858b-299edc777495"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatosplenic T\u2011cell lymphoma\n  (primarily in adolescents and young adult males with Crohn\u2019s disease or\n  ulcerative colitis), Merkel cell carcinoma<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">, Kaposi\u2019s sarcoma</ins></span>.</span></p>\n</td>\n</tr>", "ID": "6166834e-a23b-4546-9a23-fd4957272e47", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>", "ID": "0583fe3f-c179-4abc-9d24-ea2f33496793", "Styles": "width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6166834e-a23b-4546-9a23-fd4957272e47"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>", "ID": "b10cce2d-54b1-45e6-adf9-5c20b47cb5a6", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0583fe3f-c179-4abc-9d24-ea2f33496793"}, {"Element": "<span lang=\"EN-GB\">Not\n  known:</span>", "ID": "d9230b70-c6f8-41f2-bcc4-2a8d657e6ef0", "Styles": "None", "Classes": "None", "Text": "Not   known:", "ParentId": "b10cce2d-54b1-45e6-adf9-5c20b47cb5a6"}, {"Element": "<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatosplenic T\u2011cell lymphoma\n  (primarily in adolescents and young adult males with Crohn\u2019s disease or\n  ulcerative colitis), Merkel cell carcinoma<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">, Kaposi\u2019s sarcoma</ins></span>.</span></p>\n</td>", "ID": "3a71e041-082d-4957-8383-ec4249699f4c", "Styles": "width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6166834e-a23b-4546-9a23-fd4957272e47"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatosplenic T\u2011cell lymphoma\n  (primarily in adolescents and young adult males with Crohn\u2019s disease or\n  ulcerative colitis), Merkel cell carcinoma<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">, Kaposi\u2019s sarcoma</ins></span>.</span></p>", "ID": "98c83efe-e111-448b-b754-e72722e0d43c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3a71e041-082d-4957-8383-ec4249699f4c"}, {"Element": "<span lang=\"EN-GB\">Hepatosplenic T\u2011cell lymphoma\n  (primarily in adolescents and young adult males with Crohn\u2019s disease or\n  ulcerative colitis), Merkel cell carcinoma<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">, Kaposi\u2019s sarcoma</ins></span>.</span>", "ID": "361238f0-9b7c-479e-ba9a-9c58d3ff2e5b", "Styles": "None", "Classes": "None", "Text": "Hepatosplenic T\u2011cell lymphoma   (primarily in adolescents and young adult males with Crohn\u2019s disease or   ulcerative colitis), Merkel cell carcinoma.", "ParentId": "98c83efe-e111-448b-b754-e72722e0d43c"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">, Kaposi\u2019s sarcoma</ins></span>", "ID": "fe35f699-5f50-4be8-b9a2-94bf86fdd714", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "361238f0-9b7c-479e-ba9a-9c58d3ff2e5b"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">, Kaposi\u2019s sarcoma</ins>", "ID": "99830e26-38fb-435e-bb4f-38bc2cb3c9e9", "Styles": "None", "Classes": "None", "Text": ", Kaposi\u2019s sarcoma", "ParentId": "fe35f699-5f50-4be8-b9a2-94bf86fdd714"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Blood and\n  lymphatic system disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "02bce245-4eeb-4c07-8301-145a09f98e79", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Blood and\n  lymphatic system disorders</span></p>\n</td>", "ID": "e13e7e49-3cfa-43aa-89fa-8d03c6157fc2", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02bce245-4eeb-4c07-8301-145a09f98e79"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Blood and\n  lymphatic system disorders</span></p>", "ID": "3f76b058-585f-4831-ac09-e5870c135269", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e13e7e49-3cfa-43aa-89fa-8d03c6157fc2"}, {"Element": "<span lang=\"EN-GB\">Blood and\n  lymphatic system disorders</span>", "ID": "c594cdf1-a1c9-42e1-a65e-3580e6ab9b1e", "Styles": "None", "Classes": "None", "Text": "Blood and   lymphatic system disorders", "ParentId": "3f76b058-585f-4831-ac09-e5870c135269"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "25e72631-204e-406e-b67a-3c1e8ca7e3d7", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02bce245-4eeb-4c07-8301-145a09f98e79"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c86ba68f-7791-4651-9f47-85ed543ab81b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "25e72631-204e-406e-b67a-3c1e8ca7e3d7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fdc98ad5-3575-4a20-8c23-80d160def4a2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c86ba68f-7791-4651-9f47-85ed543ab81b"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia, leucopenia, anaemia,\n  lymphadenopathy.</span></p>\n</td>\n</tr>", "ID": "ecd604d0-f9f7-4356-8bff-be150a617fed", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "b424dcbd-775f-453f-923b-9718e2df6788", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ecd604d0-f9f7-4356-8bff-be150a617fed"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "042129cc-11e3-470f-8183-b99b0532dfed", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b424dcbd-775f-453f-923b-9718e2df6788"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "5cbf02de-047c-4686-a8aa-26057c613947", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "042129cc-11e3-470f-8183-b99b0532dfed"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia, leucopenia, anaemia,\n  lymphadenopathy.</span></p>\n</td>", "ID": "f54547ee-5f8f-489b-8bb4-50aa654dff54", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ecd604d0-f9f7-4356-8bff-be150a617fed"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Neutropenia, leucopenia, anaemia,\n  lymphadenopathy.</span></p>", "ID": "9831bb81-29e8-40ec-9d70-1a5c4e0a45aa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f54547ee-5f8f-489b-8bb4-50aa654dff54"}, {"Element": "<span lang=\"EN-GB\">Neutropenia, leucopenia, anaemia,\n  lymphadenopathy.</span>", "ID": "b9778bf6-8919-4e52-a905-e8e7064a6ec6", "Styles": "None", "Classes": "None", "Text": "Neutropenia, leucopenia, anaemia,   lymphadenopathy.", "ParentId": "9831bb81-29e8-40ec-9d70-1a5c4e0a45aa"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Thrombocytopenia, lymphopenia, lymphocytosis.\n  </span></p>\n</td>\n</tr>", "ID": "569e99a4-b563-41e1-9001-480923771ba2", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "cc172894-293a-487f-a00a-a3bfb77d1350", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "569e99a4-b563-41e1-9001-480923771ba2"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "993d1c9b-9daf-4394-a223-fa25ec614c5f", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cc172894-293a-487f-a00a-a3bfb77d1350"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "4bfdc3bc-fdba-48e7-8d4c-cc222356ef01", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "993d1c9b-9daf-4394-a223-fa25ec614c5f"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Thrombocytopenia, lymphopenia, lymphocytosis.\n  </span></p>\n</td>", "ID": "39b44218-2f66-4654-8958-66312d110709", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "569e99a4-b563-41e1-9001-480923771ba2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Thrombocytopenia, lymphopenia, lymphocytosis.\n  </span></p>", "ID": "71a36097-69f5-4dde-8eda-015c28f04460", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "39b44218-2f66-4654-8958-66312d110709"}, {"Element": "<span lang=\"EN-GB\">Thrombocytopenia, lymphopenia, lymphocytosis.\n  </span>", "ID": "fa8543f7-413e-445e-8ed4-24a807293751", "Styles": "None", "Classes": "None", "Text": "Thrombocytopenia, lymphopenia, lymphocytosis.   ", "ParentId": "71a36097-69f5-4dde-8eda-015c28f04460"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Agranulocytosis (including infants\n  exposed <i>in utero </i>to infliximab), thrombotic thrombocytopenic purpura,\n  pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.</span></p>\n</td>\n</tr>", "ID": "2af5c8fd-9198-4456-aa8b-17e39b4705f1", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "ef7f8460-9f9d-418b-a60c-30471c00637e", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2af5c8fd-9198-4456-aa8b-17e39b4705f1"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "ebbb61a5-90cb-48c4-b0b5-a8b1fc32fa8b", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ef7f8460-9f9d-418b-a60c-30471c00637e"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "00414d16-9796-485e-ac98-c0994baa012a", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "ebbb61a5-90cb-48c4-b0b5-a8b1fc32fa8b"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Agranulocytosis (including infants\n  exposed <i>in utero </i>to infliximab), thrombotic thrombocytopenic purpura,\n  pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.</span></p>\n</td>", "ID": "ba4c8ac9-2ef2-4d70-ba16-74a8aaca9264", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2af5c8fd-9198-4456-aa8b-17e39b4705f1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Agranulocytosis (including infants\n  exposed <i>in utero </i>to infliximab), thrombotic thrombocytopenic purpura,\n  pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.</span></p>", "ID": "3a9150fa-3243-4b25-8db0-9a596c2736ae", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ba4c8ac9-2ef2-4d70-ba16-74a8aaca9264"}, {"Element": "<span lang=\"EN-GB\">Agranulocytosis (including infants\n  exposed <i>in utero </i>to infliximab), thrombotic thrombocytopenic purpura,\n  pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.</span>", "ID": "ac26ea96-fd4a-44e1-be94-81e97f9a8691", "Styles": "None", "Classes": "None", "Text": "Agranulocytosis (including infants   exposed to infliximab), thrombotic thrombocytopenic purpura,   pancytopenia, haemolytic anaemia, idiopathic thrombocytopenic purpura.", "ParentId": "3a9150fa-3243-4b25-8db0-9a596c2736ae"}, {"Element": "<i>in utero </i>", "ID": "f33099d8-e90b-44f8-b07d-94843a7a94ad", "Styles": "None", "Classes": "None", "Text": "in utero ", "ParentId": "ac26ea96-fd4a-44e1-be94-81e97f9a8691"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Immune\n  system disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "b61e550f-9228-4dca-a336-fd59d348a649", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Immune\n  system disorders</span></p>\n</td>", "ID": "4ac5b700-b264-4ec8-afd6-e92b5d15c8f8", "Styles": "width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b61e550f-9228-4dca-a336-fd59d348a649"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Immune\n  system disorders</span></p>", "ID": "c65e4367-6fef-4874-800c-e880acb816af", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4ac5b700-b264-4ec8-afd6-e92b5d15c8f8"}, {"Element": "<span lang=\"EN-GB\">Immune\n  system disorders</span>", "ID": "e19cc4ac-c611-4930-a60f-5b406f88c4c0", "Styles": "None", "Classes": "None", "Text": "Immune   system disorders", "ParentId": "c65e4367-6fef-4874-800c-e880acb816af"}, {"Element": "<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "85e3e221-85a3-4bb7-b138-3249370633f7", "Styles": "width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b61e550f-9228-4dca-a336-fd59d348a649"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fcce8916-b015-4d21-b1a6-5400e456f060", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "85e3e221-85a3-4bb7-b138-3249370633f7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa7a549e-a050-454e-bc32-3f450baa56a9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fcce8916-b015-4d21-b1a6-5400e456f060"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Allergic respiratory symptom<span style=\"layout-grid-mode:line\">.</span></span></p>\n</td>\n</tr>", "ID": "f73bcf3a-bcfe-4c00-bc31-5721cb13a745", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "b28cfc3e-f521-4095-8877-f0aacdb592a4", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f73bcf3a-bcfe-4c00-bc31-5721cb13a745"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "a346fadf-c007-463d-ba62-073ec67c3168", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b28cfc3e-f521-4095-8877-f0aacdb592a4"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "2283dd8d-75c4-4e80-b7d1-5695cf10f37f", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "a346fadf-c007-463d-ba62-073ec67c3168"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Allergic respiratory symptom<span style=\"layout-grid-mode:line\">.</span></span></p>\n</td>", "ID": "adf499c1-b3d9-4f85-86f5-23c7902d43e4", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f73bcf3a-bcfe-4c00-bc31-5721cb13a745"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Allergic respiratory symptom<span style=\"layout-grid-mode:line\">.</span></span></p>", "ID": "f6b764f8-b9f7-4e38-9334-ae415d47d8b7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "adf499c1-b3d9-4f85-86f5-23c7902d43e4"}, {"Element": "<span lang=\"EN-GB\">Allergic respiratory symptom<span style=\"layout-grid-mode:line\">.</span></span>", "ID": "f2664a77-a76a-4d07-9bcd-a7dbce9c8d41", "Styles": "None", "Classes": "None", "Text": "Allergic respiratory symptom", "ParentId": "f6b764f8-b9f7-4e38-9334-ae415d47d8b7"}, {"Element": "<span style=\"layout-grid-mode:line\">.</span>", "ID": "e39439c1-6493-45a1-87a3-1ef1c070998d", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": ".", "ParentId": "f2664a77-a76a-4d07-9bcd-a7dbce9c8d41"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reaction, lupus\u2011like\n  syndrome, serum sickness or<span style=\"layout-grid-mode:line\"> serum\n  sickness\u2011like reaction</span>.</span></p>\n</td>\n</tr>", "ID": "0ab5da50-326e-4f79-bf6b-09f22acdbefe", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "951feb5c-5180-41ba-8bbc-2861ea3aecf0", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0ab5da50-326e-4f79-bf6b-09f22acdbefe"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "71088555-9c7b-4119-b132-1fd80dae7cf2", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "951feb5c-5180-41ba-8bbc-2861ea3aecf0"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "ae576a4a-a027-4b1b-aebd-c31f2a27c47e", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "71088555-9c7b-4119-b132-1fd80dae7cf2"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reaction, lupus\u2011like\n  syndrome, serum sickness or<span style=\"layout-grid-mode:line\"> serum\n  sickness\u2011like reaction</span>.</span></p>\n</td>", "ID": "35d977d7-1438-4ab6-aaa6-a94306f1e28a", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0ab5da50-326e-4f79-bf6b-09f22acdbefe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic reaction, lupus\u2011like\n  syndrome, serum sickness or<span style=\"layout-grid-mode:line\"> serum\n  sickness\u2011like reaction</span>.</span></p>", "ID": "6ef66505-aa3f-473c-be38-912dbbbd734b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "35d977d7-1438-4ab6-aaa6-a94306f1e28a"}, {"Element": "<span lang=\"EN-GB\">Anaphylactic reaction, lupus\u2011like\n  syndrome, serum sickness or<span style=\"layout-grid-mode:line\"> serum\n  sickness\u2011like reaction</span>.</span>", "ID": "85b4404f-cd27-4bf1-8a64-8903c191371e", "Styles": "None", "Classes": "None", "Text": "Anaphylactic reaction, lupus\u2011like   syndrome, serum sickness or.", "ParentId": "6ef66505-aa3f-473c-be38-912dbbbd734b"}, {"Element": "<span style=\"layout-grid-mode:line\"> serum\n  sickness\u2011like reaction</span>", "ID": "9528102a-a72a-40a4-b69b-de4b90feee93", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": " serum   sickness\u2011like reaction", "ParentId": "85b4404f-cd27-4bf1-8a64-8903c191371e"}, {"Element": "<tr style=\"page-break-inside:avoid !msorm\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-left:solid windowtext 1.0pt !msorm;\n  padding:0in 5.4pt 0in 5.4pt !msorm\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-right:solid windowtext 1.0pt !msorm;\n  padding:0in 5.4pt 0in 5.4pt !msorm\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic shock, vasculitis, sarcoid\u2011like\n  reaction.</span></p>\n</td>\n</tr>", "ID": "1b616f4d-0ac3-426c-a006-d5ebaa317d7d", "Styles": "page-break-inside:avoid !msorm", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-left:solid windowtext 1.0pt !msorm;\n  padding:0in 5.4pt 0in 5.4pt !msorm\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "7e3d5315-08d2-4a80-a549-2c9d47fb8743", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-left:solid windowtext 1.0pt !msorm;\n  padding:0in 5.4pt 0in 5.4pt !msorm", "Classes": "None", "Text": "  ", "ParentId": "1b616f4d-0ac3-426c-a006-d5ebaa317d7d"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "a554a2bd-087f-42ac-9640-da793d2613b3", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e3d5315-08d2-4a80-a549-2c9d47fb8743"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "4134bd18-d40a-4a18-af5f-ccaba91a941a", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "a554a2bd-087f-42ac-9640-da793d2613b3"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-right:solid windowtext 1.0pt !msorm;\n  padding:0in 5.4pt 0in 5.4pt !msorm\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic shock, vasculitis, sarcoid\u2011like\n  reaction.</span></p>\n</td>", "ID": "a9f6f62c-fbd5-4f73-96d0-2b93698d1aab", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt;border:none !msorm;border-right:solid windowtext 1.0pt !msorm;\n  padding:0in 5.4pt 0in 5.4pt !msorm", "Classes": "None", "Text": "  ", "ParentId": "1b616f4d-0ac3-426c-a006-d5ebaa317d7d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Anaphylactic shock, vasculitis, sarcoid\u2011like\n  reaction.</span></p>", "ID": "53e000d7-917b-43cb-a1ab-ad2b858db744", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a9f6f62c-fbd5-4f73-96d0-2b93698d1aab"}, {"Element": "<span lang=\"EN-GB\">Anaphylactic shock, vasculitis, sarcoid\u2011like\n  reaction.</span>", "ID": "edb88b4e-30b2-4650-b73b-d592ec8b55ff", "Styles": "None", "Classes": "None", "Text": "Anaphylactic shock, vasculitis, sarcoid\u2011like   reaction.", "ParentId": "53e000d7-917b-43cb-a1ab-ad2b858db744"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Psychiatric\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "c7c26612-c69a-4b02-b68b-f826ff28f0a9", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Psychiatric\n  disorders</span></p>\n</td>", "ID": "cae3a344-c7ab-4930-869c-0b3f5aa71ea1", "Styles": "width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c7c26612-c69a-4b02-b68b-f826ff28f0a9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Psychiatric\n  disorders</span></p>", "ID": "4b04f5fb-8975-4ac4-9b90-fd4fbd860b54", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cae3a344-c7ab-4930-869c-0b3f5aa71ea1"}, {"Element": "<span lang=\"EN-GB\">Psychiatric\n  disorders</span>", "ID": "d6530d3a-0ad4-42bf-ad35-6118c396da69", "Styles": "None", "Classes": "None", "Text": "Psychiatric   disorders", "ParentId": "4b04f5fb-8975-4ac4-9b90-fd4fbd860b54"}, {"Element": "<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "cbe2ea04-e2d9-4975-b3da-14d62c539244", "Styles": "width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c7c26612-c69a-4b02-b68b-f826ff28f0a9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5b2a8632-4ace-4c0f-9b4d-62fa94ab1235", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cbe2ea04-e2d9-4975-b3da-14d62c539244"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d0fcc4da-a535-4dd4-a542-58e2ba75bf06", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5b2a8632-4ace-4c0f-9b4d-62fa94ab1235"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Depression, insomnia.</span></p>\n</td>\n</tr>", "ID": "cb4ac705-35c5-4372-8fe7-58f5e71e86d0", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "1c246676-1225-4201-897d-c0c401af0a16", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cb4ac705-35c5-4372-8fe7-58f5e71e86d0"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "b4ebe597-9d58-478f-994b-d4f6ae3b3ecb", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1c246676-1225-4201-897d-c0c401af0a16"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "7230dd70-6ec9-4fb3-b8c0-cfc09f0ea01d", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "b4ebe597-9d58-478f-994b-d4f6ae3b3ecb"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Depression, insomnia.</span></p>\n</td>", "ID": "6669e5b1-963e-4e65-83b6-1d4bb45dbcbb", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cb4ac705-35c5-4372-8fe7-58f5e71e86d0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Depression, insomnia.</span></p>", "ID": "4e66b4f3-5d63-469e-84d0-92c01d611b67", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6669e5b1-963e-4e65-83b6-1d4bb45dbcbb"}, {"Element": "<span lang=\"EN-GB\">Depression, insomnia.</span>", "ID": "66cefcd7-e186-41df-a444-34e9afc606a6", "Styles": "None", "Classes": "None", "Text": "Depression, insomnia.", "ParentId": "4e66b4f3-5d63-469e-84d0-92c01d611b67"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"FR\">Amnesia, agitation, confusion, somnolence,\n  nervousness.</span></p>\n</td>\n</tr>", "ID": "6acd9d5d-8c9a-4e92-a140-7dd2cce47b48", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "e42db6cc-d53e-406f-9545-39c3f526b9d1", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6acd9d5d-8c9a-4e92-a140-7dd2cce47b48"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "854768ac-2764-4d0c-87f9-9d8e09ead9d1", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e42db6cc-d53e-406f-9545-39c3f526b9d1"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "43892134-c808-4456-b5f3-edfce422f1a3", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "854768ac-2764-4d0c-87f9-9d8e09ead9d1"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"FR\">Amnesia, agitation, confusion, somnolence,\n  nervousness.</span></p>\n</td>", "ID": "33cc4cb6-0fef-4ece-863e-d3c855da33a9", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6acd9d5d-8c9a-4e92-a140-7dd2cce47b48"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"FR\">Amnesia, agitation, confusion, somnolence,\n  nervousness.</span></p>", "ID": "a75ed4b0-cd5b-4278-9f11-599ca926173a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "33cc4cb6-0fef-4ece-863e-d3c855da33a9"}, {"Element": "<span lang=\"FR\">Amnesia, agitation, confusion, somnolence,\n  nervousness.</span>", "ID": "fa3b77c5-573e-4108-83ce-28f1876485e7", "Styles": "None", "Classes": "None", "Text": "Amnesia, agitation, confusion, somnolence,   nervousness.", "ParentId": "a75ed4b0-cd5b-4278-9f11-599ca926173a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Apathy.</span></p>\n</td>\n</tr>", "ID": "2dff43a3-becc-4b0e-81cd-d91295bc2067", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "71df1982-3c68-44bc-9ca5-6713a192fcd6", "Styles": "width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2dff43a3-becc-4b0e-81cd-d91295bc2067"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "1ac6755f-899f-4c7f-97e0-588d914aeac8", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "71df1982-3c68-44bc-9ca5-6713a192fcd6"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "f0661558-b6f5-42e9-bf5b-415168435378", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "1ac6755f-899f-4c7f-97e0-588d914aeac8"}, {"Element": "<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Apathy.</span></p>\n</td>", "ID": "33c148ee-d28d-40ca-80d4-87819a765182", "Styles": "width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2dff43a3-becc-4b0e-81cd-d91295bc2067"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Apathy.</span></p>", "ID": "b7f0752a-4f73-49b3-a551-dd3440da1e98", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "33c148ee-d28d-40ca-80d4-87819a765182"}, {"Element": "<span lang=\"EN-GB\">Apathy.</span>", "ID": "ffd978a4-760c-4eca-b765-2f990f61b3df", "Styles": "None", "Classes": "None", "Text": "Apathy.", "ParentId": "b7f0752a-4f73-49b3-a551-dd3440da1e98"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nervous\n  system disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "6cb87704-025c-40c5-ae5f-f7ecbad921cf", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nervous\n  system disorders</span></p>\n</td>", "ID": "8959f659-b280-471c-8799-8ce4c4ea694c", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6cb87704-025c-40c5-ae5f-f7ecbad921cf"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Nervous\n  system disorders</span></p>", "ID": "b887627a-ab24-436e-b6b9-5f9e629c0fd7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8959f659-b280-471c-8799-8ce4c4ea694c"}, {"Element": "<span lang=\"EN-GB\">Nervous\n  system disorders</span>", "ID": "d31f57d3-c0b7-43bc-b711-665cfbcc7a9e", "Styles": "None", "Classes": "None", "Text": "Nervous   system disorders", "ParentId": "b887627a-ab24-436e-b6b9-5f9e629c0fd7"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "05c8a117-c1fa-4936-a49a-0b9cd2477023", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6cb87704-025c-40c5-ae5f-f7ecbad921cf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0bcacfa3-8daf-4c3b-bcfb-7ae8cba0376e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "05c8a117-c1fa-4936-a49a-0b9cd2477023"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bfbbf40b-72a5-4a34-9f92-cc9f58010bda", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0bcacfa3-8daf-4c3b-bcfb-7ae8cba0376e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Headache.</span></p>\n</td>\n</tr>", "ID": "2a3ae711-c0e6-4bd9-b242-8fcf5f34673d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>", "ID": "eeead4f7-a7c4-48a2-909f-107407aeeff8", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2a3ae711-c0e6-4bd9-b242-8fcf5f34673d"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>", "ID": "09d45591-934c-441f-b26d-0cc38e376aff", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eeead4f7-a7c4-48a2-909f-107407aeeff8"}, {"Element": "<span lang=\"EN-GB\">Very\n  common:</span>", "ID": "13940e67-7105-42dd-b593-bc16888b107d", "Styles": "None", "Classes": "None", "Text": "Very   common:", "ParentId": "09d45591-934c-441f-b26d-0cc38e376aff"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Headache.</span></p>\n</td>", "ID": "2d7f9af2-bb05-422d-a2f1-8030fd2a8668", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2a3ae711-c0e6-4bd9-b242-8fcf5f34673d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Headache.</span></p>", "ID": "f22f7cb6-9d35-450a-aeed-abca8d82b9ac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2d7f9af2-bb05-422d-a2f1-8030fd2a8668"}, {"Element": "<span lang=\"EN-GB\">Headache.</span>", "ID": "39411dc0-f6e7-4a48-8e17-dce3f566aafb", "Styles": "None", "Classes": "None", "Text": "Headache.", "ParentId": "f22f7cb6-9d35-450a-aeed-abca8d82b9ac"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertigo, dizziness, hypoaesthesia,\n  paraesthesia.</span></p>\n</td>\n</tr>", "ID": "8d84f263-e65f-42f1-b6dc-8e59dec30fe9", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "7c6ddf47-70a0-413d-9c02-97d85be580a2", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8d84f263-e65f-42f1-b6dc-8e59dec30fe9"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "a1da2df3-4803-4fd0-901c-a8525bc0b708", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7c6ddf47-70a0-413d-9c02-97d85be580a2"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "b9352590-09c3-42ef-a2b6-4dcaf92f861e", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "a1da2df3-4803-4fd0-901c-a8525bc0b708"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertigo, dizziness, hypoaesthesia,\n  paraesthesia.</span></p>\n</td>", "ID": "7076e681-c3d6-4668-bdfc-9a41b8bbf093", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8d84f263-e65f-42f1-b6dc-8e59dec30fe9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vertigo, dizziness, hypoaesthesia,\n  paraesthesia.</span></p>", "ID": "43de95db-9028-434d-a6e8-25d1e0070724", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7076e681-c3d6-4668-bdfc-9a41b8bbf093"}, {"Element": "<span lang=\"EN-GB\">Vertigo, dizziness, hypoaesthesia,\n  paraesthesia.</span>", "ID": "4fa1c673-5549-4419-9dec-eaf1dac67d49", "Styles": "None", "Classes": "None", "Text": "Vertigo, dizziness, hypoaesthesia,   paraesthesia.", "ParentId": "43de95db-9028-434d-a6e8-25d1e0070724"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Seizure, neuropathy.</span></p>\n</td>\n</tr>", "ID": "e3c6f511-4060-4b5b-8837-ae2a80b10f69", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "081c3907-17dd-4817-aa78-fdab35528a81", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e3c6f511-4060-4b5b-8837-ae2a80b10f69"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "968bfa51-9c50-45e3-9898-3e8324d0f70e", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "081c3907-17dd-4817-aa78-fdab35528a81"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "cba466e5-0fa2-4cf1-ab3a-d24b87efa4f3", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "968bfa51-9c50-45e3-9898-3e8324d0f70e"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Seizure, neuropathy.</span></p>\n</td>", "ID": "94af5051-be80-46b1-bb70-476b1ac7aa1e", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e3c6f511-4060-4b5b-8837-ae2a80b10f69"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Seizure, neuropathy.</span></p>", "ID": "707519c4-82a0-46ce-ad7c-3cac7eaaf17d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "94af5051-be80-46b1-bb70-476b1ac7aa1e"}, {"Element": "<span lang=\"EN-GB\">Seizure, neuropathy.</span>", "ID": "ff4db471-829d-4d4f-8b35-ca930c9b28b2", "Styles": "None", "Classes": "None", "Text": "Seizure, neuropathy.", "ParentId": "707519c4-82a0-46ce-ad7c-3cac7eaaf17d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Transverse myelitis, central nervous\n  system demyelinating disorders (multiple sclerosis\u2011like disease and\n  optic neuritis), peripheral demyelinating disorders (such as Guillain\u2011Barr\u00e9\n  syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal\n  motor neuropathy).</span></p>\n</td>\n</tr>", "ID": "ac643b97-9ee1-49bf-917e-ae48ab277147", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "3fc74dd3-4b95-41f8-8461-ad09e18518ba", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ac643b97-9ee1-49bf-917e-ae48ab277147"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "986a66f6-b4c2-4466-b873-e63157cd130d", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3fc74dd3-4b95-41f8-8461-ad09e18518ba"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "44e04bcf-4dcd-4504-929a-1c3277a64c69", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "986a66f6-b4c2-4466-b873-e63157cd130d"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Transverse myelitis, central nervous\n  system demyelinating disorders (multiple sclerosis\u2011like disease and\n  optic neuritis), peripheral demyelinating disorders (such as Guillain\u2011Barr\u00e9\n  syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal\n  motor neuropathy).</span></p>\n</td>", "ID": "8916956c-18e5-49aa-bc82-9b84ec49d0f5", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ac643b97-9ee1-49bf-917e-ae48ab277147"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Transverse myelitis, central nervous\n  system demyelinating disorders (multiple sclerosis\u2011like disease and\n  optic neuritis), peripheral demyelinating disorders (such as Guillain\u2011Barr\u00e9\n  syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal\n  motor neuropathy).</span></p>", "ID": "37003dfa-652c-471e-ad78-47d43ffbea0c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8916956c-18e5-49aa-bc82-9b84ec49d0f5"}, {"Element": "<span lang=\"EN-GB\">Transverse myelitis, central nervous\n  system demyelinating disorders (multiple sclerosis\u2011like disease and\n  optic neuritis), peripheral demyelinating disorders (such as Guillain\u2011Barr\u00e9\n  syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal\n  motor neuropathy).</span>", "ID": "5a67bfd9-4d79-4e3c-895c-54eebf7c1012", "Styles": "None", "Classes": "None", "Text": "Transverse myelitis, central nervous   system demyelinating disorders (multiple sclerosis\u2011like disease and   optic neuritis), peripheral demyelinating disorders (such as Guillain\u2011Barr\u00e9   syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal   motor neuropathy).", "ParentId": "37003dfa-652c-471e-ad78-47d43ffbea0c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cerebrovascular accidents in close temporal\n  association with infusion.</span></p>\n</td>\n</tr>", "ID": "7ec2fd66-ac7a-4b23-af85-102c4c95d6ee", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not known:</span></p>\n</td>", "ID": "d90d66df-7061-4b1d-b9b7-006ddfcff240", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7ec2fd66-ac7a-4b23-af85-102c4c95d6ee"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not known:</span></p>", "ID": "7a0f445b-ee76-4cd8-9fbd-e0ef81d08472", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d90d66df-7061-4b1d-b9b7-006ddfcff240"}, {"Element": "<span lang=\"EN-GB\">Not known:</span>", "ID": "d1a76bee-6e9d-42ae-a5d9-48dbc9afd81e", "Styles": "None", "Classes": "None", "Text": "Not known:", "ParentId": "7a0f445b-ee76-4cd8-9fbd-e0ef81d08472"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cerebrovascular accidents in close temporal\n  association with infusion.</span></p>\n</td>", "ID": "62cec9f5-d2a7-4f46-b5f6-2c72a37c0f7b", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7ec2fd66-ac7a-4b23-af85-102c4c95d6ee"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cerebrovascular accidents in close temporal\n  association with infusion.</span></p>", "ID": "5480e748-ec28-4a9b-a181-ae793ea09edc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "62cec9f5-d2a7-4f46-b5f6-2c72a37c0f7b"}, {"Element": "<span lang=\"EN-GB\">Cerebrovascular accidents in close temporal\n  association with infusion.</span>", "ID": "ecdde7cc-43dd-42d6-9a6c-ec685e218335", "Styles": "None", "Classes": "None", "Text": "Cerebrovascular accidents in close temporal   association with infusion.", "ParentId": "5480e748-ec28-4a9b-a181-ae793ea09edc"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Eye\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "af215029-a1d9-4b76-b85a-0099d4ff8550", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Eye\n  disorders</span></p>\n</td>", "ID": "9ade3356-bafa-4580-ba52-19fe0b4b7705", "Styles": "width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "af215029-a1d9-4b76-b85a-0099d4ff8550"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Eye\n  disorders</span></p>", "ID": "3522fb21-cf2a-4e07-904c-3a228b7353ca", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9ade3356-bafa-4580-ba52-19fe0b4b7705"}, {"Element": "<span lang=\"EN-GB\">Eye\n  disorders</span>", "ID": "659a4ce4-20d2-41d7-97af-bff775cc77ab", "Styles": "None", "Classes": "None", "Text": "Eye   disorders", "ParentId": "3522fb21-cf2a-4e07-904c-3a228b7353ca"}, {"Element": "<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "1cb61685-9711-411c-a253-09248bb61c73", "Styles": "width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "af215029-a1d9-4b76-b85a-0099d4ff8550"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2d341ac8-6df5-44bf-9859-bdde5ded4ecb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1cb61685-9711-411c-a253-09248bb61c73"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b99ee96f-921e-4b14-a9cf-61bc475c7465", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2d341ac8-6df5-44bf-9859-bdde5ded4ecb"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Conjunctivitis.</span></p>\n</td>\n</tr>", "ID": "277daef0-0cfa-41a2-9e92-316461307c0b", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "4d51cc1e-46e5-4340-a0d9-aa749c06c6d5", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "277daef0-0cfa-41a2-9e92-316461307c0b"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "0b56b03f-aaef-40e7-b48b-bfeaf394b22e", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d51cc1e-46e5-4340-a0d9-aa749c06c6d5"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "d9ad1143-64e1-49e3-8e8f-9bed3751f66b", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "0b56b03f-aaef-40e7-b48b-bfeaf394b22e"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Conjunctivitis.</span></p>\n</td>", "ID": "a68b127b-4f9c-4523-acc5-bfcd93659bfe", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "277daef0-0cfa-41a2-9e92-316461307c0b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Conjunctivitis.</span></p>", "ID": "b364462a-076e-436e-a519-ea7b182dc20d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a68b127b-4f9c-4523-acc5-bfcd93659bfe"}, {"Element": "<span lang=\"EN-GB\">Conjunctivitis.</span>", "ID": "c82e0d09-f4e1-498a-b769-d7a4fd0b8d43", "Styles": "None", "Classes": "None", "Text": "Conjunctivitis.", "ParentId": "b364462a-076e-436e-a519-ea7b182dc20d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keratitis, periorbital oedema, hordeolum.</span></p>\n</td>\n</tr>", "ID": "4abdc413-fb69-479c-ab57-90925eeb8fd7", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "47df4ea6-52f1-484a-8301-e19549b31712", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4abdc413-fb69-479c-ab57-90925eeb8fd7"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "49ad0f76-c7f1-47f3-9534-2354b9eb059e", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "47df4ea6-52f1-484a-8301-e19549b31712"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "93eb94c5-f770-433b-9e8e-c368b2a7a263", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "49ad0f76-c7f1-47f3-9534-2354b9eb059e"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keratitis, periorbital oedema, hordeolum.</span></p>\n</td>", "ID": "5ae41e4b-a3cb-4bb8-96dc-8742e78e49f9", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4abdc413-fb69-479c-ab57-90925eeb8fd7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keratitis, periorbital oedema, hordeolum.</span></p>", "ID": "d4729b45-f85c-4003-b32e-21a2bf83750e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ae41e4b-a3cb-4bb8-96dc-8742e78e49f9"}, {"Element": "<span lang=\"EN-GB\">Keratitis, periorbital oedema, hordeolum.</span>", "ID": "aa6191c1-0b20-4155-83e9-20b9ba9e3b36", "Styles": "None", "Classes": "None", "Text": "Keratitis, periorbital oedema, hordeolum.", "ParentId": "d4729b45-f85c-4003-b32e-21a2bf83750e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Endophthalmitis.</span></p>\n</td>\n</tr>", "ID": "b925b708-16de-4ba7-a0d0-e120072089eb", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "7f4e8adc-a3ad-4dfc-b685-0089ed12c1c3", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b925b708-16de-4ba7-a0d0-e120072089eb"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "9913edf7-afd8-4a1b-b800-e214512afcb4", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7f4e8adc-a3ad-4dfc-b685-0089ed12c1c3"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "77cad705-f245-4ca8-b096-61c904cf8e50", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "9913edf7-afd8-4a1b-b800-e214512afcb4"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Endophthalmitis.</span></p>\n</td>", "ID": "6821d42a-6753-4039-bbd8-8414c4a312b2", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b925b708-16de-4ba7-a0d0-e120072089eb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Endophthalmitis.</span></p>", "ID": "58408b3a-da5e-4502-a2fb-b46323844243", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6821d42a-6753-4039-bbd8-8414c4a312b2"}, {"Element": "<span lang=\"EN-GB\">Endophthalmitis.</span>", "ID": "f389be73-80e0-4735-8bac-1c332a8cb94a", "Styles": "None", "Classes": "None", "Text": "Endophthalmitis.", "ParentId": "58408b3a-da5e-4502-a2fb-b46323844243"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Transient visual loss occurring during or\n  within 2\u00a0hours of infusion.</span></p>\n</td>\n</tr>", "ID": "5faac551-50a2-4f19-b272-5416d99e5032", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>", "ID": "89065c8c-3ead-4394-b49e-eb1965ad32e9", "Styles": "width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5faac551-50a2-4f19-b272-5416d99e5032"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>", "ID": "1ff7e8e4-e72f-4889-ade0-abbc0e16fa57", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "89065c8c-3ead-4394-b49e-eb1965ad32e9"}, {"Element": "<span lang=\"EN-GB\">Not\n  known:</span>", "ID": "a23b39e5-4921-4972-a7b1-199e905792c2", "Styles": "None", "Classes": "None", "Text": "Not   known:", "ParentId": "1ff7e8e4-e72f-4889-ade0-abbc0e16fa57"}, {"Element": "<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Transient visual loss occurring during or\n  within 2\u00a0hours of infusion.</span></p>\n</td>", "ID": "4b8d4b78-86f6-4534-8263-d5d654f473d4", "Styles": "width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5faac551-50a2-4f19-b272-5416d99e5032"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Transient visual loss occurring during or\n  within 2\u00a0hours of infusion.</span></p>", "ID": "9eb44e5d-028e-4e56-a423-630983af0de4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4b8d4b78-86f6-4534-8263-d5d654f473d4"}, {"Element": "<span lang=\"EN-GB\">Transient visual loss occurring during or\n  within 2\u00a0hours of infusion.</span>", "ID": "6f92c7fc-a1fd-4c63-aef2-bcd7ae0687d6", "Styles": "None", "Classes": "None", "Text": "Transient visual loss occurring during or   within 2\u00a0hours of infusion.", "ParentId": "9eb44e5d-028e-4e56-a423-630983af0de4"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Cardiac disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "55eb3dd3-df50-4ee8-bd3a-53ccb6b51486", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Cardiac disorders</span></p>\n</td>", "ID": "ffbd3563-b46d-451d-aeab-d3268b5d4fbc", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "55eb3dd3-df50-4ee8-bd3a-53ccb6b51486"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Cardiac disorders</span></p>", "ID": "eea37c07-f723-4141-9472-444a77458aa4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ffbd3563-b46d-451d-aeab-d3268b5d4fbc"}, {"Element": "<span lang=\"EN-GB\">Cardiac disorders</span>", "ID": "4df12567-ab35-4cae-a5a3-214735a44c08", "Styles": "None", "Classes": "None", "Text": "Cardiac disorders", "ParentId": "eea37c07-f723-4141-9472-444a77458aa4"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "36765024-c952-40a1-ab82-75c5f07fc06c", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "55eb3dd3-df50-4ee8-bd3a-53ccb6b51486"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "698de4ac-b31b-4c09-b765-afd1872bcdfe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "36765024-c952-40a1-ab82-75c5f07fc06c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c111b8f7-94dd-4c32-9b7b-736127f13398", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "698de4ac-b31b-4c09-b765-afd1872bcdfe"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tachycardia, palpitation.</span></p>\n</td>\n</tr>", "ID": "16f0a0f2-0242-42c3-9893-79ca50e808dc", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "ac3a2420-b8f0-41ea-959c-48e570a3f15e", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "16f0a0f2-0242-42c3-9893-79ca50e808dc"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "4866d4cc-feca-46b5-814c-c55833a86ddf", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ac3a2420-b8f0-41ea-959c-48e570a3f15e"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "a7e0515e-a529-4084-88db-c781acc6d1f9", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "4866d4cc-feca-46b5-814c-c55833a86ddf"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tachycardia, palpitation.</span></p>\n</td>", "ID": "f0bfb2b1-33a9-4b50-b9c4-bed0efcb1cd9", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "16f0a0f2-0242-42c3-9893-79ca50e808dc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tachycardia, palpitation.</span></p>", "ID": "03d579c5-6ae0-460d-9f0a-259f8206f983", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f0bfb2b1-33a9-4b50-b9c4-bed0efcb1cd9"}, {"Element": "<span lang=\"EN-GB\">Tachycardia, palpitation.</span>", "ID": "a197c647-49d2-4f0e-a229-f0dcbfa30936", "Styles": "None", "Classes": "None", "Text": "Tachycardia, palpitation.", "ParentId": "03d579c5-6ae0-460d-9f0a-259f8206f983"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cardiac failure (new onset or worsening),\n  arrhythmia, syncope, bradycardia.</span></p>\n</td>\n</tr>", "ID": "3a65db97-2f33-4b04-b349-b0fd9dc85018", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "57330da8-e977-4fbe-a32d-b2d5c33cc58e", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3a65db97-2f33-4b04-b349-b0fd9dc85018"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "c4d31126-7e47-4182-874a-04365f34ddee", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "57330da8-e977-4fbe-a32d-b2d5c33cc58e"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "83f581f6-2677-43c6-be72-940cc7c91518", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "c4d31126-7e47-4182-874a-04365f34ddee"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cardiac failure (new onset or worsening),\n  arrhythmia, syncope, bradycardia.</span></p>\n</td>", "ID": "30cab3c2-a84f-4591-a9b1-6db7e65b83e1", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3a65db97-2f33-4b04-b349-b0fd9dc85018"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cardiac failure (new onset or worsening),\n  arrhythmia, syncope, bradycardia.</span></p>", "ID": "65ba05c9-8404-489b-80b9-256f110229e6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "30cab3c2-a84f-4591-a9b1-6db7e65b83e1"}, {"Element": "<span lang=\"EN-GB\">Cardiac failure (new onset or worsening),\n  arrhythmia, syncope, bradycardia.</span>", "ID": "64da04ba-ebc8-440a-b5af-61892323d70d", "Styles": "None", "Classes": "None", "Text": "Cardiac failure (new onset or worsening),   arrhythmia, syncope, bradycardia.", "ParentId": "65ba05c9-8404-489b-80b9-256f110229e6"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cyanosis, pericardial effusion.</span></p>\n</td>\n</tr>", "ID": "8e9d7834-c7bc-4d18-97bf-b958e7198095", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "0772f5cc-34f3-45ce-8648-149787e4f3b4", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8e9d7834-c7bc-4d18-97bf-b958e7198095"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "237598ca-d026-4b3d-9342-c6a41bcc13d7", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0772f5cc-34f3-45ce-8648-149787e4f3b4"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "0c37e7ff-51bb-4571-acce-ed940e53b598", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "237598ca-d026-4b3d-9342-c6a41bcc13d7"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cyanosis, pericardial effusion.</span></p>\n</td>", "ID": "5a3b4a37-c0e7-473a-aa7d-b3c164450081", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8e9d7834-c7bc-4d18-97bf-b958e7198095"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cyanosis, pericardial effusion.</span></p>", "ID": "e9df0cb1-54cc-4fac-b491-7d12da7dc1a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5a3b4a37-c0e7-473a-aa7d-b3c164450081"}, {"Element": "<span lang=\"EN-GB\">Cyanosis, pericardial effusion.</span>", "ID": "afa85826-e814-4e61-a5d4-3822af5623d7", "Styles": "None", "Classes": "None", "Text": "Cyanosis, pericardial effusion.", "ParentId": "e9df0cb1-54cc-4fac-b491-7d12da7dc1a7"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Myocardial ischaemia/myocardial\n  infarction</span><span lang=\"EN-GB\">.</span></p>\n</td>\n</tr>", "ID": "d6cc7624-e433-44a2-a639-51c23eb4457f", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>", "ID": "dfbd912e-f88e-49cc-8c4e-2a7aa7548362", "Styles": "width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d6cc7624-e433-44a2-a639-51c23eb4457f"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>", "ID": "06f1f0ef-5245-4bdf-959b-d9d572e4e518", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dfbd912e-f88e-49cc-8c4e-2a7aa7548362"}, {"Element": "<span lang=\"EN-GB\">Not\n  known:</span>", "ID": "3932de89-56e9-4201-94a1-63f8ac0f70f9", "Styles": "None", "Classes": "None", "Text": "Not   known:", "ParentId": "06f1f0ef-5245-4bdf-959b-d9d572e4e518"}, {"Element": "<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Myocardial ischaemia/myocardial\n  infarction</span><span lang=\"EN-GB\">.</span></p>\n</td>", "ID": "06a3caa9-f9a9-488a-bbb8-7ab883cb1c54", "Styles": "width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d6cc7624-e433-44a2-a639-51c23eb4457f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Myocardial ischaemia/myocardial\n  infarction</span><span lang=\"EN-GB\">.</span></p>", "ID": "6e55c146-7b6e-4887-8149-f8e59b73dd6e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "06a3caa9-f9a9-488a-bbb8-7ab883cb1c54"}, {"Element": "<span lang=\"EN-GB\">Myocardial ischaemia/myocardial\n  infarction</span>", "ID": "54afcbb5-adb1-42dd-99f3-bf624345de7a", "Styles": "None", "Classes": "None", "Text": "Myocardial ischaemia/myocardial   infarction", "ParentId": "6e55c146-7b6e-4887-8149-f8e59b73dd6e"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "0f6ecc09-6804-4690-9542-a0e307cc2b4b", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "6e55c146-7b6e-4887-8149-f8e59b73dd6e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vascular\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "37679447-45c8-4b20-a85a-ee74760c3989", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vascular\n  disorders</span></p>\n</td>", "ID": "6219e4af-d937-442d-86f0-19d459b106af", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "37679447-45c8-4b20-a85a-ee74760c3989"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Vascular\n  disorders</span></p>", "ID": "92e22c82-24c0-4457-ab93-c89b4b43bf45", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6219e4af-d937-442d-86f0-19d459b106af"}, {"Element": "<span lang=\"EN-GB\">Vascular\n  disorders</span>", "ID": "3164e5c8-8c70-4b5a-8e15-df2801f3e077", "Styles": "None", "Classes": "None", "Text": "Vascular   disorders", "ParentId": "92e22c82-24c0-4457-ab93-c89b4b43bf45"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "c06a6715-d009-4639-b007-c2a5ae1c0630", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "37679447-45c8-4b20-a85a-ee74760c3989"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5d8819e6-1687-4ab5-98c2-2c23d38ad872", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c06a6715-d009-4639-b007-c2a5ae1c0630"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ddbc1b20-7655-4ab2-ad45-1271be11eccb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5d8819e6-1687-4ab5-98c2-2c23d38ad872"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypotension, hypertension, ecchymosis,\n  hot flush, flushing.</span></p>\n</td>\n</tr>", "ID": "684fc997-a3db-416d-a184-fa7719956a93", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "0aede621-4b29-4a47-a010-175adf46b0b5", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "684fc997-a3db-416d-a184-fa7719956a93"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "8f11c3a9-3c48-4d9e-a641-1893552e5d89", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0aede621-4b29-4a47-a010-175adf46b0b5"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "1978c911-333d-482b-801a-12ae31926003", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "8f11c3a9-3c48-4d9e-a641-1893552e5d89"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypotension, hypertension, ecchymosis,\n  hot flush, flushing.</span></p>\n</td>", "ID": "2da047c0-2bda-4462-9837-afc7978ae9d2", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "684fc997-a3db-416d-a184-fa7719956a93"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hypotension, hypertension, ecchymosis,\n  hot flush, flushing.</span></p>", "ID": "cd0aa5d9-b70e-4dec-8664-d39837afc0d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2da047c0-2bda-4462-9837-afc7978ae9d2"}, {"Element": "<span lang=\"EN-GB\">Hypotension, hypertension, ecchymosis,\n  hot flush, flushing.</span>", "ID": "e5492cad-a524-4805-a19c-284c3b3e18aa", "Styles": "None", "Classes": "None", "Text": "Hypotension, hypertension, ecchymosis,   hot flush, flushing.", "ParentId": "cd0aa5d9-b70e-4dec-8664-d39837afc0d4"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Peripheral ischaemia, thrombophlebitis,\n  haematoma.</span></p>\n</td>\n</tr>", "ID": "3677bcda-faf0-4a90-8f72-87a96570b644", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "829f039b-721a-4412-b59d-5b31ef3086c7", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3677bcda-faf0-4a90-8f72-87a96570b644"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "183e50fa-5aa6-410b-918c-fe2da81ea1d9", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "829f039b-721a-4412-b59d-5b31ef3086c7"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "ce1badf4-f1e4-411a-83d3-43107fef7e1e", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "183e50fa-5aa6-410b-918c-fe2da81ea1d9"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Peripheral ischaemia, thrombophlebitis,\n  haematoma.</span></p>\n</td>", "ID": "d0b952c4-ef81-4238-a1f1-c3ea49c9ef78", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3677bcda-faf0-4a90-8f72-87a96570b644"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Peripheral ischaemia, thrombophlebitis,\n  haematoma.</span></p>", "ID": "7625b0dd-9c31-45cc-8d81-4721b9fec2fb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d0b952c4-ef81-4238-a1f1-c3ea49c9ef78"}, {"Element": "<span lang=\"EN-GB\">Peripheral ischaemia, thrombophlebitis,\n  haematoma.</span>", "ID": "f6bd7b27-3f9b-4a2d-aaa8-8f212b07ab75", "Styles": "None", "Classes": "None", "Text": "Peripheral ischaemia, thrombophlebitis,   haematoma.", "ParentId": "7625b0dd-9c31-45cc-8d81-4721b9fec2fb"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Circulatory failure, petechia, vasospasm.</span></p>\n</td>\n</tr>", "ID": "f8060375-4da9-4bd3-b319-0812494e1ace", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "51e710e0-afae-41d9-a122-9890f953ba7d", "Styles": "width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f8060375-4da9-4bd3-b319-0812494e1ace"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "a5ddd32d-b749-423e-be9f-5c01d654a3a6", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "51e710e0-afae-41d9-a122-9890f953ba7d"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "b99fc4fb-cc7c-463c-8574-f109c643aae6", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "a5ddd32d-b749-423e-be9f-5c01d654a3a6"}, {"Element": "<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Circulatory failure, petechia, vasospasm.</span></p>\n</td>", "ID": "c48e4a9a-fbfd-4e22-a958-0c877725bdd9", "Styles": "width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f8060375-4da9-4bd3-b319-0812494e1ace"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Circulatory failure, petechia, vasospasm.</span></p>", "ID": "06fb4874-07c2-4012-b3c8-b7a113ddbd70", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c48e4a9a-fbfd-4e22-a958-0c877725bdd9"}, {"Element": "<span lang=\"EN-GB\">Circulatory failure, petechia, vasospasm.</span>", "ID": "d90165a3-c3f7-42cc-becc-89b24f2a38f7", "Styles": "None", "Classes": "None", "Text": "Circulatory failure, petechia, vasospasm.", "ParentId": "06fb4874-07c2-4012-b3c8-b7a113ddbd70"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Respiratory,\n  thoracic and mediastinal disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "2dd2b773-47fe-4255-b80c-4268062e210a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Respiratory,\n  thoracic and mediastinal disorders</span></p>\n</td>", "ID": "a4bd45eb-3c64-4fc4-b219-333f0606199b", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2dd2b773-47fe-4255-b80c-4268062e210a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Respiratory,\n  thoracic and mediastinal disorders</span></p>", "ID": "e979efff-8f36-47af-b2b9-5129f6920dd9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a4bd45eb-3c64-4fc4-b219-333f0606199b"}, {"Element": "<span lang=\"EN-GB\">Respiratory,\n  thoracic and mediastinal disorders</span>", "ID": "d5c789b4-40ee-4988-b276-db90740c5d3a", "Styles": "None", "Classes": "None", "Text": "Respiratory,   thoracic and mediastinal disorders", "ParentId": "e979efff-8f36-47af-b2b9-5129f6920dd9"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "337796c9-6875-452e-99ee-30f40dfe1b0a", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2dd2b773-47fe-4255-b80c-4268062e210a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f8a003f9-659d-47f0-b133-e150eed35663", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "337796c9-6875-452e-99ee-30f40dfe1b0a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "50707e4f-e3c7-4166-ac91-b3f3700418e1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f8a003f9-659d-47f0-b133-e150eed35663"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Upper respiratory tract infection, sinusitis.</span></p>\n</td>\n</tr>", "ID": "1dfc41a0-005e-442e-aecd-fa0f98e943ca", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>", "ID": "c1aeb3ec-4591-4bc5-90b3-e2f3ec6bf52b", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1dfc41a0-005e-442e-aecd-fa0f98e943ca"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>", "ID": "cb86196a-358e-46fb-9a00-c0bb69dfd205", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c1aeb3ec-4591-4bc5-90b3-e2f3ec6bf52b"}, {"Element": "<span lang=\"EN-GB\">Very\n  common:</span>", "ID": "804e1ecb-0f5a-4b1d-b55a-23c636ee5773", "Styles": "None", "Classes": "None", "Text": "Very   common:", "ParentId": "cb86196a-358e-46fb-9a00-c0bb69dfd205"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Upper respiratory tract infection, sinusitis.</span></p>\n</td>", "ID": "58da505e-ea18-49b5-aecb-0ba956724aa3", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1dfc41a0-005e-442e-aecd-fa0f98e943ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Upper respiratory tract infection, sinusitis.</span></p>", "ID": "3025feb5-86cd-458f-bb22-48ac0a0451b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "58da505e-ea18-49b5-aecb-0ba956724aa3"}, {"Element": "<span lang=\"EN-GB\">Upper respiratory tract infection, sinusitis.</span>", "ID": "483e8dd4-3f76-4b3f-ac8a-beb87fd6a11e", "Styles": "None", "Classes": "None", "Text": "Upper respiratory tract infection, sinusitis.", "ParentId": "3025feb5-86cd-458f-bb22-48ac0a0451b8"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lower respiratory tract infection (e.g.\n  bronchitis, pneumonia), dyspnoea, epistaxis.</span></p>\n</td>\n</tr>", "ID": "75c888c0-2407-4453-9374-590b3cb0ee12", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "ad8de21e-77a2-4a37-be85-cb2fb56d0347", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "75c888c0-2407-4453-9374-590b3cb0ee12"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "e1d1c53d-92ca-44e4-a70a-d13129b50879", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ad8de21e-77a2-4a37-be85-cb2fb56d0347"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "90bd3169-2f62-44b4-93ba-a2f699afc995", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "e1d1c53d-92ca-44e4-a70a-d13129b50879"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lower respiratory tract infection (e.g.\n  bronchitis, pneumonia), dyspnoea, epistaxis.</span></p>\n</td>", "ID": "ba65cf9b-8222-434c-a18e-197ae4551fa7", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "75c888c0-2407-4453-9374-590b3cb0ee12"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lower respiratory tract infection (e.g.\n  bronchitis, pneumonia), dyspnoea, epistaxis.</span></p>", "ID": "21c6fe98-92d4-427b-8f9c-f4764b658bbc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ba65cf9b-8222-434c-a18e-197ae4551fa7"}, {"Element": "<span lang=\"EN-GB\">Lower respiratory tract infection (e.g.\n  bronchitis, pneumonia), dyspnoea, epistaxis.</span>", "ID": "89a57ff2-5d4b-456b-8c40-72dcef9d4bab", "Styles": "None", "Classes": "None", "Text": "Lower respiratory tract infection (e.g.   bronchitis, pneumonia), dyspnoea, epistaxis.", "ParentId": "21c6fe98-92d4-427b-8f9c-f4764b658bbc"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pulmonary oedema, bronchospasm, pleurisy,\n  pleural effusion.</span></p>\n</td>\n</tr>", "ID": "63f80316-ecd8-414b-83b7-a0405e63d559", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "df00f5ea-eb70-41be-b48a-df18fa74d601", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "63f80316-ecd8-414b-83b7-a0405e63d559"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "f3ecf670-6221-41ea-ae30-be43b9f5cd83", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "df00f5ea-eb70-41be-b48a-df18fa74d601"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "7539bc67-2f51-41a8-baf8-4d2b0413c777", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "f3ecf670-6221-41ea-ae30-be43b9f5cd83"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pulmonary oedema, bronchospasm, pleurisy,\n  pleural effusion.</span></p>\n</td>", "ID": "e81597c8-7d3a-4795-9ed8-b0811447ecb2", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "63f80316-ecd8-414b-83b7-a0405e63d559"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pulmonary oedema, bronchospasm, pleurisy,\n  pleural effusion.</span></p>", "ID": "834bbdde-424b-4a3b-bd64-4f71d5ad79f9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e81597c8-7d3a-4795-9ed8-b0811447ecb2"}, {"Element": "<span lang=\"EN-GB\">Pulmonary oedema, bronchospasm, pleurisy,\n  pleural effusion.</span>", "ID": "c19cc39e-966d-42f3-a093-3438595becab", "Styles": "None", "Classes": "None", "Text": "Pulmonary oedema, bronchospasm, pleurisy,   pleural effusion.", "ParentId": "834bbdde-424b-4a3b-bd64-4f71d5ad79f9"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Interstitial lung disease (including\n  rapidly progressive disease, lung fibrosis and pneumonitis).</span></p>\n</td>\n</tr>", "ID": "31655617-07b8-4c58-aab8-fb6fe8922116", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "9e58926f-a964-4ed2-a545-142f326080af", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "31655617-07b8-4c58-aab8-fb6fe8922116"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "2aaf6628-4f50-4b5a-af20-087a668f1e37", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e58926f-a964-4ed2-a545-142f326080af"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "3a83246a-93ed-47fc-8412-7514d50df1a1", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "2aaf6628-4f50-4b5a-af20-087a668f1e37"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Interstitial lung disease (including\n  rapidly progressive disease, lung fibrosis and pneumonitis).</span></p>\n</td>", "ID": "da8b3620-3e63-499c-b4a5-8eb189f4b90a", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "31655617-07b8-4c58-aab8-fb6fe8922116"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Interstitial lung disease (including\n  rapidly progressive disease, lung fibrosis and pneumonitis).</span></p>", "ID": "39f8da44-b6a9-4bb8-88e2-8393c2413b6a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da8b3620-3e63-499c-b4a5-8eb189f4b90a"}, {"Element": "<span lang=\"EN-GB\">Interstitial lung disease (including\n  rapidly progressive disease, lung fibrosis and pneumonitis).</span>", "ID": "330846c0-3573-41c5-8978-290956d20956", "Styles": "None", "Classes": "None", "Text": "Interstitial lung disease (including   rapidly progressive disease, lung fibrosis and pneumonitis).", "ParentId": "39f8da44-b6a9-4bb8-88e2-8393c2413b6a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Gastrointestinal\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "eaeeab35-a709-43d3-8ce4-8be3d14db546", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Gastrointestinal\n  disorders</span></p>\n</td>", "ID": "767ef0b6-0b64-456a-a0d7-e864ccc6a7a2", "Styles": "width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eaeeab35-a709-43d3-8ce4-8be3d14db546"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Gastrointestinal\n  disorders</span></p>", "ID": "daa2335d-b20a-4d6d-a008-98ebc9b82c05", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "767ef0b6-0b64-456a-a0d7-e864ccc6a7a2"}, {"Element": "<span lang=\"EN-GB\">Gastrointestinal\n  disorders</span>", "ID": "d975ce34-5930-4f82-8c2f-4186854bac52", "Styles": "None", "Classes": "None", "Text": "Gastrointestinal   disorders", "ParentId": "daa2335d-b20a-4d6d-a008-98ebc9b82c05"}, {"Element": "<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "12ff9525-8070-45f2-b9dd-b90d0cde6500", "Styles": "width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eaeeab35-a709-43d3-8ce4-8be3d14db546"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8884effa-6c58-4aab-ae4a-3d836e84e70e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "12ff9525-8070-45f2-b9dd-b90d0cde6500"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7e01f702-2f7b-4275-a486-55c95db7e5a4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8884effa-6c58-4aab-ae4a-3d836e84e70e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Abdominal pain, nausea.</span></p>\n</td>\n</tr>", "ID": "0e029e3b-c3c6-4953-9b45-4222e13b3245", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>", "ID": "02840c03-2bc8-44e9-9ea5-fd822e335d24", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0e029e3b-c3c6-4953-9b45-4222e13b3245"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>", "ID": "f29f741c-10fc-42d8-be3a-0e25995f3974", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "02840c03-2bc8-44e9-9ea5-fd822e335d24"}, {"Element": "<span lang=\"EN-GB\">Very\n  common:</span>", "ID": "9a864add-35ab-4f8a-b393-321949ef3cfb", "Styles": "None", "Classes": "None", "Text": "Very   common:", "ParentId": "f29f741c-10fc-42d8-be3a-0e25995f3974"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Abdominal pain, nausea.</span></p>\n</td>", "ID": "3cdf2b95-b2bf-4a31-8d2d-db5ae95bb31e", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0e029e3b-c3c6-4953-9b45-4222e13b3245"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Abdominal pain, nausea.</span></p>", "ID": "062e7186-1762-4688-afae-b5f42a7b1458", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3cdf2b95-b2bf-4a31-8d2d-db5ae95bb31e"}, {"Element": "<span lang=\"EN-GB\">Abdominal pain, nausea.</span>", "ID": "865d54bd-ef91-4963-8b43-f2c896c4125d", "Styles": "None", "Classes": "None", "Text": "Abdominal pain, nausea.", "ParentId": "062e7186-1762-4688-afae-b5f42a7b1458"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gastrointestinal haemorrhage, diarrhoea,\n  dyspepsia, gastroesophageal reflux, constipation.</span></p>\n</td>\n</tr>", "ID": "f382d6de-d6fa-4abe-94c8-6ae34a8aef09", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "a6b4cb05-f33b-40a3-8013-d616fb68289a", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f382d6de-d6fa-4abe-94c8-6ae34a8aef09"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "81fadf25-fbb8-4280-b0fa-2c550f1819d0", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a6b4cb05-f33b-40a3-8013-d616fb68289a"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "058823b1-c6fe-4401-b671-564f722c6dab", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "81fadf25-fbb8-4280-b0fa-2c550f1819d0"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gastrointestinal haemorrhage, diarrhoea,\n  dyspepsia, gastroesophageal reflux, constipation.</span></p>\n</td>", "ID": "799dc9a3-f3b3-465d-8431-9a0422eafbb6", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f382d6de-d6fa-4abe-94c8-6ae34a8aef09"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Gastrointestinal haemorrhage, diarrhoea,\n  dyspepsia, gastroesophageal reflux, constipation.</span></p>", "ID": "c4a25a25-e985-4f17-8840-f158393caa48", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "799dc9a3-f3b3-465d-8431-9a0422eafbb6"}, {"Element": "<span lang=\"EN-GB\">Gastrointestinal haemorrhage, diarrhoea,\n  dyspepsia, gastroesophageal reflux, constipation.</span>", "ID": "80f84f5d-a4d9-47c9-b182-0d89d1c6add1", "Styles": "None", "Classes": "None", "Text": "Gastrointestinal haemorrhage, diarrhoea,   dyspepsia, gastroesophageal reflux, constipation.", "ParentId": "c4a25a25-e985-4f17-8840-f158393caa48"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intestinal perforation, intestinal stenosis,\n  diverticulitis, pancreatitis, cheilitis.</span></p>\n</td>\n</tr>", "ID": "83cd60c4-a851-46e2-b7f1-c68707339da5", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "2be714e7-5d90-429c-a016-c73dc7c3ebb9", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "83cd60c4-a851-46e2-b7f1-c68707339da5"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "b5c185eb-d605-4021-bb98-99f9c79df433", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2be714e7-5d90-429c-a016-c73dc7c3ebb9"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "d2d6a0b4-359c-4acc-9438-2243d070bcf2", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "b5c185eb-d605-4021-bb98-99f9c79df433"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intestinal perforation, intestinal stenosis,\n  diverticulitis, pancreatitis, cheilitis.</span></p>\n</td>", "ID": "fc9054f9-c417-46c8-9179-4028b82bc187", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "83cd60c4-a851-46e2-b7f1-c68707339da5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Intestinal perforation, intestinal stenosis,\n  diverticulitis, pancreatitis, cheilitis.</span></p>", "ID": "a7106afd-e63f-4c92-9a88-8054d96a918f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fc9054f9-c417-46c8-9179-4028b82bc187"}, {"Element": "<span lang=\"EN-GB\">Intestinal perforation, intestinal stenosis,\n  diverticulitis, pancreatitis, cheilitis.</span>", "ID": "e503c0a3-4e53-428f-bc32-e175b95e5577", "Styles": "None", "Classes": "None", "Text": "Intestinal perforation, intestinal stenosis,   diverticulitis, pancreatitis, cheilitis.", "ParentId": "a7106afd-e63f-4c92-9a88-8054d96a918f"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatobiliary\n  disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "5a4ea3dc-7a34-4a83-8d93-b33f6a6bab26", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatobiliary\n  disorders</span></p>\n</td>", "ID": "769ca87d-0180-4fad-b724-66241f41d536", "Styles": "width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5a4ea3dc-7a34-4a83-8d93-b33f6a6bab26"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hepatobiliary\n  disorders</span></p>", "ID": "212d2bc7-6ba9-48bb-b7c3-457570ee42ea", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "769ca87d-0180-4fad-b724-66241f41d536"}, {"Element": "<span lang=\"EN-GB\">Hepatobiliary\n  disorders</span>", "ID": "210939ac-ab70-457c-a1d8-251324248af9", "Styles": "None", "Classes": "None", "Text": "Hepatobiliary   disorders", "ParentId": "212d2bc7-6ba9-48bb-b7c3-457570ee42ea"}, {"Element": "<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "ebb75092-3aff-4216-810a-f2ac4ba3b25d", "Styles": "width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5a4ea3dc-7a34-4a83-8d93-b33f6a6bab26"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "936996e2-7e36-4a05-9abd-985f8eae0def", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ebb75092-3aff-4216-810a-f2ac4ba3b25d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0d6f4b6b-5df2-4080-babb-35d620d02ed8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "936996e2-7e36-4a05-9abd-985f8eae0def"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatic function abnormal, transaminases\n  increased.</span></p>\n</td>\n</tr>", "ID": "3479100f-bfd9-446e-95f4-eb09732f353b", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "c5beea2a-8a29-4a92-a50e-a456229e6cd0", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3479100f-bfd9-446e-95f4-eb09732f353b"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "6445d44c-4350-469f-8429-06c38ca246b0", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c5beea2a-8a29-4a92-a50e-a456229e6cd0"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "2cef1e8b-fcb2-4230-bad2-c4fff9733da5", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "6445d44c-4350-469f-8429-06c38ca246b0"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatic function abnormal, transaminases\n  increased.</span></p>\n</td>", "ID": "abc2e373-a3d2-4e12-8f36-77598ae82f4c", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3479100f-bfd9-446e-95f4-eb09732f353b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatic function abnormal, transaminases\n  increased.</span></p>", "ID": "6da99343-7d61-4224-ad12-eece89e27086", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "abc2e373-a3d2-4e12-8f36-77598ae82f4c"}, {"Element": "<span lang=\"EN-GB\">Hepatic function abnormal, transaminases\n  increased.</span>", "ID": "03b24f50-c498-4628-baf7-14cd005e2288", "Styles": "None", "Classes": "None", "Text": "Hepatic function abnormal, transaminases   increased.", "ParentId": "6da99343-7d61-4224-ad12-eece89e27086"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatitis, hepatocellular damage,\n  cholecystitis.</span></p>\n</td>\n</tr>", "ID": "9bcb2740-05ba-4762-970d-fe4bfd2ab02b", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "7304e369-5ed2-42a2-bb85-f232e6f92afb", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9bcb2740-05ba-4762-970d-fe4bfd2ab02b"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "1f242c78-2fd9-4e9c-84af-4122e0c51276", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7304e369-5ed2-42a2-bb85-f232e6f92afb"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "915d5d2e-32c2-475f-a720-774c8b9979fa", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "1f242c78-2fd9-4e9c-84af-4122e0c51276"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatitis, hepatocellular damage,\n  cholecystitis.</span></p>\n</td>", "ID": "93099cab-ec20-4b80-a2f0-f1c797234732", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9bcb2740-05ba-4762-970d-fe4bfd2ab02b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Hepatitis, hepatocellular damage,\n  cholecystitis.</span></p>", "ID": "de7e10cd-0710-4860-bd61-7ee2e9ccf99d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "93099cab-ec20-4b80-a2f0-f1c797234732"}, {"Element": "<span lang=\"EN-GB\">Hepatitis, hepatocellular damage,\n  cholecystitis.</span>", "ID": "dd95307b-ffc6-4206-afea-99f3075b5cba", "Styles": "None", "Classes": "None", "Text": "Hepatitis, hepatocellular damage,   cholecystitis.", "ParentId": "de7e10cd-0710-4860-bd61-7ee2e9ccf99d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoimmune hepatitis, jaundice.</span></p>\n</td>\n</tr>", "ID": "d68a9155-a29a-460a-a882-c0b12078f020", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "54a9e659-6aec-4580-9023-23c6a61ddc8f", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d68a9155-a29a-460a-a882-c0b12078f020"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "efbae7c1-9be6-4911-adb2-45ff385224d5", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "54a9e659-6aec-4580-9023-23c6a61ddc8f"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "5e0f1766-b47e-4c99-bea8-a46f72941e63", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "efbae7c1-9be6-4911-adb2-45ff385224d5"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoimmune hepatitis, jaundice.</span></p>\n</td>", "ID": "3e41cb2d-b968-47c3-b733-0fd9a621f6cb", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d68a9155-a29a-460a-a882-c0b12078f020"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoimmune hepatitis, jaundice.</span></p>", "ID": "5ca03396-f9a6-4945-b579-430e1c85a9c9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3e41cb2d-b968-47c3-b733-0fd9a621f6cb"}, {"Element": "<span lang=\"EN-GB\">Autoimmune hepatitis, jaundice.</span>", "ID": "0422b0b9-0fa5-433b-9d91-1d6797861ac0", "Styles": "None", "Classes": "None", "Text": "Autoimmune hepatitis, jaundice.", "ParentId": "5ca03396-f9a6-4945-b579-430e1c85a9c9"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Liver failure.</span></p>\n</td>\n</tr>", "ID": "2b3277ca-8cc6-453d-a77a-5ccfe3440897", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>", "ID": "bc2a8b31-6acf-4247-8ad2-c177dff68ae3", "Styles": "width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2b3277ca-8cc6-453d-a77a-5ccfe3440897"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>", "ID": "a8c8b4b7-2552-4077-b227-0346975903da", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bc2a8b31-6acf-4247-8ad2-c177dff68ae3"}, {"Element": "<span lang=\"EN-GB\">Not\n  known:</span>", "ID": "72228ff2-8148-420f-8619-54c21c2f4126", "Styles": "None", "Classes": "None", "Text": "Not   known:", "ParentId": "a8c8b4b7-2552-4077-b227-0346975903da"}, {"Element": "<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Liver failure.</span></p>\n</td>", "ID": "efa0a889-540d-4ea1-9ede-c175f78a4bd5", "Styles": "width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2b3277ca-8cc6-453d-a77a-5ccfe3440897"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Liver failure.</span></p>", "ID": "2dbf7007-d4ad-4000-aa7a-159765f44a37", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "efa0a889-540d-4ea1-9ede-c175f78a4bd5"}, {"Element": "<span lang=\"EN-GB\">Liver failure.</span>", "ID": "0355bd5f-fd1f-4266-b90c-8cfb44cfcaba", "Styles": "None", "Classes": "None", "Text": "Liver failure.", "ParentId": "2dbf7007-d4ad-4000-aa7a-159765f44a37"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Skin and subcutaneous\n  tissue disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "b5a6e2d0-4905-4349-97d3-561fd055ca57", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Skin and subcutaneous\n  tissue disorders</span></p>\n</td>", "ID": "761bc6d2-ef74-4843-9ad5-43d91d2e7ce4", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b5a6e2d0-4905-4349-97d3-561fd055ca57"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Skin and subcutaneous\n  tissue disorders</span></p>", "ID": "ed40ad22-b07d-49a5-8ae9-25936ea89d58", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "761bc6d2-ef74-4843-9ad5-43d91d2e7ce4"}, {"Element": "<span lang=\"EN-GB\">Skin and subcutaneous\n  tissue disorders</span>", "ID": "3712ef47-cf57-4538-8b08-69def081bb20", "Styles": "None", "Classes": "None", "Text": "Skin and subcutaneous   tissue disorders", "ParentId": "ed40ad22-b07d-49a5-8ae9-25936ea89d58"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "44e5c0f9-63ce-464a-b91b-159a7833a3f6", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b5a6e2d0-4905-4349-97d3-561fd055ca57"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5b4593da-0a96-4dfd-ba96-7f13cc310aa1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "44e5c0f9-63ce-464a-b91b-159a7833a3f6"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0e2c24ec-9f83-45d6-9087-9dd1c7eb36c0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5b4593da-0a96-4dfd-ba96-7f13cc310aa1"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">New onset or worsening psoriasis\n  including pustular psoriasis (primarily palm &amp; soles), urticaria, rash,\n  pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.</span></p>\n</td>\n</tr>", "ID": "db7272c0-6536-40a3-8360-65ab040da85c", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "02fdd992-5c3c-4500-9aa5-81ca60c1066d", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "db7272c0-6536-40a3-8360-65ab040da85c"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "a6fb1839-d1f5-4b0a-b168-211708b12d74", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "02fdd992-5c3c-4500-9aa5-81ca60c1066d"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "ad4c7880-41e7-4bbb-a225-7f218fba877d", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "a6fb1839-d1f5-4b0a-b168-211708b12d74"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">New onset or worsening psoriasis\n  including pustular psoriasis (primarily palm &amp; soles), urticaria, rash,\n  pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.</span></p>\n</td>", "ID": "85a6c8e8-60ed-406a-9611-d8d5b8efb269", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "db7272c0-6536-40a3-8360-65ab040da85c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">New onset or worsening psoriasis\n  including pustular psoriasis (primarily palm &amp; soles), urticaria, rash,\n  pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.</span></p>", "ID": "da28c8be-5979-4a56-b0e1-04f249f1a904", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "85a6c8e8-60ed-406a-9611-d8d5b8efb269"}, {"Element": "<span lang=\"EN-GB\">New onset or worsening psoriasis\n  including pustular psoriasis (primarily palm &amp; soles), urticaria, rash,\n  pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.</span>", "ID": "c15bdad9-07ea-4329-a3cd-9926fb5cc1c9", "Styles": "None", "Classes": "None", "Text": "New onset or worsening psoriasis   including pustular psoriasis (primarily palm & soles), urticaria, rash,   pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.", "ParentId": "da28c8be-5979-4a56-b0e1-04f249f1a904"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bullous eruption, seborrhoea, rosacea,\n  skin papilloma, hyperkeratosis, abnormal skin pigmentation.</span></p>\n</td>\n</tr>", "ID": "224ee307-6af3-4cc8-90b7-68bad8e777a7", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "b0dfa92b-176d-40c9-a4a2-05973e39038b", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "224ee307-6af3-4cc8-90b7-68bad8e777a7"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "f4a23295-0ad1-498f-9c65-be8553c8dbc8", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b0dfa92b-176d-40c9-a4a2-05973e39038b"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "3fe7648c-98a0-4434-bf24-6a471aead464", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "f4a23295-0ad1-498f-9c65-be8553c8dbc8"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bullous eruption, seborrhoea, rosacea,\n  skin papilloma, hyperkeratosis, abnormal skin pigmentation.</span></p>\n</td>", "ID": "31c1e3ba-17c9-4aac-a1bb-9faa010c57a2", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "224ee307-6af3-4cc8-90b7-68bad8e777a7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Bullous eruption, seborrhoea, rosacea,\n  skin papilloma, hyperkeratosis, abnormal skin pigmentation.</span></p>", "ID": "478f9174-16a7-4339-95fc-e77ef2020527", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "31c1e3ba-17c9-4aac-a1bb-9faa010c57a2"}, {"Element": "<span lang=\"EN-GB\">Bullous eruption, seborrhoea, rosacea,\n  skin papilloma, hyperkeratosis, abnormal skin pigmentation.</span>", "ID": "2ffb20b4-e894-4096-96f3-0cb82db7a9c2", "Styles": "None", "Classes": "None", "Text": "Bullous eruption, seborrhoea, rosacea,   skin papilloma, hyperkeratosis, abnormal skin pigmentation.", "ParentId": "478f9174-16a7-4339-95fc-e77ef2020527"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Toxic epidermal necrolysis, Stevens\u2011Johnson\n  Syndrome, erythema multiforme, furunculosis, linear IgA bullous dermatosis\n  (LABD), acute generalised exanthematous pustulosis (AGEP), lichenoid\n  reactions.</span></p>\n</td>\n</tr>", "ID": "7892aed0-4a77-4005-a15d-25856443f998", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "b3098f22-576d-4763-9ce0-58db6288e298", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7892aed0-4a77-4005-a15d-25856443f998"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "e52e93a8-111d-40d8-b48e-aa322ffcda0a", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b3098f22-576d-4763-9ce0-58db6288e298"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "ea4193d2-88d6-4a66-acf1-dd235a947929", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "e52e93a8-111d-40d8-b48e-aa322ffcda0a"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Toxic epidermal necrolysis, Stevens\u2011Johnson\n  Syndrome, erythema multiforme, furunculosis, linear IgA bullous dermatosis\n  (LABD), acute generalised exanthematous pustulosis (AGEP), lichenoid\n  reactions.</span></p>\n</td>", "ID": "a2776b4d-c689-4769-814d-79fe937dbc19", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7892aed0-4a77-4005-a15d-25856443f998"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Toxic epidermal necrolysis, Stevens\u2011Johnson\n  Syndrome, erythema multiforme, furunculosis, linear IgA bullous dermatosis\n  (LABD), acute generalised exanthematous pustulosis (AGEP), lichenoid\n  reactions.</span></p>", "ID": "c5056d1c-f92e-40df-a466-ab7d9bdbbec2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a2776b4d-c689-4769-814d-79fe937dbc19"}, {"Element": "<span lang=\"EN-GB\">Toxic epidermal necrolysis, Stevens\u2011Johnson\n  Syndrome, erythema multiforme, furunculosis, linear IgA bullous dermatosis\n  (LABD), acute generalised exanthematous pustulosis (AGEP), lichenoid\n  reactions.</span>", "ID": "75c2a061-4ef9-484d-8b6a-25b8e357cf0c", "Styles": "None", "Classes": "None", "Text": "Toxic epidermal necrolysis, Stevens\u2011Johnson   Syndrome, erythema multiforme, furunculosis, linear IgA bullous dermatosis   (LABD), acute generalised exanthematous pustulosis (AGEP), lichenoid   reactions.", "ParentId": "c5056d1c-f92e-40df-a466-ab7d9bdbbec2"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Worsening of symptoms of dermatomyositis.</span></p>\n</td>\n</tr>", "ID": "e7d9eaed-0a77-4722-bdf5-9bec9f1cf5ff", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>\n</td>", "ID": "7001040e-f1e8-4bb5-8d7f-8a8822ca75ea", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e7d9eaed-0a77-4722-bdf5-9bec9f1cf5ff"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Not\n  known:</span></p>", "ID": "2c47449e-e24e-4ed9-8328-aa5719de2020", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7001040e-f1e8-4bb5-8d7f-8a8822ca75ea"}, {"Element": "<span lang=\"EN-GB\">Not\n  known:</span>", "ID": "79832ab6-8d41-4bc0-8855-28e858508b40", "Styles": "None", "Classes": "None", "Text": "Not   known:", "ParentId": "2c47449e-e24e-4ed9-8328-aa5719de2020"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Worsening of symptoms of dermatomyositis.</span></p>\n</td>", "ID": "10662960-b580-4b6b-91da-719353d92356", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e7d9eaed-0a77-4722-bdf5-9bec9f1cf5ff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Worsening of symptoms of dermatomyositis.</span></p>", "ID": "2c1c6c09-a77e-4071-92a1-4017752077e7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "10662960-b580-4b6b-91da-719353d92356"}, {"Element": "<span lang=\"EN-GB\">Worsening of symptoms of dermatomyositis.</span>", "ID": "ef1eb362-3803-4e1e-8390-6d9f85f4a114", "Styles": "None", "Classes": "None", "Text": "Worsening of symptoms of dermatomyositis.", "ParentId": "2c1c6c09-a77e-4071-92a1-4017752077e7"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Musculoskeletal\n  and connective tissue disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "6a45ae37-eb1d-4e2f-886c-9e67b2f54f4a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Musculoskeletal\n  and connective tissue disorders</span></p>\n</td>", "ID": "842db970-2137-4d9c-9267-b00cacf5d285", "Styles": "width:162.25pt;border-top:solid windowtext 1.0pt;\n  border-left:solid windowtext 1.0pt;border-bottom:none;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6a45ae37-eb1d-4e2f-886c-9e67b2f54f4a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Musculoskeletal\n  and connective tissue disorders</span></p>", "ID": "f6a526f7-4a8c-4205-9b3b-e856c88b2a72", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "842db970-2137-4d9c-9267-b00cacf5d285"}, {"Element": "<span lang=\"EN-GB\">Musculoskeletal\n  and connective tissue disorders</span>", "ID": "6620e85f-b62b-417a-acd6-5729e498929a", "Styles": "None", "Classes": "None", "Text": "Musculoskeletal   and connective tissue disorders", "ParentId": "f6a526f7-4a8c-4205-9b3b-e856c88b2a72"}, {"Element": "<td style=\"width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "8b1aa0d5-b684-4baf-87a0-b170f0c33224", "Styles": "width:291.35pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6a45ae37-eb1d-4e2f-886c-9e67b2f54f4a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "192e43b5-0e45-4f1e-9077-1a345d32addd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b1aa0d5-b684-4baf-87a0-b170f0c33224"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "97c0c430-5db2-4149-8307-3ce3808eeb22", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "192e43b5-0e45-4f1e-9077-1a345d32addd"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arthralgia, myalgia, back pain.</span></p>\n</td>\n</tr>", "ID": "c92481cf-8ad2-43d9-8a18-73fd11e36aea", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "1e1a4879-d584-4cac-b012-8a2a3ad7720f", "Styles": "width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c92481cf-8ad2-43d9-8a18-73fd11e36aea"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "7c0fc878-e8a9-4e04-945c-7d2d0b2a32b8", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1e1a4879-d584-4cac-b012-8a2a3ad7720f"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "d7684e0d-5226-4464-91f1-ce1f0ccd2e83", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "7c0fc878-e8a9-4e04-945c-7d2d0b2a32b8"}, {"Element": "<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arthralgia, myalgia, back pain.</span></p>\n</td>", "ID": "4164e122-51f5-4bf2-a31f-0833897c3247", "Styles": "width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c92481cf-8ad2-43d9-8a18-73fd11e36aea"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Arthralgia, myalgia, back pain.</span></p>", "ID": "00960d78-6330-4bdb-844a-c2f999960959", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4164e122-51f5-4bf2-a31f-0833897c3247"}, {"Element": "<span lang=\"EN-GB\">Arthralgia, myalgia, back pain.</span>", "ID": "87f4f74d-b279-4c2f-9abc-28ef56c0f7e2", "Styles": "None", "Classes": "None", "Text": "Arthralgia, myalgia, back pain.", "ParentId": "00960d78-6330-4bdb-844a-c2f999960959"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Renal and\n  urinary disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "c3d9e7cd-3f7c-4213-8b52-135d02c705b2", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Renal and\n  urinary disorders</span></p>\n</td>", "ID": "9b2a9fc1-ebec-47bb-9577-74b543928e65", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c3d9e7cd-3f7c-4213-8b52-135d02c705b2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Renal and\n  urinary disorders</span></p>", "ID": "c1ff2622-6776-4e5a-abe8-8ab447ac88f3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9b2a9fc1-ebec-47bb-9577-74b543928e65"}, {"Element": "<span lang=\"EN-GB\">Renal and\n  urinary disorders</span>", "ID": "163a18a9-6e4a-4b41-969c-061d19946f51", "Styles": "None", "Classes": "None", "Text": "Renal and   urinary disorders", "ParentId": "c1ff2622-6776-4e5a-abe8-8ab447ac88f3"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "5ebe8086-5fd8-42c8-98ba-18a99f5fe62d", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c3d9e7cd-3f7c-4213-8b52-135d02c705b2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9235359d-5e03-46aa-b9f8-b9b18182734c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5ebe8086-5fd8-42c8-98ba-18a99f5fe62d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c544a696-a751-469d-9387-a1a1f7cfb938", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9235359d-5e03-46aa-b9f8-b9b18182734c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Urinary tract infection.</span></p>\n</td>\n</tr>", "ID": "73d7d67d-fec3-4de6-83bb-84230ef2403e", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "05bad457-a74d-468b-9647-dedd921c1247", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "73d7d67d-fec3-4de6-83bb-84230ef2403e"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "ce0f0dc6-e4bc-448d-b5b2-770f97d1c66b", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "05bad457-a74d-468b-9647-dedd921c1247"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "76b85942-4b14-4952-9ff3-cf06cb1d3ccd", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "ce0f0dc6-e4bc-448d-b5b2-770f97d1c66b"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Urinary tract infection.</span></p>\n</td>", "ID": "a4c29ca1-48ca-473c-81a5-3123d7da1c9c", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "73d7d67d-fec3-4de6-83bb-84230ef2403e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Urinary tract infection.</span></p>", "ID": "1012625f-eb35-4243-ab19-ba28e0c41c5e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a4c29ca1-48ca-473c-81a5-3123d7da1c9c"}, {"Element": "<span lang=\"EN-GB\">Urinary tract infection.</span>", "ID": "55d7dc6d-4351-4032-ae9e-99e4c14d9d94", "Styles": "None", "Classes": "None", "Text": "Urinary tract infection.", "ParentId": "1012625f-eb35-4243-ab19-ba28e0c41c5e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pyelonephritis.</span></p>\n</td>\n</tr>", "ID": "c2fe2cf3-1db5-45b4-890a-67aefe39d3d1", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "0700bf15-bf4e-43ea-add8-f52cbc552bc3", "Styles": "width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2fe2cf3-1db5-45b4-890a-67aefe39d3d1"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "cbed243a-40d2-44af-95e0-2edbb99bdebc", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0700bf15-bf4e-43ea-add8-f52cbc552bc3"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "83f1e9c6-10db-46d0-a739-2158a823d25d", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "cbed243a-40d2-44af-95e0-2edbb99bdebc"}, {"Element": "<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pyelonephritis.</span></p>\n</td>", "ID": "bd757aea-7b99-488b-9bc0-34a4009fafe4", "Styles": "width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2fe2cf3-1db5-45b4-890a-67aefe39d3d1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pyelonephritis.</span></p>", "ID": "b0855854-498b-4c1a-9283-fb9d531548da", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd757aea-7b99-488b-9bc0-34a4009fafe4"}, {"Element": "<span lang=\"EN-GB\">Pyelonephritis.</span>", "ID": "ecccbc12-1de6-40c2-b26d-88cef2cb7f96", "Styles": "None", "Classes": "None", "Text": "Pyelonephritis.", "ParentId": "b0855854-498b-4c1a-9283-fb9d531548da"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reproductive\n  system and breast disorders</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "b048803d-4680-4c7c-bf00-8e339ecddb74", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reproductive\n  system and breast disorders</span></p>\n</td>", "ID": "bbe7bbe8-86ad-49ec-94ab-a3e58f65f7c9", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b048803d-4680-4c7c-bf00-8e339ecddb74"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reproductive\n  system and breast disorders</span></p>", "ID": "a66b5b02-0091-4983-aaa9-009f44b5945a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bbe7bbe8-86ad-49ec-94ab-a3e58f65f7c9"}, {"Element": "<span lang=\"EN-GB\">Reproductive\n  system and breast disorders</span>", "ID": "7d2aadfb-3df2-48f6-b88a-a3d0d9181c71", "Styles": "None", "Classes": "None", "Text": "Reproductive   system and breast disorders", "ParentId": "a66b5b02-0091-4983-aaa9-009f44b5945a"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "3dc392ac-253c-46dd-ac67-76433df479f4", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b048803d-4680-4c7c-bf00-8e339ecddb74"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a622a4ee-20f2-4b51-ada5-86d29f0d411f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3dc392ac-253c-46dd-ac67-76433df479f4"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ea2319a8-a886-4b72-a541-3d9ac28f12b4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a622a4ee-20f2-4b51-ada5-86d29f0d411f"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vaginitis.</span></p>\n</td>\n</tr>", "ID": "be0507d1-5a34-4c37-8840-397c837f6583", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "2d206ebd-f8f3-4fad-8d60-31269ad1843d", "Styles": "width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "be0507d1-5a34-4c37-8840-397c837f6583"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "a61adc1a-7513-46f0-b76e-968f18145ae8", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2d206ebd-f8f3-4fad-8d60-31269ad1843d"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "291940dd-2a06-48d5-85a1-9efc49abf251", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "a61adc1a-7513-46f0-b76e-968f18145ae8"}, {"Element": "<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vaginitis.</span></p>\n</td>", "ID": "9b97b9b0-5fa0-4805-a3bd-85431cfa608e", "Styles": "width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "be0507d1-5a34-4c37-8840-397c837f6583"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Vaginitis.</span></p>", "ID": "0248f986-5303-4252-83e0-d67e2aebca69", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9b97b9b0-5fa0-4805-a3bd-85431cfa608e"}, {"Element": "<span lang=\"EN-GB\">Vaginitis.</span>", "ID": "7c84ab0d-00f5-4361-92b4-af38f80ca6ce", "Styles": "None", "Classes": "None", "Text": "Vaginitis.", "ParentId": "0248f986-5303-4252-83e0-d67e2aebca69"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">General\n  disorders and administration site conditions</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "897f9caa-a6d9-41bf-8559-7df17d55abea", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">General\n  disorders and administration site conditions</span></p>\n</td>", "ID": "673d2849-e46a-4431-913a-f9d418cff4f4", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "897f9caa-a6d9-41bf-8559-7df17d55abea"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">General\n  disorders and administration site conditions</span></p>", "ID": "73d4d776-f5b0-4d6c-ac88-c5630a0d21cd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "673d2849-e46a-4431-913a-f9d418cff4f4"}, {"Element": "<span lang=\"EN-GB\">General\n  disorders and administration site conditions</span>", "ID": "8291829b-671a-439d-8587-3952bd963a63", "Styles": "None", "Classes": "None", "Text": "General   disorders and administration site conditions", "ParentId": "73d4d776-f5b0-4d6c-ac88-c5630a0d21cd"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "1fbe54bd-9bd3-4b14-b079-faea265fbd79", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "897f9caa-a6d9-41bf-8559-7df17d55abea"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "35bb5d1d-92e7-4907-892e-80e6d9e26c95", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1fbe54bd-9bd3-4b14-b079-faea265fbd79"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e92b3e98-7f02-47e0-9211-de0a046f3b14", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "35bb5d1d-92e7-4907-892e-80e6d9e26c95"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infusion\u2011related reaction, pain.</span></p>\n</td>\n</tr>", "ID": "29a37f34-df3f-482b-8289-0bf1d30b57d5", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>\n</td>", "ID": "9a76a825-9e75-43c8-a3d2-4d501a445c31", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "29a37f34-df3f-482b-8289-0bf1d30b57d5"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Very\n  common:</span></p>", "ID": "f5f27f13-46e4-4a20-a100-40553e6415e0", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9a76a825-9e75-43c8-a3d2-4d501a445c31"}, {"Element": "<span lang=\"EN-GB\">Very\n  common:</span>", "ID": "e1050b06-2a95-4869-920f-4c37f9bcc916", "Styles": "None", "Classes": "None", "Text": "Very   common:", "ParentId": "f5f27f13-46e4-4a20-a100-40553e6415e0"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infusion\u2011related reaction, pain.</span></p>\n</td>", "ID": "fa396672-d41a-4fb2-adb5-ee17e603abfd", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "29a37f34-df3f-482b-8289-0bf1d30b57d5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infusion\u2011related reaction, pain.</span></p>", "ID": "290627bc-73b3-43a6-b9c8-9c8ebf06c757", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fa396672-d41a-4fb2-adb5-ee17e603abfd"}, {"Element": "<span lang=\"EN-GB\">Infusion\u2011related reaction, pain.</span>", "ID": "422536f3-81c7-4af6-a907-39fa656a50ca", "Styles": "None", "Classes": "None", "Text": "Infusion\u2011related reaction, pain.", "ParentId": "290627bc-73b3-43a6-b9c8-9c8ebf06c757"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Chest pain, fatigue, fever, injection\n  site reaction, chills, oedema.</span></p>\n</td>\n</tr>", "ID": "4bfca5a4-2e3a-421d-b368-211a09321576", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>\n</td>", "ID": "e57e28a8-17a2-4539-b105-adee8a6fa0e3", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4bfca5a4-2e3a-421d-b368-211a09321576"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Common:</span></p>", "ID": "cf58d76f-06b6-495a-9683-c3769889b4c0", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e57e28a8-17a2-4539-b105-adee8a6fa0e3"}, {"Element": "<span lang=\"EN-GB\">Common:</span>", "ID": "e89dc9d9-6bf6-409d-b21e-60482468627e", "Styles": "None", "Classes": "None", "Text": "Common:", "ParentId": "cf58d76f-06b6-495a-9683-c3769889b4c0"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Chest pain, fatigue, fever, injection\n  site reaction, chills, oedema.</span></p>\n</td>", "ID": "f8689986-a737-4123-8e98-2fbbaa359e48", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4bfca5a4-2e3a-421d-b368-211a09321576"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Chest pain, fatigue, fever, injection\n  site reaction, chills, oedema.</span></p>", "ID": "a6a6d13c-f3d2-4793-8f3f-8d8b69085057", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f8689986-a737-4123-8e98-2fbbaa359e48"}, {"Element": "<span lang=\"EN-GB\">Chest pain, fatigue, fever, injection\n  site reaction, chills, oedema.</span>", "ID": "418d982a-f897-4fd6-9501-3ddf42b25f0b", "Styles": "None", "Classes": "None", "Text": "Chest pain, fatigue, fever, injection   site reaction, chills, oedema.", "ParentId": "a6a6d13c-f3d2-4793-8f3f-8d8b69085057"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Impaired healing.</span></p>\n</td>\n</tr>", "ID": "9369e09c-25e8-4536-8b03-2580ff3bd087", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "e836fda4-7920-45b0-9ebc-a31edef526c8", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9369e09c-25e8-4536-8b03-2580ff3bd087"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "3a82352a-0030-4c43-878f-dcf1b633007e", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e836fda4-7920-45b0-9ebc-a31edef526c8"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "0e9ef4cf-be28-41f4-a7ab-f9457ccc47be", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "3a82352a-0030-4c43-878f-dcf1b633007e"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Impaired healing.</span></p>\n</td>", "ID": "03f42af8-520e-4426-8372-b4e6d3a5ce66", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9369e09c-25e8-4536-8b03-2580ff3bd087"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Impaired healing.</span></p>", "ID": "0543f02f-1636-48ed-b37d-9cedb6fe366c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "03f42af8-520e-4426-8372-b4e6d3a5ce66"}, {"Element": "<span lang=\"EN-GB\">Impaired healing.</span>", "ID": "18974a00-4301-4fc4-b5a7-e62c236b30c6", "Styles": "None", "Classes": "None", "Text": "Impaired healing.", "ParentId": "0543f02f-1636-48ed-b37d-9cedb6fe366c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Granulomatous lesion.</span></p>\n</td>\n</tr>", "ID": "4f322d62-5f1a-4e3d-a2f0-ae8cf53fc292", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "8ea352a5-1718-4e2b-9e56-942b108ed458", "Styles": "width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4f322d62-5f1a-4e3d-a2f0-ae8cf53fc292"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "f44e9a85-2392-4beb-8228-b351539c56c2", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8ea352a5-1718-4e2b-9e56-942b108ed458"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "10d6f590-7686-4501-b9f4-227f89cc9e41", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "f44e9a85-2392-4beb-8228-b351539c56c2"}, {"Element": "<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Granulomatous lesion.</span></p>\n</td>", "ID": "6f617f8b-195e-4066-8a59-af2f9c517dba", "Styles": "width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4f322d62-5f1a-4e3d-a2f0-ae8cf53fc292"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Granulomatous lesion.</span></p>", "ID": "ec6a42d6-a3e9-4903-8415-8aed2bf8f505", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6f617f8b-195e-4066-8a59-af2f9c517dba"}, {"Element": "<span lang=\"EN-GB\">Granulomatous lesion.</span>", "ID": "785f2c90-a0cd-448e-8116-02001bf84769", "Styles": "None", "Classes": "None", "Text": "Granulomatous lesion.", "ParentId": "ec6a42d6-a3e9-4903-8415-8aed2bf8f505"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Investigations</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "7a668bb6-8dd9-4cc7-9ee1-b5850f36a07a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Investigations</span></p>\n</td>", "ID": "2f685910-f55f-497c-917c-48fb4e91ebf2", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7a668bb6-8dd9-4cc7-9ee1-b5850f36a07a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Investigations</span></p>", "ID": "50819d86-e533-4c6b-ab8f-c736d2808a66", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2f685910-f55f-497c-917c-48fb4e91ebf2"}, {"Element": "<span lang=\"EN-GB\">Investigations</span>", "ID": "0b9df7f5-d93b-4ec3-9858-d187c354316b", "Styles": "None", "Classes": "None", "Text": "Investigations", "ParentId": "50819d86-e533-4c6b-ab8f-c736d2808a66"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "0f83abde-07c8-4a31-a5ed-c9f106ccf9e5", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7a668bb6-8dd9-4cc7-9ee1-b5850f36a07a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7375aa4a-783d-4dd8-9c65-eb719f923b1a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0f83abde-07c8-4a31-a5ed-c9f106ccf9e5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "57e47241-0ebb-45bb-a2ae-6377442cba32", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7375aa4a-783d-4dd8-9c65-eb719f923b1a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>\n<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoantibody positive.</span></p>\n</td>\n</tr>", "ID": "6c58a2ac-234f-4a45-8723-d3cf402dcff5", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>\n</td>", "ID": "0f4449df-9ddb-42d9-a63a-2ef5d2d46137", "Styles": "width:162.25pt;border:none;border-left:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6c58a2ac-234f-4a45-8723-d3cf402dcff5"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Uncommon:</span></p>", "ID": "721a3635-ab7c-4015-a979-fc5e6f99bba3", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0f4449df-9ddb-42d9-a63a-2ef5d2d46137"}, {"Element": "<span lang=\"EN-GB\">Uncommon:</span>", "ID": "4aff9a2f-e7d8-48da-865c-eee1df643911", "Styles": "None", "Classes": "None", "Text": "Uncommon:", "ParentId": "721a3635-ab7c-4015-a979-fc5e6f99bba3"}, {"Element": "<td style=\"width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoantibody positive.</span></p>\n</td>", "ID": "b04cfe1a-d57d-4d34-b6bd-8c1602ea35fe", "Styles": "width:291.35pt;border:none;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6c58a2ac-234f-4a45-8723-d3cf402dcff5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Autoantibody positive.</span></p>", "ID": "92765e61-d661-435b-838f-28a45f8e65dd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b04cfe1a-d57d-4d34-b6bd-8c1602ea35fe"}, {"Element": "<span lang=\"EN-GB\">Autoantibody positive.</span>", "ID": "294f04ae-bcc9-45d0-ad9f-43dd8398f145", "Styles": "None", "Classes": "None", "Text": "Autoantibody positive.", "ParentId": "92765e61-d661-435b-838f-28a45f8e65dd"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>\n<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Complement factor abnormal.</span></p>\n</td>\n</tr>", "ID": "0d428048-dc8f-430f-b520-7a9f93aec5ee", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td style=\"width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"216\">\n<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>\n</td>", "ID": "43e149d6-f6c7-48e6-8e35-b5028a907796", "Styles": "width:162.25pt;border-top:none;border-left:\n  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:\n  none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0d428048-dc8f-430f-b520-7a9f93aec5ee"}, {"Element": "<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right\"><span lang=\"EN-GB\">Rare:</span></p>", "ID": "c232cc03-e1d8-4ccf-b650-72338cf7ba49", "Styles": "text-align:right", "Classes": "['MsoNormal']", "Text": "", "ParentId": "43e149d6-f6c7-48e6-8e35-b5028a907796"}, {"Element": "<span lang=\"EN-GB\">Rare:</span>", "ID": "04518dc8-84a3-44e2-95b2-80dc112ec2e2", "Styles": "None", "Classes": "None", "Text": "Rare:", "ParentId": "c232cc03-e1d8-4ccf-b650-72338cf7ba49"}, {"Element": "<td style=\"width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"388\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Complement factor abnormal.</span></p>\n</td>", "ID": "2aed1b13-3c6e-453d-ad72-3ecfb6d6c392", "Styles": "width:291.35pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0d428048-dc8f-430f-b520-7a9f93aec5ee"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Complement factor abnormal.</span></p>", "ID": "37cd8bca-7b1e-4157-b7a3-5abd36f4a70b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2aed1b13-3c6e-453d-ad72-3ecfb6d6c392"}, {"Element": "<span lang=\"EN-GB\">Complement factor abnormal.</span>", "ID": "e7787e25-eeac-4c37-afa2-2801c47104d9", "Styles": "None", "Classes": "None", "Text": "Complement factor abnormal.", "ParentId": "37cd8bca-7b1e-4157-b7a3-5abd36f4a70b"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\">*\u00a0\u00a0 </span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">including\n  bovine tuberculosis (disseminated BCG infection), see section\u00a04.4</span></p>\n</td>\n</tr>", "ID": "3664f4cc-fb5b-42a4-a32c-b133bf354c2c", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "3e2337c4-ad07-4bd9-b459-2257a80adc8f"}, {"Element": "<td colspan=\"2\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\">*\u00a0\u00a0 </span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">including\n  bovine tuberculosis (disseminated BCG infection), see section\u00a04.4</span></p>\n</td>", "ID": "8288144b-f796-4897-9014-7e5a870b33f8", "Styles": "width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3664f4cc-fb5b-42a4-a32c-b133bf354c2c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\">*\u00a0\u00a0 </span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">including\n  bovine tuberculosis (disseminated BCG infection), see section\u00a04.4</span></p>", "ID": "33b06c3b-435c-4759-9cb3-75384d900ec8", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8288144b-f796-4897-9014-7e5a870b33f8"}, {"Element": "<span lang=\"EN-GB\">*\u00a0\u00a0 </span>", "ID": "32f3a056-988b-405e-88b6-7ff44525c346", "Styles": "None", "Classes": "None", "Text": "*\u00a0\u00a0 ", "ParentId": "33b06c3b-435c-4759-9cb3-75384d900ec8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">including\n  bovine tuberculosis (disseminated BCG infection), see section\u00a04.4</span>", "ID": "e64a125a-432f-4bb2-8709-047cb2bfc9c3", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "including   bovine tuberculosis (disseminated BCG infection), see section\u00a04.4", "ParentId": "33b06c3b-435c-4759-9cb3-75384d900ec8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6830aa1c-b520-41cd-bcae-68ff555334b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dd555184-505b-4f60-a081-027f837024e6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6830aa1c-b520-41cd-bcae-68ff555334b6"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Description of selected adverse drug reactions</span></u></p>", "ID": "2f982049-1f15-4a42-aa5d-ddd2bf7c3ddd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Description of selected adverse drug reactions</span></u>", "ID": "dc7fcbae-2cc8-42bb-8df1-500926138f40", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2f982049-1f15-4a42-aa5d-ddd2bf7c3ddd"}, {"Element": "<span lang=\"EN-GB\">Description of selected adverse drug reactions</span>", "ID": "8551eb7a-2713-4418-8921-a19a518a23d8", "Styles": "None", "Classes": "None", "Text": "Description of selected adverse drug reactions", "ParentId": "dc7fcbae-2cc8-42bb-8df1-500926138f40"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9908fc46-e873-49de-955b-6c2f6db173e0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "50464b1e-9d3e-4c06-b8f0-5c771ab97357", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9908fc46-e873-49de-955b-6c2f6db173e0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Infusion\u2011related reactions</span></u></p>", "ID": "c20c465a-904b-4306-9fb7-9be231ee2123", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Infusion\u2011related reactions</span></u>", "ID": "70893fa8-5bab-4289-b842-1bd64f7782bd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c20c465a-904b-4306-9fb7-9be231ee2123"}, {"Element": "<span lang=\"EN-GB\">Infusion\u2011related reactions</span>", "ID": "fd461f98-415e-462a-ba05-fe73ff828a1d", "Styles": "None", "Classes": "None", "Text": "Infusion\u2011related reactions", "ParentId": "70893fa8-5bab-4289-b842-1bd64f7782bd"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">An infusion\u2011related\nreaction was defined in clinical studies as any adverse event occurring during an\ninfusion or within 1\u00a0hour after an infusion. In Phase III clinical\nstudies, 18% of infliximab\u2011treated patients compared with 5% of placebo\u2011treated\npatients experienced an infusion\u2011related reaction. Overall, a higher\nproportion of patients receiving infliximab monotherapy experienced an infusion\u2011related\nreaction compared to patients receiving infliximab with concomitant immunomodulators.\nApproximately 3% of patients discontinued treatment due to infusion\u2011related\nreactions and all patients recovered with or without medical therapy. Of\ninfliximab\u2011treated patients who had an infusion reaction during the\ninduction period, through week\u00a06, 27% experienced an infusion reaction\nduring the maintenance period, week\u00a07 through week\u00a054. Of patients\nwho did not have an infusion reaction during the induction period, 9%\nexperienced an infusion reaction during the maintenance period.</span></p>", "ID": "886d8057-c01e-4512-82cc-6c1bf04c6cda", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">An infusion\u2011related\nreaction was defined in clinical studies as any adverse event occurring during an\ninfusion or within 1\u00a0hour after an infusion. In Phase III clinical\nstudies, 18% of infliximab\u2011treated patients compared with 5% of placebo\u2011treated\npatients experienced an infusion\u2011related reaction. Overall, a higher\nproportion of patients receiving infliximab monotherapy experienced an infusion\u2011related\nreaction compared to patients receiving infliximab with concomitant immunomodulators.\nApproximately 3% of patients discontinued treatment due to infusion\u2011related\nreactions and all patients recovered with or without medical therapy. Of\ninfliximab\u2011treated patients who had an infusion reaction during the\ninduction period, through week\u00a06, 27% experienced an infusion reaction\nduring the maintenance period, week\u00a07 through week\u00a054. Of patients\nwho did not have an infusion reaction during the induction period, 9%\nexperienced an infusion reaction during the maintenance period.</span>", "ID": "494b8889-0ead-4077-a6bd-ed54251ade8a", "Styles": "None", "Classes": "None", "Text": "An infusion\u2011related reaction was defined in clinical studies as any adverse event occurring during an infusion or within 1\u00a0hour after an infusion. In Phase III clinical studies, 18% of infliximab\u2011treated patients compared with 5% of placebo\u2011treated patients experienced an infusion\u2011related reaction. Overall, a higher proportion of patients receiving infliximab monotherapy experienced an infusion\u2011related reaction compared to patients receiving infliximab with concomitant immunomodulators. Approximately 3% of patients discontinued treatment due to infusion\u2011related reactions and all patients recovered with or without medical therapy. Of infliximab\u2011treated patients who had an infusion reaction during the induction period, through week\u00a06, 27% experienced an infusion reaction during the maintenance period, week\u00a07 through week\u00a054. Of patients who did not have an infusion reaction during the induction period, 9% experienced an infusion reaction during the maintenance period.", "ParentId": "886d8057-c01e-4512-82cc-6c1bf04c6cda"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f324be30-68f6-4985-99c6-99ee54aa840e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6f7641bb-4a28-4dd3-8feb-5bb6ef0d730e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f324be30-68f6-4985-99c6-99ee54aa840e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In a clinical\nstudy of patients with rheumatoid arthritis (ASPIRE), </span><span lang=\"EN-GB\">infusions\nwere to be administered over 2\u00a0hours for the first 3\u00a0infusions. The\nduration of subsequent infusions could be shortened to not less than\n40\u00a0minutes in patients who did not experience serious infusion reactions.\nIn this trial, </span><span lang=\"EN-GB\">sixty six percent of the patients (686\nout of 1,040) received at least one shortened infusion of 90\u00a0minutes or\nless and 44% of the patients (454 out of 1,040) received at least one shortened\ninfusion of 60\u00a0minutes or less. Of the infliximab</span><span lang=\"EN-GB\">\u2011</span><span lang=\"EN-GB\">treated patients who received at least one shortened infusion,\ninfusion\u2011related reactions occurred in 15% of patients and serious\ninfusion reactions occurred in 0.4% of patients.</span></p>", "ID": "082380ee-98a8-4944-a3aa-52acfb9e2ba3", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In a clinical\nstudy of patients with rheumatoid arthritis (ASPIRE), </span>", "ID": "863c1db4-a1c6-460e-8f85-fbac79323a0a", "Styles": "None", "Classes": "None", "Text": "In a clinical study of patients with rheumatoid arthritis (ASPIRE), ", "ParentId": "082380ee-98a8-4944-a3aa-52acfb9e2ba3"}, {"Element": "<span lang=\"EN-GB\">infusions\nwere to be administered over 2\u00a0hours for the first 3\u00a0infusions. The\nduration of subsequent infusions could be shortened to not less than\n40\u00a0minutes in patients who did not experience serious infusion reactions.\nIn this trial, </span>", "ID": "1a079f0b-1409-4c45-9d8a-7012a4ccdc8e", "Styles": "None", "Classes": "None", "Text": "infusions were to be administered over 2\u00a0hours for the first 3\u00a0infusions. The duration of subsequent infusions could be shortened to not less than 40\u00a0minutes in patients who did not experience serious infusion reactions. In this trial, ", "ParentId": "082380ee-98a8-4944-a3aa-52acfb9e2ba3"}, {"Element": "<span lang=\"EN-GB\">sixty six percent of the patients (686\nout of 1,040) received at least one shortened infusion of 90\u00a0minutes or\nless and 44% of the patients (454 out of 1,040) received at least one shortened\ninfusion of 60\u00a0minutes or less. Of the infliximab</span>", "ID": "18b2672c-ad95-4a0a-8e5a-6b4fc05d0b93", "Styles": "None", "Classes": "None", "Text": "sixty six percent of the patients (686 out of 1,040) received at least one shortened infusion of 90\u00a0minutes or less and 44% of the patients (454 out of 1,040) received at least one shortened infusion of 60\u00a0minutes or less. Of the infliximab", "ParentId": "082380ee-98a8-4944-a3aa-52acfb9e2ba3"}, {"Element": "<span lang=\"EN-GB\">\u2011</span>", "ID": "fc031805-52be-4907-90b9-db2512967a2b", "Styles": "None", "Classes": "None", "Text": "\u2011", "ParentId": "082380ee-98a8-4944-a3aa-52acfb9e2ba3"}, {"Element": "<span lang=\"EN-GB\">treated patients who received at least one shortened infusion,\ninfusion\u2011related reactions occurred in 15% of patients and serious\ninfusion reactions occurred in 0.4% of patients.</span>", "ID": "8c4fab4c-de33-4ecc-aee3-9264e48cbb08", "Styles": "None", "Classes": "None", "Text": "treated patients who received at least one shortened infusion, infusion\u2011related reactions occurred in 15% of patients and serious infusion reactions occurred in 0.4% of patients.", "ParentId": "082380ee-98a8-4944-a3aa-52acfb9e2ba3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "4cacfd38-b10d-4e23-87fd-52d0a8ca6aa9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "37eee6d1-2233-4f73-9be9-d624f0df9ce9", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "4cacfd38-b10d-4e23-87fd-52d0a8ca6aa9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In a clinical study of patients with\nCrohn\u2019s disease (SONIC), infusion\u2011related reactions occurred in\n16.6% (27/163) of patients receiving infliximab monotherapy, 5% (9/179) of\npatients receiving infliximab in combination with AZA, and 5.6% (9/161) of\npatients receiving AZA monotherapy. </span><span lang=\"EN-GB\">One</span><span lang=\"EN-GB\"> serious infusion reaction (&lt;\u00a01%) occurred in a patient on\ninfliximab monotherapy.</span></p>", "ID": "2ce521c5-a8d2-4664-ad30-47b1980912f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In a clinical study of patients with\nCrohn\u2019s disease (SONIC), infusion\u2011related reactions occurred in\n16.6% (27/163) of patients receiving infliximab monotherapy, 5% (9/179) of\npatients receiving infliximab in combination with AZA, and 5.6% (9/161) of\npatients receiving AZA monotherapy. </span>", "ID": "bc7c7df7-4031-4a6e-bb24-4e58e12d01c8", "Styles": "None", "Classes": "None", "Text": "In a clinical study of patients with Crohn\u2019s disease (SONIC), infusion\u2011related reactions occurred in 16.6% (27/163) of patients receiving infliximab monotherapy, 5% (9/179) of patients receiving infliximab in combination with AZA, and 5.6% (9/161) of patients receiving AZA monotherapy. ", "ParentId": "2ce521c5-a8d2-4664-ad30-47b1980912f6"}, {"Element": "<span lang=\"EN-GB\">One</span>", "ID": "42fff16d-3d4e-4105-9d13-12497a9c1a66", "Styles": "None", "Classes": "None", "Text": "One", "ParentId": "2ce521c5-a8d2-4664-ad30-47b1980912f6"}, {"Element": "<span lang=\"EN-GB\"> serious infusion reaction (&lt;\u00a01%) occurred in a patient on\ninfliximab monotherapy.</span>", "ID": "55a4dbae-7328-42b9-844e-000924db1d5e", "Styles": "None", "Classes": "None", "Text": " serious infusion reaction (<\u00a01%) occurred in a patient on infliximab monotherapy.", "ParentId": "2ce521c5-a8d2-4664-ad30-47b1980912f6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "8f69afff-a024-4d08-b16e-6e2f8320f846", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "9d7be2af-734b-4412-bd70-0a8c25e125b6", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "8f69afff-a024-4d08-b16e-6e2f8320f846"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">In post\u2011marketing\nexperience, cases of anaphylactic\u2011like reactions, including\nlaryngeal/pharyngeal oedema and severe bronchospasm, and seizure have been\nassociated with Remicade administration </span><span lang=\"EN-GB\">(see\nsection\u00a04.4)</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">.</span></p>", "ID": "ce623037-16d9-4df0-b461-d8c3a0f77e8b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">In post\u2011marketing\nexperience, cases of anaphylactic\u2011like reactions, including\nlaryngeal/pharyngeal oedema and severe bronchospasm, and seizure have been\nassociated with Remicade administration </span>", "ID": "b8b7b5fc-f2c9-492b-afea-bfb6a2becb97", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "In post\u2011marketing experience, cases of anaphylactic\u2011like reactions, including laryngeal/pharyngeal oedema and severe bronchospasm, and seizure have been associated with Remicade administration ", "ParentId": "ce623037-16d9-4df0-b461-d8c3a0f77e8b"}, {"Element": "<span lang=\"EN-GB\">(see\nsection\u00a04.4)</span>", "ID": "e0e9fb40-46f4-40b1-9614-f723447eebf6", "Styles": "None", "Classes": "None", "Text": "(see section\u00a04.4)", "ParentId": "ce623037-16d9-4df0-b461-d8c3a0f77e8b"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">.</span>", "ID": "23997da6-2e36-403a-8d92-ee92db05c388", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": ".", "ParentId": "ce623037-16d9-4df0-b461-d8c3a0f77e8b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Cases of transient visual loss occurring\nduring or within 2\u00a0hours of Remicade infusion have been reported. Events\n(some fatal) of m</span><span lang=\"EN-GB\">yocardial ischaemia/infarction and\narrhythmia have been reported, some in close temporal association with infusion\nof infliximab; </span><span lang=\"EN-GB\">cerebrovascular accidents have also been\nreported in close temporal association with infusion of infliximab</span><span lang=\"EN-GB\">.</span></p>", "ID": "a0261cc5-22c0-4842-95ee-936d872da9e8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Cases of transient visual loss occurring\nduring or within 2\u00a0hours of Remicade infusion have been reported. Events\n(some fatal) of m</span>", "ID": "e9546652-d111-42bb-ab1e-b0735dee84ee", "Styles": "None", "Classes": "None", "Text": "Cases of transient visual loss occurring during or within 2\u00a0hours of Remicade infusion have been reported. Events (some fatal) of m", "ParentId": "a0261cc5-22c0-4842-95ee-936d872da9e8"}, {"Element": "<span lang=\"EN-GB\">yocardial ischaemia/infarction and\narrhythmia have been reported, some in close temporal association with infusion\nof infliximab; </span>", "ID": "7436ce5a-7616-42c5-9435-78705ed6b4b5", "Styles": "None", "Classes": "None", "Text": "yocardial ischaemia/infarction and arrhythmia have been reported, some in close temporal association with infusion of infliximab; ", "ParentId": "a0261cc5-22c0-4842-95ee-936d872da9e8"}, {"Element": "<span lang=\"EN-GB\">cerebrovascular accidents have also been\nreported in close temporal association with infusion of infliximab</span>", "ID": "dada9f40-ca64-4ce8-8583-fbc0973a8e38", "Styles": "None", "Classes": "None", "Text": "cerebrovascular accidents have also been reported in close temporal association with infusion of infliximab", "ParentId": "a0261cc5-22c0-4842-95ee-936d872da9e8"}, {"Element": "<span lang=\"EN-GB\">.</span>", "ID": "69c8bb52-2532-4f5f-a850-5e9ae2db238b", "Styles": "None", "Classes": "None", "Text": ".", "ParentId": "a0261cc5-22c0-4842-95ee-936d872da9e8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "2b149e3e-6a0d-42b9-acd3-a6973fbb481b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "e91a28b8-bbe0-40a0-8c88-18534dce5316", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "2b149e3e-6a0d-42b9-acd3-a6973fbb481b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infusion\nreactions following re\u2011administration of Remicade</span></u></p>", "ID": "b134f71b-8d7f-49f1-939b-3af5ca681dc4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Infusion\nreactions following re\u2011administration of Remicade</span></u>", "ID": "b60367f2-0b99-4e4f-b828-40b3adc547a3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b134f71b-8d7f-49f1-939b-3af5ca681dc4"}, {"Element": "<span lang=\"EN-GB\">Infusion\nreactions following re\u2011administration of Remicade</span>", "ID": "6e8e9aa7-510e-4071-b727-d11539a12e47", "Styles": "None", "Classes": "None", "Text": "Infusion reactions following re\u2011administration of Remicade", "ParentId": "b60367f2-0b99-4e4f-b828-40b3adc547a3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">A clinical study in patients with moderate to\nsevere psoriasis was designed to assess the efficacy and safety of long\u2011term\nmaintenance therapy versus re\u2011treatment with an induction regimen of\nRemicade (maximum of four infusions at 0, 2, 6 and 14\u00a0weeks) following\ndisease flare. Patients did not receive any concomitant immunosuppressant\ntherapy. In the re\u2011treatment arm, 4% (8/219) of patients experienced a\nserious infusion reaction versus &lt;\u00a01% (1/222) on maintenance therapy.\nThe majority of serious infusion reactions occurred during the second infusion\nat week\u00a02. The interval between the last maintenance dose and the first re\u2011induction\ndose ranged from 35\u2011231\u00a0days. Symptoms included, but were not\nlimited to, dyspnea, urticaria, facial oedema, and hypotension. In all cases,\nRemicade treatment was discontinued and/or other treatment instituted with\ncomplete resolution of signs and symptoms.</span></p>", "ID": "413607b0-cc83-4826-aaaf-affadfa36133", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">A clinical study in patients with moderate to\nsevere psoriasis was designed to assess the efficacy and safety of long\u2011term\nmaintenance therapy versus re\u2011treatment with an induction regimen of\nRemicade (maximum of four infusions at 0, 2, 6 and 14\u00a0weeks) following\ndisease flare. Patients did not receive any concomitant immunosuppressant\ntherapy. In the re\u2011treatment arm, 4% (8/219) of patients experienced a\nserious infusion reaction versus &lt;\u00a01% (1/222) on maintenance therapy.\nThe majority of serious infusion reactions occurred during the second infusion\nat week\u00a02. The interval between the last maintenance dose and the first re\u2011induction\ndose ranged from 35\u2011231\u00a0days. Symptoms included, but were not\nlimited to, dyspnea, urticaria, facial oedema, and hypotension. In all cases,\nRemicade treatment was discontinued and/or other treatment instituted with\ncomplete resolution of signs and symptoms.</span>", "ID": "ddbdc9df-e0ff-45d2-8d5e-5f9b70e641e4", "Styles": "None", "Classes": "None", "Text": "A clinical study in patients with moderate to severe psoriasis was designed to assess the efficacy and safety of long\u2011term maintenance therapy versus re\u2011treatment with an induction regimen of Remicade (maximum of four infusions at 0, 2, 6 and 14\u00a0weeks) following disease flare. Patients did not receive any concomitant immunosuppressant therapy. In the re\u2011treatment arm, 4% (8/219) of patients experienced a serious infusion reaction versus <\u00a01% (1/222) on maintenance therapy. The majority of serious infusion reactions occurred during the second infusion at week\u00a02. The interval between the last maintenance dose and the first re\u2011induction dose ranged from 35\u2011231\u00a0days. Symptoms included, but were not limited to, dyspnea, urticaria, facial oedema, and hypotension. In all cases, Remicade treatment was discontinued and/or other treatment instituted with complete resolution of signs and symptoms.", "ParentId": "413607b0-cc83-4826-aaaf-affadfa36133"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7eb04650-a9f1-46d3-a280-f07eaf0e3d04", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ce4e1042-2139-4828-9c2c-58a67f6e2512", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7eb04650-a9f1-46d3-a280-f07eaf0e3d04"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Delayed\nhypersensitivity</span></u></p>", "ID": "1c45ebfe-1fbd-4be7-a232-0348a83e67bd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Delayed\nhypersensitivity</span></u>", "ID": "8970df93-06ae-4b96-8c5f-289dd992b448", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1c45ebfe-1fbd-4be7-a232-0348a83e67bd"}, {"Element": "<span lang=\"EN-GB\">Delayed\nhypersensitivity</span>", "ID": "fb98a3aa-7a91-46d2-9f17-e7aa85dcbf0b", "Styles": "None", "Classes": "None", "Text": "Delayed hypersensitivity", "ParentId": "8970df93-06ae-4b96-8c5f-289dd992b448"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical studies delayed\nhypersensitivity reactions have been uncommon and have occurred after Remicade\u2011free\nintervals of less than 1\u00a0year. In the psoriasis studies, delayed\nhypersensitivity reactions occurred early in the treatment course. Signs and\nsymptoms included myalgia and/or arthralgia with fever and/or rash, with some\npatients experiencing pruritus, facial, hand or lip oedema, dysphagia, urticaria,\nsore throat and headache.</span></p>", "ID": "031bfa7a-baf9-4b03-96da-23e0edde7d7e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In clinical studies delayed\nhypersensitivity reactions have been uncommon and have occurred after Remicade\u2011free\nintervals of less than 1\u00a0year. In the psoriasis studies, delayed\nhypersensitivity reactions occurred early in the treatment course. Signs and\nsymptoms included myalgia and/or arthralgia with fever and/or rash, with some\npatients experiencing pruritus, facial, hand or lip oedema, dysphagia, urticaria,\nsore throat and headache.</span>", "ID": "feb2e62c-c638-4161-83d8-fcbc8c2e6bb7", "Styles": "None", "Classes": "None", "Text": "In clinical studies delayed hypersensitivity reactions have been uncommon and have occurred after Remicade\u2011free intervals of less than 1\u00a0year. In the psoriasis studies, delayed hypersensitivity reactions occurred early in the treatment course. Signs and symptoms included myalgia and/or arthralgia with fever and/or rash, with some patients experiencing pruritus, facial, hand or lip oedema, dysphagia, urticaria, sore throat and headache.", "ParentId": "031bfa7a-baf9-4b03-96da-23e0edde7d7e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5da199df-f11f-4b45-b960-c2401e7ed5ff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7b5b53a7-91ac-4984-81a8-c71e91540c15", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5da199df-f11f-4b45-b960-c2401e7ed5ff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There are insufficient data on the\nincidence of delayed hypersensitivity reactions after Remicade\u2011free\nintervals of more than 1\u00a0year but limited data from clinical studies\nsuggest an increased risk for delayed hypersensitivity with increasing Remicade\u2011free\ninterval </span><span lang=\"EN-GB\">(see section\u00a04.4).</span></p>", "ID": "7382476e-7825-4c00-8414-56589e2a5113", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">There are insufficient data on the\nincidence of delayed hypersensitivity reactions after Remicade\u2011free\nintervals of more than 1\u00a0year but limited data from clinical studies\nsuggest an increased risk for delayed hypersensitivity with increasing Remicade\u2011free\ninterval </span>", "ID": "3eebf3fd-ef8d-4150-ad72-06432ad9ecb1", "Styles": "None", "Classes": "None", "Text": "There are insufficient data on the incidence of delayed hypersensitivity reactions after Remicade\u2011free intervals of more than 1\u00a0year but limited data from clinical studies suggest an increased risk for delayed hypersensitivity with increasing Remicade\u2011free interval ", "ParentId": "7382476e-7825-4c00-8414-56589e2a5113"}, {"Element": "<span lang=\"EN-GB\">(see section\u00a04.4).</span>", "ID": "06854fb6-a9a2-4eb4-a65d-ca8e61b151d7", "Styles": "None", "Classes": "None", "Text": "(see section\u00a04.4).", "ParentId": "7382476e-7825-4c00-8414-56589e2a5113"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "60cdee9f-0380-408e-99d5-d2e466a36a6b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0fd98c2e-1a2a-420e-94e3-0ddb5de0254f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "60cdee9f-0380-408e-99d5-d2e466a36a6b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">In a 1\u2011year\nclinical study with repeated infusions in patients with Crohn's disease (ACCENT\nI study), the incidence of serum sickness\u2011like reactions was 2.4%.</span></p>", "ID": "7c796a54-f229-402c-b84c-7c7ee11823a5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">In a 1\u2011year\nclinical study with repeated infusions in patients with Crohn's disease (ACCENT\nI study), the incidence of serum sickness\u2011like reactions was 2.4%.</span>", "ID": "e40d9d54-bef3-4c25-b8bd-1bdfb0c36ec7", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "In a 1\u2011year clinical study with repeated infusions in patients with Crohn's disease (ACCENT I study), the incidence of serum sickness\u2011like reactions was 2.4%.", "ParentId": "7c796a54-f229-402c-b84c-7c7ee11823a5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "16786c63-ff0a-4883-b974-80f3c5d5cf0e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "57f30b21-6220-46ed-9268-05a9e464fda3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "16786c63-ff0a-4883-b974-80f3c5d5cf0e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immunogenicity</span></u></p>", "ID": "295f9b2e-a232-4a5c-b9d0-3b5bca12d068", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Immunogenicity</span></u>", "ID": "7051023c-8486-4f9d-8092-6f9037404c20", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "295f9b2e-a232-4a5c-b9d0-3b5bca12d068"}, {"Element": "<span lang=\"EN-GB\">Immunogenicity</span>", "ID": "b656d966-a264-4e0a-aca6-d9a9559bdc6f", "Styles": "None", "Classes": "None", "Text": "Immunogenicity", "ParentId": "7051023c-8486-4f9d-8092-6f9037404c20"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients who developed antibodies to\ninfliximab were more likely (approximately 2\u20113\u00a0fold) to develop\ninfusion\u2011related reactions. Use of concomitant immunosuppressant agents\nappeared to reduce the frequency of infusion\u2011related reactions.</span></p>", "ID": "d3eee1ec-e476-4257-885b-9a4f8ba65ad6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Patients who developed antibodies to\ninfliximab were more likely (approximately 2\u20113\u00a0fold) to develop\ninfusion\u2011related reactions. Use of concomitant immunosuppressant agents\nappeared to reduce the frequency of infusion\u2011related reactions.</span>", "ID": "ffdeef55-103d-4724-a6f4-b2a0b89f1ca1", "Styles": "None", "Classes": "None", "Text": "Patients who developed antibodies to infliximab were more likely (approximately 2\u20113\u00a0fold) to develop infusion\u2011related reactions. Use of concomitant immunosuppressant agents appeared to reduce the frequency of infusion\u2011related reactions.", "ParentId": "d3eee1ec-e476-4257-885b-9a4f8ba65ad6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical studies using single and multiple\ninfliximab doses ranging from 1 to 20\u00a0mg/kg, antibodies to infliximab were\ndetected in 14% of\u00a0patients with any immunosuppressant therapy, and in 24%\nof\u00a0patients without immunosuppressant therapy. In rheumatoid arthritis\npatients who received the recommended repeated treatment dose regimens with\nmethotrexate, 8% of\u00a0patients developed antibodies to infliximab. In\npsoriatic arthritis patients who received 5\u00a0mg/kg with and without\nmethotrexate, antibodies occurred overall in 15% of patients (antibodies occurred\nin 4% of patients receiving methotrexate and in 26% of patients not receiving\nmethotrexate at baseline). In Crohn's disease patients who received maintenance\ntreatment, antibodies to infliximab occurred overall in 3.3% of patients receiving\nimmunosuppressants and in 13.3% of patients not receiving immunosuppressants.\nThe antibody incidence was 2\u20113\u00a0fold higher for patients treated\nepisodically. Due to methodological limitations, a negative assay did not\nexclude the presence of antibodies to infliximab. Some patients who developed\nhigh titres of antibodies to infliximab had evidence of reduced efficacy. In\npsoriasis patients treated with infliximab as a maintenance regimen in the\nabsence of concomitant immunomodulators, approximately 28% developed antibodies\nto infliximab (see section\u00a04.4: \u201cInfusion reactions and\nhypersensitivity\u201d).</span></p>", "ID": "0bd56c25-370f-4349-a186-dba7a9ae9f7f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In clinical studies using single and multiple\ninfliximab doses ranging from 1 to 20\u00a0mg/kg, antibodies to infliximab were\ndetected in 14% of\u00a0patients with any immunosuppressant therapy, and in 24%\nof\u00a0patients without immunosuppressant therapy. In rheumatoid arthritis\npatients who received the recommended repeated treatment dose regimens with\nmethotrexate, 8% of\u00a0patients developed antibodies to infliximab. In\npsoriatic arthritis patients who received 5\u00a0mg/kg with and without\nmethotrexate, antibodies occurred overall in 15% of patients (antibodies occurred\nin 4% of patients receiving methotrexate and in 26% of patients not receiving\nmethotrexate at baseline). In Crohn's disease patients who received maintenance\ntreatment, antibodies to infliximab occurred overall in 3.3% of patients receiving\nimmunosuppressants and in 13.3% of patients not receiving immunosuppressants.\nThe antibody incidence was 2\u20113\u00a0fold higher for patients treated\nepisodically. Due to methodological limitations, a negative assay did not\nexclude the presence of antibodies to infliximab. Some patients who developed\nhigh titres of antibodies to infliximab had evidence of reduced efficacy. In\npsoriasis patients treated with infliximab as a maintenance regimen in the\nabsence of concomitant immunomodulators, approximately 28% developed antibodies\nto infliximab (see section\u00a04.4: \u201cInfusion reactions and\nhypersensitivity\u201d).</span>", "ID": "32b58fde-80fb-4fd2-ba87-0497796c2cfd", "Styles": "None", "Classes": "None", "Text": "In clinical studies using single and multiple infliximab doses ranging from 1 to 20\u00a0mg/kg, antibodies to infliximab were detected in 14% of\u00a0patients with any immunosuppressant therapy, and in 24% of\u00a0patients without immunosuppressant therapy. In rheumatoid arthritis patients who received the recommended repeated treatment dose regimens with methotrexate, 8% of\u00a0patients developed antibodies to infliximab. In psoriatic arthritis patients who received 5\u00a0mg/kg with and without methotrexate, antibodies occurred overall in 15% of patients (antibodies occurred in 4% of patients receiving methotrexate and in 26% of patients not receiving methotrexate at baseline). In Crohn's disease patients who received maintenance treatment, antibodies to infliximab occurred overall in 3.3% of patients receiving immunosuppressants and in 13.3% of patients not receiving immunosuppressants. The antibody incidence was 2\u20113\u00a0fold higher for patients treated episodically. Due to methodological limitations, a negative assay did not exclude the presence of antibodies to infliximab. Some patients who developed high titres of antibodies to infliximab had evidence of reduced efficacy. In psoriasis patients treated with infliximab as a maintenance regimen in the absence of concomitant immunomodulators, approximately 28% developed antibodies to infliximab (see section\u00a04.4: \u201cInfusion reactions and hypersensitivity\u201d).", "ParentId": "0bd56c25-370f-4349-a186-dba7a9ae9f7f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8c2698ce-ac5e-468b-b7d4-61be9ae01592", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6be3edc9-946b-4050-bf83-3e85efc42a3b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8c2698ce-ac5e-468b-b7d4-61be9ae01592"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Infections</span></u></p>", "ID": "9e6aee22-8258-4c33-9b09-da21c910cfd0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Infections</span></u>", "ID": "ad9ed029-dcd2-45ae-a783-ce730b711a74", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9e6aee22-8258-4c33-9b09-da21c910cfd0"}, {"Element": "<span lang=\"EN-GB\">Infections</span>", "ID": "af410eb3-02e4-4956-abca-a09403687b0b", "Styles": "None", "Classes": "None", "Text": "Infections", "ParentId": "ad9ed029-dcd2-45ae-a783-ce730b711a74"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tuberculosis, bacterial infections,\nincluding sepsis and pneumonia, invasive fungal, viral, and other opportunistic\ninfections have been observed in patients receiving Remicade. Some of these\ninfections have been fatal; the most frequently reported opportunistic\ninfections </span><span lang=\"EN-GB\">with a mortality rate of &gt;\u00a05% </span><span lang=\"EN-GB\">include pneumocystosis, candidiasis, listeriosis and aspergillosis\n(see section\u00a04.4).</span></p>", "ID": "aceec512-15fe-48c4-b2ba-b7441b5beaff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Tuberculosis, bacterial infections,\nincluding sepsis and pneumonia, invasive fungal, viral, and other opportunistic\ninfections have been observed in patients receiving Remicade. Some of these\ninfections have been fatal; the most frequently reported opportunistic\ninfections </span>", "ID": "b643af3e-7fe3-4587-b64f-79d361aec0b9", "Styles": "None", "Classes": "None", "Text": "Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other opportunistic infections have been observed in patients receiving Remicade. Some of these infections have been fatal; the most frequently reported opportunistic infections ", "ParentId": "aceec512-15fe-48c4-b2ba-b7441b5beaff"}, {"Element": "<span lang=\"EN-GB\">with a mortality rate of &gt;\u00a05% </span>", "ID": "28c73211-7ade-4f7d-a4d8-7cb06ee042d2", "Styles": "None", "Classes": "None", "Text": "with a mortality rate of >\u00a05% ", "ParentId": "aceec512-15fe-48c4-b2ba-b7441b5beaff"}, {"Element": "<span lang=\"EN-GB\">include pneumocystosis, candidiasis, listeriosis and aspergillosis\n(see section\u00a04.4).</span>", "ID": "564a2609-7aab-45b1-b1e9-3eb4e818a6c5", "Styles": "None", "Classes": "None", "Text": "include pneumocystosis, candidiasis, listeriosis and aspergillosis (see section\u00a04.4).", "ParentId": "aceec512-15fe-48c4-b2ba-b7441b5beaff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "eaf6e484-9185-4428-b16e-04d612f01311", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e7fe8e42-d052-45ed-828b-f6241b689b83", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eaf6e484-9185-4428-b16e-04d612f01311"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical studies 36% of infliximab\u2011treated\npatients were treated for infections compared with 25% of placebo\u2011treated\npatients.</span></p>", "ID": "710604d3-8f41-4678-ab89-49bdb1bcd652", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In clinical studies 36% of infliximab\u2011treated\npatients were treated for infections compared with 25% of placebo\u2011treated\npatients.</span>", "ID": "04e6f46f-af69-4d82-9282-6dd70f46b7af", "Styles": "None", "Classes": "None", "Text": "In clinical studies 36% of infliximab\u2011treated patients were treated for infections compared with 25% of placebo\u2011treated patients.", "ParentId": "710604d3-8f41-4678-ab89-49bdb1bcd652"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fa79102c-0946-4f81-826c-baf8838cbfe2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "83f900af-39fd-4e31-9477-6c7497b17b0d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fa79102c-0946-4f81-826c-baf8838cbfe2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In rheumatoid arthritis clinical studies,\nthe incidence of serious infections including pneumonia was higher in\ninfliximab plus methotrexate\u2011treated patients compared with methotrexate\nalone especially at doses of 6\u00a0mg/kg or greater (see section\u00a04.4).</span></p>", "ID": "de1ef4a1-d3e6-43f7-aabe-2a85ec1a084f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In rheumatoid arthritis clinical studies,\nthe incidence of serious infections including pneumonia was higher in\ninfliximab plus methotrexate\u2011treated patients compared with methotrexate\nalone especially at doses of 6\u00a0mg/kg or greater (see section\u00a04.4).</span>", "ID": "506fc6bb-82dd-4604-8535-8c963f5ba78f", "Styles": "None", "Classes": "None", "Text": "In rheumatoid arthritis clinical studies, the incidence of serious infections including pneumonia was higher in infliximab plus methotrexate\u2011treated patients compared with methotrexate alone especially at doses of 6\u00a0mg/kg or greater (see section\u00a04.4).", "ParentId": "de1ef4a1-d3e6-43f7-aabe-2a85ec1a084f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "65c9f49f-f257-4b86-9bb6-c85606c79069", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "708fcb66-8690-4e4f-b981-1f928c8cde9b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "65c9f49f-f257-4b86-9bb6-c85606c79069"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In post\u2011marketing spontaneous\nreporting, infections are the most common serious adverse reaction. Some of the\ncases have resulted in a fatal outcome. Nearly 50% of reported deaths have been\nassociated with infection. Cases of tuberculosis, sometimes fatal, including\nmiliary tuberculosis and tuberculosis with extra\u2011pulmonary location have\nbeen reported (see section\u00a04.4).</span></p>", "ID": "a85293b3-3273-4b15-b21e-3a64c2fa55ce", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In post\u2011marketing spontaneous\nreporting, infections are the most common serious adverse reaction. Some of the\ncases have resulted in a fatal outcome. Nearly 50% of reported deaths have been\nassociated with infection. Cases of tuberculosis, sometimes fatal, including\nmiliary tuberculosis and tuberculosis with extra\u2011pulmonary location have\nbeen reported (see section\u00a04.4).</span>", "ID": "fda215b2-6b26-4fe1-920a-442c374efb37", "Styles": "None", "Classes": "None", "Text": "In post\u2011marketing spontaneous reporting, infections are the most common serious adverse reaction. Some of the cases have resulted in a fatal outcome. Nearly 50% of reported deaths have been associated with infection. Cases of tuberculosis, sometimes fatal, including miliary tuberculosis and tuberculosis with extra\u2011pulmonary location have been reported (see section\u00a04.4).", "ParentId": "a85293b3-3273-4b15-b21e-3a64c2fa55ce"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "6897e85c-d7e1-4148-bae4-9222ef39a042", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "a6aa8e38-4f70-4fcd-a32f-2ba0711056c1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6897e85c-d7e1-4148-bae4-9222ef39a042"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "437a8cdd-48ae-4f00-8976-159172f2fd6b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a6aa8e38-4f70-4fcd-a32f-2ba0711056c1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Malignancies and lymphoproliferative disorders</span></u></p>", "ID": "24d31b7d-e644-4c63-acae-150f3996fb79", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Malignancies and lymphoproliferative disorders</span></u>", "ID": "5b906d38-6d9d-47fe-acaf-4267d0080bd2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "24d31b7d-e644-4c63-acae-150f3996fb79"}, {"Element": "<span lang=\"EN-GB\">Malignancies and lymphoproliferative disorders</span>", "ID": "79ca9626-9dfd-45c4-9999-2e3741560acf", "Styles": "None", "Classes": "None", "Text": "Malignancies and lymphoproliferative disorders", "ParentId": "5b906d38-6d9d-47fe-acaf-4267d0080bd2"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">In clinical studies with infliximab </span><span lang=\"EN-GB\">in which 5,780\u00a0patients were treated,</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> representing </span><span lang=\"EN-GB\">5,494</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0patient years, </span><span lang=\"EN-GB\">5\u00a0</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">cases\nof lymphomas and </span><span lang=\"EN-GB\">26\u00a0non\u2011lymphoma\nmalignancies</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> were\ndetected as compared with </span><span lang=\"EN-GB\">no lymphomas and 1\u00a0non\u2011lymphoma\nmalignancy</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> in 1,600\u00a0placebo\u2011treated\npatients representing</span><span lang=\"EN-GB\"> 941</span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0patient years.</span></p>", "ID": "d00fca53-4cfb-439e-bc27-4bd9683c4609", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">In clinical studies with infliximab </span>", "ID": "91a92b5c-c77c-4e31-a12d-b030c24c0a00", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "In clinical studies with infliximab ", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<span lang=\"EN-GB\">in which 5,780\u00a0patients were treated,</span>", "ID": "b1e06b2b-fba3-4062-a739-6972641dec82", "Styles": "None", "Classes": "None", "Text": "in which 5,780\u00a0patients were treated,", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> representing </span>", "ID": "d6617968-f851-4bbc-92d6-33093cedc231", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": " representing ", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<span lang=\"EN-GB\">5,494</span>", "ID": "2eb6cac2-52ce-4432-827a-2b852db1076a", "Styles": "None", "Classes": "None", "Text": "5,494", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0patient years, </span>", "ID": "dff38922-184e-4e42-b0ff-b39f4002f3c8", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0patient years, ", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<span lang=\"EN-GB\">5\u00a0</span>", "ID": "d9d87fda-cc0b-495e-9ca4-a7c7248d345a", "Styles": "None", "Classes": "None", "Text": "5\u00a0", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">cases\nof lymphomas and </span>", "ID": "b9514fb6-798a-4464-9a1f-15127f8f8023", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "cases of lymphomas and ", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<span lang=\"EN-GB\">26\u00a0non\u2011lymphoma\nmalignancies</span>", "ID": "496cbb5f-2ba9-4a81-a777-f9b9e05f6570", "Styles": "None", "Classes": "None", "Text": "26\u00a0non\u2011lymphoma malignancies", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> were\ndetected as compared with </span>", "ID": "45137b3f-641e-45e9-a785-c7e1703a9f1a", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": " were detected as compared with ", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<span lang=\"EN-GB\">no lymphomas and 1\u00a0non\u2011lymphoma\nmalignancy</span>", "ID": "4ad021fa-0264-4d98-ad72-81941c3dbdb1", "Styles": "None", "Classes": "None", "Text": "no lymphomas and 1\u00a0non\u2011lymphoma malignancy", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> in 1,600\u00a0placebo\u2011treated\npatients representing</span>", "ID": "a7a572d2-d052-4080-a111-f2a587179212", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": " in 1,600\u00a0placebo\u2011treated patients representing", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<span lang=\"EN-GB\"> 941</span>", "ID": "7d9d635b-a97a-4bbb-bca5-cf19b035fe32", "Styles": "None", "Classes": "None", "Text": " 941", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0patient years.</span>", "ID": "20f21111-9bc7-4081-a120-0cb48cdb995e", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0patient years.", "ParentId": "d00fca53-4cfb-439e-bc27-4bd9683c4609"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d9a6c45e-dc0f-4b98-9d9b-8625d82978b7", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eaf82f4c-34ce-4d25-a560-3e63149db2a2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d9a6c45e-dc0f-4b98-9d9b-8625d82978b7"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In long\u2011term\nsafety follow\u2011up of clinical studies with infliximab of up to 5\u00a0years,\nrepresenting 6,234\u00a0patients\u2011years (3,210\u00a0patients), 5\u00a0cases\nof lymphoma and 38\u00a0cases of non\u2011lymphoma malignancies were reported.</span></p>", "ID": "59a643a9-fd76-49f5-bf39-831750a39677", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In long\u2011term\nsafety follow\u2011up of clinical studies with infliximab of up to 5\u00a0years,\nrepresenting 6,234\u00a0patients\u2011years (3,210\u00a0patients), 5\u00a0cases\nof lymphoma and 38\u00a0cases of non\u2011lymphoma malignancies were reported.</span>", "ID": "50b616ce-3790-4d2d-9fd6-c1eb693876ff", "Styles": "None", "Classes": "None", "Text": "In long\u2011term safety follow\u2011up of clinical studies with infliximab of up to 5\u00a0years, representing 6,234\u00a0patients\u2011years (3,210\u00a0patients), 5\u00a0cases of lymphoma and 38\u00a0cases of non\u2011lymphoma malignancies were reported.", "ParentId": "59a643a9-fd76-49f5-bf39-831750a39677"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e9624490-c2de-4689-8bd7-ab652dee54f5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fffde3f1-bbaf-4573-8f59-856cd535b478", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e9624490-c2de-4689-8bd7-ab652dee54f5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Cases of malignancies, including lymphoma, have\nalso been reported in the post\u2011marketing setting </span><span lang=\"EN-GB\">(see\nsection\u00a04.4).</span></p>", "ID": "d9ab9482-fd3d-472d-a5d1-da07dd726fbe", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Cases of malignancies, including lymphoma, have\nalso been reported in the post\u2011marketing setting </span>", "ID": "2b200174-b932-41b7-ac03-c9c58ef0c20d", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Cases of malignancies, including lymphoma, have also been reported in the post\u2011marketing setting ", "ParentId": "d9ab9482-fd3d-472d-a5d1-da07dd726fbe"}, {"Element": "<span lang=\"EN-GB\">(see\nsection\u00a04.4).</span>", "ID": "597face1-fc42-4e38-a3ef-da31c20828a7", "Styles": "None", "Classes": "None", "Text": "(see section\u00a04.4).", "ParentId": "d9ab9482-fd3d-472d-a5d1-da07dd726fbe"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b0155287-c0ed-4517-bc8a-51d954aa6e3b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2a17070c-28cc-42b3-b765-4dc8464b02d0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b0155287-c0ed-4517-bc8a-51d954aa6e3b"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In an\nexploratory clinical study involving patients with moderate to severe COPD who\nwere either current smokers or ex\u2011smokers, 157\u00a0adult patients were\ntreated with Remicade at doses similar to those used in rheumatoid arthritis\nand Crohn\u2019s disease. Nine of these patients developed malignancies,\nincluding 1\u00a0lymphoma. The median duration of follow\u2011up was 0.8\u00a0years\n(incidence 5.7% [95% CI 2.65%\u201110.6%]. There was one reported malignancy\namongst 77\u00a0control patients (median duration of follow\u2011up 0.8\u00a0years;\nincidence 1.3% [95% CI 0.03%\u20117.0%]). The majority of the malignancies\ndeveloped in the lung or head and neck.</span></p>", "ID": "bd5993ea-24b2-4ffd-925b-2c95019bdad2", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In an\nexploratory clinical study involving patients with moderate to severe COPD who\nwere either current smokers or ex\u2011smokers, 157\u00a0adult patients were\ntreated with Remicade at doses similar to those used in rheumatoid arthritis\nand Crohn\u2019s disease. Nine of these patients developed malignancies,\nincluding 1\u00a0lymphoma. The median duration of follow\u2011up was 0.8\u00a0years\n(incidence 5.7% [95% CI 2.65%\u201110.6%]. There was one reported malignancy\namongst 77\u00a0control patients (median duration of follow\u2011up 0.8\u00a0years;\nincidence 1.3% [95% CI 0.03%\u20117.0%]). The majority of the malignancies\ndeveloped in the lung or head and neck.</span>", "ID": "77b4a761-0710-4d87-a6a7-0eadfe8b78d8", "Styles": "None", "Classes": "None", "Text": "In an exploratory clinical study involving patients with moderate to severe COPD who were either current smokers or ex\u2011smokers, 157\u00a0adult patients were treated with Remicade at doses similar to those used in rheumatoid arthritis and Crohn\u2019s disease. Nine of these patients developed malignancies, including 1\u00a0lymphoma. The median duration of follow\u2011up was 0.8\u00a0years (incidence 5.7% [95% CI 2.65%\u201110.6%]. There was one reported malignancy amongst 77\u00a0control patients (median duration of follow\u2011up 0.8\u00a0years; incidence 1.3% [95% CI 0.03%\u20117.0%]). The majority of the malignancies developed in the lung or head and neck.", "ParentId": "bd5993ea-24b2-4ffd-925b-2c95019bdad2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "ee2e1a87-12d0-4c86-99dc-217b0df507ea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "459a2bde-4f87-447c-ad0d-f82e59ec24f8", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "ee2e1a87-12d0-4c86-99dc-217b0df507ea"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">A population\u2011based retrospective\ncohort study found an increased incidence of cervical cancer in women with\nrheumatoid arthritis treated with infliximab compared to biologics\u2011na\u00efve\npatients or the general population, including those over 60\u00a0years of age\n(see section\u00a04.4).</span></p>", "ID": "6ec0af57-3332-416c-b20e-27a9eab7f4b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">A population\u2011based retrospective\ncohort study found an increased incidence of cervical cancer in women with\nrheumatoid arthritis treated with infliximab compared to biologics\u2011na\u00efve\npatients or the general population, including those over 60\u00a0years of age\n(see section\u00a04.4).</span>", "ID": "73db28bd-e3ad-4a05-8beb-e97c0a48bcc7", "Styles": "None", "Classes": "None", "Text": "A population\u2011based retrospective cohort study found an increased incidence of cervical cancer in women with rheumatoid arthritis treated with infliximab compared to biologics\u2011na\u00efve patients or the general population, including those over 60\u00a0years of age (see section\u00a04.4).", "ParentId": "6ec0af57-3332-416c-b20e-27a9eab7f4b4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "6967ce72-6a7f-4f58-ba07-a6881e732a47", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "4bbb1c09-1739-4cfc-8672-7223961cc3cf", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "6967ce72-6a7f-4f58-ba07-a6881e732a47"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In addition, post\u2011marketing cases of\nhepatosplenic T\u2011cell lymphoma have been reported in patients treated with\nRemicade with the vast majority of cases occurring in Crohn\u2019s disease </span><span lang=\"EN-GB\">and ulcerative colitis, and most of whom were adolescent or young\nadult males</span><span lang=\"EN-GB\"> (see section\u00a04.4).</span></p>", "ID": "e781927e-45b1-4f92-84f7-e0f28d743089", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In addition, post\u2011marketing cases of\nhepatosplenic T\u2011cell lymphoma have been reported in patients treated with\nRemicade with the vast majority of cases occurring in Crohn\u2019s disease </span>", "ID": "139df3a4-83c0-4c63-9e93-e1821cef678f", "Styles": "None", "Classes": "None", "Text": "In addition, post\u2011marketing cases of hepatosplenic T\u2011cell lymphoma have been reported in patients treated with Remicade with the vast majority of cases occurring in Crohn\u2019s disease ", "ParentId": "e781927e-45b1-4f92-84f7-e0f28d743089"}, {"Element": "<span lang=\"EN-GB\">and ulcerative colitis, and most of whom were adolescent or young\nadult males</span>", "ID": "bb7d8f19-00cf-40c8-a928-7fa5ba0b4681", "Styles": "None", "Classes": "None", "Text": "and ulcerative colitis, and most of whom were adolescent or young adult males", "ParentId": "e781927e-45b1-4f92-84f7-e0f28d743089"}, {"Element": "<span lang=\"EN-GB\"> (see section\u00a04.4).</span>", "ID": "c117dd50-9ab4-4352-92b3-119d208b4050", "Styles": "None", "Classes": "None", "Text": " (see section\u00a04.4).", "ParentId": "e781927e-45b1-4f92-84f7-e0f28d743089"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "ec9d3a03-cb3a-443e-9b2b-cda8aa361dbb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "a3c91659-fb49-4d6f-a07f-334b72bf5a0d", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "ec9d3a03-cb3a-443e-9b2b-cda8aa361dbb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Heart\nfailure</span></u></p>", "ID": "e682ffb0-8b94-4b49-b962-82248f6fe35c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Heart\nfailure</span></u>", "ID": "d3b2811f-fc43-4801-98be-158e9acc7f48", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e682ffb0-8b94-4b49-b962-82248f6fe35c"}, {"Element": "<span lang=\"EN-GB\">Heart\nfailure</span>", "ID": "9d50e251-7726-4296-9c96-6c92b370314e", "Styles": "None", "Classes": "None", "Text": "Heart failure", "ParentId": "d3b2811f-fc43-4801-98be-158e9acc7f48"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In a Phase II study aimed at evaluating\nRemicade in CHF, higher incidence of mortality due to worsening of heart\nfailure were seen in patients treated with Remicade, especially those treated\nwith the higher dose of 10\u00a0mg/kg (i.e. twice the maximum approved dose).\nIn this study 150\u00a0patients with NYHA Class III\u2011IV CHF (left\nventricular ejection fraction \u2264\u00a035%) were treated with\n3\u00a0infusions of Remicade 5\u00a0mg/kg, 10\u00a0mg/kg, or placebo over 6\u00a0weeks.\nAt 38\u00a0weeks, 9 of 101\u00a0patients treated with Remicade (2 at 5\u00a0mg/kg\nand 7 at 10\u00a0mg/kg) died compared to one death among the 49\u00a0patients\non placebo.</span></p>", "ID": "a744fac3-73be-48fc-a29f-9edefa889e10", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In a Phase II study aimed at evaluating\nRemicade in CHF, higher incidence of mortality due to worsening of heart\nfailure were seen in patients treated with Remicade, especially those treated\nwith the higher dose of 10\u00a0mg/kg (i.e. twice the maximum approved dose).\nIn this study 150\u00a0patients with NYHA Class III\u2011IV CHF (left\nventricular ejection fraction \u2264\u00a035%) were treated with\n3\u00a0infusions of Remicade 5\u00a0mg/kg, 10\u00a0mg/kg, or placebo over 6\u00a0weeks.\nAt 38\u00a0weeks, 9 of 101\u00a0patients treated with Remicade (2 at 5\u00a0mg/kg\nand 7 at 10\u00a0mg/kg) died compared to one death among the 49\u00a0patients\non placebo.</span>", "ID": "504a9875-b951-4998-bb8c-841d46804708", "Styles": "None", "Classes": "None", "Text": "In a Phase II study aimed at evaluating Remicade in CHF, higher incidence of mortality due to worsening of heart failure were seen in patients treated with Remicade, especially those treated with the higher dose of 10\u00a0mg/kg (i.e. twice the maximum approved dose). In this study 150\u00a0patients with NYHA Class III\u2011IV CHF (left ventricular ejection fraction \u2264\u00a035%) were treated with 3\u00a0infusions of Remicade 5\u00a0mg/kg, 10\u00a0mg/kg, or placebo over 6\u00a0weeks. At 38\u00a0weeks, 9 of 101\u00a0patients treated with Remicade (2 at 5\u00a0mg/kg and 7 at 10\u00a0mg/kg) died compared to one death among the 49\u00a0patients on placebo.", "ParentId": "a744fac3-73be-48fc-a29f-9edefa889e10"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There have been post\u2011marketing\nreports of worsening heart failure, with and without identifiable precipitating\nfactors, in patients taking Remicade. There have also been post\u2011marketing\nreports of new onset heart failure, including heart failure in patients without\nknown pre\u2011existing cardiovascular disease. Some of these patients have\nbeen under 50\u00a0years of age.</span></p>", "ID": "8c9ade25-c5fd-439d-b44a-b3f4df62675f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">There have been post\u2011marketing\nreports of worsening heart failure, with and without identifiable precipitating\nfactors, in patients taking Remicade. There have also been post\u2011marketing\nreports of new onset heart failure, including heart failure in patients without\nknown pre\u2011existing cardiovascular disease. Some of these patients have\nbeen under 50\u00a0years of age.</span>", "ID": "3347f0ff-a9eb-489c-ab89-881db56fa27c", "Styles": "None", "Classes": "None", "Text": "There have been post\u2011marketing reports of worsening heart failure, with and without identifiable precipitating factors, in patients taking Remicade. There have also been post\u2011marketing reports of new onset heart failure, including heart failure in patients without known pre\u2011existing cardiovascular disease. Some of these patients have been under 50\u00a0years of age.", "ParentId": "8c9ade25-c5fd-439d-b44a-b3f4df62675f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b91c90e4-1ca1-4f10-a1d5-2e5c0e666904", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b49c76b-f24e-4fd7-8df9-8d21137c349c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b91c90e4-1ca1-4f10-a1d5-2e5c0e666904"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\nevents</span></u></p>", "ID": "7caa356f-b6ad-4da4-ade3-16ad2598a49e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Hepatobiliary\nevents</span></u>", "ID": "a89bd95c-5b59-490f-96b7-c553fabbd2c5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7caa356f-b6ad-4da4-ade3-16ad2598a49e"}, {"Element": "<span lang=\"EN-GB\">Hepatobiliary\nevents</span>", "ID": "9e2d6da2-c2bf-4ad5-ab74-edd8cc8837c1", "Styles": "None", "Classes": "None", "Text": "Hepatobiliary events", "ParentId": "a89bd95c-5b59-490f-96b7-c553fabbd2c5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In clinical studies, mild or moderate\nelevations of ALT and AST have been observed in patients receiving Remicade\nwithout progression to severe hepatic injury. Elevations of ALT \u2265\u00a05\u00a0x\u00a0Upper\nLimit of Normal (ULN) have been observed (see Table\u00a02). Elevations of\naminotransferases were observed (ALT more common than AST) in a greater\nproportion of patients receiving Remicade than in controls, both when Remicade\nwas given as monotherapy and when it was used in combination with other\nimmunosuppressive agents. Most aminotransferase abnormalities were transient;\nhowever, a small number of patients experienced more prolonged elevations. In\ngeneral, patients who developed ALT and AST elevations were asymptomatic, and\nthe abnormalities decreased or resolved with either continuation or\ndiscontinuation of Remicade, or modification of concomitant therapy.<i> </i>In\npost\u2011marketing surveillance, cases of jaundice and hepatitis, some with\nfeatures of autoimmune hepatitis, have been reported in patients receiving\nRemicade (see section\u00a04.4).</span></p>", "ID": "c2fa776f-dd02-498c-b26f-cf66b706165a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In clinical studies, mild or moderate\nelevations of ALT and AST have been observed in patients receiving Remicade\nwithout progression to severe hepatic injury. Elevations of ALT \u2265\u00a05\u00a0x\u00a0Upper\nLimit of Normal (ULN) have been observed (see Table\u00a02). Elevations of\naminotransferases were observed (ALT more common than AST) in a greater\nproportion of patients receiving Remicade than in controls, both when Remicade\nwas given as monotherapy and when it was used in combination with other\nimmunosuppressive agents. Most aminotransferase abnormalities were transient;\nhowever, a small number of patients experienced more prolonged elevations. In\ngeneral, patients who developed ALT and AST elevations were asymptomatic, and\nthe abnormalities decreased or resolved with either continuation or\ndiscontinuation of Remicade, or modification of concomitant therapy.<i> </i>In\npost\u2011marketing surveillance, cases of jaundice and hepatitis, some with\nfeatures of autoimmune hepatitis, have been reported in patients receiving\nRemicade (see section\u00a04.4).</span>", "ID": "2601d27b-17e9-440f-b2c0-c9c478cf0cc3", "Styles": "None", "Classes": "None", "Text": "In clinical studies, mild or moderate elevations of ALT and AST have been observed in patients receiving Remicade without progression to severe hepatic injury. Elevations of ALT \u2265\u00a05\u00a0x\u00a0Upper Limit of Normal (ULN) have been observed (see Table\u00a02). Elevations of aminotransferases were observed (ALT more common than AST) in a greater proportion of patients receiving Remicade than in controls, both when Remicade was given as monotherapy and when it was used in combination with other immunosuppressive agents. Most aminotransferase abnormalities were transient; however, a small number of patients experienced more prolonged elevations. In general, patients who developed ALT and AST elevations were asymptomatic, and the abnormalities decreased or resolved with either continuation or discontinuation of Remicade, or modification of concomitant therapy.In post\u2011marketing surveillance, cases of jaundice and hepatitis, some with features of autoimmune hepatitis, have been reported in patients receiving Remicade (see section\u00a04.4).", "ParentId": "c2fa776f-dd02-498c-b26f-cf66b706165a"}, {"Element": "<i> </i>", "ID": "58f75a57-f24d-4c6a-9103-742d088cbe05", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "2601d27b-17e9-440f-b2c0-c9c478cf0cc3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f794212f-cc84-4f9c-ab3a-c3b7ddf9671c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "08d4f3f5-b4f5-4ccd-aaa2-7a86fa541bc0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f794212f-cc84-4f9c-ab3a-c3b7ddf9671c"}, {"Element": "<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"9\" style=\"width:457.9pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"611\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a02</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Proportion of patients with increased ALT activity\n  in clinical studies</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td rowspan=\"2\" style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Indication</span></p>\n</td>\n<td colspan=\"2\" style=\"width:99.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"133\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Number of patients<sup>3</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:99.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"133\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median follow\u2011up (wks)<sup>4</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:98.55pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a03\u00a0x ULN</span></p>\n</td>\n<td colspan=\"2\" style=\"width:100.25pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a05\u00a0x ULN</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Rheumatoid\n  arthritis<sup>1</sup></span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">375</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,087</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.3</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.2%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.9%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.8%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.9%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Crohn\u2019s\n  disease<sup>2</sup></span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">324</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1034</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.7</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">54.0</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.9%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Crohn\u2019s disease</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">139</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.0</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.4%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ulcerative\n  colitis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">242</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">482</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.8</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.2%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.5%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Ulcerative colitis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">60</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">49.4</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.7%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.7%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ankylosing\n  spondylitis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">76</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">275</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">24.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">101.9</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">9.5%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.6%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Psoriatic\n  arthritis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">98</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">191</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">18.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">39.1</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.8%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Plaque psoriasis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">281</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,175</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">16.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">50.1</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.7%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.4%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"9\" style=\"width:457.9pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"611\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">1</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients received methotrexate while infliximab patients received both\n  infliximab and methotrexate.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">2</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients in the 2\u00a0Phase III studies in Crohn\u2019s disease, ACCENT I and\n  ACCENT II, received an initial dose of 5\u00a0mg/kg infliximab at study start\n  and were on placebo in the maintenance phase. Patients who were randomised to\n  the placebo maintenance group and then later crossed over to infliximab are\n  included in the infliximab group in the ALT analysis. In the Phase IIIb trial\n  in Crohn\u2019s disease, SONIC, placebo patients received AZA 2.5\u00a0mg/kg/day\n  as active control in addition to placebo infliximab infusions.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">3</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Number\n  of patients evaluated for ALT.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">4</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Median\n  follow\u2011up is based on patients treated.</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "d59832e7-d0fc-4895-aacb-c63cc3efa41a", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"9\" style=\"width:457.9pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"611\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a02</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Proportion of patients with increased ALT activity\n  in clinical studies</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td rowspan=\"2\" style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Indication</span></p>\n</td>\n<td colspan=\"2\" style=\"width:99.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"133\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Number of patients<sup>3</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:99.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"133\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median follow\u2011up (wks)<sup>4</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:98.55pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a03\u00a0x ULN</span></p>\n</td>\n<td colspan=\"2\" style=\"width:100.25pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a05\u00a0x ULN</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Rheumatoid\n  arthritis<sup>1</sup></span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">375</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,087</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.3</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.2%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.9%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.8%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.9%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Crohn\u2019s\n  disease<sup>2</sup></span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">324</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1034</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.7</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">54.0</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.9%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Crohn\u2019s disease</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">139</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.0</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.4%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ulcerative\n  colitis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">242</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">482</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.8</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.2%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.5%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Ulcerative colitis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">60</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">49.4</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.7%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.7%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ankylosing\n  spondylitis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">76</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">275</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">24.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">101.9</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">9.5%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.6%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Psoriatic\n  arthritis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">98</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">191</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">18.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">39.1</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.8%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Plaque psoriasis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">281</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,175</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">16.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">50.1</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.7%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.4%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"9\" style=\"width:457.9pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"611\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">1</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients received methotrexate while infliximab patients received both\n  infliximab and methotrexate.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">2</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients in the 2\u00a0Phase III studies in Crohn\u2019s disease, ACCENT I and\n  ACCENT II, received an initial dose of 5\u00a0mg/kg infliximab at study start\n  and were on placebo in the maintenance phase. Patients who were randomised to\n  the placebo maintenance group and then later crossed over to infliximab are\n  included in the infliximab group in the ALT analysis. In the Phase IIIb trial\n  in Crohn\u2019s disease, SONIC, placebo patients received AZA 2.5\u00a0mg/kg/day\n  as active control in addition to placebo infliximab infusions.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">3</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Number\n  of patients evaluated for ALT.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">4</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Median\n  follow\u2011up is based on patients treated.</span></p>\n</td>\n</tr>\n</table>", "ID": "3c37d30f-38ad-478e-a341-064ef862011e", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "             ", "ParentId": "d59832e7-d0fc-4895-aacb-c63cc3efa41a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"9\" style=\"width:457.9pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"611\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a02</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Proportion of patients with increased ALT activity\n  in clinical studies</span></b></p>\n</td>\n</tr>", "ID": "c251c4ae-871c-49ba-849a-ab8fdbb28825", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "3c37d30f-38ad-478e-a341-064ef862011e"}, {"Element": "<td colspan=\"9\" style=\"width:457.9pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"611\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a02</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Proportion of patients with increased ALT activity\n  in clinical studies</span></b></p>\n</td>", "ID": "18e10326-3976-42f2-b92a-39d8c049cf88", "Styles": "width:457.9pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "c251c4ae-871c-49ba-849a-ab8fdbb28825"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a02</span></b></p>", "ID": "7afed2a3-78f9-4b4a-b465-6a6e4b5c1e97", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18e10326-3976-42f2-b92a-39d8c049cf88"}, {"Element": "<b><span lang=\"EN-GB\">Table\u00a02</span></b>", "ID": "9b2bdcc2-121d-4832-937a-672242202ab0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7afed2a3-78f9-4b4a-b465-6a6e4b5c1e97"}, {"Element": "<span lang=\"EN-GB\">Table\u00a02</span>", "ID": "dfdae8f0-770b-4928-86a7-7dc96da2205b", "Styles": "None", "Classes": "None", "Text": "Table\u00a02", "ParentId": "9b2bdcc2-121d-4832-937a-672242202ab0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Proportion of patients with increased ALT activity\n  in clinical studies</span></b></p>", "ID": "32a4d33d-7f46-4bfd-9941-2b96497c2dd8", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18e10326-3976-42f2-b92a-39d8c049cf88"}, {"Element": "<b><span lang=\"EN-GB\">Proportion of patients with increased ALT activity\n  in clinical studies</span></b>", "ID": "6f0465a1-940f-46ab-80e4-7a35d58b810c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "32a4d33d-7f46-4bfd-9941-2b96497c2dd8"}, {"Element": "<span lang=\"EN-GB\">Proportion of patients with increased ALT activity\n  in clinical studies</span>", "ID": "40e09300-a6c4-4a11-a043-fcac6706f68f", "Styles": "None", "Classes": "None", "Text": "Proportion of patients with increased ALT activity   in clinical studies", "ParentId": "6f0465a1-940f-46ab-80e4-7a35d58b810c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td rowspan=\"2\" style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Indication</span></p>\n</td>\n<td colspan=\"2\" style=\"width:99.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"133\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Number of patients<sup>3</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:99.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"133\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median follow\u2011up (wks)<sup>4</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:98.55pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a03\u00a0x ULN</span></p>\n</td>\n<td colspan=\"2\" style=\"width:100.25pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a05\u00a0x ULN</span></p>\n</td>\n</tr>", "ID": "8b1d3a1e-62e2-4c0e-8d1d-82b4b97065d9", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "3c37d30f-38ad-478e-a341-064ef862011e"}, {"Element": "<td rowspan=\"2\" style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Indication</span></p>\n</td>", "ID": "e3becabc-073c-4784-9a85-e8b49eab5c5f", "Styles": "width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8b1d3a1e-62e2-4c0e-8d1d-82b4b97065d9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Indication</span></p>", "ID": "7240594c-f76c-4f4b-b3d4-d84c6b2d2c04", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3becabc-073c-4784-9a85-e8b49eab5c5f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Indication</span>", "ID": "18acea1b-56f3-489e-ad0e-7d722802a65d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Indication", "ParentId": "7240594c-f76c-4f4b-b3d4-d84c6b2d2c04"}, {"Element": "<td colspan=\"2\" style=\"width:99.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"133\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Number of patients<sup>3</sup></span></p>\n</td>", "ID": "e9e6fdc5-8492-451c-b87c-b0466fdb94cb", "Styles": "width:99.4pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8b1d3a1e-62e2-4c0e-8d1d-82b4b97065d9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Number of patients<sup>3</sup></span></p>", "ID": "ee878af7-a239-4655-b947-c9bd22d31d55", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e9e6fdc5-8492-451c-b87c-b0466fdb94cb"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Number of patients<sup>3</sup></span>", "ID": "bd32bbe1-8943-454d-bfbc-cfd3b92f9719", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Number of patients", "ParentId": "ee878af7-a239-4655-b947-c9bd22d31d55"}, {"Element": "<sup>3</sup>", "ID": "6b6fabc9-3eee-4851-9c89-41ec8d9a9ed3", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "bd32bbe1-8943-454d-bfbc-cfd3b92f9719"}, {"Element": "<td colspan=\"2\" style=\"width:99.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"133\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median follow\u2011up (wks)<sup>4</sup></span></p>\n</td>", "ID": "d2cdfe19-b73f-4551-a441-f71f9a9283dc", "Styles": "width:99.5pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8b1d3a1e-62e2-4c0e-8d1d-82b4b97065d9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median follow\u2011up (wks)<sup>4</sup></span></p>", "ID": "ebca22f8-73e9-4e60-a25f-420397c7975b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d2cdfe19-b73f-4551-a441-f71f9a9283dc"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median follow\u2011up (wks)<sup>4</sup></span>", "ID": "3488d532-3989-48ba-9c3d-9d0a4017940e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Median follow\u2011up (wks)", "ParentId": "ebca22f8-73e9-4e60-a25f-420397c7975b"}, {"Element": "<sup>4</sup>", "ID": "abb02e0a-6997-49b5-9d01-402f3d8954fe", "Styles": "None", "Classes": "None", "Text": "4", "ParentId": "3488d532-3989-48ba-9c3d-9d0a4017940e"}, {"Element": "<td colspan=\"2\" style=\"width:98.55pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"131\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a03\u00a0x ULN</span></p>\n</td>", "ID": "c7aafd6e-7885-434e-95dc-663145f18504", "Styles": "width:98.55pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8b1d3a1e-62e2-4c0e-8d1d-82b4b97065d9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a03\u00a0x ULN</span></p>", "ID": "fda521cf-2727-490d-968e-6af29a2d8c3e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c7aafd6e-7885-434e-95dc-663145f18504"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a03\u00a0x ULN</span>", "ID": "79057bc3-e2fc-4906-9213-a2518dec87d3", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u2265\u00a03\u00a0x ULN", "ParentId": "fda521cf-2727-490d-968e-6af29a2d8c3e"}, {"Element": "<td colspan=\"2\" style=\"width:100.25pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"134\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a05\u00a0x ULN</span></p>\n</td>", "ID": "abc53dee-6172-4481-acba-bf7c2605a14f", "Styles": "width:100.25pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8b1d3a1e-62e2-4c0e-8d1d-82b4b97065d9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a05\u00a0x ULN</span></p>", "ID": "2229c6ce-40b8-4450-bf84-9ce2c2897a56", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "abc53dee-6172-4481-acba-bf7c2605a14f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u2265\u00a05\u00a0x ULN</span>", "ID": "4783206d-94de-426f-be1e-32d176acad81", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u2265\u00a05\u00a0x ULN", "ParentId": "2229c6ce-40b8-4450-bf84-9ce2c2897a56"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>\n</tr>", "ID": "51c22c9e-6116-4df8-9594-7b176f16fab4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "         ", "ParentId": "3c37d30f-38ad-478e-a341-064ef862011e"}, {"Element": "<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>", "ID": "adb894ed-5209-45f2-aeca-a6b39a11e9ff", "Styles": "width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51c22c9e-6116-4df8-9594-7b176f16fab4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>", "ID": "bd3ea52e-5b4e-4d31-b2d1-93d2bbbb19cf", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "adb894ed-5209-45f2-aeca-a6b39a11e9ff"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span>", "ID": "6623333a-d169-4ecf-84f5-76883a94344f", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "placebo", "ParentId": "bd3ea52e-5b4e-4d31-b2d1-93d2bbbb19cf"}, {"Element": "<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>", "ID": "2e769b9f-cdaf-4d49-bb8b-41cbee5133a8", "Styles": "width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51c22c9e-6116-4df8-9594-7b176f16fab4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>", "ID": "3f55bb8e-788e-4c23-888e-e61a71d6e66b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2e769b9f-cdaf-4d49-bb8b-41cbee5133a8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span>", "ID": "98ad08ac-7048-4d4a-b85e-f5a0e4e9f303", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "infliximab", "ParentId": "3f55bb8e-788e-4c23-888e-e61a71d6e66b"}, {"Element": "<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>", "ID": "af3ca883-9a82-49d1-bd25-abd31cca750b", "Styles": "width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51c22c9e-6116-4df8-9594-7b176f16fab4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>", "ID": "d4cfbc3d-4774-4e3f-9195-7e40855d31e9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "af3ca883-9a82-49d1-bd25-abd31cca750b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span>", "ID": "5c0ef112-6b4f-44fd-8a58-b1630fc95e05", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "placebo", "ParentId": "d4cfbc3d-4774-4e3f-9195-7e40855d31e9"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>", "ID": "61b53442-60b4-4a0b-ba6f-e9af31a8ff9f", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51c22c9e-6116-4df8-9594-7b176f16fab4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>", "ID": "ddaac30a-301b-48f2-96be-26c318ef9f1b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "61b53442-60b4-4a0b-ba6f-e9af31a8ff9f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span>", "ID": "ee4ead9b-fa38-4978-86b2-1b0f63f17b78", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "infliximab", "ParentId": "ddaac30a-301b-48f2-96be-26c318ef9f1b"}, {"Element": "<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>", "ID": "0f5d276a-8797-45aa-a8ae-ffe920c7f31d", "Styles": "width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51c22c9e-6116-4df8-9594-7b176f16fab4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>", "ID": "404851c6-79c6-47aa-80cb-b3c7ba047840", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0f5d276a-8797-45aa-a8ae-ffe920c7f31d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span>", "ID": "b915a784-a546-4d9e-ab68-70af6a745b28", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "placebo", "ParentId": "404851c6-79c6-47aa-80cb-b3c7ba047840"}, {"Element": "<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>", "ID": "7cedb952-7195-4e86-a734-dca7e02a963e", "Styles": "width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51c22c9e-6116-4df8-9594-7b176f16fab4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>", "ID": "a7fd188d-acca-4fd2-8359-65ba923d77fa", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7cedb952-7195-4e86-a734-dca7e02a963e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span>", "ID": "9d6b9e56-9dd9-41f1-961a-0872f57311fc", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "infliximab", "ParentId": "a7fd188d-acca-4fd2-8359-65ba923d77fa"}, {"Element": "<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>\n</td>", "ID": "0364dc88-6b1e-46e5-a9e7-58c389964559", "Styles": "width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51c22c9e-6116-4df8-9594-7b176f16fab4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span></p>", "ID": "df59fa38-7086-4d12-9746-d1d138d65d0d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0364dc88-6b1e-46e5-a9e7-58c389964559"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">placebo</span>", "ID": "b6739afa-b312-4e0b-b7fc-aeb4fb511097", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "placebo", "ParentId": "df59fa38-7086-4d12-9746-d1d138d65d0d"}, {"Element": "<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>\n</td>", "ID": "74e6809f-7525-49be-b12a-6b461ccfda15", "Styles": "width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51c22c9e-6116-4df8-9594-7b176f16fab4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span></p>", "ID": "c9ef6567-be4c-4380-8384-38ba19e228f9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "74e6809f-7525-49be-b12a-6b461ccfda15"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span>", "ID": "e84fd760-4138-49a9-bd33-b567fd26ad59", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "infliximab", "ParentId": "c9ef6567-be4c-4380-8384-38ba19e228f9"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Rheumatoid\n  arthritis<sup>1</sup></span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">375</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,087</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.3</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.2%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.9%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.8%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.9%</span></p>\n</td>\n</tr>", "ID": "ee74803b-0229-43f8-ba88-14e53be7e1a4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "          ", "ParentId": "3c37d30f-38ad-478e-a341-064ef862011e"}, {"Element": "<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Rheumatoid\n  arthritis<sup>1</sup></span></p>\n</td>", "ID": "1ed24cd4-165b-4a32-b4f5-d4d4691d5f89", "Styles": "width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee74803b-0229-43f8-ba88-14e53be7e1a4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Rheumatoid\n  arthritis<sup>1</sup></span></p>", "ID": "5db7ab40-7aa3-4881-8f24-d446b5e8e15e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1ed24cd4-165b-4a32-b4f5-d4d4691d5f89"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Rheumatoid\n  arthritis<sup>1</sup></span>", "ID": "9bb242de-6348-4271-80dd-f1618cb62dd4", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Rheumatoid   arthritis", "ParentId": "5db7ab40-7aa3-4881-8f24-d446b5e8e15e"}, {"Element": "<sup>1</sup>", "ID": "0220e7eb-f030-44b6-8c1a-ee9aa831ca02", "Styles": "None", "Classes": "None", "Text": "1", "ParentId": "9bb242de-6348-4271-80dd-f1618cb62dd4"}, {"Element": "<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">375</span></p>\n</td>", "ID": "0abaeb66-d4b8-493b-bab5-a1cf3a99b974", "Styles": "width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee74803b-0229-43f8-ba88-14e53be7e1a4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">375</span></p>", "ID": "3212a479-2b49-42bf-b91c-d8ae926f1467", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0abaeb66-d4b8-493b-bab5-a1cf3a99b974"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">375</span>", "ID": "a9a6f6dc-0c2b-4f49-b4f1-6bd724865c0a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "375", "ParentId": "3212a479-2b49-42bf-b91c-d8ae926f1467"}, {"Element": "<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,087</span></p>\n</td>", "ID": "02607cea-8dcc-45c6-b557-4d513f2daff9", "Styles": "width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee74803b-0229-43f8-ba88-14e53be7e1a4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,087</span></p>", "ID": "a8236ce3-115b-4b70-9705-fa8cfcb46ac8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "02607cea-8dcc-45c6-b557-4d513f2daff9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,087</span>", "ID": "28dee622-217f-41b9-99c4-4a07190ad67e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "1,087", "ParentId": "a8236ce3-115b-4b70-9705-fa8cfcb46ac8"}, {"Element": "<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.1</span></p>\n</td>", "ID": "a7223ea0-83b2-4f18-8f64-9f10abfcb256", "Styles": "width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee74803b-0229-43f8-ba88-14e53be7e1a4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.1</span></p>", "ID": "27345a23-1133-4d31-aae4-450852a1d647", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a7223ea0-83b2-4f18-8f64-9f10abfcb256"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.1</span>", "ID": "1fb42da9-79d1-4c22-93e0-8e2c517e3f28", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "58.1", "ParentId": "27345a23-1133-4d31-aae4-450852a1d647"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.3</span></p>\n</td>", "ID": "331c8ef6-cf3e-4d97-af65-31a663bdd0ed", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee74803b-0229-43f8-ba88-14e53be7e1a4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.3</span></p>", "ID": "d6fc9384-ca44-4337-a206-5acbbaac2643", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "331c8ef6-cf3e-4d97-af65-31a663bdd0ed"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">58.3</span>", "ID": "ed68e9ad-9258-4d7b-beaa-36f39ab121cc", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "58.3", "ParentId": "d6fc9384-ca44-4337-a206-5acbbaac2643"}, {"Element": "<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.2%</span></p>\n</td>", "ID": "c8fec853-7b7c-4b22-a317-1ec01ca8a5c4", "Styles": "width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee74803b-0229-43f8-ba88-14e53be7e1a4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.2%</span></p>", "ID": "fb9e4eb9-0d26-4cab-8479-54f398786ce9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c8fec853-7b7c-4b22-a317-1ec01ca8a5c4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.2%</span>", "ID": "f0cc4ff5-28d5-4d12-a82d-ccb4b78c2fdb", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "3.2%", "ParentId": "fb9e4eb9-0d26-4cab-8479-54f398786ce9"}, {"Element": "<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.9%</span></p>\n</td>", "ID": "e44ae1dd-7bc4-4ba8-ad34-91be2cc5e965", "Styles": "width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee74803b-0229-43f8-ba88-14e53be7e1a4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.9%</span></p>", "ID": "8b427e14-c3be-4684-bec0-993c228c56ae", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e44ae1dd-7bc4-4ba8-ad34-91be2cc5e965"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.9%</span>", "ID": "1eaccb9d-048c-466f-9b17-52bb4e5fc9ae", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "3.9%", "ParentId": "8b427e14-c3be-4684-bec0-993c228c56ae"}, {"Element": "<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.8%</span></p>\n</td>", "ID": "1f30455c-02d4-4952-9f29-a077993fe535", "Styles": "width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee74803b-0229-43f8-ba88-14e53be7e1a4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.8%</span></p>", "ID": "d4c3366c-7509-4885-8aaa-7e39e384dbea", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1f30455c-02d4-4952-9f29-a077993fe535"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.8%</span>", "ID": "d9345e95-35a2-478b-b294-a854d494a0a7", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.8%", "ParentId": "d4c3366c-7509-4885-8aaa-7e39e384dbea"}, {"Element": "<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.9%</span></p>\n</td>", "ID": "c665bab0-1fc8-4442-9877-0d3ad22b1e09", "Styles": "width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee74803b-0229-43f8-ba88-14e53be7e1a4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.9%</span></p>", "ID": "3eb325b7-1bc2-4cb1-906a-4f5c5bc306bd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c665bab0-1fc8-4442-9877-0d3ad22b1e09"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.9%</span>", "ID": "0a3f8799-b3dd-4178-a718-4a61e6b6b0d8", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.9%", "ParentId": "3eb325b7-1bc2-4cb1-906a-4f5c5bc306bd"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Crohn\u2019s\n  disease<sup>2</sup></span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">324</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1034</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.7</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">54.0</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.9%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span></p>\n</td>\n</tr>", "ID": "6cc943d9-06e3-44f8-b5e3-adefb629bbc8", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "          ", "ParentId": "3c37d30f-38ad-478e-a341-064ef862011e"}, {"Element": "<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Crohn\u2019s\n  disease<sup>2</sup></span></p>\n</td>", "ID": "817a42fa-4629-4eb9-8e26-a7d6b6502afb", "Styles": "width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6cc943d9-06e3-44f8-b5e3-adefb629bbc8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Crohn\u2019s\n  disease<sup>2</sup></span></p>", "ID": "4a82605e-f923-4386-a67b-0b184cdaa0d8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "817a42fa-4629-4eb9-8e26-a7d6b6502afb"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Crohn\u2019s\n  disease<sup>2</sup></span>", "ID": "44b05095-7bb2-403e-a72f-2cb1a2578e5b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Crohn\u2019s   disease", "ParentId": "4a82605e-f923-4386-a67b-0b184cdaa0d8"}, {"Element": "<sup>2</sup>", "ID": "63a8fa90-850a-48e0-837f-1670bb3ab0f4", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "44b05095-7bb2-403e-a72f-2cb1a2578e5b"}, {"Element": "<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">324</span></p>\n</td>", "ID": "38552cf2-d92f-46a3-b73c-dac65fe889e2", "Styles": "width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6cc943d9-06e3-44f8-b5e3-adefb629bbc8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">324</span></p>", "ID": "7d1bec1b-4419-431e-af82-d8f0cb3a3a4d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "38552cf2-d92f-46a3-b73c-dac65fe889e2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">324</span>", "ID": "6130790c-96d0-410e-95f2-e1d360465f37", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "324", "ParentId": "7d1bec1b-4419-431e-af82-d8f0cb3a3a4d"}, {"Element": "<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1034</span></p>\n</td>", "ID": "b12aab48-d0dd-4de0-a469-990c8c795527", "Styles": "width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6cc943d9-06e3-44f8-b5e3-adefb629bbc8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1034</span></p>", "ID": "2c0c8b6c-dd1d-4f86-a950-098ff1b24f6b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b12aab48-d0dd-4de0-a469-990c8c795527"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">1034</span>", "ID": "36ce367c-c043-4b56-91ed-8df26a85dbd3", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "1034", "ParentId": "2c0c8b6c-dd1d-4f86-a950-098ff1b24f6b"}, {"Element": "<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.7</span></p>\n</td>", "ID": "85c05748-0334-4eef-a9ed-db13183fa8e6", "Styles": "width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6cc943d9-06e3-44f8-b5e3-adefb629bbc8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.7</span></p>", "ID": "0b4051a2-158b-48f2-a0e4-56f168576e9f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "85c05748-0334-4eef-a9ed-db13183fa8e6"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.7</span>", "ID": "a13b861a-87bc-4e22-aea2-e43d1af28c37", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "53.7", "ParentId": "0b4051a2-158b-48f2-a0e4-56f168576e9f"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">54.0</span></p>\n</td>", "ID": "21774fbc-11de-4036-8c8f-49b41b8a02db", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6cc943d9-06e3-44f8-b5e3-adefb629bbc8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">54.0</span></p>", "ID": "18605578-9205-4a28-b20b-295458b032f5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "21774fbc-11de-4036-8c8f-49b41b8a02db"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">54.0</span>", "ID": "abe7b8c2-5c24-47d9-91d2-3c0f2ef4442e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "54.0", "ParentId": "18605578-9205-4a28-b20b-295458b032f5"}, {"Element": "<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2%</span></p>\n</td>", "ID": "4cf86feb-c110-4789-ba8d-07d144fb821d", "Styles": "width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6cc943d9-06e3-44f8-b5e3-adefb629bbc8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2%</span></p>", "ID": "e16ef47d-211e-4e84-8e10-556e9066ac18", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4cf86feb-c110-4789-ba8d-07d144fb821d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.2%</span>", "ID": "b5c18f41-de26-45ca-844e-4a8dedfc36fa", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "2.2%", "ParentId": "e16ef47d-211e-4e84-8e10-556e9066ac18"}, {"Element": "<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.9%</span></p>\n</td>", "ID": "ec38dcc8-b447-487d-bff7-ee2e1aa06767", "Styles": "width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6cc943d9-06e3-44f8-b5e3-adefb629bbc8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.9%</span></p>", "ID": "f8915bc1-4035-4b65-9bb9-c40302ed8dc8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec38dcc8-b447-487d-bff7-ee2e1aa06767"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.9%</span>", "ID": "97aa73d8-5add-4534-9147-197e53e7181c", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "4.9%", "ParentId": "f8915bc1-4035-4b65-9bb9-c40302ed8dc8"}, {"Element": "<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>", "ID": "af8172f4-e2be-44c0-a430-3f9ee75e9063", "Styles": "width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6cc943d9-06e3-44f8-b5e3-adefb629bbc8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>", "ID": "d7e86fb3-6b0b-447b-84e6-8d15fdabf329", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "af8172f4-e2be-44c0-a430-3f9ee75e9063"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span>", "ID": "4a1b7ef9-0ea6-4f22-84cd-adeca1d37c3c", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.0%", "ParentId": "d7e86fb3-6b0b-447b-84e6-8d15fdabf329"}, {"Element": "<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span></p>\n</td>", "ID": "5c1c3d32-bdfd-422d-ae98-ea57f03760ef", "Styles": "width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "6cc943d9-06e3-44f8-b5e3-adefb629bbc8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span></p>", "ID": "2f27b2db-edb1-422c-8894-ac3b6e3e59a9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5c1c3d32-bdfd-422d-ae98-ea57f03760ef"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span>", "ID": "7b9b7a34-d3e0-4a08-b41a-cd16a3fe461d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "1.5%", "ParentId": "2f27b2db-edb1-422c-8894-ac3b6e3e59a9"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Crohn\u2019s disease</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">139</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.0</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.4%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span></p>\n</td>\n</tr>", "ID": "782623ce-df44-4693-b747-553a02ffeebf", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "          ", "ParentId": "3c37d30f-38ad-478e-a341-064ef862011e"}, {"Element": "<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Crohn\u2019s disease</span></p>\n</td>", "ID": "d8f8a58e-72fe-4e3e-8cf9-74cb6d053ea4", "Styles": "width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "782623ce-df44-4693-b747-553a02ffeebf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Crohn\u2019s disease</span></p>", "ID": "a5ed0d79-0776-4be6-b6c3-1020c7447685", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d8f8a58e-72fe-4e3e-8cf9-74cb6d053ea4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Crohn\u2019s disease</span>", "ID": "da82cbca-0fc7-48c2-8286-36d319ca246e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Paediatric   Crohn\u2019s disease", "ParentId": "a5ed0d79-0776-4be6-b6c3-1020c7447685"}, {"Element": "<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>", "ID": "fbfc49c6-c572-440b-8b1c-fbb5941b5b55", "Styles": "width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "782623ce-df44-4693-b747-553a02ffeebf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>", "ID": "b0df6812-4d38-4b70-aa2a-111abefeb65e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fbfc49c6-c572-440b-8b1c-fbb5941b5b55"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span>", "ID": "f3e37c87-775d-472b-9e8f-e52189ed8330", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "N/A", "ParentId": "b0df6812-4d38-4b70-aa2a-111abefeb65e"}, {"Element": "<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">139</span></p>\n</td>", "ID": "d1339e0f-5656-4df5-affa-2f8f93dd5289", "Styles": "width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "782623ce-df44-4693-b747-553a02ffeebf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">139</span></p>", "ID": "6b1cf621-f5e5-4910-9ebd-de912e6f86da", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d1339e0f-5656-4df5-affa-2f8f93dd5289"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">139</span>", "ID": "a1769ea3-ba2b-443e-9907-b9c69a1ed5b9", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "139", "ParentId": "6b1cf621-f5e5-4910-9ebd-de912e6f86da"}, {"Element": "<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>", "ID": "5530e16d-682d-4aad-bacf-f06b43c029a4", "Styles": "width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "782623ce-df44-4693-b747-553a02ffeebf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>", "ID": "e9dc2792-8c95-4fdf-8c0e-ec865a86bf51", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5530e16d-682d-4aad-bacf-f06b43c029a4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span>", "ID": "539aad1d-c142-4eea-887a-7227ea56fc70", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "N/A", "ParentId": "e9dc2792-8c95-4fdf-8c0e-ec865a86bf51"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.0</span></p>\n</td>", "ID": "644cea70-7f35-4c61-bf12-f9ac664b9782", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "782623ce-df44-4693-b747-553a02ffeebf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.0</span></p>", "ID": "6311b014-d815-4774-b694-01678dd20b72", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "644cea70-7f35-4c61-bf12-f9ac664b9782"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">53.0</span>", "ID": "4de1b0bb-4b08-4967-be6e-9cc59d06be85", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "53.0", "ParentId": "6311b014-d815-4774-b694-01678dd20b72"}, {"Element": "<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>", "ID": "92046ad6-c9b2-47a7-9b22-f0ae894d2c34", "Styles": "width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "782623ce-df44-4693-b747-553a02ffeebf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>", "ID": "65d25224-2968-469d-a5a5-1c3e1a20b180", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "92046ad6-c9b2-47a7-9b22-f0ae894d2c34"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span>", "ID": "c8a7589e-4a88-4ff4-aa7b-6170380fbcdd", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "N/A", "ParentId": "65d25224-2968-469d-a5a5-1c3e1a20b180"}, {"Element": "<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.4%</span></p>\n</td>", "ID": "85b9b4fe-7ac9-4c59-83b7-c207932c1c7a", "Styles": "width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "782623ce-df44-4693-b747-553a02ffeebf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.4%</span></p>", "ID": "cd5da985-54e5-4c6f-8f8b-c05689a75e09", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "85b9b4fe-7ac9-4c59-83b7-c207932c1c7a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.4%</span>", "ID": "48828e9c-f0b4-4c4a-a537-ad296fb12f5c", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "4.4%", "ParentId": "cd5da985-54e5-4c6f-8f8b-c05689a75e09"}, {"Element": "<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>", "ID": "852190f1-d578-4a3e-b2f5-e53cde2f7ae9", "Styles": "width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "782623ce-df44-4693-b747-553a02ffeebf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>", "ID": "ac890f71-3e40-4f1b-bb99-af40cd07763c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "852190f1-d578-4a3e-b2f5-e53cde2f7ae9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span>", "ID": "a27680b4-10ca-4a6c-8217-4e4a68402b57", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "N/A", "ParentId": "ac890f71-3e40-4f1b-bb99-af40cd07763c"}, {"Element": "<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span></p>\n</td>", "ID": "f222801e-9e7a-4c68-aed7-0a4af4c0ac2e", "Styles": "width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "782623ce-df44-4693-b747-553a02ffeebf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span></p>", "ID": "39c4a1f5-9d09-41a2-a448-dbc7d2639144", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f222801e-9e7a-4c68-aed7-0a4af4c0ac2e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.5%</span>", "ID": "d4d8679c-22a1-4b49-8a27-b43342f49285", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "1.5%", "ParentId": "39c4a1f5-9d09-41a2-a448-dbc7d2639144"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ulcerative\n  colitis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">242</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">482</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.8</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.2%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.5%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6%</span></p>\n</td>\n</tr>", "ID": "8f9473f5-f574-4d20-aece-91aa764a4167", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "          ", "ParentId": "3c37d30f-38ad-478e-a341-064ef862011e"}, {"Element": "<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ulcerative\n  colitis</span></p>\n</td>", "ID": "929f6e77-daae-48aa-8f61-6dfeac9a26c8", "Styles": "width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f9473f5-f574-4d20-aece-91aa764a4167"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ulcerative\n  colitis</span></p>", "ID": "a784e165-82ea-4301-ade6-fd86c81bdcb2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "929f6e77-daae-48aa-8f61-6dfeac9a26c8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ulcerative\n  colitis</span>", "ID": "6aabbdca-cdb2-4864-af58-afd7c448202b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Ulcerative   colitis", "ParentId": "a784e165-82ea-4301-ade6-fd86c81bdcb2"}, {"Element": "<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">242</span></p>\n</td>", "ID": "2eb51e6a-2275-46f8-8c24-166380e807f6", "Styles": "width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f9473f5-f574-4d20-aece-91aa764a4167"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">242</span></p>", "ID": "986bc6c2-b7d9-4e2f-8126-8ff32290981d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2eb51e6a-2275-46f8-8c24-166380e807f6"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">242</span>", "ID": "9379d788-9049-49f0-b268-187aa6ba82ee", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "242", "ParentId": "986bc6c2-b7d9-4e2f-8126-8ff32290981d"}, {"Element": "<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">482</span></p>\n</td>", "ID": "1d9ada51-1b31-44bf-b7d6-d2bdc761aa08", "Styles": "width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f9473f5-f574-4d20-aece-91aa764a4167"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">482</span></p>", "ID": "ebb53890-15f8-4118-b8d6-b67ba35c9bab", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1d9ada51-1b31-44bf-b7d6-d2bdc761aa08"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">482</span>", "ID": "38c23112-bfc4-4b59-8f26-609bf2da9635", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "482", "ParentId": "ebb53890-15f8-4118-b8d6-b67ba35c9bab"}, {"Element": "<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.1</span></p>\n</td>", "ID": "84a662b4-147b-4817-b4c2-d58adfd6cabc", "Styles": "width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f9473f5-f574-4d20-aece-91aa764a4167"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.1</span></p>", "ID": "74d37f58-b012-4e3c-9bb3-9a2f296b9cb8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "84a662b4-147b-4817-b4c2-d58adfd6cabc"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.1</span>", "ID": "50b1d5e6-370b-4a97-b76f-f24009028132", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "30.1", "ParentId": "74d37f58-b012-4e3c-9bb3-9a2f296b9cb8"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.8</span></p>\n</td>", "ID": "576de914-d47c-4c35-9144-aeb960234a53", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f9473f5-f574-4d20-aece-91aa764a4167"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.8</span></p>", "ID": "a3f7df49-014d-49df-9c00-e9fcc123c117", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "576de914-d47c-4c35-9144-aeb960234a53"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">30.8</span>", "ID": "f5bf4ca9-7685-40ca-81c1-9b05ec8f9d2b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "30.8", "ParentId": "a3f7df49-014d-49df-9c00-e9fcc123c117"}, {"Element": "<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.2%</span></p>\n</td>", "ID": "c7197a55-4136-42fa-9127-12805dcce3c2", "Styles": "width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f9473f5-f574-4d20-aece-91aa764a4167"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.2%</span></p>", "ID": "38e52297-eef1-4ecf-a5e8-3cbf8dee41a3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c7197a55-4136-42fa-9127-12805dcce3c2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.2%</span>", "ID": "d0a4370b-d611-49ff-9a71-936b11e85718", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "1.2%", "ParentId": "38e52297-eef1-4ecf-a5e8-3cbf8dee41a3"}, {"Element": "<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.5%</span></p>\n</td>", "ID": "d10c1606-4934-461f-9d6e-b40611af01ce", "Styles": "width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f9473f5-f574-4d20-aece-91aa764a4167"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.5%</span></p>", "ID": "780a1a31-ee41-4221-a88e-5dcc894f0e07", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d10c1606-4934-461f-9d6e-b40611af01ce"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.5%</span>", "ID": "4379d17c-8592-4e8b-b9f0-abcf9347b742", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "2.5%", "ParentId": "780a1a31-ee41-4221-a88e-5dcc894f0e07"}, {"Element": "<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span></p>\n</td>", "ID": "141c5a66-b9ec-49fc-9569-9937b842c72b", "Styles": "width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f9473f5-f574-4d20-aece-91aa764a4167"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span></p>", "ID": "1f9dfef0-b460-4778-810e-43f50415107b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "141c5a66-b9ec-49fc-9569-9937b842c72b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span>", "ID": "a9e18972-ebea-4c4d-bde2-174d907272fe", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.4%", "ParentId": "1f9dfef0-b460-4778-810e-43f50415107b"}, {"Element": "<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6%</span></p>\n</td>", "ID": "d23d8313-52b1-4eb4-8f1f-6f4fdd3cf28e", "Styles": "width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f9473f5-f574-4d20-aece-91aa764a4167"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6%</span></p>", "ID": "46defb1b-3fdd-44fc-92e8-941af4357547", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d23d8313-52b1-4eb4-8f1f-6f4fdd3cf28e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6%</span>", "ID": "1e0433de-74af-44b0-8221-caa559080cda", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.6%", "ParentId": "46defb1b-3fdd-44fc-92e8-941af4357547"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Ulcerative colitis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">60</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">49.4</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.7%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.7%</span></p>\n</td>\n</tr>", "ID": "722a5864-f0b4-4252-9e68-6fe8226e7fe9", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "          ", "ParentId": "3c37d30f-38ad-478e-a341-064ef862011e"}, {"Element": "<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Ulcerative colitis</span></p>\n</td>", "ID": "b0feece4-0fce-4052-9bf5-54fdf607b86f", "Styles": "width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "722a5864-f0b4-4252-9e68-6fe8226e7fe9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Ulcerative colitis</span></p>", "ID": "7bf7671d-6119-46f8-8c1f-0a0cf06fcb25", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b0feece4-0fce-4052-9bf5-54fdf607b86f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Paediatric\n  Ulcerative colitis</span>", "ID": "dbe65e71-127c-4abe-b35c-07c1ffd57bae", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Paediatric   Ulcerative colitis", "ParentId": "7bf7671d-6119-46f8-8c1f-0a0cf06fcb25"}, {"Element": "<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>", "ID": "0576b24a-c8e6-4d21-aaca-fea20b1cac4b", "Styles": "width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "722a5864-f0b4-4252-9e68-6fe8226e7fe9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>", "ID": "602522d9-e612-48ec-9667-77ab58e1ca47", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0576b24a-c8e6-4d21-aaca-fea20b1cac4b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span>", "ID": "4f0b57f7-249a-4190-b9fb-4ce15f9ff9d9", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "N/A", "ParentId": "602522d9-e612-48ec-9667-77ab58e1ca47"}, {"Element": "<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">60</span></p>\n</td>", "ID": "0e1c803a-5fc8-44cd-9500-47a0f8b31d68", "Styles": "width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "722a5864-f0b4-4252-9e68-6fe8226e7fe9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">60</span></p>", "ID": "1e0f0202-070e-4738-8d77-f5cb5470da19", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0e1c803a-5fc8-44cd-9500-47a0f8b31d68"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">60</span>", "ID": "fbc0a236-821b-4b16-91f1-a5af1c42d43d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "60", "ParentId": "1e0f0202-070e-4738-8d77-f5cb5470da19"}, {"Element": "<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>", "ID": "b0f64f6b-15d5-4a6d-8183-cf1670b60417", "Styles": "width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "722a5864-f0b4-4252-9e68-6fe8226e7fe9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>", "ID": "9ccc569b-a613-45bd-9cb0-f577a5b63847", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b0f64f6b-15d5-4a6d-8183-cf1670b60417"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span>", "ID": "ddd65b68-5f36-45c1-acca-1fde9597fca9", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "N/A", "ParentId": "9ccc569b-a613-45bd-9cb0-f577a5b63847"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">49.4</span></p>\n</td>", "ID": "8b131515-2d41-465b-b714-c83d92c16f24", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "722a5864-f0b4-4252-9e68-6fe8226e7fe9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">49.4</span></p>", "ID": "8298463b-a715-4d50-9558-0798d962cd40", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b131515-2d41-465b-b714-c83d92c16f24"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">49.4</span>", "ID": "0a3a564c-b7d7-49fb-bd6d-2600e5295a82", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "49.4", "ParentId": "8298463b-a715-4d50-9558-0798d962cd40"}, {"Element": "<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>", "ID": "edb30e36-d092-4bd6-8195-7c108292708a", "Styles": "width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "722a5864-f0b4-4252-9e68-6fe8226e7fe9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>", "ID": "cab57498-87fa-4200-95d2-6a61056c8b05", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "edb30e36-d092-4bd6-8195-7c108292708a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span>", "ID": "faf91830-02e9-4573-9097-60ee7e1982d9", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "N/A", "ParentId": "cab57498-87fa-4200-95d2-6a61056c8b05"}, {"Element": "<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.7%</span></p>\n</td>", "ID": "d4bbaf38-9f5d-4301-a417-4a426c20df59", "Styles": "width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "722a5864-f0b4-4252-9e68-6fe8226e7fe9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.7%</span></p>", "ID": "65e45ba8-bf7c-48e9-bb51-63ef1b8aa996", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d4bbaf38-9f5d-4301-a417-4a426c20df59"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.7%</span>", "ID": "e222b84a-34d9-47fc-b7ba-5dd2a6ccacc8", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "6.7%", "ParentId": "65e45ba8-bf7c-48e9-bb51-63ef1b8aa996"}, {"Element": "<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>\n</td>", "ID": "27ace757-88f1-497b-8308-b1d12cf53c62", "Styles": "width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "722a5864-f0b4-4252-9e68-6fe8226e7fe9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span></p>", "ID": "9bb4b05b-f479-46e5-8691-2e0f08588625", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "27ace757-88f1-497b-8308-b1d12cf53c62"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">N/A</span>", "ID": "f55cc6b6-f46b-4525-96bd-425704d0b7f9", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "N/A", "ParentId": "9bb4b05b-f479-46e5-8691-2e0f08588625"}, {"Element": "<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.7%</span></p>\n</td>", "ID": "28a1f670-714a-43e6-8b42-ea0184c40487", "Styles": "width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "722a5864-f0b4-4252-9e68-6fe8226e7fe9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.7%</span></p>", "ID": "eceab021-ae1e-417e-9f80-f1d57e8ab374", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "28a1f670-714a-43e6-8b42-ea0184c40487"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.7%</span>", "ID": "4a9351d7-accd-4a03-ad1a-2d4a61af8922", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "1.7%", "ParentId": "eceab021-ae1e-417e-9f80-f1d57e8ab374"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ankylosing\n  spondylitis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">76</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">275</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">24.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">101.9</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">9.5%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.6%</span></p>\n</td>\n</tr>", "ID": "43629cb3-c0ac-4b95-bd66-1d536ed45798", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "          ", "ParentId": "3c37d30f-38ad-478e-a341-064ef862011e"}, {"Element": "<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ankylosing\n  spondylitis</span></p>\n</td>", "ID": "0cf2ddb9-20cc-4c55-8c9c-1687a6c4f7c8", "Styles": "width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43629cb3-c0ac-4b95-bd66-1d536ed45798"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ankylosing\n  spondylitis</span></p>", "ID": "d10255f7-094a-4c4b-a413-b7d9fe5b50a1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0cf2ddb9-20cc-4c55-8c9c-1687a6c4f7c8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Ankylosing\n  spondylitis</span>", "ID": "80265226-8cf2-4610-b2a1-bb9d4970dbb5", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Ankylosing   spondylitis", "ParentId": "d10255f7-094a-4c4b-a413-b7d9fe5b50a1"}, {"Element": "<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">76</span></p>\n</td>", "ID": "890679f0-1ec3-46ec-9972-769022e3c54a", "Styles": "width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43629cb3-c0ac-4b95-bd66-1d536ed45798"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">76</span></p>", "ID": "39964332-2a6d-44b1-b9b6-1d62d57dd9e6", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "890679f0-1ec3-46ec-9972-769022e3c54a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">76</span>", "ID": "9800415b-9f74-44c7-8004-a3d1f3fbb34f", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "76", "ParentId": "39964332-2a6d-44b1-b9b6-1d62d57dd9e6"}, {"Element": "<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">275</span></p>\n</td>", "ID": "2bb0d802-9708-4c34-be2d-a9d92fbde643", "Styles": "width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43629cb3-c0ac-4b95-bd66-1d536ed45798"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">275</span></p>", "ID": "a2136935-bb9b-4f29-a18c-5fb3b5c2d539", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2bb0d802-9708-4c34-be2d-a9d92fbde643"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">275</span>", "ID": "7d924d8a-5def-46d3-a28a-34fb5c7622a1", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "275", "ParentId": "a2136935-bb9b-4f29-a18c-5fb3b5c2d539"}, {"Element": "<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">24.1</span></p>\n</td>", "ID": "87b0e81d-2be1-4737-8180-1bbd529b6cbf", "Styles": "width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43629cb3-c0ac-4b95-bd66-1d536ed45798"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">24.1</span></p>", "ID": "a43f3367-d4cf-424a-9729-2e7e1cd1c87f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "87b0e81d-2be1-4737-8180-1bbd529b6cbf"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">24.1</span>", "ID": "74007ac6-fd86-42da-8c41-e64f95eb07fa", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "24.1", "ParentId": "a43f3367-d4cf-424a-9729-2e7e1cd1c87f"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">101.9</span></p>\n</td>", "ID": "dea1fd53-771f-4438-aa16-3ae7ec5d444e", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43629cb3-c0ac-4b95-bd66-1d536ed45798"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">101.9</span></p>", "ID": "6f052eae-5ec8-437f-801b-64a3212477cd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dea1fd53-771f-4438-aa16-3ae7ec5d444e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">101.9</span>", "ID": "d7383f18-118d-43e5-81fa-2d4c69dd2a10", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "101.9", "ParentId": "6f052eae-5ec8-437f-801b-64a3212477cd"}, {"Element": "<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>", "ID": "b1a74049-3c10-4943-8156-48e9bf6ba985", "Styles": "width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43629cb3-c0ac-4b95-bd66-1d536ed45798"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>", "ID": "dc2bb667-9813-4237-8be7-18c8b96d5fc1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1a74049-3c10-4943-8156-48e9bf6ba985"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span>", "ID": "e1a9a88f-0a4c-4acc-bcc8-76b889d8def4", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.0%", "ParentId": "dc2bb667-9813-4237-8be7-18c8b96d5fc1"}, {"Element": "<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">9.5%</span></p>\n</td>", "ID": "680719e3-fd27-41fb-bbbb-9bc5290422ce", "Styles": "width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43629cb3-c0ac-4b95-bd66-1d536ed45798"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">9.5%</span></p>", "ID": "21cb5b2a-08c7-45a2-b3d3-77098bef827a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "680719e3-fd27-41fb-bbbb-9bc5290422ce"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">9.5%</span>", "ID": "c709cd03-f80a-4d60-8cca-0daebc3ae1a5", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "9.5%", "ParentId": "21cb5b2a-08c7-45a2-b3d3-77098bef827a"}, {"Element": "<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>", "ID": "622a070f-fbe3-4a8f-8f25-e7fc72dba117", "Styles": "width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43629cb3-c0ac-4b95-bd66-1d536ed45798"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>", "ID": "480b3886-4524-4550-bb75-056cf2f4cc0e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "622a070f-fbe3-4a8f-8f25-e7fc72dba117"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span>", "ID": "f1c15094-f93d-4e00-afdf-f02e65b310f8", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.0%", "ParentId": "480b3886-4524-4550-bb75-056cf2f4cc0e"}, {"Element": "<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.6%</span></p>\n</td>", "ID": "b7dd8f08-ac80-496e-abfc-e45562d34281", "Styles": "width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "43629cb3-c0ac-4b95-bd66-1d536ed45798"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.6%</span></p>", "ID": "16e29f65-3a5f-4d5e-a2d1-5c4b48355fdd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b7dd8f08-ac80-496e-abfc-e45562d34281"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.6%</span>", "ID": "6ff8b6fe-58d3-4e4a-97c7-aa302202993e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "3.6%", "ParentId": "16e29f65-3a5f-4d5e-a2d1-5c4b48355fdd"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Psoriatic\n  arthritis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">98</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">191</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">18.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">39.1</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.8%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1%</span></p>\n</td>\n</tr>", "ID": "51022596-e67b-456d-b30e-9b344a5920f8", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "          ", "ParentId": "3c37d30f-38ad-478e-a341-064ef862011e"}, {"Element": "<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Psoriatic\n  arthritis</span></p>\n</td>", "ID": "4b9641f1-b469-435b-817d-bd93d9952a83", "Styles": "width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51022596-e67b-456d-b30e-9b344a5920f8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Psoriatic\n  arthritis</span></p>", "ID": "8052d589-4f63-4e4d-a539-b63eecc92e06", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4b9641f1-b469-435b-817d-bd93d9952a83"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Psoriatic\n  arthritis</span>", "ID": "dac78298-c614-464e-a7e9-aa3c1a457fe3", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Psoriatic   arthritis", "ParentId": "8052d589-4f63-4e4d-a539-b63eecc92e06"}, {"Element": "<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">98</span></p>\n</td>", "ID": "82aee688-10c1-4d6d-a7c5-39a55593f06b", "Styles": "width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51022596-e67b-456d-b30e-9b344a5920f8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">98</span></p>", "ID": "aabee7c8-3f8e-4e93-90da-b9c8812cf6da", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "82aee688-10c1-4d6d-a7c5-39a55593f06b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">98</span>", "ID": "8a84e42c-f015-4dd0-8312-7dcdf3ced98c", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "98", "ParentId": "aabee7c8-3f8e-4e93-90da-b9c8812cf6da"}, {"Element": "<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">191</span></p>\n</td>", "ID": "365d1653-638a-4e7c-a841-ffc00226c2d9", "Styles": "width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51022596-e67b-456d-b30e-9b344a5920f8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">191</span></p>", "ID": "60c342c9-938a-4968-a1b1-08b52f6232c1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "365d1653-638a-4e7c-a841-ffc00226c2d9"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">191</span>", "ID": "3375859c-c1ef-43c1-af4c-16fba5609924", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "191", "ParentId": "60c342c9-938a-4968-a1b1-08b52f6232c1"}, {"Element": "<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">18.1</span></p>\n</td>", "ID": "0632c3e4-ba60-4e2e-9e51-7dc6961982fe", "Styles": "width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51022596-e67b-456d-b30e-9b344a5920f8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">18.1</span></p>", "ID": "43aab4ec-8252-41da-b1d2-b93db1a07249", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0632c3e4-ba60-4e2e-9e51-7dc6961982fe"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">18.1</span>", "ID": "53738284-82b8-4179-824e-8629279ee06e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "18.1", "ParentId": "43aab4ec-8252-41da-b1d2-b93db1a07249"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">39.1</span></p>\n</td>", "ID": "cc24e5b9-3a4a-4cd4-9546-f4013b8546fe", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51022596-e67b-456d-b30e-9b344a5920f8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">39.1</span></p>", "ID": "3b8a394f-6953-4eb2-b5d7-fc2dc8c40a8c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cc24e5b9-3a4a-4cd4-9546-f4013b8546fe"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">39.1</span>", "ID": "ed34333b-59b7-452e-9b20-419258eeadc9", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "39.1", "ParentId": "3b8a394f-6953-4eb2-b5d7-fc2dc8c40a8c"}, {"Element": "<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>", "ID": "7c9fdb7b-a809-4945-99f5-b996e855e87e", "Styles": "width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51022596-e67b-456d-b30e-9b344a5920f8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>", "ID": "38d5fb4f-b161-4ddf-bb14-aaf70a4e4b11", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7c9fdb7b-a809-4945-99f5-b996e855e87e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span>", "ID": "c167413f-c5a2-46ee-b60b-25c914a8246d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.0%", "ParentId": "38d5fb4f-b161-4ddf-bb14-aaf70a4e4b11"}, {"Element": "<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.8%</span></p>\n</td>", "ID": "3f9cef55-1b25-47c5-957c-2fe7e5036eca", "Styles": "width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51022596-e67b-456d-b30e-9b344a5920f8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.8%</span></p>", "ID": "044b2983-9b33-4c2c-9914-4db1f4541c18", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3f9cef55-1b25-47c5-957c-2fe7e5036eca"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">6.8%</span>", "ID": "abedc760-1108-4dbb-a33f-2d2028c6400d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "6.8%", "ParentId": "044b2983-9b33-4c2c-9914-4db1f4541c18"}, {"Element": "<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>", "ID": "2f002b6a-895c-428a-b8f4-6aba63738eef", "Styles": "width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51022596-e67b-456d-b30e-9b344a5920f8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>", "ID": "b607b4a6-1eef-43f0-8e5d-a44b537e1319", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2f002b6a-895c-428a-b8f4-6aba63738eef"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span>", "ID": "e6eac6ae-4b54-4853-bc83-462912485a37", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.0%", "ParentId": "b607b4a6-1eef-43f0-8e5d-a44b537e1319"}, {"Element": "<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1%</span></p>\n</td>", "ID": "63cf37a5-db06-4360-b616-ebe01e1a8cfd", "Styles": "width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "51022596-e67b-456d-b30e-9b344a5920f8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1%</span></p>", "ID": "96117f2d-f409-40ec-813a-d1270f4dcdb6", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "63cf37a5-db06-4360-b616-ebe01e1a8cfd"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">2.1%</span>", "ID": "4c9ddc5c-1f20-4ec3-bccc-24fabf5f7dea", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "2.1%", "ParentId": "96117f2d-f409-40ec-813a-d1270f4dcdb6"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Plaque psoriasis</span></p>\n</td>\n<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">281</span></p>\n</td>\n<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,175</span></p>\n</td>\n<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">16.1</span></p>\n</td>\n<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">50.1</span></p>\n</td>\n<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span></p>\n</td>\n<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.7%</span></p>\n</td>\n<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>\n<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.4%</span></p>\n</td>\n</tr>", "ID": "363e9c79-2789-49c4-bc34-e65606251be0", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "          ", "ParentId": "3c37d30f-38ad-478e-a341-064ef862011e"}, {"Element": "<td style=\"width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"80\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Plaque psoriasis</span></p>\n</td>", "ID": "5f5a0528-0f36-4971-9f16-f3581039c759", "Styles": "width:60.2pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "363e9c79-2789-49c4-bc34-e65606251be0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Plaque psoriasis</span></p>", "ID": "2ae8681c-600e-45b8-a2a3-eb014affbd2b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f5a0528-0f36-4971-9f16-f3581039c759"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Plaque psoriasis</span>", "ID": "a5a32682-2d54-4f3c-bd59-5a562d55967f", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Plaque psoriasis", "ParentId": "2ae8681c-600e-45b8-a2a3-eb014affbd2b"}, {"Element": "<td style=\"width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"59\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">281</span></p>\n</td>", "ID": "141f7a92-9b34-4e5e-a943-8ae8f4e6b482", "Styles": "width:44.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "363e9c79-2789-49c4-bc34-e65606251be0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">281</span></p>", "ID": "697c169b-c709-4a8b-bc56-b4324fb13c67", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "141f7a92-9b34-4e5e-a943-8ae8f4e6b482"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">281</span>", "ID": "5708b296-4fd5-42e6-9633-6cd0dc8c9c68", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "281", "ParentId": "697c169b-c709-4a8b-bc56-b4324fb13c67"}, {"Element": "<td style=\"width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,175</span></p>\n</td>", "ID": "20e36507-59c6-4940-9ca8-862b40038e35", "Styles": "width:55.2pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "363e9c79-2789-49c4-bc34-e65606251be0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,175</span></p>", "ID": "8aa161d9-cb9d-4ff9-8630-a51d5995b061", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "20e36507-59c6-4940-9ca8-862b40038e35"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">1,175</span>", "ID": "00deeab1-e0a5-4197-990d-30de01cbb916", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "1,175", "ParentId": "8aa161d9-cb9d-4ff9-8630-a51d5995b061"}, {"Element": "<td style=\"width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"61\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">16.1</span></p>\n</td>", "ID": "7fc6a489-dcf2-45a2-98e6-d77dcc579724", "Styles": "width:45.5pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "363e9c79-2789-49c4-bc34-e65606251be0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">16.1</span></p>", "ID": "40c7240f-d58a-42e1-8917-bac357371674", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7fc6a489-dcf2-45a2-98e6-d77dcc579724"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">16.1</span>", "ID": "239e7ba0-60a8-400a-8262-f8f96f2b6dc9", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "16.1", "ParentId": "40c7240f-d58a-42e1-8917-bac357371674"}, {"Element": "<td style=\"width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">50.1</span></p>\n</td>", "ID": "87708f64-1148-4b7b-8ca7-352ce5c003b0", "Styles": "width:.75in;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "363e9c79-2789-49c4-bc34-e65606251be0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">50.1</span></p>", "ID": "13243385-bcf6-47c7-8612-87a5fb228b45", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "87708f64-1148-4b7b-8ca7-352ce5c003b0"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">50.1</span>", "ID": "5a7f1cf0-b4ed-4252-83d0-480e37f12340", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "50.1", "ParentId": "13243385-bcf6-47c7-8612-87a5fb228b45"}, {"Element": "<td style=\"width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span></p>\n</td>", "ID": "ea45908d-49d4-486d-b8a7-119852464817", "Styles": "width:45.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "363e9c79-2789-49c4-bc34-e65606251be0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span></p>", "ID": "783ed04c-77c9-40c5-9053-6b3d87404b1c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ea45908d-49d4-486d-b8a7-119852464817"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.4%</span>", "ID": "0cb48245-d636-481d-af54-6747a1775f8d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.4%", "ParentId": "783ed04c-77c9-40c5-9053-6b3d87404b1c"}, {"Element": "<td style=\"width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"71\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.7%</span></p>\n</td>", "ID": "d952282b-1391-4687-88d2-0572ea5edf99", "Styles": "width:53.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "363e9c79-2789-49c4-bc34-e65606251be0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.7%</span></p>", "ID": "3e9e9e6a-d94f-4f74-a8a3-d8feda433a3f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d952282b-1391-4687-88d2-0572ea5edf99"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.7%</span>", "ID": "9e61a3a2-7e25-4148-9a71-34a207c80916", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "7.7%", "ParentId": "3e9e9e6a-d94f-4f74-a8a3-d8feda433a3f"}, {"Element": "<td style=\"width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"60\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>\n</td>", "ID": "4d83e009-591f-4359-9428-6e2642f33d40", "Styles": "width:44.8pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "363e9c79-2789-49c4-bc34-e65606251be0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span></p>", "ID": "61060b19-6192-42b9-8318-ca0e92ce3f49", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d83e009-591f-4359-9428-6e2642f33d40"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.0%</span>", "ID": "d4f8e7c5-e723-4b08-ba82-e11c37e841e1", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.0%", "ParentId": "61060b19-6192-42b9-8318-ca0e92ce3f49"}, {"Element": "<td style=\"width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"74\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.4%</span></p>\n</td>", "ID": "2ab12f36-e5aa-4427-8d33-6f0c8f4a09d7", "Styles": "width:55.45pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "363e9c79-2789-49c4-bc34-e65606251be0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.4%</span></p>", "ID": "f528eb7a-7d6a-4ab4-9df2-1f6e3fa4ebac", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2ab12f36-e5aa-4427-8d33-6f0c8f4a09d7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">3.4%</span>", "ID": "bd061837-9003-4934-889e-786dfc6849db", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "3.4%", "ParentId": "f528eb7a-7d6a-4ab4-9df2-1f6e3fa4ebac"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"9\" style=\"width:457.9pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"611\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">1</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients received methotrexate while infliximab patients received both\n  infliximab and methotrexate.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">2</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients in the 2\u00a0Phase III studies in Crohn\u2019s disease, ACCENT I and\n  ACCENT II, received an initial dose of 5\u00a0mg/kg infliximab at study start\n  and were on placebo in the maintenance phase. Patients who were randomised to\n  the placebo maintenance group and then later crossed over to infliximab are\n  included in the infliximab group in the ALT analysis. In the Phase IIIb trial\n  in Crohn\u2019s disease, SONIC, placebo patients received AZA 2.5\u00a0mg/kg/day\n  as active control in addition to placebo infliximab infusions.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">3</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Number\n  of patients evaluated for ALT.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">4</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Median\n  follow\u2011up is based on patients treated.</span></p>\n</td>\n</tr>", "ID": "5c78e421-2f0a-47ac-aba8-bb31fa715f67", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "3c37d30f-38ad-478e-a341-064ef862011e"}, {"Element": "<td colspan=\"9\" style=\"width:457.9pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"611\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">1</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients received methotrexate while infliximab patients received both\n  infliximab and methotrexate.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">2</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients in the 2\u00a0Phase III studies in Crohn\u2019s disease, ACCENT I and\n  ACCENT II, received an initial dose of 5\u00a0mg/kg infliximab at study start\n  and were on placebo in the maintenance phase. Patients who were randomised to\n  the placebo maintenance group and then later crossed over to infliximab are\n  included in the infliximab group in the ALT analysis. In the Phase IIIb trial\n  in Crohn\u2019s disease, SONIC, placebo patients received AZA 2.5\u00a0mg/kg/day\n  as active control in addition to placebo infliximab infusions.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">3</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Number\n  of patients evaluated for ALT.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">4</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Median\n  follow\u2011up is based on patients treated.</span></p>\n</td>", "ID": "12a2fd91-9acd-4d67-8cd7-a5b52aa4bb4e", "Styles": "width:457.9pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "5c78e421-2f0a-47ac-aba8-bb31fa715f67"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">1</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients received methotrexate while infliximab patients received both\n  infliximab and methotrexate.</span></p>", "ID": "9d87b704-927a-4b92-b3be-5d149780b009", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "12a2fd91-9acd-4d67-8cd7-a5b52aa4bb4e"}, {"Element": "<sup><span lang=\"EN-GB\">1</span></sup>", "ID": "71e95391-f63d-4d11-8b95-de59cec43209", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9d87b704-927a-4b92-b3be-5d149780b009"}, {"Element": "<span lang=\"EN-GB\">1</span>", "ID": "1aad39d2-b353-4d1c-a342-781243d76d60", "Styles": "None", "Classes": "None", "Text": "1", "ParentId": "71e95391-f63d-4d11-8b95-de59cec43209"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients received methotrexate while infliximab patients received both\n  infliximab and methotrexate.</span>", "ID": "34298563-ff13-4999-adfd-87c45a7651d8", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 Placebo   patients received methotrexate while infliximab patients received both   infliximab and methotrexate.", "ParentId": "9d87b704-927a-4b92-b3be-5d149780b009"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">2</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients in the 2\u00a0Phase III studies in Crohn\u2019s disease, ACCENT I and\n  ACCENT II, received an initial dose of 5\u00a0mg/kg infliximab at study start\n  and were on placebo in the maintenance phase. Patients who were randomised to\n  the placebo maintenance group and then later crossed over to infliximab are\n  included in the infliximab group in the ALT analysis. In the Phase IIIb trial\n  in Crohn\u2019s disease, SONIC, placebo patients received AZA 2.5\u00a0mg/kg/day\n  as active control in addition to placebo infliximab infusions.</span></p>", "ID": "ff83fc01-8ee9-4501-b656-10b8655f3468", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "12a2fd91-9acd-4d67-8cd7-a5b52aa4bb4e"}, {"Element": "<sup><span lang=\"EN-GB\">2</span></sup>", "ID": "9116bc73-b34b-45e9-ac93-c27134f74842", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ff83fc01-8ee9-4501-b656-10b8655f3468"}, {"Element": "<span lang=\"EN-GB\">2</span>", "ID": "e654ae6b-a4e1-4c2b-a254-1dece1448070", "Styles": "None", "Classes": "None", "Text": "2", "ParentId": "9116bc73-b34b-45e9-ac93-c27134f74842"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Placebo\n  patients in the 2\u00a0Phase III studies in Crohn\u2019s disease, ACCENT I and\n  ACCENT II, received an initial dose of 5\u00a0mg/kg infliximab at study start\n  and were on placebo in the maintenance phase. Patients who were randomised to\n  the placebo maintenance group and then later crossed over to infliximab are\n  included in the infliximab group in the ALT analysis. In the Phase IIIb trial\n  in Crohn\u2019s disease, SONIC, placebo patients received AZA 2.5\u00a0mg/kg/day\n  as active control in addition to placebo infliximab infusions.</span>", "ID": "6e2754b7-2bac-4c4d-9979-84d464ae2028", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 Placebo   patients in the 2\u00a0Phase III studies in Crohn\u2019s disease, ACCENT I and   ACCENT II, received an initial dose of 5\u00a0mg/kg infliximab at study start   and were on placebo in the maintenance phase. Patients who were randomised to   the placebo maintenance group and then later crossed over to infliximab are   included in the infliximab group in the ALT analysis. In the Phase IIIb trial   in Crohn\u2019s disease, SONIC, placebo patients received AZA 2.5\u00a0mg/kg/day   as active control in addition to placebo infliximab infusions.", "ParentId": "ff83fc01-8ee9-4501-b656-10b8655f3468"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">3</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Number\n  of patients evaluated for ALT.</span></p>", "ID": "7a85667e-eef4-470d-93a3-73c09b28167c", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "12a2fd91-9acd-4d67-8cd7-a5b52aa4bb4e"}, {"Element": "<sup><span lang=\"EN-GB\">3</span></sup>", "ID": "fbc8f2a1-b8ab-4dec-b90b-00b4e2915823", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7a85667e-eef4-470d-93a3-73c09b28167c"}, {"Element": "<span lang=\"EN-GB\">3</span>", "ID": "1b179a42-1bdf-4360-824a-3a4c80257ad9", "Styles": "None", "Classes": "None", "Text": "3", "ParentId": "fbc8f2a1-b8ab-4dec-b90b-00b4e2915823"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Number\n  of patients evaluated for ALT.</span>", "ID": "69280df0-a189-47bf-b2c3-f09b6c94c4dd", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 Number   of patients evaluated for ALT.", "ParentId": "7a85667e-eef4-470d-93a3-73c09b28167c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">4</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Median\n  follow\u2011up is based on patients treated.</span></p>", "ID": "241a7c92-9590-4cea-b664-03c8238d2d20", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "12a2fd91-9acd-4d67-8cd7-a5b52aa4bb4e"}, {"Element": "<sup><span lang=\"EN-GB\">4</span></sup>", "ID": "5fea87fd-8016-4332-bf10-70bc5828d20c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "241a7c92-9590-4cea-b664-03c8238d2d20"}, {"Element": "<span lang=\"EN-GB\">4</span>", "ID": "9f65c29f-e953-42d4-9cfc-c6a601abcf8f", "Styles": "None", "Classes": "None", "Text": "4", "ParentId": "5fea87fd-8016-4332-bf10-70bc5828d20c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Median\n  follow\u2011up is based on patients treated.</span>", "ID": "468a1ed8-1f86-4b72-842f-381c6a49f669", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 Median   follow\u2011up is based on patients treated.", "ParentId": "241a7c92-9590-4cea-b664-03c8238d2d20"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9a180a5d-a74a-47f6-b95a-af4770b97915", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "32f651db-951a-44f7-bc55-9be62ad419a4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9a180a5d-a74a-47f6-b95a-af4770b97915"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Antinuclear\nantibodies (ANA)/Anti\u2011double\u2011stranded DNA (dsDNA) antibodies</span></u></p>", "ID": "91ef78db-fc28-4915-85ca-3fa3bca35934", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Antinuclear\nantibodies (ANA)/Anti\u2011double\u2011stranded DNA (dsDNA) antibodies</span></u>", "ID": "5044f481-c548-48ad-8f6f-7411d89eac4a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "91ef78db-fc28-4915-85ca-3fa3bca35934"}, {"Element": "<span lang=\"EN-GB\">Antinuclear\nantibodies (ANA)/Anti\u2011double\u2011stranded DNA (dsDNA) antibodies</span>", "ID": "7b624390-b403-4907-ab74-551771735113", "Styles": "None", "Classes": "None", "Text": "Antinuclear antibodies (ANA)/Anti\u2011double\u2011stranded DNA (dsDNA) antibodies", "ParentId": "5044f481-c548-48ad-8f6f-7411d89eac4a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Approximately half of infliximab\u2011treated\npatients in clinical studies who were ANA negative at baseline developed a\npositive ANA during the study compared with approximately one\u00a0fifth of\nplacebo\u2011treated patients. Anti\u2011dsDNA antibodies were newly detected\nin approximately 17% of infliximab\u2011treated patients compared with 0% of\nplacebo\u2011treated patients. At the last evaluation, 57% of infliximab\u2011treated\npatients remained anti\u2011dsDNA positive. Reports of lupus and lupus\u2011like\nsyndromes, however, remain uncommon (see section\u00a04.4).</span></p>", "ID": "d77208e6-ea4b-4300-9752-12a4e1a5fa0b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Approximately half of infliximab\u2011treated\npatients in clinical studies who were ANA negative at baseline developed a\npositive ANA during the study compared with approximately one\u00a0fifth of\nplacebo\u2011treated patients. Anti\u2011dsDNA antibodies were newly detected\nin approximately 17% of infliximab\u2011treated patients compared with 0% of\nplacebo\u2011treated patients. At the last evaluation, 57% of infliximab\u2011treated\npatients remained anti\u2011dsDNA positive. Reports of lupus and lupus\u2011like\nsyndromes, however, remain uncommon (see section\u00a04.4).</span>", "ID": "c100161d-4b59-40eb-aa47-d0396e4a6b6d", "Styles": "None", "Classes": "None", "Text": "Approximately half of infliximab\u2011treated patients in clinical studies who were ANA negative at baseline developed a positive ANA during the study compared with approximately one\u00a0fifth of placebo\u2011treated patients. Anti\u2011dsDNA antibodies were newly detected in approximately 17% of infliximab\u2011treated patients compared with 0% of placebo\u2011treated patients. At the last evaluation, 57% of infliximab\u2011treated patients remained anti\u2011dsDNA positive. Reports of lupus and lupus\u2011like syndromes, however, remain uncommon (see section\u00a04.4).", "ParentId": "d77208e6-ea4b-4300-9752-12a4e1a5fa0b"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "e1e9418d-9a2f-4a79-b7d5-5c3f9591a8df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "e29b5ed0-bed7-4652-8c36-43c73d3f8830", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e1e9418d-9a2f-4a79-b7d5-5c3f9591a8df"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "354cb384-d9b9-4ea9-8354-963d5aa6e835", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e29b5ed0-bed7-4652-8c36-43c73d3f8830"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "b00cb230-6d85-479a-964d-3de4b1dc2791", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "354cb384-d9b9-4ea9-8354-963d5aa6e835"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Paediatric\npopulation</span></u></b></p>", "ID": "4b03f897-2065-48c7-bcf5-b8c1e0c7e3f3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><u><span lang=\"EN-GB\">Paediatric\npopulation</span></u></b>", "ID": "e7618f19-7b86-48cc-83a5-26d824fcd7bd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4b03f897-2065-48c7-bcf5-b8c1e0c7e3f3"}, {"Element": "<u><span lang=\"EN-GB\">Paediatric\npopulation</span></u>", "ID": "3188789d-1f85-4706-939a-774dcdc0a01e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e7618f19-7b86-48cc-83a5-26d824fcd7bd"}, {"Element": "<span lang=\"EN-GB\">Paediatric\npopulation</span>", "ID": "d5a55ce4-1cc7-488a-8e70-ac06d4dbbae8", "Styles": "None", "Classes": "None", "Text": "Paediatric population", "ParentId": "3188789d-1f85-4706-939a-774dcdc0a01e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Juvenile\nrheumatoid arthritis patients</span></u></p>", "ID": "9182c8a7-9bc2-4639-981e-8d0582f85552", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Juvenile\nrheumatoid arthritis patients</span></u>", "ID": "06107442-db96-4042-8e91-cc342cc359e8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9182c8a7-9bc2-4639-981e-8d0582f85552"}, {"Element": "<span lang=\"EN-GB\">Juvenile\nrheumatoid arthritis patients</span>", "ID": "aa877f9b-74b2-4374-ab6c-28f1e8eb5e4d", "Styles": "None", "Classes": "None", "Text": "Juvenile rheumatoid arthritis patients", "ParentId": "06107442-db96-4042-8e91-cc342cc359e8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade was studied in a clinical study </span><span lang=\"EN-GB\">in</span><span lang=\"EN-GB\"> 120\u00a0patients </span><span lang=\"EN-GB\">(age range: 4\u201117\u00a0years old) </span><span lang=\"EN-GB\">with\nactive juvenile rheumatoid arthritis despite methotrexate. </span><span lang=\"EN-GB\">Patients received 3 or 6\u00a0mg/kg infliximab as a 3\u2011dose\ninduction regimen (weeks\u00a00, 2, 6 or weeks\u00a014, 16, 20\u00a0respectively)\nfollowed by maintenance therapy every 8\u00a0weeks, in combination with methotrexate.</span></p>", "ID": "636571a3-98ad-4093-b198-b96b19dd71db", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade was studied in a clinical study </span>", "ID": "ab795bbd-a824-44d1-8ecc-f5828c642a6b", "Styles": "None", "Classes": "None", "Text": "Remicade was studied in a clinical study ", "ParentId": "636571a3-98ad-4093-b198-b96b19dd71db"}, {"Element": "<span lang=\"EN-GB\">in</span>", "ID": "c34aed85-5efd-4e8d-92a5-f80eca3d4412", "Styles": "None", "Classes": "None", "Text": "in", "ParentId": "636571a3-98ad-4093-b198-b96b19dd71db"}, {"Element": "<span lang=\"EN-GB\"> 120\u00a0patients </span>", "ID": "b06d3794-0dc6-4126-939d-81767d5c0241", "Styles": "None", "Classes": "None", "Text": " 120\u00a0patients ", "ParentId": "636571a3-98ad-4093-b198-b96b19dd71db"}, {"Element": "<span lang=\"EN-GB\">(age range: 4\u201117\u00a0years old) </span>", "ID": "40097652-d78e-4015-be5f-ccbc6c160e68", "Styles": "None", "Classes": "None", "Text": "(age range: 4\u201117\u00a0years old) ", "ParentId": "636571a3-98ad-4093-b198-b96b19dd71db"}, {"Element": "<span lang=\"EN-GB\">with\nactive juvenile rheumatoid arthritis despite methotrexate. </span>", "ID": "a9696c28-2cfb-43f3-a0f8-7864656d62f7", "Styles": "None", "Classes": "None", "Text": "with active juvenile rheumatoid arthritis despite methotrexate. ", "ParentId": "636571a3-98ad-4093-b198-b96b19dd71db"}, {"Element": "<span lang=\"EN-GB\">Patients received 3 or 6\u00a0mg/kg infliximab as a 3\u2011dose\ninduction regimen (weeks\u00a00, 2, 6 or weeks\u00a014, 16, 20\u00a0respectively)\nfollowed by maintenance therapy every 8\u00a0weeks, in combination with methotrexate.</span>", "ID": "4c4a5e0c-5874-47be-8d26-3b3cc370ccbe", "Styles": "None", "Classes": "None", "Text": "Patients received 3 or 6\u00a0mg/kg infliximab as a 3\u2011dose induction regimen (weeks\u00a00, 2, 6 or weeks\u00a014, 16, 20\u00a0respectively) followed by maintenance therapy every 8\u00a0weeks, in combination with methotrexate.", "ParentId": "636571a3-98ad-4093-b198-b96b19dd71db"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0e3ef0e1-c3eb-4d7b-bd6c-d27269e0eaf6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0532d31d-0ca3-4c6a-8227-a6c5b41f120c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0e3ef0e1-c3eb-4d7b-bd6c-d27269e0eaf6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion\nreactions</span></p>", "ID": "736df03e-9426-472c-bdfe-0308ace8cb47", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infusion\nreactions</span>", "ID": "ed3d4fc4-10fd-48ec-abe4-a0a1f6dd9f34", "Styles": "None", "Classes": "None", "Text": "Infusion reactions", "ParentId": "736df03e-9426-472c-bdfe-0308ace8cb47"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infusion reactions occurred in 35% of\npatients with juvenile rheumatoid arthritis receiving 3\u00a0mg/kg compared\nwith 17.5% of patients receiving 6\u00a0mg/kg. In the 3\u00a0mg/kg Remicade\ngroup, 4 out of 60\u00a0patients had a serious infusion reaction and\n3\u00a0patients reported a possible anaphylactic reaction (2 of which were\namong the serious infusion reactions). In the 6\u00a0mg/kg group, 2 out of 57\u00a0patients\nhad a serious infusion reaction, one of whom had a possible anaphylactic\nreaction (see section\u00a04.4).</span></p>", "ID": "3977a0e8-57e2-49a9-8fca-150a27d81fe6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infusion reactions occurred in 35% of\npatients with juvenile rheumatoid arthritis receiving 3\u00a0mg/kg compared\nwith 17.5% of patients receiving 6\u00a0mg/kg. In the 3\u00a0mg/kg Remicade\ngroup, 4 out of 60\u00a0patients had a serious infusion reaction and\n3\u00a0patients reported a possible anaphylactic reaction (2 of which were\namong the serious infusion reactions). In the 6\u00a0mg/kg group, 2 out of 57\u00a0patients\nhad a serious infusion reaction, one of whom had a possible anaphylactic\nreaction (see section\u00a04.4).</span>", "ID": "537cea61-83d1-4c72-9450-dbe737e119d7", "Styles": "None", "Classes": "None", "Text": "Infusion reactions occurred in 35% of patients with juvenile rheumatoid arthritis receiving 3\u00a0mg/kg compared with 17.5% of patients receiving 6\u00a0mg/kg. In the 3\u00a0mg/kg Remicade group, 4 out of 60\u00a0patients had a serious infusion reaction and 3\u00a0patients reported a possible anaphylactic reaction (2 of which were among the serious infusion reactions). In the 6\u00a0mg/kg group, 2 out of 57\u00a0patients had a serious infusion reaction, one of whom had a possible anaphylactic reaction (see section\u00a04.4).", "ParentId": "3977a0e8-57e2-49a9-8fca-150a27d81fe6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e9904939-9540-40c8-8c24-e7157e5d062d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3f3058a4-5344-4ec4-a4a9-01ef1fc5d204", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e9904939-9540-40c8-8c24-e7157e5d062d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Immunogenicity</span></p>", "ID": "4f068df1-6e09-49c9-98d0-6c3230bb9f9a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Immunogenicity</span>", "ID": "28f1a1c3-fe56-4b25-a007-c867fc8c3813", "Styles": "None", "Classes": "None", "Text": "Immunogenicity", "ParentId": "4f068df1-6e09-49c9-98d0-6c3230bb9f9a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Antibodies to infliximab developed in 38%\nof patients receiving 3\u00a0mg/kg compared with 12% of patients receiving 6\u00a0mg/kg.\nThe antibody titres were notably higher for the 3\u00a0mg/kg compared to the 6\u00a0mg/kg\ngroup.</span></p>", "ID": "552c4891-55ba-4eb1-901c-fe9099cf9bd4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Antibodies to infliximab developed in 38%\nof patients receiving 3\u00a0mg/kg compared with 12% of patients receiving 6\u00a0mg/kg.\nThe antibody titres were notably higher for the 3\u00a0mg/kg compared to the 6\u00a0mg/kg\ngroup.</span>", "ID": "cf4f9189-e5d3-4fc7-b112-099760244afc", "Styles": "None", "Classes": "None", "Text": "Antibodies to infliximab developed in 38% of patients receiving 3\u00a0mg/kg compared with 12% of patients receiving 6\u00a0mg/kg. The antibody titres were notably higher for the 3\u00a0mg/kg compared to the 6\u00a0mg/kg group.", "ParentId": "552c4891-55ba-4eb1-901c-fe9099cf9bd4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f852d6e0-5bac-4ba0-946e-8dd0bd998903", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8623a47f-66b0-48e6-aece-1f566e4e5f47", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f852d6e0-5bac-4ba0-946e-8dd0bd998903"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections</span></p>", "ID": "a6ce65a2-a579-4669-ba3b-25059682a069", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infections</span>", "ID": "dc9944f8-0b75-4c4f-9ab3-f93337e7223a", "Styles": "None", "Classes": "None", "Text": "Infections", "ParentId": "a6ce65a2-a579-4669-ba3b-25059682a069"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infections occurred in 68% (41/60) of\nchildren receiving 3\u00a0mg/kg over 52\u00a0weeks, 65% (37/57) of children\nreceiving infliximab 6\u00a0mg/kg over 38\u00a0weeks and 47% (28/60) of\nchildren receiving placebo over 14\u00a0weeks (see section\u00a04.4).</span></p>", "ID": "01113729-00cb-48bb-ae2d-f4de5c6913fb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infections occurred in 68% (41/60) of\nchildren receiving 3\u00a0mg/kg over 52\u00a0weeks, 65% (37/57) of children\nreceiving infliximab 6\u00a0mg/kg over 38\u00a0weeks and 47% (28/60) of\nchildren receiving placebo over 14\u00a0weeks (see section\u00a04.4).</span>", "ID": "db8fa2c3-2d26-4203-840b-b955230209a0", "Styles": "None", "Classes": "None", "Text": "Infections occurred in 68% (41/60) of children receiving 3\u00a0mg/kg over 52\u00a0weeks, 65% (37/57) of children receiving infliximab 6\u00a0mg/kg over 38\u00a0weeks and 47% (28/60) of children receiving placebo over 14\u00a0weeks (see section\u00a04.4).", "ParentId": "01113729-00cb-48bb-ae2d-f4de5c6913fb"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "7e69ebc4-d233-4c2b-89dd-f593838c29c6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "5e6438a4-a378-4a80-80ad-55a1d944475a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7e69ebc4-d233-4c2b-89dd-f593838c29c6"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8a23d15f-85c7-452c-b8df-05e6cd095b21", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5e6438a4-a378-4a80-80ad-55a1d944475a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\nCrohn\u2019s disease patients</span></u></p>", "ID": "a827a3d0-3485-44c2-a1f0-58c0ea069c11", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Paediatric\nCrohn\u2019s disease patients</span></u>", "ID": "131eaa5c-301c-4c15-be6e-8abcad1ab8ca", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a827a3d0-3485-44c2-a1f0-58c0ea069c11"}, {"Element": "<span lang=\"EN-GB\">Paediatric\nCrohn\u2019s disease patients</span>", "ID": "bbb21a40-e0fd-49ff-bbca-f89bf09ee820", "Styles": "None", "Classes": "None", "Text": "Paediatric Crohn\u2019s disease patients", "ParentId": "131eaa5c-301c-4c15-be6e-8abcad1ab8ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The following adverse reactions were\nreported more commonly in paediatric Crohn\u2019s disease patients in the\nREACH study (see section\u00a05.1) than in adult Crohn\u2019s disease\npatients: anaemia (10.7%), blood in stool (9.7%), leucopenia (8.7%), flushing\n(8.7%), viral infection (7.8%), neutropenia (6.8%), bacterial infection (5.8%),\nand respiratory tract allergic reaction (5.8%). In addition, bone fracture\n(6.8%) was reported, however, a causal association has not been established. Other\nspecial considerations are discussed below.</span></p>", "ID": "4d328712-8db4-467b-a085-a109fb006147", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The following adverse reactions were\nreported more commonly in paediatric Crohn\u2019s disease patients in the\nREACH study (see section\u00a05.1) than in adult Crohn\u2019s disease\npatients: anaemia (10.7%), blood in stool (9.7%), leucopenia (8.7%), flushing\n(8.7%), viral infection (7.8%), neutropenia (6.8%), bacterial infection (5.8%),\nand respiratory tract allergic reaction (5.8%). In addition, bone fracture\n(6.8%) was reported, however, a causal association has not been established. Other\nspecial considerations are discussed below.</span>", "ID": "0fa16d3b-ea05-4637-90f9-8d841e912d09", "Styles": "None", "Classes": "None", "Text": "The following adverse reactions were reported more commonly in paediatric Crohn\u2019s disease patients in the REACH study (see section\u00a05.1) than in adult Crohn\u2019s disease patients: anaemia (10.7%), blood in stool (9.7%), leucopenia (8.7%), flushing (8.7%), viral infection (7.8%), neutropenia (6.8%), bacterial infection (5.8%), and respiratory tract allergic reaction (5.8%). In addition, bone fracture (6.8%) was reported, however, a causal association has not been established. Other special considerations are discussed below.", "ParentId": "4d328712-8db4-467b-a085-a109fb006147"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u></p>", "ID": "828eedd9-62dd-453e-a708-f0c273c31a1e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span></u>", "ID": "a099e94f-8bbc-4149-b6e6-c2d3d3d4e6a9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "828eedd9-62dd-453e-a708-f0c273c31a1e"}, {"Element": "<span lang=\"EN-GB\"><span style=\"text-decoration:none\">\u00a0</span></span>", "ID": "63b1aaa3-f7cf-49c6-91af-59a0d8ee8de4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a099e94f-8bbc-4149-b6e6-c2d3d3d4e6a9"}, {"Element": "<span style=\"text-decoration:none\">\u00a0</span>", "ID": "715eca93-8647-473a-af77-06776f339933", "Styles": "text-decoration:none", "Classes": "None", "Text": "\u00a0", "ParentId": "63b1aaa3-f7cf-49c6-91af-59a0d8ee8de4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion\u2011related\nreactions</span></p>", "ID": "b233d019-cfa5-4175-8c65-c35114bc9c47", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infusion\u2011related\nreactions</span>", "ID": "9dc69efd-9c87-495a-8f60-d6e760f6695c", "Styles": "None", "Classes": "None", "Text": "Infusion\u2011related reactions", "ParentId": "b233d019-cfa5-4175-8c65-c35114bc9c47"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In REACH, 17.5% of randomised patients\nexperienced 1 or more infusion reactions. There were no serious infusion\nreactions, and 2\u00a0subjects in REACH had non\u2011serious anaphylactic\nreactions.</span></p>", "ID": "a8a07705-e202-43e5-97a3-18de9315f364", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In REACH, 17.5% of randomised patients\nexperienced 1 or more infusion reactions. There were no serious infusion\nreactions, and 2\u00a0subjects in REACH had non\u2011serious anaphylactic\nreactions.</span>", "ID": "b49a5863-cf0a-4277-bc99-e295bc9d3dbe", "Styles": "None", "Classes": "None", "Text": "In REACH, 17.5% of randomised patients experienced 1 or more infusion reactions. There were no serious infusion reactions, and 2\u00a0subjects in REACH had non\u2011serious anaphylactic reactions.", "ParentId": "a8a07705-e202-43e5-97a3-18de9315f364"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6e5d2957-aa40-4711-bda4-a4128474d6a5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa625208-27a0-4869-a5b7-70f5c3ba0212", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6e5d2957-aa40-4711-bda4-a4128474d6a5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Immunogenicity</span></p>", "ID": "9ba50aca-60e4-42aa-98b7-b5df17adff1e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Immunogenicity</span>", "ID": "fd6cab62-1508-4fc0-96c2-16d3ea3796e9", "Styles": "None", "Classes": "None", "Text": "Immunogenicity", "ParentId": "9ba50aca-60e4-42aa-98b7-b5df17adff1e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Antibodies to infliximab were detected in 3\n(2.9%) paediatric patients.</span></p>", "ID": "415ed87e-20a1-491a-86a4-b7eb5cd1c71a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Antibodies to infliximab were detected in 3\n(2.9%) paediatric patients.</span>", "ID": "a690ce59-633c-413c-a5fd-4fff7d494915", "Styles": "None", "Classes": "None", "Text": "Antibodies to infliximab were detected in 3 (2.9%) paediatric patients.", "ParentId": "415ed87e-20a1-491a-86a4-b7eb5cd1c71a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "acf5b5a4-9d4d-4df1-a61f-d6f025b6a8cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "11994a81-249d-45f1-92f7-0c9a25498362", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "acf5b5a4-9d4d-4df1-a61f-d6f025b6a8cd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections</span></p>", "ID": "664d3b24-a3a6-4b18-9254-51acb683e979", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infections</span>", "ID": "21b620eb-e039-496e-a23c-1ab1f0492b5d", "Styles": "None", "Classes": "None", "Text": "Infections", "ParentId": "664d3b24-a3a6-4b18-9254-51acb683e979"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the REACH study, infections were\nreported in 56.3% of randomised subjects treated with infliximab. Infections\nwere reported more frequently for subjects who received q8\u00a0week as opposed\nto q12\u00a0week infusions (73.6% and 38.0%, respectively), while serious\ninfections were reported for 3\u00a0subjects in the q8\u00a0week and\n4\u00a0subjects in the q12\u00a0week maintenance treatment group. The most\ncommonly reported infections were upper respiratory tract infection and\npharyngitis, and the most commonly reported serious infection was abscess.\nThree cases of pneumonia (1\u00a0serious) and 2\u00a0cases of herpes zoster\n(both non\u2011serious) were reported.</span></p>", "ID": "6b95e649-2fe7-469e-8322-baa2ec256770", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In the REACH study, infections were\nreported in 56.3% of randomised subjects treated with infliximab. Infections\nwere reported more frequently for subjects who received q8\u00a0week as opposed\nto q12\u00a0week infusions (73.6% and 38.0%, respectively), while serious\ninfections were reported for 3\u00a0subjects in the q8\u00a0week and\n4\u00a0subjects in the q12\u00a0week maintenance treatment group. The most\ncommonly reported infections were upper respiratory tract infection and\npharyngitis, and the most commonly reported serious infection was abscess.\nThree cases of pneumonia (1\u00a0serious) and 2\u00a0cases of herpes zoster\n(both non\u2011serious) were reported.</span>", "ID": "6eb38936-9428-428e-9108-b126e9fad48d", "Styles": "None", "Classes": "None", "Text": "In the REACH study, infections were reported in 56.3% of randomised subjects treated with infliximab. Infections were reported more frequently for subjects who received q8\u00a0week as opposed to q12\u00a0week infusions (73.6% and 38.0%, respectively), while serious infections were reported for 3\u00a0subjects in the q8\u00a0week and 4\u00a0subjects in the q12\u00a0week maintenance treatment group. The most commonly reported infections were upper respiratory tract infection and pharyngitis, and the most commonly reported serious infection was abscess. Three cases of pneumonia (1\u00a0serious) and 2\u00a0cases of herpes zoster (both non\u2011serious) were reported.", "ParentId": "6b95e649-2fe7-469e-8322-baa2ec256770"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9ee0eb64-ac55-4807-a0aa-81a74a8cdba8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be703b60-5ab8-48c5-bd59-f877d4270c39", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9ee0eb64-ac55-4807-a0aa-81a74a8cdba8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\nulcerative colitis patients</span></u></p>", "ID": "5e67016e-1052-41d3-b206-9ced3ee32dc6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Paediatric\nulcerative colitis patients</span></u>", "ID": "d9cd80c0-5dc4-4496-9a41-b72b8c541b69", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5e67016e-1052-41d3-b206-9ced3ee32dc6"}, {"Element": "<span lang=\"EN-GB\">Paediatric\nulcerative colitis patients</span>", "ID": "e488403b-a10e-4a3e-99d8-f5179101537e", "Styles": "None", "Classes": "None", "Text": "Paediatric ulcerative colitis patients", "ParentId": "d9cd80c0-5dc4-4496-9a41-b72b8c541b69"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Overall, the adverse reactions reported in\nthe paediatric ulcerative colitis trial (C0168T72) and adult ulcerative colitis\n(ACT\u00a01 and ACT\u00a02) studies were generally consistent. In C0168T72, the\nmost common adverse reactions were upper respiratory tract infection,\npharyngitis, abdominal pain, fever, and headache. The most common adverse event\nwas worsening of ulcerative colitis, the incidence of which was higher in\npatients on the q12\u00a0week vs. the q8\u00a0week dosing regimen.</span></p>", "ID": "32cd3014-fee3-4ee9-bd41-44570ba159d6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Overall, the adverse reactions reported in\nthe paediatric ulcerative colitis trial (C0168T72) and adult ulcerative colitis\n(ACT\u00a01 and ACT\u00a02) studies were generally consistent. In C0168T72, the\nmost common adverse reactions were upper respiratory tract infection,\npharyngitis, abdominal pain, fever, and headache. The most common adverse event\nwas worsening of ulcerative colitis, the incidence of which was higher in\npatients on the q12\u00a0week vs. the q8\u00a0week dosing regimen.</span>", "ID": "0b44b5db-8c5f-47cb-aecf-8eb2bce63040", "Styles": "None", "Classes": "None", "Text": "Overall, the adverse reactions reported in the paediatric ulcerative colitis trial (C0168T72) and adult ulcerative colitis (ACT\u00a01 and ACT\u00a02) studies were generally consistent. In C0168T72, the most common adverse reactions were upper respiratory tract infection, pharyngitis, abdominal pain, fever, and headache. The most common adverse event was worsening of ulcerative colitis, the incidence of which was higher in patients on the q12\u00a0week vs. the q8\u00a0week dosing regimen.", "ParentId": "32cd3014-fee3-4ee9-bd41-44570ba159d6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "153c932b-2bc0-4caf-a578-07bbbc66f44f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7eae820e-76a4-4826-8d81-609a18d14ea8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "153c932b-2bc0-4caf-a578-07bbbc66f44f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infusion\u2011related\nreactions</span></p>", "ID": "2482e658-ebb3-444f-99c8-87a008de27e6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infusion\u2011related\nreactions</span>", "ID": "4f9a97ce-f401-4d1e-9e69-3dd722fe91d2", "Styles": "None", "Classes": "None", "Text": "Infusion\u2011related reactions", "ParentId": "2482e658-ebb3-444f-99c8-87a008de27e6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Overall, 8 (13.3%) of 60\u00a0treated patients\nexperienced one or more infusion reactions, with 4 of 22 (18.2%) in the q8\u00a0week\nand 3 of 23 (13.0%) in the q12\u00a0week treatment maintenance group. No\nserious infusion reactions were reported. All infusion reactions were mild or\nmoderate in intensity.</span></p>", "ID": "3fdfd765-c3bd-4a51-ba69-d73410f594a2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Overall, 8 (13.3%) of 60\u00a0treated patients\nexperienced one or more infusion reactions, with 4 of 22 (18.2%) in the q8\u00a0week\nand 3 of 23 (13.0%) in the q12\u00a0week treatment maintenance group. No\nserious infusion reactions were reported. All infusion reactions were mild or\nmoderate in intensity.</span>", "ID": "c545c8a4-fbd8-4fde-9e9c-58549d3a84c9", "Styles": "None", "Classes": "None", "Text": "Overall, 8 (13.3%) of 60\u00a0treated patients experienced one or more infusion reactions, with 4 of 22 (18.2%) in the q8\u00a0week and 3 of 23 (13.0%) in the q12\u00a0week treatment maintenance group. No serious infusion reactions were reported. All infusion reactions were mild or moderate in intensity.", "ParentId": "3fdfd765-c3bd-4a51-ba69-d73410f594a2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "80f97c4c-67d4-4b17-8aa1-19d919e9aa86", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "58b970e6-9658-459d-9f86-5dea47fbbe43", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "80f97c4c-67d4-4b17-8aa1-19d919e9aa86"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Immunogenicity</span></p>", "ID": "c89f616f-cd7c-4a0b-9d8e-a02f209d9ff8", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Immunogenicity</span>", "ID": "e75f5e80-dd5b-41fc-854d-464ca3c5b338", "Styles": "None", "Classes": "None", "Text": "Immunogenicity", "ParentId": "c89f616f-cd7c-4a0b-9d8e-a02f209d9ff8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Antibodies to infliximab were detected in\n4\u00a0(7.7%) patients through week\u00a054.</span></p>", "ID": "97510a4c-b265-4e68-b989-1b7ec4ca5693", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Antibodies to infliximab were detected in\n4\u00a0(7.7%) patients through week\u00a054.</span>", "ID": "ea54868f-dc1e-4522-9702-fafacc861ef8", "Styles": "None", "Classes": "None", "Text": "Antibodies to infliximab were detected in 4\u00a0(7.7%) patients through week\u00a054.", "ParentId": "97510a4c-b265-4e68-b989-1b7ec4ca5693"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "40146af4-8f6e-4bcb-a9e8-c87498ced57b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a4627296-7ddb-4b1b-86b7-b6e9fa20f660", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "40146af4-8f6e-4bcb-a9e8-c87498ced57b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Infections</span></p>", "ID": "731f6ba6-f6a1-472b-8a52-73a563a88caa", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infections</span>", "ID": "845bd623-dc1e-4e1f-a14e-20ee695eb33e", "Styles": "None", "Classes": "None", "Text": "Infections", "ParentId": "731f6ba6-f6a1-472b-8a52-73a563a88caa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infections were reported in 31 (51.7%) of\n60\u00a0treated patients in C0168T72 and 22 (36.7%) required oral or parenteral\nantimicrobial treatment. The proportion of patients with infections in C0168T72\nwas similar to that in the paediatric Crohn\u2019s disease study (REACH) but\nhigher than the proportion in the adults ulcerative colitis studies (ACT\u00a01\nand ACT\u00a02). The overall incidence of infections in C0168T72 was 13/22\n(59%) in the every 8\u00a0week maintenance treatment group and 14/23 (60.9%) in\nthe every 12\u00a0week maintenance treatment group. Upper respiratory tract\ninfection (7/60 [12%]) and pharyngitis (5/60 [8%]) were the most frequently\nreported respiratory system infections. Serious infections were reported in 12%\n(7/60) of all treated patients.</span></p>", "ID": "8daf178f-b371-4312-84dc-e5e7b3e521fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infections were reported in 31 (51.7%) of\n60\u00a0treated patients in C0168T72 and 22 (36.7%) required oral or parenteral\nantimicrobial treatment. The proportion of patients with infections in C0168T72\nwas similar to that in the paediatric Crohn\u2019s disease study (REACH) but\nhigher than the proportion in the adults ulcerative colitis studies (ACT\u00a01\nand ACT\u00a02). The overall incidence of infections in C0168T72 was 13/22\n(59%) in the every 8\u00a0week maintenance treatment group and 14/23 (60.9%) in\nthe every 12\u00a0week maintenance treatment group. Upper respiratory tract\ninfection (7/60 [12%]) and pharyngitis (5/60 [8%]) were the most frequently\nreported respiratory system infections. Serious infections were reported in 12%\n(7/60) of all treated patients.</span>", "ID": "ab587bd7-28a7-4507-893f-33b2cf679224", "Styles": "None", "Classes": "None", "Text": "Infections were reported in 31 (51.7%) of 60\u00a0treated patients in C0168T72 and 22 (36.7%) required oral or parenteral antimicrobial treatment. The proportion of patients with infections in C0168T72 was similar to that in the paediatric Crohn\u2019s disease study (REACH) but higher than the proportion in the adults ulcerative colitis studies (ACT\u00a01 and ACT\u00a02). The overall incidence of infections in C0168T72 was 13/22 (59%) in the every 8\u00a0week maintenance treatment group and 14/23 (60.9%) in the every 12\u00a0week maintenance treatment group. Upper respiratory tract infection (7/60 [12%]) and pharyngitis (5/60 [8%]) were the most frequently reported respiratory system infections. Serious infections were reported in 12% (7/60) of all treated patients.", "ParentId": "8daf178f-b371-4312-84dc-e5e7b3e521fd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d14ac7aa-ea7f-47a3-a4f8-7254ad9ffacd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c4dd8b60-ec73-4523-9777-882b53cf2632", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d14ac7aa-ea7f-47a3-a4f8-7254ad9ffacd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In this study, there were more patients in\nthe 12 to 17\u00a0year age group than in the 6 to 11\u00a0year age group (45/60\n[75.0%]) vs.15/60 [25.0%]). While the numbers of patients in each subgroup are\ntoo small to make any definitive conclusions about the effect of age on safety\nevents, there were higher proportions of patients with serious adverse events\nand discontinuation due to adverse events in the younger age group than in the older\nage group. While the proportion of patients with infections was also higher in\nthe younger age group, for serious infections, the proportions were similar in\nthe two age groups. Overall proportions of adverse events and infusion\nreactions were similar between the 6 to 11 and 12 to 17\u00a0year age groups.</span></p>", "ID": "c89fe01c-d4b0-4b16-b92c-3d7b52f85bd3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In this study, there were more patients in\nthe 12 to 17\u00a0year age group than in the 6 to 11\u00a0year age group (45/60\n[75.0%]) vs.15/60 [25.0%]). While the numbers of patients in each subgroup are\ntoo small to make any definitive conclusions about the effect of age on safety\nevents, there were higher proportions of patients with serious adverse events\nand discontinuation due to adverse events in the younger age group than in the older\nage group. While the proportion of patients with infections was also higher in\nthe younger age group, for serious infections, the proportions were similar in\nthe two age groups. Overall proportions of adverse events and infusion\nreactions were similar between the 6 to 11 and 12 to 17\u00a0year age groups.</span>", "ID": "c5e4dcac-75de-4194-9bd3-6bda024168a7", "Styles": "None", "Classes": "None", "Text": "In this study, there were more patients in the 12 to 17\u00a0year age group than in the 6 to 11\u00a0year age group (45/60 [75.0%]) vs.15/60 [25.0%]). While the numbers of patients in each subgroup are too small to make any definitive conclusions about the effect of age on safety events, there were higher proportions of patients with serious adverse events and discontinuation due to adverse events in the younger age group than in the older age group. While the proportion of patients with infections was also higher in the younger age group, for serious infections, the proportions were similar in the two age groups. Overall proportions of adverse events and infusion reactions were similar between the 6 to 11 and 12 to 17\u00a0year age groups.", "ParentId": "c89fe01c-d4b0-4b16-b92c-3d7b52f85bd3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d392113e-c30f-4d8b-a3aa-575d6c8b8532", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d3dbf2dc-acb6-4b85-908b-72a8c2a0be64", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d392113e-c30f-4d8b-a3aa-575d6c8b8532"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Post\u2011marketing\nexperience</span></u></p>", "ID": "17b7729e-7a64-4a0e-b698-9591b0002fb4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Post\u2011marketing\nexperience</span></u>", "ID": "e16f53c2-7e55-466a-bdf7-db31e6e558e3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "17b7729e-7a64-4a0e-b698-9591b0002fb4"}, {"Element": "<span lang=\"EN-GB\">Post\u2011marketing\nexperience</span>", "ID": "5fc8051c-dc42-4135-8c03-5bbc08292082", "Styles": "None", "Classes": "None", "Text": "Post\u2011marketing experience", "ParentId": "e16f53c2-7e55-466a-bdf7-db31e6e558e3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Post\u2011marketing spontaneous serious\nadverse reactions with infliximab in the paediatric population have included\nmalignancies including hepatosplenic T\u2011cell lymphomas, transient hepatic\nenzyme abnormalities, lupus\u2011like syndromes, and positive auto\u2011antibodies\n(see sections\u00a04.4 and 4.8).</span></p>", "ID": "38c20f4f-8486-4d12-906e-fc1db792c89b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Post\u2011marketing spontaneous serious\nadverse reactions with infliximab in the paediatric population have included\nmalignancies including hepatosplenic T\u2011cell lymphomas, transient hepatic\nenzyme abnormalities, lupus\u2011like syndromes, and positive auto\u2011antibodies\n(see sections\u00a04.4 and 4.8).</span>", "ID": "cafd10c3-fd8b-47f2-a11e-1e03c29c36b3", "Styles": "None", "Classes": "None", "Text": "Post\u2011marketing spontaneous serious adverse reactions with infliximab in the paediatric population have included malignancies including hepatosplenic T\u2011cell lymphomas, transient hepatic enzyme abnormalities, lupus\u2011like syndromes, and positive auto\u2011antibodies (see sections\u00a04.4 and 4.8).", "ParentId": "38c20f4f-8486-4d12-906e-fc1db792c89b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c5a54812-97e4-4674-a34c-f3d20c50792b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "62209089-be88-4faa-995c-b3b4f73399e5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5a54812-97e4-4674-a34c-f3d20c50792b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Additional\ninformation on special populations</span></b></p>", "ID": "c5ffb4cf-a9e8-430b-af06-06ff97ef9ea0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Additional\ninformation on special populations</span></b>", "ID": "db398cca-509b-4ec3-887c-41485625b2fa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c5ffb4cf-a9e8-430b-af06-06ff97ef9ea0"}, {"Element": "<span lang=\"EN-GB\">Additional\ninformation on special populations</span>", "ID": "4463da56-20a4-461a-9690-d4da925b8c05", "Styles": "None", "Classes": "None", "Text": "Additional information on special populations", "ParentId": "db398cca-509b-4ec3-887c-41485625b2fa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly</span></i></p>", "ID": "e4ebf9f8-3024-4caa-81a9-165daa081b85", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Elderly</span></i>", "ID": "21baf923-98f5-473d-8b3a-c512591a8f82", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e4ebf9f8-3024-4caa-81a9-165daa081b85"}, {"Element": "<span lang=\"EN-GB\">Elderly</span>", "ID": "8f173adf-010f-4493-8e76-782a3d198e48", "Styles": "None", "Classes": "None", "Text": "Elderly", "ParentId": "21baf923-98f5-473d-8b3a-c512591a8f82"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">In rheumatoid\narthritis clinical studies, the incidence of serious infections was greater in\ninfliximab plus methotrexate\u2011treated patients 65\u00a0years and older\n(11.3%) than in those under 65\u00a0years of age (</span><span lang=\"EN-GB\">4.6%).\nIn patients treated with methotrexate alone, the incidence of serious\ninfections<span style=\"layout-grid-mode:line\"> was 5.2% </span>in patients 65\u00a0years\nand older compared to 2.7% in patients under 65 </span><span lang=\"EN-GB\">(see\nsection\u00a04.4).</span></p>", "ID": "1bcf8154-49f0-43da-8c46-c311e1eaa2a1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">In rheumatoid\narthritis clinical studies, the incidence of serious infections was greater in\ninfliximab plus methotrexate\u2011treated patients 65\u00a0years and older\n(11.3%) than in those under 65\u00a0years of age (</span>", "ID": "dff3ac87-44a8-476d-b954-3211ddb0f464", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "In rheumatoid arthritis clinical studies, the incidence of serious infections was greater in infliximab plus methotrexate\u2011treated patients 65\u00a0years and older (11.3%) than in those under 65\u00a0years of age (", "ParentId": "1bcf8154-49f0-43da-8c46-c311e1eaa2a1"}, {"Element": "<span lang=\"EN-GB\">4.6%).\nIn patients treated with methotrexate alone, the incidence of serious\ninfections<span style=\"layout-grid-mode:line\"> was 5.2% </span>in patients 65\u00a0years\nand older compared to 2.7% in patients under 65 </span>", "ID": "c57c5ff8-f70a-4617-b4c2-869d063c4187", "Styles": "None", "Classes": "None", "Text": "4.6%). In patients treated with methotrexate alone, the incidence of serious infectionsin patients 65\u00a0years and older compared to 2.7% in patients under 65 ", "ParentId": "1bcf8154-49f0-43da-8c46-c311e1eaa2a1"}, {"Element": "<span style=\"layout-grid-mode:line\"> was 5.2% </span>", "ID": "5031ce11-8f10-4c91-908d-d959bbebe559", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": " was 5.2% ", "ParentId": "c57c5ff8-f70a-4617-b4c2-869d063c4187"}, {"Element": "<span lang=\"EN-GB\">(see\nsection\u00a04.4).</span>", "ID": "dfe5f57e-b711-4162-8acc-7435da6ee085", "Styles": "None", "Classes": "None", "Text": "(see section\u00a04.4).", "ParentId": "1bcf8154-49f0-43da-8c46-c311e1eaa2a1"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "4aec4ebb-7d56-4cf0-a3da-083ae6e206c2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "94df0527-6d3b-4afd-bfaa-d639c67b41bb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4aec4ebb-7d56-4cf0-a3da-083ae6e206c2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5033a4a8-2ea1-4bc8-8a34-e9f893ea8e7f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94df0527-6d3b-4afd-bfaa-d639c67b41bb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u></p>", "ID": "f8a08515-9189-42ce-a084-3c31ad3296b5", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Reporting of suspected adverse reactions</span></u>", "ID": "9f9a9ce0-e77a-45d7-8aca-73afb2e5064e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f8a08515-9189-42ce-a084-3c31ad3296b5"}, {"Element": "<span lang=\"EN-GB\">Reporting of suspected adverse reactions</span>", "ID": "6f5fb7ac-02c6-4127-8608-ba6db5ccb84d", "Styles": "None", "Classes": "None", "Text": "Reporting of suspected adverse reactions", "ParentId": "9f9a9ce0-e77a-45d7-8aca-73afb2e5064e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after\nauthorisation of the medicinal product is important. It allows continued\nmonitoring of the benefit/risk balance of the medicinal product. Healthcare\nprofessionals are asked to report any suspected adverse reactions <span style=\"background:silver\">via the national reporting system listed in <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a></span>.</span></p>", "ID": "04ea4330-46fd-4d05-bf77-37c8314bbeea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Reporting suspected adverse reactions after\nauthorisation of the medicinal product is important. It allows continued\nmonitoring of the benefit/risk balance of the medicinal product. Healthcare\nprofessionals are asked to report any suspected adverse reactions <span style=\"background:silver\">via the national reporting system listed in <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a></span>.</span>", "ID": "9fb9bf45-c3a1-47ed-9247-693b317849a6", "Styles": "None", "Classes": "None", "Text": "Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions .", "ParentId": "04ea4330-46fd-4d05-bf77-37c8314bbeea"}, {"Element": "<span style=\"background:silver\">via the national reporting system listed in <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a></span>", "ID": "574198c7-6233-4623-8437-816b299c7774", "Styles": "background:silver", "Classes": "None", "Text": "via the national reporting system listed in ", "ParentId": "9fb9bf45-c3a1-47ed-9247-693b317849a6"}, {"Element": "<a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a>", "ID": "e7b6ba4c-0819-4cdc-bd77-819b711e1b98", "Styles": "None", "Classes": "None", "Text": "Appendix V", "ParentId": "574198c7-6233-4623-8437-816b299c7774"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "9f86a67e-e669-490e-9d84-07a3f3b0a637", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "e7911a17-f662-4a50-b2ff-1ae8f671c863", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9f86a67e-e669-490e-9d84-07a3f3b0a637"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4543ab6b-bb27-4304-b97b-35cdcc197e9b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e7911a17-f662-4a50-b2ff-1ae8f671c863"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></b></p>", "ID": "28132b27-f5ca-47ca-bbd9-b05321a6ae75", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span></b>", "ID": "ce789d6d-72d5-4103-b0b9-edcdbf51c7aa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "28132b27-f5ca-47ca-bbd9-b05321a6ae75"}, {"Element": "<span lang=\"EN-GB\">4.9\u00a0\u00a0\u00a0\u00a0 Overdose</span>", "ID": "1c311900-3efc-407c-9032-f0bef293a1f4", "Styles": "None", "Classes": "None", "Text": "4.9\u00a0\u00a0\u00a0\u00a0 Overdose", "ParentId": "ce789d6d-72d5-4103-b0b9-edcdbf51c7aa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6f95efb5-ae82-4ba0-84e8-5c8172d1fac1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5089daee-3778-4c9d-b781-54d83ea86819", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6f95efb5-ae82-4ba0-84e8-5c8172d1fac1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">No case of overdose has been reported.\nSingle doses up to 20\u00a0mg/kg have been administered without toxic effects.</span></p>", "ID": "e4e06d2e-087a-4ce8-9ccf-0d93aff9cdd1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">No case of overdose has been reported.\nSingle doses up to 20\u00a0mg/kg have been administered without toxic effects.</span>", "ID": "2c3021ff-5d00-4c2f-8901-ac3e90ce0c8e", "Styles": "None", "Classes": "None", "Text": "No case of overdose has been reported. Single doses up to 20\u00a0mg/kg have been administered without toxic effects.", "ParentId": "e4e06d2e-087a-4ce8-9ccf-0d93aff9cdd1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4b0e5719-82d8-4f3a-aa00-65654d856e50", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b2074e02-f185-425f-8499-245ea113aec5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4b0e5719-82d8-4f3a-aa00-65654d856e50"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "20419dab-a30f-44ad-aaa3-5946fa38cf8b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "68ef926f-9d9f-41ed-80ae-440a2854601d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "20419dab-a30f-44ad-aaa3-5946fa38cf8b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span></b></p>", "ID": "98e6e824-1c18-4e02-8f9f-c5da63ba83de", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span></b>", "ID": "06ae4762-2151-49e6-baf9-5bb17d6a370e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "98e6e824-1c18-4e02-8f9f-c5da63ba83de"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL\nPROPERTIES</span>", "ID": "5067053c-21ad-4396-bf9f-895bd8cc0d20", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACOLOGICAL PROPERTIES", "ParentId": "06ae4762-2151-49e6-baf9-5bb17d6a370e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "af0497ec-20ee-499c-9ab7-5dd64a509a10", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b9bdb085-8f77-4b37-b751-8b5dc6b7fefc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "af0497ec-20ee-499c-9ab7-5dd64a509a10"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></b></p>", "ID": "1fcf6e4d-85dc-4419-8261-638971ff2f0f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span></b>", "ID": "e9e8a318-b820-496b-a9ae-085b7f35b670", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1fcf6e4d-85dc-4419-8261-638971ff2f0f"}, {"Element": "<span lang=\"EN-GB\">5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic\nproperties</span>", "ID": "83f24140-b00b-4e67-ab62-86ca90bfd755", "Styles": "None", "Classes": "None", "Text": "5.1\u00a0\u00a0\u00a0\u00a0 Pharmacodynamic properties", "ParentId": "e9e8a318-b820-496b-a9ae-085b7f35b670"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "da2bc94f-b5ca-4558-bb66-ea40771a92a5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a4a47994-68e2-4a95-8fbb-a9959173e903", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "da2bc94f-b5ca-4558-bb66-ea40771a92a5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Pharmacotherapeutic group: </span><a name=\"_Hlk509410677\"><span lang=\"EN-GB\">Immunosuppressants</span></a><span lang=\"EN-GB\">, tumour necrosis factor alpha (TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">) inhibitors, ATC\ncode: L04AB02.</span></p>", "ID": "13cc4493-14d5-401a-8d0a-dae20b68a6b2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Pharmacotherapeutic group: </span>", "ID": "276744fc-d340-412f-b334-7a032917b1fc", "Styles": "None", "Classes": "None", "Text": "Pharmacotherapeutic group: ", "ParentId": "13cc4493-14d5-401a-8d0a-dae20b68a6b2"}, {"Element": "<a name=\"_Hlk509410677\"><span lang=\"EN-GB\">Immunosuppressants</span></a>", "ID": "43d2da13-800a-453c-8ac1-0f453899469b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "13cc4493-14d5-401a-8d0a-dae20b68a6b2"}, {"Element": "<span lang=\"EN-GB\">Immunosuppressants</span>", "ID": "54a436c9-bed3-4e7a-894f-261c4dd2b762", "Styles": "None", "Classes": "None", "Text": "Immunosuppressants", "ParentId": "43d2da13-800a-453c-8ac1-0f453899469b"}, {"Element": "<span lang=\"EN-GB\">, tumour necrosis factor alpha (TNF</span>", "ID": "0dde84ba-b9ec-4453-82e6-f208cef63bae", "Styles": "None", "Classes": "None", "Text": ", tumour necrosis factor alpha (TNF", "ParentId": "13cc4493-14d5-401a-8d0a-dae20b68a6b2"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "547fee0a-62b6-418d-8a1e-e7708d94e09c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "13cc4493-14d5-401a-8d0a-dae20b68a6b2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "45176338-a7e8-4d0a-bcb7-70c3e399f91c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "547fee0a-62b6-418d-8a1e-e7708d94e09c"}, {"Element": "<span lang=\"EN-GB\">) inhibitors, ATC\ncode: L04AB02.</span>", "ID": "cd7b103d-6e27-4475-bfea-32af042ed3ea", "Styles": "None", "Classes": "None", "Text": ") inhibitors, ATC code: L04AB02.", "ParentId": "13cc4493-14d5-401a-8d0a-dae20b68a6b2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "42426cb1-a4f4-4931-8fab-29e45eb1730e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "59b43b1f-4a16-44b0-bd25-96d953b94c30", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "42426cb1-a4f4-4931-8fab-29e45eb1730e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Mechanism\nof action</span></u></b></p>", "ID": "26e05552-635b-4fab-962b-fdabf88705ea", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><u><span lang=\"EN-GB\">Mechanism\nof action</span></u></b>", "ID": "247a42fa-ce6f-47a9-a17e-b3c0f4c95778", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "26e05552-635b-4fab-962b-fdabf88705ea"}, {"Element": "<u><span lang=\"EN-GB\">Mechanism\nof action</span></u>", "ID": "bb86b80c-1b34-4604-9188-ada0f10c6e08", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "247a42fa-ce6f-47a9-a17e-b3c0f4c95778"}, {"Element": "<span lang=\"EN-GB\">Mechanism\nof action</span>", "ID": "b77075cd-7b0d-42f9-ba73-c027d0aa41ed", "Styles": "None", "Classes": "None", "Text": "Mechanism of action", "ParentId": "bb86b80c-1b34-4604-9188-ada0f10c6e08"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab is a chimeric human\u2011murine\nmonoclonal antibody that binds with high affinity to both soluble and\ntransmembrane forms of TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> but not to lymphotoxin </span><span lang=\"EN-GB\" style=\"font-family:\nSymbol\">a</span><span lang=\"EN-GB\"> (TNF<sub>\u00df</sub>).</span></p>", "ID": "d3e56027-d72b-498a-ac8f-9ce080cc4a10", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infliximab is a chimeric human\u2011murine\nmonoclonal antibody that binds with high affinity to both soluble and\ntransmembrane forms of TNF</span>", "ID": "6970d4a9-e900-488c-ade6-8701b7b5009d", "Styles": "None", "Classes": "None", "Text": "Infliximab is a chimeric human\u2011murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNF", "ParentId": "d3e56027-d72b-498a-ac8f-9ce080cc4a10"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "a15295b7-4366-4a39-90c1-49039f69dc91", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d3e56027-d72b-498a-ac8f-9ce080cc4a10"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "2be57af4-67d5-4de9-8b84-71df753de20d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "a15295b7-4366-4a39-90c1-49039f69dc91"}, {"Element": "<span lang=\"EN-GB\"> but not to lymphotoxin </span>", "ID": "295def4b-6b17-4481-a981-741bfcf841c9", "Styles": "None", "Classes": "None", "Text": " but not to lymphotoxin ", "ParentId": "d3e56027-d72b-498a-ac8f-9ce080cc4a10"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:\nSymbol\">a</span>", "ID": "7abd1ba8-2af7-470b-9e07-96f0d48dca00", "Styles": "font-family:\nSymbol", "Classes": "None", "Text": "a", "ParentId": "d3e56027-d72b-498a-ac8f-9ce080cc4a10"}, {"Element": "<span lang=\"EN-GB\"> (TNF<sub>\u00df</sub>).</span>", "ID": "13f48ff5-9f88-4ceb-97d5-e2dcf54c5922", "Styles": "None", "Classes": "None", "Text": " (TNF).", "ParentId": "d3e56027-d72b-498a-ac8f-9ce080cc4a10"}, {"Element": "<sub>\u00df</sub>", "ID": "a9c43a08-9ccf-424f-899a-cf08a0d759c5", "Styles": "None", "Classes": "None", "Text": "\u00df", "ParentId": "13f48ff5-9f88-4ceb-97d5-e2dcf54c5922"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f6b98b3c-1ace-499e-a6db-b50ae7504c64", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0062f484-b41f-493d-a6ca-94408dbc2d2e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f6b98b3c-1ace-499e-a6db-b50ae7504c64"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Pharmacodynamic\neffects</span></u></b></p>", "ID": "6a288042-e1ad-4900-9a31-fccfb814d299", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><u><span lang=\"EN-GB\">Pharmacodynamic\neffects</span></u></b>", "ID": "4587fd0b-0367-47f6-82d2-b280e2aa57b6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6a288042-e1ad-4900-9a31-fccfb814d299"}, {"Element": "<u><span lang=\"EN-GB\">Pharmacodynamic\neffects</span></u>", "ID": "f55b295b-20b7-47ed-8c70-d537ecc35dd6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4587fd0b-0367-47f6-82d2-b280e2aa57b6"}, {"Element": "<span lang=\"EN-GB\">Pharmacodynamic\neffects</span>", "ID": "6e442bb0-dc4f-4cb1-b7ae-c9cadc0d8872", "Styles": "None", "Classes": "None", "Text": "Pharmacodynamic effects", "ParentId": "f55b295b-20b7-47ed-8c70-d537ecc35dd6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab inhibits the functional activity\nof TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> in a wide variety of <i>in vitro </i>bioassays. Infliximab\nprevented disease in transgenic mice that develop polyarthritis as a result of\nconstitutive expression of human TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> and when\nadministered after disease onset, it allowed eroded joints to heal. <i>In vivo</i>,\ninfliximab rapidly forms stable complexes with human TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">, a\nprocess that parallels the loss of TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> bioactivity.</span></p>", "ID": "970d731f-846a-49d6-84f8-9f5e96810e9c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infliximab inhibits the functional activity\nof TNF</span>", "ID": "55268ff8-132f-4119-a86c-67539a6d7545", "Styles": "None", "Classes": "None", "Text": "Infliximab inhibits the functional activity of TNF", "ParentId": "970d731f-846a-49d6-84f8-9f5e96810e9c"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "5285684f-fdca-4df9-9138-6f905ae80fc3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "970d731f-846a-49d6-84f8-9f5e96810e9c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "13c19640-441a-4e5b-8fa9-84e253e2c083", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "5285684f-fdca-4df9-9138-6f905ae80fc3"}, {"Element": "<span lang=\"EN-GB\"> in a wide variety of <i>in vitro </i>bioassays. Infliximab\nprevented disease in transgenic mice that develop polyarthritis as a result of\nconstitutive expression of human TNF</span>", "ID": "cac880f1-a68f-4bda-bc06-180c173d642c", "Styles": "None", "Classes": "None", "Text": " in a wide variety of bioassays. Infliximab prevented disease in transgenic mice that develop polyarthritis as a result of constitutive expression of human TNF", "ParentId": "970d731f-846a-49d6-84f8-9f5e96810e9c"}, {"Element": "<i>in vitro </i>", "ID": "9d4c3b1d-0daa-4f5e-b962-3fe3294cacb8", "Styles": "None", "Classes": "None", "Text": "in vitro ", "ParentId": "cac880f1-a68f-4bda-bc06-180c173d642c"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "78b12fd7-2d69-45b0-811e-e9be8bccf531", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "970d731f-846a-49d6-84f8-9f5e96810e9c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "78e35cac-7f0e-4f30-935c-64d1a806077c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "78b12fd7-2d69-45b0-811e-e9be8bccf531"}, {"Element": "<span lang=\"EN-GB\"> and when\nadministered after disease onset, it allowed eroded joints to heal. <i>In vivo</i>,\ninfliximab rapidly forms stable complexes with human TNF</span>", "ID": "1a9afdef-7ed1-4e26-b005-ab643df9793e", "Styles": "None", "Classes": "None", "Text": " and when administered after disease onset, it allowed eroded joints to heal. , infliximab rapidly forms stable complexes with human TNF", "ParentId": "970d731f-846a-49d6-84f8-9f5e96810e9c"}, {"Element": "<i>In vivo</i>", "ID": "701c967f-6790-473a-a19b-de88a35484c2", "Styles": "None", "Classes": "None", "Text": "In vivo", "ParentId": "1a9afdef-7ed1-4e26-b005-ab643df9793e"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "58003c08-b734-4052-90c4-138c96362d11", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "970d731f-846a-49d6-84f8-9f5e96810e9c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "74072cfe-b8b9-40a1-a5e4-b3dfc828c8b6", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "58003c08-b734-4052-90c4-138c96362d11"}, {"Element": "<span lang=\"EN-GB\">, a\nprocess that parallels the loss of TNF</span>", "ID": "fcdf2d87-8c83-4061-9883-36df300f5815", "Styles": "None", "Classes": "None", "Text": ", a process that parallels the loss of TNF", "ParentId": "970d731f-846a-49d6-84f8-9f5e96810e9c"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "7e15f9d7-2a0a-4755-ba1f-8646cbc7c98f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "970d731f-846a-49d6-84f8-9f5e96810e9c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "b25ab8b5-4fbf-41f3-beec-3f60083c7669", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "7e15f9d7-2a0a-4755-ba1f-8646cbc7c98f"}, {"Element": "<span lang=\"EN-GB\"> bioactivity.</span>", "ID": "bd539b03-5f8f-4bed-bdcf-280d2d4aa58b", "Styles": "None", "Classes": "None", "Text": " bioactivity.", "ParentId": "970d731f-846a-49d6-84f8-9f5e96810e9c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e3674161-5965-46d0-a534-0923af171da0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "068372bb-3341-469b-8500-1835d758526c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e3674161-5965-46d0-a534-0923af171da0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Elevated concentrations of TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> have been\nfound in the joints of rheumatoid arthritis patients and correlate with\nelevated disease activity. In rheumatoid arthritis, treatment with infliximab\nreduced infiltration of inflammatory cells into inflamed areas of the joint as\nwell as expression of molecules mediating cellular adhesion, chemoattraction\nand tissue degradation. After infliximab treatment, patients exhibited\ndecreased levels of serum interleukin\u00a06 (IL\u20116) and C\u2011reactive\nprotein (CRP)<b>, </b>and increased haemoglobin levels in rheumatoid arthritis\npatients with reduced haemoglobin levels, compared with baseline. Peripheral\nblood lymphocytes further showed no significant decrease in number or in\nproliferative responses to <i>in vitro</i> mitogenic stimulation when compared\nwith untreated patients\u2019 cells. In psoriasis patients, treatment with\ninfliximab resulted in decreases in epidermal inflammation and normalisation of\nkeratinocyte differentiation in psoriatic plaques. In psoriatic arthritis,\nshort term treatment with Remicade reduced the number of T\u2011cells and\nblood vessels in the synovium and psoriatic skin.</span></p>", "ID": "374db513-2402-460a-acdb-76859b7e72d8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Elevated concentrations of TNF</span>", "ID": "fb0948e5-b517-4714-bff2-ab5a34a1f177", "Styles": "None", "Classes": "None", "Text": "Elevated concentrations of TNF", "ParentId": "374db513-2402-460a-acdb-76859b7e72d8"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "faa95bad-8ed9-4290-b7c9-a2f26501f974", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "374db513-2402-460a-acdb-76859b7e72d8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "7ab2984c-b935-4ea4-97b2-83f256608581", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "faa95bad-8ed9-4290-b7c9-a2f26501f974"}, {"Element": "<span lang=\"EN-GB\"> have been\nfound in the joints of rheumatoid arthritis patients and correlate with\nelevated disease activity. In rheumatoid arthritis, treatment with infliximab\nreduced infiltration of inflammatory cells into inflamed areas of the joint as\nwell as expression of molecules mediating cellular adhesion, chemoattraction\nand tissue degradation. After infliximab treatment, patients exhibited\ndecreased levels of serum interleukin\u00a06 (IL\u20116) and C\u2011reactive\nprotein (CRP)<b>, </b>and increased haemoglobin levels in rheumatoid arthritis\npatients with reduced haemoglobin levels, compared with baseline. Peripheral\nblood lymphocytes further showed no significant decrease in number or in\nproliferative responses to <i>in vitro</i> mitogenic stimulation when compared\nwith untreated patients\u2019 cells. In psoriasis patients, treatment with\ninfliximab resulted in decreases in epidermal inflammation and normalisation of\nkeratinocyte differentiation in psoriatic plaques. In psoriatic arthritis,\nshort term treatment with Remicade reduced the number of T\u2011cells and\nblood vessels in the synovium and psoriatic skin.</span>", "ID": "c0090513-c0d0-4068-a8cc-d26dbd2582e0", "Styles": "None", "Classes": "None", "Text": " have been found in the joints of rheumatoid arthritis patients and correlate with elevated disease activity. In rheumatoid arthritis, treatment with infliximab reduced infiltration of inflammatory cells into inflamed areas of the joint as well as expression of molecules mediating cellular adhesion, chemoattraction and tissue degradation. After infliximab treatment, patients exhibited decreased levels of serum interleukin\u00a06 (IL\u20116) and C\u2011reactive protein (CRP)and increased haemoglobin levels in rheumatoid arthritis patients with reduced haemoglobin levels, compared with baseline. Peripheral blood lymphocytes further showed no significant decrease in number or in proliferative responses to  mitogenic stimulation when compared with untreated patients\u2019 cells. In psoriasis patients, treatment with infliximab resulted in decreases in epidermal inflammation and normalisation of keratinocyte differentiation in psoriatic plaques. In psoriatic arthritis, short term treatment with Remicade reduced the number of T\u2011cells and blood vessels in the synovium and psoriatic skin.", "ParentId": "374db513-2402-460a-acdb-76859b7e72d8"}, {"Element": "<b>, </b>", "ID": "43b583f4-0ee5-41fd-b69d-39ff7971c851", "Styles": "None", "Classes": "None", "Text": ", ", "ParentId": "c0090513-c0d0-4068-a8cc-d26dbd2582e0"}, {"Element": "<i>in vitro</i>", "ID": "d84f023c-391c-41d3-b1ad-bfe0a50b50a8", "Styles": "None", "Classes": "None", "Text": "in vitro", "ParentId": "c0090513-c0d0-4068-a8cc-d26dbd2582e0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9d7d7590-527b-425d-b64c-e79f6798a35d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "83260a59-4595-4745-a913-6ccdf5a36384", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9d7d7590-527b-425d-b64c-e79f6798a35d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Histological evaluation of colonic\nbiopsies, obtained before and 4\u00a0weeks after administration of infliximab,\nrevealed a substantial reduction in detectable TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">. Infliximab\ntreatment of Crohn\u2019s disease patients was also associated with a substantial\nreduction of the commonly elevated serum inflammatory marker, CRP. Total\nperipheral white blood cell counts were minimally affected in infliximab\u2011treated\npatients, although changes in lymphocytes, monocytes and neutrophils reflected\nshifts towards normal ranges. Peripheral blood mononuclear cells (PBMC) from\ninfliximab\u2011treated patients showed undiminished proliferative\nresponsiveness to stimuli compared with untreated patients, and no substantial\nchanges in cytokine production by stimulated PBMC were observed following\ntreatment with infliximab. Analysis of lamina propria mononuclear cells\nobtained by biopsy of the intestinal mucosa showed that infliximab treatment\ncaused a reduction in the number of cells capable of expressing TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> and\ninterferon</span><span lang=\"EN-GB\" style=\"font-family:Symbol\">g</span><span lang=\"EN-GB\">. Additional histological studies provided evidence that treatment\nwith infliximab reduces the infiltration of inflammatory cells into affected\nareas of the intestine and the presence of inflammation markers at these sites.\nEndoscopic studies of intestinal mucosa have shown evidence of mucosal healing\nin infliximab\u2011treated patients.</span></p>", "ID": "9d9ccbaa-52ab-411d-8e1d-2ce5caa5a2ef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Histological evaluation of colonic\nbiopsies, obtained before and 4\u00a0weeks after administration of infliximab,\nrevealed a substantial reduction in detectable TNF</span>", "ID": "084f04e7-9234-4a56-bcdc-84000452db9d", "Styles": "None", "Classes": "None", "Text": "Histological evaluation of colonic biopsies, obtained before and 4\u00a0weeks after administration of infliximab, revealed a substantial reduction in detectable TNF", "ParentId": "9d9ccbaa-52ab-411d-8e1d-2ce5caa5a2ef"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "88a8ce83-e7aa-4d66-bcef-55776f69a9c7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9d9ccbaa-52ab-411d-8e1d-2ce5caa5a2ef"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "ab02ee4e-5d1f-4b74-bd9d-235a31abc19a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "88a8ce83-e7aa-4d66-bcef-55776f69a9c7"}, {"Element": "<span lang=\"EN-GB\">. Infliximab\ntreatment of Crohn\u2019s disease patients was also associated with a substantial\nreduction of the commonly elevated serum inflammatory marker, CRP. Total\nperipheral white blood cell counts were minimally affected in infliximab\u2011treated\npatients, although changes in lymphocytes, monocytes and neutrophils reflected\nshifts towards normal ranges. Peripheral blood mononuclear cells (PBMC) from\ninfliximab\u2011treated patients showed undiminished proliferative\nresponsiveness to stimuli compared with untreated patients, and no substantial\nchanges in cytokine production by stimulated PBMC were observed following\ntreatment with infliximab. Analysis of lamina propria mononuclear cells\nobtained by biopsy of the intestinal mucosa showed that infliximab treatment\ncaused a reduction in the number of cells capable of expressing TNF</span>", "ID": "809e590b-d376-4618-9a09-02a2911881e6", "Styles": "None", "Classes": "None", "Text": ". Infliximab treatment of Crohn\u2019s disease patients was also associated with a substantial reduction of the commonly elevated serum inflammatory marker, CRP. Total peripheral white blood cell counts were minimally affected in infliximab\u2011treated patients, although changes in lymphocytes, monocytes and neutrophils reflected shifts towards normal ranges. Peripheral blood mononuclear cells (PBMC) from infliximab\u2011treated patients showed undiminished proliferative responsiveness to stimuli compared with untreated patients, and no substantial changes in cytokine production by stimulated PBMC were observed following treatment with infliximab. Analysis of lamina propria mononuclear cells obtained by biopsy of the intestinal mucosa showed that infliximab treatment caused a reduction in the number of cells capable of expressing TNF", "ParentId": "9d9ccbaa-52ab-411d-8e1d-2ce5caa5a2ef"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "db2ac013-f01a-4026-a15b-5a0c6718d025", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9d9ccbaa-52ab-411d-8e1d-2ce5caa5a2ef"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "38534fc2-d6e2-4742-a9c1-ee0984f6448e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "db2ac013-f01a-4026-a15b-5a0c6718d025"}, {"Element": "<span lang=\"EN-GB\"> and\ninterferon</span>", "ID": "35fec6a6-404a-4909-a115-0e1b1abd2462", "Styles": "None", "Classes": "None", "Text": " and interferon", "ParentId": "9d9ccbaa-52ab-411d-8e1d-2ce5caa5a2ef"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">g</span>", "ID": "b952321d-e5fb-4db0-95b3-36b8d0c2be4f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "g", "ParentId": "9d9ccbaa-52ab-411d-8e1d-2ce5caa5a2ef"}, {"Element": "<span lang=\"EN-GB\">. Additional histological studies provided evidence that treatment\nwith infliximab reduces the infiltration of inflammatory cells into affected\nareas of the intestine and the presence of inflammation markers at these sites.\nEndoscopic studies of intestinal mucosa have shown evidence of mucosal healing\nin infliximab\u2011treated patients.</span>", "ID": "26d62f71-5bec-49ae-b65f-f490fc586c9c", "Styles": "None", "Classes": "None", "Text": ". Additional histological studies provided evidence that treatment with infliximab reduces the infiltration of inflammatory cells into affected areas of the intestine and the presence of inflammation markers at these sites. Endoscopic studies of intestinal mucosa have shown evidence of mucosal healing in infliximab\u2011treated patients.", "ParentId": "9d9ccbaa-52ab-411d-8e1d-2ce5caa5a2ef"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a713aac3-adf0-41d6-ac21-26b7796f0351", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2cb12732-bafb-4411-859d-5ac33eb33319", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a713aac3-adf0-41d6-ac21-26b7796f0351"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Clinical\nefficacy and safety</span></u></b></p>", "ID": "0413f28a-fd76-40f4-b92f-4bfad5981020", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><u><span lang=\"EN-GB\">Clinical\nefficacy and safety</span></u></b>", "ID": "6c2eead4-f056-4db0-ba3b-5e975d1b0f56", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0413f28a-fd76-40f4-b92f-4bfad5981020"}, {"Element": "<u><span lang=\"EN-GB\">Clinical\nefficacy and safety</span></u>", "ID": "74f09e91-14dd-4cec-bfcb-4343d179cdde", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6c2eead4-f056-4db0-ba3b-5e975d1b0f56"}, {"Element": "<span lang=\"EN-GB\">Clinical\nefficacy and safety</span>", "ID": "da8dab74-5f73-4962-b921-aff43fbad6e9", "Styles": "None", "Classes": "None", "Text": "Clinical efficacy and safety", "ParentId": "74f09e91-14dd-4cec-bfcb-4343d179cdde"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Adult\nrheumatoid arthritis</span></u></p>", "ID": "418dc0c2-ac8f-488e-8f42-1014cfc49db5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Adult\nrheumatoid arthritis</span></u>", "ID": "801f54a5-53b4-4910-a524-8f93f1e3c5a6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "418dc0c2-ac8f-488e-8f42-1014cfc49db5"}, {"Element": "<span lang=\"EN-GB\">Adult\nrheumatoid arthritis</span>", "ID": "8667f8d4-5619-4472-ae02-a8b2e737eaf0", "Styles": "None", "Classes": "None", "Text": "Adult rheumatoid arthritis", "ParentId": "801f54a5-53b4-4910-a524-8f93f1e3c5a6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of infliximab was assessed in\ntwo multicentre, randomised, double\u2011blind,<b> </b>pivotal clinical\nstudies: ATTRACT and ASPIRE. In both studies concurrent use of stable doses of\nfolic acid, oral corticosteroids (\u2264\u00a010\u00a0mg/day) and/or non\u2011steroidal\nantiinflammatory drugs (NSAIDs) was permitted.</span></p>", "ID": "338526db-b30a-4214-bff1-e04aa7ccfeb8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The efficacy of infliximab was assessed in\ntwo multicentre, randomised, double\u2011blind,<b> </b>pivotal clinical\nstudies: ATTRACT and ASPIRE. In both studies concurrent use of stable doses of\nfolic acid, oral corticosteroids (\u2264\u00a010\u00a0mg/day) and/or non\u2011steroidal\nantiinflammatory drugs (NSAIDs) was permitted.</span>", "ID": "813c9246-6537-4945-bf37-82d6b64cfb89", "Styles": "None", "Classes": "None", "Text": "The efficacy of infliximab was assessed in two multicentre, randomised, double\u2011blind,pivotal clinical studies: ATTRACT and ASPIRE. In both studies concurrent use of stable doses of folic acid, oral corticosteroids (\u2264\u00a010\u00a0mg/day) and/or non\u2011steroidal antiinflammatory drugs (NSAIDs) was permitted.", "ParentId": "338526db-b30a-4214-bff1-e04aa7ccfeb8"}, {"Element": "<b> </b>", "ID": "4d372ecc-375a-486c-8cd2-aca3527bc052", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "813c9246-6537-4945-bf37-82d6b64cfb89"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "237759c2-a38b-4307-b78f-6a5d5c6c778f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b298dbd6-445a-4024-93af-812a43f9200b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "237759c2-a38b-4307-b78f-6a5d5c6c778f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoints were the reduction of\nsigns and symptoms as assessed by the American College of Rheumatology criteria\n(ACR20 for ATTRACT, landmark ACR\u2011N for ASPIRE), the prevention of\nstructural joint damage, and the improvement in physical function. A reduction\nin signs and symptoms was defined to be at least a 20% improvement (ACR20) in\nboth tender and swollen joint counts, and in 3 of the following 5\u00a0criteria:\n(1) evaluator\u2019s global assessment, (2) patient\u2019s global assessment,\n(3) functional/disability measure, (4) visual analogue pain scale and (5)\nerythrocyte sedimentation rate or C\u2011reactive protein. ACR\u2011N uses\nthe same criteria as the ACR20, calculated by taking the lowest percent\nimprovement in swollen joint count, tender joint count, and the median of the\nremaining 5\u00a0components of the ACR response. Structural joint damage (erosions\nand joint space narrowing) in both hands and feet was measured by the change\nfrom baseline in the total van der Heijde\u2011modified Sharp score (0\u2011440).\nThe Health Assessment Questionnaire (HAQ; scale\u00a00\u20113) was used to\nmeasure patients\u2019 average change from baseline scores over time, in\nphysical function.</span></p>", "ID": "a88e7e16-4af8-459e-93a4-8d03ad6813c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The primary endpoints were the reduction of\nsigns and symptoms as assessed by the American College of Rheumatology criteria\n(ACR20 for ATTRACT, landmark ACR\u2011N for ASPIRE), the prevention of\nstructural joint damage, and the improvement in physical function. A reduction\nin signs and symptoms was defined to be at least a 20% improvement (ACR20) in\nboth tender and swollen joint counts, and in 3 of the following 5\u00a0criteria:\n(1) evaluator\u2019s global assessment, (2) patient\u2019s global assessment,\n(3) functional/disability measure, (4) visual analogue pain scale and (5)\nerythrocyte sedimentation rate or C\u2011reactive protein. ACR\u2011N uses\nthe same criteria as the ACR20, calculated by taking the lowest percent\nimprovement in swollen joint count, tender joint count, and the median of the\nremaining 5\u00a0components of the ACR response. Structural joint damage (erosions\nand joint space narrowing) in both hands and feet was measured by the change\nfrom baseline in the total van der Heijde\u2011modified Sharp score (0\u2011440).\nThe Health Assessment Questionnaire (HAQ; scale\u00a00\u20113) was used to\nmeasure patients\u2019 average change from baseline scores over time, in\nphysical function.</span>", "ID": "c5bbdc7b-b2d9-4ae3-9a61-67bfda65000c", "Styles": "None", "Classes": "None", "Text": "The primary endpoints were the reduction of signs and symptoms as assessed by the American College of Rheumatology criteria (ACR20 for ATTRACT, landmark ACR\u2011N for ASPIRE), the prevention of structural joint damage, and the improvement in physical function. A reduction in signs and symptoms was defined to be at least a 20% improvement (ACR20) in both tender and swollen joint counts, and in 3 of the following 5\u00a0criteria: (1) evaluator\u2019s global assessment, (2) patient\u2019s global assessment, (3) functional/disability measure, (4) visual analogue pain scale and (5) erythrocyte sedimentation rate or C\u2011reactive protein. ACR\u2011N uses the same criteria as the ACR20, calculated by taking the lowest percent improvement in swollen joint count, tender joint count, and the median of the remaining 5\u00a0components of the ACR response. Structural joint damage (erosions and joint space narrowing) in both hands and feet was measured by the change from baseline in the total van der Heijde\u2011modified Sharp score (0\u2011440). The Health Assessment Questionnaire (HAQ; scale\u00a00\u20113) was used to measure patients\u2019 average change from baseline scores over time, in physical function.", "ParentId": "a88e7e16-4af8-459e-93a4-8d03ad6813c8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "392b124a-8e3d-4d1a-ae1e-69ab0c313421", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "17a33855-0ae6-47ea-abdc-78ce83f6de2b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "392b124a-8e3d-4d1a-ae1e-69ab0c313421"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The ATTRACT study evaluated responses at\n30, 54 and 102\u00a0weeks in a placebo\u2011controlled study of 428\u00a0patients\nwith active rheumatoid arthritis despite treatment with methotrexate.\nApproximately 50% of patients were in functional Class III. Patients received\nplacebo, 3\u00a0mg/kg or 10\u00a0mg/kg infliximab at weeks\u00a00, 2 and 6, and\nthen every 4 or 8\u00a0weeks thereafter. All patients were on stable\nmethotrexate doses (median 15\u00a0mg/wk) for 6\u00a0months prior to enrolment\nand were to remain on stable doses throughout the study.</span></p>", "ID": "0546a6ba-b0fa-4205-8e89-51e3d0a04024", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The ATTRACT study evaluated responses at\n30, 54 and 102\u00a0weeks in a placebo\u2011controlled study of 428\u00a0patients\nwith active rheumatoid arthritis despite treatment with methotrexate.\nApproximately 50% of patients were in functional Class III. Patients received\nplacebo, 3\u00a0mg/kg or 10\u00a0mg/kg infliximab at weeks\u00a00, 2 and 6, and\nthen every 4 or 8\u00a0weeks thereafter. All patients were on stable\nmethotrexate doses (median 15\u00a0mg/wk) for 6\u00a0months prior to enrolment\nand were to remain on stable doses throughout the study.</span>", "ID": "8715784f-f2a2-4a04-bd5e-b8bbdc6d012d", "Styles": "None", "Classes": "None", "Text": "The ATTRACT study evaluated responses at 30, 54 and 102\u00a0weeks in a placebo\u2011controlled study of 428\u00a0patients with active rheumatoid arthritis despite treatment with methotrexate. Approximately 50% of patients were in functional Class III. Patients received placebo, 3\u00a0mg/kg or 10\u00a0mg/kg infliximab at weeks\u00a00, 2 and 6, and then every 4 or 8\u00a0weeks thereafter. All patients were on stable methotrexate doses (median 15\u00a0mg/wk) for 6\u00a0months prior to enrolment and were to remain on stable doses throughout the study.", "ParentId": "0546a6ba-b0fa-4205-8e89-51e3d0a04024"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Results from week\u00a054 (ACR20, total van\nder Heijde\u2011modified Sharp score and HAQ) are shown in Table\u00a03.\nHigher degrees of clinical response (ACR50 and ACR70) were observed in all\ninfliximab groups at 30 and 54\u00a0weeks compared with methotrexate alone.</span></p>", "ID": "1a8d4518-fce3-403e-bc3a-1d28c94477f6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Results from week\u00a054 (ACR20, total van\nder Heijde\u2011modified Sharp score and HAQ) are shown in Table\u00a03.\nHigher degrees of clinical response (ACR50 and ACR70) were observed in all\ninfliximab groups at 30 and 54\u00a0weeks compared with methotrexate alone.</span>", "ID": "2af0845b-738f-494d-a7ee-08fd90d05264", "Styles": "None", "Classes": "None", "Text": "Results from week\u00a054 (ACR20, total van der Heijde\u2011modified Sharp score and HAQ) are shown in Table\u00a03. Higher degrees of clinical response (ACR50 and ACR70) were observed in all infliximab groups at 30 and 54\u00a0weeks compared with methotrexate alone.", "ParentId": "1a8d4518-fce3-403e-bc3a-1d28c94477f6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "138c7315-9254-4ae3-9f92-0e3de824af87", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "075b9e68-ad5e-4765-95aa-b4d27064ca6a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "138c7315-9254-4ae3-9f92-0e3de824af87"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">A reduction in the rate of the progression\nof structural joint damage (erosions and joint space narrowing) was observed in\nall infliximab groups at 54\u00a0weeks (Table\u00a03).</span></p>", "ID": "67c963b7-fe7a-49dc-8d8d-5f9d435b3c33", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">A reduction in the rate of the progression\nof structural joint damage (erosions and joint space narrowing) was observed in\nall infliximab groups at 54\u00a0weeks (Table\u00a03).</span>", "ID": "95e8db3f-0179-429b-afad-37ab494e7947", "Styles": "None", "Classes": "None", "Text": "A reduction in the rate of the progression of structural joint damage (erosions and joint space narrowing) was observed in all infliximab groups at 54\u00a0weeks (Table\u00a03).", "ParentId": "67c963b7-fe7a-49dc-8d8d-5f9d435b3c33"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2b2d57a4-e587-49b4-ba3b-a5fc8cb81bfa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "188bd333-d2c3-4b20-8bf1-75edf70aa096", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2b2d57a4-e587-49b4-ba3b-a5fc8cb81bfa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The effects observed at 54\u00a0weeks were\nmaintained through 102\u00a0weeks. Due to a number of treatment withdrawals,\nthe magnitude of the effect difference between infliximab and the methotrexate\nalone group cannot be defined.</span></p>", "ID": "76d14890-21c9-4d15-b60c-1cbf18b37cfc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The effects observed at 54\u00a0weeks were\nmaintained through 102\u00a0weeks. Due to a number of treatment withdrawals,\nthe magnitude of the effect difference between infliximab and the methotrexate\nalone group cannot be defined.</span>", "ID": "a05159a7-d972-4777-a92f-37de70045b0c", "Styles": "None", "Classes": "None", "Text": "The effects observed at 54\u00a0weeks were maintained through 102\u00a0weeks. Due to a number of treatment withdrawals, the magnitude of the effect difference between infliximab and the methotrexate alone group cannot be defined.", "ParentId": "76d14890-21c9-4d15-b60c-1cbf18b37cfc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d61b188d-1ee5-415b-8a93-a15ff912579f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "499b1929-1225-4b4b-9867-d8faa02b75ff", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d61b188d-1ee5-415b-8a93-a15ff912579f"}, {"Element": "<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Table\u00a03</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Effects on ACR20,\n  Structural Joint Damage and Physical Function at week\u00a054, ATTRACT</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:204.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"273\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td colspan=\"5\" style=\"width:257.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" width=\"343\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span><sup><span lang=\"EN-GB\">b</span></sup></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"205\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Control</span><sup><span lang=\"EN-GB\">a</span></sup></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">All infliximab</span><sup><span lang=\"EN-GB\">b</span></sup></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with\n  ACR20 response/</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients\n  evaluated (%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">15/88</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(17%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">36/86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(42%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">41/86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">51/87</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">48/81</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">176/340</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(52%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Total score</span><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> (van der\n  Heijde\u2011modified Sharp score)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Change from\n  baseline (Mean \u00b1 SD</span><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\">)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.0\u00a0\u00b1\u00a010.3</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.3\u00a0\u00b1\u00a06.0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.6\u00a0\u00b1\u00a08.5</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.2\u00a0\u00b1\u00a03.6</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u20110.7\u00a0\u00b1\u00a03.8</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6\u00a0\u00b1\u00a05.9</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(Interquartile\n  range)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.5,9.7)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,3.0)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20112.5,3.0)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,2.0)</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">\u20110.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20113.0,1.5)</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.8,2.0)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with no\n  deterioration/patients evaluated (%)</span><sup><span lang=\"EN-GB\">c</span></sup></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">13/64</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">34/71</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">35/71</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(49%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">37/77</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">44/66</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(67%)</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">150/285</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(53%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:\n  line\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">HAQ change from\n  baseline over time<sup>e</sup> (patients evaluated)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">86</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">85</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">81</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">339</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Mean \u00b1 SD</span><sup><span lang=\"EN-GB\">c</span></sup></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.2\u00a0\u00b1\u00a00.3</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.3</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.4</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.5</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 control\u00a0=\u00a0</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">All patients had active RA despite\n  treatment with stable methotrexate doses for 6\u00a0months prior to enrolment\n  and were to remain on stable doses throughout the study. Concurrent use of\n  stable doses of oral corticosteroids (\u2264\u00a010\u00a0mg/day) and/or\n  NSAIDs was permitted, and folate supplementation was given.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 all\n  infliximab doses given in combination with methotrexate and</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> folate with some on corticosteroids\n  and/or NSAIDs</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">e</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "4464ed33-e1e9-414a-a34a-03d1a9515da3", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Table\u00a03</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Effects on ACR20,\n  Structural Joint Damage and Physical Function at week\u00a054, ATTRACT</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:204.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"273\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td colspan=\"5\" style=\"width:257.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" width=\"343\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span><sup><span lang=\"EN-GB\">b</span></sup></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"205\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Control</span><sup><span lang=\"EN-GB\">a</span></sup></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">All infliximab</span><sup><span lang=\"EN-GB\">b</span></sup></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with\n  ACR20 response/</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients\n  evaluated (%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">15/88</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(17%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">36/86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(42%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">41/86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">51/87</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">48/81</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">176/340</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(52%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Total score</span><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> (van der\n  Heijde\u2011modified Sharp score)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Change from\n  baseline (Mean \u00b1 SD</span><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\">)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.0\u00a0\u00b1\u00a010.3</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.3\u00a0\u00b1\u00a06.0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.6\u00a0\u00b1\u00a08.5</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.2\u00a0\u00b1\u00a03.6</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u20110.7\u00a0\u00b1\u00a03.8</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6\u00a0\u00b1\u00a05.9</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(Interquartile\n  range)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.5,9.7)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,3.0)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20112.5,3.0)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,2.0)</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">\u20110.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20113.0,1.5)</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.8,2.0)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with no\n  deterioration/patients evaluated (%)</span><sup><span lang=\"EN-GB\">c</span></sup></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">13/64</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">34/71</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">35/71</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(49%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">37/77</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">44/66</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(67%)</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">150/285</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(53%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:\n  line\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">HAQ change from\n  baseline over time<sup>e</sup> (patients evaluated)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">86</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">85</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">81</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">339</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Mean \u00b1 SD</span><sup><span lang=\"EN-GB\">c</span></sup></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.2\u00a0\u00b1\u00a00.3</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.3</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.4</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.5</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 control\u00a0=\u00a0</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">All patients had active RA despite\n  treatment with stable methotrexate doses for 6\u00a0months prior to enrolment\n  and were to remain on stable doses throughout the study. Concurrent use of\n  stable doses of oral corticosteroids (\u2264\u00a010\u00a0mg/day) and/or\n  NSAIDs was permitted, and folate supplementation was given.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 all\n  infliximab doses given in combination with methotrexate and</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> folate with some on corticosteroids\n  and/or NSAIDs</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">e</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span></p>\n</td>\n</tr>\n</table>", "ID": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "              ", "ParentId": "4464ed33-e1e9-414a-a34a-03d1a9515da3"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Table\u00a03</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Effects on ACR20,\n  Structural Joint Damage and Physical Function at week\u00a054, ATTRACT</span></b></p>\n</td>\n</tr>", "ID": "d4490e82-e73d-4397-81e7-a2ac1552c5c2", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td colspan=\"7\" style=\"width:461.45pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Table\u00a03</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Effects on ACR20,\n  Structural Joint Damage and Physical Function at week\u00a054, ATTRACT</span></b></p>\n</td>", "ID": "a2127bec-a26d-4d70-92d2-94eb250e4302", "Styles": "width:461.45pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "d4490e82-e73d-4397-81e7-a2ac1552c5c2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Table\u00a03</span></b></p>", "ID": "e7cdc0ec-fc2e-49ee-a6a0-9d4a3384b8ee", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a2127bec-a26d-4d70-92d2-94eb250e4302"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Table\u00a03</span></b>", "ID": "9e07339f-56c1-480c-8a07-0843b5eeb4c7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e7cdc0ec-fc2e-49ee-a6a0-9d4a3384b8ee"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Table\u00a03</span>", "ID": "d107d086-5bce-4823-a6f6-0a41c8e8293d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Table\u00a03", "ParentId": "9e07339f-56c1-480c-8a07-0843b5eeb4c7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Effects on ACR20,\n  Structural Joint Damage and Physical Function at week\u00a054, ATTRACT</span></b></p>", "ID": "5fa8df2f-ddad-42e5-b8e7-4924f17c8381", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a2127bec-a26d-4d70-92d2-94eb250e4302"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Effects on ACR20,\n  Structural Joint Damage and Physical Function at week\u00a054, ATTRACT</span></b>", "ID": "b9d96236-3e05-4831-b9fb-a1c689bc8cc1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5fa8df2f-ddad-42e5-b8e7-4924f17c8381"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Effects on ACR20,\n  Structural Joint Damage and Physical Function at week\u00a054, ATTRACT</span>", "ID": "4d482419-c08c-477c-93d5-e8881e19f971", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Effects on ACR20,   Structural Joint Damage and Physical Function at week\u00a054, ATTRACT", "ParentId": "b9d96236-3e05-4831-b9fb-a1c689bc8cc1"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:204.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"273\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td colspan=\"5\" style=\"width:257.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" width=\"343\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span><sup><span lang=\"EN-GB\">b</span></sup></p>\n</td>\n</tr>", "ID": "c2e53d85-0d13-4a19-9db5-e64f012d2d51", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td colspan=\"2\" style=\"width:204.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"273\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "492923ae-0ee5-4040-b124-8cdd4f97fb8b", "Styles": "width:204.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "c2e53d85-0d13-4a19-9db5-e64f012d2d51"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "f2d5d56b-e5d6-466e-9a42-1bea493232b5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "492923ae-0ee5-4040-b124-8cdd4f97fb8b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "8fea6804-76f1-418c-a2f7-4ad3bcfe903f", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "f2d5d56b-e5d6-466e-9a42-1bea493232b5"}, {"Element": "<td colspan=\"5\" style=\"width:257.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" width=\"343\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span><sup><span lang=\"EN-GB\">b</span></sup></p>\n</td>", "ID": "e4ee709e-fedd-4361-9f64-d6c61ef6d26e", "Styles": "width:257.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "c2e53d85-0d13-4a19-9db5-e64f012d2d51"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span><sup><span lang=\"EN-GB\">b</span></sup></p>", "ID": "3442a87b-c305-4452-8725-110c070a3c88", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e4ee709e-fedd-4361-9f64-d6c61ef6d26e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">infliximab</span>", "ID": "e2c3b5ef-a14f-4be7-a0c5-294426131388", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "infliximab", "ParentId": "3442a87b-c305-4452-8725-110c070a3c88"}, {"Element": "<sup><span lang=\"EN-GB\">b</span></sup>", "ID": "10e0ad0e-fef7-4ff8-b764-db1cae46598c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3442a87b-c305-4452-8725-110c070a3c88"}, {"Element": "<span lang=\"EN-GB\">b</span>", "ID": "f756baf8-66a4-4dd6-a34c-088d1767ce93", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "10e0ad0e-fef7-4ff8-b764-db1cae46598c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"205\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Control</span><sup><span lang=\"EN-GB\">a</span></sup></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">All infliximab</span><sup><span lang=\"EN-GB\">b</span></sup></p>\n</td>\n</tr>", "ID": "3e675db0-6e48-47ca-87e9-c30f0006c75e", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td style=\"width:153.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"205\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "7aa94853-1e01-4abb-a702-243c6b9d5d0c", "Styles": "width:153.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "3e675db0-6e48-47ca-87e9-c30f0006c75e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "1042728a-2938-4c9a-91df-7853a8637fa7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7aa94853-1e01-4abb-a702-243c6b9d5d0c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "c7c8f545-333b-4a15-9697-35620a5c1dbc", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "1042728a-2938-4c9a-91df-7853a8637fa7"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Control</span><sup><span lang=\"EN-GB\">a</span></sup></p>\n</td>", "ID": "18e28e2b-f332-4e5d-a310-2b91505c6ab6", "Styles": "width:51.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "3e675db0-6e48-47ca-87e9-c30f0006c75e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Control</span><sup><span lang=\"EN-GB\">a</span></sup></p>", "ID": "39629c54-3b7c-42c7-8fe6-0701d0b48287", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18e28e2b-f332-4e5d-a310-2b91505c6ab6"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Control</span>", "ID": "2d5c68d1-bd88-4015-98da-1ba063f377fb", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Control", "ParentId": "39629c54-3b7c-42c7-8fe6-0701d0b48287"}, {"Element": "<sup><span lang=\"EN-GB\">a</span></sup>", "ID": "5305e228-67a8-42de-ac8f-5a468e2be719", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "39629c54-3b7c-42c7-8fe6-0701d0b48287"}, {"Element": "<span lang=\"EN-GB\">a</span>", "ID": "6d829ea8-b5ab-49a7-9f40-178e37045c59", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "5305e228-67a8-42de-ac8f-5a468e2be719"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span></p>\n</td>", "ID": "9f0c1ce5-5843-4317-bab6-687705ac478a", "Styles": "width:51.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "3e675db0-6e48-47ca-87e9-c30f0006c75e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span></p>", "ID": "9fff1739-2315-460d-89ba-b62a6c8a15a0", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9f0c1ce5-5843-4317-bab6-687705ac478a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span>", "ID": "a88ec7d5-642c-462f-9f12-907c088bce41", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "3\u00a0mg/kg", "ParentId": "9fff1739-2315-460d-89ba-b62a6c8a15a0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span></p>", "ID": "15b47b4b-5f40-482d-86e9-3b4c667c8925", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9f0c1ce5-5843-4317-bab6-687705ac478a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span>", "ID": "063824fd-7fc6-4759-a351-c42341a05b20", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "q\u00a08\u00a0wks", "ParentId": "15b47b4b-5f40-482d-86e9-3b4c667c8925"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span></p>\n</td>", "ID": "b13f57b0-f54c-40e5-bcb1-9f3a936e0fb6", "Styles": "width:51.0pt;border-top:none;border-left:none;\n  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "3e675db0-6e48-47ca-87e9-c30f0006c75e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span></p>", "ID": "4b1067ec-e298-4f94-b117-6cc10ac32164", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b13f57b0-f54c-40e5-bcb1-9f3a936e0fb6"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">3\u00a0mg/kg</span>", "ID": "aa9ae319-ecc3-4e46-baa1-828f8cfa6426", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "3\u00a0mg/kg", "ParentId": "4b1067ec-e298-4f94-b117-6cc10ac32164"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span></p>", "ID": "f02fea5c-8f21-4731-a4a9-0fba612227e4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b13f57b0-f54c-40e5-bcb1-9f3a936e0fb6"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span>", "ID": "f8744d8d-4fd3-4fb9-9b33-4a4cf773636f", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "q\u00a04\u00a0wks", "ParentId": "f02fea5c-8f21-4731-a4a9-0fba612227e4"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span></p>\n</td>", "ID": "7a0e428e-8b17-432b-830c-14ba00e7f249", "Styles": "width:51.0pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "3e675db0-6e48-47ca-87e9-c30f0006c75e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span></p>", "ID": "e355b5e3-e32b-48c4-b5c1-c3759135873f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a0e428e-8b17-432b-830c-14ba00e7f249"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span>", "ID": "c2a9c2e3-affc-4ef3-b154-86e56ed00802", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "10\u00a0mg/kg", "ParentId": "e355b5e3-e32b-48c4-b5c1-c3759135873f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span></p>", "ID": "15ca8f6a-3b81-4f91-8589-b5dc4a0398ae", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a0e428e-8b17-432b-830c-14ba00e7f249"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a08\u00a0wks</span>", "ID": "a8851348-edd1-4788-acca-390e3b08e29b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "q\u00a08\u00a0wks", "ParentId": "15ca8f6a-3b81-4f91-8589-b5dc4a0398ae"}, {"Element": "<td style=\"width:50.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span></p>\n</td>", "ID": "cea9d253-eabb-4aa8-ba53-095d84f5bde1", "Styles": "width:50.2pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "3e675db0-6e48-47ca-87e9-c30f0006c75e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span></p>", "ID": "b55abc41-2474-4d0d-bb13-f0486eb10af4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cea9d253-eabb-4aa8-ba53-095d84f5bde1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">10\u00a0mg/kg</span>", "ID": "a080186c-0a17-46d6-bee3-460b67ace5c2", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "10\u00a0mg/kg", "ParentId": "b55abc41-2474-4d0d-bb13-f0486eb10af4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span></p>", "ID": "31ea9933-4d28-4df8-952c-dcac3ca54f88", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cea9d253-eabb-4aa8-ba53-095d84f5bde1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">q\u00a04\u00a0wks</span>", "ID": "08a52e25-b6c3-44fe-9d30-95b83a915792", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "q\u00a04\u00a0wks", "ParentId": "31ea9933-4d28-4df8-952c-dcac3ca54f88"}, {"Element": "<td style=\"width:53.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">All infliximab</span><sup><span lang=\"EN-GB\">b</span></sup></p>\n</td>", "ID": "204e1408-91a7-4c1e-82ae-0517151d81fa", "Styles": "width:53.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "3e675db0-6e48-47ca-87e9-c30f0006c75e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">All infliximab</span><sup><span lang=\"EN-GB\">b</span></sup></p>", "ID": "6c301bae-396e-404a-b4fb-88a0866f8e83", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "204e1408-91a7-4c1e-82ae-0517151d81fa"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">All infliximab</span>", "ID": "c3c35faa-881f-4829-b898-73086ae5ec14", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "All infliximab", "ParentId": "6c301bae-396e-404a-b4fb-88a0866f8e83"}, {"Element": "<sup><span lang=\"EN-GB\">b</span></sup>", "ID": "bdd0b0ab-5901-47f0-8a60-47d619e0111a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6c301bae-396e-404a-b4fb-88a0866f8e83"}, {"Element": "<span lang=\"EN-GB\">b</span>", "ID": "10335012-7e9c-4d95-8454-c9ff5362ed50", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "bdd0b0ab-5901-47f0-8a60-47d619e0111a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with\n  ACR20 response/</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients\n  evaluated (%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">15/88</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(17%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">36/86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(42%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">41/86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">51/87</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">48/81</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">176/340</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(52%)</span></p>\n</td>\n</tr>", "ID": "911ab68a-89b7-48be-b94e-e878e68a60e7", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with\n  ACR20 response/</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients\n  evaluated (%)</span></p>\n</td>", "ID": "908e13cd-2eb5-4429-8e4d-bb50965c353c", "Styles": "width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "911ab68a-89b7-48be-b94e-e878e68a60e7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with\n  ACR20 response/</span></p>", "ID": "b84d7487-afd1-4d21-825a-d649bc22d6df", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "908e13cd-2eb5-4429-8e4d-bb50965c353c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with\n  ACR20 response/</span>", "ID": "f7dae340-d6d5-4a7d-a6fc-b001ea51ea9d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Patients with   ACR20 response/", "ParentId": "b84d7487-afd1-4d21-825a-d649bc22d6df"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients\n  evaluated (%)</span></p>", "ID": "eceff4ad-4d45-46f3-8763-087adc8a6ba4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "908e13cd-2eb5-4429-8e4d-bb50965c353c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients\n  evaluated (%)</span>", "ID": "6b82d065-02bd-42f1-ae61-3499f14e2332", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Patients   evaluated (%)", "ParentId": "eceff4ad-4d45-46f3-8763-087adc8a6ba4"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">15/88</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(17%)</span></p>\n</td>", "ID": "22492567-711d-4b34-acbc-24c6b0059b41", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "911ab68a-89b7-48be-b94e-e878e68a60e7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">15/88</span></p>", "ID": "2818ce25-f3f0-4eea-8f11-c2374842e47c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22492567-711d-4b34-acbc-24c6b0059b41"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">15/88</span>", "ID": "a88ec020-4b8c-4525-ac9e-a4e9fa74c143", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "15/88", "ParentId": "2818ce25-f3f0-4eea-8f11-c2374842e47c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(17%)</span></p>", "ID": "ce65760a-4984-4626-9d0f-33a421f59f08", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22492567-711d-4b34-acbc-24c6b0059b41"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(17%)</span>", "ID": "70652f87-113d-4945-baf5-20fc87d5dc9a", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(17%)", "ParentId": "ce65760a-4984-4626-9d0f-33a421f59f08"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">36/86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(42%)</span></p>\n</td>", "ID": "efba6067-822d-43d1-8fb0-22b62dba4330", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "911ab68a-89b7-48be-b94e-e878e68a60e7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">36/86</span></p>", "ID": "a31adad0-89fa-494b-a054-dfce65d933b2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "efba6067-822d-43d1-8fb0-22b62dba4330"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">36/86</span>", "ID": "5d9718b2-a0f4-405a-9074-a190a5866bc6", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "36/86", "ParentId": "a31adad0-89fa-494b-a054-dfce65d933b2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(42%)</span></p>", "ID": "833e3bbc-074b-4769-af4d-9cfecca09a23", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "efba6067-822d-43d1-8fb0-22b62dba4330"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(42%)</span>", "ID": "ac9da97c-1cfd-46bf-8101-59a9db6f2f30", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(42%)", "ParentId": "833e3bbc-074b-4769-af4d-9cfecca09a23"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">41/86</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>", "ID": "e3d54bf9-f883-418a-b89e-9e4fccb920ec", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "911ab68a-89b7-48be-b94e-e878e68a60e7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">41/86</span></p>", "ID": "a7c9f4fe-ca56-4e47-b530-c4b22b085452", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3d54bf9-f883-418a-b89e-9e4fccb920ec"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">41/86</span>", "ID": "fcf8049e-16c3-4c29-9aac-b0a5a7f989d4", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "41/86", "ParentId": "a7c9f4fe-ca56-4e47-b530-c4b22b085452"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>", "ID": "904ef2ce-5291-44c9-9da0-1c814a69400e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e3d54bf9-f883-418a-b89e-9e4fccb920ec"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span>", "ID": "5ac8f987-39e6-4fc4-9c45-04e5fd83bdab", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(48%)", "ParentId": "904ef2ce-5291-44c9-9da0-1c814a69400e"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">51/87</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span></p>\n</td>", "ID": "56df9841-1c00-493b-a7a5-972f802d21fe", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "911ab68a-89b7-48be-b94e-e878e68a60e7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">51/87</span></p>", "ID": "b25147b1-d14a-4395-a7e5-5e4b92af6d87", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "56df9841-1c00-493b-a7a5-972f802d21fe"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">51/87</span>", "ID": "f9cdc483-a85d-4e48-85aa-bc25a47d337a", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "51/87", "ParentId": "b25147b1-d14a-4395-a7e5-5e4b92af6d87"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span></p>", "ID": "69161070-89bb-44a9-a092-5845a68f8104", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "56df9841-1c00-493b-a7a5-972f802d21fe"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span>", "ID": "2f346590-d62e-433c-81a0-62e5e6613ff4", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(59%)", "ParentId": "69161070-89bb-44a9-a092-5845a68f8104"}, {"Element": "<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">48/81</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span></p>\n</td>", "ID": "7dce5888-e6bc-44b1-b9ef-b6096aa0c824", "Styles": "width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "911ab68a-89b7-48be-b94e-e878e68a60e7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">48/81</span></p>", "ID": "2d717b3f-3bd6-4f3a-b6dd-af42ae32d92a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7dce5888-e6bc-44b1-b9ef-b6096aa0c824"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">48/81</span>", "ID": "f7d208ae-dd8e-494e-bb15-71a50f8bd844", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "48/81", "ParentId": "2d717b3f-3bd6-4f3a-b6dd-af42ae32d92a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span></p>", "ID": "09c49a90-0dc8-487b-9f0f-ea37d151579f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7dce5888-e6bc-44b1-b9ef-b6096aa0c824"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(59%)</span>", "ID": "e296ac83-d465-4aa5-803b-0e09aa4d37a2", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(59%)", "ParentId": "09c49a90-0dc8-487b-9f0f-ea37d151579f"}, {"Element": "<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">176/340</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(52%)</span></p>\n</td>", "ID": "63822637-6587-4271-9f50-a2da44c4b273", "Styles": "width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "911ab68a-89b7-48be-b94e-e878e68a60e7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">176/340</span></p>", "ID": "c3655855-67a6-4ceb-a7e1-62f94adb276b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "63822637-6587-4271-9f50-a2da44c4b273"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">176/340</span>", "ID": "fa6f41b4-f4f9-48b9-aa19-c62556b578b5", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "176/340", "ParentId": "c3655855-67a6-4ceb-a7e1-62f94adb276b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(52%)</span></p>", "ID": "ca0a187d-40de-492c-9bd8-8a5472f4dd81", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "63822637-6587-4271-9f50-a2da44c4b273"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(52%)</span>", "ID": "f79ea3a2-2904-4bec-af27-748639278f74", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(52%)", "ParentId": "ca0a187d-40de-492c-9bd8-8a5472f4dd81"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "e2d25169-1cb3-4401-bfdc-004777081a9d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td colspan=\"7\" style=\"width:461.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "6248a6b5-d657-4a35-803b-17b59df0251a", "Styles": "width:461.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "e2d25169-1cb3-4401-bfdc-004777081a9d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "76a052a8-4b3c-4574-bf74-edd3fa356803", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6248a6b5-d657-4a35-803b-17b59df0251a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "8ca17988-0488-4f0e-b249-2521feae92c6", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "76a052a8-4b3c-4574-bf74-edd3fa356803"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Total score</span><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> (van der\n  Heijde\u2011modified Sharp score)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>\n</tr>", "ID": "5275db12-0df1-49e2-8572-adf37c01d726", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Total score</span><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> (van der\n  Heijde\u2011modified Sharp score)</span></p>\n</td>", "ID": "a0e81aa7-0d78-4e64-bb6d-1b50ebc51be4", "Styles": "width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "5275db12-0df1-49e2-8572-adf37c01d726"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Total score</span><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> (van der\n  Heijde\u2011modified Sharp score)</span></p>", "ID": "1623261c-5403-4d30-8fe6-afe8c1164d7c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a0e81aa7-0d78-4e64-bb6d-1b50ebc51be4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Total score</span>", "ID": "e27e6d6a-6137-4cea-9d9c-a4043e340ded", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Total score", "ParentId": "1623261c-5403-4d30-8fe6-afe8c1164d7c"}, {"Element": "<sup><span lang=\"EN-GB\">d</span></sup>", "ID": "fe247e51-5d96-47c9-b447-5327f0eaddea", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1623261c-5403-4d30-8fe6-afe8c1164d7c"}, {"Element": "<span lang=\"EN-GB\">d</span>", "ID": "2bba87bc-2bf3-4cff-8e50-e35f1c666d64", "Styles": "None", "Classes": "None", "Text": "d", "ParentId": "fe247e51-5d96-47c9-b447-5327f0eaddea"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\"> (van der\n  Heijde\u2011modified Sharp score)</span>", "ID": "552b6d67-5158-49dc-a641-88f5b07e605e", "Styles": "font-size:10.0pt", "Classes": "None", "Text": " (van der   Heijde\u2011modified Sharp score)", "ParentId": "1623261c-5403-4d30-8fe6-afe8c1164d7c"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "a6a23ca2-e0a9-4766-b08c-d31faec6f0b8", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "5275db12-0df1-49e2-8572-adf37c01d726"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "d609c334-6f83-4828-80f6-d9188cca2382", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a6a23ca2-e0a9-4766-b08c-d31faec6f0b8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "59d32102-a167-49ef-8592-177b16867933", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "d609c334-6f83-4828-80f6-d9188cca2382"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "3b71d09b-bc4a-4438-901e-9f19095de30a", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "5275db12-0df1-49e2-8572-adf37c01d726"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "e2377eeb-38da-477c-bb38-2acb9362ebe0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3b71d09b-bc4a-4438-901e-9f19095de30a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "7ab341e4-abfa-4740-b3c9-bc54ee85664d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "e2377eeb-38da-477c-bb38-2acb9362ebe0"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "aa6cef88-3b7d-41e1-b92a-d091b22abd24", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "5275db12-0df1-49e2-8572-adf37c01d726"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "9cb060bb-30bf-4bbc-9f33-d3270f670eca", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aa6cef88-3b7d-41e1-b92a-d091b22abd24"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "fca80ee7-7172-4ca9-aa3f-b868da40ce24", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "9cb060bb-30bf-4bbc-9f33-d3270f670eca"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "bdb60f5f-a5c1-4c8b-8882-8e786be0815e", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "5275db12-0df1-49e2-8572-adf37c01d726"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "5b8a8a46-0b9e-4fd3-b6a1-37e373cf87d8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdb60f5f-a5c1-4c8b-8882-8e786be0815e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "685c6bec-fc8e-4a5a-bdad-191dcbae2e13", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "5b8a8a46-0b9e-4fd3-b6a1-37e373cf87d8"}, {"Element": "<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "525d1f2d-0063-4a3a-97c7-44802f18f58e", "Styles": "width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "5275db12-0df1-49e2-8572-adf37c01d726"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "1a1973a7-6650-4537-a611-91e605a39c0b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "525d1f2d-0063-4a3a-97c7-44802f18f58e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "79d6614e-89aa-416e-8d04-b5f2069dc67f", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "1a1973a7-6650-4537-a611-91e605a39c0b"}, {"Element": "<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>\n</td>", "ID": "4d9695a0-b492-4a72-a9ca-1ed6bedaaca1", "Styles": "width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "5275db12-0df1-49e2-8572-adf37c01d726"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span></p>", "ID": "abe2dea6-7458-4e04-9098-d350e58f623a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d9695a0-b492-4a72-a9ca-1ed6bedaaca1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u00a0</span>", "ID": "ee902741-390f-4bf2-8e24-79dd6dde4f61", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u00a0", "ParentId": "abe2dea6-7458-4e04-9098-d350e58f623a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Change from\n  baseline (Mean \u00b1 SD</span><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\">)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.0\u00a0\u00b1\u00a010.3</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.3\u00a0\u00b1\u00a06.0</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.6\u00a0\u00b1\u00a08.5</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.2\u00a0\u00b1\u00a03.6</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u20110.7\u00a0\u00b1\u00a03.8</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6\u00a0\u00b1\u00a05.9</span></p>\n</td>\n</tr>", "ID": "62184c28-0b2b-4f72-bc55-f4b56c0f9ca4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Change from\n  baseline (Mean \u00b1 SD</span><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\">)</span></p>\n</td>", "ID": "e9a7989b-b424-4a19-b8ee-8adb6acf974f", "Styles": "width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "62184c28-0b2b-4f72-bc55-f4b56c0f9ca4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Change from\n  baseline (Mean \u00b1 SD</span><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:10.0pt\">)</span></p>", "ID": "8c4a4c8a-2e70-4d39-ad2a-66f111440bb8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e9a7989b-b424-4a19-b8ee-8adb6acf974f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Change from\n  baseline (Mean \u00b1 SD</span>", "ID": "a3c1180d-0e4d-4ed8-a5f3-54859ecec100", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Change from   baseline (Mean \u00b1 SD", "ParentId": "8c4a4c8a-2e70-4d39-ad2a-66f111440bb8"}, {"Element": "<sup><span lang=\"EN-GB\">c</span></sup>", "ID": "46c6c809-72f7-456c-bfdc-0be8cd0be2fe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c4a4c8a-2e70-4d39-ad2a-66f111440bb8"}, {"Element": "<span lang=\"EN-GB\">c</span>", "ID": "4f2a67b4-01e1-4d2d-8f14-a0b6bce6686c", "Styles": "None", "Classes": "None", "Text": "c", "ParentId": "46c6c809-72f7-456c-bfdc-0be8cd0be2fe"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">)</span>", "ID": "dc941dc6-0d99-4edf-a832-a3d5742f69eb", "Styles": "font-size:10.0pt", "Classes": "None", "Text": ")", "ParentId": "8c4a4c8a-2e70-4d39-ad2a-66f111440bb8"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.0\u00a0\u00b1\u00a010.3</span></p>\n</td>", "ID": "8974d61b-1bcd-4de7-8021-197536d01b31", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "62184c28-0b2b-4f72-bc55-f4b56c0f9ca4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.0\u00a0\u00b1\u00a010.3</span></p>", "ID": "53b98ac9-e7b2-4d00-a394-e34b1b628240", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8974d61b-1bcd-4de7-8021-197536d01b31"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">7.0\u00a0\u00b1\u00a010.3</span>", "ID": "2cf073c5-ab40-44f1-806c-84d9572e0b29", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "7.0\u00a0\u00b1\u00a010.3", "ParentId": "53b98ac9-e7b2-4d00-a394-e34b1b628240"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.3\u00a0\u00b1\u00a06.0</span></p>\n</td>", "ID": "18a70dcd-bc97-418b-9cc7-f939fc8ef853", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "62184c28-0b2b-4f72-bc55-f4b56c0f9ca4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.3\u00a0\u00b1\u00a06.0</span></p>", "ID": "7efb3518-b4c2-4a21-adf0-9708ccabaa53", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18a70dcd-bc97-418b-9cc7-f939fc8ef853"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.3\u00a0\u00b1\u00a06.0</span>", "ID": "69553083-a69b-4978-a18e-b0219c50a786", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "1.3\u00a0\u00b1\u00a06.0", "ParentId": "7efb3518-b4c2-4a21-adf0-9708ccabaa53"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.6\u00a0\u00b1\u00a08.5</span></p>\n</td>", "ID": "ca61b5f6-5578-467e-939f-c8191d8a3193", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "62184c28-0b2b-4f72-bc55-f4b56c0f9ca4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.6\u00a0\u00b1\u00a08.5</span></p>", "ID": "52f30c00-1359-4cb3-a4a7-29b1e0ede9f5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ca61b5f6-5578-467e-939f-c8191d8a3193"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">1.6\u00a0\u00b1\u00a08.5</span>", "ID": "9c84c460-683c-4f8a-8965-b27318c23478", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "1.6\u00a0\u00b1\u00a08.5", "ParentId": "52f30c00-1359-4cb3-a4a7-29b1e0ede9f5"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.2\u00a0\u00b1\u00a03.6</span></p>\n</td>", "ID": "177266db-0a75-4700-870a-126f8c148ca5", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "62184c28-0b2b-4f72-bc55-f4b56c0f9ca4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.2\u00a0\u00b1\u00a03.6</span></p>", "ID": "7045edd1-8aaa-4549-a38e-56019ecb2a64", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "177266db-0a75-4700-870a-126f8c148ca5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.2\u00a0\u00b1\u00a03.6</span>", "ID": "02b24e3b-6826-40cb-a8fc-97437567cd8b", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.2\u00a0\u00b1\u00a03.6", "ParentId": "7045edd1-8aaa-4549-a38e-56019ecb2a64"}, {"Element": "<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u20110.7\u00a0\u00b1\u00a03.8</span></p>\n</td>", "ID": "6c0d6339-98b7-4528-a1fe-639716210cab", "Styles": "width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "62184c28-0b2b-4f72-bc55-f4b56c0f9ca4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u20110.7\u00a0\u00b1\u00a03.8</span></p>", "ID": "1a0b78a6-ae88-48e9-981d-e97faa53b1b1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6c0d6339-98b7-4528-a1fe-639716210cab"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">\u20110.7\u00a0\u00b1\u00a03.8</span>", "ID": "98bce6b7-7338-4589-b89d-5ad3477c6303", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "\u20110.7\u00a0\u00b1\u00a03.8", "ParentId": "1a0b78a6-ae88-48e9-981d-e97faa53b1b1"}, {"Element": "<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6\u00a0\u00b1\u00a05.9</span></p>\n</td>", "ID": "54f317e4-44ad-4573-97d4-22730ddb6547", "Styles": "width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "62184c28-0b2b-4f72-bc55-f4b56c0f9ca4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6\u00a0\u00b1\u00a05.9</span></p>", "ID": "3b0611aa-335b-4148-9cd2-43f926a03226", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "54f317e4-44ad-4573-97d4-22730ddb6547"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">0.6\u00a0\u00b1\u00a05.9</span>", "ID": "7ebd7469-9d93-427c-a36b-f40d95db4c7d", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "0.6\u00a0\u00b1\u00a05.9", "ParentId": "3b0611aa-335b-4148-9cd2-43f926a03226"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(Interquartile\n  range)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.5,9.7)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,3.0)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20112.5,3.0)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,2.0)</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">\u20110.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20113.0,1.5)</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.8,2.0)</span></p>\n</td>\n</tr>", "ID": "81ede09d-3476-4d02-9e2a-dad807b34acb", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(Interquartile\n  range)</span></p>\n</td>", "ID": "8c964fb3-0ffa-4a08-9cec-af30a3e4a2cc", "Styles": "width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "81ede09d-3476-4d02-9e2a-dad807b34acb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median</span></p>", "ID": "7399eabc-5a1c-45e1-a6a0-f13d3ed94217", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c964fb3-0ffa-4a08-9cec-af30a3e4a2cc"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Median</span>", "ID": "152e73e3-a64c-434b-aef8-f7a4e4112a2c", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Median", "ParentId": "7399eabc-5a1c-45e1-a6a0-f13d3ed94217"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(Interquartile\n  range)</span></p>", "ID": "69cb91ed-8df3-47b2-9470-258301eb915b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c964fb3-0ffa-4a08-9cec-af30a3e4a2cc"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(Interquartile\n  range)</span>", "ID": "1fb23b71-683e-45dc-a8f8-ef549a121295", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(Interquartile   range)", "ParentId": "69cb91ed-8df3-47b2-9470-258301eb915b"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.5,9.7)</span></p>\n</td>", "ID": "128b4e6a-e4dd-49c0-b3c7-0f498d5cfe8f", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "81ede09d-3476-4d02-9e2a-dad807b34acb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.0</span></p>", "ID": "0bfa7988-c6d3-49fd-a4b8-2d5d39aa8fb4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "128b4e6a-e4dd-49c0-b3c7-0f498d5cfe8f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">4.0</span>", "ID": "ec8d56a1-310b-46ad-82d8-cba186d5b198", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "4.0", "ParentId": "0bfa7988-c6d3-49fd-a4b8-2d5d39aa8fb4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.5,9.7)</span></p>", "ID": "3f97b7f3-9dda-44c5-917d-8efe35aff282", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "128b4e6a-e4dd-49c0-b3c7-0f498d5cfe8f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(0.5,9.7)</span>", "ID": "cde5308a-7d10-4659-b566-c6c9cbccd3cd", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(0.5,9.7)", "ParentId": "3f97b7f3-9dda-44c5-917d-8efe35aff282"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,3.0)</span></p>\n</td>", "ID": "dea3a97f-d2f5-48d0-bcf6-50dbef3dd6c7", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "81ede09d-3476-4d02-9e2a-dad807b34acb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span></p>", "ID": "7830c704-218f-4475-ab1b-c1ceda302dfa", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dea3a97f-d2f5-48d0-bcf6-50dbef3dd6c7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span>", "ID": "787e4425-74f8-4e6b-864e-68a0d554c4c4", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "0.5", "ParentId": "7830c704-218f-4475-ab1b-c1ceda302dfa"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,3.0)</span></p>", "ID": "9dc7c5b7-8edf-4d79-acd8-8675039155c5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dea3a97f-d2f5-48d0-bcf6-50dbef3dd6c7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,3.0)</span>", "ID": "b2a5545b-4d83-498c-8dbd-6c9e525a7675", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(\u20111.5,3.0)", "ParentId": "9dc7c5b7-8edf-4d79-acd8-8675039155c5"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20112.5,3.0)</span></p>\n</td>", "ID": "c53a3d33-b0c4-4122-a20b-8b399cba470f", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "81ede09d-3476-4d02-9e2a-dad807b34acb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.1</span></p>", "ID": "84398373-8599-4fec-9e3a-44b0dad4c801", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c53a3d33-b0c4-4122-a20b-8b399cba470f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.1</span>", "ID": "9fbd1cef-ece5-4dd4-84d1-ac1a3933720d", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "0.1", "ParentId": "84398373-8599-4fec-9e3a-44b0dad4c801"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20112.5,3.0)</span></p>", "ID": "b8d97306-9b5c-4c0e-9f7f-e60f0b504621", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c53a3d33-b0c4-4122-a20b-8b399cba470f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20112.5,3.0)</span>", "ID": "62d9f119-b40e-4c9e-93e9-2a03c8d4ae26", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(\u20112.5,3.0)", "ParentId": "b8d97306-9b5c-4c0e-9f7f-e60f0b504621"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,2.0)</span></p>\n</td>", "ID": "ab6d9577-fad0-44c2-8474-bc73aa728647", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "81ede09d-3476-4d02-9e2a-dad807b34acb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span></p>", "ID": "124c298c-f645-4b64-9ba2-cf94f409d384", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ab6d9577-fad0-44c2-8474-bc73aa728647"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5</span>", "ID": "e201a20f-b082-40df-a4e7-dc055d769d8c", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "0.5", "ParentId": "124c298c-f645-4b64-9ba2-cf94f409d384"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,2.0)</span></p>", "ID": "3c7d92ab-dc7d-4573-9cac-69b51b962b56", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ab6d9577-fad0-44c2-8474-bc73aa728647"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.5,2.0)</span>", "ID": "75361ffc-ad04-4d85-87ee-ff388a153021", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(\u20111.5,2.0)", "ParentId": "3c7d92ab-dc7d-4573-9cac-69b51b962b56"}, {"Element": "<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">\u20110.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20113.0,1.5)</span></p>\n</td>", "ID": "c65cecb9-2790-41ec-8428-30af8abb6668", "Styles": "width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "81ede09d-3476-4d02-9e2a-dad807b34acb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">\u20110.5</span></p>", "ID": "847dd9af-f463-4d38-98d7-6d912d388aec", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c65cecb9-2790-41ec-8428-30af8abb6668"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">\u20110.5</span>", "ID": "3af1c1c1-71c2-4304-95dd-9e9fe6610b88", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "\u20110.5", "ParentId": "847dd9af-f463-4d38-98d7-6d912d388aec"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20113.0,1.5)</span></p>", "ID": "c6b25606-14c6-4a8c-86ff-856ecf3d8502", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c65cecb9-2790-41ec-8428-30af8abb6668"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20113.0,1.5)</span>", "ID": "ad40f59f-f25c-4a8e-91d4-99dba49c576c", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(\u20113.0,1.5)", "ParentId": "c6b25606-14c6-4a8c-86ff-856ecf3d8502"}, {"Element": "<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.8,2.0)</span></p>\n</td>", "ID": "d8812260-fa45-4f6b-9e72-0170f05ac003", "Styles": "width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "81ede09d-3476-4d02-9e2a-dad807b34acb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.0</span></p>", "ID": "54ce79bc-320a-4ce9-ba41-e2397a51f358", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d8812260-fa45-4f6b-9e72-0170f05ac003"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.0</span>", "ID": "039e9e60-8ef0-48fe-9078-e3642fdcb5bc", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "0.0", "ParentId": "54ce79bc-320a-4ce9-ba41-e2397a51f358"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.8,2.0)</span></p>", "ID": "f209646b-dfc8-48f7-88b2-eb8ddc6f40fd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d8812260-fa45-4f6b-9e72-0170f05ac003"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(\u20111.8,2.0)</span>", "ID": "1df65189-b9d8-4f28-b9b6-9e75f820d0a6", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(\u20111.8,2.0)", "ParentId": "f209646b-dfc8-48f7-88b2-eb8ddc6f40fd"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with no\n  deterioration/patients evaluated (%)</span><sup><span lang=\"EN-GB\">c</span></sup></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">13/64</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">34/71</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">35/71</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(49%)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">37/77</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">44/66</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(67%)</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">150/285</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(53%)</span></p>\n</td>\n</tr>", "ID": "e0e96d09-62eb-49b9-8cd9-20a17188b3a6", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with no\n  deterioration/patients evaluated (%)</span><sup><span lang=\"EN-GB\">c</span></sup></p>\n</td>", "ID": "fce9062d-7821-4bd8-a9c6-0c380c0b249c", "Styles": "width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "e0e96d09-62eb-49b9-8cd9-20a17188b3a6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with no\n  deterioration/patients evaluated (%)</span><sup><span lang=\"EN-GB\">c</span></sup></p>", "ID": "244f520e-5384-42ff-a3b5-9074b8884e8d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fce9062d-7821-4bd8-a9c6-0c380c0b249c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Patients with no\n  deterioration/patients evaluated (%)</span>", "ID": "8a3a6349-0be7-4a53-a307-5c22cb17743a", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Patients with no   deterioration/patients evaluated (%)", "ParentId": "244f520e-5384-42ff-a3b5-9074b8884e8d"}, {"Element": "<sup><span lang=\"EN-GB\">c</span></sup>", "ID": "7d99bf5d-9372-4c9c-bb4d-94f2f5164a07", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "244f520e-5384-42ff-a3b5-9074b8884e8d"}, {"Element": "<span lang=\"EN-GB\">c</span>", "ID": "2d70ee4a-d75f-42f7-ab30-f91c045e0499", "Styles": "None", "Classes": "None", "Text": "c", "ParentId": "7d99bf5d-9372-4c9c-bb4d-94f2f5164a07"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">13/64</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20%)</span></p>\n</td>", "ID": "e0db730e-dc39-4568-b809-7f47ed21b598", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "e0e96d09-62eb-49b9-8cd9-20a17188b3a6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">13/64</span></p>", "ID": "b6860982-5f42-4d7f-98b5-b3d994690764", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e0db730e-dc39-4568-b809-7f47ed21b598"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">13/64</span>", "ID": "49ca8bdf-dc96-4195-af28-b26f2de1d442", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "13/64", "ParentId": "b6860982-5f42-4d7f-98b5-b3d994690764"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20%)</span></p>", "ID": "3a384ee5-eacd-4a5c-9924-76187ac26594", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e0db730e-dc39-4568-b809-7f47ed21b598"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">(20%)</span>", "ID": "3216e7b6-6167-40a5-9a92-6f3a990278f4", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "(20%)", "ParentId": "3a384ee5-eacd-4a5c-9924-76187ac26594"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">34/71</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>", "ID": "0954e3ec-9eb1-49b1-b834-d00a12dde3f6", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "e0e96d09-62eb-49b9-8cd9-20a17188b3a6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">34/71</span></p>", "ID": "ae237829-ab90-4fcd-89dc-3f682e9daa87", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0954e3ec-9eb1-49b1-b834-d00a12dde3f6"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">34/71</span>", "ID": "dfe5f63c-3428-457b-b10b-df17f5713068", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "34/71", "ParentId": "ae237829-ab90-4fcd-89dc-3f682e9daa87"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>", "ID": "37ab43f9-7fcf-4269-8794-a71ade24d6fc", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0954e3ec-9eb1-49b1-b834-d00a12dde3f6"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span>", "ID": "94aaade8-7c0d-4f2d-9a25-ffb634a49ace", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(48%)", "ParentId": "37ab43f9-7fcf-4269-8794-a71ade24d6fc"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">35/71</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(49%)</span></p>\n</td>", "ID": "7f3252fc-f401-499b-8058-25d9be1e24a5", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "e0e96d09-62eb-49b9-8cd9-20a17188b3a6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">35/71</span></p>", "ID": "a2b9e5f9-67a1-4153-bf13-dec714abcb6d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7f3252fc-f401-499b-8058-25d9be1e24a5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">35/71</span>", "ID": "28908a08-b191-4a87-81b8-052719446e59", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "35/71", "ParentId": "a2b9e5f9-67a1-4153-bf13-dec714abcb6d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(49%)</span></p>", "ID": "96ef5c00-2289-458d-9564-a9c17cd705da", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7f3252fc-f401-499b-8058-25d9be1e24a5"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(49%)</span>", "ID": "0c1fe6bb-dfcb-49b0-88fe-e821160df6f5", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(49%)", "ParentId": "96ef5c00-2289-458d-9564-a9c17cd705da"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">37/77</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>\n</td>", "ID": "2581f236-8d96-47ce-bf77-70c2e5440e05", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "e0e96d09-62eb-49b9-8cd9-20a17188b3a6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">37/77</span></p>", "ID": "8db070ff-2aaa-4804-ba57-3c0280ae57cb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2581f236-8d96-47ce-bf77-70c2e5440e05"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">37/77</span>", "ID": "593a74a5-3ffc-4070-9696-46da06449982", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "37/77", "ParentId": "8db070ff-2aaa-4804-ba57-3c0280ae57cb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span></p>", "ID": "8c0fa252-04dd-498d-916a-3057cc9adb41", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2581f236-8d96-47ce-bf77-70c2e5440e05"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(48%)</span>", "ID": "a4602d40-86b0-46c5-856a-2b66e386837e", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(48%)", "ParentId": "8c0fa252-04dd-498d-916a-3057cc9adb41"}, {"Element": "<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">44/66</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(67%)</span></p>\n</td>", "ID": "63fb409e-367a-4efe-a9d4-d8520f8e4fc1", "Styles": "width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "e0e96d09-62eb-49b9-8cd9-20a17188b3a6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">44/66</span></p>", "ID": "ceb9471b-943e-4666-acbb-e0779e4d84cb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "63fb409e-367a-4efe-a9d4-d8520f8e4fc1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">44/66</span>", "ID": "47fa066c-bd9c-40de-875e-265272d6b5bf", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "44/66", "ParentId": "ceb9471b-943e-4666-acbb-e0779e4d84cb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(67%)</span></p>", "ID": "cedf06bd-3072-4a2d-bfdf-8bd0fa320514", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "63fb409e-367a-4efe-a9d4-d8520f8e4fc1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(67%)</span>", "ID": "91c6c0d4-58f5-409f-bea4-d83e5bdcc5be", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(67%)", "ParentId": "cedf06bd-3072-4a2d-bfdf-8bd0fa320514"}, {"Element": "<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">150/285</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(53%)</span></p>\n</td>", "ID": "7018c0e7-1f3c-403b-8b53-653f93de2652", "Styles": "width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "e0e96d09-62eb-49b9-8cd9-20a17188b3a6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">150/285</span></p>", "ID": "bb75d397-26d2-4c0b-b1da-c26cc6353e6a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7018c0e7-1f3c-403b-8b53-653f93de2652"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">150/285</span>", "ID": "8e82e4af-9e5f-495e-92bb-dd7ef1335544", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "150/285", "ParentId": "bb75d397-26d2-4c0b-b1da-c26cc6353e6a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(53%)</span></p>", "ID": "1a312edc-2a09-444a-93d3-07fb4f704747", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7018c0e7-1f3c-403b-8b53-653f93de2652"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">(53%)</span>", "ID": "61987d98-e78d-4e60-af78-ece845bde51c", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "(53%)", "ParentId": "1a312edc-2a09-444a-93d3-07fb4f704747"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:\n  line\">\u00a0</span></p>\n</td>\n</tr>", "ID": "8aeaedde-43f9-4ca5-bbbf-12cef686360d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td colspan=\"7\" style=\"width:461.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:\n  line\">\u00a0</span></p>\n</td>", "ID": "5dc3d237-4024-48de-82df-98068399a6d8", "Styles": "width:461.45pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8aeaedde-43f9-4ca5-bbbf-12cef686360d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:\n  line\">\u00a0</span></p>", "ID": "8edb6d43-ee5d-4b0c-8aef-b1208d991a75", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5dc3d237-4024-48de-82df-98068399a6d8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:\n  line\">\u00a0</span>", "ID": "e7e2877b-724a-4954-acf6-8f6a2f6d6e00", "Styles": "font-size:10.0pt;layout-grid-mode:\n  line", "Classes": "None", "Text": "\u00a0", "ParentId": "8edb6d43-ee5d-4b0c-8aef-b1208d991a75"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">HAQ change from\n  baseline over time<sup>e</sup> (patients evaluated)</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">86</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">85</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">81</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">339</span></p>\n</td>\n</tr>", "ID": "fb14829e-ea2c-43c7-ad1b-ab4d94af49eb", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">HAQ change from\n  baseline over time<sup>e</sup> (patients evaluated)</span></p>\n</td>", "ID": "58d7f5ee-a6b1-4742-8dc0-f48dfb4176f2", "Styles": "width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "fb14829e-ea2c-43c7-ad1b-ab4d94af49eb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">HAQ change from\n  baseline over time<sup>e</sup> (patients evaluated)</span></p>", "ID": "09cc3e34-8553-49ec-9bf9-d21e8bd71893", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "58d7f5ee-a6b1-4742-8dc0-f48dfb4176f2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">HAQ change from\n  baseline over time<sup>e</sup> (patients evaluated)</span>", "ID": "91ca99f2-af94-4d6d-a14f-a19b1f42e7a2", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "HAQ change from   baseline over time (patients evaluated)", "ParentId": "09cc3e34-8553-49ec-9bf9-d21e8bd71893"}, {"Element": "<sup>e</sup>", "ID": "8fc23edd-8cbc-45bf-9379-cfaed313d3f2", "Styles": "None", "Classes": "None", "Text": "e", "ParentId": "91ca99f2-af94-4d6d-a14f-a19b1f42e7a2"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span></p>\n</td>", "ID": "18e52b2c-9f6d-41a9-a206-3d56367cfb98", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "fb14829e-ea2c-43c7-ad1b-ab4d94af49eb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span></p>", "ID": "ff0504f3-d65a-4570-aba9-40138c6db5af", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "18e52b2c-9f6d-41a9-a206-3d56367cfb98"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span>", "ID": "d7371e9f-492e-48d3-ac59-dfc87fa835f1", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "87", "ParentId": "ff0504f3-d65a-4570-aba9-40138c6db5af"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">86</span></p>\n</td>", "ID": "32b398cc-ba9c-445a-b7ba-ce07b561c5ef", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "fb14829e-ea2c-43c7-ad1b-ab4d94af49eb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">86</span></p>", "ID": "8a442515-60da-489c-be11-e734847b88f7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "32b398cc-ba9c-445a-b7ba-ce07b561c5ef"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">86</span>", "ID": "2489c895-abc3-4cdf-a574-4e9d00e33500", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "86", "ParentId": "8a442515-60da-489c-be11-e734847b88f7"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">85</span></p>\n</td>", "ID": "370e136b-2de1-4196-8a28-439bea7fd14b", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "fb14829e-ea2c-43c7-ad1b-ab4d94af49eb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">85</span></p>", "ID": "11fdddaf-be96-4546-a183-80c09f70c199", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "370e136b-2de1-4196-8a28-439bea7fd14b"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">85</span>", "ID": "8c7bec6e-1e32-490c-9b60-c9774e851ace", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "85", "ParentId": "11fdddaf-be96-4546-a183-80c09f70c199"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span></p>\n</td>", "ID": "f38f7485-3709-409d-8bc4-0b75fcadf585", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "fb14829e-ea2c-43c7-ad1b-ab4d94af49eb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span></p>", "ID": "8a58b77d-a3f8-4c50-8670-2bf3703f6919", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f38f7485-3709-409d-8bc4-0b75fcadf585"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">87</span>", "ID": "0f735e0f-03ec-4aab-8843-9eab3f45e886", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "87", "ParentId": "8a58b77d-a3f8-4c50-8670-2bf3703f6919"}, {"Element": "<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">81</span></p>\n</td>", "ID": "2de636a0-a963-493f-b036-4e4035191d00", "Styles": "width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "fb14829e-ea2c-43c7-ad1b-ab4d94af49eb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">81</span></p>", "ID": "139aceab-177c-4c8e-a115-b0c54908f0ec", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2de636a0-a963-493f-b036-4e4035191d00"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">81</span>", "ID": "9efabcda-ea05-4b63-b6c2-b8d77899cdea", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "81", "ParentId": "139aceab-177c-4c8e-a115-b0c54908f0ec"}, {"Element": "<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">339</span></p>\n</td>", "ID": "bb13a8b5-5517-4a6b-bbbe-6c080b084a85", "Styles": "width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "fb14829e-ea2c-43c7-ad1b-ab4d94af49eb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">339</span></p>", "ID": "2d7e7d29-0107-4ef3-8ee3-b0dbc7fe45b1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bb13a8b5-5517-4a6b-bbbe-6c080b084a85"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">339</span>", "ID": "a26e73ce-0a80-43c9-a0f4-b8378369a317", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "339", "ParentId": "2d7e7d29-0107-4ef3-8ee3-b0dbc7fe45b1"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Mean \u00b1 SD</span><sup><span lang=\"EN-GB\">c</span></sup></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.2\u00a0\u00b1\u00a00.3</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.3</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.4</span></p>\n</td>\n<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.5</span></p>\n</td>\n<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span></p>\n</td>\n<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span></p>\n</td>\n</tr>", "ID": "bc508fd1-a750-46a1-b493-e6deb78c37f7", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td style=\"width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt\" width=\"205\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Mean \u00b1 SD</span><sup><span lang=\"EN-GB\">c</span></sup></p>\n</td>", "ID": "f72b3aae-c469-4b05-b34f-12f7c9c9e726", "Styles": "width:153.45pt;border:solid windowtext 1.0pt;border-top:\n  none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bc508fd1-a750-46a1-b493-e6deb78c37f7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">Mean \u00b1 SD</span><sup><span lang=\"EN-GB\">c</span></sup></p>", "ID": "fa4285e5-eafe-4506-8ed4-791cc3abdfb4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f72b3aae-c469-4b05-b34f-12f7c9c9e726"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\">Mean \u00b1 SD</span>", "ID": "a386508e-6f53-4924-bb10-58f5c8d26513", "Styles": "font-size:10.0pt", "Classes": "None", "Text": "Mean \u00b1 SD", "ParentId": "fa4285e5-eafe-4506-8ed4-791cc3abdfb4"}, {"Element": "<sup><span lang=\"EN-GB\">c</span></sup>", "ID": "53a5a906-4ecc-478a-921c-0e3b4e51f698", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "fa4285e5-eafe-4506-8ed4-791cc3abdfb4"}, {"Element": "<span lang=\"EN-GB\">c</span>", "ID": "0f9c3d12-bb30-45fa-a273-2fc410b1f7f7", "Styles": "None", "Classes": "None", "Text": "c", "ParentId": "53a5a906-4ecc-478a-921c-0e3b4e51f698"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.2\u00a0\u00b1\u00a00.3</span></p>\n</td>", "ID": "14f83627-9b40-4224-acb1-009e05bec5ac", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bc508fd1-a750-46a1-b493-e6deb78c37f7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.2\u00a0\u00b1\u00a00.3</span></p>", "ID": "331281e4-e3ab-457b-a88b-5197c24f0a8f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "14f83627-9b40-4224-acb1-009e05bec5ac"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.2\u00a0\u00b1\u00a00.3</span>", "ID": "3a790e70-0ecb-4a1b-9254-ca5d3d03fc1d", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "0.2\u00a0\u00b1\u00a00.3", "ParentId": "331281e4-e3ab-457b-a88b-5197c24f0a8f"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.3</span></p>\n</td>", "ID": "d1291648-6b09-47c4-be77-08d04b7d210e", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bc508fd1-a750-46a1-b493-e6deb78c37f7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.3</span></p>", "ID": "5a053f4a-1621-48c9-838a-dfa1fb48d932", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d1291648-6b09-47c4-be77-08d04b7d210e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.3</span>", "ID": "4f03348d-5627-4161-899c-2591c2277f67", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "0.4\u00a0\u00b1\u00a00.3", "ParentId": "5a053f4a-1621-48c9-838a-dfa1fb48d932"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.4</span></p>\n</td>", "ID": "7e9383f8-2238-40c6-bf61-49941f763597", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bc508fd1-a750-46a1-b493-e6deb78c37f7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.4</span></p>", "ID": "885f1cbf-a519-42ab-a7c6-75fcdf250443", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e9383f8-2238-40c6-bf61-49941f763597"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.4</span>", "ID": "7051b418-2ca7-4d91-ba80-84c7f08a9c06", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "0.5\u00a0\u00b1\u00a00.4", "ParentId": "885f1cbf-a519-42ab-a7c6-75fcdf250443"}, {"Element": "<td style=\"width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"68\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.5</span></p>\n</td>", "ID": "6369bfa1-953c-407c-a3b0-fd903e40d46d", "Styles": "width:51.0pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bc508fd1-a750-46a1-b493-e6deb78c37f7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.5</span></p>", "ID": "400ee814-a900-4d91-ab24-94d16452c45a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6369bfa1-953c-407c-a3b0-fd903e40d46d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.5\u00a0\u00b1\u00a00.5</span>", "ID": "6d15689e-1cf0-44f2-87bc-af83545be5d6", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "0.5\u00a0\u00b1\u00a00.5", "ParentId": "400ee814-a900-4d91-ab24-94d16452c45a"}, {"Element": "<td style=\"width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"67\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span></p>\n</td>", "ID": "9d6c815d-42e2-4bd6-bc00-2d3631c05615", "Styles": "width:50.2pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bc508fd1-a750-46a1-b493-e6deb78c37f7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span></p>", "ID": "56e327de-ce6f-4876-9492-5b966a301d46", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d6c815d-42e2-4bd6-bc00-2d3631c05615"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span>", "ID": "ac5b258f-872e-466e-abd1-e66cbb34e4bf", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "0.4\u00a0\u00b1\u00a00.4", "ParentId": "56e327de-ce6f-4876-9492-5b966a301d46"}, {"Element": "<td style=\"width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" width=\"72\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span></p>\n</td>", "ID": "52141ac8-43f1-412e-a0ba-1eea9e25f849", "Styles": "width:53.8pt;border-top:none;border-left:none;border-bottom:\n  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bc508fd1-a750-46a1-b493-e6deb78c37f7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span></p>", "ID": "9334889a-918d-489a-ad09-81f0a39af01c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52141ac8-43f1-412e-a0ba-1eea9e25f849"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt;layout-grid-mode:line\">0.4\u00a0\u00b1\u00a00.4</span>", "ID": "ef867f8f-090d-48bb-aba5-121b05040299", "Styles": "font-size:10.0pt;layout-grid-mode:line", "Classes": "None", "Text": "0.4\u00a0\u00b1\u00a00.4", "ParentId": "9334889a-918d-489a-ad09-81f0a39af01c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"7\" style=\"width:461.45pt;border:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 control\u00a0=\u00a0</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">All patients had active RA despite\n  treatment with stable methotrexate doses for 6\u00a0months prior to enrolment\n  and were to remain on stable doses throughout the study. Concurrent use of\n  stable doses of oral corticosteroids (\u2264\u00a010\u00a0mg/day) and/or\n  NSAIDs was permitted, and folate supplementation was given.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 all\n  infliximab doses given in combination with methotrexate and</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> folate with some on corticosteroids\n  and/or NSAIDs</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">e</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span></p>\n</td>\n</tr>", "ID": "eaaf7596-a9df-4704-8c74-0b3c6cd1ee59", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "7adb6d47-3afc-4cf7-82d6-373b8a5f9f28"}, {"Element": "<td colspan=\"7\" style=\"width:461.45pt;border:none;padding:0in 5.4pt 0in 2.85pt\" width=\"615\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 control\u00a0=\u00a0</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">All patients had active RA despite\n  treatment with stable methotrexate doses for 6\u00a0months prior to enrolment\n  and were to remain on stable doses throughout the study. Concurrent use of\n  stable doses of oral corticosteroids (\u2264\u00a010\u00a0mg/day) and/or\n  NSAIDs was permitted, and folate supplementation was given.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 all\n  infliximab doses given in combination with methotrexate and</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> folate with some on corticosteroids\n  and/or NSAIDs</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">e</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span></p>\n</td>", "ID": "8f7d53b8-d98f-4c11-9bfc-2728cb95da4f", "Styles": "width:461.45pt;border:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "      ", "ParentId": "eaaf7596-a9df-4704-8c74-0b3c6cd1ee59"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 control\u00a0=\u00a0</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\">All patients had active RA despite\n  treatment with stable methotrexate doses for 6\u00a0months prior to enrolment\n  and were to remain on stable doses throughout the study. Concurrent use of\n  stable doses of oral corticosteroids (\u2264\u00a010\u00a0mg/day) and/or\n  NSAIDs was permitted, and folate supplementation was given.</span></p>", "ID": "7f368de6-6104-4df8-a59d-ab3f15f17d3c", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f7d53b8-d98f-4c11-9bfc-2728cb95da4f"}, {"Element": "<sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup>", "ID": "72466184-947a-45f9-961f-cf271720d01d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7f368de6-6104-4df8-a59d-ab3f15f17d3c"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span>", "ID": "f8d12b57-0444-4b2e-b89f-105514baaa5d", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "a", "ParentId": "72466184-947a-45f9-961f-cf271720d01d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 control\u00a0=\u00a0</span>", "ID": "47d5be14-78e3-4893-ab7f-a16f449c4888", "Styles": "font-size:9.0pt;layout-grid-mode:line", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 control\u00a0=\u00a0", "ParentId": "7f368de6-6104-4df8-a59d-ab3f15f17d3c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">All patients had active RA despite\n  treatment with stable methotrexate doses for 6\u00a0months prior to enrolment\n  and were to remain on stable doses throughout the study. Concurrent use of\n  stable doses of oral corticosteroids (\u2264\u00a010\u00a0mg/day) and/or\n  NSAIDs was permitted, and folate supplementation was given.</span>", "ID": "4332a169-94ae-4c44-acaa-ed7c6306c623", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "All patients had active RA despite   treatment with stable methotrexate doses for 6\u00a0months prior to enrolment   and were to remain on stable doses throughout the study. Concurrent use of   stable doses of oral corticosteroids (\u2264\u00a010\u00a0mg/day) and/or   NSAIDs was permitted, and folate supplementation was given.", "ParentId": "7f368de6-6104-4df8-a59d-ab3f15f17d3c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 all\n  infliximab doses given in combination with methotrexate and</span><span lang=\"EN-GB\" style=\"font-size:9.0pt\"> folate with some on corticosteroids\n  and/or NSAIDs</span></p>", "ID": "2094149b-5962-4c5c-a5be-f0494225d8a2", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f7d53b8-d98f-4c11-9bfc-2728cb95da4f"}, {"Element": "<sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup>", "ID": "5fbce558-dea6-44a0-90cc-ed022d4536de", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2094149b-5962-4c5c-a5be-f0494225d8a2"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span>", "ID": "44f2d2b7-3a2b-4365-bae7-161d6ddc37dd", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "b", "ParentId": "5fbce558-dea6-44a0-90cc-ed022d4536de"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 all\n  infliximab doses given in combination with methotrexate and</span>", "ID": "100a19e9-aae3-4cc9-b154-2f2493d65361", "Styles": "font-size:9.0pt;layout-grid-mode:line", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 all   infliximab doses given in combination with methotrexate and", "ParentId": "2094149b-5962-4c5c-a5be-f0494225d8a2"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\"> folate with some on corticosteroids\n  and/or NSAIDs</span>", "ID": "786a3654-9909-402d-ab1e-57e3e0420e96", "Styles": "font-size:9.0pt", "Classes": "None", "Text": " folate with some on corticosteroids   and/or NSAIDs", "ParentId": "2094149b-5962-4c5c-a5be-f0494225d8a2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control</span></span></p>", "ID": "bb2ac8ad-7dcf-40d9-b97b-94ecde740287", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f7d53b8-d98f-4c11-9bfc-2728cb95da4f"}, {"Element": "<sup><span lang=\"EN-GB\">c</span></sup>", "ID": "9dbddd7d-34bd-4e16-8189-56bdcb521ffc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bb2ac8ad-7dcf-40d9-b97b-94ecde740287"}, {"Element": "<span lang=\"EN-GB\">c</span>", "ID": "3b1e5b47-ecc5-4f14-8873-5592d50c7c1c", "Styles": "None", "Classes": "None", "Text": "c", "ParentId": "9dbddd7d-34bd-4e16-8189-56bdcb521ffc"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control</span></span>", "ID": "efe7fdeb-8780-45ab-9328-519e9959fcb0", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "bb2ac8ad-7dcf-40d9-b97b-94ecde740287"}, {"Element": "<span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control</span>", "ID": "4cc9b9d6-1333-49dd-8928-a66167d305b0", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "p\u00a0<\u00a00.001, for each infliximab   treatment group vs. control", "ParentId": "efe7fdeb-8780-45ab-9328-519e9959fcb0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span></p>", "ID": "5304f77f-7bca-4d9b-96b9-e44b2668a8ee", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f7d53b8-d98f-4c11-9bfc-2728cb95da4f"}, {"Element": "<sup><span lang=\"EN-GB\">d</span></sup>", "ID": "06bd0868-b75d-4564-a74f-9f3d7b77e9a7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5304f77f-7bca-4d9b-96b9-e44b2668a8ee"}, {"Element": "<span lang=\"EN-GB\">d</span>", "ID": "0e0cb49c-feb1-4b29-88e5-d07bebec79de", "Styles": "None", "Classes": "None", "Text": "d", "ParentId": "06bd0868-b75d-4564-a74f-9f3d7b77e9a7"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span>", "ID": "a21b2409-94c4-4405-9ce2-2af48c229a9f", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 greater   values indicate more joint damage.", "ParentId": "5304f77f-7bca-4d9b-96b9-e44b2668a8ee"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">e</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span></p>", "ID": "0cf2d6a3-2ba2-4bec-b39c-d2ee59335a04", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f7d53b8-d98f-4c11-9bfc-2728cb95da4f"}, {"Element": "<sup><span lang=\"EN-GB\">e</span></sup>", "ID": "baa302ab-5207-4153-8fbf-93c23f28b2ff", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0cf2d6a3-2ba2-4bec-b39c-d2ee59335a04"}, {"Element": "<span lang=\"EN-GB\">e</span>", "ID": "3bed81c8-e6d0-43f7-afad-7a491ec4f4d1", "Styles": "None", "Classes": "None", "Text": "e", "ParentId": "baa302ab-5207-4153-8fbf-93c23f28b2ff"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span>", "ID": "e55fcb53-55ee-4a2c-b7c7-27035a2dee3f", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health   Assessment Questionnaire; greater values indicate less disability.", "ParentId": "0cf2d6a3-2ba2-4bec-b39c-d2ee59335a04"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c15e2d76-c892-46dc-9a8f-624238b28faa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2de1cd1f-b510-4e19-8f2e-ee88e98aacaf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c15e2d76-c892-46dc-9a8f-624238b28faa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The ASPIRE study evaluated responses at\n54\u00a0weeks in 1,004\u00a0methotrexate naive patients with early (<span style=\"layout-grid-mode:line\">\u2264\u00a03\u00a0years disease duration, median\n0.6\u00a0years) </span>active rheumatoid arthritis (median swollen and tender\njoint count of 19 and 31, respectively). All patients received methotrexate\n(optimised to 20\u00a0mg/wk by week\u00a08) and either placebo, 3\u00a0mg/kg or\n6\u00a0mg/kg infliximab at weeks\u00a00, 2, and 6 and every 8\u00a0weeks\nthereafter. Results from week\u00a054 are shown in Table\u00a04.</span></p>", "ID": "62239be2-67c3-430a-8641-bf854b3627ee", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The ASPIRE study evaluated responses at\n54\u00a0weeks in 1,004\u00a0methotrexate naive patients with early (<span style=\"layout-grid-mode:line\">\u2264\u00a03\u00a0years disease duration, median\n0.6\u00a0years) </span>active rheumatoid arthritis (median swollen and tender\njoint count of 19 and 31, respectively). All patients received methotrexate\n(optimised to 20\u00a0mg/wk by week\u00a08) and either placebo, 3\u00a0mg/kg or\n6\u00a0mg/kg infliximab at weeks\u00a00, 2, and 6 and every 8\u00a0weeks\nthereafter. Results from week\u00a054 are shown in Table\u00a04.</span>", "ID": "ffe1a5f7-ed20-4f19-9728-d5812653dd1d", "Styles": "None", "Classes": "None", "Text": "The ASPIRE study evaluated responses at 54\u00a0weeks in 1,004\u00a0methotrexate naive patients with early (active rheumatoid arthritis (median swollen and tender joint count of 19 and 31, respectively). All patients received methotrexate (optimised to 20\u00a0mg/wk by week\u00a08) and either placebo, 3\u00a0mg/kg or 6\u00a0mg/kg infliximab at weeks\u00a00, 2, and 6 and every 8\u00a0weeks thereafter. Results from week\u00a054 are shown in Table\u00a04.", "ParentId": "62239be2-67c3-430a-8641-bf854b3627ee"}, {"Element": "<span style=\"layout-grid-mode:line\">\u2264\u00a03\u00a0years disease duration, median\n0.6\u00a0years) </span>", "ID": "698e5a08-420d-4c72-92b8-abd52fd1ba0e", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u2264\u00a03\u00a0years disease duration, median 0.6\u00a0years) ", "ParentId": "ffe1a5f7-ed20-4f19-9728-d5812653dd1d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "52a53204-c6ad-4196-8ef7-bb3dab7d978d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3f0b33b7-0d50-4a35-90de-c0fd4bb34735", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "52a53204-c6ad-4196-8ef7-bb3dab7d978d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">After 54\u00a0weeks of treatment, both\ndoses of infliximab + methotrexate resulted in statistically significantly\ngreater improvement in signs and symptoms compared to methotrexate alone as\nmeasured by the proportion of patients achieving ACR20, 50 and\n70\u00a0responses.</span></p>", "ID": "8a98be37-5de8-424b-a3d8-c57046935a76", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">After 54\u00a0weeks of treatment, both\ndoses of infliximab + methotrexate resulted in statistically significantly\ngreater improvement in signs and symptoms compared to methotrexate alone as\nmeasured by the proportion of patients achieving ACR20, 50 and\n70\u00a0responses.</span>", "ID": "34883051-1e9d-46be-b119-adf5232d6d58", "Styles": "None", "Classes": "None", "Text": "After 54\u00a0weeks of treatment, both doses of infliximab + methotrexate resulted in statistically significantly greater improvement in signs and symptoms compared to methotrexate alone as measured by the proportion of patients achieving ACR20, 50 and 70\u00a0responses.", "ParentId": "8a98be37-5de8-424b-a3d8-c57046935a76"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "825fc337-926e-4a74-987e-7ec8ff74eb38", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "55c0665a-5ac3-456f-bda0-131327039e23", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "825fc337-926e-4a74-987e-7ec8ff74eb38"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In ASPIRE, more than 90% of patients had at\nleast two evaluable X\u2011rays. Reduction in the rate of progression of\nstructural damage was observed at weeks\u00a030 and 54 in the infliximab +\nmethotrexate groups compared to methotrexate alone.</span></p>", "ID": "7abdc4f7-3e13-4a25-a765-6542592d0735", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In ASPIRE, more than 90% of patients had at\nleast two evaluable X\u2011rays. Reduction in the rate of progression of\nstructural damage was observed at weeks\u00a030 and 54 in the infliximab +\nmethotrexate groups compared to methotrexate alone.</span>", "ID": "790bbbf0-1c75-450a-9461-00ad7beb813b", "Styles": "None", "Classes": "None", "Text": "In ASPIRE, more than 90% of patients had at least two evaluable X\u2011rays. Reduction in the rate of progression of structural damage was observed at weeks\u00a030 and 54 in the infliximab + methotrexate groups compared to methotrexate alone.", "ParentId": "7abdc4f7-3e13-4a25-a765-6542592d0735"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4902058a-be64-4c3c-8719-cd2f1bb2c584", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "420a4936-6e97-4c41-939f-a7af89a4ca02", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4902058a-be64-4c3c-8719-cd2f1bb2c584"}, {"Element": "<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"5\" style=\"width:452.25pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"603\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a04</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on ACRn, Structural Joint Damage and\n  Physical Function at week\u00a054, ASPIRE</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:254.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"339\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:197.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"264\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab +\u00a0MTX</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo +\u00a0MTX</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">6\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combined</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Subjects randomised</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">282</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">359</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">363</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">722</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Percentage ACR improvement</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24.8\u00a0\u00b1\u00a059.7</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">37.3\u00a0\u00b1\u00a052.8</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">42.0\u00a0\u00b1\u00a047.3</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">39.6\u00a0\u00b1\u00a050.1</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Change from baseline in total van der\n  Heijde\u2011modified Sharp score<sup>b</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3.70\u00a0\u00b1\u00a09.61</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.42\u00a0\u00b1\u00a05.82</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.51\u00a0\u00b1\u00a05.55</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.46\u00a0\u00b1\u00a05.68</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.43</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Improvement from baseline in HAQ averaged\n  over time from week\u00a030 to week\u00a054<sup>c</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>d</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.68\u00a0\u00b1\u00a00.63</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.80\u00a0\u00b1\u00a00.65</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.88\u00a0\u00b1\u00a00.65</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.84\u00a0\u00b1\u00a00.65</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"5\" style=\"width:452.25pt;border:none;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"603\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control.</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 p\u00a0=\u00a00.030\n  and &lt;\u00a00.001 for the 3\u00a0mg/kg and 6\u00a0mg/kg treatment groups\n  respectively vs. placebo + MTX.</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "901cfa43-1e30-482e-9a27-90a596ccec01", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"5\" style=\"width:452.25pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"603\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a04</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on ACRn, Structural Joint Damage and\n  Physical Function at week\u00a054, ASPIRE</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:254.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"339\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:197.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"264\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab +\u00a0MTX</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo +\u00a0MTX</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">6\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combined</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Subjects randomised</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">282</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">359</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">363</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">722</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Percentage ACR improvement</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24.8\u00a0\u00b1\u00a059.7</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">37.3\u00a0\u00b1\u00a052.8</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">42.0\u00a0\u00b1\u00a047.3</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">39.6\u00a0\u00b1\u00a050.1</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Change from baseline in total van der\n  Heijde\u2011modified Sharp score<sup>b</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3.70\u00a0\u00b1\u00a09.61</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.42\u00a0\u00b1\u00a05.82</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.51\u00a0\u00b1\u00a05.55</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.46\u00a0\u00b1\u00a05.68</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.43</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Improvement from baseline in HAQ averaged\n  over time from week\u00a030 to week\u00a054<sup>c</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>d</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.68\u00a0\u00b1\u00a00.63</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.80\u00a0\u00b1\u00a00.65</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.88\u00a0\u00b1\u00a00.65</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.84\u00a0\u00b1\u00a00.65</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"5\" style=\"width:452.25pt;border:none;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"603\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control.</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 p\u00a0=\u00a00.030\n  and &lt;\u00a00.001 for the 3\u00a0mg/kg and 6\u00a0mg/kg treatment groups\n  respectively vs. placebo + MTX.</span></p>\n</td>\n</tr>\n</table>", "ID": "c0e4e657-5218-4f84-9541-fac690ce3fe4", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "             ", "ParentId": "901cfa43-1e30-482e-9a27-90a596ccec01"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"5\" style=\"width:452.25pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"603\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a04</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on ACRn, Structural Joint Damage and\n  Physical Function at week\u00a054, ASPIRE</span></b></p>\n</td>\n</tr>", "ID": "4be709fb-c5bf-4d10-b119-2724971ebbe9", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "c0e4e657-5218-4f84-9541-fac690ce3fe4"}, {"Element": "<td colspan=\"5\" style=\"width:452.25pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"603\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a04</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on ACRn, Structural Joint Damage and\n  Physical Function at week\u00a054, ASPIRE</span></b></p>\n</td>", "ID": "afd9d4e2-b0b7-460f-bbbe-5c865321b33d", "Styles": "width:452.25pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "4be709fb-c5bf-4d10-b119-2724971ebbe9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a04</span></b></p>", "ID": "1dab5bc8-1fa2-4f85-8ff3-5d9e352a8464", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "afd9d4e2-b0b7-460f-bbbe-5c865321b33d"}, {"Element": "<b><span lang=\"EN-GB\">Table\u00a04</span></b>", "ID": "620168c0-3fd3-4e27-a344-9d6315ead2a3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1dab5bc8-1fa2-4f85-8ff3-5d9e352a8464"}, {"Element": "<span lang=\"EN-GB\">Table\u00a04</span>", "ID": "707f93b7-196a-4756-9ded-7059014f6c36", "Styles": "None", "Classes": "None", "Text": "Table\u00a04", "ParentId": "620168c0-3fd3-4e27-a344-9d6315ead2a3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on ACRn, Structural Joint Damage and\n  Physical Function at week\u00a054, ASPIRE</span></b></p>", "ID": "e4d93767-f622-4c27-b7fc-a89eac9ce40d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "afd9d4e2-b0b7-460f-bbbe-5c865321b33d"}, {"Element": "<b><span lang=\"EN-GB\">Effects on ACRn, Structural Joint Damage and\n  Physical Function at week\u00a054, ASPIRE</span></b>", "ID": "95398361-5137-48f2-8b82-895672d8aa56", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e4d93767-f622-4c27-b7fc-a89eac9ce40d"}, {"Element": "<span lang=\"EN-GB\">Effects on ACRn, Structural Joint Damage and\n  Physical Function at week\u00a054, ASPIRE</span>", "ID": "ebf38b83-02f2-481e-bd5f-69c92bb390a4", "Styles": "None", "Classes": "None", "Text": "Effects on ACRn, Structural Joint Damage and   Physical Function at week\u00a054, ASPIRE", "ParentId": "95398361-5137-48f2-8b82-895672d8aa56"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:254.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"339\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:197.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"264\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab +\u00a0MTX</span></p>\n</td>\n</tr>", "ID": "0e790c6f-01ce-480a-9c59-4dc47692aa31", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "c0e4e657-5218-4f84-9541-fac690ce3fe4"}, {"Element": "<td colspan=\"2\" style=\"width:254.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"339\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "88894f17-7da3-432c-a51f-5b7d90297e82", "Styles": "width:254.5pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "0e790c6f-01ce-480a-9c59-4dc47692aa31"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fad6690d-e77f-47ad-99bd-620cecfb224d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "88894f17-7da3-432c-a51f-5b7d90297e82"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b8c14d8-c7c7-45cf-a745-4756f4ceaa81", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fad6690d-e77f-47ad-99bd-620cecfb224d"}, {"Element": "<td colspan=\"3\" style=\"width:197.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"264\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab +\u00a0MTX</span></p>\n</td>", "ID": "809e5fe0-7dc9-43a8-bff6-fa90f038b911", "Styles": "width:197.75pt;border-top:none;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "0e790c6f-01ce-480a-9c59-4dc47692aa31"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab +\u00a0MTX</span></p>", "ID": "befd48cc-fb16-4589-b33b-1daa332b7aa9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "809e5fe0-7dc9-43a8-bff6-fa90f038b911"}, {"Element": "<span lang=\"EN-GB\">Infliximab +\u00a0MTX</span>", "ID": "7c2d45c8-284e-478e-8fbb-1e121f5529c3", "Styles": "None", "Classes": "None", "Text": "Infliximab +\u00a0MTX", "ParentId": "befd48cc-fb16-4589-b33b-1daa332b7aa9"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo +\u00a0MTX</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">6\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combined</span></p>\n</td>\n</tr>", "ID": "305527d8-6322-4fe6-b098-d8b5a558bd4e", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "c0e4e657-5218-4f84-9541-fac690ce3fe4"}, {"Element": "<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "747fc5c3-061d-49c2-ba5f-c277f0235e6e", "Styles": "width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "305527d8-6322-4fe6-b098-d8b5a558bd4e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dc544117-aa21-44e8-9b51-a65515439c7b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "747fc5c3-061d-49c2-ba5f-c277f0235e6e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b9fc7789-cf9c-4579-be76-3d6e16e62643", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dc544117-aa21-44e8-9b51-a65515439c7b"}, {"Element": "<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo +\u00a0MTX</span></p>\n</td>", "ID": "a471bf92-5e22-4b0c-a96a-09fb8cd34a90", "Styles": "width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "305527d8-6322-4fe6-b098-d8b5a558bd4e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo +\u00a0MTX</span></p>", "ID": "0499f91a-8ed3-4648-a8db-84520cd8e637", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a471bf92-5e22-4b0c-a96a-09fb8cd34a90"}, {"Element": "<span lang=\"EN-GB\">Placebo +\u00a0MTX</span>", "ID": "41696257-df2b-434e-b4ff-bd443e0636df", "Styles": "None", "Classes": "None", "Text": "Placebo +\u00a0MTX", "ParentId": "0499f91a-8ed3-4648-a8db-84520cd8e637"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3\u00a0mg/kg</span></p>\n</td>", "ID": "7e4f7b15-071e-439e-8157-a9b265ca6e6b", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "305527d8-6322-4fe6-b098-d8b5a558bd4e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">3\u00a0mg/kg</span></p>", "ID": "eb5a9c8c-f552-4875-b1ce-491920eefb94", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e4f7b15-071e-439e-8157-a9b265ca6e6b"}, {"Element": "<span lang=\"EN-GB\">3\u00a0mg/kg</span>", "ID": "4a2b2916-6213-49de-8197-bd2fd23550db", "Styles": "None", "Classes": "None", "Text": "3\u00a0mg/kg", "ParentId": "eb5a9c8c-f552-4875-b1ce-491920eefb94"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">6\u00a0mg/kg</span></p>\n</td>", "ID": "3bd332d6-c7fb-4ff5-baf1-9cd3db518609", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "305527d8-6322-4fe6-b098-d8b5a558bd4e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">6\u00a0mg/kg</span></p>", "ID": "e35dfbd7-2aab-48b4-8efd-b734c2c072e9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3bd332d6-c7fb-4ff5-baf1-9cd3db518609"}, {"Element": "<span lang=\"EN-GB\">6\u00a0mg/kg</span>", "ID": "d97574da-52d2-44d6-98d3-ce3f49bba051", "Styles": "None", "Classes": "None", "Text": "6\u00a0mg/kg", "ParentId": "e35dfbd7-2aab-48b4-8efd-b734c2c072e9"}, {"Element": "<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combined</span></p>\n</td>", "ID": "8057195a-deb4-4ad9-af23-d309c7da2fb9", "Styles": "width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "305527d8-6322-4fe6-b098-d8b5a558bd4e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combined</span></p>", "ID": "6a4294fe-28dd-456b-9f26-a77c4cb654c3", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8057195a-deb4-4ad9-af23-d309c7da2fb9"}, {"Element": "<span lang=\"EN-GB\">Combined</span>", "ID": "ddb33890-bc07-40d0-b24a-b501629af70e", "Styles": "None", "Classes": "None", "Text": "Combined", "ParentId": "6a4294fe-28dd-456b-9f26-a77c4cb654c3"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Subjects randomised</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">282</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">359</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">363</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">722</span></p>\n</td>\n</tr>", "ID": "cbd277d5-a5a2-47f9-8231-2268b962b71d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "c0e4e657-5218-4f84-9541-fac690ce3fe4"}, {"Element": "<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Subjects randomised</span></p>\n</td>", "ID": "100f9805-7b51-464d-ab21-464448004fe6", "Styles": "width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "cbd277d5-a5a2-47f9-8231-2268b962b71d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Subjects randomised</span></p>", "ID": "a1f0a453-348f-4406-bb9a-3e438fb0650c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "100f9805-7b51-464d-ab21-464448004fe6"}, {"Element": "<span lang=\"EN-GB\">Subjects randomised</span>", "ID": "bcea8a29-843a-43a1-b2c1-f0c8e0571f6e", "Styles": "None", "Classes": "None", "Text": "Subjects randomised", "ParentId": "a1f0a453-348f-4406-bb9a-3e438fb0650c"}, {"Element": "<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">282</span></p>\n</td>", "ID": "e513a1fd-6dca-498e-9457-d8f1b4721874", "Styles": "width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "cbd277d5-a5a2-47f9-8231-2268b962b71d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">282</span></p>", "ID": "31301d68-d37a-47e4-baf1-cab65f936e2d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e513a1fd-6dca-498e-9457-d8f1b4721874"}, {"Element": "<span lang=\"EN-GB\">282</span>", "ID": "7cf53b9b-bd27-4770-bced-445d9e084baa", "Styles": "None", "Classes": "None", "Text": "282", "ParentId": "31301d68-d37a-47e4-baf1-cab65f936e2d"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">359</span></p>\n</td>", "ID": "b4a9f4b3-6c6d-4718-930b-e4072fe0b3c3", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "cbd277d5-a5a2-47f9-8231-2268b962b71d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">359</span></p>", "ID": "a16c6c7d-6945-4014-b8f6-819523f846cc", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b4a9f4b3-6c6d-4718-930b-e4072fe0b3c3"}, {"Element": "<span lang=\"EN-GB\">359</span>", "ID": "b6c5409f-9991-4082-9471-81b657c9fc6e", "Styles": "None", "Classes": "None", "Text": "359", "ParentId": "a16c6c7d-6945-4014-b8f6-819523f846cc"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">363</span></p>\n</td>", "ID": "39b05397-9795-4d03-a40f-1f0d6f23a213", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "cbd277d5-a5a2-47f9-8231-2268b962b71d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">363</span></p>", "ID": "ebc171a0-6f4a-4931-99a4-20d8ccee3155", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "39b05397-9795-4d03-a40f-1f0d6f23a213"}, {"Element": "<span lang=\"EN-GB\">363</span>", "ID": "91c5c3d2-7def-45c3-b7ca-6f4328750932", "Styles": "None", "Classes": "None", "Text": "363", "ParentId": "ebc171a0-6f4a-4931-99a4-20d8ccee3155"}, {"Element": "<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">722</span></p>\n</td>", "ID": "51039cfc-1563-439e-950d-bb1a7a357be3", "Styles": "width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "cbd277d5-a5a2-47f9-8231-2268b962b71d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">722</span></p>", "ID": "7520b4f6-aeb7-4379-b741-43740d841c76", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "51039cfc-1563-439e-950d-bb1a7a357be3"}, {"Element": "<span lang=\"EN-GB\">722</span>", "ID": "8a9022a3-a02b-418d-adda-d95995c59a4e", "Styles": "None", "Classes": "None", "Text": "722", "ParentId": "7520b4f6-aeb7-4379-b741-43740d841c76"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Percentage ACR improvement</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "4de594cf-f30e-43c5-8316-e6e861f4dc39", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "c0e4e657-5218-4f84-9541-fac690ce3fe4"}, {"Element": "<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Percentage ACR improvement</span></p>\n</td>", "ID": "e803de5f-0949-4f44-8afe-7d9763b77b3c", "Styles": "width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "4de594cf-f30e-43c5-8316-e6e861f4dc39"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Percentage ACR improvement</span></p>", "ID": "bbf24c98-1baf-454c-b46e-d9f4efd27ca7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e803de5f-0949-4f44-8afe-7d9763b77b3c"}, {"Element": "<span lang=\"EN-GB\">Percentage ACR improvement</span>", "ID": "2dc453f8-b5d0-4445-bb9a-18a467f1a550", "Styles": "None", "Classes": "None", "Text": "Percentage ACR improvement", "ParentId": "bbf24c98-1baf-454c-b46e-d9f4efd27ca7"}, {"Element": "<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "355c1f76-f8fb-4e34-9f86-ffcf7343b676", "Styles": "width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "4de594cf-f30e-43c5-8316-e6e861f4dc39"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1fb65445-6a22-40da-9d1f-accfd97beb06", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "355c1f76-f8fb-4e34-9f86-ffcf7343b676"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "50f1fc77-8c92-4c6a-9ce1-ed97f47635fa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1fb65445-6a22-40da-9d1f-accfd97beb06"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "627a3236-853f-4f5b-af02-1682183f4e53", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "4de594cf-f30e-43c5-8316-e6e861f4dc39"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7ccb71c1-d3f6-4148-bb10-7674953af5f3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "627a3236-853f-4f5b-af02-1682183f4e53"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cd554dc6-70b9-4505-9cdc-bca8649160fd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7ccb71c1-d3f6-4148-bb10-7674953af5f3"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "52162123-664f-46b7-8fe4-dc8743144492", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "4de594cf-f30e-43c5-8316-e6e861f4dc39"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e1a7280c-69e8-4785-9a66-8e94443a25a1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52162123-664f-46b7-8fe4-dc8743144492"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f4e9c6ed-8a15-4d92-941d-72a96550d970", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e1a7280c-69e8-4785-9a66-8e94443a25a1"}, {"Element": "<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "a0526b15-f15b-4137-9af9-ce93372fcc5d", "Styles": "width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "4de594cf-f30e-43c5-8316-e6e861f4dc39"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f12f73de-c35f-4c7c-bfb8-ae191ce5ddc0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a0526b15-f15b-4137-9af9-ce93372fcc5d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e346c254-c21d-4d57-b669-c8d903edd20d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f12f73de-c35f-4c7c-bfb8-ae191ce5ddc0"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24.8\u00a0\u00b1\u00a059.7</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">37.3\u00a0\u00b1\u00a052.8</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">42.0\u00a0\u00b1\u00a047.3</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">39.6\u00a0\u00b1\u00a050.1</span></p>\n</td>\n</tr>", "ID": "bc605ed4-93ef-4176-bcde-6caea7d18402", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "c0e4e657-5218-4f84-9541-fac690ce3fe4"}, {"Element": "<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span></p>\n</td>", "ID": "ffb827f8-e4bf-4731-b56e-8883df9892ef", "Styles": "width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bc605ed4-93ef-4176-bcde-6caea7d18402"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span></p>", "ID": "18c86df7-6474-4807-b469-559a3049ff14", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ffb827f8-e4bf-4731-b56e-8883df9892ef"}, {"Element": "<span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span>", "ID": "c5d7ce2b-5c6d-4ed2-b83b-adbc02964cb7", "Styles": "None", "Classes": "None", "Text": "Mean \u00b1 SD", "ParentId": "18c86df7-6474-4807-b469-559a3049ff14"}, {"Element": "<sup>a</sup>", "ID": "436d26b1-b3e5-42dc-9e28-94d86f83f6e7", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "c5d7ce2b-5c6d-4ed2-b83b-adbc02964cb7"}, {"Element": "<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24.8\u00a0\u00b1\u00a059.7</span></p>\n</td>", "ID": "b668a163-d180-4de9-a2ec-b28ad3728134", "Styles": "width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bc605ed4-93ef-4176-bcde-6caea7d18402"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24.8\u00a0\u00b1\u00a059.7</span></p>", "ID": "8c4044b5-4c95-41f9-9946-dbbf75896674", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b668a163-d180-4de9-a2ec-b28ad3728134"}, {"Element": "<span lang=\"EN-GB\">24.8\u00a0\u00b1\u00a059.7</span>", "ID": "c8b1fe71-ed7c-4781-b81e-24a0d312c1f5", "Styles": "None", "Classes": "None", "Text": "24.8\u00a0\u00b1\u00a059.7", "ParentId": "8c4044b5-4c95-41f9-9946-dbbf75896674"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">37.3\u00a0\u00b1\u00a052.8</span></p>\n</td>", "ID": "56e057af-8801-4fab-bfb0-0130a5c03452", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bc605ed4-93ef-4176-bcde-6caea7d18402"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">37.3\u00a0\u00b1\u00a052.8</span></p>", "ID": "d5575dea-38a8-4d67-a4cc-28be195143aa", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "56e057af-8801-4fab-bfb0-0130a5c03452"}, {"Element": "<span lang=\"EN-GB\">37.3\u00a0\u00b1\u00a052.8</span>", "ID": "f5c0d8ee-67db-44f1-b7e4-73e7d6e246bb", "Styles": "None", "Classes": "None", "Text": "37.3\u00a0\u00b1\u00a052.8", "ParentId": "d5575dea-38a8-4d67-a4cc-28be195143aa"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">42.0\u00a0\u00b1\u00a047.3</span></p>\n</td>", "ID": "9b5a8e4a-465b-427b-a9f5-124e93c3b756", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bc605ed4-93ef-4176-bcde-6caea7d18402"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">42.0\u00a0\u00b1\u00a047.3</span></p>", "ID": "334ce476-c9b6-4dae-89b7-7fc8952cbbc7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9b5a8e4a-465b-427b-a9f5-124e93c3b756"}, {"Element": "<span lang=\"EN-GB\">42.0\u00a0\u00b1\u00a047.3</span>", "ID": "182788d1-9175-4999-adf0-2b285bbd05b2", "Styles": "None", "Classes": "None", "Text": "42.0\u00a0\u00b1\u00a047.3", "ParentId": "334ce476-c9b6-4dae-89b7-7fc8952cbbc7"}, {"Element": "<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">39.6\u00a0\u00b1\u00a050.1</span></p>\n</td>", "ID": "39a95967-50a7-4724-947c-bfe67c984b5d", "Styles": "width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "bc605ed4-93ef-4176-bcde-6caea7d18402"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">39.6\u00a0\u00b1\u00a050.1</span></p>", "ID": "56e446bc-f269-487f-be18-0e3843dd7b71", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "39a95967-50a7-4724-947c-bfe67c984b5d"}, {"Element": "<span lang=\"EN-GB\">39.6\u00a0\u00b1\u00a050.1</span>", "ID": "435235de-7d11-4e89-8961-bee8e9813840", "Styles": "None", "Classes": "None", "Text": "39.6\u00a0\u00b1\u00a050.1", "ParentId": "56e446bc-f269-487f-be18-0e3843dd7b71"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Change from baseline in total van der\n  Heijde\u2011modified Sharp score<sup>b</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "879d85f8-2509-4b24-80b5-001f122d7d73", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "c0e4e657-5218-4f84-9541-fac690ce3fe4"}, {"Element": "<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Change from baseline in total van der\n  Heijde\u2011modified Sharp score<sup>b</sup></span></p>\n</td>", "ID": "6d4e5309-692a-49af-8478-a35be459c903", "Styles": "width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "879d85f8-2509-4b24-80b5-001f122d7d73"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Change from baseline in total van der\n  Heijde\u2011modified Sharp score<sup>b</sup></span></p>", "ID": "31762ac9-46ea-481a-91a4-a54b031a15ea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6d4e5309-692a-49af-8478-a35be459c903"}, {"Element": "<span lang=\"EN-GB\">Change from baseline in total van der\n  Heijde\u2011modified Sharp score<sup>b</sup></span>", "ID": "04952072-b799-4b3b-ad04-fc5d7cec098c", "Styles": "None", "Classes": "None", "Text": "Change from baseline in total van der   Heijde\u2011modified Sharp score", "ParentId": "31762ac9-46ea-481a-91a4-a54b031a15ea"}, {"Element": "<sup>b</sup>", "ID": "0d4149ef-ac28-48a9-96a8-76dfee52ea18", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "04952072-b799-4b3b-ad04-fc5d7cec098c"}, {"Element": "<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "3d54db55-3e4a-4a8c-aa4e-b752f5efda51", "Styles": "width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "879d85f8-2509-4b24-80b5-001f122d7d73"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bee51b33-0f55-461f-af2c-840b965d693a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3d54db55-3e4a-4a8c-aa4e-b752f5efda51"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d1eb2a1a-f97b-40f2-8f35-6f9d9692bf52", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bee51b33-0f55-461f-af2c-840b965d693a"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "168da1a2-a451-43df-87db-007e254e5f87", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "879d85f8-2509-4b24-80b5-001f122d7d73"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "318d8707-af87-45af-a63f-a4e7744d614e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "168da1a2-a451-43df-87db-007e254e5f87"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a74d69bb-23b0-49a5-ab03-8669cb8f810f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "318d8707-af87-45af-a63f-a4e7744d614e"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "b0a07d28-e523-473b-9220-4386bf131cda", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "879d85f8-2509-4b24-80b5-001f122d7d73"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "93930ad6-575c-459a-bb17-cba38802259e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b0a07d28-e523-473b-9220-4386bf131cda"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3bd2a9b7-94c8-4320-a4aa-885dee9b031f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "93930ad6-575c-459a-bb17-cba38802259e"}, {"Element": "<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "4f9f177e-b84b-477d-816c-dbea0588cdf1", "Styles": "width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "879d85f8-2509-4b24-80b5-001f122d7d73"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5c974441-1314-4508-864c-72300b950f22", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4f9f177e-b84b-477d-816c-dbea0588cdf1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3fdc88db-147c-4fc5-bcfe-8a5af324d33e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5c974441-1314-4508-864c-72300b950f22"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3.70\u00a0\u00b1\u00a09.61</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.42\u00a0\u00b1\u00a05.82</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.51\u00a0\u00b1\u00a05.55</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.46\u00a0\u00b1\u00a05.68</span></p>\n</td>\n</tr>", "ID": "c3c91416-3786-46c6-8302-0fa6f076e80e", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "c0e4e657-5218-4f84-9541-fac690ce3fe4"}, {"Element": "<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span></p>\n</td>", "ID": "3671f4a7-9c73-4e56-b2d2-c26508b6e5f6", "Styles": "width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "c3c91416-3786-46c6-8302-0fa6f076e80e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span></p>", "ID": "3271bb35-ef5a-4a8c-82ae-7f4426b13b10", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3671f4a7-9c73-4e56-b2d2-c26508b6e5f6"}, {"Element": "<span lang=\"EN-GB\">Mean \u00b1 SD<sup>a</sup></span>", "ID": "5718b1f3-0244-4d3b-b297-2bf8fa1741a9", "Styles": "None", "Classes": "None", "Text": "Mean \u00b1 SD", "ParentId": "3271bb35-ef5a-4a8c-82ae-7f4426b13b10"}, {"Element": "<sup>a</sup>", "ID": "83b66a95-1fdf-461f-a2dc-4af4346f7bbe", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "5718b1f3-0244-4d3b-b297-2bf8fa1741a9"}, {"Element": "<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3.70\u00a0\u00b1\u00a09.61</span></p>\n</td>", "ID": "fe786c54-9c91-4e50-a21b-d96ca0593144", "Styles": "width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "c3c91416-3786-46c6-8302-0fa6f076e80e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3.70\u00a0\u00b1\u00a09.61</span></p>", "ID": "a7bda592-4337-476c-86c4-2303ef3c2ad7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fe786c54-9c91-4e50-a21b-d96ca0593144"}, {"Element": "<span lang=\"EN-GB\">3.70\u00a0\u00b1\u00a09.61</span>", "ID": "52e9aeba-6648-4e17-9629-6a15f2132c52", "Styles": "None", "Classes": "None", "Text": "3.70\u00a0\u00b1\u00a09.61", "ParentId": "a7bda592-4337-476c-86c4-2303ef3c2ad7"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.42\u00a0\u00b1\u00a05.82</span></p>\n</td>", "ID": "c209ebd5-e1d3-40ee-8ac0-869cfec5d887", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "c3c91416-3786-46c6-8302-0fa6f076e80e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.42\u00a0\u00b1\u00a05.82</span></p>", "ID": "a00c257f-3c15-477f-af8a-610632efa340", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c209ebd5-e1d3-40ee-8ac0-869cfec5d887"}, {"Element": "<span lang=\"EN-GB\">0.42\u00a0\u00b1\u00a05.82</span>", "ID": "2fe8bf97-1a24-48e3-aced-48be05734fbb", "Styles": "None", "Classes": "None", "Text": "0.42\u00a0\u00b1\u00a05.82", "ParentId": "a00c257f-3c15-477f-af8a-610632efa340"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.51\u00a0\u00b1\u00a05.55</span></p>\n</td>", "ID": "7a793553-7db5-4fa5-a5d3-d795b975b490", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "c3c91416-3786-46c6-8302-0fa6f076e80e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.51\u00a0\u00b1\u00a05.55</span></p>", "ID": "884cd1d3-6d83-486c-899c-327895a90e7b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a793553-7db5-4fa5-a5d3-d795b975b490"}, {"Element": "<span lang=\"EN-GB\">0.51\u00a0\u00b1\u00a05.55</span>", "ID": "6da454bc-fd0d-47ed-92ee-399351d501fd", "Styles": "None", "Classes": "None", "Text": "0.51\u00a0\u00b1\u00a05.55", "ParentId": "884cd1d3-6d83-486c-899c-327895a90e7b"}, {"Element": "<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.46\u00a0\u00b1\u00a05.68</span></p>\n</td>", "ID": "a13a39d7-23d0-43ac-a9c9-4d6c3ad23940", "Styles": "width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "c3c91416-3786-46c6-8302-0fa6f076e80e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.46\u00a0\u00b1\u00a05.68</span></p>", "ID": "abc90b4c-c437-4c55-8917-6ebe9fdc1a28", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a13a39d7-23d0-43ac-a9c9-4d6c3ad23940"}, {"Element": "<span lang=\"EN-GB\">0.46\u00a0\u00b1\u00a05.68</span>", "ID": "a5931ea4-6d6a-4f32-9884-00af6435f6fd", "Styles": "None", "Classes": "None", "Text": "0.46\u00a0\u00b1\u00a05.68", "ParentId": "abc90b4c-c437-4c55-8917-6ebe9fdc1a28"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median</span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.43</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>\n</tr>", "ID": "d212487f-b08d-4e00-8d31-d249d5bcd5a8", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "c0e4e657-5218-4f84-9541-fac690ce3fe4"}, {"Element": "<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median</span></p>\n</td>", "ID": "33ccf4bb-5757-4b21-9b74-c996d4e4eaef", "Styles": "width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "d212487f-b08d-4e00-8d31-d249d5bcd5a8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median</span></p>", "ID": "74be03da-5897-4415-b387-d6437d77b1a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "33ccf4bb-5757-4b21-9b74-c996d4e4eaef"}, {"Element": "<span lang=\"EN-GB\">Median</span>", "ID": "02afaea3-5cc2-44e3-ac2e-2ce91d5ac0a4", "Styles": "None", "Classes": "None", "Text": "Median", "ParentId": "74be03da-5897-4415-b387-d6437d77b1a7"}, {"Element": "<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.43</span></p>\n</td>", "ID": "d8569b6e-bcac-443c-9b46-8d94e9d0f630", "Styles": "width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "d212487f-b08d-4e00-8d31-d249d5bcd5a8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.43</span></p>", "ID": "3993a520-104e-4e73-924a-3eafd067f598", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d8569b6e-bcac-443c-9b46-8d94e9d0f630"}, {"Element": "<span lang=\"EN-GB\">0.43</span>", "ID": "ceb6d65e-fe5f-4f66-a6d5-ddbf21d729a0", "Styles": "None", "Classes": "None", "Text": "0.43", "ParentId": "3993a520-104e-4e73-924a-3eafd067f598"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>", "ID": "d6c73394-221f-42e1-aed3-98bdfd52af0d", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "d212487f-b08d-4e00-8d31-d249d5bcd5a8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>", "ID": "4697c80a-30f2-4794-a4b6-0385e770d3d5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d6c73394-221f-42e1-aed3-98bdfd52af0d"}, {"Element": "<span lang=\"EN-GB\">0.00</span>", "ID": "c890f641-b953-4b01-9bd0-e1ea71943dae", "Styles": "None", "Classes": "None", "Text": "0.00", "ParentId": "4697c80a-30f2-4794-a4b6-0385e770d3d5"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>", "ID": "7ac3741e-0bb7-4e80-b29f-8b5c579d716e", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "d212487f-b08d-4e00-8d31-d249d5bcd5a8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>", "ID": "861cb781-8063-436c-8b06-780a4e28265e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7ac3741e-0bb7-4e80-b29f-8b5c579d716e"}, {"Element": "<span lang=\"EN-GB\">0.00</span>", "ID": "87f08929-3d5e-4638-ae67-47a8da7c1991", "Styles": "None", "Classes": "None", "Text": "0.00", "ParentId": "861cb781-8063-436c-8b06-780a4e28265e"}, {"Element": "<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>\n</td>", "ID": "2f2fdc99-18fa-4c2a-9099-4f9ec4d38aa3", "Styles": "width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "d212487f-b08d-4e00-8d31-d249d5bcd5a8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.00</span></p>", "ID": "f76d344e-f039-42fd-9dad-963f835f4a31", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2f2fdc99-18fa-4c2a-9099-4f9ec4d38aa3"}, {"Element": "<span lang=\"EN-GB\">0.00</span>", "ID": "b6d475aa-4fd1-4785-9aaf-1260640eb784", "Styles": "None", "Classes": "None", "Text": "0.00", "ParentId": "f76d344e-f039-42fd-9dad-963f835f4a31"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Improvement from baseline in HAQ averaged\n  over time from week\u00a030 to week\u00a054<sup>c</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "1060d39d-7cd3-4843-8e7c-351e672761d1", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "c0e4e657-5218-4f84-9541-fac690ce3fe4"}, {"Element": "<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Improvement from baseline in HAQ averaged\n  over time from week\u00a030 to week\u00a054<sup>c</sup></span></p>\n</td>", "ID": "6edf721e-d0d6-495a-aad3-4927ef16e7e6", "Styles": "width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "1060d39d-7cd3-4843-8e7c-351e672761d1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Improvement from baseline in HAQ averaged\n  over time from week\u00a030 to week\u00a054<sup>c</sup></span></p>", "ID": "b451e6ed-5ef8-4df6-be8a-0c18ee03d646", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6edf721e-d0d6-495a-aad3-4927ef16e7e6"}, {"Element": "<span lang=\"EN-GB\">Improvement from baseline in HAQ averaged\n  over time from week\u00a030 to week\u00a054<sup>c</sup></span>", "ID": "2c096236-3b2d-4441-b95d-6902e1607f6c", "Styles": "None", "Classes": "None", "Text": "Improvement from baseline in HAQ averaged   over time from week\u00a030 to week\u00a054", "ParentId": "b451e6ed-5ef8-4df6-be8a-0c18ee03d646"}, {"Element": "<sup>c</sup>", "ID": "a08cdd88-805c-478e-aabb-173f0b437101", "Styles": "None", "Classes": "None", "Text": "c", "ParentId": "2c096236-3b2d-4441-b95d-6902e1607f6c"}, {"Element": "<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "4bf74498-132a-42a3-afe5-3613b199a132", "Styles": "width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "1060d39d-7cd3-4843-8e7c-351e672761d1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "10f3e039-944d-4645-8d04-443c7b251c5c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4bf74498-132a-42a3-afe5-3613b199a132"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fc4ef341-dfad-4d3a-959f-1c590ad6bba5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "10f3e039-944d-4645-8d04-443c7b251c5c"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "c9a7ff43-7225-4c0b-a627-ce98bb35657b", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "1060d39d-7cd3-4843-8e7c-351e672761d1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1c168ae1-e4c1-48f1-b8ba-52acbae5370d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c9a7ff43-7225-4c0b-a627-ce98bb35657b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f14239cf-79e7-40ee-9d3f-fad724916b45", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1c168ae1-e4c1-48f1-b8ba-52acbae5370d"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "f2c053c9-0bf4-4848-8c30-395ad340ad33", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "1060d39d-7cd3-4843-8e7c-351e672761d1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a85f919c-90c8-4bf7-9eda-c77ce1b5d1f4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f2c053c9-0bf4-4848-8c30-395ad340ad33"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e561095c-d56b-4393-aae3-7141a48d847e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a85f919c-90c8-4bf7-9eda-c77ce1b5d1f4"}, {"Element": "<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "ef8297e4-0fe5-428a-88ea-5f032dfcd094", "Styles": "width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "1060d39d-7cd3-4843-8e7c-351e672761d1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aa7f10c3-0d38-4472-91f2-c29561921e32", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ef8297e4-0fe5-428a-88ea-5f032dfcd094"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "20f1b7f1-cc96-4e6d-9917-fb0dd1411505", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aa7f10c3-0d38-4472-91f2-c29561921e32"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>d</sup></span></p>\n</td>\n<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.68\u00a0\u00b1\u00a00.63</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.80\u00a0\u00b1\u00a00.65</span></p>\n</td>\n<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.88\u00a0\u00b1\u00a00.65</span></p>\n</td>\n<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.84\u00a0\u00b1\u00a00.65</span></p>\n</td>\n</tr>", "ID": "8dba4ce7-f975-4dcd-80db-c6a9fb0d38c7", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "c0e4e657-5218-4f84-9541-fac690ce3fe4"}, {"Element": "<td style=\"width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"231\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>d</sup></span></p>\n</td>", "ID": "40034eea-279b-48ed-82e2-01388330ad1b", "Styles": "width:172.95pt;border:solid windowtext 1.0pt;\n  border-top:none;padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8dba4ce7-f975-4dcd-80db-c6a9fb0d38c7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mean \u00b1 SD<sup>d</sup></span></p>", "ID": "2df0588e-c80e-4f6e-b787-ad69eb09382d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "40034eea-279b-48ed-82e2-01388330ad1b"}, {"Element": "<span lang=\"EN-GB\">Mean \u00b1 SD<sup>d</sup></span>", "ID": "a1693033-5fae-4585-b36a-3f9da297af80", "Styles": "None", "Classes": "None", "Text": "Mean \u00b1 SD", "ParentId": "2df0588e-c80e-4f6e-b787-ad69eb09382d"}, {"Element": "<sup>d</sup>", "ID": "7dc2de3b-8cb2-455f-9fce-367aa664cc52", "Styles": "None", "Classes": "None", "Text": "d", "ParentId": "a1693033-5fae-4585-b36a-3f9da297af80"}, {"Element": "<td style=\"width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"109\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.68\u00a0\u00b1\u00a00.63</span></p>\n</td>", "ID": "35b4e573-05c3-4317-b1ba-fa88172588f1", "Styles": "width:81.55pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8dba4ce7-f975-4dcd-80db-c6a9fb0d38c7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.68\u00a0\u00b1\u00a00.63</span></p>", "ID": "da058b8e-8cc1-41b9-90f2-f829ba282923", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "35b4e573-05c3-4317-b1ba-fa88172588f1"}, {"Element": "<span lang=\"EN-GB\">0.68\u00a0\u00b1\u00a00.63</span>", "ID": "730d1825-bacb-40f5-9af2-09d2593e0f45", "Styles": "None", "Classes": "None", "Text": "0.68\u00a0\u00b1\u00a00.63", "ParentId": "da058b8e-8cc1-41b9-90f2-f829ba282923"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.80\u00a0\u00b1\u00a00.65</span></p>\n</td>", "ID": "fcb32c2f-84e1-4f8d-9235-70537ff789a5", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8dba4ce7-f975-4dcd-80db-c6a9fb0d38c7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.80\u00a0\u00b1\u00a00.65</span></p>", "ID": "d093c392-51b6-452e-8042-ba05392b146b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fcb32c2f-84e1-4f8d-9235-70537ff789a5"}, {"Element": "<span lang=\"EN-GB\">0.80\u00a0\u00b1\u00a00.65</span>", "ID": "412acc71-0325-4188-bd0d-04805e86ce3b", "Styles": "None", "Classes": "None", "Text": "0.80\u00a0\u00b1\u00a00.65", "ParentId": "d093c392-51b6-452e-8042-ba05392b146b"}, {"Element": "<td style=\"width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"85\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.88\u00a0\u00b1\u00a00.65</span></p>\n</td>", "ID": "8d53823e-5d21-47a4-aee6-4f9e788e2c28", "Styles": "width:63.8pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8dba4ce7-f975-4dcd-80db-c6a9fb0d38c7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.88\u00a0\u00b1\u00a00.65</span></p>", "ID": "398c7521-1667-406c-bb9a-80d373a030db", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8d53823e-5d21-47a4-aee6-4f9e788e2c28"}, {"Element": "<span lang=\"EN-GB\">0.88\u00a0\u00b1\u00a00.65</span>", "ID": "7e1d3ba6-cdc0-43b2-b13c-99ba2702dd1a", "Styles": "None", "Classes": "None", "Text": "0.88\u00a0\u00b1\u00a00.65", "ParentId": "398c7521-1667-406c-bb9a-80d373a030db"}, {"Element": "<td style=\"width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"94\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.84\u00a0\u00b1\u00a00.65</span></p>\n</td>", "ID": "3a148750-9560-4b00-9c27-035d187e8e4e", "Styles": "width:70.15pt;border-top:none;border-left:\n  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "8dba4ce7-f975-4dcd-80db-c6a9fb0d38c7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.84\u00a0\u00b1\u00a00.65</span></p>", "ID": "b7ba4df4-993b-4540-bf8a-1da590a08038", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3a148750-9560-4b00-9c27-035d187e8e4e"}, {"Element": "<span lang=\"EN-GB\">0.84\u00a0\u00b1\u00a00.65</span>", "ID": "aca016ec-1275-420f-b749-e36dc98da52f", "Styles": "None", "Classes": "None", "Text": "0.84\u00a0\u00b1\u00a00.65", "ParentId": "b7ba4df4-993b-4540-bf8a-1da590a08038"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"5\" style=\"width:452.25pt;border:none;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"603\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control.</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 p\u00a0=\u00a00.030\n  and &lt;\u00a00.001 for the 3\u00a0mg/kg and 6\u00a0mg/kg treatment groups\n  respectively vs. placebo + MTX.</span></p>\n</td>\n</tr>", "ID": "1baef900-8bac-4705-a3ff-427ec0e6fd6d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "c0e4e657-5218-4f84-9541-fac690ce3fe4"}, {"Element": "<td colspan=\"5\" style=\"width:452.25pt;border:none;\n  padding:0in 1.4pt 0in 2.85pt\" valign=\"bottom\" width=\"603\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control.</span></span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 p\u00a0=\u00a00.030\n  and &lt;\u00a00.001 for the 3\u00a0mg/kg and 6\u00a0mg/kg treatment groups\n  respectively vs. placebo + MTX.</span></p>\n</td>", "ID": "d2e96c4d-80f7-4a68-bd9d-c5a19f0ac675", "Styles": "width:452.25pt;border:none;\n  padding:0in 1.4pt 0in 2.85pt", "Classes": "None", "Text": "     ", "ParentId": "1baef900-8bac-4705-a3ff-427ec0e6fd6d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control.</span></span></p>", "ID": "03c5ffb3-f539-47f7-b762-facf8bc866e6", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d2e96c4d-80f7-4a68-bd9d-c5a19f0ac675"}, {"Element": "<sup><span lang=\"EN-GB\">a</span></sup>", "ID": "fdd168ab-25b6-4a43-87f2-c27a7c0ee3fe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "03c5ffb3-f539-47f7-b762-facf8bc866e6"}, {"Element": "<span lang=\"EN-GB\">a</span>", "ID": "e8665732-a869-48c0-83b0-4a4a2164cef3", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "fdd168ab-25b6-4a43-87f2-c27a7c0ee3fe"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control.</span></span>", "ID": "cc9504c6-9a33-4f58-b393-fd2d831ec16c", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "03c5ffb3-f539-47f7-b762-facf8bc866e6"}, {"Element": "<span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. control.</span>", "ID": "e7af14c8-5671-452f-8bd1-96971a3958d4", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "p\u00a0<\u00a00.001, for each infliximab   treatment group vs. control.", "ParentId": "cc9504c6-9a33-4f58-b393-fd2d831ec16c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span></p>", "ID": "943cbf90-4139-4f63-ab59-eb336271c6f5", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d2e96c4d-80f7-4a68-bd9d-c5a19f0ac675"}, {"Element": "<sup><span lang=\"EN-GB\">b</span></sup>", "ID": "ede13bf5-283d-405f-ad8d-da8f148140d0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "943cbf90-4139-4f63-ab59-eb336271c6f5"}, {"Element": "<span lang=\"EN-GB\">b</span>", "ID": "71a2c9d7-f0cc-4dd1-9611-257bb7961246", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "ede13bf5-283d-405f-ad8d-da8f148140d0"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 greater\n  values indicate more joint damage.</span>", "ID": "77bee7f9-94e3-470d-8915-7d54a7edd686", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 greater   values indicate more joint damage.", "ParentId": "943cbf90-4139-4f63-ab59-eb336271c6f5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span></p>", "ID": "5e07e7d8-6aa3-41c3-a89b-4ea832874339", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d2e96c4d-80f7-4a68-bd9d-c5a19f0ac675"}, {"Element": "<sup><span lang=\"EN-GB\">c</span></sup>", "ID": "4989177b-a5c7-43d2-ab71-3042c08b4d30", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5e07e7d8-6aa3-41c3-a89b-4ea832874339"}, {"Element": "<span lang=\"EN-GB\">c</span>", "ID": "214202af-7823-44c3-a062-6c17f4697604", "Styles": "None", "Classes": "None", "Text": "c", "ParentId": "4989177b-a5c7-43d2-ab71-3042c08b4d30"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health\n  Assessment Questionnaire; greater values indicate less disability.</span>", "ID": "c3670752-4e76-47a4-a60e-7f229b4e4797", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 HAQ\u00a0=\u00a0Health   Assessment Questionnaire; greater values indicate less disability.", "ParentId": "5e07e7d8-6aa3-41c3-a89b-4ea832874339"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">d</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 p\u00a0=\u00a00.030\n  and &lt;\u00a00.001 for the 3\u00a0mg/kg and 6\u00a0mg/kg treatment groups\n  respectively vs. placebo + MTX.</span></p>", "ID": "f27dba96-f4a3-40a8-ae71-c4e472ca2f3e", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d2e96c4d-80f7-4a68-bd9d-c5a19f0ac675"}, {"Element": "<sup><span lang=\"EN-GB\">d</span></sup>", "ID": "cabc95fe-9ca5-489b-9c43-f663274e91fe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f27dba96-f4a3-40a8-ae71-c4e472ca2f3e"}, {"Element": "<span lang=\"EN-GB\">d</span>", "ID": "6197b67c-4f16-4b0d-a817-cbdc4f783d14", "Styles": "None", "Classes": "None", "Text": "d", "ParentId": "cabc95fe-9ca5-489b-9c43-f663274e91fe"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 p\u00a0=\u00a00.030\n  and &lt;\u00a00.001 for the 3\u00a0mg/kg and 6\u00a0mg/kg treatment groups\n  respectively vs. placebo + MTX.</span>", "ID": "dbe36d9c-e0fd-4a46-bb1b-bfd38fde58be", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 p\u00a0=\u00a00.030   and <\u00a00.001 for the 3\u00a0mg/kg and 6\u00a0mg/kg treatment groups   respectively vs. placebo + MTX.", "ParentId": "f27dba96-f4a3-40a8-ae71-c4e472ca2f3e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a8f37c6e-72bf-4764-b69f-6c07120c27c5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ad7b35e3-79ab-44a6-b6db-cc5d2627b22b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a8f37c6e-72bf-4764-b69f-6c07120c27c5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Data to support\ndose titration in rheumatoid arthritis come from ATTRACT, ASPIRE and the START\nstudy. START was a randomised, multicenter, double\u2011blind, 3\u2011arm,\nparallel\u2011group safety study. In one of the study arms (group 2, n\u00a0=\u00a0329),\npatients with an inadequate response were allowed to dose titrate with 1.5\u00a0mg/kg\nincrements from 3 up to 9\u00a0mg/kg. <a name=\"OLE_LINK2\">The majority (67%) of\nthese patients did not require any dose titration. </a>Of the patients who\nrequired a dose titration, 80% achieved clinical response and the majority\n(64%) of these required only one adjustment of 1.5\u00a0mg/kg.</span></p>", "ID": "71ea5680-a742-4833-8582-78e951ec022b", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Data to support\ndose titration in rheumatoid arthritis come from ATTRACT, ASPIRE and the START\nstudy. START was a randomised, multicenter, double\u2011blind, 3\u2011arm,\nparallel\u2011group safety study. In one of the study arms (group 2, n\u00a0=\u00a0329),\npatients with an inadequate response were allowed to dose titrate with 1.5\u00a0mg/kg\nincrements from 3 up to 9\u00a0mg/kg. <a name=\"OLE_LINK2\">The majority (67%) of\nthese patients did not require any dose titration. </a>Of the patients who\nrequired a dose titration, 80% achieved clinical response and the majority\n(64%) of these required only one adjustment of 1.5\u00a0mg/kg.</span>", "ID": "57b8536b-d75e-4b2d-ad20-3f2f3f4bacc5", "Styles": "None", "Classes": "None", "Text": "Data to support dose titration in rheumatoid arthritis come from ATTRACT, ASPIRE and the START study. START was a randomised, multicenter, double\u2011blind, 3\u2011arm, parallel\u2011group safety study. In one of the study arms (group 2, n\u00a0=\u00a0329), patients with an inadequate response were allowed to dose titrate with 1.5\u00a0mg/kg increments from 3 up to 9\u00a0mg/kg. Of the patients who required a dose titration, 80% achieved clinical response and the majority (64%) of these required only one adjustment of 1.5\u00a0mg/kg.", "ParentId": "71ea5680-a742-4833-8582-78e951ec022b"}, {"Element": "<a name=\"OLE_LINK2\">The majority (67%) of\nthese patients did not require any dose titration. </a>", "ID": "c2948d37-9b28-41a9-8754-deb3cbac3de2", "Styles": "None", "Classes": "None", "Text": "The majority (67%) of these patients did not require any dose titration. ", "ParentId": "57b8536b-d75e-4b2d-ad20-3f2f3f4bacc5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "21640147-924f-466d-b4c9-b9194fa41072", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bd6980ec-70fc-435e-92ad-33d55aacd20b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "21640147-924f-466d-b4c9-b9194fa41072"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Adult Crohn\u2019s disease</span></u></p>", "ID": "9fae9ada-1ac3-4e66-9878-02a40685b478", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Adult Crohn\u2019s disease</span></u>", "ID": "9e03fc94-5cf6-4a06-802b-9d96236f692a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9fae9ada-1ac3-4e66-9878-02a40685b478"}, {"Element": "<span lang=\"EN-GB\">Adult Crohn\u2019s disease</span>", "ID": "bad568a1-810d-40be-88bd-7e29c4e00e44", "Styles": "None", "Classes": "None", "Text": "Adult Crohn\u2019s disease", "ParentId": "9e03fc94-5cf6-4a06-802b-9d96236f692a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Induction\ntreatment in moderately to severely active Crohn\u2019s disease</span></i></p>", "ID": "c1f539ac-3495-4c89-9082-65835384ed4d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Induction\ntreatment in moderately to severely active Crohn\u2019s disease</span></i>", "ID": "fdcd8864-2599-410c-962c-11aeb40377fe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c1f539ac-3495-4c89-9082-65835384ed4d"}, {"Element": "<span lang=\"EN-GB\">Induction\ntreatment in moderately to severely active Crohn\u2019s disease</span>", "ID": "65f10214-0742-4f7e-af61-cc1b308260c5", "Styles": "None", "Classes": "None", "Text": "Induction treatment in moderately to severely active Crohn\u2019s disease", "ParentId": "fdcd8864-2599-410c-962c-11aeb40377fe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of a single dose treatment\nwith infliximab was assessed in 108\u00a0patients with active Crohn\u2019s\ndisease (Crohn\u2019s Disease Activity Index (CDAI)\u00a0\u2265\u00a0220\u00a0\u2264\u00a0400)\nin a randomised, double\u2011blinded, placebo\u2011controlled, dose\u2011response\nstudy. Of these 108\u00a0patients, 27 were treated with the recommended dosage\nof infliximab 5\u00a0mg/kg. All patients had experienced an inadequate response\nto prior conventional therapies. Concurrent use of stable doses of conventional\ntherapies was permitted, and 92% of patients continued to receive these\ntherapies.</span></p>", "ID": "b82c2f57-23ab-4c65-8058-24f82a1f4ff6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The efficacy of a single dose treatment\nwith infliximab was assessed in 108\u00a0patients with active Crohn\u2019s\ndisease (Crohn\u2019s Disease Activity Index (CDAI)\u00a0\u2265\u00a0220\u00a0\u2264\u00a0400)\nin a randomised, double\u2011blinded, placebo\u2011controlled, dose\u2011response\nstudy. Of these 108\u00a0patients, 27 were treated with the recommended dosage\nof infliximab 5\u00a0mg/kg. All patients had experienced an inadequate response\nto prior conventional therapies. Concurrent use of stable doses of conventional\ntherapies was permitted, and 92% of patients continued to receive these\ntherapies.</span>", "ID": "1d54fcbf-b780-4e4c-8c21-6824e951dde8", "Styles": "None", "Classes": "None", "Text": "The efficacy of a single dose treatment with infliximab was assessed in 108\u00a0patients with active Crohn\u2019s disease (Crohn\u2019s Disease Activity Index (CDAI)\u00a0\u2265\u00a0220\u00a0\u2264\u00a0400) in a randomised, double\u2011blinded, placebo\u2011controlled, dose\u2011response study. Of these 108\u00a0patients, 27 were treated with the recommended dosage of infliximab 5\u00a0mg/kg. All patients had experienced an inadequate response to prior conventional therapies. Concurrent use of stable doses of conventional therapies was permitted, and 92% of patients continued to receive these therapies.", "ParentId": "b82c2f57-23ab-4c65-8058-24f82a1f4ff6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2e06a166-c8f3-4e0f-ae71-cb100897a4d1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "768d7952-1638-4d70-851f-b150b106d3a0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2e06a166-c8f3-4e0f-ae71-cb100897a4d1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint was the proportion of\npatients who experienced a clinical response, defined as a decrease in CDAI by \u2265\u00a070\u00a0points\nfrom baseline at the 4\u2011week evaluation and without an increase in the use\nof medicinal products or surgery for Crohn\u2019s disease. Patients who\nresponded at week\u00a04 were followed to week\u00a012. Secondary endpoints\nincluded the proportion of patients in clinical remission at week\u00a04\n(CDAI\u00a0&lt;\u00a0150) and clinical response over time.</span></p>", "ID": "8e657c87-7cc3-4682-bc99-66aaa09f3cc3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The primary endpoint was the proportion of\npatients who experienced a clinical response, defined as a decrease in CDAI by \u2265\u00a070\u00a0points\nfrom baseline at the 4\u2011week evaluation and without an increase in the use\nof medicinal products or surgery for Crohn\u2019s disease. Patients who\nresponded at week\u00a04 were followed to week\u00a012. Secondary endpoints\nincluded the proportion of patients in clinical remission at week\u00a04\n(CDAI\u00a0&lt;\u00a0150) and clinical response over time.</span>", "ID": "b3201913-57cc-44d4-93f2-e55514b89276", "Styles": "None", "Classes": "None", "Text": "The primary endpoint was the proportion of patients who experienced a clinical response, defined as a decrease in CDAI by \u2265\u00a070\u00a0points from baseline at the 4\u2011week evaluation and without an increase in the use of medicinal products or surgery for Crohn\u2019s disease. Patients who responded at week\u00a04 were followed to week\u00a012. Secondary endpoints included the proportion of patients in clinical remission at week\u00a04 (CDAI\u00a0<\u00a0150) and clinical response over time.", "ParentId": "8e657c87-7cc3-4682-bc99-66aaa09f3cc3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5d5f15d2-344d-4773-b8ba-3ef9160073f1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8bf955e3-be94-4b93-bb21-3118a4544fbb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5d5f15d2-344d-4773-b8ba-3ef9160073f1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">At week\u00a04, following administration of\na single dose, 22/27\u00a0(81%) of infliximab\u2011treated patients receiving\na 5\u00a0mg/kg dose achieved a clinical response vs. 4/25\u00a0(16%) of the\nplacebo\u2011treated patients (p\u00a0&lt;\u00a00.001). Also at week\u00a04,\n13/27\u00a0(48%) of infliximab\u2011treated patients achieved a clinical\nremission (CDAI\u00a0&lt;\u00a0150) vs. 1/25\u00a0(4%) of placebo\u2011treated\npatients. A response was observed within 2\u00a0weeks, with a maximum response\nat 4\u00a0weeks. At the last observation at 12\u00a0weeks, 13/27\u00a0(48%) of\ninfliximab\u2011treated patients were still responding.</span></p>", "ID": "7348df34-3c3d-4456-a246-38b5e9d3333f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">At week\u00a04, following administration of\na single dose, 22/27\u00a0(81%) of infliximab\u2011treated patients receiving\na 5\u00a0mg/kg dose achieved a clinical response vs. 4/25\u00a0(16%) of the\nplacebo\u2011treated patients (p\u00a0&lt;\u00a00.001). Also at week\u00a04,\n13/27\u00a0(48%) of infliximab\u2011treated patients achieved a clinical\nremission (CDAI\u00a0&lt;\u00a0150) vs. 1/25\u00a0(4%) of placebo\u2011treated\npatients. A response was observed within 2\u00a0weeks, with a maximum response\nat 4\u00a0weeks. At the last observation at 12\u00a0weeks, 13/27\u00a0(48%) of\ninfliximab\u2011treated patients were still responding.</span>", "ID": "943944e7-bda2-47cc-bc73-9f5822599d17", "Styles": "None", "Classes": "None", "Text": "At week\u00a04, following administration of a single dose, 22/27\u00a0(81%) of infliximab\u2011treated patients receiving a 5\u00a0mg/kg dose achieved a clinical response vs. 4/25\u00a0(16%) of the placebo\u2011treated patients (p\u00a0<\u00a00.001). Also at week\u00a04, 13/27\u00a0(48%) of infliximab\u2011treated patients achieved a clinical remission (CDAI\u00a0<\u00a0150) vs. 1/25\u00a0(4%) of placebo\u2011treated patients. A response was observed within 2\u00a0weeks, with a maximum response at 4\u00a0weeks. At the last observation at 12\u00a0weeks, 13/27\u00a0(48%) of infliximab\u2011treated patients were still responding.", "ParentId": "7348df34-3c3d-4456-a246-38b5e9d3333f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a5927e7a-ad6a-4e47-b236-71aa2bd61b5c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "995ec437-1d87-4ea8-8854-641a1d6b94b0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a5927e7a-ad6a-4e47-b236-71aa2bd61b5c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Maintenance\ntreatment in moderately to severely active Crohn\u2019s disease in adults</span></i></p>", "ID": "01ea6bbf-b23f-4411-888e-718b9050445f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Maintenance\ntreatment in moderately to severely active Crohn\u2019s disease in adults</span></i>", "ID": "007a3835-d49b-4543-b4ba-1b271423e569", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "01ea6bbf-b23f-4411-888e-718b9050445f"}, {"Element": "<span lang=\"EN-GB\">Maintenance\ntreatment in moderately to severely active Crohn\u2019s disease in adults</span>", "ID": "429be6d3-1af2-4d8f-9b0c-5b0741d58ec4", "Styles": "None", "Classes": "None", "Text": "Maintenance treatment in moderately to severely active Crohn\u2019s disease in adults", "ParentId": "007a3835-d49b-4543-b4ba-1b271423e569"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of repeated infusions with\ninfliximab was studied in a 1\u2011year clinical study (ACCENT I).</span></p>", "ID": "26353839-7ddd-4ae8-958b-a625fc206f1f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The efficacy of repeated infusions with\ninfliximab was studied in a 1\u2011year clinical study (ACCENT I).</span>", "ID": "70130987-4cb8-4edc-a8bf-a690fcaf7859", "Styles": "None", "Classes": "None", "Text": "The efficacy of repeated infusions with infliximab was studied in a 1\u2011year clinical study (ACCENT I).", "ParentId": "26353839-7ddd-4ae8-958b-a625fc206f1f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">A total of 573\u00a0patients with\nmoderately to severely active Crohn\u2019s disease (CDAI\u00a0\u2265\u00a0220\u00a0\u2264\u00a0400)\nreceived a single infusion of 5\u00a0mg/kg at week\u00a00. 178 of the\n580\u00a0enrolled patients (30.7%) were defined as having severe disease (CDAI\nscore &gt;\u00a0300 and concomitant corticosteroid and/or immunosuppressants)\ncorresponding to the population defined in the indication (see section\u00a04.1).\nAt week\u00a02, all patients were assessed for clinical response and randomised\nto one of 3\u00a0treatment groups; a placebo maintenance group, 5\u00a0mg/kg\nmaintenance group and 10\u00a0mg/kg maintenance group. All 3\u00a0groups\nreceived repeated infusions at week\u00a02, 6 and every 8\u00a0weeks\nthereafter.</span></p>", "ID": "8c7ad581-bb73-4eb4-a174-74ac48f75436", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">A total of 573\u00a0patients with\nmoderately to severely active Crohn\u2019s disease (CDAI\u00a0\u2265\u00a0220\u00a0\u2264\u00a0400)\nreceived a single infusion of 5\u00a0mg/kg at week\u00a00. 178 of the\n580\u00a0enrolled patients (30.7%) were defined as having severe disease (CDAI\nscore &gt;\u00a0300 and concomitant corticosteroid and/or immunosuppressants)\ncorresponding to the population defined in the indication (see section\u00a04.1).\nAt week\u00a02, all patients were assessed for clinical response and randomised\nto one of 3\u00a0treatment groups; a placebo maintenance group, 5\u00a0mg/kg\nmaintenance group and 10\u00a0mg/kg maintenance group. All 3\u00a0groups\nreceived repeated infusions at week\u00a02, 6 and every 8\u00a0weeks\nthereafter.</span>", "ID": "c77091b0-1755-48d2-a0b0-104ae6416cc5", "Styles": "None", "Classes": "None", "Text": "A total of 573\u00a0patients with moderately to severely active Crohn\u2019s disease (CDAI\u00a0\u2265\u00a0220\u00a0\u2264\u00a0400) received a single infusion of 5\u00a0mg/kg at week\u00a00. 178 of the 580\u00a0enrolled patients (30.7%) were defined as having severe disease (CDAI score >\u00a0300 and concomitant corticosteroid and/or immunosuppressants) corresponding to the population defined in the indication (see section\u00a04.1). At week\u00a02, all patients were assessed for clinical response and randomised to one of 3\u00a0treatment groups; a placebo maintenance group, 5\u00a0mg/kg maintenance group and 10\u00a0mg/kg maintenance group. All 3\u00a0groups received repeated infusions at week\u00a02, 6 and every 8\u00a0weeks thereafter.", "ParentId": "8c7ad581-bb73-4eb4-a174-74ac48f75436"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0c645425-92c3-44f1-aa81-fd2e308cd53f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "519eda46-c9b5-43b9-bd34-02e0924c22a8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0c645425-92c3-44f1-aa81-fd2e308cd53f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Of the 573\u00a0patients randomised, 335\n(58%) achieved clinical response by week\u00a02. These patients were classified\nas week\u20112 responders and were included in the primary analysis (see Table\u00a05).\nAmong patients classified as non\u2011responders at week\u00a02, 32% (26/81)\nin the placebo maintenance group and 42% (68/163) in the infliximab group\nachieved clinical response by week\u00a06. There was no difference between\ngroups in the number of late responders thereafter.</span></p>", "ID": "fbbd2554-8046-490e-8c30-efb48757a1e1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Of the 573\u00a0patients randomised, 335\n(58%) achieved clinical response by week\u00a02. These patients were classified\nas week\u20112 responders and were included in the primary analysis (see Table\u00a05).\nAmong patients classified as non\u2011responders at week\u00a02, 32% (26/81)\nin the placebo maintenance group and 42% (68/163) in the infliximab group\nachieved clinical response by week\u00a06. There was no difference between\ngroups in the number of late responders thereafter.</span>", "ID": "ca858e4f-bfd5-41ae-be89-ad8c17c83fe3", "Styles": "None", "Classes": "None", "Text": "Of the 573\u00a0patients randomised, 335 (58%) achieved clinical response by week\u00a02. These patients were classified as week\u20112 responders and were included in the primary analysis (see Table\u00a05). Among patients classified as non\u2011responders at week\u00a02, 32% (26/81) in the placebo maintenance group and 42% (68/163) in the infliximab group achieved clinical response by week\u00a06. There was no difference between groups in the number of late responders thereafter.", "ParentId": "fbbd2554-8046-490e-8c30-efb48757a1e1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6fdb4659-1b45-41e1-a48a-133ffe38aec7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e9ccf264-288f-4dd7-99d4-eb7e90cb705d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6fdb4659-1b45-41e1-a48a-133ffe38aec7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The co\u2011primary endpoints were the\nproportion of patients in clinical remission (CDAI\u00a0&lt;\u00a0150) at week\u00a030\nand time to loss of response through week\u00a054. Corticosteroid tapering was\npermitted after week\u00a06.</span></p>", "ID": "b54ad626-9763-4e8b-84f0-193ba0ab9bea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The co\u2011primary endpoints were the\nproportion of patients in clinical remission (CDAI\u00a0&lt;\u00a0150) at week\u00a030\nand time to loss of response through week\u00a054. Corticosteroid tapering was\npermitted after week\u00a06.</span>", "ID": "26c9323a-7c4b-4ff9-9b4f-af052ee582bd", "Styles": "None", "Classes": "None", "Text": "The co\u2011primary endpoints were the proportion of patients in clinical remission (CDAI\u00a0<\u00a0150) at week\u00a030 and time to loss of response through week\u00a054. Corticosteroid tapering was permitted after week\u00a06.", "ParentId": "b54ad626-9763-4e8b-84f0-193ba0ab9bea"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b3206534-5583-477c-ad68-8510adb1973b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "743be002-d286-42d1-8c77-a742863dc627", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b3206534-5583-477c-ad68-8510adb1973b"}, {"Element": "<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a05</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on response and remission rate, data from\n  ACCENT I (week\u20112 responders)</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:325.95pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"435\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">ACCENT I (week\u20112 responders)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">% of Patients</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0110)</span></p>\n</td>\n<td style=\"width:108.65pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0113)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(p value)</span></p>\n</td>\n<td style=\"width:108.65pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0112)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(p value)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median time to loss of response through week\u00a054</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19\u00a0weeks</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38\u00a0weeks</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.002)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&gt;\u00a054\u00a0weeks</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a030</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Response<sup>a</sup></span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.3</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">51.3</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">59.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Remission</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">20.9</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.9</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.003)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Steroid\u2011Free Remission</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">10.7\n  (6/56)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">31.0\n  (18/58)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.008)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.8\n  (21/57)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a054</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Response<sup>a</sup></span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15.5</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47.7</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Remission</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13.6</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">28.3</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.007)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.4</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained Steroid\u2011Free Remission<sup>b</sup></span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5.7\n  (3/53)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">17.9\n  (10/56)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.075)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">28.6\n  (16/56)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.002)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Reduction\n  in CDAI \u2265\u00a025% and \u2265\u00a070\u00a0points.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 CDAI\u00a0&lt;\u00a0150\n  at both week\u00a030 and 54 and not receiving corticosteroids in the\n  3\u00a0months prior to week\u00a054 among patients who were receiving\n  corticosteroids at baseline.</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "cab14af1-f881-477b-8508-849bb943443a", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a05</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on response and remission rate, data from\n  ACCENT I (week\u20112 responders)</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:325.95pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"435\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">ACCENT I (week\u20112 responders)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">% of Patients</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0110)</span></p>\n</td>\n<td style=\"width:108.65pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0113)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(p value)</span></p>\n</td>\n<td style=\"width:108.65pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0112)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(p value)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median time to loss of response through week\u00a054</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19\u00a0weeks</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38\u00a0weeks</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.002)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&gt;\u00a054\u00a0weeks</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a030</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Response<sup>a</sup></span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.3</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">51.3</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">59.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Remission</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">20.9</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.9</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.003)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Steroid\u2011Free Remission</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">10.7\n  (6/56)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">31.0\n  (18/58)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.008)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.8\n  (21/57)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a054</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Response<sup>a</sup></span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15.5</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47.7</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Remission</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13.6</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">28.3</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.007)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.4</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained Steroid\u2011Free Remission<sup>b</sup></span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5.7\n  (3/53)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">17.9\n  (10/56)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.075)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">28.6\n  (16/56)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.002)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Reduction\n  in CDAI \u2265\u00a025% and \u2265\u00a070\u00a0points.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 CDAI\u00a0&lt;\u00a0150\n  at both week\u00a030 and 54 and not receiving corticosteroids in the\n  3\u00a0months prior to week\u00a054 among patients who were receiving\n  corticosteroids at baseline.</span></p>\n</td>\n</tr>\n</table>", "ID": "98242987-5310-42c5-8682-c42c7651a2b2", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "              ", "ParentId": "cab14af1-f881-477b-8508-849bb943443a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a05</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on response and remission rate, data from\n  ACCENT I (week\u20112 responders)</span></b></p>\n</td>\n</tr>", "ID": "a5c6d845-314f-4dcf-b466-e618888745f6", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td colspan=\"4\" style=\"width:6.3in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a05</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on response and remission rate, data from\n  ACCENT I (week\u20112 responders)</span></b></p>\n</td>", "ID": "6ad65aed-541e-45e0-ad01-28e17b48a500", "Styles": "width:6.3in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "a5c6d845-314f-4dcf-b466-e618888745f6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a05</span></b></p>", "ID": "5ed609c2-6569-4f46-b14f-f20f15e45e14", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6ad65aed-541e-45e0-ad01-28e17b48a500"}, {"Element": "<b><span lang=\"EN-GB\">Table\u00a05</span></b>", "ID": "51ea6ee5-dba7-47d9-9e6c-1584ec9cc392", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5ed609c2-6569-4f46-b14f-f20f15e45e14"}, {"Element": "<span lang=\"EN-GB\">Table\u00a05</span>", "ID": "00ea0b33-e081-40cd-9639-4ff41b5f3f3f", "Styles": "None", "Classes": "None", "Text": "Table\u00a05", "ParentId": "51ea6ee5-dba7-47d9-9e6c-1584ec9cc392"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on response and remission rate, data from\n  ACCENT I (week\u20112 responders)</span></b></p>", "ID": "3a5b5ea3-a7e5-45de-a76b-ba4849971f6e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6ad65aed-541e-45e0-ad01-28e17b48a500"}, {"Element": "<b><span lang=\"EN-GB\">Effects on response and remission rate, data from\n  ACCENT I (week\u20112 responders)</span></b>", "ID": "53f42b75-829f-46f7-8e94-6cea652793a2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3a5b5ea3-a7e5-45de-a76b-ba4849971f6e"}, {"Element": "<span lang=\"EN-GB\">Effects on response and remission rate, data from\n  ACCENT I (week\u20112 responders)</span>", "ID": "84fd6cae-101e-4f7e-93aa-94400a91b4ee", "Styles": "None", "Classes": "None", "Text": "Effects on response and remission rate, data from   ACCENT I (week\u20112 responders)", "ParentId": "53f42b75-829f-46f7-8e94-6cea652793a2"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:325.95pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"435\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">ACCENT I (week\u20112 responders)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">% of Patients</span></p>\n</td>\n</tr>", "ID": "23822334-d0e3-4edb-8752-0af55ae8a390", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "30a0d375-59b2-4e37-bf4f-2c341dc32040", "Styles": "width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "23822334-d0e3-4edb-8752-0af55ae8a390"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "08d5d330-c81a-40e3-baf9-419cfdfa3e28", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "30a0d375-59b2-4e37-bf4f-2c341dc32040"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1a1dfeb4-c2e4-457e-84aa-72c041f50d6c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "08d5d330-c81a-40e3-baf9-419cfdfa3e28"}, {"Element": "<td colspan=\"3\" style=\"width:325.95pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"435\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">ACCENT I (week\u20112 responders)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">% of Patients</span></p>\n</td>", "ID": "0c6e02fa-09ff-47cc-9b2c-1f5ea87f2dc5", "Styles": "width:325.95pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "23822334-d0e3-4edb-8752-0af55ae8a390"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">ACCENT I (week\u20112 responders)</span></p>", "ID": "ec2b761f-7bc9-4fea-a4cd-37bd9ba0e17d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0c6e02fa-09ff-47cc-9b2c-1f5ea87f2dc5"}, {"Element": "<span lang=\"EN-GB\">ACCENT I (week\u20112 responders)</span>", "ID": "3c2e7535-bb5b-4f42-a563-d1575c05a8d9", "Styles": "None", "Classes": "None", "Text": "ACCENT I (week\u20112 responders)", "ParentId": "ec2b761f-7bc9-4fea-a4cd-37bd9ba0e17d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">% of Patients</span></p>", "ID": "0390d276-a677-4e8c-89a6-96711aeb250a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0c6e02fa-09ff-47cc-9b2c-1f5ea87f2dc5"}, {"Element": "<span lang=\"EN-GB\">% of Patients</span>", "ID": "6d317a64-c54d-4da7-99db-88d1e660c672", "Styles": "None", "Classes": "None", "Text": "% of Patients", "ParentId": "0390d276-a677-4e8c-89a6-96711aeb250a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0110)</span></p>\n</td>\n<td style=\"width:108.65pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0113)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(p value)</span></p>\n</td>\n<td style=\"width:108.65pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0112)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(p value)</span></p>\n</td>\n</tr>", "ID": "8643b56f-579e-40b5-a340-18fbe03c45c5", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td style=\"width:127.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "fc61cc3d-1dcd-49fe-9191-ac630edda327", "Styles": "width:127.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8643b56f-579e-40b5-a340-18fbe03c45c5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9a043359-bc3f-45c5-9ed4-0984d9699cf4", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fc61cc3d-1dcd-49fe-9191-ac630edda327"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "883a0180-8ab3-4ade-a575-b96df3bbf9da", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9a043359-bc3f-45c5-9ed4-0984d9699cf4"}, {"Element": "<td style=\"width:108.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0110)</span></p>\n</td>", "ID": "7990a312-8465-4ef7-ad07-b4327bb11104", "Styles": "width:108.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "8643b56f-579e-40b5-a340-18fbe03c45c5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo Maintenance</span></p>", "ID": "532682a3-5b36-4b0d-bf73-6994ab85f7d1", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7990a312-8465-4ef7-ad07-b4327bb11104"}, {"Element": "<span lang=\"EN-GB\">Placebo Maintenance</span>", "ID": "a33790d6-9f10-4bae-ac25-12824e65607c", "Styles": "None", "Classes": "None", "Text": "Placebo Maintenance", "ParentId": "532682a3-5b36-4b0d-bf73-6994ab85f7d1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f7481f06-f818-4f80-ad40-d77d3c6a3673", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7990a312-8465-4ef7-ad07-b4327bb11104"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9578f674-26a8-45ab-b1e9-30d673d2c6b5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f7481f06-f818-4f80-ad40-d77d3c6a3673"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0110)</span></p>", "ID": "b0e19b32-3d8b-4a4b-9892-bf9d5807c9dd", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7990a312-8465-4ef7-ad07-b4327bb11104"}, {"Element": "<span lang=\"EN-GB\">(n\u00a0=\u00a0110)</span>", "ID": "057ad2d3-9225-4150-b5e4-ab8437d5dc66", "Styles": "None", "Classes": "None", "Text": "(n\u00a0=\u00a0110)", "ParentId": "b0e19b32-3d8b-4a4b-9892-bf9d5807c9dd"}, {"Element": "<td style=\"width:108.65pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0113)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(p value)</span></p>\n</td>", "ID": "19ab931e-7797-43f0-b850-fc579b8dceb1", "Styles": "width:108.65pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "8643b56f-579e-40b5-a340-18fbe03c45c5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab Maintenance</span></p>", "ID": "19fc7980-4d91-4e9f-a6f8-afbf3d3d15b6", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "19ab931e-7797-43f0-b850-fc579b8dceb1"}, {"Element": "<span lang=\"EN-GB\">Infliximab Maintenance</span>", "ID": "927da35e-af74-4b83-a672-029747b1df02", "Styles": "None", "Classes": "None", "Text": "Infliximab Maintenance", "ParentId": "19fc7980-4d91-4e9f-a6f8-afbf3d3d15b6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>", "ID": "9fafba4a-df71-4383-83fd-94f80a5f7394", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "19ab931e-7797-43f0-b850-fc579b8dceb1"}, {"Element": "<span lang=\"EN-GB\">5\u00a0mg/kg</span>", "ID": "c7610082-4316-4e59-a748-c026bfe694d5", "Styles": "None", "Classes": "None", "Text": "5\u00a0mg/kg", "ParentId": "9fafba4a-df71-4383-83fd-94f80a5f7394"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0113)</span></p>", "ID": "10c0bdba-8281-4943-ad7f-e204e45fd54e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "19ab931e-7797-43f0-b850-fc579b8dceb1"}, {"Element": "<span lang=\"EN-GB\">(n\u00a0=\u00a0113)</span>", "ID": "9a580834-0786-4964-8ddb-87f4df8c369a", "Styles": "None", "Classes": "None", "Text": "(n\u00a0=\u00a0113)", "ParentId": "10c0bdba-8281-4943-ad7f-e204e45fd54e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(p value)</span></p>", "ID": "0754d5da-f267-429f-b555-d719245f4240", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "19ab931e-7797-43f0-b850-fc579b8dceb1"}, {"Element": "<span lang=\"EN-GB\">(p value)</span>", "ID": "7142a33c-7e7d-4ca6-b3e6-b4e5daf00ebb", "Styles": "None", "Classes": "None", "Text": "(p value)", "ParentId": "0754d5da-f267-429f-b555-d719245f4240"}, {"Element": "<td style=\"width:108.65pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0112)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(p value)</span></p>\n</td>", "ID": "bd0d650f-2386-4828-9d73-e501215906c0", "Styles": "width:108.65pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "8643b56f-579e-40b5-a340-18fbe03c45c5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>", "ID": "21b76ad6-0031-4a7f-9448-da1c7e9e831a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd0d650f-2386-4828-9d73-e501215906c0"}, {"Element": "<span lang=\"EN-GB\">Infliximab</span>", "ID": "daa4e13b-dc9e-4d26-b9f6-be1df292e73d", "Styles": "None", "Classes": "None", "Text": "Infliximab", "ParentId": "21b76ad6-0031-4a7f-9448-da1c7e9e831a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>", "ID": "e276252a-dc3d-4d1e-a78d-f532c1d999f9", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd0d650f-2386-4828-9d73-e501215906c0"}, {"Element": "<span lang=\"EN-GB\">Maintenance</span>", "ID": "f885b7c4-38db-4389-9f50-f813b2ac8817", "Styles": "None", "Classes": "None", "Text": "Maintenance", "ParentId": "e276252a-dc3d-4d1e-a78d-f532c1d999f9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10\u00a0mg/kg</span></p>", "ID": "0c9b877f-1eb6-484b-b2ba-171a4d2ca6f1", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd0d650f-2386-4828-9d73-e501215906c0"}, {"Element": "<span lang=\"EN-GB\">10\u00a0mg/kg</span>", "ID": "786eba8d-0562-4604-8e49-cfe51b27aaac", "Styles": "None", "Classes": "None", "Text": "10\u00a0mg/kg", "ParentId": "0c9b877f-1eb6-484b-b2ba-171a4d2ca6f1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a0112)</span></p>", "ID": "07c574c9-cb84-4e79-9d4c-93d504e50d57", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd0d650f-2386-4828-9d73-e501215906c0"}, {"Element": "<span lang=\"EN-GB\">(n\u00a0=\u00a0112)</span>", "ID": "9cf2e8c7-8da3-4a43-8df4-184e3e651bee", "Styles": "None", "Classes": "None", "Text": "(n\u00a0=\u00a0112)", "ParentId": "07c574c9-cb84-4e79-9d4c-93d504e50d57"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(p value)</span></p>", "ID": "3dff61ac-6885-4e4d-bcb7-f4f8ad696383", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd0d650f-2386-4828-9d73-e501215906c0"}, {"Element": "<span lang=\"EN-GB\">(p value)</span>", "ID": "139ee9d1-48e6-4de4-948c-bd0fefe98ca0", "Styles": "None", "Classes": "None", "Text": "(p value)", "ParentId": "3dff61ac-6885-4e4d-bcb7-f4f8ad696383"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median time to loss of response through week\u00a054</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19\u00a0weeks</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38\u00a0weeks</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.002)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&gt;\u00a054\u00a0weeks</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>", "ID": "8f22e7f4-62a1-4eb1-9ea0-45342fe52077", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median time to loss of response through week\u00a054</span></p>\n</td>", "ID": "4a593b43-b2f6-4ef2-bb4e-42850f0f2407", "Styles": "width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f22e7f4-62a1-4eb1-9ea0-45342fe52077"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median time to loss of response through week\u00a054</span></p>", "ID": "6b1a6df1-9edd-4fa8-8fb0-dbd47091b41a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4a593b43-b2f6-4ef2-bb4e-42850f0f2407"}, {"Element": "<span lang=\"EN-GB\">Median time to loss of response through week\u00a054</span>", "ID": "cf9ece3b-a6bd-42fa-99c2-9ef1ac32d54d", "Styles": "None", "Classes": "None", "Text": "Median time to loss of response through week\u00a054", "ParentId": "6b1a6df1-9edd-4fa8-8fb0-dbd47091b41a"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19\u00a0weeks</span></p>\n</td>", "ID": "4b2ce658-9a7d-44e2-8722-d03224d249a3", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f22e7f4-62a1-4eb1-9ea0-45342fe52077"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19\u00a0weeks</span></p>", "ID": "753a9100-f8c3-48df-9844-b31952fe1b08", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4b2ce658-9a7d-44e2-8722-d03224d249a3"}, {"Element": "<span lang=\"EN-GB\">19\u00a0weeks</span>", "ID": "5f3da3e5-f694-47b7-9e74-667a974ab155", "Styles": "None", "Classes": "None", "Text": "19\u00a0weeks", "ParentId": "753a9100-f8c3-48df-9844-b31952fe1b08"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38\u00a0weeks</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.002)</span></p>\n</td>", "ID": "080c2092-ebc7-45da-afed-376f5f60226c", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "8f22e7f4-62a1-4eb1-9ea0-45342fe52077"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38\u00a0weeks</span></p>", "ID": "6bad4cfd-001a-4108-b2fc-876881a2ce8a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "080c2092-ebc7-45da-afed-376f5f60226c"}, {"Element": "<span lang=\"EN-GB\">38\u00a0weeks</span>", "ID": "b6c3b325-22b2-4106-927e-f346523651c3", "Styles": "None", "Classes": "None", "Text": "38\u00a0weeks", "ParentId": "6bad4cfd-001a-4108-b2fc-876881a2ce8a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.002)</span></p>", "ID": "24cf652e-025b-4d7e-8111-821024015252", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "080c2092-ebc7-45da-afed-376f5f60226c"}, {"Element": "<span lang=\"EN-GB\">(0.002)</span>", "ID": "a4e93371-7188-431b-b621-afebaf3309f0", "Styles": "None", "Classes": "None", "Text": "(0.002)", "ParentId": "24cf652e-025b-4d7e-8111-821024015252"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&gt;\u00a054\u00a0weeks</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>", "ID": "0bfebbbe-37a6-4897-be6b-44cd99badb3f", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "8f22e7f4-62a1-4eb1-9ea0-45342fe52077"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&gt;\u00a054\u00a0weeks</span></p>", "ID": "eaed7e14-a338-456e-94ba-3b68694c7f04", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0bfebbbe-37a6-4897-be6b-44cd99badb3f"}, {"Element": "<span lang=\"EN-GB\">&gt;\u00a054\u00a0weeks</span>", "ID": "632707e8-3d59-4962-850d-b56df3782838", "Styles": "None", "Classes": "None", "Text": ">\u00a054\u00a0weeks", "ParentId": "eaed7e14-a338-456e-94ba-3b68694c7f04"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>", "ID": "feb1b424-d540-4903-83e9-f53d0080064a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0bfebbbe-37a6-4897-be6b-44cd99badb3f"}, {"Element": "<span lang=\"EN-GB\">(&lt;\u00a00.001)</span>", "ID": "ea90183d-9bf9-496d-a738-acdd72cb9d1b", "Styles": "None", "Classes": "None", "Text": "(<\u00a00.001)", "ParentId": "feb1b424-d540-4903-83e9-f53d0080064a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a030</span></b></p>\n</td>\n</tr>", "ID": "ead93101-bf2c-4e27-86a5-50f08b53e16d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a030</span></b></p>\n</td>", "ID": "1740286b-4ad6-4d83-b893-6b8d03f9af95", "Styles": "width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ead93101-bf2c-4e27-86a5-50f08b53e16d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a030</span></b></p>", "ID": "92fbd3bb-0387-41a7-84b2-fbd943d70f78", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1740286b-4ad6-4d83-b893-6b8d03f9af95"}, {"Element": "<b><span lang=\"EN-GB\">Week\u00a030</span></b>", "ID": "55fd2496-3986-4ab0-bbe3-f0846f3008d7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "92fbd3bb-0387-41a7-84b2-fbd943d70f78"}, {"Element": "<span lang=\"EN-GB\">Week\u00a030</span>", "ID": "fe25aced-f882-45fb-b5d8-aeffd233c1b3", "Styles": "None", "Classes": "None", "Text": "Week\u00a030", "ParentId": "55fd2496-3986-4ab0-bbe3-f0846f3008d7"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Response<sup>a</sup></span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.3</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">51.3</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">59.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>", "ID": "133fd3b9-08f1-4cae-bb0a-f1029d4adddf", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Response<sup>a</sup></span></p>\n</td>", "ID": "7b0086da-ce9a-46c4-a02b-c0c01f937ab6", "Styles": "width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "133fd3b9-08f1-4cae-bb0a-f1029d4adddf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Response<sup>a</sup></span></p>", "ID": "0e29e749-6b58-4e6a-a787-436f342d282e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b0086da-ce9a-46c4-a02b-c0c01f937ab6"}, {"Element": "<span lang=\"EN-GB\">Clinical Response<sup>a</sup></span>", "ID": "655bdf21-ccb8-4973-b087-11b5d0b3f0f7", "Styles": "None", "Classes": "None", "Text": "Clinical Response", "ParentId": "0e29e749-6b58-4e6a-a787-436f342d282e"}, {"Element": "<sup>a</sup>", "ID": "38f105c0-e63f-4029-96a7-7bb112355a8c", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "655bdf21-ccb8-4973-b087-11b5d0b3f0f7"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.3</span></p>\n</td>", "ID": "05ab552d-cb0a-4925-9086-86ec4b0fcde4", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "133fd3b9-08f1-4cae-bb0a-f1029d4adddf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.3</span></p>", "ID": "a4864f26-31be-4d13-b663-388bff6a6544", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "05ab552d-cb0a-4925-9086-86ec4b0fcde4"}, {"Element": "<span lang=\"EN-GB\">27.3</span>", "ID": "310bcc76-2134-46cd-ad5a-6a23dc8803fd", "Styles": "None", "Classes": "None", "Text": "27.3", "ParentId": "a4864f26-31be-4d13-b663-388bff6a6544"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">51.3</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>", "ID": "0ae80689-e7a4-4126-bd2a-a6dc1625fe68", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "133fd3b9-08f1-4cae-bb0a-f1029d4adddf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">51.3</span></p>", "ID": "6dc595e2-b0e6-4688-823f-d8eb8ad5e342", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0ae80689-e7a4-4126-bd2a-a6dc1625fe68"}, {"Element": "<span lang=\"EN-GB\">51.3</span>", "ID": "5230f680-8ee4-410a-8521-5e970a8227dd", "Styles": "None", "Classes": "None", "Text": "51.3", "ParentId": "6dc595e2-b0e6-4688-823f-d8eb8ad5e342"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>", "ID": "36098fd9-8ea5-4bf2-a7c1-6ec1e2729682", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0ae80689-e7a4-4126-bd2a-a6dc1625fe68"}, {"Element": "<span lang=\"EN-GB\">(&lt;\u00a00.001)</span>", "ID": "6bb5edf1-1930-4874-af94-980677960449", "Styles": "None", "Classes": "None", "Text": "(<\u00a00.001)", "ParentId": "36098fd9-8ea5-4bf2-a7c1-6ec1e2729682"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">59.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>", "ID": "1095ce74-29da-4c1c-8072-40e4ab74dffd", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "133fd3b9-08f1-4cae-bb0a-f1029d4adddf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">59.1</span></p>", "ID": "b939f46e-c4ff-44bb-92f5-3b9f52485cc4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1095ce74-29da-4c1c-8072-40e4ab74dffd"}, {"Element": "<span lang=\"EN-GB\">59.1</span>", "ID": "cb2198bd-9744-474c-801d-c6b27a8624cc", "Styles": "None", "Classes": "None", "Text": "59.1", "ParentId": "b939f46e-c4ff-44bb-92f5-3b9f52485cc4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>", "ID": "82af4f72-45af-40e8-a082-861e5fab915d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1095ce74-29da-4c1c-8072-40e4ab74dffd"}, {"Element": "<span lang=\"EN-GB\">(&lt;\u00a00.001)</span>", "ID": "c3ba6d4c-31ce-4f81-befc-21030d5e3eb5", "Styles": "None", "Classes": "None", "Text": "(<\u00a00.001)", "ParentId": "82af4f72-45af-40e8-a082-861e5fab915d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Remission</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">20.9</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.9</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.003)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>", "ID": "44a78f81-9fc9-4b6e-bff3-4d03cdb2e433", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Remission</span></p>\n</td>", "ID": "7ceafa58-8153-4bb2-aec0-aa2d89aa7ea4", "Styles": "width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "44a78f81-9fc9-4b6e-bff3-4d03cdb2e433"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Remission</span></p>", "ID": "38fca588-d536-4605-b678-65c13ffe5fdb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7ceafa58-8153-4bb2-aec0-aa2d89aa7ea4"}, {"Element": "<span lang=\"EN-GB\">Clinical Remission</span>", "ID": "1d65b71e-f0c1-4254-a39c-d7c28747bb9b", "Styles": "None", "Classes": "None", "Text": "Clinical Remission", "ParentId": "38fca588-d536-4605-b678-65c13ffe5fdb"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">20.9</span></p>\n</td>", "ID": "35c29da0-935e-4ff5-898c-34286e844726", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "44a78f81-9fc9-4b6e-bff3-4d03cdb2e433"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">20.9</span></p>", "ID": "8b951b56-7974-42b6-b894-889e86b435a6", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "35c29da0-935e-4ff5-898c-34286e844726"}, {"Element": "<span lang=\"EN-GB\">20.9</span>", "ID": "2e738cde-c58a-4d1a-a6d4-16455674eae6", "Styles": "None", "Classes": "None", "Text": "20.9", "ParentId": "8b951b56-7974-42b6-b894-889e86b435a6"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.9</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.003)</span></p>\n</td>", "ID": "52f0a860-234a-484e-8041-20c1d343e8f6", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "44a78f81-9fc9-4b6e-bff3-4d03cdb2e433"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.9</span></p>", "ID": "fb048410-ba8d-471d-9d5d-07695702c6cd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52f0a860-234a-484e-8041-20c1d343e8f6"}, {"Element": "<span lang=\"EN-GB\">38.9</span>", "ID": "6af569fb-ffa7-4a39-8a95-3d8a49b1a371", "Styles": "None", "Classes": "None", "Text": "38.9", "ParentId": "fb048410-ba8d-471d-9d5d-07695702c6cd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.003)</span></p>", "ID": "75e77a5a-26cd-44ab-aad0-851a199da724", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "52f0a860-234a-484e-8041-20c1d343e8f6"}, {"Element": "<span lang=\"EN-GB\">(0.003)</span>", "ID": "bc8ed1e4-469b-48ee-9553-db5c553d3c5d", "Styles": "None", "Classes": "None", "Text": "(0.003)", "ParentId": "75e77a5a-26cd-44ab-aad0-851a199da724"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45.5</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>", "ID": "09c7b550-999e-450c-853d-3b211e980029", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "44a78f81-9fc9-4b6e-bff3-4d03cdb2e433"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45.5</span></p>", "ID": "8cbcf99c-7927-494b-9832-6096705fb351", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "09c7b550-999e-450c-853d-3b211e980029"}, {"Element": "<span lang=\"EN-GB\">45.5</span>", "ID": "7b28f97f-1771-4e3b-a679-8dadbdcb7466", "Styles": "None", "Classes": "None", "Text": "45.5", "ParentId": "8cbcf99c-7927-494b-9832-6096705fb351"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>", "ID": "f5f31466-2a86-471b-a930-9944e3c07bd8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "09c7b550-999e-450c-853d-3b211e980029"}, {"Element": "<span lang=\"EN-GB\">(&lt;\u00a00.001)</span>", "ID": "e25ed959-9fb3-42c0-aa95-8505170456cc", "Styles": "None", "Classes": "None", "Text": "(<\u00a00.001)", "ParentId": "f5f31466-2a86-471b-a930-9944e3c07bd8"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Steroid\u2011Free Remission</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">10.7\n  (6/56)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">31.0\n  (18/58)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.008)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.8\n  (21/57)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.001)</span></p>\n</td>\n</tr>", "ID": "1709c2b7-aebf-47fc-b348-2ced77d46d99", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Steroid\u2011Free Remission</span></p>\n</td>", "ID": "01e30361-3acb-41e0-87cb-da538b669fed", "Styles": "width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1709c2b7-aebf-47fc-b348-2ced77d46d99"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Steroid\u2011Free Remission</span></p>", "ID": "462e1f44-4481-4fdc-a6ba-a84f6e4e8c0e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "01e30361-3acb-41e0-87cb-da538b669fed"}, {"Element": "<span lang=\"EN-GB\">Steroid\u2011Free Remission</span>", "ID": "95b1a360-178b-4d31-9b27-f17066293b51", "Styles": "None", "Classes": "None", "Text": "Steroid\u2011Free Remission", "ParentId": "462e1f44-4481-4fdc-a6ba-a84f6e4e8c0e"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">10.7\n  (6/56)</span></p>\n</td>", "ID": "8894394a-21ee-4c8f-a38e-9fa77acb4fd6", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "1709c2b7-aebf-47fc-b348-2ced77d46d99"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">10.7\n  (6/56)</span></p>", "ID": "5ada26ab-2c4f-4cde-8b98-44fc07179fe2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8894394a-21ee-4c8f-a38e-9fa77acb4fd6"}, {"Element": "<span lang=\"EN-GB\">10.7\n  (6/56)</span>", "ID": "b2f61d2e-be11-4bdb-958a-c108d843f8a7", "Styles": "None", "Classes": "None", "Text": "10.7   (6/56)", "ParentId": "5ada26ab-2c4f-4cde-8b98-44fc07179fe2"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">31.0\n  (18/58)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.008)</span></p>\n</td>", "ID": "fd0c1db7-d216-4d26-9ba9-ea62601952db", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "1709c2b7-aebf-47fc-b348-2ced77d46d99"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">31.0\n  (18/58)</span></p>", "ID": "e24ef4c3-79b1-4f74-ab89-232d0773a839", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd0c1db7-d216-4d26-9ba9-ea62601952db"}, {"Element": "<span lang=\"EN-GB\">31.0\n  (18/58)</span>", "ID": "b38edf03-f126-4cbc-a5a7-7a068f2aba58", "Styles": "None", "Classes": "None", "Text": "31.0   (18/58)", "ParentId": "e24ef4c3-79b1-4f74-ab89-232d0773a839"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.008)</span></p>", "ID": "4caee34e-a764-417f-aa11-ba76c3154196", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd0c1db7-d216-4d26-9ba9-ea62601952db"}, {"Element": "<span lang=\"EN-GB\">(0.008)</span>", "ID": "36a3b111-0259-4463-a5ab-069e49e0223a", "Styles": "None", "Classes": "None", "Text": "(0.008)", "ParentId": "4caee34e-a764-417f-aa11-ba76c3154196"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.8\n  (21/57)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.001)</span></p>\n</td>", "ID": "958137c5-87f4-47fe-a760-84cf56705185", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "1709c2b7-aebf-47fc-b348-2ced77d46d99"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.8\n  (21/57)</span></p>", "ID": "1d704a98-5c49-4c1e-87d7-ba798aae0df6", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "958137c5-87f4-47fe-a760-84cf56705185"}, {"Element": "<span lang=\"EN-GB\">36.8\n  (21/57)</span>", "ID": "f80498f4-d633-4fdf-8090-ee480abf0444", "Styles": "None", "Classes": "None", "Text": "36.8   (21/57)", "ParentId": "1d704a98-5c49-4c1e-87d7-ba798aae0df6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.001)</span></p>", "ID": "eb862d64-0a8f-4f6f-9e67-e76536f7c1ff", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "958137c5-87f4-47fe-a760-84cf56705185"}, {"Element": "<span lang=\"EN-GB\">(0.001)</span>", "ID": "efae87dd-389f-46fd-9261-3c531de63a44", "Styles": "None", "Classes": "None", "Text": "(0.001)", "ParentId": "eb862d64-0a8f-4f6f-9e67-e76536f7c1ff"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a054</span></b></p>\n</td>\n</tr>", "ID": "e4c322d3-71fa-4382-ace7-8a476b232c1f", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a054</span></b></p>\n</td>", "ID": "458421b8-4173-4f75-b750-445fed590405", "Styles": "width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e4c322d3-71fa-4382-ace7-8a476b232c1f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a054</span></b></p>", "ID": "98a7e923-ee08-4e5b-817e-3946856431a3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "458421b8-4173-4f75-b750-445fed590405"}, {"Element": "<b><span lang=\"EN-GB\">Week\u00a054</span></b>", "ID": "4136c54b-f6c0-4911-af89-b5939e1a71ed", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "98a7e923-ee08-4e5b-817e-3946856431a3"}, {"Element": "<span lang=\"EN-GB\">Week\u00a054</span>", "ID": "0e31d00f-6b4e-4bde-80e1-9b30f35b5721", "Styles": "None", "Classes": "None", "Text": "Week\u00a054", "ParentId": "4136c54b-f6c0-4911-af89-b5939e1a71ed"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Response<sup>a</sup></span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15.5</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47.7</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>", "ID": "0d750ce5-27ed-417c-b86d-2fcebbef9292", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Response<sup>a</sup></span></p>\n</td>", "ID": "5536f94a-4d3c-4c86-94ca-0bbfeefe21bc", "Styles": "width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0d750ce5-27ed-417c-b86d-2fcebbef9292"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Response<sup>a</sup></span></p>", "ID": "ef26306f-0b7d-4efb-bde9-f72983ea6441", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5536f94a-4d3c-4c86-94ca-0bbfeefe21bc"}, {"Element": "<span lang=\"EN-GB\">Clinical Response<sup>a</sup></span>", "ID": "dcf75952-d740-415e-adff-0dd71f2feedd", "Styles": "None", "Classes": "None", "Text": "Clinical Response", "ParentId": "ef26306f-0b7d-4efb-bde9-f72983ea6441"}, {"Element": "<sup>a</sup>", "ID": "a3796438-e72e-4613-8975-c5175bff959e", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "dcf75952-d740-415e-adff-0dd71f2feedd"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15.5</span></p>\n</td>", "ID": "97d4d7a1-ce68-4967-8966-9ce61f30461e", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0d750ce5-27ed-417c-b86d-2fcebbef9292"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15.5</span></p>", "ID": "9c9e7631-7930-4ea5-a8fd-97c1e3925441", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "97d4d7a1-ce68-4967-8966-9ce61f30461e"}, {"Element": "<span lang=\"EN-GB\">15.5</span>", "ID": "a09695be-fe70-45a5-9577-7654f6eb8540", "Styles": "None", "Classes": "None", "Text": "15.5", "ParentId": "9c9e7631-7930-4ea5-a8fd-97c1e3925441"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.1</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>", "ID": "634a26f5-9381-46be-849b-7b7e4d6bf111", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "0d750ce5-27ed-417c-b86d-2fcebbef9292"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.1</span></p>", "ID": "ef449956-9e4d-46d8-8f6f-fcb1d6e13183", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "634a26f5-9381-46be-849b-7b7e4d6bf111"}, {"Element": "<span lang=\"EN-GB\">38.1</span>", "ID": "1777d88d-c653-4838-9296-e9aadd815eea", "Styles": "None", "Classes": "None", "Text": "38.1", "ParentId": "ef449956-9e4d-46d8-8f6f-fcb1d6e13183"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>", "ID": "f4f311ef-88ec-4e91-a31e-82b3715a7e68", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "634a26f5-9381-46be-849b-7b7e4d6bf111"}, {"Element": "<span lang=\"EN-GB\">(&lt;\u00a00.001)</span>", "ID": "749b4308-1f45-42ca-8317-f000b83dbb84", "Styles": "None", "Classes": "None", "Text": "(<\u00a00.001)", "ParentId": "f4f311ef-88ec-4e91-a31e-82b3715a7e68"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47.7</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>", "ID": "e47ffc6a-6f2e-451a-9e12-f59a3984a4a6", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "0d750ce5-27ed-417c-b86d-2fcebbef9292"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47.7</span></p>", "ID": "d73cad00-1fec-4d72-a32a-65e12bfe77aa", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e47ffc6a-6f2e-451a-9e12-f59a3984a4a6"}, {"Element": "<span lang=\"EN-GB\">47.7</span>", "ID": "8b9ee046-a838-48c5-bfa1-69d4006c1229", "Styles": "None", "Classes": "None", "Text": "47.7", "ParentId": "d73cad00-1fec-4d72-a32a-65e12bfe77aa"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>", "ID": "27214c15-8c1e-4c3f-bda2-40fea82d3a07", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e47ffc6a-6f2e-451a-9e12-f59a3984a4a6"}, {"Element": "<span lang=\"EN-GB\">(&lt;\u00a00.001)</span>", "ID": "21cc202d-7c6d-47e6-bbe3-7ed3478aad70", "Styles": "None", "Classes": "None", "Text": "(<\u00a00.001)", "ParentId": "27214c15-8c1e-4c3f-bda2-40fea82d3a07"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Remission</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13.6</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">28.3</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.007)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.4</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>\n</tr>", "ID": "9250714f-221b-44a9-968c-67d94f66bd0d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td style=\"width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Remission</span></p>\n</td>", "ID": "f5f99edb-59c1-4c94-a9b6-8b47da168e6f", "Styles": "width:127.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9250714f-221b-44a9-968c-67d94f66bd0d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical Remission</span></p>", "ID": "118ddaf5-3025-4f9c-be34-94cc2cb7b74f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f5f99edb-59c1-4c94-a9b6-8b47da168e6f"}, {"Element": "<span lang=\"EN-GB\">Clinical Remission</span>", "ID": "59d9ce32-c135-485b-9aae-6634e63de38a", "Styles": "None", "Classes": "None", "Text": "Clinical Remission", "ParentId": "118ddaf5-3025-4f9c-be34-94cc2cb7b74f"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13.6</span></p>\n</td>", "ID": "77d2dfb0-2986-4679-9ca2-84209f514d3a", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9250714f-221b-44a9-968c-67d94f66bd0d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13.6</span></p>", "ID": "02acfefc-94ab-4b8c-b9c9-c6a9180a9928", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "77d2dfb0-2986-4679-9ca2-84209f514d3a"}, {"Element": "<span lang=\"EN-GB\">13.6</span>", "ID": "95c9093e-b3b0-40cd-b409-c180b1d886bb", "Styles": "None", "Classes": "None", "Text": "13.6", "ParentId": "02acfefc-94ab-4b8c-b9c9-c6a9180a9928"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">28.3</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.007)</span></p>\n</td>", "ID": "a0085564-a5cd-4c76-8c05-a998d06ff290", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "9250714f-221b-44a9-968c-67d94f66bd0d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">28.3</span></p>", "ID": "916ce372-069a-410a-87a3-25270b4704ca", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a0085564-a5cd-4c76-8c05-a998d06ff290"}, {"Element": "<span lang=\"EN-GB\">28.3</span>", "ID": "4b4c2d9d-9167-4486-9d1c-b5cc806186ce", "Styles": "None", "Classes": "None", "Text": "28.3", "ParentId": "916ce372-069a-410a-87a3-25270b4704ca"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.007)</span></p>", "ID": "9eed9bf1-34d3-4cff-a7ff-9ae3bc78febc", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a0085564-a5cd-4c76-8c05-a998d06ff290"}, {"Element": "<span lang=\"EN-GB\">(0.007)</span>", "ID": "be682e10-e961-475f-be95-0fd0da875bc9", "Styles": "None", "Classes": "None", "Text": "(0.007)", "ParentId": "9eed9bf1-34d3-4cff-a7ff-9ae3bc78febc"}, {"Element": "<td style=\"width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.4</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>\n</td>", "ID": "3eb71b3e-3156-401a-8fd5-5c35856d472f", "Styles": "width:108.65pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "9250714f-221b-44a9-968c-67d94f66bd0d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">38.4</span></p>", "ID": "e3e209c9-1afa-45fd-a9c7-248ad534b054", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3eb71b3e-3156-401a-8fd5-5c35856d472f"}, {"Element": "<span lang=\"EN-GB\">38.4</span>", "ID": "c946ece8-6bbb-4735-949b-f490f4f44e90", "Styles": "None", "Classes": "None", "Text": "38.4", "ParentId": "e3e209c9-1afa-45fd-a9c7-248ad534b054"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(&lt;\u00a00.001)</span></p>", "ID": "f5e4d56a-65a3-4f71-abea-7491bcc67147", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3eb71b3e-3156-401a-8fd5-5c35856d472f"}, {"Element": "<span lang=\"EN-GB\">(&lt;\u00a00.001)</span>", "ID": "aa5b3cc9-223a-4d4b-b30f-3899446a12b8", "Styles": "None", "Classes": "None", "Text": "(<\u00a00.001)", "ParentId": "f5e4d56a-65a3-4f71-abea-7491bcc67147"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:127.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained Steroid\u2011Free Remission<sup>b</sup></span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5.7\n  (3/53)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">17.9\n  (10/56)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.075)</span></p>\n</td>\n<td style=\"width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">28.6\n  (16/56)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.002)</span></p>\n</td>\n</tr>", "ID": "5dbec6f1-3c13-4763-814c-91e689c7c339", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td style=\"width:127.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained Steroid\u2011Free Remission<sup>b</sup></span></p>\n</td>", "ID": "2aaba70b-7da8-4b8c-bd33-ef41b43a10d9", "Styles": "width:127.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5dbec6f1-3c13-4763-814c-91e689c7c339"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained Steroid\u2011Free Remission<sup>b</sup></span></p>", "ID": "97a8559f-c60b-4ba6-aae4-6fd5559ccaa9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2aaba70b-7da8-4b8c-bd33-ef41b43a10d9"}, {"Element": "<span lang=\"EN-GB\">Sustained Steroid\u2011Free Remission<sup>b</sup></span>", "ID": "12b1fbdf-c185-48f6-bb27-8c3b0dc4a05f", "Styles": "None", "Classes": "None", "Text": "Sustained Steroid\u2011Free Remission", "ParentId": "97a8559f-c60b-4ba6-aae4-6fd5559ccaa9"}, {"Element": "<sup>b</sup>", "ID": "7ed38c89-f797-4fc9-92cd-574892169e37", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "12b1fbdf-c185-48f6-bb27-8c3b0dc4a05f"}, {"Element": "<td style=\"width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5.7\n  (3/53)</span></p>\n</td>", "ID": "cf5f62fd-43e9-4a7f-aadc-c5d11e8e7d7b", "Styles": "width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5dbec6f1-3c13-4763-814c-91e689c7c339"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5.7\n  (3/53)</span></p>", "ID": "05b5978f-d75d-4aa5-a06a-7365ce7e544d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf5f62fd-43e9-4a7f-aadc-c5d11e8e7d7b"}, {"Element": "<span lang=\"EN-GB\">5.7\n  (3/53)</span>", "ID": "b3a2b36c-b3ed-40ff-8699-dad3df08cda2", "Styles": "None", "Classes": "None", "Text": "5.7   (3/53)", "ParentId": "05b5978f-d75d-4aa5-a06a-7365ce7e544d"}, {"Element": "<td style=\"width:108.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">17.9\n  (10/56)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.075)</span></p>\n</td>", "ID": "f2567d7d-429e-441f-b424-c19c2bee13e3", "Styles": "width:108.65pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "5dbec6f1-3c13-4763-814c-91e689c7c339"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">17.9\n  (10/56)</span></p>", "ID": "0c470a9e-2912-40c9-ac01-0e9234f94cd4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f2567d7d-429e-441f-b424-c19c2bee13e3"}, {"Element": "<span lang=\"EN-GB\">17.9\n  (10/56)</span>", "ID": "018a7b88-a9d2-499c-805f-7c12066c81e9", "Styles": "None", "Classes": "None", "Text": "17.9   (10/56)", "ParentId": "0c470a9e-2912-40c9-ac01-0e9234f94cd4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.075)</span></p>", "ID": "20de627e-09d5-427b-8fd2-8d9f81f61897", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f2567d7d-429e-441f-b424-c19c2bee13e3"}, {"Element": "<span lang=\"EN-GB\">(0.075)</span>", "ID": "b5df2a04-0306-4fee-ba91-e1f68c044983", "Styles": "None", "Classes": "None", "Text": "(0.075)", "ParentId": "20de627e-09d5-427b-8fd2-8d9f81f61897"}, {"Element": "<td style=\"width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" width=\"145\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">28.6\n  (16/56)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.002)</span></p>\n</td>", "ID": "538b0fc0-bba7-4b8a-80c0-2e7f364ac499", "Styles": "width:108.65pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "5dbec6f1-3c13-4763-814c-91e689c7c339"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">28.6\n  (16/56)</span></p>", "ID": "55d64a6e-8397-4b9d-861e-9ea60742bbb5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "538b0fc0-bba7-4b8a-80c0-2e7f364ac499"}, {"Element": "<span lang=\"EN-GB\">28.6\n  (16/56)</span>", "ID": "e3e36cb2-5766-42fc-83d3-7bebffb6ca21", "Styles": "None", "Classes": "None", "Text": "28.6   (16/56)", "ParentId": "55d64a6e-8397-4b9d-861e-9ea60742bbb5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(0.002)</span></p>", "ID": "a7d5d6db-4510-46b1-961f-23e8b6d93e79", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "538b0fc0-bba7-4b8a-80c0-2e7f364ac499"}, {"Element": "<span lang=\"EN-GB\">(0.002)</span>", "ID": "ae847bad-40fa-4d51-a08d-c43332a1ae52", "Styles": "None", "Classes": "None", "Text": "(0.002)", "ParentId": "a7d5d6db-4510-46b1-961f-23e8b6d93e79"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Reduction\n  in CDAI \u2265\u00a025% and \u2265\u00a070\u00a0points.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 CDAI\u00a0&lt;\u00a0150\n  at both week\u00a030 and 54 and not receiving corticosteroids in the\n  3\u00a0months prior to week\u00a054 among patients who were receiving\n  corticosteroids at baseline.</span></p>\n</td>\n</tr>", "ID": "64bc63ae-88e4-47ac-94e2-20fb5aff7ff4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "98242987-5310-42c5-8682-c42c7651a2b2"}, {"Element": "<td colspan=\"4\" style=\"width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Reduction\n  in CDAI \u2265\u00a025% and \u2265\u00a070\u00a0points.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 CDAI\u00a0&lt;\u00a0150\n  at both week\u00a030 and 54 and not receiving corticosteroids in the\n  3\u00a0months prior to week\u00a054 among patients who were receiving\n  corticosteroids at baseline.</span></p>\n</td>", "ID": "02305f9b-3008-4cf2-a9be-b9a023034f09", "Styles": "width:6.3in;border:none;padding:\n  0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "64bc63ae-88e4-47ac-94e2-20fb5aff7ff4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Reduction\n  in CDAI \u2265\u00a025% and \u2265\u00a070\u00a0points.</span></p>", "ID": "e5f95544-1ab3-44ea-b11a-93fcf67f7aee", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "02305f9b-3008-4cf2-a9be-b9a023034f09"}, {"Element": "<sup><span lang=\"EN-GB\">a</span></sup>", "ID": "13ce5289-99a4-4336-b6cd-e3d355498c11", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e5f95544-1ab3-44ea-b11a-93fcf67f7aee"}, {"Element": "<span lang=\"EN-GB\">a</span>", "ID": "f0f1be3f-ed2c-46a3-9b21-4eeb7392534e", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "13ce5289-99a4-4336-b6cd-e3d355498c11"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Reduction\n  in CDAI \u2265\u00a025% and \u2265\u00a070\u00a0points.</span>", "ID": "040ed054-e571-4f15-9b80-c8878f047dbb", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 Reduction   in CDAI \u2265\u00a025% and \u2265\u00a070\u00a0points.", "ParentId": "e5f95544-1ab3-44ea-b11a-93fcf67f7aee"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 CDAI\u00a0&lt;\u00a0150\n  at both week\u00a030 and 54 and not receiving corticosteroids in the\n  3\u00a0months prior to week\u00a054 among patients who were receiving\n  corticosteroids at baseline.</span></p>", "ID": "f31f7871-8675-4411-8efb-7e5738195b34", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "02305f9b-3008-4cf2-a9be-b9a023034f09"}, {"Element": "<sup><span lang=\"EN-GB\">b</span></sup>", "ID": "a2deeff0-fe19-43cf-a431-cc2d49048a5e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f31f7871-8675-4411-8efb-7e5738195b34"}, {"Element": "<span lang=\"EN-GB\">b</span>", "ID": "0df3b03a-3bf9-4b83-8690-85ab0d6462eb", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "a2deeff0-fe19-43cf-a431-cc2d49048a5e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 CDAI\u00a0&lt;\u00a0150\n  at both week\u00a030 and 54 and not receiving corticosteroids in the\n  3\u00a0months prior to week\u00a054 among patients who were receiving\n  corticosteroids at baseline.</span>", "ID": "b44127f2-c03b-4d79-8c51-4db9efde7d1b", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 CDAI\u00a0<\u00a0150   at both week\u00a030 and 54 and not receiving corticosteroids in the   3\u00a0months prior to week\u00a054 among patients who were receiving   corticosteroids at baseline.", "ParentId": "f31f7871-8675-4411-8efb-7e5738195b34"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d36d51ea-a29c-48b8-af19-c0370140174c", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c151f7c6-7690-473d-9f88-ed99215b6077", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d36d51ea-a29c-48b8-af19-c0370140174c"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Beginning at\nweek\u00a014, patients who had responded to treatment, but subsequently lost\ntheir clinical benefit, were allowed to cross over to a dose of infliximab 5\u00a0mg/kg\nhigher than the dose to which they were originally randomised. Eighty\u00a0nine\npercent (50/56) of patients who lost clinical response on infliximab 5\u00a0mg/kg\nmaintenance therapy after week\u00a014 responded to treatment with infliximab\n10\u00a0mg/kg.</span></p>", "ID": "dda095ad-6692-4bb6-9b99-c8055a9f52cc", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Beginning at\nweek\u00a014, patients who had responded to treatment, but subsequently lost\ntheir clinical benefit, were allowed to cross over to a dose of infliximab 5\u00a0mg/kg\nhigher than the dose to which they were originally randomised. Eighty\u00a0nine\npercent (50/56) of patients who lost clinical response on infliximab 5\u00a0mg/kg\nmaintenance therapy after week\u00a014 responded to treatment with infliximab\n10\u00a0mg/kg.</span>", "ID": "dc740082-b786-4d36-bf9a-1d8e978225e0", "Styles": "None", "Classes": "None", "Text": "Beginning at week\u00a014, patients who had responded to treatment, but subsequently lost their clinical benefit, were allowed to cross over to a dose of infliximab 5\u00a0mg/kg higher than the dose to which they were originally randomised. Eighty\u00a0nine percent (50/56) of patients who lost clinical response on infliximab 5\u00a0mg/kg maintenance therapy after week\u00a014 responded to treatment with infliximab 10\u00a0mg/kg.", "ParentId": "dda095ad-6692-4bb6-9b99-c8055a9f52cc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9c4f6629-cb1c-4dcb-ab5e-1c8a4ae7f917", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c0bd6dfc-4e6c-4a2b-a1c2-0980bd31cf16", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9c4f6629-cb1c-4dcb-ab5e-1c8a4ae7f917"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Improvements in quality of life measures, a\nreduction in disease\u2011related hospitalisations and corticosteroid use were\nseen in the infliximab maintenance groups compared with the placebo maintenance\ngroup at weeks\u00a030 and 54.</span></p>", "ID": "39e3a6e8-d98e-47e6-baf0-7d13ba1082db", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Improvements in quality of life measures, a\nreduction in disease\u2011related hospitalisations and corticosteroid use were\nseen in the infliximab maintenance groups compared with the placebo maintenance\ngroup at weeks\u00a030 and 54.</span>", "ID": "8dd7ea48-b0ae-41a4-a657-5df0506ae60a", "Styles": "None", "Classes": "None", "Text": "Improvements in quality of life measures, a reduction in disease\u2011related hospitalisations and corticosteroid use were seen in the infliximab maintenance groups compared with the placebo maintenance group at weeks\u00a030 and 54.", "ParentId": "39e3a6e8-d98e-47e6-baf0-7d13ba1082db"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1a660ac6-89b6-44f4-925a-23418bedc537", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "00e67e5b-1d48-4f1e-ad0d-ef42b7c6a556", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1a660ac6-89b6-44f4-925a-23418bedc537"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab with or without AZA was assessed\nin a randomised, double\u2011blind, active comparator study (SONIC) of 508\u00a0adult\npatients with moderate to severe Crohn\u2019s disease (CDAI\u00a0\u2265\u00a0220\u00a0\u2264\u00a0450)\nwho were naive to biologics and immunosuppressants </span><span lang=\"EN-GB\">and\nhad a median disease duration of 2.3\u00a0years. </span><span lang=\"EN-GB\">At\nbaseline 27.4% of patients were receiving systemic corticosteroids, 14.2% of\npatients were receiving budesonide, and 54.3% of patients were receiving 5\u2011ASA\ncompounds. Patients were randomised to receive AZA monotherapy, infliximab\nmonotherapy, or infliximab plus AZA combination therapy. Infliximab was\nadministered at a dose of 5\u00a0mg/kg at weeks\u00a00, 2, 6, and then every 8\u00a0weeks.\nAZA was given at a dose of 2.5\u00a0mg/kg daily.</span></p>", "ID": "71bb0f8a-04ae-4fbc-9271-883112050748", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infliximab with or without AZA was assessed\nin a randomised, double\u2011blind, active comparator study (SONIC) of 508\u00a0adult\npatients with moderate to severe Crohn\u2019s disease (CDAI\u00a0\u2265\u00a0220\u00a0\u2264\u00a0450)\nwho were naive to biologics and immunosuppressants </span>", "ID": "637628d6-ae1e-477e-85ac-f39ce204f1ca", "Styles": "None", "Classes": "None", "Text": "Infliximab with or without AZA was assessed in a randomised, double\u2011blind, active comparator study (SONIC) of 508\u00a0adult patients with moderate to severe Crohn\u2019s disease (CDAI\u00a0\u2265\u00a0220\u00a0\u2264\u00a0450) who were naive to biologics and immunosuppressants ", "ParentId": "71bb0f8a-04ae-4fbc-9271-883112050748"}, {"Element": "<span lang=\"EN-GB\">and\nhad a median disease duration of 2.3\u00a0years. </span>", "ID": "01a87d9d-99dc-41aa-bebf-4890d79ab3e6", "Styles": "None", "Classes": "None", "Text": "and had a median disease duration of 2.3\u00a0years. ", "ParentId": "71bb0f8a-04ae-4fbc-9271-883112050748"}, {"Element": "<span lang=\"EN-GB\">At\nbaseline 27.4% of patients were receiving systemic corticosteroids, 14.2% of\npatients were receiving budesonide, and 54.3% of patients were receiving 5\u2011ASA\ncompounds. Patients were randomised to receive AZA monotherapy, infliximab\nmonotherapy, or infliximab plus AZA combination therapy. Infliximab was\nadministered at a dose of 5\u00a0mg/kg at weeks\u00a00, 2, 6, and then every 8\u00a0weeks.\nAZA was given at a dose of 2.5\u00a0mg/kg daily.</span>", "ID": "c24e435f-aae6-49ba-9589-50df86765b51", "Styles": "None", "Classes": "None", "Text": "At baseline 27.4% of patients were receiving systemic corticosteroids, 14.2% of patients were receiving budesonide, and 54.3% of patients were receiving 5\u2011ASA compounds. Patients were randomised to receive AZA monotherapy, infliximab monotherapy, or infliximab plus AZA combination therapy. Infliximab was administered at a dose of 5\u00a0mg/kg at weeks\u00a00, 2, 6, and then every 8\u00a0weeks. AZA was given at a dose of 2.5\u00a0mg/kg daily.", "ParentId": "71bb0f8a-04ae-4fbc-9271-883112050748"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4c346a8a-49e0-496a-9616-696b6d1ed0ef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0124369a-fde6-424d-a995-9aeb814312af", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4c346a8a-49e0-496a-9616-696b6d1ed0ef"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The primary endpoint of the study was\ncorticosteroid\u2011free clinical remission at week\u00a026, defined as\npatients in clinical remission (CDAI of &lt;\u00a0150) who, for at least\n3\u00a0weeks, had not taken oral systemic corticosteroids (prednisone or\nequivalent) or budesonide at a dose &gt;\u00a06\u00a0mg/day. For results see\nTable\u00a06. The proportions of patients with mucosal healing at week\u00a026\u00a0were\nsignificantly greater in the infliximab plus AZA combination (43.9%,\np\u00a0&lt;\u00a00.001) and infliximab monotherapy groups (30.1%, p\u00a0=\u00a00.023)\ncompared to the AZA monotherapy group (16.5%).</span></p>", "ID": "ba10fff2-2a5f-458a-9eb0-56cb5f6abeb7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The primary endpoint of the study was\ncorticosteroid\u2011free clinical remission at week\u00a026, defined as\npatients in clinical remission (CDAI of &lt;\u00a0150) who, for at least\n3\u00a0weeks, had not taken oral systemic corticosteroids (prednisone or\nequivalent) or budesonide at a dose &gt;\u00a06\u00a0mg/day. For results see\nTable\u00a06. The proportions of patients with mucosal healing at week\u00a026\u00a0were\nsignificantly greater in the infliximab plus AZA combination (43.9%,\np\u00a0&lt;\u00a00.001) and infliximab monotherapy groups (30.1%, p\u00a0=\u00a00.023)\ncompared to the AZA monotherapy group (16.5%).</span>", "ID": "91f11eb3-d054-4c21-a2e9-058a4cd0767a", "Styles": "None", "Classes": "None", "Text": "The primary endpoint of the study was corticosteroid\u2011free clinical remission at week\u00a026, defined as patients in clinical remission (CDAI of <\u00a0150) who, for at least 3\u00a0weeks, had not taken oral systemic corticosteroids (prednisone or equivalent) or budesonide at a dose >\u00a06\u00a0mg/day. For results see Table\u00a06. The proportions of patients with mucosal healing at week\u00a026\u00a0were significantly greater in the infliximab plus AZA combination (43.9%, p\u00a0<\u00a00.001) and infliximab monotherapy groups (30.1%, p\u00a0=\u00a00.023) compared to the AZA monotherapy group (16.5%).", "ParentId": "ba10fff2-2a5f-458a-9eb0-56cb5f6abeb7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "95231fd3-c88f-4302-a258-a12a2b46bbf1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "89de8e9b-ce94-40e3-9a06-bf8a13d9d299", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "95231fd3-c88f-4302-a258-a12a2b46bbf1"}, {"Element": "<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a06</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Percent of patients achieving corticosteroid\u2011free\n  clinical remission at week\u00a026, SONIC</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"185\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">AZA</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab + AZA</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combination Therapy</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a026</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"185\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">All randomised patients</span></p>\n</td>\n<td style=\"width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">30.0%\n  (51/170)</span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">44.4%\n  (75/169)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(p\u00a0=\u00a00.006)<sup>*</sup></span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56.8%\n  (96/169)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(p\u00a0&lt;\u00a00.001)<sup>*</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 P\u2011values\n  represent each infliximab treatment group vs. AZA monotherapy.</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "31355fbc-edf1-480d-986d-3876044f413f", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a06</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Percent of patients achieving corticosteroid\u2011free\n  clinical remission at week\u00a026, SONIC</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"185\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">AZA</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab + AZA</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combination Therapy</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a026</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"185\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">All randomised patients</span></p>\n</td>\n<td style=\"width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">30.0%\n  (51/170)</span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">44.4%\n  (75/169)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(p\u00a0=\u00a00.006)<sup>*</sup></span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56.8%\n  (96/169)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(p\u00a0&lt;\u00a00.001)<sup>*</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 P\u2011values\n  represent each infliximab treatment group vs. AZA monotherapy.</span></p>\n</td>\n</tr>\n</table>", "ID": "639a6c29-c23a-45da-9245-56fc7b1d3fe2", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "      ", "ParentId": "31355fbc-edf1-480d-986d-3876044f413f"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a06</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Percent of patients achieving corticosteroid\u2011free\n  clinical remission at week\u00a026, SONIC</span></b></p>\n</td>\n</tr>", "ID": "152369bb-7c26-4b87-a4dc-f4cc33290f9a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "639a6c29-c23a-45da-9245-56fc7b1d3fe2"}, {"Element": "<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a06</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Percent of patients achieving corticosteroid\u2011free\n  clinical remission at week\u00a026, SONIC</span></b></p>\n</td>", "ID": "397199ba-1f34-4548-b7b5-4c84e5af4bc8", "Styles": "width:453.55pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "152369bb-7c26-4b87-a4dc-f4cc33290f9a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a06</span></b></p>", "ID": "8a6d69b4-f79f-4d8f-bf11-a5f24bdaa192", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "397199ba-1f34-4548-b7b5-4c84e5af4bc8"}, {"Element": "<b><span lang=\"EN-GB\">Table\u00a06</span></b>", "ID": "2be43ee1-f346-4f56-ad17-9c47183dd9a1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8a6d69b4-f79f-4d8f-bf11-a5f24bdaa192"}, {"Element": "<span lang=\"EN-GB\">Table\u00a06</span>", "ID": "9de90c02-6619-4117-aa23-c571e0c4cd87", "Styles": "None", "Classes": "None", "Text": "Table\u00a06", "ParentId": "2be43ee1-f346-4f56-ad17-9c47183dd9a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Percent of patients achieving corticosteroid\u2011free\n  clinical remission at week\u00a026, SONIC</span></b></p>", "ID": "117326e2-965f-4c57-8e7e-3e631c166e48", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "397199ba-1f34-4548-b7b5-4c84e5af4bc8"}, {"Element": "<b><span lang=\"EN-GB\">Percent of patients achieving corticosteroid\u2011free\n  clinical remission at week\u00a026, SONIC</span></b>", "ID": "4393fedc-a275-459a-9053-433db21969c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "117326e2-965f-4c57-8e7e-3e631c166e48"}, {"Element": "<span lang=\"EN-GB\">Percent of patients achieving corticosteroid\u2011free\n  clinical remission at week\u00a026, SONIC</span>", "ID": "56c02213-c915-453b-b684-cc8956a2d30d", "Styles": "None", "Classes": "None", "Text": "Percent of patients achieving corticosteroid\u2011free   clinical remission at week\u00a026, SONIC", "ParentId": "4393fedc-a275-459a-9053-433db21969c0"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"185\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">AZA</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab + AZA</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combination Therapy</span></p>\n</td>\n</tr>", "ID": "33341e4d-270e-4adc-bc6a-e9594c2ce952", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "639a6c29-c23a-45da-9245-56fc7b1d3fe2"}, {"Element": "<td style=\"width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"185\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "1c5e014f-b938-41fd-91b3-cb753e58d540", "Styles": "width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "33341e4d-270e-4adc-bc6a-e9594c2ce952"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0c933e22-0e9a-473f-a71a-f8625e424634", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1c5e014f-b938-41fd-91b3-cb753e58d540"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a1c51e0d-88da-4d1f-8d6f-5d01ca5f5dfd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0c933e22-0e9a-473f-a71a-f8625e424634"}, {"Element": "<td style=\"width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">AZA</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>\n</td>", "ID": "f9c10ab5-15ea-4d9d-ba05-d44d95211902", "Styles": "width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "33341e4d-270e-4adc-bc6a-e9594c2ce952"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">AZA</span></p>", "ID": "9d535a35-2383-4e18-8ea7-3bd919af1388", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f9c10ab5-15ea-4d9d-ba05-d44d95211902"}, {"Element": "<span lang=\"EN-GB\">AZA</span>", "ID": "aba29401-f660-48e7-bb66-9c4dd03191e8", "Styles": "None", "Classes": "None", "Text": "AZA", "ParentId": "9d535a35-2383-4e18-8ea7-3bd919af1388"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>", "ID": "ba4f30f1-bbd4-4e49-aa13-e90566fdb0e1", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f9c10ab5-15ea-4d9d-ba05-d44d95211902"}, {"Element": "<span lang=\"EN-GB\">Monotherapy</span>", "ID": "c45a06a6-e8e6-44c2-8800-7755112b1484", "Styles": "None", "Classes": "None", "Text": "Monotherapy", "ParentId": "ba4f30f1-bbd4-4e49-aa13-e90566fdb0e1"}, {"Element": "<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>\n</td>", "ID": "a974e6eb-9126-4e82-b77c-b024f3bb4a09", "Styles": "width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "33341e4d-270e-4adc-bc6a-e9594c2ce952"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>", "ID": "adfe0aff-b3dc-4d61-b625-f240961f981c", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a974e6eb-9126-4e82-b77c-b024f3bb4a09"}, {"Element": "<span lang=\"EN-GB\">Infliximab</span>", "ID": "db8a64ab-b7db-450d-bb40-3f40ed8e55cb", "Styles": "None", "Classes": "None", "Text": "Infliximab", "ParentId": "adfe0aff-b3dc-4d61-b625-f240961f981c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Monotherapy</span></p>", "ID": "e04c8d16-7230-45fd-bb26-4274566af1ae", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a974e6eb-9126-4e82-b77c-b024f3bb4a09"}, {"Element": "<span lang=\"EN-GB\">Monotherapy</span>", "ID": "04beac4a-c9b5-4629-9217-755c8bfba6c1", "Styles": "None", "Classes": "None", "Text": "Monotherapy", "ParentId": "e04c8d16-7230-45fd-bb26-4274566af1ae"}, {"Element": "<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab + AZA</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combination Therapy</span></p>\n</td>", "ID": "e879072e-4b0e-48ae-b38e-94d731419672", "Styles": "width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "33341e4d-270e-4adc-bc6a-e9594c2ce952"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab + AZA</span></p>", "ID": "b5bb30c2-5673-44af-b75b-9d00fa35fbd6", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e879072e-4b0e-48ae-b38e-94d731419672"}, {"Element": "<span lang=\"EN-GB\">Infliximab + AZA</span>", "ID": "5679cae8-9477-47f2-b34c-f86005d6586b", "Styles": "None", "Classes": "None", "Text": "Infliximab + AZA", "ParentId": "b5bb30c2-5673-44af-b75b-9d00fa35fbd6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combination Therapy</span></p>", "ID": "18174a5f-1d4e-4458-a8f1-c6136c457adf", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e879072e-4b0e-48ae-b38e-94d731419672"}, {"Element": "<span lang=\"EN-GB\">Combination Therapy</span>", "ID": "69358150-107f-45c4-996e-e122c377351c", "Styles": "None", "Classes": "None", "Text": "Combination Therapy", "ParentId": "18174a5f-1d4e-4458-a8f1-c6136c457adf"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a026</span></b></p>\n</td>\n</tr>", "ID": "a11af617-e61a-43bd-8b6d-69965a262e38", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "639a6c29-c23a-45da-9245-56fc7b1d3fe2"}, {"Element": "<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"bottom\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a026</span></b></p>\n</td>", "ID": "fe0796f6-5ff5-4c85-a95b-8869897bbbb1", "Styles": "width:453.55pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "a11af617-e61a-43bd-8b6d-69965a262e38"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a026</span></b></p>", "ID": "8ad3f4c2-fefc-4654-b127-ed09a244bbf3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fe0796f6-5ff5-4c85-a95b-8869897bbbb1"}, {"Element": "<b><span lang=\"EN-GB\">Week\u00a026</span></b>", "ID": "bb107507-dd6e-410b-bec2-5b170aebd5b1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8ad3f4c2-fefc-4654-b127-ed09a244bbf3"}, {"Element": "<span lang=\"EN-GB\">Week\u00a026</span>", "ID": "95343dde-fae5-421f-96f8-dc232b11484e", "Styles": "None", "Classes": "None", "Text": "Week\u00a026", "ParentId": "bb107507-dd6e-410b-bec2-5b170aebd5b1"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"185\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">All randomised patients</span></p>\n</td>\n<td style=\"width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">30.0%\n  (51/170)</span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">44.4%\n  (75/169)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(p\u00a0=\u00a00.006)<sup>*</sup></span></p>\n</td>\n<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56.8%\n  (96/169)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(p\u00a0&lt;\u00a00.001)<sup>*</sup></span></p>\n</td>\n</tr>", "ID": "73a83dd7-2e04-4455-81fa-8557b7ad1875", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "639a6c29-c23a-45da-9245-56fc7b1d3fe2"}, {"Element": "<td style=\"width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"185\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">All randomised patients</span></p>\n</td>", "ID": "6fa89c62-6613-4604-9a22-02a00c993d72", "Styles": "width:138.6pt;border:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "73a83dd7-2e04-4455-81fa-8557b7ad1875"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">All randomised patients</span></p>", "ID": "880efcff-98ac-42c4-b35d-bbb65ea0b5d7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6fa89c62-6613-4604-9a22-02a00c993d72"}, {"Element": "<span lang=\"EN-GB\">All randomised patients</span>", "ID": "7fe13239-be37-4407-8745-ba3e5259f845", "Styles": "None", "Classes": "None", "Text": "All randomised patients", "ParentId": "880efcff-98ac-42c4-b35d-bbb65ea0b5d7"}, {"Element": "<td style=\"width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">30.0%\n  (51/170)</span></p>\n</td>", "ID": "e8b865e4-a408-404a-95c9-ffea5e749b68", "Styles": "width:104.95pt;border:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "73a83dd7-2e04-4455-81fa-8557b7ad1875"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">30.0%\n  (51/170)</span></p>", "ID": "638cf7e4-bc27-41ef-a401-a6eac731b59e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e8b865e4-a408-404a-95c9-ffea5e749b68"}, {"Element": "<span lang=\"EN-GB\">30.0%\n  (51/170)</span>", "ID": "9e92777c-f20c-4d65-b976-16dbec40ec4d", "Styles": "None", "Classes": "None", "Text": "30.0%   (51/170)", "ParentId": "638cf7e4-bc27-41ef-a401-a6eac731b59e"}, {"Element": "<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">44.4%\n  (75/169)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(p\u00a0=\u00a00.006)<sup>*</sup></span></p>\n</td>", "ID": "ff73dea4-b230-4eed-bd17-64873d5804f9", "Styles": "width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "73a83dd7-2e04-4455-81fa-8557b7ad1875"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">44.4%\n  (75/169)</span></p>", "ID": "9477b3be-9f9e-41cb-8505-7b10d0a9a009", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff73dea4-b230-4eed-bd17-64873d5804f9"}, {"Element": "<span lang=\"EN-GB\">44.4%\n  (75/169)</span>", "ID": "241a9a79-74bc-48ed-aff3-d5c0f24ad5f4", "Styles": "None", "Classes": "None", "Text": "44.4%   (75/169)", "ParentId": "9477b3be-9f9e-41cb-8505-7b10d0a9a009"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(p\u00a0=\u00a00.006)<sup>*</sup></span></p>", "ID": "ac36de08-20f7-4210-9aae-5d7d4ba48067", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff73dea4-b230-4eed-bd17-64873d5804f9"}, {"Element": "<span lang=\"EN-GB\">(p\u00a0=\u00a00.006)<sup>*</sup></span>", "ID": "acc4155a-dee9-40da-8dfc-f7b471bea7fb", "Styles": "None", "Classes": "None", "Text": "(p\u00a0=\u00a00.006)", "ParentId": "ac36de08-20f7-4210-9aae-5d7d4ba48067"}, {"Element": "<sup>*</sup>", "ID": "cc61dd27-000c-4f6b-9027-d5a15bf2185e", "Styles": "None", "Classes": "None", "Text": "*", "ParentId": "acc4155a-dee9-40da-8dfc-f7b471bea7fb"}, {"Element": "<td style=\"width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"140\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56.8%\n  (96/169)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(p\u00a0&lt;\u00a00.001)<sup>*</sup></span></p>\n</td>", "ID": "367e6c16-7e9e-4880-8209-b2ef10ceccaa", "Styles": "width:105.0pt;border:none;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "   ", "ParentId": "73a83dd7-2e04-4455-81fa-8557b7ad1875"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">56.8%\n  (96/169)</span></p>", "ID": "f9e824e8-fe88-45d3-b881-ca5ec3f07f8a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "367e6c16-7e9e-4880-8209-b2ef10ceccaa"}, {"Element": "<span lang=\"EN-GB\">56.8%\n  (96/169)</span>", "ID": "22be753d-fabd-40aa-add8-25e7fcd1e35f", "Styles": "None", "Classes": "None", "Text": "56.8%   (96/169)", "ParentId": "f9e824e8-fe88-45d3-b881-ca5ec3f07f8a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(p\u00a0&lt;\u00a00.001)<sup>*</sup></span></p>", "ID": "9d36caf9-4480-4ffa-ad44-c0ce10f6cc28", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "367e6c16-7e9e-4880-8209-b2ef10ceccaa"}, {"Element": "<span lang=\"EN-GB\">(p\u00a0&lt;\u00a00.001)<sup>*</sup></span>", "ID": "1cc467d6-aa25-4b59-b213-cc4c5d829c47", "Styles": "None", "Classes": "None", "Text": "(p\u00a0<\u00a00.001)", "ParentId": "9d36caf9-4480-4ffa-ad44-c0ce10f6cc28"}, {"Element": "<sup>*</sup>", "ID": "699bff6f-8d84-438a-b390-4b3bdb752703", "Styles": "None", "Classes": "None", "Text": "*", "ParentId": "1cc467d6-aa25-4b59-b213-cc4c5d829c47"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 P\u2011values\n  represent each infliximab treatment group vs. AZA monotherapy.</span></p>\n</td>\n</tr>", "ID": "d27f708e-9fec-42c9-a5f3-19747beed894", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "639a6c29-c23a-45da-9245-56fc7b1d3fe2"}, {"Element": "<td colspan=\"4\" style=\"width:453.55pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 P\u2011values\n  represent each infliximab treatment group vs. AZA monotherapy.</span></p>\n</td>", "ID": "da7ac8d0-e3a3-4669-b5d5-1b64bb1f2e55", "Styles": "width:453.55pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "d27f708e-9fec-42c9-a5f3-19747beed894"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 P\u2011values\n  represent each infliximab treatment group vs. AZA monotherapy.</span></p>", "ID": "971204af-5d85-4053-960d-71d4326a698b", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da7ac8d0-e3a3-4669-b5d5-1b64bb1f2e55"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 P\u2011values\n  represent each infliximab treatment group vs. AZA monotherapy.</span>", "ID": "2e020da7-2443-4956-8e63-515ae7fb8191", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "*\u00a0\u00a0\u00a0 P\u2011values   represent each infliximab treatment group vs. AZA monotherapy.", "ParentId": "971204af-5d85-4053-960d-71d4326a698b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "52579499-2e6a-4759-baf6-43082e9cf2b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d30f6b39-ccfa-4b45-87a3-cfaf49152c6b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "52579499-2e6a-4759-baf6-43082e9cf2b8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Similar trends in the achievement of\ncorticosteroid\u2011free clinical remission were observed at week\u00a050. </span><span lang=\"EN-GB\">Furthermore, improved quality of life as measured by IBDQ was\nobserved with infliximab.</span></p>", "ID": "b593b904-3da6-460c-b184-2b9ec499fe82", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Similar trends in the achievement of\ncorticosteroid\u2011free clinical remission were observed at week\u00a050. </span>", "ID": "71301c7b-ea38-4666-842b-83e7e533e06c", "Styles": "None", "Classes": "None", "Text": "Similar trends in the achievement of corticosteroid\u2011free clinical remission were observed at week\u00a050. ", "ParentId": "b593b904-3da6-460c-b184-2b9ec499fe82"}, {"Element": "<span lang=\"EN-GB\">Furthermore, improved quality of life as measured by IBDQ was\nobserved with infliximab.</span>", "ID": "6475491f-3c9e-46a5-a852-f5a276adc507", "Styles": "None", "Classes": "None", "Text": "Furthermore, improved quality of life as measured by IBDQ was observed with infliximab.", "ParentId": "b593b904-3da6-460c-b184-2b9ec499fe82"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b679992b-c7b9-4cd5-98b5-cd84a48c3ee8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "272c0b13-1355-4725-807b-d8285c7c127c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b679992b-c7b9-4cd5-98b5-cd84a48c3ee8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Induction\ntreatment in fistulising active Crohn\u2019s disease</span></i></p>", "ID": "56f062a8-804c-4da6-9171-a7a5e6cfbe15", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Induction\ntreatment in fistulising active Crohn\u2019s disease</span></i>", "ID": "84e7cf21-dbd3-4294-924d-913bb123fd70", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "56f062a8-804c-4da6-9171-a7a5e6cfbe15"}, {"Element": "<span lang=\"EN-GB\">Induction\ntreatment in fistulising active Crohn\u2019s disease</span>", "ID": "86777963-7fc1-45dd-8e80-cbace83b343d", "Styles": "None", "Classes": "None", "Text": "Induction treatment in fistulising active Crohn\u2019s disease", "ParentId": "84e7cf21-dbd3-4294-924d-913bb123fd70"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy was assessed in a randomised,\ndouble\u2011blinded, placebo\u2011controlled study in 94\u00a0patients with\nfistulising Crohn\u2019s disease who had fistulae that were of at least\n3\u00a0months\u2019 duration. Thirty\u00a0one of these patients were treated\nwith infliximab 5\u00a0mg/kg. Approximately 93% of the patients had previously\nreceived antibiotic or immunosuppressive therapy.</span></p>", "ID": "38497b23-435a-4c04-8221-2aaec1ed7a0e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The efficacy was assessed in a randomised,\ndouble\u2011blinded, placebo\u2011controlled study in 94\u00a0patients with\nfistulising Crohn\u2019s disease who had fistulae that were of at least\n3\u00a0months\u2019 duration. Thirty\u00a0one of these patients were treated\nwith infliximab 5\u00a0mg/kg. Approximately 93% of the patients had previously\nreceived antibiotic or immunosuppressive therapy.</span>", "ID": "4075cbae-5842-4727-9a4d-51c8fef3d693", "Styles": "None", "Classes": "None", "Text": "The efficacy was assessed in a randomised, double\u2011blinded, placebo\u2011controlled study in 94\u00a0patients with fistulising Crohn\u2019s disease who had fistulae that were of at least 3\u00a0months\u2019 duration. Thirty\u00a0one of these patients were treated with infliximab 5\u00a0mg/kg. Approximately 93% of the patients had previously received antibiotic or immunosuppressive therapy.", "ParentId": "38497b23-435a-4c04-8221-2aaec1ed7a0e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ec360c08-3387-439b-99ef-b5d65d78405c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "596f5363-11bf-4551-b9d6-9f4cf5e59b91", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ec360c08-3387-439b-99ef-b5d65d78405c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Concurrent use of stable doses of\nconventional therapies was permitted, and 83% of patients continued to receive\nat least one of these therapies. Patients received three doses of either\nplacebo or infliximab at weeks\u00a00, 2 and 6. Patients were followed up to 26\u00a0weeks.\nThe primary endpoint was the proportion of patients who experienced a clinical\nresponse, defined as\u00a0\u2265\u00a050% reduction from baseline in the\nnumber of fistulae draining upon gentle compression on at least two consecutive\nvisits (4\u00a0weeks apart), without an increase in the use of medicinal\nproducts or surgery for Crohn\u2019s disease.</span></p>", "ID": "277114ad-986e-4b10-bcf6-6a842bc170dd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Concurrent use of stable doses of\nconventional therapies was permitted, and 83% of patients continued to receive\nat least one of these therapies. Patients received three doses of either\nplacebo or infliximab at weeks\u00a00, 2 and 6. Patients were followed up to 26\u00a0weeks.\nThe primary endpoint was the proportion of patients who experienced a clinical\nresponse, defined as\u00a0\u2265\u00a050% reduction from baseline in the\nnumber of fistulae draining upon gentle compression on at least two consecutive\nvisits (4\u00a0weeks apart), without an increase in the use of medicinal\nproducts or surgery for Crohn\u2019s disease.</span>", "ID": "98df394b-a4a1-4a5b-8842-bacb0c203fc4", "Styles": "None", "Classes": "None", "Text": "Concurrent use of stable doses of conventional therapies was permitted, and 83% of patients continued to receive at least one of these therapies. Patients received three doses of either placebo or infliximab at weeks\u00a00, 2 and 6. Patients were followed up to 26\u00a0weeks. The primary endpoint was the proportion of patients who experienced a clinical response, defined as\u00a0\u2265\u00a050% reduction from baseline in the number of fistulae draining upon gentle compression on at least two consecutive visits (4\u00a0weeks apart), without an increase in the use of medicinal products or surgery for Crohn\u2019s disease.", "ParentId": "277114ad-986e-4b10-bcf6-6a842bc170dd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d6d768f1-ddb5-41cb-883e-96c66edf19f0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "94655593-333b-4d32-aaa4-985d0fd892ed", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d6d768f1-ddb5-41cb-883e-96c66edf19f0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sixty\u00a0eight percent (21/31) of\ninfliximab\u2011treated patients receiving a 5\u00a0mg/kg dose regimen\nachieved a clinical response vs. 26% (8/31) placebo\u2011treated patients (p\u00a0=\u00a00.002).\nThe median time to onset of response in the infliximab\u2011treated group was\n2\u00a0weeks. The median duration of response was 12\u00a0weeks. Additionally,\nclosure of all fistulae was achieved in 55% of infliximab\u2011treated\npatients compared with 13% of placebo\u2011treated patients (p\u00a0=\u00a00.001).</span></p>", "ID": "b8887ea2-e2e3-4986-9fd1-4628e3be6845", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Sixty\u00a0eight percent (21/31) of\ninfliximab\u2011treated patients receiving a 5\u00a0mg/kg dose regimen\nachieved a clinical response vs. 26% (8/31) placebo\u2011treated patients (p\u00a0=\u00a00.002).\nThe median time to onset of response in the infliximab\u2011treated group was\n2\u00a0weeks. The median duration of response was 12\u00a0weeks. Additionally,\nclosure of all fistulae was achieved in 55% of infliximab\u2011treated\npatients compared with 13% of placebo\u2011treated patients (p\u00a0=\u00a00.001).</span>", "ID": "46515252-4683-4c0e-bfe6-588bba7d8c62", "Styles": "None", "Classes": "None", "Text": "Sixty\u00a0eight percent (21/31) of infliximab\u2011treated patients receiving a 5\u00a0mg/kg dose regimen achieved a clinical response vs. 26% (8/31) placebo\u2011treated patients (p\u00a0=\u00a00.002). The median time to onset of response in the infliximab\u2011treated group was 2\u00a0weeks. The median duration of response was 12\u00a0weeks. Additionally, closure of all fistulae was achieved in 55% of infliximab\u2011treated patients compared with 13% of placebo\u2011treated patients (p\u00a0=\u00a00.001).", "ParentId": "b8887ea2-e2e3-4986-9fd1-4628e3be6845"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "47465e3a-f58f-4612-bc73-ecb1f70dbb5f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7ccb7ae4-13a7-4047-b138-12d1c41b0a9e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "47465e3a-f58f-4612-bc73-ecb1f70dbb5f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Maintenance\ntreatment in fistulising active Crohn\u2019s disease</span></i></p>", "ID": "677177b4-0b16-46a9-9358-e890a56387a3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Maintenance\ntreatment in fistulising active Crohn\u2019s disease</span></i>", "ID": "8c3e479b-fbe5-487d-8269-bf76fbc6f12e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "677177b4-0b16-46a9-9358-e890a56387a3"}, {"Element": "<span lang=\"EN-GB\">Maintenance\ntreatment in fistulising active Crohn\u2019s disease</span>", "ID": "13005d2c-a3c4-4b4f-97be-4a51a23d8b95", "Styles": "None", "Classes": "None", "Text": "Maintenance treatment in fistulising active Crohn\u2019s disease", "ParentId": "8c3e479b-fbe5-487d-8269-bf76fbc6f12e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of repeated infusions with\ninfliximab in patients with fistulising Crohn\u2019s disease was studied in a\n1\u2011year clinical study (ACCENT II). A total of 306\u00a0patients received\n3\u00a0doses of infliximab 5\u00a0mg/kg at week\u00a00, 2 and 6. At baseline,\n87% of the patients had perianal fistulae, 14% had abdominal fistulae, 9% had\nrectovaginal fistulae. The median CDAI score was 180. At week\u00a014,\n282\u00a0patients were assessed for clinical response and randomised to receive\neither placebo or 5\u00a0mg/kg infliximab every 8\u00a0weeks through week\u00a046.</span></p>", "ID": "e4061754-0ae4-4d29-a2f0-cbe168e7b78c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The efficacy of repeated infusions with\ninfliximab in patients with fistulising Crohn\u2019s disease was studied in a\n1\u2011year clinical study (ACCENT II). A total of 306\u00a0patients received\n3\u00a0doses of infliximab 5\u00a0mg/kg at week\u00a00, 2 and 6. At baseline,\n87% of the patients had perianal fistulae, 14% had abdominal fistulae, 9% had\nrectovaginal fistulae. The median CDAI score was 180. At week\u00a014,\n282\u00a0patients were assessed for clinical response and randomised to receive\neither placebo or 5\u00a0mg/kg infliximab every 8\u00a0weeks through week\u00a046.</span>", "ID": "6756d2b1-3f80-42ba-a7ee-2cc06f306651", "Styles": "None", "Classes": "None", "Text": "The efficacy of repeated infusions with infliximab in patients with fistulising Crohn\u2019s disease was studied in a 1\u2011year clinical study (ACCENT II). A total of 306\u00a0patients received 3\u00a0doses of infliximab 5\u00a0mg/kg at week\u00a00, 2 and 6. At baseline, 87% of the patients had perianal fistulae, 14% had abdominal fistulae, 9% had rectovaginal fistulae. The median CDAI score was 180. At week\u00a014, 282\u00a0patients were assessed for clinical response and randomised to receive either placebo or 5\u00a0mg/kg infliximab every 8\u00a0weeks through week\u00a046.", "ParentId": "e4061754-0ae4-4d29-a2f0-cbe168e7b78c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f6f389db-f354-45ee-8149-f35e739c1e13", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e6f6f858-dcd0-4638-a18c-fa0fe6653b54", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f6f389db-f354-45ee-8149-f35e739c1e13"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u201114\u00a0responders (195/282)\nwere analysed for the primary endpoint, which was time from randomisation to\nloss of response (see Table\u00a07). Corticosteroid tapering was permitted\nafter week\u00a06.</span></p>", "ID": "f9ed52bd-4ebd-4bd9-9856-b647e153d96c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Week\u201114\u00a0responders (195/282)\nwere analysed for the primary endpoint, which was time from randomisation to\nloss of response (see Table\u00a07). Corticosteroid tapering was permitted\nafter week\u00a06.</span>", "ID": "fc6275a5-8e5c-46b5-a557-ff9c35bfcb49", "Styles": "None", "Classes": "None", "Text": "Week\u201114\u00a0responders (195/282) were analysed for the primary endpoint, which was time from randomisation to loss of response (see Table\u00a07). Corticosteroid tapering was permitted after week\u00a06.", "ParentId": "f9ed52bd-4ebd-4bd9-9856-b647e153d96c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c5307d6e-e135-45a9-8cb3-6a190328e7af", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "57c01a6d-9597-4aeb-80cf-beb5f34d6da9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5307d6e-e135-45a9-8cb3-6a190328e7af"}, {"Element": "<div align=\"center\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a07</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on response rate, data from ACCENT II\n  (week\u201114\u00a0responders)</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:265.25pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"354\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ACCENT II\n  (week\u201114\u00a0responders)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:88.4pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a099)</span></p>\n</td>\n<td style=\"width:88.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(5\u00a0mg/kg)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a096)</span></p>\n</td>\n<td style=\"width:88.45pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">p\u2011value</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median time to loss of response<sup> </sup>through\n  week\u00a054</span></p>\n</td>\n<td style=\"width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14\u00a0weeks</span></p>\n</td>\n<td style=\"width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&gt;\u00a040\u00a0weeks</span></p>\n</td>\n<td style=\"width:88.45pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&lt;\u00a00.001</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a054</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Fistula Response (%)<sup>a</sup></span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">23.5</span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46.2</span></p>\n</td>\n<td style=\"width:88.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.001</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Complete fistula response (%)<sup>b</sup></span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.4</span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.3</span></p>\n</td>\n<td style=\"width:88.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.009</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;border-top:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 A\n  \u2265\u00a050% reduction from baseline in the number of draining fistulas\n  over a period of \u2265\u00a04\u00a0weeks.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Absence\n  of any draining fistulas.</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "cbe55613-519a-4ea3-9db4-9bc90df561d4", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a07</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on response rate, data from ACCENT II\n  (week\u201114\u00a0responders)</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:265.25pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"354\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ACCENT II\n  (week\u201114\u00a0responders)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:88.4pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a099)</span></p>\n</td>\n<td style=\"width:88.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(5\u00a0mg/kg)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a096)</span></p>\n</td>\n<td style=\"width:88.45pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">p\u2011value</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median time to loss of response<sup> </sup>through\n  week\u00a054</span></p>\n</td>\n<td style=\"width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14\u00a0weeks</span></p>\n</td>\n<td style=\"width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&gt;\u00a040\u00a0weeks</span></p>\n</td>\n<td style=\"width:88.45pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&lt;\u00a00.001</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a054</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Fistula Response (%)<sup>a</sup></span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">23.5</span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46.2</span></p>\n</td>\n<td style=\"width:88.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.001</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Complete fistula response (%)<sup>b</sup></span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.4</span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.3</span></p>\n</td>\n<td style=\"width:88.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.009</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;border-top:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 A\n  \u2265\u00a050% reduction from baseline in the number of draining fistulas\n  over a period of \u2265\u00a04\u00a0weeks.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Absence\n  of any draining fistulas.</span></p>\n</td>\n</tr>\n</table>", "ID": "f5a5ff13-d983-4a53-8dee-2ef71fe455b9", "Styles": "border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "         ", "ParentId": "cbe55613-519a-4ea3-9db4-9bc90df561d4"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a07</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on response rate, data from ACCENT II\n  (week\u201114\u00a0responders)</span></b></p>\n</td>\n</tr>", "ID": "1274012d-56f4-4f02-a987-428256c9beeb", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "f5a5ff13-d983-4a53-8dee-2ef71fe455b9"}, {"Element": "<td colspan=\"4\" style=\"width:6.3in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a07</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on response rate, data from ACCENT II\n  (week\u201114\u00a0responders)</span></b></p>\n</td>", "ID": "e26f5dcb-51a9-4773-8de8-76d5c260f88d", "Styles": "width:6.3in;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "1274012d-56f4-4f02-a987-428256c9beeb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a07</span></b></p>", "ID": "715fe7c4-9405-4372-b660-d6f438bba7c7", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e26f5dcb-51a9-4773-8de8-76d5c260f88d"}, {"Element": "<b><span lang=\"EN-GB\">Table\u00a07</span></b>", "ID": "edb63e4d-3056-4bb9-b923-96bef6d6ce20", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "715fe7c4-9405-4372-b660-d6f438bba7c7"}, {"Element": "<span lang=\"EN-GB\">Table\u00a07</span>", "ID": "f6e7fa6b-357e-4cf1-8894-cfa58535d1be", "Styles": "None", "Classes": "None", "Text": "Table\u00a07", "ParentId": "edb63e4d-3056-4bb9-b923-96bef6d6ce20"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on response rate, data from ACCENT II\n  (week\u201114\u00a0responders)</span></b></p>", "ID": "1bba6d55-b5a6-43b2-abde-e1979b8af1f6", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e26f5dcb-51a9-4773-8de8-76d5c260f88d"}, {"Element": "<b><span lang=\"EN-GB\">Effects on response rate, data from ACCENT II\n  (week\u201114\u00a0responders)</span></b>", "ID": "ed14cbb7-099f-40f6-8350-36772896343c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1bba6d55-b5a6-43b2-abde-e1979b8af1f6"}, {"Element": "<span lang=\"EN-GB\">Effects on response rate, data from ACCENT II\n  (week\u201114\u00a0responders)</span>", "ID": "c70ab4b6-23c3-41b2-a2ab-7e1e96899c57", "Styles": "None", "Classes": "None", "Text": "Effects on response rate, data from ACCENT II   (week\u201114\u00a0responders)", "ParentId": "ed14cbb7-099f-40f6-8350-36772896343c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"3\" style=\"width:265.25pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"354\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ACCENT II\n  (week\u201114\u00a0responders)</span></p>\n</td>\n</tr>", "ID": "da4eeb9b-2b72-4dd1-9164-6e4f477da9a4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "f5a5ff13-d983-4a53-8dee-2ef71fe455b9"}, {"Element": "<td style=\"width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "b68f74d3-6188-46c0-9024-70de9ca6f6bf", "Styles": "width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "da4eeb9b-2b72-4dd1-9164-6e4f477da9a4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "210fbb08-4bb0-4719-9d16-f256588be35f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b68f74d3-6188-46c0-9024-70de9ca6f6bf"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0ec1216c-a731-4e02-8517-0bb9c3879b36", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "210fbb08-4bb0-4719-9d16-f256588be35f"}, {"Element": "<td colspan=\"3\" style=\"width:265.25pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"354\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ACCENT II\n  (week\u201114\u00a0responders)</span></p>\n</td>", "ID": "0ff89db3-b51b-43fa-8305-972d2b27de70", "Styles": "width:265.25pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "da4eeb9b-2b72-4dd1-9164-6e4f477da9a4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ACCENT II\n  (week\u201114\u00a0responders)</span></p>", "ID": "76f296bc-ce1e-4cf0-8a98-0e95ad6b99b6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0ff89db3-b51b-43fa-8305-972d2b27de70"}, {"Element": "<span lang=\"EN-GB\">ACCENT II\n  (week\u201114\u00a0responders)</span>", "ID": "462ac741-00f5-423a-b392-63b03a3cca9d", "Styles": "None", "Classes": "None", "Text": "ACCENT II   (week\u201114\u00a0responders)", "ParentId": "76f296bc-ce1e-4cf0-8a98-0e95ad6b99b6"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:88.4pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a099)</span></p>\n</td>\n<td style=\"width:88.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(5\u00a0mg/kg)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a096)</span></p>\n</td>\n<td style=\"width:88.45pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">p\u2011value</span></p>\n</td>\n</tr>", "ID": "d27fca35-bd72-4c53-bc88-07397570b51d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "f5a5ff13-d983-4a53-8dee-2ef71fe455b9"}, {"Element": "<td style=\"width:188.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "1b78f9f3-b983-4f90-9f92-12ca400cba5e", "Styles": "width:188.35pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d27fca35-bd72-4c53-bc88-07397570b51d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9ab8ca16-c8d3-4fcc-8548-755c2685d8e9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1b78f9f3-b983-4f90-9f92-12ca400cba5e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8d3a7758-2b81-4dae-b69d-c43d913b640f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9ab8ca16-c8d3-4fcc-8548-755c2685d8e9"}, {"Element": "<td style=\"width:88.4pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a099)</span></p>\n</td>", "ID": "5c05576c-3196-43d5-ab35-55c72943121f", "Styles": "width:88.4pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "d27fca35-bd72-4c53-bc88-07397570b51d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo</span></p>", "ID": "6b5d2a6f-3043-4bb0-a95c-f30fb9fa9aa5", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5c05576c-3196-43d5-ab35-55c72943121f"}, {"Element": "<span lang=\"EN-GB\">Placebo</span>", "ID": "ac3acdfc-36f9-461e-a998-59108bf6a0a2", "Styles": "None", "Classes": "None", "Text": "Placebo", "ParentId": "6b5d2a6f-3043-4bb0-a95c-f30fb9fa9aa5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>", "ID": "b63ff122-08dd-46a6-ba81-91bf494f1562", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5c05576c-3196-43d5-ab35-55c72943121f"}, {"Element": "<span lang=\"EN-GB\">Maintenance</span>", "ID": "35510b5f-68c9-4a28-a103-346181a9d42f", "Styles": "None", "Classes": "None", "Text": "Maintenance", "ParentId": "b63ff122-08dd-46a6-ba81-91bf494f1562"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a099)</span></p>", "ID": "1e77f881-cd1a-48cf-900d-c2f9636dfb5d", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5c05576c-3196-43d5-ab35-55c72943121f"}, {"Element": "<span lang=\"EN-GB\">(n\u00a0=\u00a099)</span>", "ID": "3a2f06f6-7dba-4acd-8868-b6d6df0aa6bc", "Styles": "None", "Classes": "None", "Text": "(n\u00a0=\u00a099)", "ParentId": "1e77f881-cd1a-48cf-900d-c2f9636dfb5d"}, {"Element": "<td style=\"width:88.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(5\u00a0mg/kg)</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a096)</span></p>\n</td>", "ID": "13bc109f-1953-41b1-80d4-e7e9de621eb6", "Styles": "width:88.4pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "d27fca35-bd72-4c53-bc88-07397570b51d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>", "ID": "8056ff37-487d-408b-be22-9b248bb85a29", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "13bc109f-1953-41b1-80d4-e7e9de621eb6"}, {"Element": "<span lang=\"EN-GB\">Infliximab</span>", "ID": "34fb4ca7-2b12-4cd5-a28b-3f8198f4cae5", "Styles": "None", "Classes": "None", "Text": "Infliximab", "ParentId": "8056ff37-487d-408b-be22-9b248bb85a29"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Maintenance</span></p>", "ID": "bce90b73-d4b8-449c-84d9-72c3a21f9143", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "13bc109f-1953-41b1-80d4-e7e9de621eb6"}, {"Element": "<span lang=\"EN-GB\">Maintenance</span>", "ID": "1e6b2c2e-b6cd-45e9-93b5-8b9fa3f6038e", "Styles": "None", "Classes": "None", "Text": "Maintenance", "ParentId": "bce90b73-d4b8-449c-84d9-72c3a21f9143"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(5\u00a0mg/kg)</span></p>", "ID": "c6ef7f71-2d3c-46d9-9f6e-cf03c7a7cd2a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "13bc109f-1953-41b1-80d4-e7e9de621eb6"}, {"Element": "<span lang=\"EN-GB\">(5\u00a0mg/kg)</span>", "ID": "79ac4474-5b9d-419c-9dac-43f820412518", "Styles": "None", "Classes": "None", "Text": "(5\u00a0mg/kg)", "ParentId": "c6ef7f71-2d3c-46d9-9f6e-cf03c7a7cd2a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(n\u00a0=\u00a096)</span></p>", "ID": "48b68bfd-48db-4cdd-a508-b13a59c5a772", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "13bc109f-1953-41b1-80d4-e7e9de621eb6"}, {"Element": "<span lang=\"EN-GB\">(n\u00a0=\u00a096)</span>", "ID": "3a7edcb0-79ef-4fba-bc54-9b61f280f575", "Styles": "None", "Classes": "None", "Text": "(n\u00a0=\u00a096)", "ParentId": "48b68bfd-48db-4cdd-a508-b13a59c5a772"}, {"Element": "<td style=\"width:88.45pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">p\u2011value</span></p>\n</td>", "ID": "516d8d53-36f2-454f-b534-e8d042a6491e", "Styles": "width:88.45pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d27fca35-bd72-4c53-bc88-07397570b51d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">p\u2011value</span></p>", "ID": "4e10838a-6eec-496d-a0bd-2ffaa2da6986", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "516d8d53-36f2-454f-b534-e8d042a6491e"}, {"Element": "<span lang=\"EN-GB\">p\u2011value</span>", "ID": "0c8e8829-9f3e-4a30-ad00-a03a734ea876", "Styles": "None", "Classes": "None", "Text": "p\u2011value", "ParentId": "4e10838a-6eec-496d-a0bd-2ffaa2da6986"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median time to loss of response<sup> </sup>through\n  week\u00a054</span></p>\n</td>\n<td style=\"width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14\u00a0weeks</span></p>\n</td>\n<td style=\"width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&gt;\u00a040\u00a0weeks</span></p>\n</td>\n<td style=\"width:88.45pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&lt;\u00a00.001</span></p>\n</td>\n</tr>", "ID": "53792754-83b7-4fca-8f04-cfe526e7c2cb", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "f5a5ff13-d983-4a53-8dee-2ef71fe455b9"}, {"Element": "<td style=\"width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median time to loss of response<sup> </sup>through\n  week\u00a054</span></p>\n</td>", "ID": "67c2e39a-1d5e-405b-8399-1caf04433e05", "Styles": "width:188.35pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "53792754-83b7-4fca-8f04-cfe526e7c2cb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Median time to loss of response<sup> </sup>through\n  week\u00a054</span></p>", "ID": "a504fc15-c4d3-42fa-b463-c4b5aa8f143b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "67c2e39a-1d5e-405b-8399-1caf04433e05"}, {"Element": "<span lang=\"EN-GB\">Median time to loss of response<sup> </sup>through\n  week\u00a054</span>", "ID": "9aa31ea7-bed2-4ec4-87f0-823f3b81b61a", "Styles": "None", "Classes": "None", "Text": "Median time to loss of responsethrough   week\u00a054", "ParentId": "a504fc15-c4d3-42fa-b463-c4b5aa8f143b"}, {"Element": "<sup> </sup>", "ID": "d6b1a8e4-fd7f-448d-9d1a-559befefd47b", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "9aa31ea7-bed2-4ec4-87f0-823f3b81b61a"}, {"Element": "<td style=\"width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14\u00a0weeks</span></p>\n</td>", "ID": "5e7454eb-132e-4b27-9265-a4ddc5db9b08", "Styles": "width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "53792754-83b7-4fca-8f04-cfe526e7c2cb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14\u00a0weeks</span></p>", "ID": "7623acf7-faa9-4908-8c85-c0be61e41621", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5e7454eb-132e-4b27-9265-a4ddc5db9b08"}, {"Element": "<span lang=\"EN-GB\">14\u00a0weeks</span>", "ID": "6067dc8d-4fd3-4238-91b8-9e1decc88643", "Styles": "None", "Classes": "None", "Text": "14\u00a0weeks", "ParentId": "7623acf7-faa9-4908-8c85-c0be61e41621"}, {"Element": "<td style=\"width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&gt;\u00a040\u00a0weeks</span></p>\n</td>", "ID": "f51a6c81-026e-4846-8b94-97ec85bf27c4", "Styles": "width:88.4pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "53792754-83b7-4fca-8f04-cfe526e7c2cb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&gt;\u00a040\u00a0weeks</span></p>", "ID": "d0b9e010-cc21-4870-b192-a6fe569d4c3c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f51a6c81-026e-4846-8b94-97ec85bf27c4"}, {"Element": "<span lang=\"EN-GB\">&gt;\u00a040\u00a0weeks</span>", "ID": "1b37a033-84ba-4baf-80fc-1a847d7bd3c6", "Styles": "None", "Classes": "None", "Text": ">\u00a040\u00a0weeks", "ParentId": "d0b9e010-cc21-4870-b192-a6fe569d4c3c"}, {"Element": "<td style=\"width:88.45pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&lt;\u00a00.001</span></p>\n</td>", "ID": "4e744f62-8e34-4cbf-bd82-4c8237c9e6de", "Styles": "width:88.45pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "53792754-83b7-4fca-8f04-cfe526e7c2cb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">&lt;\u00a00.001</span></p>", "ID": "39df8795-469c-4071-83cb-b151a33b2b75", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4e744f62-8e34-4cbf-bd82-4c8237c9e6de"}, {"Element": "<span lang=\"EN-GB\">&lt;\u00a00.001</span>", "ID": "4bce2750-6074-44f2-b864-c364fd9ccef4", "Styles": "None", "Classes": "None", "Text": "<\u00a00.001", "ParentId": "39df8795-469c-4071-83cb-b151a33b2b75"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a054</span></b></p>\n</td>\n</tr>", "ID": "a2a5e8b4-c947-49e5-8f47-afcadaec9ee0", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "f5a5ff13-d983-4a53-8dee-2ef71fe455b9"}, {"Element": "<td colspan=\"4\" style=\"width:6.3in;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a054</span></b></p>\n</td>", "ID": "bbd5233e-5ac3-4645-ab1f-4dfd56a7b687", "Styles": "width:6.3in;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a2a5e8b4-c947-49e5-8f47-afcadaec9ee0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a054</span></b></p>", "ID": "6cd111ab-b065-4ef2-94f4-d107472c8196", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bbd5233e-5ac3-4645-ab1f-4dfd56a7b687"}, {"Element": "<b><span lang=\"EN-GB\">Week\u00a054</span></b>", "ID": "0044208e-72fc-48b5-9882-bb386b8853f6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6cd111ab-b065-4ef2-94f4-d107472c8196"}, {"Element": "<span lang=\"EN-GB\">Week\u00a054</span>", "ID": "0d3c210f-9ca7-404c-bee2-aceb21326565", "Styles": "None", "Classes": "None", "Text": "Week\u00a054", "ParentId": "0044208e-72fc-48b5-9882-bb386b8853f6"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Fistula Response (%)<sup>a</sup></span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">23.5</span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46.2</span></p>\n</td>\n<td style=\"width:88.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.001</span></p>\n</td>\n</tr>", "ID": "301762ec-5e99-40dd-a60e-8be8fc901349", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "f5a5ff13-d983-4a53-8dee-2ef71fe455b9"}, {"Element": "<td style=\"width:188.35pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Fistula Response (%)<sup>a</sup></span></p>\n</td>", "ID": "4a0e2d6f-aba1-4fff-bae3-c77ad8ec2f9a", "Styles": "width:188.35pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "301762ec-5e99-40dd-a60e-8be8fc901349"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Fistula Response (%)<sup>a</sup></span></p>", "ID": "74efa8d6-3d26-44a2-af40-3fb91516ea0b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4a0e2d6f-aba1-4fff-bae3-c77ad8ec2f9a"}, {"Element": "<span lang=\"EN-GB\">Fistula Response (%)<sup>a</sup></span>", "ID": "a286d61e-f856-48c5-97e7-4e32a1a53ab8", "Styles": "None", "Classes": "None", "Text": "Fistula Response (%)", "ParentId": "74efa8d6-3d26-44a2-af40-3fb91516ea0b"}, {"Element": "<sup>a</sup>", "ID": "60a5ae49-b39d-4700-9718-13a947de2913", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "a286d61e-f856-48c5-97e7-4e32a1a53ab8"}, {"Element": "<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">23.5</span></p>\n</td>", "ID": "bb772a58-23c3-44e7-9232-88453de9d098", "Styles": "width:88.4pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "301762ec-5e99-40dd-a60e-8be8fc901349"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">23.5</span></p>", "ID": "36692592-9e21-405a-88b9-53781d9467f4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bb772a58-23c3-44e7-9232-88453de9d098"}, {"Element": "<span lang=\"EN-GB\">23.5</span>", "ID": "063c38f6-ab02-4964-9f99-fb1886c4c7e4", "Styles": "None", "Classes": "None", "Text": "23.5", "ParentId": "36692592-9e21-405a-88b9-53781d9467f4"}, {"Element": "<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46.2</span></p>\n</td>", "ID": "39977834-c73b-43c2-9230-a9c93b64de4d", "Styles": "width:88.4pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "301762ec-5e99-40dd-a60e-8be8fc901349"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46.2</span></p>", "ID": "c48aaac8-fcac-4989-ba72-e206124c931e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "39977834-c73b-43c2-9230-a9c93b64de4d"}, {"Element": "<span lang=\"EN-GB\">46.2</span>", "ID": "07beff81-0df6-4c7f-801f-89e0fc79724e", "Styles": "None", "Classes": "None", "Text": "46.2", "ParentId": "c48aaac8-fcac-4989-ba72-e206124c931e"}, {"Element": "<td style=\"width:88.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.001</span></p>\n</td>", "ID": "83b4241a-8471-4dd2-ac8d-e29e9169e139", "Styles": "width:88.45pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "301762ec-5e99-40dd-a60e-8be8fc901349"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.001</span></p>", "ID": "7874db97-23ef-4adb-b849-f104735ed840", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "83b4241a-8471-4dd2-ac8d-e29e9169e139"}, {"Element": "<span lang=\"EN-GB\">0.001</span>", "ID": "dfd0c0fe-98c5-441d-96f5-16252371c0e2", "Styles": "None", "Classes": "None", "Text": "0.001", "ParentId": "7874db97-23ef-4adb-b849-f104735ed840"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:188.35pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Complete fistula response (%)<sup>b</sup></span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.4</span></p>\n</td>\n<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.3</span></p>\n</td>\n<td style=\"width:88.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.009</span></p>\n</td>\n</tr>", "ID": "237a7694-e3cc-40ed-b016-866eb659a3b0", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "     ", "ParentId": "f5a5ff13-d983-4a53-8dee-2ef71fe455b9"}, {"Element": "<td style=\"width:188.35pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"251\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Complete fistula response (%)<sup>b</sup></span></p>\n</td>", "ID": "9e6f758a-6dbe-4552-9a1d-f845763d1644", "Styles": "width:188.35pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "237a7694-e3cc-40ed-b016-866eb659a3b0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Complete fistula response (%)<sup>b</sup></span></p>", "ID": "07efd4d5-74a4-40e8-b4c2-98235b3a1185", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e6f758a-6dbe-4552-9a1d-f845763d1644"}, {"Element": "<span lang=\"EN-GB\">Complete fistula response (%)<sup>b</sup></span>", "ID": "70e83287-b403-429e-86b1-a8da4eabf805", "Styles": "None", "Classes": "None", "Text": "Complete fistula response (%)", "ParentId": "07efd4d5-74a4-40e8-b4c2-98235b3a1185"}, {"Element": "<sup>b</sup>", "ID": "9ed12184-aa51-4b0d-ab7c-742296d8b2a6", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "70e83287-b403-429e-86b1-a8da4eabf805"}, {"Element": "<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.4</span></p>\n</td>", "ID": "ce75d14b-3d6f-46d3-8d5a-9bd03e9eeae3", "Styles": "width:88.4pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "237a7694-e3cc-40ed-b016-866eb659a3b0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.4</span></p>", "ID": "13496e3b-ea46-4a77-aea9-aca31e056a23", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ce75d14b-3d6f-46d3-8d5a-9bd03e9eeae3"}, {"Element": "<span lang=\"EN-GB\">19.4</span>", "ID": "bee93ddc-dfa3-41de-92ff-46a6d70cc4c6", "Styles": "None", "Classes": "None", "Text": "19.4", "ParentId": "13496e3b-ea46-4a77-aea9-aca31e056a23"}, {"Element": "<td style=\"width:88.4pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.3</span></p>\n</td>", "ID": "c8f09f4f-137e-4d5d-a032-9a53178094b9", "Styles": "width:88.4pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "237a7694-e3cc-40ed-b016-866eb659a3b0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.3</span></p>", "ID": "819ceb0b-2b5e-42a5-af31-ea222f6cb2ba", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c8f09f4f-137e-4d5d-a032-9a53178094b9"}, {"Element": "<span lang=\"EN-GB\">36.3</span>", "ID": "36f95251-caac-4c52-951b-4d49534896e6", "Styles": "None", "Classes": "None", "Text": "36.3", "ParentId": "819ceb0b-2b5e-42a5-af31-ea222f6cb2ba"}, {"Element": "<td style=\"width:88.45pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"118\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.009</span></p>\n</td>", "ID": "22857d72-87c9-4bc8-bb7c-9468cf40a3aa", "Styles": "width:88.45pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "237a7694-e3cc-40ed-b016-866eb659a3b0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0.009</span></p>", "ID": "df4e1c05-34e8-42e2-b98e-50714514ecbe", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22857d72-87c9-4bc8-bb7c-9468cf40a3aa"}, {"Element": "<span lang=\"EN-GB\">0.009</span>", "ID": "5400e4f0-9116-4efe-beda-a781c56b6ed3", "Styles": "None", "Classes": "None", "Text": "0.009", "ParentId": "df4e1c05-34e8-42e2-b98e-50714514ecbe"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"4\" style=\"width:6.3in;border:none;border-top:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 A\n  \u2265\u00a050% reduction from baseline in the number of draining fistulas\n  over a period of \u2265\u00a04\u00a0weeks.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Absence\n  of any draining fistulas.</span></p>\n</td>\n</tr>", "ID": "5688062d-1aee-4c43-ab07-122ac5393556", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "f5a5ff13-d983-4a53-8dee-2ef71fe455b9"}, {"Element": "<td colspan=\"4\" style=\"width:6.3in;border:none;border-top:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"605\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 A\n  \u2265\u00a050% reduction from baseline in the number of draining fistulas\n  over a period of \u2265\u00a04\u00a0weeks.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Absence\n  of any draining fistulas.</span></p>\n</td>", "ID": "e216d179-b202-408a-8f1d-deac38721aa4", "Styles": "width:6.3in;border:none;border-top:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "5688062d-1aee-4c43-ab07-122ac5393556"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 A\n  \u2265\u00a050% reduction from baseline in the number of draining fistulas\n  over a period of \u2265\u00a04\u00a0weeks.</span></p>", "ID": "42c72291-b994-4ec0-940e-4a5f80b4db3a", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e216d179-b202-408a-8f1d-deac38721aa4"}, {"Element": "<sup><span lang=\"EN-GB\">a</span></sup>", "ID": "bdd41830-8e99-415d-8295-4a24c72dd8f8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "42c72291-b994-4ec0-940e-4a5f80b4db3a"}, {"Element": "<span lang=\"EN-GB\">a</span>", "ID": "3675f618-b982-4761-a75d-154fddc2f54c", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "bdd41830-8e99-415d-8295-4a24c72dd8f8"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 A\n  \u2265\u00a050% reduction from baseline in the number of draining fistulas\n  over a period of \u2265\u00a04\u00a0weeks.</span>", "ID": "54e19feb-5aef-492a-9c91-0b88b86d956f", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 A   \u2265\u00a050% reduction from baseline in the number of draining fistulas   over a period of \u2265\u00a04\u00a0weeks.", "ParentId": "42c72291-b994-4ec0-940e-4a5f80b4db3a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Absence\n  of any draining fistulas.</span></p>", "ID": "b16a5739-7d53-4efc-b82c-e9f34f1e325d", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e216d179-b202-408a-8f1d-deac38721aa4"}, {"Element": "<sup><span lang=\"EN-GB\">b</span></sup>", "ID": "86ca4e8e-b91f-4d5f-9eb7-9ba2232a49c3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b16a5739-7d53-4efc-b82c-e9f34f1e325d"}, {"Element": "<span lang=\"EN-GB\">b</span>", "ID": "2420da08-157e-4bd0-8e21-fd8e2fb10dbc", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "86ca4e8e-b91f-4d5f-9eb7-9ba2232a49c3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Absence\n  of any draining fistulas.</span>", "ID": "7753fe4d-3f09-44ae-b396-fcfcf38411e9", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 Absence   of any draining fistulas.", "ParentId": "b16a5739-7d53-4efc-b82c-e9f34f1e325d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "99072a1b-3016-4d5d-8312-a64d479cccf1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e80f1ee9-1da3-4c69-9106-ee22959c6cb1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "99072a1b-3016-4d5d-8312-a64d479cccf1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Beginning at week\u00a022, patients who\ninitially responded to treatment and subsequently lost their response were\neligible to cross over to active re\u2011treatment every 8\u00a0weeks at a\ndose of infliximab 5\u00a0mg/kg higher than the dose to which they were\noriginally randomised. Among patients in the infliximab 5\u00a0mg/kg group who\ncrossed over because of loss of fistula response after week\u00a022, 57%\n(12/21) responded to re\u2011treatment with infliximab 10\u00a0mg/kg every 8\u00a0weeks.</span></p>", "ID": "3fe10bda-fe98-48d5-9b10-89d2f7972117", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Beginning at week\u00a022, patients who\ninitially responded to treatment and subsequently lost their response were\neligible to cross over to active re\u2011treatment every 8\u00a0weeks at a\ndose of infliximab 5\u00a0mg/kg higher than the dose to which they were\noriginally randomised. Among patients in the infliximab 5\u00a0mg/kg group who\ncrossed over because of loss of fistula response after week\u00a022, 57%\n(12/21) responded to re\u2011treatment with infliximab 10\u00a0mg/kg every 8\u00a0weeks.</span>", "ID": "61176a8e-8dd3-4eb6-8129-51e9d006c6ce", "Styles": "None", "Classes": "None", "Text": "Beginning at week\u00a022, patients who initially responded to treatment and subsequently lost their response were eligible to cross over to active re\u2011treatment every 8\u00a0weeks at a dose of infliximab 5\u00a0mg/kg higher than the dose to which they were originally randomised. Among patients in the infliximab 5\u00a0mg/kg group who crossed over because of loss of fistula response after week\u00a022, 57% (12/21) responded to re\u2011treatment with infliximab 10\u00a0mg/kg every 8\u00a0weeks.", "ParentId": "3fe10bda-fe98-48d5-9b10-89d2f7972117"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a0315278-8928-484b-a24f-aa999e2ad866", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "09bc7cbc-ba33-4313-b7ce-c990961ce706", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a0315278-8928-484b-a24f-aa999e2ad866"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">There was no significant difference between\nplacebo and infliximab for the proportion of patients with sustained closure of\nall fistulas through week\u00a054, for symptoms such as proctalgia, abscesses\nand urinary tract infection or for number of newly developed fistulas during\ntreatment.</span></p>", "ID": "e6273a19-07c3-4db2-9e9f-feef981a1e9c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">There was no significant difference between\nplacebo and infliximab for the proportion of patients with sustained closure of\nall fistulas through week\u00a054, for symptoms such as proctalgia, abscesses\nand urinary tract infection or for number of newly developed fistulas during\ntreatment.</span>", "ID": "1ca92dea-d0db-434c-8de8-8c1a5c84874c", "Styles": "None", "Classes": "None", "Text": "There was no significant difference between placebo and infliximab for the proportion of patients with sustained closure of all fistulas through week\u00a054, for symptoms such as proctalgia, abscesses and urinary tract infection or for number of newly developed fistulas during treatment.", "ParentId": "e6273a19-07c3-4db2-9e9f-feef981a1e9c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5ea2afa5-c93e-435d-9534-20fd0fa16d64", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d5c16bec-6b92-4475-8362-9e606d84e037", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5ea2afa5-c93e-435d-9534-20fd0fa16d64"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Maintenance therapy with infliximab every 8\u00a0weeks\nsignificantly reduced disease\u2011related hospitalisations and surgeries\ncompared with placebo. Furthermore, a reduction in corticosteroid use and\nimprovements in quality of life were observed.</span></p>", "ID": "6dffbffa-43aa-4916-ac8f-b66ed8d0684b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Maintenance therapy with infliximab every 8\u00a0weeks\nsignificantly reduced disease\u2011related hospitalisations and surgeries\ncompared with placebo. Furthermore, a reduction in corticosteroid use and\nimprovements in quality of life were observed.</span>", "ID": "1f3a7a87-168b-4adf-b6fd-2fe140f51b40", "Styles": "None", "Classes": "None", "Text": "Maintenance therapy with infliximab every 8\u00a0weeks significantly reduced disease\u2011related hospitalisations and surgeries compared with placebo. Furthermore, a reduction in corticosteroid use and improvements in quality of life were observed.", "ParentId": "6dffbffa-43aa-4916-ac8f-b66ed8d0684b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0f7bc180-576d-404d-9bfc-d690c3bbc383", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "38fdc8ef-5f0f-424d-9605-0ef52380fb0d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0f7bc180-576d-404d-9bfc-d690c3bbc383"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Adult ulcerative\ncolitis</span></u></p>", "ID": "a25d6d21-3b5f-4bcd-a3b0-8ed8122e0b62", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Adult ulcerative\ncolitis</span></u>", "ID": "fcf89a6c-a365-4227-8658-0a50efed9374", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a25d6d21-3b5f-4bcd-a3b0-8ed8122e0b62"}, {"Element": "<span lang=\"EN-GB\">Adult ulcerative\ncolitis</span>", "ID": "a7721d21-1047-4146-b23d-ba05b37a849f", "Styles": "None", "Classes": "None", "Text": "Adult ulcerative colitis", "ParentId": "fcf89a6c-a365-4227-8658-0a50efed9374"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of Remicade were\nassessed in two (ACT\u00a01 and ACT\u00a02) randomised, double\u2011blind,\nplacebo\u2011controlled clinical studies in adult patients with moderately to\nseverely active ulcerative colitis (Mayo score 6 to 12; Endoscopy subscore \u2265\u00a02)\nwith an inadequate response to conventional therapies [</span><span lang=\"EN-GB\">oral\ncorticosteroids, aminosalicylates and/or immunomodulators (6\u2011MP, AZA)]. </span><span lang=\"EN-GB\">Concomitant stable doses of oral aminosalicylates, corticosteroids,\nand/or immunomodulatory agents were permitted. In both studies, patients were\nrandomised to receive either placebo, 5\u00a0mg/kg Remicade, or 10\u00a0mg/kg\nRemicade at weeks\u00a00, 2, 6, 14 and 22, and in ACT\u00a01 at weeks\u00a030,\n38 and 46. Corticosteroid taper was permitted after week\u00a08.</span></p>", "ID": "4c722141-3f81-4228-bada-27b69648fa28", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of Remicade were\nassessed in two (ACT\u00a01 and ACT\u00a02) randomised, double\u2011blind,\nplacebo\u2011controlled clinical studies in adult patients with moderately to\nseverely active ulcerative colitis (Mayo score 6 to 12; Endoscopy subscore \u2265\u00a02)\nwith an inadequate response to conventional therapies [</span>", "ID": "3b233980-6870-483e-8fe3-81dd0f9e5edc", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of Remicade were assessed in two (ACT\u00a01 and ACT\u00a02) randomised, double\u2011blind, placebo\u2011controlled clinical studies in adult patients with moderately to severely active ulcerative colitis (Mayo score 6 to 12; Endoscopy subscore \u2265\u00a02) with an inadequate response to conventional therapies [", "ParentId": "4c722141-3f81-4228-bada-27b69648fa28"}, {"Element": "<span lang=\"EN-GB\">oral\ncorticosteroids, aminosalicylates and/or immunomodulators (6\u2011MP, AZA)]. </span>", "ID": "1573a76c-a4fd-452a-805b-3edfeacc2e43", "Styles": "None", "Classes": "None", "Text": "oral corticosteroids, aminosalicylates and/or immunomodulators (6\u2011MP, AZA)]. ", "ParentId": "4c722141-3f81-4228-bada-27b69648fa28"}, {"Element": "<span lang=\"EN-GB\">Concomitant stable doses of oral aminosalicylates, corticosteroids,\nand/or immunomodulatory agents were permitted. In both studies, patients were\nrandomised to receive either placebo, 5\u00a0mg/kg Remicade, or 10\u00a0mg/kg\nRemicade at weeks\u00a00, 2, 6, 14 and 22, and in ACT\u00a01 at weeks\u00a030,\n38 and 46. Corticosteroid taper was permitted after week\u00a08.</span>", "ID": "a85d3fdd-e5ed-4429-9986-16dd3e043ac5", "Styles": "None", "Classes": "None", "Text": "Concomitant stable doses of oral aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted. In both studies, patients were randomised to receive either placebo, 5\u00a0mg/kg Remicade, or 10\u00a0mg/kg Remicade at weeks\u00a00, 2, 6, 14 and 22, and in ACT\u00a01 at weeks\u00a030, 38 and 46. Corticosteroid taper was permitted after week\u00a08.", "ParentId": "4c722141-3f81-4228-bada-27b69648fa28"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "805a8e28-b515-41a6-bdf2-83edc5ce2fdd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c9976380-04c0-4960-929e-d256550b73d7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "805a8e28-b515-41a6-bdf2-83edc5ce2fdd"}, {"Element": "<div align=\"center\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a08</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on clinical response, clinical remission\n  and mucosal healing at weeks\u00a08 and\u00a030.</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Combined data from ACT\u00a01 &amp; 2</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:223.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"298\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"4\" style=\"width:230.75pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"308\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo</span></p>\n</td>\n<td style=\"width:77.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:77.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:75.3pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combined</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Subjects randomised</span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">244</span></p>\n</td>\n<td style=\"width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242</span></p>\n</td>\n<td style=\"width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242</span></p>\n</td>\n<td style=\"width:75.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">484</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical response and in sustained clinical response</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical response at week\u00a08<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.2%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">66.9%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">65.3%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">66.1%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical response at week\u00a030<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.9%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">49.6%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">55.4%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52.5%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(clinical response at both</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.3%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45.0%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">49.6%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47.3%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical remission and sustained remission</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical remission at week\u00a08<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">10.2%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.4%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">29.8%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.1%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical remission at week\u00a030<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13.1%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">29.8%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.4%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.1%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained remission</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(in remission at both</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5.3%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.0%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24.4%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">21.7%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects with mucosal healing</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mucosal healing at week\u00a08<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">32.4%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61.2%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">60.3%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">60.7%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mucosal healing at week\u00a030<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.5%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48.3%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52.9%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">50.6%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"606\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. placebo.</span></span></p>\n</td>\n</tr>\n<tr height=\"0\">\n<td style=\"border:none\" width=\"195\"></td>\n<td style=\"border:none\" width=\"103\"></td>\n<td style=\"border:none\" width=\"0\"></td>\n<td style=\"border:none\" width=\"103\"></td>\n<td style=\"border:none\" width=\"103\"></td>\n<td style=\"border:none\" width=\"100\"></td>\n</tr>\n</table>\n</div>", "ID": "6364e4fb-e4e3-4366-a4a3-5ee10be87a4c", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a08</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on clinical response, clinical remission\n  and mucosal healing at weeks\u00a08 and\u00a030.</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Combined data from ACT\u00a01 &amp; 2</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:223.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"298\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"4\" style=\"width:230.75pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"308\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo</span></p>\n</td>\n<td style=\"width:77.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:77.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:75.3pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combined</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Subjects randomised</span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">244</span></p>\n</td>\n<td style=\"width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242</span></p>\n</td>\n<td style=\"width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242</span></p>\n</td>\n<td style=\"width:75.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">484</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical response and in sustained clinical response</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical response at week\u00a08<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.2%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">66.9%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">65.3%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">66.1%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical response at week\u00a030<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.9%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">49.6%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">55.4%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52.5%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(clinical response at both</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.3%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45.0%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">49.6%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47.3%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical remission and sustained remission</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical remission at week\u00a08<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">10.2%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.4%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">29.8%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.1%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical remission at week\u00a030<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13.1%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">29.8%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.4%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.1%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained remission</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(in remission at both</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5.3%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.0%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24.4%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">21.7%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects with mucosal healing</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mucosal healing at week\u00a08<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">32.4%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61.2%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">60.3%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">60.7%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mucosal healing at week\u00a030<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.5%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48.3%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52.9%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">50.6%</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"606\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. placebo.</span></span></p>\n</td>\n</tr>\n<tr height=\"0\">\n<td style=\"border:none\" width=\"195\"></td>\n<td style=\"border:none\" width=\"103\"></td>\n<td style=\"border:none\" width=\"0\"></td>\n<td style=\"border:none\" width=\"103\"></td>\n<td style=\"border:none\" width=\"103\"></td>\n<td style=\"border:none\" width=\"100\"></td>\n</tr>\n</table>", "ID": "797c1b6e-bab0-4f33-81c6-0653732641b6", "Styles": "border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "                  ", "ParentId": "6364e4fb-e4e3-4366-a4a3-5ee10be87a4c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a08</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on clinical response, clinical remission\n  and mucosal healing at weeks\u00a08 and\u00a030.</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Combined data from ACT\u00a01 &amp; 2</span></b></p>\n</td>\n</tr>", "ID": "89cd0d34-0c68-4785-9061-92e1160f0238", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td colspan=\"6\" style=\"width:454.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a08</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on clinical response, clinical remission\n  and mucosal healing at weeks\u00a08 and\u00a030.</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Combined data from ACT\u00a01 &amp; 2</span></b></p>\n</td>", "ID": "a9e1a069-40a2-49e7-8ca6-7991638dd94d", "Styles": "width:454.25pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "89cd0d34-0c68-4785-9061-92e1160f0238"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a08</span></b></p>", "ID": "505383da-0a99-497d-84b5-835e1152caa7", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a9e1a069-40a2-49e7-8ca6-7991638dd94d"}, {"Element": "<b><span lang=\"EN-GB\">Table\u00a08</span></b>", "ID": "41dba930-32c2-4ec1-8972-42610c0792f6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "505383da-0a99-497d-84b5-835e1152caa7"}, {"Element": "<span lang=\"EN-GB\">Table\u00a08</span>", "ID": "fd1d47b8-3890-420c-8ec8-d5a9e502bca3", "Styles": "None", "Classes": "None", "Text": "Table\u00a08", "ParentId": "41dba930-32c2-4ec1-8972-42610c0792f6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on clinical response, clinical remission\n  and mucosal healing at weeks\u00a08 and\u00a030.</span></b></p>", "ID": "21de502e-e44d-4f36-bf91-41c7df3b3077", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a9e1a069-40a2-49e7-8ca6-7991638dd94d"}, {"Element": "<b><span lang=\"EN-GB\">Effects on clinical response, clinical remission\n  and mucosal healing at weeks\u00a08 and\u00a030.</span></b>", "ID": "603c2f19-9aaa-46b9-aca9-3a63ce27a62c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "21de502e-e44d-4f36-bf91-41c7df3b3077"}, {"Element": "<span lang=\"EN-GB\">Effects on clinical response, clinical remission\n  and mucosal healing at weeks\u00a08 and\u00a030.</span>", "ID": "d03c96f2-c110-4959-90a2-a0bbb0efa840", "Styles": "None", "Classes": "None", "Text": "Effects on clinical response, clinical remission   and mucosal healing at weeks\u00a08 and\u00a030.", "ParentId": "603c2f19-9aaa-46b9-aca9-3a63ce27a62c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Combined data from ACT\u00a01 &amp; 2</span></b></p>", "ID": "11ecdde1-0c10-44ba-840f-9179699eec71", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a9e1a069-40a2-49e7-8ca6-7991638dd94d"}, {"Element": "<b><span lang=\"EN-GB\">Combined data from ACT\u00a01 &amp; 2</span></b>", "ID": "fc1b8ece-a1aa-432a-9ac5-d78da4809276", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "11ecdde1-0c10-44ba-840f-9179699eec71"}, {"Element": "<span lang=\"EN-GB\">Combined data from ACT\u00a01 &amp; 2</span>", "ID": "c856cf01-b8ca-49bf-a6b0-b64043f97b94", "Styles": "None", "Classes": "None", "Text": "Combined data from ACT\u00a01 & 2", "ParentId": "fc1b8ece-a1aa-432a-9ac5-d78da4809276"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"2\" style=\"width:223.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"298\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"4\" style=\"width:230.75pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"308\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n</td>\n</tr>", "ID": "0a2f83dc-e13a-4937-80ba-264c63b88dc4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td colspan=\"2\" style=\"width:223.5pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"298\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "9064998f-bb8a-4e46-b837-fefe6ba8b0a7", "Styles": "width:223.5pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0a2f83dc-e13a-4937-80ba-264c63b88dc4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8f6e040a-971a-4917-b579-6766531cddd5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9064998f-bb8a-4e46-b837-fefe6ba8b0a7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ffcabaef-f91d-4d60-a3c0-d21bde3042de", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8f6e040a-971a-4917-b579-6766531cddd5"}, {"Element": "<td colspan=\"4\" style=\"width:230.75pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"308\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n</td>", "ID": "c3767747-ced0-480e-81e5-54150be63115", "Styles": "width:230.75pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0a2f83dc-e13a-4937-80ba-264c63b88dc4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>", "ID": "709724a8-070f-452d-9599-331cc1a34449", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c3767747-ced0-480e-81e5-54150be63115"}, {"Element": "<span lang=\"EN-GB\">Infliximab</span>", "ID": "dc6c5b55-0454-4977-a116-b806d938ad41", "Styles": "None", "Classes": "None", "Text": "Infliximab", "ParentId": "709724a8-070f-452d-9599-331cc1a34449"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo</span></p>\n</td>\n<td style=\"width:77.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:77.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10\u00a0mg/kg</span></p>\n</td>\n<td style=\"width:75.3pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combined</span></p>\n</td>\n</tr>", "ID": "63f588a6-cbe3-432b-a332-f4f0329a11dc", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td style=\"width:146.3pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "e55ff898-9752-42d3-9e81-ac58d7e451aa", "Styles": "width:146.3pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "63f588a6-cbe3-432b-a332-f4f0329a11dc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "33303744-284b-48f3-879d-2858b74cb68b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e55ff898-9752-42d3-9e81-ac58d7e451aa"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ccb1f327-c771-4f99-a566-3fd5384f2d22", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "33303744-284b-48f3-879d-2858b74cb68b"}, {"Element": "<td colspan=\"2\" style=\"width:77.55pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo</span></p>\n</td>", "ID": "0c56b912-4ce6-451f-9603-cd8db90ef6e4", "Styles": "width:77.55pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "63f588a6-cbe3-432b-a332-f4f0329a11dc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo</span></p>", "ID": "b70a3776-dd20-40ab-9cbf-20c5bf33eec0", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0c56b912-4ce6-451f-9603-cd8db90ef6e4"}, {"Element": "<span lang=\"EN-GB\">Placebo</span>", "ID": "1c10fd61-ed31-42f8-b797-a6d36255a843", "Styles": "None", "Classes": "None", "Text": "Placebo", "ParentId": "b70a3776-dd20-40ab-9cbf-20c5bf33eec0"}, {"Element": "<td style=\"width:77.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n</td>", "ID": "601359f4-b45c-467a-a37d-82d784fe93bf", "Styles": "width:77.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "63f588a6-cbe3-432b-a332-f4f0329a11dc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>", "ID": "cb095dac-5e8c-4720-88aa-3156f7a15b18", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "601359f4-b45c-467a-a37d-82d784fe93bf"}, {"Element": "<span lang=\"EN-GB\">5\u00a0mg/kg</span>", "ID": "6b0cd28f-beae-4e59-bf26-82ce257a32ac", "Styles": "None", "Classes": "None", "Text": "5\u00a0mg/kg", "ParentId": "cb095dac-5e8c-4720-88aa-3156f7a15b18"}, {"Element": "<td style=\"width:77.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10\u00a0mg/kg</span></p>\n</td>", "ID": "4b0ab48d-21c5-429a-adeb-c78a8933298f", "Styles": "width:77.55pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "63f588a6-cbe3-432b-a332-f4f0329a11dc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">10\u00a0mg/kg</span></p>", "ID": "2f4dd842-ecf6-4ad5-9173-fce16da4d56b", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4b0ab48d-21c5-429a-adeb-c78a8933298f"}, {"Element": "<span lang=\"EN-GB\">10\u00a0mg/kg</span>", "ID": "5df3fcf1-84aa-4c3f-9b34-7c2cfac952c7", "Styles": "None", "Classes": "None", "Text": "10\u00a0mg/kg", "ParentId": "2f4dd842-ecf6-4ad5-9173-fce16da4d56b"}, {"Element": "<td style=\"width:75.3pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combined</span></p>\n</td>", "ID": "d51a7078-a377-4932-b0d7-f5d6baeeeeca", "Styles": "width:75.3pt;border-top:solid windowtext 1.0pt;\n  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "63f588a6-cbe3-432b-a332-f4f0329a11dc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Combined</span></p>", "ID": "6749ed65-45dd-4a91-ab80-41b2b71310ef", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d51a7078-a377-4932-b0d7-f5d6baeeeeca"}, {"Element": "<span lang=\"EN-GB\">Combined</span>", "ID": "4b486c9b-2aff-403b-9de7-81dc4c179c31", "Styles": "None", "Classes": "None", "Text": "Combined", "ParentId": "6749ed65-45dd-4a91-ab80-41b2b71310ef"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Subjects randomised</span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">244</span></p>\n</td>\n<td style=\"width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242</span></p>\n</td>\n<td style=\"width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242</span></p>\n</td>\n<td style=\"width:75.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">484</span></p>\n</td>\n</tr>", "ID": "cb8d3fa9-b6aa-4306-a640-312a520ed312", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td style=\"width:146.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Subjects randomised</span></p>\n</td>", "ID": "3df5a4c9-fca3-4368-934b-3424300b67e0", "Styles": "width:146.3pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cb8d3fa9-b6aa-4306-a640-312a520ed312"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Subjects randomised</span></p>", "ID": "1f1668cf-af66-4bf6-82ce-c9d3606d7a7b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3df5a4c9-fca3-4368-934b-3424300b67e0"}, {"Element": "<span lang=\"EN-GB\">Subjects randomised</span>", "ID": "131a3bc5-bb5c-4eaf-bd70-f039a269ee74", "Styles": "None", "Classes": "None", "Text": "Subjects randomised", "ParentId": "1f1668cf-af66-4bf6-82ce-c9d3606d7a7b"}, {"Element": "<td colspan=\"2\" style=\"width:77.55pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">244</span></p>\n</td>", "ID": "70182441-bb38-433c-a9ab-3c03f506b074", "Styles": "width:77.55pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cb8d3fa9-b6aa-4306-a640-312a520ed312"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">244</span></p>", "ID": "ef4b6804-2a5a-4182-a6b2-8ef9015958b1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "70182441-bb38-433c-a9ab-3c03f506b074"}, {"Element": "<span lang=\"EN-GB\">244</span>", "ID": "c39ee004-9da9-49b4-8bc5-b91eef1ab2e3", "Styles": "None", "Classes": "None", "Text": "244", "ParentId": "ef4b6804-2a5a-4182-a6b2-8ef9015958b1"}, {"Element": "<td style=\"width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242</span></p>\n</td>", "ID": "7e434267-b858-4f2f-9c2e-37c013d3bfe3", "Styles": "width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cb8d3fa9-b6aa-4306-a640-312a520ed312"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242</span></p>", "ID": "1a51aacd-3d53-4325-a682-d119fc5ac25f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e434267-b858-4f2f-9c2e-37c013d3bfe3"}, {"Element": "<span lang=\"EN-GB\">242</span>", "ID": "c1991513-a4fa-4845-bd9d-e18ee41086f6", "Styles": "None", "Classes": "None", "Text": "242", "ParentId": "1a51aacd-3d53-4325-a682-d119fc5ac25f"}, {"Element": "<td style=\"width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242</span></p>\n</td>", "ID": "d741ac40-394d-4332-9d75-a6f7bc58e45f", "Styles": "width:77.55pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cb8d3fa9-b6aa-4306-a640-312a520ed312"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242</span></p>", "ID": "a2ebdbe2-7cf1-486e-be86-565ab7c2a553", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d741ac40-394d-4332-9d75-a6f7bc58e45f"}, {"Element": "<span lang=\"EN-GB\">242</span>", "ID": "a3062e89-ecb2-410f-ab86-006799d2d325", "Styles": "None", "Classes": "None", "Text": "242", "ParentId": "a2ebdbe2-7cf1-486e-be86-565ab7c2a553"}, {"Element": "<td style=\"width:75.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">484</span></p>\n</td>", "ID": "db1094d4-2b3f-4c1d-9796-42d93dbdd75b", "Styles": "width:75.3pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cb8d3fa9-b6aa-4306-a640-312a520ed312"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">484</span></p>", "ID": "8c34e439-f8cc-4124-96ab-7598efa880bd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "db1094d4-2b3f-4c1d-9796-42d93dbdd75b"}, {"Element": "<span lang=\"EN-GB\">484</span>", "ID": "44c5218a-87e7-4565-aa43-a31395d4558a", "Styles": "None", "Classes": "None", "Text": "484", "ParentId": "8c34e439-f8cc-4124-96ab-7598efa880bd"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical response and in sustained clinical response</span></b></p>\n</td>\n</tr>", "ID": "adb206ac-3be4-4855-81a6-42ea81749c71", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td colspan=\"6\" style=\"width:454.25pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical response and in sustained clinical response</span></b></p>\n</td>", "ID": "651dcc41-9a7c-4a84-9598-8a353568bb41", "Styles": "width:454.25pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "adb206ac-3be4-4855-81a6-42ea81749c71"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical response and in sustained clinical response</span></b></p>", "ID": "29da945d-805c-46a3-9fac-24d3b19313dc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "651dcc41-9a7c-4a84-9598-8a353568bb41"}, {"Element": "<b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical response and in sustained clinical response</span></b>", "ID": "5f3f82d7-2f44-46ed-9843-8c39e3917dba", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "29da945d-805c-46a3-9fac-24d3b19313dc"}, {"Element": "<span lang=\"EN-GB\">Percentage\n  of subjects in clinical response and in sustained clinical response</span>", "ID": "da37dcc2-8dde-47fc-86e1-857466c4ac4b", "Styles": "None", "Classes": "None", "Text": "Percentage   of subjects in clinical response and in sustained clinical response", "ParentId": "5f3f82d7-2f44-46ed-9843-8c39e3917dba"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical response at week\u00a08<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.2%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">66.9%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">65.3%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">66.1%</span></p>\n</td>\n</tr>", "ID": "2edaff1c-933a-4998-8b06-29d0a065e68b", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical response at week\u00a08<sup>a</sup></span></p>\n</td>", "ID": "60787ecb-52a6-4234-bc40-8882fc5237a3", "Styles": "width:146.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2edaff1c-933a-4998-8b06-29d0a065e68b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical response at week\u00a08<sup>a</sup></span></p>", "ID": "e3c9e913-2c5b-4de3-9043-d98ffc107b5c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "60787ecb-52a6-4234-bc40-8882fc5237a3"}, {"Element": "<span lang=\"EN-GB\">Clinical response at week\u00a08<sup>a</sup></span>", "ID": "11b212e5-1b61-414e-a052-8829d2f701c1", "Styles": "None", "Classes": "None", "Text": "Clinical response at week\u00a08", "ParentId": "e3c9e913-2c5b-4de3-9043-d98ffc107b5c"}, {"Element": "<sup>a</sup>", "ID": "56828702-2d86-4671-b976-480e0963db8c", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "11b212e5-1b61-414e-a052-8829d2f701c1"}, {"Element": "<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.2%</span></p>\n</td>", "ID": "9d435012-faea-4d9d-9b90-6f0b2c287784", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2edaff1c-933a-4998-8b06-29d0a065e68b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.2%</span></p>", "ID": "9a2567a4-9d76-434d-9c2e-267cd056ce5f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d435012-faea-4d9d-9b90-6f0b2c287784"}, {"Element": "<span lang=\"EN-GB\">33.2%</span>", "ID": "15a662bd-88b7-4acb-87d2-c0e5b8eb072e", "Styles": "None", "Classes": "None", "Text": "33.2%", "ParentId": "9a2567a4-9d76-434d-9c2e-267cd056ce5f"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">66.9%</span></p>\n</td>", "ID": "278b98bc-e717-43ce-ba0d-cf605842b049", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2edaff1c-933a-4998-8b06-29d0a065e68b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">66.9%</span></p>", "ID": "13997803-b7bb-473c-89aa-b1f653edd10e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "278b98bc-e717-43ce-ba0d-cf605842b049"}, {"Element": "<span lang=\"EN-GB\">66.9%</span>", "ID": "f2da1e1e-fd45-4471-947d-39bef11371b7", "Styles": "None", "Classes": "None", "Text": "66.9%", "ParentId": "13997803-b7bb-473c-89aa-b1f653edd10e"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">65.3%</span></p>\n</td>", "ID": "7e3fbb50-73f6-4783-8c12-754ec25d64c2", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2edaff1c-933a-4998-8b06-29d0a065e68b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">65.3%</span></p>", "ID": "5d390711-873b-4075-835b-f5317fd7a4c2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e3fbb50-73f6-4783-8c12-754ec25d64c2"}, {"Element": "<span lang=\"EN-GB\">65.3%</span>", "ID": "f05f9945-dd62-4acf-a822-343562554f8e", "Styles": "None", "Classes": "None", "Text": "65.3%", "ParentId": "5d390711-873b-4075-835b-f5317fd7a4c2"}, {"Element": "<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">66.1%</span></p>\n</td>", "ID": "c0a26fbc-906a-42de-9b28-ff0366bb8730", "Styles": "width:75.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2edaff1c-933a-4998-8b06-29d0a065e68b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">66.1%</span></p>", "ID": "b3b27ab7-c95e-4aa8-ab06-7355b653ea96", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c0a26fbc-906a-42de-9b28-ff0366bb8730"}, {"Element": "<span lang=\"EN-GB\">66.1%</span>", "ID": "5cf7a0e2-f5a4-4628-807d-f10f7b607d8c", "Styles": "None", "Classes": "None", "Text": "66.1%", "ParentId": "b3b27ab7-c95e-4aa8-ab06-7355b653ea96"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical response at week\u00a030<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.9%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">49.6%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">55.4%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52.5%</span></p>\n</td>\n</tr>", "ID": "c2b47fd1-3833-46d3-b36d-5931df9c5f99", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical response at week\u00a030<sup>a</sup></span></p>\n</td>", "ID": "9125370b-a323-4dc6-882a-3c3a5ae7867e", "Styles": "width:146.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2b47fd1-3833-46d3-b36d-5931df9c5f99"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical response at week\u00a030<sup>a</sup></span></p>", "ID": "2137c998-7808-40d8-a816-689a3566e9fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9125370b-a323-4dc6-882a-3c3a5ae7867e"}, {"Element": "<span lang=\"EN-GB\">Clinical response at week\u00a030<sup>a</sup></span>", "ID": "f8dd9e56-68af-43a1-9db4-bc80f025cfe7", "Styles": "None", "Classes": "None", "Text": "Clinical response at week\u00a030", "ParentId": "2137c998-7808-40d8-a816-689a3566e9fe"}, {"Element": "<sup>a</sup>", "ID": "6ffcfe1e-63fe-465a-b6c6-e3a49829db34", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "f8dd9e56-68af-43a1-9db4-bc80f025cfe7"}, {"Element": "<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.9%</span></p>\n</td>", "ID": "5a73769a-1d14-49c2-8eb8-3ef3102c02d5", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2b47fd1-3833-46d3-b36d-5931df9c5f99"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.9%</span></p>", "ID": "928de3ca-6b7c-4be1-8c26-59f36bbc279c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5a73769a-1d14-49c2-8eb8-3ef3102c02d5"}, {"Element": "<span lang=\"EN-GB\">27.9%</span>", "ID": "6e054ae8-dc62-4578-baa0-ffba52779883", "Styles": "None", "Classes": "None", "Text": "27.9%", "ParentId": "928de3ca-6b7c-4be1-8c26-59f36bbc279c"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">49.6%</span></p>\n</td>", "ID": "e51c6a63-8f6a-481d-95a7-14117163763f", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2b47fd1-3833-46d3-b36d-5931df9c5f99"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">49.6%</span></p>", "ID": "61c51e0d-e91e-4993-ab3b-bfd05cb495d7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e51c6a63-8f6a-481d-95a7-14117163763f"}, {"Element": "<span lang=\"EN-GB\">49.6%</span>", "ID": "f7b3ff04-ce30-4e64-b338-8245f366d255", "Styles": "None", "Classes": "None", "Text": "49.6%", "ParentId": "61c51e0d-e91e-4993-ab3b-bfd05cb495d7"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">55.4%</span></p>\n</td>", "ID": "c55d2bb0-4b78-425f-9d90-c44ce9b2d332", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2b47fd1-3833-46d3-b36d-5931df9c5f99"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">55.4%</span></p>", "ID": "d2bb3b94-57e8-4508-afc0-212afffd20ec", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c55d2bb0-4b78-425f-9d90-c44ce9b2d332"}, {"Element": "<span lang=\"EN-GB\">55.4%</span>", "ID": "1dab0e85-7f79-44c1-a53c-3d7287431b09", "Styles": "None", "Classes": "None", "Text": "55.4%", "ParentId": "d2bb3b94-57e8-4508-afc0-212afffd20ec"}, {"Element": "<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52.5%</span></p>\n</td>", "ID": "ba5b41be-3ad9-432c-a6cd-69992548f5de", "Styles": "width:75.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c2b47fd1-3833-46d3-b36d-5931df9c5f99"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52.5%</span></p>", "ID": "fa12c5e2-6142-4070-b437-142eb29686c5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ba5b41be-3ad9-432c-a6cd-69992548f5de"}, {"Element": "<span lang=\"EN-GB\">52.5%</span>", "ID": "10684e4d-d7ff-4f78-acad-d0e3de5f0873", "Styles": "None", "Classes": "None", "Text": "52.5%", "ParentId": "fa12c5e2-6142-4070-b437-142eb29686c5"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(clinical response at both</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.3%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45.0%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">49.6%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47.3%</span></p>\n</td>\n</tr>", "ID": "a7ff57f3-370e-433a-8935-659f857d37c3", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(clinical response at both</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span></p>\n</td>", "ID": "04b726ec-7b4a-4116-b4ab-3a2b02074a91", "Styles": "width:146.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "a7ff57f3-370e-433a-8935-659f857d37c3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained response</span></p>", "ID": "bc8f3397-ffd9-4cbf-b5cc-f02afee7ccd9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04b726ec-7b4a-4116-b4ab-3a2b02074a91"}, {"Element": "<span lang=\"EN-GB\">Sustained response</span>", "ID": "ae33b830-9a17-4ac0-ae88-6865d92d3ea5", "Styles": "None", "Classes": "None", "Text": "Sustained response", "ParentId": "bc8f3397-ffd9-4cbf-b5cc-f02afee7ccd9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">(clinical response at both</span></p>", "ID": "050adcf6-631c-4339-b8a8-b892ac18aa7d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04b726ec-7b4a-4116-b4ab-3a2b02074a91"}, {"Element": "<span lang=\"EN-GB\">(clinical response at both</span>", "ID": "22221d14-b50d-4afb-9eef-ce3386421538", "Styles": "None", "Classes": "None", "Text": "(clinical response at both", "ParentId": "050adcf6-631c-4339-b8a8-b892ac18aa7d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span></p>", "ID": "79d69473-9706-47a6-a9d4-bf7e0fbdca1a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04b726ec-7b4a-4116-b4ab-3a2b02074a91"}, {"Element": "<span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span>", "ID": "546327cb-4138-4ea9-bd5f-5b03966aa1f6", "Styles": "None", "Classes": "None", "Text": "week\u00a08 and week\u00a030)", "ParentId": "79d69473-9706-47a6-a9d4-bf7e0fbdca1a"}, {"Element": "<sup>a</sup>", "ID": "ce0fb7bf-e9d9-4b07-b4e8-2687eac0cc2c", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "546327cb-4138-4ea9-bd5f-5b03966aa1f6"}, {"Element": "<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.3%</span></p>\n</td>", "ID": "174da06f-8a43-4255-86f9-fd8ca2197d3d", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a7ff57f3-370e-433a-8935-659f857d37c3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.3%</span></p>", "ID": "d5350330-ac37-4074-b097-91b98e790f2d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "174da06f-8a43-4255-86f9-fd8ca2197d3d"}, {"Element": "<span lang=\"EN-GB\">19.3%</span>", "ID": "1eb7fd2d-78cc-4e55-aa07-cf5d12c568ed", "Styles": "None", "Classes": "None", "Text": "19.3%", "ParentId": "d5350330-ac37-4074-b097-91b98e790f2d"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45.0%</span></p>\n</td>", "ID": "3cce23d6-6c7c-4b16-8d88-953d081467b5", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a7ff57f3-370e-433a-8935-659f857d37c3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">45.0%</span></p>", "ID": "b3aaae5f-1e36-4539-911d-22b4766885ac", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3cce23d6-6c7c-4b16-8d88-953d081467b5"}, {"Element": "<span lang=\"EN-GB\">45.0%</span>", "ID": "843ae372-980e-4d3a-ba4b-629ce49d3587", "Styles": "None", "Classes": "None", "Text": "45.0%", "ParentId": "b3aaae5f-1e36-4539-911d-22b4766885ac"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">49.6%</span></p>\n</td>", "ID": "615822a4-efaa-43b2-9fee-3007efeb5740", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a7ff57f3-370e-433a-8935-659f857d37c3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">49.6%</span></p>", "ID": "b6c6d0de-951b-40f6-8c36-01e2ee97ee16", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "615822a4-efaa-43b2-9fee-3007efeb5740"}, {"Element": "<span lang=\"EN-GB\">49.6%</span>", "ID": "ba8c09c4-7cdf-4630-8551-edcd0eda2236", "Styles": "None", "Classes": "None", "Text": "49.6%", "ParentId": "b6c6d0de-951b-40f6-8c36-01e2ee97ee16"}, {"Element": "<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47.3%</span></p>\n</td>", "ID": "1bbb0104-765e-4c24-8f69-74e22f32e84b", "Styles": "width:75.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "a7ff57f3-370e-433a-8935-659f857d37c3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">47.3%</span></p>", "ID": "b59d0532-8945-442d-8d43-e9595913176c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1bbb0104-765e-4c24-8f69-74e22f32e84b"}, {"Element": "<span lang=\"EN-GB\">47.3%</span>", "ID": "8edc098e-5689-4c1a-884a-54914c5505b4", "Styles": "None", "Classes": "None", "Text": "47.3%", "ParentId": "b59d0532-8945-442d-8d43-e9595913176c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical remission and sustained remission</span></b></p>\n</td>\n</tr>", "ID": "c547e937-cfd9-4277-b1d0-02c2ebc7cddc", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical remission and sustained remission</span></b></p>\n</td>", "ID": "d6d2dbb5-ef52-40c0-a0cd-1b4556bdba1f", "Styles": "width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "c547e937-cfd9-4277-b1d0-02c2ebc7cddc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical remission and sustained remission</span></b></p>", "ID": "d3c38523-1f03-483a-b478-6c1a317e133f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d6d2dbb5-ef52-40c0-a0cd-1b4556bdba1f"}, {"Element": "<b><span lang=\"EN-GB\">Percentage\n  of subjects in clinical remission and sustained remission</span></b>", "ID": "2771eab0-17da-4cea-9a35-a8476de36042", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d3c38523-1f03-483a-b478-6c1a317e133f"}, {"Element": "<span lang=\"EN-GB\">Percentage\n  of subjects in clinical remission and sustained remission</span>", "ID": "a0419211-09c6-4d52-b6c4-dc67986599aa", "Styles": "None", "Classes": "None", "Text": "Percentage   of subjects in clinical remission and sustained remission", "ParentId": "2771eab0-17da-4cea-9a35-a8476de36042"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical remission at week\u00a08<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">10.2%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.4%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">29.8%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.1%</span></p>\n</td>\n</tr>", "ID": "955b1e60-dd70-465c-a3c2-028540636607", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical remission at week\u00a08<sup>a</sup></span></p>\n</td>", "ID": "889cc9ca-0220-4289-b11e-96c03f224c97", "Styles": "width:146.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "955b1e60-dd70-465c-a3c2-028540636607"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical remission at week\u00a08<sup>a</sup></span></p>", "ID": "3c528a8d-ccc1-4507-b238-baa76eb4ce66", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "889cc9ca-0220-4289-b11e-96c03f224c97"}, {"Element": "<span lang=\"EN-GB\">Clinical remission at week\u00a08<sup>a</sup></span>", "ID": "b96caf92-2948-4e00-8475-8bb2cffad017", "Styles": "None", "Classes": "None", "Text": "Clinical remission at week\u00a08", "ParentId": "3c528a8d-ccc1-4507-b238-baa76eb4ce66"}, {"Element": "<sup>a</sup>", "ID": "55c12bbe-5133-4039-a85e-bcc6402ca453", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "b96caf92-2948-4e00-8475-8bb2cffad017"}, {"Element": "<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">10.2%</span></p>\n</td>", "ID": "7f3f947a-e958-4e10-91b9-adc500f142d7", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "955b1e60-dd70-465c-a3c2-028540636607"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">10.2%</span></p>", "ID": "0fc699e0-01b7-4b06-b757-29c0c05693f2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7f3f947a-e958-4e10-91b9-adc500f142d7"}, {"Element": "<span lang=\"EN-GB\">10.2%</span>", "ID": "78579bd9-439a-47f6-9e41-31852a9dfb21", "Styles": "None", "Classes": "None", "Text": "10.2%", "ParentId": "0fc699e0-01b7-4b06-b757-29c0c05693f2"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.4%</span></p>\n</td>", "ID": "ea7dbbc2-3eb7-4a33-bf06-7ead62b23088", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "955b1e60-dd70-465c-a3c2-028540636607"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.4%</span></p>", "ID": "6d6d287d-686f-490c-bcaf-95b949d6a6bf", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ea7dbbc2-3eb7-4a33-bf06-7ead62b23088"}, {"Element": "<span lang=\"EN-GB\">36.4%</span>", "ID": "1444f870-1726-47ea-ae23-99b6987b499b", "Styles": "None", "Classes": "None", "Text": "36.4%", "ParentId": "6d6d287d-686f-490c-bcaf-95b949d6a6bf"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">29.8%</span></p>\n</td>", "ID": "603c81cc-e2cc-4f92-b9ae-1f55d9df85ff", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "955b1e60-dd70-465c-a3c2-028540636607"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">29.8%</span></p>", "ID": "e625ccbb-57df-4e21-8a66-8863a8d130fc", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "603c81cc-e2cc-4f92-b9ae-1f55d9df85ff"}, {"Element": "<span lang=\"EN-GB\">29.8%</span>", "ID": "a83db4c8-8e38-40f0-85f4-f8949cdb31e7", "Styles": "None", "Classes": "None", "Text": "29.8%", "ParentId": "e625ccbb-57df-4e21-8a66-8863a8d130fc"}, {"Element": "<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.1%</span></p>\n</td>", "ID": "5f75a0b6-9006-4f6e-bbb9-687db9a83351", "Styles": "width:75.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "955b1e60-dd70-465c-a3c2-028540636607"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.1%</span></p>", "ID": "bc4c53b7-c6c1-452f-8c5d-2489533ae076", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f75a0b6-9006-4f6e-bbb9-687db9a83351"}, {"Element": "<span lang=\"EN-GB\">33.1%</span>", "ID": "f4dc3296-3747-42bb-959c-cdff68ce5c89", "Styles": "None", "Classes": "None", "Text": "33.1%", "ParentId": "bc4c53b7-c6c1-452f-8c5d-2489533ae076"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical remission at week\u00a030<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13.1%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">29.8%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.4%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.1%</span></p>\n</td>\n</tr>", "ID": "d9ff887a-3231-450f-bd09-c1992dd1e21f", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical remission at week\u00a030<sup>a</sup></span></p>\n</td>", "ID": "b00ec81d-4f8b-4180-86e1-27eb982687fd", "Styles": "width:146.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d9ff887a-3231-450f-bd09-c1992dd1e21f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Clinical remission at week\u00a030<sup>a</sup></span></p>", "ID": "fa683fba-1408-4bd6-a5ab-e849ccc07bff", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b00ec81d-4f8b-4180-86e1-27eb982687fd"}, {"Element": "<span lang=\"EN-GB\">Clinical remission at week\u00a030<sup>a</sup></span>", "ID": "5149795b-6be0-46f3-b516-7cb85a02a104", "Styles": "None", "Classes": "None", "Text": "Clinical remission at week\u00a030", "ParentId": "fa683fba-1408-4bd6-a5ab-e849ccc07bff"}, {"Element": "<sup>a</sup>", "ID": "2c205a80-35d4-4366-ac5d-f730caeda4ac", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "5149795b-6be0-46f3-b516-7cb85a02a104"}, {"Element": "<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13.1%</span></p>\n</td>", "ID": "484b270c-64b0-4a24-adab-c7cbce76ad82", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d9ff887a-3231-450f-bd09-c1992dd1e21f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">13.1%</span></p>", "ID": "4691833f-b204-434e-8b10-731f40b3057d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "484b270c-64b0-4a24-adab-c7cbce76ad82"}, {"Element": "<span lang=\"EN-GB\">13.1%</span>", "ID": "b4c9b7b2-4b8a-4c20-8081-f07b89d3003a", "Styles": "None", "Classes": "None", "Text": "13.1%", "ParentId": "4691833f-b204-434e-8b10-731f40b3057d"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">29.8%</span></p>\n</td>", "ID": "765444ff-dc33-42bf-8a93-1ad2be400d8f", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d9ff887a-3231-450f-bd09-c1992dd1e21f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">29.8%</span></p>", "ID": "4257046a-9de7-40f7-9e9d-5880e3abaac4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "765444ff-dc33-42bf-8a93-1ad2be400d8f"}, {"Element": "<span lang=\"EN-GB\">29.8%</span>", "ID": "c6a3ab46-a05a-4fe7-b878-bbab308cca0f", "Styles": "None", "Classes": "None", "Text": "29.8%", "ParentId": "4257046a-9de7-40f7-9e9d-5880e3abaac4"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.4%</span></p>\n</td>", "ID": "921b1644-c211-4c1f-9b2e-267ba155fa43", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d9ff887a-3231-450f-bd09-c1992dd1e21f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">36.4%</span></p>", "ID": "7911c51f-b91b-44fa-a471-ba56486da843", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "921b1644-c211-4c1f-9b2e-267ba155fa43"}, {"Element": "<span lang=\"EN-GB\">36.4%</span>", "ID": "eef85a91-afe0-4d6e-b73a-05710a283226", "Styles": "None", "Classes": "None", "Text": "36.4%", "ParentId": "7911c51f-b91b-44fa-a471-ba56486da843"}, {"Element": "<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.1%</span></p>\n</td>", "ID": "da268b2e-1e04-4341-b6e5-6b3d8e20eaf7", "Styles": "width:75.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d9ff887a-3231-450f-bd09-c1992dd1e21f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33.1%</span></p>", "ID": "100085f4-c7c1-4538-a53b-b7fbbaa9e905", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da268b2e-1e04-4341-b6e5-6b3d8e20eaf7"}, {"Element": "<span lang=\"EN-GB\">33.1%</span>", "ID": "6c849f6f-91d0-4337-afd4-87e7fa799daa", "Styles": "None", "Classes": "None", "Text": "33.1%", "ParentId": "100085f4-c7c1-4538-a53b-b7fbbaa9e905"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained remission</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(in remission at both</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5.3%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.0%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24.4%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">21.7%</span></p>\n</td>\n</tr>", "ID": "34e75443-86bb-4834-8a0e-baba03385bde", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained remission</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(in remission at both</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span></p>\n</td>", "ID": "468a4970-a4c8-4cf5-80a5-6bbedf680a35", "Styles": "width:146.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "34e75443-86bb-4834-8a0e-baba03385bde"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sustained remission</span></p>", "ID": "bcdb1b54-f826-491e-92b2-a1bf346bb62c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "468a4970-a4c8-4cf5-80a5-6bbedf680a35"}, {"Element": "<span lang=\"EN-GB\">Sustained remission</span>", "ID": "2292d252-4d63-42aa-9e8c-a1fc954347fa", "Styles": "None", "Classes": "None", "Text": "Sustained remission", "ParentId": "bcdb1b54-f826-491e-92b2-a1bf346bb62c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">(in remission at both</span></p>", "ID": "70d7baf3-c496-4148-87bb-9fb4a2978a4f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "468a4970-a4c8-4cf5-80a5-6bbedf680a35"}, {"Element": "<span lang=\"EN-GB\">(in remission at both</span>", "ID": "9cb07cfc-69c3-4eeb-9b36-9a5300a27259", "Styles": "None", "Classes": "None", "Text": "(in remission at both", "ParentId": "70d7baf3-c496-4148-87bb-9fb4a2978a4f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span></p>", "ID": "82e9ffca-4f7b-49be-b5f6-60a5a2e98a30", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "468a4970-a4c8-4cf5-80a5-6bbedf680a35"}, {"Element": "<span lang=\"EN-GB\">week\u00a08 and week\u00a030)<sup>a</sup></span>", "ID": "fd26835a-4d97-4f36-881f-6b7c1fc99a72", "Styles": "None", "Classes": "None", "Text": "week\u00a08 and week\u00a030)", "ParentId": "82e9ffca-4f7b-49be-b5f6-60a5a2e98a30"}, {"Element": "<sup>a</sup>", "ID": "6cdc3c4e-6856-44b7-a300-8941f3b029ac", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "fd26835a-4d97-4f36-881f-6b7c1fc99a72"}, {"Element": "<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5.3%</span></p>\n</td>", "ID": "bc52851b-f535-4640-976a-1311a1e11482", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "34e75443-86bb-4834-8a0e-baba03385bde"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5.3%</span></p>", "ID": "124d3fce-dcd4-4314-aba7-42f3e6a04943", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bc52851b-f535-4640-976a-1311a1e11482"}, {"Element": "<span lang=\"EN-GB\">5.3%</span>", "ID": "6d6582e3-070e-4dcc-8ed7-ee107f580a4f", "Styles": "None", "Classes": "None", "Text": "5.3%", "ParentId": "124d3fce-dcd4-4314-aba7-42f3e6a04943"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.0%</span></p>\n</td>", "ID": "fe5c3ee8-1dbd-4e78-8cfd-b50e5692a15e", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "34e75443-86bb-4834-8a0e-baba03385bde"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">19.0%</span></p>", "ID": "92119605-4330-4dc4-bd15-8fb2ebb87bf2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fe5c3ee8-1dbd-4e78-8cfd-b50e5692a15e"}, {"Element": "<span lang=\"EN-GB\">19.0%</span>", "ID": "c83d4c89-65ff-48a2-8b17-5188f780a112", "Styles": "None", "Classes": "None", "Text": "19.0%", "ParentId": "92119605-4330-4dc4-bd15-8fb2ebb87bf2"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24.4%</span></p>\n</td>", "ID": "032601e0-af44-468e-9d5d-5d8224200e54", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "34e75443-86bb-4834-8a0e-baba03385bde"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24.4%</span></p>", "ID": "d643d459-01b1-442e-8d32-8da799f05f2b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "032601e0-af44-468e-9d5d-5d8224200e54"}, {"Element": "<span lang=\"EN-GB\">24.4%</span>", "ID": "8b958281-ecc7-4276-9f32-d39b5ed9e166", "Styles": "None", "Classes": "None", "Text": "24.4%", "ParentId": "d643d459-01b1-442e-8d32-8da799f05f2b"}, {"Element": "<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">21.7%</span></p>\n</td>", "ID": "976a38a0-0039-4e7b-be00-ba75a45eafa0", "Styles": "width:75.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "34e75443-86bb-4834-8a0e-baba03385bde"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">21.7%</span></p>", "ID": "6bea40c5-32de-41d1-b1fd-55d68d7dc644", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "976a38a0-0039-4e7b-be00-ba75a45eafa0"}, {"Element": "<span lang=\"EN-GB\">21.7%</span>", "ID": "cc02e36f-8485-4d29-81b1-1077065a483e", "Styles": "None", "Classes": "None", "Text": "21.7%", "ParentId": "6bea40c5-32de-41d1-b1fd-55d68d7dc644"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects with mucosal healing</span></b></p>\n</td>\n</tr>", "ID": "0f1d6536-1213-4957-80af-39af08587cbc", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"606\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects with mucosal healing</span></b></p>\n</td>", "ID": "4c22cbac-1121-4dee-85d3-661a7e992921", "Styles": "width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0f1d6536-1213-4957-80af-39af08587cbc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Percentage\n  of subjects with mucosal healing</span></b></p>", "ID": "64dae380-10d5-4b4b-a727-ab7a0cb9bf9e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4c22cbac-1121-4dee-85d3-661a7e992921"}, {"Element": "<b><span lang=\"EN-GB\">Percentage\n  of subjects with mucosal healing</span></b>", "ID": "7ae6c09e-068c-40ae-984a-e741a38ec149", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "64dae380-10d5-4b4b-a727-ab7a0cb9bf9e"}, {"Element": "<span lang=\"EN-GB\">Percentage\n  of subjects with mucosal healing</span>", "ID": "b928b3bb-0c12-4538-8ab4-bd4df9ad3c79", "Styles": "None", "Classes": "None", "Text": "Percentage   of subjects with mucosal healing", "ParentId": "7ae6c09e-068c-40ae-984a-e741a38ec149"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mucosal healing at week\u00a08<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">32.4%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61.2%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">60.3%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">60.7%</span></p>\n</td>\n</tr>", "ID": "799ea2a3-da75-4d6f-a465-41fa31b989da", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mucosal healing at week\u00a08<sup>a</sup></span></p>\n</td>", "ID": "84c947ee-2f34-4858-8e41-99a86eca719f", "Styles": "width:146.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "799ea2a3-da75-4d6f-a465-41fa31b989da"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mucosal healing at week\u00a08<sup>a</sup></span></p>", "ID": "e272286b-bbd2-4e1a-bf4d-a1d19821c96d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "84c947ee-2f34-4858-8e41-99a86eca719f"}, {"Element": "<span lang=\"EN-GB\">Mucosal healing at week\u00a08<sup>a</sup></span>", "ID": "34bf37ce-ab3e-4ffa-8a5d-27e0de723e47", "Styles": "None", "Classes": "None", "Text": "Mucosal healing at week\u00a08", "ParentId": "e272286b-bbd2-4e1a-bf4d-a1d19821c96d"}, {"Element": "<sup>a</sup>", "ID": "f9c417af-784e-461a-aa4f-0850344cb082", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "34bf37ce-ab3e-4ffa-8a5d-27e0de723e47"}, {"Element": "<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">32.4%</span></p>\n</td>", "ID": "37b4a96d-480d-4737-925c-23f175b0f55f", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "799ea2a3-da75-4d6f-a465-41fa31b989da"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">32.4%</span></p>", "ID": "8543c13d-8383-48fa-86f3-967e66f06b91", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "37b4a96d-480d-4737-925c-23f175b0f55f"}, {"Element": "<span lang=\"EN-GB\">32.4%</span>", "ID": "cd338423-f65a-44a9-906a-8b7e3ab961cf", "Styles": "None", "Classes": "None", "Text": "32.4%", "ParentId": "8543c13d-8383-48fa-86f3-967e66f06b91"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61.2%</span></p>\n</td>", "ID": "fb9e9ae3-3eb9-469e-a814-e101e63f954d", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "799ea2a3-da75-4d6f-a465-41fa31b989da"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61.2%</span></p>", "ID": "211f61cb-2fe6-4743-8751-b41b3071f1ae", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fb9e9ae3-3eb9-469e-a814-e101e63f954d"}, {"Element": "<span lang=\"EN-GB\">61.2%</span>", "ID": "9d2e66c8-d919-4f6b-9d72-32bb31d99cf1", "Styles": "None", "Classes": "None", "Text": "61.2%", "ParentId": "211f61cb-2fe6-4743-8751-b41b3071f1ae"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">60.3%</span></p>\n</td>", "ID": "0e5a8e95-7fe2-4986-b1e5-1c75e9dd00fc", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "799ea2a3-da75-4d6f-a465-41fa31b989da"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">60.3%</span></p>", "ID": "1fe27f60-eba9-4ca7-9579-78c70c2d48bc", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0e5a8e95-7fe2-4986-b1e5-1c75e9dd00fc"}, {"Element": "<span lang=\"EN-GB\">60.3%</span>", "ID": "bd2fda0d-9191-43ca-a24f-625496c2ed34", "Styles": "None", "Classes": "None", "Text": "60.3%", "ParentId": "1fe27f60-eba9-4ca7-9579-78c70c2d48bc"}, {"Element": "<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">60.7%</span></p>\n</td>", "ID": "c199fa87-e7ce-4bef-a4d5-7edc7b46eb23", "Styles": "width:75.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "799ea2a3-da75-4d6f-a465-41fa31b989da"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">60.7%</span></p>", "ID": "0b252174-5db2-4275-8e1a-ea6c2961830b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c199fa87-e7ce-4bef-a4d5-7edc7b46eb23"}, {"Element": "<span lang=\"EN-GB\">60.7%</span>", "ID": "059c0143-bd02-4067-8d64-4ef16d466957", "Styles": "None", "Classes": "None", "Text": "60.7%", "ParentId": "0b252174-5db2-4275-8e1a-ea6c2961830b"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mucosal healing at week\u00a030<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.5%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48.3%</span></p>\n</td>\n<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52.9%</span></p>\n</td>\n<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">50.6%</span></p>\n</td>\n</tr>", "ID": "d41c6974-2cbd-4f44-8b18-a3c4d88c64b3", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "      ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td style=\"width:146.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"195\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mucosal healing at week\u00a030<sup>a</sup></span></p>\n</td>", "ID": "a9b76638-4674-4bca-ac7a-c857e5ce629e", "Styles": "width:146.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d41c6974-2cbd-4f44-8b18-a3c4d88c64b3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Mucosal healing at week\u00a030<sup>a</sup></span></p>", "ID": "c8558b7c-8af5-41ee-a042-3bce5e18807e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a9b76638-4674-4bca-ac7a-c857e5ce629e"}, {"Element": "<span lang=\"EN-GB\">Mucosal healing at week\u00a030<sup>a</sup></span>", "ID": "9910ea98-1b94-4c19-a418-6d879e68c426", "Styles": "None", "Classes": "None", "Text": "Mucosal healing at week\u00a030", "ParentId": "c8558b7c-8af5-41ee-a042-3bce5e18807e"}, {"Element": "<sup>a</sup>", "ID": "2c4aa35b-9488-4ae7-a519-ff14a7be4dfa", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "9910ea98-1b94-4c19-a418-6d879e68c426"}, {"Element": "<td colspan=\"2\" style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.5%</span></p>\n</td>", "ID": "b6126fcc-3532-4ac4-81f4-c5e9f7c50410", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d41c6974-2cbd-4f44-8b18-a3c4d88c64b3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27.5%</span></p>", "ID": "67252872-de87-4310-b92e-56f3e435d327", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b6126fcc-3532-4ac4-81f4-c5e9f7c50410"}, {"Element": "<span lang=\"EN-GB\">27.5%</span>", "ID": "968a3b12-3265-476d-ab71-41e4139fc8f7", "Styles": "None", "Classes": "None", "Text": "27.5%", "ParentId": "67252872-de87-4310-b92e-56f3e435d327"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48.3%</span></p>\n</td>", "ID": "4e7fb0d1-9455-4f8f-958f-b512b4c84d55", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d41c6974-2cbd-4f44-8b18-a3c4d88c64b3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48.3%</span></p>", "ID": "2f7a4489-de80-4f7f-8236-dfdf40d9df95", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4e7fb0d1-9455-4f8f-958f-b512b4c84d55"}, {"Element": "<span lang=\"EN-GB\">48.3%</span>", "ID": "7bf0631b-3165-4254-817e-ce8e92c1263f", "Styles": "None", "Classes": "None", "Text": "48.3%", "ParentId": "2f7a4489-de80-4f7f-8236-dfdf40d9df95"}, {"Element": "<td style=\"width:77.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"103\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52.9%</span></p>\n</td>", "ID": "81986c3f-f056-4086-80d0-81f1353d9f24", "Styles": "width:77.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d41c6974-2cbd-4f44-8b18-a3c4d88c64b3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52.9%</span></p>", "ID": "6aee246a-bf88-4866-99dd-d9558ae2dc73", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "81986c3f-f056-4086-80d0-81f1353d9f24"}, {"Element": "<span lang=\"EN-GB\">52.9%</span>", "ID": "a283c42e-7b0d-4241-83fd-9651ba12b6b7", "Styles": "None", "Classes": "None", "Text": "52.9%", "ParentId": "6aee246a-bf88-4866-99dd-d9558ae2dc73"}, {"Element": "<td style=\"width:75.3pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"100\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">50.6%</span></p>\n</td>", "ID": "cf2e542d-a674-4c5b-ab80-3cd625638a8e", "Styles": "width:75.3pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d41c6974-2cbd-4f44-8b18-a3c4d88c64b3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">50.6%</span></p>", "ID": "48c459bc-9b57-4409-b85d-8b78e891872a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf2e542d-a674-4c5b-ab80-3cd625638a8e"}, {"Element": "<span lang=\"EN-GB\">50.6%</span>", "ID": "ecc25674-62eb-428d-b600-7673958a47fe", "Styles": "None", "Classes": "None", "Text": "50.6%", "ParentId": "48c459bc-9b57-4409-b85d-8b78e891872a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"606\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. placebo.</span></span></p>\n</td>\n</tr>", "ID": "038a48e7-d009-42bf-b45a-7b27e77c121b", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td colspan=\"6\" style=\"width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"606\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. placebo.</span></span></p>\n</td>", "ID": "74868472-c393-4ea4-9705-2daf289a5ae4", "Styles": "width:454.25pt;border:none;\n  border-top:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "038a48e7-d009-42bf-b45a-7b27e77c121b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. placebo.</span></span></p>", "ID": "5a34e6f9-3fa2-4d4e-830e-1b9f75dcf721", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "74868472-c393-4ea4-9705-2daf289a5ae4"}, {"Element": "<sup><span lang=\"EN-GB\">a</span></sup>", "ID": "d0b05bb5-734e-44d5-99ab-b8b835fbfc5f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5a34e6f9-3fa2-4d4e-830e-1b9f75dcf721"}, {"Element": "<span lang=\"EN-GB\">a</span>", "ID": "aed513d1-8a92-4b6a-9d3f-d677518d5187", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "d0b05bb5-734e-44d5-99ab-b8b835fbfc5f"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 <span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. placebo.</span></span>", "ID": "2212a732-e9de-44dd-a224-16f8f5e47bbb", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5a34e6f9-3fa2-4d4e-830e-1b9f75dcf721"}, {"Element": "<span style=\"layout-grid-mode:line\">p\u00a0&lt;\u00a00.001, for each infliximab\n  treatment group vs. placebo.</span>", "ID": "e93eed27-ebfb-498a-be97-e6b48c550eb4", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "p\u00a0<\u00a00.001, for each infliximab   treatment group vs. placebo.", "ParentId": "2212a732-e9de-44dd-a224-16f8f5e47bbb"}, {"Element": "<tr height=\"0\">\n<td style=\"border:none\" width=\"195\"></td>\n<td style=\"border:none\" width=\"103\"></td>\n<td style=\"border:none\" width=\"0\"></td>\n<td style=\"border:none\" width=\"103\"></td>\n<td style=\"border:none\" width=\"103\"></td>\n<td style=\"border:none\" width=\"100\"></td>\n</tr>", "ID": "25afe55c-2222-48db-907e-7fc7a2449d52", "Styles": "None", "Classes": "None", "Text": "       ", "ParentId": "797c1b6e-bab0-4f33-81c6-0653732641b6"}, {"Element": "<td style=\"border:none\" width=\"195\"></td>", "ID": "067cf8b8-0b6c-4c56-b539-bf4a615d7c5f", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "25afe55c-2222-48db-907e-7fc7a2449d52"}, {"Element": "<td style=\"border:none\" width=\"103\"></td>", "ID": "7a05b1da-67b5-4ab9-8992-bffdee34b151", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "25afe55c-2222-48db-907e-7fc7a2449d52"}, {"Element": "<td style=\"border:none\" width=\"0\"></td>", "ID": "4288a403-6631-4161-85ac-f96488ed9c1f", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "25afe55c-2222-48db-907e-7fc7a2449d52"}, {"Element": "<td style=\"border:none\" width=\"103\"></td>", "ID": "678325cb-202f-40ce-90d4-9561fa2abe1d", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "25afe55c-2222-48db-907e-7fc7a2449d52"}, {"Element": "<td style=\"border:none\" width=\"103\"></td>", "ID": "19332a92-ebd5-4770-8497-117a5912c6c9", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "25afe55c-2222-48db-907e-7fc7a2449d52"}, {"Element": "<td style=\"border:none\" width=\"100\"></td>", "ID": "1322a1f2-942e-4f89-827d-35d7f6c564ae", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "25afe55c-2222-48db-907e-7fc7a2449d52"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f50a4cd4-1323-438b-976b-37a7b111c3ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ce0f361d-4917-48d2-8371-a380ff4da536", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f50a4cd4-1323-438b-976b-37a7b111c3ca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The efficacy of Remicade through week\u00a054\nwas assessed in the ACT\u00a01 study.</span></p>", "ID": "0ccb6375-42a9-4237-b2c2-4d7d336c254d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The efficacy of Remicade through week\u00a054\nwas assessed in the ACT\u00a01 study.</span>", "ID": "5e18b72f-36ec-4ad9-b99f-bc3f8564218e", "Styles": "None", "Classes": "None", "Text": "The efficacy of Remicade through week\u00a054 was assessed in the ACT\u00a01 study.", "ParentId": "0ccb6375-42a9-4237-b2c2-4d7d336c254d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">At\u00a054\u00a0weeks, 44.9% of patients in\nthe combined infliximab treatment group were in clinical response compared to\n19.8% in the placebo treatment group (p\u00a0&lt;\u00a00.001). Clinical\nremission and mucosal healing occurred in a greater proportion of patients in\nthe combined infliximab treatment group compared to the placebo treatment group\nat week\u00a054 (34.6% vs. 16.5%, p\u00a0&lt;\u00a00.001 and 46.1% vs. 18.2%,\np\u00a0&lt;\u00a00.001, respectively). The proportions of patients in sustained\nresponse and sustained remission at week\u00a054 were greater in the combined\ninfliximab treatment group than in the placebo treatment group (37.9% vs.\n14.0%, p\u00a0&lt;\u00a00.001; and 20.2% vs. 6.6%, p\u00a0&lt;\u00a00.001,\nrespectively).</span></p>", "ID": "cf27e1d5-008a-4df9-a6a9-390bd39f2433", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">At\u00a054\u00a0weeks, 44.9% of patients in\nthe combined infliximab treatment group were in clinical response compared to\n19.8% in the placebo treatment group (p\u00a0&lt;\u00a00.001). Clinical\nremission and mucosal healing occurred in a greater proportion of patients in\nthe combined infliximab treatment group compared to the placebo treatment group\nat week\u00a054 (34.6% vs. 16.5%, p\u00a0&lt;\u00a00.001 and 46.1% vs. 18.2%,\np\u00a0&lt;\u00a00.001, respectively). The proportions of patients in sustained\nresponse and sustained remission at week\u00a054 were greater in the combined\ninfliximab treatment group than in the placebo treatment group (37.9% vs.\n14.0%, p\u00a0&lt;\u00a00.001; and 20.2% vs. 6.6%, p\u00a0&lt;\u00a00.001,\nrespectively).</span>", "ID": "08b40809-6f73-4351-a0e3-f62e1059a619", "Styles": "None", "Classes": "None", "Text": "At\u00a054\u00a0weeks, 44.9% of patients in the combined infliximab treatment group were in clinical response compared to 19.8% in the placebo treatment group (p\u00a0<\u00a00.001). Clinical remission and mucosal healing occurred in a greater proportion of patients in the combined infliximab treatment group compared to the placebo treatment group at week\u00a054 (34.6% vs. 16.5%, p\u00a0<\u00a00.001 and 46.1% vs. 18.2%, p\u00a0<\u00a00.001, respectively). The proportions of patients in sustained response and sustained remission at week\u00a054 were greater in the combined infliximab treatment group than in the placebo treatment group (37.9% vs. 14.0%, p\u00a0<\u00a00.001; and 20.2% vs. 6.6%, p\u00a0<\u00a00.001, respectively).", "ParentId": "cf27e1d5-008a-4df9-a6a9-390bd39f2433"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "55652aa8-3cd0-4509-9ebd-c549536f1d6c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "990bc99a-9344-4d06-84c2-db623d1dc6e5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "55652aa8-3cd0-4509-9ebd-c549536f1d6c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">A greater proportion of patients in the\ncombined infliximab treatment group were able to discontinue corticosteroids\nwhile remaining in clinical remission compared to the placebo treatment group\nat both week\u00a030 (22.3% vs. 7.2%, p\u00a0&lt;\u00a00.001, pooled ACT\u00a01\n&amp; ACT\u00a02 data) and week\u00a054 (21.0% vs. 8.9%, p\u00a0=\u00a00.022,\nACT1 data).</span></p>", "ID": "acc70ecf-d28c-421a-aaaf-c26f8071ebd1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">A greater proportion of patients in the\ncombined infliximab treatment group were able to discontinue corticosteroids\nwhile remaining in clinical remission compared to the placebo treatment group\nat both week\u00a030 (22.3% vs. 7.2%, p\u00a0&lt;\u00a00.001, pooled ACT\u00a01\n&amp; ACT\u00a02 data) and week\u00a054 (21.0% vs. 8.9%, p\u00a0=\u00a00.022,\nACT1 data).</span>", "ID": "fca2ea7a-11c9-4de7-b26f-e36875ec9bf1", "Styles": "None", "Classes": "None", "Text": "A greater proportion of patients in the combined infliximab treatment group were able to discontinue corticosteroids while remaining in clinical remission compared to the placebo treatment group at both week\u00a030 (22.3% vs. 7.2%, p\u00a0<\u00a00.001, pooled ACT\u00a01 & ACT\u00a02 data) and week\u00a054 (21.0% vs. 8.9%, p\u00a0=\u00a00.022, ACT1 data).", "ParentId": "acc70ecf-d28c-421a-aaaf-c26f8071ebd1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "98d5c15d-4bc9-43b8-a09d-145448d287ce", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "035306ea-e8af-4872-922b-51aeac1e2cac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "98d5c15d-4bc9-43b8-a09d-145448d287ce"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The pooled data\nanalysis from the ACT\u00a01 and ACT\u00a02 studies and their extensions,\nanalysed from baseline through 54\u00a0weeks, demonstrated a reduction of\nulcerative colitis\u2011related hospitalisations and surgical procedures with\ninfliximab treatment. The number of ulcerative colitis\u2011related\nhospitalisations was significantly lower in the 5 and 10\u00a0mg/kg infliximab\ntreatment groups than in the placebo group (mean number of hospitalisations per\n100\u00a0subject\u2011years: 21 and 19 vs. 40 in the placebo group; p\u00a0=\u00a00.019\nand p\u00a0=\u00a00.007, respectively). The number of ulcerative colitis\u2011related\nsurgical procedures was also lower in the 5 and 10\u00a0mg/kg infliximab\ntreatment groups than in the placebo group (mean number of surgical procedures\nper 100\u00a0subject\u2011years: 22 and 19 vs. 34<i>; </i>p\u00a0=\u00a00.145\nand p\u00a0=\u00a00.022, respectively).</span></p>", "ID": "06396bd0-5063-433f-8ffb-97738c9515dc", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The pooled data\nanalysis from the ACT\u00a01 and ACT\u00a02 studies and their extensions,\nanalysed from baseline through 54\u00a0weeks, demonstrated a reduction of\nulcerative colitis\u2011related hospitalisations and surgical procedures with\ninfliximab treatment. The number of ulcerative colitis\u2011related\nhospitalisations was significantly lower in the 5 and 10\u00a0mg/kg infliximab\ntreatment groups than in the placebo group (mean number of hospitalisations per\n100\u00a0subject\u2011years: 21 and 19 vs. 40 in the placebo group; p\u00a0=\u00a00.019\nand p\u00a0=\u00a00.007, respectively). The number of ulcerative colitis\u2011related\nsurgical procedures was also lower in the 5 and 10\u00a0mg/kg infliximab\ntreatment groups than in the placebo group (mean number of surgical procedures\nper 100\u00a0subject\u2011years: 22 and 19 vs. 34<i>; </i>p\u00a0=\u00a00.145\nand p\u00a0=\u00a00.022, respectively).</span>", "ID": "c87f15da-18ad-4c9e-bd19-eaf99231c10e", "Styles": "None", "Classes": "None", "Text": "The pooled data analysis from the ACT\u00a01 and ACT\u00a02 studies and their extensions, analysed from baseline through 54\u00a0weeks, demonstrated a reduction of ulcerative colitis\u2011related hospitalisations and surgical procedures with infliximab treatment. The number of ulcerative colitis\u2011related hospitalisations was significantly lower in the 5 and 10\u00a0mg/kg infliximab treatment groups than in the placebo group (mean number of hospitalisations per 100\u00a0subject\u2011years: 21 and 19 vs. 40 in the placebo group; p\u00a0=\u00a00.019 and p\u00a0=\u00a00.007, respectively). The number of ulcerative colitis\u2011related surgical procedures was also lower in the 5 and 10\u00a0mg/kg infliximab treatment groups than in the placebo group (mean number of surgical procedures per 100\u00a0subject\u2011years: 22 and 19 vs. 34p\u00a0=\u00a00.145 and p\u00a0=\u00a00.022, respectively).", "ParentId": "06396bd0-5063-433f-8ffb-97738c9515dc"}, {"Element": "<i>; </i>", "ID": "6dbccf71-c666-4e08-9bca-977f269ddf00", "Styles": "None", "Classes": "None", "Text": "; ", "ParentId": "c87f15da-18ad-4c9e-bd19-eaf99231c10e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "667d4aa3-269a-4195-8fcf-9c24421c2227", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0125f74a-bac0-4381-b560-68a9092e284d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "667d4aa3-269a-4195-8fcf-9c24421c2227"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The proportion\nof subjects who underwent colectomy at any time within 54\u00a0weeks following\nthe first infusion of study agent were collected and pooled from the ACT\u00a01\nand ACT\u00a02 studies and their extensions. Fewer subjects underwent colectomy\nin the 5\u00a0mg/kg infliximab group (28/242 or 11.6% [N.S.]) and the\n10\u00a0mg/kg infliximab group (18/242 or 7.4% [p\u00a0=\u00a00.011]) than in\nthe placebo group (36/244; 14.8%).</span></p>", "ID": "ecb8fa56-fabd-4662-8190-b1d42207c3d0", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The proportion\nof subjects who underwent colectomy at any time within 54\u00a0weeks following\nthe first infusion of study agent were collected and pooled from the ACT\u00a01\nand ACT\u00a02 studies and their extensions. Fewer subjects underwent colectomy\nin the 5\u00a0mg/kg infliximab group (28/242 or 11.6% [N.S.]) and the\n10\u00a0mg/kg infliximab group (18/242 or 7.4% [p\u00a0=\u00a00.011]) than in\nthe placebo group (36/244; 14.8%).</span>", "ID": "daa679f7-2d20-4fda-b9ac-2e234682e33c", "Styles": "None", "Classes": "None", "Text": "The proportion of subjects who underwent colectomy at any time within 54\u00a0weeks following the first infusion of study agent were collected and pooled from the ACT\u00a01 and ACT\u00a02 studies and their extensions. Fewer subjects underwent colectomy in the 5\u00a0mg/kg infliximab group (28/242 or 11.6% [N.S.]) and the 10\u00a0mg/kg infliximab group (18/242 or 7.4% [p\u00a0=\u00a00.011]) than in the placebo group (36/244; 14.8%).", "ParentId": "ecb8fa56-fabd-4662-8190-b1d42207c3d0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2693ba7e-3da7-406e-9b78-4e010815871b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d8716002-5121-4a8b-b9dd-1b4faf515154", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2693ba7e-3da7-406e-9b78-4e010815871b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The reduction in incidence of colectomy was\nalso examined in another randomised, double\u2011blind study (C0168Y06) in\nhospitalised patients </span><span lang=\"EN-GB\">(n\u00a0=\u00a045) </span><span lang=\"EN-GB\">with moderately to severely active ulcerative colitis who failed to\nrespond to intravenous corticosteroids and who were therefore at higher risk\nfor colectomy. Significantly fewer colectomies occurred within 3\u00a0months of\nstudy infusion in patients who received a single dose of 5\u00a0mg/kg\ninfliximab compared to patients who received placebo (29.2% vs. 66.7%\nrespectively, p\u00a0=\u00a00.017).</span></p>", "ID": "66b4638a-0a5c-4067-8565-058bb173a77c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The reduction in incidence of colectomy was\nalso examined in another randomised, double\u2011blind study (C0168Y06) in\nhospitalised patients </span>", "ID": "06f9edb3-0a93-49b0-88ea-bc8a2be28f72", "Styles": "None", "Classes": "None", "Text": "The reduction in incidence of colectomy was also examined in another randomised, double\u2011blind study (C0168Y06) in hospitalised patients ", "ParentId": "66b4638a-0a5c-4067-8565-058bb173a77c"}, {"Element": "<span lang=\"EN-GB\">(n\u00a0=\u00a045) </span>", "ID": "cbfb3ad3-601b-4576-bc91-2cdee6450fdb", "Styles": "None", "Classes": "None", "Text": "(n\u00a0=\u00a045) ", "ParentId": "66b4638a-0a5c-4067-8565-058bb173a77c"}, {"Element": "<span lang=\"EN-GB\">with moderately to severely active ulcerative colitis who failed to\nrespond to intravenous corticosteroids and who were therefore at higher risk\nfor colectomy. Significantly fewer colectomies occurred within 3\u00a0months of\nstudy infusion in patients who received a single dose of 5\u00a0mg/kg\ninfliximab compared to patients who received placebo (29.2% vs. 66.7%\nrespectively, p\u00a0=\u00a00.017).</span>", "ID": "d55afca6-a004-44a8-9291-1d75e1355137", "Styles": "None", "Classes": "None", "Text": "with moderately to severely active ulcerative colitis who failed to respond to intravenous corticosteroids and who were therefore at higher risk for colectomy. Significantly fewer colectomies occurred within 3\u00a0months of study infusion in patients who received a single dose of 5\u00a0mg/kg infliximab compared to patients who received placebo (29.2% vs. 66.7% respectively, p\u00a0=\u00a00.017).", "ParentId": "66b4638a-0a5c-4067-8565-058bb173a77c"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "53b56a85-a536-4e9a-8779-8968456b3e84", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "41515cc1-1de1-4548-8cba-7e0ebb118754", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "53b56a85-a536-4e9a-8779-8968456b3e84"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In ACT\u00a01 and ACT\u00a02, infliximab\nimproved quality of life, confirmed by statistically significant improvement in\nboth a disease specific measure, IBDQ, and by improvement in the generic 36\u2011item\nshort form survey SF\u201136.</span></p>", "ID": "5c3f52ca-e013-42e6-80de-0a29f9750cc4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In ACT\u00a01 and ACT\u00a02, infliximab\nimproved quality of life, confirmed by statistically significant improvement in\nboth a disease specific measure, IBDQ, and by improvement in the generic 36\u2011item\nshort form survey SF\u201136.</span>", "ID": "58fa6306-c562-42b3-be8d-7e9ca5728594", "Styles": "None", "Classes": "None", "Text": "In ACT\u00a01 and ACT\u00a02, infliximab improved quality of life, confirmed by statistically significant improvement in both a disease specific measure, IBDQ, and by improvement in the generic 36\u2011item short form survey SF\u201136.", "ParentId": "5c3f52ca-e013-42e6-80de-0a29f9750cc4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0a5776e8-fffb-4fbe-b931-08122fff3eaa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5b17e1ba-0557-46ac-a368-b0f4dd19953f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a5776e8-fffb-4fbe-b931-08122fff3eaa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Adult\nankylosing spondylitis</span></u></p>", "ID": "bd89d35a-6ac0-4982-a998-5bc996bf41b4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Adult\nankylosing spondylitis</span></u>", "ID": "004460c7-5371-4651-887e-98ae8ae06abc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bd89d35a-6ac0-4982-a998-5bc996bf41b4"}, {"Element": "<span lang=\"EN-GB\">Adult\nankylosing spondylitis</span>", "ID": "bc7ff36d-43cd-49a2-afec-5a02998527a3", "Styles": "None", "Classes": "None", "Text": "Adult ankylosing spondylitis", "ParentId": "004460c7-5371-4651-887e-98ae8ae06abc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Efficacy and safety of infliximab were\nassessed in two multicenter, double\u2011blind, placebo\u2011controlled\nstudies in patients with active ankylosing spondylitis (Bath Ankylosing\nSpondylitis Disease Activity Index [BASDAI] score \u2265\u00a04 and spinal\npain \u2265\u00a04 on a scale of 1\u201110).</span></p>", "ID": "9488ca10-34ea-4379-b1a0-f9e870cb1dfd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Efficacy and safety of infliximab were\nassessed in two multicenter, double\u2011blind, placebo\u2011controlled\nstudies in patients with active ankylosing spondylitis (Bath Ankylosing\nSpondylitis Disease Activity Index [BASDAI] score \u2265\u00a04 and spinal\npain \u2265\u00a04 on a scale of 1\u201110).</span>", "ID": "f0f90134-bad4-4039-bdab-f7c367d2eeba", "Styles": "None", "Classes": "None", "Text": "Efficacy and safety of infliximab were assessed in two multicenter, double\u2011blind, placebo\u2011controlled studies in patients with active ankylosing spondylitis (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] score \u2265\u00a04 and spinal pain \u2265\u00a04 on a scale of 1\u201110).", "ParentId": "9488ca10-34ea-4379-b1a0-f9e870cb1dfd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "20aa43f8-48a7-4418-ac01-ee4d8b0d83c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ab7de6f6-4d6b-4164-a164-632fd2dac68c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "20aa43f8-48a7-4418-ac01-ee4d8b0d83c8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the first study (P01522), which had a\n3\u00a0month double\u2011blind phase, 70\u00a0patients received either 5\u00a0mg/kg\ninfliximab or placebo at weeks\u00a00, 2, 6 (35\u00a0patients in each group).\nAt week\u00a012, placebo patients were switched to infliximab 5\u00a0mg/kg\nevery 6\u00a0weeks up to week\u00a054. After the first year of the study,\n53\u00a0patients continued into an open\u2011label extension to week\u00a0102.</span></p>", "ID": "99948adb-dda8-4ac1-8b7d-5c78fe676ce7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In the first study (P01522), which had a\n3\u00a0month double\u2011blind phase, 70\u00a0patients received either 5\u00a0mg/kg\ninfliximab or placebo at weeks\u00a00, 2, 6 (35\u00a0patients in each group).\nAt week\u00a012, placebo patients were switched to infliximab 5\u00a0mg/kg\nevery 6\u00a0weeks up to week\u00a054. After the first year of the study,\n53\u00a0patients continued into an open\u2011label extension to week\u00a0102.</span>", "ID": "b75d65aa-67cc-46a9-87de-fddfadc4ef78", "Styles": "None", "Classes": "None", "Text": "In the first study (P01522), which had a 3\u00a0month double\u2011blind phase, 70\u00a0patients received either 5\u00a0mg/kg infliximab or placebo at weeks\u00a00, 2, 6 (35\u00a0patients in each group). At week\u00a012, placebo patients were switched to infliximab 5\u00a0mg/kg every 6\u00a0weeks up to week\u00a054. After the first year of the study, 53\u00a0patients continued into an open\u2011label extension to week\u00a0102.", "ParentId": "99948adb-dda8-4ac1-8b7d-5c78fe676ce7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dfa78798-69d2-4bde-be49-55e52a13bd2e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8913d88f-7b85-4742-8fd0-7a7b287167f4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dfa78798-69d2-4bde-be49-55e52a13bd2e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the second clinical study (ASSERT), 279\u00a0patients\nwere randomised to receive either placebo (Group\u00a01, n\u00a0=\u00a078) or 5\u00a0mg/kg\ninfliximab (Group\u00a02, n\u00a0=\u00a0201) at 0, 2 and 6\u00a0weeks and every\n6\u00a0weeks to week\u00a024. Thereafter, all subjects continued on infliximab\nevery 6\u00a0weeks to week\u00a096. Group\u00a01 received 5\u00a0mg/kg\ninfliximab. In group\u00a02, starting with the week\u00a036 infusion, patients\nwho had a BASDAI \u2265\u00a03 at 2\u00a0consecutive visits, received 7.5\u00a0mg/kg\ninfliximab every 6\u00a0weeks thereafter through week\u00a096.</span></p>", "ID": "ae5d793f-3f17-426c-96e6-86a6598072f1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In the second clinical study (ASSERT), 279\u00a0patients\nwere randomised to receive either placebo (Group\u00a01, n\u00a0=\u00a078) or 5\u00a0mg/kg\ninfliximab (Group\u00a02, n\u00a0=\u00a0201) at 0, 2 and 6\u00a0weeks and every\n6\u00a0weeks to week\u00a024. Thereafter, all subjects continued on infliximab\nevery 6\u00a0weeks to week\u00a096. Group\u00a01 received 5\u00a0mg/kg\ninfliximab. In group\u00a02, starting with the week\u00a036 infusion, patients\nwho had a BASDAI \u2265\u00a03 at 2\u00a0consecutive visits, received 7.5\u00a0mg/kg\ninfliximab every 6\u00a0weeks thereafter through week\u00a096.</span>", "ID": "421735c5-f090-4863-9932-29060389d437", "Styles": "None", "Classes": "None", "Text": "In the second clinical study (ASSERT), 279\u00a0patients were randomised to receive either placebo (Group\u00a01, n\u00a0=\u00a078) or 5\u00a0mg/kg infliximab (Group\u00a02, n\u00a0=\u00a0201) at 0, 2 and 6\u00a0weeks and every 6\u00a0weeks to week\u00a024. Thereafter, all subjects continued on infliximab every 6\u00a0weeks to week\u00a096. Group\u00a01 received 5\u00a0mg/kg infliximab. In group\u00a02, starting with the week\u00a036 infusion, patients who had a BASDAI \u2265\u00a03 at 2\u00a0consecutive visits, received 7.5\u00a0mg/kg infliximab every 6\u00a0weeks thereafter through week\u00a096.", "ParentId": "ae5d793f-3f17-426c-96e6-86a6598072f1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "91108aea-ce97-43e8-a9fb-6876339c7298", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "52c0056e-c85c-4b77-922e-b0be6d1be49e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "91108aea-ce97-43e8-a9fb-6876339c7298"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In ASSERT, improvement in signs and\nsymptoms was observed as early as week\u00a02. At week\u00a024, the number of\nASAS\u00a020 responders was 15/78 (19%) in the placebo group, and 123/201 (61%)\nin the 5\u00a0mg/kg infliximab group (p\u00a0&lt;\u00a00.001). There were 95\u00a0subjects\nfrom group\u00a02 who continued on 5\u00a0mg/kg every 6\u00a0weeks. At\n102\u00a0weeks there were 80\u00a0subjects still on infliximab treatment and among\nthose, 71 (89%) were ASAS\u00a020 responders.</span></p>", "ID": "f3b9cf27-40a0-4414-9a7d-5ed5e822982e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In ASSERT, improvement in signs and\nsymptoms was observed as early as week\u00a02. At week\u00a024, the number of\nASAS\u00a020 responders was 15/78 (19%) in the placebo group, and 123/201 (61%)\nin the 5\u00a0mg/kg infliximab group (p\u00a0&lt;\u00a00.001). There were 95\u00a0subjects\nfrom group\u00a02 who continued on 5\u00a0mg/kg every 6\u00a0weeks. At\n102\u00a0weeks there were 80\u00a0subjects still on infliximab treatment and among\nthose, 71 (89%) were ASAS\u00a020 responders.</span>", "ID": "30bcdfb2-8d45-4e08-909f-3a9e48966cd4", "Styles": "None", "Classes": "None", "Text": "In ASSERT, improvement in signs and symptoms was observed as early as week\u00a02. At week\u00a024, the number of ASAS\u00a020 responders was 15/78 (19%) in the placebo group, and 123/201 (61%) in the 5\u00a0mg/kg infliximab group (p\u00a0<\u00a00.001). There were 95\u00a0subjects from group\u00a02 who continued on 5\u00a0mg/kg every 6\u00a0weeks. At 102\u00a0weeks there were 80\u00a0subjects still on infliximab treatment and among those, 71 (89%) were ASAS\u00a020 responders.", "ParentId": "f3b9cf27-40a0-4414-9a7d-5ed5e822982e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c8f163b9-e132-45be-928c-247d553b4814", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2d361903-2a84-4b91-9f13-869ece5f2648", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c8f163b9-e132-45be-928c-247d553b4814"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In P01522, improvement in signs and\nsymptoms was also observed as early as week\u00a02. At week\u00a012, the number\nof BASDAI\u00a050 responders were 3/35 (9%) in the placebo group, and 20/35\n(57%) in the 5\u00a0mg/kg group (p\u00a0&lt;\u00a00.01). There were\n53\u00a0subjects who continued on 5\u00a0mg/kg every 6\u00a0weeks. At\n102\u00a0weeks there were 49\u00a0subjects still on infliximab treatment and\namong those, 30 (61%) were BASDAI\u00a050 responders.</span></p>", "ID": "c8c06cc3-2a26-4313-8ad6-9dab68f423d3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In P01522, improvement in signs and\nsymptoms was also observed as early as week\u00a02. At week\u00a012, the number\nof BASDAI\u00a050 responders were 3/35 (9%) in the placebo group, and 20/35\n(57%) in the 5\u00a0mg/kg group (p\u00a0&lt;\u00a00.01). There were\n53\u00a0subjects who continued on 5\u00a0mg/kg every 6\u00a0weeks. At\n102\u00a0weeks there were 49\u00a0subjects still on infliximab treatment and\namong those, 30 (61%) were BASDAI\u00a050 responders.</span>", "ID": "3eedd955-2a03-4b2f-a61b-f8adeb4cb218", "Styles": "None", "Classes": "None", "Text": "In P01522, improvement in signs and symptoms was also observed as early as week\u00a02. At week\u00a012, the number of BASDAI\u00a050 responders were 3/35 (9%) in the placebo group, and 20/35 (57%) in the 5\u00a0mg/kg group (p\u00a0<\u00a00.01). There were 53\u00a0subjects who continued on 5\u00a0mg/kg every 6\u00a0weeks. At 102\u00a0weeks there were 49\u00a0subjects still on infliximab treatment and among those, 30 (61%) were BASDAI\u00a050 responders.", "ParentId": "c8c06cc3-2a26-4313-8ad6-9dab68f423d3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0c95ab05-378a-4f57-8c8a-1fd79fa081f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b6ae033-54ea-4b2e-b2cf-8b72675e4556", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0c95ab05-378a-4f57-8c8a-1fd79fa081f2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In both studies, physical function and\nquality of life as measured by the BASFI and the physical component score of\nthe SF\u201136 were also improved significantly.</span></p>", "ID": "1d903c49-0536-46c4-96c4-47784e5103cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In both studies, physical function and\nquality of life as measured by the BASFI and the physical component score of\nthe SF\u201136 were also improved significantly.</span>", "ID": "a7408610-f070-477c-ad04-cf0f4b6ba3ba", "Styles": "None", "Classes": "None", "Text": "In both studies, physical function and quality of life as measured by the BASFI and the physical component score of the SF\u201136 were also improved significantly.", "ParentId": "1d903c49-0536-46c4-96c4-47784e5103cd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dcb2d3d5-c281-481e-9143-252505dc1159", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a216528f-970f-441a-9819-52ae7bf5e007", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dcb2d3d5-c281-481e-9143-252505dc1159"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Adult\npsoriatic arthritis</span></u></p>", "ID": "1a622ab8-1d9c-4492-b0db-c6912a4938cb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Adult\npsoriatic arthritis</span></u>", "ID": "20ab9c91-e2aa-4153-8b95-384ecdf1070a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1a622ab8-1d9c-4492-b0db-c6912a4938cb"}, {"Element": "<span lang=\"EN-GB\">Adult\npsoriatic arthritis</span>", "ID": "7ee95abf-e759-4be2-9736-89a4a5c4cc91", "Styles": "None", "Classes": "None", "Text": "Adult psoriatic arthritis", "ParentId": "20ab9c91-e2aa-4153-8b95-384ecdf1070a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Efficacy and safety were assessed in two\nmulticenter, double\u2011blind, placebo\u2011controlled studies in patients\nwith active psoriatic arthritis.</span></p>", "ID": "b0271ff0-b3a2-4cdc-b306-1068a7113ae4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Efficacy and safety were assessed in two\nmulticenter, double\u2011blind, placebo\u2011controlled studies in patients\nwith active psoriatic arthritis.</span>", "ID": "e529f533-26e7-49bb-b22e-8c0fba657c59", "Styles": "None", "Classes": "None", "Text": "Efficacy and safety were assessed in two multicenter, double\u2011blind, placebo\u2011controlled studies in patients with active psoriatic arthritis.", "ParentId": "b0271ff0-b3a2-4cdc-b306-1068a7113ae4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2f053e6e-7c44-41fd-ab33-069174800180", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "348fc54c-53a8-4e5c-9a15-28a4225b4939", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f053e6e-7c44-41fd-ab33-069174800180"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the first clinical study (IMPACT),\nefficacy and safety of infliximab were studied in 104\u00a0patients with active\npolyarticular psoriatic arthritis. During the 16\u2011week double\u2011blind\nphase, patients received either 5\u00a0mg/kg infliximab or placebo at weeks\u00a00,\n2, 6, and 14 (52\u00a0patients in each group). Starting at week\u00a016,\nplacebo patients were switched to infliximab and all patients subsequently\nreceived 5\u00a0mg/kg infliximab every 8\u00a0weeks up to week\u00a046. After\nthe first year of the study, 78\u00a0patients continued into an open\u2011label\nextension to week\u00a098.</span></p>", "ID": "574d6dd0-390e-4db3-a493-23cddcaff64e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In the first clinical study (IMPACT),\nefficacy and safety of infliximab were studied in 104\u00a0patients with active\npolyarticular psoriatic arthritis. During the 16\u2011week double\u2011blind\nphase, patients received either 5\u00a0mg/kg infliximab or placebo at weeks\u00a00,\n2, 6, and 14 (52\u00a0patients in each group). Starting at week\u00a016,\nplacebo patients were switched to infliximab and all patients subsequently\nreceived 5\u00a0mg/kg infliximab every 8\u00a0weeks up to week\u00a046. After\nthe first year of the study, 78\u00a0patients continued into an open\u2011label\nextension to week\u00a098.</span>", "ID": "db1f77dd-f3cd-4a31-ba81-eb2ffce7900c", "Styles": "None", "Classes": "None", "Text": "In the first clinical study (IMPACT), efficacy and safety of infliximab were studied in 104\u00a0patients with active polyarticular psoriatic arthritis. During the 16\u2011week double\u2011blind phase, patients received either 5\u00a0mg/kg infliximab or placebo at weeks\u00a00, 2, 6, and 14 (52\u00a0patients in each group). Starting at week\u00a016, placebo patients were switched to infliximab and all patients subsequently received 5\u00a0mg/kg infliximab every 8\u00a0weeks up to week\u00a046. After the first year of the study, 78\u00a0patients continued into an open\u2011label extension to week\u00a098.", "ParentId": "574d6dd0-390e-4db3-a493-23cddcaff64e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d5cce20-6d6f-49bb-bf2f-b7c12292c7ec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e3efc84d-fdb8-40e7-a39d-641a3867fc63", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d5cce20-6d6f-49bb-bf2f-b7c12292c7ec"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the second clinical study (IMPACT\u00a02),\nefficacy and safety of infliximab were studied in 200\u00a0patients with active\npsoriatic arthritis (\u2265\u00a05\u00a0swollen joints and \u2265\u00a05\u00a0tender\njoints). Forty\u00a0six percent of patients continued on stable doses of\nmethotrexate (\u2264\u00a025\u00a0mg/week). During the 24\u2011week double\u2011blind\nphase, patients received either 5\u00a0mg/kg infliximab or placebo at weeks\u00a00,\n2, 6, 14, and 22 (100\u00a0patients in each group). At week\u00a016,\n47\u00a0placebo patients with &lt;\u00a010% improvement from baseline in both\nswollen and tender joint counts were switched to infliximab induction (early\nescape). At week\u00a024, all placebo\u2011treated patients crossed over to\ninfliximab induction. Dosing continued for all patients through week\u00a046.</span></p>", "ID": "d7f32a4a-ae66-4659-beb6-0b52ea729e07", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In the second clinical study (IMPACT\u00a02),\nefficacy and safety of infliximab were studied in 200\u00a0patients with active\npsoriatic arthritis (\u2265\u00a05\u00a0swollen joints and \u2265\u00a05\u00a0tender\njoints). Forty\u00a0six percent of patients continued on stable doses of\nmethotrexate (\u2264\u00a025\u00a0mg/week). During the 24\u2011week double\u2011blind\nphase, patients received either 5\u00a0mg/kg infliximab or placebo at weeks\u00a00,\n2, 6, 14, and 22 (100\u00a0patients in each group). At week\u00a016,\n47\u00a0placebo patients with &lt;\u00a010% improvement from baseline in both\nswollen and tender joint counts were switched to infliximab induction (early\nescape). At week\u00a024, all placebo\u2011treated patients crossed over to\ninfliximab induction. Dosing continued for all patients through week\u00a046.</span>", "ID": "e31ab45f-3b72-4b25-b1d3-6ca46f984d54", "Styles": "None", "Classes": "None", "Text": "In the second clinical study (IMPACT\u00a02), efficacy and safety of infliximab were studied in 200\u00a0patients with active psoriatic arthritis (\u2265\u00a05\u00a0swollen joints and \u2265\u00a05\u00a0tender joints). Forty\u00a0six percent of patients continued on stable doses of methotrexate (\u2264\u00a025\u00a0mg/week). During the 24\u2011week double\u2011blind phase, patients received either 5\u00a0mg/kg infliximab or placebo at weeks\u00a00, 2, 6, 14, and 22 (100\u00a0patients in each group). At week\u00a016, 47\u00a0placebo patients with <\u00a010% improvement from baseline in both swollen and tender joint counts were switched to infliximab induction (early escape). At week\u00a024, all placebo\u2011treated patients crossed over to infliximab induction. Dosing continued for all patients through week\u00a046.", "ParentId": "d7f32a4a-ae66-4659-beb6-0b52ea729e07"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ecc32d1c-69e6-4df9-8ce1-18d762f4fc92", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5f0ea62d-85d3-496c-a211-b13b4054d028", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ecc32d1c-69e6-4df9-8ce1-18d762f4fc92"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Key efficacy results for IMPACT and IMPACT\u00a02\nare shown in Table\u00a09 below:</span></p>", "ID": "02878baa-9d1f-475f-8179-5cc709e510d5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Key efficacy results for IMPACT and IMPACT\u00a02\nare shown in Table\u00a09 below:</span>", "ID": "1fcfdfd2-f8aa-4288-9007-a45595d748ee", "Styles": "None", "Classes": "None", "Text": "Key efficacy results for IMPACT and IMPACT\u00a02 are shown in Table\u00a09 below:", "ParentId": "02878baa-9d1f-475f-8179-5cc709e510d5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "59d989fa-b8ac-4b5c-a9bf-1efb65a20a8a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "156f3d25-7106-4079-b7bb-4b79e3883ad5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "59d989fa-b8ac-4b5c-a9bf-1efb65a20a8a"}, {"Element": "<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"8\" style=\"width:100.0%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a09</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on ACR and PASI in IMPACT and IMPACT\u00a02</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"4\" style=\"width:38.86%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">IMPACT</span></p>\n</td>\n<td colspan=\"3\" style=\"width:38.68%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">IMPACT\u00a02*</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Placebo\n  (week\u00a016)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab\n  (week\u00a016)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a098)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Placebo</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a024)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab\n  (week\u00a024)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a054)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients randomised</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">N/A<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">ACR response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(% of patients)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">78</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a020\n  response*</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5(10%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34\n  (65%)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48\n  (62%)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">16\n  (16%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">54\n  (54%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">53\n  (53%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a050\n  response*</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0(0%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24\n  (46%)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">35\n  (45%)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">4\n  (4%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">41(41%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33\n  (33%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a070\n  response*</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0(0%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15\n  (29%)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27\n  (35%)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27\n  (27%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">20\n  (20%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PASI response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(% of patients)<sup>b</sup></span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">87</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">83</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">82</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">PASI\u00a075\n  response**</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">50\n  (60%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40\n  (48.8%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"8\" style=\"width:100.0%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 ITT\u2011analysis\n  where subjects with missing data were included as non\u2011responders.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Week\u00a098\n  data for IMPACT includes combined placebo crossover and infliximab patients\n  who entered the open\u2011label extension.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Based\n  on patients with PASI \u2265\u00a02.5 at baseline for IMPACT, and patients\n  with \u2265\u00a03% BSA psoriasis skin involvement at baseline in IMPACT\u00a02.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">**\u00a0 PASI\u00a075 response for IMPACT\n  not included due to low N; p\u00a0&lt;\u00a00.001 for infliximab vs. placebo\n  at week\u00a024 for IMPACT\u00a02.</span></p>\n</td>\n</tr>\n<tr height=\"0\">\n<td style=\"border:none\" width=\"136\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"0\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n</tr>\n</table>\n</div>", "ID": "8895620b-63ae-4039-83c9-728c2d865ab4", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"8\" style=\"width:100.0%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a09</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on ACR and PASI in IMPACT and IMPACT\u00a02</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"4\" style=\"width:38.86%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">IMPACT</span></p>\n</td>\n<td colspan=\"3\" style=\"width:38.68%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">IMPACT\u00a02*</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Placebo\n  (week\u00a016)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab\n  (week\u00a016)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a098)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Placebo</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a024)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab\n  (week\u00a024)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a054)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients randomised</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">N/A<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">ACR response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(% of patients)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">78</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a020\n  response*</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5(10%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34\n  (65%)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48\n  (62%)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">16\n  (16%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">54\n  (54%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">53\n  (53%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a050\n  response*</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0(0%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24\n  (46%)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">35\n  (45%)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">4\n  (4%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">41(41%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33\n  (33%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a070\n  response*</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0(0%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15\n  (29%)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27\n  (35%)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27\n  (27%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">20\n  (20%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PASI response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(% of patients)<sup>b</sup></span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">87</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">83</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">82</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">PASI\u00a075\n  response**</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">50\n  (60%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40\n  (48.8%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"8\" style=\"width:100.0%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 ITT\u2011analysis\n  where subjects with missing data were included as non\u2011responders.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Week\u00a098\n  data for IMPACT includes combined placebo crossover and infliximab patients\n  who entered the open\u2011label extension.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Based\n  on patients with PASI \u2265\u00a02.5 at baseline for IMPACT, and patients\n  with \u2265\u00a03% BSA psoriasis skin involvement at baseline in IMPACT\u00a02.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">**\u00a0 PASI\u00a075 response for IMPACT\n  not included due to low N; p\u00a0&lt;\u00a00.001 for infliximab vs. placebo\n  at week\u00a024 for IMPACT\u00a02.</span></p>\n</td>\n</tr>\n<tr height=\"0\">\n<td style=\"border:none\" width=\"136\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"0\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n</tr>\n</table>", "ID": "addd5df2-37ce-41b8-80bb-fd44912373be", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "                ", "ParentId": "8895620b-63ae-4039-83c9-728c2d865ab4"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"8\" style=\"width:100.0%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a09</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on ACR and PASI in IMPACT and IMPACT\u00a02</span></b></p>\n</td>\n</tr>", "ID": "1206bc62-c7c6-4567-a339-f60f252e8ae7", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td colspan=\"8\" style=\"width:100.0%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a09</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on ACR and PASI in IMPACT and IMPACT\u00a02</span></b></p>\n</td>", "ID": "db5ab02f-fae4-48ae-98ac-6978447bb206", "Styles": "width:100.0%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "1206bc62-c7c6-4567-a339-f60f252e8ae7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a09</span></b></p>", "ID": "472cfeb6-1760-4529-be87-4e7bb0e0cc33", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "db5ab02f-fae4-48ae-98ac-6978447bb206"}, {"Element": "<b><span lang=\"EN-GB\">Table\u00a09</span></b>", "ID": "dbcefdab-8239-4b7f-9a60-e89ec991f4bc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "472cfeb6-1760-4529-be87-4e7bb0e0cc33"}, {"Element": "<span lang=\"EN-GB\">Table\u00a09</span>", "ID": "4eaa8439-0c35-43b5-8d02-27cf7ba26a85", "Styles": "None", "Classes": "None", "Text": "Table\u00a09", "ParentId": "dbcefdab-8239-4b7f-9a60-e89ec991f4bc"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Effects on ACR and PASI in IMPACT and IMPACT\u00a02</span></b></p>", "ID": "54a04e7c-d959-4ba7-8c3e-6f3825205152", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "db5ab02f-fae4-48ae-98ac-6978447bb206"}, {"Element": "<b><span lang=\"EN-GB\">Effects on ACR and PASI in IMPACT and IMPACT\u00a02</span></b>", "ID": "030f9e3b-e9a3-4878-9d67-2c40906919c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "54a04e7c-d959-4ba7-8c3e-6f3825205152"}, {"Element": "<span lang=\"EN-GB\">Effects on ACR and PASI in IMPACT and IMPACT\u00a02</span>", "ID": "828d2084-31a5-4189-adf1-9c9896f8f4fa", "Styles": "None", "Classes": "None", "Text": "Effects on ACR and PASI in IMPACT and IMPACT\u00a02", "ParentId": "030f9e3b-e9a3-4878-9d67-2c40906919c0"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"4\" style=\"width:38.86%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">IMPACT</span></p>\n</td>\n<td colspan=\"3\" style=\"width:38.68%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">IMPACT\u00a02*</span></p>\n</td>\n</tr>", "ID": "03e83bad-e91b-44c5-8353-8c5190acdf6a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "1a7726da-a15f-4813-8635-59ae357197bd", "Styles": "width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "03e83bad-e91b-44c5-8353-8c5190acdf6a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c66e57ad-de6f-4110-b0e3-393a74e1c6d5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1a7726da-a15f-4813-8635-59ae357197bd"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a8fb9c1d-1036-414a-b717-f96342c0bad8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c66e57ad-de6f-4110-b0e3-393a74e1c6d5"}, {"Element": "<td colspan=\"4\" style=\"width:38.86%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">IMPACT</span></p>\n</td>", "ID": "177ec675-9cc8-4ffd-b6db-20a318f33584", "Styles": "width:38.86%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "03e83bad-e91b-44c5-8353-8c5190acdf6a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">IMPACT</span></p>", "ID": "59ec35df-18bc-43c7-b024-084ffdaf6497", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "177ec675-9cc8-4ffd-b6db-20a318f33584"}, {"Element": "<span lang=\"EN-GB\">IMPACT</span>", "ID": "c3cec3ef-05fa-4dc9-a4ff-17a0750d7888", "Styles": "None", "Classes": "None", "Text": "IMPACT", "ParentId": "59ec35df-18bc-43c7-b024-084ffdaf6497"}, {"Element": "<td colspan=\"3\" style=\"width:38.68%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"38%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">IMPACT\u00a02*</span></p>\n</td>", "ID": "149b0783-7052-4f6e-8195-61857f95a4a1", "Styles": "width:38.68%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "03e83bad-e91b-44c5-8353-8c5190acdf6a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">IMPACT\u00a02*</span></p>", "ID": "f7e39ca4-d0a5-404f-b4c9-4625e7f6d343", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "149b0783-7052-4f6e-8195-61857f95a4a1"}, {"Element": "<span lang=\"EN-GB\">IMPACT\u00a02*</span>", "ID": "ab7f5ee1-1a41-4d23-a64f-75e939d932d7", "Styles": "None", "Classes": "None", "Text": "IMPACT\u00a02*", "ParentId": "f7e39ca4-d0a5-404f-b4c9-4625e7f6d343"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Placebo\n  (week\u00a016)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab\n  (week\u00a016)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a098)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Placebo</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a024)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab\n  (week\u00a024)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a054)</span></p>\n</td>\n</tr>", "ID": "73dfded3-1c22-4770-82d1-a7a54aa73dda", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"width:22.46%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "cf62afa3-4109-4a1f-b560-95e765e73a4a", "Styles": "width:22.46%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "73dfded3-1c22-4770-82d1-a7a54aa73dda"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bb8757e3-8774-4059-a3fa-e41df825be1c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cf62afa3-4109-4a1f-b560-95e765e73a4a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "38b8923c-8fe1-4010-b5e1-3f75f0fbfcce", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bb8757e3-8774-4059-a3fa-e41df825be1c"}, {"Element": "<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Placebo\n  (week\u00a016)</span></p>\n</td>", "ID": "9db75f78-6845-4548-8f57-104d069ca275", "Styles": "width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "73dfded3-1c22-4770-82d1-a7a54aa73dda"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Placebo\n  (week\u00a016)</span></p>", "ID": "06444aab-93d5-477b-b73d-6b4bfc319855", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9db75f78-6845-4548-8f57-104d069ca275"}, {"Element": "<span lang=\"EN-GB\">Placebo\n  (week\u00a016)</span>", "ID": "c6d53e85-6f69-47ae-a666-9e9e38d68eb4", "Styles": "None", "Classes": "None", "Text": "Placebo   (week\u00a016)", "ParentId": "06444aab-93d5-477b-b73d-6b4bfc319855"}, {"Element": "<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab\n  (week\u00a016)</span></p>\n</td>", "ID": "c8caf728-6eea-400f-9f9b-1ce80651757c", "Styles": "width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "73dfded3-1c22-4770-82d1-a7a54aa73dda"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab\n  (week\u00a016)</span></p>", "ID": "18ddcd29-a409-4520-8e55-1bbd61c66bcc", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c8caf728-6eea-400f-9f9b-1ce80651757c"}, {"Element": "<span lang=\"EN-GB\">Infliximab\n  (week\u00a016)</span>", "ID": "23453235-0cab-4b6d-8cf6-19d03b47e238", "Styles": "None", "Classes": "None", "Text": "Infliximab   (week\u00a016)", "ParentId": "18ddcd29-a409-4520-8e55-1bbd61c66bcc"}, {"Element": "<td style=\"width:12.94%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a098)</span></p>\n</td>", "ID": "51f88aac-c49b-4236-b616-02066e1b4786", "Styles": "width:12.94%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "73dfded3-1c22-4770-82d1-a7a54aa73dda"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab</span></p>", "ID": "c1fc4f09-5a9f-4763-bf6b-72875160816a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "51f88aac-c49b-4236-b616-02066e1b4786"}, {"Element": "<span lang=\"EN-GB\">Infliximab</span>", "ID": "14ab9eee-23da-408e-9f20-8486268179f4", "Styles": "None", "Classes": "None", "Text": "Infliximab", "ParentId": "c1fc4f09-5a9f-4763-bf6b-72875160816a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a098)</span></p>", "ID": "a3e1225f-ebb8-45e4-b88f-48927d5e02ad", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "51f88aac-c49b-4236-b616-02066e1b4786"}, {"Element": "<span lang=\"EN-GB\">(week\u00a098)</span>", "ID": "f63f4d22-9833-4b2f-ae03-9155f21f7c43", "Styles": "None", "Classes": "None", "Text": "(week\u00a098)", "ParentId": "a3e1225f-ebb8-45e4-b88f-48927d5e02ad"}, {"Element": "<td colspan=\"2\" style=\"width:12.92%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Placebo</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a024)</span></p>\n</td>", "ID": "e26e6987-261a-4066-8657-5f69e7d311c6", "Styles": "width:12.92%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "73dfded3-1c22-4770-82d1-a7a54aa73dda"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Placebo</span></p>", "ID": "3acf4143-ab74-4ab0-a9a4-61028e313e1f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e26e6987-261a-4066-8657-5f69e7d311c6"}, {"Element": "<span lang=\"EN-GB\">Placebo</span>", "ID": "6026b3a4-73c4-43f6-b6ea-5797550e225e", "Styles": "None", "Classes": "None", "Text": "Placebo", "ParentId": "3acf4143-ab74-4ab0-a9a4-61028e313e1f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a024)</span></p>", "ID": "b9074b5c-4103-4acc-b7a9-561dce4f839a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e26e6987-261a-4066-8657-5f69e7d311c6"}, {"Element": "<span lang=\"EN-GB\">(week\u00a024)</span>", "ID": "cb1027cf-7f18-4ddc-a56c-1899eace7fb8", "Styles": "None", "Classes": "None", "Text": "(week\u00a024)", "ParentId": "b9074b5c-4103-4acc-b7a9-561dce4f839a"}, {"Element": "<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab\n  (week\u00a024)</span></p>\n</td>", "ID": "8638a20c-eb2b-4bf7-8b42-1f5233a8ee6b", "Styles": "width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "73dfded3-1c22-4770-82d1-a7a54aa73dda"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab\n  (week\u00a024)</span></p>", "ID": "75efb4c1-9740-4de4-b2e7-18194395080a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8638a20c-eb2b-4bf7-8b42-1f5233a8ee6b"}, {"Element": "<span lang=\"EN-GB\">Infliximab\n  (week\u00a024)</span>", "ID": "3163dd60-b371-4a03-a75d-bb7e59afb4dc", "Styles": "None", "Classes": "None", "Text": "Infliximab   (week\u00a024)", "ParentId": "75efb4c1-9740-4de4-b2e7-18194395080a"}, {"Element": "<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a054)</span></p>\n</td>", "ID": "d999da44-a1c8-4f87-9cc7-57345ff5893e", "Styles": "width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "73dfded3-1c22-4770-82d1-a7a54aa73dda"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">Infliximab</span></p>", "ID": "a0b5096d-7ce8-4b2e-a8f7-0e788063228d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d999da44-a1c8-4f87-9cc7-57345ff5893e"}, {"Element": "<span lang=\"EN-GB\">Infliximab</span>", "ID": "9c02b76b-7cc9-4de5-8fde-6bd211f08fcd", "Styles": "None", "Classes": "None", "Text": "Infliximab", "ParentId": "a0b5096d-7ce8-4b2e-a8f7-0e788063228d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">(week\u00a054)</span></p>", "ID": "27e5dbc0-7de1-4e78-aa19-17714e08012a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d999da44-a1c8-4f87-9cc7-57345ff5893e"}, {"Element": "<span lang=\"EN-GB\">(week\u00a054)</span>", "ID": "f515e4a8-5499-4feb-a7b8-965d7cf25128", "Styles": "None", "Classes": "None", "Text": "(week\u00a054)", "ParentId": "27e5dbc0-7de1-4e78-aa19-17714e08012a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients randomised</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">N/A<sup>a</sup></span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>", "ID": "3a817dd8-b511-4d64-8256-dd55d9b092d3", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients randomised</span></p>\n</td>", "ID": "379d9d39-50b9-4996-a850-5d19e2ab9fec", "Styles": "width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3a817dd8-b511-4d64-8256-dd55d9b092d3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients randomised</span></p>", "ID": "5463ff34-a88e-4001-9228-9c77ed38a11c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "379d9d39-50b9-4996-a850-5d19e2ab9fec"}, {"Element": "<span lang=\"EN-GB\">Patients randomised</span>", "ID": "67b3f8d6-fb33-4774-b1cb-6c9051639a82", "Styles": "None", "Classes": "None", "Text": "Patients randomised", "ParentId": "5463ff34-a88e-4001-9228-9c77ed38a11c"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>", "ID": "6050711a-6747-430a-a405-ff5c3d9d1582", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3a817dd8-b511-4d64-8256-dd55d9b092d3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>", "ID": "a7f6e58e-26f9-44cd-87ee-0eb3c559ff17", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6050711a-6747-430a-a405-ff5c3d9d1582"}, {"Element": "<span lang=\"EN-GB\">52</span>", "ID": "39fb9239-0e41-4812-acb5-2649b18c9cc7", "Styles": "None", "Classes": "None", "Text": "52", "ParentId": "a7f6e58e-26f9-44cd-87ee-0eb3c559ff17"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>", "ID": "8e287efc-807d-4e98-a3c5-50670cab96f0", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3a817dd8-b511-4d64-8256-dd55d9b092d3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>", "ID": "b7941357-aa05-4847-aada-78a10307a736", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8e287efc-807d-4e98-a3c5-50670cab96f0"}, {"Element": "<span lang=\"EN-GB\">52</span>", "ID": "7d53dc66-0a3e-4454-b968-4e4aede79c57", "Styles": "None", "Classes": "None", "Text": "52", "ParentId": "b7941357-aa05-4847-aada-78a10307a736"}, {"Element": "<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">N/A<sup>a</sup></span></p>\n</td>", "ID": "ec4d16bd-e83d-4458-94ed-d77cccb1a9df", "Styles": "width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3a817dd8-b511-4d64-8256-dd55d9b092d3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">N/A<sup>a</sup></span></p>", "ID": "a71b3374-4523-462a-bcb7-968fdfd9330e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec4d16bd-e83d-4458-94ed-d77cccb1a9df"}, {"Element": "<span lang=\"EN-GB\">N/A<sup>a</sup></span>", "ID": "e14bff0d-a401-4df7-830e-173c576a6ea4", "Styles": "None", "Classes": "None", "Text": "N/A", "ParentId": "a71b3374-4523-462a-bcb7-968fdfd9330e"}, {"Element": "<sup>a</sup>", "ID": "a617f788-87ca-4a82-bfcf-64659f374f9b", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "e14bff0d-a401-4df7-830e-173c576a6ea4"}, {"Element": "<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "05c41cce-7464-4489-8a02-d4c3676d7d3e", "Styles": "width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3a817dd8-b511-4d64-8256-dd55d9b092d3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>", "ID": "0912a0d3-73ce-4417-92f2-079247236f81", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "05c41cce-7464-4489-8a02-d4c3676d7d3e"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "7bd385cf-f301-4e19-bc86-c08a9ca99217", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "0912a0d3-73ce-4417-92f2-079247236f81"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "3a92cbd6-1fd1-4a05-86e2-3e314f5567f5", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3a817dd8-b511-4d64-8256-dd55d9b092d3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>", "ID": "d17f6982-a2eb-46be-991b-c3713ccde728", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3a92cbd6-1fd1-4a05-86e2-3e314f5567f5"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "f8efff1b-d537-4f60-9165-9d3961e07883", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "d17f6982-a2eb-46be-991b-c3713ccde728"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "755ca689-4004-4cd7-aaf9-ffb6999731aa", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "3a817dd8-b511-4d64-8256-dd55d9b092d3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>", "ID": "46bd8093-91ea-4b9e-8e5a-64c14ec9f705", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "755ca689-4004-4cd7-aaf9-ffb6999731aa"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "3d743317-4465-4410-ac1c-5ea120466bde", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "46bd8093-91ea-4b9e-8e5a-64c14ec9f705"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "5fe04ab4-c041-4adf-9633-6fbdcbdfa49f", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "fa69cf82-ba2b-4869-ae5c-06e9452a7dec", "Styles": "width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5fe04ab4-c041-4adf-9633-6fbdcbdfa49f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1bce614e-824a-4d5e-a3e2-1b3e5844fd18", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fa69cf82-ba2b-4869-ae5c-06e9452a7dec"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "036b0f8c-a18d-4ac4-b14e-6e472a723f8c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1bce614e-824a-4d5e-a3e2-1b3e5844fd18"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "b50e3a37-a15a-43d2-9978-651881e1ef4e", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5fe04ab4-c041-4adf-9633-6fbdcbdfa49f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "07c3b91e-9852-4f45-8405-15500b67fc7a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b50e3a37-a15a-43d2-9978-651881e1ef4e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "944b957a-a884-4201-97e6-db60342bae05", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "07c3b91e-9852-4f45-8405-15500b67fc7a"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "51dc184e-545a-4044-83ee-141136ac372e", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5fe04ab4-c041-4adf-9633-6fbdcbdfa49f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bcef3825-cca9-47ed-b4fc-392fef1240e9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "51dc184e-545a-4044-83ee-141136ac372e"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "de478e69-2e2c-4087-bee2-0a9b58d58fd0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bcef3825-cca9-47ed-b4fc-392fef1240e9"}, {"Element": "<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "6341ce30-fbe0-455f-a2ab-01e4612f8491", "Styles": "width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5fe04ab4-c041-4adf-9633-6fbdcbdfa49f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d165817f-525f-4131-bddb-defa72909564", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6341ce30-fbe0-455f-a2ab-01e4612f8491"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "879464dc-b20e-4d6a-a0ff-60b8287a118e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d165817f-525f-4131-bddb-defa72909564"}, {"Element": "<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "91f9aefc-82fd-4d64-a4ff-b9b21f9752ec", "Styles": "width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5fe04ab4-c041-4adf-9633-6fbdcbdfa49f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fd6335da-ba13-43e5-8d1d-fa1b525325e5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "91f9aefc-82fd-4d64-a4ff-b9b21f9752ec"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "86f308f7-58ca-44b4-b0bd-58792aafb47f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fd6335da-ba13-43e5-8d1d-fa1b525325e5"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "97ca9a0f-39db-4b35-85e0-14f745e06664", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5fe04ab4-c041-4adf-9633-6fbdcbdfa49f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "681abd87-a155-4e7a-b1e6-b0248e7a7765", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "97ca9a0f-39db-4b35-85e0-14f745e06664"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ab8c3e19-f616-4698-b750-e1bf96009e51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "681abd87-a155-4e7a-b1e6-b0248e7a7765"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "c2b41fb9-393d-432b-b5e0-f978e1b476f0", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5fe04ab4-c041-4adf-9633-6fbdcbdfa49f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dfb9747f-890b-47e8-81c1-5db0b8c6214a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c2b41fb9-393d-432b-b5e0-f978e1b476f0"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5a05e1bd-a9e2-4717-8ca2-faf63c30ec85", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dfb9747f-890b-47e8-81c1-5db0b8c6214a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">ACR response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(% of patients)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "d6846586-05a1-4667-b872-a669dc98e618", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">ACR response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(% of patients)</span></p>\n</td>", "ID": "7a82ab77-227d-489c-b10a-cedbbc0f4598", "Styles": "width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "d6846586-05a1-4667-b872-a669dc98e618"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">ACR response</span></p>", "ID": "074d5b4f-ef9d-4861-b514-bdee9c37111d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a82ab77-227d-489c-b10a-cedbbc0f4598"}, {"Element": "<span lang=\"EN-GB\">ACR response</span>", "ID": "a88e5684-27f5-4a3a-8dfa-0ff3373c82c0", "Styles": "None", "Classes": "None", "Text": "ACR response", "ParentId": "074d5b4f-ef9d-4861-b514-bdee9c37111d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">(% of patients)</span></p>", "ID": "20084970-ee3f-4a36-8e95-b101a1808733", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7a82ab77-227d-489c-b10a-cedbbc0f4598"}, {"Element": "<span lang=\"EN-GB\">(% of patients)</span>", "ID": "ef9c217d-0876-441d-9aee-991344d34f5a", "Styles": "None", "Classes": "None", "Text": "(% of patients)", "ParentId": "20084970-ee3f-4a36-8e95-b101a1808733"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "6379850f-b642-4a85-b1d9-c6a92dfe9d10", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d6846586-05a1-4667-b872-a669dc98e618"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "13fcdc1a-02d4-442e-82f7-80838f09b049", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6379850f-b642-4a85-b1d9-c6a92dfe9d10"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "57042c43-febf-40cf-8d12-a1e6634e1957", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "13fcdc1a-02d4-442e-82f7-80838f09b049"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "c69b5a35-3664-4431-bf08-e525b40df3d9", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d6846586-05a1-4667-b872-a669dc98e618"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c65a1d74-cfd3-49b0-a94b-cee0e9a7d951", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c69b5a35-3664-4431-bf08-e525b40df3d9"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4773517a-9a77-44ff-8724-c557efbf5253", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c65a1d74-cfd3-49b0-a94b-cee0e9a7d951"}, {"Element": "<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "21f814b9-ca6f-4bf5-b915-9dc0d3b60dc4", "Styles": "width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d6846586-05a1-4667-b872-a669dc98e618"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "852c94a3-96d8-449d-90af-20c1e8a5fd97", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "21f814b9-ca6f-4bf5-b915-9dc0d3b60dc4"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "713025f6-f1de-4cff-813c-a56a7a725324", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "852c94a3-96d8-449d-90af-20c1e8a5fd97"}, {"Element": "<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "0e50ddd0-2dfb-4fa7-9ae0-9207b0ab81a0", "Styles": "width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d6846586-05a1-4667-b872-a669dc98e618"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ee64d629-c7c5-4b7e-a743-f5648c899581", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0e50ddd0-2dfb-4fa7-9ae0-9207b0ab81a0"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "06bf8e1a-f258-43b4-be91-207709e72a88", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ee64d629-c7c5-4b7e-a743-f5648c899581"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "67e4bf9d-0e51-41e0-aff8-c61c10865b56", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d6846586-05a1-4667-b872-a669dc98e618"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "82e2dc33-259c-4e9b-b00a-92dc9a83b870", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "67e4bf9d-0e51-41e0-aff8-c61c10865b56"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2f1800f8-c647-4625-b677-0fcc8314113e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "82e2dc33-259c-4e9b-b00a-92dc9a83b870"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "644a3875-86b8-4b3d-b2f7-31baa0681896", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "d6846586-05a1-4667-b872-a669dc98e618"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2a2c8671-0874-464e-a5a3-3463b509d0e8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "644a3875-86b8-4b3d-b2f7-31baa0681896"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "51f85ab2-9afb-4648-ac4d-8919a592454a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2a2c8671-0874-464e-a5a3-3463b509d0e8"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">78</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>\n</tr>", "ID": "7bd9aa77-bf42-48af-b6b1-4667a4c6e6f2", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>", "ID": "9aab6f72-6f12-492a-9369-2a2e46c95e0f", "Styles": "width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7bd9aa77-bf42-48af-b6b1-4667a4c6e6f2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>", "ID": "9aeffa20-2b86-4b90-876f-5e0815e31894", "Styles": "margin-left:14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9aab6f72-6f12-492a-9369-2a2e46c95e0f"}, {"Element": "<span lang=\"EN-GB\">N</span>", "ID": "17376295-df4d-4344-8355-d7ed06b7df48", "Styles": "None", "Classes": "None", "Text": "N", "ParentId": "9aeffa20-2b86-4b90-876f-5e0815e31894"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>", "ID": "8687bafe-510b-4d23-a77f-75a9398e04c4", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7bd9aa77-bf42-48af-b6b1-4667a4c6e6f2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>", "ID": "5c590858-d7d9-4aa8-b492-3b4598945a6d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8687bafe-510b-4d23-a77f-75a9398e04c4"}, {"Element": "<span lang=\"EN-GB\">52</span>", "ID": "e156bdba-0ac2-4e9f-ae75-2055d840131a", "Styles": "None", "Classes": "None", "Text": "52", "ParentId": "5c590858-d7d9-4aa8-b492-3b4598945a6d"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>\n</td>", "ID": "e58ef01e-ede7-4c30-b773-19caacb23c5f", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7bd9aa77-bf42-48af-b6b1-4667a4c6e6f2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52</span></p>", "ID": "7e7f01bf-a3d3-41c6-8b13-7cbbbd442326", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e58ef01e-ede7-4c30-b773-19caacb23c5f"}, {"Element": "<span lang=\"EN-GB\">52</span>", "ID": "a3e4533a-21b9-4f81-8061-3fd32d554407", "Styles": "None", "Classes": "None", "Text": "52", "ParentId": "7e7f01bf-a3d3-41c6-8b13-7cbbbd442326"}, {"Element": "<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">78</span></p>\n</td>", "ID": "0e1f3660-e66d-40f0-8825-b010b86fd91d", "Styles": "width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7bd9aa77-bf42-48af-b6b1-4667a4c6e6f2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">78</span></p>", "ID": "51c016aa-2c87-4725-b87b-d2969fd56868", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0e1f3660-e66d-40f0-8825-b010b86fd91d"}, {"Element": "<span lang=\"EN-GB\">78</span>", "ID": "ad950d87-0741-431f-ba9c-f1937c3fb60a", "Styles": "None", "Classes": "None", "Text": "78", "ParentId": "51c016aa-2c87-4725-b87b-d2969fd56868"}, {"Element": "<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "9427fc44-b4db-4a2b-a55e-da09553b28d7", "Styles": "width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7bd9aa77-bf42-48af-b6b1-4667a4c6e6f2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>", "ID": "8babc2b6-9844-4d7c-a38c-3467a7ef51c2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9427fc44-b4db-4a2b-a55e-da09553b28d7"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "268b5091-a462-45ae-a73d-d4d36d2e6bf5", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "8babc2b6-9844-4d7c-a38c-3467a7ef51c2"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "07a93c1b-7dd2-4830-bf47-5b61577202a7", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7bd9aa77-bf42-48af-b6b1-4667a4c6e6f2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>", "ID": "69d94cce-3b45-496d-b31c-0dd6de7139b3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "07a93c1b-7dd2-4830-bf47-5b61577202a7"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "4049b36b-0e9c-4fe2-b714-bd74ace087f6", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "69d94cce-3b45-496d-b31c-0dd6de7139b3"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>\n</td>", "ID": "e5f4b56e-cbfc-4784-b34d-8b65c8f5a12a", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "7bd9aa77-bf42-48af-b6b1-4667a4c6e6f2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">100</span></p>", "ID": "827fec01-c69a-40f8-8bbf-b7af969fd610", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e5f4b56e-cbfc-4784-b34d-8b65c8f5a12a"}, {"Element": "<span lang=\"EN-GB\">100</span>", "ID": "d12788b2-39a0-4739-aa02-3965e247208a", "Styles": "None", "Classes": "None", "Text": "100", "ParentId": "827fec01-c69a-40f8-8bbf-b7af969fd610"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a020\n  response*</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5(10%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34\n  (65%)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48\n  (62%)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">16\n  (16%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">54\n  (54%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">53\n  (53%)</span></p>\n</td>\n</tr>", "ID": "8664c3aa-0019-4671-b6f0-8b0d5e63a7a9", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a020\n  response*</span></p>\n</td>", "ID": "c5ec126d-5c73-4a51-9c00-11aa47e65c12", "Styles": "width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8664c3aa-0019-4671-b6f0-8b0d5e63a7a9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a020\n  response*</span></p>", "ID": "c05be795-9d67-4a8f-acf9-8b9cb2bd4c51", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c5ec126d-5c73-4a51-9c00-11aa47e65c12"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a020\n  response*</span>", "ID": "483a9e32-5fad-4ab3-9dc5-dbf3ce2dab6e", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "ACR\u00a020   response*", "ParentId": "c05be795-9d67-4a8f-acf9-8b9cb2bd4c51"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5(10%)</span></p>\n</td>", "ID": "64acf412-8012-4c68-8b4b-7758df6e7cc4", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8664c3aa-0019-4671-b6f0-8b0d5e63a7a9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5(10%)</span></p>", "ID": "c7f773c5-5c52-4ecb-b62c-b0252c04e645", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "64acf412-8012-4c68-8b4b-7758df6e7cc4"}, {"Element": "<span lang=\"EN-GB\">5(10%)</span>", "ID": "ce104d2f-2b40-4017-b064-2b7ab977a097", "Styles": "None", "Classes": "None", "Text": "5(10%)", "ParentId": "c7f773c5-5c52-4ecb-b62c-b0252c04e645"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34\n  (65%)</span></p>\n</td>", "ID": "2ffc8cbc-1752-4a59-9eca-22e0419c9b4c", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8664c3aa-0019-4671-b6f0-8b0d5e63a7a9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34\n  (65%)</span></p>", "ID": "f2b7203b-8cb3-4e83-b066-1d41a4827a82", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2ffc8cbc-1752-4a59-9eca-22e0419c9b4c"}, {"Element": "<span lang=\"EN-GB\">34\n  (65%)</span>", "ID": "bcb07c19-37c0-49e2-a0b8-68fce814971c", "Styles": "None", "Classes": "None", "Text": "34   (65%)", "ParentId": "f2b7203b-8cb3-4e83-b066-1d41a4827a82"}, {"Element": "<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48\n  (62%)</span></p>\n</td>", "ID": "afa8725a-2d2b-4bef-90a9-b18bc3d49ab2", "Styles": "width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8664c3aa-0019-4671-b6f0-8b0d5e63a7a9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">48\n  (62%)</span></p>", "ID": "dd265e5c-cb35-4ae8-a05b-072883297030", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "afa8725a-2d2b-4bef-90a9-b18bc3d49ab2"}, {"Element": "<span lang=\"EN-GB\">48\n  (62%)</span>", "ID": "020e07e0-dc33-4824-9fe4-ee24c7c0c067", "Styles": "None", "Classes": "None", "Text": "48   (62%)", "ParentId": "dd265e5c-cb35-4ae8-a05b-072883297030"}, {"Element": "<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">16\n  (16%)</span></p>\n</td>", "ID": "ed4d332f-3150-4597-9341-f87e6ae8e430", "Styles": "width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8664c3aa-0019-4671-b6f0-8b0d5e63a7a9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">16\n  (16%)</span></p>", "ID": "79a94e29-c4de-44e2-b19e-32fbb4a6b6b7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ed4d332f-3150-4597-9341-f87e6ae8e430"}, {"Element": "<span lang=\"EN-GB\">16\n  (16%)</span>", "ID": "1b09ce76-dc14-4390-971d-6706968622f7", "Styles": "None", "Classes": "None", "Text": "16   (16%)", "ParentId": "79a94e29-c4de-44e2-b19e-32fbb4a6b6b7"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">54\n  (54%)</span></p>\n</td>", "ID": "116a0c8b-bcc6-4592-81a1-5052fa1a464c", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8664c3aa-0019-4671-b6f0-8b0d5e63a7a9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">54\n  (54%)</span></p>", "ID": "14db189c-6ad7-4a22-abc5-4f320181f0e9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "116a0c8b-bcc6-4592-81a1-5052fa1a464c"}, {"Element": "<span lang=\"EN-GB\">54\n  (54%)</span>", "ID": "e327b841-9f02-4f94-be25-1a46f87f3eb5", "Styles": "None", "Classes": "None", "Text": "54   (54%)", "ParentId": "14db189c-6ad7-4a22-abc5-4f320181f0e9"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">53\n  (53%)</span></p>\n</td>", "ID": "90d6cca6-540c-4706-849c-38433e10fb08", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8664c3aa-0019-4671-b6f0-8b0d5e63a7a9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">53\n  (53%)</span></p>", "ID": "d47ace3f-8238-463a-af86-51d61feaeb1a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "90d6cca6-540c-4706-849c-38433e10fb08"}, {"Element": "<span lang=\"EN-GB\">53\n  (53%)</span>", "ID": "97a60350-f059-4c0e-ad1f-2d004be2e331", "Styles": "None", "Classes": "None", "Text": "53   (53%)", "ParentId": "d47ace3f-8238-463a-af86-51d61feaeb1a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a050\n  response*</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0(0%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24\n  (46%)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">35\n  (45%)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">4\n  (4%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">41(41%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33\n  (33%)</span></p>\n</td>\n</tr>", "ID": "02b764cc-d806-4800-937f-37d2a9292aa6", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a050\n  response*</span></p>\n</td>", "ID": "2f204d66-4c19-4ffd-92a7-1072378f0ed5", "Styles": "width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02b764cc-d806-4800-937f-37d2a9292aa6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a050\n  response*</span></p>", "ID": "8cc34c0c-4177-4cf5-a8bf-e78f21631faa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2f204d66-4c19-4ffd-92a7-1072378f0ed5"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a050\n  response*</span>", "ID": "72f2fe5c-7cbe-4f72-85b9-35c362f89ab5", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "ACR\u00a050   response*", "ParentId": "8cc34c0c-4177-4cf5-a8bf-e78f21631faa"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0(0%)</span></p>\n</td>", "ID": "2e8d4c4a-1e45-42db-846d-b590eb619435", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02b764cc-d806-4800-937f-37d2a9292aa6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0(0%)</span></p>", "ID": "54145135-2fc1-4ef2-acbe-2cf70e699d25", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2e8d4c4a-1e45-42db-846d-b590eb619435"}, {"Element": "<span lang=\"EN-GB\">0(0%)</span>", "ID": "1279da0f-d875-4960-8b44-f7e80ebf8bde", "Styles": "None", "Classes": "None", "Text": "0(0%)", "ParentId": "54145135-2fc1-4ef2-acbe-2cf70e699d25"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24\n  (46%)</span></p>\n</td>", "ID": "90e60967-985a-40d7-b990-ad49366d5de9", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02b764cc-d806-4800-937f-37d2a9292aa6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">24\n  (46%)</span></p>", "ID": "31650e71-e022-47d7-98f8-c3e8132ebbec", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "90e60967-985a-40d7-b990-ad49366d5de9"}, {"Element": "<span lang=\"EN-GB\">24\n  (46%)</span>", "ID": "aeac2732-1c2a-4865-a380-fa0c3a69d172", "Styles": "None", "Classes": "None", "Text": "24   (46%)", "ParentId": "31650e71-e022-47d7-98f8-c3e8132ebbec"}, {"Element": "<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">35\n  (45%)</span></p>\n</td>", "ID": "5d391ff9-6192-4643-882e-e5e6c0d61479", "Styles": "width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02b764cc-d806-4800-937f-37d2a9292aa6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">35\n  (45%)</span></p>", "ID": "9931d377-5dba-4a9a-b3ca-0b02222dd988", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5d391ff9-6192-4643-882e-e5e6c0d61479"}, {"Element": "<span lang=\"EN-GB\">35\n  (45%)</span>", "ID": "e0d37961-20b2-4838-8e48-69570439674d", "Styles": "None", "Classes": "None", "Text": "35   (45%)", "ParentId": "9931d377-5dba-4a9a-b3ca-0b02222dd988"}, {"Element": "<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">4\n  (4%)</span></p>\n</td>", "ID": "c7463188-9922-4138-902d-c4b5275f5d38", "Styles": "width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02b764cc-d806-4800-937f-37d2a9292aa6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">4\n  (4%)</span></p>", "ID": "563fd672-36c5-48d5-86d2-ae5d27e532d9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c7463188-9922-4138-902d-c4b5275f5d38"}, {"Element": "<span lang=\"EN-GB\">4\n  (4%)</span>", "ID": "83e9df50-0dfa-4a35-bab1-7dc6d06537a4", "Styles": "None", "Classes": "None", "Text": "4   (4%)", "ParentId": "563fd672-36c5-48d5-86d2-ae5d27e532d9"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">41(41%)</span></p>\n</td>", "ID": "173bb8a8-0625-4da9-a5c8-f3b079c9199b", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02b764cc-d806-4800-937f-37d2a9292aa6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">41(41%)</span></p>", "ID": "d5196f16-a634-4098-98fb-61f963e967b0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "173bb8a8-0625-4da9-a5c8-f3b079c9199b"}, {"Element": "<span lang=\"EN-GB\">41(41%)</span>", "ID": "d2695e8b-c5bd-4eb5-955a-2e8d92b245e6", "Styles": "None", "Classes": "None", "Text": "41(41%)", "ParentId": "d5196f16-a634-4098-98fb-61f963e967b0"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33\n  (33%)</span></p>\n</td>", "ID": "d09623ec-e9e2-4c83-aea1-43511ee9c571", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02b764cc-d806-4800-937f-37d2a9292aa6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">33\n  (33%)</span></p>", "ID": "d55744ba-3cb6-4b50-b13e-758a0a83e344", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d09623ec-e9e2-4c83-aea1-43511ee9c571"}, {"Element": "<span lang=\"EN-GB\">33\n  (33%)</span>", "ID": "289ae28c-1c2d-437e-9d31-b2aa1f9278c7", "Styles": "None", "Classes": "None", "Text": "33   (33%)", "ParentId": "d55744ba-3cb6-4b50-b13e-758a0a83e344"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a070\n  response*</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0(0%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15\n  (29%)</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27\n  (35%)</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27\n  (27%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">20\n  (20%)</span></p>\n</td>\n</tr>", "ID": "5ca01a19-3344-409c-81fd-6fc39aac899b", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a070\n  response*</span></p>\n</td>", "ID": "97bd2ae6-7cb5-486a-9253-92013008c4cb", "Styles": "width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5ca01a19-3344-409c-81fd-6fc39aac899b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a070\n  response*</span></p>", "ID": "946337b5-a0ad-45b5-a78c-297d41cd0253", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "97bd2ae6-7cb5-486a-9253-92013008c4cb"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">ACR\u00a070\n  response*</span>", "ID": "51e456e9-2546-4720-bd8e-0edb65ee2765", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "ACR\u00a070   response*", "ParentId": "946337b5-a0ad-45b5-a78c-297d41cd0253"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0(0%)</span></p>\n</td>", "ID": "9b762046-8249-48ba-a2bb-7fbcab9c34f2", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5ca01a19-3344-409c-81fd-6fc39aac899b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">0(0%)</span></p>", "ID": "4ee4c462-a1b9-48c9-b78d-b70ad583b026", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9b762046-8249-48ba-a2bb-7fbcab9c34f2"}, {"Element": "<span lang=\"EN-GB\">0(0%)</span>", "ID": "0aa5ab36-8d06-49f1-9a17-08243d1cbeaf", "Styles": "None", "Classes": "None", "Text": "0(0%)", "ParentId": "4ee4c462-a1b9-48c9-b78d-b70ad583b026"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15\n  (29%)</span></p>\n</td>", "ID": "2672fcf8-83e5-4634-ba14-1f8a5f9d1d58", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5ca01a19-3344-409c-81fd-6fc39aac899b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15\n  (29%)</span></p>", "ID": "39c9dccc-c2db-41d2-986e-2becde5ad32c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2672fcf8-83e5-4634-ba14-1f8a5f9d1d58"}, {"Element": "<span lang=\"EN-GB\">15\n  (29%)</span>", "ID": "350cefd3-960f-4c0e-a359-48f8809b29c8", "Styles": "None", "Classes": "None", "Text": "15   (29%)", "ParentId": "39c9dccc-c2db-41d2-986e-2becde5ad32c"}, {"Element": "<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27\n  (35%)</span></p>\n</td>", "ID": "2ea66a33-d9a9-40a7-93b7-b9732b816e79", "Styles": "width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5ca01a19-3344-409c-81fd-6fc39aac899b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27\n  (35%)</span></p>", "ID": "b3c442b7-4ff0-481a-abd6-4f478a006adb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2ea66a33-d9a9-40a7-93b7-b9732b816e79"}, {"Element": "<span lang=\"EN-GB\">27\n  (35%)</span>", "ID": "ae99420c-225b-4f5c-b146-7594d74f81f6", "Styles": "None", "Classes": "None", "Text": "27   (35%)", "ParentId": "b3c442b7-4ff0-481a-abd6-4f478a006adb"}, {"Element": "<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2%)</span></p>\n</td>", "ID": "749e2d2c-09ae-4198-a1dd-b8ef7d84fad6", "Styles": "width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5ca01a19-3344-409c-81fd-6fc39aac899b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2%)</span></p>", "ID": "93539b28-d749-4abc-9946-a0355eba9764", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "749e2d2c-09ae-4198-a1dd-b8ef7d84fad6"}, {"Element": "<span lang=\"EN-GB\">2\n  (2%)</span>", "ID": "2158a4ed-07c3-4366-9426-7c0368ccb1cd", "Styles": "None", "Classes": "None", "Text": "2   (2%)", "ParentId": "93539b28-d749-4abc-9946-a0355eba9764"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27\n  (27%)</span></p>\n</td>", "ID": "a9a22e4d-2b5a-4578-b364-377a4e6a1680", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5ca01a19-3344-409c-81fd-6fc39aac899b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27\n  (27%)</span></p>", "ID": "6011ce97-d343-4082-84bd-cbda30e48b65", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a9a22e4d-2b5a-4578-b364-377a4e6a1680"}, {"Element": "<span lang=\"EN-GB\">27\n  (27%)</span>", "ID": "e31c1995-c404-4fe5-a4e6-1e9e0b42b4bb", "Styles": "None", "Classes": "None", "Text": "27   (27%)", "ParentId": "6011ce97-d343-4082-84bd-cbda30e48b65"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">20\n  (20%)</span></p>\n</td>", "ID": "4186c3ed-9332-4ca1-b31a-b225ba4c80cc", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5ca01a19-3344-409c-81fd-6fc39aac899b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">20\n  (20%)</span></p>", "ID": "c8cd91f7-02b0-4580-81b5-7339821a12a7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4186c3ed-9332-4ca1-b31a-b225ba4c80cc"}, {"Element": "<span lang=\"EN-GB\">20\n  (20%)</span>", "ID": "c6efa137-457a-47bc-a780-72f35daa3269", "Styles": "None", "Classes": "None", "Text": "20   (20%)", "ParentId": "c8cd91f7-02b0-4580-81b5-7339821a12a7"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PASI response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(% of patients)<sup>b</sup></span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "558973bd-c43c-47d6-aa8c-d8d5aac196a3", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PASI response</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(% of patients)<sup>b</sup></span></p>\n</td>", "ID": "aabacf91-a9cd-473f-a2dd-ca74df40c105", "Styles": "width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "558973bd-c43c-47d6-aa8c-d8d5aac196a3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">PASI response</span></p>", "ID": "64f39ba1-7bdc-40a6-89a2-729722db4e68", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aabacf91-a9cd-473f-a2dd-ca74df40c105"}, {"Element": "<span lang=\"EN-GB\">PASI response</span>", "ID": "9d8c17c8-9342-4c08-92d9-ef915cee3b63", "Styles": "None", "Classes": "None", "Text": "PASI response", "ParentId": "64f39ba1-7bdc-40a6-89a2-729722db4e68"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">(% of patients)<sup>b</sup></span></p>", "ID": "99e7c736-8da0-4215-9217-4ac10cce5dac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aabacf91-a9cd-473f-a2dd-ca74df40c105"}, {"Element": "<span lang=\"EN-GB\">(% of patients)<sup>b</sup></span>", "ID": "73678707-5cd6-4d6a-ac68-d80289539534", "Styles": "None", "Classes": "None", "Text": "(% of patients)", "ParentId": "99e7c736-8da0-4215-9217-4ac10cce5dac"}, {"Element": "<sup>b</sup>", "ID": "4f78a186-21cb-454a-a21a-f8aae6175bd6", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "73678707-5cd6-4d6a-ac68-d80289539534"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "32db1c0a-35b1-490c-99b2-1b8e664d64ad", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "558973bd-c43c-47d6-aa8c-d8d5aac196a3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c4c7a48f-90c0-441e-8538-f588b4b781e3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "32db1c0a-35b1-490c-99b2-1b8e664d64ad"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3ca6fd4c-664f-4660-b1aa-b61bb8f2fa5e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c4c7a48f-90c0-441e-8538-f588b4b781e3"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "600b7e7b-97d2-4485-982b-debdcd2777f7", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "558973bd-c43c-47d6-aa8c-d8d5aac196a3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f12f426a-a561-4626-ac9b-1fbb2d67d227", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "600b7e7b-97d2-4485-982b-debdcd2777f7"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b336aa8-abc7-4d6e-ae6c-6b4c624a9b8b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f12f426a-a561-4626-ac9b-1fbb2d67d227"}, {"Element": "<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "0c3e249d-c5d3-4e75-aac9-71ec4dd937de", "Styles": "width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "558973bd-c43c-47d6-aa8c-d8d5aac196a3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a973d19f-ceae-466a-a919-8dfe9b4470a2", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0c3e249d-c5d3-4e75-aac9-71ec4dd937de"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "436fd008-b3c1-434a-ba3e-f94424a05eb7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a973d19f-ceae-466a-a919-8dfe9b4470a2"}, {"Element": "<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "ce562b8e-4f4e-4a51-b597-28b2caf8242a", "Styles": "width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "558973bd-c43c-47d6-aa8c-d8d5aac196a3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4afc9ffd-5f25-4e36-95fc-359d49c0b3b5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ce562b8e-4f4e-4a51-b597-28b2caf8242a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "916ac4e1-070f-446a-a839-da4b7bcec8f7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4afc9ffd-5f25-4e36-95fc-359d49c0b3b5"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "fe0ea2a3-429a-458d-a5e6-95661503fbd6", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "558973bd-c43c-47d6-aa8c-d8d5aac196a3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f7ec5d16-a9c3-4d3d-a591-5e20ffbac514", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fe0ea2a3-429a-458d-a5e6-95661503fbd6"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "825e1b1a-ee2d-462f-852f-9b1e71b74853", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f7ec5d16-a9c3-4d3d-a591-5e20ffbac514"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "7deb0bb8-4f40-4b8d-bdf7-d4cbb1a0439b", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "558973bd-c43c-47d6-aa8c-d8d5aac196a3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bdcc785b-d48b-424e-b78f-b6bace975cdf", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7deb0bb8-4f40-4b8d-bdf7-d4cbb1a0439b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eba2676d-707d-43e9-a54f-d84efac4e2b3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bdcc785b-d48b-424e-b78f-b6bace975cdf"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">87</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">83</span></p>\n</td>\n<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">82</span></p>\n</td>\n</tr>", "ID": "8953ed77-d4bf-41d4-943c-a1c56d5e6916", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"22%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>", "ID": "bcd01836-e3f7-4073-9117-b3336c700c53", "Styles": "width:22.46%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8953ed77-d4bf-41d4-943c-a1c56d5e6916"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>", "ID": "41aa3b02-803b-4c0d-ab9e-665e878f47eb", "Styles": "margin-left:14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bcd01836-e3f7-4073-9117-b3336c700c53"}, {"Element": "<span lang=\"EN-GB\">N</span>", "ID": "93f098f3-3bab-49fe-a98e-7fe6eaea7294", "Styles": "None", "Classes": "None", "Text": "N", "ParentId": "41aa3b02-803b-4c0d-ab9e-665e878f47eb"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "104abddb-9144-4c69-80ab-a451f7010f4f", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8953ed77-d4bf-41d4-943c-a1c56d5e6916"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e1af8d5b-8893-4ebf-958d-fa2003b8d96f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "104abddb-9144-4c69-80ab-a451f7010f4f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "004511ea-ee91-498c-aff1-c3d9530573e6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e1af8d5b-8893-4ebf-958d-fa2003b8d96f"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "3c636eec-bb81-4c1a-bd8b-1e0b8cca1c7c", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8953ed77-d4bf-41d4-943c-a1c56d5e6916"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "281d7847-24ce-4c88-90e8-59167054d05c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3c636eec-bb81-4c1a-bd8b-1e0b8cca1c7c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f8f23ad8-d365-40e5-9169-bbf97309c4dd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "281d7847-24ce-4c88-90e8-59167054d05c"}, {"Element": "<td style=\"width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "184fedb3-fcb3-4de4-9901-92adcbf30a32", "Styles": "width:12.94%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8953ed77-d4bf-41d4-943c-a1c56d5e6916"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b056b778-1e1a-416a-a2ca-1357296dcfc5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "184fedb3-fcb3-4de4-9901-92adcbf30a32"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "54244a01-088c-4687-a883-92e92c542db3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b056b778-1e1a-416a-a2ca-1357296dcfc5"}, {"Element": "<td colspan=\"2\" style=\"width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">87</span></p>\n</td>", "ID": "11b0992e-9621-4204-85f2-b0a5a5ea2f31", "Styles": "width:12.92%;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8953ed77-d4bf-41d4-943c-a1c56d5e6916"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">87</span></p>", "ID": "a3d309cf-db67-43c0-b76c-b2d56fcd7a86", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "11b0992e-9621-4204-85f2-b0a5a5ea2f31"}, {"Element": "<span lang=\"EN-GB\">87</span>", "ID": "24e3d7fd-bef3-4c85-889c-33c9e51d920d", "Styles": "None", "Classes": "None", "Text": "87", "ParentId": "a3d309cf-db67-43c0-b76c-b2d56fcd7a86"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">83</span></p>\n</td>", "ID": "999ac76f-637e-414d-b449-beff4badb023", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8953ed77-d4bf-41d4-943c-a1c56d5e6916"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">83</span></p>", "ID": "89da0168-5ab9-468f-a72d-3ae0cbc23d59", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "999ac76f-637e-414d-b449-beff4badb023"}, {"Element": "<span lang=\"EN-GB\">83</span>", "ID": "329b30b5-4f61-4a2c-9865-929a7e03f7d8", "Styles": "None", "Classes": "None", "Text": "83", "ParentId": "89da0168-5ab9-468f-a72d-3ae0cbc23d59"}, {"Element": "<td style=\"width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">82</span></p>\n</td>", "ID": "181b69c3-dc86-43e6-aff1-9bd01b5e2ad9", "Styles": "width:12.92%;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8953ed77-d4bf-41d4-943c-a1c56d5e6916"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">82</span></p>", "ID": "ecbbfee6-e960-42d8-8811-2fa2149e1b59", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "181b69c3-dc86-43e6-aff1-9bd01b5e2ad9"}, {"Element": "<span lang=\"EN-GB\">82</span>", "ID": "e40a2154-7314-40c8-8f3a-62aebd578b95", "Styles": "None", "Classes": "None", "Text": "82", "ParentId": "ecbbfee6-e960-42d8-8811-2fa2149e1b59"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:22.46%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">PASI\u00a075\n  response**</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:12.94%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td colspan=\"2\" style=\"width:12.92%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">50\n  (60%)</span></p>\n</td>\n<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40\n  (48.8%)</span></p>\n</td>\n</tr>", "ID": "daf8027e-19ab-4086-9ae4-669c68c4b419", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "        ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"width:22.46%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"22%\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">PASI\u00a075\n  response**</span></p>\n</td>", "ID": "2af065e4-2466-4583-837b-7f6a9be00787", "Styles": "width:22.46%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "daf8027e-19ab-4086-9ae4-669c68c4b419"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">PASI\u00a075\n  response**</span></p>", "ID": "7709e554-4564-4e60-a8af-79cb3bb28499", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2af065e4-2466-4583-837b-7f6a9be00787"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">PASI\u00a075\n  response**</span>", "ID": "a8271a3e-f0ca-4f07-bf1c-f8bfa5d525f9", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "PASI\u00a075   response**", "ParentId": "7709e554-4564-4e60-a8af-79cb3bb28499"}, {"Element": "<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "0822c86e-7094-4997-ae92-a50768aa278f", "Styles": "width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "daf8027e-19ab-4086-9ae4-669c68c4b419"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "51241bf6-d684-46e1-b07c-05790a522915", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0822c86e-7094-4997-ae92-a50768aa278f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "68c4304e-add0-4f79-ad54-a361d4f80e81", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "51241bf6-d684-46e1-b07c-05790a522915"}, {"Element": "<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "7b7ca8b1-1c23-437c-adb2-1b2fd4eedb20", "Styles": "width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "daf8027e-19ab-4086-9ae4-669c68c4b419"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9e50871f-f5e4-4743-8217-1710b7e654ca", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b7ca8b1-1c23-437c-adb2-1b2fd4eedb20"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f02f37f7-6ea9-4668-8fd5-9a51f77f29eb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9e50871f-f5e4-4743-8217-1710b7e654ca"}, {"Element": "<td style=\"width:12.94%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "f61839eb-d6e2-49fc-be07-dd8f62f17ebd", "Styles": "width:12.94%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "daf8027e-19ab-4086-9ae4-669c68c4b419"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4d88793c-798a-41a1-a74b-262086f99388", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f61839eb-d6e2-49fc-be07-dd8f62f17ebd"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3d312ab7-e721-49f7-892d-f21f28d9aee9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4d88793c-798a-41a1-a74b-262086f99388"}, {"Element": "<td colspan=\"2\" style=\"width:12.92%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1%)</span></p>\n</td>", "ID": "69ec7cc9-1109-483f-be68-1e3a233d4472", "Styles": "width:12.92%;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "daf8027e-19ab-4086-9ae4-669c68c4b419"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1%)</span></p>", "ID": "6a9213b7-259a-4c55-8c8d-6b92a55895f5", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "69ec7cc9-1109-483f-be68-1e3a233d4472"}, {"Element": "<span lang=\"EN-GB\">1\n  (1%)</span>", "ID": "e2c0c11d-af69-46b1-94ca-0404d37baf4d", "Styles": "None", "Classes": "None", "Text": "1   (1%)", "ParentId": "6a9213b7-259a-4c55-8c8d-6b92a55895f5"}, {"Element": "<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">50\n  (60%)</span></p>\n</td>", "ID": "f3686f5d-5e1b-458f-8f54-9c93d3e417f6", "Styles": "width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "daf8027e-19ab-4086-9ae4-669c68c4b419"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">50\n  (60%)</span></p>", "ID": "1d0d13db-ba2f-43c7-a9ca-18800b400dbc", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f3686f5d-5e1b-458f-8f54-9c93d3e417f6"}, {"Element": "<span lang=\"EN-GB\">50\n  (60%)</span>", "ID": "ed306fec-6b37-4eb2-8770-a9216eee8e65", "Styles": "None", "Classes": "None", "Text": "50   (60%)", "ParentId": "1d0d13db-ba2f-43c7-a9ca-18800b400dbc"}, {"Element": "<td style=\"width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt\" valign=\"top\" width=\"12%\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40\n  (48.8%)</span></p>\n</td>", "ID": "49903ceb-5c0e-4787-98fd-fc157304ee90", "Styles": "width:12.92%;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt", "Classes": "None", "Text": "  ", "ParentId": "daf8027e-19ab-4086-9ae4-669c68c4b419"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">40\n  (48.8%)</span></p>", "ID": "d20cf9b9-786c-450c-a9d9-dd57aa9f2e4a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "49903ceb-5c0e-4787-98fd-fc157304ee90"}, {"Element": "<span lang=\"EN-GB\">40\n  (48.8%)</span>", "ID": "3f0b8780-0eae-4dc1-9531-59ac219bd7d9", "Styles": "None", "Classes": "None", "Text": "40   (48.8%)", "ParentId": "d20cf9b9-786c-450c-a9d9-dd57aa9f2e4a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"8\" style=\"width:100.0%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 ITT\u2011analysis\n  where subjects with missing data were included as non\u2011responders.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Week\u00a098\n  data for IMPACT includes combined placebo crossover and infliximab patients\n  who entered the open\u2011label extension.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Based\n  on patients with PASI \u2265\u00a02.5 at baseline for IMPACT, and patients\n  with \u2265\u00a03% BSA psoriasis skin involvement at baseline in IMPACT\u00a02.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">**\u00a0 PASI\u00a075 response for IMPACT\n  not included due to low N; p\u00a0&lt;\u00a00.001 for infliximab vs. placebo\n  at week\u00a024 for IMPACT\u00a02.</span></p>\n</td>\n</tr>", "ID": "bdf29750-7753-410c-aa45-a4b600eaa8d6", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td colspan=\"8\" style=\"width:100.0%;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"100%\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 ITT\u2011analysis\n  where subjects with missing data were included as non\u2011responders.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Week\u00a098\n  data for IMPACT includes combined placebo crossover and infliximab patients\n  who entered the open\u2011label extension.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Based\n  on patients with PASI \u2265\u00a02.5 at baseline for IMPACT, and patients\n  with \u2265\u00a03% BSA psoriasis skin involvement at baseline in IMPACT\u00a02.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">**\u00a0 PASI\u00a075 response for IMPACT\n  not included due to low N; p\u00a0&lt;\u00a00.001 for infliximab vs. placebo\n  at week\u00a024 for IMPACT\u00a02.</span></p>\n</td>", "ID": "3620c63e-a3cd-4447-bf84-41410d499861", "Styles": "width:100.0%;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "bdf29750-7753-410c-aa45-a4b600eaa8d6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 ITT\u2011analysis\n  where subjects with missing data were included as non\u2011responders.</span></p>", "ID": "215a711d-e289-4b6a-9327-5225ec34d9b5", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3620c63e-a3cd-4447-bf84-41410d499861"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">*\u00a0\u00a0\u00a0 ITT\u2011analysis\n  where subjects with missing data were included as non\u2011responders.</span>", "ID": "7bb2f7bf-a783-4bb0-bae1-1f9c77c2d9b6", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "*\u00a0\u00a0\u00a0 ITT\u2011analysis   where subjects with missing data were included as non\u2011responders.", "ParentId": "215a711d-e289-4b6a-9327-5225ec34d9b5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Week\u00a098\n  data for IMPACT includes combined placebo crossover and infliximab patients\n  who entered the open\u2011label extension.</span></p>", "ID": "30654a97-cbc0-459d-8c77-9143bd7ede98", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3620c63e-a3cd-4447-bf84-41410d499861"}, {"Element": "<sup><span lang=\"EN-GB\">a</span></sup>", "ID": "26cc01dd-6e74-4c03-8838-f01b13757d7c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "30654a97-cbc0-459d-8c77-9143bd7ede98"}, {"Element": "<span lang=\"EN-GB\">a</span>", "ID": "697b8fb2-359d-43cd-a736-11d4ee24dab4", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "26cc01dd-6e74-4c03-8838-f01b13757d7c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Week\u00a098\n  data for IMPACT includes combined placebo crossover and infliximab patients\n  who entered the open\u2011label extension.</span>", "ID": "f5ccaf17-9a24-45bc-8c2e-fc8c797e54b1", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 Week\u00a098   data for IMPACT includes combined placebo crossover and infliximab patients   who entered the open\u2011label extension.", "ParentId": "30654a97-cbc0-459d-8c77-9143bd7ede98"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Based\n  on patients with PASI \u2265\u00a02.5 at baseline for IMPACT, and patients\n  with \u2265\u00a03% BSA psoriasis skin involvement at baseline in IMPACT\u00a02.</span></p>", "ID": "078e0095-8403-4f8b-b109-4232f3223f2f", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3620c63e-a3cd-4447-bf84-41410d499861"}, {"Element": "<sup><span lang=\"EN-GB\">b</span></sup>", "ID": "147c1f3f-f920-453c-8615-6dba00a0956e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "078e0095-8403-4f8b-b109-4232f3223f2f"}, {"Element": "<span lang=\"EN-GB\">b</span>", "ID": "f5d5fb83-e8d9-4e17-8d21-13504e29f2fb", "Styles": "None", "Classes": "None", "Text": "b", "ParentId": "147c1f3f-f920-453c-8615-6dba00a0956e"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Based\n  on patients with PASI \u2265\u00a02.5 at baseline for IMPACT, and patients\n  with \u2265\u00a03% BSA psoriasis skin involvement at baseline in IMPACT\u00a02.</span>", "ID": "ea5fb17d-8918-4d1c-91ab-10057377cb9f", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 Based   on patients with PASI \u2265\u00a02.5 at baseline for IMPACT, and patients   with \u2265\u00a03% BSA psoriasis skin involvement at baseline in IMPACT\u00a02.", "ParentId": "078e0095-8403-4f8b-b109-4232f3223f2f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><span lang=\"EN-GB\" style=\"font-size:9.0pt\">**\u00a0 PASI\u00a075 response for IMPACT\n  not included due to low N; p\u00a0&lt;\u00a00.001 for infliximab vs. placebo\n  at week\u00a024 for IMPACT\u00a02.</span></p>", "ID": "14955c70-7ade-4a59-90ed-94e10592a632", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3620c63e-a3cd-4447-bf84-41410d499861"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">**\u00a0 PASI\u00a075 response for IMPACT\n  not included due to low N; p\u00a0&lt;\u00a00.001 for infliximab vs. placebo\n  at week\u00a024 for IMPACT\u00a02.</span>", "ID": "844b420d-ef39-4af7-aa82-a3253e0d6543", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "**\u00a0 PASI\u00a075 response for IMPACT   not included due to low N; p\u00a0<\u00a00.001 for infliximab vs. placebo   at week\u00a024 for IMPACT\u00a02.", "ParentId": "14955c70-7ade-4a59-90ed-94e10592a632"}, {"Element": "<tr height=\"0\">\n<td style=\"border:none\" width=\"136\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"0\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n<td style=\"border:none\" width=\"78\"></td>\n</tr>", "ID": "8a37e6d8-bcdd-400d-8188-67fb70d4cf71", "Styles": "None", "Classes": "None", "Text": "         ", "ParentId": "addd5df2-37ce-41b8-80bb-fd44912373be"}, {"Element": "<td style=\"border:none\" width=\"136\"></td>", "ID": "003d3bb0-3259-40ca-9667-002afbfaa4ac", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "8a37e6d8-bcdd-400d-8188-67fb70d4cf71"}, {"Element": "<td style=\"border:none\" width=\"78\"></td>", "ID": "10b9267a-f49d-47bf-9fd7-f903b52b4c2b", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "8a37e6d8-bcdd-400d-8188-67fb70d4cf71"}, {"Element": "<td style=\"border:none\" width=\"78\"></td>", "ID": "7156a495-2834-40c5-ad76-8fa59d33b40d", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "8a37e6d8-bcdd-400d-8188-67fb70d4cf71"}, {"Element": "<td style=\"border:none\" width=\"78\"></td>", "ID": "4d66a4b2-530e-45f1-9373-b03d6c59bbba", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "8a37e6d8-bcdd-400d-8188-67fb70d4cf71"}, {"Element": "<td style=\"border:none\" width=\"0\"></td>", "ID": "c28c0477-ee68-4be9-8ec3-c1beb525bc8a", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "8a37e6d8-bcdd-400d-8188-67fb70d4cf71"}, {"Element": "<td style=\"border:none\" width=\"78\"></td>", "ID": "f9c598ef-8ab0-4df9-b7da-5b30461741a2", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "8a37e6d8-bcdd-400d-8188-67fb70d4cf71"}, {"Element": "<td style=\"border:none\" width=\"78\"></td>", "ID": "8dc43ab3-bc66-4f49-8e38-d63864a62489", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "8a37e6d8-bcdd-400d-8188-67fb70d4cf71"}, {"Element": "<td style=\"border:none\" width=\"78\"></td>", "ID": "4e03b693-3360-4407-b049-0e27018c34a7", "Styles": "border:none", "Classes": "None", "Text": "", "ParentId": "8a37e6d8-bcdd-400d-8188-67fb70d4cf71"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a32359c0-52b7-44fc-a224-a28243f0174a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4d87090d-9a4f-4284-8153-0a4667f18143", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a32359c0-52b7-44fc-a224-a28243f0174a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In IMPACT and IMPACT\u00a02, clinical\nresponses were observed as early as week\u00a02 and were maintained through\nweek\u00a098 and week\u00a054 respectively. Efficacy has been demonstrated with\nor without concomitant use of methotrexate. Decreases in parameters of\nperipheral activity characteristic of psoriatic arthritis (such as number of\nswollen joints, number of painful/tender joints, dactylitis and presence of\nenthesopathy) were seen in the infliximab\u2011treated patients.</span></p>", "ID": "893b56e4-97a2-48ba-ae5f-79789e39a10f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In IMPACT and IMPACT\u00a02, clinical\nresponses were observed as early as week\u00a02 and were maintained through\nweek\u00a098 and week\u00a054 respectively. Efficacy has been demonstrated with\nor without concomitant use of methotrexate. Decreases in parameters of\nperipheral activity characteristic of psoriatic arthritis (such as number of\nswollen joints, number of painful/tender joints, dactylitis and presence of\nenthesopathy) were seen in the infliximab\u2011treated patients.</span>", "ID": "981f8a62-0777-4e73-b39e-d184b49dc135", "Styles": "None", "Classes": "None", "Text": "In IMPACT and IMPACT\u00a02, clinical responses were observed as early as week\u00a02 and were maintained through week\u00a098 and week\u00a054 respectively. Efficacy has been demonstrated with or without concomitant use of methotrexate. Decreases in parameters of peripheral activity characteristic of psoriatic arthritis (such as number of swollen joints, number of painful/tender joints, dactylitis and presence of enthesopathy) were seen in the infliximab\u2011treated patients.", "ParentId": "893b56e4-97a2-48ba-ae5f-79789e39a10f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e8c4a01a-d886-43ad-aa53-05ff95342268", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ceff3e30-dde8-4090-a37e-58dddf8e264e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e8c4a01a-d886-43ad-aa53-05ff95342268"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Radiographic changes were assessed in\nIMPACT\u00a02. Radiographs of hands and feet were collected at baseline, weeks\u00a024\nand\u00a054. Infliximab treatment reduced the rate of progression of peripheral\njoint damage compared with placebo treatment at the week\u00a024 primary\nendpoint as measured by change from baseline in total modified vdH\u2011S\nscore (mean \u00b1 SD score was 0.82\u00a0\u00b1\u00a02.62 in the placebo\ngroup compared with \u20110.70\u00a0\u00b1\u00a02.53 in the infliximab\ngroup; p\u00a0&lt;\u00a00.001). In the infliximab group, the mean change in\ntotal modified vdH\u2011S score remained below 0 at the week\u00a054\ntimepoint.</span></p>", "ID": "e9b768ac-d718-4b0a-8f43-c198c1ecca03", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Radiographic changes were assessed in\nIMPACT\u00a02. Radiographs of hands and feet were collected at baseline, weeks\u00a024\nand\u00a054. Infliximab treatment reduced the rate of progression of peripheral\njoint damage compared with placebo treatment at the week\u00a024 primary\nendpoint as measured by change from baseline in total modified vdH\u2011S\nscore (mean \u00b1 SD score was 0.82\u00a0\u00b1\u00a02.62 in the placebo\ngroup compared with \u20110.70\u00a0\u00b1\u00a02.53 in the infliximab\ngroup; p\u00a0&lt;\u00a00.001). In the infliximab group, the mean change in\ntotal modified vdH\u2011S score remained below 0 at the week\u00a054\ntimepoint.</span>", "ID": "fa3ace4d-b0a3-419b-8c98-359611905f0b", "Styles": "None", "Classes": "None", "Text": "Radiographic changes were assessed in IMPACT\u00a02. Radiographs of hands and feet were collected at baseline, weeks\u00a024 and\u00a054. Infliximab treatment reduced the rate of progression of peripheral joint damage compared with placebo treatment at the week\u00a024 primary endpoint as measured by change from baseline in total modified vdH\u2011S score (mean \u00b1 SD score was 0.82\u00a0\u00b1\u00a02.62 in the placebo group compared with \u20110.70\u00a0\u00b1\u00a02.53 in the infliximab group; p\u00a0<\u00a00.001). In the infliximab group, the mean change in total modified vdH\u2011S score remained below 0 at the week\u00a054 timepoint.", "ParentId": "e9b768ac-d718-4b0a-8f43-c198c1ecca03"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "15c0257f-8471-48db-9e67-44c8ebd5f95a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "12c324ea-f097-4653-a491-706655adecb7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "15c0257f-8471-48db-9e67-44c8ebd5f95a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab\u2011treated patients\ndemonstrated significant improvement in physical function as assessed by HAQ.\nSignificant improvements in health\u2011related quality of life were also\ndemonstrated as measured by the physical and mental component summary scores of\nthe SF\u201136 in IMPACT\u00a02.</span></p>", "ID": "b5cd0e32-536c-4c1a-8a8b-a11c87523c7f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infliximab\u2011treated patients\ndemonstrated significant improvement in physical function as assessed by HAQ.\nSignificant improvements in health\u2011related quality of life were also\ndemonstrated as measured by the physical and mental component summary scores of\nthe SF\u201136 in IMPACT\u00a02.</span>", "ID": "72a5278d-9f07-41b5-80f3-56c486cc19c2", "Styles": "None", "Classes": "None", "Text": "Infliximab\u2011treated patients demonstrated significant improvement in physical function as assessed by HAQ. Significant improvements in health\u2011related quality of life were also demonstrated as measured by the physical and mental component summary scores of the SF\u201136 in IMPACT\u00a02.", "ParentId": "b5cd0e32-536c-4c1a-8a8b-a11c87523c7f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6ec2465d-58f7-4f51-882f-a09076edda6d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "df2fd9d8-b738-44f4-95a7-83f8bc7098e7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6ec2465d-58f7-4f51-882f-a09076edda6d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Adult\npsoriasis</span></u></p>", "ID": "19b74619-ee22-4aa5-a830-aec8d1349f07", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Adult\npsoriasis</span></u>", "ID": "a93decb8-038d-46e7-9660-5466767cad72", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "19b74619-ee22-4aa5-a830-aec8d1349f07"}, {"Element": "<span lang=\"EN-GB\">Adult\npsoriasis</span>", "ID": "1e88dd79-ea75-4f79-bea3-f318522ca523", "Styles": "None", "Classes": "None", "Text": "Adult psoriasis", "ParentId": "a93decb8-038d-46e7-9660-5466767cad72"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">The efficacy of\ninfliximab was assessed in two multicenter, randomised, double\u2011blind<b> </b>studies:\nSPIRIT and EXPRESS. Patients in both studies had plaque psoriasis (Body Surface\nArea [BSA] \u2265\u00a010% and Psoriasis Area and Severity Index [PASI] score \u2265\u00a012).\nThe primary endpoint in both studies was the percent of patients who achieved \u2265\u00a075%\nimprovement in PASI from baseline at week\u00a010.</span></p>", "ID": "6225a376-3b89-4625-902a-8194ae9697d7", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The efficacy of\ninfliximab was assessed in two multicenter, randomised, double\u2011blind<b> </b>studies:\nSPIRIT and EXPRESS. Patients in both studies had plaque psoriasis (Body Surface\nArea [BSA] \u2265\u00a010% and Psoriasis Area and Severity Index [PASI] score \u2265\u00a012).\nThe primary endpoint in both studies was the percent of patients who achieved \u2265\u00a075%\nimprovement in PASI from baseline at week\u00a010.</span>", "ID": "7d9746f7-f9f0-49b0-933c-3c0d52caeccb", "Styles": "None", "Classes": "None", "Text": "The efficacy of infliximab was assessed in two multicenter, randomised, double\u2011blindstudies: SPIRIT and EXPRESS. Patients in both studies had plaque psoriasis (Body Surface Area [BSA] \u2265\u00a010% and Psoriasis Area and Severity Index [PASI] score \u2265\u00a012). The primary endpoint in both studies was the percent of patients who achieved \u2265\u00a075% improvement in PASI from baseline at week\u00a010.", "ParentId": "6225a376-3b89-4625-902a-8194ae9697d7"}, {"Element": "<b> </b>", "ID": "29800ac3-87e7-4a71-a184-63b9dd9f914f", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "7d9746f7-f9f0-49b0-933c-3c0d52caeccb"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "75fa6818-e30c-4c2d-ba13-fabe6fb48ff3", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "74404114-6d1c-4ba5-a962-8e425fc75e80", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "75fa6818-e30c-4c2d-ba13-fabe6fb48ff3"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">SPIRIT\nevaluated the efficacy of infliximab induction therapy in 249\u00a0patients\nwith plaque psoriasis that had previously received PUVA or systemic therapy.\nPatients received either 3 or 5\u00a0mg/kg infliximab or placebo infusions at\nweeks\u00a00, 2 and 6. Patients with a PGA score \u2265\u00a03 were eligible\nto receive an additional infusion of the same treatment at week\u00a026.</span></p>", "ID": "6fef5344-dfcf-4b08-a776-ef48e3c03217", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">SPIRIT\nevaluated the efficacy of infliximab induction therapy in 249\u00a0patients\nwith plaque psoriasis that had previously received PUVA or systemic therapy.\nPatients received either 3 or 5\u00a0mg/kg infliximab or placebo infusions at\nweeks\u00a00, 2 and 6. Patients with a PGA score \u2265\u00a03 were eligible\nto receive an additional infusion of the same treatment at week\u00a026.</span>", "ID": "e1d955f6-6a7c-4fcc-b078-c0e8bb91fd63", "Styles": "None", "Classes": "None", "Text": "SPIRIT evaluated the efficacy of infliximab induction therapy in 249\u00a0patients with plaque psoriasis that had previously received PUVA or systemic therapy. Patients received either 3 or 5\u00a0mg/kg infliximab or placebo infusions at weeks\u00a00, 2 and 6. Patients with a PGA score \u2265\u00a03 were eligible to receive an additional infusion of the same treatment at week\u00a026.", "ParentId": "6fef5344-dfcf-4b08-a776-ef48e3c03217"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">In SPIRIT, </span><span lang=\"EN-GB\">the proportion of patients achieving PASI\u00a075 at week\u00a010\nwas 71.7% in the 3\u00a0mg/kg infliximab group, 87.9% in the 5\u00a0mg/kg\ninfliximab group, and 5.9% in the placebo group (p\u00a0&lt;\u00a00.001). By\nweek\u00a026, twenty weeks after the last induction dose, 30% of patients in\nthe 5\u00a0mg/kg group and 13.8% of patients in the 3\u00a0mg/kg group were\nPASI\u00a075 responders. Between weeks\u00a06 and 26, symptoms of psoriasis\ngradually returned with a median time to disease relapse of &gt;\u00a020\u00a0weeks.\nNo rebound was observed.</span></p>", "ID": "b443b4c6-0e0b-448f-b5e4-c9091c46b6ba", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In SPIRIT, </span>", "ID": "dff7c65a-7887-4a83-a5e5-ad94e097b0de", "Styles": "None", "Classes": "None", "Text": "In SPIRIT, ", "ParentId": "b443b4c6-0e0b-448f-b5e4-c9091c46b6ba"}, {"Element": "<span lang=\"EN-GB\">the proportion of patients achieving PASI\u00a075 at week\u00a010\nwas 71.7% in the 3\u00a0mg/kg infliximab group, 87.9% in the 5\u00a0mg/kg\ninfliximab group, and 5.9% in the placebo group (p\u00a0&lt;\u00a00.001). By\nweek\u00a026, twenty weeks after the last induction dose, 30% of patients in\nthe 5\u00a0mg/kg group and 13.8% of patients in the 3\u00a0mg/kg group were\nPASI\u00a075 responders. Between weeks\u00a06 and 26, symptoms of psoriasis\ngradually returned with a median time to disease relapse of &gt;\u00a020\u00a0weeks.\nNo rebound was observed.</span>", "ID": "8618eceb-f8f5-4a0d-9b04-008148c0fd59", "Styles": "None", "Classes": "None", "Text": "the proportion of patients achieving PASI\u00a075 at week\u00a010 was 71.7% in the 3\u00a0mg/kg infliximab group, 87.9% in the 5\u00a0mg/kg infliximab group, and 5.9% in the placebo group (p\u00a0<\u00a00.001). By week\u00a026, twenty weeks after the last induction dose, 30% of patients in the 5\u00a0mg/kg group and 13.8% of patients in the 3\u00a0mg/kg group were PASI\u00a075 responders. Between weeks\u00a06 and 26, symptoms of psoriasis gradually returned with a median time to disease relapse of >\u00a020\u00a0weeks. No rebound was observed.", "ParentId": "b443b4c6-0e0b-448f-b5e4-c9091c46b6ba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXPRESS evaluated the efficacy of\ninfliximab induction and maintenance therapy in 378\u00a0patients with plaque\npsoriasis. Patients received 5\u00a0mg/kg infliximab\u2011 or placebo\u2011infusions\nat weeks\u00a00, 2 and 6 followed by maintenance therapy every 8\u00a0weeks\nthrough week\u00a022 in the placebo group and through week\u00a046 in the\ninfliximab group. A</span><span lang=\"EN-GB\">t week\u00a024, the placebo group\ncrossed over to infliximab induction therapy (5\u00a0mg/kg) followed by\ninfliximab maintenance therapy (5\u00a0mg/kg).</span><span lang=\"EN-GB\"> Nail\npsoriasis was assessed using the Nail Psoriasis Severity Index (NAPSI). </span><span lang=\"EN-GB\">Prior therapy with PUVA, methotrexate, ciclosporin, or acitretin had\nbeen received by 71.4% of patients</span><span lang=\"EN-GB\">, although they were\nnot necessarily therapy resistant</span><span lang=\"EN-GB\">. </span><span lang=\"EN-GB\">Key results are presented in Table\u00a010. In infliximab treated\nsubjects, significant PASI\u00a050 responses were apparent at the first visit\n(week\u00a02) and PASI\u00a075 responses by the second visit (week\u00a06).\nEfficacy was similar in the subgroup of patients that were exposed to previous\nsystemic therapies compared to the overall study population.</span></p>", "ID": "5e21e5cf-019e-46be-810f-0a96e578dc03", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">EXPRESS evaluated the efficacy of\ninfliximab induction and maintenance therapy in 378\u00a0patients with plaque\npsoriasis. Patients received 5\u00a0mg/kg infliximab\u2011 or placebo\u2011infusions\nat weeks\u00a00, 2 and 6 followed by maintenance therapy every 8\u00a0weeks\nthrough week\u00a022 in the placebo group and through week\u00a046 in the\ninfliximab group. A</span>", "ID": "3094ae7d-5426-43c7-afed-4c2bc3701387", "Styles": "None", "Classes": "None", "Text": "EXPRESS evaluated the efficacy of infliximab induction and maintenance therapy in 378\u00a0patients with plaque psoriasis. Patients received 5\u00a0mg/kg infliximab\u2011 or placebo\u2011infusions at weeks\u00a00, 2 and 6 followed by maintenance therapy every 8\u00a0weeks through week\u00a022 in the placebo group and through week\u00a046 in the infliximab group. A", "ParentId": "5e21e5cf-019e-46be-810f-0a96e578dc03"}, {"Element": "<span lang=\"EN-GB\">t week\u00a024, the placebo group\ncrossed over to infliximab induction therapy (5\u00a0mg/kg) followed by\ninfliximab maintenance therapy (5\u00a0mg/kg).</span>", "ID": "a3cc4dbc-4abb-4d44-b0f0-e60a344bed3b", "Styles": "None", "Classes": "None", "Text": "t week\u00a024, the placebo group crossed over to infliximab induction therapy (5\u00a0mg/kg) followed by infliximab maintenance therapy (5\u00a0mg/kg).", "ParentId": "5e21e5cf-019e-46be-810f-0a96e578dc03"}, {"Element": "<span lang=\"EN-GB\"> Nail\npsoriasis was assessed using the Nail Psoriasis Severity Index (NAPSI). </span>", "ID": "2cdcf3d3-1a6a-45b5-aa80-7a629e654ab9", "Styles": "None", "Classes": "None", "Text": " Nail psoriasis was assessed using the Nail Psoriasis Severity Index (NAPSI). ", "ParentId": "5e21e5cf-019e-46be-810f-0a96e578dc03"}, {"Element": "<span lang=\"EN-GB\">Prior therapy with PUVA, methotrexate, ciclosporin, or acitretin had\nbeen received by 71.4% of patients</span>", "ID": "2b5188fb-831d-4da8-b0e3-ec83b6a54273", "Styles": "None", "Classes": "None", "Text": "Prior therapy with PUVA, methotrexate, ciclosporin, or acitretin had been received by 71.4% of patients", "ParentId": "5e21e5cf-019e-46be-810f-0a96e578dc03"}, {"Element": "<span lang=\"EN-GB\">, although they were\nnot necessarily therapy resistant</span>", "ID": "cac257c1-f2f5-4e15-bf88-93159b9a46e7", "Styles": "None", "Classes": "None", "Text": ", although they were not necessarily therapy resistant", "ParentId": "5e21e5cf-019e-46be-810f-0a96e578dc03"}, {"Element": "<span lang=\"EN-GB\">. </span>", "ID": "20055049-d125-44f8-a1ad-18737af4a520", "Styles": "None", "Classes": "None", "Text": ". ", "ParentId": "5e21e5cf-019e-46be-810f-0a96e578dc03"}, {"Element": "<span lang=\"EN-GB\">Key results are presented in Table\u00a010. In infliximab treated\nsubjects, significant PASI\u00a050 responses were apparent at the first visit\n(week\u00a02) and PASI\u00a075 responses by the second visit (week\u00a06).\nEfficacy was similar in the subgroup of patients that were exposed to previous\nsystemic therapies compared to the overall study population.</span>", "ID": "b8274eef-8401-4367-bc40-9a79caed752c", "Styles": "None", "Classes": "None", "Text": "Key results are presented in Table\u00a010. In infliximab treated subjects, significant PASI\u00a050 responses were apparent at the first visit (week\u00a02) and PASI\u00a075 responses by the second visit (week\u00a06). Efficacy was similar in the subgroup of patients that were exposed to previous systemic therapies compared to the overall study population.", "ParentId": "5e21e5cf-019e-46be-810f-0a96e578dc03"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bbac7dd2-1cf0-49d3-a4dd-2f308770c65f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b06945f0-44a2-42eb-bbfa-84dec3fcaa94", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bbac7dd2-1cf0-49d3-a4dd-2f308770c65f"}, {"Element": "<div align=\"center\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:448.4pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"598\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a010</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Summary of PASI response, PGA response and percent\n  of patients with all nails cleared at weeks\u00a010, 24 and 50. EXPRESS</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:127.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo \u2192 Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(at week\u00a024)</span></p>\n</td>\n<td style=\"width:84.0pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a010</span></b></p>\n</td>\n<td style=\"width:127.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">301</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1.3%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">172\n  (57.1%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242\n  (80.4%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">6\n  (7.8%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">274\n  (91.0%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3\n  (3.9%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242\n  (82.9%)<sup>ab</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14\n  (18.2%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">275\n  (94.2%)<sup>ab</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a024</span></b></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">276</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1.3%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">161\n  (58.3%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3\n  (3.9%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">227\n  (82.2%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5\n  (6.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">248\n  (89.9%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">203\n  (73.6%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15\n  (19.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">246\n  (89.1%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a050</span></b></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">68</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">281</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34\n  (50.0%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">127\n  (45.2%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52\n  (76.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">170\n  (60.5%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61\n  (89.7%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">193\n  (68.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46\n  (67.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">149\n  (53.0%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">59\n  (86.8%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">189\n  (67.3%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">All\n  nails cleared<sup>c</sup></span></b></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a010</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1/65\n  (1.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">16/235\n  (6.8%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a024</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3/65\n  (4.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">58/223\n  (26.0%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a050</span></p>\n</td>\n<td style=\"width:127.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27/64\n  (42.2%)</span></p>\n</td>\n<td style=\"width:84.0pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">92/226\n  (40.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:448.4pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"598\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 p\u00a0&lt;\u00a00.001,\n  for each infliximab treatment group vs. control.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 n\u00a0=\u00a0292.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Analysis\n  was based on subjects with nail psoriasis at baseline (81.8% of subjects).\n  Mean baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group.</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "e8a503f0-5e87-463d-abad-47ed672e78d1", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:448.4pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"598\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a010</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Summary of PASI response, PGA response and percent\n  of patients with all nails cleared at weeks\u00a010, 24 and 50. EXPRESS</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:127.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo \u2192 Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(at week\u00a024)</span></p>\n</td>\n<td style=\"width:84.0pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a010</span></b></p>\n</td>\n<td style=\"width:127.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">301</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1.3%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">172\n  (57.1%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242\n  (80.4%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">6\n  (7.8%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">274\n  (91.0%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3\n  (3.9%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242\n  (82.9%)<sup>ab</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14\n  (18.2%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">275\n  (94.2%)<sup>ab</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a024</span></b></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">276</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1.3%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">161\n  (58.3%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3\n  (3.9%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">227\n  (82.2%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5\n  (6.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">248\n  (89.9%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">203\n  (73.6%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15\n  (19.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">246\n  (89.1%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a050</span></b></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">68</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">281</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34\n  (50.0%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">127\n  (45.2%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52\n  (76.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">170\n  (60.5%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61\n  (89.7%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">193\n  (68.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46\n  (67.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">149\n  (53.0%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">59\n  (86.8%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">189\n  (67.3%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">All\n  nails cleared<sup>c</sup></span></b></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a010</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1/65\n  (1.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">16/235\n  (6.8%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a024</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3/65\n  (4.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">58/223\n  (26.0%)<sup>a</sup></span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a050</span></p>\n</td>\n<td style=\"width:127.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27/64\n  (42.2%)</span></p>\n</td>\n<td style=\"width:84.0pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">92/226\n  (40.7%)</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:448.4pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"598\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 p\u00a0&lt;\u00a00.001,\n  for each infliximab treatment group vs. control.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 n\u00a0=\u00a0292.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Analysis\n  was based on subjects with nail psoriasis at baseline (81.8% of subjects).\n  Mean baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group.</span></p>\n</td>\n</tr>\n</table>", "ID": "3b4f773b-0afe-472c-bc20-883eacc67a34", "Styles": "border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "                             ", "ParentId": "e8a503f0-5e87-463d-abad-47ed672e78d1"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:448.4pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"598\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a010</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Summary of PASI response, PGA response and percent\n  of patients with all nails cleared at weeks\u00a010, 24 and 50. EXPRESS</span></b></p>\n</td>\n</tr>", "ID": "e116bb73-c644-4476-99ce-09fd29ee4672", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td colspan=\"3\" style=\"width:448.4pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"598\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a010</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Summary of PASI response, PGA response and percent\n  of patients with all nails cleared at weeks\u00a010, 24 and 50. EXPRESS</span></b></p>\n</td>", "ID": "20402c5a-1dd4-42c6-a92e-9553b7df2b06", "Styles": "width:448.4pt;border:none;\n  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "e116bb73-c644-4476-99ce-09fd29ee4672"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Table\u00a010</span></b></p>", "ID": "41fbd617-afac-428b-ac02-09b251cf4812", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "20402c5a-1dd4-42c6-a92e-9553b7df2b06"}, {"Element": "<b><span lang=\"EN-GB\">Table\u00a010</span></b>", "ID": "73dec451-2288-4899-9b86-0ee48566317a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "41fbd617-afac-428b-ac02-09b251cf4812"}, {"Element": "<span lang=\"EN-GB\">Table\u00a010</span>", "ID": "33b4aebd-f71d-4419-96f3-ceae396bf385", "Styles": "None", "Classes": "None", "Text": "Table\u00a010", "ParentId": "73dec451-2288-4899-9b86-0ee48566317a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><b><span lang=\"EN-GB\">Summary of PASI response, PGA response and percent\n  of patients with all nails cleared at weeks\u00a010, 24 and 50. EXPRESS</span></b></p>", "ID": "427edaff-25b9-4f61-a351-5ce1acb6b737", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "20402c5a-1dd4-42c6-a92e-9553b7df2b06"}, {"Element": "<b><span lang=\"EN-GB\">Summary of PASI response, PGA response and percent\n  of patients with all nails cleared at weeks\u00a010, 24 and 50. EXPRESS</span></b>", "ID": "cd9782de-ba1a-486f-b260-57907bc9c597", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "427edaff-25b9-4f61-a351-5ce1acb6b737"}, {"Element": "<span lang=\"EN-GB\">Summary of PASI response, PGA response and percent\n  of patients with all nails cleared at weeks\u00a010, 24 and 50. EXPRESS</span>", "ID": "3fe82ce9-d858-4745-b606-05e4d80c6add", "Styles": "None", "Classes": "None", "Text": "Summary of PASI response, PGA response and percent   of patients with all nails cleared at weeks\u00a010, 24 and 50. EXPRESS", "ParentId": "cd9782de-ba1a-486f-b260-57907bc9c597"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:127.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo \u2192 Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(at week\u00a024)</span></p>\n</td>\n<td style=\"width:84.0pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n</td>\n</tr>", "ID": "b25f8c50-9732-41a2-ab1e-976bd558cd9b", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "d427cba3-bbd7-49f5-a5ba-0f63a1077b31", "Styles": "width:236.85pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b25f8c50-9732-41a2-ab1e-976bd558cd9b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "22bdbe84-27dd-4039-813a-a32623fe9d83", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d427cba3-bbd7-49f5-a5ba-0f63a1077b31"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5d98560d-ef88-45bb-8f5d-907b84f2e0b9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "22bdbe84-27dd-4039-813a-a32623fe9d83"}, {"Element": "<td style=\"width:127.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo \u2192 Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(at week\u00a024)</span></p>\n</td>", "ID": "a74f8893-c276-4c87-8d53-8fd520844e7f", "Styles": "width:127.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "b25f8c50-9732-41a2-ab1e-976bd558cd9b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Placebo \u2192 Infliximab</span></p>", "ID": "36269b6c-1f7d-40c8-8134-4a28f2492405", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a74f8893-c276-4c87-8d53-8fd520844e7f"}, {"Element": "<span lang=\"EN-GB\">Placebo \u2192 Infliximab</span>", "ID": "b0ed6d29-b7d7-4be2-8c3f-18d3c80596fe", "Styles": "None", "Classes": "None", "Text": "Placebo \u2192 Infliximab", "ParentId": "36269b6c-1f7d-40c8-8134-4a28f2492405"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>", "ID": "328217ef-7bb0-4da5-8653-e535a5ded791", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a74f8893-c276-4c87-8d53-8fd520844e7f"}, {"Element": "<span lang=\"EN-GB\">5\u00a0mg/kg</span>", "ID": "bf1c2a7f-c22c-4c6d-8bc4-753a9fb81bb2", "Styles": "None", "Classes": "None", "Text": "5\u00a0mg/kg", "ParentId": "328217ef-7bb0-4da5-8653-e535a5ded791"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">(at week\u00a024)</span></p>", "ID": "27e4c5cb-f8b6-443e-8bdc-4fa3a2b2b50a", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a74f8893-c276-4c87-8d53-8fd520844e7f"}, {"Element": "<span lang=\"EN-GB\">(at week\u00a024)</span>", "ID": "96513b18-b3c1-444b-8697-909e56c254a1", "Styles": "None", "Classes": "None", "Text": "(at week\u00a024)", "ParentId": "27e4c5cb-f8b6-443e-8bdc-4fa3a2b2b50a"}, {"Element": "<td style=\"width:84.0pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>\n</td>", "ID": "e03bc87e-1b99-4c18-a4b2-3ad7fe615520", "Styles": "width:84.0pt;border:none;border-bottom:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "   ", "ParentId": "b25f8c50-9732-41a2-ab1e-976bd558cd9b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">Infliximab</span></p>", "ID": "3d2c3dae-eefc-436f-8e94-cf8f07c581ed", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e03bc87e-1b99-4c18-a4b2-3ad7fe615520"}, {"Element": "<span lang=\"EN-GB\">Infliximab</span>", "ID": "afc2dd83-41d0-4339-9b01-855e17a929a7", "Styles": "None", "Classes": "None", "Text": "Infliximab", "ParentId": "3d2c3dae-eefc-436f-8e94-cf8f07c581ed"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">5\u00a0mg/kg</span></p>", "ID": "9edd2309-698a-4742-95f8-ab2dad34d02f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e03bc87e-1b99-4c18-a4b2-3ad7fe615520"}, {"Element": "<span lang=\"EN-GB\">5\u00a0mg/kg</span>", "ID": "3b1168ff-3dc1-4c6c-a880-346106eadf22", "Styles": "None", "Classes": "None", "Text": "5\u00a0mg/kg", "ParentId": "9edd2309-698a-4742-95f8-ab2dad34d02f"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a010</span></b></p>\n</td>\n<td style=\"width:127.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "e2ca5926-e580-4ca7-97d8-74f24ce01710", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a010</span></b></p>\n</td>", "ID": "d40af644-d404-45be-b2d9-69f43ba59167", "Styles": "width:236.85pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e2ca5926-e580-4ca7-97d8-74f24ce01710"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a010</span></b></p>", "ID": "cf0d290d-89e2-4438-aca3-d466bc51cc9b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d40af644-d404-45be-b2d9-69f43ba59167"}, {"Element": "<b><span lang=\"EN-GB\">Week\u00a010</span></b>", "ID": "7d10b942-eb09-4a9c-8d78-8e027aae55b5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cf0d290d-89e2-4438-aca3-d466bc51cc9b"}, {"Element": "<span lang=\"EN-GB\">Week\u00a010</span>", "ID": "b6b659f1-46c5-4edd-9cd5-453a98ddb502", "Styles": "None", "Classes": "None", "Text": "Week\u00a010", "ParentId": "7d10b942-eb09-4a9c-8d78-8e027aae55b5"}, {"Element": "<td style=\"width:127.55pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "92032814-b655-4099-91f3-0cad1f4d8202", "Styles": "width:127.55pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e2ca5926-e580-4ca7-97d8-74f24ce01710"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aed1a11a-a245-4f19-b1f7-0e82031fc1ed", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "92032814-b655-4099-91f3-0cad1f4d8202"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e854d7a5-837a-4670-ba9f-7c809273bfc7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aed1a11a-a245-4f19-b1f7-0e82031fc1ed"}, {"Element": "<td style=\"width:84.0pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "7f03218c-88c7-4741-a165-bfb1e0d52b37", "Styles": "width:84.0pt;border:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "e2ca5926-e580-4ca7-97d8-74f24ce01710"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cdeda842-33e3-4a1e-a61a-cd4961ec9398", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7f03218c-88c7-4741-a165-bfb1e0d52b37"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9a41b240-9276-4f36-a602-639a3536be6e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cdeda842-33e3-4a1e-a61a-cd4961ec9398"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">301</span></p>\n</td>\n</tr>", "ID": "cbd3c2a8-f4df-4a92-84e1-cbaf06241728", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>", "ID": "0970bb6e-5dfe-42c4-b58a-c37b099fdd44", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cbd3c2a8-f4df-4a92-84e1-cbaf06241728"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>", "ID": "d2bf6e90-e920-4098-8724-f2f89064da1a", "Styles": "margin-left:14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0970bb6e-5dfe-42c4-b58a-c37b099fdd44"}, {"Element": "<span lang=\"EN-GB\">N</span>", "ID": "9e6f3df8-7635-4895-a349-bf0dbbbca5a1", "Styles": "None", "Classes": "None", "Text": "N", "ParentId": "d2bf6e90-e920-4098-8724-f2f89064da1a"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77</span></p>\n</td>", "ID": "7dabd0d7-d4a5-4c81-8afc-bcb4c702a4a1", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cbd3c2a8-f4df-4a92-84e1-cbaf06241728"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77</span></p>", "ID": "3cc348d7-d7b3-40db-aa32-42279ebbaab9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7dabd0d7-d4a5-4c81-8afc-bcb4c702a4a1"}, {"Element": "<span lang=\"EN-GB\">77</span>", "ID": "925ab744-c4ab-4f9b-b0d9-ec130944d4f1", "Styles": "None", "Classes": "None", "Text": "77", "ParentId": "3cc348d7-d7b3-40db-aa32-42279ebbaab9"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">301</span></p>\n</td>", "ID": "cd444c5b-e110-4842-a244-1f8150cc4399", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cbd3c2a8-f4df-4a92-84e1-cbaf06241728"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">301</span></p>", "ID": "1c7792bd-a69b-42b2-a921-74a32db4f41e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cd444c5b-e110-4842-a244-1f8150cc4399"}, {"Element": "<span lang=\"EN-GB\">301</span>", "ID": "9d5436dd-67f2-44b7-8807-951a9e3240d1", "Styles": "None", "Classes": "None", "Text": "301", "ParentId": "1c7792bd-a69b-42b2-a921-74a32db4f41e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1.3%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">172\n  (57.1%)<sup>a</sup></span></p>\n</td>\n</tr>", "ID": "84039480-8aaa-468c-81da-9ba94977e6c0", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>", "ID": "09584a0a-a9a7-46b7-8536-36300598bcd2", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "84039480-8aaa-468c-81da-9ba94977e6c0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>", "ID": "87140d9b-a043-47e0-b936-93dba38bbf80", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "09584a0a-a9a7-46b7-8536-36300598bcd2"}, {"Element": "<span lang=\"EN-GB\">\u2265\u00a090% improvement</span>", "ID": "190056e4-6ddc-49db-b4d0-baa3238e60de", "Styles": "None", "Classes": "None", "Text": "\u2265\u00a090% improvement", "ParentId": "87140d9b-a043-47e0-b936-93dba38bbf80"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1.3%)</span></p>\n</td>", "ID": "6c0fa625-2773-407c-b03c-9d8a56247fe0", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "84039480-8aaa-468c-81da-9ba94977e6c0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1.3%)</span></p>", "ID": "5e5b40cf-838f-45dc-bb26-9a826adbc898", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6c0fa625-2773-407c-b03c-9d8a56247fe0"}, {"Element": "<span lang=\"EN-GB\">1\n  (1.3%)</span>", "ID": "392e00ca-6b05-4ba4-b063-40a6ec488c58", "Styles": "None", "Classes": "None", "Text": "1   (1.3%)", "ParentId": "5e5b40cf-838f-45dc-bb26-9a826adbc898"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">172\n  (57.1%)<sup>a</sup></span></p>\n</td>", "ID": "5e96cd45-6e81-4313-a43f-fd890518f381", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "84039480-8aaa-468c-81da-9ba94977e6c0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">172\n  (57.1%)<sup>a</sup></span></p>", "ID": "10391e15-2ac4-49a7-8f20-8b2a76eb9a12", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5e96cd45-6e81-4313-a43f-fd890518f381"}, {"Element": "<span lang=\"EN-GB\">172\n  (57.1%)<sup>a</sup></span>", "ID": "4ff6651d-2d41-4644-8a71-ad0158420775", "Styles": "None", "Classes": "None", "Text": "172   (57.1%)", "ParentId": "10391e15-2ac4-49a7-8f20-8b2a76eb9a12"}, {"Element": "<sup>a</sup>", "ID": "822bf6ef-7725-4135-9389-bb9be5bae8f9", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "4ff6651d-2d41-4644-8a71-ad0158420775"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242\n  (80.4%)<sup>a</sup></span></p>\n</td>\n</tr>", "ID": "2071ef53-99df-486f-b2f6-d6fc42428136", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>", "ID": "26d162d2-0029-444e-9ef3-6f3433f43204", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2071ef53-99df-486f-b2f6-d6fc42428136"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>", "ID": "70ba608e-43f8-42cc-bac0-c46c0fb5dc3f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "26d162d2-0029-444e-9ef3-6f3433f43204"}, {"Element": "<span lang=\"EN-GB\">\u2265\u00a075% improvement</span>", "ID": "ac09a5fe-5f8c-4073-849f-f9f4c2b0e9c8", "Styles": "None", "Classes": "None", "Text": "\u2265\u00a075% improvement", "ParentId": "70ba608e-43f8-42cc-bac0-c46c0fb5dc3f"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2.6%)</span></p>\n</td>", "ID": "6cf6ba43-323d-46f8-8934-d3bda58f5f6d", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2071ef53-99df-486f-b2f6-d6fc42428136"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2.6%)</span></p>", "ID": "05000d85-1473-4c58-a2d4-57f15766e4d3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6cf6ba43-323d-46f8-8934-d3bda58f5f6d"}, {"Element": "<span lang=\"EN-GB\">2\n  (2.6%)</span>", "ID": "eab206de-4542-42ca-a0d3-a73eb5ccb3d9", "Styles": "None", "Classes": "None", "Text": "2   (2.6%)", "ParentId": "05000d85-1473-4c58-a2d4-57f15766e4d3"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242\n  (80.4%)<sup>a</sup></span></p>\n</td>", "ID": "f52c911c-e9e9-43ee-865a-aebf91911d16", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2071ef53-99df-486f-b2f6-d6fc42428136"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242\n  (80.4%)<sup>a</sup></span></p>", "ID": "9054ba84-e8e0-4ff0-aa82-860c14309570", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f52c911c-e9e9-43ee-865a-aebf91911d16"}, {"Element": "<span lang=\"EN-GB\">242\n  (80.4%)<sup>a</sup></span>", "ID": "b3ed7b1a-fdb9-4954-9691-0d47cb633443", "Styles": "None", "Classes": "None", "Text": "242   (80.4%)", "ParentId": "9054ba84-e8e0-4ff0-aa82-860c14309570"}, {"Element": "<sup>a</sup>", "ID": "3dc9fc7d-67e0-4441-b1be-7edfdd87ce51", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "b3ed7b1a-fdb9-4954-9691-0d47cb633443"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">6\n  (7.8%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">274\n  (91.0%)</span></p>\n</td>\n</tr>", "ID": "2cfcd75d-f4b4-4900-8055-3a72128a4286", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>", "ID": "301ebeca-c099-48a5-ae0e-0250134553ea", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2cfcd75d-f4b4-4900-8055-3a72128a4286"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>", "ID": "b5daeb33-c888-44ef-8f02-dabd2ccdfa81", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "301ebeca-c099-48a5-ae0e-0250134553ea"}, {"Element": "<span lang=\"EN-GB\">\u2265\u00a050% improvement</span>", "ID": "d0a6b0dd-276f-47b6-bcc7-67232f2d4109", "Styles": "None", "Classes": "None", "Text": "\u2265\u00a050% improvement", "ParentId": "b5daeb33-c888-44ef-8f02-dabd2ccdfa81"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">6\n  (7.8%)</span></p>\n</td>", "ID": "a7a09e01-b999-4c35-b528-fbb81f5bd5aa", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2cfcd75d-f4b4-4900-8055-3a72128a4286"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">6\n  (7.8%)</span></p>", "ID": "1611a95a-0567-464e-9252-88ad7ed3b6b3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a7a09e01-b999-4c35-b528-fbb81f5bd5aa"}, {"Element": "<span lang=\"EN-GB\">6\n  (7.8%)</span>", "ID": "23593480-e465-4caf-8b6f-867f49ed2d05", "Styles": "None", "Classes": "None", "Text": "6   (7.8%)", "ParentId": "1611a95a-0567-464e-9252-88ad7ed3b6b3"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">274\n  (91.0%)</span></p>\n</td>", "ID": "d56c1b02-2fa0-429d-bab7-0d8ae3cf6a82", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "2cfcd75d-f4b4-4900-8055-3a72128a4286"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">274\n  (91.0%)</span></p>", "ID": "42215202-3d1b-45e7-b40f-cc824553af4d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d56c1b02-2fa0-429d-bab7-0d8ae3cf6a82"}, {"Element": "<span lang=\"EN-GB\">274\n  (91.0%)</span>", "ID": "2d352b5f-cd79-4cf7-afd2-1a9ce1822948", "Styles": "None", "Classes": "None", "Text": "274   (91.0%)", "ParentId": "42215202-3d1b-45e7-b40f-cc824553af4d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3\n  (3.9%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242\n  (82.9%)<sup>ab</sup></span></p>\n</td>\n</tr>", "ID": "83da711c-9307-472a-9343-12685c466e4d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>", "ID": "671be421-f663-4d99-9e06-f061b67209bd", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "83da711c-9307-472a-9343-12685c466e4d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>", "ID": "1b7c48e1-1b69-4a78-b46e-1e9077b724cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "671be421-f663-4d99-9e06-f061b67209bd"}, {"Element": "<span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span>", "ID": "6db9a2f3-d539-4daa-81c8-4af7526242ce", "Styles": "None", "Classes": "None", "Text": "PGA of cleared (0) or minimal (1)", "ParentId": "1b7c48e1-1b69-4a78-b46e-1e9077b724cd"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3\n  (3.9%)</span></p>\n</td>", "ID": "b317f292-d302-450f-aa86-965f254226fd", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "83da711c-9307-472a-9343-12685c466e4d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3\n  (3.9%)</span></p>", "ID": "32f607af-5f4c-47bb-81eb-f396aea00955", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b317f292-d302-450f-aa86-965f254226fd"}, {"Element": "<span lang=\"EN-GB\">3\n  (3.9%)</span>", "ID": "4ef33b04-e131-4036-b6a1-2d949ae55dbd", "Styles": "None", "Classes": "None", "Text": "3   (3.9%)", "ParentId": "32f607af-5f4c-47bb-81eb-f396aea00955"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242\n  (82.9%)<sup>ab</sup></span></p>\n</td>", "ID": "4da6aca5-3a1c-4d25-a3c4-793457707409", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "83da711c-9307-472a-9343-12685c466e4d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">242\n  (82.9%)<sup>ab</sup></span></p>", "ID": "b654cd49-087e-4a00-84e7-c06604320017", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4da6aca5-3a1c-4d25-a3c4-793457707409"}, {"Element": "<span lang=\"EN-GB\">242\n  (82.9%)<sup>ab</sup></span>", "ID": "2935a8d4-33ed-43cd-8519-f44004a16e43", "Styles": "None", "Classes": "None", "Text": "242   (82.9%)", "ParentId": "b654cd49-087e-4a00-84e7-c06604320017"}, {"Element": "<sup>ab</sup>", "ID": "6b763dd4-096a-4767-bbfc-78b1b1565779", "Styles": "None", "Classes": "None", "Text": "ab", "ParentId": "2935a8d4-33ed-43cd-8519-f44004a16e43"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14\n  (18.2%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">275\n  (94.2%)<sup>ab</sup></span></p>\n</td>\n</tr>", "ID": "8f7439fa-7d24-453f-ae88-7773fb694994", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>", "ID": "e2a14714-21cd-4ec5-b66a-34e49ec3c5b1", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f7439fa-7d24-453f-ae88-7773fb694994"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>", "ID": "a7e24dc3-f31a-4867-9801-02cdb264ca4a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e2a14714-21cd-4ec5-b66a-34e49ec3c5b1"}, {"Element": "<span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span>", "ID": "2e3c2540-a5ce-460a-8f9b-b4746828b536", "Styles": "None", "Classes": "None", "Text": "PGA of cleared (0), minimal (1), or mild   (2)", "ParentId": "a7e24dc3-f31a-4867-9801-02cdb264ca4a"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14\n  (18.2%)</span></p>\n</td>", "ID": "af97e83b-f071-41f4-96d6-c37bb34a08c3", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f7439fa-7d24-453f-ae88-7773fb694994"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">14\n  (18.2%)</span></p>", "ID": "bd32e138-460a-49da-8828-2a1a28fdae54", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "af97e83b-f071-41f4-96d6-c37bb34a08c3"}, {"Element": "<span lang=\"EN-GB\">14\n  (18.2%)</span>", "ID": "3bbfcb56-b2a0-4bc9-9d11-393487ebd7e9", "Styles": "None", "Classes": "None", "Text": "14   (18.2%)", "ParentId": "bd32e138-460a-49da-8828-2a1a28fdae54"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">275\n  (94.2%)<sup>ab</sup></span></p>\n</td>", "ID": "eac36bd2-afbc-4d29-a9d7-d5522d6eeb82", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "8f7439fa-7d24-453f-ae88-7773fb694994"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">275\n  (94.2%)<sup>ab</sup></span></p>", "ID": "b76e3181-43a6-493e-8833-06453b5fc1c6", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "eac36bd2-afbc-4d29-a9d7-d5522d6eeb82"}, {"Element": "<span lang=\"EN-GB\">275\n  (94.2%)<sup>ab</sup></span>", "ID": "521b716a-cd0a-4c39-9b3d-34cb821287d3", "Styles": "None", "Classes": "None", "Text": "275   (94.2%)", "ParentId": "b76e3181-43a6-493e-8833-06453b5fc1c6"}, {"Element": "<sup>ab</sup>", "ID": "e575e61e-57c8-4513-8785-e527ee8b407c", "Styles": "None", "Classes": "None", "Text": "ab", "ParentId": "521b716a-cd0a-4c39-9b3d-34cb821287d3"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a024</span></b></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "02bada25-6b9e-4002-b47e-c5294b4cd19a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a024</span></b></p>\n</td>", "ID": "6ca9d3b5-4fca-4ff7-a2cf-07810873cd87", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02bada25-6b9e-4002-b47e-c5294b4cd19a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a024</span></b></p>", "ID": "b6078c76-234e-45ae-9ee2-7f3e4dc4166d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6ca9d3b5-4fca-4ff7-a2cf-07810873cd87"}, {"Element": "<b><span lang=\"EN-GB\">Week\u00a024</span></b>", "ID": "5fda4820-423e-4d64-b133-a34396bb8cb7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b6078c76-234e-45ae-9ee2-7f3e4dc4166d"}, {"Element": "<span lang=\"EN-GB\">Week\u00a024</span>", "ID": "fd178ee2-7103-4546-8803-1cd50b439f8c", "Styles": "None", "Classes": "None", "Text": "Week\u00a024", "ParentId": "5fda4820-423e-4d64-b133-a34396bb8cb7"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "9e5aad7e-d346-4df6-b926-a3b96e39bb4b", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02bada25-6b9e-4002-b47e-c5294b4cd19a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "64dec03d-93eb-4a14-8ec0-ccd6880b58bd", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9e5aad7e-d346-4df6-b926-a3b96e39bb4b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "da52ae32-b2b5-4223-9fdf-b5947c712a2e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "64dec03d-93eb-4a14-8ec0-ccd6880b58bd"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "6816a70e-48aa-4e90-8abf-4d4d9f2a8efc", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "02bada25-6b9e-4002-b47e-c5294b4cd19a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e28201c1-66c1-44e2-b7b2-b882a3e5cdc1", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6816a70e-48aa-4e90-8abf-4d4d9f2a8efc"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a9586554-5f2f-4480-9f2b-4efee41c3efa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e28201c1-66c1-44e2-b7b2-b882a3e5cdc1"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">276</span></p>\n</td>\n</tr>", "ID": "36c8c038-5520-440c-ace5-c67ef02a5d01", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>", "ID": "939b26dd-0ded-4ad0-b105-bd3ffe6b75c4", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "36c8c038-5520-440c-ace5-c67ef02a5d01"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>", "ID": "d336facf-6fa4-4622-8155-191288ffeadf", "Styles": "margin-left:14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "939b26dd-0ded-4ad0-b105-bd3ffe6b75c4"}, {"Element": "<span lang=\"EN-GB\">N</span>", "ID": "b870017a-2b30-440d-95e2-14bef03163bf", "Styles": "None", "Classes": "None", "Text": "N", "ParentId": "d336facf-6fa4-4622-8155-191288ffeadf"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77</span></p>\n</td>", "ID": "7dcf5907-ee30-4937-867d-5fc3b3870185", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "36c8c038-5520-440c-ace5-c67ef02a5d01"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">77</span></p>", "ID": "00396f5b-9ebc-46d1-abba-fe1db9251607", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7dcf5907-ee30-4937-867d-5fc3b3870185"}, {"Element": "<span lang=\"EN-GB\">77</span>", "ID": "7fcfe7ab-3482-4149-b7b4-e3f4d65ba813", "Styles": "None", "Classes": "None", "Text": "77", "ParentId": "00396f5b-9ebc-46d1-abba-fe1db9251607"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">276</span></p>\n</td>", "ID": "ff1d8842-5ce1-48f0-9bd5-85c033cead9a", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "36c8c038-5520-440c-ace5-c67ef02a5d01"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">276</span></p>", "ID": "0562df96-e779-49a3-87ef-c8c9c6731439", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff1d8842-5ce1-48f0-9bd5-85c033cead9a"}, {"Element": "<span lang=\"EN-GB\">276</span>", "ID": "fc1a48f2-c431-429a-9461-508f238ae4be", "Styles": "None", "Classes": "None", "Text": "276", "ParentId": "0562df96-e779-49a3-87ef-c8c9c6731439"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1.3%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">161\n  (58.3%)<sup>a</sup></span></p>\n</td>\n</tr>", "ID": "9f9c8e5f-777d-4c4a-b3bc-5d6a62e355e4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>", "ID": "83058ce5-7a22-414e-bb05-6b5e3b856d37", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9f9c8e5f-777d-4c4a-b3bc-5d6a62e355e4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>", "ID": "f7e568af-2c6b-420f-8cdf-ca7b6cb94e73", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "83058ce5-7a22-414e-bb05-6b5e3b856d37"}, {"Element": "<span lang=\"EN-GB\">\u2265\u00a090% improvement</span>", "ID": "2ed2ffcf-425d-4f8a-aca0-74c8aaa270f9", "Styles": "None", "Classes": "None", "Text": "\u2265\u00a090% improvement", "ParentId": "f7e568af-2c6b-420f-8cdf-ca7b6cb94e73"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1.3%)</span></p>\n</td>", "ID": "ad4f4bea-7574-4a79-a3a7-97b50024bc07", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9f9c8e5f-777d-4c4a-b3bc-5d6a62e355e4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1\n  (1.3%)</span></p>", "ID": "e313324d-3ef9-49a7-b5a6-1277d494d51b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ad4f4bea-7574-4a79-a3a7-97b50024bc07"}, {"Element": "<span lang=\"EN-GB\">1\n  (1.3%)</span>", "ID": "8a01920f-3b05-4728-9853-ed4c637024fb", "Styles": "None", "Classes": "None", "Text": "1   (1.3%)", "ParentId": "e313324d-3ef9-49a7-b5a6-1277d494d51b"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">161\n  (58.3%)<sup>a</sup></span></p>\n</td>", "ID": "deed9586-973c-4b00-af33-e49a48ad82ec", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "9f9c8e5f-777d-4c4a-b3bc-5d6a62e355e4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">161\n  (58.3%)<sup>a</sup></span></p>", "ID": "b732b240-5424-41c8-b690-b09f36c10c77", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "deed9586-973c-4b00-af33-e49a48ad82ec"}, {"Element": "<span lang=\"EN-GB\">161\n  (58.3%)<sup>a</sup></span>", "ID": "6bbef43c-9dc8-458f-a338-3f6a52192671", "Styles": "None", "Classes": "None", "Text": "161   (58.3%)", "ParentId": "b732b240-5424-41c8-b690-b09f36c10c77"}, {"Element": "<sup>a</sup>", "ID": "cfd5adaf-108d-4fb7-83a4-b892c03e1468", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "6bbef43c-9dc8-458f-a338-3f6a52192671"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3\n  (3.9%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">227\n  (82.2%)<sup>a</sup></span></p>\n</td>\n</tr>", "ID": "aef61779-34fa-4512-9ec2-8112ca7a13d3", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>", "ID": "70fa01e5-699c-4ce1-b40f-cf4f9bf8c23a", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "aef61779-34fa-4512-9ec2-8112ca7a13d3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>", "ID": "7e326959-5515-4235-915f-091742090046", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "70fa01e5-699c-4ce1-b40f-cf4f9bf8c23a"}, {"Element": "<span lang=\"EN-GB\">\u2265\u00a075% improvement</span>", "ID": "db03ad28-1e72-4ca7-85be-f160d72b138d", "Styles": "None", "Classes": "None", "Text": "\u2265\u00a075% improvement", "ParentId": "7e326959-5515-4235-915f-091742090046"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3\n  (3.9%)</span></p>\n</td>", "ID": "f6464b75-85ae-494f-9157-e91db7124ce4", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "aef61779-34fa-4512-9ec2-8112ca7a13d3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3\n  (3.9%)</span></p>", "ID": "8be83889-dba3-446d-a038-13949bdc2056", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f6464b75-85ae-494f-9157-e91db7124ce4"}, {"Element": "<span lang=\"EN-GB\">3\n  (3.9%)</span>", "ID": "d3125873-e23c-495f-86e8-292400c92389", "Styles": "None", "Classes": "None", "Text": "3   (3.9%)", "ParentId": "8be83889-dba3-446d-a038-13949bdc2056"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">227\n  (82.2%)<sup>a</sup></span></p>\n</td>", "ID": "9721590d-5ef3-4893-af32-2ad2a475b4c4", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "aef61779-34fa-4512-9ec2-8112ca7a13d3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">227\n  (82.2%)<sup>a</sup></span></p>", "ID": "b490a979-ba36-4b80-941f-e5976165ab54", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9721590d-5ef3-4893-af32-2ad2a475b4c4"}, {"Element": "<span lang=\"EN-GB\">227\n  (82.2%)<sup>a</sup></span>", "ID": "8960ecdc-a9f9-4fcd-88da-257942992667", "Styles": "None", "Classes": "None", "Text": "227   (82.2%)", "ParentId": "b490a979-ba36-4b80-941f-e5976165ab54"}, {"Element": "<sup>a</sup>", "ID": "2d6c3ef1-481f-40d5-ac37-e947c78a8b64", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "8960ecdc-a9f9-4fcd-88da-257942992667"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5\n  (6.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">248\n  (89.9%)</span></p>\n</td>\n</tr>", "ID": "f1f2f73f-bc25-456b-b6f8-17a83b2b0bc6", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>", "ID": "2026a3fa-3104-4ba0-aabe-fb50098ed0da", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f1f2f73f-bc25-456b-b6f8-17a83b2b0bc6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>", "ID": "fc935b82-63d1-4533-ad22-f7d53630bb64", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2026a3fa-3104-4ba0-aabe-fb50098ed0da"}, {"Element": "<span lang=\"EN-GB\">\u2265\u00a050% improvement</span>", "ID": "07aa44e7-aa34-4849-ba6d-8a3442480b96", "Styles": "None", "Classes": "None", "Text": "\u2265\u00a050% improvement", "ParentId": "fc935b82-63d1-4533-ad22-f7d53630bb64"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5\n  (6.5%)</span></p>\n</td>", "ID": "c4f201b2-f856-4c4f-8b10-e338db24026c", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f1f2f73f-bc25-456b-b6f8-17a83b2b0bc6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">5\n  (6.5%)</span></p>", "ID": "10a07e6c-6a72-49f2-ab36-142a633412b7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c4f201b2-f856-4c4f-8b10-e338db24026c"}, {"Element": "<span lang=\"EN-GB\">5\n  (6.5%)</span>", "ID": "bfcfcbbf-bf8e-49e1-84ac-c6804ffa482d", "Styles": "None", "Classes": "None", "Text": "5   (6.5%)", "ParentId": "10a07e6c-6a72-49f2-ab36-142a633412b7"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">248\n  (89.9%)</span></p>\n</td>", "ID": "f4810c4c-b324-4306-9f31-c161f29db0f4", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f1f2f73f-bc25-456b-b6f8-17a83b2b0bc6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">248\n  (89.9%)</span></p>", "ID": "17247b90-a8d1-40cf-8aef-19bac8c69e17", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f4810c4c-b324-4306-9f31-c161f29db0f4"}, {"Element": "<span lang=\"EN-GB\">248\n  (89.9%)</span>", "ID": "cf446819-b94a-4145-a65a-01add11cc435", "Styles": "None", "Classes": "None", "Text": "248   (89.9%)", "ParentId": "17247b90-a8d1-40cf-8aef-19bac8c69e17"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">203\n  (73.6%)<sup>a</sup></span></p>\n</td>\n</tr>", "ID": "0dcd5dd3-8d04-4322-a158-bd869c390221", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>", "ID": "480bd3b7-35a5-4829-a560-9cf114d2f72d", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0dcd5dd3-8d04-4322-a158-bd869c390221"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>", "ID": "b6c706f2-3ddb-4039-9b78-76f7a2f97e53", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "480bd3b7-35a5-4829-a560-9cf114d2f72d"}, {"Element": "<span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span>", "ID": "7c1707c6-a04b-4e35-a0de-e54274bcaec2", "Styles": "None", "Classes": "None", "Text": "PGA of cleared (0) or minimal (1)", "ParentId": "b6c706f2-3ddb-4039-9b78-76f7a2f97e53"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2.6%)</span></p>\n</td>", "ID": "45c62c53-d1a5-427c-a404-9a0ff6b543db", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0dcd5dd3-8d04-4322-a158-bd869c390221"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">2\n  (2.6%)</span></p>", "ID": "4ace5113-4ecd-47f2-b5f1-d94ff9cb9f17", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "45c62c53-d1a5-427c-a404-9a0ff6b543db"}, {"Element": "<span lang=\"EN-GB\">2\n  (2.6%)</span>", "ID": "22d8708e-63fd-49d6-8697-cffdf98b2c3e", "Styles": "None", "Classes": "None", "Text": "2   (2.6%)", "ParentId": "4ace5113-4ecd-47f2-b5f1-d94ff9cb9f17"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">203\n  (73.6%)<sup>a</sup></span></p>\n</td>", "ID": "62b15130-4ab5-4870-a87e-18ddab68479f", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "0dcd5dd3-8d04-4322-a158-bd869c390221"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">203\n  (73.6%)<sup>a</sup></span></p>", "ID": "bdf2a87a-16e6-426c-9aa9-e99aa96e4ee8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "62b15130-4ab5-4870-a87e-18ddab68479f"}, {"Element": "<span lang=\"EN-GB\">203\n  (73.6%)<sup>a</sup></span>", "ID": "561a6817-5c29-430d-be4f-6786627cd3aa", "Styles": "None", "Classes": "None", "Text": "203   (73.6%)", "ParentId": "bdf2a87a-16e6-426c-9aa9-e99aa96e4ee8"}, {"Element": "<sup>a</sup>", "ID": "d05f5bf7-935a-4af3-b60b-751984e50a02", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "561a6817-5c29-430d-be4f-6786627cd3aa"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15\n  (19.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">246\n  (89.1%)<sup>a</sup></span></p>\n</td>\n</tr>", "ID": "13b20bc3-8cd9-4efe-9aba-8a62f90460b6", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>", "ID": "2fbed126-8c0e-4b6a-8546-d252e56e8b5c", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "13b20bc3-8cd9-4efe-9aba-8a62f90460b6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>", "ID": "9678b4df-ae91-4737-a377-a5555e65f8da", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "2fbed126-8c0e-4b6a-8546-d252e56e8b5c"}, {"Element": "<span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span>", "ID": "0cc78a03-4e7d-45e2-bfcd-dee0f5bb6fe0", "Styles": "None", "Classes": "None", "Text": "PGA of cleared (0), minimal (1), or mild   (2)", "ParentId": "9678b4df-ae91-4737-a377-a5555e65f8da"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15\n  (19.5%)</span></p>\n</td>", "ID": "34236e38-1967-480d-83de-a8e291cb3f1b", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "13b20bc3-8cd9-4efe-9aba-8a62f90460b6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">15\n  (19.5%)</span></p>", "ID": "7c68e7f7-b17a-4f70-8fb1-c04e11e80cc1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "34236e38-1967-480d-83de-a8e291cb3f1b"}, {"Element": "<span lang=\"EN-GB\">15\n  (19.5%)</span>", "ID": "cf533087-7859-43cf-962b-796c44591ec1", "Styles": "None", "Classes": "None", "Text": "15   (19.5%)", "ParentId": "7c68e7f7-b17a-4f70-8fb1-c04e11e80cc1"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">246\n  (89.1%)<sup>a</sup></span></p>\n</td>", "ID": "0fd7e78f-e618-41eb-bc26-1dd887faefa3", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "13b20bc3-8cd9-4efe-9aba-8a62f90460b6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">246\n  (89.1%)<sup>a</sup></span></p>", "ID": "84c3e3ba-e6f9-47d3-aa10-79e32cc0fa29", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0fd7e78f-e618-41eb-bc26-1dd887faefa3"}, {"Element": "<span lang=\"EN-GB\">246\n  (89.1%)<sup>a</sup></span>", "ID": "47d0d434-6bc2-471d-b18c-d27e7740f495", "Styles": "None", "Classes": "None", "Text": "246   (89.1%)", "ParentId": "84c3e3ba-e6f9-47d3-aa10-79e32cc0fa29"}, {"Element": "<sup>a</sup>", "ID": "1bf4e088-5aad-47d4-9282-2861b8921980", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "47d0d434-6bc2-471d-b18c-d27e7740f495"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a050</span></b></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "f1cee3b4-0212-40db-abcf-929555deb359", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a050</span></b></p>\n</td>", "ID": "850a6d58-ed79-463c-9b5b-0ff9bad5a620", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f1cee3b4-0212-40db-abcf-929555deb359"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Week\u00a050</span></b></p>", "ID": "1008ed95-ca1e-4934-96cf-3a719c7ec322", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "850a6d58-ed79-463c-9b5b-0ff9bad5a620"}, {"Element": "<b><span lang=\"EN-GB\">Week\u00a050</span></b>", "ID": "49fe3138-d4c3-4106-84b6-eccd08c15095", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1008ed95-ca1e-4934-96cf-3a719c7ec322"}, {"Element": "<span lang=\"EN-GB\">Week\u00a050</span>", "ID": "d8ae7500-8ac0-4853-99d3-588083878ff9", "Styles": "None", "Classes": "None", "Text": "Week\u00a050", "ParentId": "49fe3138-d4c3-4106-84b6-eccd08c15095"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "e064b859-e748-402d-befc-1f64f392c8a0", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f1cee3b4-0212-40db-abcf-929555deb359"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c59583d3-b31a-4e93-b38e-9dc26f1ea504", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e064b859-e748-402d-befc-1f64f392c8a0"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fcc06b99-93ee-4ebd-805b-aacc382af67e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c59583d3-b31a-4e93-b38e-9dc26f1ea504"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "5217a88c-4799-42ea-8434-ccacad64f646", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "f1cee3b4-0212-40db-abcf-929555deb359"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c0556abe-cd76-4b8f-bb90-4de2e7fb525e", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5217a88c-4799-42ea-8434-ccacad64f646"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f9d9979a-9a61-4b29-a5c7-ac738b427918", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c0556abe-cd76-4b8f-bb90-4de2e7fb525e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">68</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">281</span></p>\n</td>\n</tr>", "ID": "eb489076-3b03-4eaf-841d-1e31160452c5", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>\n</td>", "ID": "00d72338-44b9-4319-bd18-c2fc767b9c7d", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb489076-3b03-4eaf-841d-1e31160452c5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt\"><span lang=\"EN-GB\">N</span></p>", "ID": "ed970683-84d2-46ee-ba01-5c20440d699f", "Styles": "margin-left:14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "00d72338-44b9-4319-bd18-c2fc767b9c7d"}, {"Element": "<span lang=\"EN-GB\">N</span>", "ID": "2e7b5b69-3a9c-4b87-9ab5-2890421d5b98", "Styles": "None", "Classes": "None", "Text": "N", "ParentId": "ed970683-84d2-46ee-ba01-5c20440d699f"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">68</span></p>\n</td>", "ID": "ae55cc61-d071-4c92-935a-c0ee3a7ae4cb", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb489076-3b03-4eaf-841d-1e31160452c5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">68</span></p>", "ID": "f257f280-5666-4091-9041-79eddf649aed", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ae55cc61-d071-4c92-935a-c0ee3a7ae4cb"}, {"Element": "<span lang=\"EN-GB\">68</span>", "ID": "a5b98f99-32d8-4eba-9260-8bfb4d418f36", "Styles": "None", "Classes": "None", "Text": "68", "ParentId": "f257f280-5666-4091-9041-79eddf649aed"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">281</span></p>\n</td>", "ID": "cd89b62c-2a33-4975-b578-a36b9af94059", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "eb489076-3b03-4eaf-841d-1e31160452c5"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">281</span></p>", "ID": "dce05e91-ab15-49a8-9ab5-694edc76f10f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "cd89b62c-2a33-4975-b578-a36b9af94059"}, {"Element": "<span lang=\"EN-GB\">281</span>", "ID": "02fdf8e6-7c72-42d8-9dfe-d151b215950d", "Styles": "None", "Classes": "None", "Text": "281", "ParentId": "dce05e91-ab15-49a8-9ab5-694edc76f10f"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34\n  (50.0%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">127\n  (45.2%)</span></p>\n</td>\n</tr>", "ID": "ef3dcb2d-5892-4f1f-bcdd-7e609dd1a23c", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>\n</td>", "ID": "ae5be49e-48a8-4cbf-80e2-e9732d0ee4ad", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ef3dcb2d-5892-4f1f-bcdd-7e609dd1a23c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a090% improvement</span></p>", "ID": "1f7af055-0f9e-4128-990a-49aeb26e1bba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ae5be49e-48a8-4cbf-80e2-e9732d0ee4ad"}, {"Element": "<span lang=\"EN-GB\">\u2265\u00a090% improvement</span>", "ID": "e25b83ea-e2de-43ed-b049-aae6f8547c8f", "Styles": "None", "Classes": "None", "Text": "\u2265\u00a090% improvement", "ParentId": "1f7af055-0f9e-4128-990a-49aeb26e1bba"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34\n  (50.0%)</span></p>\n</td>", "ID": "bd66d965-f485-47e6-acff-3423e9216dd2", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ef3dcb2d-5892-4f1f-bcdd-7e609dd1a23c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">34\n  (50.0%)</span></p>", "ID": "db1a2f89-dfcc-4bd3-a2bd-e69a5d7d72ff", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bd66d965-f485-47e6-acff-3423e9216dd2"}, {"Element": "<span lang=\"EN-GB\">34\n  (50.0%)</span>", "ID": "84bb26dc-67f3-45df-b8fa-eeb96ced62aa", "Styles": "None", "Classes": "None", "Text": "34   (50.0%)", "ParentId": "db1a2f89-dfcc-4bd3-a2bd-e69a5d7d72ff"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">127\n  (45.2%)</span></p>\n</td>", "ID": "c45fea4c-9818-4d0d-a984-2b154ca24291", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ef3dcb2d-5892-4f1f-bcdd-7e609dd1a23c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">127\n  (45.2%)</span></p>", "ID": "022a72b3-a1d5-46ee-8dbe-3f3e84c46db3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c45fea4c-9818-4d0d-a984-2b154ca24291"}, {"Element": "<span lang=\"EN-GB\">127\n  (45.2%)</span>", "ID": "c5cfdef2-a414-41d9-8500-8580e5a6d190", "Styles": "None", "Classes": "None", "Text": "127   (45.2%)", "ParentId": "022a72b3-a1d5-46ee-8dbe-3f3e84c46db3"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52\n  (76.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">170\n  (60.5%)</span></p>\n</td>\n</tr>", "ID": "332d8241-d383-4f34-8e54-531ce08b4c50", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>\n</td>", "ID": "92230e70-1def-4119-a014-ed8bc533dff3", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "332d8241-d383-4f34-8e54-531ce08b4c50"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a075% improvement</span></p>", "ID": "ae8e2715-cbdc-449e-ac8c-b782d2d98aec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "92230e70-1def-4119-a014-ed8bc533dff3"}, {"Element": "<span lang=\"EN-GB\">\u2265\u00a075% improvement</span>", "ID": "f87da9ee-1f96-4000-8cf4-1cda736c3d3f", "Styles": "None", "Classes": "None", "Text": "\u2265\u00a075% improvement", "ParentId": "ae8e2715-cbdc-449e-ac8c-b782d2d98aec"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52\n  (76.5%)</span></p>\n</td>", "ID": "399f69db-69c9-4c90-bf1d-b7a5f61781af", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "332d8241-d383-4f34-8e54-531ce08b4c50"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">52\n  (76.5%)</span></p>", "ID": "2bfb6f62-85a1-4740-ae50-f6d2611447aa", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "399f69db-69c9-4c90-bf1d-b7a5f61781af"}, {"Element": "<span lang=\"EN-GB\">52\n  (76.5%)</span>", "ID": "e9e74b06-6c99-4de6-960d-a77687da4ea7", "Styles": "None", "Classes": "None", "Text": "52   (76.5%)", "ParentId": "2bfb6f62-85a1-4740-ae50-f6d2611447aa"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">170\n  (60.5%)</span></p>\n</td>", "ID": "04eb80d4-2dee-47c7-b378-b325d7f6aa6a", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "332d8241-d383-4f34-8e54-531ce08b4c50"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">170\n  (60.5%)</span></p>", "ID": "ef906d68-c010-4926-bb10-d7764c42733b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "04eb80d4-2dee-47c7-b378-b325d7f6aa6a"}, {"Element": "<span lang=\"EN-GB\">170\n  (60.5%)</span>", "ID": "b9037b10-2a1d-455c-904d-d0e1f306043c", "Styles": "None", "Classes": "None", "Text": "170   (60.5%)", "ParentId": "ef906d68-c010-4926-bb10-d7764c42733b"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61\n  (89.7%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">193\n  (68.7%)</span></p>\n</td>\n</tr>", "ID": "ee0bdad4-e5e1-4251-be47-0710d04f3164", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>\n</td>", "ID": "5743b87f-07ee-4e30-86cd-51b9d61fe365", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee0bdad4-e5e1-4251-be47-0710d04f3164"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u2265\u00a050% improvement</span></p>", "ID": "ba1a58a4-ded2-4eed-8024-71080e9afcf8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5743b87f-07ee-4e30-86cd-51b9d61fe365"}, {"Element": "<span lang=\"EN-GB\">\u2265\u00a050% improvement</span>", "ID": "2def71a1-093e-43e4-8a8c-29024cc2302d", "Styles": "None", "Classes": "None", "Text": "\u2265\u00a050% improvement", "ParentId": "ba1a58a4-ded2-4eed-8024-71080e9afcf8"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61\n  (89.7%)</span></p>\n</td>", "ID": "1645c6c8-2c37-4334-9214-77c7a3eba50c", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee0bdad4-e5e1-4251-be47-0710d04f3164"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">61\n  (89.7%)</span></p>", "ID": "18c154b0-be0c-4e9c-b7f5-d96f0f1b8c62", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1645c6c8-2c37-4334-9214-77c7a3eba50c"}, {"Element": "<span lang=\"EN-GB\">61\n  (89.7%)</span>", "ID": "0a52b059-622f-4f24-a7eb-facb123c3c83", "Styles": "None", "Classes": "None", "Text": "61   (89.7%)", "ParentId": "18c154b0-be0c-4e9c-b7f5-d96f0f1b8c62"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">193\n  (68.7%)</span></p>\n</td>", "ID": "ac1e753b-c5e5-4a7d-ae5c-80d418c7c97b", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "ee0bdad4-e5e1-4251-be47-0710d04f3164"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">193\n  (68.7%)</span></p>", "ID": "3a3779b0-2d16-438f-9623-6a244d9874a9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ac1e753b-c5e5-4a7d-ae5c-80d418c7c97b"}, {"Element": "<span lang=\"EN-GB\">193\n  (68.7%)</span>", "ID": "fd0bc4c4-65e6-4886-ae05-adadb0fc41d0", "Styles": "None", "Classes": "None", "Text": "193   (68.7%)", "ParentId": "3a3779b0-2d16-438f-9623-6a244d9874a9"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46\n  (67.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">149\n  (53.0%)</span></p>\n</td>\n</tr>", "ID": "939094c4-9341-4140-b46b-7a531b973a9d", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>\n</td>", "ID": "0e73ca09-5a2b-4148-8e72-34a7ab39beea", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "939094c4-9341-4140-b46b-7a531b973a9d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span></p>", "ID": "67311786-39d0-4ca8-8197-91f611352010", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0e73ca09-5a2b-4148-8e72-34a7ab39beea"}, {"Element": "<span lang=\"EN-GB\">PGA of cleared (0) or minimal (1)</span>", "ID": "e03adf4d-33ef-44e1-a418-f24ed7f0a960", "Styles": "None", "Classes": "None", "Text": "PGA of cleared (0) or minimal (1)", "ParentId": "67311786-39d0-4ca8-8197-91f611352010"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46\n  (67.6%)</span></p>\n</td>", "ID": "7b1b12fa-01a0-4f59-a4f5-afbd783c74b1", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "939094c4-9341-4140-b46b-7a531b973a9d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">46\n  (67.6%)</span></p>", "ID": "195cc033-004a-4ff0-a064-f90d887c81d4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7b1b12fa-01a0-4f59-a4f5-afbd783c74b1"}, {"Element": "<span lang=\"EN-GB\">46\n  (67.6%)</span>", "ID": "ddb43ce6-b508-42a1-aeb5-f17ab768400c", "Styles": "None", "Classes": "None", "Text": "46   (67.6%)", "ParentId": "195cc033-004a-4ff0-a064-f90d887c81d4"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">149\n  (53.0%)</span></p>\n</td>", "ID": "6a3b85c2-cbf8-44d9-8b2b-e95f08d2b848", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "939094c4-9341-4140-b46b-7a531b973a9d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">149\n  (53.0%)</span></p>", "ID": "47f30c28-bba1-4876-9fdb-e9e45dbc59f0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6a3b85c2-cbf8-44d9-8b2b-e95f08d2b848"}, {"Element": "<span lang=\"EN-GB\">149\n  (53.0%)</span>", "ID": "1a117825-4968-4fff-bb0d-25415a4d5b3d", "Styles": "None", "Classes": "None", "Text": "149   (53.0%)", "ParentId": "47f30c28-bba1-4876-9fdb-e9e45dbc59f0"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">59\n  (86.8%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">189\n  (67.3%)</span></p>\n</td>\n</tr>", "ID": "cb08a1af-abbb-47f0-b681-f25364c253a7", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>\n</td>", "ID": "946b8724-6f71-45c8-a7df-24d40e8a6173", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cb08a1af-abbb-47f0-b681-f25364c253a7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span></p>", "ID": "68607413-6a69-4991-b46b-931591a1ea0a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "946b8724-6f71-45c8-a7df-24d40e8a6173"}, {"Element": "<span lang=\"EN-GB\">PGA of cleared (0), minimal (1), or mild\n  (2)</span>", "ID": "9bb529ba-6df2-4a29-95a6-ede06d045f1d", "Styles": "None", "Classes": "None", "Text": "PGA of cleared (0), minimal (1), or mild   (2)", "ParentId": "68607413-6a69-4991-b46b-931591a1ea0a"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">59\n  (86.8%)</span></p>\n</td>", "ID": "aac97325-f4ac-4ad1-b10f-4c49feaf0554", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cb08a1af-abbb-47f0-b681-f25364c253a7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">59\n  (86.8%)</span></p>", "ID": "432276d4-90f4-4051-bac0-ee93c202da74", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "aac97325-f4ac-4ad1-b10f-4c49feaf0554"}, {"Element": "<span lang=\"EN-GB\">59\n  (86.8%)</span>", "ID": "e52ba6fb-ba22-49fb-932e-353ae0129360", "Styles": "None", "Classes": "None", "Text": "59   (86.8%)", "ParentId": "432276d4-90f4-4051-bac0-ee93c202da74"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">189\n  (67.3%)</span></p>\n</td>", "ID": "da6ae6bf-d6b3-4d36-ada6-bfc88149281f", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "cb08a1af-abbb-47f0-b681-f25364c253a7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">189\n  (67.3%)</span></p>", "ID": "540ecfd6-acc3-4f1e-ab0a-68d76cb283bb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "da6ae6bf-d6b3-4d36-ada6-bfc88149281f"}, {"Element": "<span lang=\"EN-GB\">189\n  (67.3%)</span>", "ID": "d96d7f82-666a-4833-ac5f-66959dc2d202", "Styles": "None", "Classes": "None", "Text": "189   (67.3%)", "ParentId": "540ecfd6-acc3-4f1e-ab0a-68d76cb283bb"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">All\n  nails cleared<sup>c</sup></span></b></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "4c3e8ab2-1e04-4bfb-a9fa-e9e9b689f711", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">All\n  nails cleared<sup>c</sup></span></b></p>\n</td>", "ID": "872d9699-ae2f-4900-93aa-dd4712da5734", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4c3e8ab2-1e04-4bfb-a9fa-e9e9b689f711"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">All\n  nails cleared<sup>c</sup></span></b></p>", "ID": "2f3092c9-5b8d-4f86-93e1-aa99f6c9381b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "872d9699-ae2f-4900-93aa-dd4712da5734"}, {"Element": "<b><span lang=\"EN-GB\">All\n  nails cleared<sup>c</sup></span></b>", "ID": "ec07a339-5da1-4375-a5ef-3d71d3195911", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2f3092c9-5b8d-4f86-93e1-aa99f6c9381b"}, {"Element": "<span lang=\"EN-GB\">All\n  nails cleared<sup>c</sup></span>", "ID": "44d42b90-e8c3-4e5f-87bb-14a9e691d7d9", "Styles": "None", "Classes": "None", "Text": "All   nails cleared", "ParentId": "ec07a339-5da1-4375-a5ef-3d71d3195911"}, {"Element": "<sup>c</sup>", "ID": "868fabb6-6fc8-42de-8dbf-51ef8941d1bc", "Styles": "None", "Classes": "None", "Text": "c", "ParentId": "44d42b90-e8c3-4e5f-87bb-14a9e691d7d9"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "fd7faa5a-ea71-4e60-907c-0e2c57d0edbf", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4c3e8ab2-1e04-4bfb-a9fa-e9e9b689f711"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cc31f339-b50a-4144-a494-61b9d5e08975", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fd7faa5a-ea71-4e60-907c-0e2c57d0edbf"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "297db104-68f9-49c6-8320-95b41094ba54", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cc31f339-b50a-4144-a494-61b9d5e08975"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "8f68c5eb-8b11-4671-9b3b-480e44659948", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4c3e8ab2-1e04-4bfb-a9fa-e9e9b689f711"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:\n  avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ca103e67-0160-4453-bdd8-73b761914a4f", "Styles": "text-align:center;page-break-after:\n  avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8f68c5eb-8b11-4671-9b3b-480e44659948"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "18b3378c-4c8e-478a-a2b7-92970555615a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ca103e67-0160-4453-bdd8-73b761914a4f"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a010</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1/65\n  (1.5%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">16/235\n  (6.8%)</span></p>\n</td>\n</tr>", "ID": "15744965-b8da-4400-b8f0-57e7dab99694", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a010</span></p>\n</td>", "ID": "22e0f3a9-7b3e-4cdb-a0f7-0eac05bc6b24", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "15744965-b8da-4400-b8f0-57e7dab99694"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a010</span></p>", "ID": "0380b473-b2f3-4c47-a9d5-a44a45f8e564", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22e0f3a9-7b3e-4cdb-a0f7-0eac05bc6b24"}, {"Element": "<span lang=\"EN-GB\">Week\u00a010</span>", "ID": "ef252e21-32d4-4c10-a9da-eb23df1c0440", "Styles": "None", "Classes": "None", "Text": "Week\u00a010", "ParentId": "0380b473-b2f3-4c47-a9d5-a44a45f8e564"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1/65\n  (1.5%)</span></p>\n</td>", "ID": "e4c0c7f0-5bff-4f26-b36b-0c9676ea3fbb", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "15744965-b8da-4400-b8f0-57e7dab99694"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">1/65\n  (1.5%)</span></p>", "ID": "9ef86420-6dd0-411b-823b-8debc93ca951", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "e4c0c7f0-5bff-4f26-b36b-0c9676ea3fbb"}, {"Element": "<span lang=\"EN-GB\">1/65\n  (1.5%)</span>", "ID": "4ecf3815-8a31-47ad-b47f-e1a7d5a9ac2e", "Styles": "None", "Classes": "None", "Text": "1/65   (1.5%)", "ParentId": "9ef86420-6dd0-411b-823b-8debc93ca951"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">16/235\n  (6.8%)</span></p>\n</td>", "ID": "a854641e-844d-415c-b791-58a6916345a4", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "15744965-b8da-4400-b8f0-57e7dab99694"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">16/235\n  (6.8%)</span></p>", "ID": "ae3ddfe7-c24d-4815-bdcf-063ef2b24e66", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a854641e-844d-415c-b791-58a6916345a4"}, {"Element": "<span lang=\"EN-GB\">16/235\n  (6.8%)</span>", "ID": "abc27915-8a3b-4a11-8d5a-180943717a13", "Styles": "None", "Classes": "None", "Text": "16/235   (6.8%)", "ParentId": "ae3ddfe7-c24d-4815-bdcf-063ef2b24e66"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a024</span></p>\n</td>\n<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3/65\n  (4.6%)</span></p>\n</td>\n<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">58/223\n  (26.0%)<sup>a</sup></span></p>\n</td>\n</tr>", "ID": "b5660b0b-fca7-4e96-a8f5-9a7230bcb03a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a024</span></p>\n</td>", "ID": "25124dbd-6e52-469d-96f7-86ad2b4b433c", "Styles": "width:236.85pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b5660b0b-fca7-4e96-a8f5-9a7230bcb03a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a024</span></p>", "ID": "ccff3621-c529-4258-ba59-15ab8529065d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "25124dbd-6e52-469d-96f7-86ad2b4b433c"}, {"Element": "<span lang=\"EN-GB\">Week\u00a024</span>", "ID": "097f5206-4398-46e5-90ec-b1a131de01f7", "Styles": "None", "Classes": "None", "Text": "Week\u00a024", "ParentId": "ccff3621-c529-4258-ba59-15ab8529065d"}, {"Element": "<td style=\"width:127.55pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3/65\n  (4.6%)</span></p>\n</td>", "ID": "26cd947a-eb67-4810-a424-1ef815dae949", "Styles": "width:127.55pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b5660b0b-fca7-4e96-a8f5-9a7230bcb03a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">3/65\n  (4.6%)</span></p>", "ID": "3a83db4a-6006-4f3d-919b-9de97f36a9c8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "26cd947a-eb67-4810-a424-1ef815dae949"}, {"Element": "<span lang=\"EN-GB\">3/65\n  (4.6%)</span>", "ID": "e9304c78-4d81-4eeb-b052-4e7f35c56f59", "Styles": "None", "Classes": "None", "Text": "3/65   (4.6%)", "ParentId": "3a83db4a-6006-4f3d-919b-9de97f36a9c8"}, {"Element": "<td style=\"width:84.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">58/223\n  (26.0%)<sup>a</sup></span></p>\n</td>", "ID": "d7e50db0-fe3b-4bfa-a1c1-a641108a7c62", "Styles": "width:84.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "b5660b0b-fca7-4e96-a8f5-9a7230bcb03a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">58/223\n  (26.0%)<sup>a</sup></span></p>", "ID": "b1185aee-6ceb-4498-b5ef-0635cbc20c9c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d7e50db0-fe3b-4bfa-a1c1-a641108a7c62"}, {"Element": "<span lang=\"EN-GB\">58/223\n  (26.0%)<sup>a</sup></span>", "ID": "6e3eff64-a8f8-4577-89d0-333461e00d51", "Styles": "None", "Classes": "None", "Text": "58/223   (26.0%)", "ParentId": "b1185aee-6ceb-4498-b5ef-0635cbc20c9c"}, {"Element": "<sup>a</sup>", "ID": "def28fb0-05ae-4604-a2c2-8ccd497a524c", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "6e3eff64-a8f8-4577-89d0-333461e00d51"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:236.85pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a050</span></p>\n</td>\n<td style=\"width:127.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27/64\n  (42.2%)</span></p>\n</td>\n<td style=\"width:84.0pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">92/226\n  (40.7%)</span></p>\n</td>\n</tr>", "ID": "4b527d2f-8036-467e-98b6-58a676d06c23", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "    ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td style=\"width:236.85pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"316\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a050</span></p>\n</td>", "ID": "27ff1fd5-4ca8-46ca-a166-f6a80f3ada45", "Styles": "width:236.85pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4b527d2f-8036-467e-98b6-58a676d06c23"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Week\u00a050</span></p>", "ID": "57c8f4a2-617d-4809-9cdf-59d0dbac4270", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "27ff1fd5-4ca8-46ca-a166-f6a80f3ada45"}, {"Element": "<span lang=\"EN-GB\">Week\u00a050</span>", "ID": "43bba05b-b1c0-41aa-b8d0-cc6f0cd0b435", "Styles": "None", "Classes": "None", "Text": "Week\u00a050", "ParentId": "57c8f4a2-617d-4809-9cdf-59d0dbac4270"}, {"Element": "<td style=\"width:127.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"170\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27/64\n  (42.2%)</span></p>\n</td>", "ID": "447a20e2-6565-40e5-bbf3-debbf2ab2226", "Styles": "width:127.55pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4b527d2f-8036-467e-98b6-58a676d06c23"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">27/64\n  (42.2%)</span></p>", "ID": "857a7634-087a-47d8-9a66-3f0e93c49b9d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "447a20e2-6565-40e5-bbf3-debbf2ab2226"}, {"Element": "<span lang=\"EN-GB\">27/64\n  (42.2%)</span>", "ID": "19b0c3b4-1043-4ac3-84e9-1c0c74e22ee9", "Styles": "None", "Classes": "None", "Text": "27/64   (42.2%)", "ParentId": "857a7634-087a-47d8-9a66-3f0e93c49b9d"}, {"Element": "<td style=\"width:84.0pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"112\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">92/226\n  (40.7%)</span></p>\n</td>", "ID": "d1564da5-1918-4952-8859-c195129b6fbe", "Styles": "width:84.0pt;border:none;border-bottom:\n  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4b527d2f-8036-467e-98b6-58a676d06c23"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">92/226\n  (40.7%)</span></p>", "ID": "5ad393e7-7ec4-4370-ac9f-0aa830fca40e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d1564da5-1918-4952-8859-c195129b6fbe"}, {"Element": "<span lang=\"EN-GB\">92/226\n  (40.7%)</span>", "ID": "449a0851-2b84-4b2f-aac3-b1d2a9aa83e7", "Styles": "None", "Classes": "None", "Text": "92/226   (40.7%)", "ParentId": "5ad393e7-7ec4-4370-ac9f-0aa830fca40e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td colspan=\"3\" style=\"width:448.4pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"598\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 p\u00a0&lt;\u00a00.001,\n  for each infliximab treatment group vs. control.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 n\u00a0=\u00a0292.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Analysis\n  was based on subjects with nail psoriasis at baseline (81.8% of subjects).\n  Mean baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group.</span></p>\n</td>\n</tr>", "ID": "69ca9caf-773a-4212-8e4c-b84cda87fdc4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "  ", "ParentId": "3b4f773b-0afe-472c-bc20-883eacc67a34"}, {"Element": "<td colspan=\"3\" style=\"width:448.4pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"bottom\" width=\"598\">\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 p\u00a0&lt;\u00a00.001,\n  for each infliximab treatment group vs. control.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 n\u00a0=\u00a0292.</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Analysis\n  was based on subjects with nail psoriasis at baseline (81.8% of subjects).\n  Mean baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group.</span></p>\n</td>", "ID": "1b29da59-538d-443f-bd09-1490125fb95e", "Styles": "width:448.4pt;border:none;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "    ", "ParentId": "69ca9caf-773a-4212-8e4c-b84cda87fdc4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 p\u00a0&lt;\u00a00.001,\n  for each infliximab treatment group vs. control.</span></p>", "ID": "00f4e7af-565b-4fd2-b03b-d1baa2d62240", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1b29da59-538d-443f-bd09-1490125fb95e"}, {"Element": "<sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span></sup>", "ID": "74e8e407-ccc0-4615-a384-fbbf6763eb44", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "00f4e7af-565b-4fd2-b03b-d1baa2d62240"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">a</span>", "ID": "9cb88078-72b4-482d-8223-7fd1f4c7848c", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "a", "ParentId": "74e8e407-ccc0-4615-a384-fbbf6763eb44"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 p\u00a0&lt;\u00a00.001,\n  for each infliximab treatment group vs. control.</span>", "ID": "7e616bda-7bfb-45cf-92a8-59d66f4e2179", "Styles": "font-size:9.0pt;layout-grid-mode:line", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 p\u00a0<\u00a00.001,   for each infliximab treatment group vs. control.", "ParentId": "00f4e7af-565b-4fd2-b03b-d1baa2d62240"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 n\u00a0=\u00a0292.</span></p>", "ID": "b8734528-bac3-491a-8dbf-48ef3eba0859", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1b29da59-538d-443f-bd09-1490125fb95e"}, {"Element": "<sup><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span></sup>", "ID": "0a310329-6237-46fb-bd26-efa60bf3fe83", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b8734528-bac3-491a-8dbf-48ef3eba0859"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">b</span>", "ID": "3da4c79a-fc5d-4e15-89ee-a9c674a1d523", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "b", "ParentId": "0a310329-6237-46fb-bd26-efa60bf3fe83"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt;layout-grid-mode:line\">\u00a0\u00a0\u00a0\u00a0 n\u00a0=\u00a0292.</span>", "ID": "f4adf4ff-e68b-4396-afc3-3995af112d24", "Styles": "font-size:9.0pt;layout-grid-mode:line", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 n\u00a0=\u00a0292.", "ParentId": "b8734528-bac3-491a-8dbf-48ef3eba0859"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:14.2pt;text-indent:-14.2pt\"><sup><span lang=\"EN-GB\">c</span></sup><span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Analysis\n  was based on subjects with nail psoriasis at baseline (81.8% of subjects).\n  Mean baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group.</span></p>", "ID": "71638b1f-aefd-457f-b17c-a7cb755532c7", "Styles": "margin-left:14.2pt;text-indent:-14.2pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1b29da59-538d-443f-bd09-1490125fb95e"}, {"Element": "<sup><span lang=\"EN-GB\">c</span></sup>", "ID": "fad829e3-27b7-4c58-aeca-a01c2841f116", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "71638b1f-aefd-457f-b17c-a7cb755532c7"}, {"Element": "<span lang=\"EN-GB\">c</span>", "ID": "da5d747c-75ba-4f3d-98a3-7757b47a8325", "Styles": "None", "Classes": "None", "Text": "c", "ParentId": "fad829e3-27b7-4c58-aeca-a01c2841f116"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:9.0pt\">\u00a0\u00a0\u00a0\u00a0 Analysis\n  was based on subjects with nail psoriasis at baseline (81.8% of subjects).\n  Mean baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group.</span>", "ID": "363a0c0d-9e37-4578-b5ce-369f36198a7e", "Styles": "font-size:9.0pt", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0 Analysis   was based on subjects with nail psoriasis at baseline (81.8% of subjects).   Mean baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group.", "ParentId": "71638b1f-aefd-457f-b17c-a7cb755532c7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4a933dce-f6ad-4fd1-96fe-d98fdfed9cf2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "19b0a2b9-501d-45a0-9156-312c5c61f260", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4a933dce-f6ad-4fd1-96fe-d98fdfed9cf2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Significant improvements from baseline were\ndemonstrated in DLQI (p\u00a0&lt;\u00a00.001) and the physical and mental\ncomponent scores of the SF 36 (p\u00a0&lt;\u00a00.001 for each component\ncomparison).</span></p>", "ID": "d2ae9cb2-51e9-48fe-b938-4caddae363fa", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Significant improvements from baseline were\ndemonstrated in DLQI (p\u00a0&lt;\u00a00.001) and the physical and mental\ncomponent scores of the SF 36 (p\u00a0&lt;\u00a00.001 for each component\ncomparison).</span>", "ID": "75b087e6-fc9e-4e0f-95bb-bf018c345a98", "Styles": "None", "Classes": "None", "Text": "Significant improvements from baseline were demonstrated in DLQI (p\u00a0<\u00a00.001) and the physical and mental component scores of the SF 36 (p\u00a0<\u00a00.001 for each component comparison).", "ParentId": "d2ae9cb2-51e9-48fe-b938-4caddae363fa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "45bbc089-85ce-47bf-9225-4d1a4900fa55", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "83d869c6-04c6-4d2f-8e54-21540cf8ad54", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "45bbc089-85ce-47bf-9225-4d1a4900fa55"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><u><span lang=\"EN-GB\">Paediatric\npopulation</span></u></b></p>", "ID": "d2e39cd8-541c-4685-94e9-390ebf37c2db", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><u><span lang=\"EN-GB\">Paediatric\npopulation</span></u></b>", "ID": "779ccb4b-9524-49cc-b809-a22eba9b17b9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d2e39cd8-541c-4685-94e9-390ebf37c2db"}, {"Element": "<u><span lang=\"EN-GB\">Paediatric\npopulation</span></u>", "ID": "feddaf66-8fc9-4356-880c-0b51158418fe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "779ccb4b-9524-49cc-b809-a22eba9b17b9"}, {"Element": "<span lang=\"EN-GB\">Paediatric\npopulation</span>", "ID": "e202861a-da62-4358-a440-c47b7cb55397", "Styles": "None", "Classes": "None", "Text": "Paediatric population", "ParentId": "feddaf66-8fc9-4356-880c-0b51158418fe"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\nCrohn\u2019s disease (6 to\u00a017\u00a0years)</span></u></p>", "ID": "8a241113-7d18-4a5c-b194-590298a73786", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Paediatric\nCrohn\u2019s disease (6 to\u00a017\u00a0years)</span></u>", "ID": "f2cc7e6a-960e-450c-ab6a-8bd096a8a998", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8a241113-7d18-4a5c-b194-590298a73786"}, {"Element": "<span lang=\"EN-GB\">Paediatric\nCrohn\u2019s disease (6 to\u00a017\u00a0years)</span>", "ID": "854331ae-e934-4f33-aa8b-2eae8d5f98c7", "Styles": "None", "Classes": "None", "Text": "Paediatric Crohn\u2019s disease (6 to\u00a017\u00a0years)", "ParentId": "f2cc7e6a-960e-450c-ab6a-8bd096a8a998"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the REACH study, 112\u00a0patients (6 to\n17\u00a0years, median age 13.0\u00a0years) with moderate to severe, active\nCrohn\u2019s disease (median paediatric CDAI of 40) and an inadequate response\nto conventional therapies were to receive 5\u00a0mg/kg infliximab at weeks\u00a00,\n2, and 6. All patients were required to be on a stable dose of 6\u2011MP, AZA\nor MTX (35% were also receiving corticosteroids at baseline). Patients assessed\nby the investigator to be in clinical response at week\u00a010 were randomised\nand received 5\u00a0mg/kg infliximab at either q8\u00a0weeks or q12\u00a0weeks\nas a maintenance treatment regimen. If response was lost during maintenance\ntreatment, crossing over to a higher dose (10\u00a0mg/kg) and/or shorter dosing\ninterval (q8\u00a0weeks) was allowed. Thirty\u00a0two (32) evaluable paediatric\npatients crossed over (9\u00a0subjects in the q8\u00a0weeks and\n23\u00a0subjects in the q12\u00a0weeks maintenance groups). Twenty\u00a0four of\nthese patients (75.0%) regained clinical response after crossing over.</span></p>", "ID": "d8a113ca-52c2-46da-9947-1c50349781be", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In the REACH study, 112\u00a0patients (6 to\n17\u00a0years, median age 13.0\u00a0years) with moderate to severe, active\nCrohn\u2019s disease (median paediatric CDAI of 40) and an inadequate response\nto conventional therapies were to receive 5\u00a0mg/kg infliximab at weeks\u00a00,\n2, and 6. All patients were required to be on a stable dose of 6\u2011MP, AZA\nor MTX (35% were also receiving corticosteroids at baseline). Patients assessed\nby the investigator to be in clinical response at week\u00a010 were randomised\nand received 5\u00a0mg/kg infliximab at either q8\u00a0weeks or q12\u00a0weeks\nas a maintenance treatment regimen. If response was lost during maintenance\ntreatment, crossing over to a higher dose (10\u00a0mg/kg) and/or shorter dosing\ninterval (q8\u00a0weeks) was allowed. Thirty\u00a0two (32) evaluable paediatric\npatients crossed over (9\u00a0subjects in the q8\u00a0weeks and\n23\u00a0subjects in the q12\u00a0weeks maintenance groups). Twenty\u00a0four of\nthese patients (75.0%) regained clinical response after crossing over.</span>", "ID": "7b9264ae-785c-425e-91e1-cf732aefbade", "Styles": "None", "Classes": "None", "Text": "In the REACH study, 112\u00a0patients (6 to 17\u00a0years, median age 13.0\u00a0years) with moderate to severe, active Crohn\u2019s disease (median paediatric CDAI of 40) and an inadequate response to conventional therapies were to receive 5\u00a0mg/kg infliximab at weeks\u00a00, 2, and 6. All patients were required to be on a stable dose of 6\u2011MP, AZA or MTX (35% were also receiving corticosteroids at baseline). Patients assessed by the investigator to be in clinical response at week\u00a010 were randomised and received 5\u00a0mg/kg infliximab at either q8\u00a0weeks or q12\u00a0weeks as a maintenance treatment regimen. If response was lost during maintenance treatment, crossing over to a higher dose (10\u00a0mg/kg) and/or shorter dosing interval (q8\u00a0weeks) was allowed. Thirty\u00a0two (32) evaluable paediatric patients crossed over (9\u00a0subjects in the q8\u00a0weeks and 23\u00a0subjects in the q12\u00a0weeks maintenance groups). Twenty\u00a0four of these patients (75.0%) regained clinical response after crossing over.", "ParentId": "d8a113ca-52c2-46da-9947-1c50349781be"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The proportion of subjects in clinical\nresponse at week\u00a010 was 88.4% (99/112). The proportion of subjects\nachieving clinical remission at week\u00a010 was 58.9% (66/112).</span></p>", "ID": "69e8ccfb-268a-4034-85d1-1adf80cb2437", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The proportion of subjects in clinical\nresponse at week\u00a010 was 88.4% (99/112). The proportion of subjects\nachieving clinical remission at week\u00a010 was 58.9% (66/112).</span>", "ID": "e6bc9c57-2a6d-40c7-80ed-99ccf9a07ffa", "Styles": "None", "Classes": "None", "Text": "The proportion of subjects in clinical response at week\u00a010 was 88.4% (99/112). The proportion of subjects achieving clinical remission at week\u00a010 was 58.9% (66/112).", "ParentId": "69e8ccfb-268a-4034-85d1-1adf80cb2437"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">At week\u00a030, the proportion of subjects\nin clinical remission was higher in the q8\u00a0week (59.6%, 31/52) than the\nq12\u00a0week maintenance treatment group (35.3%, 18/51; p\u00a0=\u00a00.013).\nAt week\u00a054, the figures were 55.8% (29/52) and 23.5% (12/51) in the q8\u00a0weeks\nand q12\u00a0weeks maintenance groups, respectively (p\u00a0&lt;\u00a00.001).</span></p>", "ID": "c66d17cf-fc2d-4efe-9e77-bd99d785285f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">At week\u00a030, the proportion of subjects\nin clinical remission was higher in the q8\u00a0week (59.6%, 31/52) than the\nq12\u00a0week maintenance treatment group (35.3%, 18/51; p\u00a0=\u00a00.013).\nAt week\u00a054, the figures were 55.8% (29/52) and 23.5% (12/51) in the q8\u00a0weeks\nand q12\u00a0weeks maintenance groups, respectively (p\u00a0&lt;\u00a00.001).</span>", "ID": "9d0f169e-8175-45ca-b2af-ff3557b9f87b", "Styles": "None", "Classes": "None", "Text": "At week\u00a030, the proportion of subjects in clinical remission was higher in the q8\u00a0week (59.6%, 31/52) than the q12\u00a0week maintenance treatment group (35.3%, 18/51; p\u00a0=\u00a00.013). At week\u00a054, the figures were 55.8% (29/52) and 23.5% (12/51) in the q8\u00a0weeks and q12\u00a0weeks maintenance groups, respectively (p\u00a0<\u00a00.001).", "ParentId": "c66d17cf-fc2d-4efe-9e77-bd99d785285f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Data about fistulas were derived from PCDAI\nscores. Of the 22\u00a0subjects that had fistulas at baseline, 63.6% (14/22),\n59.1% (13/22) and 68.2% (15/22) were in complete fistula response at week\u00a010,\n30 and 54, respectively, in the combined q8\u00a0weeks and q12\u00a0weeks\nmaintenance groups.</span></p>", "ID": "1879d434-3f5f-49b9-b551-e1b92fdf13c5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Data about fistulas were derived from PCDAI\nscores. Of the 22\u00a0subjects that had fistulas at baseline, 63.6% (14/22),\n59.1% (13/22) and 68.2% (15/22) were in complete fistula response at week\u00a010,\n30 and 54, respectively, in the combined q8\u00a0weeks and q12\u00a0weeks\nmaintenance groups.</span>", "ID": "08192a11-3593-4dee-b618-d31d65b53ff8", "Styles": "None", "Classes": "None", "Text": "Data about fistulas were derived from PCDAI scores. Of the 22\u00a0subjects that had fistulas at baseline, 63.6% (14/22), 59.1% (13/22) and 68.2% (15/22) were in complete fistula response at week\u00a010, 30 and 54, respectively, in the combined q8\u00a0weeks and q12\u00a0weeks maintenance groups.", "ParentId": "1879d434-3f5f-49b9-b551-e1b92fdf13c5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ef27a218-35f9-44d9-9d76-586ee7f3d291", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1b0cbc3c-bc39-4bb6-b6fa-d147dd90dac1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ef27a218-35f9-44d9-9d76-586ee7f3d291"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In addition, statistically and clinically\nsignificant improvements in quality of life and height, as well as a\nsignificant reduction in corticosteroid use, were observed versus baseline.</span></p>", "ID": "88672b40-1659-48f4-b7ab-3a0e5b40e20b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In addition, statistically and clinically\nsignificant improvements in quality of life and height, as well as a\nsignificant reduction in corticosteroid use, were observed versus baseline.</span>", "ID": "5a2bc539-cedf-43f5-af46-d6cb1def4f16", "Styles": "None", "Classes": "None", "Text": "In addition, statistically and clinically significant improvements in quality of life and height, as well as a significant reduction in corticosteroid use, were observed versus baseline.", "ParentId": "88672b40-1659-48f4-b7ab-3a0e5b40e20b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e9a425ce-d8c9-41c1-9c82-28b00502db59", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b11567dd-c668-41a1-be52-717bfc15dc51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e9a425ce-d8c9-41c1-9c82-28b00502db59"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\nulcerative colitis (6 to 17\u00a0years)</span></u></p>", "ID": "b1521734-d695-4dd1-a28d-84b6c0a9e1b9", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Paediatric\nulcerative colitis (6 to 17\u00a0years)</span></u>", "ID": "66e2c464-d657-48f1-a639-1b3507f5c8f8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b1521734-d695-4dd1-a28d-84b6c0a9e1b9"}, {"Element": "<span lang=\"EN-GB\">Paediatric\nulcerative colitis (6 to 17\u00a0years)</span>", "ID": "b68e9fd8-1577-4d52-8fd6-e8cd32eec89f", "Styles": "None", "Classes": "None", "Text": "Paediatric ulcerative colitis (6 to 17\u00a0years)", "ParentId": "66e2c464-d657-48f1-a639-1b3507f5c8f8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The safety and efficacy of infliximab were\nassessed in a multicenter, randomised, open\u2011label, parallel\u2011group\nclinical study (C0168T72) in 60\u00a0paediatric patients aged 6 through 17\u00a0years\n(median age 14.5\u00a0years) with moderately to severely active ulcerative\ncolitis (Mayo score of 6 to 12; endoscopic subscore \u2265\u00a02) with an\ninadequate response to conventional therapies. At baseline 53% of patients were\nreceiving immunomodulator therapy (6\u2011MP, AZA and/or MTX) and 62% of\npatients were receiving corticosteroids. Discontinuation of immunomodulators\nand corticosteroid taper were permitted after week\u00a00.</span></p>", "ID": "eb782495-733f-43f5-99e8-5b26c6e743af", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The safety and efficacy of infliximab were\nassessed in a multicenter, randomised, open\u2011label, parallel\u2011group\nclinical study (C0168T72) in 60\u00a0paediatric patients aged 6 through 17\u00a0years\n(median age 14.5\u00a0years) with moderately to severely active ulcerative\ncolitis (Mayo score of 6 to 12; endoscopic subscore \u2265\u00a02) with an\ninadequate response to conventional therapies. At baseline 53% of patients were\nreceiving immunomodulator therapy (6\u2011MP, AZA and/or MTX) and 62% of\npatients were receiving corticosteroids. Discontinuation of immunomodulators\nand corticosteroid taper were permitted after week\u00a00.</span>", "ID": "0610f7b9-cfdb-4d94-960f-0e0dea9a6867", "Styles": "None", "Classes": "None", "Text": "The safety and efficacy of infliximab were assessed in a multicenter, randomised, open\u2011label, parallel\u2011group clinical study (C0168T72) in 60\u00a0paediatric patients aged 6 through 17\u00a0years (median age 14.5\u00a0years) with moderately to severely active ulcerative colitis (Mayo score of 6 to 12; endoscopic subscore \u2265\u00a02) with an inadequate response to conventional therapies. At baseline 53% of patients were receiving immunomodulator therapy (6\u2011MP, AZA and/or MTX) and 62% of patients were receiving corticosteroids. Discontinuation of immunomodulators and corticosteroid taper were permitted after week\u00a00.", "ParentId": "eb782495-733f-43f5-99e8-5b26c6e743af"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b782f22b-97b4-4298-afa4-e0ffc6af3b51", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a22a6737-cdef-4068-8f6e-95d3d0a4e4b2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b782f22b-97b4-4298-afa4-e0ffc6af3b51"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">All patients received an induction regimen\nof 5\u00a0mg/kg infliximab at weeks\u00a00, 2, and 6. Patients who did not\nrespond to infliximab at week\u00a08 (n\u00a0=\u00a015) received no further medicinal\nproduct and returned for safety follow\u2011up. At week\u00a08, 45\u00a0patients\nwere randomised and received 5\u00a0mg/kg infliximab at either q8\u00a0weeks or\nq12\u00a0weeks as a maintenance treatment regimen.</span></p>", "ID": "2a01226c-d389-4578-9b6e-8e547e6df97d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">All patients received an induction regimen\nof 5\u00a0mg/kg infliximab at weeks\u00a00, 2, and 6. Patients who did not\nrespond to infliximab at week\u00a08 (n\u00a0=\u00a015) received no further medicinal\nproduct and returned for safety follow\u2011up. At week\u00a08, 45\u00a0patients\nwere randomised and received 5\u00a0mg/kg infliximab at either q8\u00a0weeks or\nq12\u00a0weeks as a maintenance treatment regimen.</span>", "ID": "017a3151-c0b1-41f1-8386-597d0f6c2081", "Styles": "None", "Classes": "None", "Text": "All patients received an induction regimen of 5\u00a0mg/kg infliximab at weeks\u00a00, 2, and 6. Patients who did not respond to infliximab at week\u00a08 (n\u00a0=\u00a015) received no further medicinal product and returned for safety follow\u2011up. At week\u00a08, 45\u00a0patients were randomised and received 5\u00a0mg/kg infliximab at either q8\u00a0weeks or q12\u00a0weeks as a maintenance treatment regimen.", "ParentId": "2a01226c-d389-4578-9b6e-8e547e6df97d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2c385e0e-0f92-496c-a858-c5ba982edcb5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2407455a-388b-4b12-a05e-4db1ff8d0d4b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2c385e0e-0f92-496c-a858-c5ba982edcb5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The proportion of patients in clinical\nresponse at week\u00a08\u00a0was 73.3% (44/60). Clinical response at week\u00a08\nwas similar between those with or without concomitant immunomodulator use at\nbaseline. Clinical remission at week\u00a08 was 33.3% (17/51) as measured by\nthe Paediatric Ulcerative Colitis Activity Index (PUCAI) score.</span></p>", "ID": "07fe6112-7877-4534-8924-8cdcca90dd48", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The proportion of patients in clinical\nresponse at week\u00a08\u00a0was 73.3% (44/60). Clinical response at week\u00a08\nwas similar between those with or without concomitant immunomodulator use at\nbaseline. Clinical remission at week\u00a08 was 33.3% (17/51) as measured by\nthe Paediatric Ulcerative Colitis Activity Index (PUCAI) score.</span>", "ID": "7528616c-52ca-47e2-9938-694a181694eb", "Styles": "None", "Classes": "None", "Text": "The proportion of patients in clinical response at week\u00a08\u00a0was 73.3% (44/60). Clinical response at week\u00a08 was similar between those with or without concomitant immunomodulator use at baseline. Clinical remission at week\u00a08 was 33.3% (17/51) as measured by the Paediatric Ulcerative Colitis Activity Index (PUCAI) score.", "ParentId": "07fe6112-7877-4534-8924-8cdcca90dd48"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cc1a7ad0-2354-4e97-a9b9-7c090ea53c4f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b9b1cd21-8b41-42e7-b91b-19864d0d5a3d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cc1a7ad0-2354-4e97-a9b9-7c090ea53c4f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">At week\u00a054, the proportion of patients\nin clinical remission as measured by the PUCAI score was 38% (8/21) in the\nq8\u00a0week maintenance group and 18% (4/22) in the q12\u00a0week maintenance\ntreatment group. </span><span lang=\"EN-GB\">For patients receiving corticosteroids\nat baseline, the proportion of patients in remission and not receiving\ncorticosteroids at week\u00a054 was 38.5% (5/13) for the q8\u00a0week and 0%\n(0/13) for the q12\u00a0week maintenance treatment group.</span></p>", "ID": "acad9322-8ee9-421e-a722-213f07ea072e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">At week\u00a054, the proportion of patients\nin clinical remission as measured by the PUCAI score was 38% (8/21) in the\nq8\u00a0week maintenance group and 18% (4/22) in the q12\u00a0week maintenance\ntreatment group. </span>", "ID": "f861ad80-38b4-4c1c-b72b-0e55da7f0c4c", "Styles": "None", "Classes": "None", "Text": "At week\u00a054, the proportion of patients in clinical remission as measured by the PUCAI score was 38% (8/21) in the q8\u00a0week maintenance group and 18% (4/22) in the q12\u00a0week maintenance treatment group. ", "ParentId": "acad9322-8ee9-421e-a722-213f07ea072e"}, {"Element": "<span lang=\"EN-GB\">For patients receiving corticosteroids\nat baseline, the proportion of patients in remission and not receiving\ncorticosteroids at week\u00a054 was 38.5% (5/13) for the q8\u00a0week and 0%\n(0/13) for the q12\u00a0week maintenance treatment group.</span>", "ID": "e16c1c49-c010-40d0-8dbd-f7639c8a870b", "Styles": "None", "Classes": "None", "Text": "For patients receiving corticosteroids at baseline, the proportion of patients in remission and not receiving corticosteroids at week\u00a054 was 38.5% (5/13) for the q8\u00a0week and 0% (0/13) for the q12\u00a0week maintenance treatment group.", "ParentId": "acad9322-8ee9-421e-a722-213f07ea072e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "743ee692-6b20-4f57-9851-6f59ef6f7746", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dfc78f6e-7fd3-42fd-b408-fd09239da205", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "743ee692-6b20-4f57-9851-6f59ef6f7746"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In this study, there were more patients in\nthe 12 to 17\u00a0year age group than in the 6 to 11\u00a0year age group (45/60\nvs.15/60). While the numbers of patients in each subgroup are too small to draw\ndefinitive conclusions about the effect of age, there was a higher number of\npatients in the younger age group who stepped up in dose or discontinued\ntreatment due to inadequate efficacy.</span></p>", "ID": "9965c84e-856f-400e-97a3-5e69a59e5976", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In this study, there were more patients in\nthe 12 to 17\u00a0year age group than in the 6 to 11\u00a0year age group (45/60\nvs.15/60). While the numbers of patients in each subgroup are too small to draw\ndefinitive conclusions about the effect of age, there was a higher number of\npatients in the younger age group who stepped up in dose or discontinued\ntreatment due to inadequate efficacy.</span>", "ID": "80e9ef7e-6b9e-4d55-9a2b-7835f0d94152", "Styles": "None", "Classes": "None", "Text": "In this study, there were more patients in the 12 to 17\u00a0year age group than in the 6 to 11\u00a0year age group (45/60 vs.15/60). While the numbers of patients in each subgroup are too small to draw definitive conclusions about the effect of age, there was a higher number of patients in the younger age group who stepped up in dose or discontinued treatment due to inadequate efficacy.", "ParentId": "9965c84e-856f-400e-97a3-5e69a59e5976"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dcd46c00-1efc-4013-b986-e2dd261031fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a67af156-566b-4321-af77-c5c1aad0ef65", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dcd46c00-1efc-4013-b986-e2dd261031fe"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><u><span lang=\"EN-GB\">Other paediatric indications</span></u></p>", "ID": "64a092e6-5a64-42e5-8883-8d3e606c86e3", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Other paediatric indications</span></u>", "ID": "ee00662b-d395-4aa9-92b5-6e7ab61ff70f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "64a092e6-5a64-42e5-8883-8d3e606c86e3"}, {"Element": "<span lang=\"EN-GB\">Other paediatric indications</span>", "ID": "e821c931-ac0e-41aa-ba75-c0b7e9257b05", "Styles": "None", "Classes": "None", "Text": "Other paediatric indications", "ParentId": "ee00662b-d395-4aa9-92b5-6e7ab61ff70f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The European Medicines Agency has waived\nthe obligation to submit the results of studies with Remicade in all subsets of\nthe paediatric population in rheumatoid arthritis, juvenile idiopathic\narthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis and Crohn's\ndisease (see section\u00a04.2 for information on paediatric use).</span></p>", "ID": "d7b6da0a-de3e-441e-bce0-5d872f72ea32", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The European Medicines Agency has waived\nthe obligation to submit the results of studies with Remicade in all subsets of\nthe paediatric population in rheumatoid arthritis, juvenile idiopathic\narthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis and Crohn's\ndisease (see section\u00a04.2 for information on paediatric use).</span>", "ID": "fb59833c-9312-437f-b57a-b40761c27038", "Styles": "None", "Classes": "None", "Text": "The European Medicines Agency has waived the obligation to submit the results of studies with Remicade in all subsets of the paediatric population in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis and Crohn's disease (see section\u00a04.2 for information on paediatric use).", "ParentId": "d7b6da0a-de3e-441e-bce0-5d872f72ea32"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "315373d3-3c43-44c0-8def-284f1593f5b3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6116891a-a8bc-4e07-b816-0fc2eb92644e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "315373d3-3c43-44c0-8def-284f1593f5b3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic\nproperties</span></b></p>", "ID": "99f7f124-d452-44a8-a95c-5cbb0f01305d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic\nproperties</span></b>", "ID": "dc2f20d8-0f17-4cac-b48a-b5de421741d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "99f7f124-d452-44a8-a95c-5cbb0f01305d"}, {"Element": "<span lang=\"EN-GB\">5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic\nproperties</span>", "ID": "dae6a2d9-4ad8-42ad-9915-5231f4df65d7", "Styles": "None", "Classes": "None", "Text": "5.2\u00a0\u00a0\u00a0\u00a0 Pharmacokinetic properties", "ParentId": "dc2f20d8-0f17-4cac-b48a-b5de421741d8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "804d152c-3713-431c-bd7e-7c443b59c3fd", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d51a4a60-4d04-4237-bb10-aa5192f0184c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "804d152c-3713-431c-bd7e-7c443b59c3fd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Single\nintravenous infusions of 1, 3, 5, 10\u00a0or 20\u00a0mg/kg of infliximab\nyielded dose proportional increases in the maximum serum concentration (C<sub>max</sub>)\nand area under the concentration\u2011time curve (AUC). The volume of\ndistribution at steady state (median\u00a0V<sub>d </sub>of 3.0 to\n4.1\u00a0litres) was not dependent on the administered dose and indicated that\ninfliximab is predominantly distributed within the vascular compartment. No\ntime\u2011dependency of the Pharmacokinetics was observed. The elimination\npathways for infliximab have not been characterised. Unchanged infliximab was\nnot detected in urine. No major age\u2011 or weight\u2011related differences\nin clearance or volume of distribution were observed in rheumatoid arthritis\npatients. </span><span lang=\"EN-GB\">The pharmacokinetics of infliximab in elderly\npatients has not been studied. Studies have not been performed in patients with\nliver or renal disease.</span></p>", "ID": "85c8be9c-f69e-4cfd-8d8e-f94161b5fc8c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Single\nintravenous infusions of 1, 3, 5, 10\u00a0or 20\u00a0mg/kg of infliximab\nyielded dose proportional increases in the maximum serum concentration (C<sub>max</sub>)\nand area under the concentration\u2011time curve (AUC). The volume of\ndistribution at steady state (median\u00a0V<sub>d </sub>of 3.0 to\n4.1\u00a0litres) was not dependent on the administered dose and indicated that\ninfliximab is predominantly distributed within the vascular compartment. No\ntime\u2011dependency of the Pharmacokinetics was observed. The elimination\npathways for infliximab have not been characterised. Unchanged infliximab was\nnot detected in urine. No major age\u2011 or weight\u2011related differences\nin clearance or volume of distribution were observed in rheumatoid arthritis\npatients. </span>", "ID": "3b53de93-6497-46dc-ae15-dfdd4aba3be0", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Single intravenous infusions of 1, 3, 5, 10\u00a0or 20\u00a0mg/kg of infliximab yielded dose proportional increases in the maximum serum concentration (C) and area under the concentration\u2011time curve (AUC). The volume of distribution at steady state (median\u00a0Vof 3.0 to 4.1\u00a0litres) was not dependent on the administered dose and indicated that infliximab is predominantly distributed within the vascular compartment. No time\u2011dependency of the Pharmacokinetics was observed. The elimination pathways for infliximab have not been characterised. Unchanged infliximab was not detected in urine. No major age\u2011 or weight\u2011related differences in clearance or volume of distribution were observed in rheumatoid arthritis patients. ", "ParentId": "85c8be9c-f69e-4cfd-8d8e-f94161b5fc8c"}, {"Element": "<sub>max</sub>", "ID": "c2eb9569-5807-43aa-ad01-015e3f3abe7e", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "3b53de93-6497-46dc-ae15-dfdd4aba3be0"}, {"Element": "<sub>d </sub>", "ID": "028212f7-a109-44eb-8b9f-361d096bb0fb", "Styles": "None", "Classes": "None", "Text": "d ", "ParentId": "3b53de93-6497-46dc-ae15-dfdd4aba3be0"}, {"Element": "<span lang=\"EN-GB\">The pharmacokinetics of infliximab in elderly\npatients has not been studied. Studies have not been performed in patients with\nliver or renal disease.</span>", "ID": "1557856b-297b-407d-8078-4833cdd36e40", "Styles": "None", "Classes": "None", "Text": "The pharmacokinetics of infliximab in elderly patients has not been studied. Studies have not been performed in patients with liver or renal disease.", "ParentId": "85c8be9c-f69e-4cfd-8d8e-f94161b5fc8c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "16a71b40-4e53-4c37-877d-f48eb11495c6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "71858b00-5e81-462f-898e-cbd2dba936af", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "16a71b40-4e53-4c37-877d-f48eb11495c6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">At single\ndoses of 3, 5, or 10\u00a0mg/kg, the median C<sub>max</sub> values were 77, 118\nand 277\u00a0micrograms/ml, respectively. The median terminal half\u2011life\nat these doses ranged from 8 to 9.5\u00a0days. In most patients, infliximab\ncould be detected in the serum for at least 8\u00a0weeks after the recommended\nsingle dose of 5\u00a0mg/kg for Crohn\u2019s disease and the rheumatoid\narthritis maintenance dose of 3\u00a0mg/kg every 8\u00a0weeks.</span></p>", "ID": "e4ce64b3-d973-4292-b8b7-c08bd639d0bf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">At single\ndoses of 3, 5, or 10\u00a0mg/kg, the median C<sub>max</sub> values were 77, 118\nand 277\u00a0micrograms/ml, respectively. The median terminal half\u2011life\nat these doses ranged from 8 to 9.5\u00a0days. In most patients, infliximab\ncould be detected in the serum for at least 8\u00a0weeks after the recommended\nsingle dose of 5\u00a0mg/kg for Crohn\u2019s disease and the rheumatoid\narthritis maintenance dose of 3\u00a0mg/kg every 8\u00a0weeks.</span>", "ID": "ec8d26d3-2136-48d8-939f-3a9f86d11345", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "At single doses of 3, 5, or 10\u00a0mg/kg, the median C values were 77, 118 and 277\u00a0micrograms/ml, respectively. The median terminal half\u2011life at these doses ranged from 8 to 9.5\u00a0days. In most patients, infliximab could be detected in the serum for at least 8\u00a0weeks after the recommended single dose of 5\u00a0mg/kg for Crohn\u2019s disease and the rheumatoid arthritis maintenance dose of 3\u00a0mg/kg every 8\u00a0weeks.", "ParentId": "e4ce64b3-d973-4292-b8b7-c08bd639d0bf"}, {"Element": "<sub>max</sub>", "ID": "c3ce4a26-ecfd-4838-8b4a-b7622bd55fd6", "Styles": "None", "Classes": "None", "Text": "max", "ParentId": "ec8d26d3-2136-48d8-939f-3a9f86d11345"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span></p>", "ID": "82e249b0-6dd9-43a0-89d5-41f7ce9b78f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">\u00a0</span>", "ID": "a32d3509-a2c7-4c50-ad1f-d6fcd6df5085", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "\u00a0", "ParentId": "82e249b0-6dd9-43a0-89d5-41f7ce9b78f2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Repeated administration of infliximab (5\u00a0mg/kg\nat 0, 2 and 6\u00a0weeks in fistulising Crohn\u2019s disease, 3 or\n10\u00a0mg/kg every 4 or 8\u00a0weeks in rheumatoid arthritis) resulted in a\nslight accumulation of infliximab in serum after the second dose. No further\nclinically relevant accumulation was observed. In most fistulising\nCrohn\u2019s disease patients, infliximab was detected in serum for\n12\u00a0weeks (range 4\u201128\u00a0weeks) after administration of the\nregimen.</span></p>", "ID": "2d19f63f-82b2-4c55-aacc-cbd7c4e8f61b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Repeated administration of infliximab (5\u00a0mg/kg\nat 0, 2 and 6\u00a0weeks in fistulising Crohn\u2019s disease, 3 or\n10\u00a0mg/kg every 4 or 8\u00a0weeks in rheumatoid arthritis) resulted in a\nslight accumulation of infliximab in serum after the second dose. No further\nclinically relevant accumulation was observed. In most fistulising\nCrohn\u2019s disease patients, infliximab was detected in serum for\n12\u00a0weeks (range 4\u201128\u00a0weeks) after administration of the\nregimen.</span>", "ID": "f6bc0240-334a-48d2-b78e-b49e38321cfe", "Styles": "None", "Classes": "None", "Text": "Repeated administration of infliximab (5\u00a0mg/kg at 0, 2 and 6\u00a0weeks in fistulising Crohn\u2019s disease, 3 or 10\u00a0mg/kg every 4 or 8\u00a0weeks in rheumatoid arthritis) resulted in a slight accumulation of infliximab in serum after the second dose. No further clinically relevant accumulation was observed. In most fistulising Crohn\u2019s disease patients, infliximab was detected in serum for 12\u00a0weeks (range 4\u201128\u00a0weeks) after administration of the regimen.", "ParentId": "2d19f63f-82b2-4c55-aacc-cbd7c4e8f61b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "13e1e6d4-de7e-499b-8856-1f48f1ca943d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "488402d6-d5e1-40af-97df-f78e8d7b783d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "13e1e6d4-de7e-499b-8856-1f48f1ca943d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric\npopulation</span></i></p>", "ID": "d5a110c8-f3a8-42a2-8954-0627febd0bdf", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<i><span lang=\"EN-GB\">Paediatric\npopulation</span></i>", "ID": "fce59904-a0c4-44b4-917e-d03088cda742", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d5a110c8-f3a8-42a2-8954-0627febd0bdf"}, {"Element": "<span lang=\"EN-GB\">Paediatric\npopulation</span>", "ID": "c9cb1d28-3894-4905-94b3-461667b2aa22", "Styles": "None", "Classes": "None", "Text": "Paediatric population", "ParentId": "fce59904-a0c4-44b4-917e-d03088cda742"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Population\npharmacokinetic analysis based on data obtained from patients with ulcerative\ncolitis (N\u00a0=\u00a060), Crohn\u2019s disease (N\u00a0=\u00a0112), juvenile\nrheumatoid arthritis (N\u00a0=\u00a0117) and Kawasaki disease (N\u00a0=\u00a016)\nwith an overall age range from 2\u00a0months to 17\u00a0years indicated that\nexposure to infliximab was dependent on body weight in a non\u2011linear way.\nFollowing administration of 5\u00a0mg/kg Remicade every 8\u00a0weeks, the\npredicted median steady\u2011state infliximab exposure (area under\nconcentration\u2011time curve at steady state, AUC<sub>ss</sub>) in paediatric\npatients aged 6\u00a0years to 17\u00a0years was approximately 20% lower than\nthe predicted median steady\u2011state drug exposure in adults. The median AUC<sub>ss</sub>\nin paediatric patients aged 2\u00a0years to less than 6\u00a0years was\npredicted to be approximately 40% lower than that in adults, although the\nnumber of patients supporting this estimate is limited.</span></p>", "ID": "abe27fd0-758c-4f3b-bcd4-97d2b209b10f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Population\npharmacokinetic analysis based on data obtained from patients with ulcerative\ncolitis (N\u00a0=\u00a060), Crohn\u2019s disease (N\u00a0=\u00a0112), juvenile\nrheumatoid arthritis (N\u00a0=\u00a0117) and Kawasaki disease (N\u00a0=\u00a016)\nwith an overall age range from 2\u00a0months to 17\u00a0years indicated that\nexposure to infliximab was dependent on body weight in a non\u2011linear way.\nFollowing administration of 5\u00a0mg/kg Remicade every 8\u00a0weeks, the\npredicted median steady\u2011state infliximab exposure (area under\nconcentration\u2011time curve at steady state, AUC<sub>ss</sub>) in paediatric\npatients aged 6\u00a0years to 17\u00a0years was approximately 20% lower than\nthe predicted median steady\u2011state drug exposure in adults. The median AUC<sub>ss</sub>\nin paediatric patients aged 2\u00a0years to less than 6\u00a0years was\npredicted to be approximately 40% lower than that in adults, although the\nnumber of patients supporting this estimate is limited.</span>", "ID": "85e83408-09e7-4327-8008-ab10223d6d71", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "Population pharmacokinetic analysis based on data obtained from patients with ulcerative colitis (N\u00a0=\u00a060), Crohn\u2019s disease (N\u00a0=\u00a0112), juvenile rheumatoid arthritis (N\u00a0=\u00a0117) and Kawasaki disease (N\u00a0=\u00a016) with an overall age range from 2\u00a0months to 17\u00a0years indicated that exposure to infliximab was dependent on body weight in a non\u2011linear way. Following administration of 5\u00a0mg/kg Remicade every 8\u00a0weeks, the predicted median steady\u2011state infliximab exposure (area under concentration\u2011time curve at steady state, AUC) in paediatric patients aged 6\u00a0years to 17\u00a0years was approximately 20% lower than the predicted median steady\u2011state drug exposure in adults. The median AUC in paediatric patients aged 2\u00a0years to less than 6\u00a0years was predicted to be approximately 40% lower than that in adults, although the number of patients supporting this estimate is limited.", "ParentId": "abe27fd0-758c-4f3b-bcd4-97d2b209b10f"}, {"Element": "<sub>ss</sub>", "ID": "dbcfc392-27a0-4089-a0bf-afab00ff42db", "Styles": "None", "Classes": "None", "Text": "ss", "ParentId": "85e83408-09e7-4327-8008-ab10223d6d71"}, {"Element": "<sub>ss</sub>", "ID": "f3aa4ee2-7183-4b19-b6ea-ccdba05f0c7e", "Styles": "None", "Classes": "None", "Text": "ss", "ParentId": "85e83408-09e7-4327-8008-ab10223d6d71"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "10602973-f16b-4459-9f12-2787d2696c3f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "85816d6e-5fb9-4bc8-a0b2-1c66f6de8998", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "10602973-f16b-4459-9f12-2787d2696c3f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span></b></p>", "ID": "a4d652d3-3aa5-4f5d-a3bc-83bec597d76c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span></b>", "ID": "bda48d8d-a7a1-4993-bbf5-1269f3e8c4c6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a4d652d3-3aa5-4f5d-a3bc-83bec597d76c"}, {"Element": "<span lang=\"EN-GB\">5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data</span>", "ID": "5a57691d-248a-4bda-8e4b-09f19fb000f4", "Styles": "None", "Classes": "None", "Text": "5.3\u00a0\u00a0\u00a0\u00a0 Preclinical safety data", "ParentId": "bda48d8d-a7a1-4993-bbf5-1269f3e8c4c6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2a138f95-199d-4063-b52c-beaf7201a329", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "866fda3b-9abc-4f60-b7d4-e2a618b1a39a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2a138f95-199d-4063-b52c-beaf7201a329"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Infliximab does not cross react with TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> from\nspecies other than human and chimpanzees. Therefore, conventional preclinical\nsafety data with infliximab are limited. In a developmental toxicity study conducted\nin mice using an analogous antibody that selectively inhibits the functional\nactivity of mouse TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\">, there was no indication of maternal toxicity, embryotoxicity or\nteratogenicity. In a fertility and general reproductive function study, the\nnumber of pregnant mice was reduced following administration of the same\nanalogous antibody. It is not known whether this finding was due to effects on\nthe males and/or the females. <span style=\"layout-grid-mode:line\">In a 6\u2011month\nrepeated dose toxicity study in mice, using the same analogous antibody against\nmouse TNF</span></span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">, crystalline deposits were observed\non the lens capsule of some of the treated male mice. No specific\nophthalmologic examinations have been performed in patients to investigate the\nrelevance of this finding for humans.</span></p>", "ID": "987eb6ec-66d6-45bc-b151-1f2d5440aae0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Infliximab does not cross react with TNF</span>", "ID": "5402ac5b-9160-4b69-93c4-9bdb5ac9a2e7", "Styles": "None", "Classes": "None", "Text": "Infliximab does not cross react with TNF", "ParentId": "987eb6ec-66d6-45bc-b151-1f2d5440aae0"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "514a5b1b-040d-48f4-a69e-e427d6a49ab1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "987eb6ec-66d6-45bc-b151-1f2d5440aae0"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "7250c041-da10-458f-8ecf-142ca51f8827", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "514a5b1b-040d-48f4-a69e-e427d6a49ab1"}, {"Element": "<span lang=\"EN-GB\"> from\nspecies other than human and chimpanzees. Therefore, conventional preclinical\nsafety data with infliximab are limited. In a developmental toxicity study conducted\nin mice using an analogous antibody that selectively inhibits the functional\nactivity of mouse TNF</span>", "ID": "652ed299-4f3d-4943-9bfc-0f08d261b62f", "Styles": "None", "Classes": "None", "Text": " from species other than human and chimpanzees. Therefore, conventional preclinical safety data with infliximab are limited. In a developmental toxicity study conducted in mice using an analogous antibody that selectively inhibits the functional activity of mouse TNF", "ParentId": "987eb6ec-66d6-45bc-b151-1f2d5440aae0"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "f217b488-4d14-4270-8214-6e98efc88d20", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "987eb6ec-66d6-45bc-b151-1f2d5440aae0"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "ec5e1a85-d6bd-4057-b938-86ce52a492ed", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "f217b488-4d14-4270-8214-6e98efc88d20"}, {"Element": "<span lang=\"EN-GB\">, there was no indication of maternal toxicity, embryotoxicity or\nteratogenicity. In a fertility and general reproductive function study, the\nnumber of pregnant mice was reduced following administration of the same\nanalogous antibody. It is not known whether this finding was due to effects on\nthe males and/or the females. <span style=\"layout-grid-mode:line\">In a 6\u2011month\nrepeated dose toxicity study in mice, using the same analogous antibody against\nmouse TNF</span></span>", "ID": "360f5c53-784e-4e61-96c6-844724cdf594", "Styles": "None", "Classes": "None", "Text": ", there was no indication of maternal toxicity, embryotoxicity or teratogenicity. In a fertility and general reproductive function study, the number of pregnant mice was reduced following administration of the same analogous antibody. It is not known whether this finding was due to effects on the males and/or the females. ", "ParentId": "987eb6ec-66d6-45bc-b151-1f2d5440aae0"}, {"Element": "<span style=\"layout-grid-mode:line\">In a 6\u2011month\nrepeated dose toxicity study in mice, using the same analogous antibody against\nmouse TNF</span>", "ID": "e6765dc9-49c9-42a9-9488-d2f7810736b2", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": "In a 6\u2011month repeated dose toxicity study in mice, using the same analogous antibody against mouse TNF", "ParentId": "360f5c53-784e-4e61-96c6-844724cdf594"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "37f40167-b9e9-42d1-a63b-caea633c5dcf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "987eb6ec-66d6-45bc-b151-1f2d5440aae0"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "dccfb9a3-b53f-4060-a2e5-cbc9dfd0c396", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "37f40167-b9e9-42d1-a63b-caea633c5dcf"}, {"Element": "<span lang=\"EN-GB\" style=\"layout-grid-mode:line\">, crystalline deposits were observed\non the lens capsule of some of the treated male mice. No specific\nophthalmologic examinations have been performed in patients to investigate the\nrelevance of this finding for humans.</span>", "ID": "6619f81a-0704-4830-a727-7830a417e092", "Styles": "layout-grid-mode:line", "Classes": "None", "Text": ", crystalline deposits were observed on the lens capsule of some of the treated male mice. No specific ophthalmologic examinations have been performed in patients to investigate the relevance of this finding for humans.", "ParentId": "987eb6ec-66d6-45bc-b151-1f2d5440aae0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Long\u2011term studies have not been\nperformed to evaluate the carcinogenic potential of infliximab. Studies in mice\ndeficient in TNF</span><sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub><span lang=\"EN-GB\"> demonstrated no increase in tumours when challenged with known\ntumour initiators and/or promoters.</span></p>", "ID": "16a3dff5-feb7-4bc3-96d9-8062641a25f4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Long\u2011term studies have not been\nperformed to evaluate the carcinogenic potential of infliximab. Studies in mice\ndeficient in TNF</span>", "ID": "f9828393-0817-4910-b6a3-1e5dee05d06b", "Styles": "None", "Classes": "None", "Text": "Long\u2011term studies have not been performed to evaluate the carcinogenic potential of infliximab. Studies in mice deficient in TNF", "ParentId": "16a3dff5-feb7-4bc3-96d9-8062641a25f4"}, {"Element": "<sub><span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span></sub>", "ID": "3dcef914-867f-4cda-8ada-f24a8f5765bd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "16a3dff5-feb7-4bc3-96d9-8062641a25f4"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">a</span>", "ID": "310a8383-b6d1-42ad-aecb-84b234dff62d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "a", "ParentId": "3dcef914-867f-4cda-8ada-f24a8f5765bd"}, {"Element": "<span lang=\"EN-GB\"> demonstrated no increase in tumours when challenged with known\ntumour initiators and/or promoters.</span>", "ID": "75d70140-4ef4-45fd-bc77-28f9789def68", "Styles": "None", "Classes": "None", "Text": " demonstrated no increase in tumours when challenged with known tumour initiators and/or promoters.", "ParentId": "16a3dff5-feb7-4bc3-96d9-8062641a25f4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fc0c932f-2fa5-48fb-89c3-df8a59a026d3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "698c815e-1a58-4276-9e9a-c2ac0c26d925", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fc0c932f-2fa5-48fb-89c3-df8a59a026d3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d2437e11-35a8-4f50-afba-1ec736a5458d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "496d721d-ce4c-4f2f-9c21-4c1b67d17d7b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d2437e11-35a8-4f50-afba-1ec736a5458d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</span></b></p>", "ID": "45617249-61f7-451f-844e-58acce2ab265", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</span></b>", "ID": "2401dbc8-4219-4fda-b9f0-21496aab5c85", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "45617249-61f7-451f-844e-58acce2ab265"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nPARTICULARS</span>", "ID": "780cb9aa-ef13-4b19-a8b0-a320eb52cecd", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL PARTICULARS", "ParentId": "2401dbc8-4219-4fda-b9f0-21496aab5c85"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "08db6718-ecb5-4130-b50b-982dbc1d6fde", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "640d1abb-231c-4445-97cc-8872174a833d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "08db6718-ecb5-4130-b50b-982dbc1d6fde"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b></p>", "ID": "671eaa1f-4d6e-489f-b52c-4c9af880f796", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span></b>", "ID": "ac28cfb0-7add-4bb4-9f08-7b1cefde9fc0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "671eaa1f-4d6e-489f-b52c-4c9af880f796"}, {"Element": "<span lang=\"EN-GB\">6.1\u00a0\u00a0\u00a0\u00a0 List of excipients</span>", "ID": "41191152-07f3-405a-b27b-c7cd62cedb6d", "Styles": "None", "Classes": "None", "Text": "6.1\u00a0\u00a0\u00a0\u00a0 List of excipients", "ParentId": "ac28cfb0-7add-4bb4-9f08-7b1cefde9fc0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dbde61b4-0966-4c32-8588-2673bec082b7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7c7029ac-64bb-4661-bbab-1e0fabe0b240", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dbde61b4-0966-4c32-8588-2673bec082b7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Sucrose</span></p>", "ID": "e4001e5d-ffcf-4310-9a71-cc346f2a57c4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Sucrose</span>", "ID": "ba2e0d66-1113-475d-9bee-76e5aee78777", "Styles": "None", "Classes": "None", "Text": "Sucrose", "ParentId": "e4001e5d-ffcf-4310-9a71-cc346f2a57c4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Polysorbate\u00a080</span></p>", "ID": "216dcb7f-6ec2-474d-8e83-66c4759c2320", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Polysorbate\u00a080</span>", "ID": "f3e47768-4db8-41dc-a9a8-c4b7a1263203", "Styles": "None", "Classes": "None", "Text": "Polysorbate\u00a080", "ParentId": "216dcb7f-6ec2-474d-8e83-66c4759c2320"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Monobasic sodium phosphate</span></p>", "ID": "b114759a-cff8-4d15-8a8a-2bd48f824185", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Monobasic sodium phosphate</span>", "ID": "9e742a11-d531-4073-8690-5b80f0560d4e", "Styles": "None", "Classes": "None", "Text": "Monobasic sodium phosphate", "ParentId": "b114759a-cff8-4d15-8a8a-2bd48f824185"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dibasic sodium phosphate</span></p>", "ID": "69549fe6-8371-4f76-b43f-99964493cfd9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Dibasic sodium phosphate</span>", "ID": "410342ec-fe22-4776-ac42-908273577c7f", "Styles": "None", "Classes": "None", "Text": "Dibasic sodium phosphate", "ParentId": "69549fe6-8371-4f76-b43f-99964493cfd9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "34c0f64b-77fb-4ed6-803b-ed01d755798c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0760410b-f576-4a63-b478-3c4c7181e17e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "34c0f64b-77fb-4ed6-803b-ed01d755798c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b></p>", "ID": "ed8f4009-3c58-470b-8da5-fbc10ceefe31", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span></b>", "ID": "74b8a9d0-76d2-435b-92d0-bef3565ca5d0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ed8f4009-3c58-470b-8da5-fbc10ceefe31"}, {"Element": "<span lang=\"EN-GB\">6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities</span>", "ID": "993e0f19-e9fc-46e8-80ff-fbc8f02fbb45", "Styles": "None", "Classes": "None", "Text": "6.2\u00a0\u00a0\u00a0\u00a0 Incompatibilities", "ParentId": "74b8a9d0-76d2-435b-92d0-bef3565ca5d0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "17a7cc82-b882-4454-86c4-e9fb04305d80", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a5fb7ddd-23b1-4da9-b1cd-0bab15f13ce6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "17a7cc82-b882-4454-86c4-e9fb04305d80"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In the absence of compatibility studies,\nthis medicinal product must not be mixed with other medicinal products.</span></p>", "ID": "40d40c36-e28e-4772-a1fb-5262f1b66fb7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In the absence of compatibility studies,\nthis medicinal product must not be mixed with other medicinal products.</span>", "ID": "ca5b3014-c242-4801-833f-8431811f41c5", "Styles": "None", "Classes": "None", "Text": "In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.", "ParentId": "40d40c36-e28e-4772-a1fb-5262f1b66fb7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2b1853f6-2da3-4e5d-9329-562ab2f75375", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "81cab612-3692-4038-8a55-ea523e6c9d93", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2b1853f6-2da3-4e5d-9329-562ab2f75375"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b></p>", "ID": "2c5aa04e-2500-443f-98af-db6a328b1672", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span></b>", "ID": "eeef48dd-1bd7-4cad-b0dc-711ec514e18e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2c5aa04e-2500-443f-98af-db6a328b1672"}, {"Element": "<span lang=\"EN-GB\">6.3\u00a0\u00a0\u00a0\u00a0 Shelf life</span>", "ID": "67ce8ca4-91d3-469b-a7ad-3ea5bbaecc29", "Styles": "None", "Classes": "None", "Text": "6.3\u00a0\u00a0\u00a0\u00a0 Shelf life", "ParentId": "eeef48dd-1bd7-4cad-b0dc-711ec514e18e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d264f2d8-3d7b-4ceb-b1a5-a2f406061b85", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "04b1a9f1-13f2-44f7-ba9e-72b971616c98", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d264f2d8-3d7b-4ceb-b1a5-a2f406061b85"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Before\nreconstitution:</span></u></p>", "ID": "a34c7bab-a195-4e66-babc-11617683da04", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Before\nreconstitution:</span></u>", "ID": "50c82ceb-7eb3-4624-9f3b-25e408dbda74", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a34c7bab-a195-4e66-babc-11617683da04"}, {"Element": "<span lang=\"EN-GB\">Before\nreconstitution:</span>", "ID": "32c6ebb0-168a-4cf0-b8af-290dbcab8c00", "Styles": "None", "Classes": "None", "Text": "Before reconstitution:", "ParentId": "50c82ceb-7eb3-4624-9f3b-25e408dbda74"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3\u00a0years\nat 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u2013<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C.</span></p>", "ID": "eda1aa2f-74b8-4895-9016-8759277d5ce0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">3\u00a0years\nat 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u2013<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C.</span>", "ID": "deac27b9-db4d-4a1f-a89c-9ce3e0b932ca", "Styles": "None", "Classes": "None", "Text": "3\u00a0years at 2\u00b0C\u20138\u00b0C.", "ParentId": "eda1aa2f-74b8-4895-9016-8759277d5ce0"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "540872be-a70b-44f0-b1eb-241a59b2064a", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "deac27b9-db4d-4a1f-a89c-9ce3e0b932ca"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "34bd0702-2e3e-4e8e-9874-283f3a83afe5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "540872be-a70b-44f0-b1eb-241a59b2064a"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "e74c1b63-e8a5-4117-8c77-ff978f5b073c", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "deac27b9-db4d-4a1f-a89c-9ce3e0b932ca"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "9d84dfa2-b400-4926-ae03-f44831df35cf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e74c1b63-e8a5-4117-8c77-ff978f5b073c"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "42d5dcb3-617a-48c3-8bda-c747b38e4707", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "deac27b9-db4d-4a1f-a89c-9ce3e0b932ca"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "a09e98dc-fef7-491e-a9c3-3cb4d4b04ddb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "42d5dcb3-617a-48c3-8bda-c747b38e4707"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "0fe2179d-2f9e-4aad-9d48-ad42eb48e329", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "deac27b9-db4d-4a1f-a89c-9ce3e0b932ca"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "52b2e111-6f36-4007-8347-5a27f782559d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0fe2179d-2f9e-4aad-9d48-ad42eb48e329"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a4c94864-1302-410d-96ba-e986f4ac3959", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e98f9efd-d3f2-4da4-9811-6c3d150ab2e2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a4c94864-1302-410d-96ba-e986f4ac3959"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade may be stored at temperatures up\nto a maximum of 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C for a single period of up\nto 6\u00a0months, but not exceeding the original expiry date. The new expiry\ndate must be written on the carton. Upon removal from refrigerated storage,\nRemicade must not be returned to refrigerated storage.</span></p>", "ID": "307a52c5-c407-47dd-8f00-6612aa56ea2a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade may be stored at temperatures up\nto a maximum of 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C for a single period of up\nto 6\u00a0months, but not exceeding the original expiry date. The new expiry\ndate must be written on the carton. Upon removal from refrigerated storage,\nRemicade must not be returned to refrigerated storage.</span>", "ID": "6f2926d3-f803-4868-8dab-e7c034124ff8", "Styles": "None", "Classes": "None", "Text": "Remicade may be stored at temperatures up to a maximum of 25\u00b0C for a single period of up to 6\u00a0months, but not exceeding the original expiry date. The new expiry date must be written on the carton. Upon removal from refrigerated storage, Remicade must not be returned to refrigerated storage.", "ParentId": "307a52c5-c407-47dd-8f00-6612aa56ea2a"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "a47f63dc-1007-4c08-8d43-b2841c2f66fa", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "6f2926d3-f803-4868-8dab-e7c034124ff8"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "b4d0cb85-759a-43c4-9f9a-c6be1fffb4d0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a47f63dc-1007-4c08-8d43-b2841c2f66fa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "559a126b-6544-4f83-941a-ee41fd95f3c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "754d6b6e-dd9b-4753-9cfc-559b5a00808f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "559a126b-6544-4f83-941a-ee41fd95f3c3"}, {"Element": "<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">After reconstitution and dilution:</span></u></p>", "ID": "753eed85-3eeb-42e7-9e19-5231a608f151", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">After reconstitution and dilution:</span></u>", "ID": "6120f1ca-7b17-49d4-989c-530fa5d165e8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "753eed85-3eeb-42e7-9e19-5231a608f151"}, {"Element": "<span lang=\"EN-GB\">After reconstitution and dilution:</span>", "ID": "85dec767-b68d-44e6-adaa-0260847872c8", "Styles": "None", "Classes": "None", "Text": "After reconstitution and dilution:", "ParentId": "6120f1ca-7b17-49d4-989c-530fa5d165e8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Chemical and physical in use stability of\nthe diluted solution has been demonstrated for up to 28\u00a0days at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C to 8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C and for an additional 24\u00a0hours\nat 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C after removal from\nrefrigeration. From a microbiological point of view, the infusion solution should\nbe administered immediately, in use storage times and conditions prior to use\nare the responsibility of the user and would normally not be longer than\n24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C to 8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C, unless\nreconstitution/dilution has been taken place in controlled and validated\naseptic conditions.</span></p>", "ID": "d2513bb3-1a19-4f8d-8cd1-f01c46b2b3ec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Chemical and physical in use stability of\nthe diluted solution has been demonstrated for up to 28\u00a0days at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C to 8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C and for an additional 24\u00a0hours\nat 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C after removal from\nrefrigeration. From a microbiological point of view, the infusion solution should\nbe administered immediately, in use storage times and conditions prior to use\nare the responsibility of the user and would normally not be longer than\n24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C to 8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C, unless\nreconstitution/dilution has been taken place in controlled and validated\naseptic conditions.</span>", "ID": "d5faad2e-af9e-4044-a42a-f1da2cb97ce2", "Styles": "None", "Classes": "None", "Text": "Chemical and physical in use stability of the diluted solution has been demonstrated for up to 28\u00a0days at 2\u00b0C to 8\u00b0C and for an additional 24\u00a0hours at 25\u00b0C after removal from refrigeration. From a microbiological point of view, the infusion solution should be administered immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24\u00a0hours at 2\u00b0C to 8\u00b0C, unless reconstitution/dilution has been taken place in controlled and validated aseptic conditions.", "ParentId": "d2513bb3-1a19-4f8d-8cd1-f01c46b2b3ec"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "265e2af9-7390-4df7-8349-5cb153d1c70a", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "d5faad2e-af9e-4044-a42a-f1da2cb97ce2"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "9d8bf6a6-2ea7-4745-b811-270bd8d82e51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "265e2af9-7390-4df7-8349-5cb153d1c70a"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "b599be3b-6f01-42c5-b33a-0a686ac5d83d", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "d5faad2e-af9e-4044-a42a-f1da2cb97ce2"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "7cd6861a-40cd-484b-9156-90592c6927d9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b599be3b-6f01-42c5-b33a-0a686ac5d83d"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "295a13ac-ce4e-45b2-aab5-d66950a2dd18", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "d5faad2e-af9e-4044-a42a-f1da2cb97ce2"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "5b109e14-9087-4567-b1b3-866396391b18", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "295a13ac-ce4e-45b2-aab5-d66950a2dd18"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "460f7af9-cf1d-4db7-b730-32ba13a97451", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "d5faad2e-af9e-4044-a42a-f1da2cb97ce2"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "fce278ea-d058-4a09-b46a-d6b4dabb4515", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "460f7af9-cf1d-4db7-b730-32ba13a97451"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "eb2b4657-9619-441e-ba6f-cb67a760ff80", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "d5faad2e-af9e-4044-a42a-f1da2cb97ce2"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "3cae5090-f722-45d5-bbe4-ed1303371f4f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "eb2b4657-9619-441e-ba6f-cb67a760ff80"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bed2133c-79b6-47b9-a8c7-49b9a6b315e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e1530a8f-351e-4ad5-8534-fd27613bbec8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bed2133c-79b6-47b9-a8c7-49b9a6b315e5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for\nstorage</span></b></p>", "ID": "5ef7bb03-aeff-4b15-859d-e5d6ebf6ea89", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for\nstorage</span></b>", "ID": "ce881662-ca1e-4574-8bb5-031c6eb4f3c8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5ef7bb03-aeff-4b15-859d-e5d6ebf6ea89"}, {"Element": "<span lang=\"EN-GB\">6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for\nstorage</span>", "ID": "6b6dc37d-4013-4cc5-b416-15a7a461e221", "Styles": "None", "Classes": "None", "Text": "6.4\u00a0\u00a0\u00a0\u00a0 Special precautions for storage", "ParentId": "ce881662-ca1e-4574-8bb5-031c6eb4f3c8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "96ee3a49-71f9-41b0-ba53-34eb3fa90a62", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2d9374a1-a229-4e11-986e-260c37c51e20", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "96ee3a49-71f9-41b0-ba53-34eb3fa90a62"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store in a refrigerator (2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C).</span></p>", "ID": "d708ff6d-d949-4e64-a276-17f74ebda53c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Store in a refrigerator (2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C).</span>", "ID": "c7cb069b-0215-402b-8e74-411935ac2de5", "Styles": "None", "Classes": "None", "Text": "Store in a refrigerator (2\u00b0C\u20118\u00b0C).", "ParentId": "d708ff6d-d949-4e64-a276-17f74ebda53c"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "8d4155e3-2925-4787-994d-69a1f7ebd019", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "c7cb069b-0215-402b-8e74-411935ac2de5"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "ec694efb-bb49-4763-bcfd-af985241831b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8d4155e3-2925-4787-994d-69a1f7ebd019"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "caf03b60-f5a8-447a-b66d-b7c6fc5353d0", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "c7cb069b-0215-402b-8e74-411935ac2de5"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "d6b95605-eed6-40c7-b1ef-2462719c4c8f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "caf03b60-f5a8-447a-b66d-b7c6fc5353d0"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "780fc9cd-6008-4552-b96b-cdff6f39f1af", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "c7cb069b-0215-402b-8e74-411935ac2de5"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "e9c14ee9-02ca-4e71-9664-25b2c37c9e2c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "780fc9cd-6008-4552-b96b-cdff6f39f1af"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "51315206-e43c-470a-80b6-df6dc072ab26", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "c7cb069b-0215-402b-8e74-411935ac2de5"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "6fe4a92b-030c-48ff-b862-2912ccc78b23", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "51315206-e43c-470a-80b6-df6dc072ab26"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "17c12800-914b-4cbd-8069-9126908487a0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "49c9b809-980a-4664-bd7d-bca08242f7cb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "17c12800-914b-4cbd-8069-9126908487a0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For storage conditions up to 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C before reconstitution of\nthe medicinal product, see section\u00a06.3.</span></p>", "ID": "4622a490-f4f0-4504-87dd-e36c1c75cbb7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">For storage conditions up to 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>\u00b0C before reconstitution of\nthe medicinal product, see section\u00a06.3.</span>", "ID": "68aeabcd-b9a9-46ba-b463-5c6c83619c44", "Styles": "None", "Classes": "None", "Text": "For storage conditions up to 25\u00b0C before reconstitution of the medicinal product, see section\u00a06.3.", "ParentId": "4622a490-f4f0-4504-87dd-e36c1c75cbb7"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del></span>", "ID": "7b444abb-4e4f-47f8-9b94-f8194955bc65", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "68aeabcd-b9a9-46ba-b463-5c6c83619c44"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:11\">\u00a0</del>", "ID": "169fe5ef-ecf4-4fc3-9ccb-f692e681438b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7b444abb-4e4f-47f8-9b94-f8194955bc65"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8ba7bb51-6ef1-43d2-90c1-5683f0233d01", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3a91a801-caa5-495b-a4bf-e328c4e21fb3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ba7bb51-6ef1-43d2-90c1-5683f0233d01"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For storage conditions after reconstitution\nof the medicinal product, see section\u00a06.3.</span></p>", "ID": "6866176d-7306-4ce2-af7e-c2de22bbadac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">For storage conditions after reconstitution\nof the medicinal product, see section\u00a06.3.</span>", "ID": "1c8077d9-318c-4b85-9278-f2f2e62d231c", "Styles": "None", "Classes": "None", "Text": "For storage conditions after reconstitution of the medicinal product, see section\u00a06.3.", "ParentId": "6866176d-7306-4ce2-af7e-c2de22bbadac"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b4732564-658c-453a-b87a-8ea282cced8b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5e3a3291-3f53-400c-aa05-93bdfadc5762", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b4732564-658c-453a-b87a-8ea282cced8b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of\ncontainer</span></b></p>", "ID": "4804ed79-4229-4a5f-b27d-776b86f0e4d1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of\ncontainer</span></b>", "ID": "cea459ab-b549-4003-a4f7-2e303a00f03f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4804ed79-4229-4a5f-b27d-776b86f0e4d1"}, {"Element": "<span lang=\"EN-GB\">6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of\ncontainer</span>", "ID": "33eab221-18d1-4492-8a38-cefb91938bc1", "Styles": "None", "Classes": "None", "Text": "6.5\u00a0\u00a0\u00a0\u00a0 Nature and contents of container", "ParentId": "cea459ab-b549-4003-a4f7-2e303a00f03f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "df998436-e924-4f44-a876-149afcec840f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dacef0ba-7e9e-41df-ad89-849fd46415bf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "df998436-e924-4f44-a876-149afcec840f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Type\u00a01 glass vial with rubber stopper\nand aluminium crimp protected by a plastic cap.</span></p>", "ID": "85727aa4-33f2-41d2-9a40-b4a49335409e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Type\u00a01 glass vial with rubber stopper\nand aluminium crimp protected by a plastic cap.</span>", "ID": "e211dc36-bac1-4b3c-a6d5-7dca8ad9dc9f", "Styles": "None", "Classes": "None", "Text": "Type\u00a01 glass vial with rubber stopper and aluminium crimp protected by a plastic cap.", "ParentId": "85727aa4-33f2-41d2-9a40-b4a49335409e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b6b1b00a-691e-476f-9ec9-a92bf6bd1436", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2d6ba9d0-6a85-44eb-8bd9-28475021c25d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b6b1b00a-691e-476f-9ec9-a92bf6bd1436"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is available in packs of 1, 2, 3,\n4 or 5\u00a0vials.</span></p>", "ID": "4b9a5647-8870-46af-9c67-e922b8cd1583", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade is available in packs of 1, 2, 3,\n4 or 5\u00a0vials.</span>", "ID": "dd0a94a7-c4bd-4999-a314-e8b0f5739677", "Styles": "None", "Classes": "None", "Text": "Remicade is available in packs of 1, 2, 3, 4 or 5\u00a0vials.", "ParentId": "4b9a5647-8870-46af-9c67-e922b8cd1583"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "36d39436-0f05-41e3-9bdd-5e364ee232fb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6fbc7ce8-e08e-4c43-8f0d-9ec9fe86c470", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "36d39436-0f05-41e3-9bdd-5e364ee232fb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.</span></p>", "ID": "f6ed5319-7f95-47b7-8d79-75c85530b82a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Not all pack sizes may be marketed.</span>", "ID": "e5410192-6b8e-40db-9f1b-cb66058a5f98", "Styles": "None", "Classes": "None", "Text": "Not all pack sizes may be marketed.", "ParentId": "f6ed5319-7f95-47b7-8d79-75c85530b82a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "03e68ebc-67cd-4ad5-a270-ba799fed57ec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e96bb496-1a01-49be-92b3-bd3c7af52c2a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03e68ebc-67cd-4ad5-a270-ba799fed57ec"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for\ndisposal and other handling</span></b></p>", "ID": "381b6d33-a155-44bf-a749-d647723ff8c4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for\ndisposal and other handling</span></b>", "ID": "7b6ca633-45e5-45ba-a816-958de48d58d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "381b6d33-a155-44bf-a749-d647723ff8c4"}, {"Element": "<span lang=\"EN-GB\">6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for\ndisposal and other handling</span>", "ID": "67dad843-a3a6-4744-9bac-3f90c8f9a8df", "Styles": "None", "Classes": "None", "Text": "6.6\u00a0\u00a0\u00a0\u00a0 Special precautions for disposal and other handling", "ParentId": "7b6ca633-45e5-45ba-a816-958de48d58d8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ce382d14-defb-4c09-b5bc-327de602a87f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "172556d2-c028-4907-9dee-104312275564", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ce382d14-defb-4c09-b5bc-327de602a87f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Calculate the dose and the\nnumber of Remicade vials needed. Each Remicade vial contains 100\u00a0mg\ninfliximab. Calculate the total volume of reconstituted Remicade solution\nrequired.</span></p>", "ID": "b5eae4d5-3038-458f-bcf8-2e997228bb2b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Calculate the dose and the\nnumber of Remicade vials needed. Each Remicade vial contains 100\u00a0mg\ninfliximab. Calculate the total volume of reconstituted Remicade solution\nrequired.</span>", "ID": "f7f15302-4865-4983-9d3f-5782e8460fde", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Calculate the dose and the number of Remicade vials needed. Each Remicade vial contains 100\u00a0mg infliximab. Calculate the total volume of reconstituted Remicade solution required.", "ParentId": "b5eae4d5-3038-458f-bcf8-2e997228bb2b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2193849c-171b-4e79-ba1e-7db39b07e12e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "44fb69f8-edbe-4211-a076-42734f2b683b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2193849c-171b-4e79-ba1e-7db39b07e12e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Under aseptic conditions,\nreconstitute each Remicade vial with 10\u00a0ml of water for injections, using\na syringe equipped with a 21\u2011gauge (0.8\u00a0mm) or smaller needle.\nRemove flip\u2011top from the vial and wipe the top with a 70% alcohol swab.\nInsert the syringe needle into the vial through the centre of the rubber\nstopper and direct the stream of water for injections to the glass wall of the\nvial. Gently swirl the solution by rotating the vial to dissolve the\nlyophilised powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE.\nFoaming of the solution on reconstitution is not unusual. Allow the\nreconstituted solution to stand for 5\u00a0minutes. Check that the solution is\ncolourless to light yellow and opalescent. The solution may develop a few fine\ntranslucent particles, as infliximab is a protein. Do not use if opaque\nparticles, discolouration, or other foreign particles are present.</span></p>", "ID": "bca950a4-be0b-4a5c-8b9f-fccd2fcf88e7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Under aseptic conditions,\nreconstitute each Remicade vial with 10\u00a0ml of water for injections, using\na syringe equipped with a 21\u2011gauge (0.8\u00a0mm) or smaller needle.\nRemove flip\u2011top from the vial and wipe the top with a 70% alcohol swab.\nInsert the syringe needle into the vial through the centre of the rubber\nstopper and direct the stream of water for injections to the glass wall of the\nvial. Gently swirl the solution by rotating the vial to dissolve the\nlyophilised powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE.\nFoaming of the solution on reconstitution is not unusual. Allow the\nreconstituted solution to stand for 5\u00a0minutes. Check that the solution is\ncolourless to light yellow and opalescent. The solution may develop a few fine\ntranslucent particles, as infliximab is a protein. Do not use if opaque\nparticles, discolouration, or other foreign particles are present.</span>", "ID": "3fab1b21-06e3-442d-9404-c4f70d04d1d6", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Under aseptic conditions, reconstitute each Remicade vial with 10\u00a0ml of water for injections, using a syringe equipped with a 21\u2011gauge (0.8\u00a0mm) or smaller needle. Remove flip\u2011top from the vial and wipe the top with a 70% alcohol swab. Insert the syringe needle into the vial through the centre of the rubber stopper and direct the stream of water for injections to the glass wall of the vial. Gently swirl the solution by rotating the vial to dissolve the lyophilised powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE. Foaming of the solution on reconstitution is not unusual. Allow the reconstituted solution to stand for 5\u00a0minutes. Check that the solution is colourless to light yellow and opalescent. The solution may develop a few fine translucent particles, as infliximab is a protein. Do not use if opaque particles, discolouration, or other foreign particles are present.", "ParentId": "bca950a4-be0b-4a5c-8b9f-fccd2fcf88e7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "38c64e1b-fe58-4c08-9d87-2d1b4243abc5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b956b423-afb8-4362-aa52-1e72700be507", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "38c64e1b-fe58-4c08-9d87-2d1b4243abc5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dilute the total volume of\nthe reconstituted Remicade solution dose to 250\u00a0ml with sodium chloride\n9\u00a0mg/ml (0.9%) solution for infusion. Do not dilute the reconstituted\nRemicade solution with any other diluent. The dilution can be accomplished by\nwithdrawing a volume of the sodium chloride 9\u00a0mg/ml (0.9%) solution for\ninfusion from the 250\u2011ml glass bottle or infusion bag equal to the volume\nof reconstituted Remicade. Slowly add the total volume of reconstituted\nRemicade solution to the 250\u2011ml infusion bottle or bag. Gently mix. For\nvolumes greater than 250\u00a0ml, either use a larger infusion bag (e.g. 500\u00a0ml,\n1000\u00a0ml) or use multiple 250\u00a0ml infusion bags to ensure that the\nconcentration of the infusion solution does not exceed 4\u00a0mg/ml. If stored\nrefrigerated after reconstitution and dilution, the infusion solution must be\nallowed to equilibrate at room temperature to 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>\u00b0C for 3\u00a0hours prior to\nStep\u00a04 (infusion). Storage beyond 24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>\u00b0C applies to preparation of\nRemicade in the infusion bag only.</span></p>", "ID": "0bb1d9ec-994e-465d-9d1b-147c064bbe1c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dilute the total volume of\nthe reconstituted Remicade solution dose to 250\u00a0ml with sodium chloride\n9\u00a0mg/ml (0.9%) solution for infusion. Do not dilute the reconstituted\nRemicade solution with any other diluent. The dilution can be accomplished by\nwithdrawing a volume of the sodium chloride 9\u00a0mg/ml (0.9%) solution for\ninfusion from the 250\u2011ml glass bottle or infusion bag equal to the volume\nof reconstituted Remicade. Slowly add the total volume of reconstituted\nRemicade solution to the 250\u2011ml infusion bottle or bag. Gently mix. For\nvolumes greater than 250\u00a0ml, either use a larger infusion bag (e.g. 500\u00a0ml,\n1000\u00a0ml) or use multiple 250\u00a0ml infusion bags to ensure that the\nconcentration of the infusion solution does not exceed 4\u00a0mg/ml. If stored\nrefrigerated after reconstitution and dilution, the infusion solution must be\nallowed to equilibrate at room temperature to 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>\u00b0C for 3\u00a0hours prior to\nStep\u00a04 (infusion). Storage beyond 24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>\u00b0C applies to preparation of\nRemicade in the infusion bag only.</span>", "ID": "b9a3ab75-d095-4621-8e81-30c40e754a50", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dilute the total volume of the reconstituted Remicade solution dose to 250\u00a0ml with sodium chloride 9\u00a0mg/ml (0.9%) solution for infusion. Do not dilute the reconstituted Remicade solution with any other diluent. The dilution can be accomplished by withdrawing a volume of the sodium chloride 9\u00a0mg/ml (0.9%) solution for infusion from the 250\u2011ml glass bottle or infusion bag equal to the volume of reconstituted Remicade. Slowly add the total volume of reconstituted Remicade solution to the 250\u2011ml infusion bottle or bag. Gently mix. For volumes greater than 250\u00a0ml, either use a larger infusion bag (e.g. 500\u00a0ml, 1000\u00a0ml) or use multiple 250\u00a0ml infusion bags to ensure that the concentration of the infusion solution does not exceed 4\u00a0mg/ml. If stored refrigerated after reconstitution and dilution, the infusion solution must be allowed to equilibrate at room temperature to 25\u00b0C for 3\u00a0hours prior to Step\u00a04 (infusion). Storage beyond 24\u00a0hours at 2\u00b0C\u20118\u00b0C applies to preparation of Remicade in the infusion bag only.", "ParentId": "0bb1d9ec-994e-465d-9d1b-147c064bbe1c"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>", "ID": "c1f11cbb-fc75-43ce-8b23-125e709bc42b", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "b9a3ab75-d095-4621-8e81-30c40e754a50"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del>", "ID": "7a597788-a7e1-41a3-94c6-6ceb2ea83450", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c1f11cbb-fc75-43ce-8b23-125e709bc42b"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>", "ID": "8ca6921b-a36c-4236-b2b8-b790ba0160e0", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "b9a3ab75-d095-4621-8e81-30c40e754a50"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del>", "ID": "ba4755bd-1093-488b-ab6e-bb2666a00b2c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ca6921b-a36c-4236-b2b8-b790ba0160e0"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>", "ID": "68e7e9ba-d13c-4496-88d3-749e25a87cc2", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "b9a3ab75-d095-4621-8e81-30c40e754a50"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del>", "ID": "17879be6-25e8-47d4-9fdb-c317cc5f7f15", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "68e7e9ba-d13c-4496-88d3-749e25a87cc2"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>", "ID": "3cd53997-15eb-456d-b1da-b345ffbf67d3", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "b9a3ab75-d095-4621-8e81-30c40e754a50"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del>", "ID": "ef827d79-cfbc-4367-ba7e-c48da99e46c6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3cd53997-15eb-456d-b1da-b345ffbf67d3"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del></span>", "ID": "241e1857-e840-4b04-a861-6ca87a4557a9", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "b9a3ab75-d095-4621-8e81-30c40e754a50"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:12\">\u00a0</del>", "ID": "439813b7-5eb3-4ebc-af6c-9578b99639d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "241e1857-e840-4b04-a861-6ca87a4557a9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "88013fa7-c551-460a-a332-d044c2e65e8a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "da25e562-4ffc-472b-be39-6e8708d79768", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "88013fa7-c551-460a-a332-d044c2e65e8a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Administer the infusion\nsolution over a period of not less than the infusion time recommended (see\nsection\u00a04.2). Use only an infusion set with an in\u2011line, sterile, non\u2011pyrogenic,\nlow protein\u2011binding filter (pore size 1.2\u00a0micrometre or less). Since\nno preservative is present, it is recommended that the administration of the\nsolution for infusion is to be started as soon as possible and within\n3\u00a0hours of reconstitution and dilution. If not used immediately, in use\nstorage times and conditions prior to use are the responsibility of the user and\nwould normally not be longer than 24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:13\">\u00a0</del></span>\u00b0C to 8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:13\">\u00a0</del></span>\u00b0C, unless reconstitution/dilution\nhas been taken place in controlled and validated aseptic conditions, (see\nsection\u00a06.3 above). Do not store any unused portion of the infusion\nsolution for reuse.</span></p>", "ID": "d5de7bbf-3adf-4a4e-8cba-bda1ddd1d7e1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Administer the infusion\nsolution over a period of not less than the infusion time recommended (see\nsection\u00a04.2). Use only an infusion set with an in\u2011line, sterile, non\u2011pyrogenic,\nlow protein\u2011binding filter (pore size 1.2\u00a0micrometre or less). Since\nno preservative is present, it is recommended that the administration of the\nsolution for infusion is to be started as soon as possible and within\n3\u00a0hours of reconstitution and dilution. If not used immediately, in use\nstorage times and conditions prior to use are the responsibility of the user and\nwould normally not be longer than 24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:13\">\u00a0</del></span>\u00b0C to 8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:13\">\u00a0</del></span>\u00b0C, unless reconstitution/dilution\nhas been taken place in controlled and validated aseptic conditions, (see\nsection\u00a06.3 above). Do not store any unused portion of the infusion\nsolution for reuse.</span>", "ID": "70c5bfa1-483e-48e5-8ab0-0a1b7f3db49f", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Administer the infusion solution over a period of not less than the infusion time recommended (see section\u00a04.2). Use only an infusion set with an in\u2011line, sterile, non\u2011pyrogenic, low protein\u2011binding filter (pore size 1.2\u00a0micrometre or less). Since no preservative is present, it is recommended that the administration of the solution for infusion is to be started as soon as possible and within 3\u00a0hours of reconstitution and dilution. If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24\u00a0hours at 2\u00b0C to 8\u00b0C, unless reconstitution/dilution has been taken place in controlled and validated aseptic conditions, (see section\u00a06.3 above). Do not store any unused portion of the infusion solution for reuse.", "ParentId": "d5de7bbf-3adf-4a4e-8cba-bda1ddd1d7e1"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:13\">\u00a0</del></span>", "ID": "13516a3a-7368-47be-9f89-66f96963926d", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "70c5bfa1-483e-48e5-8ab0-0a1b7f3db49f"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:13\">\u00a0</del>", "ID": "06d46687-d321-464e-a806-c7ad0e23d74a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "13516a3a-7368-47be-9f89-66f96963926d"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:13\">\u00a0</del></span>", "ID": "1b9ede9e-70d0-4bdc-a510-2ca7029b6498", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "70c5bfa1-483e-48e5-8ab0-0a1b7f3db49f"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:13\">\u00a0</del>", "ID": "590762d0-dcdd-411e-85c0-ecf45a8229ae", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1b9ede9e-70d0-4bdc-a510-2ca7029b6498"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0a111460-44a9-4d67-ac99-34d7ddd1e2b3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fa1bb0c7-4d02-4f36-8116-35ce41d558fe", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a111460-44a9-4d67-ac99-34d7ddd1e2b3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 No physical biochemical\ncompatibility studies have been conducted to evaluate the co\u2011administration\nof Remicade with other agents. Do not infuse Remicade concomitantly in the same\nintravenous line with other agents.</span></p>", "ID": "48323593-9c04-496c-8a5d-79aedaf914d5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 No physical biochemical\ncompatibility studies have been conducted to evaluate the co\u2011administration\nof Remicade with other agents. Do not infuse Remicade concomitantly in the same\nintravenous line with other agents.</span>", "ID": "fe04d39b-0ec0-4d2f-9dbe-8d3f1ba7d1d1", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 No physical biochemical compatibility studies have been conducted to evaluate the co\u2011administration of Remicade with other agents. Do not infuse Remicade concomitantly in the same intravenous line with other agents.", "ParentId": "48323593-9c04-496c-8a5d-79aedaf914d5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "68af8a70-dbd5-44e1-ad22-2eec77e820ac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "15a46d7c-093e-4c82-ae80-5253a57263b5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "68af8a70-dbd5-44e1-ad22-2eec77e820ac"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Visually inspect Remicade for\nparticulate matter or discolouration prior to administration. Do not use if\nvisibly opaque particles, discolouration or foreign particles are observed.</span></p>", "ID": "202a5534-0d30-4b5b-8dee-e50de55c540e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Visually inspect Remicade for\nparticulate matter or discolouration prior to administration. Do not use if\nvisibly opaque particles, discolouration or foreign particles are observed.</span>", "ID": "6f3ab4a2-306e-41e0-8b7b-28cb9961c90f", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Visually inspect Remicade for particulate matter or discolouration prior to administration. Do not use if visibly opaque particles, discolouration or foreign particles are observed.", "ParentId": "202a5534-0d30-4b5b-8dee-e50de55c540e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8031a8a0-231a-4b3f-aae6-06a423f002c6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f5a70310-acee-4b0f-8ec0-c494ede1425c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8031a8a0-231a-4b3f-aae6-06a423f002c6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Any unused medicinal product\nor waste material should be disposed of in accordance with local requirements.</span></p>", "ID": "c4845169-43a8-4a2f-9fb0-31b70ec74faf", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Any unused medicinal product\nor waste material should be disposed of in accordance with local requirements.</span>", "ID": "27d210b8-8de9-434f-b241-852fe2032203", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Any unused medicinal product or waste material should be disposed of in accordance with local requirements.", "ParentId": "c4845169-43a8-4a2f-9fb0-31b70ec74faf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9f799ad0-3eb2-468a-8646-3697b8ae9fcd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a84f73e1-0d38-48c2-8030-a778ca8a33df", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9f799ad0-3eb2-468a-8646-3697b8ae9fcd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "595100aa-2ab0-4985-b122-032eee87072b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "acd836a1-dc88-40a3-a228-ab97697f949c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "595100aa-2ab0-4985-b122-032eee87072b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span></b></p>", "ID": "af1f98dd-7294-4a86-87bc-e2a10def85f1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span></b>", "ID": "1195c093-37d3-45f2-99f6-72ad4a017416", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "af1f98dd-7294-4a86-87bc-e2a10def85f1"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION HOLDER</span>", "ID": "95cf0e86-cabc-41c3-a7f9-158d2721d4cd", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION HOLDER", "ParentId": "1195c093-37d3-45f2-99f6-72ad4a017416"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "628dd6e3-445d-4a93-950e-af22a6175536", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "00c50e09-717f-440d-9f81-bdf1fddd47c2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "628dd6e3-445d-4a93-950e-af22a6175536"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Janssen Biologics B.V.</span></p>", "ID": "9974efd2-6b5c-4f71-956e-ef9c969f4862", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Janssen Biologics B.V.</span>", "ID": "15a56dd0-366f-4b4c-ac60-1aa2d1843b41", "Styles": "None", "Classes": "None", "Text": "Janssen Biologics B.V.", "ParentId": "9974efd2-6b5c-4f71-956e-ef9c969f4862"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">Einsteinweg 101</span></p>", "ID": "de9feb5b-7cab-4c2f-a7f5-300839845a9e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"DE\">Einsteinweg 101</span>", "ID": "beb969d3-29d9-40b9-91dd-bdd9ccc35229", "Styles": "None", "Classes": "None", "Text": "Einsteinweg 101", "ParentId": "de9feb5b-7cab-4c2f-a7f5-300839845a9e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">2333 CB Leiden</span></p>", "ID": "2c503362-2b47-4fc8-9141-0583cf77702c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"DE\">2333 CB Leiden</span>", "ID": "89611a8a-5dcd-4740-84a6-e0216d16ae4e", "Styles": "None", "Classes": "None", "Text": "2333 CB Leiden", "ParentId": "2c503362-2b47-4fc8-9141-0583cf77702c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">The Netherlands</span></p>", "ID": "f1baa317-6d0c-40ce-93e6-461accedb167", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"DE\">The Netherlands</span>", "ID": "820c484d-13c4-4244-b7c1-90d797436ece", "Styles": "None", "Classes": "None", "Text": "The Netherlands", "ParentId": "f1baa317-6d0c-40ce-93e6-461accedb167"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>", "ID": "01ba593f-95ce-4126-8ead-0b9790c47c6e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"DE\">\u00a0</span>", "ID": "18e87eb9-cd05-4825-9baa-21854c3b84ed", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "01ba593f-95ce-4126-8ead-0b9790c47c6e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>", "ID": "94a86065-9253-4f17-967f-29149bf909d4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"DE\">\u00a0</span>", "ID": "60886b0f-5d43-4e31-ab19-77a0fedc0381", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "94a86065-9253-4f17-967f-29149bf909d4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"DE\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b></p>", "ID": "0d4ce703-f9d1-4eea-9016-b6e06e31d390", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"DE\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span></b>", "ID": "75ce22b3-b822-4351-b7fc-a16f508f4226", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0d4ce703-f9d1-4eea-9016-b6e06e31d390"}, {"Element": "<span lang=\"DE\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING\nAUTHORISATION NUMBER(S)</span>", "ID": "ab0372a7-0c77-4121-aca4-915749b0fc87", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)", "ParentId": "75ce22b3-b822-4351-b7fc-a16f508f4226"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"DE\">\u00a0</span></p>", "ID": "5835731f-9dad-456d-beaf-7b589f756a15", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"DE\">\u00a0</span>", "ID": "e4aa6d23-f86e-4a8e-84a9-95c4c289a1d8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5835731f-9dad-456d-beaf-7b589f756a15"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">EU/1/99/116/001</span></p>", "ID": "3bd0df13-45fd-4a3b-aba5-a3d4d033e4fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"DE\">EU/1/99/116/001</span>", "ID": "388288fa-1d3b-4779-97e3-052095cf9f56", "Styles": "None", "Classes": "None", "Text": "EU/1/99/116/001", "ParentId": "3bd0df13-45fd-4a3b-aba5-a3d4d033e4fe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">EU/1/99/116/002</span></p>", "ID": "b23f9de9-f4ff-46ef-8a90-fcec1768b3e2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"DE\">EU/1/99/116/002</span>", "ID": "03d8ac63-4409-4e18-83c7-35b8862914dc", "Styles": "None", "Classes": "None", "Text": "EU/1/99/116/002", "ParentId": "b23f9de9-f4ff-46ef-8a90-fcec1768b3e2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/99/116/003</span></p>", "ID": "497873a2-3f06-4152-9f54-e110dfc24388", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">EU/1/99/116/003</span>", "ID": "50b49fd3-7c1f-4ec4-a8d5-c95b9576d9ca", "Styles": "None", "Classes": "None", "Text": "EU/1/99/116/003", "ParentId": "497873a2-3f06-4152-9f54-e110dfc24388"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/99/116/004</span></p>", "ID": "ddcc66c9-7d2e-499c-8f81-1f488386aa92", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">EU/1/99/116/004</span>", "ID": "0d9e183b-f653-4eb7-b646-dde162af784b", "Styles": "None", "Classes": "None", "Text": "EU/1/99/116/004", "ParentId": "ddcc66c9-7d2e-499c-8f81-1f488386aa92"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EU/1/99/116/005</span></p>", "ID": "0ebbbb26-4a99-4228-84bd-e5ec5e808316", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">EU/1/99/116/005</span>", "ID": "58cd3da1-9cec-472a-acb2-bbb9ae319585", "Styles": "None", "Classes": "None", "Text": "EU/1/99/116/005", "ParentId": "0ebbbb26-4a99-4228-84bd-e5ec5e808316"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f9910c9e-af69-46fa-817b-d05722a3599d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8ef2b3cf-0db3-4ea5-a402-d5704b476407", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f9910c9e-af69-46fa-817b-d05722a3599d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c58e1324-011c-4819-8f93-fdab031a3b8a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b39ad06-b22a-4e4a-a433-230c9eeb3518", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c58e1324-011c-4819-8f93-fdab031a3b8a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>", "ID": "49f8c294-3da2-4a9b-ab21-28e4ae66dd26", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b>", "ID": "17d718ac-1dea-455f-997f-17b6abc61f69", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "49f8c294-3da2-4a9b-ab21-28e4ae66dd26"}, {"Element": "<span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST\nAUTHORISATION/RENEWAL OF THE AUTHORISATION</span>", "ID": "c721bfd7-b417-42c0-9ebf-47520dc0b674", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION", "ParentId": "17d718ac-1dea-455f-997f-17b6abc61f69"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b6d2e7b7-99fd-41c8-993d-a9b311b9bcf5", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "29ddb8f9-42cc-49ef-bed8-a5ee8e1775fa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b6d2e7b7-99fd-41c8-993d-a9b311b9bcf5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of first authorisation: 13 August\n1999.</span></p>", "ID": "3e400c04-70d8-4573-9964-3e859f89e4a8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Date of first authorisation: 13 August\n1999.</span>", "ID": "d4e74a59-228a-4334-9de1-3de9438f35c3", "Styles": "None", "Classes": "None", "Text": "Date of first authorisation: 13 August 1999.", "ParentId": "3e400c04-70d8-4573-9964-3e859f89e4a8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Date of latest renewal: 2 July 2009.</span></p>", "ID": "9672f0ce-f606-4787-9aaa-4ea2dc0a939f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Date of latest renewal: 2 July 2009.</span>", "ID": "b3ded6ba-f66d-4598-953d-a1ac79086346", "Styles": "None", "Classes": "None", "Text": "Date of latest renewal: 2 July 2009.", "ParentId": "9672f0ce-f606-4787-9aaa-4ea2dc0a939f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6b01c564-112b-48d6-b7e1-6f3f0a3236f7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8b8c227a-9a7d-47e2-bc03-c80f7ea8f0d9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6b01c564-112b-48d6-b7e1-6f3f0a3236f7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e6d86a06-d796-4837-981d-4b6247e347a4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3e3a4f2f-df9f-464d-8f2f-ddfdfaa3c532", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e6d86a06-d796-4837-981d-4b6247e347a4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE\nTEXT</span></b></p>", "ID": "4dd5b5b2-5565-4161-8508-d06652aa757b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE\nTEXT</span></b>", "ID": "86a5180a-5dd4-4aaa-b90e-6c1326030c69", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4dd5b5b2-5565-4161-8508-d06652aa757b"}, {"Element": "<span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE\nTEXT</span>", "ID": "fd46f2c5-481d-4cda-8aa0-a3f031f0bac6", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 DATE OF REVISION OF THE TEXT", "ParentId": "86a5180a-5dd4-4aaa-b90e-6c1326030c69"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "af80afbf-d396-4a93-bb01-f79392a76881", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "35253e57-5ee9-4971-8476-66f07fcd870e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "af80afbf-d396-4a93-bb01-f79392a76881"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "62344b81-fda3-48ea-8f1d-a5bf160c6801", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fae1f4bf-6b87-4a12-898f-4aeeeb392f61", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "62344b81-fda3-48ea-8f1d-a5bf160c6801"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d72dadb6-953c-4a8b-9705-d48a3e4238fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cfef99bb-580d-421a-9faa-f64c375e8b46", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d72dadb6-953c-4a8b-9705-d48a3e4238fd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "676b1504-d709-4bae-9058-874a825c2f80", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "519cac24-3af2-43b0-9c08-512b7d9e6692", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "676b1504-d709-4bae-9058-874a825c2f80"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Detailed\ninformation on this product is available on the website of the European\nMedicines Agency <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a></span></p>", "ID": "478e4cdd-926c-4366-b141-9d4d4afd67ff", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Detailed\ninformation on this product is available on the website of the European\nMedicines Agency <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a></span>", "ID": "42af72eb-e0b6-40b7-b451-a602d89b98d7", "Styles": "None", "Classes": "None", "Text": "Detailed information on this product is available on the website of the European Medicines Agency ", "ParentId": "478e4cdd-926c-4366-b141-9d4d4afd67ff"}, {"Element": "<a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a>", "ID": "6b0af285-d0b0-46ae-bea0-f7be15f7a38a", "Styles": "None", "Classes": "None", "Text": "http://www.ema.europa.eu", "ParentId": "42af72eb-e0b6-40b7-b451-a602d89b98d7"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "3b6ac8c9-afca-47a2-9edc-ab254535dd94", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "39df7ad3-4375-4d5f-9870-5de09e5c2714", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "3b6ac8c9-afca-47a2-9edc-ab254535dd94"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2d541c39-5a72-4454-840c-3c9ae7e44f3b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3c36315b-738c-4f59-bad0-66bd3b43c9f7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2d541c39-5a72-4454-840c-3c9ae7e44f3b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9dbbb48c-1158-47fc-b46f-da60297469d0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5fa11a31-f000-44c5-ada0-7d2e5dc6a6e0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9dbbb48c-1158-47fc-b46f-da60297469d0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3f4f9506-f885-43cc-9506-8cd6f92a75e8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1993a7af-68bf-4194-8a16-ab0af5555c90", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3f4f9506-f885-43cc-9506-8cd6f92a75e8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fa19ac09-c4d6-40b2-a6f8-c8dc3d3383a1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "66435f5f-352c-4ede-b210-bf4033e0f0f9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fa19ac09-c4d6-40b2-a6f8-c8dc3d3383a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "23ac8400-31b9-4a4b-ae06-07a51700bd2d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fdeef680-32f8-42bb-a895-085dcc69e2cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "23ac8400-31b9-4a4b-ae06-07a51700bd2d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "11a52ae8-8ee3-4121-957a-b5a41d8aba6a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a352ab58-0d2c-484d-8247-e7bb8bbc24a2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "11a52ae8-8ee3-4121-957a-b5a41d8aba6a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c43c2846-21c8-4ac8-90a2-bab428c5dacf", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3de4b167-87b9-4e30-87f9-6bbabb96a493", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c43c2846-21c8-4ac8-90a2-bab428c5dacf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f4121d76-8970-402e-9a68-44456adc4916", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a1e2c167-8e5b-41c5-8cf4-7c5a239d82d6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4121d76-8970-402e-9a68-44456adc4916"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c5626e02-e1c7-4a79-88d5-d978997b8120", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7fa65145-321b-4747-a35e-628b606eb44f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c5626e02-e1c7-4a79-88d5-d978997b8120"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "776c257f-4415-4d10-9469-72e779fc4f83", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b4ea134c-7bf3-46c9-8f1a-b19ff53edfca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "776c257f-4415-4d10-9469-72e779fc4f83"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "34c00fdb-7fff-41a7-96e0-959a756572a1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e06964eb-b3cf-4074-95c0-cef63b12e512", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "34c00fdb-7fff-41a7-96e0-959a756572a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e612de8f-91ed-45b3-be53-25731dda398f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2d985e77-0a29-4ced-8253-bb9a52bcc456", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e612de8f-91ed-45b3-be53-25731dda398f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b61f1b29-781d-4780-a77a-68abeefed7a1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b58d6f3-016e-4679-a0af-1fbba8791730", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b61f1b29-781d-4780-a77a-68abeefed7a1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a955f534-e11f-438c-b30e-ff294271f99c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0490d510-8a87-4d93-bbe6-a39ac741edd1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a955f534-e11f-438c-b30e-ff294271f99c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f840f2ca-97bb-478d-8bf8-b0e5961bf6a4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "776a7ad6-2410-4528-ade7-7e136a9ee35e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f840f2ca-97bb-478d-8bf8-b0e5961bf6a4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a6a51cf5-25bd-44bf-b4e3-3cfb2c35af25", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8499caed-0f85-4930-a866-f3a21f0710be", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a6a51cf5-25bd-44bf-b4e3-3cfb2c35af25"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "56d47e55-d232-4535-8028-6c029aea4d43", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "73d3ae9d-8353-4101-8a13-33cd40d9ddcc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "56d47e55-d232-4535-8028-6c029aea4d43"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e1723202-d7df-4230-acb2-42cf7f73f834", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "068305a8-b6bc-424d-8e5d-31f1ac5e004b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e1723202-d7df-4230-acb2-42cf7f73f834"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1c2728e0-f2e3-4aab-8357-45d87822e324", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "18da5866-1475-4c12-84d1-ab5fae981f9d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1c2728e0-f2e3-4aab-8357-45d87822e324"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f4c44d8f-f8cc-400b-a056-62e279b67bf6", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "01e98c89-c4ad-42b2-b126-0efd07522e42", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f4c44d8f-f8cc-400b-a056-62e279b67bf6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1c550f4d-73d5-484c-b546-f6f766df5cf3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b7c886e9-6b9d-4879-b7ba-98b0e83a6f8a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1c550f4d-73d5-484c-b546-f6f766df5cf3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "65e9ed2f-3294-4938-907b-bd93d229949d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fe1ca9ab-e57c-445b-b48f-4ad512fe810f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "65e9ed2f-3294-4938-907b-bd93d229949d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "01babfc5-43fb-4bc0-b128-af982886340b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8d772c3a-b31b-4d04-8377-2532788435fa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "01babfc5-43fb-4bc0-b128-af982886340b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nII</span></b></p>", "ID": "cbee3f13-86ef-4e2a-bb99-c3027ba8e6bb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX\nII</span></b>", "ID": "5468c85f-43cf-4832-962b-92de7b2abda7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cbee3f13-86ef-4e2a-bb99-c3027ba8e6bb"}, {"Element": "<span lang=\"EN-GB\">ANNEX\nII</span>", "ID": "4acd75b2-5fe6-4e0c-8498-246358e872c8", "Styles": "None", "Classes": "None", "Text": "ANNEX II", "ParentId": "5468c85f-43cf-4832-962b-92de7b2abda7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e64b6b37-d217-4770-af51-dda0edb8243a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "989b16eb-8bca-4b35-b9f3-224340c9a309", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e64b6b37-d217-4770-af51-dda0edb8243a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:42.55pt;margin-bottom:\n0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) OF THE BIOLOGICAL\nACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</span></b></p>", "ID": "bda54279-2989-4e3f-96d7-7561f3cbbb32", "Styles": "margin-top:0in;margin-right:42.55pt;margin-bottom:\n0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) OF THE BIOLOGICAL\nACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</span></b>", "ID": "bf97950b-f041-419f-b43e-147a0974d290", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bda54279-2989-4e3f-96d7-7561f3cbbb32"}, {"Element": "<span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) OF THE BIOLOGICAL\nACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE</span>", "ID": "5c2061ff-f825-4d6c-a8a3-e94747f7ee2f", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE", "ParentId": "bf97950b-f041-419f-b43e-147a0974d290"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d498664e-c358-4678-b552-6ea09bb9f66a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ac6e833a-9168-49f0-8a47-912922720aa1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d498664e-c358-4678-b552-6ea09bb9f66a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:42.55pt;margin-bottom:\n0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS\nREGARDING SUPPLY AND USE</span></b></p>", "ID": "ff449e3b-24c0-40c6-80dd-8fa094f56a79", "Styles": "margin-top:0in;margin-right:42.55pt;margin-bottom:\n0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS\nREGARDING SUPPLY AND USE</span></b>", "ID": "6808d3f9-513c-490b-b4bd-6f9e8913a9bf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ff449e3b-24c0-40c6-80dd-8fa094f56a79"}, {"Element": "<span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS\nREGARDING SUPPLY AND USE</span>", "ID": "71ad25fe-9127-40db-a24f-f8b150f51127", "Styles": "None", "Classes": "None", "Text": "B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE", "ParentId": "6808d3f9-513c-490b-b4bd-6f9e8913a9bf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2cbf1b08-a415-40e4-9a13-9b054acdb7cb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6e93b3ce-bec1-4c4a-b0b2-68893ee38536", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2cbf1b08-a415-40e4-9a13-9b054acdb7cb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:42.55pt;margin-bottom:\n0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS\nOF THE MARKETING AUTHORISATION</span></b></p>", "ID": "422dfd3a-46bd-463d-ac1d-678accfeaa07", "Styles": "margin-top:0in;margin-right:42.55pt;margin-bottom:\n0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS\nOF THE MARKETING AUTHORISATION</span></b>", "ID": "aae7546d-9e23-46a6-91be-099e4de9308f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "422dfd3a-46bd-463d-ac1d-678accfeaa07"}, {"Element": "<span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS\nOF THE MARKETING AUTHORISATION</span>", "ID": "f72e55c1-a82d-42a6-9560-8572f34fd047", "Styles": "None", "Classes": "None", "Text": "C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION", "ParentId": "aae7546d-9e23-46a6-91be-099e4de9308f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5f3e620d-537e-4325-957e-1a774ad2ac62", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5988b9f7-6425-4f0f-a226-d686d34cfade", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5f3e620d-537e-4325-957e-1a774ad2ac62"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:42.55pt;margin-bottom:\n0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH\nREGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>", "ID": "04daddea-2ad1-47aa-bd7c-88c815048834", "Styles": "margin-top:0in;margin-right:42.55pt;margin-bottom:\n0in;margin-left:70.9pt;margin-bottom:.0001pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH\nREGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b>", "ID": "5b9c82b1-57ba-4a36-bf6f-dfef33e48fa6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "04daddea-2ad1-47aa-bd7c-88c815048834"}, {"Element": "<span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH\nREGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span>", "ID": "4e45dc7f-b4c3-4f25-8ee5-1109fe6c7733", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT", "ParentId": "5b9c82b1-57ba-4a36-bf6f-dfef33e48fa6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f706729b-9eb6-4e82-bdb1-0b1207365f1a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4bfc4f1a-a4c5-418b-8bdf-7c1e3c83c909", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f706729b-9eb6-4e82-bdb1-0b1207365f1a"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "36df9f4f-d80c-4ab5-be7e-36363767cbf7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "9cafe090-e8b8-45ef-bbb9-bef5a4adb535", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "36df9f4f-d80c-4ab5-be7e-36363767cbf7"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "0238d0a4-932c-45cb-98b7-d5204a9b8dfe", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "9cafe090-e8b8-45ef-bbb9-bef5a4adb535"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) OF\nTHE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH\nRELEASE</span></b></p>", "ID": "e18b9a7c-ea0e-42f8-a79b-c2a402db3690", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) OF\nTHE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH\nRELEASE</span></b>", "ID": "68f0f0d6-df2a-453e-af9f-a56ff421be0a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e18b9a7c-ea0e-42f8-a79b-c2a402db3690"}, {"Element": "<span lang=\"EN-GB\">A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) OF\nTHE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH\nRELEASE</span>", "ID": "c4572f4a-affd-44ea-a455-f98cd1dcda44", "Styles": "None", "Classes": "None", "Text": "A.\u00a0\u00a0\u00a0\u00a0\u00a0 MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE", "ParentId": "68f0f0d6-df2a-453e-af9f-a56ff421be0a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e7f66afa-e174-40d7-bbfb-137fc76faf16", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2e9cc35e-47fd-4ee9-b664-d5adf9790649", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e7f66afa-e174-40d7-bbfb-137fc76faf16"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Names and\naddresses of the manufacturer(s) of the biological active substance(s)</span></u></p>", "ID": "c9e83e9e-effd-4b80-9904-9a47471ed984", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Names and\naddresses of the manufacturer(s) of the biological active substance(s)</span></u>", "ID": "967e7108-a721-43b9-a7d9-680f21715327", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c9e83e9e-effd-4b80-9904-9a47471ed984"}, {"Element": "<span lang=\"EN-GB\">Names and\naddresses of the manufacturer(s) of the biological active substance(s)</span>", "ID": "b5a9dc92-c96f-4827-830f-02cd77293b2a", "Styles": "None", "Classes": "None", "Text": "Names and addresses of the manufacturer(s) of the biological active substance(s)", "ParentId": "967e7108-a721-43b9-a7d9-680f21715327"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b2c82dbe-9d43-4a77-b22c-4d425349788f", "Styles": "page-break-after:avoid;text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "191fc62a-4747-43a1-afef-d31eedc691de", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b2c82dbe-9d43-4a77-b22c-4d425349788f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Janssen\nBiologics B.V., Einsteinweg 101, 2333 CB Leiden, The Netherlands</span></p>", "ID": "c4afe200-e612-4665-a044-f2031d14a7ce", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Janssen\nBiologics B.V., Einsteinweg 101, 2333 CB Leiden, The Netherlands</span>", "ID": "d86da416-ddbd-460a-b116-3290b57778f0", "Styles": "None", "Classes": "None", "Text": "Janssen Biologics B.V., Einsteinweg 101, 2333 CB Leiden, The Netherlands", "ParentId": "c4afe200-e612-4665-a044-f2031d14a7ce"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5e31c3e0-d49b-49be-9e29-5776f7f051fb", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a5ae4698-9c45-4185-b373-9097177f9219", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5e31c3e0-d49b-49be-9e29-5776f7f051fb"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Janssen Biotech\nInc., 200 Great Valley Parkway Malvern, Pennsylvania 19355\u20111307, United\nStates of America</span></p>", "ID": "42f27412-6d48-4e3b-a557-8cbec9a35efa", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Janssen Biotech\nInc., 200 Great Valley Parkway Malvern, Pennsylvania 19355\u20111307, United\nStates of America</span>", "ID": "658308ed-b593-42fd-ba13-51516206ed26", "Styles": "None", "Classes": "None", "Text": "Janssen Biotech Inc., 200 Great Valley Parkway Malvern, Pennsylvania 19355\u20111307, United States of America", "ParentId": "42f27412-6d48-4e3b-a557-8cbec9a35efa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b3e8345a-704d-4d08-bfa8-b7cb31d6ee0f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f1cee87e-b985-4e8d-a25c-5e40d449d6ed", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b3e8345a-704d-4d08-bfa8-b7cb31d6ee0f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Name and\naddress of the manufacturer(s) responsible for batch release</span></u></p>", "ID": "dfdb996c-b83a-4511-a748-84def8370bd7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Name and\naddress of the manufacturer(s) responsible for batch release</span></u>", "ID": "a6a5edaf-0254-4536-bc8b-eb13602356d8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "dfdb996c-b83a-4511-a748-84def8370bd7"}, {"Element": "<span lang=\"EN-GB\">Name and\naddress of the manufacturer(s) responsible for batch release</span>", "ID": "9451e1b7-20ed-49ff-89c3-faa1aacb3f1c", "Styles": "None", "Classes": "None", "Text": "Name and address of the manufacturer(s) responsible for batch release", "ParentId": "a6a5edaf-0254-4536-bc8b-eb13602356d8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "76770d20-dbb9-4f5e-ad02-707c2ede1d95", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a8af5e4f-ffea-40d0-b1b2-479519c12ea4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "76770d20-dbb9-4f5e-ad02-707c2ede1d95"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Janssen Biologics B.V., Einsteinweg 101,\n2333 CB Leiden, The Netherlands</span></p>", "ID": "ae541013-c06b-4356-bff1-a4ecde2cf314", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Janssen Biologics B.V., Einsteinweg 101,\n2333 CB Leiden, The Netherlands</span>", "ID": "9f31d550-ab5d-4974-b168-b9f037007d09", "Styles": "None", "Classes": "None", "Text": "Janssen Biologics B.V., Einsteinweg 101, 2333 CB Leiden, The Netherlands", "ParentId": "ae541013-c06b-4356-bff1-a4ecde2cf314"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ba89e351-610d-474f-a5a2-44a70772f531", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "771fb2f4-d533-47e5-9694-8218404c0019", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ba89e351-610d-474f-a5a2-44a70772f531"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "23402f57-a7f2-43e2-ae4a-759c15b5f10a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "53a6b001-fa40-451e-8f26-790aa811f501", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "23402f57-a7f2-43e2-ae4a-759c15b5f10a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>", "ID": "ef47b4c3-6a81-40e0-8555-998aae63a81e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS REGARDING SUPPLY AND USE</span></b>", "ID": "d368a202-8c28-469c-9b66-46018433d0b1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ef47b4c3-6a81-40e0-8555-998aae63a81e"}, {"Element": "<span lang=\"EN-GB\">B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS REGARDING SUPPLY AND USE</span>", "ID": "d3c9127f-befe-409b-bcd6-ee3b0808c58c", "Styles": "None", "Classes": "None", "Text": "B.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE", "ParentId": "d368a202-8c28-469c-9b66-46018433d0b1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "672e13bc-a0a7-4f71-9554-f44f69612485", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "61a754ee-5e1c-49e7-ba37-ec559ee08138", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "672e13bc-a0a7-4f71-9554-f44f69612485"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (see Annex I: Summary of Product Characteristics, section\u00a04.2).</span></p>", "ID": "ae6a9699-c59e-4272-8e09-93e9784f8cc7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Medicinal product subject to restricted\nmedical prescription (see Annex I: Summary of Product Characteristics, section\u00a04.2).</span>", "ID": "07cdfaf9-6b75-4323-a933-d738bbc583e9", "Styles": "None", "Classes": "None", "Text": "Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section\u00a04.2).", "ParentId": "ae6a9699-c59e-4272-8e09-93e9784f8cc7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "65b8ea6c-b7a9-435c-8e72-8ddb340006ac", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c5fa0908-63ab-457d-9d27-93b4c6861a4d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "65b8ea6c-b7a9-435c-8e72-8ddb340006ac"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "707122e9-cf66-47a5-b0be-1cfebcb7a126", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c818583a-020b-45ae-9570-d48540aa3e51", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "707122e9-cf66-47a5-b0be-1cfebcb7a126"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS\nAND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>", "ID": "3f78978b-bf21-4c4d-9be8-245f6ef3f79c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS\nAND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b>", "ID": "f28a15d3-43d4-4734-8f58-8f171fd911fd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3f78978b-bf21-4c4d-9be8-245f6ef3f79c"}, {"Element": "<span lang=\"EN-GB\">C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS\nAND REQUIREMENTS OF THE MARKETING AUTHORISATION</span>", "ID": "27f6c1e1-ad36-46ff-9894-fcdc985962d8", "Styles": "None", "Classes": "None", "Text": "C.\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION", "ParentId": "f28a15d3-43d4-4734-8f58-8f171fd911fd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "de47b3c0-b04c-4adf-8371-9b107b950c90", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c5da2603-9aa2-42c3-b75f-9c5dc7ed0059", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "de47b3c0-b04c-4adf-8371-9b107b950c90"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Periodic <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">S</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">s</ins></span>afety <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">U</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">u</ins></span>pdate <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">R</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">r</ins></span>eports<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\"> (PSURs)</ins></span></span></b></p>", "ID": "6febf86d-f2b5-4040-bddd-a494967315e1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "03360a16-11b6-44cf-b244-d43864211ade", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6febf86d-f2b5-4040-bddd-a494967315e1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2e8e4a9a-844e-4312-a9d0-d05a05b380d9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "03360a16-11b6-44cf-b244-d43864211ade"}, {"Element": "<b><span lang=\"EN-GB\">Periodic <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">S</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">s</ins></span>afety <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">U</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">u</ins></span>pdate <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">R</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">r</ins></span>eports<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\"> (PSURs)</ins></span></span></b>", "ID": "6c0df76e-74b2-4ac0-8748-cd118492ddb1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6febf86d-f2b5-4040-bddd-a494967315e1"}, {"Element": "<span lang=\"EN-GB\">Periodic <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">S</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">s</ins></span>afety <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">U</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">u</ins></span>pdate <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">R</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">r</ins></span>eports<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\"> (PSURs)</ins></span></span>", "ID": "1feed415-b08e-4f4c-9bd5-6badb37fb62a", "Styles": "None", "Classes": "None", "Text": "Periodic afety pdate eports", "ParentId": "6c0df76e-74b2-4ac0-8748-cd118492ddb1"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">S</del></span>", "ID": "0edad9da-5f51-408c-a09c-46ec4743143c", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "1feed415-b08e-4f4c-9bd5-6badb37fb62a"}, {"Element": "<del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">S</del>", "ID": "0e42cb58-6474-47eb-81ea-f2d281691679", "Styles": "None", "Classes": "None", "Text": "S", "ParentId": "0edad9da-5f51-408c-a09c-46ec4743143c"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">s</ins></span>", "ID": "0f17b771-d8ea-44b4-9020-192c66d288f0", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "1feed415-b08e-4f4c-9bd5-6badb37fb62a"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">s</ins>", "ID": "dd4b1182-fb7a-477f-87b8-276072179570", "Styles": "None", "Classes": "None", "Text": "s", "ParentId": "0f17b771-d8ea-44b4-9020-192c66d288f0"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">U</del></span>", "ID": "aa0b2a94-08c9-4068-9431-bce81d9a14ff", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "1feed415-b08e-4f4c-9bd5-6badb37fb62a"}, {"Element": "<del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">U</del>", "ID": "8c232d53-2d86-4e4d-aff2-058a8d6d9433", "Styles": "None", "Classes": "None", "Text": "U", "ParentId": "aa0b2a94-08c9-4068-9431-bce81d9a14ff"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">u</ins></span>", "ID": "40d8794e-2269-4f54-936a-8c8dbda53a2c", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "1feed415-b08e-4f4c-9bd5-6badb37fb62a"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">u</ins>", "ID": "bf5c45e0-9b4e-402d-b489-90c2ebc7e6f6", "Styles": "None", "Classes": "None", "Text": "u", "ParentId": "40d8794e-2269-4f54-936a-8c8dbda53a2c"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">R</del></span>", "ID": "79b35e9c-92a2-46df-bf29-c1981d617cd8", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "1feed415-b08e-4f4c-9bd5-6badb37fb62a"}, {"Element": "<del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">R</del>", "ID": "802035cd-eeba-4939-84eb-3035c87fb529", "Styles": "None", "Classes": "None", "Text": "R", "ParentId": "79b35e9c-92a2-46df-bf29-c1981d617cd8"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">r</ins></span>", "ID": "c2e678c7-e5bc-453c-b435-be638edfd50c", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "1feed415-b08e-4f4c-9bd5-6badb37fb62a"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">r</ins>", "ID": "4de9d0a0-00cd-4078-a0f7-2b8645866c63", "Styles": "None", "Classes": "None", "Text": "r", "ParentId": "c2e678c7-e5bc-453c-b435-be638edfd50c"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\"> (PSURs)</ins></span>", "ID": "7205c7fb-c948-445d-aa98-fb83bd538ccc", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "1feed415-b08e-4f4c-9bd5-6badb37fb62a"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\"> (PSURs)</ins>", "ID": "e263a263-ef74-4b6b-81e5-ccf9b003ec1e", "Styles": "None", "Classes": "None", "Text": " (PSURs)", "ParentId": "7205c7fb-c948-445d-aa98-fb83bd538ccc"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ee28a218-1505-4a4f-99e6-0730e8647f23", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "401b60f6-f20e-4750-9af3-5895562fe160", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ee28a218-1505-4a4f-99e6-0730e8647f23"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The requirements for submission of <span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">PSURs</ins></span><span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">periodic safety update reports</del></span> for\nthis medicinal product are set out in the list of Union reference dates (EURD\nlist) provided for under Article 107c(7) of Directive 2001/83</span><span lang=\"EN-GB\">/EC and any subsequent updates published on the European medicines\nweb\u2011portal.</span></p>", "ID": "7a37bb57-6a52-48ac-acd9-8eafd27430c5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The requirements for submission of <span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">PSURs</ins></span><span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">periodic safety update reports</del></span> for\nthis medicinal product are set out in the list of Union reference dates (EURD\nlist) provided for under Article 107c(7) of Directive 2001/83</span>", "ID": "c9fd2b8b-4162-4b69-8332-4d738f7ed8d9", "Styles": "None", "Classes": "None", "Text": "The requirements for submission of  for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83", "ParentId": "7a37bb57-6a52-48ac-acd9-8eafd27430c5"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">PSURs</ins></span>", "ID": "37aee17d-9196-484a-9b1c-651f1c7ff9b5", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "c9fd2b8b-4162-4b69-8332-4d738f7ed8d9"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">PSURs</ins>", "ID": "65891a8b-4fac-40d2-b4ec-c3b00aa96567", "Styles": "None", "Classes": "None", "Text": "PSURs", "ParentId": "37aee17d-9196-484a-9b1c-651f1c7ff9b5"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">periodic safety update reports</del></span>", "ID": "594d4656-b0ec-4bf6-906e-807a2c124658", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "c9fd2b8b-4162-4b69-8332-4d738f7ed8d9"}, {"Element": "<del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:11\">periodic safety update reports</del>", "ID": "be18cc0c-e1f1-4852-9c9d-c61ef7e072d8", "Styles": "None", "Classes": "None", "Text": "periodic safety update reports", "ParentId": "594d4656-b0ec-4bf6-906e-807a2c124658"}, {"Element": "<span lang=\"EN-GB\">/EC and any subsequent updates published on the European medicines\nweb\u2011portal.</span>", "ID": "f26e0065-5680-4632-827d-f9544343cd51", "Styles": "None", "Classes": "None", "Text": "/EC and any subsequent updates published on the European medicines web\u2011portal.", "ParentId": "7a37bb57-6a52-48ac-acd9-8eafd27430c5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8d50f03d-4795-4bb3-b047-77e1aa2a4565", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "795975a7-1c80-4e0a-bc11-5c556e03c90d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8d50f03d-4795-4bb3-b047-77e1aa2a4565"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "57026ff2-5320-4053-b593-0b92c621a35a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "49c44f7d-dc60-42ce-9f3a-ee806f45f1e5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "57026ff2-5320-4053-b593-0b92c621a35a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>", "ID": "6ffd06e6-faee-4539-9d45-a28856c3fbd9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b>", "ID": "51c00a0d-2dd3-4a44-bc84-5101e00472a5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6ffd06e6-faee-4539-9d45-a28856c3fbd9"}, {"Element": "<span lang=\"EN-GB\">D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR\nRESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span>", "ID": "d9bb2a6f-2ee5-4941-8110-ba8c126d9920", "Styles": "None", "Classes": "None", "Text": "D.\u00a0\u00a0\u00a0\u00a0\u00a0 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT", "ParentId": "51c00a0d-2dd3-4a44-bc84-5101e00472a5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cdd3a718-6be4-4a03-96db-17e356412139", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1eee5e3c-1bae-455d-ac2d-e1e62db6adf0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cdd3a718-6be4-4a03-96db-17e356412139"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Risk <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">M</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">m</ins></span>anagement <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">P</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">p</ins></span>lan (RMP)</span></b></p>", "ID": "e2939c16-fd86-4c72-973c-b273c5ba2373", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "eeaa5de4-5478-4a50-aece-bd66aa2cf4c0", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e2939c16-fd86-4c72-973c-b273c5ba2373"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "55fb76f2-3a4c-4ff4-9f12-fa2b20205f68", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "eeaa5de4-5478-4a50-aece-bd66aa2cf4c0"}, {"Element": "<b><span lang=\"EN-GB\">Risk <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">M</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">m</ins></span>anagement <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">P</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">p</ins></span>lan (RMP)</span></b>", "ID": "9c27b6c9-5bc8-4e48-8711-910b2f335bec", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e2939c16-fd86-4c72-973c-b273c5ba2373"}, {"Element": "<span lang=\"EN-GB\">Risk <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">M</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">m</ins></span>anagement <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">P</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">p</ins></span>lan (RMP)</span>", "ID": "bf8c58ec-5b40-4644-b1c8-838d79e63270", "Styles": "None", "Classes": "None", "Text": "Risk anagement lan (RMP)", "ParentId": "9c27b6c9-5bc8-4e48-8711-910b2f335bec"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">M</del></span>", "ID": "40c3ce76-23a3-4cb1-a37f-fd1030f8dec4", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "bf8c58ec-5b40-4644-b1c8-838d79e63270"}, {"Element": "<del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">M</del>", "ID": "0c2ca6f1-8a42-4589-99d6-19a1f8813fb8", "Styles": "None", "Classes": "None", "Text": "M", "ParentId": "40c3ce76-23a3-4cb1-a37f-fd1030f8dec4"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">m</ins></span>", "ID": "3e8e906d-1704-46a8-b92c-312bd77e8333", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "bf8c58ec-5b40-4644-b1c8-838d79e63270"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">m</ins>", "ID": "fe00c467-7b8d-4a6e-870f-45af77b6b452", "Styles": "None", "Classes": "None", "Text": "m", "ParentId": "3e8e906d-1704-46a8-b92c-312bd77e8333"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">P</del></span>", "ID": "4f1d74c9-d602-46fc-aad0-13aca3d70b75", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "bf8c58ec-5b40-4644-b1c8-838d79e63270"}, {"Element": "<del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">P</del>", "ID": "14b366bd-032c-4559-88b5-f2d297d45a05", "Styles": "None", "Classes": "None", "Text": "P", "ParentId": "4f1d74c9-d602-46fc-aad0-13aca3d70b75"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">p</ins></span>", "ID": "658f8f44-9b94-45ba-98a7-b03b4522f071", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "bf8c58ec-5b40-4644-b1c8-838d79e63270"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:12\">p</ins>", "ID": "a94435f1-3744-4bdb-a828-e25f810c5a19", "Styles": "None", "Classes": "None", "Text": "p", "ParentId": "658f8f44-9b94-45ba-98a7-b03b4522f071"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "996e5e03-dfe3-4217-aa8b-06a93581d298", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa42767e-51a1-494d-898e-4b32f75e1a33", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "996e5e03-dfe3-4217-aa8b-06a93581d298"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The <span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:13\">marketing au</ins></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:29\">thorisation holder (</ins></span>MAH<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:29\">)</ins></span> shall perform the required pharmacovigilance\nactivities and interventions detailed in the agreed RMP presented in Module\n1.8.2 of the <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">M</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">m</ins></span>arketing <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">A</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">a</ins></span>uthorisation and any agreed subsequent\nupdates of the RMP.</span></p>", "ID": "a5699121-5aa3-40a4-b64f-5b343c994356", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The <span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:13\">marketing au</ins></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:29\">thorisation holder (</ins></span>MAH<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:29\">)</ins></span> shall perform the required pharmacovigilance\nactivities and interventions detailed in the agreed RMP presented in Module\n1.8.2 of the <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">M</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">m</ins></span>arketing <span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">A</del></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">a</ins></span>uthorisation and any agreed subsequent\nupdates of the RMP.</span>", "ID": "466bf051-0251-481f-9a40-7a210db71a70", "Styles": "None", "Classes": "None", "Text": "The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the arketing uthorisation and any agreed subsequent updates of the RMP.", "ParentId": "a5699121-5aa3-40a4-b64f-5b343c994356"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:13\">marketing au</ins></span>", "ID": "6af7f339-ccef-4177-b4de-a50df8e2e567", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "466bf051-0251-481f-9a40-7a210db71a70"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:13\">marketing au</ins>", "ID": "96effef8-d380-4965-878e-2bcc39a17f61", "Styles": "None", "Classes": "None", "Text": "marketing au", "ParentId": "6af7f339-ccef-4177-b4de-a50df8e2e567"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:29\">thorisation holder (</ins></span>", "ID": "5ea93552-aa1b-47f3-b6bf-825961135233", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "466bf051-0251-481f-9a40-7a210db71a70"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:29\">thorisation holder (</ins>", "ID": "1ea50da3-770d-48ad-9c8d-ae9f6ba362a7", "Styles": "None", "Classes": "None", "Text": "thorisation holder (", "ParentId": "5ea93552-aa1b-47f3-b6bf-825961135233"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:29\">)</ins></span>", "ID": "10ae03e7-02ec-4505-8c7c-fd39ce30ed51", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "466bf051-0251-481f-9a40-7a210db71a70"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:29\">)</ins>", "ID": "1dbdf62d-deca-47ae-8a20-dff6acc5bca3", "Styles": "None", "Classes": "None", "Text": ")", "ParentId": "10ae03e7-02ec-4505-8c7c-fd39ce30ed51"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">M</del></span>", "ID": "22a08d9e-65c1-4b93-ae2a-86a744e069ff", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "466bf051-0251-481f-9a40-7a210db71a70"}, {"Element": "<del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">M</del>", "ID": "52d9b957-be93-4c09-bdd9-d7e4759f7f6d", "Styles": "None", "Classes": "None", "Text": "M", "ParentId": "22a08d9e-65c1-4b93-ae2a-86a744e069ff"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">m</ins></span>", "ID": "de06957d-2248-4b43-9ae4-88cfc70d5495", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "466bf051-0251-481f-9a40-7a210db71a70"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">m</ins>", "ID": "36f89cc7-5a83-492f-8c82-02c353546c30", "Styles": "None", "Classes": "None", "Text": "m", "ParentId": "de06957d-2248-4b43-9ae4-88cfc70d5495"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">A</del></span>", "ID": "0efe2395-f5a7-4590-88ee-35c1dc5b8341", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "466bf051-0251-481f-9a40-7a210db71a70"}, {"Element": "<del cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">A</del>", "ID": "b3363d25-3a91-40ff-b60f-ee24dd2cd376", "Styles": "None", "Classes": "None", "Text": "A", "ParentId": "0efe2395-f5a7-4590-88ee-35c1dc5b8341"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">a</ins></span>", "ID": "c4ae44e3-8b85-46c5-a78f-f1c892b6d199", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "466bf051-0251-481f-9a40-7a210db71a70"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-24T08:31\">a</ins>", "ID": "e8f2efc2-b638-4f08-bee8-712b754d51ab", "Styles": "None", "Classes": "None", "Text": "a", "ParentId": "c4ae44e3-8b85-46c5-a78f-f1c892b6d199"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1d46112c-9fd6-4410-8f77-b13933022a51", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ec1e0dca-4ab6-4a42-8207-5e6feae20a07", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1d46112c-9fd6-4410-8f77-b13933022a51"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">An updated RMP should be submitted:</span></p>", "ID": "cd352070-debf-487c-8d71-a7894d5f5e24", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">An updated RMP should be submitted:</span>", "ID": "dc317e34-2e24-42c9-b602-a9510ef58c8f", "Styles": "None", "Classes": "None", "Text": "An updated RMP should be submitted:", "ParentId": "cd352070-debf-487c-8d71-a7894d5f5e24"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">At the request of the European Medicines Agency;</span></p>", "ID": "1dfdbba1-a026-4835-a2ac-fce7b41c479f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7dd9f555-20b2-4edc-86b1-16fe32ca89c8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1dfdbba1-a026-4835-a2ac-fce7b41c479f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b04914e1-0d5d-4bbf-9f37-ad69f5ec6eeb", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7dd9f555-20b2-4edc-86b1-16fe32ca89c8"}, {"Element": "<span lang=\"EN-GB\">At the request of the European Medicines Agency;</span>", "ID": "4e7d1201-5ef1-4dbb-b5a5-dd2aa4e37e43", "Styles": "None", "Classes": "None", "Text": "At the request of the European Medicines Agency;", "ParentId": "1dfdbba1-a026-4835-a2ac-fce7b41c479f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Whenever the risk management system is modified,\nespecially as the result of new information being received that may lead to a\nsignificant change to the benefit/risk profile or as the result of an important\n(pharmacovigilance or risk minimisation) milestone being reached.</span></p>", "ID": "03ad7a4c-b414-43b2-bb67-1396b1b5443a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "028dee78-3d8c-4195-ab2c-8864b34a5998", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "03ad7a4c-b414-43b2-bb67-1396b1b5443a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "46b46874-bcc4-4461-b858-6942c37e8303", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "028dee78-3d8c-4195-ab2c-8864b34a5998"}, {"Element": "<span lang=\"EN-GB\">Whenever the risk management system is modified,\nespecially as the result of new information being received that may lead to a\nsignificant change to the benefit/risk profile or as the result of an important\n(pharmacovigilance or risk minimisation) milestone being reached.</span>", "ID": "3ef21175-8b89-4fe9-8477-2f2493245543", "Styles": "None", "Classes": "None", "Text": "Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.", "ParentId": "03ad7a4c-b414-43b2-bb67-1396b1b5443a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6d2e2ca0-67bb-43bf-b85d-8943b6745efe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "45e2afdc-f894-4361-941f-aa0db1608174", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6d2e2ca0-67bb-43bf-b85d-8943b6745efe"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Additional risk minimisation measures</span></b></p>", "ID": "9bff4fc3-e6f8-4fce-b986-97a0a2bafffa", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "fd5d9a2d-ed8e-4862-980a-2236dc113f65", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9bff4fc3-e6f8-4fce-b986-97a0a2bafffa"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "70e05f0f-87d4-41cd-9d05-f53f4d5807ee", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "fd5d9a2d-ed8e-4862-980a-2236dc113f65"}, {"Element": "<b><span lang=\"EN-GB\">Additional risk minimisation measures</span></b>", "ID": "d85134bd-bea0-4b21-bb94-4dc08420a925", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9bff4fc3-e6f8-4fce-b986-97a0a2bafffa"}, {"Element": "<span lang=\"EN-GB\">Additional risk minimisation measures</span>", "ID": "0bfeb5b5-602d-4b2d-af1b-c903e165e445", "Styles": "None", "Classes": "None", "Text": "Additional risk minimisation measures", "ParentId": "d85134bd-bea0-4b21-bb94-4dc08420a925"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "38e35606-edad-4439-b2db-53297323222c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "78d755e7-9f6f-4306-9530-1f0e1c60ac41", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "38e35606-edad-4439-b2db-53297323222c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The educational programme consists of a patient\nreminder card to be held by the patient. The card is aimed at both serving as a\nreminder to record the dates and outcomes of specific tests and to facilitate\nthe patient sharing of special information with healthcare professionals(s) (HCPs)\ntreating the patient about on\u2011going treatment with the product.</span></p>", "ID": "5db62ea2-5160-472b-a55e-89e103e98e24", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The educational programme consists of a patient\nreminder card to be held by the patient. The card is aimed at both serving as a\nreminder to record the dates and outcomes of specific tests and to facilitate\nthe patient sharing of special information with healthcare professionals(s) (HCPs)\ntreating the patient about on\u2011going treatment with the product.</span>", "ID": "89f7962e-b438-4dfa-86e6-e8111bd33051", "Styles": "None", "Classes": "None", "Text": "The educational programme consists of a patient reminder card to be held by the patient. The card is aimed at both serving as a reminder to record the dates and outcomes of specific tests and to facilitate the patient sharing of special information with healthcare professionals(s) (HCPs) treating the patient about on\u2011going treatment with the product.", "ParentId": "5db62ea2-5160-472b-a55e-89e103e98e24"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bcb64a2f-7358-459d-ac46-0ef3b2dbaa94", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "db952440-2027-4ef6-8db2-7ca003fa5abf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bcb64a2f-7358-459d-ac46-0ef3b2dbaa94"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">The patient reminder card </span></b><span lang=\"EN-GB\">shall contain the following key messages:</span></p>", "ID": "975ac56e-d781-440b-bb2d-481a275b1d8e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">The patient reminder card </span></b>", "ID": "cdf19043-e541-4bce-8c9c-de79cad0ec92", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "975ac56e-d781-440b-bb2d-481a275b1d8e"}, {"Element": "<span lang=\"EN-GB\">The patient reminder card </span>", "ID": "abdf6d42-b6da-4afd-b703-e905a12e172f", "Styles": "None", "Classes": "None", "Text": "The patient reminder card ", "ParentId": "cdf19043-e541-4bce-8c9c-de79cad0ec92"}, {"Element": "<span lang=\"EN-GB\">shall contain the following key messages:</span>", "ID": "66fba431-a9d8-4c89-8bcf-91f7d960e3b7", "Styles": "None", "Classes": "None", "Text": "shall contain the following key messages:", "ParentId": "975ac56e-d781-440b-bb2d-481a275b1d8e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e90089d0-1ea2-4e83-b126-6c832d833fd0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "21b7000c-35dc-481c-9279-122bbd40a72e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e90089d0-1ea2-4e83-b126-6c832d833fd0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A reminder to patients to show the patient reminder\ncard to all treating HCPs, including in conditions of emergency, and a message for\nHCPs that the patient is using Remicade</span></p>", "ID": "1f7bd197-bbd2-417e-9a8f-5ac617dd58ef", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4b0cc2f7-3553-4394-84cc-096c50a03d69", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1f7bd197-bbd2-417e-9a8f-5ac617dd58ef"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0f9fef0a-15c7-44b0-b750-6c82131ee0f2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4b0cc2f7-3553-4394-84cc-096c50a03d69"}, {"Element": "<span lang=\"EN-GB\">A reminder to patients to show the patient reminder\ncard to all treating HCPs, including in conditions of emergency, and a message for\nHCPs that the patient is using Remicade</span>", "ID": "e91095ca-a4bb-4b61-a2f6-cc692a11769c", "Styles": "None", "Classes": "None", "Text": "A reminder to patients to show the patient reminder card to all treating HCPs, including in conditions of emergency, and a message for HCPs that the patient is using Remicade", "ParentId": "1f7bd197-bbd2-417e-9a8f-5ac617dd58ef"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ea0892b5-78cd-4166-8438-2deea2ed8eab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "608b6158-ddb6-4634-8d6a-5c58832e66d5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ea0892b5-78cd-4166-8438-2deea2ed8eab"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A statement that the brand name and batch number\nshould be recorded</span></p>", "ID": "5fbe3b8f-7b40-4115-b8d5-ca21e9ef1b27", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "cf8e5b74-5cce-4185-8078-1d86a25288c4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5fbe3b8f-7b40-4115-b8d5-ca21e9ef1b27"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "04b47162-e07e-4893-a6e7-d1f4b93eff24", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "cf8e5b74-5cce-4185-8078-1d86a25288c4"}, {"Element": "<span lang=\"EN-GB\">A statement that the brand name and batch number\nshould be recorded</span>", "ID": "713694e1-a34f-4a7e-a56c-51412160ff07", "Styles": "None", "Classes": "None", "Text": "A statement that the brand name and batch number should be recorded", "ParentId": "5fbe3b8f-7b40-4115-b8d5-ca21e9ef1b27"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "263c48ed-f583-4e21-be79-121e1fe3ca24", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1af2b8f0-7388-4b50-9a0e-456fbed78e61", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "263c48ed-f583-4e21-be79-121e1fe3ca24"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Provision to record the type, date, and result\nof TB screenings</span></p>", "ID": "508ac87d-c4c0-4704-9d93-0bfbe2781709", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "240229a7-600f-4fd2-b1a5-99e6cfb0e40b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "508ac87d-c4c0-4704-9d93-0bfbe2781709"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "20af1cc6-2e1e-40b7-96bf-195c198c529c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "240229a7-600f-4fd2-b1a5-99e6cfb0e40b"}, {"Element": "<span lang=\"EN-GB\">Provision to record the type, date, and result\nof TB screenings</span>", "ID": "1a1b0716-5e35-4339-8856-319fb853ff41", "Styles": "None", "Classes": "None", "Text": "Provision to record the type, date, and result of TB screenings", "ParentId": "508ac87d-c4c0-4704-9d93-0bfbe2781709"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8e08c6dd-3149-4903-8c72-f3a0d289ad52", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1acbf43f-264f-4974-9ca8-0bc9d781c08b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8e08c6dd-3149-4903-8c72-f3a0d289ad52"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">That treatment with Remicade may increase the\nrisks of serious infections/sepsis, opportunistic infections, tuberculosis,\nhepatitis B reactivation, and BCG breakthrough in infants with <i>in utero</i>\nexposure to infliximab, and when to seek attention from a HCP</span></p>", "ID": "c7f69ebf-da5e-4371-b164-bd15f3951886", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c0da3d61-0bff-4c04-8459-c541e4a84314", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c7f69ebf-da5e-4371-b164-bd15f3951886"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "4d656068-0e75-4022-912d-6feb7933751e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c0da3d61-0bff-4c04-8459-c541e4a84314"}, {"Element": "<span lang=\"EN-GB\">That treatment with Remicade may increase the\nrisks of serious infections/sepsis, opportunistic infections, tuberculosis,\nhepatitis B reactivation, and BCG breakthrough in infants with <i>in utero</i>\nexposure to infliximab, and when to seek attention from a HCP</span>", "ID": "7c2db270-994f-4d18-99f9-0856059c5b73", "Styles": "None", "Classes": "None", "Text": "That treatment with Remicade may increase the risks of serious infections/sepsis, opportunistic infections, tuberculosis, hepatitis B reactivation, and BCG breakthrough in infants with  exposure to infliximab, and when to seek attention from a HCP", "ParentId": "c7f69ebf-da5e-4371-b164-bd15f3951886"}, {"Element": "<i>in utero</i>", "ID": "7a1252bd-e388-413c-a85e-a9aeb3a0f89b", "Styles": "None", "Classes": "None", "Text": "in utero", "ParentId": "7c2db270-994f-4d18-99f9-0856059c5b73"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "170862b6-94b0-4caf-ad16-694b62080ff9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fdf73a57-2231-45b1-9d4a-fb1dfa51f745", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "170862b6-94b0-4caf-ad16-694b62080ff9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Contact details of the prescriber</span></p>", "ID": "f61e3c04-d48e-4e3a-9389-381b231b7b12", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5544e264-8b25-46e4-8bb7-b3fd75cc5b41", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f61e3c04-d48e-4e3a-9389-381b231b7b12"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c6591448-6edb-45ad-b51a-9e71755c24cc", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5544e264-8b25-46e4-8bb7-b3fd75cc5b41"}, {"Element": "<span lang=\"EN-GB\">Contact details of the prescriber</span>", "ID": "53294881-0e2d-4f3f-96d4-1ae2c1477c22", "Styles": "None", "Classes": "None", "Text": "Contact details of the prescriber", "ParentId": "f61e3c04-d48e-4e3a-9389-381b231b7b12"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "8fd189d9-096c-4bf0-bcf3-e6408343091a", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "10121253-f8be-4c48-8180-f0d0976e7f19", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "8fd189d9-096c-4bf0-bcf3-e6408343091a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f3c3cd16-f65f-4625-b205-b2181d369b89", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d0cfbe21-98b1-439b-8f3b-964e29243161", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f3c3cd16-f65f-4625-b205-b2181d369b89"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3fe7a747-64e4-4400-906e-7f2585e7785b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6c13abec-1b96-4187-8905-b4fb543ca9d8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3fe7a747-64e4-4400-906e-7f2585e7785b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9493751f-8003-48d7-a6b1-f9ac2445ab3f", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "49594c4a-8594-47e1-a296-7b99152d54c5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9493751f-8003-48d7-a6b1-f9ac2445ab3f"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "80e83ab5-e8fa-4c5a-aecf-8965e4bf546e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e3d4f8d9-d07a-4638-85f8-7e62d859f770", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "80e83ab5-e8fa-4c5a-aecf-8965e4bf546e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e54a70f5-3d33-406f-88df-911c43528654", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4e6844cd-0c46-42d7-92ff-c267a0c4bb95", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e54a70f5-3d33-406f-88df-911c43528654"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6e84cd61-6b0b-4571-8c75-c83285707fea", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "18865ee0-6dca-4bec-bc08-1a9ea3383fd9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6e84cd61-6b0b-4571-8c75-c83285707fea"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9f768988-ca8b-4ca3-81a5-a4fd2886a5e4", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f7190206-db19-401d-a57a-a79734e6ff31", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9f768988-ca8b-4ca3-81a5-a4fd2886a5e4"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fa11035b-8417-4980-ae73-cce918bdfe35", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "58f40209-9da9-45af-b8ab-fb8730bb7a07", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fa11035b-8417-4980-ae73-cce918bdfe35"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0a37c082-1233-45bf-a25a-753ce8c28af0", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9c76fe92-1385-4ad6-acd4-de24bbafdf74", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a37c082-1233-45bf-a25a-753ce8c28af0"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f7f762de-9709-4dec-94bc-50a7e93538e1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0b499d35-d00c-4a0d-a22a-c73e7bd37866", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f7f762de-9709-4dec-94bc-50a7e93538e1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b6221790-9ad9-44f8-b816-de3d9994dc97", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5e781e96-1e91-41b6-a5c5-b5e6d6e4cd41", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b6221790-9ad9-44f8-b816-de3d9994dc97"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a97a1f72-c795-4ca6-aecf-077c43bdde71", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9e76ed6b-4440-4cf3-8c4a-d71fc1bd61da", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a97a1f72-c795-4ca6-aecf-077c43bdde71"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "814d0e27-2ea1-46eb-a3c1-256ba44f52ff", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a8aafa2c-c2d0-45be-bdc7-defc377204df", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "814d0e27-2ea1-46eb-a3c1-256ba44f52ff"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "268a41b3-f084-439b-a562-3a5b13218dbd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7f47e1b8-d914-49ba-a643-198c619141f7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "268a41b3-f084-439b-a562-3a5b13218dbd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "83967837-def2-4001-b582-dcae14164c0c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "638cce8d-936d-4c45-8e2d-e680db9e219a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "83967837-def2-4001-b582-dcae14164c0c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a34dfec8-5975-4411-a0f5-390ffa2b3346", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "89801a04-aabd-4d55-809c-8424e63e0689", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a34dfec8-5975-4411-a0f5-390ffa2b3346"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3d7c2835-b204-4fce-a393-f8f28cfc6acf", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c0d32d2d-b041-4a88-bc87-b7dfd64ae2c1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3d7c2835-b204-4fce-a393-f8f28cfc6acf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "956b5e72-46e0-420f-bc31-1471530eac53", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9ed89bbf-039a-4ac4-9e1c-5ea6c4dfe837", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "956b5e72-46e0-420f-bc31-1471530eac53"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4d9132fc-fa17-40cf-b03e-efeac514884b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3154009c-d7fa-4424-838b-58378c58085e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4d9132fc-fa17-40cf-b03e-efeac514884b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d43f8e60-f445-4d89-9f6f-4a5bd0e1edd3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1e95410e-6b2f-4928-a2e8-f1a85aaf46b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d43f8e60-f445-4d89-9f6f-4a5bd0e1edd3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dc944f55-26a2-4192-9fdf-73eae144d351", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "667cea31-e447-41f6-bd17-96c0c742ac62", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dc944f55-26a2-4192-9fdf-73eae144d351"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9383b514-34f4-411e-8365-28304bd103b1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa503617-ab2b-49b3-bfa8-1c9fca4fd280", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9383b514-34f4-411e-8365-28304bd103b1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "11497f78-58b0-4c84-84ba-5e6ecb048597", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4ee5c19b-06ff-456e-ab77-86fb56008019", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "11497f78-58b0-4c84-84ba-5e6ecb048597"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\nIII</span></b></p>", "ID": "a0d5bba4-b91a-46b5-bb85-8bed36731e58", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">ANNEX\nIII</span></b>", "ID": "670c3dc5-95a8-4762-8123-6ac23678db59", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a0d5bba4-b91a-46b5-bb85-8bed36731e58"}, {"Element": "<span lang=\"EN-GB\">ANNEX\nIII</span>", "ID": "e452cd40-9578-44b1-b472-aae42ec31a13", "Styles": "None", "Classes": "None", "Text": "ANNEX III", "ParentId": "670c3dc5-95a8-4762-8123-6ac23678db59"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "6d543e43-d669-47be-94c7-633aca981960", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "a8e2b596-72e1-49cc-8afd-c95029e2c6bf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6d543e43-d669-47be-94c7-633aca981960"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9aab7be7-c22f-4bc7-997d-d498b4bfb59d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a8e2b596-72e1-49cc-8afd-c95029e2c6bf"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">LABELLING\nAND PACKAGE LEAFLET</span></b></p>", "ID": "9ba79122-af42-4a06-8acd-bfbd3a4dabad", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">LABELLING\nAND PACKAGE LEAFLET</span></b>", "ID": "6ee96ef6-d891-43cc-922a-0295892333c9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9ba79122-af42-4a06-8acd-bfbd3a4dabad"}, {"Element": "<span lang=\"EN-GB\">LABELLING\nAND PACKAGE LEAFLET</span>", "ID": "ba1edf9c-d3ea-442a-a2b1-cec911bd5b69", "Styles": "None", "Classes": "None", "Text": "LABELLING AND PACKAGE LEAFLET", "ParentId": "6ee96ef6-d891-43cc-922a-0295892333c9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cead8188-6508-45ac-b919-57de41d0d95a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6211ca54-61bb-4a72-8635-35807e4aa715", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cead8188-6508-45ac-b919-57de41d0d95a"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "4384e136-2be8-46ff-83d8-917341ecdc5c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "47ec6db6-e79a-4062-8343-007195479a76", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "4384e136-2be8-46ff-83d8-917341ecdc5c"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "764cc217-131d-473a-a525-39e8768e605f", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "47ec6db6-e79a-4062-8343-007195479a76"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "c4fa9c9a-294f-443e-a9b4-2418a1c007af", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "2393ffcb-4319-4b3c-ba19-80027a883188", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c4fa9c9a-294f-443e-a9b4-2418a1c007af"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a3fd2c09-7eba-4aae-b757-bec846095123", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2393ffcb-4319-4b3c-ba19-80027a883188"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c1121e3-c28c-46a0-97b3-99f4423a2119", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bc6ae02b-f961-4896-ba01-81ea24405396", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c1121e3-c28c-46a0-97b3-99f4423a2119"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "54e66ab3-a360-40e6-9e1d-72ec76d1c583", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "aa80019f-e143-47dc-9b1d-0943457d276f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "54e66ab3-a360-40e6-9e1d-72ec76d1c583"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "18db0ce7-3ce1-4ee7-a540-ad6bb18b7648", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "924b0529-e82a-4c70-8d6f-6f242083ec52", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "18db0ce7-3ce1-4ee7-a540-ad6bb18b7648"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "752dfa02-f35a-43b7-9e89-073a58019916", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0ec9e02d-68f1-4b9e-a646-27e5ec9f5a08", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "752dfa02-f35a-43b7-9e89-073a58019916"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0081ec1c-78c5-4d6d-a647-fc5e6f4c5c2d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e97903d0-4762-4e66-8722-7616cc08bb71", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0081ec1c-78c5-4d6d-a647-fc5e6f4c5c2d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ab811f64-0192-40cd-803b-db40ea479f08", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e22931dd-cc1a-41f9-b6ce-a34a1077d606", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ab811f64-0192-40cd-803b-db40ea479f08"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "79b9973e-ba55-4af8-83e8-bd816dd0417b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "77f355fd-6886-40a1-b0e8-6d3a7c962da9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "79b9973e-ba55-4af8-83e8-bd816dd0417b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e8a3d89c-3851-47ba-b2df-8be61463e7fe", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ffd4024b-e54f-4d71-823c-b4abd942eeab", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e8a3d89c-3851-47ba-b2df-8be61463e7fe"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "830bb498-d045-46b5-a5d8-baa58b26d96a", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7e5062df-a259-48c2-be72-f428184364ed", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "830bb498-d045-46b5-a5d8-baa58b26d96a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "72232181-6d8f-4303-a02a-aaa475fba289", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "897d6797-9369-4ef7-b224-6fd6f0844a3c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "72232181-6d8f-4303-a02a-aaa475fba289"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7cc009ea-3911-4590-9c65-617633e8bc12", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4df9e7bb-4a4b-475b-bfd5-39b121035435", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7cc009ea-3911-4590-9c65-617633e8bc12"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "27d3a68e-4156-4a07-822a-42e3b8f2823e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bd243582-27f4-4786-99fc-f663db0057d0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "27d3a68e-4156-4a07-822a-42e3b8f2823e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a38b745b-f766-4520-92ec-e0e3e53d651e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "19542315-f42d-4d98-999f-ab9eda960e46", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a38b745b-f766-4520-92ec-e0e3e53d651e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "107de052-ab3f-4445-9ac6-c2ad9a75a1fb", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b800dde2-fccb-49f1-bbba-0f98c27a9479", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "107de052-ab3f-4445-9ac6-c2ad9a75a1fb"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2bf35a0f-5cb3-4a3f-9c9d-d06239bd05a7", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4368117a-b975-4395-9de7-883dc94880b3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2bf35a0f-5cb3-4a3f-9c9d-d06239bd05a7"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e4faee0b-7b09-4ef1-8943-59231290c24b", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1c02219b-f3b2-4eb4-bab9-d4707637170d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e4faee0b-7b09-4ef1-8943-59231290c24b"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "92266881-6df0-4d91-af92-0af0a8813bbe", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d4bf6e89-da1a-436c-abdb-b4d597f12e8c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "92266881-6df0-4d91-af92-0af0a8813bbe"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a159ed0f-0fd5-40ec-9fe0-0c469a3ef4fa", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cfd07ddc-6ec7-47de-b6cb-fb2997e037eb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a159ed0f-0fd5-40ec-9fe0-0c469a3ef4fa"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aff2a5ed-fc0a-4f69-8c5d-e3b3fe426053", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dd4d2f18-628c-400b-9d0a-8c6961abe708", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aff2a5ed-fc0a-4f69-8c5d-e3b3fe426053"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c0c327ea-5a44-4036-8ad8-c15f3676be6d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a4944639-4e30-4154-bc85-5bf1c8a9cb15", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c0c327ea-5a44-4036-8ad8-c15f3676be6d"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "48a23dea-dea2-4012-bccf-e77c43f37b6e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "881448b4-05c2-4c85-bf32-c9c64060bca1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "48a23dea-dea2-4012-bccf-e77c43f37b6e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4fa7bed4-824e-43ff-a70a-3205f811e9e3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fe35bbdb-1f7d-4c05-a428-de793c06fbac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4fa7bed4-824e-43ff-a70a-3205f811e9e3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">A.\nLABELLING</span></b></p>", "ID": "abd1fb77-94c8-4cbf-81b0-543b9e073244", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">A.\nLABELLING</span></b>", "ID": "b463033b-99d2-4d5b-a330-af176e058a94", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "abd1fb77-94c8-4cbf-81b0-543b9e073244"}, {"Element": "<span lang=\"EN-GB\">A.\nLABELLING</span>", "ID": "38603484-1428-4dd1-ba0a-40d9894e720b", "Styles": "None", "Classes": "None", "Text": "A. LABELLING", "ParentId": "b463033b-99d2-4d5b-a330-af176e058a94"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c06ceff-209f-4766-8b86-7d6d7d8bb345", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a42ea877-2b4d-4a61-a9b5-8134a7248d59", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c06ceff-209f-4766-8b86-7d6d7d8bb345"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "c10732d3-ebbd-480e-8047-67b783a678ca", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "9ccb1d53-16ad-4bd3-a4ed-7334cb0eff18", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "c10732d3-ebbd-480e-8047-67b783a678ca"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "2fff28a0-da4e-4435-a59b-23d6a49791f4", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "9ccb1d53-16ad-4bd3-a4ed-7334cb0eff18"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE\nOUTER PACKAGING</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON</span></b></p>\n</div>", "ID": "ef4045c3-01e2-473b-8164-edc9cd8e2cca", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE\nOUTER PACKAGING</span></b></p>", "ID": "64883fcc-ba22-471b-81c9-c0b077b2c145", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ef4045c3-01e2-473b-8164-edc9cd8e2cca"}, {"Element": "<b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE\nOUTER PACKAGING</span></b>", "ID": "22833e23-e064-49f0-800f-c210ca9ae78e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "64883fcc-ba22-471b-81c9-c0b077b2c145"}, {"Element": "<span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE\nOUTER PACKAGING</span>", "ID": "70042a41-f269-40d7-b525-0639efaf78c2", "Styles": "None", "Classes": "None", "Text": "PARTICULARS TO APPEAR ON THE OUTER PACKAGING", "ParentId": "22833e23-e064-49f0-800f-c210ca9ae78e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "46121424-5d5d-4294-b94a-ca213c32fae1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ef4045c3-01e2-473b-8164-edc9cd8e2cca"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "0b4529f1-264d-408e-bba0-05be9344303c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "46121424-5d5d-4294-b94a-ca213c32fae1"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b077ef49-7ace-4f03-b550-0fd22091ff65", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0b4529f1-264d-408e-bba0-05be9344303c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON</span></b></p>", "ID": "8c611682-9d7b-4e0f-9cd7-6aad6129efb2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ef4045c3-01e2-473b-8164-edc9cd8e2cca"}, {"Element": "<b><span lang=\"EN-GB\">CARTON</span></b>", "ID": "85f78c04-a147-4c64-aae5-45c135a1e492", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c611682-9d7b-4e0f-9cd7-6aad6129efb2"}, {"Element": "<span lang=\"EN-GB\">CARTON</span>", "ID": "66e95ca4-4aa7-41e6-b44d-4f5be28545b6", "Styles": "None", "Classes": "None", "Text": "CARTON", "ParentId": "85f78c04-a147-4c64-aae5-45c135a1e492"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "438e66fa-bd45-4e38-b8e5-ae33548605ba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d24eb129-56c3-49e4-9991-4c7c1dc93269", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "438e66fa-bd45-4e38-b8e5-ae33548605ba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f08a2875-2d24-40e8-a639-7f0ba3f90f7c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "63dbc1b2-5281-4d5c-9bd3-121e004d5cf1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f08a2875-2d24-40e8-a639-7f0ba3f90f7c"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>\n</div>", "ID": "345701da-6093-464d-924f-36206f243a7c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b></p>", "ID": "e3e01df0-e91c-415a-a095-2f7ecdff88d4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "345701da-6093-464d-924f-36206f243a7c"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span></b>", "ID": "891e1085-ef6b-4d40-ada5-32b44c5a0445", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e3e01df0-e91c-415a-a095-2f7ecdff88d4"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME\nOF THE MEDICINAL PRODUCT</span>", "ID": "dbf8c722-363d-4a97-9fb4-456381b72233", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT", "ParentId": "891e1085-ef6b-4d40-ada5-32b44c5a0445"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "efeefa2e-c1f1-488d-9d27-9f2798e96c47", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e1aa77e5-63e0-4c05-bf1f-89aa4db66377", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "efeefa2e-c1f1-488d-9d27-9f2798e96c47"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Remicade 100\u00a0mg powder for concentrate for\nsolution for infusion</span></p>", "ID": "766ee6c7-a140-43ff-802f-e6cf570cb061", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade 100\u00a0mg powder for concentrate for\nsolution for infusion</span>", "ID": "834313b7-4600-42de-b4cd-0d13eced31db", "Styles": "None", "Classes": "None", "Text": "Remicade 100\u00a0mg powder for concentrate for solution for infusion", "ParentId": "766ee6c7-a140-43ff-802f-e6cf570cb061"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">infliximab</span></p>", "ID": "0680fcb8-7bbc-4b16-a5db-3f721bfb38ad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">infliximab</span>", "ID": "cc03f934-08b0-481f-b466-c71f6717857a", "Styles": "None", "Classes": "None", "Text": "infliximab", "ParentId": "0680fcb8-7bbc-4b16-a5db-3f721bfb38ad"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "533fdea7-3d60-443f-8e36-61c32371adf7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5b1a20dd-2d9d-4f59-9373-755ea3e971d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "533fdea7-3d60-443f-8e36-61c32371adf7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6b778713-3d08-449c-b9c7-a8ddd96e54c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4deb645e-89aa-4605-a19e-0249bb346003", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6b778713-3d08-449c-b9c7-a8ddd96e54c3"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>\n</div>", "ID": "a75e4c31-5b59-4514-98d4-d405756a1238", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b></p>", "ID": "73b80de1-b35f-4d54-8185-9b18197cde0b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a75e4c31-5b59-4514-98d4-d405756a1238"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span></b>", "ID": "4d2f49b0-0066-47a8-b28d-0c85080d00ca", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "73b80de1-b35f-4d54-8185-9b18197cde0b"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT\nOF ACTIVE SUBSTANCE(S)</span>", "ID": "3d30e509-877f-4e17-abef-a9eb8623628e", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 STATEMENT OF ACTIVE SUBSTANCE(S)", "ParentId": "4d2f49b0-0066-47a8-b28d-0c85080d00ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "90c25d4a-98fd-4a76-8293-22288c02e948", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "49e84ef4-331a-4c3e-b607-79c7504ff934", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "90c25d4a-98fd-4a76-8293-22288c02e948"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Each vial contains 100\u00a0mg of\ninfliximab.</span></p>", "ID": "aadbcae4-088b-430b-b65b-bf2203948bab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Each vial contains 100\u00a0mg of\ninfliximab.</span>", "ID": "9b9b494b-9e41-4eb0-a3dd-64200e31e779", "Styles": "None", "Classes": "None", "Text": "Each vial contains 100\u00a0mg of infliximab.", "ParentId": "aadbcae4-088b-430b-b65b-bf2203948bab"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">After reconstitution one ml contains 10\u00a0mg\nof infliximab.</span></p>", "ID": "04bff589-1568-4aa1-91cf-13cf0c22194d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">After reconstitution one ml contains 10\u00a0mg\nof infliximab.</span>", "ID": "01c17b58-00f1-462c-95be-b5a3dce55bb5", "Styles": "None", "Classes": "None", "Text": "After reconstitution one ml contains 10\u00a0mg of infliximab.", "ParentId": "04bff589-1568-4aa1-91cf-13cf0c22194d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3bf20201-3592-4df1-9791-d6a90b726b3c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b8e446f8-a122-49f8-aebb-98742479fed8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3bf20201-3592-4df1-9791-d6a90b726b3c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "15970098-2ad0-46a1-b1cf-cf8988a97384", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "22ac8dcf-3f3c-4053-87e9-9a4b6c8e7b91", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "15970098-2ad0-46a1-b1cf-cf8988a97384"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>\n</div>", "ID": "4d11c9c4-68eb-49ff-bfae-58abb7b63d46", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b></p>", "ID": "cd0bc274-1e2f-41de-ac28-2a2f8db8e0ee", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4d11c9c4-68eb-49ff-bfae-58abb7b63d46"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span></b>", "ID": "8c8ec016-f226-48c2-94b5-c97f0a3b2fa7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cd0bc274-1e2f-41de-ac28-2a2f8db8e0ee"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST\nOF EXCIPIENTS</span>", "ID": "a4134c8c-c5ce-4d5c-9841-f9b80c54260a", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 LIST OF EXCIPIENTS", "ParentId": "8c8ec016-f226-48c2-94b5-c97f0a3b2fa7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4bd3fe85-5e90-41ae-ac20-01d2842ef161", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "36524f81-fb54-46e6-b8a5-74c81d251e64", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4bd3fe85-5e90-41ae-ac20-01d2842ef161"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Excipients: sucrose, polysorbate\u00a080, monobasic\nsodium phosphate and dibasic sodium phosphate.</span></p>", "ID": "4e7e9f9e-f87e-405d-bf46-85cd2724ac35", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Excipients: sucrose, polysorbate\u00a080, monobasic\nsodium phosphate and dibasic sodium phosphate.</span>", "ID": "524a0efe-41cf-48c1-a544-2b5aeef33369", "Styles": "None", "Classes": "None", "Text": "Excipients: sucrose, polysorbate\u00a080, monobasic sodium phosphate and dibasic sodium phosphate.", "ParentId": "4e7e9f9e-f87e-405d-bf46-85cd2724ac35"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "449393bb-148f-4163-b99f-25d2bd74f492", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "797ee070-764d-4a1b-9cbb-96bb4a0e4ab0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "449393bb-148f-4163-b99f-25d2bd74f492"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "84e60cf0-f8c9-488d-8e18-33472e75b497", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "18802529-63e0-4538-a562-8a9388465b2b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "84e60cf0-f8c9-488d-8e18-33472e75b497"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>\n</div>", "ID": "9fac2e8f-d2e7-49ba-b395-18449eb090d9", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b></p>", "ID": "6be30ba2-fe28-4ee3-a00a-d48590702b2d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9fac2e8f-d2e7-49ba-b395-18449eb090d9"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span></b>", "ID": "b8e44aa4-1be9-4c1a-957e-8f28e7993e45", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6be30ba2-fe28-4ee3-a00a-d48590702b2d"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL\nFORM AND CONTENTS</span>", "ID": "8af92014-9fbe-4510-9b81-da4347986bf0", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 PHARMACEUTICAL FORM AND CONTENTS", "ParentId": "b8e44aa4-1be9-4c1a-957e-8f28e7993e45"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">\u00a0</span></p>", "ID": "c8d85691-95f7-4efa-95f4-78871a3b4029", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">\u00a0</span>", "ID": "a1bc7904-13bd-48d2-a3ca-dd6aea13539b", "Styles": "background:silver", "Classes": "None", "Text": "\u00a0", "ParentId": "c8d85691-95f7-4efa-95f4-78871a3b4029"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">Powder for concentrate for solution for infusion</span></p>", "ID": "5b8863a0-0712-4402-8cce-ab60acfc2d72", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">Powder for concentrate for solution for infusion</span>", "ID": "e3f36a21-5cc1-4495-99d6-e91bd87ee56a", "Styles": "background:silver", "Classes": "None", "Text": "Powder for concentrate for solution for infusion", "ParentId": "5b8863a0-0712-4402-8cce-ab60acfc2d72"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">1\u00a0vial 100\u00a0mg</span></p>", "ID": "f9f1afdb-27c4-4098-8e1f-abf880a45007", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">1\u00a0vial 100\u00a0mg</span>", "ID": "c0e70608-181d-4222-8f77-f77eab32d865", "Styles": "None", "Classes": "None", "Text": "1\u00a0vial 100\u00a0mg", "ParentId": "f9f1afdb-27c4-4098-8e1f-abf880a45007"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\" style=\"background:silver\">2\u00a0vials\n100\u00a0mg</span></p>", "ID": "e9699a6f-34dc-4304-984a-513b4bdc121c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"DE\" style=\"background:silver\">2\u00a0vials\n100\u00a0mg</span>", "ID": "d41c038f-8c8e-486d-ac46-3a48cb536722", "Styles": "background:silver", "Classes": "None", "Text": "2\u00a0vials 100\u00a0mg", "ParentId": "e9699a6f-34dc-4304-984a-513b4bdc121c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\" style=\"background:silver\">3\u00a0vials\n100\u00a0mg</span></p>", "ID": "1c300c91-0576-441f-84a4-fb4091ad00c0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"DE\" style=\"background:silver\">3\u00a0vials\n100\u00a0mg</span>", "ID": "55fff0c2-4eb0-4a8c-9cc2-c1be76ceac0e", "Styles": "background:silver", "Classes": "None", "Text": "3\u00a0vials 100\u00a0mg", "ParentId": "1c300c91-0576-441f-84a4-fb4091ad00c0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\" style=\"background:silver\">4\u00a0vials\n100\u00a0mg</span></p>", "ID": "037e610b-2786-417b-8101-7f10521781a9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"DE\" style=\"background:silver\">4\u00a0vials\n100\u00a0mg</span>", "ID": "8d3da1af-94b9-44f2-bcad-7e2cd92dfa7b", "Styles": "background:silver", "Classes": "None", "Text": "4\u00a0vials 100\u00a0mg", "ParentId": "037e610b-2786-417b-8101-7f10521781a9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">5\u00a0vials\n100\u00a0mg</span></p>", "ID": "066ea7eb-a101-499c-90f9-a20bb1c7abf8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">5\u00a0vials\n100\u00a0mg</span>", "ID": "be004a82-c9a0-4855-a028-19843ba7405a", "Styles": "background:silver", "Classes": "None", "Text": "5\u00a0vials 100\u00a0mg", "ParentId": "066ea7eb-a101-499c-90f9-a20bb1c7abf8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d73c8851-c431-4e32-abbd-2554ca039867", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b28cf12e-a46d-4cc0-ad3f-726f9d3a9d52", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d73c8851-c431-4e32-abbd-2554ca039867"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ec299729-9248-45e2-8913-4cba81bb696d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4f9b86d2-6969-4221-a928-aa05c6e28487", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ec299729-9248-45e2-8913-4cba81bb696d"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>", "ID": "098efaa6-582d-4935-a6f6-418d447e21a9", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "245097ef-e807-4f13-9a4f-b65b15e11c5d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "098efaa6-582d-4935-a6f6-418d447e21a9"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span></b>", "ID": "ce7a9aef-9f73-48c5-9466-4591186a96ca", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "245097ef-e807-4f13-9a4f-b65b15e11c5d"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD\nAND ROUTE(S) OF ADMINISTRATION</span>", "ID": "8b221f43-f272-45a6-a521-260dcb28bba4", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD AND ROUTE(S) OF ADMINISTRATION", "ParentId": "ce7a9aef-9f73-48c5-9466-4591186a96ca"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3f6f8681-beb0-452e-a5ef-d4dff2cabb95", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c56316db-3ab0-4dd0-9d54-100ec6770121", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3f6f8681-beb0-452e-a5ef-d4dff2cabb95"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Read the package leaflet before use.</span></p>", "ID": "47024e6d-0ad6-449d-bf02-e71bf3fcb7f5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Read the package leaflet before use.</span>", "ID": "1f2f0d45-a79c-4c0c-9564-f82184d7cbfe", "Styles": "None", "Classes": "None", "Text": "Read the package leaflet before use.", "ParentId": "47024e6d-0ad6-449d-bf02-e71bf3fcb7f5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Intravenous use.</span></p>", "ID": "b7f519a7-0e33-43ec-8d4d-85a580767172", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Intravenous use.</span>", "ID": "ebdaaa02-bdce-4977-affa-e362c3cb9cd0", "Styles": "None", "Classes": "None", "Text": "Intravenous use.", "ParentId": "b7f519a7-0e33-43ec-8d4d-85a580767172"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Reconstitute and dilute before use.</span></p>", "ID": "e6b81c68-f38d-46ee-ab33-30fb7ebf96b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Reconstitute and dilute before use.</span>", "ID": "da5efbec-de9d-4513-862a-0bebeccd70eb", "Styles": "None", "Classes": "None", "Text": "Reconstitute and dilute before use.", "ParentId": "e6b81c68-f38d-46ee-ab33-30fb7ebf96b6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6e385b78-5c59-4bc2-ba70-6e3492552030", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f771a1ec-de22-4d10-af72-dfd19beb96be", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6e385b78-5c59-4bc2-ba70-6e3492552030"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2a3bff5d-9690-4b62-b318-4ab7eddb54ea", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3ee082f5-3392-47f8-bef1-35e5178411ea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2a3bff5d-9690-4b62-b318-4ab7eddb54ea"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b></p>\n</div>", "ID": "8e050db9-44c1-4322-9ef1-41e77ada3523", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b></p>", "ID": "e2992811-981d-48da-ae91-77f7e9f035cc", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8e050db9-44c1-4322-9ef1-41e77ada3523"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span></b>", "ID": "868aca79-8e70-4cc0-8226-fb7b8afd69b1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e2992811-981d-48da-ae91-77f7e9f035cc"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL\nWARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\nCHILDREN</span>", "ID": "d9d9cdd7-9a04-4bed-8f77-a76dee95983b", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN", "ParentId": "868aca79-8e70-4cc0-8226-fb7b8afd69b1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a89eb357-2c13-4c7b-84ee-0fb428d2364b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "81256ba0-f272-4dbe-82d5-59d7b82f1af1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a89eb357-2c13-4c7b-84ee-0fb428d2364b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><span lang=\"EN-GB\">Keep out of the sight and reach of children.</span></p>", "ID": "89843d28-c54b-4a71-9f94-8ad0317bc799", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Keep out of the sight and reach of children.</span>", "ID": "a5b2b7b9-e0eb-454d-a9e9-3d5d309b2911", "Styles": "None", "Classes": "None", "Text": "Keep out of the sight and reach of children.", "ParentId": "89843d28-c54b-4a71-9f94-8ad0317bc799"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "73fe42a7-e6be-4f5b-a0e9-60119dadd9c8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "57719646-b949-42aa-a3d8-63ddfd5b2d4d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "73fe42a7-e6be-4f5b-a0e9-60119dadd9c8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ce68ddc6-410a-4a4f-be0a-ebdf16fa6959", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "44fab203-3070-4dce-a90c-7ab326a22ec8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ce68ddc6-410a-4a4f-be0a-ebdf16fa6959"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>\n</div>", "ID": "34eaf505-d655-4b8b-bbb5-72c975a184a4", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b></p>", "ID": "2cd55712-6c4d-43e9-b91b-4bd2596e13e8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "34eaf505-d655-4b8b-bbb5-72c975a184a4"}, {"Element": "<b><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span></b>", "ID": "c36587f7-13bd-497f-9e6f-fcef1ac0b086", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2cd55712-6c4d-43e9-b91b-4bd2596e13e8"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER\nSPECIAL WARNING(S), IF NECESSARY</span>", "ID": "356ae200-1373-4529-a7d5-ce0acb1c5001", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER SPECIAL WARNING(S), IF NECESSARY", "ParentId": "c36587f7-13bd-497f-9e6f-fcef1ac0b086"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "73b1223e-6652-41f1-acc8-19822dd427ac", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c96b93b5-c99c-4822-b3ab-1334debdec34", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "73b1223e-6652-41f1-acc8-19822dd427ac"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2bc7ebcc-f307-4000-aad9-f2b058c380a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5fa65994-a635-40fb-9c1e-0686842d0a8b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2bc7ebcc-f307-4000-aad9-f2b058c380a7"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>\n</div>", "ID": "354f8003-5e0b-4851-8841-3416242acd0e", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b></p>", "ID": "b8af0a58-93d8-4051-8534-bd6f2d153535", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "354f8003-5e0b-4851-8841-3416242acd0e"}, {"Element": "<b><span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span></b>", "ID": "09b8e9d9-4eca-43f1-8677-ae6beca04abf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b8af0a58-93d8-4051-8534-bd6f2d153535"}, {"Element": "<span lang=\"EN-GB\">8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY\nDATE</span>", "ID": "17c65c50-a680-4bd6-be8f-1e836e5efe02", "Styles": "None", "Classes": "None", "Text": "8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "09b8e9d9-4eca-43f1-8677-ae6beca04abf"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "073ad46a-0346-4cb7-99a0-7200c21161ac", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "dbdeb5f9-5e0a-47fd-86db-d0ff8e8eddf6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "073ad46a-0346-4cb7-99a0-7200c21161ac"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "1e27e3d1-2617-4f40-8537-7e4fb4ad8736", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">EXP</span>", "ID": "e32932c3-edbf-4e48-9253-7ccd8c07467b", "Styles": "None", "Classes": "None", "Text": "EXP", "ParentId": "1e27e3d1-2617-4f40-8537-7e4fb4ad8736"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">EXP, if not\nrefrigerated ___________________</span></p>", "ID": "a05954b3-56e6-45ef-84fd-453e3180ac00", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">EXP, if not\nrefrigerated ___________________</span>", "ID": "34910724-cc8a-43f5-bddd-ec5dc24d8261", "Styles": "None", "Classes": "None", "Text": "EXP, if not refrigerated ___________________", "ParentId": "a05954b3-56e6-45ef-84fd-453e3180ac00"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "778e6cd8-cc83-4969-83ee-b93db782f447", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "75fe19a0-67c5-4f27-b55c-3d6bb2ffac43", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "778e6cd8-cc83-4969-83ee-b93db782f447"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c15d1525-5b46-4b1c-b67b-ad083681fbe2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a84f140e-783b-4388-ba15-37a3a1cf32ea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c15d1525-5b46-4b1c-b67b-ad083681fbe2"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS</span></b></p>\n</div>", "ID": "4abd4050-2754-4337-b6a1-06efae836950", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS</span></b></p>", "ID": "7ba92fd1-abf8-48cd-a618-f8a81b536646", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4abd4050-2754-4337-b6a1-06efae836950"}, {"Element": "<b><span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS</span></b>", "ID": "f2505948-3240-45ed-bfb7-59fff94b6e1a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7ba92fd1-abf8-48cd-a618-f8a81b536646"}, {"Element": "<span lang=\"EN-GB\">9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS</span>", "ID": "5169f581-5fdc-484a-b0e0-fc4906fcf57c", "Styles": "None", "Classes": "None", "Text": "9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SPECIAL STORAGE CONDITIONS", "ParentId": "f2505948-3240-45ed-bfb7-59fff94b6e1a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9dbc1431-d67f-4bd4-a962-88e6716b6c39", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d51cc6de-fb3e-4f0b-b6cb-b5de40125998", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9dbc1431-d67f-4bd4-a962-88e6716b6c39"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store in a refrigerator.</span></p>", "ID": "64fee5a7-2283-41b3-8795-619411d0f71a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Store in a refrigerator.</span>", "ID": "4e89e94c-a068-48c2-ac9c-c50fc5cf5b2e", "Styles": "None", "Classes": "None", "Text": "Store in a refrigerator.", "ParentId": "64fee5a7-2283-41b3-8795-619411d0f71a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Can be stored at room temperature (up to 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">\u00a0</del></span>\u00b0C) for a single period up\nto 6\u00a0months, but not exceeding the original expiry date.</span></p>", "ID": "b18b3ad6-6edf-4382-b0e4-5b04bc90dea2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Can be stored at room temperature (up to 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">\u00a0</del></span>\u00b0C) for a single period up\nto 6\u00a0months, but not exceeding the original expiry date.</span>", "ID": "83724a10-0b7b-4b61-a0f8-3cf43b3843d2", "Styles": "None", "Classes": "None", "Text": "Can be stored at room temperature (up to 25\u00b0C) for a single period up to 6\u00a0months, but not exceeding the original expiry date.", "ParentId": "b18b3ad6-6edf-4382-b0e4-5b04bc90dea2"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">\u00a0</del></span>", "ID": "0a358ed9-2628-4f11-a069-0d450527f96b", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "83724a10-0b7b-4b61-a0f8-3cf43b3843d2"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">\u00a0</del>", "ID": "a68c4d67-d292-4d99-910f-f2c892a22221", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0a358ed9-2628-4f11-a069-0d450527f96b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ef2ee013-6e5e-42b0-8772-6188c41db96b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "722715ce-2b0e-4abe-bc21-379070083517", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ef2ee013-6e5e-42b0-8772-6188c41db96b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "585ec728-2053-47b6-8937-83d29f361eb1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "81d9510f-377e-4be0-a89e-430f6bc18491", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "585ec728-2053-47b6-8937-83d29f361eb1"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>\n</div>", "ID": "7bb1506f-24a8-45a8-8c47-4c4bd5c705ed", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>", "ID": "36ff8819-f72d-4121-8aa2-de3f1f4e35bc", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7bb1506f-24a8-45a8-8c47-4c4bd5c705ed"}, {"Element": "<b><span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b>", "ID": "a5859b15-93a1-4825-bc7d-e354a37fbe5d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "36ff8819-f72d-4121-8aa2-de3f1f4e35bc"}, {"Element": "<span lang=\"EN-GB\">10.\u00a0\u00a0\u00a0\u00a0 SPECIAL\nPRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS\nDERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span>", "ID": "e554456f-fb02-476c-8948-282c90df61d8", "Styles": "None", "Classes": "None", "Text": "10.\u00a0\u00a0\u00a0\u00a0 SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE", "ParentId": "a5859b15-93a1-4825-bc7d-e354a37fbe5d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "230a3d30-7ccb-4229-a836-7a33d8c6548d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d1242edd-2c69-41bc-b16a-b56a94230d90", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "230a3d30-7ccb-4229-a836-7a33d8c6548d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b38e7299-a62e-43f8-bab3-d1c125d3463d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "301a2ed4-93df-4ea8-8ee8-6e49911f9e04", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b38e7299-a62e-43f8-bab3-d1c125d3463d"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME AND ADDRESS OF THE MARKETING\nAUTHORISATION HOLDER</span></b></p>\n</div>", "ID": "c6ce2de4-d451-427b-93f1-fb6f02763998", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME AND ADDRESS OF THE MARKETING\nAUTHORISATION HOLDER</span></b></p>", "ID": "df614884-cbeb-4444-9f2a-5064923581c2", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c6ce2de4-d451-427b-93f1-fb6f02763998"}, {"Element": "<b><span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME AND ADDRESS OF THE MARKETING\nAUTHORISATION HOLDER</span></b>", "ID": "471a437d-13e7-4e21-afcf-d71fe159987a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "df614884-cbeb-4444-9f2a-5064923581c2"}, {"Element": "<span lang=\"EN-GB\">11.\u00a0\u00a0\u00a0\u00a0 NAME AND ADDRESS OF THE MARKETING\nAUTHORISATION HOLDER</span>", "ID": "36a08717-d3a8-4199-b02a-7ebff1b30bfe", "Styles": "None", "Classes": "None", "Text": "11.\u00a0\u00a0\u00a0\u00a0 NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER", "ParentId": "471a437d-13e7-4e21-afcf-d71fe159987a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c90b39d3-f332-4127-a77f-7d1016f68f5c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ba599ff8-f99d-4b5f-b06b-88dddfb6c4d7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c90b39d3-f332-4127-a77f-7d1016f68f5c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Janssen\nBiologics B.V.</span></p>", "ID": "05b9a6b1-6b0c-4b28-82d2-f138062cdb8a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Janssen\nBiologics B.V.</span>", "ID": "afe4c4fc-6c5d-4ffe-9105-36b0f8c440fc", "Styles": "None", "Classes": "None", "Text": "Janssen Biologics B.V.", "ParentId": "05b9a6b1-6b0c-4b28-82d2-f138062cdb8a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Einsteinweg\n101</span></p>", "ID": "89fd7b3a-5872-4318-af23-1f60e2a8a9f6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Einsteinweg\n101</span>", "ID": "bb3468cb-abfc-488f-9142-a2e46871d519", "Styles": "None", "Classes": "None", "Text": "Einsteinweg 101", "ParentId": "89fd7b3a-5872-4318-af23-1f60e2a8a9f6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">2333 CB\nLeiden</span></p>", "ID": "b5a36d1d-c3c7-43a2-a21c-297bc9d6557f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">2333 CB\nLeiden</span>", "ID": "7f81905d-cfe3-4c28-aa2d-faeb0e8a9e77", "Styles": "None", "Classes": "None", "Text": "2333 CB Leiden", "ParentId": "b5a36d1d-c3c7-43a2-a21c-297bc9d6557f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The\nNetherlands</span></p>", "ID": "724f44cd-ebb7-4a37-afd8-6bcc75925efa", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The\nNetherlands</span>", "ID": "e44f54ee-0300-40c8-97fa-68042007a4f0", "Styles": "None", "Classes": "None", "Text": "The Netherlands", "ParentId": "724f44cd-ebb7-4a37-afd8-6bcc75925efa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4057c8a1-40ac-4010-a07b-753172318d68", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cb4483e8-5197-4641-9715-501108b19b84", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4057c8a1-40ac-4010-a07b-753172318d68"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6b3b12c2-7063-45c0-b166-f5a26913d89e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5817398b-e819-4e47-a163-5352960abd1f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6b3b12c2-7063-45c0-b166-f5a26913d89e"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)</span></b></p>\n</div>", "ID": "c44ab552-66a2-4f02-be5e-2b545517e7b1", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)</span></b></p>", "ID": "bddd55b8-1737-469b-9a39-9797cacda3f0", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c44ab552-66a2-4f02-be5e-2b545517e7b1"}, {"Element": "<b><span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)</span></b>", "ID": "ac61addf-a40c-4e1a-85c4-aa3361288824", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bddd55b8-1737-469b-9a39-9797cacda3f0"}, {"Element": "<span lang=\"EN-GB\">12.\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)</span>", "ID": "c55c5dc0-f4cb-4081-b2ac-13c7e4ac3fe5", "Styles": "None", "Classes": "None", "Text": "12.\u00a0\u00a0\u00a0\u00a0 MARKETING AUTHORISATION NUMBER(S)", "ParentId": "ac61addf-a40c-4e1a-85c4-aa3361288824"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cfe3fab0-eca6-40eb-acff-d62ad4cfbf96", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "542c72ec-844f-4b23-9fde-16277b25c01c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cfe3fab0-eca6-40eb-acff-d62ad4cfbf96"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">EU/1/99/116/001\n<span style=\"background:silver\">1\u00a0vial 100\u00a0mg</span></span></p>", "ID": "f8d3f3a5-2321-41dd-96dc-e9c228f87adc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">EU/1/99/116/001\n<span style=\"background:silver\">1\u00a0vial 100\u00a0mg</span></span>", "ID": "e4989661-39f6-4061-b07c-138f1344a826", "Styles": "None", "Classes": "None", "Text": "EU/1/99/116/001 ", "ParentId": "f8d3f3a5-2321-41dd-96dc-e9c228f87adc"}, {"Element": "<span style=\"background:silver\">1\u00a0vial 100\u00a0mg</span>", "ID": "c66413e8-2027-4693-be57-21c6a442a719", "Styles": "background:silver", "Classes": "None", "Text": "1\u00a0vial 100\u00a0mg", "ParentId": "e4989661-39f6-4061-b07c-138f1344a826"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">EU/1/99/116/002 2\u00a0vials 100\u00a0mg</span></p>", "ID": "88410dc0-d463-4e8e-b741-7d78135c1f6c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">EU/1/99/116/002 2\u00a0vials 100\u00a0mg</span>", "ID": "adef63b9-ca11-435f-8c9f-e13fd1fb8dc1", "Styles": "background:silver", "Classes": "None", "Text": "EU/1/99/116/002 2\u00a0vials 100\u00a0mg", "ParentId": "88410dc0-d463-4e8e-b741-7d78135c1f6c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">EU/1/99/116/003 3\u00a0vials 100\u00a0mg</span></p>", "ID": "0bf515e8-db61-47e4-8f74-8a62869cccc3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">EU/1/99/116/003 3\u00a0vials 100\u00a0mg</span>", "ID": "07541848-db91-4e05-a0d5-69aecf07bec3", "Styles": "background:silver", "Classes": "None", "Text": "EU/1/99/116/003 3\u00a0vials 100\u00a0mg", "ParentId": "0bf515e8-db61-47e4-8f74-8a62869cccc3"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">EU/1/99/116/004 4\u00a0vials 100\u00a0mg</span></p>", "ID": "c9b671f7-5c08-4247-97c7-e9949fab25ba", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">EU/1/99/116/004 4\u00a0vials 100\u00a0mg</span>", "ID": "97128c21-b8fb-4d6c-9ccb-580b3ca0aeee", "Styles": "background:silver", "Classes": "None", "Text": "EU/1/99/116/004 4\u00a0vials 100\u00a0mg", "ParentId": "c9b671f7-5c08-4247-97c7-e9949fab25ba"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">EU/1/99/116/005 5\u00a0vials 100\u00a0mg</span></p>", "ID": "3e4d2667-0d6a-4b2c-b25d-d928dae96f5e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">EU/1/99/116/005 5\u00a0vials 100\u00a0mg</span>", "ID": "378ae65d-fe0a-44d9-9a66-148fece1573f", "Styles": "background:silver", "Classes": "None", "Text": "EU/1/99/116/005 5\u00a0vials 100\u00a0mg", "ParentId": "3e4d2667-0d6a-4b2c-b25d-d928dae96f5e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7db84d26-74c0-4444-8f7f-10731ce3886f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3c3ec61c-e7b9-46f0-813f-94cdffbefbce", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7db84d26-74c0-4444-8f7f-10731ce3886f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "da8f89f4-9d79-4f0d-8907-d991b8a5477e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "de83802a-5da5-43eb-9224-373a717c8935", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "da8f89f4-9d79-4f0d-8907-d991b8a5477e"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span></b></p>\n</div>", "ID": "3b212cc0-d37c-492c-8920-800433d90860", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span></b></p>", "ID": "807f6056-6e5f-49b1-b45e-c606972bfb0c", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3b212cc0-d37c-492c-8920-800433d90860"}, {"Element": "<b><span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span></b>", "ID": "71dabe7e-1f5d-4788-ae35-7438c80d345e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "807f6056-6e5f-49b1-b45e-c606972bfb0c"}, {"Element": "<span lang=\"EN-GB\">13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span>", "ID": "17939071-4ea1-4e4d-a2d9-ed16716c5613", "Styles": "None", "Classes": "None", "Text": "13.\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "71dabe7e-1f5d-4788-ae35-7438c80d345e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "65dfa22a-da58-4fe4-af83-47f853bde16c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a4eeb09d-f00b-4c3d-ad51-c9f7f0e8e88f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "65dfa22a-da58-4fe4-af83-47f853bde16c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch</span></p>", "ID": "506433d8-bfe0-463b-91c9-de50ccfde2f9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Batch</span>", "ID": "bf78ada1-9734-4015-9210-3c47c46209e8", "Styles": "None", "Classes": "None", "Text": "Batch", "ParentId": "506433d8-bfe0-463b-91c9-de50ccfde2f9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "91209128-8db7-4fe3-80ed-f286417e3c1d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "08bfb705-d797-4b72-9e6a-431ee37e1690", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "91209128-8db7-4fe3-80ed-f286417e3c1d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "00baa800-5a57-4921-862a-d92c552b765a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4fead3b3-642b-4c37-86e4-51bb61567b67", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "00baa800-5a57-4921-862a-d92c552b765a"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>\n</div>", "ID": "fefdcc33-dbd2-40d3-ab1e-522ac7a7729f", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span></b></p>", "ID": "a651da42-6611-47dc-b9ac-3d9e36f5df6e", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fefdcc33-dbd2-40d3-ab1e-522ac7a7729f"}, {"Element": "<b><span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span></b>", "ID": "6573faa1-74a2-4fe4-ba77-511d9069b6c1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a651da42-6611-47dc-b9ac-3d9e36f5df6e"}, {"Element": "<span lang=\"EN-GB\">14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY</span>", "ID": "412e7b31-016c-486a-b9e6-fbe52c595bff", "Styles": "None", "Classes": "None", "Text": "14.\u00a0\u00a0\u00a0\u00a0 GENERAL CLASSIFICATION FOR SUPPLY", "ParentId": "6573faa1-74a2-4fe4-ba77-511d9069b6c1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "45b5c30e-6ae4-49c8-898d-434ce40bdcd0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d20e8b4d-c84a-449b-b417-e99b61adba02", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "45b5c30e-6ae4-49c8-898d-434ce40bdcd0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7171f3e0-cd14-4c8c-81d8-fc6fb221121e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b40eaa78-024f-48d7-bd85-a01dc743455b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7171f3e0-cd14-4c8c-81d8-fc6fb221121e"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE</span></b></p>\n</div>", "ID": "c69857dd-44de-4434-b1b2-245364f77cf8", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE</span></b></p>", "ID": "41536a39-ed81-4e52-9399-c03c3c8975b8", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c69857dd-44de-4434-b1b2-245364f77cf8"}, {"Element": "<b><span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE</span></b>", "ID": "c89202f4-a3e5-433a-9612-172d33e39bda", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "41536a39-ed81-4e52-9399-c03c3c8975b8"}, {"Element": "<span lang=\"EN-GB\">15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE</span>", "ID": "42ad6106-7343-4b14-ae1e-6750ad90fc83", "Styles": "None", "Classes": "None", "Text": "15.\u00a0\u00a0\u00a0\u00a0 INSTRUCTIONS ON USE", "ParentId": "c89202f4-a3e5-433a-9612-172d33e39bda"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c890e408-dbca-44fe-87ea-d1d8e11c3b31", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5f8f2f69-09f5-4cd6-8778-8d1ab1b01fcc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c890e408-dbca-44fe-87ea-d1d8e11c3b31"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "35f8d545-df58-4b8d-a5a1-17b025a0c558", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c3683a07-840a-436c-88dc-bb9d747fbd0d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "35f8d545-df58-4b8d-a5a1-17b025a0c558"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</span></b></p>\n</div>", "ID": "b661bece-f558-41ac-a0c1-41f1fbeb813f", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</span></b></p>", "ID": "e475f033-a5de-417e-a418-e9da1ab050e4", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b661bece-f558-41ac-a0c1-41f1fbeb813f"}, {"Element": "<b><span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</span></b>", "ID": "e1a38f71-b377-4d22-9522-ca55cd07e1ea", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e475f033-a5de-417e-a418-e9da1ab050e4"}, {"Element": "<span lang=\"EN-GB\">16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE</span>", "ID": "6f717eff-4610-44b6-b528-576015535da6", "Styles": "None", "Classes": "None", "Text": "16.\u00a0\u00a0\u00a0\u00a0 INFORMATION IN BRAILLE", "ParentId": "e1a38f71-b377-4d22-9522-ca55cd07e1ea"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8ffe7d98-d5e1-4bad-9a53-a83090c94736", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "37027a64-03ab-4b23-8fca-3cd87c514169", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ffe7d98-d5e1-4bad-9a53-a83090c94736"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">Justification for\nnot including Braille accepted.</span></p>", "ID": "81ff8b2c-777c-44b7-b03e-e0239402449e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">Justification for\nnot including Braille accepted.</span>", "ID": "a57bc746-9a78-4fb2-8fc4-4a15f63c7eb6", "Styles": "background:silver", "Classes": "None", "Text": "Justification for not including Braille accepted.", "ParentId": "81ff8b2c-777c-44b7-b03e-e0239402449e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ce9e8fdc-fead-4caa-99f5-0cc86ed8048e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "60099fbf-ddd0-4392-99d5-34ca4f3a4886", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ce9e8fdc-fead-4caa-99f5-0cc86ed8048e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9b748c07-ed38-4a2c-a479-8529da817360", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b0aeb232-12b6-48e6-a715-9e3302d5f900", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9b748c07-ed38-4a2c-a479-8529da817360"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b></p>\n</div>", "ID": "79795372-79a1-4161-8d82-e13014579e7c", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b></p>", "ID": "eb100608-5442-4ab1-8957-c7e26178c5c8", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "79795372-79a1-4161-8d82-e13014579e7c"}, {"Element": "<b><span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span></b>", "ID": "4a297777-ad2b-49bc-bfc0-019fadd332ec", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "eb100608-5442-4ab1-8957-c7e26178c5c8"}, {"Element": "<span lang=\"EN-GB\">17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE</span>", "ID": "5cb082e2-060e-463b-b7e3-d2b23ad00eae", "Styles": "None", "Classes": "None", "Text": "17.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 2D BARCODE", "ParentId": "4a297777-ad2b-49bc-bfc0-019fadd332ec"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "601bdb9a-66a1-46c3-9a96-b183fed0421c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0d4cb94a-11c7-4559-b74f-a89014146c29", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "601bdb9a-66a1-46c3-9a96-b183fed0421c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"background:silver\">2D barcode\ncarrying the unique identifier included.</span></p>", "ID": "aa3a1479-22de-4461-9375-dd5fc7b9bc64", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"background:silver\">2D barcode\ncarrying the unique identifier included.</span>", "ID": "c8985f48-cb41-400d-a1cd-1b6c67c434b4", "Styles": "background:silver", "Classes": "None", "Text": "2D barcode carrying the unique identifier included.", "ParentId": "aa3a1479-22de-4461-9375-dd5fc7b9bc64"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a16a4a8b-5038-4ec3-b3ad-520bad08d79f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ce790912-0547-4c57-8b40-02b51d87b839", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a16a4a8b-5038-4ec3-b3ad-520bad08d79f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "14361967-a5b1-4d42-b0bf-d61c601b84cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e052914a-483c-48a9-9844-7ec9fb64a645", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "14361967-a5b1-4d42-b0bf-d61c601b84cd"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 HUMAN READABLE\nDATA</span></b></p>\n</div>", "ID": "22134967-bd3e-4da7-b56c-15f3c1860c58", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 HUMAN READABLE\nDATA</span></b></p>", "ID": "c7e272c7-3205-4bc5-899f-76f46ecdc1cb", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "22134967-bd3e-4da7-b56c-15f3c1860c58"}, {"Element": "<b><span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 HUMAN READABLE\nDATA</span></b>", "ID": "9a97a98a-e92e-40ab-bbe3-1dd0468d91f0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c7e272c7-3205-4bc5-899f-76f46ecdc1cb"}, {"Element": "<span lang=\"EN-GB\">18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 HUMAN READABLE\nDATA</span>", "ID": "8a61695e-5e74-4b3b-9c0e-48beca967f22", "Styles": "None", "Classes": "None", "Text": "18.\u00a0\u00a0\u00a0\u00a0 UNIQUE IDENTIFIER \u2013 HUMAN READABLE DATA", "ParentId": "9a97a98a-e92e-40ab-bbe3-1dd0468d91f0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0471bd81-8a80-4f09-a8cb-8b640878c3f0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "87c4a9f5-1e39-45ee-a15b-36febe45892c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0471bd81-8a80-4f09-a8cb-8b640878c3f0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PC<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del></span></span></p>", "ID": "49b7dab2-1843-4204-9a0f-3bf8c159ece2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">PC<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del></span></span>", "ID": "648d2399-7c3a-433f-982f-9d79df038d23", "Styles": "None", "Classes": "None", "Text": "PC", "ParentId": "49b7dab2-1843-4204-9a0f-3bf8c159ece2"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del></span>", "ID": "7b8c4732-f6dd-400e-9a89-e89b3f463429", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "648d2399-7c3a-433f-982f-9d79df038d23"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del>", "ID": "36799981-e278-4f88-828c-ccad46c8689b", "Styles": "None", "Classes": "None", "Text": ":", "ParentId": "7b8c4732-f6dd-400e-9a89-e89b3f463429"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">SN<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del></span></span></p>", "ID": "76af467f-1a55-49e2-adff-d3480b6bd2bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">SN<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del></span></span>", "ID": "b0bed665-6529-4b32-8e3c-8c0579183cc1", "Styles": "None", "Classes": "None", "Text": "SN", "ParentId": "76af467f-1a55-49e2-adff-d3480b6bd2bb"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del></span>", "ID": "88ac8470-a1c4-4842-98ee-c5107b74dcc6", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "b0bed665-6529-4b32-8e3c-8c0579183cc1"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del>", "ID": "7751434f-6502-4a1f-8ea7-49ad4e8efca7", "Styles": "None", "Classes": "None", "Text": ":", "ParentId": "88ac8470-a1c4-4842-98ee-c5107b74dcc6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">NN<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del></span></span></p>", "ID": "9ba66159-f9a7-4e13-9f5c-dbcf5a9033c4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">NN<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del></span></span>", "ID": "4338bfe9-4f80-4bec-96f2-054f45f9e693", "Styles": "None", "Classes": "None", "Text": "NN", "ParentId": "9ba66159-f9a7-4e13-9f5c-dbcf5a9033c4"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del></span>", "ID": "4cf130e8-9e69-402c-817a-82218f39b055", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "4338bfe9-4f80-4bec-96f2-054f45f9e693"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:16\">:</del>", "ID": "e2447a12-06a5-48b9-8286-cf319b375a97", "Styles": "None", "Classes": "None", "Text": ":", "ParentId": "4cf130e8-9e69-402c-817a-82218f39b055"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "321914e8-d807-44a8-ae01-5f1dddc5dfe9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "0b6b5f73-5df7-49ea-acb3-798e855c18fd", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "321914e8-d807-44a8-ae01-5f1dddc5dfe9"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "a377ff79-838e-4a43-96f9-fed044bbccba", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "0b6b5f73-5df7-49ea-acb3-798e855c18fd"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR\nON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL LABEL</span></b></p>\n</div>", "ID": "d779eb78-89b0-4b76-8e70-5a4890bf6a5e", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "    ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR\nON SMALL IMMEDIATE PACKAGING UNITS</span></b></p>", "ID": "5a9e4681-fd49-4e9b-a765-99ce134cac10", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d779eb78-89b0-4b76-8e70-5a4890bf6a5e"}, {"Element": "<b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR\nON SMALL IMMEDIATE PACKAGING UNITS</span></b>", "ID": "bab6c31e-6f22-4f97-9acc-4e3f39562503", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5a9e4681-fd49-4e9b-a765-99ce134cac10"}, {"Element": "<span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR\nON SMALL IMMEDIATE PACKAGING UNITS</span>", "ID": "905c2054-93a2-4193-a96c-1be301b8fcf9", "Styles": "None", "Classes": "None", "Text": "MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS", "ParentId": "bab6c31e-6f22-4f97-9acc-4e3f39562503"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "237a6bf9-20b2-48b6-91da-a34f8a91ee6d", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d779eb78-89b0-4b76-8e70-5a4890bf6a5e"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "4d02a8f0-33d0-4b68-8927-b8ebebe0d3e1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "237a6bf9-20b2-48b6-91da-a34f8a91ee6d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ff5e8f5e-e3be-4911-bb48-6b36429bae7d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4d02a8f0-33d0-4b68-8927-b8ebebe0d3e1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL LABEL</span></b></p>", "ID": "03da50d4-c6ed-4ea4-acf1-cf117226d646", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d779eb78-89b0-4b76-8e70-5a4890bf6a5e"}, {"Element": "<b><span lang=\"EN-GB\">VIAL LABEL</span></b>", "ID": "e0521c3d-afc5-4071-9444-2645e2a64316", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "03da50d4-c6ed-4ea4-acf1-cf117226d646"}, {"Element": "<span lang=\"EN-GB\">VIAL LABEL</span>", "ID": "50f6374d-2f68-4410-af86-cad568e2475d", "Styles": "None", "Classes": "None", "Text": "VIAL LABEL", "ParentId": "e0521c3d-afc5-4071-9444-2645e2a64316"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "258eae9a-8a5e-41ed-8508-39bdb8d206b9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "85832a62-dfbb-48f5-8b91-8e1a29bcd724", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "258eae9a-8a5e-41ed-8508-39bdb8d206b9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fc7b6bde-ad5a-4f2c-aa4b-4343a7dd84d8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be8fa96f-e0b7-4345-b58f-f8a72045778f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fc7b6bde-ad5a-4f2c-aa4b-4343a7dd84d8"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>\n</div>", "ID": "3cd250bb-7b94-445a-a5b8-d1a0b695d6e5", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT\nAND ROUTE(S) OF ADMINISTRATION</span></b></p>", "ID": "02a84451-630a-4c9d-83f0-ba9addddfc3d", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3cd250bb-7b94-445a-a5b8-d1a0b695d6e5"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT\nAND ROUTE(S) OF ADMINISTRATION</span></b>", "ID": "2ff07394-e438-4025-8383-61038f69ceae", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "02a84451-630a-4c9d-83f0-ba9addddfc3d"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT\nAND ROUTE(S) OF ADMINISTRATION</span>", "ID": "3face53b-9580-4ea7-a156-f8a52476d765", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION", "ParentId": "2ff07394-e438-4025-8383-61038f69ceae"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "672bcd18-cdeb-4c1b-b038-a8d44e65351e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4a240b97-57ee-4223-b025-ff6fb7fcf2e9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "672bcd18-cdeb-4c1b-b038-a8d44e65351e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Remicade\n100\u00a0mg powder for concentrate</span></p>", "ID": "9032ed3e-6b64-43fb-9b0e-2ec74813afa1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade\n100\u00a0mg powder for concentrate</span>", "ID": "95d52072-5fd4-4190-a933-2b3af5c1c1c2", "Styles": "None", "Classes": "None", "Text": "Remicade 100\u00a0mg powder for concentrate", "ParentId": "9032ed3e-6b64-43fb-9b0e-2ec74813afa1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">infliximab</span></p>", "ID": "a7498856-d1ba-4ffc-aae3-43772bbaad9f", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">infliximab</span>", "ID": "f7698982-3de7-4b43-874e-0cfd33b80ea1", "Styles": "None", "Classes": "None", "Text": "infliximab", "ParentId": "a7498856-d1ba-4ffc-aae3-43772bbaad9f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">IV</span></p>", "ID": "91aba43c-7493-430e-a704-a5b105955d73", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">IV</span>", "ID": "86a0d245-80cd-4e97-8737-ad413f53af35", "Styles": "None", "Classes": "None", "Text": "IV", "ParentId": "91aba43c-7493-430e-a704-a5b105955d73"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "10c3b0dd-bfbb-41fe-80c8-fcf9f67a2179", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "3c08f281-eefa-45c2-8312-8104ddbfc529", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "10c3b0dd-bfbb-41fe-80c8-fcf9f67a2179"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0c846c89-a3ff-4180-9ddc-b9ce495ac0bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0645125e-1c52-45ac-9527-267b7283834e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0c846c89-a3ff-4180-9ddc-b9ce495ac0bb"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD OF ADMINISTRATION</span></b></p>\n</div>", "ID": "1d49168a-b588-4fea-82cc-a4322b1749e3", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD OF ADMINISTRATION</span></b></p>", "ID": "6fda792c-0f75-4ee6-869f-d9efe0cf73e6", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1d49168a-b588-4fea-82cc-a4322b1749e3"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD OF ADMINISTRATION</span></b>", "ID": "8337ffad-1c91-4bb6-9082-23cdc3b8ed39", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6fda792c-0f75-4ee6-869f-d9efe0cf73e6"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD OF ADMINISTRATION</span>", "ID": "f2a7e828-6ad6-4b86-9bbf-1b14ca24539e", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 METHOD OF ADMINISTRATION", "ParentId": "8337ffad-1c91-4bb6-9082-23cdc3b8ed39"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "64de0704-ec16-4cc4-8446-01ad43816268", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8671e567-ea8e-4a9e-b84a-0e706e3a09c0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "64de0704-ec16-4cc4-8446-01ad43816268"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">For intravenous\nuse after reconstitution and dilution.</span></p>", "ID": "1a168369-ffcd-4443-b432-a12ca15751ba", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">For intravenous\nuse after reconstitution and dilution.</span>", "ID": "9aa04487-5bfb-43ea-88ba-30e0d11c3cf0", "Styles": "None", "Classes": "None", "Text": "For intravenous use after reconstitution and dilution.", "ParentId": "1a168369-ffcd-4443-b432-a12ca15751ba"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "93a81159-453c-40f5-9386-ea8567efab9b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e515ebbf-fc4e-41ab-b717-9f2e4afe3062", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "93a81159-453c-40f5-9386-ea8567efab9b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7688a76e-3b65-46d3-b616-603dd41ef7b1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f3dc5d8f-fcba-4a09-a2cc-0c6b169264e8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7688a76e-3b65-46d3-b616-603dd41ef7b1"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span></b></p>\n</div>", "ID": "868924b6-fece-4b70-84d4-cc6f73e86d39", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span></b></p>", "ID": "4190df73-9c4e-41c3-b5aa-14af4ee6568a", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "868924b6-fece-4b70-84d4-cc6f73e86d39"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span></b>", "ID": "30f6d97d-ef93-44e2-9fa6-4f787a7b9a38", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4190df73-9c4e-41c3-b5aa-14af4ee6568a"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE</span>", "ID": "3348cf1b-b77b-4995-bd3d-aa0f4e468492", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EXPIRY DATE", "ParentId": "30f6d97d-ef93-44e2-9fa6-4f787a7b9a38"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "93202b4c-749d-4ad0-935d-516ad4be517d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "71483644-9db1-44f9-96b8-efff111ce1ad", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "93202b4c-749d-4ad0-935d-516ad4be517d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">EXP</span></p>", "ID": "ae78b989-e1ce-4071-90be-52482cb29051", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">EXP</span>", "ID": "27dd2610-cc6d-46be-88b8-8f4c06e33d90", "Styles": "None", "Classes": "None", "Text": "EXP", "ParentId": "ae78b989-e1ce-4071-90be-52482cb29051"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3c95d515-3b7a-4c89-85bd-4c576c2e4ea2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e0d05355-da87-41ea-8ca6-a208145fabd1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3c95d515-3b7a-4c89-85bd-4c576c2e4ea2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "250a0f6a-73b9-4ec5-b4bc-9f79c9943303", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "99b63a1f-115b-4f7b-a77c-a65578c66b3d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "250a0f6a-73b9-4ec5-b4bc-9f79c9943303"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span></b></p>\n</div>", "ID": "3cdef0c8-7510-4c99-a86a-11928a28f35e", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span></b></p>", "ID": "4ec92d24-d756-42c9-84fe-f0761dd674e5", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3cdef0c8-7510-4c99-a86a-11928a28f35e"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span></b>", "ID": "a45921c6-62cc-4ec4-bf50-db2d841f34e1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4ec92d24-d756-42c9-84fe-f0761dd674e5"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER</span>", "ID": "aef9937a-55dd-4a36-bf9a-ccb81f70707a", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BATCH NUMBER", "ParentId": "a45921c6-62cc-4ec4-bf50-db2d841f34e1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "65711311-7cdc-4987-8e21-c6170558ecc8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d3a2ea8b-e6fc-4b8d-9c3b-be1a76fbfd8e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "65711311-7cdc-4987-8e21-c6170558ecc8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Batch</span></p>", "ID": "66611010-b7b0-4441-9a06-c96839d62dcc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Batch</span>", "ID": "9ee9facc-f63d-4176-b937-69f26c92bd8c", "Styles": "None", "Classes": "None", "Text": "Batch", "ParentId": "66611010-b7b0-4441-9a06-c96839d62dcc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cca0912c-799d-4022-8416-b88798cd22d1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bca0b324-5a1d-44d8-bd0b-f9e018d708ad", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cca0912c-799d-4022-8416-b88798cd22d1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "04cee482-9bd4-453e-bbfb-8f5a1c59ada2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2fc058f-c310-4ae9-9a6a-26ee4216c9ec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "04cee482-9bd4-453e-bbfb-8f5a1c59ada2"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS BY WEIGHT, BY VOLUME\nOR BY UNIT</span></b></p>\n</div>", "ID": "ffa54ffd-90c0-4848-9308-0af7f7e6e5ca", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS BY WEIGHT, BY VOLUME\nOR BY UNIT</span></b></p>", "ID": "6200ec35-d88a-4af3-9a2e-0cc40f5ba462", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ffa54ffd-90c0-4848-9308-0af7f7e6e5ca"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS BY WEIGHT, BY VOLUME\nOR BY UNIT</span></b>", "ID": "6373daed-fa23-43a0-898d-7b17ca5290f4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6200ec35-d88a-4af3-9a2e-0cc40f5ba462"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS BY WEIGHT, BY VOLUME\nOR BY UNIT</span>", "ID": "20b0f80e-05a8-4457-acec-989ae22310f5", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT", "ParentId": "6373daed-fa23-43a0-898d-7b17ca5290f4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "62336bbc-b049-43d4-8e86-6702998524b0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "edbff48c-2bb0-4ced-b7de-0123402cdc13", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "62336bbc-b049-43d4-8e86-6702998524b0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">100\u00a0mg</span></p>", "ID": "0ef25be5-1540-4548-8e8c-fa14dc0b6829", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">100\u00a0mg</span>", "ID": "02c2ffb2-e364-41a6-aed4-a4cce9a92346", "Styles": "None", "Classes": "None", "Text": "100\u00a0mg", "ParentId": "0ef25be5-1540-4548-8e8c-fa14dc0b6829"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3b6b69df-aeae-4d64-a875-c13ae3b9c7e5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5773e91b-861f-4cda-80fc-7b6c07b5a97d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3b6b69df-aeae-4d64-a875-c13ae3b9c7e5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6bee5881-9cd8-4d77-8ff7-a796afbe9bca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d14e98ae-37d7-4a8a-9a56-09ad121e719c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6bee5881-9cd8-4d77-8ff7-a796afbe9bca"}, {"Element": "<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\">\n<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b></p>\n</div>", "ID": "47305425-1a22-48df-925e-c6803dcfa777", "Styles": "border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b></p>", "ID": "bd2ce236-b97c-47fa-9fca-ab0b8d6ff965", "Styles": "page-break-after:avoid;border:none;padding:0in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "47305425-1a22-48df-925e-c6803dcfa777"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span></b>", "ID": "e1815f23-f47b-45a3-8beb-28ef2cc06704", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bd2ce236-b97c-47fa-9fca-ab0b8d6ff965"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER</span>", "ID": "bda4e4ca-c9ca-44b5-b38a-81f4dfdfd222", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 OTHER", "ParentId": "e1815f23-f47b-45a3-8beb-28ef2cc06704"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5486b430-6446-43a1-b22e-181a95a83fed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a4897c63-3a7b-47b6-bbb1-f282985b829c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5486b430-6446-43a1-b22e-181a95a83fed"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4fd901e2-5f3b-4e75-8778-c2722ac5c683", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bc5647c4-8157-4258-a365-6dd4861efa22", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4fd901e2-5f3b-4e75-8778-c2722ac5c683"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "3686fdbd-38b7-4636-8b13-438cb5ffa735", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "8e410c25-006f-48ed-a25e-ee57ecc19ddf", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "3686fdbd-38b7-4636-8b13-438cb5ffa735"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a8ab3500-9a38-4da4-a31d-da8bee0f0f32", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9ca399fd-7e9a-4642-bd74-24661122ebec", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a8ab3500-9a38-4da4-a31d-da8bee0f0f32"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"619\">\n<tr>\n<td style=\"width:232.2pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"font-size:16.0pt\">Remicade</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">infliximab</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"font-size:16.0pt\">Patient Reminder Card</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Name patient:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Name doctor:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Telephone number doctor:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">This patient reminder card contains\n  important safety information that you need to be aware of before and during\n  treatment with Remicade.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Show this card to any doctor involved in\n  your treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Please read the Remicade \u2018Package\n  Leaflet\u2019 carefully before you start using this medicine.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of Remicade therapy initiation:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Current administrations:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is important that you and your doctor\n  record the brand name and batch number of your medicine.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ask your doctor to record the type and\n  date of last screening(s) for tuberculosis (TB) below:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Test\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Test</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Date</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Result:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Result:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Please make sure you also have a list of\n  all other medicines that you are using with you at any visit to a healthcare\n  professional.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">List of allergies:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">List of other medicines:</span></p>\n</td>\n<td style=\"width:232.2pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:14.0pt\">Infections</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Before treatment with Remicade</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor if you have an infection even\n  if it is a very minor one</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">It is very important that you tell your doctor\n  if you have ever had TB, or if you have been in close contact with someone\n  who has had TB. Your doctor will test you to see if you have TB. Ask your\n  doctor to record the type and date of your last screening(s) for TB on the\n  card</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor if you have hepatitis B or if\n  you know or suspect you are a carrier of the hepatitis B virus.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">During treatment with Remicade</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor straight away if you have\n  signs of an infection. Signs include a fever, feeling tired, (persistent)\n  cough, shortness of breath, weight loss, night sweats, diarrhea, wounds,\n  dental problems, burning when urinating or \u2018flu\u2011like\u2019\n  signs.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:14.0pt\">Pregnancy and\n  Vaccinations</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">In case you have received Remicade while you\n  were pregnant, it is important that you inform your baby\u2019s doctor about\n  it before your baby receives any vaccine. Your baby should not receive a\n  \u2018live vaccine\u2019, such as BCG (used to prevent tuberculosis) within\n  6\u00a0months after birth.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep this card with you for 4\u00a0months\n  after your dose of Remicade, or in case of pregnancy for at least\n  6\u00a0months after the birth of your baby. Side effects may occur a long\n  time after your last dose.</span></p>\n</td>\n</tr>\n</table>", "ID": "0e2ce950-73b3-4a22-b6bb-c9dcdcb4900d", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<tr>\n<td style=\"width:232.2pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"font-size:16.0pt\">Remicade</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">infliximab</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"font-size:16.0pt\">Patient Reminder Card</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Name patient:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Name doctor:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Telephone number doctor:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">This patient reminder card contains\n  important safety information that you need to be aware of before and during\n  treatment with Remicade.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Show this card to any doctor involved in\n  your treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Please read the Remicade \u2018Package\n  Leaflet\u2019 carefully before you start using this medicine.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of Remicade therapy initiation:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Current administrations:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is important that you and your doctor\n  record the brand name and batch number of your medicine.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ask your doctor to record the type and\n  date of last screening(s) for tuberculosis (TB) below:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Test\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Test</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Date</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Result:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Result:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Please make sure you also have a list of\n  all other medicines that you are using with you at any visit to a healthcare\n  professional.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">List of allergies:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">List of other medicines:</span></p>\n</td>\n<td style=\"width:232.2pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:14.0pt\">Infections</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Before treatment with Remicade</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor if you have an infection even\n  if it is a very minor one</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">It is very important that you tell your doctor\n  if you have ever had TB, or if you have been in close contact with someone\n  who has had TB. Your doctor will test you to see if you have TB. Ask your\n  doctor to record the type and date of your last screening(s) for TB on the\n  card</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor if you have hepatitis B or if\n  you know or suspect you are a carrier of the hepatitis B virus.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">During treatment with Remicade</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor straight away if you have\n  signs of an infection. Signs include a fever, feeling tired, (persistent)\n  cough, shortness of breath, weight loss, night sweats, diarrhea, wounds,\n  dental problems, burning when urinating or \u2018flu\u2011like\u2019\n  signs.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:14.0pt\">Pregnancy and\n  Vaccinations</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">In case you have received Remicade while you\n  were pregnant, it is important that you inform your baby\u2019s doctor about\n  it before your baby receives any vaccine. Your baby should not receive a\n  \u2018live vaccine\u2019, such as BCG (used to prevent tuberculosis) within\n  6\u00a0months after birth.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep this card with you for 4\u00a0months\n  after your dose of Remicade, or in case of pregnancy for at least\n  6\u00a0months after the birth of your baby. Side effects may occur a long\n  time after your last dose.</span></p>\n</td>\n</tr>", "ID": "f4eab976-75f6-42be-8599-04db97da047a", "Styles": "None", "Classes": "None", "Text": "   ", "ParentId": "0e2ce950-73b3-4a22-b6bb-c9dcdcb4900d"}, {"Element": "<td style=\"width:232.2pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\">\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"font-size:16.0pt\">Remicade</span></b></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">infliximab</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"font-size:16.0pt\">Patient Reminder Card</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Name patient:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Name doctor:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Telephone number doctor:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">This patient reminder card contains\n  important safety information that you need to be aware of before and during\n  treatment with Remicade.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Show this card to any doctor involved in\n  your treatment.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Please read the Remicade \u2018Package\n  Leaflet\u2019 carefully before you start using this medicine.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of Remicade therapy initiation:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Current administrations:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is important that you and your doctor\n  record the brand name and batch number of your medicine.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ask your doctor to record the type and\n  date of last screening(s) for tuberculosis (TB) below:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Test\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Test</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Date</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Result:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Result:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Please make sure you also have a list of\n  all other medicines that you are using with you at any visit to a healthcare\n  professional.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">List of allergies:</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">List of other medicines:</span></p>\n</td>", "ID": "53193870-4d72-41cc-b913-950aa89d934a", "Styles": "width:232.2pt;border:solid windowtext 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "                                ", "ParentId": "f4eab976-75f6-42be-8599-04db97da047a"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"font-size:16.0pt\">Remicade</span></b></p>", "ID": "8e922e25-afbc-4b1f-b2be-6993d9d2e477", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:16.0pt\">Remicade</span></b>", "ID": "fc6f9d59-8253-496a-adb0-f029ac92cf85", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8e922e25-afbc-4b1f-b2be-6993d9d2e477"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:16.0pt\">Remicade</span>", "ID": "6afc020c-8fee-43c8-b4de-32b8175458a5", "Styles": "font-size:16.0pt", "Classes": "None", "Text": "Remicade", "ParentId": "fc6f9d59-8253-496a-adb0-f029ac92cf85"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">infliximab</span></p>", "ID": "6bd05733-52e3-4944-8a48-d6fef7dbece8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">infliximab</span>", "ID": "35975caa-54db-4f37-9590-6e1f792fc2d7", "Styles": "None", "Classes": "None", "Text": "infliximab", "ParentId": "6bd05733-52e3-4944-8a48-d6fef7dbece8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "60c6088b-45ba-4908-bd26-4fd4ec0ab650", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d5cc76c2-39ad-4202-9e3e-b8f98d7f0f41", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "60c6088b-45ba-4908-bd26-4fd4ec0ab650"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\" style=\"font-size:16.0pt\">Patient Reminder Card</span></b></p>", "ID": "6e27d068-3e51-4292-85c8-0b5adfe81b1d", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:16.0pt\">Patient Reminder Card</span></b>", "ID": "6dec6d7b-6206-4970-8745-cb6caf7a7112", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6e27d068-3e51-4292-85c8-0b5adfe81b1d"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:16.0pt\">Patient Reminder Card</span>", "ID": "03f6ece4-6c9d-498b-a1b4-d52a26513295", "Styles": "font-size:16.0pt", "Classes": "None", "Text": "Patient Reminder Card", "ParentId": "6dec6d7b-6206-4970-8745-cb6caf7a7112"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c05f827a-6b5e-430d-b485-c6b21fc4788d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1868953f-8efc-4919-abd8-0f7f4c883ab0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c05f827a-6b5e-430d-b485-c6b21fc4788d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Name patient:</span></p>", "ID": "4e196eab-011e-4bbc-9c60-de7b56e32a6f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">Name patient:</span>", "ID": "e40ff321-cdd8-48ab-a64e-190d10f34d61", "Styles": "None", "Classes": "None", "Text": "Name patient:", "ParentId": "4e196eab-011e-4bbc-9c60-de7b56e32a6f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Name doctor:</span></p>", "ID": "237bba6c-be4c-4e55-b0a9-4138bd5243b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">Name doctor:</span>", "ID": "4f723bb9-1d19-484e-896e-bc9b8e643fdf", "Styles": "None", "Classes": "None", "Text": "Name doctor:", "ParentId": "237bba6c-be4c-4e55-b0a9-4138bd5243b6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Telephone number doctor:</span></p>", "ID": "722f1b6a-b045-41b0-917f-6f153b4cee82", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">Telephone number doctor:</span>", "ID": "77cfc45d-199c-47da-9ef8-7ee4be8e5125", "Styles": "None", "Classes": "None", "Text": "Telephone number doctor:", "ParentId": "722f1b6a-b045-41b0-917f-6f153b4cee82"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "10746bff-0b14-42ca-bc47-d53aa97fd9fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1aa64243-22ea-455f-ab04-1a1b80ff9bba", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "10746bff-0b14-42ca-bc47-d53aa97fd9fd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">This patient reminder card contains\n  important safety information that you need to be aware of before and during\n  treatment with Remicade.</span></p>", "ID": "f6afa2a6-3898-405d-8018-df84bc1acec3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">This patient reminder card contains\n  important safety information that you need to be aware of before and during\n  treatment with Remicade.</span>", "ID": "80b1de6d-c908-4173-8928-745db049a344", "Styles": "None", "Classes": "None", "Text": "This patient reminder card contains   important safety information that you need to be aware of before and during   treatment with Remicade.", "ParentId": "f6afa2a6-3898-405d-8018-df84bc1acec3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6707ee25-9f7e-4fee-9562-f4984cb8b726", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e066f31f-17cd-4036-a02d-caf677c2117b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6707ee25-9f7e-4fee-9562-f4984cb8b726"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Show this card to any doctor involved in\n  your treatment.</span></p>", "ID": "cc9cf75b-8b0c-4066-b8e9-291860f50152", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">Show this card to any doctor involved in\n  your treatment.</span>", "ID": "1da6b638-d3e3-430f-91ed-083ebabe618c", "Styles": "None", "Classes": "None", "Text": "Show this card to any doctor involved in   your treatment.", "ParentId": "cc9cf75b-8b0c-4066-b8e9-291860f50152"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "fe74eac4-471f-4f9d-9fd2-f2aed82bcb5c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "004be1a2-76c2-4caa-8fea-045678d2a074", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fe74eac4-471f-4f9d-9fd2-f2aed82bcb5c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Please read the Remicade \u2018Package\n  Leaflet\u2019 carefully before you start using this medicine.</span></p>", "ID": "6d93dd90-a447-49a5-92fa-f3ca0fabb06e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">Please read the Remicade \u2018Package\n  Leaflet\u2019 carefully before you start using this medicine.</span>", "ID": "ae203964-a7b7-4d30-83da-3bdb1f29cec7", "Styles": "None", "Classes": "None", "Text": "Please read the Remicade \u2018Package   Leaflet\u2019 carefully before you start using this medicine.", "ParentId": "6d93dd90-a447-49a5-92fa-f3ca0fabb06e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5ba84296-5416-4ac7-857a-c81611114b83", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "93fadac4-66bc-4cb9-bdf1-7ca3e5fa558f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5ba84296-5416-4ac7-857a-c81611114b83"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date of Remicade therapy initiation:</span></p>", "ID": "85d30b2e-85eb-4288-a9de-6c381310d3bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">Date of Remicade therapy initiation:</span>", "ID": "9f7ba5b4-76ba-41bc-a41a-c01be6590c07", "Styles": "None", "Classes": "None", "Text": "Date of Remicade therapy initiation:", "ParentId": "85d30b2e-85eb-4288-a9de-6c381310d3bb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2bd202e0-99fb-47dc-8ddf-16eb07e56228", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8b7e0a6c-8d74-4dd1-8c7a-fb4f775a88c0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2bd202e0-99fb-47dc-8ddf-16eb07e56228"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Current administrations:</span></p>", "ID": "5d6a0095-3373-411b-bcf8-02f38264316c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">Current administrations:</span>", "ID": "91278a45-b292-4bef-801a-2eb3ab9d1cb9", "Styles": "None", "Classes": "None", "Text": "Current administrations:", "ParentId": "5d6a0095-3373-411b-bcf8-02f38264316c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d79bee47-1d84-449d-9eed-c62098a1f37a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f80b4e4e-8f20-49b6-bf70-91e0668f7b47", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d79bee47-1d84-449d-9eed-c62098a1f37a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">It is important that you and your doctor\n  record the brand name and batch number of your medicine.</span></p>", "ID": "bbd86c8a-7872-4aa4-b48a-dada4319f372", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">It is important that you and your doctor\n  record the brand name and batch number of your medicine.</span>", "ID": "7bc30562-09f9-47fd-a2d7-bcbca78d1360", "Styles": "None", "Classes": "None", "Text": "It is important that you and your doctor   record the brand name and batch number of your medicine.", "ParentId": "bbd86c8a-7872-4aa4-b48a-dada4319f372"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "846d8ee8-6dbe-4bf4-80f6-3b999db84850", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "38133899-0ae2-4128-8dda-c0a93c4504ea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "846d8ee8-6dbe-4bf4-80f6-3b999db84850"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ask your doctor to record the type and\n  date of last screening(s) for tuberculosis (TB) below:</span></p>", "ID": "139b2b0e-1906-46f5-8528-1e496d3e9df1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">Ask your doctor to record the type and\n  date of last screening(s) for tuberculosis (TB) below:</span>", "ID": "438b98a5-8a87-4ae6-9338-1cadc9816326", "Styles": "None", "Classes": "None", "Text": "Ask your doctor to record the type and   date of last screening(s) for tuberculosis (TB) below:", "ParentId": "139b2b0e-1906-46f5-8528-1e496d3e9df1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Test\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Test</span></p>", "ID": "04ce7ec3-ac64-4204-b66a-d2e37555ceeb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">Test\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Test</span>", "ID": "16c16683-4c36-4ca9-9363-b0a0b799bd77", "Styles": "None", "Classes": "None", "Text": "Test\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Test", "ParentId": "04ce7ec3-ac64-4204-b66a-d2e37555ceeb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Date\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Date</span></p>", "ID": "f40d0d18-0749-425d-be2a-81a2a9af2f2e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">Date\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Date</span>", "ID": "3b80f947-b20c-4f60-af5b-756936eb6eff", "Styles": "None", "Classes": "None", "Text": "Date\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Date", "ParentId": "f40d0d18-0749-425d-be2a-81a2a9af2f2e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Result:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Result:</span></p>", "ID": "477172b6-2d55-4ef5-9b69-999c6fffbf5d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">Result:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Result:</span>", "ID": "15ef2465-d2fb-4cb9-81c0-8b646150353b", "Styles": "None", "Classes": "None", "Text": "Result:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Result:", "ParentId": "477172b6-2d55-4ef5-9b69-999c6fffbf5d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8bac0497-e69a-4a4c-afdb-fbf59f0e0fb8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f09079c5-3631-4759-9a69-2250c2185cc1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8bac0497-e69a-4a4c-afdb-fbf59f0e0fb8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Please make sure you also have a list of\n  all other medicines that you are using with you at any visit to a healthcare\n  professional.</span></p>", "ID": "9f0fd780-f1cb-4ce1-84d5-6e0018ca6032", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">Please make sure you also have a list of\n  all other medicines that you are using with you at any visit to a healthcare\n  professional.</span>", "ID": "c27b5cbc-1e14-4ac5-8a14-5a41e9e64ed7", "Styles": "None", "Classes": "None", "Text": "Please make sure you also have a list of   all other medicines that you are using with you at any visit to a healthcare   professional.", "ParentId": "9f0fd780-f1cb-4ce1-84d5-6e0018ca6032"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8e2349e1-3b31-447d-ab9b-72294c311694", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d5aa7763-4da9-469f-a1fa-68efd9f52e23", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8e2349e1-3b31-447d-ab9b-72294c311694"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">List of allergies:</span></p>", "ID": "c404920f-f986-479d-af3d-8ee8be6079d2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">List of allergies:</span>", "ID": "66ac4304-f1a1-4c6f-9bc3-3e7f09d9ba4f", "Styles": "None", "Classes": "None", "Text": "List of allergies:", "ParentId": "c404920f-f986-479d-af3d-8ee8be6079d2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "83691d84-289b-4fc6-b341-6dce7aea95ab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7efcc7c3-f024-44a6-a214-8968067542ab", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "83691d84-289b-4fc6-b341-6dce7aea95ab"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">List of other medicines:</span></p>", "ID": "bc4d6234-43b9-4e58-a786-da7ff57fbcf7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "53193870-4d72-41cc-b913-950aa89d934a"}, {"Element": "<span lang=\"EN-GB\">List of other medicines:</span>", "ID": "5c3b6a98-a006-42ea-92e9-34831c405f15", "Styles": "None", "Classes": "None", "Text": "List of other medicines:", "ParentId": "bc4d6234-43b9-4e58-a786-da7ff57fbcf7"}, {"Element": "<td style=\"width:232.2pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:14.0pt\">Infections</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Before treatment with Remicade</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor if you have an infection even\n  if it is a very minor one</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">It is very important that you tell your doctor\n  if you have ever had TB, or if you have been in close contact with someone\n  who has had TB. Your doctor will test you to see if you have TB. Ask your\n  doctor to record the type and date of your last screening(s) for TB on the\n  card</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor if you have hepatitis B or if\n  you know or suspect you are a carrier of the hepatitis B virus.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">During treatment with Remicade</span></b></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor straight away if you have\n  signs of an infection. Signs include a fever, feeling tired, (persistent)\n  cough, shortness of breath, weight loss, night sweats, diarrhea, wounds,\n  dental problems, burning when urinating or \u2018flu\u2011like\u2019\n  signs.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:14.0pt\">Pregnancy and\n  Vaccinations</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">In case you have received Remicade while you\n  were pregnant, it is important that you inform your baby\u2019s doctor about\n  it before your baby receives any vaccine. Your baby should not receive a\n  \u2018live vaccine\u2019, such as BCG (used to prevent tuberculosis) within\n  6\u00a0months after birth.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep this card with you for 4\u00a0months\n  after your dose of Remicade, or in case of pregnancy for at least\n  6\u00a0months after the birth of your baby. Side effects may occur a long\n  time after your last dose.</span></p>\n</td>", "ID": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a", "Styles": "width:232.2pt;border:solid windowtext 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "                ", "ParentId": "f4eab976-75f6-42be-8599-04db97da047a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:14.0pt\">Infections</span></b></p>", "ID": "6bc37b77-dfbe-4275-b61d-9ffc0b967684", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:14.0pt\">Infections</span></b>", "ID": "9e3bb484-1ec5-4d33-9fdf-29b01867a4e9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6bc37b77-dfbe-4275-b61d-9ffc0b967684"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:14.0pt\">Infections</span>", "ID": "805ae8c0-481d-4968-9def-ebdb3f131274", "Styles": "font-size:14.0pt", "Classes": "None", "Text": "Infections", "ParentId": "9e3bb484-1ec5-4d33-9fdf-29b01867a4e9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aa01701f-7d24-464d-8f62-50f27d829cb2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "01ac2d42-1736-480f-ad55-a4aa3f616a18", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aa01701f-7d24-464d-8f62-50f27d829cb2"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Before treatment with Remicade</span></b></p>", "ID": "c9b180c4-9254-4572-b337-813f089305d8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<b><span lang=\"EN-GB\">Before treatment with Remicade</span></b>", "ID": "b7aa32b8-f153-44ed-bd30-acd81981893f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c9b180c4-9254-4572-b337-813f089305d8"}, {"Element": "<span lang=\"EN-GB\">Before treatment with Remicade</span>", "ID": "bb830a22-ffa5-4116-8e47-8d8d0661f6ea", "Styles": "None", "Classes": "None", "Text": "Before treatment with Remicade", "ParentId": "b7aa32b8-f153-44ed-bd30-acd81981893f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor if you have an infection even\n  if it is a very minor one</span></p>", "ID": "f8ec8be0-bb5f-406b-9a4a-e9809ef7ceea", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span>", "ID": "42543b6f-3dd1-4082-a536-9ee5f2ffa06a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f8ec8be0-bb5f-406b-9a4a-e9809ef7ceea"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span>", "ID": "3e3ebadc-c6cd-40de-a775-ceb530bfc5d3", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0   ", "ParentId": "42543b6f-3dd1-4082-a536-9ee5f2ffa06a"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor if you have an infection even\n  if it is a very minor one</span>", "ID": "127dcce5-b07c-4301-b3ac-8b7643c81b23", "Styles": "None", "Classes": "None", "Text": "Tell your doctor if you have an infection even   if it is a very minor one", "ParentId": "f8ec8be0-bb5f-406b-9a4a-e9809ef7ceea"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">It is very important that you tell your doctor\n  if you have ever had TB, or if you have been in close contact with someone\n  who has had TB. Your doctor will test you to see if you have TB. Ask your\n  doctor to record the type and date of your last screening(s) for TB on the\n  card</span></p>", "ID": "da07e300-b6c0-4576-81ce-38cc2ffe4937", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span>", "ID": "88e68138-29ed-48d0-b9b3-5ea57e379817", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "da07e300-b6c0-4576-81ce-38cc2ffe4937"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span>", "ID": "494933f1-2bbc-44d9-a6a8-1a469c6ce602", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0   ", "ParentId": "88e68138-29ed-48d0-b9b3-5ea57e379817"}, {"Element": "<span lang=\"EN-GB\">It is very important that you tell your doctor\n  if you have ever had TB, or if you have been in close contact with someone\n  who has had TB. Your doctor will test you to see if you have TB. Ask your\n  doctor to record the type and date of your last screening(s) for TB on the\n  card</span>", "ID": "9208ba2c-8af1-49e0-9c27-d3e94f6055a7", "Styles": "None", "Classes": "None", "Text": "It is very important that you tell your doctor   if you have ever had TB, or if you have been in close contact with someone   who has had TB. Your doctor will test you to see if you have TB. Ask your   doctor to record the type and date of your last screening(s) for TB on the   card", "ParentId": "da07e300-b6c0-4576-81ce-38cc2ffe4937"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor if you have hepatitis B or if\n  you know or suspect you are a carrier of the hepatitis B virus.</span></p>", "ID": "cad390e5-101c-484b-b889-f3d6d8ce3f10", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span>", "ID": "bff2b0ab-9306-46b9-ad44-f89bbab232b8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "cad390e5-101c-484b-b889-f3d6d8ce3f10"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span>", "ID": "46023d57-acff-48f9-92ca-1c87c873d090", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0   ", "ParentId": "bff2b0ab-9306-46b9-ad44-f89bbab232b8"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor if you have hepatitis B or if\n  you know or suspect you are a carrier of the hepatitis B virus.</span>", "ID": "b96e1b34-6014-4b03-bcdc-9cc0c3b82165", "Styles": "None", "Classes": "None", "Text": "Tell your doctor if you have hepatitis B or if   you know or suspect you are a carrier of the hepatitis B virus.", "ParentId": "cad390e5-101c-484b-b889-f3d6d8ce3f10"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bfc72a5f-d5bb-40b3-b8bc-cf81e3e7b458", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7719e793-6393-475c-b1ea-07cb242711ca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bfc72a5f-d5bb-40b3-b8bc-cf81e3e7b458"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">During treatment with Remicade</span></b></p>", "ID": "099f44ed-83aa-4ff0-9994-a915c3eb2bda", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<b><span lang=\"EN-GB\">During treatment with Remicade</span></b>", "ID": "42e1bf54-8696-44f3-bcfa-0fd0e6c70c7a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "099f44ed-83aa-4ff0-9994-a915c3eb2bda"}, {"Element": "<span lang=\"EN-GB\">During treatment with Remicade</span>", "ID": "09e4d13c-c3ab-458f-9b90-547c6c7d28db", "Styles": "None", "Classes": "None", "Text": "During treatment with Remicade", "ParentId": "42e1bf54-8696-44f3-bcfa-0fd0e6c70c7a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">Tell your doctor straight away if you have\n  signs of an infection. Signs include a fever, feeling tired, (persistent)\n  cough, shortness of breath, weight loss, night sweats, diarrhea, wounds,\n  dental problems, burning when urinating or \u2018flu\u2011like\u2019\n  signs.</span></p>", "ID": "059535c9-3c04-4dac-9269-ce1d0c324ee0", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span>", "ID": "223506cc-06e3-47e5-a47b-fc41d27f0d46", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "059535c9-3c04-4dac-9269-ce1d0c324ee0"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span>", "ID": "b55db63f-59aa-414a-adf0-10fd469b6e90", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0   ", "ParentId": "223506cc-06e3-47e5-a47b-fc41d27f0d46"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor straight away if you have\n  signs of an infection. Signs include a fever, feeling tired, (persistent)\n  cough, shortness of breath, weight loss, night sweats, diarrhea, wounds,\n  dental problems, burning when urinating or \u2018flu\u2011like\u2019\n  signs.</span>", "ID": "404592f6-d084-4670-9ea0-be0c962e0d5e", "Styles": "None", "Classes": "None", "Text": "Tell your doctor straight away if you have   signs of an infection. Signs include a fever, feeling tired, (persistent)   cough, shortness of breath, weight loss, night sweats, diarrhea, wounds,   dental problems, burning when urinating or \u2018flu\u2011like\u2019   signs.", "ParentId": "059535c9-3c04-4dac-9269-ce1d0c324ee0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f22f585d-ff1b-462b-a688-6393dc28772a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c5db235d-0cb4-4086-ba44-cf65b09c34e4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f22f585d-ff1b-462b-a688-6393dc28772a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\" style=\"font-size:14.0pt\">Pregnancy and\n  Vaccinations</span></b></p>", "ID": "8ec10706-bb8b-4c21-a5d8-29b3ef03d91c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<b><span lang=\"EN-GB\" style=\"font-size:14.0pt\">Pregnancy and\n  Vaccinations</span></b>", "ID": "8c933679-2638-46dc-9475-34b55706ef59", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8ec10706-bb8b-4c21-a5d8-29b3ef03d91c"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:14.0pt\">Pregnancy and\n  Vaccinations</span>", "ID": "07bd2e0d-7914-4699-b708-66cb69ad3812", "Styles": "font-size:14.0pt", "Classes": "None", "Text": "Pregnancy and   Vaccinations", "ParentId": "8c933679-2638-46dc-9475-34b55706ef59"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b2de1854-0fee-4aa7-96d5-201d917bc585", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "047e23a2-fc12-4d4d-9988-184cebea367d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b2de1854-0fee-4aa7-96d5-201d917bc585"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span><span lang=\"EN-GB\">In case you have received Remicade while you\n  were pregnant, it is important that you inform your baby\u2019s doctor about\n  it before your baby receives any vaccine. Your baby should not receive a\n  \u2018live vaccine\u2019, such as BCG (used to prevent tuberculosis) within\n  6\u00a0months after birth.</span></p>", "ID": "3cd6f257-0fd1-4093-a913-b21235ed215c", "Styles": "margin-left:.25in;text-indent:-.25in", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span></span>", "ID": "71476175-7e5d-4b02-a912-f144489b34af", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3cd6f257-0fd1-4093-a913-b21235ed215c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n  </span>", "ID": "15856ed1-e521-4aed-8a91-2564dc4b72cc", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0   ", "ParentId": "71476175-7e5d-4b02-a912-f144489b34af"}, {"Element": "<span lang=\"EN-GB\">In case you have received Remicade while you\n  were pregnant, it is important that you inform your baby\u2019s doctor about\n  it before your baby receives any vaccine. Your baby should not receive a\n  \u2018live vaccine\u2019, such as BCG (used to prevent tuberculosis) within\n  6\u00a0months after birth.</span>", "ID": "a5cfe227-718a-4fad-99dd-c3131f8192c5", "Styles": "None", "Classes": "None", "Text": "In case you have received Remicade while you   were pregnant, it is important that you inform your baby\u2019s doctor about   it before your baby receives any vaccine. Your baby should not receive a   \u2018live vaccine\u2019, such as BCG (used to prevent tuberculosis) within   6\u00a0months after birth.", "ParentId": "3cd6f257-0fd1-4093-a913-b21235ed215c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6a1e2095-e833-4f92-907f-cfc6fc0684a4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a79d731b-6599-40a6-ab8f-ce6bc372bb6c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6a1e2095-e833-4f92-907f-cfc6fc0684a4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Keep this card with you for 4\u00a0months\n  after your dose of Remicade, or in case of pregnancy for at least\n  6\u00a0months after the birth of your baby. Side effects may occur a long\n  time after your last dose.</span></p>", "ID": "f01a09b6-0e62-4079-b238-c7c5353c0bba", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9d63a2c6-98ab-45f5-b19e-e3a6d4479e0a"}, {"Element": "<span lang=\"EN-GB\">Keep this card with you for 4\u00a0months\n  after your dose of Remicade, or in case of pregnancy for at least\n  6\u00a0months after the birth of your baby. Side effects may occur a long\n  time after your last dose.</span>", "ID": "99fe721c-f641-494c-addf-3b169f3a6346", "Styles": "None", "Classes": "None", "Text": "Keep this card with you for 4\u00a0months   after your dose of Remicade, or in case of pregnancy for at least   6\u00a0months after the birth of your baby. Side effects may occur a long   time after your last dose.", "ParentId": "f01a09b6-0e62-4079-b238-c7c5353c0bba"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "a09d829b-8d1b-4f3c-a320-59640ccba366", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "13bb91f3-17f9-4906-bf90-a69c62635139", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a09d829b-8d1b-4f3c-a320-59640ccba366"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1edc8120-6a44-4ad0-8937-0e146f4f4647", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "13bb91f3-17f9-4906-bf90-a69c62635139"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "5be7079f-aef0-435d-8d5c-5b0654f0c63c", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "28cc2777-80db-45ca-9f13-64aed1f8ef42", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "5be7079f-aef0-435d-8d5c-5b0654f0c63c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f2cfeb73-10af-4cbd-a9d2-882a74c0f3ef", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b0b4e271-16b2-409f-97a1-b6f8ce7634bd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f2cfeb73-10af-4cbd-a9d2-882a74c0f3ef"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9a6325b2-06fd-4be9-abf8-cd74e72bd064", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a91140c2-9d90-40e9-9cc9-ad16f4dd741a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9a6325b2-06fd-4be9-abf8-cd74e72bd064"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "da9addc3-96d7-422c-b372-75c44c3e9ee1", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7a79b561-dbad-4274-8677-e2b8f6701edd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "da9addc3-96d7-422c-b372-75c44c3e9ee1"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a825a2e1-548c-4849-a944-6594d92c78f8", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a85c3dab-6b56-4b0c-aadc-6bc35fc212b5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a825a2e1-548c-4849-a944-6594d92c78f8"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "96d1afae-ba61-4fa6-b5b5-a11da7a0cbf3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "70094834-553f-480e-ba2b-20b08856db33", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "96d1afae-ba61-4fa6-b5b5-a11da7a0cbf3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4f256767-f126-4459-a3f6-db113ac5f545", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0418a936-6333-4ca0-b492-edca46e622c5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4f256767-f126-4459-a3f6-db113ac5f545"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "684d9fd8-35d7-4077-a114-4b5d27132e98", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "10e81597-9b46-4491-993e-1ad53480882e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "684d9fd8-35d7-4077-a114-4b5d27132e98"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c05fd6a-2a62-4aec-8338-44607318f031", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7f1c6e90-fd9f-4445-844d-eb3ee740b0ea", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c05fd6a-2a62-4aec-8338-44607318f031"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1069408a-2409-4854-b132-87055b5d0eee", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f7107509-0334-4d84-a391-55c9f5a2229e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1069408a-2409-4854-b132-87055b5d0eee"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e42c5a30-c835-4071-a1ca-1ad2fc19c53c", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "01d824c9-a107-40d7-a70e-dc5fbd132450", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e42c5a30-c835-4071-a1ca-1ad2fc19c53c"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9acd0d18-712d-4baa-a727-849e719081dd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9b5c198e-f901-4f63-9839-ee4117257c2a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9acd0d18-712d-4baa-a727-849e719081dd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "89dcf21a-0861-4232-9b08-cd239dd4c066", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "845b0a20-81fc-41e2-8c94-5b57492a7603", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "89dcf21a-0861-4232-9b08-cd239dd4c066"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9390bfcf-e740-485c-b344-a6eb4e0e2257", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "98d80a4b-aaf6-483b-b7d4-08b7b0707bc0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9390bfcf-e740-485c-b344-a6eb4e0e2257"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8a3e5f79-7cbf-4ecf-a141-c64ea5c60801", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fce5406e-1c2b-4915-aef2-2d8575cad00c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8a3e5f79-7cbf-4ecf-a141-c64ea5c60801"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7bf4c2e5-a7aa-4aea-a32c-26021d816643", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4f30c174-27aa-4bcd-8d3d-7f8ec90a3500", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7bf4c2e5-a7aa-4aea-a32c-26021d816643"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1dd1b8fe-f607-4606-8079-c89f3ceeaf5e", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "73213fa8-053b-40c5-848f-594fad156cbb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1dd1b8fe-f607-4606-8079-c89f3ceeaf5e"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7fa20c65-a784-41f5-8f30-c0e4ef4409d6", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bc023aed-0c7c-482f-9b92-d895798616b7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7fa20c65-a784-41f5-8f30-c0e4ef4409d6"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b215e037-724c-4f6a-b987-cae312a0c6a3", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6aecfbd0-9fee-4c29-a04f-35cc14541219", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b215e037-724c-4f6a-b987-cae312a0c6a3"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "38909c3a-7f8b-488a-a9d6-df7950d39cb9", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d9cca99d-a577-4e70-a835-061cef049150", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "38909c3a-7f8b-488a-a9d6-df7950d39cb9"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "43a9eaad-4a0b-4d1b-b726-ac7ba91de4dd", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f3580ca3-e973-4b12-9759-ce09efd6c8fd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "43a9eaad-4a0b-4d1b-b726-ac7ba91de4dd"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "59a68405-2fa1-4fe9-bc43-04c85306e457", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6a5dca06-bffe-4cf7-ac7d-b5cfbc4bcf20", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "59a68405-2fa1-4fe9-bc43-04c85306e457"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e95c00c4-e8cb-4c96-8ff7-3118a5c2e535", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b5c38f9f-e7d2-4e07-8db1-e6c963abb063", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e95c00c4-e8cb-4c96-8ff7-3118a5c2e535"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9a5b5f3e-51bb-46d1-a428-f4cbc3784106", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b93f6b79-6e48-43d7-9f31-12cb2a5f6fe3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9a5b5f3e-51bb-46d1-a428-f4cbc3784106"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">B.\nPACKAGE LEAFLET</span></b></p>", "ID": "3d5458b5-9add-4e21-8252-163617f54d25", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">B.\nPACKAGE LEAFLET</span></b>", "ID": "1a0b0331-bfcb-415e-8482-71f3e4f2c189", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3d5458b5-9add-4e21-8252-163617f54d25"}, {"Element": "<span lang=\"EN-GB\">B.\nPACKAGE LEAFLET</span>", "ID": "62fcd445-df2f-460d-bb7d-863fae8c8a6d", "Styles": "None", "Classes": "None", "Text": "B. PACKAGE LEAFLET", "ParentId": "1a0b0331-bfcb-415e-8482-71f3e4f2c189"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bb1eda0a-84c7-47c3-9122-c3389d119428", "Styles": "text-align:center", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6b922a44-7adb-4fd5-936e-0205b9250d07", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bb1eda0a-84c7-47c3-9122-c3389d119428"}, {"Element": "<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span></b>", "ID": "8dc1ff57-4a07-436a-b891-b3bf58fd492c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "dd2a934f-09e5-42db-86cd-759f5436b873", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "8dc1ff57-4a07-436a-b891-b3bf58fd492c"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "36101be7-3835-4ad0-b402-1af62d82f1df", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "dd2a934f-09e5-42db-86cd-759f5436b873"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:avoid\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user</span></b></p>", "ID": "1bac914a-e632-4942-a6f7-bc432aa93f0f", "Styles": "text-align:center;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Package leaflet: Information for the user</span></b>", "ID": "1ce7f9f8-3b0b-4a09-a5e1-e749c9bd5813", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1bac914a-e632-4942-a6f7-bc432aa93f0f"}, {"Element": "<span lang=\"EN-GB\">Package leaflet: Information for the user</span>", "ID": "6c7ddee3-d060-4296-9dbf-5f660e898490", "Styles": "None", "Classes": "None", "Text": "Package leaflet: Information for the user", "ParentId": "1ce7f9f8-3b0b-4a09-a5e1-e749c9bd5813"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "016467dc-7b9f-4453-867c-4c6c5949bb73", "Styles": "text-align:center;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "8ec741dd-f847-4b02-8c7d-e0d6aeedf1f2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "016467dc-7b9f-4453-867c-4c6c5949bb73"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e5a6d925-1a02-4334-a0d9-19cd97efbf1a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8ec741dd-f847-4b02-8c7d-e0d6aeedf1f2"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:avoid\"><b><span lang=\"EN-GB\">Remicade </span></b><b><span lang=\"EN-GB\">100\u00a0mg powder for\nconcentrate for solution for infusion</span></b></p>", "ID": "4961fc0a-b3d7-4e30-999d-3707478e7bfd", "Styles": "text-align:center;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Remicade </span></b>", "ID": "8e61c96c-4b46-4966-8e3f-3033bea9c329", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4961fc0a-b3d7-4e30-999d-3707478e7bfd"}, {"Element": "<span lang=\"EN-GB\">Remicade </span>", "ID": "b05280fb-454e-4244-8fb7-2ef4b6b51803", "Styles": "None", "Classes": "None", "Text": "Remicade ", "ParentId": "8e61c96c-4b46-4966-8e3f-3033bea9c329"}, {"Element": "<b><span lang=\"EN-GB\">100\u00a0mg powder for\nconcentrate for solution for infusion</span></b>", "ID": "39d80691-2bd1-4ca4-9952-1be5ef58b635", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4961fc0a-b3d7-4e30-999d-3707478e7bfd"}, {"Element": "<span lang=\"EN-GB\">100\u00a0mg powder for\nconcentrate for solution for infusion</span>", "ID": "2a93254f-f5ba-45b1-a913-f8df1b4d4e30", "Styles": "None", "Classes": "None", "Text": "100\u00a0mg powder for concentrate for solution for infusion", "ParentId": "39d80691-2bd1-4ca4-9952-1be5ef58b635"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:avoid\"><span lang=\"EN-GB\">infliximab</span></p>", "ID": "b8e7e775-941c-40ad-b1b9-4e192a8a5925", "Styles": "text-align:center;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">infliximab</span>", "ID": "f5f53f34-e106-4398-83a5-fcc37ed5758a", "Styles": "None", "Classes": "None", "Text": "infliximab", "ParentId": "b8e7e775-941c-40ad-b1b9-4e192a8a5925"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7295424d-93d1-499e-ae78-8707dd1bd814", "Styles": "text-align:center;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "56e7a3e8-d923-4f51-9c3a-a623011c4fac", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7295424d-93d1-499e-ae78-8707dd1bd814"}, {"Element": "<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e358b09a-0ffc-48cd-a98f-89881c0b7fa0", "Styles": "text-align:center;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ab909b6f-b5b7-40d5-8e55-cf8becc66577", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e358b09a-0ffc-48cd-a98f-89881c0b7fa0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Read all\nof this leaflet carefully before you start using this medicine because it\ncontains important information for you.</span></b></p>", "ID": "d851529b-58ac-4277-bebb-d1ba53d4b7fc", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Read all\nof this leaflet carefully before you start using this medicine because it\ncontains important information for you.</span></b>", "ID": "2f3bc6c1-45ac-4117-a10f-f436c3b850ef", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d851529b-58ac-4277-bebb-d1ba53d4b7fc"}, {"Element": "<span lang=\"EN-GB\">Read all\nof this leaflet carefully before you start using this medicine because it\ncontains important information for you.</span>", "ID": "db18a446-d02f-472c-bc7a-7bc1dd8eedbb", "Styles": "None", "Classes": "None", "Text": "Read all of this leaflet carefully before you start using this medicine because it contains important information for you.", "ParentId": "2f3bc6c1-45ac-4117-a10f-f436c3b850ef"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it\nagain.</span></p>", "ID": "b1d0e7a1-25ee-48a0-b265-341aff7e8f3b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "89659d0b-2b6e-46bd-9a3d-03b458beade2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b1d0e7a1-25ee-48a0-b265-341aff7e8f3b"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7108464c-baf3-44cc-b95a-398a292d76bb", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "89659d0b-2b6e-46bd-9a3d-03b458beade2"}, {"Element": "<span lang=\"EN-GB\">Keep this leaflet. You may need to read it\nagain.</span>", "ID": "a7e6e893-a605-4037-98ee-d70d193b6636", "Styles": "None", "Classes": "None", "Text": "Keep this leaflet. You may need to read it again.", "ParentId": "b1d0e7a1-25ee-48a0-b265-341aff7e8f3b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Your doctor will also give you a patient reminder\ncard, which contains important safety information you need to be aware of\nbefore and during your treatment with Remicade.</span></p>", "ID": "09f8e17f-f7c6-4b03-a9a7-31c9b527a23e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "bcfdb9f8-1242-465a-8706-e06218bbbd10", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "09f8e17f-f7c6-4b03-a9a7-31c9b527a23e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "44840ee2-7d83-4ee1-a18c-1da92aa5a163", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "bcfdb9f8-1242-465a-8706-e06218bbbd10"}, {"Element": "<span lang=\"EN-GB\">Your doctor will also give you a patient reminder\ncard, which contains important safety information you need to be aware of\nbefore and during your treatment with Remicade.</span>", "ID": "c2b0a0cd-0d7b-4157-b0e4-e96c443319b9", "Styles": "None", "Classes": "None", "Text": "Your doctor will also give you a patient reminder card, which contains important safety information you need to be aware of before and during your treatment with Remicade.", "ParentId": "09f8e17f-f7c6-4b03-a9a7-31c9b527a23e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you have any further questions, ask your\ndoctor.</span></p>", "ID": "b1692ba8-8b79-476d-8e21-0e163bffd206", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "b4c04e71-d6a7-42bb-95f7-4efc56bf1cfb", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b1692ba8-8b79-476d-8e21-0e163bffd206"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "fd492b59-4186-4d61-82c8-641d1233fab2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "b4c04e71-d6a7-42bb-95f7-4efc56bf1cfb"}, {"Element": "<span lang=\"EN-GB\">If you have any further questions, ask your\ndoctor.</span>", "ID": "c3395db3-4f20-4880-9f94-869a4d55c982", "Styles": "None", "Classes": "None", "Text": "If you have any further questions, ask your doctor.", "ParentId": "b1692ba8-8b79-476d-8e21-0e163bffd206"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">This medicine has been prescribed for you only.\nDo not pass it on to others. It may harm them, even if their signs of illness are\nthe same as yours.</span></p>", "ID": "95fecade-03fd-455f-96df-bfcdbafe7c01", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "2358eeeb-92e4-473c-90c7-5d37e1b5a31a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "95fecade-03fd-455f-96df-bfcdbafe7c01"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "34c1dd15-b21a-4d2f-9724-f0e39272c8e9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2358eeeb-92e4-473c-90c7-5d37e1b5a31a"}, {"Element": "<span lang=\"EN-GB\">This medicine has been prescribed for you only.\nDo not pass it on to others. It may harm them, even if their signs of illness are\nthe same as yours.</span>", "ID": "76281abb-6c9a-49ba-a56a-e3804231954a", "Styles": "None", "Classes": "None", "Text": "This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.", "ParentId": "95fecade-03fd-455f-96df-bfcdbafe7c01"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you get any side effects, talk to your\ndoctor. This includes any possible side effects not listed in this leaflet. See\nsection 4.</span></p>", "ID": "335f3dd5-0d1d-4922-80fc-bc3d4cc70cbb", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "71d003a9-43b2-4ee4-a69d-f2b5fd66b672", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "335f3dd5-0d1d-4922-80fc-bc3d4cc70cbb"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "30fa405d-ef0b-43d4-bab6-dcf2140eef3a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "71d003a9-43b2-4ee4-a69d-f2b5fd66b672"}, {"Element": "<span lang=\"EN-GB\">If you get any side effects, talk to your\ndoctor. This includes any possible side effects not listed in this leaflet. See\nsection 4.</span>", "ID": "4f748679-8478-44e9-b73f-b8ed60fc03eb", "Styles": "None", "Classes": "None", "Text": "If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.", "ParentId": "335f3dd5-0d1d-4922-80fc-bc3d4cc70cbb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3da5d619-1f4a-49f0-abc7-c2f7b5ffe8b9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "408f8a2d-c84b-441c-b684-68d0013de77a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3da5d619-1f4a-49f0-abc7-c2f7b5ffe8b9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What is\nin this leaflet:</span></b></p>", "ID": "d0cde92d-2eef-428c-b5fc-c3373a37d848", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">What is\nin this leaflet:</span></b>", "ID": "a8da0637-d406-403e-9902-93ba1d548a13", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d0cde92d-2eef-428c-b5fc-c3373a37d848"}, {"Element": "<span lang=\"EN-GB\">What is\nin this leaflet:</span>", "ID": "10ede5ad-fdaa-4b7d-9a9f-38cee82f5f35", "Styles": "None", "Classes": "None", "Text": "What is in this leaflet:", "ParentId": "a8da0637-d406-403e-9902-93ba1d548a13"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nRemicade is and what it is used for</span></p>", "ID": "d0e3dacf-aff0-42ab-b5a7-6acc12e25eb7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nRemicade is and what it is used for</span>", "ID": "e764e1f2-32de-4a8b-bcb2-7c1b0bb0240c", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Remicade is and what it is used for", "ParentId": "d0e3dacf-aff0-42ab-b5a7-6acc12e25eb7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you use Remicade</span></p>", "ID": "7c3f4851-b63d-43eb-b361-1dc529807fc6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What\nyou need to know before you use Remicade</span>", "ID": "b53b9bcd-665b-4e89-9db9-a7c1fdd67c1c", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you use Remicade", "ParentId": "7c3f4851-b63d-43eb-b361-1dc529807fc6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nRemicade will be given</span></p>", "ID": "8c6b77fd-c6fc-489d-acc4-bf5e2b802ba2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nRemicade will be given</span>", "ID": "f3f494d9-2d45-4a47-bdca-9e2b84d506d3", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Remicade will be given", "ParentId": "8c6b77fd-c6fc-489d-acc4-bf5e2b802ba2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span></p>", "ID": "07b0358d-6699-4dba-b44f-e83a7da5870e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible\nside effects</span>", "ID": "8d3e06aa-fda0-4e9b-800d-82fac45adfef", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "07b0358d-6699-4dba-b44f-e83a7da5870e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Remicade</span></p>", "ID": "41def76d-c430-499e-8e7f-041f41d054a1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Remicade</span>", "ID": "7c5a29af-e4ed-4342-8b3e-7e06edd9bc1b", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Remicade", "ParentId": "41def76d-c430-499e-8e7f-041f41d054a1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span></p>", "ID": "9d66c629-1ac1-4eda-8ab4-107f802dc0b0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents\nof the pack and other information</span>", "ID": "aa63cdf1-03d9-4833-a398-171eb594fa93", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information", "ParentId": "9d66c629-1ac1-4eda-8ab4-107f802dc0b0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "47291b5e-fac4-47b1-b524-6b1e7793e7fb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "72e020a9-44e2-4e54-86ba-6f9fac558564", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "47291b5e-fac4-47b1-b524-6b1e7793e7fb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8e52c8de-eff3-4304-ac16-5550b3aefc0b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c085793d-0378-4119-9473-62b2356ca079", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8e52c8de-eff3-4304-ac16-5550b3aefc0b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Remicade\nis and what it is used for</span></b></p>", "ID": "c9874954-54a6-4cdf-a0ec-cc3e6bc64ead", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Remicade\nis and what it is used for</span></b>", "ID": "02123977-4ba2-430a-9167-ecfb9f7da7dd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c9874954-54a6-4cdf-a0ec-cc3e6bc64ead"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Remicade\nis and what it is used for</span>", "ID": "89bf8f97-d7c0-4522-9f28-f6add64b5071", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What Remicade is and what it is used for", "ParentId": "02123977-4ba2-430a-9167-ecfb9f7da7dd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "66e180c8-6f82-46d8-913c-4c03b55c6819", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "25a5295d-0dc3-47ca-b6f3-7d02b30e8d36", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "66e180c8-6f82-46d8-913c-4c03b55c6819"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade contains the active substance\ninfliximab. Infliximab is a monoclonal antibody \u2013 a type of protein that\nattaches to a specific target in the body called TNF (tumour necrosis factor)\nalpha.</span></p>", "ID": "581d0b9d-4b64-4d40-bed0-89db31b12aef", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade contains the active substance\ninfliximab. Infliximab is a monoclonal antibody \u2013 a type of protein that\nattaches to a specific target in the body called TNF (tumour necrosis factor)\nalpha.</span>", "ID": "4e24e045-ac8e-4a1d-aa0b-e1b9b53cf2a8", "Styles": "None", "Classes": "None", "Text": "Remicade contains the active substance infliximab. Infliximab is a monoclonal antibody \u2013 a type of protein that attaches to a specific target in the body called TNF (tumour necrosis factor) alpha.", "ParentId": "581d0b9d-4b64-4d40-bed0-89db31b12aef"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bc213e63-893a-4aa5-87a7-b2196928efe3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f8623972-8e93-4a2e-be79-5ed9d8bcf93c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bc213e63-893a-4aa5-87a7-b2196928efe3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade belongs to a group of medicines\ncalled \u2018TNF blockers\u2019. It is used in adults for the following\ninflammatory diseases:</span></p>", "ID": "3f31f875-3c2a-4712-a12d-ecf037afc620", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade belongs to a group of medicines\ncalled \u2018TNF blockers\u2019. It is used in adults for the following\ninflammatory diseases:</span>", "ID": "4a98a2f2-9769-42ce-89c0-2d0f05dfe10c", "Styles": "None", "Classes": "None", "Text": "Remicade belongs to a group of medicines called \u2018TNF blockers\u2019. It is used in adults for the following inflammatory diseases:", "ParentId": "3f31f875-3c2a-4712-a12d-ecf037afc620"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Rheumatoid arthritis</span></p>", "ID": "b8f8c426-558e-483e-ae54-da3ded919581", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "af6789c0-af6f-44b4-8d90-1fc49b9c6538", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b8f8c426-558e-483e-ae54-da3ded919581"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "df547c19-541a-4feb-a71a-dc6a71cfcd6f", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "af6789c0-af6f-44b4-8d90-1fc49b9c6538"}, {"Element": "<span lang=\"EN-GB\">Rheumatoid arthritis</span>", "ID": "e085fb45-64d7-4a2b-b2b0-ee967f658fd2", "Styles": "None", "Classes": "None", "Text": "Rheumatoid arthritis", "ParentId": "b8f8c426-558e-483e-ae54-da3ded919581"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Psoriatic arthritis</span></p>", "ID": "c70dfffd-c2bd-463f-9d67-58fffc2bc1f9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "e0e0ba93-22c9-4769-aa15-7f1406945d5f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c70dfffd-c2bd-463f-9d67-58fffc2bc1f9"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8a52ed65-a0f6-46e1-89d8-0ae240e6c094", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "e0e0ba93-22c9-4769-aa15-7f1406945d5f"}, {"Element": "<span lang=\"EN-GB\">Psoriatic arthritis</span>", "ID": "357d84aa-69de-4c16-b6cd-612330162efa", "Styles": "None", "Classes": "None", "Text": "Psoriatic arthritis", "ParentId": "c70dfffd-c2bd-463f-9d67-58fffc2bc1f9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Ankylosing spondylitis (Bechterew\u2019s\ndisease)</span></p>", "ID": "3c880dd6-28a1-4c90-ae0d-cdcbcaee8920", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "55899fff-05f7-4fdd-bc07-f4a083acf932", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3c880dd6-28a1-4c90-ae0d-cdcbcaee8920"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "9c57e886-2257-405d-86b6-b1ad9f197d86", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "55899fff-05f7-4fdd-bc07-f4a083acf932"}, {"Element": "<span lang=\"EN-GB\">Ankylosing spondylitis (Bechterew\u2019s\ndisease)</span>", "ID": "d19e583f-960f-40ad-a575-e8202ea5fcb3", "Styles": "None", "Classes": "None", "Text": "Ankylosing spondylitis (Bechterew\u2019s disease)", "ParentId": "3c880dd6-28a1-4c90-ae0d-cdcbcaee8920"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Psoriasis.</span></p>", "ID": "5726f85d-2e41-4906-8bc7-d59d1a76a216", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7a525acf-8a2f-4836-a4a9-be176614cb8f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5726f85d-2e41-4906-8bc7-d59d1a76a216"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0b7b3160-5e81-451f-98e1-754e645e7f0b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7a525acf-8a2f-4836-a4a9-be176614cb8f"}, {"Element": "<span lang=\"EN-GB\">Psoriasis.</span>", "ID": "cfb544b7-a9b4-43f0-b16f-16e1122ee33c", "Styles": "None", "Classes": "None", "Text": "Psoriasis.", "ParentId": "5726f85d-2e41-4906-8bc7-d59d1a76a216"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "07412629-41e4-4377-83b4-f83e73384a7e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "27cdef4f-15b4-43fe-bbb7-ffa6b406af00", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "07412629-41e4-4377-83b4-f83e73384a7e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is also used in adults and\nchildren 6\u00a0years of age or older for:</span></p>", "ID": "57ae404b-a5a1-4592-959d-0645993db4d6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade is also used in adults and\nchildren 6\u00a0years of age or older for:</span>", "ID": "3e75a783-066a-408e-9d17-dd0043e73ff1", "Styles": "None", "Classes": "None", "Text": "Remicade is also used in adults and children 6\u00a0years of age or older for:", "ParentId": "57ae404b-a5a1-4592-959d-0645993db4d6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Crohn\u2019s disease</span></p>", "ID": "2f204521-69c9-45ee-a5b8-ed8702f5d905", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "90ce10b8-e596-4db2-a5ce-d1ff3a671278", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2f204521-69c9-45ee-a5b8-ed8702f5d905"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d0025fe5-1ffa-4400-9e1c-cd3f654ec68f", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "90ce10b8-e596-4db2-a5ce-d1ff3a671278"}, {"Element": "<span lang=\"EN-GB\">Crohn\u2019s disease</span>", "ID": "4ee76d28-11a1-4cc6-b6b3-27f3646d13fb", "Styles": "None", "Classes": "None", "Text": "Crohn\u2019s disease", "ParentId": "2f204521-69c9-45ee-a5b8-ed8702f5d905"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Ulcerative colitis.</span></p>", "ID": "0361a3e2-bd95-47ca-8e5a-3e498c107c15", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5cc83829-4ff0-4246-af34-174194583e2b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0361a3e2-bd95-47ca-8e5a-3e498c107c15"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ed7ae5f7-1463-4890-8e45-f1228b6460e9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5cc83829-4ff0-4246-af34-174194583e2b"}, {"Element": "<span lang=\"EN-GB\">Ulcerative colitis.</span>", "ID": "b541f876-42a1-48a2-af38-1c14d03158ff", "Styles": "None", "Classes": "None", "Text": "Ulcerative colitis.", "ParentId": "0361a3e2-bd95-47ca-8e5a-3e498c107c15"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9516fe62-1de4-459f-8b74-cdca0122401c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bf8c679f-ca66-440a-9308-8e50dd2be2f3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9516fe62-1de4-459f-8b74-cdca0122401c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade works by selectively attaching to\nTNF alpha and blocking its action. TNF alpha is involved in inflammatory\nprocesses of the body so blocking it can reduce the inflammation in your body.</span></p>", "ID": "78a537ad-0540-46ac-8158-fd68b7eac8d7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade works by selectively attaching to\nTNF alpha and blocking its action. TNF alpha is involved in inflammatory\nprocesses of the body so blocking it can reduce the inflammation in your body.</span>", "ID": "dbef0ab6-7263-4280-b930-db25642f9c33", "Styles": "None", "Classes": "None", "Text": "Remicade works by selectively attaching to TNF alpha and blocking its action. TNF alpha is involved in inflammatory processes of the body so blocking it can reduce the inflammation in your body.", "ParentId": "78a537ad-0540-46ac-8158-fd68b7eac8d7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cef4ec97-38f4-4d21-8f66-9f1a1674be84", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "30dda362-6caa-49ad-b903-2878c7798ade", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cef4ec97-38f4-4d21-8f66-9f1a1674be84"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Rheumatoid\narthritis</span></b></p>", "ID": "184c61c6-e9bc-405c-93e0-93e5e3e22a86", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Rheumatoid\narthritis</span></b>", "ID": "6881d7f1-514a-4d89-a5cf-d85f9376a247", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "184c61c6-e9bc-405c-93e0-93e5e3e22a86"}, {"Element": "<span lang=\"EN-GB\">Rheumatoid\narthritis</span>", "ID": "cdfa820f-0dd0-463a-9f3a-a01bcd00a0b4", "Styles": "None", "Classes": "None", "Text": "Rheumatoid arthritis", "ParentId": "6881d7f1-514a-4d89-a5cf-d85f9376a247"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Rheumatoid arthritis is an inflammatory\ndisease of the joints. If you have active rheumatoid arthritis you will first\nbe given other medicines. If these medicines do not work well enough, you will\nbe given Remicade which you will take in combination with another medicine\ncalled methotrexate to:</span></p>", "ID": "b6b662e8-259b-4e7f-884a-cf911892ceb0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Rheumatoid arthritis is an inflammatory\ndisease of the joints. If you have active rheumatoid arthritis you will first\nbe given other medicines. If these medicines do not work well enough, you will\nbe given Remicade which you will take in combination with another medicine\ncalled methotrexate to:</span>", "ID": "a9c83a70-034b-4115-8e48-e3a4418ef737", "Styles": "None", "Classes": "None", "Text": "Rheumatoid arthritis is an inflammatory disease of the joints. If you have active rheumatoid arthritis you will first be given other medicines. If these medicines do not work well enough, you will be given Remicade which you will take in combination with another medicine called methotrexate to:", "ParentId": "b6b662e8-259b-4e7f-884a-cf911892ceb0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Reduce the signs and symptoms of your disease</span></p>", "ID": "d88bdc6f-c1b3-4028-947a-72e7de3eab64", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5c059184-e2ae-4b1c-a011-d12240c053a7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d88bdc6f-c1b3-4028-947a-72e7de3eab64"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "3b1bd588-7e27-4e26-a80b-dc462db6a968", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5c059184-e2ae-4b1c-a011-d12240c053a7"}, {"Element": "<span lang=\"EN-GB\">Reduce the signs and symptoms of your disease</span>", "ID": "57bca26f-4880-4792-bfd5-faeca51889d5", "Styles": "None", "Classes": "None", "Text": "Reduce the signs and symptoms of your disease", "ParentId": "d88bdc6f-c1b3-4028-947a-72e7de3eab64"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Slow down the damage in your joints</span></p>", "ID": "f08ca525-1d5a-4473-a9b2-3fccb77a67dd", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7a24b153-d778-4bef-8a67-1e0fac833361", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f08ca525-1d5a-4473-a9b2-3fccb77a67dd"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6df6ccac-f0d6-4d85-b36c-e260a6a26429", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7a24b153-d778-4bef-8a67-1e0fac833361"}, {"Element": "<span lang=\"EN-GB\">Slow down the damage in your joints</span>", "ID": "5d0666cf-c04c-4af5-92c3-b57db516bce2", "Styles": "None", "Classes": "None", "Text": "Slow down the damage in your joints", "ParentId": "f08ca525-1d5a-4473-a9b2-3fccb77a67dd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Improve your physical function.</span></p>", "ID": "c66b1bdc-f271-4248-97c3-25680db9bbd0", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c9fe60df-22e1-494d-a788-349bd328090e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c66b1bdc-f271-4248-97c3-25680db9bbd0"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "f1b42067-af9b-465c-955f-5213d8e675d6", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c9fe60df-22e1-494d-a788-349bd328090e"}, {"Element": "<span lang=\"EN-GB\">Improve your physical function.</span>", "ID": "6af6a8df-5566-4977-892a-4ea3dd68f0d3", "Styles": "None", "Classes": "None", "Text": "Improve your physical function.", "ParentId": "c66b1bdc-f271-4248-97c3-25680db9bbd0"}, {"Element": "<p class=\"MsoDate\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e7302d8c-2bf6-408a-a0e1-ab340745244e", "Styles": "None", "Classes": "['MsoDate']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "ace133f9-34ee-47fa-8472-aeedb7d955be", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e7302d8c-2bf6-408a-a0e1-ab340745244e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Psoriatic\narthritis</span></b></p>", "ID": "4495829a-45e5-40e1-a0a5-dbf39b39a95a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Psoriatic\narthritis</span></b>", "ID": "deb925bb-f9e7-4089-9a4f-f0d4196a585f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4495829a-45e5-40e1-a0a5-dbf39b39a95a"}, {"Element": "<span lang=\"EN-GB\">Psoriatic\narthritis</span>", "ID": "6d5a2c7a-843a-45a5-8c33-766bd8f16432", "Styles": "None", "Classes": "None", "Text": "Psoriatic arthritis", "ParentId": "deb925bb-f9e7-4089-9a4f-f0d4196a585f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Psoriatic arthritis is an inflammatory\ndisease of the joints, usually accompanied by psoriasis. If you have active\npsoriatic arthritis you will first be given other medicines. If these medicines\ndo not work well enough, you will be given Remicade to:</span></p>", "ID": "d3ec4986-70bb-48d7-9310-39c1bac37137", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Psoriatic arthritis is an inflammatory\ndisease of the joints, usually accompanied by psoriasis. If you have active\npsoriatic arthritis you will first be given other medicines. If these medicines\ndo not work well enough, you will be given Remicade to:</span>", "ID": "3746ca8e-9330-41f9-bbf8-589546e8608b", "Styles": "None", "Classes": "None", "Text": "Psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis. If you have active psoriatic arthritis you will first be given other medicines. If these medicines do not work well enough, you will be given Remicade to:", "ParentId": "d3ec4986-70bb-48d7-9310-39c1bac37137"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Reduce the signs and symptoms of your disease</span></p>", "ID": "9171d6ae-7d4b-403a-846f-0f857cfd769c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "d39e410a-41bf-43bd-b0f4-dba2c9ef21a6", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9171d6ae-7d4b-403a-846f-0f857cfd769c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "80fe89ad-c42b-4f96-b01d-a71414d80958", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "d39e410a-41bf-43bd-b0f4-dba2c9ef21a6"}, {"Element": "<span lang=\"EN-GB\">Reduce the signs and symptoms of your disease</span>", "ID": "9a0dc325-f66a-426a-a118-2359c00509b0", "Styles": "None", "Classes": "None", "Text": "Reduce the signs and symptoms of your disease", "ParentId": "9171d6ae-7d4b-403a-846f-0f857cfd769c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Slow down the damage in your joints</span></p>", "ID": "bdc3d682-69ed-4a58-b75c-45a2f944f4e8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "049c51f5-a63f-4758-aacf-bbd309628617", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "bdc3d682-69ed-4a58-b75c-45a2f944f4e8"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "fe3aaccc-fe20-4818-a9d5-870448e75c64", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "049c51f5-a63f-4758-aacf-bbd309628617"}, {"Element": "<span lang=\"EN-GB\">Slow down the damage in your joints</span>", "ID": "fa403857-5ab3-4798-8be0-55b0e36ce713", "Styles": "None", "Classes": "None", "Text": "Slow down the damage in your joints", "ParentId": "bdc3d682-69ed-4a58-b75c-45a2f944f4e8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Improve your physical function.</span></p>", "ID": "b056c2d7-beb6-454f-a727-5eb92ae54b73", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f7b6a0d8-6ede-47b0-bde3-0261c3535c10", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b056c2d7-beb6-454f-a727-5eb92ae54b73"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "124a50ae-3e02-498f-9484-54f188245002", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f7b6a0d8-6ede-47b0-bde3-0261c3535c10"}, {"Element": "<span lang=\"EN-GB\">Improve your physical function.</span>", "ID": "fe8c4999-7523-4b68-adf8-112f5eb96871", "Styles": "None", "Classes": "None", "Text": "Improve your physical function.", "ParentId": "b056c2d7-beb6-454f-a727-5eb92ae54b73"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "27059122-2ebe-49d1-897b-487bd68c5d75", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2e1f4280-244d-4c16-bfc2-b052b889f879", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "27059122-2ebe-49d1-897b-487bd68c5d75"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Ankylosing\nspondylitis (Bechterew\u2019s disease)</span></b></p>", "ID": "ae78a66b-45ce-4279-bf78-ab8f9332860b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Ankylosing\nspondylitis (Bechterew\u2019s disease)</span></b>", "ID": "7cdd8dd6-115f-44ac-9161-37b00db88dee", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ae78a66b-45ce-4279-bf78-ab8f9332860b"}, {"Element": "<span lang=\"EN-GB\">Ankylosing\nspondylitis (Bechterew\u2019s disease)</span>", "ID": "21d7ac60-9a2e-400e-914d-781f6ff961b5", "Styles": "None", "Classes": "None", "Text": "Ankylosing spondylitis (Bechterew\u2019s disease)", "ParentId": "7cdd8dd6-115f-44ac-9161-37b00db88dee"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ankylosing spondylitis is an inflammatory\ndisease of the spine. If you have ankylosing spondylitis you will first be given\nother medicines. If these medicines do not work well enough, you will be given\nRemicade to:</span></p>", "ID": "7c7f18e6-54db-4f06-a7ad-5a505b0824fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Ankylosing spondylitis is an inflammatory\ndisease of the spine. If you have ankylosing spondylitis you will first be given\nother medicines. If these medicines do not work well enough, you will be given\nRemicade to:</span>", "ID": "81b39f68-ab59-479f-938b-4586f0e7729a", "Styles": "None", "Classes": "None", "Text": "Ankylosing spondylitis is an inflammatory disease of the spine. If you have ankylosing spondylitis you will first be given other medicines. If these medicines do not work well enough, you will be given Remicade to:", "ParentId": "7c7f18e6-54db-4f06-a7ad-5a505b0824fd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Reduce the signs and symptoms of your disease</span></p>", "ID": "c2693a3c-6f83-4319-859f-1589cc096802", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "6c440406-c642-4de3-806e-899fb1469f87", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c2693a3c-6f83-4319-859f-1589cc096802"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "82bfa085-5f7f-4d69-8ec1-496350a64d08", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "6c440406-c642-4de3-806e-899fb1469f87"}, {"Element": "<span lang=\"EN-GB\">Reduce the signs and symptoms of your disease</span>", "ID": "8620210d-b9ed-4fc6-8d54-f25eeb3d0776", "Styles": "None", "Classes": "None", "Text": "Reduce the signs and symptoms of your disease", "ParentId": "c2693a3c-6f83-4319-859f-1589cc096802"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Improve your physical function.</span></p>", "ID": "41b6eb1e-3b0c-47ef-8af7-1f1a51de1eca", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "fae1c5e4-6bcd-49b1-848d-e61340436a08", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "41b6eb1e-3b0c-47ef-8af7-1f1a51de1eca"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b092ccf1-1f8d-4192-a6a8-1adabb5feb3f", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "fae1c5e4-6bcd-49b1-848d-e61340436a08"}, {"Element": "<span lang=\"EN-GB\">Improve your physical function.</span>", "ID": "89eac2bb-01bb-4731-af85-4a82345cd6f0", "Styles": "None", "Classes": "None", "Text": "Improve your physical function.", "ParentId": "41b6eb1e-3b0c-47ef-8af7-1f1a51de1eca"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5d40f001-a9de-4f49-bc68-f868e2c64762", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f367e30a-859e-4970-b2cf-97150911aadb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5d40f001-a9de-4f49-bc68-f868e2c64762"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Psoriasis</span></b></p>", "ID": "e9bc17ab-85f1-4c26-b51c-3ed2c7889b08", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Psoriasis</span></b>", "ID": "520ff85e-8373-4481-b28f-e37dc09f7573", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e9bc17ab-85f1-4c26-b51c-3ed2c7889b08"}, {"Element": "<span lang=\"EN-GB\">Psoriasis</span>", "ID": "846dc1ba-8989-4c37-8858-babeb60b111b", "Styles": "None", "Classes": "None", "Text": "Psoriasis", "ParentId": "520ff85e-8373-4481-b28f-e37dc09f7573"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Psoriasis is an inflammatory disease of the\nskin. If you have moderate to severe plaque psoriasis, you will first be given\nother medicines or treatments, such as phototherapy. If these medicines or\ntreatments do not work well enough, you will be given Remicade to reduce the signs\nand symptoms of your disease.</span></p>", "ID": "ac15b1c0-12e4-4598-93b9-6714a6a26d27", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Psoriasis is an inflammatory disease of the\nskin. If you have moderate to severe plaque psoriasis, you will first be given\nother medicines or treatments, such as phototherapy. If these medicines or\ntreatments do not work well enough, you will be given Remicade to reduce the signs\nand symptoms of your disease.</span>", "ID": "5060fc8a-68ed-4933-a08a-9f7b24b6fce6", "Styles": "None", "Classes": "None", "Text": "Psoriasis is an inflammatory disease of the skin. If you have moderate to severe plaque psoriasis, you will first be given other medicines or treatments, such as phototherapy. If these medicines or treatments do not work well enough, you will be given Remicade to reduce the signs and symptoms of your disease.", "ParentId": "ac15b1c0-12e4-4598-93b9-6714a6a26d27"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d898ddd9-3504-4b80-a92a-9199d83741f9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c8c45246-0ba3-4c08-b74d-765324804f5d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d898ddd9-3504-4b80-a92a-9199d83741f9"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Ulcerative\ncolitis</span></b></p>", "ID": "c26d0b0c-7abf-4f9c-a0a0-1a89018a6f5c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Ulcerative\ncolitis</span></b>", "ID": "45db1d50-60f0-4297-a2c4-d49b60a9489f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c26d0b0c-7abf-4f9c-a0a0-1a89018a6f5c"}, {"Element": "<span lang=\"EN-GB\">Ulcerative\ncolitis</span>", "ID": "967c2903-6f78-47a4-aec6-e84cb9f68649", "Styles": "None", "Classes": "None", "Text": "Ulcerative colitis", "ParentId": "45db1d50-60f0-4297-a2c4-d49b60a9489f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ulcerative colitis is an inflammatory\ndisease of the bowel. If you have ulcerative colitis you will first be given\nother medicines. If these medicines do not work well enough, you will be given\nRemicade to treat your disease.</span></p>", "ID": "406d0ccb-5599-4982-9ed6-e8faf4288095", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Ulcerative colitis is an inflammatory\ndisease of the bowel. If you have ulcerative colitis you will first be given\nother medicines. If these medicines do not work well enough, you will be given\nRemicade to treat your disease.</span>", "ID": "92183201-ef87-4df3-a06d-2ca9891cdcb2", "Styles": "None", "Classes": "None", "Text": "Ulcerative colitis is an inflammatory disease of the bowel. If you have ulcerative colitis you will first be given other medicines. If these medicines do not work well enough, you will be given Remicade to treat your disease.", "ParentId": "406d0ccb-5599-4982-9ed6-e8faf4288095"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6ccf1942-dd67-4023-a23e-82a1d23f09e6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1d14fd69-8c18-4f0b-812b-21c453dee04d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6ccf1942-dd67-4023-a23e-82a1d23f09e6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Crohn\u2019s\ndisease</span></b></p>", "ID": "542fc3e5-0617-4906-a524-f87028966eec", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Crohn\u2019s\ndisease</span></b>", "ID": "e889800c-5e46-4e51-832a-dc55b6ce4a21", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "542fc3e5-0617-4906-a524-f87028966eec"}, {"Element": "<span lang=\"EN-GB\">Crohn\u2019s\ndisease</span>", "ID": "419671e3-1d78-4feb-8974-10080cf1f5b8", "Styles": "None", "Classes": "None", "Text": "Crohn\u2019s disease", "ParentId": "e889800c-5e46-4e51-832a-dc55b6ce4a21"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Crohn\u2019s disease is an inflammatory\ndisease of the bowel. If you have Crohn\u2019s disease you will first be given\nother medicines. If these medicines do not work well enough, you will be given\nRemicade to:</span></p>", "ID": "8866e904-7720-4af2-b7aa-85b84ae75247", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Crohn\u2019s disease is an inflammatory\ndisease of the bowel. If you have Crohn\u2019s disease you will first be given\nother medicines. If these medicines do not work well enough, you will be given\nRemicade to:</span>", "ID": "adbba8a8-548c-4106-8158-dcb8460ca28b", "Styles": "None", "Classes": "None", "Text": "Crohn\u2019s disease is an inflammatory disease of the bowel. If you have Crohn\u2019s disease you will first be given other medicines. If these medicines do not work well enough, you will be given Remicade to:", "ParentId": "8866e904-7720-4af2-b7aa-85b84ae75247"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Treat active Crohn\u2019s disease</span></p>", "ID": "cc61925b-1dc1-4f65-8fdd-af82d45069ca", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3b532967-a56e-4187-937f-759fc0f7f76f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "cc61925b-1dc1-4f65-8fdd-af82d45069ca"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "1687d287-ef35-4f53-842b-4ed2d2596dee", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3b532967-a56e-4187-937f-759fc0f7f76f"}, {"Element": "<span lang=\"EN-GB\">Treat active Crohn\u2019s disease</span>", "ID": "5ede1c57-b377-44bd-87d8-17eefde05995", "Styles": "None", "Classes": "None", "Text": "Treat active Crohn\u2019s disease", "ParentId": "cc61925b-1dc1-4f65-8fdd-af82d45069ca"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Reduce the number of abnormal openings\n(fistulae) between your bowel and your skin that have not been controlled by\nother medicines or surgery.</span></p>", "ID": "6b41b53d-6837-402b-b023-fbf48febb6ae", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "9aa2a7b3-a8b6-423f-8ee7-60658bb94995", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6b41b53d-6837-402b-b023-fbf48febb6ae"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7f868493-65ad-49c6-af4f-0d6e4ea66ac1", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "9aa2a7b3-a8b6-423f-8ee7-60658bb94995"}, {"Element": "<span lang=\"EN-GB\">Reduce the number of abnormal openings\n(fistulae) between your bowel and your skin that have not been controlled by\nother medicines or surgery.</span>", "ID": "96d6b720-90eb-4f40-a1cd-6d18f2f76f5a", "Styles": "None", "Classes": "None", "Text": "Reduce the number of abnormal openings (fistulae) between your bowel and your skin that have not been controlled by other medicines or surgery.", "ParentId": "6b41b53d-6837-402b-b023-fbf48febb6ae"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5f2728e7-a51d-4f52-a039-14931f7b234b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "314e302c-806f-4025-9533-df70d3f5aef9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5f2728e7-a51d-4f52-a039-14931f7b234b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d7a22521-d4c6-45d3-9185-aaabd5896447", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "65e17e53-bbcf-4fc8-a8f9-0968dd8737c3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d7a22521-d4c6-45d3-9185-aaabd5896447"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need\nto know before you use Remicade</span></b></p>", "ID": "980f497b-da91-4650-b649-59ac223ae0df", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need\nto know before you use Remicade</span></b>", "ID": "d0ff264c-0aed-4619-ba26-81cce076401b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "980f497b-da91-4650-b649-59ac223ae0df"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need\nto know before you use Remicade</span>", "ID": "80c08f1c-403b-4a98-9e87-6d58270ad263", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 What you need to know before you use Remicade", "ParentId": "d0ff264c-0aed-4619-ba26-81cce076401b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9be26977-729c-4439-b6f3-a5ed568ecfa2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fc34b8e5-222f-45c7-90fc-a0af2d395060", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9be26977-729c-4439-b6f3-a5ed568ecfa2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">You\nshould not be given Remicade if:</span></b></p>", "ID": "4ad1d44b-7921-41bc-989c-6467a8b8aa03", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">You\nshould not be given Remicade if:</span></b>", "ID": "7b4b6615-b76a-47bc-9364-fa77df12bf6c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4ad1d44b-7921-41bc-989c-6467a8b8aa03"}, {"Element": "<span lang=\"EN-GB\">You\nshould not be given Remicade if:</span>", "ID": "bd327ac4-b872-4bf9-a1eb-944782a6a3e5", "Styles": "None", "Classes": "None", "Text": "You should not be given Remicade if:", "ParentId": "7b4b6615-b76a-47bc-9364-fa77df12bf6c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You are allergic to infliximab or to any of the\nother ingredients in Remicade (listed in section\u00a06).</span></p>", "ID": "1c8ae126-041d-4856-a083-1aeb74d8e888", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "e519729c-2927-44f6-9f34-d4501ba16b52", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1c8ae126-041d-4856-a083-1aeb74d8e888"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7b9648dd-2f8b-40de-84a1-33864e18f463", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "e519729c-2927-44f6-9f34-d4501ba16b52"}, {"Element": "<span lang=\"EN-GB\">You are allergic to infliximab or to any of the\nother ingredients in Remicade (listed in section\u00a06).</span>", "ID": "efadeb0c-57bf-4888-993c-0086513dda7d", "Styles": "None", "Classes": "None", "Text": "You are allergic to infliximab or to any of the other ingredients in Remicade (listed in section\u00a06).", "ParentId": "1c8ae126-041d-4856-a083-1aeb74d8e888"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You are allergic (hypersensitive) to proteins\nthat come from mice.</span></p>", "ID": "23d0febe-281d-4772-a826-0eeeca4d0d35", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "96759c93-e3a7-475b-a8ed-8f0111d355ee", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "23d0febe-281d-4772-a826-0eeeca4d0d35"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d5f1927e-dac4-4ca5-a00b-39607b303b5c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "96759c93-e3a7-475b-a8ed-8f0111d355ee"}, {"Element": "<span lang=\"EN-GB\">You are allergic (hypersensitive) to proteins\nthat come from mice.</span>", "ID": "ea903e0e-22e1-41c1-b15c-5d4669cf1694", "Styles": "None", "Classes": "None", "Text": "You are allergic (hypersensitive) to proteins that come from mice.", "ParentId": "23d0febe-281d-4772-a826-0eeeca4d0d35"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You have tuberculosis (TB) or another serious\ninfection such as pneumonia or sepsis.</span></p>", "ID": "5574e404-b2c5-4f58-a6c5-32b41c51a135", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "27ff1b7d-0c9a-4b7a-9fcd-0daa55a2d46d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5574e404-b2c5-4f58-a6c5-32b41c51a135"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d1309b7a-bc9a-4800-b4c3-4920b8036a4b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "27ff1b7d-0c9a-4b7a-9fcd-0daa55a2d46d"}, {"Element": "<span lang=\"EN-GB\">You have tuberculosis (TB) or another serious\ninfection such as pneumonia or sepsis.</span>", "ID": "b7683c45-000f-4105-958e-a035943b6f7d", "Styles": "None", "Classes": "None", "Text": "You have tuberculosis (TB) or another serious infection such as pneumonia or sepsis.", "ParentId": "5574e404-b2c5-4f58-a6c5-32b41c51a135"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You have heart failure that is moderate or\nsevere.</span></p>", "ID": "e17ed919-36aa-4ab5-8fa3-aa865ef306bf", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7510812d-7c36-4e6e-a65e-0cbb14ee6a4c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e17ed919-36aa-4ab5-8fa3-aa865ef306bf"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0c48370e-f656-4b18-9ea4-3e61d182b28d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7510812d-7c36-4e6e-a65e-0cbb14ee6a4c"}, {"Element": "<span lang=\"EN-GB\">You have heart failure that is moderate or\nsevere.</span>", "ID": "1bc72d24-7a8f-47e9-b952-76d846d51688", "Styles": "None", "Classes": "None", "Text": "You have heart failure that is moderate or severe.", "ParentId": "e17ed919-36aa-4ab5-8fa3-aa865ef306bf"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3a41ec80-5c57-4f70-ab0e-f1397eaaf953", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bfa2bfbc-0102-4630-9999-14ef5f81107e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3a41ec80-5c57-4f70-ab0e-f1397eaaf953"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Do not use Remicade if any of the above\napplies to you. If you are not sure, talk to your doctor before you are given\nRemicade.</span></p>", "ID": "f854d40e-6ea6-4012-9cd9-86d8e2be9ea8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Do not use Remicade if any of the above\napplies to you. If you are not sure, talk to your doctor before you are given\nRemicade.</span>", "ID": "5f983147-7a3b-4c48-a777-1e0fdcd1b70c", "Styles": "None", "Classes": "None", "Text": "Do not use Remicade if any of the above applies to you. If you are not sure, talk to your doctor before you are given Remicade.", "ParentId": "f854d40e-6ea6-4012-9cd9-86d8e2be9ea8"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "a58a21b3-d69b-4158-87f9-929d224d5097", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "aa5953cf-16ff-4841-9d38-8de1052b87bf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a58a21b3-d69b-4158-87f9-929d224d5097"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "11f7ee14-e767-4771-888d-1f381bea6196", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aa5953cf-16ff-4841-9d38-8de1052b87bf"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings\nand precautions</span></b></p>", "ID": "69296a34-a2d9-45ee-ad59-2a387b4aa314", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Warnings\nand precautions</span></b>", "ID": "83b5aa24-4f4f-47a6-ba5d-d11e391ef468", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "69296a34-a2d9-45ee-ad59-2a387b4aa314"}, {"Element": "<span lang=\"EN-GB\">Warnings\nand precautions</span>", "ID": "4ff699c9-c3ba-47bb-9331-2b652c08f3dc", "Styles": "None", "Classes": "None", "Text": "Warnings and precautions", "ParentId": "83b5aa24-4f4f-47a6-ba5d-d11e391ef468"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Talk to your doctor before or during\ntreatment with Remicade if you have:</span></p>", "ID": "8ddb01aa-0258-4311-b2f7-0aff9b1d4c9d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Talk to your doctor before or during\ntreatment with Remicade if you have:</span>", "ID": "fbc8afcc-542f-4a56-adf8-7245217c9dc5", "Styles": "None", "Classes": "None", "Text": "Talk to your doctor before or during treatment with Remicade if you have:", "ParentId": "8ddb01aa-0258-4311-b2f7-0aff9b1d4c9d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f02142cf-a5bd-449f-90bf-24079a81e241", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e9959862-52c7-472a-9a03-122b421c9e5f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f02142cf-a5bd-449f-90bf-24079a81e241"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Had treatment with Remicade before</span></u></p>", "ID": "3e273efa-7a08-4c9a-b3ce-55cd7b217e46", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Had treatment with Remicade before</span></u>", "ID": "b9871169-ac28-4721-b6da-7ff600338e54", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3e273efa-7a08-4c9a-b3ce-55cd7b217e46"}, {"Element": "<span lang=\"EN-GB\">Had treatment with Remicade before</span>", "ID": "9afc0142-31e3-49b8-91f6-3a0a496fc9ad", "Styles": "None", "Classes": "None", "Text": "Had treatment with Remicade before", "ParentId": "b9871169-ac28-4721-b6da-7ff600338e54"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor if you have had treatment with\nRemicade in the past and are now starting Remicade treatment again.</span></p>", "ID": "78d123fd-824a-45d0-bc4b-fcecd992eed2", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "bad005ad-43cf-408f-a84d-10f717215906", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "78d123fd-824a-45d0-bc4b-fcecd992eed2"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0d7b9eee-5c89-426e-a7b4-1a274a2bbaf7", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "bad005ad-43cf-408f-a84d-10f717215906"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor if you have had treatment with\nRemicade in the past and are now starting Remicade treatment again.</span>", "ID": "3187f0e7-4fe0-4d0b-b089-2a23f9cb11f1", "Styles": "None", "Classes": "None", "Text": "Tell your doctor if you have had treatment with Remicade in the past and are now starting Remicade treatment again.", "ParentId": "78d123fd-824a-45d0-bc4b-fcecd992eed2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">If you have had\na break in your Remicade treatment of more than 16\u00a0weeks, there is a higher\nrisk for allergic reactions when you start the treatment again.</span></p>", "ID": "25e39323-2386-4297-a4fa-7e47b1a3953b", "Styles": "margin-left:28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">If you have had\na break in your Remicade treatment of more than 16\u00a0weeks, there is a higher\nrisk for allergic reactions when you start the treatment again.</span>", "ID": "acdc30e1-c0c9-4d52-9679-5307b0fb44e8", "Styles": "None", "Classes": "None", "Text": "If you have had a break in your Remicade treatment of more than 16\u00a0weeks, there is a higher risk for allergic reactions when you start the treatment again.", "ParentId": "25e39323-2386-4297-a4fa-7e47b1a3953b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9a91fddc-1766-4eba-9a4b-79057cdd2601", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e83e9556-a6f2-445c-80a1-8e4d990ee74e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9a91fddc-1766-4eba-9a4b-79057cdd2601"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Infections</span></u></p>", "ID": "42f5a9c9-8ac5-4f7c-8d40-aff10005ae48", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Infections</span></u>", "ID": "5359a355-b657-4f6c-8134-881e21003a14", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "42f5a9c9-8ac5-4f7c-8d40-aff10005ae48"}, {"Element": "<span lang=\"EN-GB\">Infections</span>", "ID": "533db6d2-3ad9-4a7c-af2e-f0023965a734", "Styles": "None", "Classes": "None", "Text": "Infections", "ParentId": "5359a355-b657-4f6c-8134-881e21003a14"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou have an infection even if it is a very minor one.</span></p>", "ID": "8bbd611a-1ca8-410b-a39e-8c1dcbb36d83", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "fa1c7041-b541-4853-8fdb-9be4987336f0", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8bbd611a-1ca8-410b-a39e-8c1dcbb36d83"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d1f1ec06-6234-4ec9-99f7-9d1b9f6a963d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "fa1c7041-b541-4853-8fdb-9be4987336f0"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou have an infection even if it is a very minor one.</span>", "ID": "2e45363d-8037-423e-af24-0ad7cb3a2033", "Styles": "None", "Classes": "None", "Text": "Tell your doctor before you are given Remicade if you have an infection even if it is a very minor one.", "ParentId": "8bbd611a-1ca8-410b-a39e-8c1dcbb36d83"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou have ever lived in or travelled to an area where infections called histoplasmosis,\ncoccidioidomycosis, or blastomycosis are common. These infections are caused by\nspecific types of fungi that can affect the lungs or other parts of your body.</span></p>", "ID": "a7cd63e0-9293-4e79-ba78-4685f84e3a97", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "83c36d70-a114-474d-8a92-882ddea47f3d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a7cd63e0-9293-4e79-ba78-4685f84e3a97"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "e0d13e77-513c-439f-b317-20f6398c4221", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "83c36d70-a114-474d-8a92-882ddea47f3d"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou have ever lived in or travelled to an area where infections called histoplasmosis,\ncoccidioidomycosis, or blastomycosis are common. These infections are caused by\nspecific types of fungi that can affect the lungs or other parts of your body.</span>", "ID": "1a728d0f-9e08-4ffa-95ff-165870e332ba", "Styles": "None", "Classes": "None", "Text": "Tell your doctor before you are given Remicade if you have ever lived in or travelled to an area where infections called histoplasmosis, coccidioidomycosis, or blastomycosis are common. These infections are caused by specific types of fungi that can affect the lungs or other parts of your body.", "ParentId": "a7cd63e0-9293-4e79-ba78-4685f84e3a97"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You may get infections more easily when you are\nbeing treated with Remicade. If you are 65 or older, you have a greater risk.</span></p>", "ID": "10b7e614-5095-4ddb-9f38-73dedace007f", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "851b3c11-08cf-410f-81c7-9699b56d688c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "10b7e614-5095-4ddb-9f38-73dedace007f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b791e436-60c5-4a58-a328-dfd4bbfc0174", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "851b3c11-08cf-410f-81c7-9699b56d688c"}, {"Element": "<span lang=\"EN-GB\">You may get infections more easily when you are\nbeing treated with Remicade. If you are 65 or older, you have a greater risk.</span>", "ID": "4c871ab4-03d9-4ed0-ac10-c1a4291335d4", "Styles": "None", "Classes": "None", "Text": "You may get infections more easily when you are being treated with Remicade. If you are 65 or older, you have a greater risk.", "ParentId": "10b7e614-5095-4ddb-9f38-73dedace007f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">These infections may be serious and include\ntuberculosis, infections caused by viruses, fungi, bacteria, or other organisms\nin the environment and sepsis that may be life\u2011threatening.</span></p>", "ID": "52761510-8103-4a31-930e-086acdcea9f2", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ddceea78-93e2-4765-9443-6094430ec607", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "52761510-8103-4a31-930e-086acdcea9f2"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "cd17f72a-df8c-4e67-895b-c985060fdfe1", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ddceea78-93e2-4765-9443-6094430ec607"}, {"Element": "<span lang=\"EN-GB\">These infections may be serious and include\ntuberculosis, infections caused by viruses, fungi, bacteria, or other organisms\nin the environment and sepsis that may be life\u2011threatening.</span>", "ID": "1cec6e65-9eec-4798-aa7d-88cd4d06e5ef", "Styles": "None", "Classes": "None", "Text": "These infections may be serious and include tuberculosis, infections caused by viruses, fungi, bacteria, or other organisms in the environment and sepsis that may be life\u2011threatening.", "ParentId": "52761510-8103-4a31-930e-086acdcea9f2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Tell your\ndoctor straight away if you get signs of infection during treatment with\nRemicade. Signs include fever, cough, flu\u2011like signs, feeling unwell, red\nor hot skin, wounds or dental problems. Your doctor may recommend temporarily stopping\nRemicade.</span></p>", "ID": "7715246e-2f32-4354-93c6-c8863f922c2f", "Styles": "margin-left:28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Tell your\ndoctor straight away if you get signs of infection during treatment with\nRemicade. Signs include fever, cough, flu\u2011like signs, feeling unwell, red\nor hot skin, wounds or dental problems. Your doctor may recommend temporarily stopping\nRemicade.</span>", "ID": "671bf68b-b944-41b9-be48-b63520e54625", "Styles": "None", "Classes": "None", "Text": "Tell your doctor straight away if you get signs of infection during treatment with Remicade. Signs include fever, cough, flu\u2011like signs, feeling unwell, red or hot skin, wounds or dental problems. Your doctor may recommend temporarily stopping Remicade.", "ParentId": "7715246e-2f32-4354-93c6-c8863f922c2f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ce15f010-a658-40de-8c83-911b3a96fd55", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5235da68-c4cd-480e-ae9d-1cd8d750d0f8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ce15f010-a658-40de-8c83-911b3a96fd55"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Tuberculosis (TB)</span></u></p>", "ID": "e1e44e78-2b08-44af-b372-42536e11359b", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Tuberculosis (TB)</span></u>", "ID": "c0ae5344-9d63-4c26-ab9f-a2b31990fdc6", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e1e44e78-2b08-44af-b372-42536e11359b"}, {"Element": "<span lang=\"EN-GB\">Tuberculosis (TB)</span>", "ID": "e8a6bb8f-f1b7-4d26-9381-cd37fcf1e3dd", "Styles": "None", "Classes": "None", "Text": "Tuberculosis (TB)", "ParentId": "c0ae5344-9d63-4c26-ab9f-a2b31990fdc6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">It is very important that you tell your doctor\nif you have ever had TB or if you have been in close contact with someone who\nhas had or has TB.</span></p>", "ID": "7dbaf7ef-db23-46f3-aaf4-1f5f1b50b9d9", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "30c0d809-ecff-4d6a-ac95-5e4a09e84d9a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7dbaf7ef-db23-46f3-aaf4-1f5f1b50b9d9"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2055e55a-ab1a-41e0-bc0d-1d6f7d30260b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "30c0d809-ecff-4d6a-ac95-5e4a09e84d9a"}, {"Element": "<span lang=\"EN-GB\">It is very important that you tell your doctor\nif you have ever had TB or if you have been in close contact with someone who\nhas had or has TB.</span>", "ID": "4be83d2c-fd81-4867-ac49-74bad53f22ac", "Styles": "None", "Classes": "None", "Text": "It is very important that you tell your doctor if you have ever had TB or if you have been in close contact with someone who has had or has TB.", "ParentId": "7dbaf7ef-db23-46f3-aaf4-1f5f1b50b9d9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Your doctor will test you to see if you have TB.\nCases of TB have been reported in patients treated with Remicade, even in patients\nwho have already been treated with medicines for TB. Your doctor will record\nthese tests on your patient reminder card.</span></p>", "ID": "99218100-f2be-49c4-9c4e-9d1649a58716", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "63129a80-1a2f-41b8-8933-4489bce63415", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "99218100-f2be-49c4-9c4e-9d1649a58716"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6908b91d-596d-431e-bd2b-457d1a22390d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "63129a80-1a2f-41b8-8933-4489bce63415"}, {"Element": "<span lang=\"EN-GB\">Your doctor will test you to see if you have TB.\nCases of TB have been reported in patients treated with Remicade, even in patients\nwho have already been treated with medicines for TB. Your doctor will record\nthese tests on your patient reminder card.</span>", "ID": "ae2efec5-7f6f-45c5-8b11-284b79a25409", "Styles": "None", "Classes": "None", "Text": "Your doctor will test you to see if you have TB. Cases of TB have been reported in patients treated with Remicade, even in patients who have already been treated with medicines for TB. Your doctor will record these tests on your patient reminder card.", "ParentId": "99218100-f2be-49c4-9c4e-9d1649a58716"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If your doctor feels that you are at risk for\nTB, you may be treated with medicines for TB before you are given Remicade.</span></p>", "ID": "72c90345-b260-40c0-9fbf-89fde03a7ac3", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "dfac0ae1-157b-4668-829c-7eb9494a873d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "72c90345-b260-40c0-9fbf-89fde03a7ac3"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ffefddf1-5af3-43de-bf84-0d199cb952ff", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "dfac0ae1-157b-4668-829c-7eb9494a873d"}, {"Element": "<span lang=\"EN-GB\">If your doctor feels that you are at risk for\nTB, you may be treated with medicines for TB before you are given Remicade.</span>", "ID": "13863b25-5a5d-4d48-b06a-2a6c533d15f6", "Styles": "None", "Classes": "None", "Text": "If your doctor feels that you are at risk for TB, you may be treated with medicines for TB before you are given Remicade.", "ParentId": "72c90345-b260-40c0-9fbf-89fde03a7ac3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Tell your doctor\nstraight away if you get signs of TB during treatment with Remicade. Signs\ninclude persistent cough, weight loss, feeling tired, fever, night sweats.</span></p>", "ID": "05ca07f9-0f4d-4407-90a1-4247dea49e13", "Styles": "margin-left:28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor\nstraight away if you get signs of TB during treatment with Remicade. Signs\ninclude persistent cough, weight loss, feeling tired, fever, night sweats.</span>", "ID": "ea0a608a-dce8-48b5-be62-c170b61f9e7c", "Styles": "None", "Classes": "None", "Text": "Tell your doctor straight away if you get signs of TB during treatment with Remicade. Signs include persistent cough, weight loss, feeling tired, fever, night sweats.", "ParentId": "05ca07f9-0f4d-4407-90a1-4247dea49e13"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e8561e0d-9ee3-4486-96eb-bba71853a430", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f07c62b6-f41c-493c-b94b-b44c732aea2c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e8561e0d-9ee3-4486-96eb-bba71853a430"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatitis B virus</span></u></p>", "ID": "afffc392-61b6-41be-8cba-e0821428f0cb", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Hepatitis B virus</span></u>", "ID": "6f0ed7fe-ddd5-4c2f-9618-621fffcc6f3d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "afffc392-61b6-41be-8cba-e0821428f0cb"}, {"Element": "<span lang=\"EN-GB\">Hepatitis B virus</span>", "ID": "2f67d2ee-662f-43af-bead-808b2a858ec9", "Styles": "None", "Classes": "None", "Text": "Hepatitis B virus", "ParentId": "6f0ed7fe-ddd5-4c2f-9618-621fffcc6f3d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou are a carrier of hepatitis B or have ever had it.</span></p>", "ID": "b7267dde-577f-4b48-b353-dc0420438182", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "841901b9-450b-4e84-bc30-e2a342dc48f2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b7267dde-577f-4b48-b353-dc0420438182"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8186db90-6579-42a8-b480-f795a2fadcfd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "841901b9-450b-4e84-bc30-e2a342dc48f2"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou are a carrier of hepatitis B or have ever had it.</span>", "ID": "7eff0711-5999-45fe-b7c0-f1b8c6dca005", "Styles": "None", "Classes": "None", "Text": "Tell your doctor before you are given Remicade if you are a carrier of hepatitis B or have ever had it.", "ParentId": "b7267dde-577f-4b48-b353-dc0420438182"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor if you think you might be at\nrisk of contracting hepatitis B.</span></p>", "ID": "f9a214ca-400a-4cf6-bbb9-92fa1a511307", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "b6036dcc-3afe-4374-9580-896402ae746f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f9a214ca-400a-4cf6-bbb9-92fa1a511307"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6bf9eb70-7d7a-4134-bed7-75db69af0d68", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "b6036dcc-3afe-4374-9580-896402ae746f"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor if you think you might be at\nrisk of contracting hepatitis B.</span>", "ID": "46fe5e39-f76e-4941-bf31-074e32b6eb2d", "Styles": "None", "Classes": "None", "Text": "Tell your doctor if you think you might be at risk of contracting hepatitis B.", "ParentId": "f9a214ca-400a-4cf6-bbb9-92fa1a511307"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Your doctor should test you for hepatitis B\nvirus.</span></p>", "ID": "dfdefd57-4aad-4857-bd51-0fd3063d1fb9", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "26567ed6-6c2b-40b4-8aeb-7eb07e13ce1e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "dfdefd57-4aad-4857-bd51-0fd3063d1fb9"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "a403ce7c-57e4-43b4-b5ff-b988185559fc", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "26567ed6-6c2b-40b4-8aeb-7eb07e13ce1e"}, {"Element": "<span lang=\"EN-GB\">Your doctor should test you for hepatitis B\nvirus.</span>", "ID": "35bb7e54-a090-46e0-a3ca-cf8798612c47", "Styles": "None", "Classes": "None", "Text": "Your doctor should test you for hepatitis B virus.", "ParentId": "dfdefd57-4aad-4857-bd51-0fd3063d1fb9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Treatment with TNF blockers such as Remicade may\nresult in reactivation of hepatitis B virus in patients who carry this virus,\nwhich can be life\u2011threatening in some cases.</span></p>", "ID": "bcc12b23-1638-4373-9822-d08188020111", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "fff109dd-9d61-463b-b694-f8c0dac55b60", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "bcc12b23-1638-4373-9822-d08188020111"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "5f3eb4df-d949-4fcf-8a48-29ba58ec4aa2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "fff109dd-9d61-463b-b694-f8c0dac55b60"}, {"Element": "<span lang=\"EN-GB\">Treatment with TNF blockers such as Remicade may\nresult in reactivation of hepatitis B virus in patients who carry this virus,\nwhich can be life\u2011threatening in some cases.</span>", "ID": "0cd5c066-ad78-44d2-90ad-b78fb796899b", "Styles": "None", "Classes": "None", "Text": "Treatment with TNF blockers such as Remicade may result in reactivation of hepatitis B virus in patients who carry this virus, which can be life\u2011threatening in some cases.", "ParentId": "bcc12b23-1638-4373-9822-d08188020111"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5511cdcb-cae3-4921-8eb1-a986e5235ee4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "07f7842e-f3d7-45ba-b751-db8c4c344456", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5511cdcb-cae3-4921-8eb1-a986e5235ee4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Heart problems</span></u></p>", "ID": "3d3aa859-b0ce-42ee-a235-121d8b81499d", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Heart problems</span></u>", "ID": "109e6b2e-2afd-4f71-b2b2-be114cfc2b0b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3d3aa859-b0ce-42ee-a235-121d8b81499d"}, {"Element": "<span lang=\"EN-GB\">Heart problems</span>", "ID": "03d1e36e-f5dc-4d8b-b979-c83ae9724d29", "Styles": "None", "Classes": "None", "Text": "Heart problems", "ParentId": "109e6b2e-2afd-4f71-b2b2-be114cfc2b0b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor if you have any heart problems,\nsuch as mild heart failure.</span></p>", "ID": "e83723ff-c645-4465-bbf9-ecf218924306", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "502d0cda-72db-4ed3-aada-d4bcb97ad3e4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e83723ff-c645-4465-bbf9-ecf218924306"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "3713b76e-11fc-49c8-83a2-0a8af3255814", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "502d0cda-72db-4ed3-aada-d4bcb97ad3e4"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor if you have any heart problems,\nsuch as mild heart failure.</span>", "ID": "12c2f04e-8dd8-4397-80a5-b423a6d76202", "Styles": "None", "Classes": "None", "Text": "Tell your doctor if you have any heart problems, such as mild heart failure.", "ParentId": "e83723ff-c645-4465-bbf9-ecf218924306"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Your doctor will want to closely monitor your\nheart.</span></p>", "ID": "4d0bd372-f840-453c-b076-1afbc75849b7", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "460a6847-3b4e-4fca-a669-a04c31af95d7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4d0bd372-f840-453c-b076-1afbc75849b7"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c25ccf91-6239-4c98-a2c1-1bee1d217086", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "460a6847-3b4e-4fca-a669-a04c31af95d7"}, {"Element": "<span lang=\"EN-GB\">Your doctor will want to closely monitor your\nheart.</span>", "ID": "c3b7e0eb-3c0a-40ed-9b1a-e78823901a9a", "Styles": "None", "Classes": "None", "Text": "Your doctor will want to closely monitor your heart.", "ParentId": "4d0bd372-f840-453c-b076-1afbc75849b7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Tell your\ndoctor straight away if you get new or worsening signs of heart failure during\ntreatment with Remicade. Signs include shortness of breath or swelling of your\nfeet.</span></p>", "ID": "bee2ebd5-4ea3-471f-9f7c-94b88864541f", "Styles": "margin-left:28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Tell your\ndoctor straight away if you get new or worsening signs of heart failure during\ntreatment with Remicade. Signs include shortness of breath or swelling of your\nfeet.</span>", "ID": "97890833-bae7-4b7c-a4cb-f2dddb71e31e", "Styles": "None", "Classes": "None", "Text": "Tell your doctor straight away if you get new or worsening signs of heart failure during treatment with Remicade. Signs include shortness of breath or swelling of your feet.", "ParentId": "bee2ebd5-4ea3-471f-9f7c-94b88864541f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f07fe94b-b1ca-4649-858f-0a8ba70b169a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "26f68da4-6e9d-4070-a06f-fc2e7779bf00", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f07fe94b-b1ca-4649-858f-0a8ba70b169a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Cancer and lymphoma</span></u></p>", "ID": "cc3704cf-e6c4-4741-97f6-a6c0dbfe446d", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Cancer and lymphoma</span></u>", "ID": "d02a456a-c567-48c8-8e36-e407ccbf8df0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "cc3704cf-e6c4-4741-97f6-a6c0dbfe446d"}, {"Element": "<span lang=\"EN-GB\">Cancer and lymphoma</span>", "ID": "c8811bd4-fa77-4402-86ce-7c62776df421", "Styles": "None", "Classes": "None", "Text": "Cancer and lymphoma", "ParentId": "d02a456a-c567-48c8-8e36-e407ccbf8df0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou have or have ever had lymphoma (a type of blood cancer) or any other\ncancer.</span></p>", "ID": "24f5f76d-ec3d-40f8-812a-dc4e2d686f7e", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "fdc711dd-beed-4850-863c-c867989f1d5f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "24f5f76d-ec3d-40f8-812a-dc4e2d686f7e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2fe1db2d-018a-4fc8-8584-332e61409219", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "fdc711dd-beed-4850-863c-c867989f1d5f"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou have or have ever had lymphoma (a type of blood cancer) or any other\ncancer.</span>", "ID": "7ac54658-e873-4260-8498-c315cc20bf9d", "Styles": "None", "Classes": "None", "Text": "Tell your doctor before you are given Remicade if you have or have ever had lymphoma (a type of blood cancer) or any other cancer.", "ParentId": "24f5f76d-ec3d-40f8-812a-dc4e2d686f7e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Patients with severe rheumatoid arthritis, who\nhave had the disease for a long time, may be at higher risk of developing\nlymphoma.</span></p>", "ID": "6cbd5289-1ca1-4744-b065-de63bdae1880", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "1d998a2b-bb8a-4a34-8c5a-4aff90772183", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6cbd5289-1ca1-4744-b065-de63bdae1880"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6293a116-6e8b-40f4-af42-3225ab4846dd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "1d998a2b-bb8a-4a34-8c5a-4aff90772183"}, {"Element": "<span lang=\"EN-GB\">Patients with severe rheumatoid arthritis, who\nhave had the disease for a long time, may be at higher risk of developing\nlymphoma.</span>", "ID": "5c450bec-7eca-40b8-afa6-14e0ec879ec8", "Styles": "None", "Classes": "None", "Text": "Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at higher risk of developing lymphoma.", "ParentId": "6cbd5289-1ca1-4744-b065-de63bdae1880"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Children and adults taking Remicade may have an\nincreased risk of developing lymphoma or another cancer.</span></p>", "ID": "3fa040f1-5f99-4989-b5a8-a897edc94676", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c2ba49e9-bce2-49fb-87d0-d396343bd6f8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3fa040f1-5f99-4989-b5a8-a897edc94676"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "71a11a20-a1a5-47bf-85f7-272e94b965ad", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c2ba49e9-bce2-49fb-87d0-d396343bd6f8"}, {"Element": "<span lang=\"EN-GB\">Children and adults taking Remicade may have an\nincreased risk of developing lymphoma or another cancer.</span>", "ID": "75985b75-6bdd-4e71-a43b-9671a1a321f9", "Styles": "None", "Classes": "None", "Text": "Children and adults taking Remicade may have an increased risk of developing lymphoma or another cancer.", "ParentId": "3fa040f1-5f99-4989-b5a8-a897edc94676"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Some patients who have received TNF\u2011blockers,\nincluding Remicade have developed a rare type of cancer called hepatosplenic T\u2011cell\nlymphoma. Of these patients, most were teenage boys or young men and most had\neither Crohn\u2019s disease or ulcerative colitis. This type of cancer has\nusually resulted in death. Almost all patients had also received medicines\ncontaining azathioprine or 6\u2011mercaptopurine in addition to TNF\u2011blockers.</span></p>", "ID": "31af198e-2662-4ffd-838d-85a106c67d75", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3c2b2318-ceac-4afd-8db1-e43be075578e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "31af198e-2662-4ffd-838d-85a106c67d75"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "3789863e-335b-4206-86d9-33108d0b7f37", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3c2b2318-ceac-4afd-8db1-e43be075578e"}, {"Element": "<span lang=\"EN-GB\">Some patients who have received TNF\u2011blockers,\nincluding Remicade have developed a rare type of cancer called hepatosplenic T\u2011cell\nlymphoma. Of these patients, most were teenage boys or young men and most had\neither Crohn\u2019s disease or ulcerative colitis. This type of cancer has\nusually resulted in death. Almost all patients had also received medicines\ncontaining azathioprine or 6\u2011mercaptopurine in addition to TNF\u2011blockers.</span>", "ID": "df416caf-4a20-459f-87e4-c5f3279d0601", "Styles": "None", "Classes": "None", "Text": "Some patients who have received TNF\u2011blockers, including Remicade have developed a rare type of cancer called hepatosplenic T\u2011cell lymphoma. Of these patients, most were teenage boys or young men and most had either Crohn\u2019s disease or ulcerative colitis. This type of cancer has usually resulted in death. Almost all patients had also received medicines containing azathioprine or 6\u2011mercaptopurine in addition to TNF\u2011blockers.", "ParentId": "31af198e-2662-4ffd-838d-85a106c67d75"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Some patients treated with infliximab have\ndeveloped certain kinds of skin cancer. If there are any changes in your skin\nor growths on the skin during or after therapy, tell your doctor.</span></p>", "ID": "cbf3dd3f-8e54-42b3-a446-b2bc62dc4207", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "05969f13-e452-4714-b7dc-575e2badaec8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "cbf3dd3f-8e54-42b3-a446-b2bc62dc4207"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "94043ef7-8809-4759-a7f4-5d1174f7bdfb", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "05969f13-e452-4714-b7dc-575e2badaec8"}, {"Element": "<span lang=\"EN-GB\">Some patients treated with infliximab have\ndeveloped certain kinds of skin cancer. If there are any changes in your skin\nor growths on the skin during or after therapy, tell your doctor.</span>", "ID": "6b1b07dc-0f55-45a2-9473-b3dbc71bf4e2", "Styles": "None", "Classes": "None", "Text": "Some patients treated with infliximab have developed certain kinds of skin cancer. If there are any changes in your skin or growths on the skin during or after therapy, tell your doctor.", "ParentId": "cbf3dd3f-8e54-42b3-a446-b2bc62dc4207"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Some women being treated for rheumatoid\narthritis with Remicade have developed cervical cancer. For women taking\nRemicade including those over 60\u00a0years of age, your doctor may recommend\nregular screening for cervical cancer.</span></p>", "ID": "f80ae452-7922-4f58-9460-8ac220884d85", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "dca78853-8ddd-4368-9340-8f9b65c1b8f1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f80ae452-7922-4f58-9460-8ac220884d85"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "43cf8a52-536d-4d74-952d-50ba64a19d48", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "dca78853-8ddd-4368-9340-8f9b65c1b8f1"}, {"Element": "<span lang=\"EN-GB\">Some women being treated for rheumatoid\narthritis with Remicade have developed cervical cancer. For women taking\nRemicade including those over 60\u00a0years of age, your doctor may recommend\nregular screening for cervical cancer.</span>", "ID": "89270d15-4277-4ae8-85ca-999993c97e2b", "Styles": "None", "Classes": "None", "Text": "Some women being treated for rheumatoid arthritis with Remicade have developed cervical cancer. For women taking Remicade including those over 60\u00a0years of age, your doctor may recommend regular screening for cervical cancer.", "ParentId": "f80ae452-7922-4f58-9460-8ac220884d85"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4d8a56e0-3fca-47dc-b666-8106de21501d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "26a424dc-9856-4116-bbef-cf8176bd8bcd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4d8a56e0-3fca-47dc-b666-8106de21501d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Lung disease or heavy smoking</span></u></p>", "ID": "a148450f-16ec-4547-8fba-1e9e7ce2537b", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Lung disease or heavy smoking</span></u>", "ID": "25fa4697-4dbb-4b7c-aeea-e3d290e7ebb4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a148450f-16ec-4547-8fba-1e9e7ce2537b"}, {"Element": "<span lang=\"EN-GB\">Lung disease or heavy smoking</span>", "ID": "7f5242be-cac1-4f05-9e37-05ae64decf63", "Styles": "None", "Classes": "None", "Text": "Lung disease or heavy smoking", "ParentId": "25fa4697-4dbb-4b7c-aeea-e3d290e7ebb4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou have a lung disease called Chronic Obstructive Pulmonary Disease (COPD) or\nif you are a heavy smoker.</span></p>", "ID": "3eecab3a-c31f-41c9-800b-4a3735108fb7", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "8515eb42-9914-4c09-9811-647117e8ae95", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3eecab3a-c31f-41c9-800b-4a3735108fb7"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "24f26e4b-7664-43c3-ae3d-bc4b2eb2493c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "8515eb42-9914-4c09-9811-647117e8ae95"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor before you are given Remicade if\nyou have a lung disease called Chronic Obstructive Pulmonary Disease (COPD) or\nif you are a heavy smoker.</span>", "ID": "d4c90424-28f1-4a92-a3ee-eaac52e93e68", "Styles": "None", "Classes": "None", "Text": "Tell your doctor before you are given Remicade if you have a lung disease called Chronic Obstructive Pulmonary Disease (COPD) or if you are a heavy smoker.", "ParentId": "3eecab3a-c31f-41c9-800b-4a3735108fb7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Patients with COPD and patients who are heavy\nsmokers may have a higher risk of developing cancer with Remicade treatment.</span></p>", "ID": "87bf041b-5db7-4f6e-b317-2f9d9cd46732", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "fbb4daa8-9e07-4a03-84b2-c93f14985404", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "87bf041b-5db7-4f6e-b317-2f9d9cd46732"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "a708b9d0-236d-4fa4-aeaf-685d4a7c6694", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "fbb4daa8-9e07-4a03-84b2-c93f14985404"}, {"Element": "<span lang=\"EN-GB\">Patients with COPD and patients who are heavy\nsmokers may have a higher risk of developing cancer with Remicade treatment.</span>", "ID": "10b36ca4-2117-4aba-bd54-476e063d7292", "Styles": "None", "Classes": "None", "Text": "Patients with COPD and patients who are heavy smokers may have a higher risk of developing cancer with Remicade treatment.", "ParentId": "87bf041b-5db7-4f6e-b317-2f9d9cd46732"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "02e7b642-9453-4da1-8230-6a9674d0681b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f8e62f5d-86b4-4c79-8bad-9cf1c7ca7ba2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "02e7b642-9453-4da1-8230-6a9674d0681b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous system disease</span></u></p>", "ID": "6d6de881-0baf-4801-b942-a843fd4687d8", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Nervous system disease</span></u>", "ID": "c55945fe-9b92-41e9-a3ad-6354471991bf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6d6de881-0baf-4801-b942-a843fd4687d8"}, {"Element": "<span lang=\"EN-GB\">Nervous system disease</span>", "ID": "a2ec41e6-572b-43d5-bb40-e183afb42506", "Styles": "None", "Classes": "None", "Text": "Nervous system disease", "ParentId": "c55945fe-9b92-41e9-a3ad-6354471991bf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor if you have or have ever had a\nproblem that affects your nervous system before you are given Remicade. This\nincludes multiple sclerosis, Guillain\u2011Barre syndrome, if you have fits or\nhave been diagnosed with \u2018optic neuritis\u2019.</span></p>", "ID": "3b98c891-6caa-47f8-934a-ade1d9b25399", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5752f39f-7726-4c94-9c7d-91146f9c8a37", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3b98c891-6caa-47f8-934a-ade1d9b25399"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "81a0de12-a27f-4717-a62c-be027196d5f9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5752f39f-7726-4c94-9c7d-91146f9c8a37"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor if you have or have ever had a\nproblem that affects your nervous system before you are given Remicade. This\nincludes multiple sclerosis, Guillain\u2011Barre syndrome, if you have fits or\nhave been diagnosed with \u2018optic neuritis\u2019.</span>", "ID": "793d91ac-497f-4c8b-84d3-0c1eb8be52df", "Styles": "None", "Classes": "None", "Text": "Tell your doctor if you have or have ever had a problem that affects your nervous system before you are given Remicade. This includes multiple sclerosis, Guillain\u2011Barre syndrome, if you have fits or have been diagnosed with \u2018optic neuritis\u2019.", "ParentId": "3b98c891-6caa-47f8-934a-ade1d9b25399"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Tell your\ndoctor straight away if you get symptoms of a nerve disease during treatment\nwith Remicade. Signs include changes in your vision, weakness in your arms or\nlegs, numbness or tingling in any part of your body.</span></p>", "ID": "096491cb-b310-456e-8b59-31b93543ec6d", "Styles": "margin-left:28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Tell your\ndoctor straight away if you get symptoms of a nerve disease during treatment\nwith Remicade. Signs include changes in your vision, weakness in your arms or\nlegs, numbness or tingling in any part of your body.</span>", "ID": "3475ac9e-9e0e-4dc9-990a-f9af976dde02", "Styles": "None", "Classes": "None", "Text": "Tell your doctor straight away if you get symptoms of a nerve disease during treatment with Remicade. Signs include changes in your vision, weakness in your arms or legs, numbness or tingling in any part of your body.", "ParentId": "096491cb-b310-456e-8b59-31b93543ec6d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5be5ba42-e07b-4718-af0d-dd98f4567243", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "42d48534-d413-4277-a825-1a3ca00af8d5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5be5ba42-e07b-4718-af0d-dd98f4567243"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Abnormal skin openings</span></u></p>", "ID": "53ab25ee-c569-451f-a5dc-5ea8f789276e", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Abnormal skin openings</span></u>", "ID": "ca1f0ab7-8812-48cc-8017-dbda7613befe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "53ab25ee-c569-451f-a5dc-5ea8f789276e"}, {"Element": "<span lang=\"EN-GB\">Abnormal skin openings</span>", "ID": "8c516447-f31f-40ca-9303-6717467be443", "Styles": "None", "Classes": "None", "Text": "Abnormal skin openings", "ParentId": "ca1f0ab7-8812-48cc-8017-dbda7613befe"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor if you have any abnormal skin\nopenings (fistulae) before you are given Remicade.</span></p>", "ID": "4c90cd55-1038-425c-9a00-44d51985b9eb", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "b8fdf2dd-328e-4041-af4e-3209b65709e2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4c90cd55-1038-425c-9a00-44d51985b9eb"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ad2f68a8-c218-4336-9e09-baacef1f5728", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "b8fdf2dd-328e-4041-af4e-3209b65709e2"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor if you have any abnormal skin\nopenings (fistulae) before you are given Remicade.</span>", "ID": "e2c10e91-762d-4aed-8028-c44299fd012a", "Styles": "None", "Classes": "None", "Text": "Tell your doctor if you have any abnormal skin openings (fistulae) before you are given Remicade.", "ParentId": "4c90cd55-1038-425c-9a00-44d51985b9eb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "98d29235-2f5d-4a48-bae9-ee09800f5a6f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "832420f8-8c7e-4902-9778-a86fe4035660", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "98d29235-2f5d-4a48-bae9-ee09800f5a6f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Vaccinations</span></u></p>", "ID": "e8aef00c-e789-48f8-b555-c1cde931a7bd", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Vaccinations</span></u>", "ID": "537f0455-afaf-4f31-be6e-9fb86c32f7b7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e8aef00c-e789-48f8-b555-c1cde931a7bd"}, {"Element": "<span lang=\"EN-GB\">Vaccinations</span>", "ID": "1407f9f7-b990-4f91-9c9c-a203f0f92f37", "Styles": "None", "Classes": "None", "Text": "Vaccinations", "ParentId": "537f0455-afaf-4f31-be6e-9fb86c32f7b7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Talk to your doctor if you recently have had or\nare due to have a vaccine.</span></p>", "ID": "5c9f7319-6764-4dfb-ac22-1a30c59abb53", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "fba869b7-0d4b-4679-b4ec-a4244ec711c2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5c9f7319-6764-4dfb-ac22-1a30c59abb53"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "e637ea6a-a3b4-4c97-a066-5ad226c80892", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "fba869b7-0d4b-4679-b4ec-a4244ec711c2"}, {"Element": "<span lang=\"EN-GB\">Talk to your doctor if you recently have had or\nare due to have a vaccine.</span>", "ID": "3c52143c-d340-40fc-ad6c-38d77a26f7e5", "Styles": "None", "Classes": "None", "Text": "Talk to your doctor if you recently have had or are due to have a vaccine.", "ParentId": "5c9f7319-6764-4dfb-ac22-1a30c59abb53"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You should receive recommended vaccinations\nbefore starting Remicade treatment. You may receive some vaccines during\ntreatment with Remicade but you should not receive live vaccines (vaccines that\ncontain a living but weakened infectious agent) while using Remicade because\nthey may cause infections.</span></p>", "ID": "5087e024-9d4c-47a7-8513-e1b57d6ab33c", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "aecae077-1b1c-4097-ba86-688fbc4d1e57", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5087e024-9d4c-47a7-8513-e1b57d6ab33c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "fbf634d7-2ba6-4c14-820a-9997edf82e65", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "aecae077-1b1c-4097-ba86-688fbc4d1e57"}, {"Element": "<span lang=\"EN-GB\">You should receive recommended vaccinations\nbefore starting Remicade treatment. You may receive some vaccines during\ntreatment with Remicade but you should not receive live vaccines (vaccines that\ncontain a living but weakened infectious agent) while using Remicade because\nthey may cause infections.</span>", "ID": "997dbc4e-2dba-4231-8ebf-4f179bd26175", "Styles": "None", "Classes": "None", "Text": "You should receive recommended vaccinations before starting Remicade treatment. You may receive some vaccines during treatment with Remicade but you should not receive live vaccines (vaccines that contain a living but weakened infectious agent) while using Remicade because they may cause infections.", "ParentId": "5087e024-9d4c-47a7-8513-e1b57d6ab33c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you received Remicade while you were\npregnant, your baby may also be at higher risk for getting an infection with\nlive vaccines for up to six months after birth. It is important that you tell\nyour baby's doctors and other healthcare professionals about your Remicade use\nso they can decide when your baby should receive any vaccine, including live vaccines\nsuch as BCG (used to prevent tuberculosis). For more information see section on\nPregnancy and breast\u2011feeding.</span></p>", "ID": "fa67b22e-0bff-48de-864c-aad8e890e369", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3482ff11-130c-4b71-8258-d55168057dee", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "fa67b22e-0bff-48de-864c-aad8e890e369"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "35fa013c-580e-41a5-bd25-9db4254c8e41", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3482ff11-130c-4b71-8258-d55168057dee"}, {"Element": "<span lang=\"EN-GB\">If you received Remicade while you were\npregnant, your baby may also be at higher risk for getting an infection with\nlive vaccines for up to six months after birth. It is important that you tell\nyour baby's doctors and other healthcare professionals about your Remicade use\nso they can decide when your baby should receive any vaccine, including live vaccines\nsuch as BCG (used to prevent tuberculosis). For more information see section on\nPregnancy and breast\u2011feeding.</span>", "ID": "bc5bb1d1-fd1b-4ba8-a0f4-aba4a06a8260", "Styles": "None", "Classes": "None", "Text": "If you received Remicade while you were pregnant, your baby may also be at higher risk for getting an infection with live vaccines for up to six months after birth. It is important that you tell your baby's doctors and other healthcare professionals about your Remicade use so they can decide when your baby should receive any vaccine, including live vaccines such as BCG (used to prevent tuberculosis). For more information see section on Pregnancy and breast\u2011feeding.", "ParentId": "fa67b22e-0bff-48de-864c-aad8e890e369"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7124cd96-2b5f-449c-968a-e1eff4022d9d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a26ed0b8-88c1-4a8d-8ff8-17ad235605e9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7124cd96-2b5f-449c-968a-e1eff4022d9d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Therapeutic infectious agents</span></u></p>", "ID": "8bd88881-4a57-45f4-9d5c-60ef96bb5396", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Therapeutic infectious agents</span></u>", "ID": "50be9a3a-47e5-4be6-b068-da4d4aa31ecc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8bd88881-4a57-45f4-9d5c-60ef96bb5396"}, {"Element": "<span lang=\"EN-GB\">Therapeutic infectious agents</span>", "ID": "161a5f07-ffee-46a5-8993-86f52e56a290", "Styles": "None", "Classes": "None", "Text": "Therapeutic infectious agents", "ParentId": "50be9a3a-47e5-4be6-b068-da4d4aa31ecc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Talk to you doctor if you have recently received\nor are scheduled to receive treatment with a therapeutic infectious agent (such\nas BCG instillation used for the treatment of cancer).</span></p>", "ID": "eb1f043c-be42-40cb-ad47-9a5addac017d", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4f507f37-6885-40b4-8784-e057d5d20c43", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "eb1f043c-be42-40cb-ad47-9a5addac017d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "229d4d47-350a-44fe-b1f4-715265f89216", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4f507f37-6885-40b4-8784-e057d5d20c43"}, {"Element": "<span lang=\"EN-GB\">Talk to you doctor if you have recently received\nor are scheduled to receive treatment with a therapeutic infectious agent (such\nas BCG instillation used for the treatment of cancer).</span>", "ID": "ac2029e8-3064-4015-a1c0-1786cbbb2964", "Styles": "None", "Classes": "None", "Text": "Talk to you doctor if you have recently received or are scheduled to receive treatment with a therapeutic infectious agent (such as BCG instillation used for the treatment of cancer).", "ParentId": "eb1f043c-be42-40cb-ad47-9a5addac017d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "468c3736-16de-4e73-894a-7835a6c72a42", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bedf81a5-0447-43f7-857d-f480ab004833", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "468c3736-16de-4e73-894a-7835a6c72a42"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Operations or dental procedures</span></u></p>", "ID": "121b3ff5-9ed4-44b4-8aa4-710b2a8c2951", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Operations or dental procedures</span></u>", "ID": "0071c534-a552-4ae5-b9b2-b707bafd9f9b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "121b3ff5-9ed4-44b4-8aa4-710b2a8c2951"}, {"Element": "<span lang=\"EN-GB\">Operations or dental procedures</span>", "ID": "944a50dc-9f92-4f81-80bf-fbb3328b0d84", "Styles": "None", "Classes": "None", "Text": "Operations or dental procedures", "ParentId": "0071c534-a552-4ae5-b9b2-b707bafd9f9b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your doctor if you are going to have any\noperations or dental procedures.</span></p>", "ID": "3a401e5c-3bf1-404d-a4bc-2766c8bb1192", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "09f3636b-b417-457a-8953-ede88606ca93", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3a401e5c-3bf1-404d-a4bc-2766c8bb1192"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "5146d744-6083-4c00-8d19-c49e209c0566", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "09f3636b-b417-457a-8953-ede88606ca93"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor if you are going to have any\noperations or dental procedures.</span>", "ID": "e39e7299-4d80-420a-9b6c-1915c9dd917f", "Styles": "None", "Classes": "None", "Text": "Tell your doctor if you are going to have any operations or dental procedures.", "ParentId": "3a401e5c-3bf1-404d-a4bc-2766c8bb1192"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tell your surgeon or dentist that you are having\ntreatment with Remicade by showing them your patient reminder card.</span></p>", "ID": "c5af3aad-b45d-4f44-a2d5-8c35896d81c7", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3be25c90-2ac7-49fa-9789-10efaf123eb3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c5af3aad-b45d-4f44-a2d5-8c35896d81c7"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "892ff133-fe38-4a04-a4f2-65846c37e6de", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3be25c90-2ac7-49fa-9789-10efaf123eb3"}, {"Element": "<span lang=\"EN-GB\">Tell your surgeon or dentist that you are having\ntreatment with Remicade by showing them your patient reminder card.</span>", "ID": "031fc7ab-0116-499c-b9c0-98c3ac668126", "Styles": "None", "Classes": "None", "Text": "Tell your surgeon or dentist that you are having treatment with Remicade by showing them your patient reminder card.", "ParentId": "c5af3aad-b45d-4f44-a2d5-8c35896d81c7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1dbfdc58-2940-41dd-ae20-2c1a746d0320", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7a81bf69-46eb-439b-97d2-035b5ee7f6cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1dbfdc58-2940-41dd-ae20-2c1a746d0320"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Liver problems</span></u></p>", "ID": "36df9fb7-5f20-4290-b65b-07e84a41329b", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Liver problems</span></u>", "ID": "386dbdee-22cd-404a-9a7a-b1333b73fd39", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "36df9fb7-5f20-4290-b65b-07e84a41329b"}, {"Element": "<span lang=\"EN-GB\">Liver problems</span>", "ID": "7c3e1bdd-13c2-41da-87c0-f164a2f2953b", "Styles": "None", "Classes": "None", "Text": "Liver problems", "ParentId": "386dbdee-22cd-404a-9a7a-b1333b73fd39"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Some patients receiving Remicade have developed\nserious liver problems.</span></p>", "ID": "774c9136-3abc-4e56-afdb-943d82e6a2d1", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "80dc7631-0935-42d7-8270-f9e76379d461", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "774c9136-3abc-4e56-afdb-943d82e6a2d1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "80d357e8-758a-45ab-9b39-7fad282620d8", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "80dc7631-0935-42d7-8270-f9e76379d461"}, {"Element": "<span lang=\"EN-GB\">Some patients receiving Remicade have developed\nserious liver problems.</span>", "ID": "e68de53c-512f-4e90-ac5e-a202315fce71", "Styles": "None", "Classes": "None", "Text": "Some patients receiving Remicade have developed serious liver problems.", "ParentId": "774c9136-3abc-4e56-afdb-943d82e6a2d1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Tell your\ndoctor straight away if you get symptoms of liver problems during treatment\nwith Remicade. Signs include yellowing of the skin and eyes, dark-brown</span><span lang=\"EN-GB\" style=\"font-size:10.0pt\"> </span><span lang=\"EN-GB\">coloured urine,\npain or swelling in the upper right side of the stomach area, joint pain, skin\nrashes, or fever.</span></p>", "ID": "cd412229-854f-4efc-a2d4-8a4a439f0ed3", "Styles": "margin-left:28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Tell your\ndoctor straight away if you get symptoms of liver problems during treatment\nwith Remicade. Signs include yellowing of the skin and eyes, dark-brown</span>", "ID": "0268a92b-0c51-4cef-a60d-f284d9e2bc74", "Styles": "None", "Classes": "None", "Text": "Tell your doctor straight away if you get symptoms of liver problems during treatment with Remicade. Signs include yellowing of the skin and eyes, dark-brown", "ParentId": "cd412229-854f-4efc-a2d4-8a4a439f0ed3"}, {"Element": "<span lang=\"EN-GB\" style=\"font-size:10.0pt\"> </span>", "ID": "002d0935-4e08-4227-b8bd-594cab051fad", "Styles": "font-size:10.0pt", "Classes": "None", "Text": " ", "ParentId": "cd412229-854f-4efc-a2d4-8a4a439f0ed3"}, {"Element": "<span lang=\"EN-GB\">coloured urine,\npain or swelling in the upper right side of the stomach area, joint pain, skin\nrashes, or fever.</span>", "ID": "85d5b965-e254-400d-bb5b-c6021f55a0e5", "Styles": "None", "Classes": "None", "Text": "coloured urine, pain or swelling in the upper right side of the stomach area, joint pain, skin rashes, or fever.", "ParentId": "cd412229-854f-4efc-a2d4-8a4a439f0ed3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "17090e93-3bef-4c55-9d9d-cd911de7df4a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "eb6ef862-cadc-46d8-a61e-cdb85558e5a6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "17090e93-3bef-4c55-9d9d-cd911de7df4a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Low blood counts</span></u></p>", "ID": "4cc9a652-3cf1-4a29-aafb-0e38b346af1d", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Low blood counts</span></u>", "ID": "c5857d70-48ba-4496-9b05-921b18599529", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4cc9a652-3cf1-4a29-aafb-0e38b346af1d"}, {"Element": "<span lang=\"EN-GB\">Low blood counts</span>", "ID": "f835bc6f-d9ec-4f2c-adc7-58933e0911dd", "Styles": "None", "Classes": "None", "Text": "Low blood counts", "ParentId": "c5857d70-48ba-4496-9b05-921b18599529"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">In some patients receiving Remicade, the body\nmay not make enough of the blood cells that help fight infections or help stop\nbleeding.</span></p>", "ID": "e06952b7-f0a8-466e-92e5-061a6a7bb496", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "9460fb05-0a01-41ff-8024-778cd00de943", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e06952b7-f0a8-466e-92e5-061a6a7bb496"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7e73f421-a6d1-4c21-9359-7af71fd7dd3d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "9460fb05-0a01-41ff-8024-778cd00de943"}, {"Element": "<span lang=\"EN-GB\">In some patients receiving Remicade, the body\nmay not make enough of the blood cells that help fight infections or help stop\nbleeding.</span>", "ID": "2b696b97-0e8f-4a3d-9f44-da2b556cfa7b", "Styles": "None", "Classes": "None", "Text": "In some patients receiving Remicade, the body may not make enough of the blood cells that help fight infections or help stop bleeding.", "ParentId": "e06952b7-f0a8-466e-92e5-061a6a7bb496"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor straight away if you get\nsymptoms of low blood counts during treatment with Remicade. Signs include persistent\nfever, bleeding or bruising more easily, small red or purple spots caused by bleeding\nunder the skin, or looking pale.</span></p>", "ID": "88b37355-74ae-456c-a3f8-22801be698a7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor straight away if you get\nsymptoms of low blood counts during treatment with Remicade. Signs include persistent\nfever, bleeding or bruising more easily, small red or purple spots caused by bleeding\nunder the skin, or looking pale.</span>", "ID": "1b532ba0-8bb3-4787-ab8a-df577182d69c", "Styles": "None", "Classes": "None", "Text": "Tell your doctor straight away if you get symptoms of low blood counts during treatment with Remicade. Signs include persistent fever, bleeding or bruising more easily, small red or purple spots caused by bleeding under the skin, or looking pale.", "ParentId": "88b37355-74ae-456c-a3f8-22801be698a7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "df2dbfad-01fa-47ae-9b21-a468044c8cd8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4e5ccb79-5a69-4788-a8c2-a1b16ec2579c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "df2dbfad-01fa-47ae-9b21-a468044c8cd8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune system disorder</span></u></p>", "ID": "c3410d4b-d6fc-4710-8566-975c29b77841", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">Immune system disorder</span></u>", "ID": "3b771cc3-8729-4c1d-aacd-c525f114fa7c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c3410d4b-d6fc-4710-8566-975c29b77841"}, {"Element": "<span lang=\"EN-GB\">Immune system disorder</span>", "ID": "0e89885f-2b8a-4684-b2c6-1729b03545d1", "Styles": "None", "Classes": "None", "Text": "Immune system disorder", "ParentId": "3b771cc3-8729-4c1d-aacd-c525f114fa7c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Some patients receiving Remicade have developed\nsymptoms of an immune system disorder called lupus.</span></p>", "ID": "4356dd26-f840-4c23-bcb7-1646a6cd7d0c", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ea029ae9-9090-4af3-a36c-f2822dfb0c37", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4356dd26-f840-4c23-bcb7-1646a6cd7d0c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "a29b91c6-c6ff-48c3-9c8b-7ecfb118fb5c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ea029ae9-9090-4af3-a36c-f2822dfb0c37"}, {"Element": "<span lang=\"EN-GB\">Some patients receiving Remicade have developed\nsymptoms of an immune system disorder called lupus.</span>", "ID": "b700d840-fd10-494f-a438-f5de13db5d69", "Styles": "None", "Classes": "None", "Text": "Some patients receiving Remicade have developed symptoms of an immune system disorder called lupus.", "ParentId": "4356dd26-f840-4c23-bcb7-1646a6cd7d0c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">Tell your\ndoctor straight away if you develop symptoms of lupus during treatment with\nRemicade. Signs include joint pain or a rash on cheeks or arms that is\nsensitive to the sun.</span></p>", "ID": "fc964704-7485-46cf-87fb-c79d79f4f9b7", "Styles": "margin-left:28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Tell your\ndoctor straight away if you develop symptoms of lupus during treatment with\nRemicade. Signs include joint pain or a rash on cheeks or arms that is\nsensitive to the sun.</span>", "ID": "f36632e1-a562-45a3-8d0a-5da532e11193", "Styles": "None", "Classes": "None", "Text": "Tell your doctor straight away if you develop symptoms of lupus during treatment with Remicade. Signs include joint pain or a rash on cheeks or arms that is sensitive to the sun.", "ParentId": "fc964704-7485-46cf-87fb-c79d79f4f9b7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4daf256f-c703-4401-bd08-43bb8e736912", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "20714eb1-9031-4fac-9524-66a6188b6145", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4daf256f-c703-4401-bd08-43bb8e736912"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><b><span lang=\"EN-GB\">Children and adolescents</span></b></p>", "ID": "bc8ba9d6-b264-4c1a-b4b2-73ca3a65c10a", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Children and adolescents</span></b>", "ID": "b964d02c-f6cd-4a9a-992e-64e6148d2a6f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "bc8ba9d6-b264-4c1a-b4b2-73ca3a65c10a"}, {"Element": "<span lang=\"EN-GB\">Children and adolescents</span>", "ID": "68aa89ac-e8c7-4bb9-97ac-c6bf1b5d8ee9", "Styles": "None", "Classes": "None", "Text": "Children and adolescents", "ParentId": "b964d02c-f6cd-4a9a-992e-64e6148d2a6f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;page-break-after:avoid\"><u><span lang=\"EN-GB\">The information above also applies to children and adolescents. In\naddition:</span></u></p>", "ID": "0adae919-5c65-4427-950a-0f786f691158", "Styles": "margin-left:28.35pt;page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<u><span lang=\"EN-GB\">The information above also applies to children and adolescents. In\naddition:</span></u>", "ID": "310e086f-a7b8-45ca-9a58-cdbb864cec4a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0adae919-5c65-4427-950a-0f786f691158"}, {"Element": "<span lang=\"EN-GB\">The information above also applies to children and adolescents. In\naddition:</span>", "ID": "caa8903f-deb9-4d11-8c7e-19323d780f71", "Styles": "None", "Classes": "None", "Text": "The information above also applies to children and adolescents. In addition:", "ParentId": "310e086f-a7b8-45ca-9a58-cdbb864cec4a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Some children and teenage patients who have\nreceived TNF\u2011blockers such as Remicade have developed cancers, including\nunusual types, which sometimes resulted in death.</span></p>", "ID": "47c79310-fadd-42bc-bb71-bee288c6f625", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "622ef95c-f413-48a4-9726-18f098c7a9aa", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "47c79310-fadd-42bc-bb71-bee288c6f625"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "cd123376-2732-4e7b-94e6-100b4a4d5d6e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "622ef95c-f413-48a4-9726-18f098c7a9aa"}, {"Element": "<span lang=\"EN-GB\">Some children and teenage patients who have\nreceived TNF\u2011blockers such as Remicade have developed cancers, including\nunusual types, which sometimes resulted in death.</span>", "ID": "b4c632b5-f83a-4ff7-8c13-cb4e16724fff", "Styles": "None", "Classes": "None", "Text": "Some children and teenage patients who have received TNF\u2011blockers such as Remicade have developed cancers, including unusual types, which sometimes resulted in death.", "ParentId": "47c79310-fadd-42bc-bb71-bee288c6f625"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">More children taking Remicade developed\ninfections as compared to adults.</span></p>", "ID": "741f2e7c-6c4d-4592-a831-eeed10cbc312", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "6ebe8010-8ecd-4bea-9853-6d8c0600bc6a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "741f2e7c-6c4d-4592-a831-eeed10cbc312"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "54ab689f-82e1-4d17-90f0-886b1b8c5a6d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "6ebe8010-8ecd-4bea-9853-6d8c0600bc6a"}, {"Element": "<span lang=\"EN-GB\">More children taking Remicade developed\ninfections as compared to adults.</span>", "ID": "4f50c496-14c1-4c25-9663-f42b10be03a9", "Styles": "None", "Classes": "None", "Text": "More children taking Remicade developed infections as compared to adults.", "ParentId": "741f2e7c-6c4d-4592-a831-eeed10cbc312"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Children should receive recommended vaccinations\nbefore starting Remicade treatment. Children may receive some vaccines during treatment\nwith Remicade but should not receive live vaccines while using Remicade.</span></p>", "ID": "3b61be17-ddf0-4b8e-8fc5-dd29f7757aab", "Styles": "margin-left:56.7pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "af12a6fb-e390-4a19-a9d8-c551dc51da73", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3b61be17-ddf0-4b8e-8fc5-dd29f7757aab"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "41b67d44-253d-4b09-8b19-ccc5ce8901f8", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "af12a6fb-e390-4a19-a9d8-c551dc51da73"}, {"Element": "<span lang=\"EN-GB\">Children should receive recommended vaccinations\nbefore starting Remicade treatment. Children may receive some vaccines during treatment\nwith Remicade but should not receive live vaccines while using Remicade.</span>", "ID": "01ad815a-f658-4021-8f33-ce88d026690d", "Styles": "None", "Classes": "None", "Text": "Children should receive recommended vaccinations before starting Remicade treatment. Children may receive some vaccines during treatment with Remicade but should not receive live vaccines while using Remicade.", "ParentId": "3b61be17-ddf0-4b8e-8fc5-dd29f7757aab"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9c0b2197-27dd-40ef-8648-9004b5d77572", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4dcf3234-3b77-49d1-81e7-38ee8e145bee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9c0b2197-27dd-40ef-8648-9004b5d77572"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you are not sure if any of the above\napply to you, talk to your doctor before you are given Remicade.</span></p>", "ID": "f79975cc-0227-4ce0-9df0-8be8463c492d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">If you are not sure if any of the above\napply to you, talk to your doctor before you are given Remicade.</span>", "ID": "bc06ffe6-bbd4-40da-b4bb-e2e89b8d24e7", "Styles": "None", "Classes": "None", "Text": "If you are not sure if any of the above apply to you, talk to your doctor before you are given Remicade.", "ParentId": "f79975cc-0227-4ce0-9df0-8be8463c492d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "ee2f9503-cdb8-4bf4-81db-195f2a0a58c5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "603b5ede-7083-4b4b-aa1e-0e2faefc16d8", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ee2f9503-cdb8-4bf4-81db-195f2a0a58c5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Other\nmedicines and Remicade</span></b></p>", "ID": "af87fcec-4bee-4780-846e-504468c2a4e7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Other\nmedicines and Remicade</span></b>", "ID": "a5991c46-fbe0-4cce-945c-6b1d431328b7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "af87fcec-4bee-4780-846e-504468c2a4e7"}, {"Element": "<span lang=\"EN-GB\">Other\nmedicines and Remicade</span>", "ID": "0a2cc4e9-330b-4949-9889-8f7449dbcd09", "Styles": "None", "Classes": "None", "Text": "Other medicines and Remicade", "ParentId": "a5991c46-fbe0-4cce-945c-6b1d431328b7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients who have inflammatory diseases\nalready take medicines to treat their problem. These medicines may cause side\neffects. Your doctor will advise you what other medicines you must keep using\nwhile you are having Remicade.</span></p>", "ID": "affd508d-6986-40ef-9372-70a464ed768b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Patients who have inflammatory diseases\nalready take medicines to treat their problem. These medicines may cause side\neffects. Your doctor will advise you what other medicines you must keep using\nwhile you are having Remicade.</span>", "ID": "b4872ef4-3201-4e24-be11-56e900818d2d", "Styles": "None", "Classes": "None", "Text": "Patients who have inflammatory diseases already take medicines to treat their problem. These medicines may cause side effects. Your doctor will advise you what other medicines you must keep using while you are having Remicade.", "ParentId": "affd508d-6986-40ef-9372-70a464ed768b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e46c9e18-c847-4732-b8b1-0c0022d9661e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f92c9f22-1864-4e06-a2e8-2b493edfabd5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e46c9e18-c847-4732-b8b1-0c0022d9661e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor if you are using or have\nrecently used any other medicines, including any other medicines to treat\nCrohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, ankylosing\nspondylitis, psoriatic arthritis or psoriasis or medicines obtained without a\nprescription, such as vitamins and herbal medicines.</span></p>", "ID": "a02d12ec-2c1d-4b95-a85f-5ca179668a9a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor if you are using or have\nrecently used any other medicines, including any other medicines to treat\nCrohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, ankylosing\nspondylitis, psoriatic arthritis or psoriasis or medicines obtained without a\nprescription, such as vitamins and herbal medicines.</span>", "ID": "a83ea47c-b1cc-4d1d-bf70-c5fad0c4f1f1", "Styles": "None", "Classes": "None", "Text": "Tell your doctor if you are using or have recently used any other medicines, including any other medicines to treat Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or psoriasis or medicines obtained without a prescription, such as vitamins and herbal medicines.", "ParentId": "a02d12ec-2c1d-4b95-a85f-5ca179668a9a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4bbc15f8-e657-4e6d-94d4-66f4a61b8ea9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "550f0c76-c002-401b-94ca-7422688f7012", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4bbc15f8-e657-4e6d-94d4-66f4a61b8ea9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">In particular, tell your doctor if you are\nusing any of the following medicines:</span></p>", "ID": "894cb0cf-32bb-4bc2-9858-74668a0ba996", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In particular, tell your doctor if you are\nusing any of the following medicines:</span>", "ID": "3919c80c-6829-48cc-abae-356d7cba377d", "Styles": "None", "Classes": "None", "Text": "In particular, tell your doctor if you are using any of the following medicines:", "ParentId": "894cb0cf-32bb-4bc2-9858-74668a0ba996"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Medicines that affect your immune system.</span></p>", "ID": "1be94656-e456-4686-97ce-91105165527a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "6af435dc-fb01-4a47-a97b-a96e4caa9cee", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1be94656-e456-4686-97ce-91105165527a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "9790b9bd-074f-49cc-9bf7-20066ba1c183", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "6af435dc-fb01-4a47-a97b-a96e4caa9cee"}, {"Element": "<span lang=\"EN-GB\">Medicines that affect your immune system.</span>", "ID": "79165aa4-ff97-4677-871c-2b4e1eb73810", "Styles": "None", "Classes": "None", "Text": "Medicines that affect your immune system.", "ParentId": "1be94656-e456-4686-97ce-91105165527a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kineret (anakinra). Remicade and Kineret should\nnot be used together.</span></p>", "ID": "4259084f-ebae-4cab-a37a-951a7901c5bd", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "eb109655-a071-4a8a-bc99-2f735e06cfcc", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4259084f-ebae-4cab-a37a-951a7901c5bd"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2c26c4d4-4f09-40d0-a897-ec1ac2aa6282", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "eb109655-a071-4a8a-bc99-2f735e06cfcc"}, {"Element": "<span lang=\"EN-GB\">Kineret (anakinra). Remicade and Kineret should\nnot be used together.</span>", "ID": "a374af8f-9bab-4647-8043-7726dd46d4ff", "Styles": "None", "Classes": "None", "Text": "Kineret (anakinra). Remicade and Kineret should not be used together.", "ParentId": "4259084f-ebae-4cab-a37a-951a7901c5bd"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Orencia (abatacept). Remicade and Orencia should\nnot be used together.</span></p>", "ID": "bfe5f4c7-846b-41b0-8d36-25c2aa164b7a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "73e9c76c-7eaf-4683-a988-b88568bf025f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "bfe5f4c7-846b-41b0-8d36-25c2aa164b7a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "9781c0bf-bd67-4579-97a5-d48d9e220b78", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "73e9c76c-7eaf-4683-a988-b88568bf025f"}, {"Element": "<span lang=\"EN-GB\">Orencia (abatacept). Remicade and Orencia should\nnot be used together.</span>", "ID": "bf3ab715-e290-48f2-81ca-e2b9306ec10d", "Styles": "None", "Classes": "None", "Text": "Orencia (abatacept). Remicade and Orencia should not be used together.", "ParentId": "bfe5f4c7-846b-41b0-8d36-25c2aa164b7a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "564d5d60-5b27-439b-8022-678f6d78fbb1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a46f1f96-6552-4cd1-b04f-df38b2aa2a6b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "564d5d60-5b27-439b-8022-678f6d78fbb1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">While using Remicade you should not receive\nlive vaccines. If you were using Remicade during pregnancy, tell your\nbaby\u2019s doctor and other healthcare professionals caring for your baby\nabout your Remicade use before the baby receives any vaccines.</span></p>", "ID": "34d82bfe-90b4-4067-a4a8-573433d91dd0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">While using Remicade you should not receive\nlive vaccines. If you were using Remicade during pregnancy, tell your\nbaby\u2019s doctor and other healthcare professionals caring for your baby\nabout your Remicade use before the baby receives any vaccines.</span>", "ID": "e24e9279-0d7c-4487-a9fd-8bdca5c7c6ec", "Styles": "None", "Classes": "None", "Text": "While using Remicade you should not receive live vaccines. If you were using Remicade during pregnancy, tell your baby\u2019s doctor and other healthcare professionals caring for your baby about your Remicade use before the baby receives any vaccines.", "ParentId": "34d82bfe-90b4-4067-a4a8-573433d91dd0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "0d5612b7-cd8e-4a5d-b518-9b2867a6529e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "6137ba53-df73-4fd3-85bf-b85f3cae86eb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "0d5612b7-cd8e-4a5d-b518-9b2867a6529e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">If you are\nnot sure if any of the above apply to you, talk to your doctor or pharmacist\nbefore using Remicade.</span></p>", "ID": "25d50145-76cf-4444-95c4-85785a9400a1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">If you are\nnot sure if any of the above apply to you, talk to your doctor or pharmacist\nbefore using Remicade.</span>", "ID": "f0d655a0-2c54-42e7-942f-db828edcae4e", "Styles": "None", "Classes": "None", "Text": "If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before using Remicade.", "ParentId": "25d50145-76cf-4444-95c4-85785a9400a1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "01397698-aace-4d68-b13c-08a81c623204", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "9160c854-2115-4386-af62-d54bde260629", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "01397698-aace-4d68-b13c-08a81c623204"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c8570808-479c-4988-87e9-bd63d26979b2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9160c854-2115-4386-af62-d54bde260629"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy,\nbreast\u2011feeding, and fertility</span></b></p>", "ID": "87b97dd0-ed8b-4f80-9f58-961dba112ee6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Pregnancy,\nbreast\u2011feeding, and fertility</span></b>", "ID": "931f02a7-aa02-4d36-bf97-02d162a67894", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "87b97dd0-ed8b-4f80-9f58-961dba112ee6"}, {"Element": "<span lang=\"EN-GB\">Pregnancy,\nbreast\u2011feeding, and fertility</span>", "ID": "1a1b02c7-de27-4614-b004-8aaf386cf48e", "Styles": "None", "Classes": "None", "Text": "Pregnancy, breast\u2011feeding, and fertility", "ParentId": "931f02a7-aa02-4d36-bf97-02d162a67894"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you are pregnant or breast\u2011feeding,\nthink you may be pregnant or are planning to have a baby, ask your doctor for\nadvice before taking this medicine. Remicade</span><span lang=\"EN-GB\"> </span><span lang=\"EN-GB\">should only be used during pregnancy if your doctor feels it is\nnecessary for you.</span></p>", "ID": "ff051d12-df65-4b5c-a8b6-d9fa576e974e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "bb3f278e-20b4-4172-b6d1-866f750a909f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ff051d12-df65-4b5c-a8b6-d9fa576e974e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "a1133f0a-38fe-46d6-af81-868cfdc2f099", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "bb3f278e-20b4-4172-b6d1-866f750a909f"}, {"Element": "<span lang=\"EN-GB\">If you are pregnant or breast\u2011feeding,\nthink you may be pregnant or are planning to have a baby, ask your doctor for\nadvice before taking this medicine. Remicade</span>", "ID": "079a835e-52bd-4ceb-8b25-c76d42b87e9f", "Styles": "None", "Classes": "None", "Text": "If you are pregnant or breast\u2011feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Remicade", "ParentId": "ff051d12-df65-4b5c-a8b6-d9fa576e974e"}, {"Element": "<span lang=\"EN-GB\"> </span>", "ID": "fa2bafe4-3337-409a-8bb0-b8ee24c3eea7", "Styles": "None", "Classes": "None", "Text": " ", "ParentId": "ff051d12-df65-4b5c-a8b6-d9fa576e974e"}, {"Element": "<span lang=\"EN-GB\">should only be used during pregnancy if your doctor feels it is\nnecessary for you.</span>", "ID": "7bd21d06-5c47-4c97-b847-c748f7ac5924", "Styles": "None", "Classes": "None", "Text": "should only be used during pregnancy if your doctor feels it is necessary for you.", "ParentId": "ff051d12-df65-4b5c-a8b6-d9fa576e974e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You should avoid getting pregnant when you are\nbeing treated with Remicade and for 6\u00a0months after you stop being treated\nwith it. Discuss the use of contraception during this time with your doctor.</span></p>", "ID": "682443cb-456f-4c3a-91be-86a0e80daeaf", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3dbe0057-17f4-4f6d-8fe4-80080e51e32e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "682443cb-456f-4c3a-91be-86a0e80daeaf"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "f2989e4f-9369-4036-898a-d3e82381592c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3dbe0057-17f4-4f6d-8fe4-80080e51e32e"}, {"Element": "<span lang=\"EN-GB\">You should avoid getting pregnant when you are\nbeing treated with Remicade and for 6\u00a0months after you stop being treated\nwith it. Discuss the use of contraception during this time with your doctor.</span>", "ID": "70423499-bb5e-4d89-a275-a9a17fe9bdaa", "Styles": "None", "Classes": "None", "Text": "You should avoid getting pregnant when you are being treated with Remicade and for 6\u00a0months after you stop being treated with it. Discuss the use of contraception during this time with your doctor.", "ParentId": "682443cb-456f-4c3a-91be-86a0e80daeaf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not breast\u2011feed when you are being\ntreated with Remicade or for 6\u00a0months after your last treatment with\nRemicade.</span></p>", "ID": "446f32e0-2ff3-4042-bf2c-da262419b390", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f7a11ddc-3448-4f30-b5e7-01e1debf31dd", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "446f32e0-2ff3-4042-bf2c-da262419b390"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "19c57db1-8a82-4ea2-bcc3-605d077b0658", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f7a11ddc-3448-4f30-b5e7-01e1debf31dd"}, {"Element": "<span lang=\"EN-GB\">Do not breast\u2011feed when you are being\ntreated with Remicade or for 6\u00a0months after your last treatment with\nRemicade.</span>", "ID": "3bd410a4-9df0-4f3c-bc28-87051ef5032f", "Styles": "None", "Classes": "None", "Text": "Do not breast\u2011feed when you are being treated with Remicade or for 6\u00a0months after your last treatment with Remicade.", "ParentId": "446f32e0-2ff3-4042-bf2c-da262419b390"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">If you received Remicade during your pregnancy,\nyour baby may have a higher risk for getting an infection.</span></p>", "ID": "97597b6c-a8d8-4707-8bda-f745612211f2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5160cee9-e307-46f0-a928-9ea0e8cb9632", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "97597b6c-a8d8-4707-8bda-f745612211f2"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "fa82f79e-5458-4a4b-ad9d-925a391c70b4", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5160cee9-e307-46f0-a928-9ea0e8cb9632"}, {"Element": "<span lang=\"EN-GB\">If you received Remicade during your pregnancy,\nyour baby may have a higher risk for getting an infection.</span>", "ID": "baa07a3e-de12-4190-b094-77c07aa0f48c", "Styles": "None", "Classes": "None", "Text": "If you received Remicade during your pregnancy, your baby may have a higher risk for getting an infection.", "ParentId": "97597b6c-a8d8-4707-8bda-f745612211f2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">It is important that you tell your baby\u2019s\ndoctors and other healthcare professionals about your Remicade use before your\nbaby is given any vaccine. If you received Remicade while pregnant, giving BCG\nvaccine (used to prevent tuberculosis) to your baby within 6\u00a0months after\nbirth may result in infection with serious complications, including death. Live\nvaccines such as BCG should not be given to your baby within 6\u00a0months\nafter birth. For more information see section on vaccination.</span></p>", "ID": "78ccccc7-b74f-4a6a-86cc-3e6c51bf7908", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "db2ded17-92ef-4a7f-96e5-2f7961005b78", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "78ccccc7-b74f-4a6a-86cc-3e6c51bf7908"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "e592e529-6873-4fe5-a6b1-ae69e877af3a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "db2ded17-92ef-4a7f-96e5-2f7961005b78"}, {"Element": "<span lang=\"EN-GB\">It is important that you tell your baby\u2019s\ndoctors and other healthcare professionals about your Remicade use before your\nbaby is given any vaccine. If you received Remicade while pregnant, giving BCG\nvaccine (used to prevent tuberculosis) to your baby within 6\u00a0months after\nbirth may result in infection with serious complications, including death. Live\nvaccines such as BCG should not be given to your baby within 6\u00a0months\nafter birth. For more information see section on vaccination.</span>", "ID": "6d7451e0-edb6-415a-a509-bfa34706faf0", "Styles": "None", "Classes": "None", "Text": "It is important that you tell your baby\u2019s doctors and other healthcare professionals about your Remicade use before your baby is given any vaccine. If you received Remicade while pregnant, giving BCG vaccine (used to prevent tuberculosis) to your baby within 6\u00a0months after birth may result in infection with serious complications, including death. Live vaccines such as BCG should not be given to your baby within 6\u00a0months after birth. For more information see section on vaccination.", "ParentId": "78ccccc7-b74f-4a6a-86cc-3e6c51bf7908"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Severely decreased numbers of white blood cells\nhave been reported in infants born to women treated with Remicade during\npregnancy. If your baby has continual fevers or infections, contact your\nbaby\u2019s doctor immediately.</span></p>", "ID": "98f19c8e-687d-4a51-bcca-595c0d033c07", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "eede5476-c2ce-424b-a895-064ceb06a647", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "98f19c8e-687d-4a51-bcca-595c0d033c07"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "dae8611c-b180-4530-9153-996d4efa8d6f", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "eede5476-c2ce-424b-a895-064ceb06a647"}, {"Element": "<span lang=\"EN-GB\">Severely decreased numbers of white blood cells\nhave been reported in infants born to women treated with Remicade during\npregnancy. If your baby has continual fevers or infections, contact your\nbaby\u2019s doctor immediately.</span>", "ID": "9e237076-b64a-44af-82f6-658eae6fcd09", "Styles": "None", "Classes": "None", "Text": "Severely decreased numbers of white blood cells have been reported in infants born to women treated with Remicade during pregnancy. If your baby has continual fevers or infections, contact your baby\u2019s doctor immediately.", "ParentId": "98f19c8e-687d-4a51-bcca-595c0d033c07"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "53a04a93-e759-48bd-b957-e9a30586d4b7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b82007ba-45c2-41b7-a84a-257c6dca8276", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "53a04a93-e759-48bd-b957-e9a30586d4b7"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Driving\nand using machines</span></b></p>", "ID": "a64401c3-c361-49f3-85a1-476e77c25a2b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Driving\nand using machines</span></b>", "ID": "8ebd7279-df5e-461e-b32d-02e117581aa1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a64401c3-c361-49f3-85a1-476e77c25a2b"}, {"Element": "<span lang=\"EN-GB\">Driving\nand using machines</span>", "ID": "ded5046f-a086-4c8f-b1fa-fe20c69bd139", "Styles": "None", "Classes": "None", "Text": "Driving and using machines", "ParentId": "8ebd7279-df5e-461e-b32d-02e117581aa1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is not likely to affect your\nability to drive or use tools or machines. If you feel tired, dizzy, or unwell\nafter having Remicade, do not drive or use any tools or machines.</span></p>", "ID": "e0a7a1f3-878a-40cc-aee8-5eed8ae139d0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade is not likely to affect your\nability to drive or use tools or machines. If you feel tired, dizzy, or unwell\nafter having Remicade, do not drive or use any tools or machines.</span>", "ID": "a3caacf1-b29d-440a-9427-db1184d64387", "Styles": "None", "Classes": "None", "Text": "Remicade is not likely to affect your ability to drive or use tools or machines. If you feel tired, dizzy, or unwell after having Remicade, do not drive or use any tools or machines.", "ParentId": "e0a7a1f3-878a-40cc-aee8-5eed8ae139d0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "7fda074f-a35a-453f-8c85-f80a6da6e532", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "be2d7fbe-9677-4ffb-a2c2-49dd8c358d12", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "7fda074f-a35a-453f-8c85-f80a6da6e532"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Remicade contains\nsodium</span></b></p>", "ID": "ec847515-8cb1-4df9-9812-5ad4ed09846b", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Remicade contains\nsodium</span></b>", "ID": "ce3199a9-3202-42cd-8882-9ea6b124c752", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ec847515-8cb1-4df9-9812-5ad4ed09846b"}, {"Element": "<span lang=\"EN-GB\">Remicade contains\nsodium</span>", "ID": "2b3f7fa2-b76c-45bf-8321-9c0cdf8b0e99", "Styles": "None", "Classes": "None", "Text": "Remicade contains sodium", "ParentId": "ce3199a9-3202-42cd-8882-9ea6b124c752"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade contains less than 1\u00a0mmol sodium\n(23\u00a0mg) per dose, that is to say essentially \u2018sodium\u2011free\u2019.\nHowever, before Remicade is given to you, it is mixed with a solution that\ncontains sodium. Talk to your doctor if you are on a low salt diet.</span></p>", "ID": "376d2a60-bf3f-47ac-a833-2669405a9f28", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade contains less than 1\u00a0mmol sodium\n(23\u00a0mg) per dose, that is to say essentially \u2018sodium\u2011free\u2019.\nHowever, before Remicade is given to you, it is mixed with a solution that\ncontains sodium. Talk to your doctor if you are on a low salt diet.</span>", "ID": "e03d28a6-9b09-4e51-b027-5145299f0f2d", "Styles": "None", "Classes": "None", "Text": "Remicade contains less than 1\u00a0mmol sodium (23\u00a0mg) per dose, that is to say essentially \u2018sodium\u2011free\u2019. However, before Remicade is given to you, it is mixed with a solution that contains sodium. Talk to your doctor if you are on a low salt diet.", "ParentId": "376d2a60-bf3f-47ac-a833-2669405a9f28"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4673e773-605d-4753-afdc-35a31145ea4e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2d105142-d8ca-420a-b8f5-c94276d0a3f0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4673e773-605d-4753-afdc-35a31145ea4e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "31c27cbd-3cd4-44f5-9ea7-a95e7b92c979", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f3c909d9-22c9-4cd1-aa5b-45a6bae97456", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "31c27cbd-3cd4-44f5-9ea7-a95e7b92c979"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Remicade\nwill be given</span></b></p>", "ID": "64c5b67b-30ad-49e2-9c05-abe0ad63b8cd", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Remicade\nwill be given</span></b>", "ID": "53ec31d3-fbd5-46c7-8f83-0898dd46fd4e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "64c5b67b-30ad-49e2-9c05-abe0ad63b8cd"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Remicade\nwill be given</span>", "ID": "4a491a34-00e1-4477-99cc-19539a4ec178", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How Remicade will be given", "ParentId": "53ec31d3-fbd5-46c7-8f83-0898dd46fd4e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "42cd79f4-03ab-4cf5-a4a4-6e7921de3294", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0089d12e-1a6a-4ec6-8b04-3a9fcbe4f498", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "42cd79f4-03ab-4cf5-a4a4-6e7921de3294"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Rheumatoid\narthritis</span></b></p>", "ID": "8e1995a5-2e81-4e97-8061-df99af4bf415", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Rheumatoid\narthritis</span></b>", "ID": "f00e06c1-58bf-4606-a575-23b5a9e1b83a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8e1995a5-2e81-4e97-8061-df99af4bf415"}, {"Element": "<span lang=\"EN-GB\">Rheumatoid\narthritis</span>", "ID": "3e305ca9-49dc-4e76-9282-375bd4503304", "Styles": "None", "Classes": "None", "Text": "Rheumatoid arthritis", "ParentId": "f00e06c1-58bf-4606-a575-23b5a9e1b83a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The usual dose is 3\u00a0mg for every kg of\nbody weight.</span></p>", "ID": "49fc4179-d777-4dce-9dec-24028144dde1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The usual dose is 3\u00a0mg for every kg of\nbody weight.</span>", "ID": "918ae7a0-7934-462b-a511-ef4804097398", "Styles": "None", "Classes": "None", "Text": "The usual dose is 3\u00a0mg for every kg of body weight.", "ParentId": "49fc4179-d777-4dce-9dec-24028144dde1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "3d749518-2c7a-483d-86ab-55bb4d2872a2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0986fa8d-4e39-45a0-b8b8-791faf2a3f09", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3d749518-2c7a-483d-86ab-55bb4d2872a2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Psoriatic\narthritis, ankylosing spondylitis (Bechterew\u2019s disease), psoriasis,\nulcerative colitis and Crohn's disease</span></b></p>", "ID": "b7337b50-6e60-429a-a5db-2863abc17c44", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Psoriatic\narthritis, ankylosing spondylitis (Bechterew\u2019s disease), psoriasis,\nulcerative colitis and Crohn's disease</span></b>", "ID": "c67dc3fa-3d83-466a-b61b-42b85c62c8b5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b7337b50-6e60-429a-a5db-2863abc17c44"}, {"Element": "<span lang=\"EN-GB\">Psoriatic\narthritis, ankylosing spondylitis (Bechterew\u2019s disease), psoriasis,\nulcerative colitis and Crohn's disease</span>", "ID": "605805bd-4426-403c-bd3e-0a5babe7f42f", "Styles": "None", "Classes": "None", "Text": "Psoriatic arthritis, ankylosing spondylitis (Bechterew\u2019s disease), psoriasis, ulcerative colitis and Crohn's disease", "ParentId": "c67dc3fa-3d83-466a-b61b-42b85c62c8b5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The usual dose is 5\u00a0mg for every kg of\nbody weight.</span></p>", "ID": "da5771e2-19ed-4cc7-bec8-e51c291bf104", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The usual dose is 5\u00a0mg for every kg of\nbody weight.</span>", "ID": "7a16b7bb-300b-41ce-96dc-6fd86ce4adac", "Styles": "None", "Classes": "None", "Text": "The usual dose is 5\u00a0mg for every kg of body weight.", "ParentId": "da5771e2-19ed-4cc7-bec8-e51c291bf104"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d7bd9221-cbcd-4d91-8033-8a46cb4cd8c1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "877c1140-7e8a-4580-a14a-bef7d51afe0a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d7bd9221-cbcd-4d91-8033-8a46cb4cd8c1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">How\nRemicade is given</span></b></p>", "ID": "b7425df8-1488-4a08-8b3a-bd26e6441e43", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">How\nRemicade is given</span></b>", "ID": "a12235aa-d0ef-4ec9-81e0-eb57c4fee57e", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b7425df8-1488-4a08-8b3a-bd26e6441e43"}, {"Element": "<span lang=\"EN-GB\">How\nRemicade is given</span>", "ID": "1033fa57-b690-4140-a5d7-8ba17a004dc7", "Styles": "None", "Classes": "None", "Text": "How Remicade is given", "ParentId": "a12235aa-d0ef-4ec9-81e0-eb57c4fee57e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Remicade will be given to you by your doctor or\nnurse.</span></p>", "ID": "922aa71a-487e-49f2-a50d-fdea4dc967be", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "06ad4011-e39a-4f17-9443-e121281d8d7b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "922aa71a-487e-49f2-a50d-fdea4dc967be"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "53cd3766-0ad8-4373-9d23-14e0e7dd6e89", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "06ad4011-e39a-4f17-9443-e121281d8d7b"}, {"Element": "<span lang=\"EN-GB\">Remicade will be given to you by your doctor or\nnurse.</span>", "ID": "6d172578-0266-48b9-a469-9099a4f7eb76", "Styles": "None", "Classes": "None", "Text": "Remicade will be given to you by your doctor or nurse.", "ParentId": "922aa71a-487e-49f2-a50d-fdea4dc967be"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Your doctor or nurse will prepare the medicine\nfor infusion.</span></p>", "ID": "9367afa1-5fae-4acb-a223-912dafc8d66f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "a1f36f1f-e952-46ae-9caf-6438c75a7968", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9367afa1-5fae-4acb-a223-912dafc8d66f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "dc45180e-6ec5-4eb2-8fd3-3e1f85e13bb9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "a1f36f1f-e952-46ae-9caf-6438c75a7968"}, {"Element": "<span lang=\"EN-GB\">Your doctor or nurse will prepare the medicine\nfor infusion.</span>", "ID": "188bf210-bd4a-4003-8bd2-fc8fd51e438d", "Styles": "None", "Classes": "None", "Text": "Your doctor or nurse will prepare the medicine for infusion.", "ParentId": "9367afa1-5fae-4acb-a223-912dafc8d66f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The medicine will be given as an infusion (drip)\n(over 2\u00a0hours) into one of your veins, usually in your arm. After the\nthird treatment, your doctor may decide to give your dose of Remicade over\n1\u00a0hour.</span></p>", "ID": "602d5c26-c416-4e4e-83e6-3d1c42b1dfa4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "78c24c39-cb9e-44b8-972d-4d51d3c21ed2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "602d5c26-c416-4e4e-83e6-3d1c42b1dfa4"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "38df27cf-243f-40d2-a013-4200d3a4cb86", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "78c24c39-cb9e-44b8-972d-4d51d3c21ed2"}, {"Element": "<span lang=\"EN-GB\">The medicine will be given as an infusion (drip)\n(over 2\u00a0hours) into one of your veins, usually in your arm. After the\nthird treatment, your doctor may decide to give your dose of Remicade over\n1\u00a0hour.</span>", "ID": "6fd8e747-3c15-42a8-95fd-91a1b3fc9f9e", "Styles": "None", "Classes": "None", "Text": "The medicine will be given as an infusion (drip) (over 2\u00a0hours) into one of your veins, usually in your arm. After the third treatment, your doctor may decide to give your dose of Remicade over 1\u00a0hour.", "ParentId": "602d5c26-c416-4e4e-83e6-3d1c42b1dfa4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">You will be monitored while you are given\nRemicade and also for 1 to 2\u00a0hours afterwards.</span></p>", "ID": "c957b7db-0ff5-47ec-839f-4e22d48b5615", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "952248ca-d706-4ee6-b60c-cad8551ecad4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c957b7db-0ff5-47ec-839f-4e22d48b5615"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0eb6d85d-71e5-482c-b1a5-7e6eda500743", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "952248ca-d706-4ee6-b60c-cad8551ecad4"}, {"Element": "<span lang=\"EN-GB\">You will be monitored while you are given\nRemicade and also for 1 to 2\u00a0hours afterwards.</span>", "ID": "097d4669-c641-4b47-8e6c-0f95c6bb00c5", "Styles": "None", "Classes": "None", "Text": "You will be monitored while you are given Remicade and also for 1 to 2\u00a0hours afterwards.", "ParentId": "c957b7db-0ff5-47ec-839f-4e22d48b5615"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "580bf5d2-e93a-4fe8-a153-64dab51b586d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a57ec123-0337-4a2c-aaee-f90815097945", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "580bf5d2-e93a-4fe8-a153-64dab51b586d"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">How much\nRemicade is given</span></b></p>", "ID": "1b38df3b-8793-42b4-954e-113bdcf4aa56", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">How much\nRemicade is given</span></b>", "ID": "4ac07e8f-6e41-44ff-baa9-8b101d070c56", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1b38df3b-8793-42b4-954e-113bdcf4aa56"}, {"Element": "<span lang=\"EN-GB\">How much\nRemicade is given</span>", "ID": "928724c0-0e1d-4f6c-b3a2-941adccad26e", "Styles": "None", "Classes": "None", "Text": "How much Remicade is given", "ParentId": "4ac07e8f-6e41-44ff-baa9-8b101d070c56"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The doctor will decide your dose and how often\nyou will be given Remicade. This will depend on your disease, weight and how\nwell you respond to Remicade.</span></p>", "ID": "187403d6-7dfc-4564-8403-20d8bb45425a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "12bafd60-353b-4a27-add2-94447d9e45c0", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "187403d6-7dfc-4564-8403-20d8bb45425a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7bd44739-4f77-41bd-acc5-31b0ec04d1c9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "12bafd60-353b-4a27-add2-94447d9e45c0"}, {"Element": "<span lang=\"EN-GB\">The doctor will decide your dose and how often\nyou will be given Remicade. This will depend on your disease, weight and how\nwell you respond to Remicade.</span>", "ID": "81318fb1-44db-429b-8570-7d55698ef146", "Styles": "None", "Classes": "None", "Text": "The doctor will decide your dose and how often you will be given Remicade. This will depend on your disease, weight and how well you respond to Remicade.", "ParentId": "187403d6-7dfc-4564-8403-20d8bb45425a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The table below shows how often you will usually\nhave this medicine after your first dose.</span></p>", "ID": "8f5e9f65-5d8b-4636-8d09-921fdb954806", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "27627736-2565-461e-85e3-ca279645967f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "8f5e9f65-5d8b-4636-8d09-921fdb954806"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "94b1a770-21bf-4afe-9847-c51b0df4f2f9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "27627736-2565-461e-85e3-ca279645967f"}, {"Element": "<span lang=\"EN-GB\">The table below shows how often you will usually\nhave this medicine after your first dose.</span>", "ID": "c0427500-737c-4895-abd6-424e0335f7c9", "Styles": "None", "Classes": "None", "Text": "The table below shows how often you will usually have this medicine after your first dose.", "ParentId": "8f5e9f65-5d8b-4636-8d09-921fdb954806"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a27084f7-1b58-419e-9d6c-2656bb569b91", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e4d3eba4-1a76-4056-b107-437e5f83d5f0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a27084f7-1b58-419e-9d6c-2656bb569b91"}, {"Element": "<div align=\"center\">\n<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:174.0pt;border:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2<sup>nd</sup> dose</span></p>\n</td>\n<td style=\"width:222.0pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2\u00a0weeks after your 1<sup>st</sup> dose</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:174.0pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">3<sup>rd</sup> dose</span></p>\n</td>\n<td style=\"width:222.0pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">6\u00a0weeks after your 1<sup>st</sup> dose</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:174.0pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Further doses</span></p>\n</td>\n<td style=\"width:222.0pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Every 6 to 8\u00a0weeks depending on your\n  disease </span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "7465be44-a002-431e-b431-5a6b5f9b379d", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:174.0pt;border:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2<sup>nd</sup> dose</span></p>\n</td>\n<td style=\"width:222.0pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2\u00a0weeks after your 1<sup>st</sup> dose</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:174.0pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">3<sup>rd</sup> dose</span></p>\n</td>\n<td style=\"width:222.0pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">6\u00a0weeks after your 1<sup>st</sup> dose</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:174.0pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Further doses</span></p>\n</td>\n<td style=\"width:222.0pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Every 6 to 8\u00a0weeks depending on your\n  disease </span></p>\n</td>\n</tr>\n</table>", "ID": "9e2f3264-7dc9-4bd8-b6aa-f0763b54f30a", "Styles": "border-collapse:collapse;border:none", "Classes": "['MsoNormalTable']", "Text": "    ", "ParentId": "7465be44-a002-431e-b431-5a6b5f9b379d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:174.0pt;border:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2<sup>nd</sup> dose</span></p>\n</td>\n<td style=\"width:222.0pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2\u00a0weeks after your 1<sup>st</sup> dose</span></p>\n</td>\n</tr>", "ID": "baa13a1b-3c1d-4fed-a029-6cf2ef2c97f0", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "9e2f3264-7dc9-4bd8-b6aa-f0763b54f30a"}, {"Element": "<td style=\"width:174.0pt;border:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2<sup>nd</sup> dose</span></p>\n</td>", "ID": "5f2562a7-7542-4a22-af65-a55d1f2fb493", "Styles": "width:174.0pt;border:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "baa13a1b-3c1d-4fed-a029-6cf2ef2c97f0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">2<sup>nd</sup> dose</span></p>", "ID": "f2dcf67a-a471-4df6-9610-f0a696f76216", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5f2562a7-7542-4a22-af65-a55d1f2fb493"}, {"Element": "<span lang=\"EN-GB\">2<sup>nd</sup> dose</span>", "ID": "14715db7-3e64-41c7-a546-f845326de9f0", "Styles": "None", "Classes": "None", "Text": "2 dose", "ParentId": "f2dcf67a-a471-4df6-9610-f0a696f76216"}, {"Element": "<sup>nd</sup>", "ID": "95442437-9f76-47a4-b38d-e2fbcb0ea375", "Styles": "None", "Classes": "None", "Text": "nd", "ParentId": "14715db7-3e64-41c7-a546-f845326de9f0"}, {"Element": "<td style=\"width:222.0pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">2\u00a0weeks after your 1<sup>st</sup> dose</span></p>\n</td>", "ID": "92dc86be-74b0-4c7d-b376-48182af05c7c", "Styles": "width:222.0pt;border:solid black 1.0pt;\n  border-left:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "baa13a1b-3c1d-4fed-a029-6cf2ef2c97f0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">2\u00a0weeks after your 1<sup>st</sup> dose</span></p>", "ID": "1e232951-a9a0-4b2e-b051-02e7822ae727", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "92dc86be-74b0-4c7d-b376-48182af05c7c"}, {"Element": "<span lang=\"EN-GB\">2\u00a0weeks after your 1<sup>st</sup> dose</span>", "ID": "5c3ecc25-40ac-4477-84a3-10d454611d4f", "Styles": "None", "Classes": "None", "Text": "2\u00a0weeks after your 1 dose", "ParentId": "1e232951-a9a0-4b2e-b051-02e7822ae727"}, {"Element": "<sup>st</sup>", "ID": "99649f8d-2d16-4b5b-88f4-e6f7b5e20b5c", "Styles": "None", "Classes": "None", "Text": "st", "ParentId": "5c3ecc25-40ac-4477-84a3-10d454611d4f"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:174.0pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">3<sup>rd</sup> dose</span></p>\n</td>\n<td style=\"width:222.0pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">6\u00a0weeks after your 1<sup>st</sup> dose</span></p>\n</td>\n</tr>", "ID": "4ccdc655-7f8c-4f5e-ac2c-eb97d3f93141", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "9e2f3264-7dc9-4bd8-b6aa-f0763b54f30a"}, {"Element": "<td style=\"width:174.0pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">3<sup>rd</sup> dose</span></p>\n</td>", "ID": "42ecef65-ef61-4e6a-967d-21b34132641d", "Styles": "width:174.0pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4ccdc655-7f8c-4f5e-ac2c-eb97d3f93141"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">3<sup>rd</sup> dose</span></p>", "ID": "5427633f-1e6a-4fe1-85c8-7b61e70988f5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "42ecef65-ef61-4e6a-967d-21b34132641d"}, {"Element": "<span lang=\"EN-GB\">3<sup>rd</sup> dose</span>", "ID": "6fa311ca-9ae7-43a4-b0ca-a0eeb19157eb", "Styles": "None", "Classes": "None", "Text": "3 dose", "ParentId": "5427633f-1e6a-4fe1-85c8-7b61e70988f5"}, {"Element": "<sup>rd</sup>", "ID": "8fb92c30-3883-4b2d-8a70-afcf989555a6", "Styles": "None", "Classes": "None", "Text": "rd", "ParentId": "6fa311ca-9ae7-43a4-b0ca-a0eeb19157eb"}, {"Element": "<td style=\"width:222.0pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">6\u00a0weeks after your 1<sup>st</sup> dose</span></p>\n</td>", "ID": "bada2afd-6c87-445a-a4c3-cb7c071bbb37", "Styles": "width:222.0pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "4ccdc655-7f8c-4f5e-ac2c-eb97d3f93141"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">6\u00a0weeks after your 1<sup>st</sup> dose</span></p>", "ID": "d13336b0-d953-489c-8c5d-fe04ebfdb0fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bada2afd-6c87-445a-a4c3-cb7c071bbb37"}, {"Element": "<span lang=\"EN-GB\">6\u00a0weeks after your 1<sup>st</sup> dose</span>", "ID": "db523693-d485-4dcd-8560-9ed8227d80cf", "Styles": "None", "Classes": "None", "Text": "6\u00a0weeks after your 1 dose", "ParentId": "d13336b0-d953-489c-8c5d-fe04ebfdb0fd"}, {"Element": "<sup>st</sup>", "ID": "684c4a5e-8430-4388-b119-ddbf693c2dce", "Styles": "None", "Classes": "None", "Text": "st", "ParentId": "db523693-d485-4dcd-8560-9ed8227d80cf"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:174.0pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Further doses</span></p>\n</td>\n<td style=\"width:222.0pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Every 6 to 8\u00a0weeks depending on your\n  disease </span></p>\n</td>\n</tr>", "ID": "5d8ccdae-8ec2-44d6-afd4-dedfb832749a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "9e2f3264-7dc9-4bd8-b6aa-f0763b54f30a"}, {"Element": "<td style=\"width:174.0pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"232\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Further doses</span></p>\n</td>", "ID": "4834480d-5be7-48e3-b3f5-eaad8deeb0e0", "Styles": "width:174.0pt;border:solid black 1.0pt;\n  border-top:none;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5d8ccdae-8ec2-44d6-afd4-dedfb832749a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Further doses</span></p>", "ID": "14f5dd5d-8129-45cb-9cbd-b286f1e48d83", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4834480d-5be7-48e3-b3f5-eaad8deeb0e0"}, {"Element": "<span lang=\"EN-GB\">Further doses</span>", "ID": "44e9ba0a-b42d-4d82-9d39-f054154b512f", "Styles": "None", "Classes": "None", "Text": "Further doses", "ParentId": "14f5dd5d-8129-45cb-9cbd-b286f1e48d83"}, {"Element": "<td style=\"width:222.0pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"296\">\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Every 6 to 8\u00a0weeks depending on your\n  disease </span></p>\n</td>", "ID": "343c4bb2-7e96-4df8-ac2e-d5e57b126627", "Styles": "width:222.0pt;border-top:none;border-left:\n  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;\n  padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "  ", "ParentId": "5d8ccdae-8ec2-44d6-afd4-dedfb832749a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Every 6 to 8\u00a0weeks depending on your\n  disease </span></p>", "ID": "fdcb2d6a-cc67-46e0-b9c4-cc23c0cd88b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "343c4bb2-7e96-4df8-ac2e-d5e57b126627"}, {"Element": "<span lang=\"EN-GB\">Every 6 to 8\u00a0weeks depending on your\n  disease </span>", "ID": "124b7cf9-75f9-48bc-9cc9-5f5316198e09", "Styles": "None", "Classes": "None", "Text": "Every 6 to 8\u00a0weeks depending on your   disease ", "ParentId": "fdcb2d6a-cc67-46e0-b9c4-cc23c0cd88b8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f6013dde-64e3-4ad5-922d-45aa2fe524bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b412b49c-d788-4cbe-ae51-c099d85183a2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f6013dde-64e3-4ad5-922d-45aa2fe524bb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Use in\nchildren and adolescents</span></b></p>", "ID": "21d7fd19-a869-40d8-a901-57aab3ba5565", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Use in\nchildren and adolescents</span></b>", "ID": "c0f3a505-690d-4341-9c24-9daa002fb17f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "21d7fd19-a869-40d8-a901-57aab3ba5565"}, {"Element": "<span lang=\"EN-GB\">Use in\nchildren and adolescents</span>", "ID": "231fc49f-1898-4330-96c0-8cfa6a638b47", "Styles": "None", "Classes": "None", "Text": "Use in children and adolescents", "ParentId": "c0f3a505-690d-4341-9c24-9daa002fb17f"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Remicade\nshould only be used in children if they are being treated for Crohn\u2019s\ndisease or ulcerative colitis. These children must be 6\u00a0years of age or\nolder.</span></p>", "ID": "0a638dce-7c9e-4ab4-8c0e-6df727991253", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade\nshould only be used in children if they are being treated for Crohn\u2019s\ndisease or ulcerative colitis. These children must be 6\u00a0years of age or\nolder.</span>", "ID": "6e0af6f7-d5c2-4b7b-880f-62615d8c49dc", "Styles": "None", "Classes": "None", "Text": "Remicade should only be used in children if they are being treated for Crohn\u2019s disease or ulcerative colitis. These children must be 6\u00a0years of age or older.", "ParentId": "0a638dce-7c9e-4ab4-8c0e-6df727991253"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "f5c3b145-3de5-48c1-a18d-20812eb3f6c2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "6837350f-da83-4c69-993d-f72e8ddc495c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f5c3b145-3de5-48c1-a18d-20812eb3f6c2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "c25cc28d-95f1-4168-ba9c-86a7d9bde82a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6837350f-da83-4c69-993d-f72e8ddc495c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\nare given too much Remicade</span></b></p>", "ID": "acbedd8e-7b62-459d-bc04-61ff8c2d5ce7", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">If you\nare given too much Remicade</span></b>", "ID": "3547a611-0e9b-4f07-811d-79c8d3c597e1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "acbedd8e-7b62-459d-bc04-61ff8c2d5ce7"}, {"Element": "<span lang=\"EN-GB\">If you\nare given too much Remicade</span>", "ID": "df346433-c0ae-4bbd-b5e5-220b46cb0be7", "Styles": "None", "Classes": "None", "Text": "If you are given too much Remicade", "ParentId": "3547a611-0e9b-4f07-811d-79c8d3c597e1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">As this medicine is being given by your\ndoctor or nurse, it is unlikely that you will be given too much. There are no\nknown side effects of having too much of Remicade.</span></p>", "ID": "88ace812-062c-40fa-a0f4-8fe664f349b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">As this medicine is being given by your\ndoctor or nurse, it is unlikely that you will be given too much. There are no\nknown side effects of having too much of Remicade.</span>", "ID": "b8a44c03-ff83-4083-a36e-f39dfa03f841", "Styles": "None", "Classes": "None", "Text": "As this medicine is being given by your doctor or nurse, it is unlikely that you will be given too much. There are no known side effects of having too much of Remicade.", "ParentId": "88ace812-062c-40fa-a0f4-8fe664f349b6"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "7aace8ef-aa3a-4133-994d-9026b67e6e13", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "3e361cb5-1025-409f-8f80-b04575689baf", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7aace8ef-aa3a-4133-994d-9026b67e6e13"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4c49e60a-2cd3-435f-8ae5-d3e70f45f8e6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3e361cb5-1025-409f-8f80-b04575689baf"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">If you\nforget or miss your Remicade infusion</span></b></p>", "ID": "ea73a3b6-3119-486f-8a8e-405138def674", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">If you\nforget or miss your Remicade infusion</span></b>", "ID": "fbc345ad-9ff4-4de8-b6ad-11f6c2c5a7fd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ea73a3b6-3119-486f-8a8e-405138def674"}, {"Element": "<span lang=\"EN-GB\">If you\nforget or miss your Remicade infusion</span>", "ID": "ef8cccdf-1e3f-4a71-8b12-ab5dc0873250", "Styles": "None", "Classes": "None", "Text": "If you forget or miss your Remicade infusion", "ParentId": "fbc345ad-9ff4-4de8-b6ad-11f6c2c5a7fd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you forget or miss an appointment to\nreceive Remicade, make another appointment as soon as possible.</span></p>", "ID": "ef45ef9d-0e7a-4c35-ab41-172f9b11b896", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">If you forget or miss an appointment to\nreceive Remicade, make another appointment as soon as possible.</span>", "ID": "9136552b-e74b-417e-b170-5f6e4658eca6", "Styles": "None", "Classes": "None", "Text": "If you forget or miss an appointment to receive Remicade, make another appointment as soon as possible.", "ParentId": "ef45ef9d-0e7a-4c35-ab41-172f9b11b896"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "46ba23f4-683c-4101-885a-ae93640a1a9a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d32b7651-a32d-4fd1-91a7-b03000fad217", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "46ba23f4-683c-4101-885a-ae93640a1a9a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">If you have any further questions on the\nuse of this medicine, ask your doctor.</span></p>", "ID": "02b4c83d-9e36-4aac-b306-abd544939c32", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">If you have any further questions on the\nuse of this medicine, ask your doctor.</span>", "ID": "bc0ff99c-f854-49b3-8eed-791add77a3e2", "Styles": "None", "Classes": "None", "Text": "If you have any further questions on the use of this medicine, ask your doctor.", "ParentId": "02b4c83d-9e36-4aac-b306-abd544939c32"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "15251b1f-f7e3-4777-82b2-7e5455cf290a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f2ff9cc3-590f-464c-a293-67d369e4e2ca", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "15251b1f-f7e3-4777-82b2-7e5455cf290a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a288e5da-3fe1-437f-ac5b-0aa6e26c826f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4f4f3ad8-74db-41b9-babe-405894ee469f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a288e5da-3fe1-437f-ac5b-0aa6e26c826f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side\neffects</span></b></p>", "ID": "acc3b57a-5146-4123-8190-ffcc248c6f2b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side\neffects</span></b>", "ID": "7c3da4ce-3e03-4b6f-895e-3ac3a67dd3b8", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "acc3b57a-5146-4123-8190-ffcc248c6f2b"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side\neffects</span>", "ID": "ccca190b-cd5d-4c49-a1cd-fa53b63eb67c", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Possible side effects", "ParentId": "7c3da4ce-3e03-4b6f-895e-3ac3a67dd3b8"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b711213e-66b5-465d-815c-9f8ce5322b33", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f993d6d6-3ce2-464b-bea5-12f0e278f149", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b711213e-66b5-465d-815c-9f8ce5322b33"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Like all medicines, this medicine can cause\nside effects, although not everybody gets them. Most side effects are mild to\nmoderate. However some patients may experience serious side effects and may\nrequire treatment. Side effects may also occur after your treatment with Remicade\nhas stopped.</span></p>", "ID": "635b206a-a77c-4795-bf42-e06df810ca52", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Like all medicines, this medicine can cause\nside effects, although not everybody gets them. Most side effects are mild to\nmoderate. However some patients may experience serious side effects and may\nrequire treatment. Side effects may also occur after your treatment with Remicade\nhas stopped.</span>", "ID": "2005e9bb-c8d7-4214-af4b-b7868663be61", "Styles": "None", "Classes": "None", "Text": "Like all medicines, this medicine can cause side effects, although not everybody gets them. Most side effects are mild to moderate. However some patients may experience serious side effects and may require treatment. Side effects may also occur after your treatment with Remicade has stopped.", "ParentId": "635b206a-a77c-4795-bf42-e06df810ca52"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c56f26fd-dfa4-43e8-b8e6-a9d4abfb726c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d420e27c-3375-47a6-94b0-e24c9ca358bd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c56f26fd-dfa4-43e8-b8e6-a9d4abfb726c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Tell your\ndoctor straight away if you notice any of the following:</span></b></p>", "ID": "25b6cc81-738a-45b8-a63f-315f6893b1df", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Tell your\ndoctor straight away if you notice any of the following:</span></b>", "ID": "98b302d5-0f96-49d7-8b91-07cb51fbecfc", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "25b6cc81-738a-45b8-a63f-315f6893b1df"}, {"Element": "<span lang=\"EN-GB\">Tell your\ndoctor straight away if you notice any of the following:</span>", "ID": "1484ce57-66f4-422c-a32b-ecdcbfc889f4", "Styles": "None", "Classes": "None", "Text": "Tell your doctor straight away if you notice any of the following:", "ParentId": "98b302d5-0f96-49d7-8b91-07cb51fbecfc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of an allergic reaction</span></b><span lang=\"EN-GB\"> such as swelling of your face, lips, mouth or throat which may\ncause difficulty in swallowing or breathing, skin rash, hives, swelling of the\nhands, feet or ankles. Some of these reactions may be serious or\nlife-threatening. An allergic reaction could happen within 2\u00a0hours of your\ninjection or later. More signs of allergic side effects that may happen up to\n12\u00a0days after your injection include pain in the muscles, fever, joint or\njaw pain, sore throat or headache.</span></p>", "ID": "446ed2fb-b2fe-4466-a8d6-143588f450cb", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "abcfe20c-4968-456e-b6b0-87e42bbece81", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "446ed2fb-b2fe-4466-a8d6-143588f450cb"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "e85ec343-d5fd-46a8-922a-f45de0b55225", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "abcfe20c-4968-456e-b6b0-87e42bbece81"}, {"Element": "<b><span lang=\"EN-GB\">Signs of an allergic reaction</span></b>", "ID": "c5dab4c4-f14c-4948-8d01-a50146b46f76", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "446ed2fb-b2fe-4466-a8d6-143588f450cb"}, {"Element": "<span lang=\"EN-GB\">Signs of an allergic reaction</span>", "ID": "43f42c06-b786-4e32-97e7-d7066fef318e", "Styles": "None", "Classes": "None", "Text": "Signs of an allergic reaction", "ParentId": "c5dab4c4-f14c-4948-8d01-a50146b46f76"}, {"Element": "<span lang=\"EN-GB\"> such as swelling of your face, lips, mouth or throat which may\ncause difficulty in swallowing or breathing, skin rash, hives, swelling of the\nhands, feet or ankles. Some of these reactions may be serious or\nlife-threatening. An allergic reaction could happen within 2\u00a0hours of your\ninjection or later. More signs of allergic side effects that may happen up to\n12\u00a0days after your injection include pain in the muscles, fever, joint or\njaw pain, sore throat or headache.</span>", "ID": "0fc94a70-f49d-4c05-a16b-b7167ee66504", "Styles": "None", "Classes": "None", "Text": " such as swelling of your face, lips, mouth or throat which may cause difficulty in swallowing or breathing, skin rash, hives, swelling of the hands, feet or ankles. Some of these reactions may be serious or life-threatening. An allergic reaction could happen within 2\u00a0hours of your injection or later. More signs of allergic side effects that may happen up to 12\u00a0days after your injection include pain in the muscles, fever, joint or jaw pain, sore throat or headache.", "ParentId": "446ed2fb-b2fe-4466-a8d6-143588f450cb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of a heart problem</span></b><span lang=\"EN-GB\"> such as chest discomfort or pain, arm pain, stomach pain, shortness\nof breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea\n(feeling sick), vomiting, fluttering or pounding in your chest, a fast or a\nslow heartbeat, and swelling of your feet.</span></p>", "ID": "5f8dbef4-f4c8-4fa4-9dd5-b27afb82a18b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f9f71914-0aef-4ad3-b93d-eaa805e50a83", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5f8dbef4-f4c8-4fa4-9dd5-b27afb82a18b"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "9d579e48-8ccc-43e8-813e-5aff00bdb215", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f9f71914-0aef-4ad3-b93d-eaa805e50a83"}, {"Element": "<b><span lang=\"EN-GB\">Signs of a heart problem</span></b>", "ID": "e5818da2-3343-465d-adf6-7c8131ea659c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5f8dbef4-f4c8-4fa4-9dd5-b27afb82a18b"}, {"Element": "<span lang=\"EN-GB\">Signs of a heart problem</span>", "ID": "8f5617d0-4044-473e-93b4-787dba6244da", "Styles": "None", "Classes": "None", "Text": "Signs of a heart problem", "ParentId": "e5818da2-3343-465d-adf6-7c8131ea659c"}, {"Element": "<span lang=\"EN-GB\"> such as chest discomfort or pain, arm pain, stomach pain, shortness\nof breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea\n(feeling sick), vomiting, fluttering or pounding in your chest, a fast or a\nslow heartbeat, and swelling of your feet.</span>", "ID": "e38508ca-0047-4cf0-9a4c-6d9f66f19790", "Styles": "None", "Classes": "None", "Text": " such as chest discomfort or pain, arm pain, stomach pain, shortness of breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea (feeling sick), vomiting, fluttering or pounding in your chest, a fast or a slow heartbeat, and swelling of your feet.", "ParentId": "5f8dbef4-f4c8-4fa4-9dd5-b27afb82a18b"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of infection (including TB)</span></b><span lang=\"EN-GB\"> such as fever, feeling tired, cough which may be persistent,\nshortness of breath, flu\u2011like symptoms, weight loss, night sweats,\ndiarrhoea, wounds, collection of pus in the gut or around the anus (abscess), dental\nproblems or burning sensation when urinating.</span></p>", "ID": "c6bbfc52-30c3-4743-88d4-a102291c614a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "cca9a912-a091-450c-ad84-238f18c23349", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c6bbfc52-30c3-4743-88d4-a102291c614a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "27dd27f9-44cb-4a84-9b81-453e0d12ef39", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "cca9a912-a091-450c-ad84-238f18c23349"}, {"Element": "<b><span lang=\"EN-GB\">Signs of infection (including TB)</span></b>", "ID": "34afa863-99b1-4e60-885a-6e48197c53de", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c6bbfc52-30c3-4743-88d4-a102291c614a"}, {"Element": "<span lang=\"EN-GB\">Signs of infection (including TB)</span>", "ID": "73d5faff-34b9-4652-a36b-2cd4a0738d5c", "Styles": "None", "Classes": "None", "Text": "Signs of infection (including TB)", "ParentId": "34afa863-99b1-4e60-885a-6e48197c53de"}, {"Element": "<span lang=\"EN-GB\"> such as fever, feeling tired, cough which may be persistent,\nshortness of breath, flu\u2011like symptoms, weight loss, night sweats,\ndiarrhoea, wounds, collection of pus in the gut or around the anus (abscess), dental\nproblems or burning sensation when urinating.</span>", "ID": "d5d14887-bb59-41a3-be38-e609e8859a4e", "Styles": "None", "Classes": "None", "Text": " such as fever, feeling tired, cough which may be persistent, shortness of breath, flu\u2011like symptoms, weight loss, night sweats, diarrhoea, wounds, collection of pus in the gut or around the anus (abscess), dental problems or burning sensation when urinating.", "ParentId": "c6bbfc52-30c3-4743-88d4-a102291c614a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Possible signs of cancer</span></b><span lang=\"EN-GB\"> including but not limited to swelling of lymph nodes, weight loss,\nfever, unusual skin nodules, changes in moles or skin colouring, or unusual\nvaginal bleeding.</span></p>", "ID": "d1f21ea7-c2b4-476c-867f-5ef1a84d9760", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f5632fde-d468-433f-b08b-9de43449bb6c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d1f21ea7-c2b4-476c-867f-5ef1a84d9760"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d790cb32-82e2-43e1-b2e2-c71ba9b80e5b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f5632fde-d468-433f-b08b-9de43449bb6c"}, {"Element": "<b><span lang=\"EN-GB\">Possible signs of cancer</span></b>", "ID": "06219e8e-540d-432f-8a3f-88c206104bee", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d1f21ea7-c2b4-476c-867f-5ef1a84d9760"}, {"Element": "<span lang=\"EN-GB\">Possible signs of cancer</span>", "ID": "9bd4e218-9a63-45dd-8588-9f9fa4ccc7b5", "Styles": "None", "Classes": "None", "Text": "Possible signs of cancer", "ParentId": "06219e8e-540d-432f-8a3f-88c206104bee"}, {"Element": "<span lang=\"EN-GB\"> including but not limited to swelling of lymph nodes, weight loss,\nfever, unusual skin nodules, changes in moles or skin colouring, or unusual\nvaginal bleeding.</span>", "ID": "bad75789-a6e5-443d-8d75-e641c6fc7a77", "Styles": "None", "Classes": "None", "Text": " including but not limited to swelling of lymph nodes, weight loss, fever, unusual skin nodules, changes in moles or skin colouring, or unusual vaginal bleeding.", "ParentId": "d1f21ea7-c2b4-476c-867f-5ef1a84d9760"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of a lung problem</span></b><span lang=\"EN-GB\"> such as coughing, breathing difficulties or tightness in the chest.</span></p>", "ID": "9ccf2537-a97c-44dd-a186-2a189ed82787", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3fa00c1f-da34-4f43-ac13-337b6ca3c13e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9ccf2537-a97c-44dd-a186-2a189ed82787"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "701ec714-5433-4ac2-9e43-da6a5a232000", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3fa00c1f-da34-4f43-ac13-337b6ca3c13e"}, {"Element": "<b><span lang=\"EN-GB\">Signs of a lung problem</span></b>", "ID": "3b3b2569-92e8-4995-8c9b-7b0292ba1eab", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9ccf2537-a97c-44dd-a186-2a189ed82787"}, {"Element": "<span lang=\"EN-GB\">Signs of a lung problem</span>", "ID": "a2d4bc02-c68e-4c2d-a75e-43e5211e25aa", "Styles": "None", "Classes": "None", "Text": "Signs of a lung problem", "ParentId": "3b3b2569-92e8-4995-8c9b-7b0292ba1eab"}, {"Element": "<span lang=\"EN-GB\"> such as coughing, breathing difficulties or tightness in the chest.</span>", "ID": "a88470a7-551c-40a6-8d21-7dc409f7f951", "Styles": "None", "Classes": "None", "Text": " such as coughing, breathing difficulties or tightness in the chest.", "ParentId": "9ccf2537-a97c-44dd-a186-2a189ed82787"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of a nervous system problem (including\neye problems)</span></b><span lang=\"EN-GB\"> such as signs of a stroke (sudden\nnumbness or weakness of your face, arm or leg, especially on one side of your\nbody; sudden confusion, trouble speaking or understanding; trouble seeing in\none or both eyes, trouble walking, dizziness, loss of balance or coordination\nor a severe headache), fits, tingling/numbness in any part of your body, or weakness\nin arms or legs, changes in eyesight such as double vision or other eye\nproblems.</span></p>", "ID": "44bb9997-92a7-425e-bd3d-4a0c6d9fd588", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ddafac03-81e3-4779-98e6-a273b7ff9ad5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "44bb9997-92a7-425e-bd3d-4a0c6d9fd588"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "9e8aff92-06c7-4346-9e73-2e7f7c407546", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ddafac03-81e3-4779-98e6-a273b7ff9ad5"}, {"Element": "<b><span lang=\"EN-GB\">Signs of a nervous system problem (including\neye problems)</span></b>", "ID": "0f7b083f-fb89-4392-9d3c-02666f77c7c4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "44bb9997-92a7-425e-bd3d-4a0c6d9fd588"}, {"Element": "<span lang=\"EN-GB\">Signs of a nervous system problem (including\neye problems)</span>", "ID": "a3cfe30d-101a-497f-bad5-8309626ae9e5", "Styles": "None", "Classes": "None", "Text": "Signs of a nervous system problem (including eye problems)", "ParentId": "0f7b083f-fb89-4392-9d3c-02666f77c7c4"}, {"Element": "<span lang=\"EN-GB\"> such as signs of a stroke (sudden\nnumbness or weakness of your face, arm or leg, especially on one side of your\nbody; sudden confusion, trouble speaking or understanding; trouble seeing in\none or both eyes, trouble walking, dizziness, loss of balance or coordination\nor a severe headache), fits, tingling/numbness in any part of your body, or weakness\nin arms or legs, changes in eyesight such as double vision or other eye\nproblems.</span>", "ID": "1187d52d-dd78-43cb-a1f9-1cfb7b44f572", "Styles": "None", "Classes": "None", "Text": " such as signs of a stroke (sudden numbness or weakness of your face, arm or leg, especially on one side of your body; sudden confusion, trouble speaking or understanding; trouble seeing in one or both eyes, trouble walking, dizziness, loss of balance or coordination or a severe headache), fits, tingling/numbness in any part of your body, or weakness in arms or legs, changes in eyesight such as double vision or other eye problems.", "ParentId": "44bb9997-92a7-425e-bd3d-4a0c6d9fd588"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of a liver problem</span></b><span lang=\"EN-GB\"> (including hepatitis B infection when you have had hepatitis B in\nthe past) such as yellowing of the skin or eyes, dark\u2011brown coloured urine,\npain or swelling in the upper right side of the stomach area, joint pain, skin\nrashes, or fever.</span></p>", "ID": "9bb431a2-4634-4d2f-b548-25287ad31691", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "31a607c8-f32a-4019-984b-868488162e31", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9bb431a2-4634-4d2f-b548-25287ad31691"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8e3a3d9c-a6e2-406b-97a2-99e1aa31cd9c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "31a607c8-f32a-4019-984b-868488162e31"}, {"Element": "<b><span lang=\"EN-GB\">Signs of a liver problem</span></b>", "ID": "3bd46de8-4505-43e3-a212-3f7841eb33b0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9bb431a2-4634-4d2f-b548-25287ad31691"}, {"Element": "<span lang=\"EN-GB\">Signs of a liver problem</span>", "ID": "136e6493-da78-41c7-a2b6-446d8592642f", "Styles": "None", "Classes": "None", "Text": "Signs of a liver problem", "ParentId": "3bd46de8-4505-43e3-a212-3f7841eb33b0"}, {"Element": "<span lang=\"EN-GB\"> (including hepatitis B infection when you have had hepatitis B in\nthe past) such as yellowing of the skin or eyes, dark\u2011brown coloured urine,\npain or swelling in the upper right side of the stomach area, joint pain, skin\nrashes, or fever.</span>", "ID": "8a60211d-1c52-498d-99db-b3da3ec3fff8", "Styles": "None", "Classes": "None", "Text": " (including hepatitis B infection when you have had hepatitis B in the past) such as yellowing of the skin or eyes, dark\u2011brown coloured urine, pain or swelling in the upper right side of the stomach area, joint pain, skin rashes, or fever.", "ParentId": "9bb431a2-4634-4d2f-b548-25287ad31691"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of an immune system disorder </span></b><span lang=\"EN-GB\">such as joint pain or a rash on cheeks or arms that is sensitive to\nthe sun (lupus) or cough, shortness of breath, fever or skin rash (sarcoidosis).</span></p>", "ID": "742d4167-ea73-4fdd-b225-cfe7125189af", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "31d77252-3ca0-4d7f-931d-520095032024", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "742d4167-ea73-4fdd-b225-cfe7125189af"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8c0dd822-6eeb-4bb8-937e-00e007b8d29f", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "31d77252-3ca0-4d7f-931d-520095032024"}, {"Element": "<b><span lang=\"EN-GB\">Signs of an immune system disorder </span></b>", "ID": "8a5ec4c3-ff74-40e1-be36-0500876cc5d7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "742d4167-ea73-4fdd-b225-cfe7125189af"}, {"Element": "<span lang=\"EN-GB\">Signs of an immune system disorder </span>", "ID": "511ecda0-c02b-45a0-8ab8-2c9f76283780", "Styles": "None", "Classes": "None", "Text": "Signs of an immune system disorder ", "ParentId": "8a5ec4c3-ff74-40e1-be36-0500876cc5d7"}, {"Element": "<span lang=\"EN-GB\">such as joint pain or a rash on cheeks or arms that is sensitive to\nthe sun (lupus) or cough, shortness of breath, fever or skin rash (sarcoidosis).</span>", "ID": "fb56cbba-e374-4c67-a964-b207b5a1731b", "Styles": "None", "Classes": "None", "Text": "such as joint pain or a rash on cheeks or arms that is sensitive to the sun (lupus) or cough, shortness of breath, fever or skin rash (sarcoidosis).", "ParentId": "742d4167-ea73-4fdd-b225-cfe7125189af"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of low blood counts</span></b><span lang=\"EN-GB\"> such as persistent fever, bleeding or bruising more easily, small\nred or purple spots caused by bleeding under the skin, or looking pale.</span></p>", "ID": "833cc15b-b204-4605-9a47-f86e0be32637", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "555cde2f-4569-438b-a6d4-7656f12b99f0", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "833cc15b-b204-4605-9a47-f86e0be32637"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2daf8d3f-5921-4ca8-856b-56488bfcf73e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "555cde2f-4569-438b-a6d4-7656f12b99f0"}, {"Element": "<b><span lang=\"EN-GB\">Signs of low blood counts</span></b>", "ID": "2668e9ca-1d89-4f7f-83a2-fd9272610eb2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "833cc15b-b204-4605-9a47-f86e0be32637"}, {"Element": "<span lang=\"EN-GB\">Signs of low blood counts</span>", "ID": "0f832824-fa27-4b00-b989-b171940f5317", "Styles": "None", "Classes": "None", "Text": "Signs of low blood counts", "ParentId": "2668e9ca-1d89-4f7f-83a2-fd9272610eb2"}, {"Element": "<span lang=\"EN-GB\"> such as persistent fever, bleeding or bruising more easily, small\nred or purple spots caused by bleeding under the skin, or looking pale.</span>", "ID": "bef7dd79-8e2b-4c99-b688-6b9e0d71c7dd", "Styles": "None", "Classes": "None", "Text": " such as persistent fever, bleeding or bruising more easily, small red or purple spots caused by bleeding under the skin, or looking pale.", "ParentId": "833cc15b-b204-4605-9a47-f86e0be32637"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><b><span lang=\"EN-GB\">Signs of serious skin problems </span></b><span lang=\"EN-GB\">such as reddish-target-like spots or circular patches often with\ncentral blisters on the trunk, large areas of peeling and shedding\n(exfoliating) skin, ulcers of mouth, throat, nose, genitals and eyes or small\npus-filled bumps that can spread over the body. These skin reactions can be accompanied\nby fever.</span></p>", "ID": "15e80c3e-68ca-4ab8-9e4b-67c847172a4d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "2bd8a96b-4964-4b64-afe1-fae72022881c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "15e80c3e-68ca-4ab8-9e4b-67c847172a4d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "e9935957-da16-4d75-8c44-4a280cedcf13", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2bd8a96b-4964-4b64-afe1-fae72022881c"}, {"Element": "<b><span lang=\"EN-GB\">Signs of serious skin problems </span></b>", "ID": "362cc4ce-9b29-404c-a974-aad2296cd4de", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "15e80c3e-68ca-4ab8-9e4b-67c847172a4d"}, {"Element": "<span lang=\"EN-GB\">Signs of serious skin problems </span>", "ID": "c6197d48-cce4-4da2-aaee-64611eefacb7", "Styles": "None", "Classes": "None", "Text": "Signs of serious skin problems ", "ParentId": "362cc4ce-9b29-404c-a974-aad2296cd4de"}, {"Element": "<span lang=\"EN-GB\">such as reddish-target-like spots or circular patches often with\ncentral blisters on the trunk, large areas of peeling and shedding\n(exfoliating) skin, ulcers of mouth, throat, nose, genitals and eyes or small\npus-filled bumps that can spread over the body. These skin reactions can be accompanied\nby fever.</span>", "ID": "7a74083e-1603-42c8-82d9-2fe5bb030b9e", "Styles": "None", "Classes": "None", "Text": "such as reddish-target-like spots or circular patches often with central blisters on the trunk, large areas of peeling and shedding (exfoliating) skin, ulcers of mouth, throat, nose, genitals and eyes or small pus-filled bumps that can spread over the body. These skin reactions can be accompanied by fever.", "ParentId": "15e80c3e-68ca-4ab8-9e4b-67c847172a4d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cee28233-c46e-42cd-a2cf-4fe7316171a5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2a516f73-b063-4126-a958-4a4cfbe6b9a0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cee28233-c46e-42cd-a2cf-4fe7316171a5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tell your doctor straight away if you\nnotice any of the above.</span></p>", "ID": "02b938c3-35f5-429a-8a23-a1341c9d0c31", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Tell your doctor straight away if you\nnotice any of the above.</span>", "ID": "37306fab-7d1e-4c47-8264-7d7e79c80edf", "Styles": "None", "Classes": "None", "Text": "Tell your doctor straight away if you notice any of the above.", "ParentId": "02b938c3-35f5-429a-8a23-a1341c9d0c31"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "95f982ef-1696-4f3b-aee4-26dc003012b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "77c359a6-05af-49dc-905a-3493b3bfa011", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "95f982ef-1696-4f3b-aee4-26dc003012b6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The following side effects have been\nobserved with Remicade:</span></p>", "ID": "cc19fbb4-1481-466e-a267-fa39a9313920", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The following side effects have been\nobserved with Remicade:</span>", "ID": "91df62b9-ca31-4f2c-8033-3ca38a15d6b3", "Styles": "None", "Classes": "None", "Text": "The following side effects have been observed with Remicade:", "ParentId": "cc19fbb4-1481-466e-a267-fa39a9313920"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4e6fad05-fb35-4437-88f8-3e91d40493eb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "52c87c10-8720-46d3-8326-05868422b3e6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4e6fad05-fb35-4437-88f8-3e91d40493eb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Very\ncommon: may affect more than 1\u00a0in 10\u00a0people</span></b></p>", "ID": "0f90eba5-7a7c-4a44-b72b-de670270376d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Very\ncommon: may affect more than 1\u00a0in 10\u00a0people</span></b>", "ID": "5afa57f8-fc89-4318-a1ca-210bac950803", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0f90eba5-7a7c-4a44-b72b-de670270376d"}, {"Element": "<span lang=\"EN-GB\">Very\ncommon: may affect more than 1\u00a0in 10\u00a0people</span>", "ID": "84dfaf56-eb43-469d-a025-a54848191369", "Styles": "None", "Classes": "None", "Text": "Very common: may affect more than 1\u00a0in 10\u00a0people", "ParentId": "5afa57f8-fc89-4318-a1ca-210bac950803"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Stomach pain, feeling sick</span></p>", "ID": "49d22fc8-6c3b-4be6-b919-7597bb3b16de", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ad0b8b86-3707-43f1-bd5b-88836e66017c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "49d22fc8-6c3b-4be6-b919-7597bb3b16de"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "95c3615c-6f4b-4325-b9e7-27d5f6e034d4", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ad0b8b86-3707-43f1-bd5b-88836e66017c"}, {"Element": "<span lang=\"EN-GB\">Stomach pain, feeling sick</span>", "ID": "8c9eeac9-b0a5-4783-a862-f045d089906f", "Styles": "None", "Classes": "None", "Text": "Stomach pain, feeling sick", "ParentId": "49d22fc8-6c3b-4be6-b919-7597bb3b16de"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Viral infections such as herpes or flu</span></p>", "ID": "a9264d6a-7dd5-4468-af05-5ba782561a52", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "2a866dc2-5426-46d3-a0eb-fbabf59a5427", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a9264d6a-7dd5-4468-af05-5ba782561a52"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "750416c5-47dd-4dd7-9d4b-a9607158e7f5", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2a866dc2-5426-46d3-a0eb-fbabf59a5427"}, {"Element": "<span lang=\"EN-GB\">Viral infections such as herpes or flu</span>", "ID": "ed2bf77e-67fd-418b-8db0-1d0eb72ea971", "Styles": "None", "Classes": "None", "Text": "Viral infections such as herpes or flu", "ParentId": "a9264d6a-7dd5-4468-af05-5ba782561a52"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Upper respiratory infections such as sinusitis</span></p>", "ID": "e290b313-735c-4452-9951-3217bc71ebe7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "dcd38bce-bc92-4637-85ea-2f686beb6190", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e290b313-735c-4452-9951-3217bc71ebe7"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "58029067-d6fd-4f30-b52b-790a81a8f5dd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "dcd38bce-bc92-4637-85ea-2f686beb6190"}, {"Element": "<span lang=\"EN-GB\">Upper respiratory infections such as sinusitis</span>", "ID": "aaec2bd5-9a29-4b04-928d-ba57bfdb77b0", "Styles": "None", "Classes": "None", "Text": "Upper respiratory infections such as sinusitis", "ParentId": "e290b313-735c-4452-9951-3217bc71ebe7"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Headache</span></p>", "ID": "ca9d38b2-3c69-42ed-9319-50d91a63dc01", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "490590d2-233d-4253-a8c8-7db3a2802c55", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ca9d38b2-3c69-42ed-9319-50d91a63dc01"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d5e2cde8-bd5f-4e62-9302-812c878c5030", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "490590d2-233d-4253-a8c8-7db3a2802c55"}, {"Element": "<span lang=\"EN-GB\">Headache</span>", "ID": "3bd08c27-a4ff-4d2c-be69-3e0512895557", "Styles": "None", "Classes": "None", "Text": "Headache", "ParentId": "ca9d38b2-3c69-42ed-9319-50d91a63dc01"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Side effect due to an infusion</span></p>", "ID": "9b867bc4-febd-49c9-8828-720625a69f2d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "0483a0dd-becc-4ad4-a5e6-b3de95a0e423", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9b867bc4-febd-49c9-8828-720625a69f2d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c22fd550-5d58-43ff-b060-fdbeed6f87c7", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "0483a0dd-becc-4ad4-a5e6-b3de95a0e423"}, {"Element": "<span lang=\"EN-GB\">Side effect due to an infusion</span>", "ID": "f66990c8-e15e-4e7f-9683-22a828a2bdd0", "Styles": "None", "Classes": "None", "Text": "Side effect due to an infusion", "ParentId": "9b867bc4-febd-49c9-8828-720625a69f2d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Pain.</span></p>", "ID": "1ea328e9-0f3f-41df-8f00-b8604d70d0fe", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "20a6ac45-6ac3-4758-84a9-02dc7425d5ca", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1ea328e9-0f3f-41df-8f00-b8604d70d0fe"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6b1e4774-0e34-4741-b667-e4c3f68e2f7c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "20a6ac45-6ac3-4758-84a9-02dc7425d5ca"}, {"Element": "<span lang=\"EN-GB\">Pain.</span>", "ID": "2ef1f579-5156-4e3d-ae62-e18ec982fef5", "Styles": "None", "Classes": "None", "Text": "Pain.", "ParentId": "1ea328e9-0f3f-41df-8f00-b8604d70d0fe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2910720d-54d5-4c4c-8f90-5aa71116aa64", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f6540d8c-d1de-4129-9621-591aa58f5175", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2910720d-54d5-4c4c-8f90-5aa71116aa64"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Common:\nmay affect up to 1\u00a0in 10\u00a0people</span></b></p>", "ID": "41fcac39-8090-4efc-9208-b923c35155a0", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Common:\nmay affect up to 1\u00a0in 10\u00a0people</span></b>", "ID": "77e31ea4-d28b-41f2-9bf7-41686b500ca5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "41fcac39-8090-4efc-9208-b923c35155a0"}, {"Element": "<span lang=\"EN-GB\">Common:\nmay affect up to 1\u00a0in 10\u00a0people</span>", "ID": "f576e20b-552c-4901-aecc-0f93bb5a0568", "Styles": "None", "Classes": "None", "Text": "Common: may affect up to 1\u00a0in 10\u00a0people", "ParentId": "77e31ea4-d28b-41f2-9bf7-41686b500ca5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Changes in how your liver works, increase in\nliver enzymes (shown in blood tests)</span></p>", "ID": "b7e3be7c-a503-44e5-b6f6-6ed07424fb45", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ead9754d-f11f-40bc-a976-a84c1769ef70", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b7e3be7c-a503-44e5-b6f6-6ed07424fb45"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6402e39f-df26-4685-a499-d772247510e9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ead9754d-f11f-40bc-a976-a84c1769ef70"}, {"Element": "<span lang=\"EN-GB\">Changes in how your liver works, increase in\nliver enzymes (shown in blood tests)</span>", "ID": "a3bc1e5f-c348-4285-8270-195a85ecffb1", "Styles": "None", "Classes": "None", "Text": "Changes in how your liver works, increase in liver enzymes (shown in blood tests)", "ParentId": "b7e3be7c-a503-44e5-b6f6-6ed07424fb45"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Lung or chest infections such as bronchitis or\npneumonia</span></p>", "ID": "3516ed75-133a-47d2-95de-757a3443afd6", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c20eca4f-5037-4dd7-b566-adda53d755ec", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "3516ed75-133a-47d2-95de-757a3443afd6"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "95d8b3ea-e199-4690-87f1-2568733c012a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c20eca4f-5037-4dd7-b566-adda53d755ec"}, {"Element": "<span lang=\"EN-GB\">Lung or chest infections such as bronchitis or\npneumonia</span>", "ID": "777e4016-8824-4639-a3b5-e7b9769347c1", "Styles": "None", "Classes": "None", "Text": "Lung or chest infections such as bronchitis or pneumonia", "ParentId": "3516ed75-133a-47d2-95de-757a3443afd6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Difficult or painful breathing, chest pain</span></p>", "ID": "21c34fe7-7ee3-40c5-9e79-8519f100bd7d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ecdd99df-d8dc-4ffa-ac0d-475c9d53b9fe", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "21c34fe7-7ee3-40c5-9e79-8519f100bd7d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "25a40ed6-29d6-44d8-ba3a-3f0e8fec24ac", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ecdd99df-d8dc-4ffa-ac0d-475c9d53b9fe"}, {"Element": "<span lang=\"EN-GB\">Difficult or painful breathing, chest pain</span>", "ID": "53bfc98c-960b-4a12-81be-7fba40db84ae", "Styles": "None", "Classes": "None", "Text": "Difficult or painful breathing, chest pain", "ParentId": "21c34fe7-7ee3-40c5-9e79-8519f100bd7d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Bleeding in the stomach or intestines,\ndiarrhoea, indigestion, heartburn, constipation</span></p>", "ID": "7bce469d-eba7-4cce-85f6-12746c716f13", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "54dbafb3-e1be-4c68-bf2d-84a22e16421a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7bce469d-eba7-4cce-85f6-12746c716f13"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "01ffe4e0-1324-4914-930c-ff23cf09c9a7", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "54dbafb3-e1be-4c68-bf2d-84a22e16421a"}, {"Element": "<span lang=\"EN-GB\">Bleeding in the stomach or intestines,\ndiarrhoea, indigestion, heartburn, constipation</span>", "ID": "28d26489-7f14-431e-95f9-cf3d7314eeb0", "Styles": "None", "Classes": "None", "Text": "Bleeding in the stomach or intestines, diarrhoea, indigestion, heartburn, constipation", "ParentId": "7bce469d-eba7-4cce-85f6-12746c716f13"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Nettle\u2011type rash (hives), itchy rash or\ndry skin</span></p>", "ID": "095eddde-a682-4c6e-a98d-916759781791", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "60776226-01d2-4c9a-9b88-bd0f5506335b", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "095eddde-a682-4c6e-a98d-916759781791"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b9d6a299-e30d-49f1-88ae-f6569dae1109", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "60776226-01d2-4c9a-9b88-bd0f5506335b"}, {"Element": "<span lang=\"EN-GB\">Nettle\u2011type rash (hives), itchy rash or\ndry skin</span>", "ID": "13b6a51f-a262-4bdc-9afb-e7320a7e09d5", "Styles": "None", "Classes": "None", "Text": "Nettle\u2011type rash (hives), itchy rash or dry skin", "ParentId": "095eddde-a682-4c6e-a98d-916759781791"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Balance problems or feeling dizzy</span></p>", "ID": "7d5e4fcc-31a9-4471-8328-ef09a6350580", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "25f0dbc6-3f1d-486b-9f8c-203a40f0f137", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7d5e4fcc-31a9-4471-8328-ef09a6350580"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8ff87614-42bb-4cf7-9b7b-2d712547d143", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "25f0dbc6-3f1d-486b-9f8c-203a40f0f137"}, {"Element": "<span lang=\"EN-GB\">Balance problems or feeling dizzy</span>", "ID": "66fac8d6-f524-4950-973e-b32d5e44019e", "Styles": "None", "Classes": "None", "Text": "Balance problems or feeling dizzy", "ParentId": "7d5e4fcc-31a9-4471-8328-ef09a6350580"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fever, increased sweating</span></p>", "ID": "10fa5173-ed04-497d-93c0-8f4f48ced5ef", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ae40af39-a7d6-42ec-a58c-7eae5793770d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "10fa5173-ed04-497d-93c0-8f4f48ced5ef"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "120459d9-a4dd-4d68-a53f-935ff0f97eae", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ae40af39-a7d6-42ec-a58c-7eae5793770d"}, {"Element": "<span lang=\"EN-GB\">Fever, increased sweating</span>", "ID": "6b0a592e-72b9-4fd4-bbfc-b7772ae23e5e", "Styles": "None", "Classes": "None", "Text": "Fever, increased sweating", "ParentId": "10fa5173-ed04-497d-93c0-8f4f48ced5ef"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Circulation problems such as low or high blood\npressure</span></p>", "ID": "518f9a5f-8ac5-4c09-bc5a-a6adad99b916", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "eaa3553f-2a97-4a79-8b5b-8cdc51829e48", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "518f9a5f-8ac5-4c09-bc5a-a6adad99b916"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0de9f76b-faac-473a-b611-026f4e5e8d01", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "eaa3553f-2a97-4a79-8b5b-8cdc51829e48"}, {"Element": "<span lang=\"EN-GB\">Circulation problems such as low or high blood\npressure</span>", "ID": "8d2715b7-1617-4d8c-9473-49d1c8cd2880", "Styles": "None", "Classes": "None", "Text": "Circulation problems such as low or high blood pressure", "ParentId": "518f9a5f-8ac5-4c09-bc5a-a6adad99b916"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Bruising, hot flush or nosebleed, warm, red skin\n(flushing)</span></p>", "ID": "dd0245f0-86d4-4dea-9bda-c698e8a31180", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "a26a317d-12cc-4ce4-af13-a2cd3a6fc4fd", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "dd0245f0-86d4-4dea-9bda-c698e8a31180"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6985611e-c758-4c60-aeb0-55e518656a56", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "a26a317d-12cc-4ce4-af13-a2cd3a6fc4fd"}, {"Element": "<span lang=\"EN-GB\">Bruising, hot flush or nosebleed, warm, red skin\n(flushing)</span>", "ID": "0791769b-7a92-4ab3-8026-b425c977fd2e", "Styles": "None", "Classes": "None", "Text": "Bruising, hot flush or nosebleed, warm, red skin (flushing)", "ParentId": "dd0245f0-86d4-4dea-9bda-c698e8a31180"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling tired or weak</span></p>", "ID": "c9d4c056-0d3f-42c9-849d-00572fe61036", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "9f9bab11-a36d-4b2d-a375-1d8ea4e68a0a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c9d4c056-0d3f-42c9-849d-00572fe61036"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d58c23d2-61f2-4fea-a760-7fde11c4cfdb", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "9f9bab11-a36d-4b2d-a375-1d8ea4e68a0a"}, {"Element": "<span lang=\"EN-GB\">Feeling tired or weak</span>", "ID": "71a0433d-0749-4ca6-b63d-5f97d0485332", "Styles": "None", "Classes": "None", "Text": "Feeling tired or weak", "ParentId": "c9d4c056-0d3f-42c9-849d-00572fe61036"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Bacterial infections such as blood poisoning,\nabscess or infection of the skin (cellulitis)</span></p>", "ID": "0305195e-1faa-49d2-ba0c-e378ba0ff658", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c3c30598-a924-4da1-9bf2-26d718d597b5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0305195e-1faa-49d2-ba0c-e378ba0ff658"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "f5b376c7-f085-4449-977f-3197e9f2d84d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c3c30598-a924-4da1-9bf2-26d718d597b5"}, {"Element": "<span lang=\"EN-GB\">Bacterial infections such as blood poisoning,\nabscess or infection of the skin (cellulitis)</span>", "ID": "8551e189-b6f8-45d0-a014-86ff915e9a3f", "Styles": "None", "Classes": "None", "Text": "Bacterial infections such as blood poisoning, abscess or infection of the skin (cellulitis)", "ParentId": "0305195e-1faa-49d2-ba0c-e378ba0ff658"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Infection of the skin due to a fungus</span></p>", "ID": "fd71f9e8-eb60-4cec-b899-480846eafbf4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4f16c748-05b3-414d-82fb-da9d838c05ec", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "fd71f9e8-eb60-4cec-b899-480846eafbf4"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "1538ff98-116e-46be-b60f-5d1e927c66db", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4f16c748-05b3-414d-82fb-da9d838c05ec"}, {"Element": "<span lang=\"EN-GB\">Infection of the skin due to a fungus</span>", "ID": "382a1698-8ccf-4dce-ba63-2ff3ca59c59e", "Styles": "None", "Classes": "None", "Text": "Infection of the skin due to a fungus", "ParentId": "fd71f9e8-eb60-4cec-b899-480846eafbf4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Blood problems such as anaemia or low white\nblood cell count</span></p>", "ID": "a2bd44ed-fe31-4bcb-aa99-006b53e4a9df", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "a86292ae-1cc5-477d-9edc-40409f584cd7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a2bd44ed-fe31-4bcb-aa99-006b53e4a9df"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c7ee98f5-df65-4d94-bf6d-36408452292a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "a86292ae-1cc5-477d-9edc-40409f584cd7"}, {"Element": "<span lang=\"EN-GB\">Blood problems such as anaemia or low white\nblood cell count</span>", "ID": "9411a4e6-d9f8-4120-82d7-ba988a1a1251", "Styles": "None", "Classes": "None", "Text": "Blood problems such as anaemia or low white blood cell count", "ParentId": "a2bd44ed-fe31-4bcb-aa99-006b53e4a9df"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Swollen lymph nodes</span></p>", "ID": "18c86154-4bd5-4bca-8619-1690ec8dc901", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "dcbb4220-b3d7-4a65-911d-d39fd47c2fc9", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "18c86154-4bd5-4bca-8619-1690ec8dc901"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "f3bcdf13-7edb-4d5c-842d-9f9774c0fbb5", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "dcbb4220-b3d7-4a65-911d-d39fd47c2fc9"}, {"Element": "<span lang=\"EN-GB\">Swollen lymph nodes</span>", "ID": "39c5a20e-9c1c-4757-8346-a7d6eaafa61f", "Styles": "None", "Classes": "None", "Text": "Swollen lymph nodes", "ParentId": "18c86154-4bd5-4bca-8619-1690ec8dc901"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Depression, problems sleeping</span></p>", "ID": "4fd3869f-a6e9-4c8d-9ec3-500b79b573c6", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ee566a1c-b2a1-4951-87a7-221f79735fef", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4fd3869f-a6e9-4c8d-9ec3-500b79b573c6"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8c6f26ae-4491-45ee-84ab-d2775eae113c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ee566a1c-b2a1-4951-87a7-221f79735fef"}, {"Element": "<span lang=\"EN-GB\">Depression, problems sleeping</span>", "ID": "c8e77f06-44ff-49a9-a9d8-7084a20a70f4", "Styles": "None", "Classes": "None", "Text": "Depression, problems sleeping", "ParentId": "4fd3869f-a6e9-4c8d-9ec3-500b79b573c6"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Eye problems, including red eyes and infections</span></p>", "ID": "b020562b-a5bd-40c7-a423-7206db1d3e9f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7a0d9e94-725b-4bd3-b1df-80a48b750f90", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b020562b-a5bd-40c7-a423-7206db1d3e9f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "cc9517be-a4c1-4cf3-9f5d-bb5aa8f84afd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7a0d9e94-725b-4bd3-b1df-80a48b750f90"}, {"Element": "<span lang=\"EN-GB\">Eye problems, including red eyes and infections</span>", "ID": "a1e6d568-be8f-4831-ae05-5f27cf1ffb27", "Styles": "None", "Classes": "None", "Text": "Eye problems, including red eyes and infections", "ParentId": "b020562b-a5bd-40c7-a423-7206db1d3e9f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fast heart beat (tachycardia) or palpitations</span></p>", "ID": "62bc867c-a0ce-42ac-a7d4-580b6c63830f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f3af21cf-360f-4717-9bba-cb231c8c3cf5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "62bc867c-a0ce-42ac-a7d4-580b6c63830f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "87f0ce41-f9bd-4d74-b24c-527bc1539704", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f3af21cf-360f-4717-9bba-cb231c8c3cf5"}, {"Element": "<span lang=\"EN-GB\">Fast heart beat (tachycardia) or palpitations</span>", "ID": "c1d0fa22-75a6-4906-8c03-3f217cd5dc75", "Styles": "None", "Classes": "None", "Text": "Fast heart beat (tachycardia) or palpitations", "ParentId": "62bc867c-a0ce-42ac-a7d4-580b6c63830f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Pain in the joints, muscles or back</span></p>", "ID": "f75c1b38-02b9-4e35-943e-20cdaa26ef03", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4f204ddd-0a8c-426e-be64-0ce8218c3ad7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "f75c1b38-02b9-4e35-943e-20cdaa26ef03"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d4b65cac-ee4d-4d53-855f-cbe8348ad922", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4f204ddd-0a8c-426e-be64-0ce8218c3ad7"}, {"Element": "<span lang=\"EN-GB\">Pain in the joints, muscles or back</span>", "ID": "076d072d-17c9-4314-813e-c3e55ca45695", "Styles": "None", "Classes": "None", "Text": "Pain in the joints, muscles or back", "ParentId": "f75c1b38-02b9-4e35-943e-20cdaa26ef03"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Urinary tract infection</span></p>", "ID": "598d615c-af13-4ab0-bb58-29c48ccb2971", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "26f4f7c4-e14a-42aa-857f-421f2ef4edb2", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "598d615c-af13-4ab0-bb58-29c48ccb2971"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ef23e1b6-d02b-4f4b-8f23-05763892e817", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "26f4f7c4-e14a-42aa-857f-421f2ef4edb2"}, {"Element": "<span lang=\"EN-GB\">Urinary tract infection</span>", "ID": "8c7eec07-da8c-4b1a-a771-7447d2529acd", "Styles": "None", "Classes": "None", "Text": "Urinary tract infection", "ParentId": "598d615c-af13-4ab0-bb58-29c48ccb2971"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Psoriasis, skin problems such as eczema and hair\nloss</span></p>", "ID": "9f441689-1990-4f7a-8108-51e664f27012", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "33b04181-8211-4780-95c1-e4999198eb3c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "9f441689-1990-4f7a-8108-51e664f27012"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "4f7a2e13-6bc2-453c-886d-daf562026b70", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "33b04181-8211-4780-95c1-e4999198eb3c"}, {"Element": "<span lang=\"EN-GB\">Psoriasis, skin problems such as eczema and hair\nloss</span>", "ID": "1e848c92-af3f-4b4f-9e4b-eb42f0fe728f", "Styles": "None", "Classes": "None", "Text": "Psoriasis, skin problems such as eczema and hair loss", "ParentId": "9f441689-1990-4f7a-8108-51e664f27012"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Reactions at the injection site such as pain,\nswelling, redness or itching</span></p>", "ID": "5b732118-24b0-467a-8bac-94e4a6dc15d9", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5d92ec52-94f3-45e9-8601-c6fa4aaf63a7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5b732118-24b0-467a-8bac-94e4a6dc15d9"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "4d2292d2-36cf-4450-bb42-c63f56b33a93", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5d92ec52-94f3-45e9-8601-c6fa4aaf63a7"}, {"Element": "<span lang=\"EN-GB\">Reactions at the injection site such as pain,\nswelling, redness or itching</span>", "ID": "5677ad1f-d549-4abf-bc32-4d3283e107d4", "Styles": "None", "Classes": "None", "Text": "Reactions at the injection site such as pain, swelling, redness or itching", "ParentId": "5b732118-24b0-467a-8bac-94e4a6dc15d9"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Chills, a build up of fluid under the skin causing\nswelling</span></p>", "ID": "5fdf4266-973c-4a57-ae0d-ce234145c32a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4ca7ad0a-91dc-431e-aa59-6ebda15c8a58", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5fdf4266-973c-4a57-ae0d-ce234145c32a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6cd0b036-91cc-4c13-92bc-1c1d1ced57b7", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4ca7ad0a-91dc-431e-aa59-6ebda15c8a58"}, {"Element": "<span lang=\"EN-GB\">Chills, a build up of fluid under the skin causing\nswelling</span>", "ID": "70016468-9af2-4748-8704-5eab0c24a6a0", "Styles": "None", "Classes": "None", "Text": "Chills, a build up of fluid under the skin causing swelling", "ParentId": "5fdf4266-973c-4a57-ae0d-ce234145c32a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling numb or having a tingling feeling.</span></p>", "ID": "c554c984-4939-42c6-8d7a-4851c0f17140", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "2248edd8-8c6a-4e25-805e-53b4bebc1caf", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c554c984-4939-42c6-8d7a-4851c0f17140"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8b7486ab-642f-4d27-a0f4-83f109dc48e4", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2248edd8-8c6a-4e25-805e-53b4bebc1caf"}, {"Element": "<span lang=\"EN-GB\">Feeling numb or having a tingling feeling.</span>", "ID": "f177f6dd-7865-4c29-be4a-225d4aa3dfb3", "Styles": "None", "Classes": "None", "Text": "Feeling numb or having a tingling feeling.", "ParentId": "c554c984-4939-42c6-8d7a-4851c0f17140"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cdfe8d0b-9dde-4c75-a23f-f1b8e5cf8d92", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d2ad1812-217d-4fbe-8303-d7c2008661bf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cdfe8d0b-9dde-4c75-a23f-f1b8e5cf8d92"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Uncommon:\nmay affect up to 1\u00a0in 100\u00a0people</span></b></p>", "ID": "b50a9cce-95de-47ea-98ad-081c9cfbd04e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Uncommon:\nmay affect up to 1\u00a0in 100\u00a0people</span></b>", "ID": "8954a391-82ba-44fe-a213-f886504102ce", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b50a9cce-95de-47ea-98ad-081c9cfbd04e"}, {"Element": "<span lang=\"EN-GB\">Uncommon:\nmay affect up to 1\u00a0in 100\u00a0people</span>", "ID": "8da3cdea-8100-44b9-aa62-3e155b8ed024", "Styles": "None", "Classes": "None", "Text": "Uncommon: may affect up to 1\u00a0in 100\u00a0people", "ParentId": "8954a391-82ba-44fe-a213-f886504102ce"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Shortage of blood supply, swelling of a vein</span></p>", "ID": "baa771c5-f9c8-41f2-92ce-2cd5783a32d4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "81da8eb8-9f8a-48c2-9d7a-bd0397cc4cb3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "baa771c5-f9c8-41f2-92ce-2cd5783a32d4"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "29f2ba8a-aaaa-4552-ab7e-76eef4f0b1d2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "81da8eb8-9f8a-48c2-9d7a-bd0397cc4cb3"}, {"Element": "<span lang=\"EN-GB\">Shortage of blood supply, swelling of a vein</span>", "ID": "966e97f2-237d-49bd-8527-b739d04cf08a", "Styles": "None", "Classes": "None", "Text": "Shortage of blood supply, swelling of a vein", "ParentId": "baa771c5-f9c8-41f2-92ce-2cd5783a32d4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Collection of blood outside the blood vessels (haematoma)\nor bruising</span></p>", "ID": "e0faa4f9-02a8-425c-9485-5cd3e1507797", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "09ef1562-1c74-4add-85b7-8f8e76323287", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e0faa4f9-02a8-425c-9485-5cd3e1507797"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "3e0f19c6-497d-45d8-8685-2edb0ba9e9a3", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "09ef1562-1c74-4add-85b7-8f8e76323287"}, {"Element": "<span lang=\"EN-GB\">Collection of blood outside the blood vessels (haematoma)\nor bruising</span>", "ID": "57d92614-5ed7-43bf-b6c9-da09cd43d663", "Styles": "None", "Classes": "None", "Text": "Collection of blood outside the blood vessels (haematoma) or bruising", "ParentId": "e0faa4f9-02a8-425c-9485-5cd3e1507797"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Skin problems such as blistering, warts,\nabnormal skin colouration or pigmentation, or swollen lips, or thickening of the\nskin, or red, scaly, and flaky skin</span></p>", "ID": "93310f58-f05a-43a2-8c78-0658d906bc0d", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "00827ee5-0643-4d0d-a8d2-06dfff3005bc", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "93310f58-f05a-43a2-8c78-0658d906bc0d"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "e2325b0b-8479-477a-89c4-7715dfb4b768", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "00827ee5-0643-4d0d-a8d2-06dfff3005bc"}, {"Element": "<span lang=\"EN-GB\">Skin problems such as blistering, warts,\nabnormal skin colouration or pigmentation, or swollen lips, or thickening of the\nskin, or red, scaly, and flaky skin</span>", "ID": "d9ed7e1b-b993-4f82-a543-462a0189a738", "Styles": "None", "Classes": "None", "Text": "Skin problems such as blistering, warts, abnormal skin colouration or pigmentation, or swollen lips, or thickening of the skin, or red, scaly, and flaky skin", "ParentId": "93310f58-f05a-43a2-8c78-0658d906bc0d"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Severe allergic reactions (e.g. anaphylaxis), an\nimmune system disorder called lupus, allergic reactions to foreign proteins</span></p>", "ID": "e838f059-63a5-46eb-9218-0622eed37642", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c3b4e06e-eac9-4724-b445-23ae9123a6a4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e838f059-63a5-46eb-9218-0622eed37642"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b37c3751-99e3-4d33-bf6b-727f1c2c407e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c3b4e06e-eac9-4724-b445-23ae9123a6a4"}, {"Element": "<span lang=\"EN-GB\">Severe allergic reactions (e.g. anaphylaxis), an\nimmune system disorder called lupus, allergic reactions to foreign proteins</span>", "ID": "1f154bc0-5a7d-4681-8022-c55d27d641a0", "Styles": "None", "Classes": "None", "Text": "Severe allergic reactions (e.g. anaphylaxis), an immune system disorder called lupus, allergic reactions to foreign proteins", "ParentId": "e838f059-63a5-46eb-9218-0622eed37642"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Wounds taking longer to heal</span></p>", "ID": "08732c41-c0aa-4086-958d-c6cc5371b7db", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "99787772-261a-4407-a79f-5fa7b54d68f3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "08732c41-c0aa-4086-958d-c6cc5371b7db"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "dd2a4069-6479-4c2b-9cb9-80e912de636e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "99787772-261a-4407-a79f-5fa7b54d68f3"}, {"Element": "<span lang=\"EN-GB\">Wounds taking longer to heal</span>", "ID": "ac59f2be-df97-4b96-aa5a-f74aef8798af", "Styles": "None", "Classes": "None", "Text": "Wounds taking longer to heal", "ParentId": "08732c41-c0aa-4086-958d-c6cc5371b7db"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Swelling of the liver (hepatitis) or gall\nbladder, liver damage</span></p>", "ID": "cce54bb3-cf3d-4d9b-8024-1699e0695f8c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "04c3c498-4f41-4088-8d81-731dc002a970", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "cce54bb3-cf3d-4d9b-8024-1699e0695f8c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7bbdf906-c925-40f9-b41d-0b992e828c85", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "04c3c498-4f41-4088-8d81-731dc002a970"}, {"Element": "<span lang=\"EN-GB\">Swelling of the liver (hepatitis) or gall\nbladder, liver damage</span>", "ID": "23d31748-48a5-4325-b89c-1acbe29c8963", "Styles": "None", "Classes": "None", "Text": "Swelling of the liver (hepatitis) or gall bladder, liver damage", "ParentId": "cce54bb3-cf3d-4d9b-8024-1699e0695f8c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Feeling forgetful, irritable, confused, nervous</span></p>", "ID": "a0b8fbe8-8112-4f3e-bb7d-d6d275c0f6a4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "65810de8-4d82-4328-8973-b39b47cc240d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a0b8fbe8-8112-4f3e-bb7d-d6d275c0f6a4"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "15cdcc8a-6b7a-4dd7-ac00-611db3d1b9f5", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "65810de8-4d82-4328-8973-b39b47cc240d"}, {"Element": "<span lang=\"EN-GB\">Feeling forgetful, irritable, confused, nervous</span>", "ID": "a907dd9d-e628-4e2a-b706-06ddfbe4735e", "Styles": "None", "Classes": "None", "Text": "Feeling forgetful, irritable, confused, nervous", "ParentId": "a0b8fbe8-8112-4f3e-bb7d-d6d275c0f6a4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Eye problems including blurred or reduced\nvision, puffy eyes or sties</span></p>", "ID": "d7aff310-f14c-4d0d-b82f-b4f35c4a0fff", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "2b091a9d-ac40-48ff-a99f-acd00ff33e84", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d7aff310-f14c-4d0d-b82f-b4f35c4a0fff"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "e09908d0-bb77-4c2e-bd9b-78c6650ccb65", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2b091a9d-ac40-48ff-a99f-acd00ff33e84"}, {"Element": "<span lang=\"EN-GB\">Eye problems including blurred or reduced\nvision, puffy eyes or sties</span>", "ID": "2c10ec0c-3e99-4d3a-be20-e269b14a748c", "Styles": "None", "Classes": "None", "Text": "Eye problems including blurred or reduced vision, puffy eyes or sties", "ParentId": "d7aff310-f14c-4d0d-b82f-b4f35c4a0fff"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">New or worsening heart failure, slow heart rate</span></p>", "ID": "2eaaa1c4-4773-4078-8978-e13e3a3e51b4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5e334c23-21fa-48d9-8309-95ec5be443a1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2eaaa1c4-4773-4078-8978-e13e3a3e51b4"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "e9671930-f401-4baf-8aa2-1621df051081", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5e334c23-21fa-48d9-8309-95ec5be443a1"}, {"Element": "<span lang=\"EN-GB\">New or worsening heart failure, slow heart rate</span>", "ID": "4a718c67-40bd-4aa6-9d53-52a4231bc5aa", "Styles": "None", "Classes": "None", "Text": "New or worsening heart failure, slow heart rate", "ParentId": "2eaaa1c4-4773-4078-8978-e13e3a3e51b4"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fainting</span></p>", "ID": "7b71ec6a-c1f8-40b9-9274-61b395ce6722", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "e9a22bdb-9eda-4bd3-869b-bf3eaf9ab615", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7b71ec6a-c1f8-40b9-9274-61b395ce6722"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "61fdaffe-c9a2-483f-aca3-3ae9bf65f6fa", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "e9a22bdb-9eda-4bd3-869b-bf3eaf9ab615"}, {"Element": "<span lang=\"EN-GB\">Fainting</span>", "ID": "df1cf20d-f516-499a-bcac-ea0823d329e0", "Styles": "None", "Classes": "None", "Text": "Fainting", "ParentId": "7b71ec6a-c1f8-40b9-9274-61b395ce6722"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Convulsions, nerve problems</span></p>", "ID": "39a2ddc4-f654-48b3-959c-aae2fd690397", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "85a16bc9-1f2c-4ecd-8af5-28f1e77bfa20", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "39a2ddc4-f654-48b3-959c-aae2fd690397"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b2418456-3bb9-4245-8361-009350366325", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "85a16bc9-1f2c-4ecd-8af5-28f1e77bfa20"}, {"Element": "<span lang=\"EN-GB\">Convulsions, nerve problems</span>", "ID": "a41716b0-800d-49c3-a4b3-f810f69a8661", "Styles": "None", "Classes": "None", "Text": "Convulsions, nerve problems", "ParentId": "39a2ddc4-f654-48b3-959c-aae2fd690397"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A hole in the bowel or blockage of the\nintestine, stomach pain or cramps</span></p>", "ID": "fe39145e-9336-4bb0-9175-c365bd4954d0", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "93f38bee-cb95-4228-a590-c9987d918d6d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "fe39145e-9336-4bb0-9175-c365bd4954d0"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2bff5fcd-4f1f-48b3-a736-754aae5ba1f0", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "93f38bee-cb95-4228-a590-c9987d918d6d"}, {"Element": "<span lang=\"EN-GB\">A hole in the bowel or blockage of the\nintestine, stomach pain or cramps</span>", "ID": "f9f1c8b9-4dd0-4734-97c4-b17900ec26c9", "Styles": "None", "Classes": "None", "Text": "A hole in the bowel or blockage of the intestine, stomach pain or cramps", "ParentId": "fe39145e-9336-4bb0-9175-c365bd4954d0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Swelling of your pancreas (pancreatitis)</span></p>", "ID": "de070c83-8952-4dac-b3e6-0915f93d786f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "2a842e42-1797-4394-904c-f8b39be3f3ae", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "de070c83-8952-4dac-b3e6-0915f93d786f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "500dd411-f8b6-4c90-8e04-0f6fc2d3fc68", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2a842e42-1797-4394-904c-f8b39be3f3ae"}, {"Element": "<span lang=\"EN-GB\">Swelling of your pancreas (pancreatitis)</span>", "ID": "300daf28-e86e-464a-892c-9263c67e3bd9", "Styles": "None", "Classes": "None", "Text": "Swelling of your pancreas (pancreatitis)", "ParentId": "de070c83-8952-4dac-b3e6-0915f93d786f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fungal infections such as yeast infection or\nfungal infection of the nails</span></p>", "ID": "c5a232ca-b6eb-4629-8715-8ec14d779783", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "370e21ab-85df-4da7-a45f-4c55c6707c4c", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c5a232ca-b6eb-4629-8715-8ec14d779783"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "eec3cfc2-9538-4b5d-b254-70227e23e970", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "370e21ab-85df-4da7-a45f-4c55c6707c4c"}, {"Element": "<span lang=\"EN-GB\">Fungal infections such as yeast infection or\nfungal infection of the nails</span>", "ID": "37ea2ac9-6d97-4f11-9631-a5795a0e529a", "Styles": "None", "Classes": "None", "Text": "Fungal infections such as yeast infection or fungal infection of the nails", "ParentId": "c5a232ca-b6eb-4629-8715-8ec14d779783"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Lung problems (such as oedema)</span></p>", "ID": "1d62b87a-12cf-4ecd-8555-828cc579475c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "099237d3-04ec-4d46-bf7a-473c47f13ba4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1d62b87a-12cf-4ecd-8555-828cc579475c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "0d19a6aa-b0bc-4d8e-8ed0-17a64ea648d4", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "099237d3-04ec-4d46-bf7a-473c47f13ba4"}, {"Element": "<span lang=\"EN-GB\">Lung problems (such as oedema)</span>", "ID": "e29b197c-6554-4220-9a24-53bc6f43eb2d", "Styles": "None", "Classes": "None", "Text": "Lung problems (such as oedema)", "ParentId": "1d62b87a-12cf-4ecd-8555-828cc579475c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fluid around the lungs (pleural effusion)</span></p>", "ID": "68513e62-7446-4be1-a2d7-88709d74aa74", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c628e172-817f-4b0b-a2ff-fb5ea8586845", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "68513e62-7446-4be1-a2d7-88709d74aa74"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b1207545-0e76-4383-a110-3f15c7459d80", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c628e172-817f-4b0b-a2ff-fb5ea8586845"}, {"Element": "<span lang=\"EN-GB\">Fluid around the lungs (pleural effusion)</span>", "ID": "b74a2551-2a69-4582-a2d6-d2aab1f8da82", "Styles": "None", "Classes": "None", "Text": "Fluid around the lungs (pleural effusion)", "ParentId": "68513e62-7446-4be1-a2d7-88709d74aa74"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Narrowed airway in the lungs, causing difficulty\nbreathing</span></p>", "ID": "2079430c-0dbb-425d-86f6-137905a1a3c5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c3b82f8e-daa6-4936-8281-a2642d2f8914", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2079430c-0dbb-425d-86f6-137905a1a3c5"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "e34c16fa-a097-4168-afd4-5bc85d80e7c2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c3b82f8e-daa6-4936-8281-a2642d2f8914"}, {"Element": "<span lang=\"EN-GB\">Narrowed airway in the lungs, causing difficulty\nbreathing</span>", "ID": "0fb3802d-5345-462e-ba44-385e1287aa15", "Styles": "None", "Classes": "None", "Text": "Narrowed airway in the lungs, causing difficulty breathing", "ParentId": "2079430c-0dbb-425d-86f6-137905a1a3c5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflamed lining of the lung, causing sharp chest\npains that feel worse with breathing (pleurisy)</span></p>", "ID": "2d358668-47ab-48bc-bc97-e8246f361b9e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "0d8a3004-60dc-4e61-83b4-88d839a908c4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2d358668-47ab-48bc-bc97-e8246f361b9e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2ddd455f-110b-4b6b-b35c-5563168c7775", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "0d8a3004-60dc-4e61-83b4-88d839a908c4"}, {"Element": "<span lang=\"EN-GB\">Inflamed lining of the lung, causing sharp chest\npains that feel worse with breathing (pleurisy)</span>", "ID": "88bc58b1-7cff-4cd5-8d77-7c7e45a7bba1", "Styles": "None", "Classes": "None", "Text": "Inflamed lining of the lung, causing sharp chest pains that feel worse with breathing (pleurisy)", "ParentId": "2d358668-47ab-48bc-bc97-e8246f361b9e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Tuberculosis</span></p>", "ID": "30fa8ed6-6764-4240-9d0d-8caff2dfb728", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3f0f2319-f0cc-45f5-817d-80e4106a26f3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "30fa8ed6-6764-4240-9d0d-8caff2dfb728"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "3c49f64e-d95a-4eba-a348-10e13776bc33", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3f0f2319-f0cc-45f5-817d-80e4106a26f3"}, {"Element": "<span lang=\"EN-GB\">Tuberculosis</span>", "ID": "238ea9a0-210c-4632-8fe3-42cc6719fcd8", "Styles": "None", "Classes": "None", "Text": "Tuberculosis", "ParentId": "30fa8ed6-6764-4240-9d0d-8caff2dfb728"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Kidney infections</span></p>", "ID": "5a508a91-db7c-4bee-9220-3200189e3c58", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c4a0aca4-c974-44eb-9034-6b477b1d99b7", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "5a508a91-db7c-4bee-9220-3200189e3c58"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c06a9281-c307-40f9-924b-429d5c962bf2", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c4a0aca4-c974-44eb-9034-6b477b1d99b7"}, {"Element": "<span lang=\"EN-GB\">Kidney infections</span>", "ID": "e23fda45-822b-4221-9ac4-c045e81f1236", "Styles": "None", "Classes": "None", "Text": "Kidney infections", "ParentId": "5a508a91-db7c-4bee-9220-3200189e3c58"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Low platelet count, too many white blood cells</span></p>", "ID": "2e16865d-c28b-42ec-840c-d81e87aadce1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "dd734913-40da-4eb5-b198-e01628cd9c48", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2e16865d-c28b-42ec-840c-d81e87aadce1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "bc5905a0-c9fd-40ab-92dd-dfcfec939108", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "dd734913-40da-4eb5-b198-e01628cd9c48"}, {"Element": "<span lang=\"EN-GB\">Low platelet count, too many white blood cells</span>", "ID": "1af733c8-ff70-419a-9e1a-521d6ff9a8ff", "Styles": "None", "Classes": "None", "Text": "Low platelet count, too many white blood cells", "ParentId": "2e16865d-c28b-42ec-840c-d81e87aadce1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Infections of the vagina</span></p>", "ID": "ce14da64-6293-40b5-8f83-a1c28df1bf62", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "f77de2d8-4526-403d-af7f-7859545aa076", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ce14da64-6293-40b5-8f83-a1c28df1bf62"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "48121cf8-100b-486c-8eeb-bcc0e5f4ed7c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "f77de2d8-4526-403d-af7f-7859545aa076"}, {"Element": "<span lang=\"EN-GB\">Infections of the vagina</span>", "ID": "af4d9674-0dbe-4fb9-877f-9e215693d99e", "Styles": "None", "Classes": "None", "Text": "Infections of the vagina", "ParentId": "ce14da64-6293-40b5-8f83-a1c28df1bf62"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Blood test result showing\n\u2018antibodies\u2019 against your own body.</span></p>", "ID": "57cc230b-f1a2-45b0-a0bb-91f5539bda9c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "66147c80-5839-4888-9b36-747885e26ab5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "57cc230b-f1a2-45b0-a0bb-91f5539bda9c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6789e607-c3df-4aaa-91bf-5967c1e9ed49", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "66147c80-5839-4888-9b36-747885e26ab5"}, {"Element": "<span lang=\"EN-GB\">Blood test result showing\n\u2018antibodies\u2019 against your own body.</span>", "ID": "6c593ed8-1cb8-4683-b8be-6ed69a94a4f4", "Styles": "None", "Classes": "None", "Text": "Blood test result showing \u2018antibodies\u2019 against your own body.", "ParentId": "57cc230b-f1a2-45b0-a0bb-91f5539bda9c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "63eeb715-3057-43e1-9b53-eefe639acfa4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "63030ed7-a073-440c-bcae-8b9c601d90e7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "63eeb715-3057-43e1-9b53-eefe639acfa4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Rare: may\naffect up to 1\u00a0in 1,000\u00a0people</span></b></p>", "ID": "c918e5b5-d0a7-4054-b532-ba7f7343445c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Rare: may\naffect up to 1\u00a0in 1,000\u00a0people</span></b>", "ID": "767c60ec-74b8-4d71-bbf7-99ee0a91f286", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "c918e5b5-d0a7-4054-b532-ba7f7343445c"}, {"Element": "<span lang=\"EN-GB\">Rare: may\naffect up to 1\u00a0in 1,000\u00a0people</span>", "ID": "6ff78444-95dc-438f-831b-470bdce20e04", "Styles": "None", "Classes": "None", "Text": "Rare: may affect up to 1\u00a0in 1,000\u00a0people", "ParentId": "767c60ec-74b8-4d71-bbf7-99ee0a91f286"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A type of blood cancer (lymphoma)</span></p>", "ID": "4a3ab32f-8650-4c83-bb81-5ca7c74b1a0c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "8c3053f4-be02-45af-aba8-e4c60319080f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4a3ab32f-8650-4c83-bb81-5ca7c74b1a0c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2736effe-b7b2-4eea-befa-2ed8d542e87c", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "8c3053f4-be02-45af-aba8-e4c60319080f"}, {"Element": "<span lang=\"EN-GB\">A type of blood cancer (lymphoma)</span>", "ID": "da383e64-3e95-43f7-93a1-0b06eb203ab3", "Styles": "None", "Classes": "None", "Text": "A type of blood cancer (lymphoma)", "ParentId": "4a3ab32f-8650-4c83-bb81-5ca7c74b1a0c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Your blood not supplying enough oxygen to your\nbody, circulation problems such as narrowing of a blood vessel</span></p>", "ID": "03133ffb-02fa-4ff3-9e41-737e628538e2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "b302dc63-021d-4a7c-b7dc-153d6e03f0d3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "03133ffb-02fa-4ff3-9e41-737e628538e2"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d7fbb299-2c2e-4fa9-b70f-da0ce92703b8", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "b302dc63-021d-4a7c-b7dc-153d6e03f0d3"}, {"Element": "<span lang=\"EN-GB\">Your blood not supplying enough oxygen to your\nbody, circulation problems such as narrowing of a blood vessel</span>", "ID": "2924fb38-e927-4977-88a5-04a7f4ee4fb4", "Styles": "None", "Classes": "None", "Text": "Your blood not supplying enough oxygen to your body, circulation problems such as narrowing of a blood vessel", "ParentId": "03133ffb-02fa-4ff3-9e41-737e628538e2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation of the lining of the brain\n(meningitis)</span></p>", "ID": "104ea090-5459-4650-951f-82c9a02ada16", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "97c90abe-b339-4bef-b12a-6975262aae68", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "104ea090-5459-4650-951f-82c9a02ada16"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "40562822-b91e-4f31-898c-bd4be2154f37", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "97c90abe-b339-4bef-b12a-6975262aae68"}, {"Element": "<span lang=\"EN-GB\">Inflammation of the lining of the brain\n(meningitis)</span>", "ID": "079d4498-31e5-4424-85ae-868376c22964", "Styles": "None", "Classes": "None", "Text": "Inflammation of the lining of the brain (meningitis)", "ParentId": "104ea090-5459-4650-951f-82c9a02ada16"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Infections due to a weakened immune system</span></p>", "ID": "47a210fe-37f5-4217-9570-cca9dff66a69", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "feebd51c-b33a-4fd5-9e2f-17497fb8b74f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "47a210fe-37f5-4217-9570-cca9dff66a69"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d3bd1b4c-ff2f-40d6-b1e4-583a2860f1f8", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "feebd51c-b33a-4fd5-9e2f-17497fb8b74f"}, {"Element": "<span lang=\"EN-GB\">Infections due to a weakened immune system</span>", "ID": "0f46f536-30f5-4e7e-b7f3-cc2ccfab4766", "Styles": "None", "Classes": "None", "Text": "Infections due to a weakened immune system", "ParentId": "47a210fe-37f5-4217-9570-cca9dff66a69"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Hepatitis B infection when you have had\nhepatitis B in the past</span></p>", "ID": "4122912e-56de-4223-94ab-a481dc7aa009", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "465235ff-09bf-47a0-a079-3a90a24590b8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4122912e-56de-4223-94ab-a481dc7aa009"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "deb2c167-6510-4e2e-b828-c1dbda7e8062", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "465235ff-09bf-47a0-a079-3a90a24590b8"}, {"Element": "<span lang=\"EN-GB\">Hepatitis B infection when you have had\nhepatitis B in the past</span>", "ID": "f0e8d2c0-565d-4625-b13b-e66035b95987", "Styles": "None", "Classes": "None", "Text": "Hepatitis B infection when you have had hepatitis B in the past", "ParentId": "4122912e-56de-4223-94ab-a481dc7aa009"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflamed liver caused by a problem with the\nimmune system (autoimmune hepatitis)</span></p>", "ID": "c61cb014-ce87-459d-adec-7c7397b6ad2f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ec5391fb-4048-4edd-a431-eaf55f8eaf13", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "c61cb014-ce87-459d-adec-7c7397b6ad2f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "23b38f00-df15-4914-85a7-187223ef7f54", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ec5391fb-4048-4edd-a431-eaf55f8eaf13"}, {"Element": "<span lang=\"EN-GB\">Inflamed liver caused by a problem with the\nimmune system (autoimmune hepatitis)</span>", "ID": "0354986e-553b-438d-807d-7031750335ce", "Styles": "None", "Classes": "None", "Text": "Inflamed liver caused by a problem with the immune system (autoimmune hepatitis)", "ParentId": "c61cb014-ce87-459d-adec-7c7397b6ad2f"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Liver problem that causes yellowing of the skin\nor eyes (jaundice)</span></p>", "ID": "62902954-cfd6-4393-a424-88836143b7fe", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "401aca3c-b715-4580-88dc-652354876ca5", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "62902954-cfd6-4393-a424-88836143b7fe"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "746324d2-6a3c-4bd1-8efd-320969846fce", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "401aca3c-b715-4580-88dc-652354876ca5"}, {"Element": "<span lang=\"EN-GB\">Liver problem that causes yellowing of the skin\nor eyes (jaundice)</span>", "ID": "9d32ddfc-0b00-41b5-9c71-22396bff3b84", "Styles": "None", "Classes": "None", "Text": "Liver problem that causes yellowing of the skin or eyes (jaundice)", "ParentId": "62902954-cfd6-4393-a424-88836143b7fe"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Abnormal tissue swelling or growth</span></p>", "ID": "4b19d361-f0e8-463f-945a-af3bc49f3087", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "7bc3cfc6-3a91-4942-a747-4301e668f0d3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4b19d361-f0e8-463f-945a-af3bc49f3087"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b5bc8fb4-7ecf-4ce0-a8ab-ec7b8c53ce47", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "7bc3cfc6-3a91-4942-a747-4301e668f0d3"}, {"Element": "<span lang=\"EN-GB\">Abnormal tissue swelling or growth</span>", "ID": "ad2ae86f-76c5-4eb3-a942-5b8432e6fd86", "Styles": "None", "Classes": "None", "Text": "Abnormal tissue swelling or growth", "ParentId": "4b19d361-f0e8-463f-945a-af3bc49f3087"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><a name=\"OLE_LINK3\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Severe allergic reaction that may cause loss of\nconsciousness and could be life-threatening (anaphylactic shock)</span></a></p>", "ID": "a200bffd-e682-4b4f-8276-0ec421fa08a1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<a name=\"OLE_LINK3\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Severe allergic reaction that may cause loss of\nconsciousness and could be life-threatening (anaphylactic shock)</span></a>", "ID": "14ebb8a9-0391-43ea-a71b-4eda7dced8c0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a200bffd-e682-4b4f-8276-0ec421fa08a1"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "3917701f-4a24-42ce-9792-55b69791b745", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "14ebb8a9-0391-43ea-a71b-4eda7dced8c0"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "36723acc-d202-4d86-b35b-55247c49713a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "3917701f-4a24-42ce-9792-55b69791b745"}, {"Element": "<span lang=\"EN-GB\">Severe allergic reaction that may cause loss of\nconsciousness and could be life-threatening (anaphylactic shock)</span>", "ID": "c551832e-b7f4-4061-b679-d88443f0ff9e", "Styles": "None", "Classes": "None", "Text": "Severe allergic reaction that may cause loss of consciousness and could be life-threatening (anaphylactic shock)", "ParentId": "14ebb8a9-0391-43ea-a71b-4eda7dced8c0"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Swelling of small blood vessels (vasculitis)</span></p>", "ID": "e87c8d3d-a8b3-40e5-97e8-739de3b0ba98", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "682e2462-d73b-4503-9ab4-65db0178c684", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e87c8d3d-a8b3-40e5-97e8-739de3b0ba98"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "035fb24f-a182-431c-99f5-51b5998644f6", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "682e2462-d73b-4503-9ab4-65db0178c684"}, {"Element": "<span lang=\"EN-GB\">Swelling of small blood vessels (vasculitis)</span>", "ID": "42d59ce6-3c6b-41f0-af98-3d5de9d7fd62", "Styles": "None", "Classes": "None", "Text": "Swelling of small blood vessels (vasculitis)", "ParentId": "e87c8d3d-a8b3-40e5-97e8-739de3b0ba98"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Immune disorders that could affect the lungs,\nskin and lymph nodes (such as sarcoidosis).</span></p>", "ID": "a794a7c1-96ea-4f6a-b405-6f8108428dcf", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "33c1bf14-7e93-49e6-9b14-b8eb8d3afb6d", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a794a7c1-96ea-4f6a-b405-6f8108428dcf"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "8a7d680f-42fe-461c-a1bc-e8ed4fa98082", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "33c1bf14-7e93-49e6-9b14-b8eb8d3afb6d"}, {"Element": "<span lang=\"EN-GB\">Immune disorders that could affect the lungs,\nskin and lymph nodes (such as sarcoidosis).</span>", "ID": "03003457-78de-4056-8e4d-1958f72d9297", "Styles": "None", "Classes": "None", "Text": "Immune disorders that could affect the lungs, skin and lymph nodes (such as sarcoidosis).", "ParentId": "a794a7c1-96ea-4f6a-b405-6f8108428dcf"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Collections of immune cells resulting from an\ninflammatory response (granulomatous lesions)</span></p>", "ID": "2e05feea-cf9a-4382-af46-6679d54ae90a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "93adec47-5a3c-459e-8e4b-a30a5305765f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "2e05feea-cf9a-4382-af46-6679d54ae90a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "efbae036-e2cf-425b-a2ff-dd3fa5f1adc7", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "93adec47-5a3c-459e-8e4b-a30a5305765f"}, {"Element": "<span lang=\"EN-GB\">Collections of immune cells resulting from an\ninflammatory response (granulomatous lesions)</span>", "ID": "e4d874ee-cfc1-439b-95b4-c3a1232364df", "Styles": "None", "Classes": "None", "Text": "Collections of immune cells resulting from an inflammatory response (granulomatous lesions)", "ParentId": "2e05feea-cf9a-4382-af46-6679d54ae90a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Lack of interest or emotion</span></p>", "ID": "b331ea11-b0b2-40d7-bf12-bc0b7107f4ee", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c7c1ac76-c7a2-4b03-8c71-a0dd81cd6569", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "b331ea11-b0b2-40d7-bf12-bc0b7107f4ee"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "204d2749-b23c-4ce6-b39b-12337bf396d9", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c7c1ac76-c7a2-4b03-8c71-a0dd81cd6569"}, {"Element": "<span lang=\"EN-GB\">Lack of interest or emotion</span>", "ID": "adc13b9e-10a7-4063-ad44-3b1286655855", "Styles": "None", "Classes": "None", "Text": "Lack of interest or emotion", "ParentId": "b331ea11-b0b2-40d7-bf12-bc0b7107f4ee"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Serious skin problems such as toxic epidermal\nnecrolysis, Stevens\u2011Johnson Syndrome and acute generalised exanthematous\npustulosis</span></p>", "ID": "4ec34742-a888-4dba-b518-f2e61bde8a0c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "5a8cd4aa-a5db-4eca-8cce-2af1dd5b21e3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "4ec34742-a888-4dba-b518-f2e61bde8a0c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "05471db1-2392-4c12-ae29-7529b3061466", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "5a8cd4aa-a5db-4eca-8cce-2af1dd5b21e3"}, {"Element": "<span lang=\"EN-GB\">Serious skin problems such as toxic epidermal\nnecrolysis, Stevens\u2011Johnson Syndrome and acute generalised exanthematous\npustulosis</span>", "ID": "ffb6191b-d1bb-4511-995f-21d198be8397", "Styles": "None", "Classes": "None", "Text": "Serious skin problems such as toxic epidermal necrolysis, Stevens\u2011Johnson Syndrome and acute generalised exanthematous pustulosis", "ParentId": "4ec34742-a888-4dba-b518-f2e61bde8a0c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Other skin problems such as erythema multiforme,\nlichenoid reactions (itchy reddish-purple skin rash and/or threadlike\nwhite-grey lines on mucous membranes), blisters and peeling skin, or boils\n(furunculosis)</span></p>", "ID": "a2616df7-59bd-49da-b437-3b11975bd2cc", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "ad366816-deea-4de7-aa7c-c322922ec884", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a2616df7-59bd-49da-b437-3b11975bd2cc"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "7a39e52e-31dd-492f-af80-1730d8ba0bf4", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "ad366816-deea-4de7-aa7c-c322922ec884"}, {"Element": "<span lang=\"EN-GB\">Other skin problems such as erythema multiforme,\nlichenoid reactions (itchy reddish-purple skin rash and/or threadlike\nwhite-grey lines on mucous membranes), blisters and peeling skin, or boils\n(furunculosis)</span>", "ID": "bed2662b-16ab-4864-b22e-9f0438b6a5c5", "Styles": "None", "Classes": "None", "Text": "Other skin problems such as erythema multiforme, lichenoid reactions (itchy reddish-purple skin rash and/or threadlike white-grey lines on mucous membranes), blisters and peeling skin, or boils (furunculosis)", "ParentId": "a2616df7-59bd-49da-b437-3b11975bd2cc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Serious nervous system disorders such as\ntransverse myelitis, multiple sclerosis\u2011like disease, optic neuritis and\nGuillain\u2011Barr\u00e9 syndrome</span></p>", "ID": "84c7142d-ee4a-42fe-8426-1057b18c7397", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "a172870a-e101-4cfa-917b-236b526e4a19", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "84c7142d-ee4a-42fe-8426-1057b18c7397"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "d06a6389-cbfe-4528-a1db-eab535351bbd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "a172870a-e101-4cfa-917b-236b526e4a19"}, {"Element": "<span lang=\"EN-GB\">Serious nervous system disorders such as\ntransverse myelitis, multiple sclerosis\u2011like disease, optic neuritis and\nGuillain\u2011Barr\u00e9 syndrome</span>", "ID": "b9c75b20-4449-46e9-ace6-2eeba1462eaa", "Styles": "None", "Classes": "None", "Text": "Serious nervous system disorders such as transverse myelitis, multiple sclerosis\u2011like disease, optic neuritis and Guillain\u2011Barr\u00e9 syndrome", "ParentId": "84c7142d-ee4a-42fe-8426-1057b18c7397"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Inflammation in the eye that may cause changes\nin the vision, including blindness</span></p>", "ID": "ecb65dc1-e2a8-4f70-826f-2ad3a71172a8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "b3ffe737-65d3-4004-aa92-e5a93b3d32d3", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "ecb65dc1-e2a8-4f70-826f-2ad3a71172a8"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "bff25a0c-b645-4c98-aa0f-f30f41363534", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "b3ffe737-65d3-4004-aa92-e5a93b3d32d3"}, {"Element": "<span lang=\"EN-GB\">Inflammation in the eye that may cause changes\nin the vision, including blindness</span>", "ID": "c313defd-d0f3-4d0f-9bb9-5cbe35d73fb7", "Styles": "None", "Classes": "None", "Text": "Inflammation in the eye that may cause changes in the vision, including blindness", "ParentId": "ecb65dc1-e2a8-4f70-826f-2ad3a71172a8"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Fluid in the lining of the heart (pericardial\neffusion)</span></p>", "ID": "474ad699-8540-4942-832e-5bb6a99c1e81", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "546c9900-a48b-44ee-8e6e-8433b2cf13b1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "474ad699-8540-4942-832e-5bb6a99c1e81"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "af806daf-9a20-4544-9d0f-7d9f919b9715", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "546c9900-a48b-44ee-8e6e-8433b2cf13b1"}, {"Element": "<span lang=\"EN-GB\">Fluid in the lining of the heart (pericardial\neffusion)</span>", "ID": "367a517c-1d96-4913-9a5c-c3c585b0cf33", "Styles": "None", "Classes": "None", "Text": "Fluid in the lining of the heart (pericardial effusion)", "ParentId": "474ad699-8540-4942-832e-5bb6a99c1e81"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Serious</span><span lang=\"EN-GB\"> lung problems\n(such as interstitial lung disease)</span></p>", "ID": "e33cda23-b42f-4d25-be21-0b37a4fdf87c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "a50de6b8-3239-44a2-9d06-fa5890eaacae", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e33cda23-b42f-4d25-be21-0b37a4fdf87c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "4d10a45c-40c9-4b73-80aa-3fc5eaf5587e", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "a50de6b8-3239-44a2-9d06-fa5890eaacae"}, {"Element": "<span lang=\"EN-GB\">Serious</span>", "ID": "25082c42-1177-4279-826a-fd5c2c18f9f2", "Styles": "None", "Classes": "None", "Text": "Serious", "ParentId": "e33cda23-b42f-4d25-be21-0b37a4fdf87c"}, {"Element": "<span lang=\"EN-GB\"> lung problems\n(such as interstitial lung disease)</span>", "ID": "3083d078-ceb8-4e3d-a121-f06fc171251b", "Styles": "None", "Classes": "None", "Text": " lung problems (such as interstitial lung disease)", "ParentId": "e33cda23-b42f-4d25-be21-0b37a4fdf87c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Melanoma (a type of skin cancer)</span></p>", "ID": "0dfca12b-b1af-4f73-a2f7-35d2aafff380", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "cc12877f-f2d3-49d3-9a50-79644d0a028f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0dfca12b-b1af-4f73-a2f7-35d2aafff380"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b35e1f3c-eab5-47da-b9e9-ebe111e5eebb", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "cc12877f-f2d3-49d3-9a50-79644d0a028f"}, {"Element": "<span lang=\"EN-GB\">Melanoma (a type of skin cancer)</span>", "ID": "3ad78d52-ff94-43c2-a69b-adc87ea56cc2", "Styles": "None", "Classes": "None", "Text": "Melanoma (a type of skin cancer)", "ParentId": "0dfca12b-b1af-4f73-a2f7-35d2aafff380"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Cervical cancer</span></p>", "ID": "88da9566-67b6-4285-bab4-9304c09df4f1", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "02a56148-9e8a-47e3-8106-bf6031d7998f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "88da9566-67b6-4285-bab4-9304c09df4f1"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "3c269bfd-d7aa-4413-93c4-d598d34c0bcd", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "02a56148-9e8a-47e3-8106-bf6031d7998f"}, {"Element": "<span lang=\"EN-GB\">Cervical cancer</span>", "ID": "42979f28-8d24-468e-a918-74c6ad116a06", "Styles": "None", "Classes": "None", "Text": "Cervical cancer", "ParentId": "88da9566-67b6-4285-bab4-9304c09df4f1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Low blood counts, including a severely decreased\nnumber of white blood cells</span></p>", "ID": "18902dad-6440-4b52-b5e5-5c3c975b9589", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "0a99cd9b-fbce-4364-9429-6f26984dc41a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "18902dad-6440-4b52-b5e5-5c3c975b9589"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ba8936e5-1ea1-40ef-8515-983c0c132918", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "0a99cd9b-fbce-4364-9429-6f26984dc41a"}, {"Element": "<span lang=\"EN-GB\">Low blood counts, including a severely decreased\nnumber of white blood cells</span>", "ID": "6f3a24ae-fb47-4f93-886d-d9052c8cb612", "Styles": "None", "Classes": "None", "Text": "Low blood counts, including a severely decreased number of white blood cells", "ParentId": "18902dad-6440-4b52-b5e5-5c3c975b9589"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Small red or purple spots caused by bleeding under\nthe skin</span></p>", "ID": "570bcdc0-f0b6-473c-9ccf-47d7de243609", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "730d2661-1632-4fd5-a513-0cdcdd5d5f61", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "570bcdc0-f0b6-473c-9ccf-47d7de243609"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "39b7e1e2-20c2-4287-b388-e7d5cc2c8a05", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "730d2661-1632-4fd5-a513-0cdcdd5d5f61"}, {"Element": "<span lang=\"EN-GB\">Small red or purple spots caused by bleeding under\nthe skin</span>", "ID": "def360fd-a7cd-4e25-98cd-9082b1ea4baa", "Styles": "None", "Classes": "None", "Text": "Small red or purple spots caused by bleeding under the skin", "ParentId": "570bcdc0-f0b6-473c-9ccf-47d7de243609"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Abnormal values of a blood protein called\n\u2018complement factor\u2019 which is part of the immune system.</span></p>", "ID": "be42a3bb-6cdd-497d-aca3-680d1058819e", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "dc7d847e-4fe6-486c-b3d8-510a5b135e37", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "be42a3bb-6cdd-497d-aca3-680d1058819e"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "1fe10119-db2b-4263-83a8-6e5847a294d1", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "dc7d847e-4fe6-486c-b3d8-510a5b135e37"}, {"Element": "<span lang=\"EN-GB\">Abnormal values of a blood protein called\n\u2018complement factor\u2019 which is part of the immune system.</span>", "ID": "0b86eafb-69c6-4de4-b29b-7ab40ac39b72", "Styles": "None", "Classes": "None", "Text": "Abnormal values of a blood protein called \u2018complement factor\u2019 which is part of the immune system.", "ParentId": "be42a3bb-6cdd-497d-aca3-680d1058819e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "aeee9050-b51f-401a-be20-c4bed3ac2e4b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d9fefbe8-88f7-458d-afaf-ab2102d99a7e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "aeee9050-b51f-401a-be20-c4bed3ac2e4b"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Not\nknown: frequency cannot be estimated from the available data</span></b></p>", "ID": "1356f11a-055d-4358-b5e7-57ae3d19f74a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Not\nknown: frequency cannot be estimated from the available data</span></b>", "ID": "639abda5-02aa-4942-8e8e-8746ca7ac66c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1356f11a-055d-4358-b5e7-57ae3d19f74a"}, {"Element": "<span lang=\"EN-GB\">Not\nknown: frequency cannot be estimated from the available data</span>", "ID": "b260cda7-0833-4746-8785-dd5b644fcff3", "Styles": "None", "Classes": "None", "Text": "Not known: frequency cannot be estimated from the available data", "ParentId": "639abda5-02aa-4942-8e8e-8746ca7ac66c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Cancer in children and adults</span></p>", "ID": "6b628631-ede8-4470-a140-f2a3d0aaad99", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "94f6be3e-f18f-4548-9cd7-ad114c80f743", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6b628631-ede8-4470-a140-f2a3d0aaad99"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "fea3973d-2ccf-4543-a2d0-017b8df55d92", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "94f6be3e-f18f-4548-9cd7-ad114c80f743"}, {"Element": "<span lang=\"EN-GB\">Cancer in children and adults</span>", "ID": "bbfb68b5-c69e-49e2-8680-030627949579", "Styles": "None", "Classes": "None", "Text": "Cancer in children and adults", "ParentId": "6b628631-ede8-4470-a140-f2a3d0aaad99"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">A rare blood cancer affecting mostly teenage boys\nor young men (hepatosplenic T\u2011cell lymphoma)</span></p>", "ID": "34253d73-c5c6-40e0-907c-60c6d0950314", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "55bc69e3-6ef5-4978-8879-310ef9725ec1", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "34253d73-c5c6-40e0-907c-60c6d0950314"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ca90c407-8a71-4320-8e5b-b065be6a2d00", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "55bc69e3-6ef5-4978-8879-310ef9725ec1"}, {"Element": "<span lang=\"EN-GB\">A rare blood cancer affecting mostly teenage boys\nor young men (hepatosplenic T\u2011cell lymphoma)</span>", "ID": "13f0946c-07c1-4573-bd65-e2948001cae1", "Styles": "None", "Classes": "None", "Text": "A rare blood cancer affecting mostly teenage boys or young men (hepatosplenic T\u2011cell lymphoma)", "ParentId": "34253d73-c5c6-40e0-907c-60c6d0950314"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Liver failure</span></p>", "ID": "d2577750-15f7-4667-8e2b-6a005d22b000", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "217b04a2-1950-41b1-ae8f-e5a5775567c9", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d2577750-15f7-4667-8e2b-6a005d22b000"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "6ab2a0ab-66a7-47b6-ab95-6dcc22aa2a0d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "217b04a2-1950-41b1-ae8f-e5a5775567c9"}, {"Element": "<span lang=\"EN-GB\">Liver failure</span>", "ID": "114eade0-b303-4986-9f74-49227dcc541a", "Styles": "None", "Classes": "None", "Text": "Liver failure", "ParentId": "d2577750-15f7-4667-8e2b-6a005d22b000"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Merkel cell carcinoma (a type of skin cancer)</span></p>", "ID": "0cdaf98c-fb1d-4b15-b994-0e2b0c68b793", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "d9b6e873-730b-4894-a680-e3725918f7ed", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0cdaf98c-fb1d-4b15-b994-0e2b0c68b793"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "b8025571-d033-43fe-8370-d44536d66f00", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "d9b6e873-730b-4894-a680-e3725918f7ed"}, {"Element": "<span lang=\"EN-GB\">Merkel cell carcinoma (a type of skin cancer)</span>", "ID": "c0864b68-18bf-448a-8bbe-ff444ad34470", "Styles": "None", "Classes": "None", "Text": "Merkel cell carcinoma (a type of skin cancer)", "ParentId": "0cdaf98c-fb1d-4b15-b994-0e2b0c68b793"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">Ka</ins></span><span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:10\">posi\u2019s sarcoma, a rare cancer related to\ninfection with human herpes virus 8. Kaposi\u2019s sarcoma most commonly\nappears as purple lesions on the skin.</ins></span></p>", "ID": "6434b043-4a5d-4655-919d-683a644c5fc7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "32196f33-07df-4736-b71c-628f48289b0f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "6434b043-4a5d-4655-919d-683a644c5fc7"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "35d0c367-850a-4bd9-9621-b56a95918e4a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "32196f33-07df-4736-b71c-628f48289b0f"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">Ka</ins></span>", "ID": "adcc4ad1-b381-4682-b2ae-5a507bc2f7f9", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "6434b043-4a5d-4655-919d-683a644c5fc7"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:09\">Ka</ins>", "ID": "0476ccb4-4aa2-4bc4-a8b4-a5ef17fa6554", "Styles": "None", "Classes": "None", "Text": "Ka", "ParentId": "adcc4ad1-b381-4682-b2ae-5a507bc2f7f9"}, {"Element": "<span class=\"msoIns\"><ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:10\">posi\u2019s sarcoma, a rare cancer related to\ninfection with human herpes virus 8. Kaposi\u2019s sarcoma most commonly\nappears as purple lesions on the skin.</ins></span>", "ID": "016dcf2d-37b0-4f9c-9de2-dbf98573e466", "Styles": "None", "Classes": "['msoIns']", "Text": "", "ParentId": "6434b043-4a5d-4655-919d-683a644c5fc7"}, {"Element": "<ins cite=\"mailto:Gates,%20Leslie%20[JRDUS%20Non-J&amp;J]\" datetime=\"2020-08-18T11:10\">posi\u2019s sarcoma, a rare cancer related to\ninfection with human herpes virus 8. Kaposi\u2019s sarcoma most commonly\nappears as purple lesions on the skin.</ins>", "ID": "43bab750-0d13-400f-a5a3-f973a3ed7971", "Styles": "None", "Classes": "None", "Text": "posi\u2019s sarcoma, a rare cancer related to infection with human herpes virus 8. Kaposi\u2019s sarcoma most commonly appears as purple lesions on the skin.", "ParentId": "016dcf2d-37b0-4f9c-9de2-dbf98573e466"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Worsening of a condition called dermatomyositis\n(seen as a skin rash accompanying muscle weakness)</span></p>", "ID": "0635a8b6-2efd-48cd-9b60-de45ac7a6b4a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4c07897b-666a-472b-b3b7-fa7b35297d74", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "0635a8b6-2efd-48cd-9b60-de45ac7a6b4a"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "5dd00c6f-281b-4936-8cbf-cc8739c3be34", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4c07897b-666a-472b-b3b7-fa7b35297d74"}, {"Element": "<span lang=\"EN-GB\">Worsening of a condition called dermatomyositis\n(seen as a skin rash accompanying muscle weakness)</span>", "ID": "5ecd6981-56d4-4a9a-bea5-2e8ad8bec515", "Styles": "None", "Classes": "None", "Text": "Worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness)", "ParentId": "0635a8b6-2efd-48cd-9b60-de45ac7a6b4a"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Heart attack</span></p>", "ID": "7d36a7e8-cc9d-4f37-ae21-6e27cdaf5d81", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "97719b89-b8bf-4f84-adf4-89d49d5c0af4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "7d36a7e8-cc9d-4f37-ae21-6e27cdaf5d81"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "c48ba2bf-81a4-40ba-a7c6-e8c379e8589b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "97719b89-b8bf-4f84-adf4-89d49d5c0af4"}, {"Element": "<span lang=\"EN-GB\">Heart attack</span>", "ID": "d038e5fe-9cd1-49d5-ad53-e21e8f2ca43f", "Styles": "None", "Classes": "None", "Text": "Heart attack", "ParentId": "7d36a7e8-cc9d-4f37-ae21-6e27cdaf5d81"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Stroke</span></p>", "ID": "aeafd4aa-ad6e-45f7-a8f7-f83221d6c471", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4d76d86c-2337-4fdf-af0c-8be35ab02d27", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "aeafd4aa-ad6e-45f7-a8f7-f83221d6c471"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "de2cbe99-c965-4281-b62f-e5f8de26d543", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4d76d86c-2337-4fdf-af0c-8be35ab02d27"}, {"Element": "<span lang=\"EN-GB\">Stroke</span>", "ID": "482f46fd-be21-48e7-97f4-8de8b76b849a", "Styles": "None", "Classes": "None", "Text": "Stroke", "ParentId": "aeafd4aa-ad6e-45f7-a8f7-f83221d6c471"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Temporary loss of sight during or within 2\u00a0hours\nof infusion</span></p>", "ID": "d2340919-7178-4a5e-bad9-c8caf3d8bb70", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "fce97cfe-1ede-42b2-8df9-1c971acdf71e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d2340919-7178-4a5e-bad9-c8caf3d8bb70"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "ca8241ef-6c07-490b-8fcc-66adc9a4b03a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "fce97cfe-1ede-42b2-8df9-1c971acdf71e"}, {"Element": "<span lang=\"EN-GB\">Temporary loss of sight during or within 2\u00a0hours\nof infusion</span>", "ID": "9b0529f9-c653-4905-81be-61dee5a2dc78", "Styles": "None", "Classes": "None", "Text": "Temporary loss of sight during or within 2\u00a0hours of infusion", "ParentId": "d2340919-7178-4a5e-bad9-c8caf3d8bb70"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Infection due to a live vaccine because of a\nweakened immune system.</span></p>", "ID": "d6116028-6ca5-4d22-98bc-3df820600f8c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "863bbbe8-66d6-49d3-9e07-435f7505d4c4", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "d6116028-6ca5-4d22-98bc-3df820600f8c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "99332909-71ca-4c4d-b030-38c5c8082c69", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "863bbbe8-66d6-49d3-9e07-435f7505d4c4"}, {"Element": "<span lang=\"EN-GB\">Infection due to a live vaccine because of a\nweakened immune system.</span>", "ID": "4da09083-e59b-4a0c-b7d6-911efa040d42", "Styles": "None", "Classes": "None", "Text": "Infection due to a live vaccine because of a weakened immune system.", "ParentId": "d6116028-6ca5-4d22-98bc-3df820600f8c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "3a0b730d-b708-4516-af54-027d285b612c", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "c6ee5db1-cfa1-497c-9f47-2bca9249abd5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3a0b730d-b708-4516-af54-027d285b612c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "4d2c909f-248b-4785-b786-682e345baa7b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c6ee5db1-cfa1-497c-9f47-2bca9249abd5"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Additional\nside effects in children and adolescents</span></b></p>", "ID": "5940f79b-3255-40b0-af7b-036403f65dff", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Additional\nside effects in children and adolescents</span></b>", "ID": "08e5f86f-390c-4fa5-9573-292a07c114a2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5940f79b-3255-40b0-af7b-036403f65dff"}, {"Element": "<span lang=\"EN-GB\">Additional\nside effects in children and adolescents</span>", "ID": "6555d15b-6c67-4391-8b99-a6e6aee92253", "Styles": "None", "Classes": "None", "Text": "Additional side effects in children and adolescents", "ParentId": "08e5f86f-390c-4fa5-9573-292a07c114a2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Children who\ntook Remicade for Crohn\u2019s disease showed some differences in side effects\ncompared with adults who took Remicade for Crohn's disease. The side effects\nthat happened more in children were: low red blood cells (anaemia), blood in\nstool, low overall levels of white blood cells (leucopenia), redness or\nblushing (flushing), viral infections, low levels of white blood cells that\nfight infection (neutropenia), bone fracture, bacterial infection and allergic\nreactions of the breathing tract.</span></p>", "ID": "4851aa7d-851f-4705-99b6-ce4d30f00c49", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Children who\ntook Remicade for Crohn\u2019s disease showed some differences in side effects\ncompared with adults who took Remicade for Crohn's disease. The side effects\nthat happened more in children were: low red blood cells (anaemia), blood in\nstool, low overall levels of white blood cells (leucopenia), redness or\nblushing (flushing), viral infections, low levels of white blood cells that\nfight infection (neutropenia), bone fracture, bacterial infection and allergic\nreactions of the breathing tract.</span>", "ID": "e93c4341-271a-4193-9f4f-10d17f8de6f2", "Styles": "None", "Classes": "None", "Text": "Children who took Remicade for Crohn\u2019s disease showed some differences in side effects compared with adults who took Remicade for Crohn's disease. The side effects that happened more in children were: low red blood cells (anaemia), blood in stool, low overall levels of white blood cells (leucopenia), redness or blushing (flushing), viral infections, low levels of white blood cells that fight infection (neutropenia), bone fracture, bacterial infection and allergic reactions of the breathing tract.", "ParentId": "4851aa7d-851f-4705-99b6-ce4d30f00c49"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dee57486-99fc-48ae-bc05-4ff84261a43e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8d1f592c-9bb3-41f6-abdf-cf832480a71a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dee57486-99fc-48ae-bc05-4ff84261a43e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting\nof side effects</span></b></p>", "ID": "0852aa5a-61bc-469b-b5c5-332e4f33cd15", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Reporting\nof side effects</span></b>", "ID": "afb5030a-13c8-41e9-9f16-6274d2abbd4c", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0852aa5a-61bc-469b-b5c5-332e4f33cd15"}, {"Element": "<span lang=\"EN-GB\">Reporting\nof side effects</span>", "ID": "003b2351-0b00-43c9-a96d-fcbc2dd4bf20", "Styles": "None", "Classes": "None", "Text": "Reporting of side effects", "ParentId": "afb5030a-13c8-41e9-9f16-6274d2abbd4c"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">If you get\nany side effects, talk to your doctor, pharmacist or nurse. This includes any\npossible side effects not listed in this leaflet. You can also report side\neffects directly via <span style=\"background:silver\">the national reporting\nsystem listed in <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a></span>. By reporting side effects you can help provide more information\non the safety of this medicine.</span></p>", "ID": "5a77b6d9-eb81-4061-85bc-b1b36cd1da84", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">If you get\nany side effects, talk to your doctor, pharmacist or nurse. This includes any\npossible side effects not listed in this leaflet. You can also report side\neffects directly via <span style=\"background:silver\">the national reporting\nsystem listed in <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a></span>. By reporting side effects you can help provide more information\non the safety of this medicine.</span>", "ID": "b5eba74f-a372-4403-98b1-68a535f99f0a", "Styles": "None", "Classes": "None", "Text": "If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via . By reporting side effects you can help provide more information on the safety of this medicine.", "ParentId": "5a77b6d9-eb81-4061-85bc-b1b36cd1da84"}, {"Element": "<span style=\"background:silver\">the national reporting\nsystem listed in <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a></span>", "ID": "ba897915-af7c-42f8-91ba-90fe360244f1", "Styles": "background:silver", "Classes": "None", "Text": "the national reporting system listed in ", "ParentId": "b5eba74f-a372-4403-98b1-68a535f99f0a"}, {"Element": "<a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">Appendix\nV</a>", "ID": "645388d1-89ff-4870-89c6-6920a94d06de", "Styles": "None", "Classes": "None", "Text": "Appendix V", "ParentId": "ba897915-af7c-42f8-91ba-90fe360244f1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "dfc27afc-591b-48b5-b627-4ecdc4c972f6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b58dbde1-0d6e-479b-a1e8-6eab7cf32d17", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dfc27afc-591b-48b5-b627-4ecdc4c972f6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8aaae8c1-e4ee-4f72-9b95-221e34f519f1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "61e9106c-41c9-47bb-88d6-15dd37f5fd52", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8aaae8c1-e4ee-4f72-9b95-221e34f519f1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><a name=\"_Hlk503423848\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Remicade</span></b></a></p>", "ID": "b5d478e6-4275-4f52-9192-c552bb065803", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<a name=\"_Hlk503423848\"><b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Remicade</span></b></a>", "ID": "66a8f27d-4c93-4130-8df0-10835ea67180", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b5d478e6-4275-4f52-9192-c552bb065803"}, {"Element": "<b><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Remicade</span></b>", "ID": "2535ae8f-423e-480b-aa13-ceead856c302", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "66a8f27d-4c93-4130-8df0-10835ea67180"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How\nto store Remicade</span>", "ID": "840f2ede-4165-4868-bab4-dd37a8025d23", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How to store Remicade", "ParentId": "2535ae8f-423e-480b-aa13-ceead856c302"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "effaba11-4c6c-4df6-97a8-e7bf242570df", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e85ad986-6646-4b00-babb-0a324f0083a6", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "effaba11-4c6c-4df6-97a8-e7bf242570df"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade will generally be stored by the\nhealth professionals. The storage details should you need them are as follows:</span></p>", "ID": "55db0d83-6f0d-45ed-aa71-16211378d124", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade will generally be stored by the\nhealth professionals. The storage details should you need them are as follows:</span>", "ID": "21c121c8-86af-4dab-9f80-6028086c00bb", "Styles": "None", "Classes": "None", "Text": "Remicade will generally be stored by the health professionals. The storage details should you need them are as follows:", "ParentId": "55db0d83-6f0d-45ed-aa71-16211378d124"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Keep this medicine out of the sight and reach of\nchildren.</span></p>", "ID": "684830d4-bb32-4ef5-9925-9588c0563612", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "2b25dc74-5621-410d-a082-5e0aa3a0acea", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "684830d4-bb32-4ef5-9925-9588c0563612"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "38c9ed92-62dd-457d-b2f1-a0640f211922", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "2b25dc74-5621-410d-a082-5e0aa3a0acea"}, {"Element": "<span lang=\"EN-GB\">Keep this medicine out of the sight and reach of\nchildren.</span>", "ID": "874334f7-1296-42d8-b608-26b0ddaee52a", "Styles": "None", "Classes": "None", "Text": "Keep this medicine out of the sight and reach of children.", "ParentId": "684830d4-bb32-4ef5-9925-9588c0563612"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not use this medicine after the expiry date\nwhich is stated on the label and the carton after \u201cEXP\u201d. The expiry\ndate refers to the last day of that month.</span></p>", "ID": "a9981f28-a56d-4278-b7da-eb8185b812f5", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "47ac479b-ff53-43cd-82c1-6191cd0afd1a", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "a9981f28-a56d-4278-b7da-eb8185b812f5"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "1cb26898-e74b-49bf-b456-cf210584bcda", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "47ac479b-ff53-43cd-82c1-6191cd0afd1a"}, {"Element": "<span lang=\"EN-GB\">Do not use this medicine after the expiry date\nwhich is stated on the label and the carton after \u201cEXP\u201d. The expiry\ndate refers to the last day of that month.</span>", "ID": "e76d572b-adc2-4dfe-a9da-12407d361bcc", "Styles": "None", "Classes": "None", "Text": "Do not use this medicine after the expiry date which is stated on the label and the carton after \u201cEXP\u201d. The expiry date refers to the last day of that month.", "ParentId": "a9981f28-a56d-4278-b7da-eb8185b812f5"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Store in a refrigerator (2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:17\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>-<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C).</span></p>", "ID": "82bd45f7-3aec-4445-9c7a-7ec400852946", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "c1422497-a857-4853-84d2-aed4e76d0d01", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "82bd45f7-3aec-4445-9c7a-7ec400852946"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "a6613c96-558c-45ee-9e4d-ffca06b28a51", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "c1422497-a857-4853-84d2-aed4e76d0d01"}, {"Element": "<span lang=\"EN-GB\">Store in a refrigerator (2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:17\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>-<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C).</span>", "ID": "be2ec3d1-587b-4cda-bf81-3804cb7e5e05", "Styles": "None", "Classes": "None", "Text": "Store in a refrigerator (2\u00b0C-8\u00b0C).", "ParentId": "82bd45f7-3aec-4445-9c7a-7ec400852946"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:17\">\u00a0</del></span>", "ID": "9403b054-c48c-4eb2-9590-7fed716e0595", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "be2ec3d1-587b-4cda-bf81-3804cb7e5e05"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:17\">\u00a0</del>", "ID": "61ef3005-42a8-4b6c-8b26-125ab25b31e4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9403b054-c48c-4eb2-9590-7fed716e0595"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>", "ID": "dc03cd3d-c1da-4167-9692-d328306cde63", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "be2ec3d1-587b-4cda-bf81-3804cb7e5e05"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del>", "ID": "dd83ea64-12b8-4e4f-ba0c-b7b0683349e2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "dc03cd3d-c1da-4167-9692-d328306cde63"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>", "ID": "3cd487ee-671a-4a41-acdf-68fd8e98f48b", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "be2ec3d1-587b-4cda-bf81-3804cb7e5e05"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del>", "ID": "8eacb4d1-9109-4b82-90b7-98f0e02fccc1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "3cd487ee-671a-4a41-acdf-68fd8e98f48b"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>", "ID": "b24395da-c853-444d-99fc-08d8d04724b2", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "be2ec3d1-587b-4cda-bf81-3804cb7e5e05"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del>", "ID": "1926c38e-1587-4772-8a4b-6d1605c4494e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b24395da-c853-444d-99fc-08d8d04724b2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">This medicine can also be stored in the original\ncarton outside of refrigerated storage up to a maximum of 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C for a single period of up\nto six months, but not beyond the original expiry date. In this situation, do\nnot return to refrigerated storage again. Write the new expiry date on the\ncarton including day/month/year. Discard this medicine if not used by the new\nexpiry date or the expiry date printed on the carton, whichever is earlier.</span></p>", "ID": "200a3732-cd1b-4595-9b8c-4126264e3da2", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "1efbbcab-7203-4969-925c-0eb3b5eddf5e", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "200a3732-cd1b-4595-9b8c-4126264e3da2"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "97481a8d-3f51-4754-85b6-b032281caa4a", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "1efbbcab-7203-4969-925c-0eb3b5eddf5e"}, {"Element": "<span lang=\"EN-GB\">This medicine can also be stored in the original\ncarton outside of refrigerated storage up to a maximum of 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C for a single period of up\nto six months, but not beyond the original expiry date. In this situation, do\nnot return to refrigerated storage again. Write the new expiry date on the\ncarton including day/month/year. Discard this medicine if not used by the new\nexpiry date or the expiry date printed on the carton, whichever is earlier.</span>", "ID": "0a9a345e-158f-4ee1-a2e7-74665e40cd6c", "Styles": "None", "Classes": "None", "Text": "This medicine can also be stored in the original carton outside of refrigerated storage up to a maximum of 25\u00b0C for a single period of up to six months, but not beyond the original expiry date. In this situation, do not return to refrigerated storage again. Write the new expiry date on the carton including day/month/year. Discard this medicine if not used by the new expiry date or the expiry date printed on the carton, whichever is earlier.", "ParentId": "200a3732-cd1b-4595-9b8c-4126264e3da2"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>", "ID": "923f4b84-0329-4697-8747-d21a1787bcdc", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "0a9a345e-158f-4ee1-a2e7-74665e40cd6c"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del>", "ID": "b0691cb3-99cb-41d6-8c79-9781fb94054e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "923f4b84-0329-4697-8747-d21a1787bcdc"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">It is recommended that when Remicade is prepared\nfor infusion, it is used as soon as possible (within 3\u00a0hours). However, if\nthe solution is prepared in germ\u2011free conditions, it can be stored in a\nrefrigerator at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C to 8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C up to 28\u00a0days and for\nan additional 24\u00a0hours at 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C after removal from the\nrefrigerator.</span></p>", "ID": "04aeaa28-4f86-41a9-915e-3efa9b739f65", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "4beefbe1-3caa-4f96-b03a-aab1b007910f", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "04aeaa28-4f86-41a9-915e-3efa9b739f65"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "2f7d0d87-525b-4819-9b2e-6035a0e9316d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "4beefbe1-3caa-4f96-b03a-aab1b007910f"}, {"Element": "<span lang=\"EN-GB\">It is recommended that when Remicade is prepared\nfor infusion, it is used as soon as possible (within 3\u00a0hours). However, if\nthe solution is prepared in germ\u2011free conditions, it can be stored in a\nrefrigerator at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C to 8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C up to 28\u00a0days and for\nan additional 24\u00a0hours at 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C after removal from the\nrefrigerator.</span>", "ID": "e520d1c4-7681-41a9-a9dc-d2726afa6a74", "Styles": "None", "Classes": "None", "Text": "It is recommended that when Remicade is prepared for infusion, it is used as soon as possible (within 3\u00a0hours). However, if the solution is prepared in germ\u2011free conditions, it can be stored in a refrigerator at 2\u00b0C to 8\u00b0C up to 28\u00a0days and for an additional 24\u00a0hours at 25\u00b0C after removal from the refrigerator.", "ParentId": "04aeaa28-4f86-41a9-915e-3efa9b739f65"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>", "ID": "be3548f1-a451-4b57-888c-f3cede02be14", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "e520d1c4-7681-41a9-a9dc-d2726afa6a74"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del>", "ID": "c0b3aff0-8482-4986-accc-ef1b54eaa48c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "be3548f1-a451-4b57-888c-f3cede02be14"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>", "ID": "63eea6ca-704c-479f-9e41-32c74460a55f", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "e520d1c4-7681-41a9-a9dc-d2726afa6a74"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del>", "ID": "9deeaba7-97b9-43f8-84fe-9a52504d54da", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "63eea6ca-704c-479f-9e41-32c74460a55f"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>", "ID": "11fa1147-ef1c-44d5-b0f2-fd5e67f2daa2", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "e520d1c4-7681-41a9-a9dc-d2726afa6a74"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del>", "ID": "6498a8e7-8594-49e7-9eed-87ac74631971", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "11fa1147-ef1c-44d5-b0f2-fd5e67f2daa2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">Do not use this medicine if it is discoloured or\nif there are particles present.</span></p>", "ID": "e17cf27a-03de-4764-b5bc-7dff374271c0", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "1e0423fd-9f4d-465c-9f0e-43364b114217", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e17cf27a-03de-4764-b5bc-7dff374271c0"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "659474f7-5171-4ffe-995f-433f7cbbbd0b", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "1e0423fd-9f4d-465c-9f0e-43364b114217"}, {"Element": "<span lang=\"EN-GB\">Do not use this medicine if it is discoloured or\nif there are particles present.</span>", "ID": "4c07fc21-e215-4045-9715-ceebb3bcc0ba", "Styles": "None", "Classes": "None", "Text": "Do not use this medicine if it is discoloured or if there are particles present.", "ParentId": "e17cf27a-03de-4764-b5bc-7dff374271c0"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "310276e6-eb70-485b-bfa2-4a3a394f7af2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "0c360f14-a1af-40d2-bc01-b02db1c850ee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "310276e6-eb70-485b-bfa2-4a3a394f7af2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4d780af3-6b6c-4ca0-8b06-d503cf9ffb33", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "64f326d3-f229-4987-a4c3-9a5ed9259cd7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4d780af3-6b6c-4ca0-8b06-d503cf9ffb33"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid\"><b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of\nthe pack and other information</span></b></p>", "ID": "7d803e0f-6401-40ae-9131-04b72195e70b", "Styles": "margin-left:28.35pt;text-indent:-28.35pt;page-break-after:\navoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of\nthe pack and other information</span></b>", "ID": "6825f311-68cd-41ca-90e1-8e9ccc2364bd", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7d803e0f-6401-40ae-9131-04b72195e70b"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of\nthe pack and other information</span>", "ID": "6e69bdcc-1897-4b2e-9023-68c04aa5b63a", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Contents of the pack and other information", "ParentId": "6825f311-68cd-41ca-90e1-8e9ccc2364bd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "12f56dad-7de0-41f9-9234-5ba758e5958e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "746f8abf-d591-4932-a625-37f655a9112b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "12f56dad-7de0-41f9-9234-5ba758e5958e"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nRemicade contains</span></b></p>", "ID": "84c44a21-40ba-42f1-8d60-c116048564a1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">What\nRemicade contains</span></b>", "ID": "91e13fe7-5512-4269-99f1-cdb7d9f20eb1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "84c44a21-40ba-42f1-8d60-c116048564a1"}, {"Element": "<span lang=\"EN-GB\">What\nRemicade contains</span>", "ID": "98b5461c-2d3b-4aca-baf4-a8aacecbb652", "Styles": "None", "Classes": "None", "Text": "What Remicade contains", "ParentId": "91e13fe7-5512-4269-99f1-cdb7d9f20eb1"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The active substance is infliximab. Each vial\ncontains 100\u00a0mg of infliximab. After preparation each ml contains 10\u00a0mg\nof infliximab</span></p>", "ID": "1d494db1-e3f4-4952-bc1b-dfedcbb8c00c", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "e33e0194-1dc4-45de-9d94-8858ce172fe8", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "1d494db1-e3f4-4952-bc1b-dfedcbb8c00c"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "fc2d99ed-70b8-4224-8b24-66159ab6ec88", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "e33e0194-1dc4-45de-9d94-8858ce172fe8"}, {"Element": "<span lang=\"EN-GB\">The active substance is infliximab. Each vial\ncontains 100\u00a0mg of infliximab. After preparation each ml contains 10\u00a0mg\nof infliximab</span>", "ID": "b8980f37-d6a3-4130-b7d5-cb5b339bad13", "Styles": "None", "Classes": "None", "Text": "The active substance is infliximab. Each vial contains 100\u00a0mg of infliximab. After preparation each ml contains 10\u00a0mg of infliximab", "ParentId": "1d494db1-e3f4-4952-bc1b-dfedcbb8c00c"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span><span lang=\"EN-GB\">The other ingredients are sucrose, polysorbate\u00a080,\nmonobasic sodium phosphate and dibasic sodium phosphate.</span></p>", "ID": "e0b8ff19-e84a-483e-997f-2b48ce307a6f", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span></span>", "ID": "486804b6-469a-45c1-8869-bdb43fd25d91", "Styles": "font-family:Symbol", "Classes": "None", "Text": "\u00b7", "ParentId": "e0b8ff19-e84a-483e-997f-2b48ce307a6f"}, {"Element": "<span style='font:7.0pt \"Times New Roman\"'>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n</span>", "ID": "1d74c1e9-82fe-420f-9740-996c20f9e27d", "Styles": "font:7.0pt \"Times New Roman\"", "Classes": "None", "Text": "\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 ", "ParentId": "486804b6-469a-45c1-8869-bdb43fd25d91"}, {"Element": "<span lang=\"EN-GB\">The other ingredients are sucrose, polysorbate\u00a080,\nmonobasic sodium phosphate and dibasic sodium phosphate.</span>", "ID": "7c93fd3a-f3c0-4de9-8d7e-4a180249c4ce", "Styles": "None", "Classes": "None", "Text": "The other ingredients are sucrose, polysorbate\u00a080, monobasic sodium phosphate and dibasic sodium phosphate.", "ParentId": "e0b8ff19-e84a-483e-997f-2b48ce307a6f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c0701835-5c7d-4322-a9ce-6bc53bf591f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b2e713b9-fa30-4564-bc4c-f8f8aa91a907", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c0701835-5c7d-4322-a9ce-6bc53bf591f2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">What\nRemicade looks like and contents of the pack</span></b></p>", "ID": "1c520f37-de02-4788-b00c-fb1c4c43b9ef", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">What\nRemicade looks like and contents of the pack</span></b>", "ID": "b97810d3-07da-41a9-8eea-3a3cd387d561", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1c520f37-de02-4788-b00c-fb1c4c43b9ef"}, {"Element": "<span lang=\"EN-GB\">What\nRemicade looks like and contents of the pack</span>", "ID": "55e93ad6-ff9a-4988-8cc0-e8b33f1f16b4", "Styles": "None", "Classes": "None", "Text": "What Remicade looks like and contents of the pack", "ParentId": "b97810d3-07da-41a9-8eea-3a3cd387d561"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is supplied as a glass vial\ncontaining a powder for concentrate for solution for infusion. The powder is a\nfreeze\u2011dried white pellet.</span></p>", "ID": "7c0e3092-ce44-4c9a-9458-a860a4b775a8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade is supplied as a glass vial\ncontaining a powder for concentrate for solution for infusion. The powder is a\nfreeze\u2011dried white pellet.</span>", "ID": "7f3dfdd5-80c4-4c6b-b238-ace3e311b66c", "Styles": "None", "Classes": "None", "Text": "Remicade is supplied as a glass vial containing a powder for concentrate for solution for infusion. The powder is a freeze\u2011dried white pellet.", "ParentId": "7c0e3092-ce44-4c9a-9458-a860a4b775a8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade is produced in packs of 1, 2, 3, 4\nor 5\u00a0vials. Not all pack sizes may be marketed.</span></p>", "ID": "a5634a7d-82c3-49ce-86b4-e7575f67d32d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade is produced in packs of 1, 2, 3, 4\nor 5\u00a0vials. Not all pack sizes may be marketed.</span>", "ID": "93d04136-5232-40b2-bd3d-1de9e8f3e5f6", "Styles": "None", "Classes": "None", "Text": "Remicade is produced in packs of 1, 2, 3, 4 or 5\u00a0vials. Not all pack sizes may be marketed.", "ParentId": "a5634a7d-82c3-49ce-86b4-e7575f67d32d"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "246a5452-6003-4947-94a5-01d0a9545e53", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "6cbb75d0-a870-4262-871c-dbebb25ef3f0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "246a5452-6003-4947-94a5-01d0a9545e53"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d6262cfe-8658-47c6-9de5-b17193da126f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6cbb75d0-a870-4262-871c-dbebb25ef3f0"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing\nAuthorisation Holder and Manufacturer</span></b></p>", "ID": "b8d0bcf5-41c7-41eb-8d68-474089b81fad", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Marketing\nAuthorisation Holder and Manufacturer</span></b>", "ID": "b3488872-ea8e-4820-a23f-4c9fec097b24", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b8d0bcf5-41c7-41eb-8d68-474089b81fad"}, {"Element": "<span lang=\"EN-GB\">Marketing\nAuthorisation Holder and Manufacturer</span>", "ID": "b13c8f77-8830-4d64-958d-8802586e89c2", "Styles": "None", "Classes": "None", "Text": "Marketing Authorisation Holder and Manufacturer", "ParentId": "b3488872-ea8e-4820-a23f-4c9fec097b24"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Janssen Biologics B.V.</span></p>", "ID": "85a26e0b-6a8d-4534-a624-2eb78b14b2c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Janssen Biologics B.V.</span>", "ID": "4dd534e3-6e59-43a4-88e7-99dbc484dc85", "Styles": "None", "Classes": "None", "Text": "Janssen Biologics B.V.", "ParentId": "85a26e0b-6a8d-4534-a624-2eb78b14b2c3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Einsteinweg\u00a0101</span></p>", "ID": "27a497b7-b35e-4a92-b920-3d89e480f57e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Einsteinweg\u00a0101</span>", "ID": "58325b53-ed9e-4c8b-a61d-8bd2ad3b14d0", "Styles": "None", "Classes": "None", "Text": "Einsteinweg\u00a0101", "ParentId": "27a497b7-b35e-4a92-b920-3d89e480f57e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">2333\u00a0CB\u00a0Leiden</span></p>", "ID": "c32b5f25-03ed-4e45-8270-d6f6787fd2fc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">2333\u00a0CB\u00a0Leiden</span>", "ID": "849e81a7-d013-4c5d-8f21-bc7da219057c", "Styles": "None", "Classes": "None", "Text": "2333\u00a0CB\u00a0Leiden", "ParentId": "c32b5f25-03ed-4e45-8270-d6f6787fd2fc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">The Netherlands</span></p>", "ID": "a965ca93-27d4-4f73-a441-1327d4333667", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">The Netherlands</span>", "ID": "1715dcb3-c904-4f41-ba1e-70f60d322ea9", "Styles": "None", "Classes": "None", "Text": "The Netherlands", "ParentId": "a965ca93-27d4-4f73-a441-1327d4333667"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "8d203a22-7b5e-47dd-b698-4d7cb04164c7", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "478356f6-0b5f-47db-a7b6-07bcc4d2831c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8d203a22-7b5e-47dd-b698-4d7cb04164c7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">For any information about this medicine,\nplease contact the local representative of the Marketing Authorisation Holder:</span></p>", "ID": "8834eeb6-4c81-4f45-a71f-76715c0bfbb5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">For any information about this medicine,\nplease contact the local representative of the Marketing Authorisation Holder:</span>", "ID": "9a0c63eb-3028-4694-8799-803b1e7ebfb8", "Styles": "None", "Classes": "None", "Text": "For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:", "ParentId": "8834eeb6-4c81-4f45-a71f-76715c0bfbb5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "bae54a58-0980-4f28-ade6-90b1c755eb25", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7ce51eea-796a-44ed-a3a4-105c14b556ad", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bae54a58-0980-4f28-ade6-90b1c755eb25"}, {"Element": "<div align=\"center\">\n<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Belgium BVBA/SPRL</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_belux@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">UAB Merck\n  Sharp &amp; Dohme</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel. + 370 5\n  278 02 47</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_lietuva@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u041c\u0435\u0440\u043a\n  \u0428\u0430\u0440\u043f \u0438 \u0414\u043e\u0443\u043c\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0422\u0435\u043b.: +359 2 819 3737</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">info\u2011msdbg@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD Belgium BVBA/SPRL</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_belux@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +420 233 010 111</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Pharma Hungary Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +36\u00a01\u00a0888\u00a05300</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">hungary_msd@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD Danmark ApS</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tlf: + 45 4482 4000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dkmail@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: 8007\n  4433 (+356 99917558)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">malta_info@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD SHARP &amp; DOHME GMBH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: 0800 673 673 673 (+49 (0) 89 4561 2612)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">e\u2011mail@msd.de</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: 0800 9999000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(+31 23 5153153)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinfo.nl@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme O\u00dc</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel.:\n  +372\u00a06144 200</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">msdeesti@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD (Norge) AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +47 32 20 73 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdnorge@msd.no</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD </span><span lang=\"EN-GB\">\u0391.\u03a6.\u0392.\u0395.\u0395.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb</span><span lang=\"EN-GB\">: +30 210 98 97 300</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_greece@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Merck Sharp &amp; Dohme Ges.m.b.H.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +43 (0) 1 26 044</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">msd\u2011medizin@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Merck Sharp &amp; Dohme de Espa\u00f1a,\n  S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 91 321 06 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_info@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Polska Sp. z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 22 549 51 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdpolska@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">MSD France</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l: + 33 (0) 1 80 46 40 40</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"PT-BR\">Merck Sharp\n  &amp; Dohme, Lda</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"PT-BR\">Tel: +351 21\n  4465700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">inform_pt@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 385 1 6611 333</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">croatia_info@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Merck Sharp &amp; Dohme Romania S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 529 29 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdromania@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme Ireland (Human Health)\n  Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: +353\n  (0)1 2998700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medinfo_ireland@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme, inovativna\n  zdravila d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +386 1 5204 201</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd.slovenia@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Vistor hf.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi: + 354 535 7000</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovensk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme, s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +421 2 58282010</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Italia S.r.l.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +39 06 361911</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinformation.it@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">MSD Finland\n  Oy</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Puh/Tel: +358\n  (0)9 804 650</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">info@msd.fi</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb.:\n  800 00 673 (+357 22866700)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">cyprus_info@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Sverige</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"DE\">Merck Sharp\n  &amp; Dohme (Sweden) AB</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: +46 77\n  5700488</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicinskinfo@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">SIA Merck\n  Sharp &amp; Dohme Latvija</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 371 67364224</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_lv@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme Limited</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1992 467272</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinformationuk@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>\n</div>", "ID": "8807a73d-8da4-4322-ad6a-090eba8f94f2", "Styles": "None", "Classes": "None", "Text": "  ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse\" width=\"605\">\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Belgium BVBA/SPRL</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_belux@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">UAB Merck\n  Sharp &amp; Dohme</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel. + 370 5\n  278 02 47</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_lietuva@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u041c\u0435\u0440\u043a\n  \u0428\u0430\u0440\u043f \u0438 \u0414\u043e\u0443\u043c\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0422\u0435\u043b.: +359 2 819 3737</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">info\u2011msdbg@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD Belgium BVBA/SPRL</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_belux@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +420 233 010 111</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Pharma Hungary Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +36\u00a01\u00a0888\u00a05300</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">hungary_msd@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD Danmark ApS</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tlf: + 45 4482 4000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dkmail@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: 8007\n  4433 (+356 99917558)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">malta_info@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD SHARP &amp; DOHME GMBH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: 0800 673 673 673 (+49 (0) 89 4561 2612)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">e\u2011mail@msd.de</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: 0800 9999000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(+31 23 5153153)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinfo.nl@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme O\u00dc</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel.:\n  +372\u00a06144 200</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">msdeesti@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD (Norge) AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +47 32 20 73 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdnorge@msd.no</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD </span><span lang=\"EN-GB\">\u0391.\u03a6.\u0392.\u0395.\u0395.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb</span><span lang=\"EN-GB\">: +30 210 98 97 300</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_greece@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Merck Sharp &amp; Dohme Ges.m.b.H.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +43 (0) 1 26 044</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">msd\u2011medizin@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Merck Sharp &amp; Dohme de Espa\u00f1a,\n  S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 91 321 06 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_info@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Polska Sp. z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 22 549 51 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdpolska@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">MSD France</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l: + 33 (0) 1 80 46 40 40</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"PT-BR\">Merck Sharp\n  &amp; Dohme, Lda</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"PT-BR\">Tel: +351 21\n  4465700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">inform_pt@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 385 1 6611 333</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">croatia_info@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Merck Sharp &amp; Dohme Romania S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 529 29 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdromania@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme Ireland (Human Health)\n  Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: +353\n  (0)1 2998700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medinfo_ireland@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme, inovativna\n  zdravila d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +386 1 5204 201</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd.slovenia@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Vistor hf.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi: + 354 535 7000</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovensk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme, s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +421 2 58282010</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Italia S.r.l.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +39 06 361911</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinformation.it@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">MSD Finland\n  Oy</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Puh/Tel: +358\n  (0)9 804 650</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">info@msd.fi</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb.:\n  800 00 673 (+357 22866700)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">cyprus_info@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Sverige</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"DE\">Merck Sharp\n  &amp; Dohme (Sweden) AB</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: +46 77\n  5700488</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicinskinfo@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>\n<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">SIA Merck\n  Sharp &amp; Dohme Latvija</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 371 67364224</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_lv@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme Limited</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1992 467272</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinformationuk@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>\n</table>", "ID": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71", "Styles": "border-collapse:collapse", "Classes": "['MsoNormalTable']", "Text": "                ", "ParentId": "8807a73d-8da4-4322-ad6a-090eba8f94f2"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Belgium BVBA/SPRL</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_belux@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">UAB Merck\n  Sharp &amp; Dohme</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel. + 370 5\n  278 02 47</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_lietuva@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "47353369-1dd7-4763-a40c-b995850ff8e4", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Belgium BVBA/SPRL</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_belux@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "302b70f8-f718-44e4-8d09-7442340fcfc8", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "47353369-1dd7-4763-a40c-b995850ff8e4"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b></p>", "ID": "3ee6a725-dd83-489f-847c-49779dcf9208", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "302b70f8-f718-44e4-8d09-7442340fcfc8"}, {"Element": "<b><span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span></b>", "ID": "068aea9a-7fae-4d18-b7df-855d71fe13af", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3ee6a725-dd83-489f-847c-49779dcf9208"}, {"Element": "<span lang=\"EN-GB\">Belgi\u00eb/Belgique/Belgien</span>", "ID": "458949e8-b1c7-425d-8089-7df6c9c1b4b1", "Styles": "None", "Classes": "None", "Text": "Belgi\u00eb/Belgique/Belgien", "ParentId": "068aea9a-7fae-4d18-b7df-855d71fe13af"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Belgium BVBA/SPRL</span></p>", "ID": "8b13e092-35ee-44b3-a42a-9c57a8b354c4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "302b70f8-f718-44e4-8d09-7442340fcfc8"}, {"Element": "<span lang=\"EN-GB\">MSD Belgium BVBA/SPRL</span>", "ID": "e2531322-98e3-4096-9d2a-9fe0dba009e6", "Styles": "None", "Classes": "None", "Text": "MSD Belgium BVBA/SPRL", "ParentId": "8b13e092-35ee-44b3-a42a-9c57a8b354c4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span></p>", "ID": "f7252459-52cc-4870-a6e2-de6eda87c61a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "302b70f8-f718-44e4-8d09-7442340fcfc8"}, {"Element": "<span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span>", "ID": "ed853729-4be7-4266-8b32-8aa5a79764c6", "Styles": "None", "Classes": "None", "Text": "T\u00e9l/Tel: +32(0)27766211", "ParentId": "f7252459-52cc-4870-a6e2-de6eda87c61a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_belux@merck.com</span></p>", "ID": "a9382ad5-9ada-4204-9a3f-e4adb131726f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "302b70f8-f718-44e4-8d09-7442340fcfc8"}, {"Element": "<span lang=\"EN-GB\">dpoc_belux@merck.com</span>", "ID": "0cc62768-ce2f-4ac6-9103-2092c6810867", "Styles": "None", "Classes": "None", "Text": "dpoc_belux@merck.com", "ParentId": "a9382ad5-9ada-4204-9a3f-e4adb131726f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a02eb185-b21b-43e6-a45a-9022d38c3431", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "302b70f8-f718-44e4-8d09-7442340fcfc8"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b2b30e57-bfbe-488f-a018-3c3fa174bce7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a02eb185-b21b-43e6-a45a-9022d38c3431"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">UAB Merck\n  Sharp &amp; Dohme</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel. + 370 5\n  278 02 47</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_lietuva@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "dfb48c80-cc33-4f82-bcee-a8a7d5069367", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "47353369-1dd7-4763-a40c-b995850ff8e4"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Lietuva</span></b></p>", "ID": "19803b70-dcb1-41b7-8594-8940dc3df680", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dfb48c80-cc33-4f82-bcee-a8a7d5069367"}, {"Element": "<b><span lang=\"EN-GB\">Lietuva</span></b>", "ID": "86e8dade-94b5-431e-86d2-a0a4d5ef233f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "19803b70-dcb1-41b7-8594-8940dc3df680"}, {"Element": "<span lang=\"EN-GB\">Lietuva</span>", "ID": "a98b3b84-e3a6-47cd-b3aa-fd75c54eadbc", "Styles": "None", "Classes": "None", "Text": "Lietuva", "ParentId": "86e8dade-94b5-431e-86d2-a0a4d5ef233f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">UAB Merck\n  Sharp &amp; Dohme</span></p>", "ID": "0bf18f1f-110c-49be-a05d-e1c47b182fe8", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dfb48c80-cc33-4f82-bcee-a8a7d5069367"}, {"Element": "<span lang=\"EN-GB\">UAB Merck\n  Sharp &amp; Dohme</span>", "ID": "642c10af-ffef-4d74-9759-964f58d9fee3", "Styles": "None", "Classes": "None", "Text": "UAB Merck   Sharp & Dohme", "ParentId": "0bf18f1f-110c-49be-a05d-e1c47b182fe8"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel. + 370 5\n  278 02 47</span></p>", "ID": "b30de724-e94f-4cfb-908e-f2402b67948f", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dfb48c80-cc33-4f82-bcee-a8a7d5069367"}, {"Element": "<span lang=\"EN-GB\">Tel. + 370 5\n  278 02 47</span>", "ID": "f9c862cc-d462-45e1-8122-6f5b15daf09b", "Styles": "None", "Classes": "None", "Text": "Tel. + 370 5   278 02 47", "ParentId": "b30de724-e94f-4cfb-908e-f2402b67948f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_lietuva@merck.com</span></p>", "ID": "c64190fd-aa41-4e10-b3bc-047f45f25db5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dfb48c80-cc33-4f82-bcee-a8a7d5069367"}, {"Element": "<span lang=\"EN-GB\">msd_lietuva@merck.com</span>", "ID": "f8790254-2d31-4d15-8a64-27625c353bb1", "Styles": "None", "Classes": "None", "Text": "msd_lietuva@merck.com", "ParentId": "c64190fd-aa41-4e10-b3bc-047f45f25db5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "af30068a-a28f-49ab-8afe-9e7fe558206c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "dfb48c80-cc33-4f82-bcee-a8a7d5069367"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a6ca72c7-a3ab-4de5-b9ea-d46e01f68736", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "af30068a-a28f-49ab-8afe-9e7fe558206c"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u041c\u0435\u0440\u043a\n  \u0428\u0430\u0440\u043f \u0438 \u0414\u043e\u0443\u043c\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0422\u0435\u043b.: +359 2 819 3737</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">info\u2011msdbg@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD Belgium BVBA/SPRL</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_belux@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "900f1d8b-1b46-45de-bd87-567ae5b0498b", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u041c\u0435\u0440\u043a\n  \u0428\u0430\u0440\u043f \u0438 \u0414\u043e\u0443\u043c\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0422\u0435\u043b.: +359 2 819 3737</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">info\u2011msdbg@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "0d968d0c-c68e-4a3a-9469-f48d23cf9a4a", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "900f1d8b-1b46-45de-bd87-567ae5b0498b"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b></p>", "ID": "8ab4fb69-4b06-4858-bc1a-0d6288bf11ec", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0d968d0c-c68e-4a3a-9469-f48d23cf9a4a"}, {"Element": "<b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span></b>", "ID": "4acaff02-0b57-46fe-a06e-0ab0720d86ff", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "8ab4fb69-4b06-4858-bc1a-0d6288bf11ec"}, {"Element": "<span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f</span>", "ID": "d75a3a04-3ff8-468b-bfe5-f017e5f739d6", "Styles": "None", "Classes": "None", "Text": "\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f", "ParentId": "4acaff02-0b57-46fe-a06e-0ab0720d86ff"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u041c\u0435\u0440\u043a\n  \u0428\u0430\u0440\u043f \u0438 \u0414\u043e\u0443\u043c\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span></p>", "ID": "1d61a667-eca3-4437-982f-c627ddddb862", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0d968d0c-c68e-4a3a-9469-f48d23cf9a4a"}, {"Element": "<span lang=\"EN-GB\">\u041c\u0435\u0440\u043a\n  \u0428\u0430\u0440\u043f \u0438 \u0414\u043e\u0443\u043c\n  \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f\n  \u0415\u041e\u041e\u0414</span>", "ID": "781bf9ff-afc0-4937-b654-08d12bf83921", "Styles": "None", "Classes": "None", "Text": "\u041c\u0435\u0440\u043a   \u0428\u0430\u0440\u043f \u0438 \u0414\u043e\u0443\u043c   \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f   \u0415\u041e\u041e\u0414", "ParentId": "1d61a667-eca3-4437-982f-c627ddddb862"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u0422\u0435\u043b.: +359 2 819 3737</span></p>", "ID": "bd3286c9-39b7-4e0a-ae86-6b845d9f0af4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0d968d0c-c68e-4a3a-9469-f48d23cf9a4a"}, {"Element": "<span lang=\"EN-GB\">\u0422\u0435\u043b.: +359 2 819 3737</span>", "ID": "e4fd2b99-ba9e-4035-9437-a9580dee723b", "Styles": "None", "Classes": "None", "Text": "\u0422\u0435\u043b.: +359 2 819 3737", "ParentId": "bd3286c9-39b7-4e0a-ae86-6b845d9f0af4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">info\u2011msdbg@merck.com</span></p>", "ID": "13e9e1cd-5e08-4e42-99a7-62f753ce34fb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0d968d0c-c68e-4a3a-9469-f48d23cf9a4a"}, {"Element": "<span lang=\"EN-GB\">info\u2011msdbg@merck.com</span>", "ID": "5719a898-4ad6-454a-b8e8-9508ee959d45", "Styles": "None", "Classes": "None", "Text": "info\u2011msdbg@merck.com", "ParentId": "13e9e1cd-5e08-4e42-99a7-62f753ce34fb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6723d3e2-f7fa-4623-9a8a-96f092f64cf2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "0d968d0c-c68e-4a3a-9469-f48d23cf9a4a"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "811f4a12-2ad1-4085-a3de-b9f5844ea8cc", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6723d3e2-f7fa-4623-9a8a-96f092f64cf2"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg/Luxemburg</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD Belgium BVBA/SPRL</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_belux@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "4f42d032-073e-466c-9ebe-5935d5a0041d", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "900f1d8b-1b46-45de-bd87-567ae5b0498b"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE\">Luxembourg/Luxemburg</span></b></p>", "ID": "29a66409-b5e0-4e58-b321-0fedff6c9dd2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4f42d032-073e-466c-9ebe-5935d5a0041d"}, {"Element": "<b><span lang=\"DE\">Luxembourg/Luxemburg</span></b>", "ID": "19741add-16dd-483c-ad68-d23de4574ffa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "29a66409-b5e0-4e58-b321-0fedff6c9dd2"}, {"Element": "<span lang=\"DE\">Luxembourg/Luxemburg</span>", "ID": "5d5a7790-7c45-4b16-90af-686513531845", "Styles": "None", "Classes": "None", "Text": "Luxembourg/Luxemburg", "ParentId": "19741add-16dd-483c-ad68-d23de4574ffa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">MSD Belgium BVBA/SPRL</span></p>", "ID": "278b2a1a-2e1a-43f8-be15-f64e4dd74919", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4f42d032-073e-466c-9ebe-5935d5a0041d"}, {"Element": "<span lang=\"DE\">MSD Belgium BVBA/SPRL</span>", "ID": "df554a22-9246-4e38-97cc-6dbd3a6d6601", "Styles": "None", "Classes": "None", "Text": "MSD Belgium BVBA/SPRL", "ParentId": "278b2a1a-2e1a-43f8-be15-f64e4dd74919"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span></p>", "ID": "b1a7db07-29b8-476d-bd1b-a7fbcf029160", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4f42d032-073e-466c-9ebe-5935d5a0041d"}, {"Element": "<span lang=\"EN-GB\">T\u00e9l/Tel: +32(0)27766211</span>", "ID": "76977784-1844-47f5-ab71-4d9ad967facb", "Styles": "None", "Classes": "None", "Text": "T\u00e9l/Tel: +32(0)27766211", "ParentId": "b1a7db07-29b8-476d-bd1b-a7fbcf029160"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_belux@merck.com</span></p>", "ID": "02d1a40b-1b6c-46be-bbb9-c7b152aa1352", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4f42d032-073e-466c-9ebe-5935d5a0041d"}, {"Element": "<span lang=\"EN-GB\">dpoc_belux@merck.com</span>", "ID": "c319a84e-4eef-478e-8d5c-27b74e75e1ee", "Styles": "None", "Classes": "None", "Text": "dpoc_belux@merck.com", "ParentId": "02d1a40b-1b6c-46be-bbb9-c7b152aa1352"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "d78825a6-8161-47e7-8ee6-de630e286f1a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4f42d032-073e-466c-9ebe-5935d5a0041d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "7a30ff31-8a5e-45cd-8789-2d60f5e91674", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d78825a6-8161-47e7-8ee6-de630e286f1a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +420 233 010 111</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Pharma Hungary Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +36\u00a01\u00a0888\u00a05300</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">hungary_msd@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "935cf682-cb6f-4515-8e69-1b898e0ca77e", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u010cesk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme s.r.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +420 233 010 111</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "b1a4f123-9cde-402a-9573-ee0e4c984cbe", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "935cf682-cb6f-4515-8e69-1b898e0ca77e"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u010cesk\u00e1 republika</span></b></p>", "ID": "2f238078-ee76-48d3-9169-0b035770fcd4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1a4f123-9cde-402a-9573-ee0e4c984cbe"}, {"Element": "<b><span lang=\"EN-GB\">\u010cesk\u00e1 republika</span></b>", "ID": "51d01824-8881-4d23-a6d3-ab7dcdce1265", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2f238078-ee76-48d3-9169-0b035770fcd4"}, {"Element": "<span lang=\"EN-GB\">\u010cesk\u00e1 republika</span>", "ID": "414edc76-e288-461c-a752-31a28d42b3dc", "Styles": "None", "Classes": "None", "Text": "\u010cesk\u00e1 republika", "ParentId": "51d01824-8881-4d23-a6d3-ab7dcdce1265"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme s.r.o.</span></p>", "ID": "3f2d3bdb-22c7-4ac2-987f-dc4709e2b3af", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1a4f123-9cde-402a-9573-ee0e4c984cbe"}, {"Element": "<span lang=\"EN-GB\">Merck Sharp &amp; Dohme s.r.o.</span>", "ID": "3aacaf05-7f74-49e7-a664-2559ce01aad3", "Styles": "None", "Classes": "None", "Text": "Merck Sharp & Dohme s.r.o.", "ParentId": "3f2d3bdb-22c7-4ac2-987f-dc4709e2b3af"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +420 233 010 111</span></p>", "ID": "6ea9f5ad-b47a-4b9b-8184-65f4b77c9e6a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1a4f123-9cde-402a-9573-ee0e4c984cbe"}, {"Element": "<span lang=\"EN-GB\">Tel: +420 233 010 111</span>", "ID": "83d0d757-1efe-41d3-97ec-2c70d4bb9c10", "Styles": "None", "Classes": "None", "Text": "Tel: +420 233 010 111", "ParentId": "6ea9f5ad-b47a-4b9b-8184-65f4b77c9e6a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span></p>", "ID": "1bc4f881-77d8-4627-b298-24a0663f7586", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1a4f123-9cde-402a-9573-ee0e4c984cbe"}, {"Element": "<span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span>", "ID": "d675f9a0-3bfa-4807-bcf8-1b7980042966", "Styles": "None", "Classes": "None", "Text": "dpoc_czechslovak@merck.com", "ParentId": "1bc4f881-77d8-4627-b298-24a0663f7586"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6c4c5c96-bc4b-4851-80fe-7bdb3ac1fcac", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b1a4f123-9cde-402a-9573-ee0e4c984cbe"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "12c80d5a-a914-454e-ae34-07de5f62e04b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6c4c5c96-bc4b-4851-80fe-7bdb3ac1fcac"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Pharma Hungary Kft.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +36\u00a01\u00a0888\u00a05300</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">hungary_msd@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "9403a8ca-0701-4caf-b9bf-69bca769fdc4", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "935cf682-cb6f-4515-8e69-1b898e0ca77e"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b></p>", "ID": "a0c2a43c-cca8-4535-a87f-71940a2315ca", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9403a8ca-0701-4caf-b9bf-69bca769fdc4"}, {"Element": "<b><span lang=\"EN-GB\">Magyarorsz\u00e1g</span></b>", "ID": "9ea59311-6750-41c8-a19a-99c88121ffbe", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a0c2a43c-cca8-4535-a87f-71940a2315ca"}, {"Element": "<span lang=\"EN-GB\">Magyarorsz\u00e1g</span>", "ID": "c2ea4b1e-8a2a-4813-b8af-afe156ebe756", "Styles": "None", "Classes": "None", "Text": "Magyarorsz\u00e1g", "ParentId": "9ea59311-6750-41c8-a19a-99c88121ffbe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Pharma Hungary Kft.</span></p>", "ID": "f1e26070-dc3e-4c37-92d2-4a0cfd1ac450", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9403a8ca-0701-4caf-b9bf-69bca769fdc4"}, {"Element": "<span lang=\"EN-GB\">MSD Pharma Hungary Kft.</span>", "ID": "00a07c65-1747-4938-bc20-546fbcfebb93", "Styles": "None", "Classes": "None", "Text": "MSD Pharma Hungary Kft.", "ParentId": "f1e26070-dc3e-4c37-92d2-4a0cfd1ac450"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel.: +36\u00a01\u00a0888\u00a05300</span></p>", "ID": "98e15b84-0cad-4ada-a970-b85f32954810", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9403a8ca-0701-4caf-b9bf-69bca769fdc4"}, {"Element": "<span lang=\"EN-GB\">Tel.: +36\u00a01\u00a0888\u00a05300</span>", "ID": "5ca8bdbb-144e-45b6-8069-6f22aca3de88", "Styles": "None", "Classes": "None", "Text": "Tel.: +36\u00a01\u00a0888\u00a05300", "ParentId": "98e15b84-0cad-4ada-a970-b85f32954810"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">hungary_msd@merck.com</span></p>", "ID": "1e07634c-c09e-4fc7-8a0f-40dda2d28778", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9403a8ca-0701-4caf-b9bf-69bca769fdc4"}, {"Element": "<span lang=\"EN-GB\">hungary_msd@merck.com</span>", "ID": "7fb8e4f5-4bed-47d0-ad5d-ae82237745c3", "Styles": "None", "Classes": "None", "Text": "hungary_msd@merck.com", "ParentId": "1e07634c-c09e-4fc7-8a0f-40dda2d28778"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "399c08c7-38d0-467f-8ef6-48a54e43c6bf", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9403a8ca-0701-4caf-b9bf-69bca769fdc4"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e4c03cce-20a3-4877-84ae-2f2d80d6d3a2", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "399c08c7-38d0-467f-8ef6-48a54e43c6bf"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD Danmark ApS</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tlf: + 45 4482 4000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dkmail@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: 8007\n  4433 (+356 99917558)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">malta_info@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "7d5ab1de-8f7c-4c37-b7d4-d27c88aa6fcf", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Danmark</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD Danmark ApS</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tlf: + 45 4482 4000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dkmail@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "ff2c76b4-b85b-4df3-b683-dd95db810474", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "7d5ab1de-8f7c-4c37-b7d4-d27c88aa6fcf"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE\">Danmark</span></b></p>", "ID": "6afa150f-81c4-46cd-b4d7-c93e6029c669", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff2c76b4-b85b-4df3-b683-dd95db810474"}, {"Element": "<b><span lang=\"DE\">Danmark</span></b>", "ID": "0969dbb9-c78a-4f24-9ba0-4cb0078d28b4", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6afa150f-81c4-46cd-b4d7-c93e6029c669"}, {"Element": "<span lang=\"DE\">Danmark</span>", "ID": "30140380-8487-41fe-be42-b55587bfe22d", "Styles": "None", "Classes": "None", "Text": "Danmark", "ParentId": "0969dbb9-c78a-4f24-9ba0-4cb0078d28b4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">MSD Danmark ApS</span></p>", "ID": "1431ca4f-f149-4956-8f85-9299af48005b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff2c76b4-b85b-4df3-b683-dd95db810474"}, {"Element": "<span lang=\"DE\">MSD Danmark ApS</span>", "ID": "324c7468-b393-4aec-8a82-d6ad101b21e8", "Styles": "None", "Classes": "None", "Text": "MSD Danmark ApS", "ParentId": "1431ca4f-f149-4956-8f85-9299af48005b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">Tlf: + 45 4482 4000</span></p>", "ID": "4de61209-f61f-4c3c-82ff-af4214f75ff4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff2c76b4-b85b-4df3-b683-dd95db810474"}, {"Element": "<span lang=\"DE\">Tlf: + 45 4482 4000</span>", "ID": "043e3c46-7b80-4769-b80a-2f264fb12741", "Styles": "None", "Classes": "None", "Text": "Tlf: + 45 4482 4000", "ParentId": "4de61209-f61f-4c3c-82ff-af4214f75ff4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">dkmail@merck.com</span></p>", "ID": "3a18cbf1-e49c-4d67-bdd5-7303ff4dbde8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff2c76b4-b85b-4df3-b683-dd95db810474"}, {"Element": "<span lang=\"EN-GB\">dkmail@merck.com</span>", "ID": "8c8df0ca-b0ad-4aad-8b36-11a05600c068", "Styles": "None", "Classes": "None", "Text": "dkmail@merck.com", "ParentId": "3a18cbf1-e49c-4d67-bdd5-7303ff4dbde8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5ac3437f-e897-4034-8325-3c2b52f92b89", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ff2c76b4-b85b-4df3-b683-dd95db810474"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a98f506c-7b50-4b61-9543-c8c73b0fd206", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5ac3437f-e897-4034-8325-3c2b52f92b89"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: 8007\n  4433 (+356 99917558)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">malta_info@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "b838c96b-2331-4579-8c74-4045e1b3682b", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "7d5ab1de-8f7c-4c37-b7d4-d27c88aa6fcf"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Malta</span></b></p>", "ID": "d8ae5e17-bac7-41ba-b9a5-6dc8b600e0f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b838c96b-2331-4579-8c74-4045e1b3682b"}, {"Element": "<b><span lang=\"EN-GB\">Malta</span></b>", "ID": "0a63cbc2-a949-4ca3-ae17-264471df2c58", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d8ae5e17-bac7-41ba-b9a5-6dc8b600e0f2"}, {"Element": "<span lang=\"EN-GB\">Malta</span>", "ID": "a171f6b8-de95-4abc-b2d8-3b3e155f9b62", "Styles": "None", "Classes": "None", "Text": "Malta", "ParentId": "0a63cbc2-a949-4ca3-ae17-264471df2c58"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span></p>", "ID": "199d83be-cf6f-4a96-9e3d-acaacd5bccd5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b838c96b-2331-4579-8c74-4045e1b3682b"}, {"Element": "<span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span>", "ID": "76ab978d-ded3-4aee-986b-bc3c165d94a5", "Styles": "None", "Classes": "None", "Text": "Merck Sharp   & Dohme Cyprus Limited", "ParentId": "199d83be-cf6f-4a96-9e3d-acaacd5bccd5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: 8007\n  4433 (+356 99917558)</span></p>", "ID": "4cf49af6-1235-4df5-baa1-bbc7dc3c31d1", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b838c96b-2331-4579-8c74-4045e1b3682b"}, {"Element": "<span lang=\"EN-GB\">Tel: 8007\n  4433 (+356 99917558)</span>", "ID": "c5f821b5-af08-4811-afa9-ceb5bfb4dda2", "Styles": "None", "Classes": "None", "Text": "Tel: 8007   4433 (+356 99917558)", "ParentId": "4cf49af6-1235-4df5-baa1-bbc7dc3c31d1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">malta_info@merck.com</span></p>", "ID": "a9503426-eee3-47d1-bdf3-8600334b5100", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b838c96b-2331-4579-8c74-4045e1b3682b"}, {"Element": "<span lang=\"EN-GB\">malta_info@merck.com</span>", "ID": "3dfb6786-e9fb-4266-ba8f-a9f6907135d7", "Styles": "None", "Classes": "None", "Text": "malta_info@merck.com", "ParentId": "a9503426-eee3-47d1-bdf3-8600334b5100"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2ca2eb29-a753-4d95-96ec-51382dce118d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b838c96b-2331-4579-8c74-4045e1b3682b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "f79e4a09-a069-440b-9fb9-cfaa11bbd206", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2ca2eb29-a753-4d95-96ec-51382dce118d"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD SHARP &amp; DOHME GMBH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: 0800 673 673 673 (+49 (0) 89 4561 2612)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">e\u2011mail@msd.de</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: 0800 9999000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(+31 23 5153153)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinfo.nl@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "00629fcd-a4d2-48bc-89d4-6957783bedb1", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">MSD SHARP &amp; DOHME GMBH</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: 0800 673 673 673 (+49 (0) 89 4561 2612)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">e\u2011mail@msd.de</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "49ecc537-81d2-4556-895d-aff216e756ac", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "00629fcd-a4d2-48bc-89d4-6957783bedb1"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE\">Deutschland</span></b></p>", "ID": "27ced7d4-18c7-4bd4-a16b-125aac1b933e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "49ecc537-81d2-4556-895d-aff216e756ac"}, {"Element": "<b><span lang=\"DE\">Deutschland</span></b>", "ID": "18899792-fb83-420a-bf7c-7f677bb837f5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "27ced7d4-18c7-4bd4-a16b-125aac1b933e"}, {"Element": "<span lang=\"DE\">Deutschland</span>", "ID": "3f15e107-5d2b-4bc5-b051-e822a0cfe3b6", "Styles": "None", "Classes": "None", "Text": "Deutschland", "ParentId": "18899792-fb83-420a-bf7c-7f677bb837f5"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">MSD SHARP &amp; DOHME GMBH</span></p>", "ID": "331db360-9a8d-47c3-afad-6c25ae7eda8b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "49ecc537-81d2-4556-895d-aff216e756ac"}, {"Element": "<span lang=\"DE\">MSD SHARP &amp; DOHME GMBH</span>", "ID": "9f3b4f94-82fc-4ce9-8d82-8c70dc001fdf", "Styles": "None", "Classes": "None", "Text": "MSD SHARP & DOHME GMBH", "ParentId": "331db360-9a8d-47c3-afad-6c25ae7eda8b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">Tel: 0800 673 673 673 (+49 (0) 89 4561 2612)</span></p>", "ID": "b0c18cbd-2dd8-4011-bcb5-49e1ecac0065", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "49ecc537-81d2-4556-895d-aff216e756ac"}, {"Element": "<span lang=\"DE\">Tel: 0800 673 673 673 (+49 (0) 89 4561 2612)</span>", "ID": "92ee0b69-db54-476f-b339-578d3dc38210", "Styles": "None", "Classes": "None", "Text": "Tel: 0800 673 673 673 (+49 (0) 89 4561 2612)", "ParentId": "b0c18cbd-2dd8-4011-bcb5-49e1ecac0065"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">e\u2011mail@msd.de</span></p>", "ID": "251421f6-ccf9-4db6-94de-9b94c22c2ccd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "49ecc537-81d2-4556-895d-aff216e756ac"}, {"Element": "<span lang=\"EN-GB\">e\u2011mail@msd.de</span>", "ID": "5d5e1ac3-7e62-4766-b4ba-7854ce6a2a7a", "Styles": "None", "Classes": "None", "Text": "e\u2011mail@msd.de", "ParentId": "251421f6-ccf9-4db6-94de-9b94c22c2ccd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e5ca3cf6-eff6-43aa-8568-09548637ed7b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "49ecc537-81d2-4556-895d-aff216e756ac"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "77b58b07-3473-4556-9247-37a294acaf22", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e5ca3cf6-eff6-43aa-8568-09548637ed7b"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Nederland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme B.V.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: 0800 9999000</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">(+31 23 5153153)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinfo.nl@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "ec6c6f8c-aa97-4cf9-a06b-3c881a37ac5b", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "       ", "ParentId": "00629fcd-a4d2-48bc-89d4-6957783bedb1"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Nederland</span></b></p>", "ID": "be6da2e6-8938-415b-afc4-6651ddf1159b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec6c6f8c-aa97-4cf9-a06b-3c881a37ac5b"}, {"Element": "<b><span lang=\"EN-GB\">Nederland</span></b>", "ID": "308b0bcd-f715-4c17-8485-2d370f3af0d7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "be6da2e6-8938-415b-afc4-6651ddf1159b"}, {"Element": "<span lang=\"EN-GB\">Nederland</span>", "ID": "fef4424c-c1fa-4e5a-919e-8dcd99240460", "Styles": "None", "Classes": "None", "Text": "Nederland", "ParentId": "308b0bcd-f715-4c17-8485-2d370f3af0d7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme B.V.</span></p>", "ID": "74dd1459-d167-4784-a4d2-304d920e0b7e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec6c6f8c-aa97-4cf9-a06b-3c881a37ac5b"}, {"Element": "<span lang=\"EN-GB\">Merck Sharp &amp; Dohme B.V.</span>", "ID": "a350b60c-97f1-45f0-a3ed-4d3500e6e7b9", "Styles": "None", "Classes": "None", "Text": "Merck Sharp & Dohme B.V.", "ParentId": "74dd1459-d167-4784-a4d2-304d920e0b7e"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: 0800 9999000</span></p>", "ID": "084e2442-80f6-4acc-b2dd-9f42b616093b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec6c6f8c-aa97-4cf9-a06b-3c881a37ac5b"}, {"Element": "<span lang=\"EN-GB\">Tel: 0800 9999000</span>", "ID": "124cb6ca-3fcc-40dc-a6eb-23ce07fd2cbe", "Styles": "None", "Classes": "None", "Text": "Tel: 0800 9999000", "ParentId": "084e2442-80f6-4acc-b2dd-9f42b616093b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">(+31 23 5153153)</span></p>", "ID": "020f2c88-8002-4f50-8166-e8d5cc1ee4ed", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec6c6f8c-aa97-4cf9-a06b-3c881a37ac5b"}, {"Element": "<span lang=\"EN-GB\">(+31 23 5153153)</span>", "ID": "2308f94b-7121-42fb-bd5c-edb26c4d3892", "Styles": "None", "Classes": "None", "Text": "(+31 23 5153153)", "ParentId": "020f2c88-8002-4f50-8166-e8d5cc1ee4ed"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinfo.nl@merck.com</span></p>", "ID": "e0ac3e0a-f6f1-4d70-a651-d1fefe3f6def", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec6c6f8c-aa97-4cf9-a06b-3c881a37ac5b"}, {"Element": "<span lang=\"EN-GB\">medicalinfo.nl@merck.com</span>", "ID": "1717cf58-7c52-4ba4-ad85-5ddc8269d498", "Styles": "None", "Classes": "None", "Text": "medicalinfo.nl@merck.com", "ParentId": "e0ac3e0a-f6f1-4d70-a651-d1fefe3f6def"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "e39412b0-dc21-495a-941d-04aa0366d525", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "ec6c6f8c-aa97-4cf9-a06b-3c881a37ac5b"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2160432a-d2e3-43fb-a3fa-30cda4fdedcd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "e39412b0-dc21-495a-941d-04aa0366d525"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme O\u00dc</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel.:\n  +372\u00a06144 200</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">msdeesti@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD (Norge) AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +47 32 20 73 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdnorge@msd.no</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "1d179531-907e-432f-b1a1-adaf802aa5f8", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Eesti</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme O\u00dc</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel.:\n  +372\u00a06144 200</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">msdeesti@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "3ef163c2-6656-4427-b95c-50a049147f8f", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "1d179531-907e-432f-b1a1-adaf802aa5f8"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Eesti</span></b></p>", "ID": "7dda7c9b-2c01-46c3-80d5-3ecac775e87f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ef163c2-6656-4427-b95c-50a049147f8f"}, {"Element": "<b><span lang=\"EN-GB\">Eesti</span></b>", "ID": "49645e56-09c3-420b-893e-2eba66bd472d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7dda7c9b-2c01-46c3-80d5-3ecac775e87f"}, {"Element": "<span lang=\"EN-GB\">Eesti</span>", "ID": "ae3e2a85-f377-42c3-883c-c19e528721a5", "Styles": "None", "Classes": "None", "Text": "Eesti", "ParentId": "49645e56-09c3-420b-893e-2eba66bd472d"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme O\u00dc</span></p>", "ID": "21c2bb7c-c036-4f0d-8902-fce709015a70", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ef163c2-6656-4427-b95c-50a049147f8f"}, {"Element": "<span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme O\u00dc</span>", "ID": "e6191006-3f55-4acd-b2f5-3a6189d21d2b", "Styles": "None", "Classes": "None", "Text": "Merck Sharp   & Dohme O\u00dc", "ParentId": "21c2bb7c-c036-4f0d-8902-fce709015a70"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel.:\n  +372\u00a06144 200</span></p>", "ID": "d5a50d65-e907-4360-99fb-e0be5c6d824e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ef163c2-6656-4427-b95c-50a049147f8f"}, {"Element": "<span lang=\"EN-GB\">Tel.:\n  +372\u00a06144 200</span>", "ID": "1cf4d655-eee8-4336-8495-4a18a1a8d3ac", "Styles": "None", "Classes": "None", "Text": "Tel.:   +372\u00a06144 200", "ParentId": "d5a50d65-e907-4360-99fb-e0be5c6d824e"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">msdeesti@merck.com</span></p>", "ID": "cbbdd4b8-6919-4986-8b50-4817b46f92c4", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ef163c2-6656-4427-b95c-50a049147f8f"}, {"Element": "<span lang=\"EN-GB\">msdeesti@merck.com</span>", "ID": "a1288e30-153f-4d1e-b320-0a8108c54e6b", "Styles": "None", "Classes": "None", "Text": "msdeesti@merck.com", "ParentId": "cbbdd4b8-6919-4986-8b50-4817b46f92c4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c23ea0d0-947c-410a-9c1c-63b9c055f849", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "3ef163c2-6656-4427-b95c-50a049147f8f"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b4242812-9759-45de-830b-cdd8e44c7589", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c23ea0d0-947c-410a-9c1c-63b9c055f849"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Norge</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD (Norge) AS</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +47 32 20 73 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdnorge@msd.no</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "a8407212-0d1b-4cf3-8ea0-9c568f286c09", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "1d179531-907e-432f-b1a1-adaf802aa5f8"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Norge</span></b></p>", "ID": "4f052ac1-267f-48dc-bc8f-c3b091ef977c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a8407212-0d1b-4cf3-8ea0-9c568f286c09"}, {"Element": "<b><span lang=\"EN-GB\">Norge</span></b>", "ID": "8784e703-a651-4e83-a597-60df9491dfc7", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "4f052ac1-267f-48dc-bc8f-c3b091ef977c"}, {"Element": "<span lang=\"EN-GB\">Norge</span>", "ID": "e0d49d97-444b-40d8-bbc7-9bcab98f288f", "Styles": "None", "Classes": "None", "Text": "Norge", "ParentId": "8784e703-a651-4e83-a597-60df9491dfc7"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD (Norge) AS</span></p>", "ID": "ace940a8-f8d0-416f-b5ed-9a032d2c0b15", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a8407212-0d1b-4cf3-8ea0-9c568f286c09"}, {"Element": "<span lang=\"EN-GB\">MSD (Norge) AS</span>", "ID": "bd2e7903-ddd6-4239-8eb8-487c3959b8f9", "Styles": "None", "Classes": "None", "Text": "MSD (Norge) AS", "ParentId": "ace940a8-f8d0-416f-b5ed-9a032d2c0b15"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tlf: +47 32 20 73 00</span></p>", "ID": "76898fef-2417-432a-98e7-06ed3d242f6f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a8407212-0d1b-4cf3-8ea0-9c568f286c09"}, {"Element": "<span lang=\"EN-GB\">Tlf: +47 32 20 73 00</span>", "ID": "20a312a2-aa62-4c2d-ab26-e865cc9176f3", "Styles": "None", "Classes": "None", "Text": "Tlf: +47 32 20 73 00", "ParentId": "76898fef-2417-432a-98e7-06ed3d242f6f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdnorge@msd.no</span></p>", "ID": "dabb2e27-e255-4980-b4c0-e3215a086e7c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a8407212-0d1b-4cf3-8ea0-9c568f286c09"}, {"Element": "<span lang=\"EN-GB\">msdnorge@msd.no</span>", "ID": "95f0f038-ae20-490b-a815-c015d0228e36", "Styles": "None", "Classes": "None", "Text": "msdnorge@msd.no", "ParentId": "dabb2e27-e255-4980-b4c0-e3215a086e7c"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "87882751-26b1-4685-b832-62c2010178e0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "a8407212-0d1b-4cf3-8ea0-9c568f286c09"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "81799330-0816-4f6a-85f4-b56c0ee37146", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "87882751-26b1-4685-b832-62c2010178e0"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD </span><span lang=\"EN-GB\">\u0391.\u03a6.\u0392.\u0395.\u0395.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb</span><span lang=\"EN-GB\">: +30 210 98 97 300</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_greece@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Merck Sharp &amp; Dohme Ges.m.b.H.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +43 (0) 1 26 044</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">msd\u2011medizin@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>\n</tr>", "ID": "b4deb37d-b471-4c69-9db0-ce676d9278c3", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD </span><span lang=\"EN-GB\">\u0391.\u03a6.\u0392.\u0395.\u0395.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb</span><span lang=\"EN-GB\">: +30 210 98 97 300</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_greece@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "7e9f0df5-74f7-463d-9a3a-a2803947fef5", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "b4deb37d-b471-4c69-9db0-ce676d9278c3"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b></p>", "ID": "0e3f6650-dc01-46bd-8297-d4e74a2c41c1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e9f0df5-74f7-463d-9a3a-a2803947fef5"}, {"Element": "<b><span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span></b>", "ID": "ffbb252a-f4e8-42e8-9e23-62825b73198b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0e3f6650-dc01-46bd-8297-d4e74a2c41c1"}, {"Element": "<span lang=\"EN-GB\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1</span>", "ID": "546455ce-15ec-4e8d-b857-ce12c612068f", "Styles": "None", "Classes": "None", "Text": "\u0395\u03bb\u03bb\u03ac\u03b4\u03b1", "ParentId": "ffbb252a-f4e8-42e8-9e23-62825b73198b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD </span><span lang=\"EN-GB\">\u0391.\u03a6.\u0392.\u0395.\u0395.</span></p>", "ID": "7e186b5a-68d2-4af0-9876-d73f8371cc9d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e9f0df5-74f7-463d-9a3a-a2803947fef5"}, {"Element": "<span lang=\"EN-GB\">MSD </span>", "ID": "c2a934ea-bf7d-4613-879e-7a5944fa654b", "Styles": "None", "Classes": "None", "Text": "MSD ", "ParentId": "7e186b5a-68d2-4af0-9876-d73f8371cc9d"}, {"Element": "<span lang=\"EN-GB\">\u0391.\u03a6.\u0392.\u0395.\u0395.</span>", "ID": "452d469c-9003-414a-a854-7154bc4cbf91", "Styles": "None", "Classes": "None", "Text": "\u0391.\u03a6.\u0392.\u0395.\u0395.", "ParentId": "7e186b5a-68d2-4af0-9876-d73f8371cc9d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb</span><span lang=\"EN-GB\">: +30 210 98 97 300</span></p>", "ID": "ac95ce5c-6538-4fe9-bd4d-cac3660a0213", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e9f0df5-74f7-463d-9a3a-a2803947fef5"}, {"Element": "<span lang=\"EN-GB\">\u03a4\u03b7\u03bb</span>", "ID": "c7796b22-a347-425c-ad74-88f2d23b3a58", "Styles": "None", "Classes": "None", "Text": "\u03a4\u03b7\u03bb", "ParentId": "ac95ce5c-6538-4fe9-bd4d-cac3660a0213"}, {"Element": "<span lang=\"EN-GB\">: +30 210 98 97 300</span>", "ID": "0e6efdb8-df95-4955-9315-38ba9c4d8ca7", "Styles": "None", "Classes": "None", "Text": ": +30 210 98 97 300", "ParentId": "ac95ce5c-6538-4fe9-bd4d-cac3660a0213"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_greece@merck.com</span></p>", "ID": "91f1e104-5ebf-4ccb-b04d-cb866f63a4fe", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e9f0df5-74f7-463d-9a3a-a2803947fef5"}, {"Element": "<span lang=\"EN-GB\">dpoc_greece@merck.com</span>", "ID": "fcd0c9b1-ab52-43ba-bde7-37beab9bbbda", "Styles": "None", "Classes": "None", "Text": "dpoc_greece@merck.com", "ParentId": "91f1e104-5ebf-4ccb-b04d-cb866f63a4fe"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "c93a8e60-df18-4b02-aeef-a75fb0abddab", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "7e9f0df5-74f7-463d-9a3a-a2803947fef5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "a6b25736-c5aa-41d2-86c3-eebde5499bef", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "c93a8e60-df18-4b02-aeef-a75fb0abddab"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00d6sterreich</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Merck Sharp &amp; Dohme Ges.m.b.H.</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +43 (0) 1 26 044</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">msd\u2011medizin@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>\n</td>", "ID": "71444ffa-ed69-4557-986d-10e2e5c636d4", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "b4deb37d-b471-4c69-9db0-ce676d9278c3"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE\">\u00d6sterreich</span></b></p>", "ID": "6ed6a173-ced8-4f45-94da-7324ea352cbc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "71444ffa-ed69-4557-986d-10e2e5c636d4"}, {"Element": "<b><span lang=\"DE\">\u00d6sterreich</span></b>", "ID": "914a6a05-2877-4bb8-ae99-6366e1be7311", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "6ed6a173-ced8-4f45-94da-7324ea352cbc"}, {"Element": "<span lang=\"DE\">\u00d6sterreich</span>", "ID": "b25c22c1-a035-4a09-b9a4-0f7dd5067fe7", "Styles": "None", "Classes": "None", "Text": "\u00d6sterreich", "ParentId": "914a6a05-2877-4bb8-ae99-6366e1be7311"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">Merck Sharp &amp; Dohme Ges.m.b.H.</span></p>", "ID": "1204ab48-1fc2-4f5c-b176-5451c2ae50b8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "71444ffa-ed69-4557-986d-10e2e5c636d4"}, {"Element": "<span lang=\"DE\">Merck Sharp &amp; Dohme Ges.m.b.H.</span>", "ID": "87fe996e-2356-4307-97fa-93b7bc1ed69b", "Styles": "None", "Classes": "None", "Text": "Merck Sharp & Dohme Ges.m.b.H.", "ParentId": "1204ab48-1fc2-4f5c-b176-5451c2ae50b8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">Tel: +43 (0) 1 26 044</span></p>", "ID": "7c425e9b-204f-434f-9c9c-6a09ec96dd3f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "71444ffa-ed69-4557-986d-10e2e5c636d4"}, {"Element": "<span lang=\"DE\">Tel: +43 (0) 1 26 044</span>", "ID": "abde7005-a06f-4a93-848f-b3a58a7de8ff", "Styles": "None", "Classes": "None", "Text": "Tel: +43 (0) 1 26 044", "ParentId": "7c425e9b-204f-434f-9c9c-6a09ec96dd3f"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">msd\u2011medizin@merck.com</span></p>", "ID": "363a5f3e-d440-40d6-9f2d-70862e48b9c6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "71444ffa-ed69-4557-986d-10e2e5c636d4"}, {"Element": "<span lang=\"DE\">msd\u2011medizin@merck.com</span>", "ID": "864f5006-2837-4aca-b521-5e7a116f15cd", "Styles": "None", "Classes": "None", "Text": "msd\u2011medizin@merck.com", "ParentId": "363a5f3e-d440-40d6-9f2d-70862e48b9c6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"DE\">\u00a0</span></p>", "ID": "8daf4c1c-97ec-455d-8d11-48854e07c845", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "71444ffa-ed69-4557-986d-10e2e5c636d4"}, {"Element": "<span lang=\"DE\">\u00a0</span>", "ID": "027205ab-c787-48d4-bc2a-b7e074124a2d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8daf4c1c-97ec-455d-8d11-48854e07c845"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Merck Sharp &amp; Dohme de Espa\u00f1a,\n  S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 91 321 06 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_info@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Polska Sp. z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 22 549 51 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdpolska@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "ee02c069-b554-41d2-ad27-4925183c40f8", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"ES\">Merck Sharp &amp; Dohme de Espa\u00f1a,\n  S.A.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 91 321 06 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_info@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "d6831304-0cbd-4997-b633-de20e345d6ab", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "ee02c069-b554-41d2-ad27-4925183c40f8"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a</span></b></p>", "ID": "ba24ec1b-c0af-4413-ba32-1ce9d1316ae0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d6831304-0cbd-4997-b633-de20e345d6ab"}, {"Element": "<b><span lang=\"ES\">Espa\u00f1a</span></b>", "ID": "9caeefb6-0111-432d-b90f-746fb156b922", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ba24ec1b-c0af-4413-ba32-1ce9d1316ae0"}, {"Element": "<span lang=\"ES\">Espa\u00f1a</span>", "ID": "9b985248-68fc-4836-a7a9-b670a4840aa9", "Styles": "None", "Classes": "None", "Text": "Espa\u00f1a", "ParentId": "9caeefb6-0111-432d-b90f-746fb156b922"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"ES\">Merck Sharp &amp; Dohme de Espa\u00f1a,\n  S.A.</span></p>", "ID": "c70229f8-68cc-44ee-ade6-3510fb1e0730", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d6831304-0cbd-4997-b633-de20e345d6ab"}, {"Element": "<span lang=\"ES\">Merck Sharp &amp; Dohme de Espa\u00f1a,\n  S.A.</span>", "ID": "e1b4af8e-a235-4db2-ab4f-c2c2dff2f056", "Styles": "None", "Classes": "None", "Text": "Merck Sharp & Dohme de Espa\u00f1a,   S.A.", "ParentId": "c70229f8-68cc-44ee-ade6-3510fb1e0730"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +34 91 321 06 00</span></p>", "ID": "56fcd106-7600-434b-a95e-c42d4a888c78", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d6831304-0cbd-4997-b633-de20e345d6ab"}, {"Element": "<span lang=\"EN-GB\">Tel: +34 91 321 06 00</span>", "ID": "8b1f2d5e-74f6-4eab-b0f2-beba94b9a3d3", "Styles": "None", "Classes": "None", "Text": "Tel: +34 91 321 06 00", "ParentId": "56fcd106-7600-434b-a95e-c42d4a888c78"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_info@merck.com</span></p>", "ID": "e93118bd-3460-4e9d-8d00-572a7ae143bb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d6831304-0cbd-4997-b633-de20e345d6ab"}, {"Element": "<span lang=\"EN-GB\">msd_info@merck.com</span>", "ID": "6b1b00e9-ad84-47a3-ac19-dc318bb52efe", "Styles": "None", "Classes": "None", "Text": "msd_info@merck.com", "ParentId": "e93118bd-3460-4e9d-8d00-572a7ae143bb"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "46c479d5-4f80-41ed-b2b6-b02cf490ab3d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "d6831304-0cbd-4997-b633-de20e345d6ab"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9c7ff325-de1f-4b8a-b733-a3d5ff46d30f", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "46c479d5-4f80-41ed-b2b6-b02cf490ab3d"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Polska Sp. z o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 22 549 51 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdpolska@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "c8a7d310-ca76-4989-ad11-8bee00f6608c", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "ee02c069-b554-41d2-ad27-4925183c40f8"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Polska</span></b></p>", "ID": "f3a819d4-b3d4-48ec-874b-1fa95f9eac9d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c8a7d310-ca76-4989-ad11-8bee00f6608c"}, {"Element": "<b><span lang=\"EN-GB\">Polska</span></b>", "ID": "4125fd19-321f-4373-865c-144eeecb2667", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f3a819d4-b3d4-48ec-874b-1fa95f9eac9d"}, {"Element": "<span lang=\"EN-GB\">Polska</span>", "ID": "ac27dcd7-8fd9-4648-898a-a47848258871", "Styles": "None", "Classes": "None", "Text": "Polska", "ParentId": "4125fd19-321f-4373-865c-144eeecb2667"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Polska Sp. z o.o.</span></p>", "ID": "a95b6fe0-b6f7-4470-8b77-9ca3431cd076", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c8a7d310-ca76-4989-ad11-8bee00f6608c"}, {"Element": "<span lang=\"EN-GB\">MSD Polska Sp. z o.o.</span>", "ID": "8d926a5e-b619-4023-a306-6a7719d5ec5a", "Styles": "None", "Classes": "None", "Text": "MSD Polska Sp. z o.o.", "ParentId": "a95b6fe0-b6f7-4470-8b77-9ca3431cd076"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +48 22 549 51 00</span></p>", "ID": "e2256f38-1bd6-436c-aa2b-17252a222ccc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c8a7d310-ca76-4989-ad11-8bee00f6608c"}, {"Element": "<span lang=\"EN-GB\">Tel: +48 22 549 51 00</span>", "ID": "12b85da6-9fc7-4313-b868-deb21bd23efa", "Styles": "None", "Classes": "None", "Text": "Tel: +48 22 549 51 00", "ParentId": "e2256f38-1bd6-436c-aa2b-17252a222ccc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdpolska@merck.com</span></p>", "ID": "eb3e637f-3e92-4d69-bfa2-9c01c2555959", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c8a7d310-ca76-4989-ad11-8bee00f6608c"}, {"Element": "<span lang=\"EN-GB\">msdpolska@merck.com</span>", "ID": "c1b32a57-6289-48bd-9c7d-220f797fafdc", "Styles": "None", "Classes": "None", "Text": "msdpolska@merck.com", "ParentId": "eb3e637f-3e92-4d69-bfa2-9c01c2555959"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "283ae80c-2b0a-405e-940d-3aec8f88021a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "c8a7d310-ca76-4989-ad11-8bee00f6608c"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9ccca80b-4580-48f8-8b60-fe474956a995", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "283ae80c-2b0a-405e-940d-3aec8f88021a"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">MSD France</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l: + 33 (0) 1 80 46 40 40</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"PT-BR\">Merck Sharp\n  &amp; Dohme, Lda</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"PT-BR\">Tel: +351 21\n  4465700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">inform_pt@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "d5653d25-bd83-416b-884d-9e48dc50f9ae", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">France</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">MSD France</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l: + 33 (0) 1 80 46 40 40</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "5a038bb3-5bf1-4300-8aa3-8c30bebee0d7", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "d5653d25-bd83-416b-884d-9e48dc50f9ae"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "dcb216f6-8eb5-4e69-99f4-131198ed7c68", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "5a038bb3-5bf1-4300-8aa3-8c30bebee0d7"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "3b667d01-7af3-4c24-b848-96bcbb584519", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "dcb216f6-8eb5-4e69-99f4-131198ed7c68"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">France</span></b></p>", "ID": "38e8bebf-041d-4ff8-a952-7b465db864b6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5a038bb3-5bf1-4300-8aa3-8c30bebee0d7"}, {"Element": "<b><span lang=\"EN-GB\">France</span></b>", "ID": "266d409b-ed72-4aad-8e29-be47ec0ba5e2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "38e8bebf-041d-4ff8-a952-7b465db864b6"}, {"Element": "<span lang=\"EN-GB\">France</span>", "ID": "811525ca-eed1-4bfc-a533-2a5f7f97281e", "Styles": "None", "Classes": "None", "Text": "France", "ParentId": "266d409b-ed72-4aad-8e29-be47ec0ba5e2"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">MSD France</span></p>", "ID": "083c258e-d305-44ca-b8e5-2ebbf98d29fa", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5a038bb3-5bf1-4300-8aa3-8c30bebee0d7"}, {"Element": "<span lang=\"EN-GB\">MSD France</span>", "ID": "1f89e8b9-3011-428e-9e56-469f81a3e61e", "Styles": "None", "Classes": "None", "Text": "MSD France", "ParentId": "083c258e-d305-44ca-b8e5-2ebbf98d29fa"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">T\u00e9l: + 33 (0) 1 80 46 40 40</span></p>", "ID": "256d28b7-4579-4dd4-83e1-e8681d2be72f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5a038bb3-5bf1-4300-8aa3-8c30bebee0d7"}, {"Element": "<span lang=\"EN-GB\">T\u00e9l: + 33 (0) 1 80 46 40 40</span>", "ID": "c923893f-0264-4f32-9994-dcae3fe13c4a", "Styles": "None", "Classes": "None", "Text": "T\u00e9l: + 33 (0) 1 80 46 40 40", "ParentId": "256d28b7-4579-4dd4-83e1-e8681d2be72f"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "552d267e-9b6f-4e0c-b279-a405d107379d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "5a038bb3-5bf1-4300-8aa3-8c30bebee0d7"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "bffdea0a-774c-47fd-9a92-3575d3b60a0f", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "552d267e-9b6f-4e0c-b279-a405d107379d"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bac2300f-bbc8-4026-929d-11be7235383e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "bffdea0a-774c-47fd-9a92-3575d3b60a0f"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"PT-BR\">Merck Sharp\n  &amp; Dohme, Lda</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"PT-BR\">Tel: +351 21\n  4465700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">inform_pt@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "fb90a895-619e-4378-895d-b43bddabf1e9", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "d5653d25-bd83-416b-884d-9e48dc50f9ae"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"PT-BR\">Portugal</span></b></p>", "ID": "2729dfd4-63ef-4a27-8a18-438f2da2efc4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fb90a895-619e-4378-895d-b43bddabf1e9"}, {"Element": "<b><span lang=\"PT-BR\">Portugal</span></b>", "ID": "fb3752f9-8108-4264-8524-cb5a5b552c73", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "2729dfd4-63ef-4a27-8a18-438f2da2efc4"}, {"Element": "<span lang=\"PT-BR\">Portugal</span>", "ID": "a6de13da-9b3f-4eb5-ab53-08976befa083", "Styles": "None", "Classes": "None", "Text": "Portugal", "ParentId": "fb3752f9-8108-4264-8524-cb5a5b552c73"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"PT-BR\">Merck Sharp\n  &amp; Dohme, Lda</span></p>", "ID": "8408826a-5c1b-4c89-8c05-3fe22ead54ce", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fb90a895-619e-4378-895d-b43bddabf1e9"}, {"Element": "<span lang=\"PT-BR\">Merck Sharp\n  &amp; Dohme, Lda</span>", "ID": "e98a025a-5a3f-4d27-9cdf-fdf0b356be58", "Styles": "None", "Classes": "None", "Text": "Merck Sharp   & Dohme, Lda", "ParentId": "8408826a-5c1b-4c89-8c05-3fe22ead54ce"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"PT-BR\">Tel: +351 21\n  4465700</span></p>", "ID": "e7fd7760-afce-4627-a4dd-d53b73308846", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fb90a895-619e-4378-895d-b43bddabf1e9"}, {"Element": "<span lang=\"PT-BR\">Tel: +351 21\n  4465700</span>", "ID": "0cab571b-d6a7-4473-b71f-ac873ada917a", "Styles": "None", "Classes": "None", "Text": "Tel: +351 21   4465700", "ParentId": "e7fd7760-afce-4627-a4dd-d53b73308846"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">inform_pt@merck.com</span></p>", "ID": "99c7cf63-6d4e-41a7-9a4c-86feae4ab931", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fb90a895-619e-4378-895d-b43bddabf1e9"}, {"Element": "<span lang=\"EN-GB\">inform_pt@merck.com</span>", "ID": "a5ac6c01-b1eb-42ea-ad89-ea83efb16d5f", "Styles": "None", "Classes": "None", "Text": "inform_pt@merck.com", "ParentId": "99c7cf63-6d4e-41a7-9a4c-86feae4ab931"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "1bc76cbc-7914-4eed-87dc-9c62b6055e1e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "fb90a895-619e-4378-895d-b43bddabf1e9"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "cf9ff999-d68f-4084-a5ba-b7a41314c88a", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "1bc76cbc-7914-4eed-87dc-9c62b6055e1e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 385 1 6611 333</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">croatia_info@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Merck Sharp &amp; Dohme Romania S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 529 29 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdromania@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "64df3da8-dfbf-4760-9bba-d988d274025a", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 385 1 6611 333</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">croatia_info@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "bdfbdc18-c8b1-4128-8da8-0ed84182deca", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "64df3da8-dfbf-4760-9bba-d988d274025a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Hrvatska</span></b></p>", "ID": "e29ad509-7bb8-4f08-8a26-de5dd1dab645", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdfbdc18-c8b1-4128-8da8-0ed84182deca"}, {"Element": "<b><span lang=\"EN-GB\">Hrvatska</span></b>", "ID": "999a1e95-5dff-467c-9af2-a3de8c76ce99", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "e29ad509-7bb8-4f08-8a26-de5dd1dab645"}, {"Element": "<span lang=\"EN-GB\">Hrvatska</span>", "ID": "21e31abc-db9c-4995-bcff-4454d4967dec", "Styles": "None", "Classes": "None", "Text": "Hrvatska", "ParentId": "999a1e95-5dff-467c-9af2-a3de8c76ce99"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme d.o.o.</span></p>", "ID": "007ef897-71e9-46d2-a3dc-ab6433cbc9c2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdfbdc18-c8b1-4128-8da8-0ed84182deca"}, {"Element": "<span lang=\"EN-GB\">Merck Sharp &amp; Dohme d.o.o.</span>", "ID": "56c98ea0-1ba4-4540-a1f8-e860473f3319", "Styles": "None", "Classes": "None", "Text": "Merck Sharp & Dohme d.o.o.", "ParentId": "007ef897-71e9-46d2-a3dc-ab6433cbc9c2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 385 1 6611 333</span></p>", "ID": "21ced6e1-679f-44b6-9a19-6a5ac830df2b", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdfbdc18-c8b1-4128-8da8-0ed84182deca"}, {"Element": "<span lang=\"EN-GB\">Tel: + 385 1 6611 333</span>", "ID": "ec1bacdc-0cc3-45d3-b847-85effebd6e7b", "Styles": "None", "Classes": "None", "Text": "Tel: + 385 1 6611 333", "ParentId": "21ced6e1-679f-44b6-9a19-6a5ac830df2b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">croatia_info@merck.com</span></p>", "ID": "c51c473a-20b0-4815-a957-c1e941e10e80", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdfbdc18-c8b1-4128-8da8-0ed84182deca"}, {"Element": "<span lang=\"EN-GB\">croatia_info@merck.com</span>", "ID": "5db11d1c-c246-45f3-87f0-06c8b025bf57", "Styles": "None", "Classes": "None", "Text": "croatia_info@merck.com", "ParentId": "c51c473a-20b0-4815-a957-c1e941e10e80"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "7b94b065-360f-4a20-a871-7b3ae4b6b698", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "bdfbdc18-c8b1-4128-8da8-0ed84182deca"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "76cfa421-9da3-4546-b3e7-9b122922bf16", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7b94b065-360f-4a20-a871-7b3ae4b6b698"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "486c8229-3fde-45b8-b7f3-579967c7765e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "76cfa421-9da3-4546-b3e7-9b122922bf16"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"IT\">Merck Sharp &amp; Dohme Romania S.R.L.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 529 29 00</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdromania@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "f6fd8d54-645b-49cb-97c4-5d16efa2a716", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "64df3da8-dfbf-4760-9bba-d988d274025a"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia</span></b></p>", "ID": "b0d01e63-c4a9-4b80-9bb1-68028df0fc9e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f6fd8d54-645b-49cb-97c4-5d16efa2a716"}, {"Element": "<b><span lang=\"IT\">Rom\u00e2nia</span></b>", "ID": "7ba89a10-2a83-4e3f-b1a6-07ec4aa32670", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "b0d01e63-c4a9-4b80-9bb1-68028df0fc9e"}, {"Element": "<span lang=\"IT\">Rom\u00e2nia</span>", "ID": "49d9e18d-3141-4ca0-bf5e-f6242d9438d8", "Styles": "None", "Classes": "None", "Text": "Rom\u00e2nia", "ParentId": "7ba89a10-2a83-4e3f-b1a6-07ec4aa32670"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"IT\">Merck Sharp &amp; Dohme Romania S.R.L.</span></p>", "ID": "f1d09bdc-8c8c-4265-a479-60e373cc60e4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f6fd8d54-645b-49cb-97c4-5d16efa2a716"}, {"Element": "<span lang=\"IT\">Merck Sharp &amp; Dohme Romania S.R.L.</span>", "ID": "c4ae1ed2-81db-48f7-8e0e-30fbbcb58fff", "Styles": "None", "Classes": "None", "Text": "Merck Sharp & Dohme Romania S.R.L.", "ParentId": "f1d09bdc-8c8c-4265-a479-60e373cc60e4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +40 21 529 29 00</span></p>", "ID": "ef0198bc-8af4-4f17-850b-9edfdf8ed3c3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f6fd8d54-645b-49cb-97c4-5d16efa2a716"}, {"Element": "<span lang=\"EN-GB\">Tel: +40 21 529 29 00</span>", "ID": "d8808735-227e-46ce-b333-30564b008890", "Styles": "None", "Classes": "None", "Text": "Tel: +40 21 529 29 00", "ParentId": "ef0198bc-8af4-4f17-850b-9edfdf8ed3c3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">msdromania@merck.com</span></p>", "ID": "93c758c1-c54d-489e-9100-46aac7e84d1e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f6fd8d54-645b-49cb-97c4-5d16efa2a716"}, {"Element": "<span lang=\"EN-GB\">msdromania@merck.com</span>", "ID": "ffafaafe-79ea-46e9-922c-045aa0817e14", "Styles": "None", "Classes": "None", "Text": "msdromania@merck.com", "ParentId": "93c758c1-c54d-489e-9100-46aac7e84d1e"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "ceae887b-dcbf-4145-857d-1a3d8bfc39cd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "f6fd8d54-645b-49cb-97c4-5d16efa2a716"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "03acd67b-8b88-4491-8e30-43a5382cab4b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ceae887b-dcbf-4145-857d-1a3d8bfc39cd"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2b1c4a70-a68a-4072-b793-8d9c539c8edb", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "03acd67b-8b88-4491-8e30-43a5382cab4b"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme Ireland (Human Health)\n  Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: +353\n  (0)1 2998700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medinfo_ireland@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme, inovativna\n  zdravila d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +386 1 5204 201</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd.slovenia@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "ca5494b1-1ab2-4251-bb8b-34df35b35bb2", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme Ireland (Human Health)\n  Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: +353\n  (0)1 2998700</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medinfo_ireland@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "b0072c6d-70ff-4360-990c-ee1cb6c85afb", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "ca5494b1-1ab2-4251-bb8b-34df35b35bb2"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Ireland</span></b></p>", "ID": "ea5f1632-efda-432c-970d-6b1c166eeee0", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b0072c6d-70ff-4360-990c-ee1cb6c85afb"}, {"Element": "<b><span lang=\"EN-GB\">Ireland</span></b>", "ID": "14f8b07c-93a5-4ca0-99b0-55ae8c3727f3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ea5f1632-efda-432c-970d-6b1c166eeee0"}, {"Element": "<span lang=\"EN-GB\">Ireland</span>", "ID": "e58a3b33-cd87-4252-b8d8-0ab8a714cfbe", "Styles": "None", "Classes": "None", "Text": "Ireland", "ParentId": "14f8b07c-93a5-4ca0-99b0-55ae8c3727f3"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme Ireland (Human Health)\n  Limited</span></p>", "ID": "15a9b925-f96b-4f98-8c11-bdb3b564bef1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b0072c6d-70ff-4360-990c-ee1cb6c85afb"}, {"Element": "<span lang=\"EN-GB\">Merck Sharp &amp; Dohme Ireland (Human Health)\n  Limited</span>", "ID": "99c6f868-adec-495c-848d-a9d5c7796c6a", "Styles": "None", "Classes": "None", "Text": "Merck Sharp & Dohme Ireland (Human Health)   Limited", "ParentId": "15a9b925-f96b-4f98-8c11-bdb3b564bef1"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: +353\n  (0)1 2998700</span></p>", "ID": "ed1e28dc-b551-4546-a901-fb12fcb961b1", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b0072c6d-70ff-4360-990c-ee1cb6c85afb"}, {"Element": "<span lang=\"EN-GB\">Tel: +353\n  (0)1 2998700</span>", "ID": "da1b8a9a-ce5c-46c4-8b8f-53a20160f369", "Styles": "None", "Classes": "None", "Text": "Tel: +353   (0)1 2998700", "ParentId": "ed1e28dc-b551-4546-a901-fb12fcb961b1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">medinfo_ireland@merck.com</span></p>", "ID": "7b24803e-2d75-412f-a02d-87792d1bbabd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b0072c6d-70ff-4360-990c-ee1cb6c85afb"}, {"Element": "<span lang=\"EN-GB\">medinfo_ireland@merck.com</span>", "ID": "3e34b0b1-22b1-4bc0-a69f-aab541611e3c", "Styles": "None", "Classes": "None", "Text": "medinfo_ireland@merck.com", "ParentId": "7b24803e-2d75-412f-a02d-87792d1bbabd"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "2f0e1402-2f89-43cb-aa7b-6645a538f9e7", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "b0072c6d-70ff-4360-990c-ee1cb6c85afb"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "bd6c27a6-f393-431f-a044-1f506f73329c", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "2f0e1402-2f89-43cb-aa7b-6645a538f9e7"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme, inovativna\n  zdravila d.o.o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +386 1 5204 201</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd.slovenia@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "23a107c5-f861-4201-97cb-851850e41ac0", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "ca5494b1-1ab2-4251-bb8b-34df35b35bb2"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovenija</span></b></p>", "ID": "0f20680e-304a-42b4-82f2-356036ec95ce", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "23a107c5-f861-4201-97cb-851850e41ac0"}, {"Element": "<b><span lang=\"EN-GB\">Slovenija</span></b>", "ID": "0465c8c0-b649-44b6-84da-5a5aea0bde1d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "0f20680e-304a-42b4-82f2-356036ec95ce"}, {"Element": "<span lang=\"EN-GB\">Slovenija</span>", "ID": "c6a02740-688d-480e-b2d7-395a4cfb9339", "Styles": "None", "Classes": "None", "Text": "Slovenija", "ParentId": "0465c8c0-b649-44b6-84da-5a5aea0bde1d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme, inovativna\n  zdravila d.o.o.</span></p>", "ID": "1b721407-1102-494e-bf36-e1cca80aeedd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "23a107c5-f861-4201-97cb-851850e41ac0"}, {"Element": "<span lang=\"EN-GB\">Merck Sharp &amp; Dohme, inovativna\n  zdravila d.o.o.</span>", "ID": "dc3aa949-f53b-4cb1-ab16-2d8f681b7de1", "Styles": "None", "Classes": "None", "Text": "Merck Sharp & Dohme, inovativna   zdravila d.o.o.", "ParentId": "1b721407-1102-494e-bf36-e1cca80aeedd"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +386 1 5204 201</span></p>", "ID": "0b93a785-f0e2-46d0-a377-fa7eb662a0dc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "23a107c5-f861-4201-97cb-851850e41ac0"}, {"Element": "<span lang=\"EN-GB\">Tel: +386 1 5204 201</span>", "ID": "5d81cca4-4c40-421c-9bab-4989a65a93bd", "Styles": "None", "Classes": "None", "Text": "Tel: +386 1 5204 201", "ParentId": "0b93a785-f0e2-46d0-a377-fa7eb662a0dc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd.slovenia@merck.com</span></p>", "ID": "02999d70-ae26-4d37-8207-bcd0bc87a2cc", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "23a107c5-f861-4201-97cb-851850e41ac0"}, {"Element": "<span lang=\"EN-GB\">msd.slovenia@merck.com</span>", "ID": "bc7b35f5-f568-403d-a711-c6f81dbd85b6", "Styles": "None", "Classes": "None", "Text": "msd.slovenia@merck.com", "ParentId": "02999d70-ae26-4d37-8207-bcd0bc87a2cc"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "969de0c9-4b70-4357-ab2e-63f1e344a31e", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "23a107c5-f861-4201-97cb-851850e41ac0"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5698bf0d-3398-41bb-88a0-ed339bf681fd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "969de0c9-4b70-4357-ab2e-63f1e344a31e"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Vistor hf.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi: + 354 535 7000</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovensk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme, s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +421 2 58282010</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "6e44f132-c540-4477-b6af-d7e3d87b4d1c", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Vistor hf.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi: + 354 535 7000</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "4064af69-0674-47ad-b9aa-a1708445c24e", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "     ", "ParentId": "6e44f132-c540-4477-b6af-d7e3d87b4d1c"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00cdsland</span></b></p>", "ID": "d5794ac2-ee51-4c29-acec-4aee53ca3a00", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4064af69-0674-47ad-b9aa-a1708445c24e"}, {"Element": "<b><span lang=\"EN-GB\">\u00cdsland</span></b>", "ID": "94eeeff9-03e9-4145-a536-73cb14d2a7d3", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "d5794ac2-ee51-4c29-acec-4aee53ca3a00"}, {"Element": "<span lang=\"EN-GB\">\u00cdsland</span>", "ID": "5f86d198-a2c2-4903-981c-311bfbf5ed43", "Styles": "None", "Classes": "None", "Text": "\u00cdsland", "ParentId": "94eeeff9-03e9-4145-a536-73cb14d2a7d3"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Vistor hf.</span></p>", "ID": "2bae4056-86cc-4439-8e0b-f0f9ebda88b9", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4064af69-0674-47ad-b9aa-a1708445c24e"}, {"Element": "<span lang=\"EN-GB\">Vistor hf.</span>", "ID": "7e6f937e-eb20-41a6-b765-0c4f8fd77e0c", "Styles": "None", "Classes": "None", "Text": "Vistor hf.", "ParentId": "2bae4056-86cc-4439-8e0b-f0f9ebda88b9"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi: + 354 535 7000</span></p>", "ID": "c1d144a0-9cb2-4ed1-8b11-9e0684c8f917", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4064af69-0674-47ad-b9aa-a1708445c24e"}, {"Element": "<span lang=\"EN-GB\">S\u00edmi: + 354 535 7000</span>", "ID": "c0d8e46a-20f1-43db-8234-566446616e51", "Styles": "None", "Classes": "None", "Text": "S\u00edmi: + 354 535 7000", "ParentId": "c1d144a0-9cb2-4ed1-8b11-9e0684c8f917"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "afc933f0-8494-4726-903f-5af11beea825", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "4064af69-0674-47ad-b9aa-a1708445c24e"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "8404b2bf-9edf-454c-ac9f-7925ee562675", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "afc933f0-8494-4726-903f-5af11beea825"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9be732d8-e6f0-4804-ae78-0ad3e069eb9e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "8404b2bf-9edf-454c-ac9f-7925ee562675"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovensk\u00e1 republika</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme, s. r. o.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +421 2 58282010</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "8e4f9e34-475d-4e5f-9477-b36516d4c996", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "6e44f132-c540-4477-b6af-d7e3d87b4d1c"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Slovensk\u00e1 republika</span></b></p>", "ID": "7f700723-bc9a-4a74-8085-7d4d05148de9", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8e4f9e34-475d-4e5f-9477-b36516d4c996"}, {"Element": "<b><span lang=\"EN-GB\">Slovensk\u00e1 republika</span></b>", "ID": "e2a9b86a-38d1-4b8e-8a3b-1fcbe0738e3a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7f700723-bc9a-4a74-8085-7d4d05148de9"}, {"Element": "<span lang=\"EN-GB\">Slovensk\u00e1 republika</span>", "ID": "17dbbe41-a3ea-430c-92fe-4ebfd5a49bbb", "Styles": "None", "Classes": "None", "Text": "Slovensk\u00e1 republika", "ParentId": "e2a9b86a-38d1-4b8e-8a3b-1fcbe0738e3a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme, s. r. o.</span></p>", "ID": "dc4101e2-95bd-4f45-a857-8f9db74278e6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8e4f9e34-475d-4e5f-9477-b36516d4c996"}, {"Element": "<span lang=\"EN-GB\">Merck Sharp &amp; Dohme, s. r. o.</span>", "ID": "135cf132-147c-4d79-9c3d-2eb1056173ae", "Styles": "None", "Classes": "None", "Text": "Merck Sharp & Dohme, s. r. o.", "ParentId": "dc4101e2-95bd-4f45-a857-8f9db74278e6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +421 2 58282010</span></p>", "ID": "6f5fb0be-f367-45bd-a6d9-126067d786b4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8e4f9e34-475d-4e5f-9477-b36516d4c996"}, {"Element": "<span lang=\"EN-GB\">Tel: +421 2 58282010</span>", "ID": "72fed4c7-f765-4c3c-b74e-b1471123c47e", "Styles": "None", "Classes": "None", "Text": "Tel: +421 2 58282010", "ParentId": "6f5fb0be-f367-45bd-a6d9-126067d786b4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span></p>", "ID": "a1da9e5f-588b-4350-83c3-2d4c97e86670", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8e4f9e34-475d-4e5f-9477-b36516d4c996"}, {"Element": "<span lang=\"EN-GB\">dpoc_czechslovak@merck.com</span>", "ID": "5de71c13-24fc-482b-86c1-1f99bd05b926", "Styles": "None", "Classes": "None", "Text": "dpoc_czechslovak@merck.com", "ParentId": "a1da9e5f-588b-4350-83c3-2d4c97e86670"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "7662314f-e5ba-4a32-81da-5fd32678e130", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8e4f9e34-475d-4e5f-9477-b36516d4c996"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "afb33723-8aa4-4a1e-b67f-226fdd6f8cb0", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "7662314f-e5ba-4a32-81da-5fd32678e130"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "d281239b-edb2-45bd-961b-2900e6df2747", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "afb33723-8aa4-4a1e-b67f-226fdd6f8cb0"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Italia S.r.l.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +39 06 361911</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinformation.it@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">MSD Finland\n  Oy</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Puh/Tel: +358\n  (0)9 804 650</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">info@msd.fi</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "1b9996da-ec9b-4888-8862-a505dce19ad9", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Italia</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Italia S.r.l.</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +39 06 361911</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinformation.it@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "1dffbc68-b898-4181-9b19-2bb7634cfd63", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "1b9996da-ec9b-4888-8862-a505dce19ad9"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Italia</span></b></p>", "ID": "3d2c3004-bbf3-4585-938b-2e8c3b29a4ad", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1dffbc68-b898-4181-9b19-2bb7634cfd63"}, {"Element": "<b><span lang=\"EN-GB\">Italia</span></b>", "ID": "284e5b69-25d9-452d-b051-366e83d5a44d", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3d2c3004-bbf3-4585-938b-2e8c3b29a4ad"}, {"Element": "<span lang=\"EN-GB\">Italia</span>", "ID": "21aa3315-291c-483e-bf3a-53aae3279db8", "Styles": "None", "Classes": "None", "Text": "Italia", "ParentId": "284e5b69-25d9-452d-b051-366e83d5a44d"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">MSD Italia S.r.l.</span></p>", "ID": "bb58c5af-f353-4473-a600-9917cc2143f1", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1dffbc68-b898-4181-9b19-2bb7634cfd63"}, {"Element": "<span lang=\"EN-GB\">MSD Italia S.r.l.</span>", "ID": "c3e768b4-b341-47ce-8200-bced5563389c", "Styles": "None", "Classes": "None", "Text": "MSD Italia S.r.l.", "ParentId": "bb58c5af-f353-4473-a600-9917cc2143f1"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +39 06 361911</span></p>", "ID": "a366d2b9-8a16-41b1-82b2-e1aa61647506", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1dffbc68-b898-4181-9b19-2bb7634cfd63"}, {"Element": "<span lang=\"EN-GB\">Tel: +39 06 361911</span>", "ID": "2f71c22d-3533-41e4-8adf-ad6cf792cced", "Styles": "None", "Classes": "None", "Text": "Tel: +39 06 361911", "ParentId": "a366d2b9-8a16-41b1-82b2-e1aa61647506"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinformation.it@merck.com</span></p>", "ID": "f3df9824-60a7-41a0-b24a-6afe0bc57427", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1dffbc68-b898-4181-9b19-2bb7634cfd63"}, {"Element": "<span lang=\"EN-GB\">medicalinformation.it@merck.com</span>", "ID": "a411d149-c4cd-43f6-9ade-9c4d6694bcc4", "Styles": "None", "Classes": "None", "Text": "medicalinformation.it@merck.com", "ParentId": "f3df9824-60a7-41a0-b24a-6afe0bc57427"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "9e0d78fc-330a-4469-bb03-c51d47ec13f4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "1dffbc68-b898-4181-9b19-2bb7634cfd63"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "85601fd8-7b88-461e-bbe5-74a2946f8cbb", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9e0d78fc-330a-4469-bb03-c51d47ec13f4"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "fb1c3b30-67a6-4b99-8ce2-1563b6ab2728", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "85601fd8-7b88-461e-bbe5-74a2946f8cbb"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">MSD Finland\n  Oy</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Puh/Tel: +358\n  (0)9 804 650</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">info@msd.fi</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "6fdbf604-5e5f-4be5-bceb-44626997e38a", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "1b9996da-ec9b-4888-8862-a505dce19ad9"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Suomi/Finland</span></b></p>", "ID": "77f15cfe-5f68-41ff-b331-7a10a470c13d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6fdbf604-5e5f-4be5-bceb-44626997e38a"}, {"Element": "<b><span lang=\"EN-GB\">Suomi/Finland</span></b>", "ID": "b89c1011-b107-4f38-bb24-053d374ca9b9", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "77f15cfe-5f68-41ff-b331-7a10a470c13d"}, {"Element": "<span lang=\"EN-GB\">Suomi/Finland</span>", "ID": "52c0cce7-be17-4f38-9a82-a25249f51461", "Styles": "None", "Classes": "None", "Text": "Suomi/Finland", "ParentId": "b89c1011-b107-4f38-bb24-053d374ca9b9"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">MSD Finland\n  Oy</span></p>", "ID": "3db58a95-6522-4e6f-9b83-dce611d09703", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6fdbf604-5e5f-4be5-bceb-44626997e38a"}, {"Element": "<span lang=\"EN-GB\">MSD Finland\n  Oy</span>", "ID": "ef6cc10f-af8b-4ec9-aa3a-90c21a779c31", "Styles": "None", "Classes": "None", "Text": "MSD Finland   Oy", "ParentId": "3db58a95-6522-4e6f-9b83-dce611d09703"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Puh/Tel: +358\n  (0)9 804 650</span></p>", "ID": "72f34c93-d505-4e4b-bbfd-db8de44009d5", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6fdbf604-5e5f-4be5-bceb-44626997e38a"}, {"Element": "<span lang=\"EN-GB\">Puh/Tel: +358\n  (0)9 804 650</span>", "ID": "5a304ddc-8d9c-4e1c-bf72-f3e862110b1b", "Styles": "None", "Classes": "None", "Text": "Puh/Tel: +358   (0)9 804 650", "ParentId": "72f34c93-d505-4e4b-bbfd-db8de44009d5"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">info@msd.fi</span></p>", "ID": "74fdab26-f696-41cd-8097-de4eba1f6df1", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6fdbf604-5e5f-4be5-bceb-44626997e38a"}, {"Element": "<span lang=\"EN-GB\">info@msd.fi</span>", "ID": "1d47f1ff-fbab-4d69-8119-ab70d53ac9b9", "Styles": "None", "Classes": "None", "Text": "info@msd.fi", "ParentId": "74fdab26-f696-41cd-8097-de4eba1f6df1"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "5c1dd4fc-034a-4f0a-94c3-7331a54ee727", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "6fdbf604-5e5f-4be5-bceb-44626997e38a"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "906864ef-58f9-459e-a094-6763e4bdaff5", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5c1dd4fc-034a-4f0a-94c3-7331a54ee727"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1f4ed717-f57c-442b-80ae-be603b134d0e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "906864ef-58f9-459e-a094-6763e4bdaff5"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb.:\n  800 00 673 (+357 22866700)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">cyprus_info@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Sverige</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"DE\">Merck Sharp\n  &amp; Dohme (Sweden) AB</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: +46 77\n  5700488</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicinskinfo@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>\n</tr>", "ID": "d8b83e18-4389-47ce-a583-f8ae65d74647", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb.:\n  800 00 673 (+357 22866700)</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">cyprus_info@merck.com</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "55e2f35b-306d-49ca-b5b1-b8b28f944c0b", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "d8b83e18-4389-47ce-a583-f8ae65d74647"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b></p>", "ID": "36c7349c-786d-4f80-ae1e-826946eb5f64", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "55e2f35b-306d-49ca-b5b1-b8b28f944c0b"}, {"Element": "<b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span></b>", "ID": "cc4ee71b-4406-474f-b89c-eab4e0f77fc1", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "36c7349c-786d-4f80-ae1e-826946eb5f64"}, {"Element": "<span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2</span>", "ID": "5171c24c-ed66-494d-9b62-62c8730becb8", "Styles": "None", "Classes": "None", "Text": "\u039a\u03cd\u03c0\u03c1\u03bf\u03c2", "ParentId": "cc4ee71b-4406-474f-b89c-eab4e0f77fc1"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span></p>", "ID": "c0587525-cc61-4b74-bebd-03883d489839", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "55e2f35b-306d-49ca-b5b1-b8b28f944c0b"}, {"Element": "<span lang=\"EN-GB\">Merck Sharp\n  &amp; Dohme Cyprus Limited</span>", "ID": "79f54da7-15d4-4c86-915b-2a99875953ec", "Styles": "None", "Classes": "None", "Text": "Merck Sharp   & Dohme Cyprus Limited", "ParentId": "c0587525-cc61-4b74-bebd-03883d489839"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">\u03a4\u03b7\u03bb.:\n  800 00 673 (+357 22866700)</span></p>", "ID": "7b1c2660-0e3b-4ab6-a7c0-6b5f88b88390", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "55e2f35b-306d-49ca-b5b1-b8b28f944c0b"}, {"Element": "<span lang=\"EN-GB\">\u03a4\u03b7\u03bb.:\n  800 00 673 (+357 22866700)</span>", "ID": "a914aeba-eafe-491b-b39e-858681801416", "Styles": "None", "Classes": "None", "Text": "\u03a4\u03b7\u03bb.:   800 00 673 (+357 22866700)", "ParentId": "7b1c2660-0e3b-4ab6-a7c0-6b5f88b88390"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">cyprus_info@merck.com</span></p>", "ID": "38ff3e4c-a233-4026-b3f0-811a37913f5f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "55e2f35b-306d-49ca-b5b1-b8b28f944c0b"}, {"Element": "<span lang=\"EN-GB\">cyprus_info@merck.com</span>", "ID": "d9d20b6b-19d8-46d6-ae8b-50d97f8ff9d8", "Styles": "None", "Classes": "None", "Text": "cyprus_info@merck.com", "ParentId": "38ff3e4c-a233-4026-b3f0-811a37913f5f"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "16525b05-2a6a-4928-85a9-fab61f53e6c8", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "55e2f35b-306d-49ca-b5b1-b8b28f944c0b"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "944744de-c095-4486-a5cc-ec01de22d187", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "16525b05-2a6a-4928-85a9-fab61f53e6c8"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5faf178b-1a63-4bbc-939b-5f3b63242e23", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "944744de-c095-4486-a5cc-ec01de22d187"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"DE\">Sverige</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"DE\">Merck Sharp\n  &amp; Dohme (Sweden) AB</span></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: +46 77\n  5700488</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicinskinfo@merck.com</span></p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>\n</td>", "ID": "8a8e4ecd-a037-4438-b296-b123d773edb4", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "d8b83e18-4389-47ce-a583-f8ae65d74647"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"DE\">Sverige</span></b></p>", "ID": "a4fafbbb-a54a-42c6-a623-f11f283bf6f3", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8a8e4ecd-a037-4438-b296-b123d773edb4"}, {"Element": "<b><span lang=\"DE\">Sverige</span></b>", "ID": "839cf5a5-760a-4633-a1a7-c6460f02e260", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "a4fafbbb-a54a-42c6-a623-f11f283bf6f3"}, {"Element": "<span lang=\"DE\">Sverige</span>", "ID": "9aa62939-bf44-4818-a8b6-c7ef526c5654", "Styles": "None", "Classes": "None", "Text": "Sverige", "ParentId": "839cf5a5-760a-4633-a1a7-c6460f02e260"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"DE\">Merck Sharp\n  &amp; Dohme (Sweden) AB</span></p>", "ID": "cf0df864-15ba-4ce2-978f-d0abd7477423", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8a8e4ecd-a037-4438-b296-b123d773edb4"}, {"Element": "<span lang=\"DE\">Merck Sharp\n  &amp; Dohme (Sweden) AB</span>", "ID": "b07d73ea-0399-42a8-9bf7-d589077e008b", "Styles": "None", "Classes": "None", "Text": "Merck Sharp   & Dohme (Sweden) AB", "ParentId": "cf0df864-15ba-4ce2-978f-d0abd7477423"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Tel: +46 77\n  5700488</span></p>", "ID": "f3f8d2f7-6df6-407b-bddc-17b91cf1c038", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8a8e4ecd-a037-4438-b296-b123d773edb4"}, {"Element": "<span lang=\"EN-GB\">Tel: +46 77\n  5700488</span>", "ID": "e0b76fca-f628-4cc6-98a4-2d00bbd7e60f", "Styles": "None", "Classes": "None", "Text": "Tel: +46 77   5700488", "ParentId": "f3f8d2f7-6df6-407b-bddc-17b91cf1c038"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicinskinfo@merck.com</span></p>", "ID": "fd04b53c-20c6-4e9b-a463-78582780bff5", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8a8e4ecd-a037-4438-b296-b123d773edb4"}, {"Element": "<span lang=\"EN-GB\">medicinskinfo@merck.com</span>", "ID": "4d848498-c825-4e94-a499-eb0e5a374c67", "Styles": "None", "Classes": "None", "Text": "medicinskinfo@merck.com", "ParentId": "fd04b53c-20c6-4e9b-a463-78582780bff5"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "704b18bf-233a-4d67-803f-63b299061bda", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8a8e4ecd-a037-4438-b296-b123d773edb4"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "fd471038-40b6-42da-ae17-e114e1327830", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "704b18bf-233a-4d67-803f-63b299061bda"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "89145406-6638-43f3-8eb0-157ce809fbd7", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "fd471038-40b6-42da-ae17-e114e1327830"}, {"Element": "<tr style=\"page-break-inside:avoid\">\n<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">SIA Merck\n  Sharp &amp; Dohme Latvija</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 371 67364224</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_lv@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme Limited</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1992 467272</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinformationuk@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>\n</tr>", "ID": "568f87dc-583b-490d-a888-888576ba83f6", "Styles": "page-break-inside:avoid", "Classes": "None", "Text": "   ", "ParentId": "bd2e43ff-5c40-4a56-9056-0d19d8eb1b71"}, {"Element": "<td style=\"width:227.7pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"304\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Latvija</span></b></p>\n<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">SIA Merck\n  Sharp &amp; Dohme Latvija</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 371 67364224</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_lv@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "8b56c542-d378-4964-8db0-7fce83e5c315", "Styles": "width:227.7pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "568f87dc-583b-490d-a888-888576ba83f6"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Latvija</span></b></p>", "ID": "1048ee56-ba20-4a0b-a664-8b49d0613799", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b56c542-d378-4964-8db0-7fce83e5c315"}, {"Element": "<b><span lang=\"EN-GB\">Latvija</span></b>", "ID": "ccca28b1-62a6-446f-90dc-55740e973b5a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "1048ee56-ba20-4a0b-a664-8b49d0613799"}, {"Element": "<span lang=\"EN-GB\">Latvija</span>", "ID": "b273d799-04c5-45d6-bc0f-00772fb8d7cc", "Styles": "None", "Classes": "None", "Text": "Latvija", "ParentId": "ccca28b1-62a6-446f-90dc-55740e973b5a"}, {"Element": "<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">SIA Merck\n  Sharp &amp; Dohme Latvija</span></p>", "ID": "0ca3f4fe-73ae-4c52-bd55-fd1db1e08223", "Styles": "text-autospace:none", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b56c542-d378-4964-8db0-7fce83e5c315"}, {"Element": "<span lang=\"EN-GB\">SIA Merck\n  Sharp &amp; Dohme Latvija</span>", "ID": "c27054c6-77a9-4fd4-bffb-ef6117e13243", "Styles": "None", "Classes": "None", "Text": "SIA Merck   Sharp & Dohme Latvija", "ParentId": "0ca3f4fe-73ae-4c52-bd55-fd1db1e08223"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: + 371 67364224</span></p>", "ID": "6c544b99-52a5-4083-acc4-aaaeec5b1605", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b56c542-d378-4964-8db0-7fce83e5c315"}, {"Element": "<span lang=\"EN-GB\">Tel: + 371 67364224</span>", "ID": "ea14fe66-aa52-4a29-9c83-938d0e697cbd", "Styles": "None", "Classes": "None", "Text": "Tel: + 371 67364224", "ParentId": "6c544b99-52a5-4083-acc4-aaaeec5b1605"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">msd_lv@merck.com</span></p>", "ID": "9aaa5523-87e5-4177-9a23-9c7b676ba226", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b56c542-d378-4964-8db0-7fce83e5c315"}, {"Element": "<span lang=\"EN-GB\">msd_lv@merck.com</span>", "ID": "9579e3b6-efd7-4e3b-a8c2-737715ebfcaf", "Styles": "None", "Classes": "None", "Text": "msd_lv@merck.com", "ParentId": "9aaa5523-87e5-4177-9a23-9c7b676ba226"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "76db1dfe-57fc-4c2b-9702-a1c0a0651b2a", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8b56c542-d378-4964-8db0-7fce83e5c315"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "04d470bd-9d5b-46c0-bf1e-09cd313984ee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "76db1dfe-57fc-4c2b-9702-a1c0a0651b2a"}, {"Element": "<td style=\"width:225.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"301\">\n<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme Limited</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1992 467272</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinformationuk@merck.com</span></p>\n<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>\n</td>", "ID": "9235c181-bea1-414e-a59b-3bff12a27ac5", "Styles": "width:225.9pt;padding:0in 5.4pt 0in 5.4pt", "Classes": "None", "Text": "      ", "ParentId": "568f87dc-583b-490d-a888-888576ba83f6"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">United Kingdom</span></b></p>", "ID": "5102ced9-f356-4b5e-b8b7-b229609acd85", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9235c181-bea1-414e-a59b-3bff12a27ac5"}, {"Element": "<b><span lang=\"EN-GB\">United Kingdom</span></b>", "ID": "c1c5b9d0-174a-4074-9276-6b30f24523ed", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "5102ced9-f356-4b5e-b8b7-b229609acd85"}, {"Element": "<span lang=\"EN-GB\">United Kingdom</span>", "ID": "83bd8500-88c0-45a2-9641-6e7ec98357e8", "Styles": "None", "Classes": "None", "Text": "United Kingdom", "ParentId": "c1c5b9d0-174a-4074-9276-6b30f24523ed"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Merck Sharp &amp; Dohme Limited</span></p>", "ID": "fc5d8002-e9d6-4e8e-a390-f01650a8f8d8", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9235c181-bea1-414e-a59b-3bff12a27ac5"}, {"Element": "<span lang=\"EN-GB\">Merck Sharp &amp; Dohme Limited</span>", "ID": "656372ef-d391-41b7-8a68-93f574812780", "Styles": "None", "Classes": "None", "Text": "Merck Sharp & Dohme Limited", "ParentId": "fc5d8002-e9d6-4e8e-a390-f01650a8f8d8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Tel: +44 (0) 1992 467272</span></p>", "ID": "5c39795d-27f0-4ea3-b7c9-ddb4f4c748e4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9235c181-bea1-414e-a59b-3bff12a27ac5"}, {"Element": "<span lang=\"EN-GB\">Tel: +44 (0) 1992 467272</span>", "ID": "706cdc8a-bab7-42d1-be01-b79a39f8ce47", "Styles": "None", "Classes": "None", "Text": "Tel: +44 (0) 1992 467272", "ParentId": "5c39795d-27f0-4ea3-b7c9-ddb4f4c748e4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">medicalinformationuk@merck.com</span></p>", "ID": "134139d3-4f58-4b3c-90f6-48ff7ce269f4", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9235c181-bea1-414e-a59b-3bff12a27ac5"}, {"Element": "<span lang=\"EN-GB\">medicalinformationuk@merck.com</span>", "ID": "6282f696-96fe-4910-8737-93a1e1041b67", "Styles": "None", "Classes": "None", "Text": "medicalinformationuk@merck.com", "ParentId": "134139d3-4f58-4b3c-90f6-48ff7ce269f4"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "6f65a690-8e8c-40c4-82f3-456059e6817d", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "9235c181-bea1-414e-a59b-3bff12a27ac5"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "e877a87c-1761-412c-b2d4-4597e7f892e4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "6f65a690-8e8c-40c4-82f3-456059e6817d"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u00a0</span></b></p>", "ID": "06f87af2-e09c-4f99-9263-43bed429e9f2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">\u00a0</span></b>", "ID": "05df3dc7-98f7-4b92-8592-658ace61b17b", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "06f87af2-e09c-4f99-9263-43bed429e9f2"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "2b6afe84-2e14-4daa-82c8-ec595ab5a1cd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "05df3dc7-98f7-4b92-8592-658ace61b17b"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">This leaflet was last revised in\n{MM/YYYY}.</span></b></p>", "ID": "f42800cb-8484-467b-9f92-ca7c6b83cb1c", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">This leaflet was last revised in\n{MM/YYYY}.</span></b>", "ID": "299baa97-1dad-403e-b058-8ce3116a5f74", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "f42800cb-8484-467b-9f92-ca7c6b83cb1c"}, {"Element": "<span lang=\"EN-GB\">This leaflet was last revised in\n{MM/YYYY}.</span>", "ID": "4b55304e-381e-454c-a75b-6812bb6ed1b0", "Styles": "None", "Classes": "None", "Text": "This leaflet was last revised in {MM/YYYY}.", "ParentId": "299baa97-1dad-403e-b058-8ce3116a5f74"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "04364822-710e-4a38-b9a5-5bf408bfff4e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8b5bf88d-3038-43be-af89-b73f74371170", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "04364822-710e-4a38-b9a5-5bf408bfff4e"}, {"Element": "<p class=\"MsoNormal\"><b><span lang=\"EN-GB\">Other sources of information</span></b></p>", "ID": "3c603ccb-b54a-4c9e-9529-c419f52c20fd", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><span lang=\"EN-GB\">Other sources of information</span></b>", "ID": "798eaafa-cd26-48d0-8050-750d0c60a0c2", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "3c603ccb-b54a-4c9e-9529-c419f52c20fd"}, {"Element": "<span lang=\"EN-GB\">Other sources of information</span>", "ID": "3c1001c1-6207-4c3e-9814-98c8feaa08ce", "Styles": "None", "Classes": "None", "Text": "Other sources of information", "ParentId": "798eaafa-cd26-48d0-8050-750d0c60a0c2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Detailed\ninformation on this medicine is available on the European Medicines Agency web\nsite: <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a>.</span></p>", "ID": "743ec106-9770-4475-ad20-000ff61eae1e", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Detailed\ninformation on this medicine is available on the European Medicines Agency web\nsite: <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a>.</span>", "ID": "1b48dd3e-b8ae-4507-84e4-373b4e79c063", "Styles": "None", "Classes": "None", "Text": "Detailed information on this medicine is available on the European Medicines Agency web site: .", "ParentId": "743ec106-9770-4475-ad20-000ff61eae1e"}, {"Element": "<a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a>", "ID": "149d2576-ab83-4f4d-9a16-efca47811c34", "Styles": "None", "Classes": "None", "Text": "http://www.ema.europa.eu", "ParentId": "1b48dd3e-b8ae-4507-84e4-373b4e79c063"}, {"Element": "<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"/>\n</span>", "ID": "6304c695-8c8a-4772-b032-575027ef4b23", "Styles": "font-size:11.0pt;font-family:\"Times New Roman\",serif", "Classes": "None", "Text": " ", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<br clear=\"all\" style=\"page-break-before:always\"/>", "ID": "b5fa49a1-c070-4232-b238-6dc95c64a004", "Styles": "page-break-before:always", "Classes": "None", "Text": "", "ParentId": "6304c695-8c8a-4772-b032-575027ef4b23"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><a name=\"OLE_LINK4\"><span lang=\"EN-GB\">The following information is intended for healthcare professionals\nonly:</span></a></p>", "ID": "ce98da6f-de6e-453e-9e02-2b1bf00cb945", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<a name=\"OLE_LINK4\"><span lang=\"EN-GB\">The following information is intended for healthcare professionals\nonly:</span></a>", "ID": "5dafac59-494c-482a-8739-f9d549cb431a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "ce98da6f-de6e-453e-9e02-2b1bf00cb945"}, {"Element": "<span lang=\"EN-GB\">The following information is intended for healthcare professionals\nonly:</span>", "ID": "c43b711e-b4d5-4d72-b65e-480b40020261", "Styles": "None", "Classes": "None", "Text": "The following information is intended for healthcare professionals only:", "ParentId": "5dafac59-494c-482a-8739-f9d549cb431a"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "9d7e4c0d-2ff4-46b8-86c6-2b323ab82ffb", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5c3d206b-2305-47bc-945b-409923e8fc86", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "9d7e4c0d-2ff4-46b8-86c6-2b323ab82ffb"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Patients\ntreated with Remicade should be given the patient reminder card.</span></p>", "ID": "5f02e83a-4534-4b30-8c51-6617cd4f5fd1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Patients\ntreated with Remicade should be given the patient reminder card.</span>", "ID": "a1c6bab0-bd68-46e8-94b8-b579c7cb9ae6", "Styles": "None", "Classes": "None", "Text": "Patients treated with Remicade should be given the patient reminder card.", "ParentId": "5f02e83a-4534-4b30-8c51-6617cd4f5fd1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "22ab67f2-2def-4658-89a5-506a9eedffe4", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "1c92af47-6e8b-48cb-be6c-fc964cf229b9", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "22ab67f2-2def-4658-89a5-506a9eedffe4"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Instructions\nfor use and handling \u2013 storage conditions</span></i></b></p>", "ID": "9dbd88cd-bf2b-4134-b900-867971ca3e6d", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><i><span lang=\"EN-GB\">Instructions\nfor use and handling \u2013 storage conditions</span></i></b>", "ID": "34b94fdc-6f7b-47b0-b78a-fecf204e0052", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9dbd88cd-bf2b-4134-b900-867971ca3e6d"}, {"Element": "<i><span lang=\"EN-GB\">Instructions\nfor use and handling \u2013 storage conditions</span></i>", "ID": "1fdce7a5-297e-4090-aa3c-a967eec904aa", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "34b94fdc-6f7b-47b0-b78a-fecf204e0052"}, {"Element": "<span lang=\"EN-GB\">Instructions\nfor use and handling \u2013 storage conditions</span>", "ID": "c9414909-5353-4884-b30c-53f9bb1169a3", "Styles": "None", "Classes": "None", "Text": "Instructions for use and handling \u2013 storage conditions", "ParentId": "1fdce7a5-297e-4090-aa3c-a967eec904aa"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "cd506e27-f6c2-4d5d-977a-67036869dd26", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "9bd7fe80-8487-4cf1-ac25-f91c968d0bee", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cd506e27-f6c2-4d5d-977a-67036869dd26"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Store at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C.</span></p>", "ID": "8785c992-d3fb-47d2-86c3-bc00d313298f", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Store at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C.</span>", "ID": "a44fb6f0-fb8e-4ac0-9550-e956c105681b", "Styles": "None", "Classes": "None", "Text": "Store at 2\u00b0C\u20118\u00b0C.", "ParentId": "8785c992-d3fb-47d2-86c3-bc00d313298f"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>", "ID": "d90d3275-7c3b-4810-a15e-f8466ee8ad05", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "a44fb6f0-fb8e-4ac0-9550-e956c105681b"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del>", "ID": "ec124f48-88c7-419a-8dc1-30e17f795cb5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d90d3275-7c3b-4810-a15e-f8466ee8ad05"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>", "ID": "246162ba-d54b-41c8-94c6-91b369729214", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "a44fb6f0-fb8e-4ac0-9550-e956c105681b"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del>", "ID": "7d58a0f0-feab-4b66-baa1-151e98e544b1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "246162ba-d54b-41c8-94c6-91b369729214"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>", "ID": "57807c3e-eeaa-42e0-ba0a-95d93e76c03a", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "a44fb6f0-fb8e-4ac0-9550-e956c105681b"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del>", "ID": "810d7b37-1633-4d5a-b0d2-9d3446e1df76", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "57807c3e-eeaa-42e0-ba0a-95d93e76c03a"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>", "ID": "ac3fd61f-80de-4d6c-a78c-75ecb6f94a8b", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "a44fb6f0-fb8e-4ac0-9550-e956c105681b"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del>", "ID": "a74fa9a9-cba2-4949-8ffc-42a4cfbae81d", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ac3fd61f-80de-4d6c-a78c-75ecb6f94a8b"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "40f7366a-c15d-49e0-956d-6a5f4a254ed6", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "33be7f55-9e43-49b0-893f-cf88782c0e2e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "40f7366a-c15d-49e0-956d-6a5f4a254ed6"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">Remicade may be stored at temperatures up\nto a maximum of 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C for a single period of up\nto 6\u00a0months, but not exceeding the original expiry date. The new expiry\ndate must be written on the carton. Upon removal from refrigerated storage,\nRemicade must not be returned to refrigerated storage.</span></p>", "ID": "ce16c9ce-354d-4a40-b5a9-40ec04993334", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">Remicade may be stored at temperatures up\nto a maximum of 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>\u00b0C for a single period of up\nto 6\u00a0months, but not exceeding the original expiry date. The new expiry\ndate must be written on the carton. Upon removal from refrigerated storage,\nRemicade must not be returned to refrigerated storage.</span>", "ID": "ab545c89-9337-40ce-a8a8-a8be48a928ec", "Styles": "None", "Classes": "None", "Text": "Remicade may be stored at temperatures up to a maximum of 25\u00b0C for a single period of up to 6\u00a0months, but not exceeding the original expiry date. The new expiry date must be written on the carton. Upon removal from refrigerated storage, Remicade must not be returned to refrigerated storage.", "ParentId": "ce16c9ce-354d-4a40-b5a9-40ec04993334"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del></span>", "ID": "856231a4-3f7d-4698-8561-c8602e999fcd", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "ab545c89-9337-40ce-a8a8-a8be48a928ec"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:18\">\u00a0</del>", "ID": "0ebdc876-2617-457b-a951-bc8bf4a4cadd", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "856231a4-3f7d-4698-8561-c8602e999fcd"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5ee878fe-ad54-43d7-81ca-15ba1d9867f1", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "044b4d47-13b2-4a48-9c1a-149396d25680", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5ee878fe-ad54-43d7-81ca-15ba1d9867f1"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><i><span lang=\"EN-GB\">Instructions\nfor use and handling \u2013 reconstitution, dilution and administration</span></i></b></p>", "ID": "9070a4cc-ac62-4503-b6df-a2ee27d5268a", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<b><i><span lang=\"EN-GB\">Instructions\nfor use and handling \u2013 reconstitution, dilution and administration</span></i></b>", "ID": "23aaf0c0-f3dc-4e99-8c9f-2fc60af12d9a", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "9070a4cc-ac62-4503-b6df-a2ee27d5268a"}, {"Element": "<i><span lang=\"EN-GB\">Instructions\nfor use and handling \u2013 reconstitution, dilution and administration</span></i>", "ID": "58723423-8d55-467b-b662-58e7e67b5841", "Styles": "None", "Classes": "None", "Text": "", "ParentId": "23aaf0c0-f3dc-4e99-8c9f-2fc60af12d9a"}, {"Element": "<span lang=\"EN-GB\">Instructions\nfor use and handling \u2013 reconstitution, dilution and administration</span>", "ID": "3ad3c244-41c1-49ea-9a82-25a8cd8fc724", "Styles": "None", "Classes": "None", "Text": "Instructions for use and handling \u2013 reconstitution, dilution and administration", "ParentId": "58723423-8d55-467b-b662-58e7e67b5841"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "727074fe-d2df-473e-8c66-379028acc2c2", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b1c91241-a029-4ad8-ae00-d716f0173659", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "727074fe-d2df-473e-8c66-379028acc2c2"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In order to\nimprove the traceability of biological medicinal products, the tradename and\nbatch number of the administered medicinal product should be clearly recorded.</span></p>", "ID": "4e547c54-4f32-4c62-8782-0c442489ade6", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">In order to\nimprove the traceability of biological medicinal products, the tradename and\nbatch number of the administered medicinal product should be clearly recorded.</span>", "ID": "d88d4edc-e39f-48d2-801c-de7c906e82a4", "Styles": "None", "Classes": "None", "Text": "In order to improve the traceability of biological medicinal products, the tradename and batch number of the administered medicinal product should be clearly recorded.", "ParentId": "4e547c54-4f32-4c62-8782-0c442489ade6"}, {"Element": "<p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b6a978b9-e847-4d25-a7cd-d50f8178f7b3", "Styles": "page-break-after:avoid", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "875d401d-451d-4208-b4eb-fc379f8fe9e0", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b6a978b9-e847-4d25-a7cd-d50f8178f7b3"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Calculate the dose and the\nnumber of Remicade vials needed. Each Remicade vial contains 100\u00a0mg\ninfliximab. Calculate the total volume of reconstituted Remicade solution\nrequired.</span></p>", "ID": "65bad45f-7229-4c60-b199-9a3d5e5d871a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Calculate the dose and the\nnumber of Remicade vials needed. Each Remicade vial contains 100\u00a0mg\ninfliximab. Calculate the total volume of reconstituted Remicade solution\nrequired.</span>", "ID": "864fdbb7-64f6-41f6-94cf-1f3be76572d8", "Styles": "None", "Classes": "None", "Text": "1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Calculate the dose and the number of Remicade vials needed. Each Remicade vial contains 100\u00a0mg infliximab. Calculate the total volume of reconstituted Remicade solution required.", "ParentId": "65bad45f-7229-4c60-b199-9a3d5e5d871a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b76092f5-a6a4-4929-8c2d-ebebd2cf6a7e", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "135185d1-46d6-4996-b0b6-b566f660a0fa", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b76092f5-a6a4-4929-8c2d-ebebd2cf6a7e"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Under aseptic conditions,\nreconstitute each Remicade vial with 10\u00a0ml of water for injections, using\na syringe equipped with a 21\u2011gauge (0.8\u00a0mm) or smaller needle.\nRemove flip\u2011top from the vial and wipe the top with a 70% alcohol swab.\nInsert the syringe needle into the vial through the centre of the rubber\nstopper and direct the stream of water for injections to the glass wall of the\nvial. Gently swirl the solution by rotating the vial to dissolve the\nlyophilised powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE.\nFoaming of the solution on reconstitution is not unusual. Allow the\nreconstituted solution to stand for 5\u00a0minutes. Check that the solution is\ncolourless to light yellow and opalescent. The solution may develop a few fine\ntranslucent particles, as infliximab is a protein. Do not use if opaque\nparticles, discolouration, or other foreign particles are present.</span></p>", "ID": "5f1063f8-59cd-42d1-8407-cfd23e4100f8", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Under aseptic conditions,\nreconstitute each Remicade vial with 10\u00a0ml of water for injections, using\na syringe equipped with a 21\u2011gauge (0.8\u00a0mm) or smaller needle.\nRemove flip\u2011top from the vial and wipe the top with a 70% alcohol swab.\nInsert the syringe needle into the vial through the centre of the rubber\nstopper and direct the stream of water for injections to the glass wall of the\nvial. Gently swirl the solution by rotating the vial to dissolve the\nlyophilised powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE.\nFoaming of the solution on reconstitution is not unusual. Allow the\nreconstituted solution to stand for 5\u00a0minutes. Check that the solution is\ncolourless to light yellow and opalescent. The solution may develop a few fine\ntranslucent particles, as infliximab is a protein. Do not use if opaque\nparticles, discolouration, or other foreign particles are present.</span>", "ID": "1137cc4c-431a-4bb3-8c2e-ab119fbbf629", "Styles": "None", "Classes": "None", "Text": "2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Under aseptic conditions, reconstitute each Remicade vial with 10\u00a0ml of water for injections, using a syringe equipped with a 21\u2011gauge (0.8\u00a0mm) or smaller needle. Remove flip\u2011top from the vial and wipe the top with a 70% alcohol swab. Insert the syringe needle into the vial through the centre of the rubber stopper and direct the stream of water for injections to the glass wall of the vial. Gently swirl the solution by rotating the vial to dissolve the lyophilised powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE. Foaming of the solution on reconstitution is not unusual. Allow the reconstituted solution to stand for 5\u00a0minutes. Check that the solution is colourless to light yellow and opalescent. The solution may develop a few fine translucent particles, as infliximab is a protein. Do not use if opaque particles, discolouration, or other foreign particles are present.", "ParentId": "5f1063f8-59cd-42d1-8407-cfd23e4100f8"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "f0d3a0cd-8935-4567-80b5-dc3dec52ce65", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "329b9057-1c13-4373-82c9-403b63393994", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "f0d3a0cd-8935-4567-80b5-dc3dec52ce65"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dilute the total volume of\nthe reconstituted Remicade solution dose to 250\u00a0ml with sodium chloride\n9\u00a0mg/ml (0.9%) solution for infusion. Do not dilute the reconstituted\nRemicade solution with any other diluent. The dilution can be accomplished by\nwithdrawing a volume of the sodium chloride 9\u00a0mg/ml (0.9%) solution for\ninfusion from the 250\u2011ml glass bottle or infusion bag equal to the volume\nof reconstituted Remicade. Slowly add the total volume of reconstituted\nRemicade solution to the 250\u2011ml infusion bottle or bag. Gently mix. For\nvolumes greater than 250\u00a0ml, either use a larger infusion bag (e.g. 500\u00a0ml,\n1000\u00a0ml) or use multiple 250\u00a0ml infusion bags to ensure that the\nconcentration of the infusion solution does not exceed 4\u00a0mg/ml. If stored\nrefrigerated after reconstitution and dilution, the infusion solution must be\nallowed to equilibrate at room temperature to 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C for 3\u00a0hours prior to\nStep\u00a04 (infusion). Storage beyond 24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C applies to preparation of\nRemicade in the infusion bag only.</span></p>", "ID": "1a9e6d33-eadd-4fd7-9fa9-3bb2de514d35", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dilute the total volume of\nthe reconstituted Remicade solution dose to 250\u00a0ml with sodium chloride\n9\u00a0mg/ml (0.9%) solution for infusion. Do not dilute the reconstituted\nRemicade solution with any other diluent. The dilution can be accomplished by\nwithdrawing a volume of the sodium chloride 9\u00a0mg/ml (0.9%) solution for\ninfusion from the 250\u2011ml glass bottle or infusion bag equal to the volume\nof reconstituted Remicade. Slowly add the total volume of reconstituted\nRemicade solution to the 250\u2011ml infusion bottle or bag. Gently mix. For\nvolumes greater than 250\u00a0ml, either use a larger infusion bag (e.g. 500\u00a0ml,\n1000\u00a0ml) or use multiple 250\u00a0ml infusion bags to ensure that the\nconcentration of the infusion solution does not exceed 4\u00a0mg/ml. If stored\nrefrigerated after reconstitution and dilution, the infusion solution must be\nallowed to equilibrate at room temperature to 25<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C for 3\u00a0hours prior to\nStep\u00a04 (infusion). Storage beyond 24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C applies to preparation of\nRemicade in the infusion bag only.</span>", "ID": "09ba21ed-f4ff-4c30-bb22-0882e81944d0", "Styles": "None", "Classes": "None", "Text": "3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Dilute the total volume of the reconstituted Remicade solution dose to 250\u00a0ml with sodium chloride 9\u00a0mg/ml (0.9%) solution for infusion. Do not dilute the reconstituted Remicade solution with any other diluent. The dilution can be accomplished by withdrawing a volume of the sodium chloride 9\u00a0mg/ml (0.9%) solution for infusion from the 250\u2011ml glass bottle or infusion bag equal to the volume of reconstituted Remicade. Slowly add the total volume of reconstituted Remicade solution to the 250\u2011ml infusion bottle or bag. Gently mix. For volumes greater than 250\u00a0ml, either use a larger infusion bag (e.g. 500\u00a0ml, 1000\u00a0ml) or use multiple 250\u00a0ml infusion bags to ensure that the concentration of the infusion solution does not exceed 4\u00a0mg/ml. If stored refrigerated after reconstitution and dilution, the infusion solution must be allowed to equilibrate at room temperature to 25\u00b0C for 3\u00a0hours prior to Step\u00a04 (infusion). Storage beyond 24\u00a0hours at 2\u00b0C\u20118\u00b0C applies to preparation of Remicade in the infusion bag only.", "ParentId": "1a9e6d33-eadd-4fd7-9fa9-3bb2de514d35"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>", "ID": "cd704035-9573-41c9-9270-e2a54acfd529", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "09ba21ed-f4ff-4c30-bb22-0882e81944d0"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del>", "ID": "f036aa80-3c89-453b-8671-095f511a96c3", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cd704035-9573-41c9-9270-e2a54acfd529"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>", "ID": "d8a6f8a9-435e-4c9b-aad7-6bdccdc6da99", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "09ba21ed-f4ff-4c30-bb22-0882e81944d0"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del>", "ID": "8d0f2b5e-2bd9-4524-8883-cde133809e3e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d8a6f8a9-435e-4c9b-aad7-6bdccdc6da99"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>", "ID": "cb7e588a-ccc2-463c-8dbe-f861529ad431", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "09ba21ed-f4ff-4c30-bb22-0882e81944d0"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del>", "ID": "702e9d19-0fa7-44b1-b582-759e8cf3fea1", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "cb7e588a-ccc2-463c-8dbe-f861529ad431"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>", "ID": "879e99b1-1ea4-4109-b4bb-16a261f61a7d", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "09ba21ed-f4ff-4c30-bb22-0882e81944d0"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del>", "ID": "fa63a949-ca3c-4127-ac7f-1e52ed68073e", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "879e99b1-1ea4-4109-b4bb-16a261f61a7d"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>", "ID": "5a466b20-f20c-4f5e-8353-95fdbe796896", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "09ba21ed-f4ff-4c30-bb22-0882e81944d0"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del>", "ID": "406ee8bd-c08c-4252-8942-62dc805bb8cf", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5a466b20-f20c-4f5e-8353-95fdbe796896"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "4e0f5980-743c-4d91-a578-9e5aea825789", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "5445b8d1-4d1a-4436-94ec-973f94239158", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "4e0f5980-743c-4d91-a578-9e5aea825789"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Administer the infusion\nsolution over a period of not less than the infusion time recommended. Use only\nan infusion set with an in\u2011line, sterile, non\u2011pyrogenic, low\nprotein\u2011binding filter (pore size 1.2\u00a0micrometre or less). Since no\npreservative is present, it is recommended that the administration of the\nsolution for infusion is to be started as soon as possible and within\n3\u00a0hours of reconstitution and dilution. If not used immediately, in use\nstorage times and conditions prior to use are the responsibility of the user\nand would normally not be longer than 24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C, unless reconstitution/dilution\nhas been taken place in controlled and validated aseptic conditions. Do not\nstore any unused portion of the infusion solution for reuse.</span></p>", "ID": "ae5f254b-ec21-4c03-8b07-c286c409c9e4", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Administer the infusion\nsolution over a period of not less than the infusion time recommended. Use only\nan infusion set with an in\u2011line, sterile, non\u2011pyrogenic, low\nprotein\u2011binding filter (pore size 1.2\u00a0micrometre or less). Since no\npreservative is present, it is recommended that the administration of the\nsolution for infusion is to be started as soon as possible and within\n3\u00a0hours of reconstitution and dilution. If not used immediately, in use\nstorage times and conditions prior to use are the responsibility of the user\nand would normally not be longer than 24\u00a0hours at 2<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u2011<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>8<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>\u00b0C, unless reconstitution/dilution\nhas been taken place in controlled and validated aseptic conditions. Do not\nstore any unused portion of the infusion solution for reuse.</span>", "ID": "69dca73c-e019-4dde-999d-aed64f386e1d", "Styles": "None", "Classes": "None", "Text": "4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Administer the infusion solution over a period of not less than the infusion time recommended. Use only an infusion set with an in\u2011line, sterile, non\u2011pyrogenic, low protein\u2011binding filter (pore size 1.2\u00a0micrometre or less). Since no preservative is present, it is recommended that the administration of the solution for infusion is to be started as soon as possible and within 3\u00a0hours of reconstitution and dilution. If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24\u00a0hours at 2\u00b0C\u20118\u00b0C, unless reconstitution/dilution has been taken place in controlled and validated aseptic conditions. Do not store any unused portion of the infusion solution for reuse.", "ParentId": "ae5f254b-ec21-4c03-8b07-c286c409c9e4"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>", "ID": "623e7283-51d5-464e-8c27-cf76731c6ab0", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "69dca73c-e019-4dde-999d-aed64f386e1d"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del>", "ID": "609e2336-30bf-40f3-aeaf-e267cdd23673", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "623e7283-51d5-464e-8c27-cf76731c6ab0"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>", "ID": "ae556553-fb18-4ccb-8e84-67ce34eabbb3", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "69dca73c-e019-4dde-999d-aed64f386e1d"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del>", "ID": "7fccb67c-1bfb-456c-8fb5-e03c59b387ad", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "ae556553-fb18-4ccb-8e84-67ce34eabbb3"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>", "ID": "d4a56948-ac87-40db-aac0-fb0ca166505a", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "69dca73c-e019-4dde-999d-aed64f386e1d"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del>", "ID": "599b13e1-8751-45d1-b163-2e602a747e95", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "d4a56948-ac87-40db-aac0-fb0ca166505a"}, {"Element": "<span class=\"msoDel\"><del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del></span>", "ID": "5d111e82-1049-4878-9747-e3044a0f38f2", "Styles": "None", "Classes": "['msoDel']", "Text": "", "ParentId": "69dca73c-e019-4dde-999d-aed64f386e1d"}, {"Element": "<del cite=\"mailto:Pawar,%20Shriya%20[JANBE%20-%20Non%20J&amp;J]\" datetime=\"2020-08-20T15:19\">\u00a0</del>", "ID": "0ede1bf8-6dcd-49bb-b54a-90be689d055b", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5d111e82-1049-4878-9747-e3044a0f38f2"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "5f89d68f-88e2-451a-a7f9-66c00866ffd2", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "80dd37d2-0f1f-4f87-a458-64481d1148d4", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "5f89d68f-88e2-451a-a7f9-66c00866ffd2"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 No physical biochemical\ncompatibility studies have been conducted to evaluate the co\u2011administration\nof Remicade with other agents. Do not infuse Remicade concomitantly in the same\nintravenous line with other agents.</span></p>", "ID": "35df9a78-9c95-4e3f-9719-abb7ec52881a", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 No physical biochemical\ncompatibility studies have been conducted to evaluate the co\u2011administration\nof Remicade with other agents. Do not infuse Remicade concomitantly in the same\nintravenous line with other agents.</span>", "ID": "55e8802e-6927-43a4-9d53-f4a5938a77da", "Styles": "None", "Classes": "None", "Text": "5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 No physical biochemical compatibility studies have been conducted to evaluate the co\u2011administration of Remicade with other agents. Do not infuse Remicade concomitantly in the same intravenous line with other agents.", "ParentId": "35df9a78-9c95-4e3f-9719-abb7ec52881a"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "a6868e0d-5be3-485c-abc7-da97b7ebfc60", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "b75413f0-5c58-4b71-a39d-bab48e730a67", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "a6868e0d-5be3-485c-abc7-da97b7ebfc60"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Visually inspect Remicade for\nparticulate matter or discolouration prior to administration. Do not use if\nvisibly opaque particles, discolouration or foreign particles are observed.</span></p>", "ID": "238d802e-f5b4-420f-936b-a26d81e861bc", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Visually inspect Remicade for\nparticulate matter or discolouration prior to administration. Do not use if\nvisibly opaque particles, discolouration or foreign particles are observed.</span>", "ID": "4744c3b0-a989-469f-b9a7-5c5f66682921", "Styles": "None", "Classes": "None", "Text": "6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Visually inspect Remicade for particulate matter or discolouration prior to administration. Do not use if visibly opaque particles, discolouration or foreign particles are observed.", "ParentId": "238d802e-f5b4-420f-936b-a26d81e861bc"}, {"Element": "<p class=\"MsoNormal\"><span lang=\"EN-GB\">\u00a0</span></p>", "ID": "b4984dc9-c9d2-4662-8e26-da76093f1fcb", "Styles": "None", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">\u00a0</span>", "ID": "8352b296-5fc0-49ff-9692-c2b2475284d5", "Styles": "None", "Classes": "None", "Text": "\u00a0", "ParentId": "b4984dc9-c9d2-4662-8e26-da76093f1fcb"}, {"Element": "<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Any unused product or waste\nmaterial should be disposed of in accordance with local requirements.</span></p>", "ID": "cb2c31fc-050c-4eec-af52-5015ac39dcc7", "Styles": "margin-left:28.35pt;text-indent:-28.35pt", "Classes": "['MsoNormal']", "Text": "", "ParentId": "8c47ffa8-0259-475d-acf9-2d9675807e72"}, {"Element": "<span lang=\"EN-GB\">7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Any unused product or waste\nmaterial should be disposed of in accordance with local requirements.</span>", "ID": "d53daf84-665f-4a17-815f-99069764920f", "Styles": "None", "Classes": "None", "Text": "7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Any unused product or waste material should be disposed of in accordance with local requirements.", "ParentId": "cb2c31fc-050c-4eec-af52-5015ac39dcc7"}]}